<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501351</article-id><article-id pub-id-type="pmcid-ver">PMC12501351.1</article-id><article-id pub-id-type="pmcaid">12501351</article-id><article-id pub-id-type="pmcaiid">12501351</article-id><article-id pub-id-type="pmid">40750516</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100318</article-id><article-id pub-id-type="pii">S2274-5807(25)00261-4</article-id><article-id pub-id-type="publisher-id">100318</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group></article-categories><title-group><article-title>Differential effects of soluble and plaque amyloid on late-life depression: The moderating role of tau pathology</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Byeon</surname><given-names initials="G">Gihwan</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Kim</surname><given-names initials="S">Suhyung</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Kim</surname><given-names initials="S">Sunghwan</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Um</surname><given-names initials="YH">Yoo Hyun</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Wang</surname><given-names initials="SM">Sheng-Min</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Ha</surname><given-names initials="S">Seunggyun</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Park</surname><given-names initials="SY">Sonya Youngju</given-names></name><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Choe</surname><given-names initials="YS">Yeong Sim</given-names></name><xref rid="aff0006" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0009"><name name-style="western"><surname>Kim</surname><given-names initials="D">Donghyeon</given-names></name><xref rid="aff0006" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Lim</surname><given-names initials="HK">Hyun Kook</given-names></name><xref rid="aff0003" ref-type="aff">c</xref><xref rid="aff0006" ref-type="aff">f</xref><xref rid="aff0007" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0011"><name name-style="western"><surname>Lee</surname><given-names initials="CU">Chang Uk</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0012"><name name-style="western"><surname>Kang</surname><given-names initials="DW">Dong Woo</given-names></name><email>kato7@hanmail.net</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><aff id="aff0001"><label>a</label>Department of Psychiatry, Seoul St. Mary&#8217;s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea</aff><aff id="aff0002"><label>b</label>Department of Psychiatry, St. Vincent&#8217;s Hospital, College of Medicine, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon-si, Gyeonggi-do 16247, Republic of Korea</aff><aff id="aff0003"><label>c</label>Department of Psychiatry, Yeouido St. Mary&#8217;s Hospital, College of Medicine, The Catholic University of Korea, 10 63-ro, Yeongdeungpo-gu, Seoul 07345, Republic of Korea</aff><aff id="aff0004"><label>d</label>Division of Nuclear Medicine, department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea</aff><aff id="aff0005"><label>e</label>Division of Nuclear Medicine, Yeouido St. Mary&#8217;s Hospital, College of Medicine, The Catholic University of Korea, 10 63-ro, Yeongdeungpo-gu, Seoul 07345, Republic of Korea</aff><aff id="aff0006"><label>f</label>Research Institute, NEUROPHET Inc., 5F, 27 Teheran-ro 4-gil, Gangnam-gu, Seoul 06232, Republic of Korea</aff><aff id="aff0007"><label>g</label>CMC Institute for Basic Medical Science, The Catholic Medical Center of The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author at: Department of Psychiatry, Seoul St. Mary&#8217;s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea. <email>kato7@hanmail.net</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>8</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100318</elocation-id><history><date date-type="received"><day>29</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>1</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><sec><title>Background</title><p>Late-life depression frequently co-occurs with Alzheimer&#8217;s disease (AD); however, the interactive effects of amyloid-beta (A&#946;) species and tau pathology on depressive symptoms remain unclear. Soluble oligomeric A&#946; (OA&#946;) and amyloid plaques may differentially influence depression depending on tau burden.</p></sec><sec><title>Objectives</title><p>To examine how plasma OA&#946; and PET-measured amyloid plaque burden are associated with depressive symptoms across varying levels of tau pathology.</p></sec><sec><title>Design</title><p>Cross-sectional analysis using generalized linear models with interaction terms, supported by stratified subgroup analyses and Johnson&#8211;Neyman procedures.</p></sec><sec><title>Setting</title><p>Memory disorder clinic at a university-affiliated hospital.</p></sec><sec><title>Participants</title><p>A total of 103 individuals, including cognitively normal controls (<italic toggle="yes">n</italic> = 24), patients with mild cognitive impairment (<italic toggle="yes">n</italic> = 54), and amyloid-positive dementia (<italic toggle="yes">n</italic> = 25), all of whom underwent plasma biomarker testing and tau and amyloid PET imaging.</p></sec><sec><title>Measurements</title><p>Depression was evaluated using the Cornell Scale for Depression in Dementia (CSDD), Hamilton Depression Rating Scale (HAM-D), and Geriatric Depression Scale&#8211;Short Version (GDS-SV). Plasma OA&#946; was measured by Multimer Detection System (MDS), and PET quantified amyloid and tau burden.</p></sec><sec><title>Results</title><p>MDS-OA&#946; showed a significant negative interaction with tau PET SUVR on depression scores (FDR-adjusted <italic toggle="yes">p</italic> &lt; 0.05). Higher OA&#946; levels were linked to greater depression severity in low-tau individuals, but inversely related in high-tau individuals. Amyloid plaque burden was associated with depression only in those with advanced tau pathology.</p></sec><sec><title>Conclusions</title><p>The association between amyloid pathology and depression differs depending on tau burden. Soluble OA&#946; may be a key contributor to depressive symptoms in early AD stages, while plaque effects become prominent later. These findings underscore the potential utility of OA&#946; as an early neuropsychiatric biomarker in AD and highlight the need to consider tau pathology when evaluating amyloid-related mood disturbances.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Alzheimer disease</kwd><kwd>Amyloid beta-peptides</kwd><kwd>Tau proteins</kwd><kwd>Depression</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="key6a">SUVR</term><def><p>Standardized uptake value ratio</p></def></def-item><def-item><term id="key7a">CSDD</term><def><p>Cornell Scale for Depression in Dementia</p></def></def-item><def-item><term id="key8a">HAM-D</term><def><p>Hamilton depression scale</p></def></def-item><def-item><term id="key9a">GDSsv</term><def><p>a short version Geriatric Depression Scale consisting of 15 questions</p></def></def-item><def-item><term id="key10a">CERAD-K</term><def><p>Korean version of Consortium to Establish a Registry for Alzheimer&#8217;s Disease</p></def></def-item><def-item><term id="key11a">OA&#946;</term><def><p>Oligomeric amyloid beta</p></def></def-item></def-list></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0009">Alzheimer&#8217;s disease (AD) is a neurodegenerative disorder that primarily affects the older adults, with a globally increasing prevalence [<xref rid="bib0001" ref-type="bibr">1</xref>]. Depression is also a common psychiatric illness in late life, affecting approximately 3 % of the healthy older adult population. However, its prevalence rises significantly among medically ill, hospitalized, or institutionalized older individuals. In particular, the prevalence of depression in patients with AD is notably high, ranging from 20 to 30 % [<xref rid="bib0002" ref-type="bibr">2</xref>,<xref rid="bib0003" ref-type="bibr">3</xref>]. Furthermore, late-life depression has been identified as a potential predictor of subsequent development of AD [<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0005" ref-type="bibr">5</xref>]. These findings suggest a close relationship between the two conditions.</p><p id="para0010">Previous studies have shown that the major pathological hallmarks of AD, amyloid-beta (A&#946;) and tau [<xref rid="bib0006" ref-type="bibr">6</xref>], are also associated with depression. A systematic review reported that non-demented older adults with depressive symptoms had significantly higher levels of A&#946; than those without such symptoms [<xref rid="bib0007" ref-type="bibr">7</xref>], On the other hand, cognitively normal older adults with depressive symptoms exhibited a higher frequency of amyloid positivity, whereas those with mild cognitive impairment (MCI) showed the opposite trend [<xref rid="bib0008" ref-type="bibr">8</xref>].</p><p id="para0011">Regarding tau pathology, a meta-analysis found no significant difference in tau burden between individuals with major depressive disorder (MDD) and those without [<xref rid="bib0009" ref-type="bibr">9</xref>]. In contrast, an imaging study demonstrated a significant association between depressive symptoms and tau deposition in the inferior temporal lobe and entorhinal cortex among cognitively normal older adults, suggesting the possibility of region-specific effects [<xref rid="bib0010" ref-type="bibr">10</xref>]. Similarly, another study found that tau deposition, but not amyloid deposition, was significantly associated with a diagnosis of depression in cognitively normal individuals [<xref rid="bib0011" ref-type="bibr">11</xref>].</p><p id="para0012">Despite these findings, the interaction between A&#946; and tau pathology in relation to depressive symptoms remains poorly understood. Given that both A&#946; and tau are core biomarkers of AD, examining their combined effects is essential to understanding the full pathological basis of depression in the context of AD. Furthermore, the synergistic interaction between A&#946; and tau pathology has been shown to play a critical role in the progression of AD [<xref rid="bib0012" ref-type="bibr">12</xref>], underscoring the need to consider their interaction when evaluating their association with depressive symptoms.</p><p id="para0013">Moreover, there has been a lack of research examining the differential impact of specific pathologic amyloid species on depression. Among these, soluble oligomerized A&#946; (OA&#946;) has been identified as the most neurotoxic species, primarily due to its ability to disrupt synaptic function, induce neuroinflammation, and impair neuronal viability even in the absence of plaque formation [<xref rid="bib0013" ref-type="bibr">13</xref>]. The recent development of multimer detection system (MDS) technology has improved the accuracy of detecting OA&#946; [<xref rid="bib0014" ref-type="bibr">14</xref>]. Distinguishing MDS-measured OA&#946; from amyloid plaque as measured by positron emission tomography (PET) imaging is essential to evaluating the predictive value of A&#946; pathology in depression.</p><p id="para0014">Therefore, in the present study, we aimed to investigate how MDS-measured OA&#946; and amyloid PET-detected A&#946; pathology interact with tau pathology, as assessed by tau PET imaging, in relation to depressive symptoms. To capture depressive symptoms across a broad cognitive spectrum, we employed a multimodal assessment approach incorporating both clinician-rated and self-reported measures, thereby enabling a comprehensive evaluation of late-life depression in individuals with varying cognitive status.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><sec id="sec0003"><label>2.1</label><title>Participants</title><p id="para0015">A total of 373 participants were initially enrolled in the study, comprising 106 cognitively normal older adults (NC) with negative A&#946;-PET scans, 18 A&#946;-PET-positive NC, 116 A&#946;-PET-negative patients with MCI, 101 A&#946;-PET-positive MCI patients, and 32 A&#946;-PET-positive dementia patients. These individuals were recruited from the Catholic Aging Brain Imaging database (CABID), which includes MRI and PET scans and clinical data of the older adults who visited the outpatient clinic at the Catholic Brain Health Center, Yeouido St. Mary&#8217;s Hospital, the Catholic University of Korea, from 2018 to 2024 <bold>(Supplementary Fig. 1).</bold></p><p id="para0016">The inclusion criteria were as follows: (1) age &#8805; 55 years and (2) absence of clinically significant psychiatric disorders, such as MDD, schizophrenia, or bipolar disorder. The cognitive normality of NC was confirmed using the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-K) battery [<xref rid="bib0015" ref-type="bibr">15</xref>], with a global Clinical Dementia Rating (CDR) score of 0. MCI was diagnosed based on the following criteria: (1) subjective memory complaints corroborated by an informant, (2) objective cognitive impairment in at least one CERAD-K domain (&#8805;1.0 SD below age- and education-adjusted norms), (3) preserved activities of daily living, (4) a global CDR score of 0.5, and (5) absence of dementia according to DSM-V criteria. Patients with dementia due to AD met the criteria for probable AD as defined by Neurological and Communicative Disorders and Stroke and AD and Related Disorders Association (NINCDS-ADRDA) and DSM-V, in addition to having A&#946;-PET-positive findings [<xref rid="bib0016" ref-type="bibr">16</xref>,<xref rid="bib0017" ref-type="bibr">17</xref>], with a global CDR score of 1. Exclusion criteria included systemic diseases known to cause cognitive impairment, severe sensory impairments, neurological conditions (e.g., brain tumors, epilepsy), cerebrovascular disease, or contraindications for imaging. All diagnoses were confirmed by two psychiatric specialists.</p><p id="para0017">From the initial cohort of 373 subjects, a subset of 103 participants (24 NC, 54 MCI, and 25 A&#946;-PET-positive dementia patients) with available depression scores, as well as Tau-PET scans, were selected for further analysis <bold>(Supplementary Fig. 1).</bold> All assessments, including brain imaging, blood sampling, and cognitive evaluations, were conducted within a three-month period at baseline. The study was conducted in accordance with ethical guidelines and approved by the Institutional Review Board (IRB No.: SC21TISI0017). Written informed consent was obtained from all participants.</p></sec><sec id="sec0004"><label>2.2</label><title>Measurement of A&#946; oligomerization in plasma</title><p id="para0018">Plasma levels of OA&#946; were quantified using the Multimer Detection System for OA&#946; (MDS-OA&#946;). Blood samples were collected via venipuncture using ethylene-diamine-tetraacetic acid (EDTA) vacutainer tubes, following established protocols for MDS-OA&#946; measurement [<xref rid="bib0018" ref-type="bibr">18</xref>]. After collection, EDTA plasma was centrifuged at 3500 rpm for 15 min at room temperature. The resulting plasma was aliquoted into 1.5-mL polypropylene tubes and stored at &#8722;70 &#176;C to &#8722;80 &#176;C. The samples were then transported to PeopleBio Inc. for MDS-OA&#946; level analysis.</p><p id="para0019">Prior to measurement, plasma aliquots were thawed at 37 &#176;C for 15 min. MDS-OA&#946; levels were measured using the multimer detection system, which is CE-marked and approved by the Korean Food and Drug Administration [<xref rid="bib0018" ref-type="bibr">[18]</xref>, <xref rid="bib0019" ref-type="bibr">[19]</xref>, <xref rid="bib0020" ref-type="bibr">[20]</xref>]. This plasma-based biomarker has been previously validated against amyloid PET positivity, with a proposed cutoff value of 0.78 ng/mL for identifying A&#946; positivity [<xref rid="bib0021" ref-type="bibr">21</xref>]. Furthermore, to classify AD risk, a two-cutoff algorithm was implemented, aligning with methodologies outlined in prior biomarker research [<xref rid="bib0022" ref-type="bibr">22</xref>]. Based on this approach, plasma MDS-OA&#946; levels were categorized into three risk groups: low risk (&lt;0.78 ng/mL), intermediate risk (0.78&#8211;0.93 ng/mL), and high risk (&#8805;0.93 ng/mL). The cutoff values were determined based on the CLSI guideline NBS 04-A, which outlines standardized procedures for establishing and validating reference intervals in clinical laboratory testing.</p></sec><sec id="sec0005"><label>2.3</label><title>Image acquisition</title><p id="para0020">All participants underwent neuroimaging using a Siemens Skyra 3T MRI scanner equipped with a 20-channel head and neck coil (Siemens Healthcare, Erlangen, Germany) for high-resolution 3D T1-weighted structural imaging. In addition, PET scans were performed using a Biograph 40 TruePoint system (Siemens Medical Solutions, Erlangen, Germany) with radiotracers [&#185;&#8312;F]-flutemetamol and [&#185;&#8312;F]-flortaucipir. PET image acquisition was initiated 90 min following intravenous administration of 185 MBq [&#185;&#8312;F]-flutemetamol, or 80 min after administration of 370 MBq [&#185;&#8312;F]-flortaucipir, with static scans acquired over a 20-minute duration. Images were reconstructed using a 2D ordered-subsets expectation-maximization (OSEM) algorithm with two iterations and 21 subsets. The final image matrix measured 256 &#215; 256 &#215; 175, with a voxel resolution of 1.3364 &#215; 1.3364 &#215; 3 mm&#179;. Prior to PET acquisition, low-dose CT scans were obtained for attenuation correction. T1-weighted MRI scans were acquired using a magnetization-prepared rapid gradient echo (MPRAGE) sequence with the following parameters: TR = 1860 ms, TE = 25.3 ms, flip angle = 9&#176;, FOV = 224 &#215; 224 mm, matrix size = 256 &#215; 256, 208 slices, and a 1.0 mm slice thickness. All imaging data were anonymized and converted from DICOM to NIfTI format using the dcm2niix conversion tool.</p></sec><sec id="sec0006"><label>2.4</label><title>Image preprocessing</title><p id="para0021">SCALE PET 2.0 (Neurophet Inc., Seoul, Republic of Korea) was used for imaging preprocessing and quantification of [<sup>18</sup>F]-flutemetamol and [<sup>18</sup>F]-flortaucipir PET/CT scans [<xref rid="bib0023" ref-type="bibr">[23]</xref>, <xref rid="bib0024" ref-type="bibr">[24]</xref>, <xref rid="bib0025" ref-type="bibr">[25]</xref>]. This process involved brain parcellation on coregistered T1-weighted MRI scans. T1-weighted MRIs were corrected for non-uniformity and field distortions before processing. PET images were registered to T1-weighted MRI space, and T1-weighted images were then linearly and non-linearly registered to the Montreal Neurological Institute (MNI) reference space. PET images underwent skull and meninges stripping and were subsequently non-linearly registered to the MNI space using transformations derived from the T1-weighted image to MNI space and PET image to T1-weighted image space. T1-weighted MR images were parcellated into 101 regions using the Desikan-Killiany atlas [<xref rid="bib0026" ref-type="bibr">26</xref>]. No partial volume corrections were applied during the analysis.</p></sec><sec id="sec0007"><label>2.5</label><title>Amyloid PET reading and quantification</title><p id="para0022">Amyloid PET images were visually interpreted by assessing regions of interest, including the lateral temporal cortex, frontal cortex, posterior cingulate and precuneus, and inferolateral parietal cortex. Positivity in any of these regions was considered sufficient for an overall positive scan. The final assessment was recorded as a dichotomous classification (positive/negative) based on visual rating, with consensus reached between two nuclear medicine physicians (SH and SYP, both with 14 years of clinical experience in nuclear medicine). Quantitative Standardized uptake value ratio (SUVR) values were used as a supplementary measure to assist visual rating, referring to a predefined global SUVR cutoff of 0.62. The pons was used as the reference region for SUVR calculation in [<sup>18</sup>F]-flutemetamol PET/CT scan studies.</p><p id="para0023">Global [<sup>18</sup>F]-flutemetamol SUVR values were calculated as the average of regional cortical SUVRs from the frontal, superior parietal, lateral temporal, anterior and posterior cingulate cortex, and precuneus, weighted by region size [<xref rid="bib0027" ref-type="bibr">27</xref>]. These global SUVR values were not only used to support the visual assessment but also served as the primary quantitative parameter for the main statistical analyses.</p></sec><sec id="sec0008"><label>2.6</label><title>Tau PET reading and quantification</title><p id="para0024">Tau pathology was assessed using Braak staging in the quantitative analysis of [&#185;&#8312;F]-flortaucipir PET/CT images. Staging was determined based on topographical involvement of specific brain regions [<xref rid="bib0028" ref-type="bibr">28</xref>]. Braak stage I was defined by tau accumulation in the entorhinal cortex. Braak stages III/IV encompassed regions including the parahippocampal and fusiform gyri, lingual gyrus, amygdala, inferior and middle temporal gyri, temporal pole, thalamus, caudal and rostral anterior cingulate, isthmus and posterior cingulate cortices, and the insula. Braak stages V/VI included more extensive neocortical regions such as the frontal, parietal, and occipital lobes; transverse and superior temporal gyri; precuneus; superior temporal sulcus banks; nucleus accumbens; caudate nucleus; putamen; motor and somatosensory cortices (precentral, postcentral, and paracentral gyri); cuneus; and pericalcarine cortex [<xref rid="bib0029" ref-type="bibr">29</xref>]. Braak stage II, which includes the hippocampus, was excluded from the analysis to avoid potential bias introduced by known off-target binding of [&#185;&#8312;F]-flortaucipir in this region [<xref rid="bib0030" ref-type="bibr">30</xref>].</p><p id="para0025">PET images were reviewed following guidelines consistent with regulatory approvals from the FDA and EMA for clinical interpretation. Two experienced nuclear medicine physicians (SH and SYP, each with 14 years of experience) performed visual assessments based on anatomical Braak staging. Quantitative evaluation using SUVR values supported the visual interpretations, with a predefined SUVR threshold of 1.3 used as a reference [<xref rid="bib0031" ref-type="bibr">31</xref>]. In cases of discrepancy between visual interpretation and quantitative analysis, raters re-evaluated the images to reach a consensus decision.</p><p id="para0026">A standardized single-threshold approach was employed to harmonize visual and quantitative findings, aiming to improve clinical consistency in tauopathy classification. This methodology has been validated in prior studies as a reliable predictor of cognitive deterioration throughout the clinical continuum of neurodegenerative disease [<xref rid="bib0028" ref-type="bibr">28</xref>]. Braak stage positivity was defined hierarchically: Braak I positivity indicated tau presence limited to the Braak I ROI; Braak III/IV positivity required additional involvement of the III/IV ROIs; and Braak V/VI positivity was assigned when all three regions (I, III/IV, and V/VI) showed tau accumulation. Participants without tau positivity in any of these ROIs were categorized as Braak stage 0.</p><p id="para0027">The temporal meta-ROI used for quantitative analysis included the entorhinal cortex, amygdala, parahippocampal gyrus, fusiform gyrus, and the inferior and middle temporal gyri [<xref rid="bib0032" ref-type="bibr">32</xref>]. The SUVR for [<sup>18</sup>F]-flortaucipir was calculated using the cerebellar cortex as the reference region to ensure consistency in measurements [<xref rid="bib0028" ref-type="bibr">28</xref>,<xref rid="bib0029" ref-type="bibr">29</xref>].</p><p id="para0028">In the present study, the main analysis utilized the meta-ROI SUVR, as it is a widely used and reliable quantitative marker that accurately reflects tau pathology [<xref rid="bib0033" ref-type="bibr">33</xref>]. Moreover, this approach increased the model degrees of freedom and facilitated a clearer interpretation of interaction effects between variables by using a continuous variable (meta-ROI SUVR) rather than a categorical variable (Braak stages) [<xref rid="bib0034" ref-type="bibr">34</xref>,<xref rid="bib0035" ref-type="bibr">35</xref>].</p><p id="para0029">Although generalized linear models (GLMs) are robust to non-normality of independent variables, the nominal nature of Braak staging and the substantial imbalance in group sizes limited its applicability in the primary analyses. Therefore, we employed the continuous meta-ROI SUVR variable to maximize statistical power and ensure a more stable estimation of interaction effects.</p></sec><sec id="sec0009"><label>2.7</label><title>Neuropsychological assessment and other clinical measures</title><p id="para0030">All participants underwent cognitive assessments using the Korean version of the CERAD-K battery [<xref rid="bib0036" ref-type="bibr">36</xref>]. The assessment battery included Korean versions of the following tests: Verbal Fluency (VF), the 15-item Boston Naming Test, and the Korean Mini-Mental State Examination (MMSE-K). Additional cognitive measures included word list memory (WLM), recall, recognition, constructional praxis, and recall (CR). A comprehensive CERAD-K score was calculated by aggregating scores from all tests, excluding MMSE-K and CR [<xref rid="bib0037" ref-type="bibr">37</xref>]. In addition, we also collected data on apolipoprotein E (<italic toggle="yes">APOE</italic>) genotypes, which may act as confounding factors in the depression of older adults [<xref rid="bib0038" ref-type="bibr">38</xref>]. <italic toggle="yes">APOE</italic> genotyping was performed using DNA extracted from participants&#8217; peripheral blood. Participants were then classified based on the presence of the <italic toggle="yes">APOE</italic> &#949;4 allele, with those carrying at least one &#949;4 allele designated as <italic toggle="yes">APOE</italic> &#949;4 carriers, while those without any &#949;4 alleles were classified as non-carriers.</p></sec><sec id="sec0010"><label>2.8</label><title>Depression scales</title><p id="para0031">In this study, depressive symptoms were assessed using three well-validated clinical rating scales: the Cornell Scale for Depression in Dementia (CSDD), the Hamilton Depression Rating Scale (HAM-D), and the Geriatric Depression Scale-Short Version (GDS-SV). Korean-translated and culturally adapted versions of these scales were used, all of which have been validated in previous studies.</p><p id="para0032">The CSDD is a clinician-rated scale specifically developed to assess depressive symptoms in individuals with cognitive impairment or dementia. It consists of 19 items evaluating mood-related signs, behavioral disturbance, physical signs, cyclic functions, and ideational disturbance, with input obtained from both the patient and an informant. The Korean version of the CSDD has demonstrated good reliability and validity in older adults with cognitive decline, with internal consistency (Cronbach&#8217;s &#945;) reported to be 0.92 and test-retest reliability of 0.91 [<xref rid="bib0039" ref-type="bibr">39</xref>].</p><p id="para0033">The HAM-D is one of the most widely used clinician-administered depression rating scales and serves as a benchmark for assessing the severity of depressive symptoms, particularly in clinical and research settings. The 17-item version was employed in this study. The Korean version of the HAM-D has shown high internal consistency (Cronbach&#8217;s &#945; = 0.89) and inter-rater reliability (<italic toggle="yes">r</italic> = 0.94) in patients with depressive disorders [<xref rid="bib0040" ref-type="bibr">40</xref>].</p><p id="para0034">The GDS-SV is a self-report measure designed for older adults, consisting of 15 yes/no questions. It is useful for screening depression in elderly populations, including those with mild cognitive impairment. The Korean version of the GDS-SV has been validated in community-dwelling older adults, showing good reliability (Cronbach&#8217;s &#945; = 0.88) and concurrent validity with other depression scales [<xref rid="bib0041" ref-type="bibr">41</xref>].</p><p id="para0035">These three complementary tools allowed for a comprehensive assessment of depressive symptoms across different cognitive statuses in our cohort, with both informant-based and self-report perspectives.</p></sec><sec id="sec0011"><label>2.9</label><title>Statistical analysis</title><p id="para0036">Statistical analyses were conducted using R software (version 4.3.2) and jamovi (version 2.6.26) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.jamovi.org" id="interref0001">https://www.jamovi.org</ext-link>). The main analysis included 24 NC, 54 patients with MCI, and 25 patients with amyloid-positive dementia, all of whom had complete data, including tau PET imaging (Supplementary Fig. 1). Analysis of variance (ANOVA) was used to evaluate group differences.</p><p id="para0037">To further investigate the distribution of plasma MDS-OA&#946; levels and global amyloid-PET SUVRs according to tau pathology burden, participants were stratified into quartiles based on the tau PET meta-ROI SUVR. The mean &#177; standard deviation (SD) of plasma MDS-OA&#946; levels and amyloid plaque burden (measured by global amyloid PET SUVR) were calculated for each tau quartile. In addition, the distribution of these biomarkers was similarly analyzed based on Braak stage classifications (Supplementary Fig. 2).</p><p id="para0038">GLMs were used to examine the interaction effects between plasma MDS-OA&#946; levels and tau PET SUVR (meta-ROI) on depressive symptom scores, including the CSDD, HAM-D, and GDS-SV. All models were adjusted for age, sex, <italic toggle="yes">APOE</italic> &#949;4 carrier status, and global CDR score. A parallel analysis was conducted replacing plasma MDS-OA&#946; with global amyloid-PET SUVR. Linearity assumptions were assessed, and quadratic terms were incorporated in cases where non-linearity was detected. To control for multiple comparisons across models involving distinct depression scales and interaction terms, <italic toggle="yes">p</italic>-values were adjusted using the Benjamini&#8211;Hochberg false discovery rate (FDR) correction.</p><p id="para0039">To aid interpretation of interaction effects, simple effect analyses were performed using Type III ANOVA at predefined values of tau PET SUVR (&#8722;1 SD, mean, +1 SD), as well as Johnson&#8211;Neyman procedures to identify regions along the tau continuum where the association between amyloid pathology and depressive symptoms was statistically significant. As these procedures were intended for interpretative support rather than confirmatory inference, no additional multiple comparison correction was applied. Statistical significance was set at a two-tailed &#945; level of 0.05.</p><p id="para0040">To address concerns regarding diagnostic heterogeneity, supplementary GLMs and stratified simple slope analyses were also conducted after excluding participants with dementia (CDR = 1, <italic toggle="yes">n</italic> = 25). These analyses followed the same covariate adjustment and modeling procedures described above. Both unadjusted and FDR-adjusted <italic toggle="yes">p</italic>-values were reported to ensure transparency.</p><p id="para0041">In addition, to examine the main effects of each biomarker on depressive symptoms, we conducted univariate linear regression analyses with plasma MDS-OA&#946;, tau PET SUVR, and global A&#946;-PET SUVR as predictors and depression scores (CSDD, HAM-D, GDS-SV) as dependent variables. These analyses were unadjusted and intended to contextualize the presence or absence of direct effects. Results of these univariate regressions are presented in Supplementary Table S1 and illustrated in Supplementary Fig. S3.</p><p id="para0042">Finally, to further evaluate whether the observed interaction between plasma MDS-OA&#946; and tau PET SUVR was attributable to a specific amyloid subgroup, additional stratified analyses were conducted in individuals classified as A&#946;-PET positive (<italic toggle="yes">n</italic> = 64) and A&#946;-PET negative (<italic toggle="yes">n</italic> = 39) subgroups. GLMs were re-estimated using the same covariate structure and outcome variables (CSDD, HAM-D, and GDS-SV) within these subgroups.</p></sec></sec><sec id="sec0012"><label>3</label><title>Results</title><sec id="sec0013"><label>3.1</label><title>Characteristics of participants</title><p id="para0043">There were significant differences among NC, those with MCI, and amyloid-positive dementia patients in terms of <italic toggle="yes">APOE</italic> &#949;4 carrier status, global amyloid PET SUVR, amyloid positivity, and meta-ROI tau PET SUVR. As expected, significant group differences were also observed in CERAD total scores and MMSE scores (<xref rid="tbl0001" ref-type="table">Table 1</xref>). However, there were no significant differences across diagnostic groups in age, sex, years of education, or MDS-OA&#946; levels. Notably, depression scores that were measured by all three scales did not differ significantly between diagnostic groups.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Baseline demographic and clinical characteristics of the study participants.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">NC (<italic toggle="yes">N</italic> = 24)</th><th valign="top" colspan="1" rowspan="1">MCI (<italic toggle="yes">N</italic> = 54)</th><th valign="top" colspan="1" rowspan="1">A&#946;&#8209;PET (+) dementia (<italic toggle="yes">N</italic> = 25)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Age (mean &#177; SD, years)</td><td valign="top" colspan="1" rowspan="1">73.0 (7.8)</td><td valign="top" colspan="1" rowspan="1">75.1 (7.0)</td><td valign="top" colspan="1" rowspan="1">74.8 (7.6)</td><td valign="top" colspan="1" rowspan="1">0.486</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sex (female, %)</td><td valign="top" colspan="1" rowspan="1">17 (70.8 %)</td><td valign="top" colspan="1" rowspan="1">40 (74.1 %)</td><td valign="top" colspan="1" rowspan="1">18 (72.0 %)</td><td valign="top" colspan="1" rowspan="1">0.952</td></tr><tr><td valign="top" colspan="1" rowspan="1">Years of education (mean &#177; SD)</td><td valign="top" colspan="1" rowspan="1">9.7 (5.6)</td><td valign="top" colspan="1" rowspan="1">10.4 (4.6)</td><td valign="top" colspan="1" rowspan="1">11.1 (4.7)</td><td valign="top" colspan="1" rowspan="1">0.618</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">APOE</italic> &#949;4 carrier status (carrier, %)</td><td valign="top" colspan="1" rowspan="1">7 (29.2 %)</td><td valign="top" colspan="1" rowspan="1">14 (25.9 %)</td><td valign="top" colspan="1" rowspan="1">18 (72.0 %)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">CSDD (mean &#177; SD)</td><td valign="top" colspan="1" rowspan="1">6.6 (6.7)</td><td valign="top" colspan="1" rowspan="1">6.7 (4.6)</td><td valign="top" colspan="1" rowspan="1">6.0 (6.3)</td><td valign="top" colspan="1" rowspan="1">0.871</td></tr><tr><td valign="top" colspan="1" rowspan="1">HAM-D (mean &#177; SD)</td><td valign="top" colspan="1" rowspan="1">8.5 (7.0)</td><td valign="top" colspan="1" rowspan="1">8.8 (4.8)</td><td valign="top" colspan="1" rowspan="1">7.2 (5.0)</td><td valign="top" colspan="1" rowspan="1">0.474</td></tr><tr><td valign="top" colspan="1" rowspan="1">GDS-SV (mean &#177; SD)</td><td valign="top" colspan="1" rowspan="1">9.6 (7.7)</td><td valign="top" colspan="1" rowspan="1">10.8 (5.5)</td><td valign="top" colspan="1" rowspan="1">8.2 (6.0)</td><td valign="top" colspan="1" rowspan="1">0.230</td></tr><tr><td valign="top" colspan="1" rowspan="1">Plasma MDS-OA&#946; level (mean &#177; SD, ng/ml)</td><td valign="top" colspan="1" rowspan="1">0.58 (0.21)</td><td valign="top" colspan="1" rowspan="1">0.62 (0.30)</td><td valign="top" colspan="1" rowspan="1">0.63 (0.22)</td><td valign="top" colspan="1" rowspan="1">0.760</td></tr><tr><td valign="top" colspan="1" rowspan="1">Plasma MDS-OA&#946; risk (n, %)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.367</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Low</td><td valign="top" colspan="1" rowspan="1">19 (79.2 %)</td><td valign="top" colspan="1" rowspan="1">36 (66.7 %)</td><td valign="top" colspan="1" rowspan="1">16 (64.0 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Intermediate</td><td valign="top" colspan="1" rowspan="1">4 (16.7 %)</td><td valign="top" colspan="1" rowspan="1">11 (20.4 %)</td><td valign="top" colspan="1" rowspan="1">8 (32.0 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;High</td><td valign="top" colspan="1" rowspan="1">1 (4.2 %)</td><td valign="top" colspan="1" rowspan="1">7 (13.0 %)</td><td valign="top" colspan="1" rowspan="1">1 (4.0 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Global [<sup>18</sup>F] Flutemetamol SUVR<sub>PONS</sub> (mean &#177; SD)</td><td valign="top" colspan="1" rowspan="1">0.58 (0.21)</td><td valign="top" colspan="1" rowspan="1">0.68 (0.21)</td><td valign="top" colspan="1" rowspan="1">0.85 (0.09)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">[<sup>18</sup>F] Flutemetamol deposition (positivity, %)</td><td valign="top" colspan="1" rowspan="1">7 (29.2 %)</td><td valign="top" colspan="1" rowspan="1">32 (59.3 %)</td><td valign="top" colspan="1" rowspan="1">25 (100.0 %)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">Global [<sup>18</sup>F] Flortaucipir SUVR<sub>CEREBELLUM</sub> (mean &#177; SD)</td><td valign="top" colspan="1" rowspan="1">1.10 (0.07)</td><td valign="top" colspan="1" rowspan="1">1.20 (0.18)</td><td valign="top" colspan="1" rowspan="1">1.48 (0.20)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Braak I</td><td valign="top" colspan="1" rowspan="1">1.16 (0.20)</td><td valign="top" colspan="1" rowspan="1">1.51 (0.40)</td><td valign="top" colspan="1" rowspan="1">1.78 (0.24)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Braak III/IV</td><td valign="top" colspan="1" rowspan="1">1.15 (0.09)</td><td valign="top" colspan="1" rowspan="1">1.30 (0.24)</td><td valign="top" colspan="1" rowspan="1">1.63 (0.22)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Braak V/VI</td><td valign="top" colspan="1" rowspan="1">1.07 (0.07)</td><td valign="top" colspan="1" rowspan="1">1.16 (0.17)</td><td valign="top" colspan="1" rowspan="1">1.43 (0.21)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Temporal meta-ROI</td><td valign="top" colspan="1" rowspan="1">1.19 (0.14)</td><td valign="top" colspan="1" rowspan="1">1.44 (0.34)</td><td valign="top" colspan="1" rowspan="1">1.92 (0.33)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">Braak stage (n, %)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Braak 0</td><td valign="top" colspan="1" rowspan="1">19 (79.2 %)</td><td valign="top" colspan="1" rowspan="1">27 (50.0 %)</td><td valign="top" colspan="1" rowspan="1">2 (8.0 %)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Braak I</td><td valign="top" colspan="1" rowspan="1">4 (16.7 %)</td><td valign="top" colspan="1" rowspan="1">7 (13.0 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Braak III/IV</td><td valign="top" colspan="1" rowspan="1">1 (4.2 %)</td><td valign="top" colspan="1" rowspan="1">12 (22.2 %)</td><td valign="top" colspan="1" rowspan="1">6 (24.0 %)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Braak V/VI</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">8 (14.8 %)</td><td valign="top" colspan="1" rowspan="1">17 (68.0 %)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">CERAD-K Battery (mean &#177; SD)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;VF</td><td valign="top" colspan="1" rowspan="1">14.9 (4.3)</td><td valign="top" colspan="1" rowspan="1">10.6 (4.1)</td><td valign="top" colspan="1" rowspan="1">6.6 (3.0)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;BNT</td><td valign="top" colspan="1" rowspan="1">12.3 (2.0)</td><td valign="top" colspan="1" rowspan="1">10.2 (2.8)</td><td valign="top" colspan="1" rowspan="1">7.6 (3.2)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;MMSE</td><td valign="top" colspan="1" rowspan="1">27.0 (1.9)</td><td valign="top" colspan="1" rowspan="1">23.0 (3.8)</td><td valign="top" colspan="1" rowspan="1">17.4 (4.1)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;WLM</td><td valign="top" colspan="1" rowspan="1">18.5 (3.1)</td><td valign="top" colspan="1" rowspan="1">12.5 (3.3)</td><td valign="top" colspan="1" rowspan="1">8.6 (2.9)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;CP</td><td valign="top" colspan="1" rowspan="1">10.2 (0.9)</td><td valign="top" colspan="1" rowspan="1">9.6 (1.4)</td><td valign="top" colspan="1" rowspan="1">8.1 (2.4)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;WLR</td><td valign="top" colspan="1" rowspan="1">6.3 (1.3)</td><td valign="top" colspan="1" rowspan="1">2.6 (1.7)</td><td valign="top" colspan="1" rowspan="1">0.4 (0.7)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;WLRc</td><td valign="top" colspan="1" rowspan="1">9.2 (0.9)</td><td valign="top" colspan="1" rowspan="1">6.4 (2.6)</td><td valign="top" colspan="1" rowspan="1">1.7 (1.6)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;CR</td><td valign="top" colspan="1" rowspan="1">6.5 (2.6)</td><td valign="top" colspan="1" rowspan="1">2.5 (2.4)</td><td valign="top" colspan="1" rowspan="1">0.3 (1.1)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;CERAD total score</td><td valign="top" colspan="1" rowspan="1">71.2 (8.6)</td><td valign="top" colspan="1" rowspan="1">51.8 (11.4)</td><td valign="top" colspan="1" rowspan="1">32.9 (8.0)</td><td valign="top" colspan="1" rowspan="1">&lt; 0.001</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note.</bold> Data are presented as mean &#177; standard deviation (SD) for continuous variables and counts (percentages) for categorical variables. Group comparisons were conducted using ANOVA for continuous variables and chi-square tests for categorical variables. <bold>Abbreviations.</bold> NC, cognitively normal; MCI, mild cognitive impairment; CDR, Clinical Dementia Rating; CSDD, Cornell Scale for Depression in Dementia; HAM-D, Hamilton Depression Rating Scale; GDS-SV, a short version Geriatric Depression Scale; MDS-OA&#946;, Multimer Detection System&#8211;oligomeric amyloid-&#946;; SUVR<sub>PONS</sub>, standardized uptake value ratio of [<sup>18</sup>F] Flutemetamol, using the pons as a reference region; SUVR<sub>CEREBELLUM</sub>, standardized uptake value ratio of [<sup>18</sup>F] Flortaucipir, using the cerebellar cortex as a reference region; CERAD-K, Korean version of Consortium to Establish a Registry for Alzheimer&#8217;s Disease; VF, verbal fluency; BNT, Boston Naming Test; MMSE, the Korean version of the Mini-Mental Status Examination; WLM, Word List Memory; CP, Constructional Praxis; WLR, Word List Recall; WLRc, Word List Recognition; CERAD total score, composite score summing scores of the CERAD-K VF, BNT, WLM, CP, WLR, and WLRc domains.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0014"><label>3.2</label><title>Amyloid beta distribution by tau burden</title><p id="para0044">When tau PET SUVR was divided into quartiles, MDS-OA&#946; levels showed an increasing trend from the 1st to the 3rd quartile, followed by a decrease in the 4th quartile. In contrast, amyloid plaque burden measured by amyloid PET exhibited a continuous increase across all four tau quartiles. In addition, a similar pattern was observed when examining MDS-OA&#946; and global amyloid PET SUVR values across different Braak stages (Supplementary Fig. 2).</p></sec><sec id="sec0015"><label>3.3</label><title>Interaction between amyloid markers and tau on depression</title><p id="para0045">Significant negative interactions were observed between plasma MDS-OA&#946; and tau PET SUVR on all three depression scales: CSDD (&#946; = &#8722;17.418, 95 % CI: &#8722;29.194 to &#8722;5.641, FDR-adjusted <italic toggle="yes">p</italic> = 0.036), HAM-D (&#946; = &#8722;18.664, 95 % CI: &#8722;29.800 to &#8722;7.528, FDR-adjusted <italic toggle="yes">p</italic> = 0.018), and GDS-SV (&#946; = &#8722;18.185, 95 % CI: &#8722;31.162 to &#8722;5.207, FDR-adjusted <italic toggle="yes">p</italic> = 0.036) (<xref rid="tbl0002" ref-type="table">Table 2</xref>). In contrast, no significant interaction effects were observed between global A&#946;-PET SUVR and tau PET SUVR on any depression measure after FDR correction.<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Interaction effects between amyloid markers (plasma or PET) and tau PET SUVR on depressive symptom scores.</p></caption><alt-text id="alt0002">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Depression scale</th><th align="left" valign="top" colspan="1" rowspan="1">Amyloid Markers</th><th valign="top" colspan="1" rowspan="1">Independent variable</th><th valign="top" colspan="1" rowspan="1">Estimate (&#946;)</th><th valign="top" colspan="1" rowspan="1">95 % CI</th><th valign="top" colspan="1" rowspan="1">FDR-adj. <italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td rowspan="6" align="left" valign="top" colspan="1">CSDD</td><td rowspan="3" align="left" valign="top" colspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">Amyloid</td><td valign="top" colspan="1" rowspan="1">0.121</td><td valign="top" colspan="1" rowspan="1">(&#8722;3.802, 4.043)</td><td valign="top" colspan="1" rowspan="1">0.952</td></tr><tr><td valign="top" colspan="1" rowspan="1">Tau</td><td valign="top" colspan="1" rowspan="1">&#8722;1.234</td><td valign="top" colspan="1" rowspan="1">(&#8722;4.720, 2.253)</td><td valign="top" colspan="1" rowspan="1">0.625</td></tr><tr><td valign="top" colspan="1" rowspan="1">Amyloid &#215; Tau</td><td valign="top" colspan="1" rowspan="1">&#8722;17.418</td><td valign="top" colspan="1" rowspan="1">(&#8722;29.194, &#8722;5.641)</td><td valign="top" colspan="1" rowspan="1"><bold>0.036*</bold></td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">PET</td><td valign="top" colspan="1" rowspan="1">Amyloid</td><td valign="top" colspan="1" rowspan="1">7.340</td><td valign="top" colspan="1" rowspan="1">(&#8722;0.347, 15.028)</td><td valign="top" colspan="1" rowspan="1">0.183</td></tr><tr><td valign="top" colspan="1" rowspan="1">Tau</td><td valign="top" colspan="1" rowspan="1">&#8722;4.792</td><td valign="top" colspan="1" rowspan="1">(&#8722;9.285, &#8722;0.299)</td><td valign="top" colspan="1" rowspan="1">0.167</td></tr><tr><td valign="top" colspan="1" rowspan="1">Amyloid &#215; Tau</td><td valign="top" colspan="1" rowspan="1">22.395</td><td valign="top" colspan="1" rowspan="1">(&#8722;0.329, 45.118)</td><td valign="top" colspan="1" rowspan="1">0.183</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">HAM-D</td><td rowspan="3" align="left" valign="top" colspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">Amyloid</td><td valign="top" colspan="1" rowspan="1">1.900</td><td valign="top" colspan="1" rowspan="1">(&#8722;1.810, 5.6094)</td><td valign="top" colspan="1" rowspan="1">0.515</td></tr><tr><td valign="top" colspan="1" rowspan="1">Tau</td><td valign="top" colspan="1" rowspan="1">&#8722;1.485</td><td valign="top" colspan="1" rowspan="1">(&#8722;4.782, 1.8125)</td><td valign="top" colspan="1" rowspan="1">0.525</td></tr><tr><td valign="top" colspan="1" rowspan="1">Amyloid &#215; Tau</td><td valign="top" colspan="1" rowspan="1">&#8722;18.664</td><td valign="top" colspan="1" rowspan="1">(&#8722;29.800, &#8722;7.528)</td><td valign="top" colspan="1" rowspan="1"><bold>0.018*</bold></td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">PET</td><td valign="top" colspan="1" rowspan="1">Amyloid</td><td valign="top" colspan="1" rowspan="1">3.387</td><td valign="top" colspan="1" rowspan="1">(&#8722;4.153, 10.927)</td><td valign="top" colspan="1" rowspan="1">0.525</td></tr><tr><td valign="top" colspan="1" rowspan="1">Tau</td><td valign="top" colspan="1" rowspan="1">&#8722;3.142</td><td valign="top" colspan="1" rowspan="1">(&#8722;7.549, 1.265)</td><td valign="top" colspan="1" rowspan="1">0.292</td></tr><tr><td valign="top" colspan="1" rowspan="1">Amyloid &#215; Tau</td><td valign="top" colspan="1" rowspan="1">7.306</td><td valign="top" colspan="1" rowspan="1">(&#8722;14.982, 29.594)</td><td valign="top" colspan="1" rowspan="1">0.625</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">GDS-SV</td><td rowspan="3" align="left" valign="top" colspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">Amyloid</td><td valign="top" colspan="1" rowspan="1">0.851</td><td valign="top" colspan="1" rowspan="1">(&#8722;3.472, 5.174)</td><td valign="top" colspan="1" rowspan="1">0.741</td></tr><tr><td valign="top" colspan="1" rowspan="1">Tau</td><td valign="top" colspan="1" rowspan="1">&#8722;0.948</td><td valign="top" colspan="1" rowspan="1">(&#8722;4.791, 2.894)</td><td valign="top" colspan="1" rowspan="1">0.708</td></tr><tr><td valign="top" colspan="1" rowspan="1">Amyloid &#215; Tau</td><td valign="top" colspan="1" rowspan="1">&#8722;18.185</td><td valign="top" colspan="1" rowspan="1">(&#8722;31.162, &#8722;5.207)</td><td valign="top" colspan="1" rowspan="1"><bold>0.036*</bold></td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">PET</td><td valign="top" colspan="1" rowspan="1">Amyloid</td><td valign="top" colspan="1" rowspan="1">6.171</td><td valign="top" colspan="1" rowspan="1">(&#8722;2.358, 14.700)</td><td valign="top" colspan="1" rowspan="1">0.292</td></tr><tr><td valign="top" colspan="1" rowspan="1">Tau</td><td valign="top" colspan="1" rowspan="1">&#8722;3.973</td><td valign="top" colspan="1" rowspan="1">(&#8722;8.958, 1.012)</td><td valign="top" colspan="1" rowspan="1">0.292</td></tr><tr><td valign="top" colspan="1" rowspan="1">Amyloid &#215; Tau</td><td valign="top" colspan="1" rowspan="1">18.818</td><td valign="top" colspan="1" rowspan="1">(&#8722;6.393, 44.029)</td><td valign="top" colspan="1" rowspan="1">0.292</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note.</bold> GLMs were used to examine the interaction between amyloid markers (MDS-OA&#946; or global A&#946;-PET SUVR) and tau PET SUVR (meta-ROI) on depressive symptom scores measured using the CSDD, HAM-D, and GDS-SV. Covariates included age, sex, <italic toggle="yes">APOE</italic> &#949;4 carrier status, and global CDR score. <italic toggle="yes">P</italic>-values were adjusted for multiple comparisons using the Benjamini&#8211;Hochberg false discovery rate (FDR) correction. *<italic toggle="yes">P</italic> &lt; 0.05. <bold>Abbreviations.</bold> Same as in <xref rid="tbl0001" ref-type="table">Table 1</xref>, except: CI, confidence interval; GLM, generalized linear model; FDR, false discovery rate.</p></fn></table-wrap-foot></table-wrap></p><p id="para0046">To address potential diagnostic heterogeneity, supplementary analyses were conducted after excluding participants with dementia (<italic toggle="yes">n</italic> = 25). The interaction effects between plasma MDS-OA&#946; and tau PET SUVR on depressive symptoms remained in the same negative direction across all three scales (CSDD: &#946; = &#8211;6.554, 95 % CI: &#8211;21.084 to 7.975, FDR-adjusted <italic toggle="yes">p</italic> = 0.460; HAM-D: &#946; = &#8211;10.011, 95 % CI: &#8211;24.681 to 4.660, FDR-adjusted <italic toggle="yes">p</italic> = 0.272; GDS-SV: &#946; = &#8211;8.952, 95 % CI: &#8211;25.858 to 7.955, FDR-adjusted <italic toggle="yes">p</italic> = 0.401), albeit with reduced statistical significance due to smaller sample size (Supplementary Table S2). Interaction effects between A&#946;-PET SUVR and tau remained nonsignificant.</p></sec><sec id="sec0016"><label>3.4</label><title>Simple effects of amyloid markers by tau PET SUVR levels</title><p id="para0047">For CSDD, among individuals with low tau burden (Tau &#8722;1 SD), higher MDS-OA&#946; levels were significantly associated with increased depression scores (&#946; = 7.070, 95 % CI: 0.954 to 13.187, <italic toggle="yes">p</italic> = 0.024). In contrast, in the high tau group (Tau +1 SD), higher MDS-OA&#946; levels were significantly associated with decreased depression scores (&#946; = &#8722;6.829, 95 % CI: &#8722;13.111 to &#8722;0.547, <italic toggle="yes">p</italic> = 0.033). A similar trend was observed when depression was measured by HAM-D (Tau &#8722;1 SD: &#946; = 9.350, 95 % CI: 3.560 to 15.131, <italic toggle="yes">p</italic> = 0.002; Tau +1 SD: &#946; = &#8722;5.550, 95 % CI: &#8722;11.490 to 0.394, <italic toggle="yes">p</italic> = 0.067) and GDS-SV (Tau &#8722;1 SD: &#946; = 8.106, 95 % CI: 1.370 to 14.847, <italic toggle="yes">p</italic> = 0.019; Tau +1 SD: &#946; = &#8722;6.405, 95 % CI: &#8722;13.330 to 0.518, <italic toggle="yes">p</italic> = 0.069) (<xref rid="tbl0003" ref-type="table">Table 3</xref> and <xref rid="fig0001" ref-type="fig">Fig. 1</xref>).<table-wrap position="float" id="tbl0003" orientation="portrait"><label>Table 3</label><caption><p>Simple effect analyses examining the association between amyloid markers and depressive symptom scores stratified by tau PET SUVR.</p></caption><alt-text id="alt0003">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Depression scale</th><th align="left" valign="top" colspan="1" rowspan="1">Tau SUVR level</th><th valign="top" colspan="1" rowspan="1">Amyloid marker</th><th valign="top" colspan="1" rowspan="1">Estimate (&#946;)</th><th valign="top" colspan="1" rowspan="1">95 % CI</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td rowspan="6" align="left" valign="top" colspan="1">CSDD</td><td rowspan="2" align="left" valign="top" colspan="1">&#8722;1 SD</td><td valign="top" colspan="1" rowspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">7.070</td><td valign="top" colspan="1" rowspan="1">(0.954, 13.187)</td><td valign="top" colspan="1" rowspan="1"><bold>0.024*</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">PET</td><td valign="top" colspan="1" rowspan="1">&#8722;1.600</td><td valign="top" colspan="1" rowspan="1">(&#8722;9.644, 6.450)</td><td valign="top" colspan="1" rowspan="1">0.695</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Mean</td><td valign="top" colspan="1" rowspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">0.121</td><td valign="top" colspan="1" rowspan="1">(&#8722;3.853, 4.094)</td><td valign="top" colspan="1" rowspan="1">0.952</td></tr><tr><td valign="top" colspan="1" rowspan="1">PET</td><td valign="top" colspan="1" rowspan="1">7.340</td><td valign="top" colspan="1" rowspan="1">(&#8722;0.446, 15.130)</td><td valign="top" colspan="1" rowspan="1">0.064</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">+1SD</td><td valign="top" colspan="1" rowspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">&#8722;6.829</td><td valign="top" colspan="1" rowspan="1">(&#8722;13.111, &#8722;0.547)</td><td valign="top" colspan="1" rowspan="1"><bold>0.033*</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">PET</td><td valign="top" colspan="1" rowspan="1">16.280</td><td valign="top" colspan="1" rowspan="1">(1.271, 31.280)</td><td valign="top" colspan="1" rowspan="1"><bold>0.034*</bold></td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">HAM-D</td><td rowspan="2" align="left" valign="top" colspan="1">&#8722;1 SD</td><td valign="top" colspan="1" rowspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">9.350</td><td valign="top" colspan="1" rowspan="1">(3.560, 15.131)</td><td valign="top" colspan="1" rowspan="1"><bold>0.002</bold> **</td></tr><tr><td valign="top" colspan="1" rowspan="1">PET</td><td valign="top" colspan="1" rowspan="1">0.472</td><td valign="top" colspan="1" rowspan="1">(&#8722;7.420, 8.370)</td><td valign="top" colspan="1" rowspan="1">0.906</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Mean</td><td valign="top" colspan="1" rowspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">1.900</td><td valign="top" colspan="1" rowspan="1">(&#8722;1.860, 5.657)</td><td valign="top" colspan="1" rowspan="1">0.318</td></tr><tr><td valign="top" colspan="1" rowspan="1">PET</td><td valign="top" colspan="1" rowspan="1">3.387</td><td valign="top" colspan="1" rowspan="1">(&#8722;4.250, 11.020)</td><td valign="top" colspan="1" rowspan="1">0.381</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">+1SD</td><td valign="top" colspan="1" rowspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">&#8722;5.550</td><td valign="top" colspan="1" rowspan="1">(&#8722;11.490, 0.394)</td><td valign="top" colspan="1" rowspan="1">0.067</td></tr><tr><td valign="top" colspan="1" rowspan="1">PET</td><td valign="top" colspan="1" rowspan="1">6.303</td><td valign="top" colspan="1" rowspan="1">(&#8722;8.410, 21.020)</td><td valign="top" colspan="1" rowspan="1">0.397</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">GDS-SV</td><td rowspan="2" align="left" valign="top" colspan="1">&#8722;1 SD</td><td valign="top" colspan="1" rowspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">8.106</td><td valign="top" colspan="1" rowspan="1">(1.370, 14.847)</td><td valign="top" colspan="1" rowspan="1"><bold>0.019*</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">PET</td><td valign="top" colspan="1" rowspan="1">&#8722;1.340</td><td valign="top" colspan="1" rowspan="1">(&#8722;10.270, 7.590)</td><td valign="top" colspan="1" rowspan="1">0.767</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Mean</td><td valign="top" colspan="1" rowspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">0.851</td><td valign="top" colspan="1" rowspan="1">(&#8722;3.530, 5.229)</td><td valign="top" colspan="1" rowspan="1">0.701</td></tr><tr><td valign="top" colspan="1" rowspan="1">PET</td><td valign="top" colspan="1" rowspan="1">6.170</td><td valign="top" colspan="1" rowspan="1">(&#8722;2.470, 14.810)</td><td valign="top" colspan="1" rowspan="1">0.159</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">+1SD</td><td valign="top" colspan="1" rowspan="1">OA&#946;</td><td valign="top" colspan="1" rowspan="1">&#8722;6.405</td><td valign="top" colspan="1" rowspan="1">(&#8722;13.330, 0.518)</td><td valign="top" colspan="1" rowspan="1">0.069</td></tr><tr><td valign="top" colspan="1" rowspan="1">PET</td><td valign="top" colspan="1" rowspan="1">13.680</td><td valign="top" colspan="1" rowspan="1">(&#8722;2.970, 30.330)</td><td valign="top" colspan="1" rowspan="1">0.106</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note.</bold> Simple effect analyses were conducted to clarify the interaction between amyloid markers (MDS-OA&#946; or global A&#946;-PET SUVR) and tau PET SUVR on depressive symptoms. Associations were evaluated at three stratified levels of tau PET SUVR (&#8722;1 SD, mean, and +1 SD) using Type III sum-of-squares ANOVA. Statistical significance was assessed using chi-square tests (two-tailed <italic toggle="yes">p</italic> &lt; 0.05). All models were adjusted for age, sex, <italic toggle="yes">APOE</italic> &#949;4 carrier status, and global CDR score. *<italic toggle="yes">p</italic> &lt; 0.05, <sup>&#8270;&#8270;</sup><italic toggle="yes">p</italic> &lt; 0.01. <bold>Abbreviations.</bold> Same as in <xref rid="tbl0001" ref-type="table">Table 1</xref>, except: CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Differential associations between amyloid biomarkers and depressive symptoms across tau pathology levels.</p><p>Note. General linear models (GLMs) were constructed to test interaction effects between amyloid markers (plasma MDS-OA&#946; and global A&#946;-PET SUVR) and tau PET SUVR (meta-ROI) on depression severity measured by CSDD, HAM-D, and GDS-SV. All models were adjusted for age, sex, <italic toggle="yes">APOE</italic> &#949;4 carrier status, and global CDR score. <italic toggle="yes">P</italic>-values were adjusted for multiple comparisons using the Benjamini&#8211;Hochberg false discovery rate (FDR) correction. *<italic toggle="yes">P</italic> &lt; 0.05. Abbreviations. Same as in <xref rid="tbl0001" ref-type="table">Table 1</xref>.</p></caption><alt-text id="alt0004">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="para0048">With regards to amyloid plaque burden, no significant association with CSDD scores was found in the low tau group (&#946; = &#8722;1.600, 95 % CI: &#8722;9.644 to 6.450, <italic toggle="yes">p</italic> = 0.695). However, in the high tau group, greater plaque burden was significantly associated with higher depression scores (&#946; = 7.560, 95 % CI: 1.271 to 31.280, <italic toggle="yes">p</italic> = 0.034). No significant associations were observed between amyloid plaque and depression when using HAM-D (Tau &#8722;1 SD: &#946; = 0.472, 95 % CI: &#8722;7.420 to 8.370, <italic toggle="yes">p</italic> = 0.906; Tau +1 SD: &#946; = 6.303, 95 % CI: &#8722;8.410 to 21.020, <italic toggle="yes">p</italic> = 0.397) or GDS-SV (Tau &#8722;1 SD: &#946; = &#8722;1.340, 95 % CI: &#8722;10.270 to 7.590, <italic toggle="yes">p</italic> = 0.767; Tau +1 SD: &#946; = 13.680, 95 % CI: &#8722;2.970 to 30.330, <italic toggle="yes">p</italic> = 0.106) (<xref rid="tbl0003" ref-type="table">Table 3</xref> and <xref rid="fig0001" ref-type="fig">Fig. 1</xref>).</p><p id="para0049">To examine whether the observed associations were influenced by the inclusion of participants with dementia, simple slope analyses were repeated after excluding dementia cases (<italic toggle="yes">n</italic> = 25). The direction and magnitude of the associations between plasma MDS-OA&#946; and depressive symptom scores remained similar across stratified tau PET SUVR levels. In the low tau group, MDS-OA&#946; was positively associated with HAM-D (&#946; = 9.010, <italic toggle="yes">p</italic> = 0.010), and this association was reduced in the high tau group (&#946; = 2.720, <italic toggle="yes">p</italic> = 0.370). For A&#946;-PET SUVR, the estimated effect size on CSDD was greater in the high tau group (&#946; = 8.337, <italic toggle="yes">p</italic> = 0.201) than in the low tau group (&#946; = &#8211;0.857, <italic toggle="yes">p</italic> = 0.856). Full results are reported in Supplementary Table S3.</p></sec><sec id="sec0017"><label>3.5</label><title>Cutoff points of meta-ROI tau SUVR where the direction of association between amyloid beta and depression scores changed</title><p id="para0050">According to the Johnson-Neyman plots, the meta-ROI tau PET SUVR thresholds at which the positive association between MDS-OA&#946; levels and depression scores ceased to be significant were 1.205 for CSDD, 1.389 for HAM-D, and 1.247 for GDS-SV. The cutoff points at which the reverse (negative) association became statistically significant were 1.832, 1.937, and 1.964, respectively. In the case of amyloid plaque burden, a significant positive association with depression was observed only for CSDD, and only when tau PET SUVR exceeded 1.551 (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>).<fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Tau PET SUVR thresholds moderating the association between amyloid biomarkers and depressive symptom scores.</p><p>Note. Johnson&#8211;Neyman plots illustrate tau PET SUVR levels at which the association between amyloid biomarkers (plasma MDS-OA&#946; or global A&#946;-PET SUVR) and depression scores (CSDD, HAM-D, GDS-SV) reached statistical significance. Shaded regions denote confidence bands, and colored segments indicate significant regions (<italic toggle="yes">P</italic> &lt; 0.05). All models were adjusted for age, sex, <italic toggle="yes">APOE</italic> &#949;4 carrier status, and global CDR score. Abbreviations. Same as in <xref rid="tbl0001" ref-type="table">Table 1</xref>.</p></caption><alt-text id="alt0005">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec0018"><label>3.6</label><title>Stratified analysis by A&#946;-PET status</title><p id="para0051">To evaluate whether the interaction between plasma MDS-OA&#946; and tau PET SUVR was preserved among individuals with confirmed amyloid pathology, stratified analyses were conducted within the A&#946;-PET positive subgroup (<italic toggle="yes">n</italic> = 64). As summarized in Supplementary Table S4, the interaction remained statistically significant for the CSDD (&#946; = &#8211;18.856, 95 % CI: &#8211;36.432 to &#8211;1.281, <italic toggle="yes">p</italic> = 0.035) and HAM-D (&#946; = &#8211;17.354, 95 % CI: &#8211;33.565 to &#8211;1.143, <italic toggle="yes">p</italic> = 0.036), and marginally significant for the GDS-SV (&#946; = &#8211;18.134, 95 % CI: &#8211;36.580 to 0.312, <italic toggle="yes">p</italic> = 0.054).</p><p id="para0052">Additionally, simple effect analyses were conducted at stratified levels of tau PET SUVR (&#8211;1 SD, mean, +1 SD) within the A&#946;-PET positive subgroup. Higher plasma MDS-OA&#946; levels were associated with lower depressive symptom scores at high tau PET SUVR (+1 SD) across all depression measures: CSDD (&#946; = &#8211;11.18, 95 % CI: &#8211;20.70 to &#8211;1.66, <italic toggle="yes">p</italic> = 0.022), HAM-D (&#946; = &#8211;8.91, 95 % CI: &#8211;17.69 to &#8211;0.13, <italic toggle="yes">p</italic> = 0.047), and GDS-SV (&#946; = &#8211;10.64, 95 % CI: &#8211;20.63 to &#8211;0.65, <italic toggle="yes">p</italic> = 0.037). No significant associations were observed at low or mean tau PET SUVR levels. Full results are provided in Supplementary Table S5.</p><p id="para0053">To complement these findings, analyses were also conducted within the A&#946;-PET negative subgroup (<italic toggle="yes">n</italic> = 39). In this group, the interaction between plasma MDS-OA&#946; and tau PET SUVR was not statistically significant for any depression measures (all <italic toggle="yes">p</italic> &gt; 0.3, Supplementary Table S4). Simple effect analyses were additionally performed for completeness, and the full results are summarized in Supplementary Table S5.</p></sec></sec><sec id="sec0019"><label>4</label><title>Discussion</title><p id="para0054">In the current study, only soluble A&#946; (MDS-OA&#946;), but not plaque A&#946; measured by amyloid PET, showed significant interactions with tau pathology in predicting depressive symptoms. Specifically, significant negative interactions were observed between MDS-OA&#946; and tau PET SUVR across all three depression measures, whereas no significant interaction was found for A&#946;-PET SUVR. This dissociation highlights the distinct temporal and mechanistic roles of soluble amyloid-&#946; oligomers and insoluble amyloid plaques in neuropsychiatric outcomes. Among participants with low tau SUVR, higher MDS-OA&#946; levels were positively associated with depressive symptoms, whereas this association was reversed in participants with high tau SUVR. In other words, MDS-OA&#946; and tau SUVR exhibited a significant negative interaction across the tau continuum. Supporting this pattern, stratified analyses restricted to the A&#946;-PET positive subgroup demonstrated a significant interaction between plasma MDS-OA&#946; and tau PET SUVR on depressive symptoms, reinforcing the robustness of this effect in individuals with confirmed amyloid pathology. Notably, in univariate analyses, none of the individual biomarkers were significantly associated with depression scores across the three measures. This underscores the importance of considering tau pathology as a moderator, rather than a direct correlate of depressive symptoms. The combination of non-significant main effects and significant interaction effects supports a model wherein the influence of amyloid pathology on mood symptoms depends on the level of tau burden.</p><p id="para0055">This result may be explained by previous studies suggesting that OA&#946; levels tend to peak before substantial tau deposition occurs in the brain and gradually decline thereafter [<xref rid="bib0042" ref-type="bibr">42</xref>]. Thus, in participants at an early stage with low tau deposition, neurotoxicity from oligomeric amyloid beta may have contributed to depressive symptoms. Previous animal studies have shown that OA&#946; contributes to the onset and exacerbation of depressive symptoms. Proposed mechanisms include synaptic dysfunction, neuroinflammation, and region-specific imbalances in monoamines and nerve growth factor within the brain [<xref rid="bib0043" ref-type="bibr">43</xref>,<xref rid="bib0044" ref-type="bibr">44</xref>]. Conversely, in participants at a more advanced stage with high tau deposition, OA&#946; levels likely declined due to conversion into amyloid plaques [<xref rid="bib0042" ref-type="bibr">42</xref>], and depressive symptoms may have been more directly driven by the increasing tau pathology [<xref rid="bib0011" ref-type="bibr">11</xref>]. Supporting this explanation, ANOVA analysis across tau SUVR level quartiles and Braak stages in the present study showed that while MDS-OA&#946; levels initially increased with tau levels, they declined in the highest tau quartile. In contrast, amyloid plaque levels (global amyloid PET SUVR) continued to increase linearly (Supplementary Fig. S2).</p><p id="para0056">A minor but noteworthy finding was that, although not consistently across all depression measures, in the high tau group, global amyloid PET SUVR showed a positive association with depression. As previously reported, the formation of amyloid plaques tends to occur in a timeframe similar to tau deposition [<xref rid="bib0042" ref-type="bibr">42</xref>]. Therefore, in the high tau group of this study, it is plausible that depressive symptoms were more directly related to deposited tau rather than the plaques themselves. Nonetheless, the neurotoxicity of the plaques may also have contributed to depressive symptoms. Supporting this, previous studies have reported a significant association between amyloid plaques measured by amyloid PET and depressive symptoms [<xref rid="bib0045" ref-type="bibr">45</xref>,<xref rid="bib0046" ref-type="bibr">46</xref>]. However, studies that examined the relationship between pre-mortem depressive symptoms and postmortem amyloid plaque burden in older adult cohorts have shown mixed evidence [<xref rid="bib0047" ref-type="bibr">[47]</xref>, <xref rid="bib0048" ref-type="bibr">[48]</xref>, <xref rid="bib0049" ref-type="bibr">[49]</xref>]. In the present study, the effect of amyloid plaques on depressive symptoms was smaller than that of OA&#946;. Considering the typical sequence of AD pathology that is amyloid accumulation, followed by tau deposition, and eventually widespread neurodegeneration [<xref rid="bib0050" ref-type="bibr">50</xref>], this finding might suggest that depressive symptoms emerging as a prodrome before substantial neurodegeneration in AD might be more strongly driven by OA&#946; than by amyloid plaque accumulation.</p><p id="para0057">According to the Johnson-Neyman plot, MDS-OA&#946; was positively associated with depression at tau SUVR levels between 1.2 and 1.4. This corresponds well with previously established thresholds from visual reads of meta-ROI tau SUVR, such as 1.41, or +2 SD above the mean of amyloid-negative controls, which is approximately 1.28 [<xref rid="bib0051" ref-type="bibr">51</xref>]. These findings may indicate that OA&#946; is more strongly related to depressive symptoms during earlier stages of tau pathology, prior to reaching established thresholds of abnormal tau accumulation. While no clear association was observed when OA&#946; levels were examined across tau SUVR quartiles, a modest inverted-U pattern emerged when stratifying participants by Braak stage, suggesting stage-dependent dynamics in OA&#946; burden (Supplementary Fig. S2). In contrast, at higher tau SUVR levels (1.832, 1.937, and 1.964), the association between MDS-OA&#946; and depressive symptoms became significantly negative. These tau levels are consistent with prior evidence indicating abnormal tau accumulation extending into the temporal neocortex, corresponding to more advanced Braak stages [<xref rid="bib0052" ref-type="bibr">52</xref>]. At these later stages, the association patterns may reflect a shift wherein OA&#946; levels are reduced due to plaque conversion, and depressive symptoms may be more closely linked to the extent of tau-related neurobiological alterations. This interpretation is further supported by the observed distributional patterns of MDS-OA&#946; and A&#946;-PET SUVR across tau strata in the current study (Supplementary Fig. S2).</p><p id="para0058">Regarding amyloid plaque, a significant positive association with depression was observed only in the CSDD at tau SUVR &#8805; 1.551. Previous research suggests that a meta-ROI SUVR in the 1.5 range likely reflects the transition between Braak stages II and III, indicating tau pathology is expanding beyond the mesial temporal lobe to the lateral temporal neocortex [<xref rid="bib0053" ref-type="bibr">53</xref>]. This phase also corresponds to a period of accelerated neurodegeneration, during which amyloid plaque might contribute to depressive symptoms. However, this association was not replicated using other depression measures such as HAM-D or GDS-SV.</p><p id="para0059">This discrepancy may be due to differences in the characteristics of the depression rating scales. The CSDD is considered more reliable for assessing depression in patients with dementia compared to other scales, as it captures a broader range of depression-related features unique to dementia and incorporates both patient and informant input [<xref rid="bib0039" ref-type="bibr">39</xref>,<xref rid="bib0054" ref-type="bibr">54</xref>]. In contrast, the GDS-SV is a self-report measure and may be less reliable in individuals with cognitive impairment [<xref rid="bib0055" ref-type="bibr">55</xref>], while the HAM-D may underreport depressive symptoms in apathetic dementia patients [<xref rid="bib0056" ref-type="bibr">56</xref>,<xref rid="bib0057" ref-type="bibr">57</xref>]. Thus, the observed amyloid plaque effect on depression in the high tau group may have only reached statistical significance when assessed with the CSDD.</p><p id="para0060">Nevertheless, these results should be interpreted with caution in view of several limitations inherent to the study, and they underscore the need for future research. First, due to the cross-sectional design, causal relationships among OA&#946;, tau, and depressive symptoms cannot be established. Prospective longitudinal studies are required to elucidate the temporal sequence and potential causality underlying these associations. Although we conducted descriptive stratifications of plasma MDS-OA&#946; and global amyloid-PET SUVR across tau PET quartiles and Braak stages, we acknowledge that the absence of clear monotonic trends in these biomarker distributions may limit the interpretability of visual inspection. Accordingly, the interpretation of our findings has been grounded in model-based statistical analyses rather than descriptive stratification, and the presented interaction effects should be interpreted within this analytical framework. This methodological emphasis is critical given the potential for misinterpretation when relying solely on visual inferences from subgroup stratifications, and future studies employing longitudinal designs and alternative statistical modeling approaches are warranted to validate the observed interaction patterns. Second, although we measured the burden of A&#946; oligomers, this study did not include direct assessment of soluble tau species. As tau pathology may contribute to depressive symptoms, the lack of soluble tau data might have led to an underestimation of its impact. Third, the study was conducted within a single-center East Asian cohort, which may restrict the generalizability of the findings due to possible selection bias and known racial and ethnic variations in AD pathophysiology and depression vulnerability. Fourth, while the MDS reflects the propensity for A&#946; oligomerization rather than providing absolute quantification, it remains effective in distinguishing oligomers from monomers and in capturing relative changes in oligomer levels [<xref rid="bib0014" ref-type="bibr">14</xref>,<xref rid="bib0058" ref-type="bibr">58</xref>]. Longitudinal studies with extended follow-up are warranted to clarify the progression of AD-related pathologies and their relationship to depression over time.</p><p id="para0061">In conclusion, the present study suggests that MDS-OA&#946; is significantly associated with the severity of depressive symptoms prior to the substantial accumulation of tau pathology. However, in individuals with advanced tau pathology involving widespread neocortical regions, tau deposition itself or possibly amyloid plaque burden may have a stronger association with depressive symptoms than plasma MDS-OA&#946; levels. These findings suggest that plasma MDS-OA&#946; may serve as a potential biomarker for identifying early affective manifestations of AD, prior to the emergence of advanced tau pathology. Furthermore, this biomarker may assist in refining clinical stratification and guiding the design of research protocols targeting early neuropsychiatric phenotypes within the AD continuum.</p></sec><sec id="sec0020"><title>Funding</title><p id="para0062">This research was supported by the Basic Science Research Program through the <funding-source id="gs0001"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source> (NRF) funded by the Ministry of Education (<award-id award-type="grant" rid="gs0001">2022R1I1A1A01053710</award-id>); a research fund of <funding-source id="gs0002">Seoul St. Mary&#8217;s Hospital, the Catholic University of Korea</funding-source> (<award-id award-type="grant" rid="gs0002">ZC23TISI0860</award-id>); the Culture, Sports, and Tourism R&amp;D Program through the <funding-source id="gs0003"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100006465</institution-id><institution>Korea Creative Content Agency</institution></institution-wrap></funding-source> grant funded by the Ministry of Culture, Sports, and Tourism of Korea in 2023 (<award-id award-type="grant" rid="gs0003">R2022020030</award-id>); the Basic Medical Science Facilitation Program through the Catholic Medical Center of the Catholic University of Korea funded by the Catholic Education Foundation; and the Institute of Clinical Medicine Research at Yeouido St. Mary&#8217;s Hospital, the <funding-source id="gs0004"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002648</institution-id><institution>Catholic University of Korea</institution></institution-wrap></funding-source>.</p></sec><sec sec-type="data-availability" id="sec0021"><title>Availability of data and materials</title><p id="para0063">The datasets generated or analyzed during the current study are not publicly available due to the Patient Data Management Protocol of Yeouido Saint Mary&#8217;s Hospital but are available from the corresponding author upon reasonable request.</p></sec><sec id="sec0021a"><title>CRediT authorship contribution statement</title><p id="para0063a"><bold>Gihwan Byeon:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Software, Resources, Methodology, Investigation, Formal analysis, Conceptualization. <bold>Suhyung Kim:</bold> Validation, Resources, Investigation, Data curation. <bold>Sunghwan Kim:</bold> Validation, Project administration, Methodology, Investigation, Data curation. <bold>Yoo Hyun Um:</bold> Validation, Resources, Project administration, Methodology, Investigation, Data curation. <bold>Sheng-Min Wang:</bold> Validation, Software, Resources, Project administration, Methodology, Investigation, Data curation. <bold>Seunggyun Ha:</bold> Validation, Resources, Methodology, Investigation, Data curation. <bold>Sonya Youngju Park:</bold> Software, Resources, Methodology, Investigation, Data curation. <bold>Yeong Sim Choe:</bold> Resources, Project administration, Methodology, Investigation, Data curation. <bold>Donghyeon Kim:</bold> Validation, Software, Resources, Methodology, Investigation, Data curation. <bold>Hyun Kook Lim:</bold> Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Data curation, Conceptualization. <bold>Chang Uk Lee:</bold> Validation, Resources, Methodology, Investigation, Data curation. <bold>Dong Woo Kang:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0066">Hyun Kook Lim was employed by NEUROPHET Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest. The data processing services provided by NEUROPHET Inc. were used to enhance the quality and analysis of the brain imaging data collected during the study. The authors declare that the research outcomes and conclusions remain unbiased and are not influenced by any commercial interests associated with NEUROPHET Inc.'s products or services.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><collab>GBD 2019 Dementia Forecasting Collaborators</collab></person-group><article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet Public Health</source><volume>7</volume><year>2022</year><fpage>e105</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Volkert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>H.</given-names></name><name name-style="western"><surname>H&#228;rter</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The prevalence of mental disorders in older people in Western countries: a meta-analysis</article-title><source>Ageing Res Rev</source><volume>12</volume><year>2013</year><fpage>339</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2012.09.004</pub-id><pub-id pub-id-type="pmid">23000171</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Andreasen</surname><given-names>P.</given-names></name><name name-style="western"><surname>L&#246;nnroos</surname><given-names>E.</given-names></name><name name-style="western"><surname>von Euler-Chelpin</surname><given-names>M.C</given-names></name></person-group><article-title>Prevalence of depression among older adults with dementia living in low- and middle-income countries: a cross-sectional study</article-title><source>Eur J Public Health</source><volume>24</volume><year>2014</year><fpage>40</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1093/eurpub/ckt087</pub-id><pub-id pub-id-type="pmid">23417621</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;iz-V&#225;zquez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gracia-Garc&#237;a</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ubillos-Landa</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Depression as a risk factor for Alzheimer&#8217;s disease: a systematic review of longitudinal meta-analyses</article-title><source>J Clin Med</source><volume>10</volume><year>2021</year><fpage>1809</fpage><pub-id pub-id-type="doi">10.3390/jcm10091809</pub-id><pub-id pub-id-type="pmid">33919227</pub-id><pub-id pub-id-type="pmcid">PMC8122638</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Diniz</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Butters</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Late-life depression and risk of vascular dementia and Alzheimer&#8217;s disease: systematic review and meta-analysis of community-based cohort studies</article-title><source>Br J Psychiatry</source><volume>202</volume><year>2013</year><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.111.101931</pub-id><pub-id pub-id-type="pmid">23637108</pub-id><pub-id pub-id-type="pmcid">PMC3640214</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Ittner</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>G&#246;tz</surname><given-names>J.</given-names></name></person-group><article-title>Amyloid-&#946; and tau&#8212;A toxic pas de deux in Alzheimer&#8217;s disease</article-title><source>Nat Rev Neurosci</source><volume>12</volume><year>2011</year><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/nrn2967</pub-id><pub-id pub-id-type="pmid">21193853</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Twait</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kamarioti</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis</article-title><source>Transl Psychiatry</source><volume>14</volume><year>2024</year><fpage>25</fpage><pub-id pub-id-type="doi">10.1038/s41398-024-02807-6</pub-id><pub-id pub-id-type="pmid">38225253</pub-id><pub-id pub-id-type="pmcid">PMC10789765</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Wiels</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Oomens</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Engelborghs</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Depressive symptoms and amyloid pathology</article-title><source>JAMA Psychiatry</source><volume>82</volume><year>2025</year><fpage>296</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2025.0123</pub-id><pub-id pub-id-type="pmid">39841452</pub-id><pub-id pub-id-type="pmcid">PMC11883504</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>J.K.</given-names></name><etal/></person-group><article-title>Tau in late-life depression: a systematic review and meta-analysis</article-title><source>J Alzheimers Dis</source><volume>54</volume><year>2016</year><fpage>615</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.3233/JAD-160460</pub-id><pub-id pub-id-type="pmid">27497481</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Gatchel</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Locascio</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Depressive symptoms and tau accumulation in the inferior temporal lobe and entorhinal cortex in cognitively normal older adults: a pilot study</article-title><source>J Alzheimers Dis</source><volume>59</volume><year>2017</year><fpage>975</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.3233/JAD-170075</pub-id><pub-id pub-id-type="pmid">28697559</pub-id><pub-id pub-id-type="pmcid">PMC5577564</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Babulal</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Roe</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Stout</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>Depression is associated with tau and not amyloid positron emission tomography in cognitively normal adults</article-title><source>J Alzheimers Dis</source><volume>74</volume><year>2020</year><fpage>1045</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.3233/JAD-191148</pub-id><pub-id pub-id-type="pmid">32144985</pub-id><pub-id pub-id-type="pmcid">PMC7183906</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Busche</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.T.</given-names></name></person-group><article-title>Synergy between amyloid-&#946; and tau in Alzheimer's disease</article-title><source>Nat Neurosci</source><volume>23</volume><year>2020</year><fpage>1183</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1038/s41593-020-0687-6</pub-id><pub-id pub-id-type="pmid">32778792</pub-id><pub-id pub-id-type="pmcid">PMC11831977</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>W.L.</given-names></name></person-group><article-title>The a&#946; oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease</article-title><source>Neurobiol Learn Mem</source><volume>96</volume><year>2011</year><fpage>529</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1016/j.nlm.2011.08.003</pub-id><pub-id pub-id-type="pmid">21914486</pub-id><pub-id pub-id-type="pmcid">PMC4390395</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Jamerlan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>An</surname><given-names>S.S.A</given-names></name></person-group><article-title>Multimer detection system: a universal assay system for differentiating protein oligomers from monomers</article-title><source>Int J Mol Sci</source><volume>26</volume><year>2025</year><fpage>1667</fpage><pub-id pub-id-type="doi">10.3390/ijms26031667</pub-id><pub-id pub-id-type="pmid">39940966</pub-id><pub-id pub-id-type="pmcid">PMC11818661</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.U.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.Y.</given-names></name><etal/></person-group><article-title>Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries</article-title><source>J Gerontol B Psychol Sci Soc Sci</source><volume>57</volume><year>2002</year><fpage>P47</fpage><lpage>P53</lpage><pub-id pub-id-type="doi">10.1093/geronb/57.1.P47</pub-id><pub-id pub-id-type="pmid">11773223</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Jacova</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria</article-title><source>Lancet Neurol</source><volume>6</volume><year>2007</year><fpage>734</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(07)70178-3</pub-id><pub-id pub-id-type="pmid">17616482</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Tay</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>New DSM-V neurocognitive disorders criteria and their impact on diagnostic classifications of mild cognitive impairment and dementia in a memory clinic setting</article-title><source>Am J Geriatr Psychiatry</source><volume>23</volume><year>2015</year><fpage>768</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1016/j.jagp.2014.09.005</pub-id><pub-id pub-id-type="pmid">25728011</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Babapour Mofrad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Plasma amyloid-&#946; oligomerization assay as a pre-screening test for amyloid status</article-title><source>Alzheimers Res Ther</source><volume>13</volume><year>2021</year><fpage>133</fpage><pub-id pub-id-type="doi">10.1186/s13195-021-00871-4</pub-id><pub-id pub-id-type="pmid">34311775</pub-id><pub-id pub-id-type="pmcid">PMC8311929</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Um</surname><given-names>Y.H.</given-names></name><etal/></person-group><article-title>Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer's disease spectrum</article-title><source>Alzheimers Res Ther</source><volume>16</volume><year>2024</year><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/s13195-024-01324-7</pub-id><pub-id pub-id-type="pmid">38468313</pub-id><pub-id pub-id-type="pmcid">PMC10926587</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>Y.H.</given-names></name><etal/></person-group><article-title>Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status</article-title><source>Alzheimers Res Ther</source><volume>14</volume><year>2022</year><fpage>162</fpage><pub-id pub-id-type="doi">10.1186/s13195-022-01058-3</pub-id><pub-id pub-id-type="pmid">36324157</pub-id><pub-id pub-id-type="pmcid">PMC9632136</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Youn</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Blood amyloid-&#946; oligomerization as a biomarker of Alzheimer's disease: a blinded validation study</article-title><source>J Alzheimers Dis</source><volume>75</volume><year>2020</year><fpage>493</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.3233/JAD-191150</pub-id><pub-id pub-id-type="pmid">32310175</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Schindler</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Galasko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Acceptable performance of blood biomarker tests of amyloid pathology &#8211; recommendations from the Global CEO Initiative on Alzheimer's Disease</article-title><source>Nat Rev Neurol</source><volume>20</volume><year>2024</year><fpage>426</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/s41582-024-00981-6</pub-id><pub-id pub-id-type="pmid">38866966</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ey Kim</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Split-attention U-net: a fully convolutional network for robust multi-label segmentation from brain MRI</article-title><source>Brain Sci</source><volume>10</volume><year>2020</year><fpage>951</fpage><pub-id pub-id-type="doi">10.3390/brainsci10120951</pub-id><pub-id pub-id-type="pmid">33322640</pub-id><pub-id pub-id-type="pmcid">PMC7764312</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>R.E.Y.</given-names></name><etal/></person-group><article-title>Development of amyloid PET analysis pipeline using deep learning-based brain MRI segmentation: a comparative validation study</article-title><source>Diagnostics (Basel)</source><volume>12</volume><year>2022</year><fpage>702</fpage><pub-id pub-id-type="doi">10.3390/diagnostics12030702</pub-id><pub-id pub-id-type="pmid">35328176</pub-id><pub-id pub-id-type="pmcid">PMC8947654</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D.W.</given-names></name><etal/></person-group><article-title>Development of a prediction model for cognitive impairment of sarcopenia using multimodal neuroimaging in non-demented older adults</article-title><source>Alzheimers Dement</source><volume>20</volume><year>2024</year><fpage>4868</fpage><lpage>4878</lpage><pub-id pub-id-type="doi">10.1002/alz.13948</pub-id><pub-id pub-id-type="pmid">38889242</pub-id><pub-id pub-id-type="pmcid">PMC11247690</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Desikan</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>S&#233;gonne</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>B.</given-names></name><etal/></person-group><article-title>An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest</article-title><source>Neuroimage</source><volume>31</volume><year>2006</year><fpage>968</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.01.021</pub-id><pub-id pub-id-type="pmid">16530430</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Thurfjell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lilja</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lundqvist</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads</article-title><source>J Nuclear Med</source><volume>55</volume><issue>10</issue><year>2014</year><fpage>1623</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.2967/jnumed.114.142109</pub-id><pub-id pub-id-type="pmid">25146124</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Biel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brendel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rubinski</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Tau-PET and in vivo braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals</article-title><source>Alzheimers Res Ther</source><volume>13</volume><year>2021</year><fpage>137</fpage><pub-id pub-id-type="doi">10.1186/s13195-021-00891-0</pub-id><pub-id pub-id-type="pmid">34384484</pub-id><pub-id pub-id-type="pmcid">PMC8361801</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><mixed-citation publication-type="other" id="tboref0001">Landau S., Ward T.J., Murphy A., Jagust W. Flortaucipir (AV-1451) processing methods. Alzheimer's Disease Neuroimaging Initiative 2016. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://adni.loni.usc.edu/methods/pet-analysis-method/pet-analysis/" id="interref0003">https://adni.loni.usc.edu/methods/pet-analysis-method/pet-analysis/</ext-link>.</mixed-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Leuzy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chiotis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lemoine</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Tau PET imaging in neurodegenerative tauopathies: still a challenge</article-title><source>Mol Psychiatry</source><volume>24</volume><year>2019</year><fpage>1112</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0346-3</pub-id><pub-id pub-id-type="pmid">30635637</pub-id><pub-id pub-id-type="pmcid">PMC6756230</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Franzmeier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Neitzel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rubinski</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease</article-title><source>Nat Commun</source><volume>11</volume><year>2020</year><fpage>347</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-14279-3</pub-id><pub-id pub-id-type="pmid">31953405</pub-id><pub-id pub-id-type="pmcid">PMC6969065</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>HJ</surname><given-names>Wiste</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Defining imaging biomarker cut points for brain aging and Alzheimer's disease</article-title><source>Alzheimers Dement</source><volume>13</volume><year>2017</year><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.08.005</pub-id><pub-id pub-id-type="pmid">27697430</pub-id><pub-id pub-id-type="pmcid">PMC5344738</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Maass</surname><given-names>A.</given-names></name><name name-style="western"><surname>Landau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease</article-title><source>Neuroimage</source><volume>157</volume><year>2017</year><fpage>448</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.06.066</pub-id><pub-id pub-id-type="pmid">28587897</pub-id><pub-id pub-id-type="pmcid">PMC5814575</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Grace-Martin</surname><given-names>K.</given-names></name></person-group><article-title>Continuous and categorical variables: the trouble with median splits</article-title><source>The Analysis Factor</source><year>2010</year><comment>Available at</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.theanalysisfactor.com/continuous-and-categorical-variables-the-trouble-with-median-splits/" id="interref0004">https://www.theanalysisfactor.com/continuous-and-categorical-variables-the-trouble-with-median-splits/</ext-link><comment>Accessed 28 April 2025</comment></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>J.</given-names></name></person-group><article-title>Overfitting regression models: problems, detection, and avoidance</article-title><source>Statistics By Jim</source><year>2019</year><comment>Available at</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://statisticsbyjim.com/regression/overfitting-regression-models/" id="interref0005">https://statisticsbyjim.com/regression/overfitting-regression-models/</ext-link><comment>Accessed 28 April 2025</comment></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.U.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>A normative study of the CERAD neuropsychological assessment battery in the Korean elderly</article-title><source>J Int Neuropsychol Soc</source><volume>10</volume><year>2004</year><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1017/S1355617704101094</pub-id><pub-id pub-id-type="pmid">14751009</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Chandler</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lacritz</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Hynan</surname><given-names>L.S.</given-names></name><etal/></person-group><article-title>A total score for the CERAD neuropsychological battery</article-title><source>Neurology</source><volume>65</volume><year>2005</year><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000167550.63000.01</pub-id><pub-id pub-id-type="pmid">16009893</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease</article-title><source>Int J Geriatr Psychiatry</source><volume>31</volume><year>2016</year><fpage>316</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1002/gps.4335</pub-id><pub-id pub-id-type="pmid">26250797</pub-id><pub-id pub-id-type="pmcid">PMC4840849</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Won</surname><given-names>W.Y.</given-names></name><etal/></person-group><article-title>Reliability and validity of the Korean version of the Cornell Scale for Depression in Dementia</article-title><source>Psychiatry Investig</source><volume>9</volume><year>2012</year><fpage>332</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.4306/pi.2012.9.4.332</pub-id><pub-id pub-id-type="pmcid">PMC3521108</pub-id><pub-id pub-id-type="pmid">23251196</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>Y.M.</given-names></name><etal/></person-group><article-title>Validity and reliability of the Korean version of the Hamilton Depression Rating Scale (K-HDRS)</article-title><source>J Korean Neuropsychiatr Assoc</source><volume>44</volume><year>2005</year><fpage>456</fpage><lpage>465</lpage></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M.J.</given-names></name></person-group><article-title>Development of the Korean version of the Geriatric Depression Scale and its short form among elderly psychiatric patients</article-title><source>J Psychosom Res</source><volume>57</volume><year>2004</year><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychores.2004.01.004</pub-id><pub-id pub-id-type="pmid">15507257</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Bl&#246;meke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rehn</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kraemer-Schulien</surname><given-names>V.</given-names></name><etal/></person-group><article-title>A&#946; oligomers peak in early stages of Alzheimer's disease preceding tau pathology</article-title><source>Alzheimers Dement (Amst)</source><volume>16</volume><year>2024</year><object-id pub-id-type="publisher-id">e12589</object-id><pub-id pub-id-type="doi">10.1002/dad2.12589</pub-id><pub-id pub-id-type="pmcid">PMC11044868</pub-id><pub-id pub-id-type="pmid">38666085</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Ledo</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Amyloid-&#946; oligomers link depressive-like behavior and cognitive deficits in mice</article-title><source>Mol Psychiatry</source><volume>18</volume><year>2013</year><fpage>1053</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1038/mp.2013.91</pub-id><pub-id pub-id-type="pmid">23183490</pub-id><pub-id pub-id-type="pmcid">PMC3781315</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Colaianna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tucci</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zotti</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state?</article-title><source>Br J Pharmacol</source><volume>159</volume><year>2010</year><fpage>1704</fpage><lpage>1715</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00654.x</pub-id><pub-id pub-id-type="pmid">20218978</pub-id><pub-id pub-id-type="pmcid">PMC2925493</pub-id></element-citation></ref><ref id="bib0045"><label>45</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Donovan</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Locascio</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Longitudinal association of amyloid beta and anxious-depressive symptoms in cognitively normal older adults</article-title><source>Am J Psychiatry</source><volume>175</volume><year>2018</year><fpage>530</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2017.17030313</pub-id><pub-id pub-id-type="pmid">29325447</pub-id><pub-id pub-id-type="pmcid">PMC5988933</pub-id></element-citation></ref><ref id="bib0046"><label>46</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Krell-Roesch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Neureiter</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging</article-title><source>Int Psychogeriatr</source><volume>30</volume><year>2018</year><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1017/S104161021700216X</pub-id><pub-id pub-id-type="pmid">29198244</pub-id><pub-id pub-id-type="pmcid">PMC5815897</pub-id></element-citation></ref><ref id="bib0047"><label>47</label><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Wennberg</surname><given-names>A.M.V.</given-names></name><name name-style="western"><surname>Whitwell</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Tosakulwong</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals</article-title><source>Neurobiol Aging</source><volume>77</volume><year>2019</year><fpage>26</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.01.016</pub-id><pub-id pub-id-type="pmid">30776649</pub-id><pub-id pub-id-type="pmcid">PMC6486870</pub-id></element-citation></ref><ref id="bib0048"><label>48</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Tsopelas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>R.</given-names></name><name name-style="western"><surname>Savva</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>Neuropathological correlates of late-life depression in older people</article-title><source>Br J Psychiatry</source><volume>198</volume><year>2011</year><fpage>109</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.110.078576</pub-id><pub-id pub-id-type="pmid">21282780</pub-id></element-citation></ref><ref id="bib0049"><label>49</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Capuano</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Clinical-pathologic study of depressive symptoms and cognitive decline in old age</article-title><source>Neurology</source><volume>83</volume><year>2014</year><fpage>702</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000715</pub-id><pub-id pub-id-type="pmid">25080520</pub-id><pub-id pub-id-type="pmcid">PMC4150132</pub-id></element-citation></ref><ref id="bib0050"><label>50</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M</given-names></name></person-group><article-title>Biomarker modeling of Alzheimer's disease</article-title><source>Neuron</source><volume>80</volume><year>2013</year><fpage>1347</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.12.003</pub-id><pub-id pub-id-type="pmid">24360540</pub-id><pub-id pub-id-type="pmcid">PMC3928967</pub-id></element-citation></ref><ref id="bib0051"><label>51</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Coomans</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>de Koning</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Rikken</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Performance of a [(18)F]Flortaucipir PET visual read method across the Alzheimer disease continuum and in dementia with lewy bodies</article-title><source>Neurology</source><volume>101</volume><year>2023</year><fpage>e1850</fpage><lpage>e1862</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000207715</pub-id><pub-id pub-id-type="pmid">37748892</pub-id><pub-id pub-id-type="pmcid">PMC10663007</pub-id></element-citation></ref><ref id="bib0052"><label>52</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Weigand</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Maass</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eglit</surname><given-names>G.L.</given-names></name><etal/></person-group><article-title>What's the cut-point?: a systematic investigation of tau PET thresholding methods</article-title><source>Alzheimers Res Ther</source><volume>14</volume><year>2022</year><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s13195-022-00960-0</pub-id><pub-id pub-id-type="pmid">35382866</pub-id><pub-id pub-id-type="pmcid">PMC8985353</pub-id></element-citation></ref><ref id="bib0053"><label>53</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>Therriault</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pascoal</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Lussier</surname><given-names>F.Z.</given-names></name><etal/></person-group><article-title>Biomarker modeling of Alzheimer's disease using PET-based Braak staging</article-title><source>Nat Aging</source><volume>2</volume><year>2022</year><fpage>526</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1038/s43587-022-00210-9</pub-id><pub-id pub-id-type="pmid">37118445</pub-id><pub-id pub-id-type="pmcid">PMC10154209</pub-id></element-citation></ref><ref id="bib0054"><label>54</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S.H.</given-names></name></person-group><article-title>Which of the Cornell Scale for Depression in Dementia or the Geriatric Depression Scale is more useful to screen for depression in older adults?</article-title><source>Asian J Psychiatr</source><volume>72</volume><year>2022</year><object-id pub-id-type="publisher-id">103147</object-id><pub-id pub-id-type="doi">10.1016/j.ajp.2022.103147</pub-id><pub-id pub-id-type="pmid">35533539</pub-id></element-citation></ref><ref id="bib0055"><label>55</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>K&#248;rner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lauritzen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abelskov</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The Geriatric Depression Scale and the Cornell Scale for Depression in dementia: a validity study</article-title><source>Nord J Psychiatry</source><volume>60</volume><year>2006</year><fpage>360</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1080/08039480600937066</pub-id><pub-id pub-id-type="pmid">17050293</pub-id></element-citation></ref><ref id="bib0056"><label>56</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Mayer</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Bay</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Politis</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS</article-title><source>Int J Geriatr Psychiatry</source><volume>21</volume><year>2006</year><fpage>930</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1002/gps.1584</pub-id><pub-id pub-id-type="pmid">16955427</pub-id></element-citation></ref><ref id="bib0057"><label>57</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Vida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Des Rosiers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carrier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>S.</given-names></name></person-group><article-title>Depression in Alzheimer's disease: receiver operating characteristic analysis of the Cornell Scale for Depression in Dementia and the Hamilton Depression Scale</article-title><source>J Geriatr Psychiatry Neurol</source><volume>7</volume><year>1994</year><fpage>159</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1177/089198879400700307</pub-id><pub-id pub-id-type="pmid">7916939</pub-id></element-citation></ref><ref id="bib0058"><label>58</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Joh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Endogenous a&#946; peptide promotes a&#946; oligomerization tendency of spiked synthetic a&#946; in Alzheimer's disease plasma</article-title><source>Mol Cell Neurosci</source><volume>111</volume><year>2021</year><object-id pub-id-type="publisher-id">103588</object-id><pub-id pub-id-type="doi">10.1016/j.mcn.2021.103588</pub-id><pub-id pub-id-type="pmid">33422673</pub-id></element-citation></ref></ref-list><sec id="sec0023" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0064a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgements</title><p id="para0065">We gratefully acknowledge the cooperation and patience of all individuals who participated in this study.</p></ack><fn-group><fn id="sec0022" fn-type="supplementary-material"><p id="para0009a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100318" id="interref0002">doi:10.1016/j.tjpad.2025.100318</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501353</article-id><article-id pub-id-type="pmcid-ver">PMC12501353.1</article-id><article-id pub-id-type="pmcaid">12501353</article-id><article-id pub-id-type="pmcaiid">12501353</article-id><article-id pub-id-type="pmid">40713260</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100303</article-id><article-id pub-id-type="pii">S2274-5807(25)00246-8</article-id><article-id pub-id-type="publisher-id">100303</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group></article-categories><title-group><article-title>Childhood maltreatment confers long-term risk for cognitive impairment: A prospective investigation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Assuras</surname><given-names initials="S">Stephanie</given-names></name><email>sa3150@columbia.edu</email><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Courtney</surname><given-names initials="K">Kellie</given-names></name><email>kellie.courtney@jjay.cuny.edu</email><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Maxfield</surname><given-names initials="M">Molly</given-names></name><email>Molly.Maxfield@asu.edu</email><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Shagalow</surname><given-names initials="S">Shaina</given-names></name><email>ss6004@cumc.columbia.edu</email><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Sherer</surname><given-names initials="S">Sara</given-names></name><email>Ss6391@cumc.columbia.edu</email><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Manly</surname><given-names initials="JJ">Jennifer J.</given-names></name><email>jjm71@cumc.columbia.edu</email><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Widom</surname><given-names initials="CS">Cathy Spatz</given-names></name><email>cwidom@jjay.cuny.edu</email><xref rid="aff0002" ref-type="aff">b</xref><xref rid="aff0006" ref-type="aff">f</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><aff id="aff0001"><label>a</label>Columbia University Medical Center, The Neurological Institute of New York, 710W. 168th St., New York City, NY 10032, USA</aff><aff id="aff0002"><label>b</label>Psychology Department, John Jay College, 524 West 59th Street, New York City, NY 10019, USA</aff><aff id="aff0003"><label>c</label>Center for Innovation in Healthy and Resilient Aging, Edson College of Nursing and Health Innovation, Arizona State University, 550N. 3rd St, Phoenix AZ 85004, USA</aff><aff id="aff0004"><label>d</label>Department of Neurology, Columbia University, 710W. 168th St., New York City, NY 10032, USA</aff><aff id="aff0005"><label>e</label>Gertrude H. Sergievsky Center and the Taub Institute for Research in Aging and Alzheimer&#8217;s disease, Columbia University, 710W 168th St, NY, NY 10032, USA</aff><aff id="aff0006"><label>f</label>Graduate Center, City University of New York, New York City, NY, USA</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author at: Psychology Department, John Jay College, City University of New York, 529 West 59th Street, New York City, NY 10019, USA. <email>cwidom@jjay.cuny.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>24</day><month>7</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100303</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>26</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract abstract-type="author-highlights" id="abs0001"><title>Highlights</title><p><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#8226;</label><p id="para0001">Cognitive repercussions of childhood maltreatment continue into late midlife.</p></list-item><list-item id="celistitem0002"><label>&#8226;</label><p id="para0002">Children with documented histories of maltreatment were followed up at mean age 59.</p></list-item><list-item id="celistitem0003"><label>&#8226;</label><p id="para0003">Maltreated group performed worse on neuropsychological tests compared to controls.</p></list-item><list-item id="celistitem0004"><label>&#8226;</label><p id="para0004">Cognitive impairment was evident across sex, race, age, and type of maltreatment.</p></list-item><list-item id="celistitem0005"><label>&#8226;</label><p id="para0005">First evidence of longterm consequences of childhood neglect for cognitive impairment.</p></list-item></list></p></abstract><abstract id="abs0002"><sec><title>Importance</title><p>Childhood maltreatment has been associated with greater risk for Alzheimer's disease and related dementias. Better understanding of this association will have implications for prevention and intervention efforts.</p></sec><sec><title>Objective</title><p>To determine whether individuals with documented histories of childhood maltreatment and matched controls differ in cognitive functioning in late midlife and whether maltreatment leads to higher rates of cognitive impairment.</p></sec><sec><title>Design</title><p>Prospective cohort design</p></sec><sec><title>Setting</title><p>Metropolitan Midwestern county area</p></sec><sec><title>Participants</title><p>Children with documented maltreatment histories and demographically matched controls were followed up into late midlife (<italic toggle="yes">N</italic> = 447, Mage = 59.4). Control group children were matched to maltreated children on age, sex, race and ethnicity, and approximate family social class during the time the cases were processed.</p></sec><sec><title>Exposure</title><p>Children with documented cases of physical and sexual abuse and neglect during 1967 to 1971 in the county juvenile (family) or adult criminal courts. Cases were restricted to children ages 0&#8211;11 at the time of the maltreatment to ensure that the temporal direction of consequences was clear.</p></sec><sec><title>Main outcome and measures</title><p>Using a comprehensive neuropsychological assessment battery, multiple tests of cognitive functioning and the Functional Activities Questionnaire were administered. Participants were categorized as having cognitive impairment with no dementia (CIND) or dementia.</p></sec><sec><title>Results</title><p>Individuals with histories of childhood maltreatment performed worse on all 12 neuropsychological tests, compared to matched controls (Cohen&#8217;s d 0.28 to 0.42) and had significantly higher risk for CIND [AOR = 1.86), amnestic CIND [AOR = 1.68) and non-amnestic [AOR = 1.48). About 13 % of maltreated individuals met criteria for amnestic CIND. Few met criteria for dementia. Males, females, Blacks, Whites, older and younger individuals, and those physically or sexually abused or neglected showed the effects of maltreatment.</p></sec><sec><title>Conclusions and relevance</title><p>Cognitive repercussions of childhood maltreatment continue into late midlife. Findings reinforce the importance of early detection and preventive interventions that may decrease risks associated with childhood maltreatment in later adulthood. Because we use documented court cases from childhood, this design reduces potential biases associated with reliance on retrospective self-reports of childhood adversities. To our knowledge, this is the first study to examine long-term consequences of childhood neglect for cognitive impairment.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Child maltreatment</kwd><kwd>Cognitive impairment</kwd><kwd>Amnestic</kwd><kwd>Nonamnestic</kwd><kwd>Dementia</kwd><kwd>Longitudinal</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0015">Childhood maltreatment has been associated with greater risk for Alzheimer&#8217;s disease and related dementias (ADRD) [<xref rid="bib0001" ref-type="bibr">[1]</xref>, <xref rid="bib0002" ref-type="bibr">[2]</xref>, <xref rid="bib0003" ref-type="bibr">[3]</xref>, <xref rid="bib0004" ref-type="bibr">[4]</xref>]. Each represents a significant public health issue at different points in the lifespan, with a childhood maltreatment incidence rate of 7.7 per 1000 US-based children (558,899 substantiated reports in 2022)[<xref rid="bib0005" ref-type="bibr">5</xref>] and an ADRD prevalence rate of one of every nine older adults (an incidence rate of 4.76 per 1000 older adults, with increasing risk with age) [<xref rid="bib0006" ref-type="bibr">6</xref>]. Each is costly for those directly affected and society at large.</p><p id="para0016">A developing scientific consensus indicates that the &#8220;origins of adult disease are often found among developmental and biological disruptions occurring during the early years of life.&#8221;[<xref rid="bib0007" ref-type="bibr">7</xref>] Scholars and public health officials interested in the determinants of health in later life have begun to adopt a life course perspective to better understand how childhood adversities and cognitive impairment and dementia are associated. However, knowledge about the relationship between childhood adversities and cognitive functioning, mild cognitive impairment (MCI), and Alzheimer&#8217;s Disease (AD) in old age is limited.</p><p id="para0017">There is increasing recognition of the importance and potential benefits of early identification of cognitive decline and developmental trajectories in individuals at risk for AD. Research has demonstrated that the neuropathological changes associated with ADRD begin decades before clear cognitive and functional decline [<xref rid="bib0008" ref-type="bibr">8</xref>,<xref rid="bib0009" ref-type="bibr">9</xref>]. Cognitive decline reaching the level of mild cognitive impairment (MCI) has also been shown to confer significant risk for progression to dementia [<xref rid="bib0010" ref-type="bibr">[10]</xref>, <xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>]. Therefore, increased impairment and accelerated decline may manifest before ADRD in individuals exposed to childhood maltreatment. Better understanding of the extent to which childhood maltreatment increases risk for ADRD would have implications for targeted prevention and intervention efforts. Early detection and diagnosis of cognitive impairment may lead to improved efforts at intervention to reduce risk or delay/slow the progression of symptoms. However, aging studies of middle-aged adults are sparse, even though the preclinical phase begins 10&#8211;15 years before the onset of the disease.</p><p id="para0018">Consistent with a life course perspective, researchers have hypothesized that long-term consequences of childhood maltreatment, including potential altered stress regulatory functions [<xref rid="bib0014" ref-type="bibr">14</xref>,<xref rid="bib0015" ref-type="bibr">15</xref>], poorer physical health [<xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>, <xref rid="bib0018" ref-type="bibr">[18]</xref>], increased psychopathology [<xref rid="bib0016" ref-type="bibr">16</xref>,<xref rid="bib0019" ref-type="bibr">[19]</xref>, <xref rid="bib0020" ref-type="bibr">[20]</xref>, <xref rid="bib0021" ref-type="bibr">[21]</xref>, <xref rid="bib0022" ref-type="bibr">[22]</xref>], reduced socioeconomic status, and worse behavioral and social outcomes [<xref rid="bib0023" ref-type="bibr">23</xref>,<xref rid="bib0024" ref-type="bibr">24</xref>], may serve to explain the relationship between childhood adversities and cognitive functioning. Increasingly, research has focused on the impact of childhood maltreatment on neurological development, affecting neuronal integrity, including both brain structure and function, as well as neuropsychological functioning [<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0025" ref-type="bibr">[25]</xref>, <xref rid="bib0026" ref-type="bibr">[26]</xref>, <xref rid="bib0027" ref-type="bibr">[27]</xref>, <xref rid="bib0028" ref-type="bibr">[28]</xref>]. In children, the consequences of child maltreatment include deficits in IQ, language, basic and complex attention, and visuo-spatial/motor abilities relative to those without a history of child maltreatment [<xref rid="bib0029" ref-type="bibr">29</xref>,<xref rid="bib0030" ref-type="bibr">30</xref>]. However, the literature is not consistent [<xref rid="bib0026" ref-type="bibr">26</xref>,<xref rid="bib0027" ref-type="bibr">27</xref>,<xref rid="bib0031" ref-type="bibr">31</xref>,<xref rid="bib0032" ref-type="bibr">32</xref>].</p><p id="para0019">This project is a continuation of a prospective longitudinal study of the long-term consequences of childhood abuse and neglect that involved a large group of children with documented histories of physical and sexual abuse and neglect and a demographically matched control group. Both groups have been followed and interviewed over multiple waves of the study. While the study was begun to examine the theory that there was a "cycle of violence" <xref rid="bib0033" ref-type="bibr">[33]</xref>, the focus of the study has expanded over the past 35 years to include multiple domains of functioning. The original study was designed to overcome many of the methodological concerns of earlier research and represents a scientifically rigorous approach to understanding the consequences of childhood maltreatment. Focusing on cognitive impairment in late midlife provides an opportunity to determine early risk trajectories that may reveal different types of cognitive decline, susceptibilities to cognitive impairment, or manifestations of deficits in functioning.</p><p id="para0020">Most studies that examine the role of childhood adversities in relation to aging, dementia, or Alzheimer&#8217;s disease have been based on specialized samples [<xref rid="bib0034" ref-type="bibr">34</xref>], brief cognitive assessments [<xref rid="bib0035" ref-type="bibr">35</xref>], or utilize cross-sectional designs and rely on retrospective reports of childhood adversities and child maltreatment [<xref rid="bib0036" ref-type="bibr">36</xref>]. Cross-sectional studies cannot demonstrate that childhood adversities cause particular outcomes, only that reporting of childhood adversities is associated with certain outcomes. There is also an almost exclusive reliance on retrospective reports of child maltreatment. Baldwin et al [<xref rid="bib0037" ref-type="bibr">37</xref>] demonstrated that prospective and retrospective methods of capturing child maltreatment identified different people. Furthermore, Danese and Widom[<xref rid="bib0038" ref-type="bibr">38</xref>] have demonstrated that research based on retrospective measures of child maltreatment significantly underestimates the extent of deficits in those with versus without a maltreatment history. In addition, the onset of dementia may affect retrospective recall of childhood experiences [<xref rid="bib0039" ref-type="bibr">39</xref>]. Current psychopathology may increase the likelihood of recall of childhood adversities, leading to spurious associations with later outcomes [<xref rid="bib0040" ref-type="bibr">40</xref>]. Our study involves documented court cases from childhood, a design characteristic that reduces the problems and potential biases associated with reliance on retrospective self-reports.</p><p id="para0021">Previous work with this sample examined risk for dementia with data collected when participants were mean age 41 [<xref rid="bib0041" ref-type="bibr">41</xref>]. That study found that 92.3 % of the participants had at least one risk factor for dementia, and 49.5 % had at least 3 risk factors. Individuals with documented histories of childhood maltreatment also had significantly more dementia risk factors compared to controls.</p><sec id="sec0002"><label>1.1</label><title>The current study</title><p id="para0022">The current work describes the new results of a longer-term follow-up of the individuals in this study who are now, on average, 59 years old. The purpose is to determine whether individuals with documented histories of childhood maltreatment and demographically matched controls differ in terms of their cognitive functioning in late midlife and the extent to which they manifest cognitive impairment with no dementia (CIND) [<xref rid="bib0042" ref-type="bibr">42</xref>], or dementia. This study provides a unique contribution to the existing literature. While some longitudinal studies have looked at lifetime cognitive differences and rates of decline in those exposed versus those unexposed to childhood adversities or maltreatment, to our knowledge, few studies have examined CIND or dementia [<xref rid="bib0025" ref-type="bibr">25</xref>]. Importantly, most studies are cross-sectional and rely on retrospective reports of childhood maltreatment, making them susceptible to recall bias [<xref rid="bib0004" ref-type="bibr">4</xref>].</p></sec><sec id="sec0003"><label>1.2</label><title>Research questions</title><p id="para0023">We have three major research questions: (1) Compared to demographically matched controls, are individuals with documented histories of childhood maltreatment at increased risk for cognitive impairment [cognitive impairment with no dementia (CIND), amnestic CIND (aCIND), and non-amnestic CIND (naCIND), and dementia] in late midlife? (2) Does the type of childhood maltreatment (i.e., neglect, physical abuse, and sexual abuse) predict different risk patterns for cognitive impairment and dementia? and (3) Are maltreated individuals who differ in demographic characteristics of sex, race, age, and level of education at differential risk for cognitive impairment and dementia compared to controls?</p></sec></sec><sec id="sec0004"><label>2</label><title>Methods and measures</title><sec id="sec0005"><label>2.1</label><title>Design</title><p id="para0024">The description of the methods for this study are similar to those published previously [<xref rid="bib0043" ref-type="bibr">43</xref>]. This prospective cohort design study of children with documented histories of childhood maltreatment and demographically matched controls who were followed into adulthood builds on existing research and has several advantages. The design includes an unambiguous operationalization of childhood maltreatment, a comparison group of children matched closely on age, sex, race and approximate family social class background, and a diverse sample of male, female, Black, and White participants who have been followed for more than 30 years across multiple waves of the study.</p><p id="para0025">The initial phase of the study was archival and compared the abused and/or neglected children to the matched comparison group on juvenile and adult criminal arrest records [<xref rid="bib0033" ref-type="bibr">33</xref>]. Subsequent phases of the study involved locating and interviewing the maltreated and comparison groups. In the current analyses, we use information from 1989&#8211;1995 (Interview 1: <italic toggle="yes">N</italic> = 1196; <italic toggle="yes">Mage</italic> = 29.2 years) and 2022&#8211;2023 (Interview 5: <italic toggle="yes">N</italic> = 447, <italic toggle="yes">Mage</italic> = 59.4 years).</p></sec><sec id="sec0006"><label>2.2</label><title>Participants</title><p id="para0026">The original sample of maltreated children (<italic toggle="yes">N</italic> = 908) represents substantiated cases of childhood physical abuse, sexual abuse, and neglect processed from 1967 to 1971 in the county juvenile (family) or adult criminal courts of a Midwestern metropolitan area. Cases of abuse and neglect were restricted to children ages 0&#8211;11 at the time of the maltreatment (age at petition) to minimize ambiguity and to maximize the likelihood that the temporal direction of consequences was clear. Since it was not possible to assign subjects randomly to groups, the assumption of equivalence for the groups is an approximation.</p><p id="para0027">A critical element of the study design involved the selection of a control group of children without documented histories of child abuse or neglect (<italic toggle="yes">N</italic> = 667) matched with the abused and neglected children on the basis of age, sex, race and ethnicity, and approximate family social class during the time that the abuse and neglect records were processed. Matching for approximate family social class was important because it is theoretically plausible that any relationship between child abuse and neglect and subsequent outcomes may be confounded with or explained by social class differences [<xref rid="bib0033" ref-type="bibr">33</xref>,<xref rid="bib0044" ref-type="bibr">44</xref>,<xref rid="bib0045" ref-type="bibr">45</xref>]. The matching procedure used here is based on proxies for social class that include neighborhood schools that children attended and hospitals of birth. The use of schools and hospital controls to match on variables that are related to outcomes is recommended when random sampling is not possible [<xref rid="bib0047" ref-type="bibr">46</xref>]. The comparison group establishes the base rates of pathology we would expect in a sample of adults from comparable circumstances who did not come to court attention in childhood as victims of abuse or neglect.</p><p id="para0028">Children who were under school age at the time of the abuse and/or neglect were matched with children of the same sex, race, date of birth (&#177;1 week), and hospital of birth through the use of county birth record information. For children of school age, records of more than 100 elementary schools for the same time period were used to find matches with children of the same sex, race, date of birth (&#177;6 months), and class in elementary school during the years 1967&#8211;1971. Overall, matches were found for 74 % of the abused and neglected children. Non-matches occurred for a number of reasons. For birth records, non-matches occurred in situations when the abused and neglected child was born outside the county or state or when date of birth information was missing. For school records, non-matches occurred because of the lack of adequate identifying information for the abused and neglected children or because the elementary school had closed and class registers were not available.</p><p id="para0029"><xref rid="tbl0001" ref-type="table">Table 1</xref> shows the sample characteristics at all waves of the study. At the first interview, the sample was 48.7 % female and 62.9 % White, non-Hispanic. Participants were asked to identify their race and ethnicity using a list on show cards. For the present analysis, race was categorized as 1) White, non-Hispanic, 2), Black, non-Hispanic, 3) Hispanic, and 4) all others. However, when stratifying by race, we only report results for White, non-Hispanic and Black, non-Hispanic participants, and exclude the small group of individuals who identified as Hispanic, Native American, Pacific Islander, or other (<italic toggle="yes">N</italic> = 13).<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Descriptive characteristics of participants across the study waves.</p></caption><alt-text id="alt0002">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Records</th><th colspan="5" align="left" valign="top" rowspan="1">Interviews<hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">1</th><th valign="top" colspan="1" rowspan="1">2</th><th valign="top" colspan="1" rowspan="1">3</th><th valign="top" colspan="1" rowspan="1">4</th><th valign="top" colspan="1" rowspan="1">5</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">DATES</td><td valign="top" colspan="1" rowspan="1">1967-1971</td><td valign="top" colspan="1" rowspan="1">1989-1995</td><td valign="top" colspan="1" rowspan="1">2000-2002</td><td valign="top" colspan="1" rowspan="1">2003-2005</td><td valign="top" colspan="1" rowspan="1">2009-2010</td><td valign="top" colspan="1" rowspan="1">2022-2023</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1">N</td><td valign="top" colspan="1" rowspan="1">1575</td><td valign="top" colspan="1" rowspan="1">1196</td><td valign="top" colspan="1" rowspan="1">896</td><td valign="top" colspan="1" rowspan="1">807</td><td valign="top" colspan="1" rowspan="1">649</td><td valign="top" colspan="1" rowspan="1">447</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1">Childhood maltreatment</td><td valign="top" colspan="1" rowspan="1">57.7</td><td valign="top" colspan="1" rowspan="1">56.5</td><td valign="top" colspan="1" rowspan="1">55.9</td><td valign="top" colspan="1" rowspan="1">56.7</td><td valign="top" colspan="1" rowspan="1">55.2</td><td valign="top" colspan="1" rowspan="1">56.8</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sex (% female)</td><td valign="top" colspan="1" rowspan="1">50.7</td><td valign="top" colspan="1" rowspan="1">48.7</td><td valign="top" colspan="1" rowspan="1">51.0</td><td valign="top" colspan="1" rowspan="1">52.7</td><td valign="top" colspan="1" rowspan="1">53.9</td><td valign="top" colspan="1" rowspan="1">56.7</td></tr><tr><td valign="top" colspan="1" rowspan="1">White (%)</td><td valign="top" colspan="1" rowspan="1">66.2</td><td valign="top" colspan="1" rowspan="1">62.9</td><td valign="top" colspan="1" rowspan="1">62.2</td><td valign="top" colspan="1" rowspan="1">60.4</td><td valign="top" colspan="1" rowspan="1">59.2</td><td valign="top" colspan="1" rowspan="1">58.8</td></tr><tr><td valign="top" colspan="1" rowspan="1">Black (%)</td><td valign="top" colspan="1" rowspan="1">32.6</td><td valign="top" colspan="1" rowspan="1">34.9</td><td valign="top" colspan="1" rowspan="1">35.2</td><td valign="top" colspan="1" rowspan="1">37.3</td><td valign="top" colspan="1" rowspan="1">34.5</td><td valign="top" colspan="1" rowspan="1">35.6</td></tr><tr><td valign="top" colspan="1" rowspan="1">Hispanic (%)</td><td valign="top" colspan="1" rowspan="1">0.3</td><td valign="top" colspan="1" rowspan="1">3.8</td><td valign="top" colspan="1" rowspan="1">4.0</td><td valign="top" colspan="1" rowspan="1">4.0</td><td valign="top" colspan="1" rowspan="1">3.7</td><td valign="top" colspan="1" rowspan="1">3.1</td></tr><tr><td valign="top" colspan="1" rowspan="1">Abuse/neglect (%)</td><td valign="top" colspan="1" rowspan="1">57.7</td><td valign="top" colspan="1" rowspan="1">56.5</td><td valign="top" colspan="1" rowspan="1">55.8</td><td valign="top" colspan="1" rowspan="1">56.8</td><td valign="top" colspan="1" rowspan="1">55.2</td><td valign="top" colspan="1" rowspan="1">56.8</td></tr><tr><td valign="top" colspan="1" rowspan="1">Physical abuse (%)</td><td valign="top" colspan="1" rowspan="1">10.2</td><td valign="top" colspan="1" rowspan="1">9.2</td><td valign="top" colspan="1" rowspan="1">8.8</td><td valign="top" colspan="1" rowspan="1">9.7</td><td valign="top" colspan="1" rowspan="1">8.3</td><td valign="top" colspan="1" rowspan="1">9.2</td></tr><tr><td valign="top" colspan="1" rowspan="1">Neglect (%)</td><td valign="top" colspan="1" rowspan="1">44.3</td><td valign="top" colspan="1" rowspan="1">45.4</td><td valign="top" colspan="1" rowspan="1">45.3</td><td valign="top" colspan="1" rowspan="1">45.9</td><td valign="top" colspan="1" rowspan="1">44.1</td><td valign="top" colspan="1" rowspan="1">45.4</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sexual abuse (%)</td><td valign="top" colspan="1" rowspan="1">9.7</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">7.6</td><td valign="top" colspan="1" rowspan="1">7.5</td><td valign="top" colspan="1" rowspan="1">8.3</td><td valign="top" colspan="1" rowspan="1">8.3</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean age at interview (SD)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">29.2 (3.8)</td><td valign="top" colspan="1" rowspan="1">39.5 (3.5)</td><td valign="top" colspan="1" rowspan="1">41.2 (3.5)</td><td valign="top" colspan="1" rowspan="1">47.0 (3.5)</td><td valign="top" colspan="1" rowspan="1">59.4 (3.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Education</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">11.5 (2.2)</td><td valign="top" colspan="1" rowspan="1">12.2 (7.2)</td><td valign="top" colspan="1" rowspan="1">12.2 (7.5)</td><td valign="top" colspan="1" rowspan="1">12.0 (5.1)</td><td valign="top" colspan="1" rowspan="1">11.7 (2.3)</td></tr></tbody></table><table-wrap-foot><fn><p>Note: The numbers of cases of specific types of abuse and neglect do not add up to the total in the abused/neglect group because some individuals (11 %) experienced more than one type of abuse or neglect. Education represents the highest grade of school completed.</p></fn></table-wrap-foot></table-wrap></p><p id="para0030">As in most longitudinal studies, there was attrition associated with death, refusals, and our inability to locate participants over the various waves of the study. To address potential attrition-related bias, we compared demographic characteristics and cognitive test scores for participants who completed Interview 5 and those who did not. There were no significant differences in terms of maltreatment status (<italic toggle="yes">p</italic> = .92) or percent White, non-Hispanic <italic toggle="yes">(p</italic> = .17). However, participants in Interview 5 were significantly more likely to be female, younger at Interviews 2 and 3, to report higher levels of education at Interview 1, and to perform better on cognitive tests at Interview 3, including Trail Making A, Trail Making B, and Matrix Reasoning [<xref rid="bib0026" ref-type="bibr">26</xref>]. Because of these findings, inverse probability weighting was applied in subsequent regression analyses.</p></sec><sec id="sec0007"><label>2.3</label><title>Procedures</title><p id="para0031">Field interviewers located and invited participants who had taken part in past waves of the study to take part in the most recent wave (Interview 5). Interviewers conducted a comprehensive cognitive assessment battery, an interview, a brief health exam including height, weight, blood pressure, pulse, and an airway resistance (peak airflow) test, and collected saliva and hair samples. Interviews were delayed because of the Covid epidemic, and when interviews began, personal protective gear was used for both participants and interviewers.</p><p id="para0032">Participants were interviewed in person in their home or other quiet location of their choosing. Interviewers were unaware of the purpose of the study and the inclusion of an abuse/neglect group. Participants were also unaware of the purpose of the study so as to avoid potential demand characteristics stemming from awareness of selection based on a history of maltreatment. In the first wave of the study, participants were told that they had been selected to participate as part of a large group of individuals who grew up in that area during the late 1960s and early 1970s. Institutional Review Board (IRB) approval was obtained for each wave of the study, including the IRB of the City University of New York (Protocol #2015&#8211;0133), where the present analyses were completed. Participants provided written or verbal (for those with limited reading ability) informed consent.</p><p id="para0033">Because of concerns with possible limitations in participants&#8217; cognitive capacity that might influence whether that participant would be capable of providing informed consent, procedures were in place to determine whether a legally authorized representative was needed to provide consent for the participant. Inspection of interviewer notes shows that there were 9 individuals where the interviewer noted that "participant is dependent on others or needs assistance; lives in a home that provides help." There were also individuals who had to be read the consent form, either because they had problems seeing or couldn't read, including 14 participants who had trouble reading and/or writing, and 27 had difficulty seeing or hearing.</p></sec><sec id="sec0008"><label>2.4</label><title>Measures</title><p id="para0034"><bold>Childhood maltreatment.</bold> Childhood maltreatment was assessed through a review of official records processed during the years 1967 to 1971 when children were ages 0&#8211;11 years. Neglect cases reflected a judgment that the parents&#8217; deficiencies in childcare were beyond those found acceptable by community and professional standards at the time. These cases represented extreme failure to provide adequate food, clothing, shelter, and medical attention to children. Physical abuse cases included injuries such as bruises, welts, burns, abrasions, lacerations, wounds, cuts, bone and skull fractures, and other evidence of physical injury. Sexual abuse cases included fondling or touching, felony sexual assault, sodomy, incest, and rape. Eleven percent of the sample experienced more than one type of maltreatment.</p><sec id="sec0009"><label>2.4.1</label><title>Cognitive status</title><p id="para0035">Multiple tests of cognitive functioning were included in the comprehensive neuropsychological assessment battery. The 12 tests were: <italic toggle="yes">Benson Complex Figure Copy</italic>; Consortium to Establish a Registry for Alzheimer&#8217;s Disease (CERAD) neuropsychological battery tests[<xref rid="bib0048" ref-type="bibr">47</xref>]: <italic toggle="yes">CERAD Category Fluency Test: Animals, CERAD Word List Learning and Recall (Immediate), and CERAD Word List Recall &#8211; Delayed; Verbal Fluency: Phonemic Letter Fluency (S); Multilingual Naming Test (MINT</italic>[<xref rid="bib0049" ref-type="bibr">48</xref>]); <italic toggle="yes">Number Span Test; Symbol-Digit Modalities Test (SDMT</italic> Smith (1982); <italic toggle="yes">Trail Making Test (A and B</italic>[<xref rid="bib0050" ref-type="bibr">49</xref>]); <italic toggle="yes">and Stroop Color and Word Test</italic> [<xref rid="bib0051" ref-type="bibr">50</xref>].</p></sec><sec id="sec0010"><label>2.4.2</label><title>Functional activities questionnaire (FAQ)</title><p id="para0036">Participants were also administered the FAQ[<xref rid="bib0052" ref-type="bibr">51</xref>] and presented with 10 routine activities for daily living, including shopping alone, remembering appointments, traveling out of the neighborhood, etc. For each activity, participants were asked whether in the past 4 weeks they had experienced any difficulty or need for help with each activity. Response options ranged from normal, have difficulty but do by myself, require assistance, or dependent (codes ranged from 0 to 3).</p></sec></sec><sec id="sec0011"><label>2.5</label><title>Determination of cognitive status</title><p id="para0037">To determine cognitive status, raw scores for each cognitive test were transformed into T scores based on population-based norms. Raw data was used for the CERAD Word List Learning Test, Letter Fluency (S), and WRAT because of the lack of appropriate norms. MOAANS and MOANS norms[<xref rid="bib0055" ref-type="bibr">[52]</xref>, <xref rid="bib0056" ref-type="bibr">[53]</xref>, <xref rid="bib0057" ref-type="bibr">[54]</xref>, <xref rid="bib0058" ref-type="bibr">[55]</xref>] were used for Trail Making, Symbol Digit Modalities Test, and Stroop. Given the ability to stratify by age, sex, and race, data from the Offspring study[<xref rid="bib0059" ref-type="bibr">56</xref>] were used for norms for the Benson Complex Figure Copy Test, Number Span test, Category Fluency Test (animals) Letter Fluency (F) and MINT. In the case of the Offspring study, only the tests administered in English were used for the norms. Norms for the WAIS-III Matrix Reasoning Test were from the manual [<xref rid="bib0060" ref-type="bibr">57</xref>].</p><p id="para0038">Kim et al.[<xref rid="bib0053" ref-type="bibr">58</xref>] have pointed out that one of the problems with the diagnosis of MCI is that there is no consistently applied diagnostic criteria and that the many different definitions sometimes compete with one another. Criteria need to balance the risk of false negatives with false positives. Saxton et al.[<xref rid="bib0054" ref-type="bibr">59</xref>] found that a neuropsychological test-based algorithm for MCI diagnosis was associated with less false positives and better predictions of progression compared to a structured clinical interview method (the Clinical Dementia Rating).</p><p id="para0039">Participants were categorized as having cognitive impairment with no dementia (CIND) if a test normative score was at least 1.5 SD below the population mean (i.e., <italic toggle="yes">T</italic> &lt; 35) and they did not meet the FAQ cutpoint for functional dependence (FAQ &lt;9). CIND was further divided into two subtypes: amnestic CIND (aCIND) and non-amnestic CIND (naCIND). Participants were categorized as aCIND if they met criteria for CIND and had scores that were 1.5 SD below the mean on at least one of the two verbal memory measures (CERAD Learning or CERAD Delayed Recall). Participants were categorized as naCIND if they met criteria for CIND and scores on both verbal memory measures (CERAD Learning and CERAD Delayed Recall) were within normal limits (i.e., <italic toggle="yes">T</italic> = 36 or greater). Participants were categorized as having dementia if they met the test normative score criteria for CIND, but had a FAQ cutpoint of 9 or higher (functionally dependent in 3 or more activities) [<xref rid="bib0061" ref-type="bibr">60</xref>].</p></sec><sec id="sec0012"><label>2.6</label><title>Statistical analysis</title><p id="para0040">Bivariate descriptive statistics for the performance of the maltreated and control groups on all cognitive assessment measures were calculated using <italic toggle="yes">t</italic>-tests. To determine effect size, we report Cohen&#8217;s d. Logistic regressions were then used to determine whether individuals with histories of childhood maltreatment (overall and by types) and controls differed in risk for CIND, aCIND, naCIND, and dementia. Adjusted odds ratios (AORs) and 95 % confidence intervals are reported controlling for participant&#8217;s sex, race, and age at the time of the interview. Analyses used inverse probability weighting to control for attrition bias. Analyses were repeated stratifying by sex, race, age, and education level. All analyses were conducted in R version 4.2.1, R-package <italic toggle="yes">lavaan</italic> version 0.6&#8211;13 [<xref rid="bib0062" ref-type="bibr">61</xref>].</p></sec></sec><sec id="sec0013"><label>3</label><title>RESULTS</title><sec id="sec0014"><label>3.1</label><title>Childhood maltreatment and cognitive tests at mean age 59</title><p id="para0041"><xref rid="tbl0002" ref-type="table">Table 2</xref> shows bivariate descriptive statistics comparing individuals with histories of childhood maltreatment with controls on all cognitive tests at average age 59. These results show significant differences on all tests, with maltreated individuals performing worse than controls. Effect sizes ranged from 0.28 to 0.42, indicating a medium effect of childhood maltreatment on cognitive functioning. <xref rid="tbl0003" ref-type="table">Table 3</xref> shows the percent of individuals in the maltreated and control groups who performed 1.5 SDs below the mean on each specific test. In all of the domains assessed, maltreated individuals were significantly more likely to perform at a lower level on at least one test than controls, and for some domains (e.g., executive functioning), all four test scores revealed significant differences in the likelihood of poor performance for the maltreated individuals.<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Bivariate descriptive statistics for maltreated and control individuals on all individual tests.</p></caption><alt-text id="alt0003">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" align="left" colspan="1" rowspan="1">Controls</th><th valign="top" align="left" colspan="1" rowspan="1">Maltreated</th><th valign="top" align="center" colspan="1" rowspan="1">T test</th><th valign="top" align="center" colspan="1" rowspan="1">p</th><th valign="top" align="center" colspan="1" rowspan="1">Cohen's d</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Benson Complex Figure Copy (M, SD)</td><td valign="top" colspan="1" rowspan="1">15.3 (1.3)</td><td valign="top" colspan="1" rowspan="1">14.6 (2.3)</td><td valign="top" colspan="1" rowspan="1">3.79</td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td valign="top" colspan="1" rowspan="1">0.35</td></tr><tr><td valign="top" colspan="1" rowspan="1">Category Fluency Test: Animals (M, SD)</td><td valign="top" colspan="1" rowspan="1">19.6 (5.5)</td><td valign="top" colspan="1" rowspan="1">18.0 (5.4)</td><td valign="top" colspan="1" rowspan="1">2.90</td><td valign="top" colspan="1" rowspan="1"><bold>0.004</bold></td><td valign="top" colspan="1" rowspan="1">0.29</td></tr><tr><td valign="top" colspan="1" rowspan="1">CERAD Word List Learning and Recall (Immediate) (M, SD)</td><td valign="top" colspan="1" rowspan="1">21.9 (3.9)</td><td valign="top" colspan="1" rowspan="1">20.4 (4.4)</td><td valign="top" colspan="1" rowspan="1">3.54</td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td valign="top" colspan="1" rowspan="1">0.35</td></tr><tr><td valign="top" colspan="1" rowspan="1">CERAD Word List Recall (delayed) (M, SD)</td><td valign="top" colspan="1" rowspan="1">7.8 (1.7)</td><td valign="top" colspan="1" rowspan="1">7.2 (2.0)</td><td valign="top" colspan="1" rowspan="1">3.32</td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td valign="top" colspan="1" rowspan="1">0.32</td></tr><tr><td valign="top" colspan="1" rowspan="1">Multilingual Naming Test (MINT) (M,SD)</td><td valign="top" colspan="1" rowspan="1">28.7 (2.1)</td><td valign="top" colspan="1" rowspan="1">27.9 (2.4)</td><td valign="top" colspan="1" rowspan="1">3.68</td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td valign="top" colspan="1" rowspan="1">0.37</td></tr><tr><td valign="top" colspan="1" rowspan="1">Number Span Forward (M, SD)</td><td valign="top" colspan="1" rowspan="1">7.8 (2.4)</td><td valign="top" colspan="1" rowspan="1">6.9 (2.4)</td><td valign="top" colspan="1" rowspan="1">3.74</td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td valign="top" colspan="1" rowspan="1">0.37</td></tr><tr><td valign="top" colspan="1" rowspan="1">Number Span Backward (M,SD)</td><td valign="top" colspan="1" rowspan="1">6.2 (2.3)</td><td valign="top" colspan="1" rowspan="1">5.3 (2.1)</td><td valign="top" colspan="1" rowspan="1">4.21</td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td valign="top" colspan="1" rowspan="1">0.42</td></tr><tr><td valign="top" colspan="1" rowspan="1">Symbol-Digit Modalities Test (M,SD)</td><td valign="top" colspan="1" rowspan="1">41.8 (9.8)</td><td valign="top" colspan="1" rowspan="1">38.8 (11.0)</td><td valign="top" colspan="1" rowspan="1">2.82</td><td valign="top" colspan="1" rowspan="1"><bold>0.005</bold></td><td valign="top" colspan="1" rowspan="1">0.28</td></tr><tr><td valign="top" colspan="1" rowspan="1">Trail Making Test A (M,SD)</td><td valign="top" colspan="1" rowspan="1">33.9 (17.2)</td><td valign="top" colspan="1" rowspan="1">40.8 (24.0)</td><td valign="top" colspan="1" rowspan="1">3.24</td><td valign="top" colspan="1" rowspan="1"><bold>0.001</bold></td><td valign="top" colspan="1" rowspan="1">0.32</td></tr><tr><td valign="top" colspan="1" rowspan="1">Trail Making Test B (M, SD)</td><td valign="top" colspan="1" rowspan="1">105.5 (67.3)</td><td valign="top" colspan="1" rowspan="1">134.3 (77.8)</td><td valign="top" colspan="1" rowspan="1">3.88</td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td valign="top" colspan="1" rowspan="1">0.39</td></tr><tr><td valign="top" colspan="1" rowspan="1">Stroop Word Test (M,SD)</td><td valign="top" colspan="1" rowspan="1">84.7 (16.2)</td><td valign="top" colspan="1" rowspan="1">77.7 (18.7)</td><td valign="top" colspan="1" rowspan="1">3.88</td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td valign="top" colspan="1" rowspan="1">0.40</td></tr><tr><td valign="top" colspan="1" rowspan="1">Stroop Color Test (M,SD)</td><td valign="top" colspan="1" rowspan="1">64.1 (13.2)</td><td valign="top" colspan="1" rowspan="1">59.1 (15.9)</td><td valign="top" colspan="1" rowspan="1">3.44</td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td valign="top" colspan="1" rowspan="1">0.34</td></tr></tbody></table><table-wrap-foot><fn><p>Note. Scores on all tests are raw scores. For Trail Making A &amp; B, the higher the scores, the worse the performance.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl0003" orientation="portrait"><label>Table 3</label><caption><p>Percent of individuals in the maltreated and control groups who performed 1.5 SDs below the mean on each specific test.</p></caption><alt-text id="alt0004">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" align="center" colspan="1" rowspan="1">Controls</th><th valign="top" align="center" colspan="1" rowspan="1">Maltreated</th><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1"/></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" align="center" colspan="1" rowspan="1">N (%)</th><th valign="top" align="center" colspan="1" rowspan="1">N (%)</th><th valign="top" align="center" colspan="1" rowspan="1">AOR (95% CI)</th><th valign="top" align="center" colspan="1" rowspan="1"><italic toggle="yes"><bold>p</bold></italic></th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>ATTENTION</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Number span forward</td><td valign="top" colspan="1" rowspan="1">2 (1.1 %)</td><td valign="top" colspan="1" rowspan="1">12 (5.0 %)</td><td valign="top" colspan="1" rowspan="1"><bold>4.33 (2.00, 10.92)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Number span backward</td><td valign="top" colspan="1" rowspan="1">4 (2.2 %)</td><td valign="top" colspan="1" rowspan="1">6 (2.5 %)</td><td valign="top" colspan="1" rowspan="1">0.93 (0.43, 2.04)</td><td valign="top" colspan="1" rowspan="1">.856</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>LANGUAGE</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Category fluency test</td><td valign="top" colspan="1" rowspan="1">3 (1.7 %)</td><td valign="top" colspan="1" rowspan="1">14 (5.9 %)</td><td valign="top" colspan="1" rowspan="1"><bold>4.34 (2.12, 10.01)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Multilingual naming test (MINT)</td><td valign="top" colspan="1" rowspan="1">5 (2.8 %)</td><td valign="top" colspan="1" rowspan="1">11 (4.6 %)</td><td valign="top" colspan="1" rowspan="1">1.60 (0.83, 3.18)</td><td valign="top" colspan="1" rowspan="1">.171</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>VISUAL SPATIAL</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Benson Complex figure test</td><td valign="top" colspan="1" rowspan="1">9 (5.0 %)</td><td valign="top" colspan="1" rowspan="1">24 (10.0 %)</td><td valign="top" colspan="1" rowspan="1"><bold>2.81 (1.75, 4.68)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>VERBAL MEMORY</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;CERAD Word List Recall (Immediate)</td><td valign="top" colspan="1" rowspan="1">18.0 (10.0 %)</td><td valign="top" colspan="1" rowspan="1">41 (17.2 %)</td><td valign="top" colspan="1" rowspan="1"><bold>1.94 (1.37, 2.76)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;CERAD Word List Recall (delayed)</td><td valign="top" colspan="1" rowspan="1">3 (1.7 %)</td><td valign="top" colspan="1" rowspan="1">14 (5.9 %)</td><td valign="top" colspan="1" rowspan="1"><bold>3.61 (1.85, 7.72)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>EXECUTIVE FUNCTIONING</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Stroop Word Test</td><td valign="top" colspan="1" rowspan="1">26 (14.4 %)</td><td valign="top" colspan="1" rowspan="1">57 (23.8 %)</td><td valign="top" colspan="1" rowspan="1"><bold>2.03 (1.50, 2.78)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Stroop Color Test</td><td valign="top" colspan="1" rowspan="1">26 (14.4 %)</td><td valign="top" colspan="1" rowspan="1">56 (23.4 %)</td><td valign="top" colspan="1" rowspan="1"><bold>1.91 (1.40, 2.62)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Trail Making Test A</td><td valign="top" colspan="1" rowspan="1">19 (10.6 %)</td><td valign="top" colspan="1" rowspan="1">43 (18.0 %)</td><td valign="top" colspan="1" rowspan="1"><bold>1.94 (1.37, 2.78)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Trail Making B</td><td valign="top" colspan="1" rowspan="1">62 (34.4 %)</td><td valign="top" colspan="1" rowspan="1">111 (46.4 %)</td><td valign="top" colspan="1" rowspan="1"><bold>2.17 (1.68, 2.80)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>PROCESSING SPEED</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Symbol-Digit Modalities Test</td><td valign="top" colspan="1" rowspan="1">25 (13.9 %)</td><td valign="top" colspan="1" rowspan="1">49 (20.5 %)</td><td valign="top" colspan="1" rowspan="1"><bold>1.72 (1.26, 2.38)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Note. AOR = adjusted odds ratio, controlling for participant&#8217;s sex, race, and age at Interview 5. Analyses included inverse probability weighting to control for attrition bias.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0015"><label>3.2</label><title>Childhood maltreatment and cognitive impairment: CIND, amnestic CIND, non-amnestic CIND, and dementia</title><p id="para0042"><xref rid="tbl0004" ref-type="table">Table 4</xref> shows that the study sample had high rates of CIND (61.9 % for the maltreated group compared to 49.4 % of the controls). In these analyses that controlled for sex, race, age at Interview 5, and education, individuals with any documented history of childhood maltreatment had significantly higher risk for CIND [AOR = 1.86 (95 % CI = 1.46&#8211;2.37)], aCIND [AOR = 1.68 (95 % CI = 1.15&#8211;2.49)], and naCIND [AOR = 1.48 ( %% CI = 1.16&#8211;1.88)], compared to controls. Very few of the sample met the criteria for dementia (4.2 % overall); however, it is noteworthy that the only individuals who met the criteria for dementia at this age were those with histories of childhood maltreatment.<table-wrap position="float" id="tbl0004" orientation="portrait"><label>Table 4</label><caption><p>Prevalence of cognitive impairment and dementia for the overall sample and specific types of child maltreatment.</p></caption><alt-text id="alt0005">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Control</th><th colspan="2" align="left" valign="top" rowspan="1">Any Maltreatment<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">Neglect<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">Sexual Abuse<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">Physical Abuse<hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1">N</th><th valign="top" colspan="1" rowspan="1">180</th><th colspan="2" align="left" valign="top" rowspan="1">239<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">191<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">35<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">40<hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">N (%)</th><th valign="top" colspan="1" rowspan="1">N (%)</th><th valign="top" colspan="1" rowspan="1">AOR (95 %CI)</th><th valign="top" colspan="1" rowspan="1">N (%)</th><th valign="top" colspan="1" rowspan="1">AOR (95 %CI)</th><th valign="top" colspan="1" rowspan="1">N (%)</th><th valign="top" colspan="1" rowspan="1">AOR (95 %CI)</th><th valign="top" colspan="1" rowspan="1">N (%)</th><th valign="top" colspan="1" rowspan="1">AOR (95 %CI)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">CIND</td><td valign="top" colspan="1" rowspan="1">89 (49.4 %)</td><td valign="top" colspan="1" rowspan="1">148 (61.9 %)</td><td valign="top" colspan="1" rowspan="1"><bold>1.86 (1.46-2.37)</bold><xref rid="tb4fn1" ref-type="table-fn">&#8270;&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">121 (63.4 %)</td><td valign="top" colspan="1" rowspan="1"><bold>2.05 (1.58-2.67)</bold><xref rid="tb4fn1" ref-type="table-fn">&#8270;&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">24 (68.6 %)</td><td valign="top" colspan="1" rowspan="1"><bold>2.12 (1.28-3.57)</bold><xref rid="tb4fn2" ref-type="table-fn">&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">16 (40.0 %)</td><td valign="top" colspan="1" rowspan="1">0.76 (0.49-1.17)</td></tr><tr><td valign="top" colspan="1" rowspan="1">CIND: Amnestic</td><td valign="top" colspan="1" rowspan="1">15 (8.3 %)</td><td valign="top" colspan="1" rowspan="1">30 (12.6 %)</td><td valign="top" colspan="1" rowspan="1"><bold>1.68 (1.15-2.49)</bold><xref rid="tb4fn2" ref-type="table-fn">&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">25 (13.1 %)</td><td valign="top" colspan="1" rowspan="1"><bold>1.68 (1.14-2.51)</bold><xref rid="tb4fn2" ref-type="table-fn">&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">4 (11.4 %)</td><td valign="top" colspan="1" rowspan="1"><bold>2.27 (1.00-5.05)</bold><xref rid="tb4fn1" ref-type="table-fn">*</xref></td><td valign="top" colspan="1" rowspan="1">6 (15.0 %)</td><td valign="top" colspan="1" rowspan="1">1.81 (0.95-3.33)</td></tr><tr><td valign="top" colspan="1" rowspan="1">CIND: Non-Amnestic</td><td valign="top" colspan="1" rowspan="1">73 (40.6 %)</td><td valign="top" colspan="1" rowspan="1">117 (49.0 %)</td><td valign="top" colspan="1" rowspan="1"><bold>1.48 (1.16-1.88)</bold><xref rid="tb4fn2" ref-type="table-fn">&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">96 (50.3 %)</td><td valign="top" colspan="1" rowspan="1"><bold>1.63 (1.27-2.09)</bold><xref rid="tb4fn3" ref-type="table-fn">&#8270;&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">20 (57.1 %)</td><td valign="top" colspan="1" rowspan="1"><bold>1.60 (0.98-2.62)</bold></td><td valign="top" colspan="1" rowspan="1">10 (25.0 %)</td><td valign="top" colspan="1" rowspan="1">0.54 (0.33-0.86)<xref rid="tb4fn1" ref-type="table-fn">*</xref></td></tr><tr><td valign="top" colspan="1" rowspan="1">Dementia</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">10 (4.2 %)</td><td valign="top" colspan="1" rowspan="1"><bold>-</bold></td><td valign="top" colspan="1" rowspan="1">8 (4.2 %)</td><td valign="top" colspan="1" rowspan="1"><bold>-</bold></td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1"><bold>-</bold></td><td valign="top" colspan="1" rowspan="1">4 (10.0 %)</td><td valign="top" colspan="1" rowspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: AOR&#8239;=&#8239;adjusted odds ratio; CIND&#8239;=&#8239;cognitive impairment, no dementia. 447 individuals participated in Interview 5, only 419 people had cognitive data. 28 did not have any or did not have enough cognitive data to make a determination about dementia or cognitive impairment. The total count for specific types of maltreatment exceeds the number of individuals in the maltreated group because some individuals experienced multiple types of maltreatment (n&#8239;=&#8239;26). Analyses use inverse probability weighting and control for participant&#8217;s sex, race, and age at Interview 5.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb4fn1"><label>&#8270;</label><p id="notep0003">p &lt;.05,</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb4fn2"><label>&#8270;&#8270;</label><p id="notep0004">p &lt;.01,</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb4fn3"><label>&#8270;&#8270;&#8270;</label><p id="notep0005">p &lt;.001.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0016"><label>3.3</label><title>Specific types of childhood maltreatment and cognitive impairment</title><p id="para0043"><xref rid="tbl0004" ref-type="table">Table 4</xref> also shows the extent of cognitive impairment in individuals with specific types of childhood maltreatment. Adults with documented histories of childhood neglect were at increased risk for all three types of cognitive impairment. Adults with documented histories of childhood sexual abuse were at increased risk for CIND and aCIND, but not naCIND. In contrast, individuals with histories of physical abuse were at decreased risk for naCIND, with 25 % of those physically abused meeting the criteria for naCIND compared to 40.6 % of controls (AOR = 0.54, 95 % CI = 0.33&#8211;0.86, <italic toggle="yes">p</italic>&lt;.01).</p></sec><sec id="sec0017"><label>3.4</label><title>Childhood maltreatment and cognitive impairment stratified by sex, race, age, and level of education</title><p id="para0044"><xref rid="tbl0005" ref-type="table">Table 5</xref> shows the results of comparisons of maltreated and control individuals stratified by sex, race, age, and level of education. The first part of this table shows that both maltreated males and females were at increased risk for CIND and naCIND, compared to controls. In addition, maltreated females were at increased risk for aCIND, compared to controls. Five percent of the maltreated males met the criteria for dementia compared to none of the controls. <xref rid="tbl0005" ref-type="table">Table 5</xref> also shows that both Black and White maltreated participants were at increased risk for CIND compared to Black and White controls. However, Black maltreated participants were also at increased risk of aCIND and naCIND compared to Black controls.<table-wrap position="float" id="tbl0005" orientation="portrait"><label>Table 5</label><caption><p>Comparisons of the extent of cognitive impairment in maltreated and control participants, stratified by sex, race, age, and education.</p></caption><alt-text id="alt0006">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="9" align="left" valign="top" rowspan="1">Cognitive Impairment<hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th colspan="4" align="left" valign="top" rowspan="1"><italic toggle="yes">Male</italic><hr/></th><th colspan="4" align="left" valign="top" rowspan="1"><italic toggle="yes">Female</italic><hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Total (N&#8239;=&#8239;181)</th><th valign="top" colspan="1" rowspan="1">Control (N&#8239;=&#8239;80)</th><th valign="top" colspan="1" rowspan="1">Maltreated (N&#8239;=&#8239;101)</th><th valign="top" colspan="1" rowspan="1">AOR (95 % CI)</th><th valign="top" colspan="1" rowspan="1">Total (N&#8239;=&#8239;238)</th><th valign="top" colspan="1" rowspan="1">Control (N&#8239;=&#8239;100)</th><th valign="top" colspan="1" rowspan="1">Maltreated (N&#8239;=&#8239;138)</th><th valign="top" colspan="1" rowspan="1">AOR (95 % CI)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Any CIND</td><td valign="top" colspan="1" rowspan="1">112 (61.9 %)</td><td valign="top" colspan="1" rowspan="1">41 (51.2 %)</td><td valign="top" colspan="1" rowspan="1">66 (65.3 %)</td><td valign="top" colspan="1" rowspan="1">2.05 (1.46-2.89)<xref rid="tb5fn4" ref-type="table-fn">&#8270;&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">135 (56.7 %)</td><td valign="top" colspan="1" rowspan="1">48 (48.0 %)</td><td valign="top" colspan="1" rowspan="1">82 (59.4 %)</td><td valign="top" colspan="1" rowspan="1">1.68 (1.18-2.39)<xref rid="tb5fn3" ref-type="table-fn">&#8270;&#8270;</xref></td></tr><tr><td valign="top" colspan="1" rowspan="1">Amnestic</td><td valign="top" colspan="1" rowspan="1">31 (17.1 %)</td><td valign="top" colspan="1" rowspan="1">10 (12.5 %)</td><td valign="top" colspan="1" rowspan="1">17 (16.8 %)</td><td valign="top" colspan="1" rowspan="1">1.56 (0.98-2.50)<xref rid="tb5fn1" ref-type="table-fn">&#8224;</xref></td><td valign="top" colspan="1" rowspan="1">19 (8.0 %)</td><td valign="top" colspan="1" rowspan="1">5 (5.0 %)</td><td valign="top" colspan="1" rowspan="1">13 (9.4 %)</td><td valign="top" colspan="1" rowspan="1">2.04 (1.05-4.21)<xref rid="tb5fn2" ref-type="table-fn">*</xref></td></tr><tr><td valign="top" colspan="1" rowspan="1">Non-Amnestic</td><td valign="top" colspan="1" rowspan="1">79 (43.6 %)</td><td valign="top" colspan="1" rowspan="1">31 (38.8 %)</td><td valign="top" colspan="1" rowspan="1">47 (46.5 %)</td><td valign="top" colspan="1" rowspan="1">1.52 (1.09-2.13)<xref rid="tb5fn2" ref-type="table-fn">*</xref></td><td valign="top" colspan="1" rowspan="1">116 (48.7 %)</td><td valign="top" colspan="1" rowspan="1">42 (42.0 %)</td><td valign="top" colspan="1" rowspan="1">70 (50.7 %)</td><td valign="top" colspan="1" rowspan="1">1.42 (1.01-2.01)<xref rid="tb5fn2" ref-type="table-fn">*</xref></td></tr><tr><td valign="top" colspan="1" rowspan="1">Dementia</td><td valign="top" colspan="1" rowspan="1">5 (2.8 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">5 (5.0 %)</td><td valign="top" colspan="1" rowspan="1">-</td><td valign="top" colspan="1" rowspan="1">5 (2.1 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">5 (3.6 %)</td><td valign="top" colspan="1" rowspan="1">-</td></tr><tr><td colspan="9" rowspan="1"><hr/></td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th colspan="4" align="left" valign="top" rowspan="1"><italic toggle="yes">Black</italic><hr/></th><th colspan="4" align="left" valign="top" rowspan="1"><italic toggle="yes">White</italic><hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Total (N&#8239;=&#8239;154)</th><th valign="top" colspan="1" rowspan="1">Control (N&#8239;=&#8239;77)</th><th valign="top" colspan="1" rowspan="1">Maltreated (N&#8239;=&#8239;77)</th><th valign="top" colspan="1" rowspan="1">AOR (95 % CI)</th><th valign="top" colspan="1" rowspan="1">Total (N&#8239;=&#8239;243)</th><th valign="top" colspan="1" rowspan="1">Control (N&#8239;=&#8239;98)</th><th valign="top" colspan="1" rowspan="1">Maltreated (N&#8239;=&#8239;145)</th><th valign="top" colspan="1" rowspan="1">AOR (95 % CI)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Any CIND</td><td valign="top" colspan="1" rowspan="1">102 (66.2 %)</td><td valign="top" colspan="1" rowspan="1">44 (57.1 %)</td><td valign="top" colspan="1" rowspan="1">56 (72.7 %)</td><td valign="top" colspan="1" rowspan="1">2.15 (1.43-3.25)<xref rid="tb5fn4" ref-type="table-fn">&#8270;&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">132 (54.3 %)</td><td valign="top" colspan="1" rowspan="1">44 (44.9 %)</td><td valign="top" colspan="1" rowspan="1">81 (55.9 %)</td><td valign="top" colspan="1" rowspan="1">1.57 (1.15-2.15)<xref rid="tb5fn3" ref-type="table-fn">&#8270;&#8270;</xref></td></tr><tr><td valign="top" colspan="1" rowspan="1">Amnestic</td><td valign="top" colspan="1" rowspan="1">20.0 (13.0 %)</td><td valign="top" colspan="1" rowspan="1">7 (9.1 %)</td><td valign="top" colspan="1" rowspan="1">12 (15.6 %)</td><td valign="top" colspan="1" rowspan="1">2.04 (1.15-3.72)<xref rid="tb5fn2" ref-type="table-fn">*</xref></td><td valign="top" colspan="1" rowspan="1">28 (11.5 %)</td><td valign="top" colspan="1" rowspan="1">8 (8.2 %)</td><td valign="top" colspan="1" rowspan="1">17 (11.7 %)</td><td valign="top" colspan="1" rowspan="1">1.43 (0.87-2.40)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Non-Amnestic</td><td valign="top" colspan="1" rowspan="1">81 (52.6 %)</td><td valign="top" colspan="1" rowspan="1">36 (46.8 %)</td><td valign="top" colspan="1" rowspan="1">44 (57.1 %)</td><td valign="top" colspan="1" rowspan="1">1.47 (1.00-2.15)<xref rid="tb5fn2" ref-type="table-fn">*</xref></td><td valign="top" colspan="1" rowspan="1">103 (42.45)</td><td valign="top" colspan="1" rowspan="1">36 (36.7 %)</td><td valign="top" colspan="1" rowspan="1">63 (43.4 %)</td><td valign="top" colspan="1" rowspan="1">1.36 (0.99-1.87)<xref rid="tb5fn1" ref-type="table-fn">&#8224;</xref></td></tr><tr><td valign="top" colspan="1" rowspan="1">Dementia</td><td valign="top" colspan="1" rowspan="1">2 (1.3 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">2 (2.6 %)</td><td valign="top" colspan="1" rowspan="1">-</td><td valign="top" colspan="1" rowspan="1">7 (2.9 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">7 (4.8 %)</td><td valign="top" colspan="1" rowspan="1">-</td></tr><tr><td colspan="9" rowspan="1"><hr/></td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th colspan="4" align="left" valign="top" rowspan="1"><italic toggle="yes">Older (Above 59)</italic><hr/></th><th colspan="4" align="left" valign="top" rowspan="1"><italic toggle="yes">Younger (Below 59)</italic><hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Total (N&#8239;=&#8239;253)</th><th valign="top" colspan="1" rowspan="1">Control (N&#8239;=&#8239;106)</th><th valign="top" colspan="1" rowspan="1">Maltreated (N&#8239;=&#8239;147)</th><th valign="top" colspan="1" rowspan="1">AOR (95 % CI)</th><th valign="top" colspan="1" rowspan="1">Total (N&#8239;=&#8239;166)</th><th valign="top" colspan="1" rowspan="1">Control (N&#8239;=&#8239;74)</th><th valign="top" colspan="1" rowspan="1">Maltreated (N&#8239;=&#8239;92)</th><th valign="top" colspan="1" rowspan="1">AOR (95 % CI)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Any CIND</td><td valign="top" colspan="1" rowspan="1">169 (66.8 %)</td><td valign="top" colspan="1" rowspan="1">58 (54.7 %)</td><td valign="top" colspan="1" rowspan="1">104 (70.7 %)</td><td valign="top" colspan="1" rowspan="1">2.08 (1.52-2.86)<xref rid="tb5fn4" ref-type="table-fn">&#8270;&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">78 (47.0 %)</td><td valign="top" colspan="1" rowspan="1">31 (41.9 %)</td><td valign="top" colspan="1" rowspan="1">44 (47.8 %)</td><td valign="top" colspan="1" rowspan="1">1.63 (1.11-2.40)<xref rid="tb5fn2" ref-type="table-fn">*</xref></td></tr><tr><td valign="top" colspan="1" rowspan="1">Amnestic</td><td valign="top" colspan="1" rowspan="1">33 (13.0 %)</td><td valign="top" colspan="1" rowspan="1">11 (10.4 %)</td><td valign="top" colspan="1" rowspan="1">18 (12.2 %)</td><td valign="top" colspan="1" rowspan="1">1.24 (0.78-1.99)</td><td valign="top" colspan="1" rowspan="1">17 (10.2 %)</td><td valign="top" colspan="1" rowspan="1">4 (5.4 %)</td><td valign="top" colspan="1" rowspan="1">12 (13.0 %)</td><td valign="top" colspan="1" rowspan="1">3.06 (1.57-6.38)<xref rid="tb5fn3" ref-type="table-fn">&#8270;&#8270;</xref></td></tr><tr><td valign="top" colspan="1" rowspan="1">Non-Amnestic</td><td valign="top" colspan="1" rowspan="1">134 (53.0 %)</td><td valign="top" colspan="1" rowspan="1">46 (43.4 %)</td><td valign="top" colspan="1" rowspan="1">85 (57.8 %)</td><td valign="top" colspan="1" rowspan="1">1.80 (1.33-2.45)<xref rid="tb5fn4" ref-type="table-fn">&#8270;&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">61 (36.7 %)</td><td valign="top" colspan="1" rowspan="1">27 (36.5 %)</td><td valign="top" colspan="1" rowspan="1">32 (34.8 %)</td><td valign="top" colspan="1" rowspan="1">1.08 (0.73-1.61)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Dementia</td><td valign="top" colspan="1" rowspan="1">7 (2.8 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">7 (4.8 %)</td><td valign="top" colspan="1" rowspan="1">-</td><td valign="top" colspan="1" rowspan="1">3 (1.8 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">3 (3.3 %)</td><td valign="top" colspan="1" rowspan="1">-</td></tr><tr><td colspan="9" rowspan="1"><hr/></td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th colspan="4" align="left" valign="top" rowspan="1"><italic toggle="yes">Graduated High School</italic><hr/></th><th colspan="4" align="left" valign="top" rowspan="1"><italic toggle="yes">Did Not Graduate High School</italic><hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Total (N&#8239;=&#8239;254)</th><th valign="top" colspan="1" rowspan="1">Control (N&#8239;=&#8239;119)</th><th valign="top" colspan="1" rowspan="1">Maltreated (N&#8239;=&#8239;135)</th><th valign="top" colspan="1" rowspan="1">AOR (95 % CI)</th><th valign="top" colspan="1" rowspan="1">Total (N&#8239;=&#8239;165)</th><th valign="top" colspan="1" rowspan="1">Control (N&#8239;=&#8239;61)</th><th valign="top" colspan="1" rowspan="1">Maltreated (N&#8239;=&#8239;104)</th><th valign="top" colspan="1" rowspan="1">AOR (95 % CI)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Any CIND</td><td valign="top" colspan="1" rowspan="1">136 (53.5 %)</td><td valign="top" colspan="1" rowspan="1">51 (42.9 %)</td><td valign="top" colspan="1" rowspan="1">80 (59.3 %)</td><td valign="top" colspan="1" rowspan="1">2.04 (1.50-2.79)<xref rid="tb5fn4" ref-type="table-fn">&#8270;&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">111 (67.3 %)</td><td valign="top" colspan="1" rowspan="1">38 (62.3 %)</td><td valign="top" colspan="1" rowspan="1">68 (65.4 %)</td><td valign="top" colspan="1" rowspan="1">1.36 (0.89-2.09)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Amnestic</td><td valign="top" colspan="1" rowspan="1">28 (11.0 %)</td><td valign="top" colspan="1" rowspan="1">9 (7.6 %)</td><td valign="top" colspan="1" rowspan="1">17 (12.6 %)</td><td valign="top" colspan="1" rowspan="1">1.84 (1.11-3.0)<xref rid="tb5fn2" ref-type="table-fn">*</xref></td><td valign="top" colspan="1" rowspan="1">22 (13.3 %)</td><td valign="top" colspan="1" rowspan="1">6 (9.8 %)</td><td valign="top" colspan="1" rowspan="1">13 (12.5 %)</td><td valign="top" colspan="1" rowspan="1">1.48 (0.82-2.72)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Non-Amnestic</td><td valign="top" colspan="1" rowspan="1">108 (42.5 %)</td><td valign="top" colspan="1" rowspan="1">42 (35.3 %)</td><td valign="top" colspan="1" rowspan="1">63 (46.7 %)</td><td valign="top" colspan="1" rowspan="1">1.64 (1.21-2.25)<xref rid="tb5fn3" ref-type="table-fn">&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">87 (52.7 %)</td><td valign="top" colspan="1" rowspan="1">31 (50.8 %)</td><td valign="top" colspan="1" rowspan="1">54 (51.9 %)</td><td valign="top" colspan="1" rowspan="1">1.08 (0.73-1.60)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Dementia</td><td valign="top" colspan="1" rowspan="1">5 (2.0 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">5 (3.7 %)</td><td valign="top" colspan="1" rowspan="1">-</td><td valign="top" colspan="1" rowspan="1">5 (3.0 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">5 (4.8 %)</td><td valign="top" colspan="1" rowspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: CIND&#8239;=&#8239;cognitive impairment, no dementia; AOR&#8239;=&#8239;adjusted odds ratio, controlling for age, sex, and race when not the object of the stratification. Analyses use inverse probability weighting.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb5fn1"><label>&#8224;</label><p id="notep0007">p &lt;.10,</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb5fn2"><label>&#8270;</label><p id="notep0008">p &lt;.05,</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb5fn3"><label>&#8270;&#8270;</label><p id="notep0009">p &lt;.01,</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb5fn4"><label>&#8270;&#8270;&#8270;</label><p id="notep0010">p &lt;.001.</p></fn></table-wrap-foot></table-wrap></p><p id="para0045">Comparing participants who were older (above age 59 &#8211; the mean age of the sample overall) and younger (below age 59), <xref rid="tbl0005" ref-type="table">Table 5</xref> shows that maltreated individuals in both age groups were at increased risk for CIND [older (AOR = 2.08 (1.52&#8211;2.86) and younger (AOR = 1.63 (1.11&#8211;2.40)], compared to controls. However, the older maltreated individuals were at increased risk for naCIND [AOR = 1.80 (1.33&#8211;2.45)], whereas younger maltreated individuals were at increased risk for aCIND [AOR = 3.06 (1.57&#8211;6.38)], compared to controls.</p><p id="para0046">Finally, <xref rid="tbl0005" ref-type="table">Table 5</xref> shows that maltreated individuals who completed high school were at increased risk for CIND, aCIND amnestic, and naCIND, compared to controls who completed high school. However, although the rates of CIND were higher than those who graduated from high school, among individuals who did not graduate from high school, there were no differences between the maltreated and control groups.</p><p id="para0047">We also tested whether age, sex, race, or level of education moderated the relationship between childhood maltreatment and cognitive impairment. The results indicated that there were no significant interactions for age, sex, or race; however, there was a significant interaction for education. <xref rid="fig0001" ref-type="fig">Fig. 1</xref> shows the significant interaction of education with childhood maltreatment predicting CIND [AOR = 1.81 (1.09&#8211;3.01), <italic toggle="yes">p</italic> = .021], revealing the negative impact of childhood maltreatment on high school graduates (that is, individuals with higher levels of education). These results show that high school graduation was not protective for individuals who were maltreated in childhood, whose risk for cognitive impairment was similar to maltreated individuals who did not graduate from high school.<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Results of OLS regressions testing whether high school graduation moderates the relationship between childhood maltreatment and CIND.</p></caption><alt-text id="alt0001">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/><attrib>Note. CIND = cognitive impairment, no dementia. <xref rid="fig0001" ref-type="fig">Fig. 1</xref> shows the interaction between childhood maltreatment and high school graduation in predicting CIND (adjusted odds ratio = 1.81, 95 % confidence interval = 1.09, 3.01, <italic toggle="yes">p</italic>= .021). Analyses use inverse probability weighting and control for age, sex, and race.</attrib></fig></p></sec></sec><sec id="sec0018"><label>4</label><title>Discussion</title><p id="para0048">This longitudinal study followed a large group of children with documented histories of abuse and neglect and a demographically matched control group into late midlife at average age 59. At that time, participants were administered a comprehensive neuropsychological battery of 12 cognitive tests to determine whether childhood maltreatment increased a person's risk for CIND, aCIND, naCIND, and dementia. These new results show that on all tests of cognitive functioning, the maltreated group performed significantly worse than the controls in late midlife, with a medium effect size of childhood maltreatment over the course of several decades. The impact of maltreatment was particularly evident in tasks of executive functioning.</p><p id="para0049">We compared the extent of maltreated individuals who had aCIND and naCIND and found that maltreated individuals overall were at greater risk for both types (amnestic and non-amnestic CIND) compared to controls. A larger percent of participants with histories of childhood maltreatment showed non-memory problems (naCIND) compared to controls. It is possible that other risk factors for poor brain health (e.g., socio-economic status, lower levels of education, and poorer access to medical care) may explain these findings. Non-amnestic CIND potentially has multiple causes, many of which may be modifiable. For example, if the naCIND is associated with cardio-vascular disease (CVD), then treatment for CVD might reduce risk for or slow down the progression of impairment to dementia [<xref rid="bib0063" ref-type="bibr">62</xref>]. Further research is needed to determine whether modifiable risk factors explain the increase in risk for naCIND for these individuals.</p><p id="para0050">About 13 % of the individuals with documented histories of childhood maltreatment also met the criteria for aCIND and were significantly more likely than the demographically matched controls to have aCIND. These findings suggest that there is a subset of individuals who have documented histories of childhood maltreatment who are at high risk of AD, compared to individuals who were demographically matched in childhood. Previous research has shown that progression to AD with amnestic CIND is more likely than progression with non-amnestic MCI [<xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>].</p><p id="para0051">Although previous studies have examined cognitive impairment using adversities or maltreatment as a single construct [<xref rid="bib0064" ref-type="bibr">63</xref>], a small number of studies have reported differences in risk for cognitive impairment by type of childhood adversity experienced [<xref rid="bib0034" ref-type="bibr">34</xref>]. Xie et al.[<xref rid="bib0002" ref-type="bibr">2</xref>] reported that emotional and physical abuse were associated with increased risk for all cause dementia in later life, whereas sexual abuse was not. Our results suggest that there may be differences in the impact of the type of childhood maltreatment experienced on cognitive functioning over time and, ultimately on risk for dementia. Individuals with histories of childhood neglect were at risk for all three types of cognitive impairment (CIND, aCIND, and naCIND). For adults with histories of childhood neglect, this increase in risk for cognitive impairment may be explained by the heavy co-occurrence of poverty with neglect. It is possible that these long-term consequences for cognitive functioning for individuals with histories of childhood neglect reflect earlier deficiencies in the provision of food and medical care by childhood caretakers that then placed these children at risk for inadequate medical and health care as they grew into adulthood. To our knowledge, this is the first study that has examined these long-term consequences for CIND as a result of childhood neglect. With these new findings, we need to address efforts to determine the mechanisms that have placed these adults at increased risk and develop prevention strategies.</p><p id="para0052">Although sparse, the existing literature is not consistent about the extent to which sexual abuse is associated with increased risk for cognitive impairment in later life. Nakayama and colleagues[<xref rid="bib0034" ref-type="bibr">34</xref>] found that adult female PTSD patients who reported sexual abuse scored more poorly on language tests and overall cognitive functioning, compared to healthy control women. In contrast, Xie et al.[<xref rid="bib0002" ref-type="bibr">2</xref>] did not find an association of sexual abuse with all cause dementia in late life. Our results show that individuals with histories of sexual abuse were at increased risk for CIND and aCIND. PTSD may play a critical role here (as suggested by the Nakayama et al.[<xref rid="bib0034" ref-type="bibr">34</xref>] findings), since individuals who have experienced childhood sexual abuse often have high rates of PTSD[<xref rid="bib0065" ref-type="bibr">64</xref>] and may have memory deficits associated with traumatic reactions to those experiences. On the other hand, in earlier work [<xref rid="bib0026" ref-type="bibr">26</xref>], childhood maltreatment overall and childhood neglect predicted poorer executive functioning and non-verbal reasoning at age 41, whereas physical and sexual abuse did not. Furthermore, a past history of PTSD did not mediate or moderate these relationships.</p><p id="para0053">In contrast to expectations, individuals with histories of childhood physical abuse were not at increased risk for CIND. Instead, there was a significant decrease in risk for naCIND for individuals with histories of childhood physical abuse. Fewer (25 %) of those with histories of physical abuse met the criteria for naCIND, compared to 40.6 % of the controls. These are surprising findings as are other trends in relation to physical abuse and cognitive functioning. Although not significant, individuals with histories of physical abuse were at higher risk for aCIND (15 % versus 8 %) and were more likely to manifest dementia in late midlife (10 % versus none) compared to the controls. Although the sample size for the physical abuse group is small, given that the results for naCIND were significant, it is hard to argue that the findings about aCIND and dementia are solely due to smaller sample of physically abused group. But these provocative findings warrant further examination.</p><p id="para0054">There is increasing recognition of the role of social determinants of health and increasing attention to the important influence of non-medical factors and conditions in which people live, work, and develop. In particular, studies have examined the role of education and income in relation to cognitive aging. Manly et al.[<xref rid="bib0066" ref-type="bibr">65</xref>] found that each additional year of education was associated with decreased risk of dementia. In our study, we used high school graduation as an indicator of level of education and found that high school graduation was protective overall, associated with better cognitive functioning scores and lower rates of CIND. However, a significant interaction showed that high school graduation was not protective for maltreated individuals. Individuals with histories of childhood maltreatment who graduated from high school (that is, maltreated individuals with higher levels of education) were at higher risk for CIND, aCIND, and naCIND compared to controls who graduated from high school.</p><p id="para0055">These unexpected findings require comment, particularly since common theories would have predicted different results. For example, the cognitive reserve hypothesis[<xref rid="bib0067" ref-type="bibr">[66]</xref>, <xref rid="bib0068" ref-type="bibr">[67]</xref>, <xref rid="bib0069" ref-type="bibr">[68]</xref>] would have predicted that enriched experiences such as getting a high school degree would protect individuals with a history of childhood maltreatment from cognitive decline. Our results do not provide support for this hypothesis. Our results show that individuals with a history of child maltreatment and a high school degree suffer from similar risk of cognitive decline as those without high school degrees. Similarly, the compensatory stress model[<xref rid="bib0070" ref-type="bibr">69</xref>] suggests that educational attainment can act as a moderator of trauma responses. Our results suggest that in the case of these maltreated individuals, educational attainment is not strong enough to prevent higher levels of cognitive impairment in individuals with histories of maltreatment. Most likely the best interpretation of these new results is to acknowledge the "Long Arm of Childhood Model"[<xref rid="bib0071" ref-type="bibr">70</xref>,<xref rid="bib0072" ref-type="bibr">71</xref>] that reflects the phenomenon whereby childhood experiences impact adult health through extended and complex pathways that include education, health behaviors, and biological processes.</p><p id="para0056">Both older and younger maltreated individuals in our study were at increased risk for any CIND, compared to demographically matched controls. However, our findings revealed differences in the types of cognitive impairment manifest by the older and younger participants. Among older participants (individuals above age 59), more maltreated individuals met the criteria for naCIND compared to younger maltreated individuals, whereas for the younger participants, maltreated individuals were at significantly increased risk for aCIND. By age, the younger participants in the study should be at lower risk for CIND. Although the younger controls have low rates of aCIND, the younger maltreated participants have the highest rates of aCIND. These findings are similar to the counterintuitive findings for education and maltreatment. That is, the group with the lower risk in general (more educated and younger) shows the greatest effect of childhood maltreatment.</p><p id="para0057">The literature on social determinants of health indicates a higher burden of dementia among Black, non-Hispanic individuals compared to White, non-Hispanic individuals [<xref rid="bib0073" ref-type="bibr">72</xref>]. In our study, we found that both Black and White maltreated children were at increased risk for CIND in late midlife, compared to Black and White controls, respectively. However, we also found that Black, non-Hispanic maltreated individuals were at increased risk for aCIND compared to Black, non-Hispanic controls (16 % versus 9 %), whereas we did not find the same effect for White, non-Hispanic maltreated individuals compared to White, non-Hispanic controls (12 % versus 8 %). These findings are consistent with the larger literature on the health burden for Black individuals and suggest that the Black, non-Hispanic maltreated individuals in our study are at higher risk of accelerated progression leading to dementia.</p><p id="para0058">Finally, our findings also reveal that even at this relatively young age, there was evidence of dementia in the sample, but only among the maltreated individuals, not the controls. Though base rates of dementia in this age group are low, early onset is rare. It is possible that the increase in functional impairment is due to the impact of other medical or psychiatric variables rather than cognitive decline, but this is difficult to determine given the very small number of cases that met the criteria for dementia.</p><sec id="sec0019"><label>4.1</label><title>Limitations</title><p id="para0059">Although these findings provide important information about the impact of childhood maltreatment on risk for cognitive impairment and dementia, some limitations should be noted. First, these findings are based on cases of childhood abuse and neglect drawn from official court records and most likely represent the most extreme cases processed in the system. Second, cases that came to the attention of the courts are skewed toward the lower end of the socio-economic spectrum and, these results cannot be generalized to abused and neglected children who grew up in middle- or upper-class homes. Third, the cases included here represented those that occurred in the late 1960s and early 1970s in the Midwest part of the United States and might differ from cases currently being processed by child protection agencies. However, these cases are comparable in demographic characteristics to the kinds of cases being processed currently by child protection services across the country. Fourth, we used algorithms to determine cognitive impairment, rather than rater diagnoses since we lacked access to other medical history information that would have been needed to make a diagnostic adjudication. For example, we did not have information about whether low cognitive scores might have occurred for other reasons, such as injury or accidents. These rates of CIND in the overall sample are high relative to other studies of similar age adults and most likely reflect the large proportion of maltreated individuals with cognitive impairment and the skewness of the sample toward the lower end of the socio-economic spectrum. We were able to investigate the potential differential effects of neglect, physical abuse, and sexual abuse, adding significantly to a literature that often combines these abuse types when examining long-term consequences associated with adverse childhood experiences. However, the sample sizes of individuals with histories of physical abuse and sexual abuse are smaller than the neglect group. Therefore, it is possible that some of the differences (or lack of significant differences) among types may be due to differences in sample sizes. Finally, our measure of functional impairment (the FAQ) was based on self-report rather than informant report. It is possible that participants lacking insight into their impairments under-reported changes in independent functioning. If this is the case, the current results may underestimate dementia prevalence.</p></sec><sec id="sec0020"><label>4.2</label><title>Conclusions</title><p id="para0060">The present study advances our understanding of the long-term consequences of childhood maltreatment in relation to cognitive functioning in late midlife. Building on earlier findings documenting poorer executive functioning and nonverbal learning in midlife (age 41) [<xref rid="bib0026" ref-type="bibr">26</xref>], these new findings indicate that the cognitive repercussions of childhood maltreatment continue into late midlife (age 59). In earlier work, we found that midlife adults who experienced childhood maltreatment possessed, on average, more dementia risk factors (that is, greater risk for low educational attainment, social isolation, smoking, and clinical depression) compared to midlife adults without a history of maltreatment [<xref rid="bib0041" ref-type="bibr">41</xref>]. These new results reveal that childhood maltreatment increases risk for cognitive impairment in late midlife. Future research should examine the extent to which poorer physical health, increased psychopathology, reduced socioeconomic status, and worse behavioral and social outcomes are some of the mechanisms by which childhood maltreatment increases risk for later impairments in cognitive functioning and point to modifiable risk factors. These findings reinforce the importance of early detection and interventions for maltreated children and adults with histories of maltreatment that may help offset some of the risks associated with childhood maltreatment in later adulthood.</p></sec></sec><sec id="sec0020a"><title>CRediT authorship contribution statement</title><p id="para0060a"><bold>Stephanie Assuras:</bold> Writing &#8211; review &amp; editing, Validation, Methodology, Investigation, Data curation. <bold>Kellie Courtney:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Methodology, Formal analysis. <bold>Molly Maxfield:</bold> Writing &#8211; review &amp; editing, Methodology, Investigation, Funding acquisition, Conceptualization. <bold>Shaina Shagalow:</bold> Writing &#8211; original draft. <bold>Sara Sherer:</bold> Validation, Investigation, Data curation. <bold>Jennifer J. Manly:</bold> Writing &#8211; review &amp; editing, Validation, Methodology, Investigation, Funding acquisition, Conceptualization. <bold>Cathy Spatz Widom:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0062">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:</p><p id="para0063">Cathy Spatz Widom reports financial support was provided by <funding-source id="gs0001"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source>. Stephanie Assuras reports financial support from <funding-source id="gs0002"><institution-wrap><institution-id institution-id-type="doi">10.13039/100019782</institution-id><institution>Columbia University</institution></institution-wrap></funding-source> that includes: employment. Molly Maxfield reports financial support from <funding-source id="gs0003"><institution-wrap><institution-id institution-id-type="doi">10.13039/100007482</institution-id><institution>Arizona State University</institution></institution-wrap></funding-source> that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Childhood physical neglect promotes development of mild cognitive impairment in old age &#8211; a case-control study</article-title><source>Psychiatry Res</source><volume>242</volume><year>2016</year><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2016.04.090</pub-id><pub-id pub-id-type="pmid">27236588</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Childhood, adulthood, and cumulative traumatic events experienced from childhood to adulthood and dementia risk: a population-based cohort study</article-title><source>J Public Health</source><year>2023</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/s10389-023-02140-8</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name></person-group><article-title>Heterogeneous adverse childhood experiences and cognitive function in an elderly Chinese population: a cohort study</article-title><source>BMJ Open</source><volume>12</volume><issue>6</issue><year>2022</year><object-id pub-id-type="publisher-id">e060477</object-id><pub-id pub-id-type="doi">10.1136/bmjopen-2021-060477</pub-id><pub-id pub-id-type="pmcid">PMC9189840</pub-id><pub-id pub-id-type="pmid">35688592</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Abouelmagd</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>AbdelMeseh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elrosasy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eldeeb</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Nabil</surname><given-names>Y.</given-names></name></person-group><article-title>Adverse childhood experiences and risk of late-life dementia: a systematic review and meta-analysis</article-title><source>Soc Psychiatry Psychiatr Epidemiol</source><year>2024</year><pub-id pub-id-type="doi">10.1007/s00127-024-02676-4</pub-id><comment>2024/05/08</comment><pub-id pub-id-type="pmcid">PMC12119739</pub-id><pub-id pub-id-type="pmid">38717478</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><collab>U.S. Department of Health &amp; Human Services</collab></person-group><article-title>Administration for children and families, administration on children, youth, and families, children's bureau</article-title><source>Child Maltreat</source><volume>2022</volume><year>2024</year></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><collab>Alzheimer's Association</collab></person-group><article-title>Alzheimer's Disease facts and figures</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>5</issue><year>2024</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13809</pub-id><pub-id pub-id-type="pmcid">PMC11095490</pub-id><pub-id pub-id-type="pmid">38689398</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Shonkoff</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Boyce</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>McEwen</surname><given-names>B.S.</given-names></name></person-group><article-title>Neuroscience, molecular biology, and the childhood roots of health disparities: building a new framework for health promotion and disease prevention</article-title><source>JAMA</source><volume>301</volume><issue>21</issue><year>2009</year><fpage>2252</fpage><lpage>2259</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.754</pub-id><comment>Jun 03</comment><pub-id pub-id-type="pmid">19491187</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Bates</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Deary</surname><given-names>I.J.</given-names></name></person-group><article-title>Is education associated with improvements in general cognitive ability, or in specific skills?</article-title><source>Dev Psychol</source><volume>51</volume><issue>5</issue><year>2015</year><fpage>573</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1037/a0038981</pub-id><comment>May</comment><pub-id pub-id-type="pmid">25775112</pub-id><pub-id pub-id-type="pmcid">PMC4445388</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Villemagne</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Pike</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Longitudinal assessment of a&#946; and cognition in aging and Alzheimer disease</article-title><source>Ann Neurol</source><volume>69</volume><issue>1</issue><year>2011</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1002/ana.22248</pub-id><comment>2011/01/01</comment><pub-id pub-id-type="pmid">21280088</pub-id><pub-id pub-id-type="pmcid">PMC3045039</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Mielke</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal</article-title><source>Neurology</source><volume>82</volume><issue>4</issue><year>2014</year><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000055</pub-id><pub-id pub-id-type="pmid">24353333</pub-id><pub-id pub-id-type="pmcid">PMC3929198</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Yeung</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>AK-y</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>JY-c</given-names></name><name name-style="western"><surname>Shek</surname><given-names>JT-l</given-names></name><name name-style="western"><surname>Leung</surname><given-names>JP-y</given-names></name><name name-style="western"><surname>Wong</surname><given-names>TC-h.</given-names></name></person-group><article-title>Differential and subtype-specific neuroimaging abnormalities in amnestic and nonamnestic mild cognitive impairment: a systematic review and meta-analysis</article-title><source>Ageing Res Rev</source><volume>80</volume><year>2022</year><object-id pub-id-type="publisher-id">101675</object-id><pub-id pub-id-type="doi">10.1016/j.arr.2022.101675</pub-id><comment>2022/09/01/</comment><pub-id pub-id-type="pmid">35724862</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Vos</surname><given-names>S.J.B.</given-names></name><name name-style="western"><surname>van Rossum</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Verhey</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI</article-title><source>Neurology</source><volume>80</volume><issue>12</issue><year>2013</year><fpage>1124</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318288690c</pub-id><comment>2013/03/19</comment><pub-id pub-id-type="pmid">23446677</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Jungwirth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zehetmayer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hinterberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tragl</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>P.</given-names></name></person-group><article-title>The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer's dementia and vascular dementia</article-title><source>Int Psychogeriatr</source><volume>24</volume><issue>6</issue><year>2012</year><fpage>959</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1017/S1041610211002870</pub-id><pub-id pub-id-type="pmid">22300486</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Aas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ueland</surname><given-names>T.</given-names></name><name name-style="western"><surname>Inova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Melle</surname><given-names>I.</given-names></name><name name-style="western"><surname>Andreassen</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Steen</surname><given-names>N.E.</given-names></name></person-group><article-title>Childhood trauma is nominally associated with elevated cortisol metabolism in severe mental disorder</article-title><source>Front Psychiatry</source><volume>11</volume><year>2020</year><fpage>391</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2020.00391</pub-id><pub-id pub-id-type="pmid">32528319</pub-id><pub-id pub-id-type="pmcid">PMC7247816</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>De Bellis</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Zisk</surname><given-names>A.</given-names></name></person-group><article-title>The biological effects of childhood trauma</article-title><source>Child Adolesc Psychiatr Clin N Am</source><volume>23</volume><issue>2</issue><year>2014</year><fpage>185</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.chc.2014.01.002</pub-id><pub-id pub-id-type="pmid">24656576</pub-id><pub-id pub-id-type="pmcid">PMC3968319</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Beilharz</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fatt</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The impact of childhood trauma on psychosocial functioning and physical health in a non-clinical community sample of young adults</article-title><source>Aust N Z J Psychiatry</source><volume>54</volume><issue>2</issue><year>2019</year><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1177/0004867419881206</pub-id><comment>2020/02/01</comment><pub-id pub-id-type="pmid">31631683</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Czaja</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.S.</given-names></name></person-group><article-title>A prospective investigation of physical health outcomes in abused and neglected children: new findings from a 30-year follow-up</article-title><source>Am J Public Health</source><volume>102</volume><issue>6</issue><year>2012</year><fpage>1135</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2011.300636</pub-id><comment>Jun</comment><pub-id pub-id-type="pmid">22515854</pub-id><pub-id pub-id-type="pmcid">PMC3483964</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pinto Pereira</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Power</surname><given-names>C.</given-names></name></person-group><article-title>Childhood maltreatment and biomarkers for cardiometabolic disease in mid-adulthood in a prospective British birth cohort: associations and potential explanations</article-title><source>BMJ Open</source><volume>9</volume><issue>3</issue><year>2019</year><object-id pub-id-type="publisher-id">e024079</object-id><pub-id pub-id-type="doi">10.1136/bmjopen-2018-024079</pub-id><pub-id pub-id-type="pmcid">PMC6475361</pub-id><pub-id pub-id-type="pmid">30904846</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Kisely</surname><given-names>S.</given-names></name><name name-style="western"><surname>Strathearn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Najman</surname><given-names>J.M.</given-names></name></person-group><article-title>Child maltreatment and mental health problems in 30-year-old adults: a birth cohort study</article-title><source>J Psychiatr Res</source><volume>129</volume><year>2020</year><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2020.06.009</pub-id><comment>2020/10/01/</comment><pub-id pub-id-type="pmid">32653613</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>P.M.</given-names></name></person-group><article-title>Childhood maltreatment and DSM-IV adult mental disorders: comparison of prospective and retrospective findings</article-title><source>Br J Psychiatry</source><volume>200</volume><issue>6</issue><year>2012</year><fpage>469</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.111.103267</pub-id><pub-id pub-id-type="pmid">22661679</pub-id><pub-id pub-id-type="pmcid">PMC3365274</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>DuMont</surname><given-names>K.</given-names></name><name name-style="western"><surname>Czaja</surname><given-names>S.J.</given-names></name></person-group><article-title>A prospective investigation of major depressive disorder and comorbidity in abused and neglected children grown up</article-title><source>Arch Gen Psychiatry</source><volume>64</volume><issue>1</issue><year>2007</year><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.64.1.49</pub-id><comment>Jan</comment><pub-id pub-id-type="pmid">17199054</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Danese</surname><given-names>A.</given-names></name><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name></person-group><article-title>Objective and subjective experiences of child maltreatment and their relationships with psychopathology</article-title><source>Nat Hum Behav</source><volume>4</volume><issue>8</issue><year>2020</year><fpage>811</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1038/s41562-020-0880-3</pub-id><pub-id pub-id-type="pmid">32424258</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Zielinski</surname><given-names>D.S.</given-names></name></person-group><article-title>Child maltreatment and adult socioeconomic well-being</article-title><source>Child Abuse Negl</source><volume>33</volume><issue>10</issue><year>2009</year><fpage>666</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1016/j.chiabu.2009.09.001</pub-id><comment>2009/10/01/</comment><pub-id pub-id-type="pmid">19811826</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Colman</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name></person-group><article-title>Childhood abuse and neglect and adult intimate relationships: a prospective study</article-title><source>Child Abuse Negl</source><volume>28</volume><issue>11</issue><year>2004</year><fpage>1133</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1016/j.chiabu.2004.02.005</pub-id><comment>Nov</comment><pub-id pub-id-type="pmid">15567020</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Geoffroy</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Pinto Pereira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Power</surname><given-names>C.</given-names></name></person-group><article-title>Child neglect and maltreatment and childhood-to-adulthood cognition and mental health in a prospective birth cohort</article-title><source>J Am Acad Child Adolesc Psychiatry</source><volume>55</volume><issue>1</issue><year>2016</year><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.jaac.2015.10.012</pub-id><comment>Jan</comment><pub-id pub-id-type="pmid">26703907</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Nikulina</surname><given-names>V.</given-names></name><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name></person-group><article-title>Child maltreatment and executive functioning in middle adulthood: a prospective examination</article-title><source>Neuropsychology</source><volume>27</volume><issue>4</issue><year>2013</year><fpage>417</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1037/a0032811</pub-id><comment>Jul</comment><pub-id pub-id-type="pmid">23876115</pub-id><pub-id pub-id-type="pmcid">PMC3855039</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name></person-group><article-title>Childhood victimization and long-term intellectual and academic outcomes</article-title><source>Child Abuse Negl</source><volume>18</volume><issue>8</issue><year>1994</year><fpage>617</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/0145-2134(94)90012-4</pub-id><comment>Aug</comment><pub-id pub-id-type="pmid">7953902</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Sumner</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Koenen</surname><given-names>K.C.</given-names></name><etal/></person-group><article-title>Childhood abuse and cognitive function in a large cohort of middle-aged women</article-title><source>Child Maltreat</source><volume>27</volume><issue>1</issue><year>2022</year><fpage>100</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1177/107755952097064</pub-id><pub-id pub-id-type="pmid">33161764</pub-id><pub-id pub-id-type="pmcid">PMC10281011</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Pears</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>P.A.</given-names></name></person-group><article-title>Emotion understanding and theory of mind among maltreated children in foster care: evidence of deficits</article-title><source>Dev Psychopathol</source><volume>17</volume><issue>1</issue><year>2005</year><fpage>47</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1017/S0954579405050030</pub-id><pub-id pub-id-type="pmid">15971759</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Nolin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ethier</surname><given-names>L.</given-names></name></person-group><article-title>Using neuropsychological profiles to classify neglected children with or without physical abuse</article-title><source>Child Abuse Negl</source><volume>31</volume><issue>6</issue><year>2007</year><fpage>631</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/j.chiabu.2006.12.009</pub-id><pub-id pub-id-type="pmid">17617456</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Bremner</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Randall</surname><given-names>P.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>T.M.</given-names></name><etal/></person-group><article-title>Deficits in short-term memory in adult survivors of childhood abuse</article-title><source>Psychiatry Res</source><volume>59</volume><year>1995</year><fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/0165-1781(95)02800-5</pub-id><pub-id pub-id-type="pmid">8771224</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Goodman</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Chalmers</surname><given-names>K.A.</given-names></name></person-group><article-title>The relationship between early life stress and working memory in adulthood: a systematic review and meta-analysis</article-title><source>Memory</source><volume>27</volume><issue>6</issue><year>2019</year><fpage>868</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1080/09658211.2018.1561897</pub-id><pub-id pub-id-type="pmid">30588865</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name></person-group><article-title>The cycle of violence</article-title><source>Science</source><volume>244</volume><issue>4901</issue><year>1989</year><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1126/science.2704995</pub-id><comment>Apr 14</comment><pub-id pub-id-type="pmid">2704995</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Nakayama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Possible long-term effects of childhood maltreatment on cognitive function in adult women with posttraumatic stress disorder</article-title><source>Front Psychiatry</source><year>2020</year><pub-id pub-id-type="doi">10.3389/fpsyt.2020.00344</pub-id><comment>2020-April-2411doi</comment><pub-id pub-id-type="pmcid">PMC7212372</pub-id><pub-id pub-id-type="pmid">32425832</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Chicoine</surname><given-names>A.X.</given-names></name><name name-style="western"><surname>Chertkow</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tardif</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Busseuil</surname><given-names>D.</given-names></name><name name-style="western"><surname>D'Antono</surname><given-names>B.</given-names></name></person-group><article-title>Childhood maltreatment, cognitive performance, and cognitive decline in middle-aged and older adults with chronic disease: a prospective study</article-title><source>J Psychosom Res</source><volume>187</volume><year>2024</year><object-id pub-id-type="publisher-id">111965</object-id><pub-id pub-id-type="doi">10.1016/j.jpsychores.2024.111965</pub-id><comment>2024/12/01/</comment><pub-id pub-id-type="pmid">39461232</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Schraedley</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Gotlib</surname><given-names>I.H.</given-names></name></person-group><article-title>Stability of retrospective reports in depression: traumatic events, past depressive episodes, and parental psychopathology</article-title><source>J Health Soc Behav</source><volume>43</volume><year>2002</year><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.2307/3090206</pub-id><pub-id pub-id-type="pmid">12467255</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Baldwin</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Reuben</surname><given-names>A.</given-names></name><name name-style="western"><surname>Newbury</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Danese</surname><given-names>A.</given-names></name></person-group><article-title>Agreement between prospective and retrospective measures of childhood maltreatment: a systematic review and meta-analysis</article-title><source>JAMA psychiatry</source><volume>76</volume><issue>6</issue><year>2019</year><fpage>584</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2019.0097</pub-id><pub-id pub-id-type="pmid">30892562</pub-id><pub-id pub-id-type="pmcid">PMC6551848</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Danese</surname><given-names>A.</given-names></name><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name></person-group><article-title>Objective and subjective experiences of childhood maltreatment and their relationships with cognitive deficits: a cohort study in the USA</article-title><source>Lancet Psychiat</source><volume>11</volume><issue>9</issue><year>2024</year><fpage>720</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(24)00224-4</pub-id><pub-id pub-id-type="pmid">39147460</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Schickedanz</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Schickedanz</surname><given-names>A.</given-names></name></person-group><article-title>The association between adverse childhood experiences and positive dementia screen in American older adults</article-title><source>J Gen Intern Med</source><volume>37</volume><issue>10</issue><year>2022</year><fpage>2398</fpage><lpage>2404</lpage><pub-id pub-id-type="doi">10.1007/s11606-021-07192-8</pub-id><pub-id pub-id-type="pmid">34782990</pub-id><pub-id pub-id-type="pmcid">PMC9360371</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.H.</given-names></name></person-group><article-title>Congruence between adolescents' self-reports and their adult retrospective reports regarding parental discipline practices during their adolescence</article-title><source>Psychol Rep</source><volume>101</volume><issue>3</issue><year>2007</year><fpage>1079</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.2466/Pr0.101.4.1079-1094</pub-id><comment>Dec</comment><pub-id pub-id-type="pmid">18361122</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Do</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Manly</surname><given-names>J.J.</given-names></name></person-group><article-title>Childhood maltreatment and dementia risk factors in midlife: a prospective investigation</article-title><source>Curr Alzheimer Res</source><year>2023</year><pub-id pub-id-type="doi">10.2174/0115672050281539231222071355</pub-id><pub-id pub-id-type="pmid">38155463</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Jacova</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Beattie</surname><given-names>B.L.</given-names></name><etal/></person-group><article-title>Cognitive impairment no dementia &#8211; Neuropsychological and neuroimaging characterization of an amnestic subgroup</article-title><source>Dement Geriatr Cogn Disord</source><volume>25</volume><issue>3</issue><year>2008</year><fpage>238</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1159/000115848</pub-id><pub-id pub-id-type="pmid">18264009</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name></person-group><article-title>Child abuse, neglect, and adult behavior: research design and findings on criminality, violence, and child abuse</article-title><source>Am J Orthopsychiatry</source><volume>59</volume><issue>3</issue><year>1989</year><fpage>355</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1111/j.1939-0025.1989.tb01671.x</pub-id><pub-id pub-id-type="pmid">2764070</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Adler</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Boyce</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chesney</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Socioeconomic status and health: the challenge of the gradient</article-title><source>Am Psychol</source><volume>49</volume><issue>1</issue><year>1994</year><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1037/0003-066X.49.1.15</pub-id><pub-id pub-id-type="pmid">8122813</pub-id></element-citation></ref><ref id="bib0045"><label>45</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Conroy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sandel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zuckerman</surname><given-names>B.</given-names></name></person-group><article-title>Poverty grown up: how childhood socioeconomic status impacts adult health</article-title><source>J Dev Behav Pediatr</source><volume>31</volume><issue>2</issue><year>2010</year><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1097/Dbp.0b013e3181c21a1b</pub-id><comment>Feb-Mar</comment><pub-id pub-id-type="pmid">20145476</pub-id></element-citation></ref><ref id="bib0047"><label>46</label><mixed-citation publication-type="other" id="sbref0047">Shadish W.R., Cook T.D., Campbell D.T. Experimental and quasi-experimental designs for generalized causal inference. Houghton-Mifflin; 2002.</mixed-citation></ref><ref id="bib0048"><label>47</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Heyman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohs</surname><given-names>R.C.</given-names></name><etal/></person-group><article-title>The consortium to establish a registry for alzheimer's disease (cerad). Part I. Clinical and neuropsychological assessment of alzheimer's disease</article-title><source>Neurology</source><volume>39</volume><issue>9</issue><year>1989</year><fpage>1159</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1212/wnl.39.9.1159</pub-id><comment>Sep</comment><pub-id pub-id-type="pmid">2771064</pub-id></element-citation></ref><ref id="bib0049"><label>48</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Gollan</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Weissberger</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Runnqvist</surname><given-names>E.</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Cera</surname><given-names>C.M.</given-names></name></person-group><article-title>Self-ratings of spoken language dominance: a Multilingual Naming test (MINT) and preliminary norms for young and aging Spanish&#8211;English bilinguals</article-title><source>Biling (Camb)</source><volume>15</volume><issue>3</issue><year>2012</year><fpage>594</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1017/S1366728911000332</pub-id><pub-id pub-id-type="pmcid">PMC4212892</pub-id><pub-id pub-id-type="pmid">25364296</pub-id></element-citation></ref><ref id="bib0050"><label>49</label><element-citation publication-type="book" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Strauss</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Spreen</surname><given-names>O.</given-names></name></person-group><part-title>A compendium of neuropsychological tests: administration, norms, and commentary</part-title><year>2006</year><publisher-name>American Chemical Society</publisher-name></element-citation></ref><ref id="bib0051"><label>50</label><element-citation publication-type="book" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Golden</surname><given-names>C.J.</given-names></name></person-group><part-title>Stroop color and word test</part-title><year>1978</year><publisher-name>Stoelting Company</publisher-name></element-citation></ref><ref id="bib0052"><label>51</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Pfeffer</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Kurosaki</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Harrah</surname><given-names>C.H.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Chance</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Filos</surname><given-names>S.</given-names></name></person-group><article-title>Measurement of functional activities in older adults in the community</article-title><source>J Gerontol</source><volume>37</volume><issue>3</issue><year>1982</year><fpage>323</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1093/geronj/37.3.323</pub-id><comment>May</comment><pub-id pub-id-type="pmid">7069156</pub-id></element-citation></ref><ref id="bib0055"><label>52</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Sheridan</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Normative symbol digit modalities test performance in a community-based sample</article-title><source>Arch Clin Neuropsychol</source><volume>21</volume><issue>1</issue><year>2006</year><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.acn.2005.07.003</pub-id><pub-id pub-id-type="pmid">16139470</pub-id></element-citation></ref><ref id="bib0056"><label>53</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Lucas</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>IR</surname><given-names>J.</given-names></name><name name-style="western"><surname>WF</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Mayo's older African Americans normative studies: normative data for commonly used clinical neuropsychological measures</article-title><source>Clin Neuropsychol</source><volume>19</volume><issue>2</issue><year>2005</year><fpage>162</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1080/13854040590945265</pub-id><comment>2005/05/01</comment><pub-id pub-id-type="pmid">16019702</pub-id></element-citation></ref><ref id="bib0057"><label>54</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Ivnik</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Malec</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Kokmen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tangalos</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Kurland</surname><given-names>L.T.</given-names></name></person-group><article-title>Mayo's Older Americans normative studies (MOANS): factor structure of a core battery</article-title><source>Psychol Assess</source><volume>4</volume><issue>3</issue><year>1992</year><fpage>382</fpage><pub-id pub-id-type="doi">10.1037/1040-3590.4.3.382</pub-id></element-citation></ref><ref id="bib0058"><label>55</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Steinberg</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>BL</surname><given-names>A.</given-names></name><name name-style="western"><surname>SG</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ivnik</surname><given-names>R.J.</given-names></name></person-group><article-title>Mayo's Older Americans normative studies: age- and IQ-adjusted norms for the trail-making test, the stroop test, and MAE controlled oral word association test</article-title><source>Clin Neuropsychol</source><volume>19</volume><issue>3&#8211;4</issue><year>2005</year><fpage>329</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1080/13854040590945210</pub-id><comment>2005/09/01</comment><pub-id pub-id-type="pmid">16120535</pub-id></element-citation></ref><ref id="bib0059"><label>56</label><mixed-citation publication-type="other" id="sbref0059">Manly J., Renter&#237;a M.A., Avila-Rieger J.F., et al. Offspring study of racial and ethnic disparities in Alzheimer&#8217;s disease: objectives and design. 2020;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://10.31234/osf.io/frbkj" id="interref0001">doi:10.31234/osf.io/frbkj</ext-link>.</mixed-citation></ref><ref id="bib0060"><label>57</label><element-citation publication-type="book" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Wechsler</surname><given-names>D.</given-names></name></person-group><part-title>WAIS-III Administration And Scoring Manual</part-title><year>1997</year><publisher-name>Psychological Corporation</publisher-name></element-citation></ref><ref id="bib0053"><label>58</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Edmonds</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Bondi</surname><given-names>M.W.</given-names></name></person-group><article-title>Comparison of cognitive impairment diagnosis criteria in clinical settings: conventional vs. neuropsychological</article-title><source>Alpha Psychiatry</source><volume>25</volume><issue>2</issue><year>2024</year><fpage>212</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.5152/alphapsychiatry.2024.231448</pub-id><comment>Mar</comment><pub-id pub-id-type="pmid">38798819</pub-id><pub-id pub-id-type="pmcid">PMC11117417</pub-id></element-citation></ref><ref id="bib0054"><label>59</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Saxton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Snitz</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>O.L.</given-names></name><etal/></person-group><article-title>Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>80</volume><issue>7</issue><year>2009</year><fpage>737</fpage><pub-id pub-id-type="doi">10.1136/jnnp.2008.160705</pub-id><pub-id pub-id-type="pmid">19279031</pub-id><pub-id pub-id-type="pmcid">PMC2698042</pub-id></element-citation></ref><ref id="bib0061"><label>60</label><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name name-style="western"><surname>Bondi</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Edmonds</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Jak</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates</article-title><source>J Alzheimers Dis</source><volume>42</volume><issue>1</issue><year>2014</year><fpage>275</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.3233/JAD-140276</pub-id><comment>2014/08/11</comment><pub-id pub-id-type="pmid">24844687</pub-id><pub-id pub-id-type="pmcid">PMC4133291</pub-id></element-citation></ref><ref id="bib0062"><label>61</label><element-citation publication-type="journal" id="sbref0062"><person-group person-group-type="author"><name name-style="western"><surname>lavaan</surname><given-names>Rosseel Y.</given-names></name></person-group><article-title>An R package for structural equation modeling</article-title><source>J Stat Softw</source><volume>48</volume><year>2012</year><fpage>1</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.18637/jss.v048.i02</pub-id></element-citation></ref><ref id="bib0063"><label>62</label><element-citation publication-type="journal" id="sbref0063"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wennberg</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Engstr&#246;m</surname><given-names>G.</given-names></name><name name-style="western"><surname>Modig</surname><given-names>K.</given-names></name></person-group><article-title>Use of common cardiovascular disease drugs and risk of dementia: a case&#8211;control study in Swedish national register data</article-title><source>Alzheimers Dement</source><volume>21</volume><issue>1</issue><year>2025</year><object-id pub-id-type="publisher-id">e14389</object-id><pub-id pub-id-type="doi">10.1002/alz.1439</pub-id><comment>2025/01/01</comment><pub-id pub-id-type="pmcid">PMC11772729</pub-id><pub-id pub-id-type="pmid">39555901</pub-id></element-citation></ref><ref id="bib0064"><label>63</label><element-citation publication-type="journal" id="sbref0064"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Zafonte</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chibnik</surname><given-names>L.B.</given-names></name><etal/></person-group><article-title>Association of adverse childhood experiences with poor neuropsychiatric health and dementia among former professional US football players</article-title><source>JAMA Netw Open</source><volume>5</volume><issue>3</issue><year>2022</year><object-id pub-id-type="publisher-id">e223299</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.3299</pub-id><pub-id pub-id-type="pmcid">PMC8941347</pub-id><pub-id pub-id-type="pmid">35315919</pub-id></element-citation></ref><ref id="bib0065"><label>64</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Widom</surname><given-names>C.S.</given-names></name></person-group><article-title>Posttraumatic stress disorder in abused and neglected children grown up</article-title><source>Am J Psychiatry</source><volume>156</volume><issue>8</issue><year>1999</year><fpage>1223</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1176/ajp.156.8.1223</pub-id><comment>Aug</comment><pub-id pub-id-type="pmid">10450264</pub-id></element-citation></ref><ref id="bib0066"><label>65</label><element-citation publication-type="journal" id="sbref0066"><person-group person-group-type="author"><name name-style="western"><surname>Manly</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Langa</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Estimating the prevalence of dementia and mild cognitive impairment in the US: the 2016 health and retirement study harmonized cognitive assessment protocol project</article-title><source>JAMA Neurol</source><volume>79</volume><issue>12</issue><year>2022</year><fpage>1242</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2022.3543</pub-id><pub-id pub-id-type="pmid">36279130</pub-id><pub-id pub-id-type="pmcid">PMC9593315</pub-id></element-citation></ref><ref id="bib0067"><label>66</label><element-citation publication-type="journal" id="sbref0067"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name></person-group><article-title>Cognitive reserve in ageing and Alzheimer&#8217;s disease</article-title><source>Lancet Neurol</source><volume>11</volume><issue>11</issue><year>2012</year><fpage>1006</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70191-6</pub-id><comment>Nov</comment><pub-id pub-id-type="pmid">23079557</pub-id><pub-id pub-id-type="pmcid">PMC3507991</pub-id></element-citation></ref><ref id="bib0068"><label>67</label><element-citation publication-type="journal" id="sbref0068"><person-group person-group-type="author"><name name-style="western"><surname>Sumowski</surname><given-names>J.F.</given-names></name></person-group><article-title>Cognitive reserve as a useful concept for early intervention research in multiple sclerosis</article-title><source>Front Neurol</source><year>2015</year><pub-id pub-id-type="doi">10.3389/fneur.2015.00176</pub-id><comment>2015-August-206doi</comment><pub-id pub-id-type="pmcid">PMC4542634</pub-id><pub-id pub-id-type="pmid">26347706</pub-id></element-citation></ref><ref id="bib0069"><label>68</label><element-citation publication-type="journal" id="sbref0069"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name></person-group><article-title>What is cognitive reserve? Theory and research application of the reserve concept</article-title><source>J Int Neuropsychol Soc</source><volume>8</volume><issue>3</issue><year>2002</year><fpage>448</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1017/S1355617702813248</pub-id><pub-id pub-id-type="pmid">11939702</pub-id></element-citation></ref><ref id="bib0070"><label>69</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nitschke</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Cooperman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Pruessner</surname><given-names>J.C.</given-names></name></person-group><article-title>Systematic manipulations of the biological stress systems result in sex-specific compensatory stress responses and negative mood outcomes</article-title><source>Neuropsychopharmacology</source><volume>45</volume><issue>10</issue><year>2020</year><fpage>1672</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1038/s41386-020-0726-8</pub-id><comment>2020/09/01</comment><pub-id pub-id-type="pmid">32498073</pub-id><pub-id pub-id-type="pmcid">PMC7421880</pub-id></element-citation></ref><ref id="bib0071"><label>70</label><element-citation publication-type="journal" id="sbref0071"><person-group person-group-type="author"><name name-style="western"><surname>Horton</surname><given-names>H.M.</given-names></name></person-group><article-title>The Long Arm of childhood hypothesis and systematic low-grade inflammation: evidence from parental education of older European adults</article-title><source>SSM Popul Health</source><volume>21</volume><year>2023</year><object-id pub-id-type="publisher-id">101334</object-id><pub-id pub-id-type="doi">10.1016/j.ssmph.2022.101334</pub-id><comment>2023/03/01/</comment><pub-id pub-id-type="pmcid">PMC9873659</pub-id><pub-id pub-id-type="pmid">36712147</pub-id></element-citation></ref><ref id="bib0072"><label>71</label><element-citation publication-type="journal" id="sbref0072"><person-group person-group-type="author"><name name-style="western"><surname>Pakpahan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kr&#246;ger</surname><given-names>H.</given-names></name></person-group><article-title>The long arm of childhood circumstances on health in old age: evidence from SHARELIFE</article-title><source>Adv Life Course Res</source><volume>31</volume><year>2017</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.alcr.2016.10.003</pub-id><comment>2017/03/01/</comment></element-citation></ref><ref id="bib0073"><label>72</label><element-citation publication-type="journal" id="sbref0073"><person-group person-group-type="author"><name name-style="western"><surname>Manly</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>M.X.</given-names></name><name name-style="western"><surname>Schupf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Vonsattel</surname><given-names>J.P.G.</given-names></name><name name-style="western"><surname>Mayeux</surname><given-names>R.</given-names></name></person-group><article-title>Frequency and course of mild cognitive impairment in a multiethnic community</article-title><source>Ann Neurol</source><volume>63</volume><issue>4</issue><year>2008</year><fpage>494</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1002/ana.21326</pub-id><comment>2008/04/01</comment><pub-id pub-id-type="pmid">18300306</pub-id><pub-id pub-id-type="pmcid">PMC2375143</pub-id></element-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501343</article-id><article-id pub-id-type="pmcid-ver">PMC12501343.1</article-id><article-id pub-id-type="pmcaid">12501343</article-id><article-id pub-id-type="pmcaiid">12501343</article-id><article-id pub-id-type="pmid">40769858</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100301</article-id><article-id pub-id-type="pii">S2274-5807(25)00244-4</article-id><article-id pub-id-type="publisher-id">100301</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group></article-categories><title-group><article-title>Medical risk factors, ApoE haplotype, and Alzheimer&#8217;s disease: a large-scale analysis</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Elias</surname><given-names initials="U">Uri</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Gazit</surname><given-names initials="L">Lidor</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Zucker</surname><given-names initials="R">Roei</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Stern</surname><given-names initials="A">Amos</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Linial</surname><given-names initials="M">Michal</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Allali</surname><given-names initials="G">Gilles</given-names></name><email>gilles.Allali@chuv.ch</email><xref rid="aff0004" ref-type="aff">d</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Ben-Hur</surname><given-names initials="T">Tamir</given-names></name><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Marshall</surname><given-names initials="GA">Gad A.</given-names></name><xref rid="aff0006" ref-type="aff">f</xref><xref rid="aff0007" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0009"><name name-style="western"><surname>Arzy</surname><given-names initials="S">Shahar</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0005" ref-type="aff">e</xref><xref rid="aff0008" ref-type="aff">h</xref></contrib><aff id="aff0001"><label>a</label>Computational Neuropsychiatry Lab, Department of Medical Neurosciences, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel</aff><aff id="aff0002"><label>b</label>The Rachel and Selim Benin School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel</aff><aff id="aff0003"><label>c</label>Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel</aff><aff id="aff0004"><label>d</label>Leenaards Memory Center, Department of Clinical Neuroscience, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.</aff><aff id="aff0005"><label>e</label>Department of Neurology, Hadassah Medical Center, Jerusalem, Israel</aff><aff id="aff0006"><label>f</label>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women&#8217;s Hospital, Harvard Medical School, Boston, MA, United States</aff><aff id="aff0007"><label>g</label>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States</aff><aff id="aff0008"><label>h</label>Department of Brain and Cognition, Hebrew University of Jerusalem, Israel</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author at: Leenards Memory Center, Lausanne University Hospital, Lausanne, Switzerland. <email>gilles.Allali@chuv.ch</email></corresp><fn id="fn1"><label>1</label><p id="notep0001">Equal contribution</p></fn></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>06</day><month>8</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100301</elocation-id><history><date date-type="received"><day>29</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>11</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><sec><title>Background</title><p>The multifactorial nature of Alzheimer&#8217;s disease (AD) has become increasingly evident. In addition to well-established features like neurodegeneration, amyloid-beta and tau deposition, or glial changes, other processes&#8212;such as metabolic, circulatory, and inflammatory factors&#8212;may also play a key role in driving or accelerating AD-related pathology and cognitive decline. These factors represent important targets for slowing disease progression.</p></sec><sec><title>Objectives</title><p>Although many studies have examined individual risk factors and meta-analyses have been performed, a large-scale, comprehensive comparison using formal medical data from a single, unified cohort is needed.</p></sec><sec><title>Design</title><p>A retrospective case-control study leveraging comprehensive health database.</p></sec><sec><title>Setting</title><p>Data were obtained from the UK-Biobank, a large (&#8764;500 K people) population-based biomedical database in the United Kingdom.</p></sec><sec><title>Participants</title><p>The study included participants aged 40-69 at enrollment between 2006 and 2010, comprising 3,843 individuals who were clinically diagnosed with AD by August 2022 and 387,275 individuals without dementia or cognitive-impairment diagnoses.</p></sec><sec><title>Measurements</title><p>ICD-10-coded diagnoses, recorded at least 10 years prior to AD diagnosis, were analyzed. Logistic regression was used to estimate the impact and significance of various medical conditions and their interactions with genetic risk factors, while accounting for demographic determinants.</p></sec><sec><title>Results</title><p>The analysis identified 45 medical factors (96 ICD-10 entities) across multiple systems&#8212;particularly metabolic, circulatory, gastrointestinal, and sensorimotor&#8212;that significantly differentiated individuals with clinical AD from cognitively unimpaired individuals. Interaction analyses revealed that circulatory and metabolic factors had a weaker influence on AD risk in Apolipoprotein E &#949;4 carriers, suggesting a gene-environment interaction in disease susceptibility.</p></sec><sec><title>Conclusions</title><p>These findings enhance the understanding of system-level risk factors for clinical AD, highlight the relevance of less frequently reported factors in the AD prevention literature&#8212;such as gastrointestinal and sensorimotor disorders&#8212;and underscore the complex interplay between genetic susceptibility and vascular risk factors.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Modifiable risk factors</kwd><kwd>Preclinical</kwd><kwd>Intervention</kwd><kwd>UK-biobank</kwd><kwd>Big-data</kwd><kwd>ApoE</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0010">The view of Alzheimer&#8217;s disease (AD) as a multifactorial disorder, related to a combination of neuropathological predispositions on the one hand and facilitation of the pathological progression by several factors on the other, has become widely accepted [<xref rid="bib0001" ref-type="bibr">[1]</xref>, <xref rid="bib0002" ref-type="bibr">[2]</xref>, <xref rid="bib0003" ref-type="bibr">[3]</xref>, <xref rid="bib0004" ref-type="bibr">[4]</xref>]. With the modest efficacy of anti-amyloid drugs at the stage of mild cognitive impairment (MCI) or mild dementia, it is clear that while amyloid and tau proteins play a crucial role in AD pathology, multiple other risk factors (RFs) are involved in the development and progression of AD. These include medical, environmental, lifestyle-related, and genetic RFs. Notably, intervention in modifiable RFs during early AD stages may reduce disease risk by up to 40% [<xref rid="bib0001" ref-type="bibr">1</xref>,<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0006" ref-type="bibr">6</xref>].</p><p id="para0011">Despite extensive research, the Lancet Commissions on dementia prevention, intervention, and care [<xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>, <xref rid="bib0009" ref-type="bibr">[9]</xref>] identified only 14 modifiable RFs associated with the development of AD with enough high-quality consistent evidence, collectively accounting for &#8764;40% of worldwide dementias. These include lower education, hypertension, high LDL, visual and hearing impairments, smoking, obesity, depression, physical inactivity, diabetes, low social contact, excessive alcohol consumption, traumatic brain injury (TBI), and air pollution. Importantly, the commission emphasized the need for individualized risk assessment and tailored interventions based on an individual's unique risk profile, preferences, and circumstances. The current work reevaluates all International Classification of Diseases (ICD) codes and their association with AD dementia, providing a comprehensive analysis.</p><p id="para0012">The quest for RFs associated with AD spans over 7,000 studies of varying validity, including interventional studies, meta-analyses, review articles, consensus conferences and working groups [<xref rid="bib0006" ref-type="bibr">6</xref>,<xref rid="bib0010" ref-type="bibr">[10]</xref>, <xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>], with RFs mostly include vascular risk factors [<xref rid="bib0014" ref-type="bibr">14</xref>]. Few studies have prospectively and comprehensively investigated primary prevention. The FINGER trial [<xref rid="bib0005" ref-type="bibr">5</xref>], a randomized controlled trial (RCT) assessing multidomain interventions (diet, exercise, cognitive training, vascular risk monitoring), showed modest cognitive benefits. While one RCT supported these findings [<xref rid="bib0015" ref-type="bibr">15</xref>], two others [<xref rid="bib0016" ref-type="bibr">16</xref>,<xref rid="bib0017" ref-type="bibr">17</xref>], and a meta-analysis [<xref rid="bib0018" ref-type="bibr">18</xref>] found no evidence that such multidomain interventions prevent dementia. A well-characterized longitudinal population-based study in cognitively unimpaired (CU) older adults identified advancing age as the strongest risk factor, with female sex, lower education level, cardiovascular risk factors, and genetic susceptibility (Apolipoprotein E (ApoE) &#949;4 allele) as important contributors to AD risk [<xref rid="bib0011" ref-type="bibr">11</xref>]. Sleep disturbances and markers of systemic inflammation (CRP, IL-6), were associated with an increased risk of AD [<xref rid="bib0019" ref-type="bibr">19</xref>]. Additionally, a large-scale analysis of 10 years of clinical records (170 million patients) identified several existing drugs with potential benefits for AD[<xref rid="bib0020" ref-type="bibr">20</xref>], suggesting links between AD and conditions like gastritis [<xref rid="bib0021" ref-type="bibr">21</xref>], epilepsy or pain [<xref rid="bib0022" ref-type="bibr">22</xref>,<xref rid="bib0023" ref-type="bibr">23</xref>], as well as hypercholesterolemia[<xref rid="bib0024" ref-type="bibr">24</xref>], and inflammation [<xref rid="bib0025" ref-type="bibr">25</xref>].</p><p id="para0013">Importantly, not much is known about the association between these risk factors and one another, and specifically the relations between genetic RFs and medical ones. Few studies have investigated the relations between established medical RFs and ApoE &#949;4 status. While several studies have found that medical RFs such as hyperlipidemia, diabetes, and hypertension have a stronger influence on AD risk in ApoE &#949;4 carriers [<xref rid="bib0026" ref-type="bibr">[26]</xref>, <xref rid="bib0027" ref-type="bibr">[27]</xref>, <xref rid="bib0028" ref-type="bibr">[28]</xref>], other studies have not observed this link [<xref rid="bib0029" ref-type="bibr">29</xref>]. Therefore, the relationship between ApoE status and medical RFs has yet to be determined.</p><p id="para0014">Taken together, despite extensive research, the number of validated AD-related RFs remains limited, and their interactions with genetic factors, specifically ApoE haplotypes and demographic determinants, are poorly understood. To address this, we analyzed the UK Biobank, a large-scale longitudinal dataset, to investigate ICD-10-coded diagnoses, and their associations with clinical-AD and ApoE haplotypes.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><sec id="sec0003"><label>2.1</label><title>Participants</title><p id="para0015">The UKB study enrolled a total of 502,253 participants, aged 40 to 69 years, during the period from 2006 to 2010 [<xref rid="bib0030" ref-type="bibr">30</xref>]. Overall, the collected data include comprehensive health records (ICD-10 codes with dates of diagnosis) from birth to last release (August 2022), as well as clinical screening, cognitive assessments, genetic profiling, neuroimaging, demographic, and wellness self-reported data. Records of participants (<xref rid="tbl0001" ref-type="table">Table 1</xref>) with ICD-10 clinical diagnosis of AD dementia (Table S1) were selected for the AD group. Participants who died during the recollection period (before August 2022) were excluded, as well as those who were diagnosed with another neurodegenerative disease or dementia during the study period (Table S2). Also excluded were participants who were under the age of 55 at the end of their medical records update (August 2022). Note that results in the group of 55&#8211;65-year-old participants were treated separately. This filtering yielded 387,275 participants with no clinical diagnosis of AD dementia or mild cognitive impairment (MCI) by the data release date, labeled as cognitively unimpaired, and 3,843 participants diagnosed with clinical-AD dementia. To minimize reverse causation, ICD-10 diagnoses were counted only if they preceded the AD diagnosis by 10 years or more. Moreover, to address the possibility that some of the participants in the CU group may have developed dementia shortly after the data release, the reference time for the CU group was set to five years before the data release date, while for the clinical-AD group, it was set to the date of clinical-AD diagnosis. Finally, to capture the dependence on age and other covariates as fully as possible, medical conditions were coded dichotomously (present/absent) to create a Boolean participant-ICD-10 code matrix.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Demographics and clinical characteristics of Alzheimer&#8217;s disease (AD) patients and cognitively unimpaired controls taken from the UK-biobank.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1"><bold>Values</bold></th><th valign="top" colspan="1" rowspan="1"><bold>AD</bold></th><th valign="top" colspan="1" rowspan="1"><bold>CU</bold></th><th valign="top" colspan="1" rowspan="1"><bold>P</bold></th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Num Total</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">3,843</td><td valign="top" colspan="1" rowspan="1">387,275</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Age</bold></td><td valign="top" colspan="1" rowspan="1">55-64<break/>65-74<break/>75-86</td><td valign="top" colspan="1" rowspan="1">148 (3.9%)<break/>1,231 (32.0%)<break/>2,464 (64.1%)</td><td valign="top" colspan="1" rowspan="1">140,356 (36.2%)<break/>193,135 (49.9%)<break/>53,784 (13.9%)</td><td valign="top" colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sex</bold></td><td valign="top" colspan="1" rowspan="1">Female<break/>Male</td><td valign="top" colspan="1" rowspan="1">2,059 (53.6%)<break/>1,784 (46.4%)</td><td valign="top" colspan="1" rowspan="1">216,981 (56.0%)<break/>170,294 (44.0%)</td><td valign="top" colspan="1" rowspan="1">0.0025</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education</bold></td><td valign="top" colspan="1" rowspan="1">Poor<break/>High School<break/>Degree</td><td valign="top" colspan="1" rowspan="1">1,519 (39.5%)<break/>1,584 (41.2%)<break/>740 (19.3%)</td><td valign="top" colspan="1" rowspan="1">74,442 (19.2%)<break/>189,319 (48.9%)<break/>123,514 (31.9%)</td><td valign="top" colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>ApoE</bold></td><td valign="top" colspan="1" rowspan="1">&#949;4/&#949;4<break/>&#949;3/&#949;4<break/>&#949;2/&#949;4<break/>&#949;3/&#949;3<break/>&#949;2/&#949;3<break/>&#949;2/&#949;2</td><td valign="top" colspan="1" rowspan="1">503 (13.1%)<break/>1,690 (44.0%)<break/>94 (2.4%)<break/>1,195 (31.1%)<break/>185 (4.8%)<break/>8 (0.2%)</td><td valign="top" colspan="1" rowspan="1">8,174 (2.1%)<break/>87,102 (22.5%)<break/>9,403 (2.4%)<break/>222,309 (57.4%)<break/>46,519 (12.0%)<break/>2,349 (0.6%)</td><td valign="top" colspan="1" rowspan="1">&lt;0.0001</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0004"><label>2.2</label><title>Statistical analysis</title><p id="para0016">Out of all ICD-10 codes, 11,910 were found at least once in the UKB records. Filtering out records with irrelevant dates, further reduced this number to 9,362. Codes that appeared in less than 0.5% of individuals in both groups were excluded, yielding 187 ICD-10 codes for further analysis. For each of these codes, we independently ran logistic regression, predicting clinical-AD from the diagnosis and a number of demographic features. For demographic confounders, age (at reference time), biological sex, and education were considered. For ethnicity, since the vast majority of UKB participants are Caucasian (94.6%), other ethnicities were excluded. Given the substantial influence of age on the outcome, which may not be adequately captured by a single linear regressor, we incorporated three age-related regressors in our model: the plain linear age, a SoftPlus (SP) function with a wide transition around 65 years old and another wide SP around 75 years. We used Python&#8217;s R-based statsmodels package, employing the formula below. In the formula, an asterisk (*) between two predictors indicates that the model includes each predictor separately, along with their interaction (Boolean variable is noted by <italic toggle="yes">is</italic>).</p><p id="para0017">We ran for each code separately a logistic regression of the form:<disp-formula id="ueqn0001"><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>A</mml:mi><mml:mi>D</mml:mi><mml:mspace width="0.28em"/><mml:mo>&#8764;</mml:mo><mml:mspace width="0.28em"/><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:munderover><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:msub><mml:mi>&#946;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#183;</mml:mo><mml:mi>C</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mtext>RF</mml:mtext></mml:msub><mml:mo>&#183;</mml:mo><mml:mtext>Boo</mml:mtext><mml:msub><mml:mi mathvariant="normal">l</mml:mi><mml:mtext>RF</mml:mtext></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula> with confounders (Conf<sub>i</sub>) based on age, education and sex. Since the relations between AD prevalence and age are nonlinear[<xref rid="bib0031" ref-type="bibr">31</xref>], the logistic regression model first calculates a score value for each subject as a linear combination of its predictor values. This score is further converted to probability value by application of a logistic function. To account for the nonlinearity dictated by the age-prevalence curve, we included the softplus (SP) function as an additive nonlinear term. We used two softplus functions with different centers (65- and 75-years-old). To these 3 predictors, we added sex (male/female), education (low/medium/high), as well as all potential interactions among them. The final model therefore contained 23 confounders per single RF related predictor, and is described in R notation as:<disp-formula id="ueqn0002"><mml:math id="M2" altimg="si2.svg"><mml:mrow><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>A</mml:mi><mml:mi>D</mml:mi><mml:mrow/><mml:mo>&#8764;</mml:mo><mml:mrow/><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mrow/><mml:mo linebreak="badbreak">+</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mo>_</mml:mo><mml:mi>S</mml:mi><mml:mi>P</mml:mi><mml:mo>_</mml:mo><mml:mn>65</mml:mn><mml:mrow/><mml:mo linebreak="badbreak">+</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mo>_</mml:mo><mml:mi>S</mml:mi><mml:mi>P</mml:mi><mml:mo>_</mml:mo><mml:mn>75</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">*</mml:mo><mml:mi>S</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mo linebreak="goodbreak">*</mml:mo><mml:mi>E</mml:mi><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>D</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:math></disp-formula></p><p id="para0019">This model was run using Python&#8217;s statsmodels package which also calculates the p-value for each predictor. All reported p-values were false discovery rate (FDR)-corrected for multiple comparisons. This procedure yielded a list of ICD-10 codes that significantly differed between clinical-AD and CU participants.</p></sec><sec id="sec0005"><label>2.3</label><title>Categorization</title><p id="para0020">ICD-10 diagnoses were assigned into different categories according to the ICD coding conventions. Similar codes were grouped together into the code with highest OR following a consensus agreement of four certified neurologists (GA, SA, TBH and GAM; Table S3).</p></sec><sec id="sec0006"><label>2.4</label><title>Demographic determinants</title><p id="para0021">To examine differences in demographic determinants, including age, sex, and education, we followed a similar procedure, incorporating an interaction term with the ICD-10 diagnosis. To ensure sufficient statistical power, these analyses were conducted on the ICD-10 categories rather than individual codes. The resulting formula is:<disp-formula id="ueqn0003"><mml:math id="M3" altimg="si3.svg"><mml:mrow><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>A</mml:mi><mml:mi>D</mml:mi><mml:mo>&#8764;</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mrow/><mml:mo linebreak="badbreak">+</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mo>_</mml:mo><mml:mi>S</mml:mi><mml:mi>P</mml:mi><mml:mo>_</mml:mo><mml:mn>75</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">*</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>E</mml:mi><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>y</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>y</mml:mi><mml:mo>:</mml:mo><mml:mi>D</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>V</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>b</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:math></disp-formula>Here, the latter variable refers to the variable of interest. This analysis was independently applied to early and late onset clinical-AD (below and above 65 years old, respectively); and sex: (males and females). For education, a single interaction term was used, with ordinal values for the different educational categories (university/college, high school, less than 12 years of formal education).</p></sec><sec id="sec0007"><label>2.5</label><title>Genetics</title><p id="para0022">The RF profile associated with different ApoE haplotypes is hypothesized to interact with AD risk. ApoE profile was extracted from the genomic data, and its prevalence across the groups was calculated (Table S5). Participants with the genotypes &#949;2/&#949;2 and &#949;2/&#949;4 ApoE haplotypes were excluded due to their very small sample sizes. The remaining haplotypes were ordered based on their AD prevalence (&#949;2/&#949;3 &lt; &#949;3/&#949;3 &lt; &#949;3/&#949;4 &lt; &#949;4/&#949;4) [<xref rid="bib0032" ref-type="bibr">32</xref>] and assigned ordinal values. This vector was then used as a predictor in a logistic regression model, following the same procedure as for the demographic determinants. The resulting formula was:<disp-formula id="ueqn0004"><mml:math id="M4" altimg="si4.svg"><mml:mrow><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>A</mml:mi><mml:mi>D</mml:mi><mml:mo>&#8764;</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mrow/><mml:mo linebreak="badbreak">+</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mo>_</mml:mo><mml:mi>S</mml:mi><mml:mi>M</mml:mi><mml:mo>_</mml:mo><mml:mn>75</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">*</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>E</mml:mi><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>A</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>E</mml:mi><mml:mi>O</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>H</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>y</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>y</mml:mi><mml:mo>:</mml:mo><mml:mi>A</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>E</mml:mi><mml:mi>O</mml:mi><mml:mi>r</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:math></disp-formula>with one-hot encoding for control, and the last term as the variable of interest.</p></sec><sec id="sec0008"><label>2.6</label><title>Power estimation for interaction analysis</title><p id="para0024">To estimate the power of the interactions, the clinical-AD probability for each subject was first estimated under the assumption of no interaction. This was then corrected according to the effect size derived from the odds-ratio of the highest rated factors. The corrected probabilities were utilized to simulate Boolean data on which the interaction model was run. Finally, the power was determined as the proportion of iterations, out of 1000, in which the interaction's p-value fell below 0.05.</p></sec></sec><sec id="sec0009"><label>3</label><title>Results</title><p id="para0025">A statistical comparison of ICD-10 codes given to UKB participants at least 10 years prior to diagnosis revealed 96 ICD-10 codes significantly associated (p&lt;0.001, FDR-corrected) with individuals clinically diagnosed with AD dementia, compared to CU UKB participants, while controlling for age, sex, and education. These codes represented 45 medical entities (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>; <xref rid="tbl0002" ref-type="table">Table 2</xref>; For examples of codes which were not included see Table S4).<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Medical risk factors for Alzheimer&#8217;s Disease</bold>. UKB-derived ICD-10 diagnoses identified as risk factors for Alzheimer&#8217;s disease (AD; represented by circles) are shown, categorized by color according to the ICD-10 classification. The size of each circle corresponds to the prevalence of the specific factor within the AD group. The color intensity of each circle reflects the associated odds ratio. <italic toggle="yes">Figure designed by Hagar Segev.</italic></p></caption><alt-text id="alt0003">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Summary statistics for Alzheimer&#8217;s disease medical risk factors.</p></caption><alt-text id="alt0002">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">#</th><th valign="top" colspan="1" rowspan="1">Code</th><th valign="top" colspan="1" rowspan="1">Name</th><th valign="top" colspan="1" rowspan="1">OR (95% CI)</th><th valign="top" colspan="1" rowspan="1">%CU / %AD</th><th valign="top" colspan="1" rowspan="1">FDR</th></tr></thead><tbody><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Endocrine, Nutritional, Metabolic</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">E10.9</td><td valign="top" colspan="1" rowspan="1">Diabetes Mellitus type I</td><td valign="top" colspan="1" rowspan="1">4.34 [3.06 &#8211; 6.17]</td><td valign="top" colspan="1" rowspan="1">0.2% / 1.1%</td><td valign="top" colspan="1" rowspan="1">1.29E-15</td></tr><tr><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">E11.9</td><td valign="top" colspan="1" rowspan="1">Diabetes Mellitus type II</td><td valign="top" colspan="1" rowspan="1">3.19 [2.74 &#8211; 3.71]</td><td valign="top" colspan="1" rowspan="1">1.2% / 6.0%</td><td valign="top" colspan="1" rowspan="1">7.45E-49</td></tr><tr><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">E66.9</td><td valign="top" colspan="1" rowspan="1">Obesity</td><td valign="top" colspan="1" rowspan="1">2.50 [1.78 &#8211; 3.51]</td><td valign="top" colspan="1" rowspan="1">0.4% / 1.1%</td><td valign="top" colspan="1" rowspan="1">2.30E-07</td></tr><tr><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">E78.0</td><td valign="top" colspan="1" rowspan="1">Hypercholesterolemia</td><td valign="top" colspan="1" rowspan="1">2.05 [1.81 &#8211; 2.33]</td><td valign="top" colspan="1" rowspan="1">2.4% / 8.5%</td><td valign="top" colspan="1" rowspan="1">3.86E-27</td></tr><tr><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">E03.9</td><td valign="top" colspan="1" rowspan="1">Hypothyroidism</td><td valign="top" colspan="1" rowspan="1">2.02 [1.63 &#8211; 2.49]</td><td valign="top" colspan="1" rowspan="1">1.0% / 2.8%</td><td valign="top" colspan="1" rowspan="1">2.50E-10</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Circulatory System</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">I50.1</td><td valign="top" colspan="1" rowspan="1">Left ventricular failure</td><td valign="top" colspan="1" rowspan="1">2.42 [1.62 &#8211; 3.63]</td><td valign="top" colspan="1" rowspan="1">0.2% / 0.8%</td><td valign="top" colspan="1" rowspan="1">2.40E-05</td></tr><tr><td valign="top" colspan="1" rowspan="1">7</td><td valign="top" colspan="1" rowspan="1">Z92.1</td><td valign="top" colspan="1" rowspan="1">Long-term use of anticoagulants (Z)</td><td valign="top" colspan="1" rowspan="1">2.39 [1.80 &#8211; 3.18]</td><td valign="top" colspan="1" rowspan="1">0.4% / 1.7%</td><td valign="top" colspan="1" rowspan="1">5.57E-09</td></tr><tr><td valign="top" colspan="1" rowspan="1">8</td><td valign="top" colspan="1" rowspan="1">I73.9</td><td valign="top" colspan="1" rowspan="1">Peripheral vascular disease</td><td valign="top" colspan="1" rowspan="1">2.38 [1.51 &#8211; 3.73]</td><td valign="top" colspan="1" rowspan="1">0.1% / 0.6%</td><td valign="top" colspan="1" rowspan="1">2.37E-04</td></tr><tr><td valign="top" colspan="1" rowspan="1">9</td><td valign="top" colspan="1" rowspan="1">Z86.7</td><td valign="top" colspan="1" rowspan="1">History of disease of the circulatory system (Z)</td><td valign="top" colspan="1" rowspan="1">2.14 [1.74 &#8211; 2.63]</td><td valign="top" colspan="1" rowspan="1">0.9% / 3.1%</td><td valign="top" colspan="1" rowspan="1">1.98E-12</td></tr><tr><td valign="top" colspan="1" rowspan="1">10</td><td valign="top" colspan="1" rowspan="1">I10</td><td valign="top" colspan="1" rowspan="1">Essential hypertension</td><td valign="top" colspan="1" rowspan="1">1.90 [1.74 &#8211; 2.08]</td><td valign="top" colspan="1" rowspan="1">5.8% / 18.0%</td><td valign="top" colspan="1" rowspan="1">3.53E-42</td></tr><tr><td valign="top" colspan="1" rowspan="1">11</td><td valign="top" colspan="1" rowspan="1">I25.9</td><td valign="top" colspan="1" rowspan="1">Ischemic heart disease</td><td valign="top" colspan="1" rowspan="1">1.77 [1.57 &#8211; 2.01]</td><td valign="top" colspan="1" rowspan="1">2.8% / 8.7%</td><td valign="top" colspan="1" rowspan="1">1.15E-18</td></tr><tr><td valign="top" colspan="1" rowspan="1">12</td><td valign="top" colspan="1" rowspan="1">R55</td><td valign="top" colspan="1" rowspan="1">Syncope and collapse (R)</td><td valign="top" colspan="1" rowspan="1">1.73 [1.37 &#8211; 2.17]</td><td valign="top" colspan="1" rowspan="1">0.9% / 2.5%</td><td valign="top" colspan="1" rowspan="1">5.18E-06</td></tr><tr><td valign="top" colspan="1" rowspan="1">13</td><td valign="top" colspan="1" rowspan="1">I20.9</td><td valign="top" colspan="1" rowspan="1">Angina pectoris</td><td valign="top" colspan="1" rowspan="1">1.72 [1.54 &#8211; 1.91]</td><td valign="top" colspan="1" rowspan="1">4.9% / 11.9%</td><td valign="top" colspan="1" rowspan="1">2.67E-22</td></tr><tr><td valign="top" colspan="1" rowspan="1">14</td><td valign="top" colspan="1" rowspan="1">I48</td><td valign="top" colspan="1" rowspan="1">Atrial fibrillation and flutter</td><td valign="top" colspan="1" rowspan="1">1.72 [1.40 &#8211; 2.11]</td><td valign="top" colspan="1" rowspan="1">0.9% / 3.2%</td><td valign="top" colspan="1" rowspan="1">3.82E-07</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Eye and Ear</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">15</td><td valign="top" colspan="1" rowspan="1">H36.0</td><td valign="top" colspan="1" rowspan="1">Diabetic retinopathy</td><td valign="top" colspan="1" rowspan="1">7.16 [4.57 &#8211; 11.22]</td><td valign="top" colspan="1" rowspan="1">0.1% / 0.7%</td><td valign="top" colspan="1" rowspan="1">5.26E-17</td></tr><tr><td valign="top" colspan="1" rowspan="1">16</td><td valign="top" colspan="1" rowspan="1">H91.9</td><td valign="top" colspan="1" rowspan="1">Hearing loss</td><td valign="top" colspan="1" rowspan="1">2.96 [1.80 &#8211; 4.87]</td><td valign="top" colspan="1" rowspan="1">0.1% / 0.6%</td><td valign="top" colspan="1" rowspan="1">2.62E-05</td></tr><tr><td valign="top" colspan="1" rowspan="1">17</td><td valign="top" colspan="1" rowspan="1">H26.9</td><td valign="top" colspan="1" rowspan="1">Cataract</td><td valign="top" colspan="1" rowspan="1">1.81 [1.50 &#8211; 2.18]</td><td valign="top" colspan="1" rowspan="1">0.9% / 3.7%</td><td valign="top" colspan="1" rowspan="1">1.53E-09</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Genitourinary System</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">18</td><td valign="top" colspan="1" rowspan="1">N39.0</td><td valign="top" colspan="1" rowspan="1">Chronic UTI</td><td valign="top" colspan="1" rowspan="1">2.15 [1.74 &#8211; 2.64]</td><td valign="top" colspan="1" rowspan="1">1.0% / 3.0%</td><td valign="top" colspan="1" rowspan="1">2.48E-12</td></tr><tr><td valign="top" colspan="1" rowspan="1">19</td><td valign="top" colspan="1" rowspan="1">N32.8</td><td valign="top" colspan="1" rowspan="1">Disorders of Bladder</td><td valign="top" colspan="1" rowspan="1">1.42 [1.23 &#8211; 1.65]</td><td valign="top" colspan="1" rowspan="1">2.6% / 6.0%</td><td valign="top" colspan="1" rowspan="1">4.52E-06</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Mental and Behavioral Disorders</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">20</td><td valign="top" colspan="1" rowspan="1">F32.9</td><td valign="top" colspan="1" rowspan="1">Depressive episode</td><td valign="top" colspan="1" rowspan="1">3.10 [2.28 &#8211; 4.23]</td><td valign="top" colspan="1" rowspan="1">0.5% / 1.3%</td><td valign="top" colspan="1" rowspan="1">2.48E-12</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Nervous System</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">21</td><td valign="top" colspan="1" rowspan="1">G40.9</td><td valign="top" colspan="1" rowspan="1">Epilepsy</td><td valign="top" colspan="1" rowspan="1">3.66 [2.58 &#8211; 5.20]</td><td valign="top" colspan="1" rowspan="1">0.3% / 1.0%</td><td valign="top" colspan="1" rowspan="1">1.83E-12</td></tr><tr><td valign="top" colspan="1" rowspan="1">22</td><td valign="top" colspan="1" rowspan="1">G47.3</td><td valign="top" colspan="1" rowspan="1">Sleep apnea</td><td valign="top" colspan="1" rowspan="1">2.03 [1.39 &#8211; 2.96]</td><td valign="top" colspan="1" rowspan="1">0.4% / 0.8%</td><td valign="top" colspan="1" rowspan="1">2.81E-04</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Digestive System</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">23</td><td valign="top" colspan="1" rowspan="1">K58.9</td><td valign="top" colspan="1" rowspan="1">Irritable bowel syndrome</td><td valign="top" colspan="1" rowspan="1">2.06 [1.47 &#8211; 2.89]</td><td valign="top" colspan="1" rowspan="1">0.5% / 1.1%</td><td valign="top" colspan="1" rowspan="1">3.93E-05</td></tr><tr><td valign="top" colspan="1" rowspan="1">24</td><td valign="top" colspan="1" rowspan="1">K52.9</td><td valign="top" colspan="1" rowspan="1">Noninfective gastroenteritis and colitis</td><td valign="top" colspan="1" rowspan="1">1.66 [1.42 &#8211; 1.93]</td><td valign="top" colspan="1" rowspan="1">2.5% / 5.5%</td><td valign="top" colspan="1" rowspan="1">3.34E-10</td></tr><tr><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">K30</td><td valign="top" colspan="1" rowspan="1">Dyspepsia</td><td valign="top" colspan="1" rowspan="1">1.48 [1.31 &#8211; 1.67]</td><td valign="top" colspan="1" rowspan="1">4.3% / 8.4%</td><td valign="top" colspan="1" rowspan="1">1.53E-09</td></tr><tr><td valign="top" colspan="1" rowspan="1">26</td><td valign="top" colspan="1" rowspan="1">K44.9</td><td valign="top" colspan="1" rowspan="1">Diaphragmatic hernia</td><td valign="top" colspan="1" rowspan="1">1.42 [1.25 &#8211; 1.62]</td><td valign="top" colspan="1" rowspan="1">3.4% / 7.1%</td><td valign="top" colspan="1" rowspan="1">3.82E-07</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Musculoskeletal System</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">27</td><td valign="top" colspan="1" rowspan="1">M81.99</td><td valign="top" colspan="1" rowspan="1">Osteoporosis</td><td valign="top" colspan="1" rowspan="1">2.60 [1.70 &#8211; 4.00]</td><td valign="top" colspan="1" rowspan="1">0.1% / 0.8%</td><td valign="top" colspan="1" rowspan="1">1.86E-05</td></tr><tr><td valign="top" colspan="1" rowspan="1">28</td><td valign="top" colspan="1" rowspan="1">M13.99</td><td valign="top" colspan="1" rowspan="1">Arthritis</td><td valign="top" colspan="1" rowspan="1">2.34 [1.62 &#8211; 3.37]</td><td valign="top" colspan="1" rowspan="1">0.2% / 1.0%</td><td valign="top" colspan="1" rowspan="1">9.74E-06</td></tr><tr><td valign="top" colspan="1" rowspan="1">29</td><td valign="top" colspan="1" rowspan="1">M79.86</td><td valign="top" colspan="1" rowspan="1">Soft tissue disorder</td><td valign="top" colspan="1" rowspan="1">2.27 [1.49 &#8211; 3.44]</td><td valign="top" colspan="1" rowspan="1">0.2% / 0.7%</td><td valign="top" colspan="1" rowspan="1">1.63E-04</td></tr><tr><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">Z96.6</td><td valign="top" colspan="1" rowspan="1">Orthopaedic joint implants</td><td valign="top" colspan="1" rowspan="1">2.20 [1.74 &#8211; 2.78]</td><td valign="top" colspan="1" rowspan="1">0.5% / 2.4%</td><td valign="top" colspan="1" rowspan="1">1.00E-10</td></tr><tr><td valign="top" colspan="1" rowspan="1">31</td><td valign="top" colspan="1" rowspan="1">M17.1</td><td valign="top" colspan="1" rowspan="1">Osteoarthritis</td><td valign="top" colspan="1" rowspan="1">2.10 [1.84 &#8211; 2.39]</td><td valign="top" colspan="1" rowspan="1">2.3% / 8.1%</td><td valign="top" colspan="1" rowspan="1">1.12E-27</td></tr><tr><td valign="top" colspan="1" rowspan="1">32</td><td valign="top" colspan="1" rowspan="1">M51.1</td><td valign="top" colspan="1" rowspan="1">Radiculopathy</td><td valign="top" colspan="1" rowspan="1">1.77 [1.40 &#8211; 2.25]</td><td valign="top" colspan="1" rowspan="1">1.0% / 2.2%</td><td valign="top" colspan="1" rowspan="1">4.52E-06</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Neoplasm and Blood</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">33</td><td valign="top" colspan="1" rowspan="1">R63.4</td><td valign="top" colspan="1" rowspan="1">Abnormal weight loss (R)</td><td valign="top" colspan="1" rowspan="1">2.73 [1.98 &#8211; 3.74]</td><td valign="top" colspan="1" rowspan="1">0.4% / 1.3%</td><td valign="top" colspan="1" rowspan="1">1.53E-09</td></tr><tr><td valign="top" colspan="1" rowspan="1">34</td><td valign="top" colspan="1" rowspan="1">Z51.1</td><td valign="top" colspan="1" rowspan="1">Chemotherapy</td><td valign="top" colspan="1" rowspan="1">2.04 [1.57 &#8211; 2.66]</td><td valign="top" colspan="1" rowspan="1">0.8% / 1.8%</td><td valign="top" colspan="1" rowspan="1">2.22E-07</td></tr><tr><td valign="top" colspan="1" rowspan="1">35</td><td valign="top" colspan="1" rowspan="1">D64.9</td><td valign="top" colspan="1" rowspan="1">Anemia</td><td valign="top" colspan="1" rowspan="1">1.83 [1.47 &#8211; 2.30]</td><td valign="top" colspan="1" rowspan="1">1.2% / 2.5%</td><td valign="top" colspan="1" rowspan="1">2.40E-07</td></tr><tr><td valign="top" colspan="1" rowspan="1">36</td><td valign="top" colspan="1" rowspan="1">Z85.3</td><td valign="top" colspan="1" rowspan="1">Malignant neoplasm of breast (Z)</td><td valign="top" colspan="1" rowspan="1">1.79 [1.46 &#8211; 2.20]</td><td valign="top" colspan="1" rowspan="1">1.1% / 3.0%</td><td valign="top" colspan="1" rowspan="1">4.00E-08</td></tr><tr><td valign="top" colspan="1" rowspan="1">37</td><td valign="top" colspan="1" rowspan="1">D12.6</td><td valign="top" colspan="1" rowspan="1">Benign neoplasm of colon</td><td valign="top" colspan="1" rowspan="1">1.52 [1.32 &#8211; 1.75]</td><td valign="top" colspan="1" rowspan="1">2.4% / 6.5%</td><td valign="top" colspan="1" rowspan="1">1.47E-08</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Factors Influencing Health</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">38</td><td valign="top" colspan="1" rowspan="1">Z86.4</td><td valign="top" colspan="1" rowspan="1">Psychoactive substance use</td><td valign="top" colspan="1" rowspan="1">3.10 [2.52 &#8211; 3.81]</td><td valign="top" colspan="1" rowspan="1">0.6% / 3.3%</td><td valign="top" colspan="1" rowspan="1">8.31E-26</td></tr><tr><td valign="top" colspan="1" rowspan="1">39</td><td valign="top" colspan="1" rowspan="1">Z60.2</td><td valign="top" colspan="1" rowspan="1">Living alone</td><td valign="top" colspan="1" rowspan="1">2.58 [1.69 &#8211; 3.93]</td><td valign="top" colspan="1" rowspan="1">0.2% / 0.8%</td><td valign="top" colspan="1" rowspan="1">1.55E-05</td></tr><tr><td valign="top" colspan="1" rowspan="1">40</td><td valign="top" colspan="1" rowspan="1">Z72.1</td><td valign="top" colspan="1" rowspan="1">Alcohol use</td><td valign="top" colspan="1" rowspan="1">2.55 [1.67 &#8211; 3.87]</td><td valign="top" colspan="1" rowspan="1">0.2% / 0.8%</td><td valign="top" colspan="1" rowspan="1">1.86E-05</td></tr><tr><td valign="top" colspan="1" rowspan="1">41</td><td valign="top" colspan="1" rowspan="1">Z72.0</td><td valign="top" colspan="1" rowspan="1">Tobacco use</td><td valign="top" colspan="1" rowspan="1">2.52 [2.08 &#8211; 3.05]</td><td valign="top" colspan="1" rowspan="1">1.3% / 3.4%</td><td valign="top" colspan="1" rowspan="1">1.58E-20</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Respiratory System</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">42</td><td valign="top" colspan="1" rowspan="1">J44.9</td><td valign="top" colspan="1" rowspan="1">COPD</td><td valign="top" colspan="1" rowspan="1">3.88 [2.83 &#8211; 5.31]</td><td valign="top" colspan="1" rowspan="1">0.2% / 1.4%</td><td valign="top" colspan="1" rowspan="1">2.08E-16</td></tr><tr><td valign="top" colspan="1" rowspan="1">43</td><td valign="top" colspan="1" rowspan="1">J22</td><td valign="top" colspan="1" rowspan="1">Lower lobe pneumonia</td><td valign="top" colspan="1" rowspan="1">2.12 [1.58 &#8211; 2.85]</td><td valign="top" colspan="1" rowspan="1">0.5% / 1.5%</td><td valign="top" colspan="1" rowspan="1">9.08E-07</td></tr><tr><td valign="top" colspan="1" rowspan="1">44</td><td valign="top" colspan="1" rowspan="1">J45.9</td><td valign="top" colspan="1" rowspan="1">Asthma</td><td valign="top" colspan="1" rowspan="1">1.70 [1.45 &#8211; 2.00]</td><td valign="top" colspan="1" rowspan="1">2.4% / 4.7%</td><td valign="top" colspan="1" rowspan="1">3.56E-10</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1"><bold>Infectious Diseases</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">45</td><td valign="top" colspan="1" rowspan="1">B95.6</td><td valign="top" colspan="1" rowspan="1">Staph aureus cause of diseases</td><td valign="top" colspan="1" rowspan="1">2.45 [1.53 &#8211; 3.94]</td><td valign="top" colspan="1" rowspan="1">0.2% / 0.5%</td><td valign="top" colspan="1" rowspan="1">2.74E-04</td></tr></tbody></table></table-wrap></p><p id="para0026">Following studies that showed different relationships between genetic AD-risk and various medical and life-style RFs [<xref rid="bib0033" ref-type="bibr">[33]</xref>, <xref rid="bib0034" ref-type="bibr">[34]</xref>, <xref rid="bib0035" ref-type="bibr">[35]</xref>], we compared ApoE status to the extracted medical RFs in the category level. Ordinal values were assigned to the ApoE status according to clinical-AD dementia prevalence in the cohort (0,1,2,3 were assigned for &#949;4/&#949;4 (5.8%), &#949;3/&#949;4 (1.9%), &#949;3/&#949;3 (0.55%) and &#949;2/&#949;3 (0.4%), respectively; Table S5). This vector demonstrated a significant interaction with codes categorized under the metabolic (p=0.004, FDR-corrected) and circulatory (p=0.001, FDR-corrected) systems. The OR showed a near-linear increase from 1.6 (&#949;4/&#949;4) to 3.4 (&#949;2/&#949;3) for the metabolic category and from 1.2 (&#949;4/&#949;4) to 2.5 (&#949;2/&#949;3) for the circulatory category (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>, Table S6). In other words, disorders elucidated in our analysis within the metabolic and circulatory categories were associated with a higher risk of clinical-AD dementia for individuals with ApoE &#949;2/&#949;3 genotype compared to those with ApoE &#949;4/&#949;4 genotype.<fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>Interaction between ApoE genotypes and medical risk factors, grouped by category</bold>. A significant interaction was observed between ApoE genotypes and the metabolic and circulatory categories, which include vascular risk factors. Genotypes are displayed in the following order: &#949;4/&#949;4 (left, dark), &#949;3/&#949;4, &#949;3/&#949;3, &#949;2/&#949;3 (right, bright). Categories with power lower than 0.8 are labeled in grey. Statistical significance was assessed using a linear trend analysis across genotypes. Odds ratios are shown on a logarithmic scale, with error bars indicating the standard error of the mean (SEM).</p></caption><alt-text id="alt0004">Fig 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="para0027">Further assessing individual disorders that constitute the metabolic and circulatory categories, showed that the involved codes include hypertension, ischemic heart disease/angina pectoris and hypercholesterolemia, which are considered main vascular risk factors (<xref rid="fig0003" ref-type="fig">Fig 3</xref>). Type II diabetes, obesity and hyperthyroidism showed a similar trend, although not significant. With respect to early vs. late onset clinical-AD, no category demonstrated a significant effect. However, it is worth noting that the number of participants with early onset clinical-AD was relatively small (n=167) (Table S7). Similarly, no significant differences were observed across risk-factors categories with respect to sex (Table S8) or education level (Table S9).<fig id="fig0003" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>Interactions between ApoE genotype and metabolic/circulatory ICD-10 codes.</bold> Hypertension, ischemic heart disease, angina pectoris, and hypercholesterolemia were found to be more prevalent in individuals with lower ApoE-related genetic risk. Genotypes are displayed in the following order: &#949;4/&#949;4 (left, dark), &#949;3/&#949;4, &#949;3/&#949;3, &#949;2/&#949;3 (right, bright). Codes with power lower than 0.8 are labeled in grey. Statistical significance was assessed using a linear trend analysis across genotypes. Odds ratios are shown on a logarithmic scale, with error bars indicating the standard error of the mean (SEM).</p></caption><alt-text id="alt0005">Fig 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0003" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="para0028">To further minimize reverse causation, we examined the interaction between each identified risk factor and the number of years since its diagnosis. We found a significant positive interaction for the risk factors with sufficient power, indicating a larger impact with more years elapsed (Table S10).</p></sec><sec id="sec0010"><label>4</label><title>Discussion</title><p id="para0029">Our analyses yielded a list of 45 medical conditions (encompassing 96 ICD-10 codes) whose prevalence was found to be significantly higher in people with a clinical diagnosis of AD dementia. Codes included major vascular RFs (e.g. diabetes, hyperlipidemia, ischemic heart disease, hypertension, atrial fibrillation), sensory (e.g. cataract, hearing loss) and motor deficits (e.g. osteoarthritis, discopathy), mental conditions (depression), gastrointestinal disorders (e.g. gastritis, GERD) or infectious conditions (e.g. chronic UTI, pneumonia). Several unique conditions were noted as well, including epilepsy, sleep apnea, anemia, chemotherapy, tobacco use, and living alone. Notably, vascular RFs (metabolic and circulatory), which have been found to play a major role in AD dementia development in the current and previous studies, were less significant in individuals carrying the ApoE &#949;4/&#949;4 and &#949;3/&#949;4 haplotypes. Level of education, sex and age did not show any further effect for risk factors in the category level. These are discussed with respect to the different categories and RFs in view of the epidemiologic, clinical and biological determinants and their potential underlying mechanisms.</p><sec id="sec0011"><label>4.1</label><title>ApoE haplotypes interaction with clinical-AD risk factors</title><p id="para0030">While the relationship between ApoE haplotypes and AD are well-documented [<xref rid="bib0036" ref-type="bibr">36</xref>,<xref rid="bib0037" ref-type="bibr">37</xref>], much less is known about the relationship of ApoE haplotypes to AD RFs [<xref rid="bib0038" ref-type="bibr">38</xref>]. RFs that were found more influential in people with ApoE &#949;4 include diabetes [<xref rid="bib0039" ref-type="bibr">39</xref>], hyperlipidemia [<xref rid="bib0027" ref-type="bibr">27</xref>], and hypertension [<xref rid="bib0026" ref-type="bibr">26</xref>]. However, these results were not consistent [<xref rid="bib0029" ref-type="bibr">29</xref>]. Similarly, physical exercise was found to be more effective in APOE &#949;4 carriers [<xref rid="bib0040" ref-type="bibr">40</xref>]. On the other hand, the association between Mediterranean diet with a reduced risk of AD was not found to differ for APOE &#949;4 carriers [<xref rid="bib0041" ref-type="bibr">41</xref>]. AD was also found to be associated with increased neuroinflammation in the presence of ApoE &#949;4, less efficient lipid transport and neuronal repair, and compromised blood-brain barrier integrity [<xref rid="bib0042" ref-type="bibr">[42]</xref>, <xref rid="bib0043" ref-type="bibr">[43]</xref>, <xref rid="bib0044" ref-type="bibr">[44]</xref>]. Our study shows that circulatory and metabolic RFs are less related to clinical-AD in ApoE &#949;4 carriers. The fact that the specific RFs mentioned by some previous studies were found to show the opposite effect in our cohort, calls for a closer examination of this important issue in prospective longitudinal large-scale studies. In view of the diverse mechanisms of ApoE &#949;4 influence, it is possible that other mechanisms, such as inflammatory or toxic related processes are more relevant for ApoE &#949;4 carriers than vascular ones. Alternatively, it is possible that once an individual has a strong AD genetic factor, the effect of other RFs diminishes, in particular vascular RFs. Yet another consideration is that for certain groups, such as African American and Hispanic older adults in the US, being an ApoE &#949;4 carrier is not influential as vascular RFs may be. Additionally, the inverse correlation between ApoE &#949;4 genotype and hypercholesterolemia in AD risk, suggests that ApoE &#949;4 does not mediate its pathogenic effect via its physiological role in lipid transport in the circulation. Moreover, the reduced role of additional systemic cardiovascular and metabolic RFs in AD development supports the notion that the pathogenic role of ApoE &#949;4 likely operates through its effects on brain cells metabolism rather than on the systemic milieu [<xref rid="bib0045" ref-type="bibr">45</xref>]. Further research is crucially needed in this fundamental aspect of AD.</p></sec><sec id="sec0012"><label>4.2</label><title>Influence of age, sex, and education on Alzheimer's disease risk</title><p id="para0031">Age is a major RF for AD. Our analysis followed the convention of early vs. late onset of clinical-AD with a cutoff of 65 years old. This led to a very low number of younger patients, which might explain the lack of age effect in our analysis. With respect to sex, there is an overall higher prevalence and incidence of clinical-AD in females compared to males, even when figures are adjusted for age and longevity [<xref rid="bib0046" ref-type="bibr">46</xref>]. This is attributed to several potential factors that could be related to RFs [<xref rid="bib0047" ref-type="bibr">47</xref>], including neuroprotective effects of estrogen and its decline during menopause or interactions between ApoE &#949;4 and estrogen, which could exacerbate AD pathology in women [<xref rid="bib0048" ref-type="bibr">48</xref>]; women&#8217;s tendency to accumulate more amyloid plaques and neurofibrillary tangles than men, even in the preclinical stages of AD [<xref rid="bib0049" ref-type="bibr">49</xref>]; or a more robust inflammatory response in females than males, which might exacerbate neurodegenerative processes in AD [<xref rid="bib0047" ref-type="bibr">47</xref>]. Finally, epidemiological studies have demonstrated an inverse relationship between education and the risk of developing AD. That is, individuals with higher levels of education exhibited a lower risk of AD [<xref rid="bib0050" ref-type="bibr">50</xref>]. Several mechanisms have been proposed to account for this effect. One line of research suggests intrinsic mechanisms including enhanced neural plasticity, or masking effect [<xref rid="bib0051" ref-type="bibr">51</xref>,<xref rid="bib0052" ref-type="bibr">52</xref>]. Another line suggests that educated individuals are more likely to engage in health-promoting behaviors (lifestyle, healthcare) [<xref rid="bib0053" ref-type="bibr">53</xref>,<xref rid="bib0054" ref-type="bibr">54</xref>]. No such effect was found in our analysis, supporting the first explanation. More data, enabling comparison of specific RFs (rather than categories) in the individual level may yield more results.</p></sec><sec id="sec0013"><label>4.3</label><title>Pathological classification of the RFs for clinical-AD</title><p id="para0032">Our analysis was based on the classification embedded in the ICD-10 system, as this system is used in the UKB. This is based foremost on classification according to systems. Nonetheless, medical reasoning is based on pathogenic classification, including vascular, inflammatory, infectious, toxic, neoplastic and metabolic factors, that merit further discussion.</p><sec id="sec0014"><label>4.3.1</label><title>Vascular</title><p id="para0033">Vascular RFs were found in our analysis to be the most influential RFs on AD development. The relationship between vascular RFs (mentioned here under both circulatory and metabolic categories) and AD is well-documented [<xref rid="bib0055" ref-type="bibr">55</xref>,<xref rid="bib0056" ref-type="bibr">56</xref>]. Vascular risk factors may contribute to the pathogenesis of AD through various mechanisms. Direct ones include reduced cerebral blood flow and microvascular damage. Specifically, hypoxia can induce the formation of amyloid-beta plaques [<xref rid="bib0057" ref-type="bibr">57</xref>], and hyperglycemia and insulin resistance, common in diabetes, can lead to the development of advanced glycation end products (AGEs) which can exacerbate amyloid-beta accumulation and tau hyperphosphorylation [<xref rid="bib0039" ref-type="bibr">39</xref>]. Cholesterol can influence the processing of amyloid precursor protein (APP), leading to increased production of amyloid-beta (A). Additionally, cholesterol may impact tau phosphorylation and neurofibrillary tangle formation [<xref rid="bib0058" ref-type="bibr">58</xref>]. Vascular RFs can contribute to AD also through systemic inflammation, oxidative stress, and altered metabolism. Another vascular RF, atrial fibrillation (AF), has been related to a greater chance of developing dementia in several recent studies, some based on the UKB [<xref rid="bib0020" ref-type="bibr">20</xref>,<xref rid="bib0059" ref-type="bibr">59</xref>,<xref rid="bib0060" ref-type="bibr">60</xref>]. Suggested mechanisms include cerebral hypoperfusion and micro-embolic strokes, and shared risk factors such as aging, hypertension, diabetes, and obesity. These conditions can contribute to endothelial dysfunction, oxidative stress, and inflammation, creating a synergistic effect that increases the likelihood of developing both AF and AD dementia [<xref rid="bib0061" ref-type="bibr">61</xref>,<xref rid="bib0062" ref-type="bibr">62</xref>]. In view of the reduced role of vascular RFs in AD pathology in ApoE &#949;4 carriers, it is important to understand whether this observation is based also on interference with these mechanisms.</p></sec><sec id="sec0015"><label>4.3.2</label><title>Inflammatory</title><p id="para0034">Chronic inflammation is a significant factor in the pathogenesis of AD [<xref rid="bib0063" ref-type="bibr">63</xref>,<xref rid="bib0064" ref-type="bibr">64</xref>]. The role of systemic immune changes in AD has been extensively discussed [<xref rid="bib0064" ref-type="bibr">64</xref>,<xref rid="bib0065" ref-type="bibr">65</xref>]. Peripheral immune responses play a significant role in supporting brain immunity and protecting against neurodegenerative modifications [<xref rid="bib0066" ref-type="bibr">66</xref>]. Inflammatory disorders found in our analysis encompass several systems: gastrointestinal (GI) (esophagitis, gastritis, enteritis, colitis), respiratory (asthma) and musculoskeletal (arthritis). Nonetheless, it remains unclear whether different systemic conditions with an inflammatory component have an additive and/or related effect and can, therefore, be categorized together. The GI system plays a major role among the RF identified. The gut-brain axis represents a bidirectional communication network between the GI tract and the central nervous system. The gut microbiota plays a crucial role in maintaining immune homeostasis and protecting against pathogens. Alterations in gut microbiota composition, which can occur with GI disorders, have been linked to neurodegenerative diseases, including AD [<xref rid="bib0067" ref-type="bibr">67</xref>,<xref rid="bib0068" ref-type="bibr">68</xref>]. Moreover, metabolites produced by gut microbiota, such as short-chain fatty acids, can influence brain function. Dysbiosis in GI disorders can alter production of these metabolites, potentially impacting neurodegeneration. Specifically, certain gut bacteria can produce amyloid proteins [<xref rid="bib0069" ref-type="bibr">69</xref>]. Chronic GI infections might increase the systemic amyloid burden, contributing to AD pathology [<xref rid="bib0070" ref-type="bibr">70</xref>]. Finally, among five drugs which were found to have a significant preventive effect in a large cohort covering over 10 years of clinical records for over 170 million patients, two were related to dyspepsia (pantoprazole and omeprazole [<xref rid="bib0020" ref-type="bibr">20</xref>]).</p></sec><sec id="sec0016"><label>4.3.3</label><title>Infectious</title><p id="para0035">Several infectious diseases have been identified in our analysis including pneumonia, staph aureus related disorders and chronic-UTI. The pathogen hypothesis in AD suggests a multifaceted interaction between infectious agents and the brain&#8217;s immune response [<xref rid="bib0063" ref-type="bibr">63</xref>,<xref rid="bib0071" ref-type="bibr">71</xref>]. Accumulating evidence supports the notion that chronic infections could play a role in AD pathogenesis [<xref rid="bib0072" ref-type="bibr">72</xref>,<xref rid="bib0073" ref-type="bibr">73</xref>]. Several pathogens have been implicated including <italic toggle="yes">herpes simplex virus type 1</italic> (HSV-1), <italic toggle="yes">Porphyromonas gingivitis</italic>, and <italic toggle="yes">Chlamydia pneumonia</italic> [<xref rid="bib0074" ref-type="bibr">[74]</xref>, <xref rid="bib0075" ref-type="bibr">[75]</xref>, <xref rid="bib0076" ref-type="bibr">[76]</xref>]. The mechanisms suggested include excessive A&#946; accumulation, immune dysregulation and chronic inflammation, as well as neurotoxicity and blood-brain barrier (BBB) dysfunction [<xref rid="bib0063" ref-type="bibr">63</xref>,<xref rid="bib0071" ref-type="bibr">71</xref>,<xref rid="bib0077" ref-type="bibr">77</xref>,<xref rid="bib0078" ref-type="bibr">78</xref>]. In our study the only chronic-UTI was found to be significantly associated with AD-dementia. It may be the case that such diseases are less well documented in the UKB: HSV-1 is mostly latent in the brain, and HSV-1 encephalitis is a rare disease. Gingivitis is treated by dentists and oral hygienists and may not be documented in the patient&#8217;s electronic health record (EHR). More research is needed to comprehensively evaluate the role of pathogens in AD development.</p></sec><sec id="sec0017"><label>4.3.4</label><title>Neoplasms</title><p id="para0036">Several RFs related to neoplastic disorders have been identified, including general (neoplasms, chemotherapy, cancer related weight loss) and specific (breast, colon) codes. Suggested mechanisms include genetic factors which can predispose individuals to both AD and cancer [<xref rid="bib0079" ref-type="bibr">79</xref>], cancer-related inflammation which can contribute to neuroinflammation, chemotherapy-related neurotoxicity and mitochondrial dysfunction [<xref rid="bib0080" ref-type="bibr">80</xref>]. Associated weight-loss may cause nutritional deficiency or hormonal imbalance that, in turn, may exacerbate AD-related pathology.</p></sec><sec id="sec0018"><label>4.3.5</label><title>Toxic</title><p id="para0037">Our study identified several toxic agents to be involved in AD. These include psychoactive substances, tobacco, and alcohol (chemotherapy may also be considered in this category). The most prevalent of these is tobacco use. Increased risk of AD in tobacco users may be related to several mechanisms [<xref rid="bib0081" ref-type="bibr">81</xref>], include oxidative damage in neuronal cells [<xref rid="bib0082" ref-type="bibr">82</xref>], chronic inflammation [<xref rid="bib0083" ref-type="bibr">83</xref>], atherosclerosis [<xref rid="bib0084" ref-type="bibr">84</xref>], and BBB dysfunction [<xref rid="bib0042" ref-type="bibr">42</xref>]. Moreover, evidence suggests that smoking may affect the metabolism of APP, leading to increased production and reduced clearance of A&#946; [<xref rid="bib0085" ref-type="bibr">85</xref>], as well as promotion of hyperphosphorylation and aggregation of tau into neurofibrillary tangles [<xref rid="bib0086" ref-type="bibr">86</xref>]. The interaction of toxic exposure and other RFs is not yet known and may account for these results as well.</p></sec><sec id="sec0019"><label>4.3.6</label><title>Sensorimotor deficits</title><p id="para0038">Our results included several sensory deficits (visual or hearing), including diabetic retinopathy, cataract and hearing loss. Sensory deficits have been increasingly linked to an elevated risk of AD and other forms of dementia [<xref rid="bib0087" ref-type="bibr">[87]</xref>, <xref rid="bib0088" ref-type="bibr">[88]</xref>, <xref rid="bib0089" ref-type="bibr">[89]</xref>, <xref rid="bib0090" ref-type="bibr">[90]</xref>]. Both visual and hearing loss are now included in the 2024 report of the Lancet standing commission <xref rid="bib0009" ref-type="bibr">[9]</xref> as based on several large-scale meta analyses [<xref rid="bib0087" ref-type="bibr">87</xref>,<xref rid="bib0091" ref-type="bibr">91</xref>]. The connections between sensory loss and cognitive decline can be explained through the Cognitive Load Hypothesis. According to this idea, when sensory input is diminished, the brain must work harder to process and interpret limited information. This increased cognitive load can lead to greater cognitive strain over time. This, however, is unlikely, as cognitive activity is protective. It is more likely that in early-stage cognitive decline, the increased cognitive strain unmasks the lack of cognitive reserves. Alternatively, such sensory deficits may lead to decreased social interaction and engagement in cognitive activities. Social isolation is a known risk factor for cognitive decline and dementia [<xref rid="bib0009" ref-type="bibr">9</xref>], as was also demonstrated in our results. Finally, sensory loss and cognitive decline may share common RFs and pathophysiological pathways, such as vascular disease, inflammation, and genetic predispositions [<xref rid="bib0089" ref-type="bibr">89</xref>,<xref rid="bib0092" ref-type="bibr">92</xref>]. Motor deficits - attributed in the current study to osteoarthritis, arthritis, radiculopathy, joint implant, or leg soft tissue disorder - have been increasingly recognized as early indicators and potential RFs for AD [<xref rid="bib0093" ref-type="bibr">93</xref>]. The relationship between motor deficits and AD is complex and multifaceted. Amyloid-&#946; plaques are commonly found in brain regions associated with motor function, and a mediation through inflammation has been proposed [<xref rid="bib0094" ref-type="bibr">94</xref>].</p></sec><sec id="sec0020"><label>4.3.7</label><title>Mental disorders, sleep and epilepsy</title><p id="para0039">Several other single factors have been found to increase AD risk. While not all of them can be discussed here, some of them &#8211; depression, social isolation, sleep apnea and epilepsy &#8211; merit such a discussion, in view of the underlying mechanisms and clinical implication. Late-life depression is a typical part of the presentation of AD, and may even precede cognitive symptoms [<xref rid="bib0095" ref-type="bibr">95</xref>]. Generally speaking, depression is associated with increased levels of proinflammatory cytokines [<xref rid="bib0096" ref-type="bibr">96</xref>]. More specifically, it has been suggested that stress and depressive symptoms can increase the production and aggregation of amyloid-&#946; and hyperphosphorylated tau proteins [<xref rid="bib0097" ref-type="bibr">97</xref>,<xref rid="bib0098" ref-type="bibr">98</xref>]. Furthermore, depressive symptoms have been linked to <italic toggle="yes">in vivo</italic> amyloid and tau pathology in older adults at risk for AD [<xref rid="bib0099" ref-type="bibr">99</xref>,<xref rid="bib0100" ref-type="bibr">100</xref>]. Another proposal is that depression can lead to dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in elevated cortisol, that in turn has been linked to hippocampal atrophy [<xref rid="bib0101" ref-type="bibr">101</xref>]. Depression also involves imbalances in neurotransmitters such as serotonin, norepinephrine, and dopamine, which may play a further role in neurodegeneration [<xref rid="bib0102" ref-type="bibr">102</xref>,<xref rid="bib0103" ref-type="bibr">103</xref>]. In this vein, living alone, and loneliness in general, have been increasingly recognized as a significant RF that can exacerbate AD [<xref rid="bib0104" ref-type="bibr">104</xref>,<xref rid="bib0105" ref-type="bibr">105</xref>]. This relationship can be understood through multiple biological and psychological mechanisms. With respect to biology, chronic stress and its relation to inflammation, as well as the HPA axis, leading to increased cortisol levels have been implicated [<xref rid="bib0063" ref-type="bibr">63</xref>,<xref rid="bib0106" ref-type="bibr">106</xref>,<xref rid="bib0107" ref-type="bibr">107</xref>]. Specifically, socially isolated animals exhibit greater amyloid-&#946; accumulation and more severe cognitive deficits compared to socially housed animals [<xref rid="bib0108" ref-type="bibr">108</xref>]. On the psychosocial level, social isolation may lead to depression, which is an established RF, and may increase stress, related to inflammation [<xref rid="bib0095" ref-type="bibr">95</xref>,<xref rid="bib0105" ref-type="bibr">105</xref>].</p><p id="para0040">Sleep apnea may represent a larger group of conditions related to abnormal sleep patterns. While other sleep-related codes did not appear in our analyses, it is possible that these conditions are under-coded in clinical practice. Sleep is essential for cognitive functions such as memory consolidation, learning, and executive function [<xref rid="bib0109" ref-type="bibr">109</xref>]. Sleep deprivation has been identified as a RF for AD in multiple studies and is listed among the Lancet Commission recommendations [<xref rid="bib0008" ref-type="bibr">8</xref>,<xref rid="bib0009" ref-type="bibr">9</xref>] as a modifiable RF. The connection between sleep deprivation and AD can be explained by several mechanisms. Most intriguing, sleep deprivation has been suggested to impair the glymphatic system, leading to reduced clearance of amyloid-&#946; and tau, which may accumulate during wakefulness [<xref rid="bib0110" ref-type="bibr">[110]</xref>, <xref rid="bib0111" ref-type="bibr">[111]</xref>, <xref rid="bib0112" ref-type="bibr">[112]</xref>]. More generally, chronic sleep deprivation has been linked to systemic inflammation, which is hypothesized to take a central part in AD pathology [<xref rid="bib0019" ref-type="bibr">19</xref>].</p><p id="para0041">Of specific interest is the involvement of epilepsy in AD [<xref rid="bib0113" ref-type="bibr">113</xref>]. Subclinical and clinical epilepsy have been found in individuals with MCI and early AD-dementia [<xref rid="bib0114" ref-type="bibr">114</xref>], suggesting that epilepsy can increase the risk of developing AD. These may be related to neuroinflammation [<xref rid="bib0115" ref-type="bibr">115</xref>] and increased amyloid-&#946; deposition and tau pathology [<xref rid="bib0116" ref-type="bibr">116</xref>], or changes in network properties that accelerate pathological propagation [<xref rid="bib0113" ref-type="bibr">113</xref>]. ApoE &#949;4 has also been associated with epilepsy [<xref rid="bib0117" ref-type="bibr">117</xref>], though such an interaction was not found here.</p></sec></sec><sec id="sec0021"><label>4.4</label><title>Relations to the Lancet consensus AD risk factors</title><p id="para0042">Of the accepted RFs found by the Lancet 2017, 2020 and 2024 commission [<xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>, <xref rid="bib0009" ref-type="bibr">[9]</xref>], most modifiable midlife (hearing loss, hypercholesterolemia, depression, diabetes, tobacco use, hypertension, obesity, alcohol use) and late life (social isolation, visual loss) RFs were identified in our analyses, which is a reassuring replication of the Lancet commission. However, physical inactivity and air pollution were not observed; this may be since these factors are typically not coded in clinical settings. TBI was also not found in our analysis. However, the prevalence of TBI in the clinical-AD group was the smallest of all factors (0.49%). Moreover, more than 50% of this latter group suffered TBI less than 1 year before clinical-AD diagnosis, and 66% suffered TBI 2 years before diagnosis, minimizing the potential impact on AD development.</p><p id="para0043">Our study has several limitations. First, participants with AD dementia were diagnosed clinically, without the use of objective biomarkers, as is highlighted throughout the manuscript. Nonetheless, since AD is the most prevalent type of dementia, and since real-world population often presents with mixed forms of dementia, these findings are still important and interesting even if they are not in a biomarker-verified AD cohort, which does not exist nowadays. Moreover, AD diagnosis was based on ICD-10 codes recorded by treating physicians in the participants' medical records. While we did not have access to the full clinical evaluations underlying each diagnosis, these codes reflect real-world clinical decision-making and are part of the UK Biobank&#8217;s standardized health data. This approach may introduce some diagnostic variability, for example due to differences in how diagnostic criteria are applied across clinicians or settings, or inconsistencies in coding practices. Nonetheless, it enables large-scale analyses that would not be feasible with direct assessments alone. Additionally, we did not include participants with MCI as this diagnosis is less reliable in this setting. Second, the number of patients suffering from AD-dementia in the UKB might not have carried sufficient statistical power to account for the large number of RFs examined and those that were not examined. Certainly, the list of RFs presented here is incomplete and should be expanded. However, it provides a comprehensive view of the role of clinical-AD RFs within different categories, as well as includes many specific ones. Moreover, power analysis at the category level showed significant results for most of the categories. Third, the population reflects Caucasian individuals living in a western country, and more specifically, the participants who volunteered for UKB were particularly healthy and highly educated limiting generalizability to other populations [<xref rid="bib0118" ref-type="bibr">118</xref>]. Fourth, ICD-10 codes do not capture all the potential RFs of clinical-AD dementia. Moreover, ICD-10 codes may not accurately reflect patients&#8217; clinical states. Nonetheless, they may serve as a good basis for the type of analyses conducted here, which can serve as a steppingstone for future studies. The exclusion of ICD-10 codes found in less than 0.5% of participants may have left out several relevant RFs, which are less coded in medical files and are known to play a role in AD, such as gingivitis or obesity. Yet, it helped maintain the high specificity of our results. Finally, data on severity of RFs, treatment presented, compliance and effect over time is crucial for better understanding these RFs and their role in AD prevention. Future participant samples and datasets should be constructed in a fashion that makes such data consistently available for analyses.</p><p id="para0044">Another important aspect that was not discussed in the current study is comorbidities. Generally speaking, the interplay between these RFs can create a vicious circle that exacerbates the pathogenesis of AD. More specifically, if several RFs may lead to AD through inflammation, their combined additive contribution may overcome a certain threshold. Alternatively, a combination of different mechanisms, such as inflammation and reduced clearance of amyloid-&#946; may be more influential. Of special importance are specific combinations of RFs, that have shown a synergistic effect. For instance, in a recent work based on the UKB, researchers have identified higher risk for dementia in people with type-2 diabetes and new onset AF [<xref rid="bib0119" ref-type="bibr">119</xref>]. Further research in a larger sample is needed to reliably elucidate such synergistic effects.</p><p id="para0045">The study also contains several important strengths. First, we had access to a very large real-world sample of older adults with a combination of clinical data from EHR records and genetic testing obtained for both cases (AD-dementia) and controls (CU). Second, our results may be more applicable to a real-world population, that more often presents with mixed forms of dementia. Third, we were powered to look at many RFs within large categories, as well as individually. Fourth, we were able to see the effect of ApoE &#603;4, a common and strong susceptibility gene for AD that is not typically obtained clinically, in conjunction with these many RFs on the presence or absence of clinical-AD dementia. Fifth, we were able to relate these RFs to demographic characteristics such as age, sex and level of education with regards to the presence or absence of clinical-AD dementia. Finally, we have reordered the ICD-10 categorization into a clinical context using medical-pathological categorization.</p></sec><sec id="sec0022"><label>4.5</label><title>Conclusion</title><p id="para0046">This study has comprehensively analyzed a large-scale dataset to elucidate a large variety of RFs of different categories for clinical-AD development, and their relationship to specific genetic and demographic determinants. The heterogeneity of these factors and sometimes also their underlying mechanism is in line with novel views of clinical-AD as a highly heterogenous disorder [<xref rid="bib0120" ref-type="bibr">120</xref>]. Our results highlighted entities which are less reported in the AD-prevention literature, such as gastrointestinal and sensorimotor disorders, and underscored the complex interaction between AD major susceptibility gene and vascular RFs. Further research should detect the relationships between specific RFs and certain clinical, genetic, and demographic characteristic, as well as their interactions, with an eye toward personalized prevention of AD.</p></sec></sec><sec sec-type="data-availability" id="sec0024"><title>Data and code availability</title><p id="para0049">Data for this study was obtained from the UKB resource under Application Number 26664. The data is available to bona fide researchers for a fee through the UKB. Source data, along with the source code for all statistical tests, are provided with this paper. The generated figures used in these analyses are available on GitHub (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/CompuNeuroPsychiatryLabEinKerem/publications_data/tree/master/UKBB_AD_RiskFactors" id="interref0001">https://github.com/CompuNeuroPsychiatryLabEinKerem/publications_data/tree/master/UKBB_AD_RiskFactors</ext-link>), with detailed instructions provided in the README.md file.</p></sec><sec id="sec0024a"><title>CRediT authorship contribution statement</title><p id="para0049a"><bold>Uri Elias:</bold> Writing &#8211; original draft, Visualization, Methodology, Formal analysis, Data curation, Conceptualization. <bold>Lidor Gazit:</bold> Writing &#8211; original draft, Visualization, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. <bold>Roei Zucker:</bold> Methodology, Data curation. <bold>Amos Stern:</bold> Formal analysis, Data curation. <bold>Michal Linial:</bold> Methodology, Formal analysis, Data curation. <bold>Gilles Allali:</bold> Writing &#8211; review &amp; editing. <bold>Tamir Ben-Hur:</bold> Writing &#8211; review &amp; editing, Conceptualization. <bold>Gad A. Marshall:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Resources, Methodology, Conceptualization. <bold>Shahar Arzy:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0051">On behalf of all authors, the corresponding author states that there is no conflict of interest.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Molinuevo</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Altomare</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carrera</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><name name-style="western"><surname>Berkhof</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Precision prevention of Alzheimer&#8217;s and other dementias: anticipating future needs in the control of risk factors and implementation of disease-modifying therapies</article-title><source>Alzheimers Dement</source><volume>16</volume><issue>10</issue><year>2020</year><fpage>1457</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1002/alz.12132</pub-id><pub-id pub-id-type="pmid">32815289</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Jutten</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Sikkes</surname><given-names>S.A.M.</given-names></name><name name-style="western"><surname>Van der Flier</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Tijms</surname><given-names>B.M.</given-names></name><etal/></person-group><article-title>Finding treatment effects in alzheimer trials in the face of disease progression heterogeneity</article-title><source>Neurology</source><volume>96</volume><issue>22</issue><year>2021</year><fpage>e2673</fpage><lpage>e2684</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000012022</pub-id><pub-id pub-id-type="pmid">34550903</pub-id><pub-id pub-id-type="pmcid">PMC8205463</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Altomare</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thal</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Ribaldi</surname><given-names>F.</given-names></name><name name-style="western"><surname>van der Kant</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><etal/></person-group><article-title>The probabilistic model of Alzheimer disease: the amyloid hypothesis revised</article-title><source>Nat Rev Neurosci</source><volume>23</volume><issue>1</issue><year>2022</year><fpage>53</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/s41583-021-00533-w</pub-id><pub-id pub-id-type="pmid">34815562</pub-id><pub-id pub-id-type="pmcid">PMC8840505</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Korczyn</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Grinberg</surname><given-names>LT.</given-names></name></person-group><article-title>Is Alzheimer disease a disease?</article-title><source>Nat Rev Neurol</source><volume>20</volume><issue>4</issue><year>2024</year><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/s41582-024-00940-4</pub-id><pub-id pub-id-type="pmid">38424454</pub-id><pub-id pub-id-type="pmcid">PMC12077607</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Ngandu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lehtisalo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lev&#228;lahti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ahtiluoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Antikainen</surname><given-names>R.</given-names></name><etal/></person-group><article-title>A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial</article-title><source>Lancet</source><volume>385</volume><issue>9984</issue><year>2015</year><fpage>2255</fpage><lpage>2263</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)60461-5</pub-id><pub-id pub-id-type="pmid">25771249</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ngandu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rusanen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Antikainen</surname><given-names>R.</given-names></name><name name-style="western"><surname>B&#228;ckman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Havulinna</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial</article-title><source>Alzheimers Dement</source><volume>14</volume><issue>3</issue><year>2018</year><fpage>263</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2017.09.006</pub-id><pub-id pub-id-type="pmid">29055814</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sommerlad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Orgeta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Costafreda</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ames</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Dementia prevention, intervention, and care</article-title><source>Lancet</source><volume>390</volume><issue>10113</issue><year>2017</year><fpage>2673</fpage><lpage>2734</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31363-6</pub-id><pub-id pub-id-type="pmid">28735855</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sommerlad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ames</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Dementia prevention, intervention, and care: 2020 report of the Lancet commission</article-title><source>Lancet</source><volume>396</volume><issue>10248</issue><year>2020</year><fpage>413</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30367-6</pub-id><pub-id pub-id-type="pmid">32738937</pub-id><pub-id pub-id-type="pmcid">PMC7392084</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Costafreda</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Selb&#230;k</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alladi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Dementia prevention, intervention, and care: 2024 report of the Lancet standing commission</article-title><source>Lancet</source><volume>404</volume><issue>10452</issue><year>2024</year><fpage>572</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)01296-0</pub-id><pub-id pub-id-type="pmid">39096926</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Reitz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mayeux</surname><given-names>R.</given-names></name></person-group><article-title>Alzheimer DIsease: epidemiology, diagnostic criteria, risk factors and biomarkers</article-title><source>Biochem Pharmacol</source><volume>88</volume><issue>4</issue><year>2014</year><fpage>640</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2013.12.024</pub-id><pub-id pub-id-type="pmid">24398425</pub-id><pub-id pub-id-type="pmcid">PMC3992261</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Pankratz</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Mielke</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Geda</surname><given-names>Y.E.</given-names></name><etal/></person-group><article-title>Predicting the risk of mild cognitive impairment in the Mayo Clinic study of aging</article-title><source>Neurology</source><volume>84</volume><issue>14</issue><year>2015</year><fpage>1433</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000001437</pub-id><pub-id pub-id-type="pmid">25788555</pub-id><pub-id pub-id-type="pmcid">PMC4395890</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Andrieu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suckling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Evangelou</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Evidence-based prevention of Alzheimer&#8217;s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>91</volume><issue>11</issue><year>2020</year><fpage>1201</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2019-321913</pub-id><pub-id pub-id-type="pmid">32690803</pub-id><pub-id pub-id-type="pmcid">PMC7569385</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Villain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Rabinovici</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cappa</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Clinical diagnosis of Alzheimer&#8217;s disease: recommendations of the international working group</article-title><source>Lancet Neurol</source><volume>20</volume><issue>6</issue><year>2021</year><fpage>484</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00066-1</pub-id><pub-id pub-id-type="pmid">33933186</pub-id><pub-id pub-id-type="pmcid">PMC8339877</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Takeda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rakugi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>R.</given-names></name></person-group><article-title>Roles of vascular risk factors in the pathogenesis of dementia</article-title><source>Hypertens Res</source><volume>43</volume><issue>3</issue><year>2020</year><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1038/s41440-019-0357-9</pub-id><pub-id pub-id-type="pmid">31723253</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Yaffe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vittinghoff</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dublin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peltz</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Fleckenstein</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>D.E.</given-names></name><etal/></person-group><article-title>Effect of personalized risk-reduction strategies on cognition and dementia risk profile among older adults: the SMARRT randomized clinical Trial</article-title><source>JAMA Intern Med</source><volume>184</volume><issue>1</issue><year>2024</year><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2023.6279</pub-id><pub-id pub-id-type="pmid">38010725</pub-id><pub-id pub-id-type="pmcid">PMC10682943</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Hoevenaar-Blom</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moll van Charante</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>van Wanrooij</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Busschers</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>van Dalen</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Targeting vascular risk factors to reduce dementia incidence in old age: extended follow-up of the prevention of dementia by intensive vascular care (preDIVA) randomized clinical trial</article-title><source>JAMA Neurol</source><volume>78</volume><issue>12</issue><year>2021</year><fpage>1527</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2021.3542</pub-id><pub-id pub-id-type="pmid">34633434</pub-id><pub-id pub-id-type="pmcid">PMC8506299</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Z&#252;lke</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Pabst</surname><given-names>A.</given-names></name><name name-style="western"><surname>Luppa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roehr</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seidling</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oey</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A Multidomain intervention against cognitive decline in an at-risk-population in Germany: results from the cluster-randomized agewell.de trial</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>1</issue><year>2024</year><fpage>615</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1002/alz.13486</pub-id><pub-id pub-id-type="pmid">37768074</pub-id><pub-id pub-id-type="pmcid">PMC10917033</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Hafdi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoevenaar-Blom</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>E.</given-names></name></person-group><article-title>Multi-domain interventions for the prevention of dementia and cognitive decline</article-title><source>Cochrane Database Syst Rev</source><volume>11</volume><issue>11</issue><year>2021</year><object-id pub-id-type="publisher-id">CD013572</object-id><pub-id pub-id-type="doi">10.1002/14651858.CD013572.pub2</pub-id><pub-id pub-id-type="pmcid">PMC8574768</pub-id><pub-id pub-id-type="pmid">34748207</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Irwin</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Vitiello</surname><given-names>MV.</given-names></name></person-group><article-title>Implications of sleep disturbance and inflammation for Alzheimer&#8217;s disease dementia</article-title><source>Lancet Neurol</source><volume>18</volume><issue>3</issue><year>2019</year><fpage>296</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30450-2</pub-id><pub-id pub-id-type="pmid">30661858</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Zang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fouladvand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Havaldar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>High-throughput target trial emulation for Alzheimer&#8217;s disease drug repurposing with real-world data</article-title><source>Nat Commun</source><volume>14</volume><issue>1</issue><year>2023</year><fpage>8180</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-43929-1</pub-id><pub-id pub-id-type="pmid">38081829</pub-id><pub-id pub-id-type="pmcid">PMC10713627</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Torres-Bondia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dakterzada</surname><given-names>F.</given-names></name><name name-style="western"><surname>Galv&#225;n</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Besanson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Proton pump inhibitors and the risk of Alzheimer&#8217;s disease and non-Alzheimer&#8217;s dementias</article-title><source>Sci Rep</source><volume>10</volume><issue>1</issue><year>2020</year><object-id pub-id-type="publisher-id">21046</object-id><pub-id pub-id-type="doi">10.1038/s41598-020-78199-0</pub-id><pub-id pub-id-type="pmcid">PMC7713356</pub-id><pub-id pub-id-type="pmid">33273636</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Koepp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Baxendale</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections</article-title><source>Brain J Neurol</source><volume>139</volume><issue>Pt 9</issue><year>2016</year><fpage>2441</fpage><lpage>2455</lpage><pub-id pub-id-type="doi">10.1093/brain/aww187</pub-id><pub-id pub-id-type="pmcid">PMC5926008</pub-id><pub-id pub-id-type="pmid">27497924</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Sanmiguel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burgos</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Bascu&#241;&#225;n</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-P&#233;rez</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Riffo-Lepe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boopathi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Gabapentin inhibits multiple steps in the amyloid beta toxicity cascade</article-title><source>ACS Chem Neurosci</source><volume>11</volume><issue>19</issue><year>2020</year><fpage>3064</fpage><lpage>3076</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.0c00414</pub-id><pub-id pub-id-type="pmid">32886489</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>McGuinness</surname><given-names>B.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Passmore</surname><given-names>P.</given-names></name></person-group><article-title>Statins for the prevention of dementia</article-title><source>Cochrane Database Syst Rev</source><volume>2016</volume><issue>1</issue><year>2016</year><object-id pub-id-type="publisher-id">CD003160</object-id><pub-id pub-id-type="doi">10.1002/14651858.CD003160.pub3</pub-id><pub-id pub-id-type="pmcid">PMC9346344</pub-id><pub-id pub-id-type="pmid">26727124</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Lehrer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rheinstein</surname><given-names>PH.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease and intranasal fluticasone propionate in the FDA medwatch adverse events database</article-title><source>J Alzheimers Dis Rep</source><volume>2</volume><issue>1</issue><year>2018</year><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.3233/ADR-170033</pub-id><pub-id pub-id-type="pmid">30159547</pub-id><pub-id pub-id-type="pmcid">PMC6110392</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Skoog</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lernfelt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Landahl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Palmertz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>L.</given-names></name><etal/></person-group><article-title>15-year longitudinal study of blood pressure and dementia</article-title><source>Lancet</source><volume>347</volume><issue>9009</issue><year>1996</year><fpage>1141</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(96)90608-x</pub-id><pub-id pub-id-type="pmid">8609748</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Reitz</surname><given-names>C.</given-names></name></person-group><article-title>Dyslipidemia and the risk of Alzheimer&#8217;s disease</article-title><source>Curr Atheroscler Rep</source><volume>15</volume><issue>3</issue><year>2013</year><fpage>307</fpage><pub-id pub-id-type="doi">10.1007/s11883-012-0307-3</pub-id><pub-id pub-id-type="pmid">23328907</pub-id><pub-id pub-id-type="pmcid">PMC3564220</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Berkowitz</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Mosconi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scheyer</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hristov</surname><given-names>H.</given-names></name><name name-style="western"><surname>Isaacson</surname><given-names>RS.</given-names></name></person-group><article-title>Clinical application of APOE in alzheimer&#8217;s prevention: a precision medicine approach</article-title><source>J Prev Alzheimers Dis</source><volume>5</volume><issue>4</issue><year>2018</year><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.14283/jpad.2018.35</pub-id><pub-id pub-id-type="pmid">30298183</pub-id><pub-id pub-id-type="pmcid">PMC6188641</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Akomolafe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meigs</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Au</surname><given-names>R.</given-names></name><name name-style="western"><surname>Green</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Farrer</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study</article-title><source>Arch Neurol</source><volume>63</volume><issue>11</issue><year>2006</year><fpage>1551</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1001/archneur.63.11.1551</pub-id><pub-id pub-id-type="pmid">17101823</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Lacey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Pell</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gallacher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smeeth</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Prospective study design and data analysis in UK Biobank</article-title><source>Sci Transl Med</source><volume>16</volume><issue>729</issue><year>2024</year><fpage>eadf4428</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adf4428</pub-id><pub-id pub-id-type="pmid">38198570</pub-id><pub-id pub-id-type="pmcid">PMC11127744</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Babbar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hasselbalch</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Croteau</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Ageing as a risk factor for neurodegenerative disease</article-title><source>Nat Rev Neurol</source><volume>15</volume><issue>10</issue><year>2019</year><fpage>565</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1038/s41582-019-0244-7</pub-id><pub-id pub-id-type="pmid">31501588</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Raber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ashford</surname><given-names>JW.</given-names></name></person-group><article-title>ApoE genotype accounts for the vast majority of AD risk and AD pathology</article-title><source>Neurobiol Aging</source><volume>25</volume><issue>5</issue><year>2004</year><fpage>641</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2003.12.023</pub-id><pub-id pub-id-type="pmid">15172743</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Linard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Letenneur</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garrigue</surname><given-names>I.</given-names></name><name name-style="western"><surname>Doize</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dartigues</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Helmer</surname><given-names>C.</given-names></name></person-group><article-title>Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><volume>16</volume><issue>1</issue><year>2020</year><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1002/alz.12008</pub-id><pub-id pub-id-type="pmid">31914220</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.T.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.T.</given-names></name></person-group><article-title>The epidemiology of alzheimer&#8217;s disease modifiable risk factors and prevention</article-title><source>J Prev Alzheimers Dis</source><volume>8</volume><issue>3</issue><year>2021</year><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.14283/jpad.2021.15</pub-id><pub-id pub-id-type="pmid">34101789</pub-id><pub-id pub-id-type="pmcid">PMC12280729</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Kolli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ware</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Langa</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Ehrlich</surname><given-names>JR.</given-names></name></person-group><article-title>Interactions between the apolipoprotein E4 gene and modifiable risk factors for cognitive impairment: a nationally representative panel study</article-title><source>BMC Geriatr</source><volume>22</volume><issue>1</issue><year>2022</year><fpage>938</fpage><pub-id pub-id-type="doi">10.1186/s12877-022-03652-w</pub-id><pub-id pub-id-type="pmid">36474172</pub-id><pub-id pub-id-type="pmcid">PMC9724385</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Corder</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Strittmatter</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Schmechel</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Gaskell</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Small</surname><given-names>G.W.</given-names></name><etal/></person-group><article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#8217;s disease in late onset families</article-title><source>Science</source><volume>261</volume><issue>5123</issue><year>1993</year><fpage>921</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1126/science.8346443</pub-id><pub-id pub-id-type="pmid">8346443</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name></person-group><article-title>Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy</article-title><source>Nat Rev Neurol</source><volume>9</volume><issue>2</issue><year>2013</year><fpage>106</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2012.263</pub-id><pub-id pub-id-type="pmid">23296339</pub-id><pub-id pub-id-type="pmcid">PMC3726719</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Farrer</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Cupples</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Haines</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kukull</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Mayeux</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease</article-title><source>J Am Med Assoc</source><volume>278</volume><issue>16</issue><year>1997</year><fpage>1349</fpage><pub-id pub-id-type="doi">10.1001/jama.1997.03550160069041</pub-id><pub-id pub-id-type="pmid">9343467</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Janson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Laedtke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Parisi</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>P.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>P.C.</given-names></name></person-group><article-title>Increased risk of type 2 diabetes in Alzheimer disease</article-title><source>Diabetes</source><volume>53</volume><issue>2</issue><year>2004</year><fpage>474</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.2337/diabetes.53.2.474</pub-id><pub-id pub-id-type="pmid">14747300</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Nielson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Woodard</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Seidenberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Durgerian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hazlett</surname><given-names>K.E.</given-names></name><etal/></person-group><article-title>Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer&#8217;s DIsease</article-title><source>Front Aging Neurosci</source><volume>6</volume><year>2014</year><fpage>61</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2014.00061</pub-id><pub-id pub-id-type="pmid">24795624</pub-id><pub-id pub-id-type="pmcid">PMC4005962</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Scarmeas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Luchsinger</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Mayeux</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name></person-group><article-title>Mediterranean diet and Alzheimer disease mortality</article-title><source>Neurology</source><volume>69</volume><issue>11</issue><year>2007</year><fpage>1084</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000277320.50685.7c</pub-id><pub-id pub-id-type="pmid">17846408</pub-id><pub-id pub-id-type="pmcid">PMC2673956</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Zlokovic</surname><given-names>BV.</given-names></name></person-group><article-title>Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer&#8217;s disease</article-title><source>Acta Neuropathol (Berl)</source><volume>118</volume><issue>1</issue><year>2009</year><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0522-3</pub-id><pub-id pub-id-type="pmid">19319544</pub-id><pub-id pub-id-type="pmcid">PMC2853006</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Castellano</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>DeMattos</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>B.W.</given-names></name><etal/></person-group><article-title>Human apoE isoforms differentially regulate brain amyloid-&#946; peptide clearance</article-title><source>Sci Transl Med</source><volume>3</volume><issue>89</issue><year>2011</year><fpage>89ra57</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002156</pub-id><pub-id pub-id-type="pmcid">PMC3192364</pub-id><pub-id pub-id-type="pmid">21715678</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Mahley</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name></person-group><article-title>Apolipoprotein E sets the stage: response to injury triggers neuropathology</article-title><source>Neuron</source><volume>76</volume><issue>5</issue><year>2012</year><fpage>871</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.11.020</pub-id><pub-id pub-id-type="pmid">23217737</pub-id><pub-id pub-id-type="pmcid">PMC4891195</pub-id></element-citation></ref><ref id="bib0045"><label>45</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Raulin</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Doss</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Trottier</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Ikezu</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CC.</given-names></name></person-group><article-title>ApoE in Alzheimer&#8217;s disease: pathophysiology and therapeutic strategies</article-title><source>Mol Neurodegener</source><volume>17</volume><issue>1</issue><year>2022</year><fpage>72</fpage><pub-id pub-id-type="doi">10.1186/s13024-022-00574-4</pub-id><pub-id pub-id-type="pmid">36348357</pub-id><pub-id pub-id-type="pmcid">PMC9644639</pub-id></element-citation></ref><ref id="bib0046"><label>46</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Vi&#241;a</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lloret</surname><given-names>A.</given-names></name></person-group><article-title>Why women have more Alzheimer&#8217;s disease than men: gender and mitochondrial toxicity of amyloid-beta peptide</article-title><source>J Alzheimers Dis</source><volume>20</volume><issue>Suppl 2</issue><year>2010</year><fpage>S527</fpage><lpage>S533</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-100501</pub-id><pub-id pub-id-type="pmid">20442496</pub-id></element-citation></ref><ref id="bib0047"><label>47</label><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Ferretti</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Iulita</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Cavedo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chiesa</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Schumacher Dimech</surname><given-names>A.</given-names></name><name name-style="western"><surname>Santuccione Chadha</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Sex differences in Alzheimer disease - the gateway to precision medicine</article-title><source>Nat Rev Neurol</source><volume>14</volume><issue>8</issue><year>2018</year><fpage>457</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41582-018-0032-9</pub-id><pub-id pub-id-type="pmid">29985474</pub-id></element-citation></ref><ref id="bib0048"><label>48</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Altmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>V.W.</given-names></name><name name-style="western"><surname>Greicius</surname><given-names>M.D.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease neuroimaging initiative investigators. Sex modifies the APOE-related risk of developing Alzheimer disease</article-title><source>Ann Neurol</source><volume>75</volume><issue>4</issue><year>2014</year><fpage>563</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1002/ana.24135</pub-id><pub-id pub-id-type="pmid">24623176</pub-id><pub-id pub-id-type="pmcid">PMC4117990</pub-id></element-citation></ref><ref id="bib0049"><label>49</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Corder</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Ghebremedhin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Thal</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Ohm</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Braak</surname><given-names>H.</given-names></name></person-group><article-title>The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism</article-title><source>Ann N Acad Sci</source><volume>1019</volume><year>2004</year><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1196/annals.1297.005</pub-id><pub-id pub-id-type="pmid">15246987</pub-id></element-citation></ref><ref id="bib0050"><label>50</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name></person-group><article-title>Influence of education and occupation on the incidence of alzheimer&#8217;s disease</article-title><source>J Am Med Assoc</source><volume>271</volume><issue>13</issue><year>1994</year><fpage>1004</fpage><pub-id pub-id-type="doi">10.1001/jama.1994.03510370056032</pub-id><pub-id pub-id-type="pmid">8139057</pub-id></element-citation></ref><ref id="bib0051"><label>51</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Amieva</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mokri</surname><given-names>H.</given-names></name><name name-style="western"><surname>Le Goff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meillon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jacqmin-Gadda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Foubert-Samier</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Compensatory mechanisms in higher-educated subjects with Alzheimer&#8217;s disease: a study of 20 years of cognitive decline</article-title><source>Brain J Neurol</source><volume>137</volume><issue>Pt 4</issue><year>2014</year><fpage>1167</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1093/brain/awu035</pub-id><pub-id pub-id-type="pmid">24578544</pub-id></element-citation></ref><ref id="bib0052"><label>52</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lamar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA.</given-names></name></person-group><article-title>Education and cognitive reserve in old age</article-title><source>Neurology</source><volume>92</volume><issue>10</issue><year>2019</year><fpage>e1041</fpage><lpage>e1050</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000007036</pub-id><pub-id pub-id-type="pmid">30728309</pub-id><pub-id pub-id-type="pmcid">PMC6442015</pub-id></element-citation></ref><ref id="bib0053"><label>53</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>Fratiglioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Paillard-Borg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name></person-group><article-title>An active and socially integrated lifestyle in late life might protect against dementia</article-title><source>Lancet Neurol</source><volume>3</volume><issue>6</issue><year>2004</year><fpage>343</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(04)00767-7</pub-id><pub-id pub-id-type="pmid">15157849</pub-id></element-citation></ref><ref id="bib0054"><label>54</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Sharp</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Gatz</surname><given-names>M.</given-names></name></person-group><article-title>Relationship between education and dementia: an updated systematic review</article-title><source>Alzheimer Dis Assoc Disord</source><volume>25</volume><issue>4</issue><year>2011</year><fpage>289</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1097/WAD.0b013e318211c83c</pub-id><pub-id pub-id-type="pmid">21750453</pub-id><pub-id pub-id-type="pmcid">PMC3193875</pub-id></element-citation></ref><ref id="bib0055"><label>55</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>de la Torre</surname><given-names>JC.</given-names></name></person-group><article-title>Vascular risk factors: a ticking time bomb to Alzheimer&#8217;s disease</article-title><source>Am J Alzheimers Dis Other Demen</source><volume>28</volume><issue>6</issue><year>2013</year><fpage>551</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1177/1533317513494457</pub-id><pub-id pub-id-type="pmid">23813612</pub-id><pub-id pub-id-type="pmcid">PMC10852736</pub-id></element-citation></ref><ref id="bib0056"><label>56</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.</given-names></name><name name-style="western"><surname>He</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name></person-group><article-title>The vascular contribution of apolipoprotein E to Alzheimer&#8217;s disease</article-title><source>Brain J Neurol</source><volume>147</volume><issue>9</issue><year>2024</year><fpage>2946</fpage><lpage>2965</lpage><pub-id pub-id-type="doi">10.1093/brain/awae156</pub-id><pub-id pub-id-type="pmid">38748848</pub-id></element-citation></ref><ref id="bib0057"><label>57</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Iadecola</surname><given-names>C.</given-names></name></person-group><article-title>The pathobiology of vascular dementia</article-title><source>Neuron</source><volume>80</volume><issue>4</issue><year>2013</year><fpage>844</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.10.008</pub-id><pub-id pub-id-type="pmid">24267647</pub-id><pub-id pub-id-type="pmcid">PMC3842016</pub-id></element-citation></ref><ref id="bib0058"><label>58</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Puglielli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tanzi</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>DM.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease: the cholesterol connection</article-title><source>Nat Neurosci</source><volume>6</volume><issue>4</issue><year>2003</year><fpage>345</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1038/nn0403-345</pub-id><pub-id pub-id-type="pmid">12658281</pub-id></element-citation></ref><ref id="bib0059"><label>59</label><element-citation publication-type="journal" id="sbref0059"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wedow</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Brazel</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use</article-title><source>Nat Genet</source><volume>51</volume><issue>2</issue><year>2019</year><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0307-5</pub-id><pub-id pub-id-type="pmid">30643251</pub-id><pub-id pub-id-type="pmcid">PMC6358542</pub-id></element-citation></ref><ref id="bib0060"><label>60</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Atrial fibrillation increases the risk of all-cause dementia, Alzheimer&#8217;s disease, and vascular dementia: a cohort study of 373, 415 participants in the UK Biobank</article-title><source>J Affect Disord</source><volume>351</volume><year>2024</year><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2024.01.224</pub-id><pub-id pub-id-type="pmid">38286227</pub-id></element-citation></ref><ref id="bib0061"><label>61</label><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name name-style="western"><surname>Kalantarian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Mansour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruskin</surname><given-names>JN.</given-names></name></person-group><article-title>Cognitive impairment associated with atrial fibrillation: a meta-analysis</article-title><source>Ann Intern Med</source><volume>158</volume><issue>5 Pt 1</issue><year>2013</year><fpage>338</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-158-5-201303050-00007</pub-id><pub-id pub-id-type="pmid">23460057</pub-id><pub-id pub-id-type="pmcid">PMC4465526</pub-id></element-citation></ref><ref id="bib0062"><label>62</label><element-citation publication-type="journal" id="sbref0062"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Le</surname><given-names>W.</given-names></name></person-group><article-title>Chronic hypoxia-induced autophagy aggravates the neuropathology of Alzheimer&#8217;s disease through AMPK-mTOR signaling in the APPSwe/PS1dE9 mouse model</article-title><source>J Alzheimers Dis</source><volume>48</volume><issue>4</issue><year>2015</year><fpage>1019</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.3233/JAD-150303</pub-id><pub-id pub-id-type="pmid">26444766</pub-id></element-citation></ref><ref id="bib0063"><label>63</label><element-citation publication-type="journal" id="sbref0063"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name></person-group><article-title>Innate immunity in Alzheimer&#8217;s disease</article-title><source>Nat Immunol</source><volume>16</volume><issue>3</issue><year>2015</year><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/ni.3102</pub-id><pub-id pub-id-type="pmid">25689443</pub-id></element-citation></ref><ref id="bib0064"><label>64</label><element-citation publication-type="journal" id="sbref0064"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deczkowska</surname><given-names>A.</given-names></name></person-group><article-title>Neurological disease as a failure of brain-immune crosstalk: the multiple faces of neuroinflammation</article-title><source>Trends Immunol</source><volume>37</volume><issue>10</issue><year>2016</year><fpage>668</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/j.it.2016.08.001</pub-id><pub-id pub-id-type="pmid">27616557</pub-id></element-citation></ref><ref id="bib0065"><label>65</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Calsolaro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Edison</surname><given-names>P.</given-names></name></person-group><article-title>Neuroinflammation in Alzheimer&#8217;s disease: current evidence and future directions</article-title><source>Alzheimers Dement</source><volume>12</volume><issue>6</issue><year>2016</year><fpage>719</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.02.010</pub-id><pub-id pub-id-type="pmid">27179961</pub-id></element-citation></ref><ref id="bib0066"><label>66</label><element-citation publication-type="journal" id="sbref0066"><person-group person-group-type="author"><name name-style="western"><surname>Castellani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>M.</given-names></name></person-group><article-title>Immunological features of non-neuronal brain cells: implications for Alzheimer&#8217;s disease immunotherapy</article-title><source>Trends Immunol</source><volume>41</volume><issue>9</issue><year>2020</year><fpage>794</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1016/j.it.2020.07.005</pub-id><pub-id pub-id-type="pmid">32800704</pub-id></element-citation></ref><ref id="bib0067"><label>67</label><element-citation publication-type="journal" id="sbref0067"><person-group person-group-type="author"><name name-style="western"><surname>Cryan</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Dinan</surname><given-names>TG.</given-names></name></person-group><article-title>Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour</article-title><source>Nat Rev Neurosci</source><volume>13</volume><issue>10</issue><year>2012</year><fpage>701</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/nrn3346</pub-id><pub-id pub-id-type="pmid">22968153</pub-id></element-citation></ref><ref id="bib0068"><label>68</label><element-citation publication-type="journal" id="sbref0068"><person-group person-group-type="author"><name name-style="western"><surname>Minter</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Crack</surname><given-names>PJ.</given-names></name></person-group><article-title>The contribution of neuroinflammation to amyloid toxicity in Alzheimer&#8217;s disease</article-title><source>J Neurochem</source><volume>136</volume><issue>3</issue><year>2016</year><fpage>457</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1111/jnc.13411</pub-id><pub-id pub-id-type="pmid">26509334</pub-id></element-citation></ref><ref id="bib0069"><label>69</label><element-citation publication-type="journal" id="sbref0069"><person-group person-group-type="author"><name name-style="western"><surname>Tremlett</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Appel-Cresswell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Finlay</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Waubant</surname><given-names>E.</given-names></name></person-group><article-title>The gut microbiome in human neurological disease: a review</article-title><source>Ann Neurol</source><volume>81</volume><issue>3</issue><year>2017</year><fpage>369</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1002/ana.24901</pub-id><pub-id pub-id-type="pmid">28220542</pub-id></element-citation></ref><ref id="bib0070"><label>70</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pogue</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lukiw</surname><given-names>WJ.</given-names></name></person-group><article-title>Pathogenic microbes, the microbiome, and Alzheimer&#8217;s disease (AD)</article-title><source>Front Aging Neurosci</source><volume>6</volume><year>2014</year><fpage>127</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2014.00127</pub-id><pub-id pub-id-type="pmid">24982633</pub-id><pub-id pub-id-type="pmcid">PMC4058571</pub-id></element-citation></ref><ref id="bib0071"><label>71</label><element-citation publication-type="journal" id="sbref0071"><person-group person-group-type="author"><name name-style="western"><surname>Moir</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Tanzi</surname><given-names>RE.</given-names></name></person-group><article-title>Low evolutionary selection pressure in senescence does not explain the persistence of a&#946; in the vertebrate genome</article-title><source>Front Aging Neurosci</source><volume>11</volume><year>2019</year><fpage>70</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2019.00070</pub-id><pub-id pub-id-type="pmid">30983989</pub-id><pub-id pub-id-type="pmcid">PMC6447958</pub-id></element-citation></ref><ref id="bib0072"><label>72</label><element-citation publication-type="journal" id="sbref0072"><person-group person-group-type="author"><name name-style="western"><surname>Douros</surname><given-names>A.</given-names></name><name name-style="western"><surname>Santella</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dell&#8217;Aniello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Azoulay</surname><given-names>L.</given-names></name><name name-style="western"><surname>Renoux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Suissa</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Infectious disease burden and the risk of Alzheimer&#8217;s disease: a population-based study</article-title><source>J Alzheimers Dis</source><volume>81</volume><issue>1</issue><year>2021</year><fpage>329</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.3233/JAD-201534</pub-id><pub-id pub-id-type="pmid">33780369</pub-id></element-citation></ref><ref id="bib0073"><label>73</label><element-citation publication-type="journal" id="sbref0073"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Blauwendraat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Iwaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bandres-Ciga</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Virus exposure and neurodegenerative disease risk across national biobanks</article-title><source>Neuron</source><volume>111</volume><issue>7</issue><year>2023</year><pub-id pub-id-type="doi">10.1016/j.neuron.2022.12.029</pub-id><comment>1086-1093.e2</comment><pub-id pub-id-type="pmcid">PMC10079561</pub-id><pub-id pub-id-type="pmid">36669485</pub-id></element-citation></ref><ref id="bib0074"><label>74</label><element-citation publication-type="journal" id="sbref0074"><person-group person-group-type="author"><name name-style="western"><surname>Itzhaki</surname><given-names>RF.</given-names></name></person-group><article-title>Herpes simplex virus type 1 and Alzheimer&#8217;s disease: increasing evidence for a major role of the virus</article-title><source>Front Aging Neurosci</source><volume>6</volume><year>2014</year><fpage>202</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2014.00202</pub-id><pub-id pub-id-type="pmid">25157230</pub-id><pub-id pub-id-type="pmcid">PMC4128394</pub-id></element-citation></ref><ref id="bib0075"><label>75</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name name-style="western"><surname>Dominy</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ermini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Benedyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marczyk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Konradi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Porphyromonas gingivalis in Alzheimer&#8217;s disease brains: evidence for disease causation and treatment with small-molecule inhibitors</article-title><source>Sci Adv</source><volume>5</volume><issue>1</issue><year>2019</year><fpage>eaau3333</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aau3333</pub-id><pub-id pub-id-type="pmid">30746447</pub-id><pub-id pub-id-type="pmcid">PMC6357742</pub-id></element-citation></ref><ref id="bib0076"><label>76</label><element-citation publication-type="journal" id="sbref0076"><person-group person-group-type="author"><name name-style="western"><surname>Little</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>MacIntyre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balin</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Appelt</surname><given-names>DM.</given-names></name></person-group><article-title>Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice</article-title><source>Neurobiol Aging</source><volume>25</volume><issue>4</issue><year>2004</year><fpage>419</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(03)00127-1</pub-id><pub-id pub-id-type="pmid">15013562</pub-id></element-citation></ref><ref id="bib0077"><label>77</label><element-citation publication-type="journal" id="sbref0077"><person-group person-group-type="author"><name name-style="western"><surname>Holmes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zotova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Woolford</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Systemic inflammation and disease progression in Alzheimer disease</article-title><source>Neurology</source><volume>73</volume><issue>10</issue><year>2009</year><fpage>768</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181b6bb95</pub-id><pub-id pub-id-type="pmid">19738171</pub-id><pub-id pub-id-type="pmcid">PMC2848584</pub-id></element-citation></ref><ref id="bib0078"><label>78</label><element-citation publication-type="journal" id="sbref0078"><person-group person-group-type="author"><name name-style="western"><surname>Zlokovic</surname><given-names>BV.</given-names></name></person-group><article-title>Neurovascular pathways to neurodegeneration in Alzheimer&#8217;s disease and other disorders</article-title><source>Nat Rev Neurosci</source><volume>12</volume><issue>12</issue><year>2011</year><fpage>723</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1038/nrn3114</pub-id><pub-id pub-id-type="pmid">22048062</pub-id><pub-id pub-id-type="pmcid">PMC4036520</pub-id></element-citation></ref><ref id="bib0079"><label>79</label><element-citation publication-type="journal" id="sbref0079"><person-group person-group-type="author"><name name-style="western"><surname>Suberbielle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Djukic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Taneja</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice</article-title><source>Nat Commun</source><volume>6</volume><year>2015</year><fpage>8897</fpage><pub-id pub-id-type="doi">10.1038/ncomms9897</pub-id><pub-id pub-id-type="pmid">26615780</pub-id><pub-id pub-id-type="pmcid">PMC4674776</pub-id></element-citation></ref><ref id="bib0080"><label>80</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name name-style="western"><surname>Ahles</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Root</surname><given-names>JC.</given-names></name></person-group><article-title>Cognitive effects of cancer and cancer treatments</article-title><source>Annu Rev Clin Psychol</source><volume>14</volume><year>2018</year><fpage>425</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1146/annurev-clinpsy-050817-084903</pub-id><pub-id pub-id-type="pmid">29345974</pub-id><pub-id pub-id-type="pmcid">PMC9118140</pub-id></element-citation></ref><ref id="bib0081"><label>81</label><element-citation publication-type="journal" id="sbref0081"><person-group person-group-type="author"><name name-style="western"><surname>Cataldo</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Prochaska</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Glantz</surname><given-names>SA.</given-names></name></person-group><article-title>Cigarette smoking is a risk factor for Alzheimer&#8217;s disease: an analysis controlling for tobacco industry affiliation</article-title><source>J Alzheimers Dis</source><volume>19</volume><issue>2</issue><year>2010</year><fpage>465</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-1240</pub-id><pub-id pub-id-type="pmid">20110594</pub-id><pub-id pub-id-type="pmcid">PMC2906761</pub-id></element-citation></ref><ref id="bib0082"><label>82</label><element-citation publication-type="journal" id="sbref0082"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Raina</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Casadesus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G.</given-names></name></person-group><article-title>Oxidative stress signalling in Alzheimer&#8217;s disease</article-title><source>Brain Res</source><volume>1000</volume><issue>1&#8211;2</issue><year>2004</year><fpage>32</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2004.01.012</pub-id><pub-id pub-id-type="pmid">15053949</pub-id></element-citation></ref><ref id="bib0083"><label>83</label><element-citation publication-type="journal" id="sbref0083"><person-group person-group-type="author"><name name-style="western"><surname>Akiyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barnum</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bradt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>Inflammation and Alzheimer&#8217;s disease</article-title><source>Neurobiol Aging</source><volume>21</volume><issue>3</issue><year>2000</year><fpage>383</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/s0197-4580(00)00124-x</pub-id><pub-id pub-id-type="pmid">10858586</pub-id><pub-id pub-id-type="pmcid">PMC3887148</pub-id></element-citation></ref><ref id="bib0084"><label>84</label><element-citation publication-type="journal" id="sbref0084"><person-group person-group-type="author"><name name-style="western"><surname>de la Torre</surname><given-names>JC.</given-names></name></person-group><article-title>Is Alzheimer&#8217;s disease a neurodegenerative or a vascular disorder? data, dogma, and dialectics</article-title><source>Lancet Neurol</source><volume>3</volume><issue>3</issue><year>2004</year><fpage>184</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(04)00683-0</pub-id><pub-id pub-id-type="pmid">14980533</pub-id></element-citation></ref><ref id="bib0085"><label>85</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name name-style="western"><surname>Panza</surname><given-names>F.</given-names></name><name name-style="western"><surname>D&#8217;Introno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Colacicco</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Capurso</surname><given-names>C.</given-names></name><name name-style="western"><surname>Del Parigi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caselli</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Current epidemiology of mild cognitive impairment and other predementia syndromes</article-title><source>Am J Geriatr Psychiatry</source><volume>13</volume><issue>8</issue><year>2005</year><fpage>633</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1176/appi.ajgp.13.8.633</pub-id><pub-id pub-id-type="pmid">16085779</pub-id></element-citation></ref><ref id="bib0086"><label>86</label><element-citation publication-type="journal" id="sbref0086"><person-group person-group-type="author"><name name-style="western"><surname>Durazzo</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M.W.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease neuroimaging initiative. smoking and increased Alzheimer&#8217;s disease risk: a review of potential mechanisms</article-title><source>Alzheimers Dement</source><volume>10</volume><issue>3 Suppl</issue><year>2014</year><fpage>S122</fpage><lpage>S145</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2014.04.009</pub-id><pub-id pub-id-type="pmid">24924665</pub-id><pub-id pub-id-type="pmcid">PMC4098701</pub-id></element-citation></ref><ref id="bib0087"><label>87</label><element-citation publication-type="journal" id="sbref0087"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>M.A.M.</given-names></name><name name-style="western"><surname>Langa</surname><given-names>KM.</given-names></name></person-group><article-title>Untreated poor vision: a contributing factor to late-life dementia</article-title><source>Am J Epidemiol</source><volume>171</volume><issue>6</issue><year>2010</year><fpage>728</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1093/aje/kwp453</pub-id><pub-id pub-id-type="pmid">20150357</pub-id><pub-id pub-id-type="pmcid">PMC2842219</pub-id></element-citation></ref><ref id="bib0088"><label>88</label><element-citation publication-type="journal" id="sbref0088"><person-group person-group-type="author"><name name-style="western"><surname>Loughrey</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>BA.</given-names></name></person-group><article-title>Association of age-related hearing loss with cognitive function, cognitive impairment, and dementia: a systematic review and meta-analysis</article-title><source>JAMA Otolaryngol&#8211; Head Neck Surg</source><volume>144</volume><issue>2</issue><year>2018</year><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1001/jamaoto.2017.2513</pub-id><pub-id pub-id-type="pmid">29222544</pub-id><pub-id pub-id-type="pmcid">PMC5824986</pub-id></element-citation></ref><ref id="bib0089"><label>89</label><element-citation publication-type="journal" id="sbref0089"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Doshi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Erus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Davatzikos</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Association of midlife hearing impairment with late-life temporal lobe volume loss</article-title><source>JAMA Otolaryngol&#8211; Head Neck Surg</source><volume>145</volume><issue>9</issue><year>2019</year><fpage>794</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1001/jamaoto.2019.1610</pub-id><pub-id pub-id-type="pmid">31268512</pub-id><pub-id pub-id-type="pmcid">PMC6613307</pub-id></element-citation></ref><ref id="bib0090"><label>90</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Pike</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burgard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chisolm</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Hearing intervention versus health education control to reduce cognitive decline in older adults with Hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial</article-title><source>Lancet</source><volume>402</volume><issue>10404</issue><year>2023</year><fpage>786</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01406-X</pub-id><pub-id pub-id-type="pmid">37478886</pub-id><pub-id pub-id-type="pmcid">PMC10529382</pub-id></element-citation></ref><ref id="bib0091"><label>91</label><element-citation publication-type="journal" id="sbref0091"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>M.</given-names></name></person-group><article-title>The association between vision impairment and incidence of dementia and cognitive impairment: a systematic review and meta-analysis</article-title><source>Ophthalmology</source><volume>128</volume><issue>8</issue><year>2021</year><fpage>1135</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2020.12.029</pub-id><pub-id pub-id-type="pmid">33422559</pub-id></element-citation></ref><ref id="bib0092"><label>92</label><mixed-citation publication-type="other" id="sbref0092">Sweller J. Cognitive load theory. In Elsevier; 2011 [cited 2024 Aug 6]. p. 37&#8211;76. (Psychology of learning and motivation; vol. 55). <pub-id pub-id-type="doi">10.1016/B978-0-12-387691-1.00002-8</pub-id>. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/B9780123876911000028" id="interref0004">https://linkinghub.elsevier.com/retrieve/pii/B9780123876911000028</ext-link>.</mixed-citation></ref><ref id="bib0093"><label>93</label><element-citation publication-type="journal" id="sbref0093"><person-group person-group-type="author"><name name-style="western"><surname>Buchman</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA.</given-names></name></person-group><article-title>Frailty is associated with incident Alzheimer&#8217;s disease and cognitive decline in the elderly</article-title><source>Psychosom Med</source><volume>69</volume><issue>5</issue><year>2007</year><fpage>483</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1097/psy.0b013e318068de1d</pub-id><pub-id pub-id-type="pmid">17556640</pub-id></element-citation></ref><ref id="bib0094"><label>94</label><element-citation publication-type="journal" id="sbref0094"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>O&#8217;Banion</surname><given-names>M.K.</given-names></name></person-group><article-title>Inflammatory processes in Alzheimer&#8217;s disease</article-title><source>J Neuroimmunol</source><volume>184</volume><issue>1&#8211;2</issue><year>2007</year><fpage>69</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2006.11.017</pub-id><pub-id pub-id-type="pmid">17222916</pub-id></element-citation></ref><ref id="bib0095"><label>95</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name name-style="western"><surname>Ownby</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Crocco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Acevedo</surname><given-names>A.</given-names></name><name name-style="western"><surname>John</surname><given-names>V.</given-names></name><name name-style="western"><surname>Loewenstein</surname><given-names>D.</given-names></name></person-group><article-title>Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis</article-title><source>Arch Gen Psychiatry</source><volume>63</volume><issue>5</issue><year>2006</year><fpage>530</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.63.5.530</pub-id><pub-id pub-id-type="pmid">16651510</pub-id><pub-id pub-id-type="pmcid">PMC3530614</pub-id></element-citation></ref><ref id="bib0096"><label>96</label><element-citation publication-type="journal" id="sbref0096"><person-group person-group-type="author"><name name-style="western"><surname>Holmes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zotova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Culliford</surname><given-names>D.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>VH.</given-names></name></person-group><article-title>Proinflammatory cytokines, sickness behavior, and Alzheimer disease</article-title><source>Neurology</source><volume>77</volume><issue>3</issue><year>2011</year><fpage>212</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318225ae07</pub-id><pub-id pub-id-type="pmid">21753171</pub-id><pub-id pub-id-type="pmcid">PMC3136056</pub-id></element-citation></ref><ref id="bib0097"><label>97</label><element-citation publication-type="journal" id="sbref0097"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pratic&#242;</surname><given-names>D.</given-names></name></person-group><article-title>Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer&#8217;s disease</article-title><source>J Alzheimers Dis</source><volume>31</volume><issue>1</issue><year>2012</year><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.3233/JAD-2012-120328</pub-id><pub-id pub-id-type="pmid">22531419</pub-id><pub-id pub-id-type="pmcid">PMC3882896</pub-id></element-citation></ref><ref id="bib0098"><label>98</label><element-citation publication-type="journal" id="sbref0098"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Csernansky</surname><given-names>JG.</given-names></name></person-group><article-title>Effects of stress and stress hormones on amyloid-beta protein and plaque deposition</article-title><source>J Alzheimers Dis</source><volume>18</volume><issue>2</issue><year>2009</year><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.3233/JAD-2009-1152</pub-id><pub-id pub-id-type="pmid">19584430</pub-id><pub-id pub-id-type="pmcid">PMC2905685</pub-id></element-citation></ref><ref id="bib0099"><label>99</label><element-citation publication-type="journal" id="sbref0099"><person-group person-group-type="author"><name name-style="western"><surname>Gatchel</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Locascio</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Chhatwal</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Depressive symptoms and tau accumulation in the inferior temporal lobe and entorhinal cortex in cognitively normal older adults: a pilot study</article-title><source>J Alzheimers Dis</source><volume>59</volume><issue>3</issue><year>2017</year><fpage>975</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.3233/JAD-170001</pub-id><pub-id pub-id-type="pmid">28697559</pub-id><pub-id pub-id-type="pmcid">PMC5577564</pub-id></element-citation></ref><ref id="bib0100"><label>100</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name name-style="western"><surname>Donovan</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Locascio</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Gatchel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanseeuw</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Rentz</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Longitudinal association of amyloid beta and anxious-depressive symptoms in cognitively normal older adults</article-title><source>Am J Psychiatry</source><volume>175</volume><issue>6</issue><year>2018</year><fpage>530</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2017.17040442</pub-id><pub-id pub-id-type="pmid">29325447</pub-id><pub-id pub-id-type="pmcid">PMC5988933</pub-id></element-citation></ref><ref id="bib0101"><label>101</label><element-citation publication-type="journal" id="sbref0101"><person-group person-group-type="author"><name name-style="western"><surname>Swaab</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lucassen</surname><given-names>PJ.</given-names></name></person-group><article-title>The stress system in the human brain in depression and neurodegeneration</article-title><source>Ageing Res Rev</source><volume>4</volume><issue>2</issue><year>2005</year><fpage>141</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2005.03.003</pub-id><pub-id pub-id-type="pmid">15996533</pub-id></element-citation></ref><ref id="bib0102"><label>102</label><element-citation publication-type="journal" id="sbref0102"><person-group person-group-type="author"><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Galecki</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>M.</given-names></name></person-group><article-title>A review on the oxidative and nitrosative stress (O&amp;NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><volume>35</volume><issue>3</issue><year>2011</year><fpage>676</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2010.05.004</pub-id><pub-id pub-id-type="pmid">20471444</pub-id></element-citation></ref><ref id="bib0103"><label>103</label><element-citation publication-type="journal" id="sbref0103"><person-group person-group-type="author"><name name-style="western"><surname>Nobili</surname><given-names>A.</given-names></name><name name-style="western"><surname>Latagliata</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Viscomi</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Cavallucci</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cutuli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Giacovazzo</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer&#8217;s disease</article-title><source>Nat Commun</source><volume>8</volume><year>2017</year><object-id pub-id-type="publisher-id">14727</object-id><pub-id pub-id-type="doi">10.1038/ncomms14727</pub-id><pub-id pub-id-type="pmcid">PMC5382255</pub-id><pub-id pub-id-type="pmid">28367951</pub-id></element-citation></ref><ref id="bib0104"><label>104</label><element-citation publication-type="journal" id="sbref0104"><person-group person-group-type="author"><name name-style="western"><surname>Fratiglioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Ericsson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maytan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name></person-group><article-title>Influence of social network on occurrence of dementia: a community-based longitudinal study</article-title><source>Lancet</source><volume>355</volume><issue>9212</issue><year>2000</year><fpage>1315</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02113-9</pub-id><pub-id pub-id-type="pmid">10776744</pub-id></element-citation></ref><ref id="bib0105"><label>105</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>Loneliness and risk of Alzheimer disease</article-title><source>Arch Gen Psychiatry</source><volume>64</volume><issue>2</issue><year>2007</year><fpage>234</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.64.2.234</pub-id><pub-id pub-id-type="pmid">17283291</pub-id></element-citation></ref><ref id="bib0106"><label>106</label><element-citation publication-type="journal" id="sbref0106"><person-group person-group-type="author"><name name-style="western"><surname>Lupien</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>de Leon</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Santi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Convit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tarshish</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>N.P.</given-names></name><etal/></person-group><article-title>Cortisol levels during human aging predict hippocampal atrophy and memory deficits</article-title><source>Nat Neurosci</source><volume>1</volume><issue>1</issue><year>1998</year><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/271</pub-id><pub-id pub-id-type="pmid">10195112</pub-id></element-citation></ref><ref id="bib0107"><label>107</label><element-citation publication-type="journal" id="sbref0107"><person-group person-group-type="author"><name name-style="western"><surname>Butterfield</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Halliwell</surname><given-names>B.</given-names></name></person-group><article-title>Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease</article-title><source>Nat Rev Neurosci</source><volume>20</volume><issue>3</issue><year>2019</year><fpage>148</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1038/s41583-019-0132-6</pub-id><pub-id pub-id-type="pmid">30737462</pub-id><pub-id pub-id-type="pmcid">PMC9382875</pub-id></element-citation></ref><ref id="bib0108"><label>108</label><element-citation publication-type="journal" id="sbref0108"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>AZ.</given-names></name></person-group><article-title>Psychological stress induces temporary masticatory muscle mechanical sensitivity in rats</article-title><source>J Biomed Biotechnol</source><volume>2011</volume><year>2011</year><object-id pub-id-type="publisher-id">720603</object-id><pub-id pub-id-type="doi">10.1155/2011/720603</pub-id><pub-id pub-id-type="pmcid">PMC3035378</pub-id><pub-id pub-id-type="pmid">21331360</pub-id></element-citation></ref><ref id="bib0109"><label>109</label><element-citation publication-type="journal" id="sbref0109"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Stickgold</surname><given-names>R.</given-names></name></person-group><article-title>Sleep, memory, and plasticity</article-title><source>Annu Rev Psychol</source><volume>57</volume><year>2006</year><fpage>139</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1146/annurev.psych.56.091103.070307</pub-id><pub-id pub-id-type="pmid">16318592</pub-id></element-citation></ref><ref id="bib0110"><label>110</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name name-style="western"><surname>Musiek</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM.</given-names></name></person-group><article-title>Mechanisms linking circadian clocks, sleep, and neurodegeneration</article-title><source>Science</source><volume>354</volume><issue>6315</issue><year>2016</year><fpage>1004</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1126/science.aah4968</pub-id><pub-id pub-id-type="pmid">27885006</pub-id><pub-id pub-id-type="pmcid">PMC5219881</pub-id></element-citation></ref><ref id="bib0111"><label>111</label><element-citation publication-type="journal" id="sbref0111"><person-group person-group-type="author"><name name-style="western"><surname>Holth</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Fritschi</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Cirrito</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Mahan</surname><given-names>T.E.</given-names></name><etal/></person-group><article-title>The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans</article-title><source>Science</source><volume>363</volume><issue>6429</issue><year>2019</year><fpage>880</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1126/science.aav2546</pub-id><pub-id pub-id-type="pmid">30679382</pub-id><pub-id pub-id-type="pmcid">PMC6410369</pub-id></element-citation></ref><ref id="bib0112"><label>112</label><element-citation publication-type="journal" id="sbref0112"><person-group person-group-type="author"><name name-style="western"><surname>Nedergaard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>SA.</given-names></name></person-group><article-title>Glymphatic failure as a final common pathway to dementia</article-title><source>Science</source><volume>370</volume><issue>6512</issue><year>2020</year><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1126/science.abb8739</pub-id><pub-id pub-id-type="pmid">33004510</pub-id><pub-id pub-id-type="pmcid">PMC8186542</pub-id></element-citation></ref><ref id="bib0113"><label>113</label><element-citation publication-type="journal" id="sbref0113"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Corriveau-Lecavalier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Franzmeier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Maass</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Connectome-based modelling of neurodegenerative diseases: towards precision medicine and mechanistic insight</article-title><source>Nat Rev Neurosci</source><volume>24</volume><issue>10</issue><year>2023</year><fpage>620</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1038/s41583-023-00731-8</pub-id><pub-id pub-id-type="pmid">37620599</pub-id></element-citation></ref><ref id="bib0114"><label>114</label><element-citation publication-type="journal" id="sbref0114"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Scarmeas</surname><given-names>N.</given-names></name></person-group><article-title>Seizures and epilepsy in Alzheimer&#8217;s disease</article-title><source>CNS Neurosci Ther</source><volume>18</volume><issue>4</issue><year>2012</year><fpage>285</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1111/j.1755-5949.2011.00251.x</pub-id><pub-id pub-id-type="pmid">22070283</pub-id><pub-id pub-id-type="pmcid">PMC3630499</pub-id></element-citation></ref><ref id="bib0115"><label>115</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name name-style="western"><surname>Vezzani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Viviani</surname><given-names>B.</given-names></name></person-group><article-title>Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability</article-title><source>Neuropharmacology</source><volume>96</volume><issue>Pt A</issue><year>2015</year><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.10.027</pub-id><pub-id pub-id-type="pmid">25445483</pub-id></element-citation></ref><ref id="bib0116"><label>116</label><element-citation publication-type="journal" id="sbref0116"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Deck</surname><given-names>G.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eskandar</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Noebels</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>AJ.</given-names></name></person-group><article-title>Silent hippocampal seizures and spikes identified by Foramen Ovale electrodes in Alzheimer&#8217;s disease</article-title><source>Nat Med</source><volume>23</volume><issue>6</issue><year>2017</year><fpage>678</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/nm.4330</pub-id><pub-id pub-id-type="pmid">28459436</pub-id><pub-id pub-id-type="pmcid">PMC5461182</pub-id></element-citation></ref><ref id="bib0117"><label>117</label><element-citation publication-type="journal" id="sbref0117"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>T.</given-names></name></person-group><article-title>Apolipoprotein E &#949;4 allele was associated with nonlesional mesial temporal lobe epilepsy in Han Chinese population</article-title><source>Medicine</source><volume>95</volume><issue>9</issue><year>2016</year><fpage>e2894</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000002894</pub-id><pub-id pub-id-type="pmid">26945380</pub-id><pub-id pub-id-type="pmcid">PMC4782864</pub-id></element-citation></ref><ref id="bib0118"><label>118</label><element-citation publication-type="journal" id="sbref0118"><person-group person-group-type="author"><name name-style="western"><surname>Brayne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moffitt</surname><given-names>TE.</given-names></name></person-group><article-title>The limitations of large-scale volunteer databases to address inequalities and global challenges in health and aging</article-title><source>Nat Aging</source><volume>2</volume><issue>9</issue><year>2022</year><fpage>775</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1038/s43587-022-00277-x</pub-id><pub-id pub-id-type="pmid">37118500</pub-id><pub-id pub-id-type="pmcid">PMC10154032</pub-id></element-citation></ref><ref id="bib0119"><label>119</label><element-citation publication-type="journal" id="sbref0119"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y.</given-names></name></person-group><article-title>Association between new-onset atrial fibrillation and dementia among individuals with type 2 diabetes</article-title><source>Diabetes Obes Metab</source><volume>26</volume><issue>9</issue><year>2024</year><fpage>3715</fpage><lpage>3722</lpage><pub-id pub-id-type="doi">10.1111/dom.15714</pub-id><pub-id pub-id-type="pmid">38874105</pub-id></element-citation></ref><ref id="bib0120"><label>120</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name name-style="western"><surname>Husain</surname><given-names>M.</given-names></name></person-group><article-title>The heterogeneity of Alzheimer&#8217;s disease</article-title><source>Brain J Neurol</source><volume>147</volume><issue>7</issue><year>2024</year><fpage>2259</fpage><lpage>2260</lpage><pub-id pub-id-type="doi">10.1093/brain/awae182</pub-id><pub-id pub-id-type="pmid">38966931</pub-id></element-citation></ref></ref-list><sec id="sec0026" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0047a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgments</title><p id="para0050">The authors are grateful to Professor Gill Livingston (University College London, UK) for her thoughtful comments and help improving this manuscript. The study was supported by the <funding-source id="gs0001">NIH</funding-source>
<award-id award-type="grant" rid="gs0001">R21 AG070877</award-id> grant to GAM and SA; SA is also supported by the <funding-source id="gs0002">Britain Israel Research and Academic Exchange Partnership (BIRAX) Ageing</funding-source> and the following funding partners: Alzheimer's Research UK, Race Against Dementia, Rosetrees (49BX21HSSA grant). SA is deeply grateful to Mr. Ronald Abramson for his insightful discussions and valuable support, which greatly facilitated this research.</p></ack><fn-group><fn id="sec0025" fn-type="supplementary-material"><p id="para0010a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100301" id="interref0002">doi:10.1016/j.tjpad.2025.100301</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="pmc-domain-id">2786</journal-id><journal-id journal-id-type="pmc-domain">medicine</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12499674</article-id><article-id pub-id-type="pmcid-ver">PMC12499674.1</article-id><article-id pub-id-type="pmcaid">12499674</article-id><article-id pub-id-type="pmcaiid">12499674</article-id><article-id pub-id-type="pmid">41054039</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000045012</article-id><article-id pub-id-type="publisher-id">MD-D-25-08686</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>5300</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>EEG patterns in critically ill comatose patients receiving complementary therapy with aromatic orifice-opening herbs: A preliminary retrospective observational study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Shang</surname><given-names initials="WJ">Wen-Jie</given-names></name><degrees>MB</degrees><email>Weijiong1234@163.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="SJ">Shi-Jia</given-names></name><degrees>MB</degrees><email>1025217075@qq.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qiu</surname><given-names initials="CL">Chang-Lin</given-names></name><degrees>MB</degrees><email>qiuhuiyx@163.com</email><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qiu</surname><given-names initials="H">Hui</given-names></name><degrees>MB</degrees><email>qiuhuiyx@163.com</email><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="LP">Li-Ping</given-names></name><degrees>MD</degrees><email>zlphmx@163.com</email><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-5353-3718</contrib-id><name name-style="western"><surname>Jiang</surname><given-names initials="Y">Yan</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Graduate School, Zhejiang Chinese Medical University, Hangzhou, China</aff><aff id="aff2"><label>b</label>Department of Neurology, Shengzhou People&#8217;s Hospital (Shengzhou Branch of the First Affiliated Hospital of Zhejiang University School of Medicine), Shaoxing, Zhejiang Province, China</aff><aff id="aff3"><label>c</label>Department of Emergency, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China</aff><aff id="aff4"><label>d</label>Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China</aff><aff id="aff5"><label>e</label>Qiu Changlin Provincial TCM Master Studio, Hangzhou, China</aff><aff id="aff6"><label>f</label>Department of Internal Medicine of TCM, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Yan Jiang, Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, China (e-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jiangyan@zcmu.edu.cn">jiangyan@zcmu.edu.cn</email>).</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>03</day><month>10</month><year>2025</year></pub-date><volume>104</volume><issue>40</issue><issue-id pub-id-type="pmc-issue-id">498401</issue-id><elocation-id>e45012</elocation-id><history><date date-type="received"><day>17</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>10</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC)</ext-link>, where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medi-104-e45012.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medi-104-e45012.pdf"/><abstract><p>Traditional Chinese aromatic orifice-opening herbs (AOOH) have historically been believed to promote consciousness recovery in coma patients. However, the electroencephalographic (EEG) physiological changes related to coma that are induced by AOOH remain unclear. This study investigates the impact of AOOH on EEG pattern in critically ill comatose patients. A retrospective analysis was performed on 74 comatose patients to investigate the effect of AOOH as a complementary therapy. Forty-four patients entered the AOOH group, and 30 patients entered the non-AOOH group. The study&#8217;s primary outcome measure was the rhythmic and periodic patterns index. It includes the generalized periodic discharges index and the lateralized periodic discharges index, which together form the periodic discharges index. It also includes the generalized rhythmic delta activity index and the lateralized rhythmic delta activity index, which together form the rhythmic delta activity (RDA) index. Other outcome measures include the EEG background abnormality grade, the Glasgow Coma Scale score, and the seizure recurrence rate. The degree of Glasgow Coma Scale improved in both groups. However, it improved more in the AOOH add-on group than in the non-AOOH group (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01). Seizure recurrence rates were 60% and 34.1%, respectively, with a significant difference between the 2 groups (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.05). AOOH add-on increases the chance of a less severe EEG background (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01). The periodic discharges index decreased significantly in the AOOH add-on group (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001) compared to the non-AOOH group (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.05). Both groups showed a decrease in RDA index (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001 for the AOOH add-on group and <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01 for the non-AOOH add-on group). However, no statistically significant differences were observed between the 2 groups regarding RDA index reduction. The reduction of lateralized periodic discharges and generalized rhythmic delta activity showed significant differences between the AOOH add-on group and the non-AOOH group (both <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.05). However, there were no differences when referring to generalized periodic discharges and lateralized rhythmic delta activity between the 2 groups (both <italic toggle="yes">P</italic>&#8197;&gt;&#8197;.05). An add-on therapy with AOOH can modulate the EEG pattern, restore consciousness, and reduce seizures following comas. The advantages and mechanisms of traditional Chinese medicine will be gradually revealed in future.</p></abstract><kwd-group><kwd>AOOH</kwd><kwd>comatose patients</kwd><kwd>critically ill</kwd><kwd>EEG pattern</kwd><kwd>RPPs</kwd></kwd-group><funding-group><award-group id="ID0EA6AE152742"><funding-source><institution-wrap><institution>Medical Science and Technology Project of Zhejiang Province</institution><institution-id institution-id-type="doi">10.13039/501100017594</institution-id></institution-wrap></funding-source><award-id>2022KY228</award-id><principal-award-recipient>Yan Jiang</principal-award-recipient></award-group><award-group id="ID0EIFAG152743"><funding-source><institution-wrap><institution>Zhejiang Traditional Chinese Medicine Administration</institution><institution-id institution-id-type="doi">10.13039/501100012175</institution-id></institution-wrap></funding-source><award-id>2022ZB123</award-id><principal-award-recipient>Yan Jiang</principal-award-recipient></award-group><award-group id="ID0EPLAG152744"><funding-source><institution-wrap><institution>Zhejiang Traditional Chinese Medicine Administration</institution><institution-id institution-id-type="doi">10.13039/501100012175</institution-id></institution-wrap></funding-source><award-id>GZS2021007</award-id><principal-award-recipient>Li-Ping Zhang</principal-award-recipient></award-group><award-group id="ID0EMNAG152745"><funding-source><institution-wrap><institution>Zhejiang Traditional Chinese Medicine Administration</institution><institution-id institution-id-type="doi">10.13039/501100012175</institution-id></institution-wrap></funding-source><award-id>2023ZF119</award-id><principal-award-recipient>Hui Qiu</principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text position="float" orientation="portrait"><sec><title>Key points</title><list list-type="simple"><list-item><label>&#8226;</label><p>Comatose patients with rhythmic and periodic electroencephalographic (EEG) patterns benefit from Chinese aromatic orifice-opening herbs (AOOH) add-on therapy.</p></list-item><list-item><label>&#8226;</label><p>Lateralized periodic discharges and generalized rhythmic delta activity were the most affected by AOOH add-on.</p></list-item><list-item><label>&#8226;</label><p>The EEG background activity improved in the AOOH add-on group.</p></list-item><list-item><label>&#8226;</label><p>AOOH add-on had a significantly lower seizure recurrence rate than those without.</p></list-item><list-item><label>&#8226;</label><p>Add-ons with AOOH showed more significant improvement in the Glasgow Coma Scale than those without.</p></list-item></list></sec></boxed-text><sec sec-type="intro"><title>1. Introduction</title><p>A coma is a prolonged state of unconsciousness, which could be caused by severe injury to the brain (such as hypoxia, trauma, strokes, brain tumors, etc).<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Although some causes of comas are treatable or reversible,<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> various factors influence the outcomes, including cause, duration, age, and preexisting medical conditions. Whether a patient can recover from a coma remains a &#8220;black box.&#8221;<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup></p><p>Patients in a coma represent a very heterogeneous group, which makes a one-size-fits-all treatment approach challenging to apply. Current treatments for patients in a coma are mainly supportive and involve a comprehensive and multidisciplinary program.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup> Traditional Chinese medicine (TCM), which has been used for centuries in China, often employs acupuncture and herbal medicine to promote awakening.<sup>[<xref rid="R6" ref-type="bibr">6</xref>&#8211;<xref rid="R8" ref-type="bibr">8</xref>]</sup></p><p>Aromatic orifice-opening herbs (AOOH) are Chinese medicinal substances with a strong, distinctive fragrance. These herbs are commonly formulated into pills or powders, with Angong Niuhuang pill (ANP) and Styrax (Suhexiang) pills (SHXP) being representative prescriptions. ANP is a well-known emergency AOOH product in China, comprising 11 main ingredients, including Bovis Calculus (Niuhuang), Moschus (Shexiang), Borneol (Bingpian), and other significant components, approved by China&#8217;s National Medical Products Administration.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup> Xingnaojing injection (XNJ) is derived from ANP and used clinically in coma patients with fever.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> In addition to ANP, the SHXP is another AOOH product approved by National Medical Products Administration that contains various aromatic awakening ingredients.<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> It is believed that patients with delirium, coma, rigidity, and seizures may benefit from the AOOH since they could open the sensory orifices and awaken the spirit in TCM theory. In the past, Chinese practitioners have used AOOH successfully to treat stroke, fever-induced comas, seizures, etc, which was also supported by various clinical observations.<sup>[<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R11" ref-type="bibr">11</xref>&#8211;<xref rid="R13" ref-type="bibr">13</xref>]</sup> Research suggests neurotransmitter regulation, anti-inflammatory properties, and improved blood-brain barrier permeability may contribute to AOOH&#8217;s efficacy, though most of these studies are animal-based.<sup>[<xref rid="R14" ref-type="bibr">14</xref>&#8211;<xref rid="R17" ref-type="bibr">17</xref>]</sup> There is a continuing need for rigorous studies to explore the neurophysiological effects of these herbs on comatose patients.</p><p>Electroencephalography (EEG) signal reflects neural activities in the cortex and subcortex.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Although predicting neurological outcomes in the early stages of a coma remains challenging, EEG reactivity and pattern are the most common predictors of prognosis.<sup>[<xref rid="R18" ref-type="bibr">18</xref>&#8211;<xref rid="R20" ref-type="bibr">20</xref>]</sup> For example, highly malignant EEG patterns are usually associated with poor neurological outcomes in patients with hypoxia due to cardiac arrest.<sup>[<xref rid="R21" ref-type="bibr">21</xref>&#8211;<xref rid="R23" ref-type="bibr">23</xref>]</sup> EEG can detect nonconvulsive status epilepticus, other subclinical seizure patterns, and rhythmic and periodic patterns (RPPs).<sup>[<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R24" ref-type="bibr">24</xref>]</sup> The main RPPs include a variety of EEG patterns, including generalized and lateralized periodic discharges (GPDs and LPDs), generalized and lateralized rhythmic delta activity (GRDA and LRDA), and bilateral independent periodic discharges, etc.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> So far, whether AOOH influences RPPs in comatose patients remains unclear.</p><p>We designed a retrospective study to observe the effect of AOOH as a complementary therapy on EEG patterns in severe coma patients. The primary objective of this study is to assess the impact of AOOH on the RPPs index, a critical EEG measure that reflects brain activity, is associated with seizure recurrence, and indicates the potential for recovery. We hypothesize that the AOOH may improve this index and enhance clinical outcomes in comatose patients.</p></sec><sec sec-type="methods"><title>2. Methods and materials</title><sec><title>2.1. Study design and participants</title><p>This retrospective observational study was conducted at a TCM tertiary hospital in Hangzhou City, eastern China. The Ethics Committee of The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China, approved this study according to the Declaration of Helsinki (IRB no. 2022-KL-017-01).</p><p>The participants were in-hospital patients with severe acute comas (Glasgow Coma Scale [GCS]&#8197;&#8804;&#8197;8 and the duration of coma &#8804;2 weeks) between January 2022 and May 2024. All patients were treated according to the hospital protocol. The AOOH add-on group includes any commonly used AOOHs, such as ANP, SHXP, or XNJ. These herbs are known for their aromatic properties and are traditionally used to open the orifices and awaken the spirit, making them suitable for treating severe comas.</p><p>An initial continuous EEG (cEEG) or routine EEG (rEEG) was required to confirm the presence of RPPs. Although cEEG use is increasing in intensive care units, the need for specialized skills to operate and interpret it limits availability in all centers.<sup>[<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>]</sup> In this study, only a small number of patients received cEEG, while the vast majority received repeated rEEG. After 72 hours of AOOH treatment, changes in RPPs on repeated rEEG were identified, and in the non-AOOH group, RPP resolution was also observed 72 hours after the initial EEG examination, following the intensive care unit treatment protocol.<sup>[<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref>]</sup> Patients who did not have EEG at both time points and those with an electrographic seizure pattern on EEG were also excluded.</p><p>In total, 177 patients with coma met the initial inclusion criteria, and 103 patients were excluded. A final total of 74 patients were included in the analysis cohort, among which 30 patients entered the non-AOOH group and 44 patients entered the AOOH group. Personalized treatment plans were developed based on TCM syndrome differentiation, which subsequently guided the selection of AOOHs. Heat-closure syndrome, characterized by symptoms such as high fever, delirium, and a red tongue with yellow coating, was treated with ANP in 24 patients (54.5%) to clear heat and open the orifices. Cold-closure syndrome, distinguished by low body temperature, cold extremities, and a pale tongue with white coating, was managed with SHXP in 6 patients (13.6%) for its warming and orifice-opening effects. Additionally, XNJ was administered to 20 patients (45.5%) with heat-closure syndrome who were unable to receive gastrointestinal treatments, as it can be delivered via injection. Each patient&#8217;s treatment plan was customized based on their specific TCM syndrome and clinical presentation. It is worth noting that the types of AOOHs used changed by some patients&#8217; alterations in syndrome types.</p><p>The flowchart is shown in Figure <xref rid="F1" ref-type="fig">1</xref>. Participants&#8217; baseline demographics and disease details were gathered from electronic medical records, and the RPPs and EEG background activity were reviewed from the EEG records (Table <xref rid="T1" ref-type="table">1</xref>). The RPPs index can be calculated as the proportion of the RPP duration relative to the total recording time. The classification criteria for RPPs are derived from the latest version of EEG terminology modified by the American Clinical Neurophysiology Society in 2021.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> This study focused on 4 main types of RPPs: LPDs, GPDs, LRDA, and GRDA (Fig. <xref rid="F2" ref-type="fig">2</xref>). The grades of EEG background abnormality are based on the classification criteria of Yale.<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup> Two qualified reviewers initially reviewed the EEG recordings separately. Any differences in their interpretations were subsequently resolved through further discussion.<sup>[<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R30" ref-type="bibr">30</xref>]</sup></p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Baseline demographic, clinical, and EEG characteristics of the study cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Non-AOOH group (n&#8197;=&#8197;30)</th><th align="center" rowspan="1" colspan="1">AOOH group (n&#8197;=&#8197;44)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, mean&#8197;&#177;&#8197;SD</td><td align="center" rowspan="1" colspan="1">69.8&#8197;&#177;&#8197;15.0</td><td align="center" rowspan="1" colspan="1">68.6&#8197;&#177;&#8197;20.3</td><td align="center" rowspan="1" colspan="1">.096<xref rid="tab1fn2" ref-type="table-fn">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Male/female</td><td align="center" rowspan="1" colspan="1">14/16</td><td align="center" rowspan="1" colspan="1">23/21</td><td align="center" rowspan="1" colspan="1">.813<xref rid="tab1fn3" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Etiology, n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.998<xref rid="tab1fn3" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Hypoxia</td><td align="center" rowspan="1" colspan="1">5 (16.7)</td><td align="center" rowspan="1" colspan="1">7 (15.9)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Trauma</td><td align="center" rowspan="1" colspan="1">6 (20.0)</td><td align="center" rowspan="1" colspan="1">9 (20.5)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Stroke</td><td align="center" rowspan="1" colspan="1">11 (36.7)</td><td align="center" rowspan="1" colspan="1">15 (34.1)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;metabolic</td><td align="center" rowspan="1" colspan="1">3 (10.0)</td><td align="center" rowspan="1" colspan="1">6 (13.6)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Encephalitis</td><td align="center" rowspan="1" colspan="1">3 (10.0)</td><td align="center" rowspan="1" colspan="1">4 (9.1)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Others</td><td align="center" rowspan="1" colspan="1">2 (6.7)</td><td align="center" rowspan="1" colspan="1">3 (6.8)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Seizure history before coma, n (%)</td><td align="center" rowspan="1" colspan="1">2 (6.7)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">.161<xref rid="tab1fn3" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">GCS, median (range)</td><td align="center" rowspan="1" colspan="1">5 (4&#8211;8)</td><td align="center" rowspan="1" colspan="1">6 (4&#8211;8)</td><td align="center" rowspan="1" colspan="1">.725<xref rid="tab1fn4" ref-type="table-fn">&#8225;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">EEG background grading, n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.136<xref rid="tab1fn3" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Normal</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mild</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mild-moderate</td><td align="center" rowspan="1" colspan="1">1 (3.3)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Moderate</td><td align="center" rowspan="1" colspan="1">5 (16.7)</td><td align="center" rowspan="1" colspan="1">6 (13.6)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Moderate-severe</td><td align="center" rowspan="1" colspan="1">11 (36.7)</td><td align="center" rowspan="1" colspan="1">27 (61.4)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Severe</td><td align="center" rowspan="1" colspan="1">13 (43.3)</td><td align="center" rowspan="1" colspan="1">11 (25.0)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RPPs pattern, n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;LPDs</td><td align="center" rowspan="1" colspan="1">16 (53.3)</td><td align="center" rowspan="1" colspan="1">28 (63.6)</td><td align="center" rowspan="1" colspan="1">.471<xref rid="tab1fn3" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;GPDs</td><td align="center" rowspan="1" colspan="1">8 (26.7)</td><td align="center" rowspan="1" colspan="1">7 (15.9)</td><td align="center" rowspan="1" colspan="1">.378<xref rid="tab1fn3" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;LRDA</td><td align="center" rowspan="1" colspan="1">9 (30.0)</td><td align="center" rowspan="1" colspan="1">12 (27.3)</td><td align="center" rowspan="1" colspan="1">.799<xref rid="tab1fn3" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;GRDA</td><td align="center" rowspan="1" colspan="1">9 (30.0)</td><td align="center" rowspan="1" colspan="1">13 (29.5)</td><td align="center" rowspan="1" colspan="1">1.000<xref rid="tab1fn3" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Types of RPPs, n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.810<xref rid="tab1fn3" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Single-type RPPs</td><td align="center" rowspan="1" colspan="1">18 (60.0)</td><td align="center" rowspan="1" colspan="1">28 (63.6)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;2 types of RPPs</td><td align="center" rowspan="1" colspan="1">12 (40.0)</td><td align="center" rowspan="1" colspan="1">16 (36.4)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>AOOH = aromatic orifice-opening herbs, EEG = electroencephalography, GCS = Glasgow Coma Scale, GPDs = generalized periodic discharges, GRDA = generalized rhythmic delta activity, LPDs = lateralized periodic discharges, LRDA = lateralized rhythmic delta activity, RPPs = rhythmic and periodic patterns.</p></fn><fn fn-type="other" id="tab1fn2"><label>*</label><p>Independent samples <italic toggle="yes">t</italic>-test.</p></fn><fn fn-type="other" id="tab1fn3"><label>&#8224;</label><p>Chi-square (&#967;<sup>2</sup>) test.</p></fn><fn fn-type="other" id="tab1fn4"><label>&#8225;</label><p>Mann&#8211;Whitney <italic toggle="yes">U</italic> test.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Study flowchart. AOOH = aromatic orifice-opening herbs, EEG = electroencephalography, GCS = Glasgow Coma Scale, HIS = hospital information system, RPPs = periodic and rhythmic patterns.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e45012-g001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Common periodic and rhythmic patterns on EEG in critically ill patients. (A) Periodic discharges on the left hemisphere montages, while not on the right hemisphere, representing the lateralized periodic discharges (LPDs). (B) Rhythmic delta activity on the left frontal, temporal, and central region, while not on the right, represent the lateralized rhythmic delta activity (LRDA). (C) Generalized periodic discharges (GPDs) at interval of 1.5 seconds on both hemispheres. (D) Generalized rhythmic delta activity (GRDA) of 2.5 Hz frequency on both hemispheres. EEG = electroencephalography.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e45012-g002.jpg"/></fig></sec><sec><title>2.2. Outcome measures</title><p>The study&#8217;s primary outcome measure was the RPPs index, comprising the periodic discharges (PDs) index (LPDs and GPDs) and the rhythmic delta activity (RDA) index (LRDA and GRDA). Other outcome measures include the EEG background abnormality grades, GCS, and seizure recurrence rate.</p></sec><sec><title>2.3. Statistical analysis</title><p>SPSS Statistics version 22.0 (IBM, Armonk) was used for data analysis. Shapiro&#8211;Wilk test was used to examine the data normality distribution. To compare the baseline characteristics between the 2 groups, we employed the independent samples <italic toggle="yes">t</italic>-test, Mann&#8211;Whitney <italic toggle="yes">U</italic> test, and chi-square (&#967;<sup>2</sup>) test. The chi-square (&#967;<sup>2</sup>) test was also used to compare seizure recurrence and distribution of EEG background grading between the groups. Paired samples <italic toggle="yes">t</italic>-test and Wilcoxon signed rank test were used to compare the RPPs index before and after treatment. Generalized estimating equations analysis with Bonferroni-corrected pairwise comparisons were used for all RPPs and GCS comparisons between groups. <italic toggle="yes">P</italic>-value &lt;.05 (two-tailed) was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>3. Results</title><sec><title>3.1. Consciousness and epileptic recurrence</title><p>Both groups show improvement in consciousness (both <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001). However, the AOOH add-on group exhibited a significantly greater degree of improvement compared to the non-AOOH group (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01) (Fig. <xref rid="F3" ref-type="fig">3</xref>A).</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>(A) The GCS scores, (B) seizure recurrence rates between the non-AOOH and AOOH groups, and (C) the distribution of EEG background grading. A generalized estimating equations (GEE) analysis with Bonferroni-corrected pairwise comparisons was used to compare the 2 groups about the GCS. The chi-square (&#967;<sup>2</sup>) test was employed to compare seizure recurrence rates and the distribution of EEG background grading between the non-AOOH and AOOH groups. **<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01 and ***<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001 compared within the group. #<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.05 and ##<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01 compared between the groups. AOOH = aromatic orifice-opening herbs, EEG = electroencephalography, GCS = Glasgow Coma Scale.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e45012-g003.jpg"/></fig><p>The seizure recurrence rates in the non-AOOH and AOOH add-on groups were 60% and 34.1%, respectively. The AOOH add-on group had a significantly lower recurrence rate compared to the non-AOOH add-on group (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.05) (Fig. <xref rid="F3" ref-type="fig">3</xref>B).</p></sec><sec><title>3.2. EEG patterns</title><p>The distribution of EEG background abnormality grading is shown in Figure <xref rid="F3" ref-type="fig">3</xref>C. The baseline levels of EEG background activity were mild-moderate or more severe in both groups. AOOH add-on increases the chance of a less severe EEG background (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01). However, the non-AOOH group did not show any difference in EEG composition before and after.</p><p>After the addition of AOOH, the PDs index decreased significantly in the AOOH add-on group (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001) (Fig. <xref rid="F4" ref-type="fig">4</xref>A). Meanwhile, compared to the non-AOOH group, significant statistical differences were observed in the PDs index reductions in the AOOH group (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.05) (Fig. <xref rid="F4" ref-type="fig">4</xref>C). The RDA index was also reduced in both groups (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01 and <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001, respectively) (Fig. <xref rid="F4" ref-type="fig">4</xref>B). However, no significant statistical difference was observed in the decrease of the RDA index between the 2 groups (<italic toggle="yes">P</italic>&#8197;&gt;&#8197;.05) (Fig. <xref rid="F4" ref-type="fig">4</xref>C).</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Comparison of rhythmic and periodic patterns (RPPs) index after adding the AOOH. In (A) and (B), paired samples <italic toggle="yes">t</italic>-tests were used to compare PDs and RDA index before and after therapy in non-AOOH groups. The Wilcoxon signed-rank test was used to compare PDs and RDA indexes in AOOH add-on groups before and after, as the data were not normally distributed. (C) A generalized estimating equations (GEE) analysis with Bonferroni-corrected pairwise comparisons was used to compare the AOOH add-on and non-AOOH groups. **<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01 and ***<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001 within group; #<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.05 compared between the 2 groups. AOOH = aromatic orifice-opening herbs, PDs = periodic discharges, RDA = rhythmic delta activity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e45012-g004.jpg"/></fig><p>The LPDs, LRDA, and GRDA significantly decreased in the AOOH add-on group (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01, and <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01, respectively) (Fig. <xref rid="F5" ref-type="fig">5</xref>A, C and D), with the reductions in LPDs and GRDA being significantly greater than those in the non-AOOH group (both <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.05) (Fig. <xref rid="F5" ref-type="fig">5</xref>A and D). However, no differences were observed in GPDs and LRDA between the 2 groups (both <italic toggle="yes">P</italic>&#8197;&gt;&#8197;.05) (Fig. <xref rid="F5" ref-type="fig">5</xref>B and C).</p><fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>Comparison of 4 kinds of rhythmic and periodic patterns (RPPs) index on EEG after addition of aromatic herbs. (A) LPDs: lateralized periodic discharges; (B) GPDs: generalized periodic discharges; (C) LRDA: lateralized rhythmic delta activity; (D) GRDA: generalized rhythmic delta activity. The Wilcoxon signed-rank test was used to compare 4 kinds of RPP indexes within groups before and after. Generalized estimating equations (GEE) analysis with Bonferroni-corrected pairwise comparisons was used to compare the non-AOOH and AOOH add-on groups. *<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.05, **<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01, and ***<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001 within group; #<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.05 comparison of RPPs index between the 2 groups. AOOH = aromatic orifice-opening herbs, EEG = electroencephalography.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e45012-g005.jpg"/></fig></sec></sec><sec sec-type="discussion"><title>4. Discussion</title><p>It is the first study to investigate the effects of AOOH on EEG patterns, which shows that comatose patients with RPPs may benefit from adding AOOH. Our study supports Chinese medical practitioners&#8217; experiences that AOOH can be used as a complementary therapy in refractory epilepsy or comatose patients.<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> According to our retrospective observation, AOOH reduced epilepsy recurrence, enhanced consciousness, alleviated the severity of the EEG background abnormalities, and reduced specific types of RPPs on EEG, such as LPDs and GRDA.</p><p>In the past 2 decades, research on EEG features, particularly RPPs, has increased significantly since cEEG monitoring was more applied in critically ill patients.<sup>[<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R32" ref-type="bibr">32</xref>&#8211;<xref rid="R34" ref-type="bibr">34</xref>]</sup> However, there are a handful of studies on intervention in RPPs, and there is even debate over when and how aggressively to treat them.<sup>[<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref>]</sup> There is general agreement that LPDs, GPDs, and LRDA are associated with seizure risk, among which LPDs are most strongly associated with seizures.<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> Additionally, LPDs have been independently linked to a higher risk of mortality.<sup>[<xref rid="R37" ref-type="bibr">37</xref>]</sup> We hypothesize that reducing LPDs is crucial for lowering seizure recurrence in our study. We also hypothesize that the use of AOOH may reduce the need for third-line antiseizure medications, including benzodiazepines and propofol, in comatose patients with RPP. Interestingly, in our study, the prescription of AOOH was guided by TCM syndrome differentiation rather than seizure type. This approach differs from the International League Against Epilepsy guidelines, which emphasize selecting antiseizure medications based on seizure type.<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup></p><p>There is no evidence that GRDA is related to seizures, but patients with GRDA may experience metabolic impairment, midline brain lesions, subcortical lesions, etc, which are more likely to lead to consciousness.<sup>[<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R39" ref-type="bibr">39</xref>]</sup> It is worth noting that abnormalities in GRDA and EEG background activity may have similar physiological significance in reflecting cerebral dysfunction. The presence of GRDA typically occurs with the slowing or other abnormalities in EEG background activity. Moreover, GRDA itself can be considered a form of background activity abnormality.<sup>[<xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R41" ref-type="bibr">41</xref>]</sup> In this study, we observed a significant reduction in both GRDA and the severity of EEG background activity, suggesting that the arousal-enhancing mechanism of AOOH may be related to both factors. Based on this inference, whether AOOH could help treat other neurological disorders characterized by EEG background abnormalities and frontally predominant GRDA, such as Alzheimer disease and other dementia,<sup>[<xref rid="R41" ref-type="bibr">41</xref>]</sup> needs further investigation.</p><p>There are significant differences between our study and the TELSTAR study, which found no significant improvement in outcomes at 3 months after treating RPPs with antiseizure treatment.<sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup> It is important to note that our study included patients with a broader range of coma causes, which differed from the TELSTAR study, in which cardiac arrest patients were the focus, who had a poorer prognosis in general than those with other etiologies of comas. In addition, we used short-term measures based on GCS and seizure activity, while TELSTAR assessed outcomes in a relatively more extended observation period. Our study suggests that AOOH affects short-term consciousness recovery and seizure recurrence, but its long-term effects are unclear.</p><p>In AOOH treatment, we emphasize making personalized plans based on each patient&#8217;s unique TCM syndrome differentiation. &#8220;Cold-closure&#8221; syndrome and &#8220;heat-closure&#8221; syndrome represent different pathological mechanisms and clinical manifestations in comatose patients. In a &#8220;cold-closure&#8221; syndrome, the invasion of cold and dampness obstructs Qi (vital energy) and blood within the body. The principle of treatment involves warming Yang and dispelling cold. In contrast, &#8220;heat-closure&#8221; syndrome is typically caused by excessive heat, resulting in an imbalance between Yin and Yang, which disrupts the normal flow of Qi and blood. The treatment aims to clear heat and restore the balance of Yin and Yang. Our team employs SHXP to address a &#8220;cold-closure&#8221; syndrome, while ANP or XNJ is used for a &#8220;heat-closure&#8221; syndrome under TCM theory.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> As the sample size is relatively small, different types of AOOH were sometimes administered sequentially for the same patient based on TCM syndrome differentiation, which limited our further analysis.</p><p>Despite the encouraging results, this retrospective study has several limitations. Firstly, the AOOH interventions in this study cannot be fully evaluated due to the lack of long-term follow-up data. Secondly, this study includes various kinds of AOOH, such as ANP, SHXP, and XNJ, which may cause much confusion about their effectiveness. Thirdly, AOOH contains various ingredients and has multiple targets, so the conclusions of this study need to be carefully promoted and expanded. Finally, this study did not consider concomitant pharmacological treatments, which may introduce confounding factors. Specifically, patients in this study often received multiple medications, such as sedatives, antiseizure medications, and neurotrophic drugs. We did not evaluate the potential effects of these medications on EEG, nor did we systematically assess how these medications interact with AOOHs. Given the complexity of the real-world clinical setting, comprehensively controlling for all potential confounding variables was challenging. A more thorough evaluation of concomitant pharmacological treatments, including their effects on EEG and interactions with AOOHs, is essential for more robust and reliable findings.</p><p>Future research should also involve larger cohorts and multicenter randomized controlled trials to validate AOOH effects on EEG patterns. Additionally, multimodal neuroimaging techniques, such as functional magnetic resonance imaging and functional near-infrared spectroscopy, along with various EEG biomarkers, including high-frequency oscillations, may contribute to the exploration of the neurobiological mechanisms underlying AOOH.</p></sec><sec sec-type="conclusions"><title>5. Conclusions</title><p>Our findings shed new light on the potential of AOOH to restore consciousness and reduce seizures in comatose patients, possibly through modulation of EEG patterns. However, many aspects of the mechanisms of AOOH remain unclear. Further research is essential to investigate the role of TCM in regulating brain function.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Yan Jiang.</p><p><bold>Data curation:</bold> Wen-Jie Shang, Shi-Jia Chen.</p><p><bold>Formal analysis:</bold> Wen-Jie Shang, Shi-Jia Chen.</p><p><bold>Funding acquisition:</bold> Hui Qiu, Li-Ping Zhang, Yan Jiang.</p><p><bold>Project administration:</bold> Yan Jiang.</p><p><bold>Supervision:</bold> Chang-Lin Qiu, Hui Qiu, Li-Ping Zhang.</p><p><bold>Writing &#8211; original draft:</bold> Wen-Jie Shang.</p><p><bold>Writing &#8211; review &amp; editing:</bold> Yan Jiang.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>ANP</term><def><p>Angong Niuhuang pill</p></def></def-item><def-item><term>AOOH</term><def><p>aromatic orifice-opening herbs</p></def></def-item><def-item><term>cEEG</term><def><p>continuous EEG</p></def></def-item><def-item><term>EEG</term><def><p>electroencephalography</p></def></def-item><def-item><term>GCS</term><def><p>Glasgow Coma Scale</p></def></def-item><def-item><term>GPDs</term><def><p>generalized periodic discharges</p></def></def-item><def-item><term>GRDA</term><def><p>generalized rhythmic delta activity</p></def></def-item><def-item><term>HIS</term><def><p>hospital information system</p></def></def-item><def-item><term>LPDs</term><def><p>lateralized periodic discharges</p></def></def-item><def-item><term>LRDA</term><def><p>lateralized rhythmic delta activity</p></def></def-item><def-item><term>PDs</term><def><p>periodic discharges</p></def></def-item><def-item><term>RDA</term><def><p>rhythmic delta activity</p></def></def-item><def-item><term>rEEG</term><def><p>routine EEG</p></def></def-item><def-item><term>RPPs</term><def><p>rhythmic and periodic patterns</p></def></def-item><def-item><term>SHXP</term><def><p>Styrax (Suhexiang) pills</p></def></def-item><def-item><term>TCM</term><def><p>traditional Chinese medicine</p></def></def-item><def-item><term>XNJ</term><def><p>xingnaojing injection</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>This work was supported by the Medical Science and Technology Project of Zhejiang Province (CN) (project No. 2022KY228) and the Zhejiang Traditional Chinese Medicine Administration (CN) (project Nos. 2022ZB123, GZS2021007, and 2023ZF119).</p></fn><fn fn-type="other"><p>The Ethics Committee of The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China, approved this study according to the Declaration of Helsinki (IRB no. 2022-KL-017-01). Since this study used retrospective data, informed consent was not required.</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.</p></fn><fn fn-type="other"><p>How to cite this article: Shang W-J, Chen S-J, Qiu C-L, Qiu H, Zhang L-P, Jiang Y. EEG patterns in critically ill comatose patients receiving complementary therapy with aromatic orifice-opening herbs: A preliminary retrospective observational study. Medicine 2025;104:40(e45012).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>D</given-names></name><name name-style="western"><surname>Edlow</surname><given-names>BL</given-names></name></person-group>. <article-title>Coma prognostication after acute brain injury: a review.</article-title><source>JAMA Neurol</source>. <year>2024</year>;<volume>81</volume>:<fpage>405</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2023.5634</pub-id><pub-id pub-id-type="pmid">38436946</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edlow</surname><given-names>JA</given-names></name><name name-style="western"><surname>Rabinstein</surname><given-names>A</given-names></name><name name-style="western"><surname>Traub</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Wijdicks</surname><given-names>EFM</given-names></name></person-group>. <article-title>Diagnosis of reversible causes of coma.</article-title><source>Lancet</source>. <year>2014</year>;<volume>384</volume>:<fpage>2064</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">24767707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)62184-4</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>D</given-names></name><name name-style="western"><surname>Abella</surname><given-names>BS</given-names></name><name name-style="western"><surname>Bass</surname><given-names>GD</given-names></name><etal/></person-group>. <article-title>The Recovery of Consciousness via Evidence-Based Medicine and Research (RECOVER) program.</article-title><source>Neurol Clin Pract</source>. <year>2024</year>;<volume>14</volume>:<fpage>e200351</fpage>.<pub-id pub-id-type="pmid">39185092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/CPJ.0000000000200351</pub-id><pub-id pub-id-type="pmcid">PMC11341005</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinoda</surname><given-names>J</given-names></name><name name-style="western"><surname>Nagamine</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Multidisciplinary attentive treatment for patients with chronic disorders of consciousness following severe traumatic brain injury in the NASVA of Japan.</article-title><source>Brain Inj</source>. <year>2019</year>;<volume>33</volume>:<fpage>1660</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">31530028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02699052.2019.1667535</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitello</surname><given-names>MM</given-names></name><name name-style="western"><surname>Laureys</surname><given-names>S</given-names></name><name name-style="western"><surname>Thibaut</surname><given-names>A</given-names></name><name name-style="western"><surname>Gosseries</surname><given-names>O</given-names></name></person-group>. <article-title>Non-pharmacologic interventions in disorders of consciousness.</article-title><source>Handb Clin Neurol</source>. <year>2025</year>;<volume>207</volume>:<fpage>197</fpage>&#8211;<lpage>216</lpage>.<pub-id pub-id-type="pmid">39986722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-443-13408-1.00007-5</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K</given-names></name><name name-style="western"><surname>Wen</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Acupuncture for poststroke coma: a systematic review and meta-analysis.</article-title><source>Complement Ther Med</source>. <year>2024</year>;<volume>82</volume>:<fpage>103046</fpage>.<pub-id pub-id-type="pmid">38704101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctim.2024.103046</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>PY</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>YC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B-R</given-names></name></person-group>. <article-title>Efficacy and safety of Wendan decoction for acute brain injury: a randomized controlled study.</article-title><source>J Altern Complement Med</source>. <year>2020</year>;<volume>26</volume>:<fpage>392</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">32207984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/acm.2019.0349</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>CL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>LP</given-names></name><etal/></person-group>. <article-title>Complementary therapy with Chinese aromatic herbs to promote awakening in a comatose patient: a case report.</article-title><source>Medicine (Baltimore)</source>. <year>2024</year>;<volume>103</volume>:<fpage>e39277</fpage>.<pub-id pub-id-type="pmid">39121268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000039277</pub-id><pub-id pub-id-type="pmcid">PMC11315557</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="book"><collab>Chinese Pharmacopoeia Commission</collab>. <source>Chinese Pharmacopoeia (2020 Edition). Part 1</source>. <publisher-name>China Medical Science Press</publisher-name>; <year>2020</year>.</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Ding</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Comprehensive chemical profiling of volatile constituents of Angong Niuhuang pill in vitro and in vivo based on gas chromatography coupled with mass spectrometry.</article-title><source>Chin Med</source>. <year>2022</year>;<volume>17</volume>:<fpage>105</fpage>.<pub-id pub-id-type="pmid">36088339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13020-022-00659-8</pub-id><pub-id pub-id-type="pmcid">PMC9464384</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Meta-analysis of the effects of xingnaojing injection on consciousness disturbance.</article-title><source>Medicine (Baltimore)</source>. <year>2016</year>;<volume>95</volume>:<fpage>e2875</fpage>.<pub-id pub-id-type="pmid">26886655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000002875</pub-id><pub-id pub-id-type="pmcid">PMC4998655</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The arousal effect of An-Gong-Niu-Huang-Wan on alcoholic-induced coma rats: a research based on EEG.</article-title><source>J Ethnopharmacol</source>. <year>2024</year>;<volume>328</volume>:<fpage>117974</fpage>.<pub-id pub-id-type="pmid">38467317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2024.117974</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiangran</surname><given-names>M</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C</given-names></name><name name-style="western"><surname>Minglin</surname><given-names>S</given-names></name><name name-style="western"><surname>Yanke</surname><given-names>AI</given-names></name><name name-style="western"><surname>Liyun</surname><given-names>HE</given-names></name><name name-style="western"><surname>Jia</surname><given-names>L</given-names></name></person-group>. <article-title>Effectiveness and safety of Angong Niuhuang pill in treatment of acute stroke: a systematic review and meta-analysis.</article-title><source>J Tradit Chin Med</source>. <year>2023</year>;<volume>43</volume>:<fpage>650</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">37454249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.19852/j.cnki.jtcm.20230526.002</pub-id><pub-id pub-id-type="pmcid">PMC10320440</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Multimodal investigation reveals the neuroprotective mechanism of Angong Niuhuang pill for intracerebral hemorrhage: converging bioinformatics, network pharmacology, and experimental validation.</article-title><source>J Ethnopharmacol</source>. <year>2024</year>;<volume>319</volume>(<issue>Pt 1</issue>):<fpage>117045</fpage>.<pub-id pub-id-type="pmid">37633621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2023.117045</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>LP</given-names></name><name name-style="western"><surname>Feng</surname><given-names>JF</given-names></name><name name-style="western"><surname>Hu</surname><given-names>KL</given-names></name></person-group>. <article-title>Progress in regulation effect of aromatic refreshing traditional Chinese medicine on BBB permeability and its mechanism.</article-title><source>Zhongguo Zhong Yao Za Zhi</source>. <year>2014</year>;<volume>39</volume>:<fpage>949</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">24956831</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>M</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name></person-group>. <article-title>New advances in traditional Chinese Medicine interventions for epilepsy: where are we and what do we know?</article-title><source>Chin Med</source>. <year>2025</year>;<volume>20</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">40098198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13020-025-01088-z</pub-id><pub-id pub-id-type="pmcid">PMC11917061</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>M</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Anticonvulsant effect of xingnaojing injection on acute seizure models in mice.</article-title><source>Clin Complement Med Pharmacol</source>. <year>2023</year>;<volume>3</volume>:<fpage>100091</fpage>.</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Tian</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>The predictive value of EEG reactivity by electrical stimulation and quantitative analysis in critically ill patients with large hemispheric infarction.</article-title><source>J Crit Care</source>. <year>2023</year>;<volume>78</volume>:<fpage>154358</fpage>.<pub-id pub-id-type="pmid">37329762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcrc.2023.154358</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snider</surname><given-names>SB</given-names></name><name name-style="western"><surname>Fong</surname><given-names>MWK</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>NM</given-names></name><etal/></person-group>. <article-title>Clinical and electroencephalographic predictors of seizures and status epilepticus in 12,450 critically Ill adults: a retrospective cohort study.</article-title><source>Crit Care Med</source>. <year>2023</year>;<volume>51</volume>:<fpage>1001</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">37010290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000005872</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez Ruiz</surname><given-names>A</given-names></name><name name-style="western"><surname>Vlachy</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JW</given-names></name><etal/></person-group>. <article-title>Association of periodic and rhythmic electroencephalographic patterns with seizures in critically Ill patients.</article-title><source>JAMA Neurol</source>. <year>2017</year>;<volume>74</volume>:<fpage>181</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27992625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2016.4990</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guedes</surname><given-names>B</given-names></name><name name-style="western"><surname>Manita</surname><given-names>M</given-names></name><name name-style="western"><surname>Rita Peralta</surname><given-names>A</given-names></name><name name-style="western"><surname>Catarina Franco</surname><given-names>A</given-names></name><name name-style="western"><surname>Bento</surname><given-names>L</given-names></name><name name-style="western"><surname>Bentes</surname><given-names>C</given-names></name></person-group>. <article-title>Prognostic significance of specific EEG patterns after cardiac arrest in a Lisbon cohort.</article-title><source>Clin Neurophysiol Pract</source>. <year>2020</year>;<volume>5</volume>:<fpage>147</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">32885107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cnp.2020.07.001</pub-id><pub-id pub-id-type="pmcid">PMC7451827</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turella</surname><given-names>S</given-names></name><name name-style="western"><surname>Dankiewicz</surname><given-names>J</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The predictive value of highly malignant EEG patterns after cardiac arrest: evaluation of the ERC-ESICM recommendations.</article-title><source>Intensive Care Med</source>. <year>2024</year>;<volume>50</volume>:<fpage>90</fpage>&#8211;<lpage>102</lpage>.<pub-id pub-id-type="pmid">38172300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-023-07280-9</pub-id><pub-id pub-id-type="pmcid">PMC10811097</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Putten</surname><given-names>MJAM</given-names></name><name name-style="western"><surname>Ruijter</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Horn</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Quantitative characterization of rhythmic and periodic EEG patterns in patients in a coma after cardiac arrest and association with outcome.</article-title><source>Neurology</source>. <year>2024</year>;<volume>103</volume>:<fpage>e209608</fpage>.<pub-id pub-id-type="pmid">38991197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000209608</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Misirocchi</surname><given-names>F</given-names></name><name name-style="western"><surname>De Stefano</surname><given-names>P</given-names></name><name name-style="western"><surname>Zilioli</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Periodic discharges and status epilepticus: a critical reappraisal.</article-title><source>Clin Neurophysiol</source>. <year>2024</year>;<volume>163</volume>:<fpage>124</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">38733702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2024.04.018</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirsch</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Fong</surname><given-names>MWK</given-names></name><name name-style="western"><surname>Leitinger</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>American Clinical Neurophysiology Society&#8217;s standardized critical care EEG terminology: 2021 version.</article-title><source>J Clin Neurophysiol</source>. <year>2021</year>;<volume>38</volume>:<fpage>1</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">33475321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNP.0000000000000806</pub-id><pub-id pub-id-type="pmcid">PMC8135051</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenter</surname><given-names>H</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>AO</given-names></name><name name-style="western"><surname>Beuchat</surname><given-names>I</given-names></name></person-group>. <article-title>Continuous versus routine electroencephalography in the intensive care unit: a review of current evidence.</article-title><source>Eur Neurol</source>. <year>2024</year>;<volume>87</volume>:<fpage>17</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">37952533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000535085</pub-id><pub-id pub-id-type="pmcid">PMC11003555</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>C-L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P-Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>IA</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S-K</given-names></name></person-group>. <article-title>The role of routine electroencephalography in the diagnosis of seizures in medical intensive care units.</article-title><source>Diagnostics (Basel)</source>. <year>2024</year>;<volume>14</volume>:<fpage>1111</fpage>.<pub-id pub-id-type="pmid">38893637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics14111111</pub-id><pub-id pub-id-type="pmcid">PMC11171977</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhakar</surname><given-names>MB</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>ZB</given-names></name><name name-style="western"><surname>Desai</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Developing a standardized approach to grading the level of brain dysfunction on EEG.</article-title><source>J Clin Neurophysiol</source>. <year>2023</year>;<volume>40</volume>:<fpage>553</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">35239553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNP.0000000000000919</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>AC</given-names></name><name name-style="western"><surname>Abdel-Baki</surname><given-names>SG</given-names></name><name name-style="western"><surname>Weedon</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>EEG interpretation reliability and interpreter confidence: a large single-center study.</article-title><source>Epilepsy Behav</source>. <year>2014</year>;<volume>32</volume>:<fpage>102</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">24531133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yebeh.2014.01.011</pub-id><pub-id pub-id-type="pmcid">PMC3965251</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahrens</surname><given-names>S</given-names></name><name name-style="western"><surname>Twanow</surname><given-names>JD</given-names></name><name name-style="western"><surname>Vidaurre</surname><given-names>J</given-names></name><name name-style="western"><surname>Gedela</surname><given-names>S</given-names></name><name name-style="western"><surname>Moore-Clingenpeel</surname><given-names>M</given-names></name><name name-style="western"><surname>Ostendorf</surname><given-names>AP</given-names></name></person-group>. <article-title>Electroencephalography technologist inter-rater agreement and interpretation of pediatric critical care electroencephalography.</article-title><source>Pediatr Neurol</source>. <year>2021</year>;<volume>115</volume>:<fpage>66</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">33333462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pediatrneurol.2020.10.016</pub-id><pub-id pub-id-type="pmcid">PMC7856064</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>F</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name></person-group>. <article-title>Review of the use of botanicals for epilepsy in complementary medical systems &#8211; traditional Chinese medicine.</article-title><source>Epilepsy Behav</source>. <year>2015</year>;<volume>52</volume>:<fpage>281</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26052078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yebeh.2015.04.050</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaspard</surname><given-names>N</given-names></name><name name-style="western"><surname>Manganas</surname><given-names>L</given-names></name><name name-style="western"><surname>Rampal</surname><given-names>N</given-names></name><name name-style="western"><surname>Petroff</surname><given-names>OAC</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>LJ</given-names></name></person-group>. <article-title>Similarity of lateralized rhythmic delta activity to periodic lateralized epileptiform discharges in critically Ill patients.</article-title><source>JAMA Neurol</source>. <year>2013</year>;<volume>70</volume>:<fpage>1288</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">23921464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2013.3475</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavvala</surname><given-names>J</given-names></name><name name-style="western"><surname>Abend</surname><given-names>N</given-names></name><name name-style="western"><surname>LaRoche</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Continuous EEG monitoring: a survey of neurophysiologists and neurointensivists.</article-title><source>Epilepsia</source>. <year>2014</year>;<volume>55</volume>:<fpage>1864</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">25266728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/epi.12809</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swisher</surname><given-names>CB</given-names></name><name name-style="western"><surname>Shah</surname><given-names>D</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>SR</given-names></name><name name-style="western"><surname>Husain</surname><given-names>AM</given-names></name></person-group>. <article-title>Baseline EEG pattern on continuous ICU EEG monitoring and incidence of seizures.</article-title><source>J Clin Neurophysiol</source>. <year>2015</year>;<volume>32</volume>:<fpage>147</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">25437330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNP.0000000000000157</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>LJ</given-names></name></person-group>. <article-title>Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns.</article-title><source>J Clin Neurophysiol</source>. <year>2005</year>;<volume>22</volume>:<fpage>79</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">15805807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.wnp.0000158699.78529.af</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruijter</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Keijzer</surname><given-names>HM</given-names></name><name name-style="western"><surname>Tjepkema-Cloostermans</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>Treating rhythmic and periodic EEG patterns in comatose survivors of cardiac arrest.</article-title><source>N Engl J Med</source>. <year>2022</year>;<volume>386</volume>:<fpage>724</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">35196426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2115998</pub-id></mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Husari</surname><given-names>KS</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>EL</given-names></name><name name-style="western"><surname>Ritzl</surname><given-names>EK</given-names></name></person-group>. <article-title>Acute and long-term outcomes of lateralized rhythmic delta activity (LRDA) versus lateralized periodic discharges (LPDs) in critically ill patients.</article-title><source>Neurocrit Care</source>. <year>2021</year>;<volume>34</volume>:<fpage>201</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32556854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12028-020-01017-y</pub-id></mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glauser</surname><given-names>T</given-names></name><name name-style="western"><surname>Ben-Menachem</surname><given-names>E</given-names></name><name name-style="western"><surname>Bourgeois</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.</article-title><source>Epilepsia</source>. <year>2006</year>;<volume>47</volume>:<fpage>1094</fpage>&#8211;<lpage>120</lpage>.<pub-id pub-id-type="pmid">16886973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1528-1167.2006.00585.x</pub-id></mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alzawahmah</surname><given-names>M</given-names></name><name name-style="western"><surname>Fong</surname><given-names>MWK</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>LJ</given-names></name></person-group>. <article-title>Neuroimaging correlates of lateralized rhythmic delta activity, lateralized periodic discharges, and generalized rhythmic delta activity on EEG in critically ill patients.</article-title><source>J Clin Neurophysiol</source>. <year>2022</year>;<volume>39</volume>:<fpage>228</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">33235178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNP.0000000000000763</pub-id></mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silva-J&#250;nior</surname><given-names>FP</given-names></name><name name-style="western"><surname>Castro</surname><given-names>LH</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>JQ</given-names></name><etal/></person-group>. <article-title>Serial and prolonged EEG monitoring in anti-N-methyl-<sc>d</sc>-aspartate receptor encephalitis.</article-title><source>Clin Neurophysiol</source>. <year>2014</year>;<volume>125</volume>:<fpage>1541</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">24457136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2014.01.001</pub-id></mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinno</surname><given-names>L</given-names></name><name name-style="western"><surname>Negrotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Falzoi</surname><given-names>C</given-names></name><name name-style="western"><surname>Messa</surname><given-names>G</given-names></name><name name-style="western"><surname>Goldoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Calzetti</surname><given-names>S</given-names></name></person-group>. <article-title>Generalized rhythmic delta activity frontally predominant differentiates dementia with Lewy bodies from Alzheimer&#8217;s disease and Parkinson&#8217;s disease dementia: a conventional electroencephalography visual analysis.</article-title><source>Clin EEG Neurosci</source>. <year>2022</year>;<volume>53</volume>:<fpage>426</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">33843293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1550059421997147</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">1761</journal-id><journal-id journal-id-type="pmc-domain">tp</journal-id><journal-title-group><journal-title>Translational Psychiatry</journal-title></journal-title-group><issn pub-type="epub">2158-3188</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12500968</article-id><article-id pub-id-type="pmcid-ver">PMC12500968.1</article-id><article-id pub-id-type="pmcaid">12500968</article-id><article-id pub-id-type="pmcaiid">12500968</article-id><article-id pub-id-type="pmid">41052990</article-id><article-id pub-id-type="doi">10.1038/s41398-025-03526-w</article-id><article-id pub-id-type="publisher-id">3526</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The blood lipidome fatty acid profile predicts the disease risk and clinical phenotypes of Alzheimer&#8217;s disease: associations from two prospective cohort studies</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Liu</surname><given-names initials="WZ">Wen-Zheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Huang</surname><given-names initials="LY">Liang-Yu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chi</surname><given-names initials="S">Song</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="YH">Ya-Hui</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tan</surname><given-names initials="CC">Chen-Chen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8759-7588</contrib-id><name name-style="western"><surname>Tan</surname><given-names initials="L">Lan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><on-behalf-of>for the Alzheimer&#8217;s Disease Neuroimaging Initiative</on-behalf-of><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3310-5875</contrib-id><name name-style="western"><surname>Xu</surname><given-names initials="W">Wei</given-names></name><address><email>dr_xuwei@qdu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021cj6z65</institution-id><institution-id institution-id-type="GRID">grid.410645.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0455 0905</institution-id><institution>Department of Neurology, Qingdao Municipal Hospital, </institution><institution>Qingdao University, </institution></institution-wrap>Qingdao, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021cj6z65</institution-id><institution-id institution-id-type="GRID">grid.410645.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0455 0905</institution-id><institution>Department of Neurology, Qingdao University Affiliated Hospital, </institution><institution>Qingdao University, </institution></institution-wrap>Qingdao, China </aff><aff id="Aff3"><label>3</label>Department of Neurology, Qingdao Hospital of Rehabilitation University, Rehabilitation University, Qingdao, China </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478532</issue-id><elocation-id>373</elocation-id><history><date date-type="received"><day>21</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>14</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41398_2025_Article_3526.pdf"/><abstract id="Abs1"><p id="Par1">The relationship between fatty acids and Alzheimer&#8217;s Disease (AD) risk has been an area of growing interest but remains insufficiently understood. This study aimed to develop and validate a fatty acid score (FAS) derived from blood fatty acid levels and explore its association with AD risk. We analyzed 148,308 UK Biobank participants (age 37&#8211;73; mean 55.96 years) with a mean follow-up of 12.3 years (maximum 16), and 1193 ADNI subjects (age 55&#8211;90; mean 73.50 years) with a mean follow-up of 4.2 years (maximum 8). Lasso regression was used to construct the FAS based on UKB, and Cox regression and linear regression was employed to assess the relationships of FAS with AD risk, cognition, hippocampal volume, and/or cerebrospinal fluid markers in both cohorts. Stratified effects by <italic toggle="yes">APOE</italic> &#949;4 status were examined. Causal mediation, proteomic, and bioinformatic analyses were performed to reveal potential mechanisms. Higher FAS was associated with increased AD risk in both cohorts (UKB: HR&#8201;=&#8201;1.298, 95% CI 1.183&#8211;1.423, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; ADNI: HR&#8201;=&#8201;1.413, 95% CI 1.105&#8211;1.808, <italic toggle="yes">P</italic>&#8201;=&#8201;0.006). In UKB, higher FAS was linked to reduced hippocampal volume (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), and in ADNI, it was associated with faster hippocampal atrophy (<italic toggle="yes">P</italic>&#8201;=&#8201;0.002) and cognitive decline (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). These associations were stronger in <italic toggle="yes">APOE</italic> &#949;4 carriers. Hippocampal volume partly mediated the link between FAS and cognitive decline. Proteomic analyses demonstrated that the protein expression levels of Adhesion G protein-coupled receptor G1 (ADGRG1), Chitinase-3-like protein 1 (CHI3L1), RNA-binding FOX-1 homolog 3 (RBFOX3), and Growth differentiation factor 15 (GDF15) could mediate the effect of FAS on AD risk. The enriched pathways include cytokine activity, neurotrophic signaling, and pathways related to nervous system development. Blood levels of fatty acid could aid in AD prediction, but further research is needed to confirm causality.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Physiology</kwd><kwd>Predictive markers</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100010040</institution-id><institution>Taishan Scholar Project of Shandong Province</institution></institution-wrap></funding-source><award-id>tsqn202211375</award-id><award-id>tsqn202312391</award-id><principal-award-recipient><name name-style="western"><surname>Ma</surname><given-names>Ya-Hui</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Wei</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Alzheimer&#8217;s Disease (AD) is the leading cause of dementia globally and places significant burdens on societies [<xref ref-type="bibr" rid="CR1">1</xref>]. It is crucial to prevent and postpone AD occurrence. Compared to the biomarker framework based on cerebrospinal fluid (CSF) or PET imaging, the blood-based biomarker exhibited multiple advantages including accessible reproducibility, non-invasiveness, ease of measurement, and cost-effectiveness [<xref ref-type="bibr" rid="CR2">2</xref>]. Identifying reliable blood signals can facilitate risk stratification and personalized intervention in early stage of AD. Lines of studies have shown that multiple circulating proteins are associated with risk of dementia [<xref ref-type="bibr" rid="CR3">3</xref>] and AD [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, peripheral blood proteins may drive AD onset by modulating neuroinflammation, metabolism, and the extracellular matrix [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par3">Recently, some specific blood fatty acids were reported to modulate the levels of peripheral blood proteins associated with AD pathology [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], making them potential biomarkers for predicting AD. We and other researchers have found that higher levels of omega-3 polyunsaturated fatty acids (PUFAs) were associated with a reduced risk of cognitive decline [<xref ref-type="bibr" rid="CR14">14</xref>] and AD [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], whereas higher levels of saturated fatty acids (SFAs) could increase the risk of AD [<xref ref-type="bibr" rid="CR17">17</xref>]. However, the associations of blood fatty acids with cognitive function [<xref ref-type="bibr" rid="CR18">18</xref>] or AD [<xref ref-type="bibr" rid="CR19">19</xref>] remained inconclusive. These inconsistencies may be attributed to variations in sample size and confounding by <italic toggle="yes">APOE</italic> genotype [<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref>]. In addition, the diverse types of blood fatty acids and their interactions will also complicate the associations [<xref ref-type="bibr" rid="CR20">20</xref>]. Therefore, a strategy of weighting and incorporating different components of blood fatty acids could better estimate the contributions to AD.</p><p id="Par4">On the other hand, the mechanisms by which blood fatty acids were associated with AD were still unclear. Previous evidence showed that disrupted fatty acid metabolism and imbalance in proportions were critically implicated in AD pathogenesis [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. High-fat diet increased hippocampal SFAs and decreased PUFAs [<xref ref-type="bibr" rid="CR25">25</xref>], while this intake triggered inflammation, endoplasmic reticulum stress, and apoptotic signaling in the murine hippocampus [<xref ref-type="bibr" rid="CR26">26</xref>]. Additionally, the omega-6/omega-3 fatty acid ratio imbalance influenced amyloid pathology in the hippocampus and cortex of transgenic mice [<xref ref-type="bibr" rid="CR27">27</xref>]. It was reasonably hypothesized that neurodegeneration and neuroinflammation could be the underlying mechanisms, but other mediating pathways could exist.</p><p id="Par5">In the present study, we aimed to (1) develop a blood FAS associated with incident AD risk using a UK cohort and validate this association in an independent North America cohort, (2) explore the relationships of the FAS with cognition, hippocampus, and cerebrospinal fluid (CSF) AD biomarkers, (3) investigate the effect of hippocampus in mediating the relationship between FAS and cognition, and (4) examine the potential biological mechanisms by which FAS was associated with AD.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participants</title><p id="Par6">The UK Biobank (UKB) is a prospective cohort study of around 500,000 individuals aged 37&#8211;73 years recruited between 2006 and 2010. UKB participants completed comprehensive assessments including questionnaires, interviews, biological sampling, and physical measurements at 22 centers across the UK [<xref ref-type="bibr" rid="CR28">28</xref>]. Baseline data covered socio-demographics, lifestyle, diet, and medical history, with follow-up via electronic health records. Ethical approval was obtained (Ref. 11/NW/0382), and all participants provided informed consent.</p><p id="Par7">Serving as the validation cohort, ADNI is an established multi-center cohort in North America (adni.loni.usc.edu). ADNI is launched to test clinical, imaging, genetic, and biochemical biomarkers of AD. The participants, aged 55&#8211;90 years, were enrolled after approval from the institutional review boards of all participating centers, with written informed consent obtained from all participants or their authorized representatives in accordance with the 1975 Declaration of Helsinki. Detailed information can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.adniinfo.org">http://www.adniinfo.org</ext-link>.</p><p id="Par8">For both cohorts, we excluded participants who were diagnosed with dementia or major neuropsychiatric disorders at baseline, or were lost to follow-up, or had incomplete covariate or fatty acid data. Any participant with a missing value for variables of interest was excluded.</p></sec><sec id="Sec4"><title>Assessment of plasma fatty acids</title><p id="Par9">In UKB, plasma fatty acids levels (absolute concentrations and percentages of specific component to total fatty acids) were measured by nuclear magnetic resonance (NMR) in blood samples [<xref ref-type="bibr" rid="CR29">29</xref>]. In ADNI, serum fatty acids were analyzed using Nightingale Health&#8217;s NMR metabolomics platform [<xref ref-type="bibr" rid="CR17">17</xref>]. For both cohorts, 17 fatty acid indicators were included: total fatty acids (TFA), saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), polyunsaturated fatty acid (PUFA), omega-3, omega-6, docosahexaenoic acid (DHA), and linoleic acid (LA), and various ratios including SFA to TFA ratio, MUFA to TFA ratio, PUFA to TFA ratio, omega-3 to TFA ratio, omega-6 to TFA ratio, DHA to TFA ratio, LA to TFA ratio, PUFA to MUFA ratio, omega-6 to omega-3 ratio.</p></sec><sec id="Sec5"><title>Diagnosis of AD dementia</title><p id="Par10">In UKB, dementia diagnoses were ascertained using the International Classification of Diseases (ICD) coding system from hospital records and death registers. The Alzheimer&#8217;s disease codes included F00, F00.0, F00.1, F00.2, F00.9, G30, G30.0, G30.1, G30.8, and G30.9. The follow-up duration was calculated as the shorter interval between the initial evaluation and the diagnosis of dementia, death, last follow-up, or loss to follow-up [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In ADNI, neuropsychological testing and diagnostic criteria details can be found on the ADNI website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://adni.loni.usc.edu/methods">http://adni.loni.usc.edu/methods</ext-link>). In brief, AD patients had an MMSE score of 20&#8211;26, a CDR-SB score of 0.5 or 1, and met the NINDS-ADRDA criteria for probable AD. Cognitive diagnoses were recorded annually, with progressors identified by changes from NC to AD dementia or MCI to AD dementia [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec6"><title>Cognitive assessments</title><p id="Par11">In UKB, the Numeric Memory Test (NMT) was selected as the primary cognitive outcome. The NMT collects comprehensive data, including the number and value of digits remembered, response accuracy, response times, and overall test completion status [<xref ref-type="bibr" rid="CR32">32</xref>]. Higher scores in NMT indicated better cognitive performance. In ADNI, cognitive functions were evaluated using multiple scales, including global cognition by the cognitive section of the Alzheimer&#8217;s Disease Assessment Scale (ADAS) and specific memory functions (MEM) by extracting relevant neuropsychological batteries to identify relevant items [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p></sec><sec id="Sec7"><title>Hippocampal volume measurement</title><p id="Par12">The volume of hippocampus in both UKB and ADNI were obtained from magnetic resonance imaging (MRI). T1-weighted and T2-FLAIR structural images were acquired in a straight sagittal orientation and centrally processed to extract hippocampal volumes. Detailed descriptions of image processing for both UKB and ADNI cohorts are available in other publications [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec8"><title>Measurements of CSF biomarkers</title><p id="Par13">Data on CSF biomarkers were accessible only in ADNI cohort. The detailed protocols for CSF procedures have been documented in [<xref ref-type="bibr" rid="CR37">37</xref>]. Briefly, concentrations of CSF A&#946;<sub>1&#8211;42</sub>, p-tau<sub>181</sub>, and total tau proteins (pg/mL) were measured using electrochemiluminescence immunoassays (Elecsys; Roche Diagnostics) on a fully automated Elecsys cobas e 601 instruments, as detailed in the UPENNBIOMK9.csv file [<xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="Sec9"><title>Blood proteomics</title><p id="Par14">In UKB, blood samples were collected in EDTA tubes, centrifuged at 2500&#8201;g for 10&#8201;min at 4&#8201;&#176;C, and the plasma was aliquoted and stored at &#8722;80&#8201;&#176;C. Proteomic assays were conducted on approximately 55,000 plasma samples using dual-barcoded antibody technology on the Olink platform [<xref ref-type="bibr" rid="CR39">39</xref>]. A total of 2923 types of proteins were retained for current analyses.</p></sec><sec id="Sec10"><title>Covariate measurements</title><p id="Par15">In UKB, the covariates included age, gender, educational attainment level, <italic toggle="yes">APOE</italic> &#949;4, Townsend deprivation index, depression, anxiety, hypertension, diabetes mellitus, hyperlipidemia, smoking, alcohol, stroke, obesity, and cancer. In ADNI, the covariates included age, gender, education, <italic toggle="yes">APOE</italic> &#949;4, diagnosis, depression, anxiety, hypertension, diabetes, smoking, stroke, obesity, and cancer. <italic toggle="yes">APOE</italic> &#949;4 carrier status was determined by genetic information (rs7412 and rs429358).</p></sec><sec id="Sec11"><title>Statistical analyses</title><p id="Par16">R software version 4.3.1 was used for statistical analyses. A two-sided <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 was considered as statistical significance. Baseline characteristics were summarized as mean (standard deviation [SD]) for normally distributed continuous variables, median (interquartile range [IQR]) for non-normally distributed continuous variables, and number (percentage) for categorical variables. The population was divided into high-risk and low-risk groups based on the highest quartile of blood fatty acid score (FAS). Comparisons between groups were performed using the Mann-Whitney U test for non-normally distributed continuous variables, the t-test for normally distributed continuous variables, and the chi-square test for categorical variables.</p><p id="Par17">The research design and flowchart are shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. Firstly, Lasso regression and Cox proportional hazards regression were employed to identify significant variables associated with risk of AD based on UKB cohort. The identified variables were then used to construct risk scores using Cox regression which met the proportional hazards assumption. The proportional hazards assumption for the Cox regression model was assessed using Schoenfeld residuals. If the assumption was violated, interaction terms with time were incorporated. Subsequently, the FAS for each participant was calculated based on the coefficients of the feature variables. Specifically, variable selection was performed using the Lasso regression model. Twenty-fold cross-validation was conducted to identify the optimal penalty parameter (lambda). Virtual vertical lines were drawn at lambda1.1SE and lambda.min, with the model at lambda.min set to 0.000 being selected as the best diagnostic model. Predictors with non-zero coefficients were considered relevant and included in further analysis to develop a more concise multi-factor Cox regression prediction model. A nomogram of the multi-factor Cox regression prediction model was then constructed using the R package &#8216;rms&#8217; to visualize the AD risk related to FAS. The population was then stratified into high-risk and low-risk groups according to the highest quartile of FAS. The restricted cubic spline analysis was used to explore the linear or nonlinear relationship between FAS and AD risk, validating the appropriateness of the group classifications. Next, multivariable Cox proportional hazard regression models were used to investigate the relationship of FAS with the risk of AD in UKB and ADNI. The &#8220;survival&#8221;, &#8220;ggplot2&#8221;, &#8220;pub&#8221;, &#8220;gritty&#8221; and &#8220;survminer&#8221; packages were used for these analyses.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Study design and workflow.</title><p>Seventeen blood fatty acid indicators were initially considered. Cox proportional hazard models were used to identify indicators closely associated with the risk of Alzheimer&#8217;s disease (AD). After Lasso regression (<italic toggle="yes">n</italic>&#8201;=&#8201;7) and considering contribution degree in the nomogram (<italic toggle="yes">n</italic>&#8201;=&#8201;2), a total of 8 indicators were finally included to construct the fatty acid risk score. The association of risk score with AD risk, cognition, hippocampus, and/or cerebrospinal fluid AD markers were tested in both UKB and ADNI cohorts. Mediation effects and interaction analyses by <italic toggle="yes">APOE</italic> &#949;4 were performed. Finally, proteomic analyses were conducted to elucidate the biological mechanisms of the interaction. &#8220;*&#8221; See e-Fig. <xref rid="MOESM1" ref-type="media">1</xref> for details. FAS Fatty acid score.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e452" position="float" orientation="portrait" xlink:href="41398_2025_3526_Fig1_HTML.jpg"/></fig></p><p id="Par18">Next, multiple linear regression models were employed to explore the associations of FAS with cognition and hippocampal volume in UKB and ADNI. All dependent variables were checked for normal distribution. When dependent variables exhibited skewed distributions, Box-Cox transformation was applied to make the data meet or approximate normality (Kolmogorov-Smirnov test <italic toggle="yes">p</italic>-value&#8201;&gt;&#8201;0.01). Residuals were visually assessed for linearity, homoscedasticity, and normality. To further validate the cross-sectional findings, the linear mixed-effects (LME) models were used to depict the longitudinal relationship of FAS with cognitive decline, hippocampal atrophy, and changing rates of CSF biomarkers in ADNI. The LME models had random intercepts and slopes for time and an unstructured covariance matrix for the random effects, and included the interaction between time (continuous) and the dependent variable as predictors. Regression diagnostics were performed, and outliers were excluded to confirm that all models satisfied the required assumptions: residuals following a normal distribution and no signs of heteroscedasticity. In all the analyses mentioned above, covariate adjustments were made across three models: Model I (no variables were adjusted), Model II (UKB: adjusted for age, gender, education, <italic toggle="yes">APOE</italic> &#949;4, and Townsend index; ADNI: adjusted for age, gender, education, <italic toggle="yes">APOE</italic> &#949;4, and baseline cognitive diagnosis [mild cognitive impairment vs. normal cognition]), and Model III (UKB: covariates from Model II plus depression, anxiety, hypertension, diabetes mellitus, hyperlipidemia, smoking, alcohol use, stroke, obesity, and cancer; ADNI: covariates from Model II plus depression, anxiety, hypertension, diabetes, smoking, stroke, obesity, and cancer). The &#8220;lm&#8221;, &#8220;name&#8221;, &#8220;ggplot2&#8221; and &#8220;car&#8221; packages were used to conduct the above analyses.</p><p id="Par19">Mediation analyses were performed to investigate the mediating role of hippocampus in the relationship of FAS with cognitive function scores in UKB and ADNI. To strengthen the robustness of our findings, we calculated the longitudinal changing rates of hippocampal atrophy and cognitive decline based on LME models and performed mediation analysis on these rates in ADNI. Covariates were consistent with those used in Model II. Mediation analyses were executed using the &#8220;Mediation&#8221; package, employing nonparametric bootstrapping with 10,000 iterations to estimate direct effects (DE), indirect effects (IE), the proportion mediated, and associated <italic toggle="yes">P</italic>-values.</p><p id="Par20">Moreover, interaction and stratified analyses by <italic toggle="yes">APOE</italic> &#949;4 status were performed to investigate whether the associations of FAS with AD risk, hippocampus, cognition, and CSF biomarkers was influenced by <italic toggle="yes">APOE</italic> &#949;4 status. As for the longitudinal interaction analyses, LME models were employed due to their suitability for managing unbalanced and censored data, as well as continuous time variables. Fixed effects included the primary effects of FAS, <italic toggle="yes">APOE</italic> &#949;4 status, and follow-up duration (time), in addition to interaction terms such as FAS&#8201;&#215;&#8201;<italic toggle="yes">APOE</italic> &#949;4, time&#8201;&#215;&#8201;FAS, time&#8201;&#215;&#8201;<italic toggle="yes">APOE</italic> &#949;4, and the three-way interaction of time&#8201;&#215;&#8201;FAS&#8201;&#215;&#8201;<italic toggle="yes">APOE</italic> &#949;4. The overall significance of the three-way interaction was assessed using a likelihood ratio test by contrasting the full model with a nested model that excluded the three-way interaction term. Diagnostic evaluations of the regression models were conducted, with outliers removed to ensure that the assumptions of normality in residuals and homoscedasticity were met. Group differences were statistically examined by comparing model coefficients using the Wald test, executed via the &#8216;aod&#8217; package.</p><p id="Par21">Lastly, proteomic and bioinformatic analyses were conducted to explore the potential biological mechanisms through which FAS was associated with AD risk. Cox proportional hazards adjusting for covariates in Model II and logistic regression models adjusting for age and gender were used to identified differentially expressed proteins associated with AD risk and FAS, respectively. Bonferroni correction was applied to define statistical significance (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;1.71&#8201;&#215;&#8201;10<sup>&#8722;5</sup>, number of proteins tested&#8201;=&#8201;2923). Mediation analyses were further used to assess the roles of the overlapped proteins in mediating the relationships of FAS with AD risk. Subsequently, functional enrichment analyses targeting these tagged proteins were performed using the STRING database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://string-db.org">http://string-db.org</ext-link>). The Benjamini-Hochberg (BH) procedure was employed for multiple testing corrections. The False Discovery Rate (FDR) value indicates the significance of the enrichment. Finally, we selected the top 10 pathways with the lowest FDR values in each category for bubble mapping. In addition, we included the FDR correction as sensitivity analysis. These results are reported in the supplementary materials.</p></sec></sec><sec id="Sec12" sec-type="results"><title>Results</title><sec id="Sec13"><title>Construction and validation of fatty acid risk score</title><p id="Par22">In UKB cohort (<italic toggle="yes">N</italic>&#8201;=&#8201;148,308; median age 57 years; maximum follow-up&#8201;=&#8201;16 years), participants with high FAS were older, were more likely to be female, had lower education levels, and had higher rates of obesity, hypertension, diabetes, smoking, and stroke (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). In ADNI cohort (<italic toggle="yes">N</italic>&#8201;=&#8201;1193; median age 74 years; maximum follow-up 8 years), participants with high FAS were more often female (<italic toggle="yes">P</italic>&#8201;=&#8201;0.004). (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Characteristics of participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" colspan="1">Characteristics</th><th colspan="4" rowspan="1">UKB</th><th colspan="4" rowspan="1">ADNI</th></tr><tr><th colspan="1" rowspan="1">Total</th><th colspan="1" rowspan="1">High-risk group</th><th colspan="1" rowspan="1">Low-risk group</th><th colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th colspan="1" rowspan="1">Total</th><th colspan="1" rowspan="1">High-risk group</th><th colspan="1" rowspan="1">Low-risk group</th><th colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr><tr><th colspan="1" rowspan="1">(<italic toggle="yes">N</italic>&#8201;=&#8201;148,308)</th><th colspan="1" rowspan="1">(<italic toggle="yes">N</italic>&#8201;=&#8201;37,077)</th><th colspan="1" rowspan="1">(<italic toggle="yes">N</italic>&#8201;=&#8201;111,231)</th><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">(<italic toggle="yes">N</italic>&#8201;=&#8201;1193)</th><th colspan="1" rowspan="1">(<italic toggle="yes">N</italic>&#8201;=&#8201;298)</th><th colspan="1" rowspan="1">(<italic toggle="yes">N</italic>&#8201;=&#8201;895)</th><th colspan="1" rowspan="1"/></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age, Years, (median [IQR])</td><td colspan="1" rowspan="1">57.00 [50.00, 62.00]</td><td colspan="1" rowspan="1">60.00 [53.00, 64.00]</td><td colspan="1" rowspan="1">56.00 [49.00, 62.00]</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">74.00 [69.00, 78.00]</td><td colspan="1" rowspan="1">74.00 [69.25, 79.00]</td><td colspan="1" rowspan="1">73.00 [69.00, 78.00]</td><td colspan="1" rowspan="1">0.081</td></tr><tr><td colspan="1" rowspan="1">Female (%)</td><td colspan="1" rowspan="1">66,742 (45.00)</td><td colspan="1" rowspan="1">19,460 (52.49)</td><td colspan="1" rowspan="1">47,282 (42.51)</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">528 (44.26)</td><td colspan="1" rowspan="1">154 (51.68)</td><td colspan="1" rowspan="1">374 (41.79)</td><td colspan="1" rowspan="1">0.004</td></tr><tr><td colspan="1" rowspan="1">APOE4 (%)</td><td colspan="1" rowspan="1">42,279 (28.51)</td><td colspan="1" rowspan="1">10,184 (27.47)</td><td colspan="1" rowspan="1">32,095 (28.85)</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">512 (42.92)</td><td colspan="1" rowspan="1">141 (47.32)</td><td colspan="1" rowspan="1">371 (41.45)</td><td colspan="1" rowspan="1">0.088</td></tr><tr><td colspan="1" rowspan="1">MCI (%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">737 (61.78)</td><td colspan="1" rowspan="1">192 (64.43)</td><td colspan="1" rowspan="1">545 (60.89)</td><td colspan="1" rowspan="1">0.308</td></tr><tr><td colspan="1" rowspan="1">TDI (median [IQR])</td><td colspan="1" rowspan="1">&#8722;2.49 [&#8722;3.83, &#8722;0.24]</td><td colspan="1" rowspan="1">&#8722;2.43 [&#8722;3.80, &#8722;0.11]</td><td colspan="1" rowspan="1">&#8722;2.50 [&#8722;3.84, &#8722;0.29]</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">Education, Years, (median [IQR])</td><td colspan="1" rowspan="1">13.00 [11.00, 22.00]</td><td colspan="1" rowspan="1">12.00 [11.00, 22.00]</td><td colspan="1" rowspan="1">14.00 [11.00, 22.00]</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">16.00 [14.00, 18.00]</td><td colspan="1" rowspan="1">15.00 [13.00, 18.00]</td><td colspan="1" rowspan="1">16.00 [14.00, 18.00]</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">Alcohol (%)</td><td colspan="1" rowspan="1">112 (0.08)</td><td colspan="1" rowspan="1">30 (0.08)</td><td colspan="1" rowspan="1">82 (0.07)</td><td colspan="1" rowspan="1">0.737</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">Anxiety (%)</td><td colspan="1" rowspan="1">1950 (1.32)</td><td colspan="1" rowspan="1">448 (1.22)</td><td colspan="1" rowspan="1">1502 (1.36)</td><td colspan="1" rowspan="1">0.043</td><td colspan="1" rowspan="1">68 (5.70)</td><td colspan="1" rowspan="1">13 (4.36)</td><td colspan="1" rowspan="1">55 (6.15)</td><td colspan="1" rowspan="1">0.315</td></tr><tr><td colspan="1" rowspan="1">Obesity (%)</td><td colspan="1" rowspan="1">51,305 (34.84)</td><td colspan="1" rowspan="1">19,050 (51.82)</td><td colspan="1" rowspan="1">32,255 (29.19)</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">420 (35.21)</td><td colspan="1" rowspan="1">93 (31.21)</td><td colspan="1" rowspan="1">327 (36.54)</td><td colspan="1" rowspan="1">0.11</td></tr><tr><td colspan="1" rowspan="1">Cancer (%)</td><td colspan="1" rowspan="1">1631 (1.11)</td><td colspan="1" rowspan="1">435 (1.18)</td><td colspan="1" rowspan="1">1196 (1.08)</td><td colspan="1" rowspan="1">0.116</td><td colspan="1" rowspan="1">194 (16.26)</td><td colspan="1" rowspan="1">47 (15.77)</td><td colspan="1" rowspan="1">147 (16.42)</td><td colspan="1" rowspan="1">0.862</td></tr><tr><td colspan="1" rowspan="1">Depression (%)</td><td colspan="1" rowspan="1">7703 (5.23)</td><td colspan="1" rowspan="1">2048 (5.57)</td><td colspan="1" rowspan="1">5655 (5.12)</td><td colspan="1" rowspan="1">0.001</td><td colspan="1" rowspan="1">250 (20.96)</td><td colspan="1" rowspan="1">52 (17.45)</td><td colspan="1" rowspan="1">198 (22.12)</td><td colspan="1" rowspan="1">0.102</td></tr><tr><td colspan="1" rowspan="1">Diabetes (%)</td><td colspan="1" rowspan="1">5430 (3.69)</td><td colspan="1" rowspan="1">3576 (9.73)</td><td colspan="1" rowspan="1">1854 (1.68)</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">97 (8.13)</td><td colspan="1" rowspan="1">24 (8.05)</td><td colspan="1" rowspan="1">73 (8.16)</td><td colspan="1" rowspan="1">0.99</td></tr><tr><td colspan="1" rowspan="1">Hyperlipidemia (%)</td><td colspan="1" rowspan="1">15,871 (10.78)</td><td colspan="1" rowspan="1">9544 (25.96)</td><td colspan="1" rowspan="1">6327 (5.73)</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">Hypertension (%)</td><td colspan="1" rowspan="1">34,269 (23.27)</td><td colspan="1" rowspan="1">14,348 (39.03)</td><td colspan="1" rowspan="1">19,921 (18.03)</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">554 (46.44)</td><td colspan="1" rowspan="1">144 (48.32)</td><td colspan="1" rowspan="1">410 (45.81)</td><td colspan="1" rowspan="1">0.493</td></tr><tr><td colspan="1" rowspan="1">Smoke (%)</td><td colspan="1" rowspan="1">90,173 (61.24)</td><td colspan="1" rowspan="1">24,255 (65.98)</td><td colspan="1" rowspan="1">65,918 (59.66)</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">209 (17.52)</td><td colspan="1" rowspan="1">37 (12.42)</td><td colspan="1" rowspan="1">172 (19.22)</td><td colspan="1" rowspan="1">0.01</td></tr><tr><td colspan="1" rowspan="1">Stroke (%)</td><td colspan="1" rowspan="1">1313 (0.89)</td><td colspan="1" rowspan="1">733 (1.99)</td><td colspan="1" rowspan="1">580 (0.52)</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">51 (4.27)</td><td colspan="1" rowspan="1">13 (4.36)</td><td colspan="1" rowspan="1">38 (4.25)</td><td colspan="1" rowspan="1">0.95</td></tr></tbody></table><table-wrap-foot><p>Mann-Whitney U test (for continuous variables with a non-normal distribution), student t test (for continuous variables with a normal distribution) and &#967;<sup>2</sup> tests (for categorical variables) were used to test the difference of baseline characteristics.</p><p><italic toggle="yes">UKB</italic> UK biobank, <italic toggle="yes">ADNI</italic> Alzheimer&#8217;s disease neuroimaging initiative, <italic toggle="yes">TDI</italic> townsend deprivation index, <italic toggle="yes">MCI</italic> mild cognitive impairment.</p></table-wrap-foot></table-wrap></p><p id="Par23">Based on LASSO regression and cross-validation, a total of ten components were chosen, including MUFA, omega-6, omega-3, DHA, LA, the SFA to TFA ratio, the MUFA to TFA ratio, the omega-3 to TFA ratio, the LA to TFA ratio, and the omega-6 to omega-3 ratio. After excluding MUFA to TFA ratio and omega-3 which had negligible contributions in the nomogram, eight components were finally retained to construct the FAS (e-Fig. <xref rid="MOESM1" ref-type="media">1</xref>). When FAS was treated as continuous variable, higher FAS was significantly associated with an increased risk of AD (hazard ratio [HR]&#8201;=&#8201;1.089, 95% confidence interval [CI]&#8201;=&#8201;1.055&#8211;1.125, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) in UKB cohort (Model II). The association still reached borderline significance in Model III (HR&#8201;=&#8201;1.033, 95% CI: 0.998&#8211;1.070, <italic toggle="yes">P</italic>&#8201;=&#8201;0.064). In ADNI, higher FAS was significantly associated with an increased risk of AD in both Model II (HR&#8201;=&#8201;1.051, 95% CI: 1.018&#8211;1.085, <italic toggle="yes">P</italic>&#8201;=&#8201;0.002) and Model III (HR&#8201;=&#8201;1.047, 95% CI: 1.014&#8211;1.081, <italic toggle="yes">P</italic>&#8201;=&#8201;0.005) (e-Table <xref rid="MOESM1" ref-type="media">1</xref>). Restricted cubic spline analysis supported the validity of the FAS high- and low-risk group stratification (e-Fig. <xref rid="MOESM1" ref-type="media">2</xref>). When FAS was treated as categorical variable, higher FAS was associated with higher risk of AD in Model II (HR&#8201;=&#8201;1.298, 95% CI: 1.183&#8211;1.423, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, Fig. <xref rid="Fig2" ref-type="fig">2A</xref>) and Model III. The associations were validated in ADNI (HR&#8201;=&#8201;1.413, 95% CI 1.105&#8211;1.808, <italic toggle="yes">P</italic>&#8201;=&#8201;0.006, Fig. <xref rid="Fig2" ref-type="fig">2B</xref>). The proportional hazards assumption for the Cox regression models in the UKB and ADNI cohort is presented in e-Fig. <xref rid="MOESM1" ref-type="media">3</xref> and detailed in e-Table <xref rid="MOESM1" ref-type="media">2</xref>. No significant interaction by <italic toggle="yes">APOE</italic> &#949;4 status was found in both cohorts (e-Table <xref rid="MOESM1" ref-type="media">1</xref>). The stratified analysis by <italic toggle="yes">APOE</italic> &#949;4 status in two cohorts revealed that the association between FAS and AD risk remained significant in the <italic toggle="yes">APOE</italic> &#949;4 carrier group, but not in the non-carrier group (e-Table <xref rid="MOESM1" ref-type="media">3</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Relationship between fatty acid score and incident risk of AD.</title><p>Higher fatty acid score was associated with elevated risk of AD in UKB <bold>A</bold> and ADNI <bold>B</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1005" position="float" orientation="portrait" xlink:href="41398_2025_3526_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec14"><title>Higher FAS was associated with lower levels and faster decline of memory function</title><p id="Par24">The characteristics of participants (<italic toggle="yes">N</italic>&#8201;=&#8201;13,035 for UKB and <italic toggle="yes">N</italic>&#8201;=&#8201;1193 for ADNI) included for analyses were given in the e-Table <xref rid="MOESM1" ref-type="media">4</xref>. The cross-sectional analyses showed that higher FAS was associated with worse numeric memory test performance (Model I, &#946;&#8201;=&#8201;&#8722;0.084, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) in UKB. The association reached borderline significance in Model II (&#946;&#8201;=&#8201;&#8722;0.036, <italic toggle="yes">P</italic>&#8201;=&#8201;0.083, Fig. <xref rid="Fig3" ref-type="fig">3A</xref>). In ADNI, individuals with higher FAS exhibited worse cognition, as indicated by a higher level of ADAS (Model II, &#946;&#8201;=&#8201;0.122, <italic toggle="yes">P</italic>&#8201;=&#8201;0.026, Fig. <xref rid="Fig3" ref-type="fig">3B</xref>) and lower scores of MEM (Model II, &#946;&#8201;=&#8201;&#8722;0.101, <italic toggle="yes">P</italic>&#8201;=&#8201;0.012, Fig. <xref rid="Fig3" ref-type="fig">3C</xref>). The associations remained significant after controlling for more covariates (e-Table <xref rid="MOESM1" ref-type="media">5</xref>). Longitudinal analyses showed that higher FAS was associated with faster cognitive decline in memory (Model II, &#946;&#8201;=&#8201;&#8722;0.034, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, Fig. <xref rid="Fig3" ref-type="fig">3D</xref>). The association remained significant in Model III. Stratified analyses by <italic toggle="yes">APOE</italic> &#949;4 status showed that the association was significant only in the <italic toggle="yes">APOE</italic> &#949;4 carrier group (&#946;&#8201;=&#8201;&#8722;0.058, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, e-Table <xref rid="MOESM1" ref-type="media">6</xref>). No association was found for changing rates of general function (Model II, &#946;&#8201;=&#8201;0.003, <italic toggle="yes">P</italic>&#8201;=&#8201;0.812, e-Table <xref rid="MOESM1" ref-type="media">7</xref>). No significant was found for interaction by <italic toggle="yes">APOE</italic> &#949;4 status (e-Table <xref rid="MOESM1" ref-type="media">8</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Hippocampal volume mediated the relationship of fatty acid score with memory function.</title><p>In UKB, numeric memory test scores were lower in the high-risk group, with marginal statistical significance <bold>A</bold>. In ADNI, ADAS <bold>B</bold> was higher and MEM <bold>C</bold> was lower in the high-risk group, with a faster rate of MEM decline <bold>D</bold>. Hippocampal volume was lower in the high-risk group in both UKB <bold>E</bold> and ADNI <bold>F</bold>, with a faster rate of decline in ADNI <bold>G</bold>. In ADNI, A&#946; levels showed no difference <bold>H</bold>, while tau <bold>I</bold> and p-tau <bold>J</bold> were higher in the high-risk group. In mediation analyses, no significant mediation was found in UKB <bold>K</bold>, but in ADNI, hippocampal volume mediated effects on MEM <bold>L</bold> and ADAS <bold>M</bold>. Longitudinal analysis in ADNI showed hippocampal changes mediated MEM decline <bold>N</bold>, but not ADAS <bold>O</bold>. AD Alzheimer&#8217;s disease, ADAS Alzheimer&#8217;s Disease Assessment Scale, MEM memory function, Numeric Test numeric memory test, IE indirect effect.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1131" position="float" orientation="portrait" xlink:href="41398_2025_3526_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec15"><title>Higher FAS was associated with lower volume and faster atrophy of hippocampus</title><p id="Par25">The characteristics of participants (<italic toggle="yes">N</italic>&#8201;=&#8201;22,626 for UKB and <italic toggle="yes">N</italic>&#8201;=&#8201;977 for ADNI) for analyses were given in the e-Table <xref rid="MOESM1" ref-type="media">9</xref>. Higher FAS was associated with lower volume of hippocampus at baseline (Model II, UKB: &#946;&#8201;=&#8201;&#8722;0.075, <italic toggle="yes">P</italic>&#8201;=&#8201;5.83&#8201;&#215;&#8201;10<sup>&#8722;7</sup>, Fig. <xref rid="Fig3" ref-type="fig">3E</xref>; ADNI: &#946;&#8201;=&#8201;&#8722;0.119, <italic toggle="yes">P</italic>&#8201;=&#8201;0.048, Fig. <xref rid="Fig3" ref-type="fig">3F</xref>). Longitudinal analyses of ADNI data showed that individuals with higher FAS exhibited faster rates of hippocampal atrophy (Model II, &#946;&#8201;=&#8201;&#8722;0.024, <italic toggle="yes">P</italic>&#8201;=&#8201;0.002, Fig. <xref rid="Fig3" ref-type="fig">3G</xref>). The associations remained significant in Model III (e-Table <xref rid="MOESM1" ref-type="media">7</xref>). No significant interaction by <italic toggle="yes">APOE</italic> &#949;4 status was found in the longitudinal analysis (e-Table <xref rid="MOESM1" ref-type="media">8</xref>). However, subgroup analyses in ADNI showed that FAS was associated with hippocampus atrophy only in <italic toggle="yes">APOE</italic> &#949;4 carrier group (&#946;&#8201;=&#8201;&#8722;0.038, <italic toggle="yes">P</italic>&#8201;=&#8201;0.003, e-Table <xref rid="MOESM1" ref-type="media">6</xref>).</p></sec><sec id="Sec16"><title>Higher FAS was associated with higher levels of CSF tau proteins</title><p id="Par26">The characteristics of ADNI participants for CSF biomarker analyses were given in the e-Table <xref rid="MOESM1" ref-type="media">10</xref>. Individuals with higher FAS were older (<italic toggle="yes">P</italic>&#8201;=&#8201;0.021), more often female (<italic toggle="yes">P</italic>&#8201;=&#8201;0.007), and had a higher prevalence of <italic toggle="yes">APOE</italic> &#949;4 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.035). Among 870 participants with baseline data of CSF biomarker, 65.4% completed at least two follow-up evaluations over a maximum of 6 years. Higher FAS was linked to higher levels of CSF t-tau (Model II, &#946;&#8201;=&#8201;0.183, <italic toggle="yes">P</italic>&#8201;=&#8201;0.015, Fig. <xref rid="Fig3" ref-type="fig">3I</xref>) and p-tau (Model II, &#946;&#8201;=&#8201;0.197, <italic toggle="yes">P</italic>&#8201;=&#8201;0.008, Fig. <xref rid="Fig3" ref-type="fig">3J</xref>). The associations remained unchanged after controlling for more covariates (e-Table <xref rid="MOESM1" ref-type="media">5</xref>). No significant correlation was found between FAS and CSF A&#946;<sub>1&#8211;42</sub> at baseline (<italic toggle="yes">P</italic>&#8201;=&#8201;0.302, Fig. <xref rid="Fig3" ref-type="fig">3H</xref>). Though no longitudinal relationships were uncovered of FAS with CSF AD markers (e-Table <xref rid="MOESM1" ref-type="media">7</xref>), the likelihood ratio test indicated that the three-way interaction of FAS&#8201;&#215;&#8201;<italic toggle="yes">APOE</italic> &#949;4&#8201;&#215;&#8201;time accounted for a significant amount of variance in CSF A&#946;<sub>1&#8211;42</sub> (Model II, <italic toggle="yes">P</italic>&#8201;=&#8201;0.017, e-Fig. <xref rid="MOESM1" ref-type="media">4A</xref>), t-tau protein (Model II, <italic toggle="yes">P</italic>&#8201;=&#8201;0.013, e-Fig. <xref rid="MOESM1" ref-type="media">4B</xref>), and p-tau protein (Model II, <italic toggle="yes">P</italic>&#8201;=&#8201;0.032, e-Fig. <xref rid="MOESM1" ref-type="media">4C</xref>). Specifically, compared to other groups, a greater rate of CSF t-tau or p-tau increase (&#946;&#8201;=&#8201;0.04, <italic toggle="yes">P</italic>&#8201;=&#8201;0.032) was observed in the <italic toggle="yes">APOE</italic> &#949;4 carriers with higher FAS group (e-Table <xref rid="MOESM1" ref-type="media">6</xref>).</p></sec><sec id="Sec17"><title>The association of FAS with cognition was mediated by hippocampus volume</title><p id="Par27">In UKB, potential mediating effects of hippocampus were found on the relationship of FAS with numeric test scores (<italic toggle="yes">P</italic>&#8201;=&#8201;0.048, Fig. <xref rid="Fig3" ref-type="fig">3K</xref>). In ADNI, hippocampus volume mediated the relationship of FAS with MEM (<italic toggle="yes">P</italic>&#8201;=&#8201;0.048, proportion&#8201;=&#8201;19.2%, Fig. <xref rid="Fig3" ref-type="fig">3L</xref>) and ADAS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.038, proportion&#8201;=&#8201;21.1%, Fig. <xref rid="Fig3" ref-type="fig">3M</xref>) scores. Furthermore, the relationship of FAS with changing rates of MEM (<italic toggle="yes">P</italic>&#8201;=&#8201;0.008, proportion&#8201;=&#8201;38.6%, Fig. <xref rid="Fig3" ref-type="fig">3N</xref>) but not ADAS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.016, proportion&#8201;=&#8201;81.7%, Fig. <xref rid="Fig3" ref-type="fig">3O</xref>) was mediated by the atrophy rate of hippocampus.</p></sec><sec id="Sec18"><title>Proteomic and bioinformatics analyses to reveal biological pathways</title><p id="Par28">After Bonferroni correction (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;1.71&#8201;&#215;&#8201;10<sup>&#8722;5</sup>), we uncovered 16 proteins associated with AD risk (Fig. <xref rid="Fig4" ref-type="fig">4A</xref>) and 968 proteins associated with higher FAS (Fig. <xref rid="Fig4" ref-type="fig">4B</xref>). The Venn diagram illustrated four overlapping proteins that were positively correlated with both AD risk and higher FAS, including ADGRG1, CHI3L1, GDF15, and RBFOX3 (Fig. <xref rid="Fig4" ref-type="fig">4C</xref>). We found that the relationships of FAS with AD risk were mediated by these four proteins (proportion ranging from 7.7&#8211;19.2%, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;2&#8201;&#215;&#8201;10<sup>&#8722;16</sup>, Fig. <xref rid="Fig4" ref-type="fig">4D</xref>). Because no significant protein-protein interaction (PPI) enrichment was found (<italic toggle="yes">P</italic>&#8201;=&#8201;0.053), we separately explored the underpinning pathways for each protein. RBFOX3 is markedly involved in nervous system development, with significant emphasis on brain regions like the dentate gyrus, subventricular zone, and hippocampus (Fig. <xref rid="Fig5" ref-type="fig">5A</xref>). ADGRG1 is enriched in key pathways, including dopamine receptor signaling and G protein-coupled receptor (GPCR) signaling pathways (Fig. <xref rid="Fig5" ref-type="fig">5B</xref>). GDF15 is primarily involved in pathways like the glial cell-derived neurotrophic factor receptor signaling pathway and transforming growth factor beta receptor signaling pathway (Fig. <xref rid="Fig5" ref-type="fig">5C</xref>). The CHI3L1 bubble chart highlights its pivotal role in immune response, cytokine signaling, and inflammatory pathways, including cytokine and inflammatory responses, cytokine-cytokine receptor interactions, and regulation of leukocyte activation (Fig. <xref rid="Fig5" ref-type="fig">5D</xref>). FDR-corrected proteomics and bioinformatics results are presented in e-Fig. <xref rid="MOESM1" ref-type="media">5</xref> and e-Table <xref rid="MOESM1" ref-type="media">11</xref>.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Screening of overlapping differential proteins and their mediating effects on AD risk.</title><p>Volcano plots of proteins associated with AD incidence <bold>A</bold> and FAS <bold>B</bold>. The Venn diagram illustrated the differential proteins among the four groups. Group A: proteins positively associated with AD incidence; Group B: proteins negatively associated with AD incidence; Group C: proteins negatively associated with higher FAS; Group D: proteins positively associated with higher FAS. Four overlapping proteins (adgrg1, chi3l1, gdf15, and rbfox3) were shared between Groups A and D, indicating significant relevance to both AD incidence and higher FAS. <bold>C</bold>. Mediation analyses indicated that the relationship between FAS and AD risk was mediated by screening differential proteins <bold>D</bold>. FAS Fatty acid score, IE indirect effect.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1370" position="float" orientation="portrait" xlink:href="41398_2025_3526_Fig4_HTML.jpg"/></fig><fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Enrichment pathways for differential proteins.</title><p>The enrichment bubble diagram showed functional and pathway analysis of four proteins, displaying the top 10 terms with the lowest <italic toggle="yes">p</italic>-values. The y-axis represented enriched pathways, the x-axis showed the gene ratio, the bubble color indicated the <italic toggle="yes">p</italic>-value, and the size reflected the number of enriched genes. KEGG, other pathways, and GO enrichment analyses were shown for enriched pathways associated with RBFOX3 <bold>A</bold>, ADGRG1 <bold>B</bold>, GDF15 <bold>C</bold>, and CHI3L1 <bold>D</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1398" position="float" orientation="portrait" xlink:href="41398_2025_3526_Fig5_HTML.jpg"/></fig></p></sec></sec><sec id="Sec19" sec-type="discussion"><title>Discussion</title><p id="Par29">In this study, we 1) developed and validated a blood fatty acid score associated with AD risk, 2) confirmed the relationships of the scores with cognitive decline, hippocampus, and CSF AD markers, especially among <italic toggle="yes">APOE</italic> &#949;4 carriers, 3) found that hippocampal neurodegeneration could mediate the effects of FAS on cognition, and 4) uncovered several pathways, such as inflammatory pathways and neurogenesis, that were potentially responsible for bridging the relationship between blood fatty acids and AD occurrence. Overall, these findings underscored critical roles of blood fatty acid metabolic homeostasis in contributing to AD development.</p><p id="Par30">Several fatty acid components included for the FAS calculation were also previously related to AD risk, such as omega-3 fatty acids family and SFAs [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Elevated omega-3 levels were considered to mitigate the risk of dementia [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], whereas SFAs were associated with cognitive decline and an increased risk of AD [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. While these results underscored the roles of omega-3 fatty acids and SFAs in AD risk, integrating these key fatty acids into a comprehensive risk score offered a more holistic approach. By integrating these key fatty acids into a comprehensive risk score, we for the first time offered a practical tool for clinicians to assist in risk assessment. In future trials, this scoring system might be used to evaluate the efficacy of dietary interventions or fatty acid supplementation in AD prevention.</p><p id="Par31">As indicated by the proteomic analyses, the mechanisms by which blood fatty acids were involved in AD occurrence included multiple processes, such as modulation of neuroinflammatory pathways, promotion of synaptic plasticity, and neurogenesis [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. CHI3L1 was found as a critical differential protein linking fatty acids to AD. CHI3L1 was primarily expressed in reactive astrocytes and microglia, acting as a key driver of neuroinflammation in AD pathogenesis [<xref ref-type="bibr" rid="CR45">45</xref>]. In genetically modified mice models, high&#8208;fat diet feeding markedly increased CHI3L1 mRNA and protein expression in white adipose tissue and lung [<xref ref-type="bibr" rid="CR46">46</xref>]. Mechanistically, SFAs might activate the TLR4&#8211;MyD88&#8211;IKK axis, leading to NF-&#954;B [<xref ref-type="bibr" rid="CR47">47</xref>&#8211;<xref ref-type="bibr" rid="CR49">49</xref>] induction and subsequent upregulation of CHI3L1 [<xref ref-type="bibr" rid="CR50">50</xref>]. CHI3L1 then engages IL-13R&#945;2 and RAGE, triggering MAPK/ERK and PI3K&#8211;Akt signaling cascades [<xref ref-type="bibr" rid="CR45">45</xref>] that exacerbate neuroinflammation and amyloid-&#946;&#8211;associated inflammatory responses, thereby aggravating AD pathology. In contrast, unsaturated fatty acids (UFAs) activate PPAR&#947; [<xref ref-type="bibr" rid="CR51">51</xref>] and Nrf2 [<xref ref-type="bibr" rid="CR52">52</xref>] pathways, suppress NF-&#954;B signaling, and downregulate CHI3L1 expression [<xref ref-type="bibr" rid="CR53">53</xref>]. Therefore, we hypothesize that modulation of CHI3L1 by distinct fatty acid species could regulate neuroinflammatory processes and thus influence AD progression. The disruption of SFA/UFA balance could amplify CHI3L1-mediated inflammation through NF-&#954;B pathways, immune activation, and cytokine release. Future animal studies are needed to validate these hypotheses. Similarly, GDF15 is induced in response to cellular stress, mitochondrial dysfunction, and inflammation to maintain cellular and tissue homeostasis [<xref ref-type="bibr" rid="CR54">54</xref>]. Saturated fatty acids promote GDF15 expression and secretion in human macrophages through inducing ER stress and activating the PERK/eIF2/CHOP signaling pathway [<xref ref-type="bibr" rid="CR55">55</xref>]. Subsequently, GDF15 alleviates neuroinflammation and energy metabolism by inhibiting the TAK1/IKK/NF-&#954;B cascade [<xref ref-type="bibr" rid="CR56">56</xref>] and modulating GFRAL-mediated central metabolic routes [<xref ref-type="bibr" rid="CR57">57</xref>], thereby indirectly mitigating amyloid-&#946; and tau pathologies. It could be reasonably postulated that neuroinflammation could at least partially underpin the association of blood fatty acid with AD.</p><p id="Par32">ADGRG1 is an adhesion G protein-coupled receptor closely associated with developmental processes [<xref ref-type="bibr" rid="CR58">58</xref>]. Although no studies have directly examined the relationship between fatty acids and ADGRG1. Other adhesion GPCRs such as GPR116 and GPR97 have been implicated in lipid homeostasis and high-fat diet&#8211;induced metabolic changes [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], suggesting potential roles for ADGRG1 in fatty acid regulation. We hypothesize that ADGRG1 may act as a novel lipid-regulatory receptor. Its intracellular G protein&#8211;coupled domains activate downstream cAMP and RhoA signaling networks [<xref ref-type="bibr" rid="CR61">61</xref>], influencing metabolic homeostasis. Notably, beyond its potential role in lipid metabolism, ADGRG1 has also been implicated in immune regulation. ADGRG1 has been shown to regulate the cytotoxicity of natural killer (NK) cells [<xref ref-type="bibr" rid="CR58">58</xref>]. As sentinels of the immune system, NK cells are pivotal in the early coordination of local inflammatory responses and have profound implications for the onset and progression of neuroinflammation in aging and AD-related neurodegenerative disease [<xref ref-type="bibr" rid="CR62">62</xref>]. Fatty acids may engage ADGRG1 through ligand binding or co-regulatory mechanisms, thereby modulating NK cell&#8211;mediated inflammatory responses to drive Alzheimer&#8217;s disease pathogenesis. Elucidating this axis could inform novel therapeutic strategies targeting both lipid metabolism and immune regulation in AD.</p><p id="Par33">In addition, our mediation analyses revealed that hippocampal volume mediated the relationship between fatty acids and cognition, especially memory function. This aligned with previous research linking fatty acids to hippocampus. High-fat diets were reported to trigger neuroinflammation in the hippocampus, promoting its atrophy and cognitive decline [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Elevated blood levels of omega-3 were instead associated with less hippocampal atrophy, better cognitive performance, and reduced risk of cognitive decline in the elderly [<xref ref-type="bibr" rid="CR64">64</xref>]. These results emphasized the modulation effects of fatty acid profile on neurodegeneration in hippocampus. The possible mechanisms included neuroinflammation, synaptic activity, and neurogenesis [<xref ref-type="bibr" rid="CR65">65</xref>]. Interestingly, our bioinformatics analyses identified RBFOX3 as a key bridging protein, which was enriched in pathways critical for hippocampal neurogenesis and synaptic plasticity in subventricular zone and dentate gyrus. These regions are vital for neuronal differentiation, synaptic remodeling, and cognition [<xref ref-type="bibr" rid="CR66">66</xref>]. RBFOX3 is crucial for neurogenesis and synaptogenesis, with knockout models showing deficits in synaptic plasticity and cognition [<xref ref-type="bibr" rid="CR67">67</xref>]. RBFOX proteins also supported neuronal maturation and axon assembly, which were critical for neuron integration into circuits [<xref ref-type="bibr" rid="CR68">68</xref>]. We thus inferred that one key pathway by which blood fatty acids influenced cognition was by regulating RBFOX3 and enhancing synaptic plasticity. Regrettably, there have been no studies confirming that fatty acids or their metabolites can regulate the expression of RBFOX3. Future studies should investigate the impact of fatty acids on RBFOX3 expression. Gene knockout techniques could be employed to investigate whether the effects of fatty acids on synaptic function are mediated through RBFOX3, in both in vivo and in vitro models.</p><p id="Par34">The interaction of fatty acids such as omega-3 with <italic toggle="yes">APOE</italic> &#949;4 gene has been a controversial topic in the field. We previously reported the cognitive and pathological benefits of omega-3 supplementation were depending on presence of <italic toggle="yes">APOE</italic> &#949;4 [<xref ref-type="bibr" rid="CR22">22</xref>], while others reported greater benefits in individuals with lower genetic risk [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. In the present study, we found that the associations of FAS with AD were more pronounced among <italic toggle="yes">APOE</italic> &#949;4 carriers, reinforcing the idea that <italic toggle="yes">APOE</italic> &#949;4 may amplify the effects of fatty acids on AD [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Two mechanisms could help explain the interaction effect. Firstly, <italic toggle="yes">APOE</italic> &#949;4 is associated with reduced delivery of DHA to the brain [<xref ref-type="bibr" rid="CR21">21</xref>], which may limit the protective effects of beneficial fatty acids. Secondly, dietary fatty acids have been shown to modulate microglial states, thereby influencing neuroinflammation and contributing to AD-related neuropathology [<xref ref-type="bibr" rid="CR71">71</xref>]. Similarly, <italic toggle="yes">APOE</italic> &#949;4 may cause overactivation of microglia and the release of pro-inflammatory cytokines, leading to neuronal damage and tau hyperphosphorylation [<xref ref-type="bibr" rid="CR72">72</xref>]. The combined effects of imbalanced fatty acid ratios and <italic toggle="yes">APOE</italic> &#949;4 may amplify neuroinflammation, thereby exacerbating the progression of AD. However, this <italic toggle="yes">APOE</italic> &#949;4&#8201;&#215;&#8201;FAS interaction should be interpreted cautiously, considering several important limitations: First, as an observational study, causal inference is difficult; the interaction may reflect shared upstream determinants rather than a true biological synergism. Second, residual confounding by unmeasured factors&#8212;such as dietary patterns, or other genetic variants&#8212;could influence both fatty acid profiles and AD risk. Finally, statistical interaction does not necessarily imply mechanistic interaction, and replication in independent cohorts with more detailed phenotyping will be necessary to confirm these findings.</p><p id="Par35">Our study demonstrated several strengths. First, we constructed a risk score by rigorously screening blood fatty acids profile associated with AD risk. This comprehensive approach allows for a thorough evaluation of the interactions among various fatty acids. Second, the association of FAS with AD was validated across independent cohorts from two different continents, enhancing the generalizability and reliability of our findings. Third, multiple methods were further used to explore the potential mechanisms. There were several limitations. First, plasma fatty acids can fluctuate with dietary intake, which may not accurately represent the accumulating levels of fatty acid during the follow-up. Second, the associations or the pathways were based on the observational study but not equal to the causal relationship. Future experiments were warranted to test the hypothesis in the future. Third, the absence of CSF data and ATN&#8208;based AD confirmation in UKB remains a key limitation of our study. Future studies should leverage multicenter cohorts with multimodal data (CSF, PET, and plasma biomarkers) to confirm these findings. Fourth, differences in ethnicity between ADNI and UKB may limit generalizability. Future studies should include multi-ethnic cohorts and adjust for ancestry to minimize confounding.</p></sec><sec id="Sec20" sec-type="conclusion"><title>Conclusion</title><p id="Par36">Overall, our study developed and validated a blood fatty acid score associated with incident AD risk in two dependent cohorts. The potential underpinning mechanisms could be hippocampal neurodegeneration, neuroinflammation, neurogenesis, and synaptic plasticity. Future researches are needed to further validate this risk score in more community-based populations as well as in the clinic settings.</p></sec><sec id="Sec21" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3526_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary materials</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p>*Data used in preparation of this article were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf">http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</ext-link>.</p></fn><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Wen-Zheng Liu, Liang-Yu Huang.</p></fn><fn><p>A full list of members and their affiliations appears in the Supplementary Information.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41398-025-03526-w.</p></sec><ack><title>Acknowledgements</title><p>This research has been conducted using the UK Biobank resource under application number 108930. The authors also thank contributors, including the staff at Alzheimer&#8217;s Disease Centers who collected samples used in this study, patients, and their families whose help and participation made this work possible. Data collection and sharing for this project were funded by the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer&#8217;s Association; Alzheimer&#8217;s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &amp; Development, LLC.; Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC.; Lumosity; Lundbeck; Merck &amp; Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fnih.org">www.fnih.org</ext-link>). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer&#8217;s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Data used in preparation of this article were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf">http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</ext-link>.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Dr. Wen-Zheng Liu and Dr. Liang-Yu Huang: analysis of the data, drafting and revision of the manuscript, and prepared all the figures. Prof. Lan Tan, Prof. Chen-Chen Tan, Prof. Song Chi, and Dr Ya-Hui Ma: revision of the manuscript. Prof. Wei Xu: conceptualization and design of the study, analysis of the data, drafting and revision of the manuscript. Data used in the preparation of this article were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by grants from the Taishan Scholar Project (NO.tsqn202211375 and NO.tsqn202312391).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data are available upon reasonable request or can be obtained from the UKB (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://biobank.ctsu.ox.ac.uk/">https://biobank.ctsu.ox.ac.uk/</ext-link>) and Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu).</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par37">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par38">The UKB and ADNI were approved by the institutional review boards of all participating centers, and written informed consent was obtained from all participants or authorized representatives according to the 1975 Declaration of Helsinki. All methods in this study were performed in accordance with the relevant guidelines and regulations, and the UK Biobank has approval from the North West Multi-centre Research Ethics Committee as a Research Tissue Bank (RTB) approval. Researchers with approved access operate under the RTB approval and do not require separate ethical approval. The ADNI was approved by the Institutional Review Boards (IRB) all participating centers.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Patterson C. World Alzheimer Report 2018: The state of the art of dementia research: New frontiers. London: Alzheimer&#8217;s Disease International; 2018. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.alzint.org/u/WorldAlzheimerReport2018.pdf">https://www.alzint.org/u/WorldAlzheimerReport2018.pdf</ext-link></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molinuevo</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ayton</surname><given-names>S</given-names></name><name name-style="western"><surname>Batrla</surname><given-names>R</given-names></name><name name-style="western"><surname>Bednar</surname><given-names>MM</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>T</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J</given-names></name><etal/></person-group><article-title>Current state of Alzheimer&#8217;s fluid biomarkers</article-title><source>Acta Neuropathol</source><year>2018</year><volume>136</volume><fpage>821</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1007/s00401-018-1932-x</pub-id><pub-id pub-id-type="pmid">30488277</pub-id><pub-id pub-id-type="pmcid">PMC6280827</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, et al. Current state of Alzheimer&#8217;s fluid biomarkers. Acta Neuropathol. 2018;136:821&#8211;53. 10.1007/s00401-018-1932-x<pub-id pub-id-type="pmid">30488277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-018-1932-x</pub-id><pub-id pub-id-type="pmcid">PMC6280827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name><name name-style="western"><surname>O&#8217;Bryant</surname><given-names>SE</given-names></name><name name-style="western"><surname>Molinuevo</surname><given-names>JL</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Masters</surname><given-names>CL</given-names></name><name name-style="western"><surname>Lista</surname><given-names>S</given-names></name><etal/></person-group><article-title>Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic</article-title><source>Nat Rev Neurol</source><year>2018</year><volume>14</volume><fpage>639</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/s41582-018-0079-7</pub-id><pub-id pub-id-type="pmid">30297701</pub-id><pub-id pub-id-type="pmcid">PMC6211654</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Hampel H, O&#8217;Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14:639&#8211;52. 10.1038/s41582-018-0079-7<pub-id pub-id-type="pmid">30297701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-018-0079-7</pub-id><pub-id pub-id-type="pmcid">PMC6211654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>A review of fluid biomarkers for Alzheimer&#8217;s disease: moving from CSF to blood</article-title><source>Neurol Ther</source><year>2017</year><volume>6</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s40120-017-0073-9</pub-id><pub-id pub-id-type="pmid">28733960</pub-id><pub-id pub-id-type="pmcid">PMC5520819</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Blennow K. A review of fluid biomarkers for Alzheimer&#8217;s disease: moving from CSF to blood. Neurol Ther. 2017;6:15&#8211;24. 10.1007/s40120-017-0073-9<pub-id pub-id-type="pmid">28733960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40120-017-0073-9</pub-id><pub-id pub-id-type="pmcid">PMC5520819</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>KY</given-names></name><name name-style="western"><surname>Shin</surname><given-names>KY</given-names></name><name name-style="western"><surname>Chang</surname><given-names>KA</given-names></name></person-group><article-title>GFAP as a potential biomarker for Alzheimer&#8217;s disease: a systematic review and meta-analysis</article-title><source>Cells</source><year>2023</year><volume>12</volume><fpage>1309</fpage><pub-id pub-id-type="doi">10.3390/cells12091309</pub-id><pub-id pub-id-type="pmid">37174709</pub-id><pub-id pub-id-type="pmcid">PMC10177296</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kim KY, Shin KY, Chang KA. GFAP as a potential biomarker for Alzheimer&#8217;s disease: a systematic review and meta-analysis. Cells. 2023;12:1309 10.3390/cells12091309<pub-id pub-id-type="pmid">37174709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12091309</pub-id><pub-id pub-id-type="pmcid">PMC10177296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>You</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>WS</given-names></name><name name-style="western"><surname>Huang</surname><given-names>YY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YR</given-names></name><etal/></person-group><article-title>Plasma proteomic profiles predict future dementia in healthy adults</article-title><source>Nat Aging</source><year>2024</year><volume>4</volume><fpage>247</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00565-0</pub-id><pub-id pub-id-type="pmid">38347190</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Guo Y, You J, Zhang Y, Liu WS, Huang YY, Zhang YR, et al. Plasma proteomic profiles predict future dementia in healthy adults. Nat Aging. 2024;4:247&#8211;60. 10.1038/s43587-023-00565-0<pub-id pub-id-type="pmid">38347190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00565-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>KA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fornage</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><etal/></person-group><article-title>Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life</article-title><source>Sci Transl Med</source><year>2023</year><volume>15</volume><fpage>eadf5681</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adf5681</pub-id><pub-id pub-id-type="pmid">37467317</pub-id><pub-id pub-id-type="pmcid">PMC10665113</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Walker KA, Chen J, Shi L, Yang Y, Fornage M, Zhou L, et al. Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life. Sci Transl Med. 2023;15:eadf5681 10.1126/scitranslmed.adf5681<pub-id pub-id-type="pmid">37467317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.adf5681</pub-id><pub-id pub-id-type="pmcid">PMC10665113</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pase</surname><given-names>MP</given-names></name><name name-style="western"><surname>Himali</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Puerta</surname><given-names>R</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>AS</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>MM</given-names></name><name name-style="western"><surname>Satizabal</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Association of plasma YKL-40 With MRI, CSF, and cognitive markers of brain health and dementia</article-title><source>Neurology</source><year>2024</year><volume>102</volume><fpage>e208075</fpage><pub-id pub-id-type="doi">10.1212/wnl.0000000000208075</pub-id><pub-id pub-id-type="pmid">38290090</pub-id><pub-id pub-id-type="pmcid">PMC11383876</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Pase MP, Himali JJ, Puerta R, Beiser AS, Gonzales MM, Satizabal CL, et al. Association of plasma YKL-40 With MRI, CSF, and cognitive markers of brain health and dementia. Neurology. 2024;102:e208075 10.1212/wnl.0000000000208075<pub-id pub-id-type="pmid">38290090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000208075</pub-id><pub-id pub-id-type="pmcid">PMC11383876</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mwale</surname><given-names>PF</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>CT</given-names></name><name name-style="western"><surname>Yen</surname><given-names>TL</given-names></name><name name-style="western"><surname>Jan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Taliyan</surname><given-names>R</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications</article-title><source>Mol Neurodegener</source><year>2025</year><volume>20</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s13024-025-00801-8</pub-id><pub-id pub-id-type="pmid">39827337</pub-id><pub-id pub-id-type="pmcid">PMC11742494</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Mwale PF, Hsieh CT, Yen TL, Jan JS, Taliyan R, Yang CH, et al. Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications. Mol Neurodegener. 2025;20:7 10.1186/s13024-025-00801-8<pub-id pub-id-type="pmid">39827337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-025-00801-8</pub-id><pub-id pub-id-type="pmcid">PMC11742494</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhauria</surname><given-names>M</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>R</given-names></name><name name-style="western"><surname>Deb</surname><given-names>S</given-names></name><name name-style="western"><surname>Shome</surname><given-names>G</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>D</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Blood-based biomarkers in Alzheimer&#8217;s disease: advancing non-invasive diagnostics and prognostics</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><fpage>10911</fpage><pub-id pub-id-type="doi">10.3390/ijms252010911</pub-id><pub-id pub-id-type="pmid">39456697</pub-id><pub-id pub-id-type="pmcid">PMC11507237</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Dhauria M, Mondal R, Deb S, Shome G, Chowdhury D, Sarkar S, et al. Blood-based biomarkers in Alzheimer&#8217;s disease: advancing non-invasive diagnostics and prognostics. Int J Mol Sci. 2024;25:10911 10.3390/ijms252010911<pub-id pub-id-type="pmid">39456697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms252010911</pub-id><pub-id pub-id-type="pmcid">PMC11507237</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ehtewish</surname><given-names>H</given-names></name><name name-style="western"><surname>Mesleh</surname><given-names>A</given-names></name><name name-style="western"><surname>Ponirakis</surname><given-names>G</given-names></name><name name-style="western"><surname>De la Fuente</surname><given-names>A</given-names></name><name name-style="western"><surname>Parray</surname><given-names>A</given-names></name><name name-style="western"><surname>Bensmail</surname><given-names>I</given-names></name><etal/></person-group><article-title>Blood-based proteomic profiling identifies potential biomarker candidates and pathogenic pathways in dementia</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>8117</fpage><pub-id pub-id-type="doi">10.3390/ijms24098117</pub-id><pub-id pub-id-type="pmid">37175824</pub-id><pub-id pub-id-type="pmcid">PMC10179172</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Ehtewish H, Mesleh A, Ponirakis G, De la Fuente A, Parray A, Bensmail I, et al. Blood-based proteomic profiling identifies potential biomarker candidates and pathogenic pathways in dementia. Int J Mol Sci. 2023;24:8117 10.3390/ijms24098117<pub-id pub-id-type="pmid">37175824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24098117</pub-id><pub-id pub-id-type="pmcid">PMC10179172</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scrimgeour</surname><given-names>AG</given-names></name><name name-style="western"><surname>Condlin</surname><given-names>ML</given-names></name><name name-style="western"><surname>Loban</surname><given-names>A</given-names></name><name name-style="western"><surname>DeMar</surname><given-names>JC</given-names></name></person-group><article-title>Omega-3 fatty acids and vitamin D decrease plasma T-tau, GFAP, and UCH-L1 in experimental traumatic brain injury</article-title><source>Front Nutr</source><year>2021</year><volume>8</volume><fpage>685220</fpage><pub-id pub-id-type="doi">10.3389/fnut.2021.685220</pub-id><pub-id pub-id-type="pmid">34150829</pub-id><pub-id pub-id-type="pmcid">PMC8211733</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Scrimgeour AG, Condlin ML, Loban A, DeMar JC. Omega-3 fatty acids and vitamin D decrease plasma T-tau, GFAP, and UCH-L1 in experimental traumatic brain injury. Front Nutr. 2021;8:685220 10.3389/fnut.2021.685220<pub-id pub-id-type="pmid">34150829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnut.2021.685220</pub-id><pub-id pub-id-type="pmcid">PMC8211733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><etal/></person-group><article-title>Serum fatty acid profiles and neurofilament light chain levels in the general population</article-title><source>J Nutr</source><year>2024</year><volume>154</volume><fpage>3070</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.tjnut.2024.07.007</pub-id><pub-id pub-id-type="pmid">39004226</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Lv X, Zhao Q, Liu Q, Ji Q, Huang X, Zhou L, et al. Serum fatty acid profiles and neurofilament light chain levels in the general population. J Nutr. 2024;154:3070&#8211;8. 10.1016/j.tjnut.2024.07.007<pub-id pub-id-type="pmid">39004226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tjnut.2024.07.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>CW</given-names></name><name name-style="western"><surname>Tan</surname><given-names>CC</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name></person-group><article-title>The relationship of Omega-3 fatty acids with dementia and cognitive decline: evidence from prospective cohort studies of supplementation, dietary intake, and blood markers</article-title><source>Am J Clin Nutr</source><year>2023</year><volume>117</volume><fpage>1096</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.ajcnut.2023.04.001</pub-id><pub-id pub-id-type="pmid">37028557</pub-id><pub-id pub-id-type="pmcid">PMC10447496</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Wei BZ, Li L, Dong CW, Tan CC, Xu W. The relationship of Omega-3 fatty acids with dementia and cognitive decline: evidence from prospective cohort studies of supplementation, dietary intake, and blood markers. Am J Clin Nutr. 2023;117:1096&#8211;109. 10.1016/j.ajcnut.2023.04.001<pub-id pub-id-type="pmid">37028557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajcnut.2023.04.001</pub-id><pub-id pub-id-type="pmcid">PMC10447496</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Deng</surname><given-names>YT</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YR</given-names></name><etal/></person-group><article-title>Circulating polyunsaturated fatty acids, fish oil supplementation, and risk of incident dementia: a prospective cohort study of 440,750 participants</article-title><source>GeroScience</source><year>2023</year><volume>45</volume><fpage>1997</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1007/s11357-023-00778-6</pub-id><pub-id pub-id-type="pmid">37046127</pub-id><pub-id pub-id-type="pmcid">PMC10400523</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">He Y, Huang SY, Wang HF, Zhang W, Deng YT, Zhang YR, et al. Circulating polyunsaturated fatty acids, fish oil supplementation, and risk of incident dementia: a prospective cohort study of 440,750 participants. GeroScience. 2023;45:1997&#8211;2009. 10.1007/s11357-023-00778-6<pub-id pub-id-type="pmid">37046127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11357-023-00778-6</pub-id><pub-id pub-id-type="pmcid">PMC10400523</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Thomas A, Baillet M, Proust-Lima C, F&#233;art C, Foubert-Samier A, Helmer C, et al. Blood polyunsaturated omega-3 fatty acids, brain atrophy, cognitive decline, and dementia risk. Alzheimers Dement. 2020. 10.1002/alz.12195.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12195</pub-id><pub-id pub-id-type="pmid">33090665</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Borenstein</surname><given-names>AR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Associations of circulating saturated long-chain fatty acids with risk of mild cognitive impairment and Alzheimer&#8217;s disease in the Alzheimer&#8217;s disease neuroimaging initiative (ADNI) cohort</article-title><source>EBioMedicine</source><year>2023</year><volume>97</volume><fpage>104818</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104818</pub-id><pub-id pub-id-type="pmid">37793213</pub-id><pub-id pub-id-type="pmcid">PMC10562835</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Fan L, Borenstein AR, Wang S, Nho K, Zhu X, Wen W, et al. Associations of circulating saturated long-chain fatty acids with risk of mild cognitive impairment and Alzheimer&#8217;s disease in the Alzheimer&#8217;s disease neuroimaging initiative (ADNI) cohort. EBioMedicine. 2023;97:104818 10.1016/j.ebiom.2023.104818<pub-id pub-id-type="pmid">37793213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2023.104818</pub-id><pub-id pub-id-type="pmcid">PMC10562835</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammann</surname><given-names>EM</given-names></name><name name-style="western"><surname>Pottala</surname><given-names>JV</given-names></name><name name-style="western"><surname>Harris</surname><given-names>WS</given-names></name><name name-style="western"><surname>Espeland</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>R</given-names></name><name name-style="western"><surname>Denburg</surname><given-names>NL</given-names></name><etal/></person-group><article-title>&#969;-3 fatty acids and domain-specific cognitive aging: secondary analyses of data from WHISCA</article-title><source>Neurology</source><year>2013</year><volume>81</volume><fpage>1484</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182a9584c</pub-id><pub-id pub-id-type="pmid">24068783</pub-id><pub-id pub-id-type="pmcid">PMC3888166</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Ammann EM, Pottala JV, Harris WS, Espeland MA, Wallace R, Denburg NL, et al. &#969;-3 fatty acids and domain-specific cognitive aging: secondary analyses of data from WHISCA. Neurology. 2013;81:1484&#8211;91. 10.1212/WNL.0b013e3182a9584c<pub-id pub-id-type="pmid">24068783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182a9584c</pub-id><pub-id pub-id-type="pmcid">PMC3888166</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>PY</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Satyanarayanan</surname><given-names>SK</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>LT</given-names></name><name name-style="western"><surname>Chien</surname><given-names>YC</given-names></name><name name-style="western"><surname>Chuu</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Omega-3 fatty acids and blood-based biomarkers in Alzheimer&#8217;s disease and mild cognitive impairment: a randomized placebo-controlled trial</article-title><source>Brain Behav Immun</source><year>2022</year><volume>99</volume><fpage>289</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2021.10.014</pub-id><pub-id pub-id-type="pmid">34755655</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Lin PY, Cheng C, Satyanarayanan SK, Chiu LT, Chien YC, Chuu CP, et al. Omega-3 fatty acids and blood-based biomarkers in Alzheimer&#8217;s disease and mild cognitive impairment: a randomized placebo-controlled trial. Brain Behav Immun. 2022;99:289&#8211;98. 10.1016/j.bbi.2021.10.014<pub-id pub-id-type="pmid">34755655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2021.10.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosseini</surname><given-names>M</given-names></name><name name-style="western"><surname>Poljak</surname><given-names>A</given-names></name><name name-style="western"><surname>Braidy</surname><given-names>N</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>J</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>P</given-names></name></person-group><article-title>Blood fatty acids in Alzheimer&#8217;s disease and mild cognitive impairment: a meta-analysis and systematic review</article-title><source>Ageing Res Rev</source><year>2020</year><volume>60</volume><fpage>101043</fpage><pub-id pub-id-type="doi">10.1016/j.arr.2020.101043</pub-id><pub-id pub-id-type="pmid">32194194</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hosseini M, Poljak A, Braidy N, Crawford J, Sachdev P. Blood fatty acids in Alzheimer&#8217;s disease and mild cognitive impairment: a meta-analysis and systematic review. Ageing Res Rev. 2020;60:101043 10.1016/j.arr.2020.101043<pub-id pub-id-type="pmid">32194194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2020.101043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dakterzada</surname><given-names>F</given-names></name><name name-style="western"><surname>Jov&#233;</surname><given-names>M</given-names></name><name name-style="western"><surname>Cantero</surname><given-names>JL</given-names></name><name name-style="western"><surname>Mota-Martorell</surname><given-names>N</given-names></name><name name-style="western"><surname>Pamplona</surname><given-names>R</given-names></name><name name-style="western"><surname>Pi&#241;oll-Ripoll</surname><given-names>G</given-names></name></person-group><article-title>The shift in the fatty acid composition of the circulating lipidome in Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><fpage>3322</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1002/alz.13792</pub-id><pub-id pub-id-type="pmid">38534027</pub-id><pub-id pub-id-type="pmcid">PMC11095469</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Dakterzada F, Jov&#233; M, Cantero JL, Mota-Martorell N, Pamplona R, Pi&#241;oll-Ripoll G. The shift in the fatty acid composition of the circulating lipidome in Alzheimer&#8217;s disease. Alzheimers Dement. 2024;20:3322&#8211;33. 10.1002/alz.13792<pub-id pub-id-type="pmid">38534027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13792</pub-id><pub-id pub-id-type="pmcid">PMC11095469</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Tan</surname><given-names>CC</given-names></name><name name-style="western"><surname>Cao</surname><given-names>XP</given-names></name><name name-style="western"><surname>Wei</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Dong</surname><given-names>CW</given-names></name><etal/></person-group><article-title>A gene-environment interplay between omega-3 supplementation and APOE &#949;4 provides insights for Alzheimer&#8217;s disease precise prevention amongst high-genetic-risk population</article-title><source>Eur J Neurol</source><year>2022</year><volume>29</volume><fpage>422</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1111/ene.15160</pub-id><pub-id pub-id-type="pmid">34710256</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Li L, Xu W, Tan CC, Cao XP, Wei BZ, Dong CW, et al. A gene-environment interplay between omega-3 supplementation and APOE &#949;4 provides insights for Alzheimer&#8217;s disease precise prevention amongst high-genetic-risk population. Eur J Neurol. 2022;29:422&#8211;31. 10.1111/ene.15160<pub-id pub-id-type="pmid">34710256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.15160</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mett</surname><given-names>J</given-names></name></person-group><article-title>The impact of medium chain and polyunsaturated &#969;-3-fatty acids on amyloid-&#946; deposition, oxidative stress and metabolic dysfunction associated with Alzheimer&#8217;s disease</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><fpage>1991</fpage><pub-id pub-id-type="doi">10.3390/antiox10121991</pub-id><pub-id pub-id-type="pmid">34943094</pub-id><pub-id pub-id-type="pmcid">PMC8698946</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Mett J. The impact of medium chain and polyunsaturated &#969;-3-fatty acids on amyloid-&#946; deposition, oxidative stress and metabolic dysfunction associated with Alzheimer&#8217;s disease. Antioxidants. 2021;10:1991 10.3390/antiox10121991<pub-id pub-id-type="pmid">34943094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox10121991</pub-id><pub-id pub-id-type="pmcid">PMC8698946</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogie</surname><given-names>JFJ</given-names></name><name name-style="western"><surname>Haidar</surname><given-names>M</given-names></name><name name-style="western"><surname>Kooij</surname><given-names>G</given-names></name><name name-style="western"><surname>Hendriks</surname><given-names>JJA</given-names></name></person-group><article-title>Fatty acid metabolism in the progression and resolution of CNS disorders</article-title><source>Adv Drug Deliv Rev</source><year>2020</year><volume>159</volume><fpage>198</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.01.004</pub-id><pub-id pub-id-type="pmid">31987838</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Bogie JFJ, Haidar M, Kooij G, Hendriks JJA. Fatty acid metabolism in the progression and resolution of CNS disorders. Adv Drug Deliv Rev. 2020;159:198&#8211;213. 10.1016/j.addr.2020.01.004<pub-id pub-id-type="pmid">31987838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2020.01.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butler</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cole</surname><given-names>RM</given-names></name><name name-style="western"><surname>Deems</surname><given-names>NP</given-names></name><name name-style="western"><surname>Belury</surname><given-names>MA</given-names></name><name name-style="western"><surname>Barrientos</surname><given-names>RM</given-names></name></person-group><article-title>Fatty food, fatty acids, and microglial priming in the adult and aged hippocampus and amygdala</article-title><source>Brain Behav Immun</source><year>2020</year><volume>89</volume><fpage>145</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.06.010</pub-id><pub-id pub-id-type="pmid">32544595</pub-id><pub-id pub-id-type="pmcid">PMC7572563</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Butler MJ, Cole RM, Deems NP, Belury MA, Barrientos RM. Fatty food, fatty acids, and microglial priming in the adult and aged hippocampus and amygdala. Brain Behav Immun. 2020;89:145&#8211;58. 10.1016/j.bbi.2020.06.010<pub-id pub-id-type="pmid">32544595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2020.06.010</pub-id><pub-id pub-id-type="pmcid">PMC7572563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakandakari</surname><given-names>S</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>VR</given-names></name><name name-style="western"><surname>Kuga</surname><given-names>GK</given-names></name><name name-style="western"><surname>Gaspar</surname><given-names>RC</given-names></name><name name-style="western"><surname>Sant&#8217;Ana</surname><given-names>MR</given-names></name><name name-style="western"><surname>Pavan</surname><given-names>ICB</given-names></name><etal/></person-group><article-title>Short-term high-fat diet modulates several inflammatory, ER stress, and apoptosis markers in the hippocampus of young mice</article-title><source>Brain Behav Immun</source><year>2019</year><volume>79</volume><fpage>284</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2019.02.016</pub-id><pub-id pub-id-type="pmid">30797044</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Nakandakari S, Mu&#241;oz VR, Kuga GK, Gaspar RC, Sant&#8217;Ana MR, Pavan ICB, et al. Short-term high-fat diet modulates several inflammatory, ER stress, and apoptosis markers in the hippocampus of young mice. Brain Behav Immun. 2019;79:284&#8211;93. 10.1016/j.bbi.2019.02.016<pub-id pub-id-type="pmid">30797044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2019.02.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ord&#243;&#241;ez-Guti&#233;rrez</surname><given-names>L</given-names></name><name name-style="western"><surname>F&#225;brias</surname><given-names>G</given-names></name><name name-style="western"><surname>Casas</surname><given-names>J</given-names></name><name name-style="western"><surname>Wandosell</surname><given-names>F</given-names></name></person-group><article-title>Diets with higher &#969;-6/&#969;-3 ratios show differences in ceramides and fatty acid levels accompanied by increased amyloid-beta in the brains of male APP/PS1 transgenic mice</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>10907</fpage><pub-id pub-id-type="doi">10.3390/ijms222010907</pub-id><pub-id pub-id-type="pmid">34681567</pub-id><pub-id pub-id-type="pmcid">PMC8535881</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ord&#243;&#241;ez-Guti&#233;rrez L, F&#225;brias G, Casas J, Wandosell F. Diets with higher &#969;-6/&#969;-3 ratios show differences in ceramides and fatty acid levels accompanied by increased amyloid-beta in the brains of male APP/PS1 transgenic mice. Int J Mol Sci. 2021;22:10907 10.3390/ijms222010907<pub-id pub-id-type="pmid">34681567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms222010907</pub-id><pub-id pub-id-type="pmcid">PMC8535881</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sudlow</surname><given-names>C</given-names></name><name name-style="western"><surname>Gallacher</surname><given-names>J</given-names></name><name name-style="western"><surname>Allen</surname><given-names>N</given-names></name><name name-style="western"><surname>Beral</surname><given-names>V</given-names></name><name name-style="western"><surname>Burton</surname><given-names>P</given-names></name><name name-style="western"><surname>Danesh</surname><given-names>J</given-names></name><etal/></person-group><article-title>UK biobank: an open access resource for identifying the causes of a wi de range of complex diseases of middle and old age</article-title><source>PLoS Med</source><year>2015</year><volume>12</volume><fpage>e1001779</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1001779</pub-id><pub-id pub-id-type="pmid">25826379</pub-id><pub-id pub-id-type="pmcid">PMC4380465</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wi de range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779 10.1371/journal.pmed.1001779<pub-id pub-id-type="pmid">25826379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1001779</pub-id><pub-id pub-id-type="pmcid">PMC4380465</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>W&#252;rtz</surname><given-names>P</given-names></name><name name-style="western"><surname>Kangas</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Soininen</surname><given-names>P</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>DA</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Ala-Korpela</surname><given-names>M</given-names></name></person-group><article-title>Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies</article-title><source>Am J Epidemiol</source><year>2017</year><volume>186</volume><fpage>1084</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1093/aje/kwx016</pub-id><pub-id pub-id-type="pmid">29106475</pub-id><pub-id pub-id-type="pmcid">PMC5860146</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">W&#252;rtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies. Am J Epidemiol. 2017;186:1084&#8211;96. 10.1093/aje/kwx016<pub-id pub-id-type="pmid">29106475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwx016</pub-id><pub-id pub-id-type="pmcid">PMC5860146</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Fish oil supplementation and risk of dementia among diabetic patients: a prospective study of 16,061 older patients</article-title><source>J Nutr Health Aging</source><year>2024</year><volume>28</volume><fpage>100176</fpage><pub-id pub-id-type="doi">10.1016/j.jnha.2024.100176</pub-id><pub-id pub-id-type="pmid">38341308</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Li Y, Liu X, Zhuang P, Zhang L, Wu Y, Wu S, et al. Fish oil supplementation and risk of dementia among diabetic patients: a prospective study of 16,061 older patients. J Nutr Health Aging. 2024;28:100176 10.1016/j.jnha.2024.100176<pub-id pub-id-type="pmid">38341308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jnha.2024.100176</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Associations of fish oil supplementation with incident dementia: evidence from the UK biobank cohort study</article-title><source>Front Neurosci</source><year>2022</year><volume>16</volume><fpage>910977</fpage><pub-id pub-id-type="doi">10.3389/fnins.2022.910977</pub-id><pub-id pub-id-type="pmid">36161159</pub-id><pub-id pub-id-type="pmcid">PMC9489907</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Huang Y, Deng Y, Zhang P, Lin J, Guo D, Yang L, et al. Associations of fish oil supplementation with incident dementia: evidence from the UK biobank cohort study. Front Neurosci. 2022;16:910977 10.3389/fnins.2022.910977<pub-id pub-id-type="pmid">36161159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2022.910977</pub-id><pub-id pub-id-type="pmcid">PMC9489907</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>HF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Rolls</surname><given-names>ET</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology</article-title><source>EBioMedicine</source><year>2022</year><volume>86</volume><fpage>104336</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104336</pub-id><pub-id pub-id-type="pmid">36356475</pub-id><pub-id pub-id-type="pmcid">PMC9649369</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Wang HF, Zhang W, Rolls ET, Li Y, Wang L, Ma YH, et al. Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology. EBioMedicine. 2022;86:104336 10.1016/j.ebiom.2022.104336<pub-id pub-id-type="pmid">36356475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2022.104336</pub-id><pub-id pub-id-type="pmcid">PMC9649369</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crane</surname><given-names>PK</given-names></name><name name-style="western"><surname>Carle</surname><given-names>A</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>LE</given-names></name><name name-style="western"><surname>Insel</surname><given-names>P</given-names></name><name name-style="western"><surname>Mackin</surname><given-names>RS</given-names></name><name name-style="western"><surname>Gross</surname><given-names>A</given-names></name><etal/></person-group><article-title>Development and assessment of a composite score for memory in the Alzheimer&#8217;s disease neuroimaging initiative (ADNI)</article-title><source>Brain Imaging Behav</source><year>2012</year><volume>6</volume><fpage>502</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s11682-012-9186-z</pub-id><pub-id pub-id-type="pmid">22782295</pub-id><pub-id pub-id-type="pmcid">PMC3806057</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer&#8217;s disease neuroimaging initiative (ADNI). Brain Imaging Behav. 2012;6:502&#8211;16. 10.1007/s11682-012-9186-z<pub-id pub-id-type="pmid">22782295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11682-012-9186-z</pub-id><pub-id pub-id-type="pmcid">PMC3806057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibbons</surname><given-names>LE</given-names></name><name name-style="western"><surname>Carle</surname><given-names>AC</given-names></name><name name-style="western"><surname>Mackin</surname><given-names>RS</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>D</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Insel</surname><given-names>P</given-names></name><etal/></person-group><article-title>A composite score for executive functioning, validated in Alzheimer&#8217;s disease neuroimaging initiative (ADNI) participants with baseline mild cognitive impairment</article-title><source>Brain Imaging Behav</source><year>2012</year><volume>6</volume><fpage>517</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1007/s11682-012-9176-1</pub-id><pub-id pub-id-type="pmid">22644789</pub-id><pub-id pub-id-type="pmcid">PMC3684181</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer&#8217;s disease neuroimaging initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6:517&#8211;27. 10.1007/s11682-012-9176-1<pub-id pub-id-type="pmid">22644789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11682-012-9176-1</pub-id><pub-id pub-id-type="pmcid">PMC3684181</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Bernstein</surname><given-names>MA</given-names></name><name name-style="western"><surname>Fox</surname><given-names>NC</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>G</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>D</given-names></name><etal/></person-group><article-title>The Alzheimer&#8217;s disease neuroimaging initiative (ADNI): MRI methods</article-title><source>J Magn Reson Imaging</source><year>2008</year><volume>27</volume><fpage>685</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1002/jmri.21049</pub-id><pub-id pub-id-type="pmid">18302232</pub-id><pub-id pub-id-type="pmcid">PMC2544629</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer&#8217;s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685&#8211;91. 10.1002/jmri.21049<pub-id pub-id-type="pmid">18302232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.21049</pub-id><pub-id pub-id-type="pmcid">PMC2544629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfaro-Almagro</surname><given-names>F</given-names></name><name name-style="western"><surname>Jenkinson</surname><given-names>M</given-names></name><name name-style="western"><surname>Bangerter</surname><given-names>NK</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>JLR</given-names></name><name name-style="western"><surname>Griffanti</surname><given-names>L</given-names></name><name name-style="western"><surname>Douaud</surname><given-names>G</given-names></name><etal/></person-group><article-title>Image processing and quality control for the first 10,000 brain imaging datasets from UK biobank</article-title><source>Neuroimage</source><year>2018</year><volume>166</volume><fpage>400</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.10.034</pub-id><pub-id pub-id-type="pmid">29079522</pub-id><pub-id pub-id-type="pmcid">PMC5770339</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Alfaro-Almagro F, Jenkinson M, Bangerter NK, Andersson JLR, Griffanti L, Douaud G, et al. Image processing and quality control for the first 10,000 brain imaging datasets from UK biobank. Neuroimage. 2018;166:400&#8211;24. 10.1016/j.neuroimage.2017.10.034<pub-id pub-id-type="pmid">29079522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2017.10.034</pub-id><pub-id pub-id-type="pmcid">PMC5770339</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>LM</given-names></name><name name-style="western"><surname>Vanderstichele</surname><given-names>H</given-names></name><name name-style="western"><surname>Knapik-Czajka</surname><given-names>M</given-names></name><name name-style="western"><surname>Clark</surname><given-names>CM</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid biomarker signature in Alzheimer&#8217;s disease neuroimaging initiative subjects</article-title><source>Ann Neurol</source><year>2009</year><volume>65</volume><fpage>403</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1002/ana.21610</pub-id><pub-id pub-id-type="pmid">19296504</pub-id><pub-id pub-id-type="pmcid">PMC2696350</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#8217;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#8211;13. 10.1002/ana.21610<pub-id pub-id-type="pmid">19296504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.21610</pub-id><pub-id pub-id-type="pmcid">PMC2696350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name><name name-style="western"><surname>Seibyl</surname><given-names>J</given-names></name><name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>T</given-names></name><etal/></person-group><article-title>CSF biomarkers of Alzheimer&#8217;s disease concord with amyloid-&#946; PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts</article-title><source>Alzheimers Dement</source><year>2018</year><volume>14</volume><fpage>1470</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.01.010</pub-id><pub-id pub-id-type="pmid">29499171</pub-id><pub-id pub-id-type="pmcid">PMC6119541</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer&#8217;s disease concord with amyloid-&#946; PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14:1470&#8211;81. 10.1016/j.jalz.2018.01.010<pub-id pub-id-type="pmid">29499171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.01.010</pub-id><pub-id pub-id-type="pmcid">PMC6119541</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>BB</given-names></name><name name-style="western"><surname>Chiou</surname><given-names>J</given-names></name><name name-style="western"><surname>Traylor</surname><given-names>M</given-names></name><name name-style="western"><surname>Benner</surname><given-names>C</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>YH</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Plasma proteomic associations with genetics and health in the UK biobank</article-title><source>Nature</source><year>2023</year><volume>622</volume><fpage>329</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06592-6</pub-id><pub-id pub-id-type="pmid">37794186</pub-id><pub-id pub-id-type="pmcid">PMC10567551</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK biobank. Nature. 2023;622:329&#8211;38. 10.1038/s41586-023-06592-6<pub-id pub-id-type="pmid">37794186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06592-6</pub-id><pub-id pub-id-type="pmcid">PMC10567551</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>M</given-names></name><name name-style="western"><surname>Furtado</surname><given-names>JD</given-names></name><name name-style="western"><surname>DeKosky</surname><given-names>ST</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>AL</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>OL</given-names></name><name name-style="western"><surname>Kuller</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Case-cohort study of plasma phospholipid fatty acid profiles, cognitive function, and risk of dementia: a secondary analysis in the <italic toggle="yes">Ginkgo</italic> evaluation of memory study</article-title><source>Am J Clin Nutr</source><year>2021</year><volume>114</volume><fpage>154</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqab087</pub-id><pub-id pub-id-type="pmid">33880495</pub-id><pub-id pub-id-type="pmcid">PMC8277434</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Koch M, Furtado JD, DeKosky ST, Fitzpatrick AL, Lopez OL, Kuller LH, et al. Case-cohort study of plasma phospholipid fatty acid profiles, cognitive function, and risk of dementia: a secondary analysis in the <italic toggle="yes">Ginkgo</italic> evaluation of memory study. Am J Clin Nutr. 2021;114:154&#8211;62. 10.1093/ajcn/nqab087<pub-id pub-id-type="pmid">33880495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcn/nqab087</pub-id><pub-id pub-id-type="pmcid">PMC8277434</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Power</surname><given-names>R</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Prado-Cabrero</surname><given-names>A</given-names></name><name name-style="western"><surname>Roche</surname><given-names>W</given-names></name><name name-style="western"><surname>Coen</surname><given-names>R</given-names></name><name name-style="western"><surname>Power</surname><given-names>T</given-names></name><etal/></person-group><article-title>Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: a randomised clinical trial</article-title><source>Clin Nutr</source><year>2022</year><volume>41</volume><fpage>405</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2021.12.004</pub-id><pub-id pub-id-type="pmid">34999335</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Power R, Nolan JM, Prado-Cabrero A, Roche W, Coen R, Power T, et al. Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: a randomised clinical trial. Clin Nutr. 2022;41:405&#8211;14. 10.1016/j.clnu.2021.12.004<pub-id pub-id-type="pmid">34999335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clnu.2021.12.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heude</surname><given-names>B</given-names></name><name name-style="western"><surname>Ducimeti&#232;re</surname><given-names>P</given-names></name><name name-style="western"><surname>Berr</surname><given-names>C</given-names></name></person-group><article-title>Cognitive decline and fatty acid composition of erythrocyte membranes&#8211;the EVA study</article-title><source>Am J Clin Nutr</source><year>2003</year><volume>77</volume><fpage>803</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/ajcn/77.4.803</pub-id><pub-id pub-id-type="pmid">12663275</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Heude B, Ducimeti&#232;re P, Berr C. Cognitive decline and fatty acid composition of erythrocyte membranes&#8211;the EVA study. Am J Clin Nutr. 2003;77:803&#8211;8. 10.1093/ajcn/77.4.803<pub-id pub-id-type="pmid">12663275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcn/77.4.803</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lay&#233;</surname><given-names>S</given-names></name><name name-style="western"><surname>Nadjar</surname><given-names>A</given-names></name><name name-style="western"><surname>Joffre</surname><given-names>C</given-names></name><name name-style="western"><surname>Bazinet</surname><given-names>RP</given-names></name></person-group><article-title>Anti-inflammatory effects of omega-3 fatty acids in the brain: physiological mechanisms and relevance to pharmacology</article-title><source>Pharmacol Rev</source><year>2018</year><volume>70</volume><fpage>12</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1124/pr.117.014092</pub-id><pub-id pub-id-type="pmid">29217656</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Lay&#233; S, Nadjar A, Joffre C, Bazinet RP. Anti-inflammatory effects of omega-3 fatty acids in the brain: physiological mechanisms and relevance to pharmacology. Pharmacol Rev. 2018;70:12&#8211;38. 10.1124/pr.117.014092<pub-id pub-id-type="pmid">29217656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/pr.117.014092</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peineau</surname><given-names>S</given-names></name><name name-style="western"><surname>Rabiant</surname><given-names>K</given-names></name><name name-style="western"><surname>Pierrefiche</surname><given-names>O</given-names></name><name name-style="western"><surname>Potier</surname><given-names>B</given-names></name></person-group><article-title>Synaptic plasticity modulation by circulating peptides and metaplasticity: involvement in Alzheimer&#8217;s disease</article-title><source>Pharmacol Res</source><year>2018</year><volume>130</volume><fpage>385</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.01.018</pub-id><pub-id pub-id-type="pmid">29425728</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Peineau S, Rabiant K, Pierrefiche O, Potier B. Synaptic plasticity modulation by circulating peptides and metaplasticity: involvement in Alzheimer&#8217;s disease. Pharmacol Res. 2018;130:385&#8211;401. 10.1016/j.phrs.2018.01.018<pub-id pub-id-type="pmid">29425728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2018.01.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Connolly</surname><given-names>K</given-names></name><name name-style="western"><surname>Lehoux</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Rourke</surname><given-names>R</given-names></name><name name-style="western"><surname>Assetta</surname><given-names>B</given-names></name><name name-style="western"><surname>Erdemir</surname><given-names>GA</given-names></name><name name-style="western"><surname>Elias</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Potential role of chitinase-3-like protein 1 (CHI3L1/YKL-40) in neurodegeneration and Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><year>2023</year><volume>19</volume><fpage>9</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1002/alz.12612</pub-id><pub-id pub-id-type="pmid">35234337</pub-id><pub-id pub-id-type="pmcid">PMC9437141</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Connolly K, Lehoux M, O&#8217;Rourke R, Assetta B, Erdemir GA, Elias JA, et al. Potential role of chitinase-3-like protein 1 (CHI3L1/YKL-40) in neurodegeneration and Alzheimer&#8217;s disease. Alzheimers Dement. 2023;19:9&#8211;24. 10.1002/alz.12612<pub-id pub-id-type="pmid">35234337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12612</pub-id><pub-id pub-id-type="pmcid">PMC9437141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahangari</surname><given-names>F</given-names></name><name name-style="western"><surname>Sood</surname><given-names>A</given-names></name><name name-style="western"><surname>Ma</surname><given-names>B</given-names></name><name name-style="western"><surname>Takyar</surname><given-names>S</given-names></name><name name-style="western"><surname>Schuyler</surname><given-names>M</given-names></name><name name-style="western"><surname>Qualls</surname><given-names>C</given-names></name><etal/></person-group><article-title>Chitinase 3-like-1 regulates both visceral fat accumulation and asthma-like Th2 inflammation</article-title><source>Am J Respir Crit Care Med</source><year>2015</year><volume>191</volume><fpage>746</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1164/rccm.201405-0796OC</pub-id><pub-id pub-id-type="pmid">25629580</pub-id><pub-id pub-id-type="pmcid">PMC4407482</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ahangari F, Sood A, Ma B, Takyar S, Schuyler M, Qualls C, et al. Chitinase 3-like-1 regulates both visceral fat accumulation and asthma-like Th2 inflammation. Am J Respir Crit Care Med. 2015;191:746&#8211;57. 10.1164/rccm.201405-0796OC<pub-id pub-id-type="pmid">25629580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201405-0796OC</pub-id><pub-id pub-id-type="pmcid">PMC4407482</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>KH</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>D</given-names></name></person-group><article-title>Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>16683</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1074/jbc.M011695200</pub-id><pub-id pub-id-type="pmid">11278967</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001;276:16683&#8211;9. 10.1074/jbc.M011695200<pub-id pub-id-type="pmid">11278967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M011695200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>H</given-names></name><name name-style="western"><surname>Kokoeva</surname><given-names>MV</given-names></name><name name-style="western"><surname>Inouye</surname><given-names>K</given-names></name><name name-style="western"><surname>Tzameli</surname><given-names>I</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name><name name-style="western"><surname>Flier</surname><given-names>JS</given-names></name></person-group><article-title>TLR4 links innate immunity and fatty acid-induced insulin resistance</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>3015</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1172/jci28898</pub-id><pub-id pub-id-type="pmid">17053832</pub-id><pub-id pub-id-type="pmcid">PMC1616196</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015&#8211;25. 10.1172/jci28898<pub-id pub-id-type="pmid">17053832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI28898</pub-id><pub-id pub-id-type="pmcid">PMC1616196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vesga-Jim&#233;nez</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name><name name-style="western"><surname>Barreto</surname><given-names>GE</given-names></name><name name-style="western"><surname>Aristiz&#225;bal-Pach&#243;n</surname><given-names>AF</given-names></name><name name-style="western"><surname>Pinz&#243;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>J</given-names></name></person-group><article-title>Fatty acids: an insight into the pathogenesis of neurodegenerative diseases and therapeutic potential</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><fpage>2577</fpage><pub-id pub-id-type="doi">10.3390/ijms23052577</pub-id><pub-id pub-id-type="pmid">35269720</pub-id><pub-id pub-id-type="pmcid">PMC8910658</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Vesga-Jim&#233;nez DJ, Martin C, Barreto GE, Aristiz&#225;bal-Pach&#243;n AF, Pinz&#243;n A, Gonz&#225;lez J. Fatty acids: an insight into the pathogenesis of neurodegenerative diseases and therapeutic potential. Int J Mol Sci. 2022;23:2577 10.3390/ijms23052577<pub-id pub-id-type="pmid">35269720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23052577</pub-id><pub-id pub-id-type="pmcid">PMC8910658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>JE</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Han</surname><given-names>SB</given-names></name><name name-style="western"><surname>Yun</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B</given-names></name><name name-style="western"><surname>Yong</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer</article-title><source>Exp Mol Med</source><year>2024</year><volume>56</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/s12276-023-01131-9</pub-id><pub-id pub-id-type="pmid">38177294</pub-id><pub-id pub-id-type="pmcid">PMC10834487</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Yu JE, Yeo IJ, Han SB, Yun J, Kim B, Yong YJ, et al. Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer. Exp Mol Med. 2024;56:1&#8211;18. 10.1038/s12276-023-01131-9<pub-id pub-id-type="pmid">38177294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-023-01131-9</pub-id><pub-id pub-id-type="pmcid">PMC10834487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>XZ</given-names></name><name name-style="western"><surname>Powis</surname><given-names>SH</given-names></name><name name-style="western"><surname>Fernando</surname><given-names>R</given-names></name><name name-style="western"><surname>Mon</surname><given-names>WY</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>DC</given-names></name><etal/></person-group><article-title>EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism</article-title><source>Kidney Int</source><year>2005</year><volume>67</volume><fpage>867</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00151.x</pub-id><pub-id pub-id-type="pmid">15698426</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Li H, Ruan XZ, Powis SH, Fernando R, Mon WY, Wheeler DC, et al. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism. Kidney Int. 2005;67:867&#8211;74. 10.1111/j.1523-1755.2005.00151.x<pub-id pub-id-type="pmid">15698426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1523-1755.2005.00151.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoo</surname><given-names>NKH</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>SR</given-names></name><name name-style="western"><surname>Schopfer</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>BA</given-names></name></person-group><article-title>Electrophilic fatty acid nitroalkenes regulate Nrf2 and NF-&#954;B signaling: a medicinal chemistry investigation of structure-function relationships</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>2295</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-20460-8</pub-id><pub-id pub-id-type="pmid">29396403</pub-id><pub-id pub-id-type="pmcid">PMC5797128</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Khoo NKH, Li L, Salvatore SR, Schopfer FJ, Freeman BA. Electrophilic fatty acid nitroalkenes regulate Nrf2 and NF-&#954;B signaling: a medicinal chemistry investigation of structure-function relationships. Sci Rep. 2018;8:2295 10.1038/s41598-018-20460-8<pub-id pub-id-type="pmid">29396403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-20460-8</pub-id><pub-id pub-id-type="pmcid">PMC5797128</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#252;bner</surname><given-names>K</given-names></name><name name-style="western"><surname>Karwelat</surname><given-names>D</given-names></name><name name-style="western"><surname>Pietsch</surname><given-names>E</given-names></name><name name-style="western"><surname>Beinborn</surname><given-names>I</given-names></name><name name-style="western"><surname>Winterberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Bedenbender</surname><given-names>K</given-names></name><etal/></person-group><article-title>NF-&#954;B-mediated inhibition of microRNA-149-5p regulates Chitinase-3-like 1 expression in human airway epithelial cells</article-title><source>Cell Signal</source><year>2020</year><volume>67</volume><fpage>109498</fpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2019.109498</pub-id><pub-id pub-id-type="pmid">31837465</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">H&#252;bner K, Karwelat D, Pietsch E, Beinborn I, Winterberg S, Bedenbender K, et al. NF-&#954;B-mediated inhibition of microRNA-149-5p regulates Chitinase-3-like 1 expression in human airway epithelial cells. Cell Signal. 2020;67:109498 10.1016/j.cellsig.2019.109498<pub-id pub-id-type="pmid">31837465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellsig.2019.109498</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rochette</surname><given-names>L</given-names></name><name name-style="western"><surname>Dogon</surname><given-names>G</given-names></name><name name-style="western"><surname>Zeller</surname><given-names>M</given-names></name><name name-style="western"><surname>Cottin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Vergely</surname><given-names>C</given-names></name></person-group><article-title>GDF15 and cardiac cells: current concepts and new insights</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>8889</fpage><pub-id pub-id-type="doi">10.3390/ijms22168889</pub-id><pub-id pub-id-type="pmid">34445593</pub-id><pub-id pub-id-type="pmcid">PMC8396208</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Rochette L, Dogon G, Zeller M, Cottin Y, Vergely C. GDF15 and cardiac cells: current concepts and new insights. Int J Mol Sci. 2021;22:8889 10.3390/ijms22168889<pub-id pub-id-type="pmid">34445593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22168889</pub-id><pub-id pub-id-type="pmcid">PMC8396208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#8217;Homme</surname><given-names>L</given-names></name><name name-style="western"><surname>Sermikli</surname><given-names>BP</given-names></name><name name-style="western"><surname>Staels</surname><given-names>B</given-names></name><name name-style="western"><surname>Piette</surname><given-names>J</given-names></name><name name-style="western"><surname>Legrand-Poels</surname><given-names>S</given-names></name><name name-style="western"><surname>Dombrowicz</surname><given-names>D</given-names></name></person-group><article-title>Saturated fatty acids promote GDF15 expression in human macrophages through the PERK/eIF2/CHOP signaling pathway</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><fpage>3771</fpage><pub-id pub-id-type="doi">10.3390/nu12123771</pub-id><pub-id pub-id-type="pmid">33302552</pub-id><pub-id pub-id-type="pmcid">PMC7764024</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">L&#8217;Homme L, Sermikli BP, Staels B, Piette J, Legrand-Poels S, Dombrowicz D. Saturated fatty acids promote GDF15 expression in human macrophages through the PERK/eIF2/CHOP signaling pathway. Nutrients. 2020;12:3771 10.3390/nu12123771<pub-id pub-id-type="pmid">33302552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu12123771</pub-id><pub-id pub-id-type="pmcid">PMC7764024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratnam</surname><given-names>NM</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Talbert</surname><given-names>EE</given-names></name><name name-style="western"><surname>Ladner</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Rajasekera</surname><given-names>PV</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>CR</given-names></name><etal/></person-group><article-title>NF-&#954;B regulates GDF-15 to suppress macrophage surveillance during early tumor development</article-title><source>J Clin Invest</source><year>2017</year><volume>127</volume><fpage>3796</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1172/jci91561</pub-id><pub-id pub-id-type="pmid">28891811</pub-id><pub-id pub-id-type="pmcid">PMC5617672</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Ratnam NM, Peterson JM, Talbert EE, Ladner KJ, Rajasekera PV, Schmidt CR, et al. NF-&#954;B regulates GDF-15 to suppress macrophage surveillance during early tumor development. J Clin Invest. 2017;127:3796&#8211;809. 10.1172/jci91561<pub-id pub-id-type="pmid">28891811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI91561</pub-id><pub-id pub-id-type="pmcid">PMC5617672</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Padkj&#230;r</surname><given-names>SB</given-names></name><etal/></person-group><article-title>GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand</article-title><source>Nat Med</source><year>2017</year><volume>23</volume><fpage>1158</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/nm.4394</pub-id><pub-id pub-id-type="pmid">28846099</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Yang L, Chang CC, Sun Z, Madsen D, Zhu H, Padkj&#230;r SB, et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med. 2017;23:1158&#8211;66. 10.1038/nm.4394<pub-id pub-id-type="pmid">28846099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.4394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>GW</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>CC</given-names></name><name name-style="western"><surname>Peng</surname><given-names>YM</given-names></name><name name-style="western"><surname>Vieira Braga</surname><given-names>FA</given-names></name><name name-style="western"><surname>Kragten</surname><given-names>NA</given-names></name><name name-style="western"><surname>Remmerswaal</surname><given-names>EB</given-names></name><etal/></person-group><article-title>The adhesion g protein-coupled receptor GPR56/ADGRG1 is an inhibitory receptor on human NK cells</article-title><source>Cell Rep</source><year>2016</year><volume>15</volume><fpage>1757</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.053</pub-id><pub-id pub-id-type="pmid">27184850</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Chang GW, Hsiao CC, Peng YM, Vieira Braga FA, Kragten NA, Remmerswaal EB, et al. The adhesion g protein-coupled receptor GPR56/ADGRG1 is an inhibitory receptor on human NK cells. Cell Rep. 2016;15:1757&#8211;70. 10.1016/j.celrep.2016.04.053<pub-id pub-id-type="pmid">27184850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2016.04.053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaczmarek</surname><given-names>I</given-names></name><name name-style="western"><surname>Such&#253;</surname><given-names>T</given-names></name><name name-style="western"><surname>Pr&#246;mel</surname><given-names>S</given-names></name><name name-style="western"><surname>Sch&#246;neberg</surname><given-names>T</given-names></name><name name-style="western"><surname>Liebscher</surname><given-names>I</given-names></name><name name-style="western"><surname>Thor</surname><given-names>D</given-names></name></person-group><article-title>The relevance of adhesion G protein-coupled receptors in metabolic functions</article-title><source>Biol Chem</source><year>2022</year><volume>403</volume><fpage>195</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1515/hsz-2021-0146</pub-id><pub-id pub-id-type="pmid">34218541</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Kaczmarek I, Such&#253; T, Pr&#246;mel S, Sch&#246;neberg T, Liebscher I, Thor D. The relevance of adhesion G protein-coupled receptors in metabolic functions. Biol Chem. 2022;403:195&#8211;209. 10.1515/hsz-2021-0146<pub-id pub-id-type="pmid">34218541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/hsz-2021-0146</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liessmann</surname><given-names>F</given-names></name><name name-style="western"><surname>von Bredow</surname><given-names>L</given-names></name><name name-style="western"><surname>Meiler</surname><given-names>J</given-names></name><name name-style="western"><surname>Liebscher</surname><given-names>I</given-names></name></person-group><article-title>Targeting adhesion G protein-coupled receptors. Current status and future perspectives</article-title><source>Structure</source><year>2024</year><volume>32</volume><fpage>2188</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.str.2024.10.022</pub-id><pub-id pub-id-type="pmid">39520987</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Liessmann F, von Bredow L, Meiler J, Liebscher I. Targeting adhesion G protein-coupled receptors. Current status and future perspectives. Structure. 2024;32:2188&#8211;205. 10.1016/j.str.2024.10.022<pub-id pub-id-type="pmid">39520987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.str.2024.10.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cai</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lo</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>GPR56 promotes diabetic kidney disease through eNOS regulation in glomerular endothelial cells</article-title><source>Diabetes</source><year>2023</year><volume>72</volume><fpage>1652</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.2337/db23-0124</pub-id><pub-id pub-id-type="pmid">37579299</pub-id><pub-id pub-id-type="pmcid">PMC10588296</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Wu J, Wang Z, Cai M, Wang X, Lo B, Li Q, et al. GPR56 promotes diabetic kidney disease through eNOS regulation in glomerular endothelial cells. Diabetes. 2023;72:1652&#8211;63. 10.2337/db23-0124<pub-id pub-id-type="pmid">37579299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db23-0124</pub-id><pub-id pub-id-type="pmcid">PMC10588296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>Natural killer cells in aging and age-related diseases</article-title><source>Neurobiol Dis</source><year>2023</year><volume>183</volume><fpage>106156</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2023.106156</pub-id><pub-id pub-id-type="pmid">37209924</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Qi C, Liu Q. Natural killer cells in aging and age-related diseases. Neurobiol Dis. 2023;183:106156 10.1016/j.nbd.2023.106156<pub-id pub-id-type="pmid">37209924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2023.106156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group><article-title>High-fat diet consumption promotes adolescent neurobehavioral abnormalities and hippocampal structural alterations via microglial overactivation accompanied by an elevated serum free fatty acid concentration</article-title><source>Brain Behav Immun</source><year>2024</year><volume>119</volume><fpage>236</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2024.04.005</pub-id><pub-id pub-id-type="pmid">38604269</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Yao X, Yang C, Jia X, Yu Z, Wang C, Zhao J, et al. High-fat diet consumption promotes adolescent neurobehavioral abnormalities and hippocampal structural alterations via microglial overactivation accompanied by an elevated serum free fatty acid concentration. Brain Behav Immun. 2024;119:236&#8211;50. 10.1016/j.bbi.2024.04.005<pub-id pub-id-type="pmid">38604269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2024.04.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Xun</surname><given-names>P</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>JD</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>KM</given-names></name><name name-style="western"><surname>Espeland</surname><given-names>MA</given-names></name><name name-style="western"><surname>Whitsel</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Erythrocyte omega-3 index, ambient fine particle exposure, and brain aging</article-title><source>Neurology</source><year>2020</year><volume>95</volume><fpage>e995</fpage><lpage>e1007</lpage><pub-id pub-id-type="doi">10.1212/wnl.0000000000010074</pub-id><pub-id pub-id-type="pmid">32669395</pub-id><pub-id pub-id-type="pmcid">PMC7668549</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Chen C, Xun P, Kaufman JD, Hayden KM, Espeland MA, Whitsel EA, et al. Erythrocyte omega-3 index, ambient fine particle exposure, and brain aging. Neurology. 2020;95:e995&#8211;e1007. 10.1212/wnl.0000000000010074<pub-id pub-id-type="pmid">32669395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000010074</pub-id><pub-id pub-id-type="pmcid">PMC7668549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crupi</surname><given-names>R</given-names></name><name name-style="western"><surname>Marino</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuzzocrea</surname><given-names>S</given-names></name></person-group><article-title>n-3 fatty acids: role in neurogenesis and neuroplasticity</article-title><source>Curr Med Chem</source><year>2013</year><volume>20</volume><fpage>2953</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.2174/09298673113209990140</pub-id><pub-id pub-id-type="pmid">23746276</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Crupi R, Marino A, Cuzzocrea S. n-3 fatty acids: role in neurogenesis and neuroplasticity. Curr Med Chem. 2013;20:2953&#8211;63. 10.2174/09298673113209990140<pub-id pub-id-type="pmid">23746276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/09298673113209990140</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Rojas</surname><given-names>J</given-names></name><name name-style="western"><surname>Kreutz</surname><given-names>MR</given-names></name></person-group><article-title>Mature granule cells of the dentate gyrus&#8211;passive bystanders or principal performers in hippocampal function?</article-title><source>Neurosci Biobehav Rev</source><year>2016</year><volume>64</volume><fpage>167</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.02.021</pub-id><pub-id pub-id-type="pmid">26949226</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Lopez-Rojas J, Kreutz MR. Mature granule cells of the dentate gyrus&#8211;passive bystanders or principal performers in hippocampal function? Neurosci Biobehav Rev. 2016;64:167&#8211;74. 10.1016/j.neubiorev.2016.02.021<pub-id pub-id-type="pmid">26949226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2016.02.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>YS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HY</given-names></name><name name-style="western"><surname>Huang</surname><given-names>DF</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>PF</given-names></name><name name-style="western"><surname>Lin</surname><given-names>MY</given-names></name><name name-style="western"><surname>Chou</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Neuronal splicing regulator RBFOX3 (NeuN) regulates adult hippocampal neurogenesis and synaptogenesis</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><fpage>e0164164</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0164164</pub-id><pub-id pub-id-type="pmid">27701470</pub-id><pub-id pub-id-type="pmcid">PMC5049801</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Lin YS, Wang HY, Huang DF, Hsieh PF, Lin MY, Chou CH, et al. Neuronal splicing regulator RBFOX3 (NeuN) regulates adult hippocampal neurogenesis and synaptogenesis. PLoS ONE. 2016;11:e0164164 10.1371/journal.pone.0164164<pub-id pub-id-type="pmid">27701470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0164164</pub-id><pub-id pub-id-type="pmcid">PMC5049801</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacko</surname><given-names>M</given-names></name><name name-style="western"><surname>Weyn-Vanhentenryck</surname><given-names>SM</given-names></name><name name-style="western"><surname>Smerdon</surname><given-names>JW</given-names></name><name name-style="western"><surname>Yan</surname><given-names>R</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Rbfox splicing factors promote neuronal maturation and axon initial segment assembly</article-title><source>Neuron</source><year>2018</year><volume>97</volume><fpage>853</fpage><lpage>68.e856</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.01.020</pub-id><pub-id pub-id-type="pmid">29398366</pub-id><pub-id pub-id-type="pmcid">PMC5823762</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Jacko M, Weyn-Vanhentenryck SM, Smerdon JW, Yan R, Feng H, Williams DJ, et al. Rbfox splicing factors promote neuronal maturation and axon initial segment assembly. Neuron. 2018;97:853&#8211;68.e856 10.1016/j.neuron.2018.01.020<pub-id pub-id-type="pmid">29398366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2018.01.020</pub-id><pub-id pub-id-type="pmcid">PMC5823762</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>TL</given-names></name><name name-style="western"><surname>Zandi</surname><given-names>PP</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>KL</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kuller</surname><given-names>LH</given-names></name><name name-style="western"><surname>Fried</surname><given-names>LP</given-names></name><etal/></person-group><article-title>Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>1409</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000183148.34197.2e</pub-id><pub-id pub-id-type="pmid">16275829</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology. 2005;65:1409&#8211;14. 10.1212/01.wnl.0000183148.34197.2e<pub-id pub-id-type="pmid">16275829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000183148.34197.2e</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daiello</surname><given-names>LA</given-names></name><name name-style="western"><surname>Gongvatana</surname><given-names>A</given-names></name><name name-style="western"><surname>Dunsiger</surname><given-names>S</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>RA</given-names></name><name name-style="western"><surname>Ott</surname><given-names>BR</given-names></name></person-group><article-title>Association of fish oil supplement use with preservation of brain volume and cognitive function</article-title><source>Alzheimers Dement</source><year>2015</year><volume>11</volume><fpage>226</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2014.02.005</pub-id><pub-id pub-id-type="pmid">24954371</pub-id><pub-id pub-id-type="pmcid">PMC4829435</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Daiello LA, Gongvatana A, Dunsiger S, Cohen RA, Ott BR. Association of fish oil supplement use with preservation of brain volume and cognitive function. Alzheimers Dement. 2015;11:226&#8211;35. 10.1016/j.jalz.2014.02.005<pub-id pub-id-type="pmid">24954371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.02.005</pub-id><pub-id pub-id-type="pmcid">PMC4829435</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desale</surname><given-names>SE</given-names></name><name name-style="western"><surname>Chinnathambi</surname><given-names>S</given-names></name></person-group><article-title>Role of dietary fatty acids in microglial polarization in Alzheimer&#8217;s disease</article-title><source>J Neuroinflammation</source><year>2020</year><volume>17</volume><fpage>93</fpage><pub-id pub-id-type="doi">10.1186/s12974-020-01742-3</pub-id><pub-id pub-id-type="pmid">32209097</pub-id><pub-id pub-id-type="pmcid">PMC7093977</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Desale SE, Chinnathambi S. Role of dietary fatty acids in microglial polarization in Alzheimer&#8217;s disease. J Neuroinflammation. 2020;17:93 10.1186/s12974-020-01742-3<pub-id pub-id-type="pmid">32209097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-020-01742-3</pub-id><pub-id pub-id-type="pmcid">PMC7093977</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parhizkar</surname><given-names>S</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><article-title>APOE mediated neuroinflammation and neurodegeneration in Alzheimer&#8217;s disease</article-title><source>Semin Immunol</source><year>2022</year><volume>59</volume><fpage>101594</fpage><pub-id pub-id-type="doi">10.1016/j.smim.2022.101594</pub-id><pub-id pub-id-type="pmid">35232622</pub-id><pub-id pub-id-type="pmcid">PMC9411266</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Parhizkar S, Holtzman DM. APOE mediated neuroinflammation and neurodegeneration in Alzheimer&#8217;s disease. Semin Immunol. 2022;59:101594 10.1016/j.smim.2022.101594<pub-id pub-id-type="pmid">35232622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smim.2022.101594</pub-id><pub-id pub-id-type="pmcid">PMC9411266</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12500692</article-id><article-id pub-id-type="pmcid-ver">PMC12500692.1</article-id><article-id pub-id-type="pmcaid">12500692</article-id><article-id pub-id-type="pmcaiid">12500692</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1681095</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Association of salivary lactoferrin, <italic toggle="yes">Porphyromoras gingivalis</italic> and stress hormone levels in patients with periodontitis: a pilot study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Antequera</surname><given-names initials="D">Desire&#233;</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Buetas</surname><given-names initials="E">Elena</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2611243/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garc&#237;a-Esteban</surname><given-names initials="S">Sandra</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Romualdi</surname><given-names initials="D">Deborah</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carrero</surname><given-names initials="L">Laura</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Municio</surname><given-names initials="C">Cristina</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3176649/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mira</surname><given-names initials="A">Alex</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Carro</surname><given-names initials="E">Eva</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2480246/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Neurobiology of Alzheimer&#8217;s DIsease Unit, Chronic Diseases Department-UFIEC, Instituto de Salud Carlos III</institution>, <addr-line>Madrid</addr-line>,&#160;<country>Spain</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>CIBER for Biomedical Research in Neurodegenerative Diseases (CIBERNED), ISCIII</institution>,&#160;<addr-line>Madrid</addr-line>,&#160;<country>Spain</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Genomics &amp; Health Department, FISABIO Foundation</institution>, <addr-line>Valencia</addr-line>,&#160;<country>Spain</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Programa de Doctorado en Ciencias Biom&#233;dicas y Salud P&#250;blica, IMIENS, Universidad Nacional de Educaci&#243;n a Distancia (UNED)</institution>,&#160;<addr-line>Madrid</addr-line>,&#160;<country>Spain</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>CIBER Center for Epidemiology and Public Health (CIBERESP), ISCIII</institution>,&#160;<addr-line>Madrid</addr-line>,&#160;<country>Spain</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/486861/overview" ext-link-type="uri">Francisco Jose Roig</ext-link>, Universidad San Jorge, Spain</p></fn><fn fn-type="edited-by"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1984078/overview" ext-link-type="uri">Anbo Dong</ext-link>, King&#8217;s College London, United Kingdom</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3163986/overview" ext-link-type="uri">Sareen Duseja</ext-link>, Narsinhbhai Patel Dental College &amp; Hospital, India</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3165512/overview" ext-link-type="uri">Zureya Fontes</ext-link>, Universidad Autonoma de Baja California Facultad de Odontologia Mexicali, Mexico</p></fn><corresp id="fn001">*Correspondence: Eva Carro, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:eva.carro@isciii.es">eva.carro@isciii.es</email></corresp><fn fn-type="other" id="fn003"><p>&#8224;ORCID: Eva Carro, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-6504-4579">orcid.org/0000-0002-6504-4579</uri>
</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480569</issue-id><elocation-id>1681095</elocation-id><history><date date-type="received"><day>06</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Antequera, Buetas, Garc&#237;a-Esteban, Romualdi, Carrero, Municio, Mira and Carro.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Antequera, Buetas, Garc&#237;a-Esteban, Romualdi, Carrero, Municio, Mira and Carro</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-16-1681095.pdf"/><abstract><sec><title>Background</title><p>Periodontitis is a prevalent inflammatory disease characterized by a dysbiotic oral microbiome, particularly involving <italic toggle="yes">Porphyromonas gingivalis</italic> (<italic toggle="yes">P. gingivalis</italic>) as a key periodontal pathogen. This disorder has also systemic implications, including links to neurodegenerative diseases such as Alzheimer&#8217;s disease (AD). Lactoferrin, an iron-binding glycoprotein involved in innate immunity, is found in elevated levels in inflammatory conditions, including periodontitis, and reduced in AD, likely due to hypothalamic-salivary gland axis dysfunction. Additionally, stress-related dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis may contribute to periodontal disease by altering immune responses, notably via elevated salivary cortisol and DHEA levels. The purpose of this study was to evaluate the relationship between salivary immune and stress biomarkers (lactoferrin, cortisol, DHEA) and the abundance of <italic toggle="yes">P. gingivalis</italic> with clinical periodontal parameters.</p></sec><sec><title>Methods</title><p>A cohort of patients with and without a history of periodontitis was analyzed. Salivary and subgingival biofilm samples were collected to detect <italic toggle="yes">P. gingivalis</italic> levels using 16S rRNA gene sequencing and to quantify salivary biomarker concentrations by ELISA. Common clinical periodontal parameters, including periodontal pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BoP), and plaque index (PI) were recorded.</p></sec><sec><title>Results</title><p>Patients with a history of periodontitis showed significantly higher salivary lactoferrin, cortisol and DHEA levels compared to controls, along with increased <italic toggle="yes">P. gingivalis</italic> abundance. Strong correlations were observed between <italic toggle="yes">P. gingivalis</italic> levels and the salivary markers: lactoferrin, cortisol and DHEA. Moreover, lactoferrin, DHEA and cortisol also positively correlated with disease severity, based on the clinical periodontal parameters BoP PPD, CAL, and PI. Similarly, salivary and subgingival <italic toggle="yes">P. gingivalis</italic> positively correlated with BoP, but, specifically, subgingival <italic toggle="yes">P. gingivalis</italic> also correlated with PPD, CAL, and PI.</p></sec><sec><title>Discussion</title><p>Our findings suggest that elevated lactoferrin, DHEA and cortisol levels reflect both immune-inflammatory and stress-mediated pathways in periodontitis, and its association with the abundance of <italic toggle="yes">P. gingivalis</italic> in saliva and subgingival area. This study supports immune and hormonal dysregulation in periodontal patients, with potential implications in systemic diseases, including such as AD, where lactoferrin levels are seriously altered.</p></sec></abstract><kwd-group><kwd>lactoferrin</kwd><kwd>cortisol</kwd><kwd>DHEA</kwd><kwd>porphyromonas gingivalis</kwd><kwd>periodontal disease</kwd><kwd>saliva</kwd><kwd>immune response</kwd><kwd>oral dysbiosis</kwd></kwd-group><funding-group><funding-statement>The authors declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by Grants from Instituto de Salud Carlos III (PI22CIII/00042), CIBERNED (CB07/502, PI2021/03), the Spanish Ministry of Science and Innovation (PID2022-139195OB-I00), and the European Union (GA-101071485). EB is supported by a grant from the Spanish Ministry of Science and Innovation with the reference PRE2019-088126.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="2"/><equation-count count="0"/><ref-count count="64"/><page-count count="13"/><word-count count="5428"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Microbial Immunology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Periodontitis, the most common oral disease in the adult population, is a dysbiotic inflammatory disease. Periodontitis can be classified as aggressive form, with early onset and rapid progression, affecting 8%, or a chronic form, affecting approximately 40% of the adult population (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). In patients with periodontitis, periodontal bacteria, their toxic products, and the locally produced proinflammatory mediators can enter the bloodstream (<xref rid="B3" ref-type="bibr">3</xref>), facilitating a potential interaction with other diseases including neurodegenerative diseases (<xref rid="B4" ref-type="bibr">4</xref>). The meta-analysis of epidemiological studies showed that subjects with periodontitis have a 1.7 times higher risk of suffering from Alzheimer&#8217;s dementia than periodontally healthy individuals.</p><p>Periodontitis is a multifactorial disease of polymicrobial origin, however, <italic toggle="yes">Porphyromonas gingivalis</italic> (<italic toggle="yes">P. gingivalis</italic>), a Gram-negative oral anaerobe, is considered a major, keystone periodontal pathogen (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). <italic toggle="yes">P. gingivalis</italic> can locally invade periodontal tissues using a panel of virulence factors that cause deregulation of the innate immune and inflammatory responses (<xref rid="B7" ref-type="bibr">7</xref>). Several studies have demonstrated correlation of subgingival and salivary levels of <italic toggle="yes">P. gingivalis</italic> in patients with periodontitis (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). Lactoferrin, an iron-binding glycoprotein, is one of the main antimicrobial proteins identified in saliva, representing the most important factor of natural immunity (<xref rid="B10" ref-type="bibr">10</xref>). Lactoferrin has been studied in relation to periodontal disease, and higher concentrations of salivary lactoferrin have been shown in patients with periodontitis (<xref rid="B11" ref-type="bibr">11</xref>&#8211;<xref rid="B13" ref-type="bibr">13</xref>). In such periodontal imbalance, lactoferrin could be released from recruited neutrophils as a potential host defense factor against oral bacteria, as previously suggested (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Moreover, salivary lactoferrin has been reported as a biomarker of cerebral vulnerability in physiological aging (<xref rid="B16" ref-type="bibr">16</xref>) and Alzheimer&#8217;s disease (AD) (<xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B19" ref-type="bibr">19</xref>). Lactoferrin concentration in saliva derives from the secretion of the salivary glands, predominantly from submandibular glands (<xref rid="B20" ref-type="bibr">20</xref>). Such secretion depends on the autonomic nervous system control and is connected with the hypothalamus (<xref rid="B21" ref-type="bibr">21</xref>). We have reported that AD-related dysfunction of the hypothalamic-salivary gland axis resulted in reduced salivary lactoferrin levels in human and mouse models of AD (<xref rid="B22" ref-type="bibr">22</xref>). On the contrary, evidence has shown that lactoferrin concentrations increase in infections and/or inflammatory situations due to the recruitment of neutrophils (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>Stress or anxiety are also increasingly identified as risk factors that can directly compromise periodontal disease through various biological mechanisms (<xref rid="B23" ref-type="bibr">23</xref>). It has been proposed that stress disrupts the balance between pro-inflammatory and anti-inflammatory responses through activation of the hypothalamic-pituitary-adrenal axis (HPA) and the sympathetic nervous system, and finally, this alteration leads to an immunosuppressive action (<xref rid="B24" ref-type="bibr">24</xref>). Therefore, stress could be altering the hypothalamic regulation of lactoferrin secretion. On the other hand, stress can lead to the dysregulation of the HPA axis that induces abnormal levels of HPA hormones, including cortisol and dehydroepiandrosterone (DHEA) (<xref rid="B25" ref-type="bibr">25</xref>). Cortisol is the most representative stress biomarker, and its higher levels have been associated with oral dysbiosis and decline of immune responses (<xref rid="B26" ref-type="bibr">26</xref>). Indeed, cortisol can increase the sensitivity to periodontal pathogens (<xref rid="B27" ref-type="bibr">27</xref>). Both salivary cortisol and the other major stress-related biomarker, DHEA, have been associated with periodontal pathology (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Hence our interest in analyzing the possible relationship between the main stress markers and lactoferrin.</p><p>In summary, oral dysbiosis is a central but complex factor in the development and progression of periodontitis, with <italic toggle="yes">P. gingivalis</italic> as the keystone pathogen (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). However, various immunological factors, including impaired HPA regulation, can lead to a loss of microbial homeostasis, associated with alterations in immune and inflammatory responses and pathogen proliferation in the oral cavity (<xref rid="B32" ref-type="bibr">32</xref>). In this context, lactoferrin is particularly relevant as it acts as an antioxidant (<xref rid="B33" ref-type="bibr">33</xref>), reduces bacterial growth (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>), and modulates inflammatory processes (<xref rid="B36" ref-type="bibr">36</xref>). The aim of this study was to elucidate the correlation of salivary biomarkers, including lactoferrin and stress markers, and the abundance of <italic toggle="yes">P. gingivalis</italic> with clinical periodontal parameters in a cohort of patients with and without periodontitis.</p></sec><sec sec-type="materials|methods" id="s2"><title>Material and methods</title><sec id="s2_1"><title>Patients</title><p>Forty volunteers were recruited during 2021 and examined by the same odontologist in the Odontology Clinic of Valencia University, Spain. To evaluate the staging and grading of periodontitis, the criteria from Tonetti et&#160;al. (<xref rid="B37" ref-type="bibr">37</xref>) were followed. Smoking more than 10 cigarettes per day, receiving antibiotic treatment in the past month, using mouth antiseptics in the last 2 weeks or having received periodontal treatment in the last 12 months were exclusion criteria. Twenty donors diagnosed with periodontitis stage III and grade B and twenty individuals with periodontal health (no attachment loss, &lt;10% of bleeding on probing and plaque) were included in the study (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). In addition, volunteers filled out a questionnaire about health status, diet, and oral hygiene habits (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>). All patients agreed with the enrollment and signed the informed consent. The study was approved by the Ethical Committee from the University of Valencia (ref. 1601392).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Demographic and clinical characteristics of the participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" colspan="2" align="left" rowspan="1">
</th><th valign="middle" align="left" rowspan="1" colspan="1">Control (n = 20)</th><th valign="middle" align="left" rowspan="1" colspan="1">PD (n = 20)</th><th valign="middle" align="left" rowspan="1" colspan="1">P-value #</th></tr></thead><tbody><tr><th valign="middle" colspan="5" align="left" rowspan="1">Physical characteristic</th></tr><tr><td valign="middle" colspan="2" align="center" rowspan="1">Age, mean (SD), y</td><td valign="middle" align="center" rowspan="1" colspan="1">50.20 (7.66)</td><td valign="middle" align="center" rowspan="1" colspan="1">52.50 (7.51)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" colspan="2" align="center" rowspan="1">Female/Male</td><td valign="middle" align="center" rowspan="1" colspan="1">12/8</td><td valign="middle" align="center" rowspan="1" colspan="1">10/10</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" colspan="2" align="center" rowspan="1">BMI (SD)</td><td valign="middle" align="center" rowspan="1" colspan="1">23.23 (2.80)</td><td valign="middle" align="center" rowspan="1" colspan="1">26.30 (5.58)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><th valign="middle" colspan="5" align="left" rowspan="1">Oral clinical parameters</th></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">PPD, mean (SD), mm</td><td valign="middle" align="center" rowspan="1" colspan="1">2.32 (0.29)</td><td valign="middle" align="center" rowspan="1" colspan="1">3.69 (0.53)</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">CAL, mean (SD), mm</td><td valign="middle" align="center" rowspan="1" colspan="1">2.38 (0.34)</td><td valign="middle" align="center" rowspan="1" colspan="1">4.45 (0.91)</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">BoP, mean (SD), %</td><td valign="middle" align="center" rowspan="1" colspan="1">4.45 (2.93)</td><td valign="middle" align="center" rowspan="1" colspan="1">52.40 (17.16)</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">PI, mean (SD), %</td><td valign="middle" align="center" rowspan="1" colspan="1">6.85 (2.52)</td><td valign="middle" align="center" rowspan="1" colspan="1">62.30 (16.80)</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><th valign="middle" colspan="5" align="left" rowspan="1">Microbiological parameters</th></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">% Porphyromonas (genus), (SD)</td><td valign="middle" align="left" rowspan="1" colspan="1">Saliva</td><td valign="middle" align="center" rowspan="1" colspan="1">5.32 (4.14)</td><td valign="middle" align="center" rowspan="1" colspan="1">9.85 (4.12)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Subgingival sulcus</td><td valign="middle" align="center" rowspan="1" colspan="1">3.13 (4.61)</td><td valign="middle" align="center" rowspan="1" colspan="1">7.99 (6.12)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">% Porphyromonas gingivalis, (SD)</td><td valign="middle" align="left" rowspan="1" colspan="1">Saliva</td><td valign="middle" align="center" rowspan="1" colspan="1">0.71 (2.32)</td><td valign="middle" align="center" rowspan="1" colspan="1">3.44 (4.32)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Subgingival sulcus</td><td valign="middle" align="center" rowspan="1" colspan="1">0.3 (0.79)</td><td valign="middle" align="center" rowspan="1" colspan="1">5.44 (5.73)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn><p>PD, Periodontal disease; SD, standard deviation; y, years; n, number; BMI, body mass index; PPD, periodontal pocket depth; CAL, clinical attachment level; BoP, bleeding on probing; PI, plaque index; ns, non-significant. #<italic toggle="yes">p</italic> value indicates statistical difference.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Health status, diet, and oral hygiene habits of the participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" colspan="2" align="left" rowspan="1"/><th valign="middle" align="left" rowspan="1" colspan="1">Control (n = 20)</th><th valign="middle" align="left" rowspan="1" colspan="1">PD (n = 20)</th><th valign="middle" align="left" rowspan="1" colspan="1">P-value #</th></tr></thead><tbody><tr><th valign="middle" colspan="5" align="left" rowspan="1">Concomitant pathologies</th></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Hypertension</td><td valign="middle" align="left" rowspan="1" colspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (0.15)</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (0.15)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">17 (0.85)</td><td valign="middle" align="right" rowspan="1" colspan="1">17 (0.85)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Cholesterol</td><td valign="middle" align="left" rowspan="1" colspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (0.15)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">16 (0.8)</td><td valign="middle" align="right" rowspan="1" colspan="1">16 (0.8)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Diabetes</td><td valign="middle" align="left" rowspan="1" colspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">2 (0.1)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">20 (1)</td><td valign="middle" align="right" rowspan="1" colspan="1">18 (0.9)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Food allergys</td><td valign="middle" align="left" rowspan="1" colspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">2 (0.1)</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.05)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">18 (0.9)</td><td valign="middle" align="right" rowspan="1" colspan="1">19 (0.95)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Intestinal diseases</td><td valign="middle" align="left" rowspan="1" colspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.05)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">16 (0.8)</td><td valign="middle" align="right" rowspan="1" colspan="1">19 (0.95)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Routine medication</td><td valign="middle" align="left" rowspan="1" colspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">9 (0.45)</td><td valign="middle" align="right" rowspan="1" colspan="1">6 (0.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">11 (0.55)</td><td valign="middle" align="right" rowspan="1" colspan="1">14 (0.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="3" align="left" colspan="1">Antibiotic use in last year</td><td valign="middle" align="left" rowspan="1" colspan="1">&lt;2 months ago</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.05)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&gt;2 months ago</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="right" rowspan="1" colspan="1">7 (0.35)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">15 (0.75)</td><td valign="middle" align="right" rowspan="1" colspan="1">12 (0.6)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Halitosis</td><td valign="middle" align="left" rowspan="1" colspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.047</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">19 (0.95)</td><td valign="middle" align="right" rowspan="1" colspan="1">14 (0.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><th valign="middle" colspan="5" align="left" rowspan="1">Life style habits</th></tr><tr><td valign="middle" rowspan="5" align="left" colspan="1">Alcohol</td><td valign="middle" align="left" rowspan="1" colspan="1">Never</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Hardly ever</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.05)</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Sometimes</td><td valign="middle" align="right" rowspan="1" colspan="1">8 (0.4)</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.05)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Usually</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (0.15)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Often</td><td valign="middle" align="right" rowspan="1" colspan="1">2 (0.1)</td><td valign="middle" align="right" rowspan="1" colspan="1">7 (0.35)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="3" align="left" colspan="1">Tobacco</td><td valign="middle" align="left" rowspan="1" colspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">15 (0.75)</td><td valign="middle" align="right" rowspan="1" colspan="1">12 (0.6)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Ex</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.05)</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="5" align="left" colspan="1">Physical activity</td><td valign="middle" align="left" rowspan="1" colspan="1">Never</td><td valign="middle" align="right" rowspan="1" colspan="1">2 (0.1)</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (0.15)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Hardly ever</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.05)</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (0.15)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Sometimes</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Usually</td><td valign="middle" align="right" rowspan="1" colspan="1">8 (0.4)</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Often</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="4" align="left" colspan="1">Diet</td><td valign="middle" align="left" rowspan="1" colspan="1">Mediterranean</td><td valign="middle" align="right" rowspan="1" colspan="1">17 (0.85)</td><td valign="middle" align="right" rowspan="1" colspan="1">14 (0.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Vegetarian</td><td valign="middle" align="right" rowspan="1" colspan="1">2 (0.1)</td><td valign="middle" align="right" rowspan="1" colspan="1">2 (0.1)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Vegan</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Others</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.05)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Household location</td><td valign="middle" align="left" rowspan="1" colspan="1">Rural area</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (0.15)</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Urban area</td><td valign="middle" align="right" rowspan="1" colspan="1">16 (0.8)</td><td valign="middle" align="right" rowspan="1" colspan="1">14 (0.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Sleep hours</td><td valign="middle" align="left" rowspan="1" colspan="1">Average a day</td><td valign="middle" align="right" rowspan="1" colspan="1">6.9</td><td valign="middle" align="right" rowspan="1" colspan="1">7.3</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Water intake</td><td valign="middle" align="left" rowspan="1" colspan="1">Average a day</td><td valign="middle" align="right" rowspan="1" colspan="1">1.5</td><td valign="middle" align="right" rowspan="1" colspan="1">1.61</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="4" align="left" colspan="1">Bowel movement frequency</td><td valign="middle" align="left" rowspan="1" colspan="1">&lt;1 a day</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.05)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">1 a day</td><td valign="middle" align="right" rowspan="1" colspan="1">8 (0.4)</td><td valign="middle" align="right" rowspan="1" colspan="1">12 (0.6)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">2 a day</td><td valign="middle" align="right" rowspan="1" colspan="1">8 (0.4)</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">3 or more a day</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">2 (0.1)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><th valign="middle" colspan="5" align="left" rowspan="1">Oral hygienic habits</th></tr><tr><td valign="middle" rowspan="4" align="center" colspan="1">Dental brush frequency,<break/>n (%)</td><td valign="middle" align="left" rowspan="1" colspan="1">&lt;1 a day</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (0.05)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">1 a day</td><td valign="middle" align="right" rowspan="1" colspan="1">2 (0.1)</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">2 a day</td><td valign="middle" align="right" rowspan="1" colspan="1">9 (0.45)</td><td valign="middle" align="right" rowspan="1" colspan="1">9 (0.45)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">3 or more a day</td><td valign="middle" align="right" rowspan="1" colspan="1">9 (0.45)</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Dental floss use, n (%)</td><td valign="middle" align="left" rowspan="1" colspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">16 (0.8)</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">4 (0.2)</td><td valign="middle" align="right" rowspan="1" colspan="1">15 (0.75)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Frequent mothwash use, n (%)</td><td valign="middle" align="left" rowspan="1" colspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (0.25)</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (0.15)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">15 (0.75)</td><td valign="middle" align="right" rowspan="1" colspan="1">17 (0.85)</td><td valign="middle" align="center" rowspan="1" colspan="1">ns</td></tr></tbody></table><table-wrap-foot><fn><p>PD, Periodontal disease; ns, non-significant; n, number; #<italic toggle="yes">p</italic> value indicates statistical difference.</p></fn></table-wrap-foot></table-wrap><p>The study workflow is represented in <xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>.</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Study work outline. Twenty patients with periodontal and 20 oral healthy individuals were included. Clinical and demographic characteristics were recorded. Saliva and subgingival biofilm samples were taken. Bacterial composition was analyzed by full-length 16S rRNA gene sequencing in both samples. Lactoferrin, cortisol and DHEA were measured in saliva samples using commercial ELISA kits. Correlations were carried out between molecular and clinical parameters.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-16-1681095-g001.jpg"><alt-text content-type="machine-generated">Flowchart illustrating a study design with two groups: control and periodontitis, each with twenty participants. Patient recruitment and data recording lead to sample collection. Subgingival biofilm and saliva samples undergo microbiome analyses using 16S rRNA sequencing with Porphyromonas gingivalis identification. Saliva samples also undergo biochemical measurement using ELISA assay for lactoferrin, cortisol, and DHEA. Correlation analysis follows.</alt-text></graphic></fig></sec><sec id="s2_2"><title>Saliva &amp; subgingival biofilm sampling</title><p>Up to 2 ml of non-stimulated saliva samples were collected into a sterile plastic tube from each participant in the daytime. Patients were advised to abstain from oral care and eating at least 1 h before saliva collection. After collection, saliva samples were stored at 4&#176;C. Before collecting subgingival samples, supragingival plaque was removed with curettes. Then, four paper points (No. 40) were placed by the odontologist into the periodontal pockets during 1 min and kept in 1 ml of RNAlater (<xref rid="B38" ref-type="bibr">38</xref>). On the same day of collection, all sample types arrived at the laboratory and were stored at -80 &#176;C until processing.</p></sec><sec id="s2_3"><title>Bacteria detection and quantification</title><p>Previous to DNA extraction, subgingival plaque samples were vortexed for 2 min in order to separate bacteria from the paper points. After that, paper points were removed, and the samples centrifuged for 30 min at 13000 rpm. To obtain the bacterial pellet in saliva samples, 250 &#956;l of saliva were centrifuged for 10 min at 13000 rpm. For all sample types, supernatants were removed, and the pellet was resuspended in 100ul of phosphate-buffered saline (PBS). DNA isolation was performed, using the MagNA Pure LC DNA Isolation Kit III for Bacteria and Fungi (Roche Diagnostics, Cat. No. 03 264 785 001) following the manufacturer&#8217;s instructions plus an additional enzymatic lysis (<xref rid="B39" ref-type="bibr">39</xref>). DNA was quantified using QubitTM 1X dsDNA HS Assay Kit according to the manufacturer&#8217;s instructions. Full length 16S rRNA gene sequencing was performed using the Sequel II Sequencing Kit 2.0 (PacBio) on the Sequel II PacBio system (<xref rid="B40" ref-type="bibr">40</xref>). Circular consensus sequences were quality checked using PacBio error&#8217;s model with DADA2 and annotated using the naive Bayesian classifier against the species train set of Silva v.138.1 database (<xref rid="B41" ref-type="bibr">41</xref>). Relative species abundance was calculated as a percentage (n&#176; of reads/total reads*100) for each sample.</p></sec><sec id="s2_4"><title>Immunoassays</title><p>Levels of salivary lactoferrin, cortisol, and DHEA concentrations were determined from saliva sampling using commercially available specific enzyme-linked immunosorbent assay (ELISA) kits. Levels of human lactoferrin in saliva samples were determined using the human LTF ELISA kit (EH0396, FineTest) according to manufacturer&#8217;s instructions. We used a Cortisol Competitive ELISA kit (EIAHCOR, Invitrogen) to measure the human salivary cortisol and the Salivary DHEA ELISA Kit (1-1202, Salimetrics) to measure the human salivary DHEA levels. All samples were measured in duplicate.</p></sec><sec id="s2_5"><title>Statistical analysis</title><p>Statistical analysis and graphs were performed using GraphPad Prism Software version 8.00 (La Jolla, CA, USA). Descriptive statistics were reported as mean &#177; standard deviation or numbers with percentages where appropriate. To analyze the distribution of discontinuous data, we used Bonferroni test. Since data were not normally distributed, statistical comparisons between the two independent groups were assessed by Mann-Whitney U test. To determine any relationship between salivary biomarkers and periodontal parameters, and given non-normally distributed data, we used Spearman correlation analysis, and predicted value of these changes were fitted using linear regression models. All p values of less than 0.05 were considered to be statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3_1"><title>Demographics and clinical characteristics</title><p>Twenty diseased patients (mean age 52.50 years) and twenty control patients without periodontitis (mean age 50.20 years) were included in this study. No difference between groups according to age, gender and body mass index (BMI) in each group was observed. The demographic data and periodontal clinical parameters of the patients included are provided in <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>. Periodontal registrations included periodontal pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BoP), and plaque index (PI), clearly exacerbated in subjects suffering from periodontal disease (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>).</p><p>Microbiome differences between oral healthy controls and periodontitis patients were previously described (<xref rid="B39" ref-type="bibr">39</xref>). In the present study, we focused on <italic toggle="yes">P. gingivalis</italic> since it is the major etiologic agent which contributes to chronic periodontitis (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Furthermore, <italic toggle="yes">P. gingivalis</italic> were identified in saliva in 50% of controls and 70% of patients. However, in the subgingival sulcus, <italic toggle="yes">P. gingivalis</italic> was only detected in 5 of the 20 controls, while it was detected in 70% of cases. The relative abundance of <italic toggle="yes">P. gingivalis</italic> was significantly higher in periodontal patients than in healthy individuals in saliva (p &lt; 0.05, <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2A</bold>
</xref>) and subgingival sulcus (p &lt; 0.001, <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2B</bold>
</xref>).</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Abundance of <italic toggle="yes">P. gingivalis</italic>, lactoferrin and stress markers in the saliva of subjects with and without periodontal disease. Quantitative analysis revealed significantly higher abundance of <italic toggle="yes">P. gingivalis</italic> in saliva <bold>(A)</bold> and subgingival sulcus <bold>(B)</bold> in patients with periodontitis compared to healthy individuals. Lactoferrin <bold>(C)</bold>, cortisol <bold>(D)</bold>, DHEA <bold>(E)</bold> and cortisol/DHEAR ratio <bold>(F)</bold> levels were significantly higher in saliva from periodontitis cases than in healthy controls. A positive correlation was detected between lactoferrin and cortisol <bold>(G)</bold> and DHEA <bold>(H)</bold> salivary levels in the analysis of the data of the whole cohort. <bold>(I)</bold> Cortisol and DHEA levels were also positively correlated in the whole cohort. However, such correlations between lactoferrin and cortisol <bold>(J)</bold> and DHEA <bold>(K)</bold> salivary levels were only observed in the periodontitis groups and not in the healthy control group. Data are expressed as mean &#177; SD. Differences between groups were assessed using the Mann-Whitney test. *<italic toggle="yes">p</italic> &lt; 0.05, ***<italic toggle="yes">p</italic> &lt; 0.001. PD, periodontal disease; DHEA, dehydroepiandrosterone.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-16-1681095-g002.jpg"><alt-text content-type="machine-generated">Graphs A to F show data comparisons between control and PD groups for various markers: P. gingivalis in saliva and subgingival areas, lactoferrin, cortisol, DHEA, and cortisol/DHEA ratio with differing significance levels. Graphs G to I illustrate correlations between lactoferrin, cortisol, and DHEA, with correlation coefficients and p-values. Graphs J and K depict the correlations separately for control and PD groups for cortisol and DHEA with lactoferrin, showing different trends and significance levels.</alt-text></graphic></fig></sec><sec id="s3_2"><title>Measurements and correlations of salivary biomarkers</title><p>Lactoferrin levels were significantly higher in saliva from periodontitis cases than in healthy controls (p &lt; 0.05, <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2C</bold>
</xref>). The obtained area under the curve (AUC) was 0.75 (95% CI, 0.58 &#8211; 0.91). We also analyzed the total salivary protein concentration, and the ratio of salivary lactoferrin content to total protein. In neither case did we find significant differences between the two study groups. Since stress is associated with periodontitis, stress markers were analyzed by specific immunoassays to confirm their association with periodontal pathology. We found that patients with periodontitis exhibited significantly increased salivary cortisol (p &lt; 0.001, <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2D</bold>
</xref>), and DHEA (p &lt; 0.05, <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2E</bold>
</xref>) levels compared to the healthy control group. The cortisol and DHEA AUC were 0.82 (95% CI, 0.68 &#8211; 0.96), and 0.70 (95% CI, 0.54 &#8211; 0.87), respectively. Moreover, the cortisol/DHEA ratio was also significantly higher in periodontitis patients compared to healthy controls (p &lt; 0.05, <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2F</bold>
</xref>). Therefore, our finding demonstrated that levels of stress-related factors, cortisol, DHEA, and cortisol/DHEA ratio, and lactoferrin, all of them modulated at hypothalamic level, were higher among patients with periodontitis than in healthy controls.</p><p>We found positive correlations between lactoferrin and cortisol (r = 4362; p &lt; 0.05; <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2G</bold>
</xref>) and DHEA (r = 5512; p &lt; 0.001; <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2H</bold>
</xref>) levels in the analysis of the data of the whole cohort. Cortisol and DHEA levels were also positively correlated among the 40 participants in the whole cohort (r = 5822; p &lt; 0.001; <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2I</bold>
</xref>). However, such correlations between lactoferrin and cortisol (r = 5074; p &lt; 0.05; <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2J</bold>
</xref>) and DHEA (r = 5765; p &lt; 0.01; <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2K</bold>
</xref>) levels were only observed in the periodontitis groups and not in the healthy control group. The linear regression analyses confirmed these correlations (<xref rid="f2" ref-type="fig">
<bold>Figures&#160;2G-K</bold>
</xref>).</p></sec><sec id="s3_3"><title>Correlations between <italic toggle="yes">P. gingivalis</italic> and salivary biomarkers</title><p>
<italic toggle="yes">P. gingivalis</italic> in the subgingival area was positively correlated with lactoferrin both in the analysis of the whole cohort (r = 0.5124, p &lt; 0.0019; <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3A</bold>
</xref>), and in the periodontitis group (r = 0.5324, p &lt; 0.001; <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3B</bold>
</xref>) but not in the healthy control group. We also found a positive correlation between the abundance of <italic toggle="yes">P. gingivalis</italic> in the subgingival area and the cortisol/DHEA ratio (r = 0.3329, p &lt; 0.05; <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3C</bold>
</xref>) in the analysis of the whole cohort but not in the subgroup analyses.</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>Correlations between <italic toggle="yes">P. gingivalis</italic> and salivary biomarkers markers in the saliva of subjects with and without periodontal disease. <italic toggle="yes">P. gingivalis</italic> in the subgingival area was positively correlated with lactoferrin in the whole cohort <bold>(A)</bold>, and in the periodontitis group <bold>(B)</bold>. <bold>(C)</bold> There was a positive correlation between the abundance of <italic toggle="yes">P. gingivalis</italic> in the subgingival area and the cortisol/DHEA ratio in the whole cohort. <italic toggle="yes">P. gingivalis</italic> in saliva showed a positive significant correlation with cortisol <bold>(D)</bold>, and with the cortisol/DHEA ratio <bold>(E)</bold> in saliva both in the analysis of the data of the whole cohort, and in the periodontitis group <bold>(F)</bold>. PD, periodontal disease; DHEA, dehydroepiandrosterone.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-16-1681095-g003.jpg"><alt-text content-type="machine-generated">Graphs show correlations between various biomarkers and the percentage of P. gingivalis. (A) Lactoferrin vs. subgingival P. gingivalis. (B) Lactoferrin vs. subglossal P. gingivalis for control and PD groups. (C) Cortisol/DHEA ratio vs. subglossal P. gingivalis. (D) Cortisol vs. P. gingivalis in saliva. (E) Cortisol/DHEA ratio vs. P. gingivalis in saliva. (F) Cortisol/DHEA ratio vs. P. gingivalis in saliva for control and PD groups. Each plot includes an r-value and p-value, indicating correlation strength and significance.</alt-text></graphic></fig><p>Additionally, <italic toggle="yes">P. gingivalis</italic> in saliva showed a positive significant correlation with cortisol levels in the data analysis of the whole cohort, as shown in the linear regression model (r = 0.4038, p &lt; 0.05; <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3D</bold>
</xref>). <italic toggle="yes">P. gingivalis</italic> was also positively correlated with the cortisol/DHEA ratio in saliva both in the analysis of the data of the whole cohort (r = 0.5790, p &lt; 0.001; <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3E</bold>
</xref>), and in the periodontitis groups (r = 0.6448, p &lt; 0.01; <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3F</bold>
</xref>) but not in the healthy control group.</p></sec><sec id="s3_4"><title>Correlations between salivary biomarkers and periodontal parameters</title><p>The association of salivary lactoferrin levels with clinical periodontal parameters was evaluated. A positive correlation was observed between lactoferrin levels and BoP in the whole cohort (r = 0.5174, p &lt; 0.01; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4A</bold>
</xref>). However, such correlation was only found in the periodontitis group (r = 0.4991, p &lt; 0.05; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4B</bold>
</xref>), as expected by the absence of periodontal pockets in the healthy control group (<xref rid="f4" ref-type="fig">
<bold>Figure&#160;4B</bold>
</xref>). Salivary lactoferrin levels also positively correlated with PPD (r = 0.4561, p &lt; 0.01; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4C</bold>
</xref>), percentage of plaque (r = 0.4887, p &lt; 0.01; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4D</bold>
</xref>), and CAL (r = 0.4071, p &lt; 0.05; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4E</bold>
</xref>) in the analysis of the data of the whole cohort but not in the subgroup analyses.</p><fig position="float" id="f4" orientation="portrait"><label>Figure&#160;4</label><caption><p>Correlations between salivary biomarkers and periodontal parameters in subjects with and without periodontal disease. A positive correlation was observed between lactoferrin levels and BoP in the whole cohort <bold>(A)</bold> and in the periodontitis group <bold>(B)</bold>. Salivary lactoferrin levels also positively correlated with PPD <bold>(C)</bold>, percentage of plaque or PI <bold>(D)</bold>, and CAL <bold>(E)</bold> in the analysis of the whole cohort but not in the subgroup analyses. Cortisol levels were positively correlated with BoP <bold>(F)</bold>, PPD <bold>(G)</bold>, percentage of plaque <bold>(H)</bold>, and CAL <bold>(I)</bold> in the whole cohort but not in the subgroup analyses. DHEA levels were found to have statistically significant association with BoP in the whole cohort <bold>(J)</bold>, and in the periodontitis group <bold>(K)</bold>. Positive correlation was also found between DHEA and PPD <bold>(L)</bold>, and percentage of plaque <bold>(M)</bold> in the whole cohort. <bold>(N)</bold> Correlation between DHEA and percentage of plaque was detected in the periodontitis group. BoP, bleeding on probing; PPD, periodontal pocket depth; PI, plaque index; CAL, clinical attachment level; PD, periodontal disease; DHEA, dehydroepiandrosterone.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-16-1681095-g004.jpg"><alt-text content-type="machine-generated">Scatter plots exploring the relationship between lactoferrin, cortisol, and DHEA levels with various periodontal parameters. Each graph includes correlation coefficients (r values) and significance levels (p values). Data is divided into control and PD groups, with trend lines and shaded confidence intervals indicating positive correlations across multiple panels.</alt-text></graphic></fig><p>Similar correlations were observed between salivary cortisol levels and periodontal parameters. We found positive correlations of cortisol levels with BoP (0.6341, p &lt; 0.0001; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4F</bold>
</xref>), PPD (r = 0.4759, p &lt; 0.01; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4G</bold>
</xref>), percentage of plaque (r = 0.6224, p &lt; 0.0001; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4H</bold>
</xref>), and CAL (r = 0.4198, p &lt; 0.01; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4I</bold>
</xref>) in the analysis of the data of the whole cohort but not in the subgroup analyses.</p><p>Salivary DHEA levels exhibited associations with periodontal parameters similar to those showed above for lactoferrin and cortisol. DHEA levels were not found to have statistically significant association with BoP in the whole cohort (r = 0.4810, p &lt; 0.01; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4J</bold>
</xref>), but such correlation was only found in the periodontitis group (r = 0.4565, p &lt; 0.05; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4K</bold>
</xref>), and not in the healthy control group, as the lineal regression model indicated (<xref rid="f4" ref-type="fig">
<bold>Figure&#160;4K</bold>
</xref>). Positive correlation was also found between DHEA and PPD (r = 0.4684, p &lt; 0.01; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4L</bold>
</xref>), and percentage of plaque (r = 0.4768, p &lt; 0.01; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4M</bold>
</xref>) in the whole cohort. Correlation between DHEA and percentage of plaque was detected in the periodontitis group (r = 0.4998, p &lt; 0.05; <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4N</bold>
</xref>), and not in the healthy control group, as the lineal regression model revealed (<xref rid="f4" ref-type="fig">
<bold>Figure&#160;4N</bold>
</xref>).</p><p>Altogether, our findings indicate that salivary lactoferrin, cortisol and DHEA can be used to predict the severity of periodontal parameters in periodontitis patients.</p></sec><sec id="s3_5"><title>Correlations between abundance of <italic toggle="yes">P. gingivalis</italic> and periodontal parameters</title><p>We assessed whether any correlation exists between clinical periodontal parameters and the abundance of <italic toggle="yes">P. gingivalis</italic> in saliva and the subgingival area (<xref rid="f5" ref-type="fig">
<bold>Figure&#160;5</bold>
</xref>). <xref rid="f5" ref-type="fig">
<bold>Figure&#160;5A</bold>
</xref> shows a positive correlation between salivary <italic toggle="yes">P. gingivalis</italic> and BoP in the whole cohort (r = 0.3540, p &lt; 0.05; <xref rid="f5" ref-type="fig">
<bold>Figure&#160;5A</bold>
</xref>), however no more statistically significant correlations with other periodontal parameters were found.</p><fig position="float" id="f5" orientation="portrait"><label>Figure&#160;5</label><caption><p>Correlations between abundance of <italic toggle="yes">P. gingivalis</italic> and periodontal parameters in subjects with and without periodontal disease. <bold>(A)</bold> A positive correlation was found between salivary <italic toggle="yes">P. gingivalis</italic> and BoP in the whole cohort. <italic toggle="yes">P. gingivalis</italic> in the subgingival area was positively correlated with BoP <bold>(B)</bold>, PPD <bold>(C)</bold>, percentage of plaque <bold>(D)</bold>, and CAL <bold>(E)</bold> in the whole cohort. BoP, bleeding on probing; PPD, periodontal pocket depth; PI, plaque index; CAL, clinical attachment level.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-16-1681095-g005.jpg"><alt-text content-type="machine-generated">Graphs labeled A to E show scatter plots with regression lines examining the relationship between P. gingivalis percentages and different periodontal measures. A correlates percentage of P. gingivalis in saliva with bleeding on probing (r = 0.3540, p = 0.0250). B correlates subgingival P. gingivalis with % BoP (r = 0.5082, p = 0.0008). C shows subgingival P. gingivalis against periodontal pocket depth (r = 0.4465, p = 0.0039). D relates subgingival P. gingivalis to % Plaque Index (r = 0.4239, p = 0.0064). E links subgingival P. gingivalis with clinical attachment loss (r = 0.3697, p = 0.0189). Gray bands indicate confidence intervals.</alt-text></graphic></fig><p>Regarding the abundance of <italic toggle="yes">P. gingivalis</italic> in the subgingival area, significant associations were observed. BoP (r = 0.5082, p &lt; 0.001; <xref rid="f5" ref-type="fig">
<bold>Figure&#160;5B</bold>
</xref>), PPD (r = 0.4465, p &lt; 0.01; <xref rid="f5" ref-type="fig">
<bold>Figure&#160;5C</bold>
</xref>), percentage of plaque (r = 0.4238, p &lt; 0.01; <xref rid="f5" ref-type="fig">
<bold>Figure&#160;5D</bold>
</xref>), and CAL (r = 0.3697, p &lt; 0.05; <xref rid="f5" ref-type="fig">
<bold>Figure&#160;5E</bold>
</xref>) correlated with the abundance of <italic toggle="yes">P. gingivalis</italic> in the subgingival area in the analysis of the data of the whole cohort.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>The present study identified significant correlations between salivary biomarkers, including lactoferrin and the stress markers cortisol and DHEA, with the abundance of <italic toggle="yes">P. gingivalis</italic> and with clinical periodontal parameters. While previous studies have shown that levels of lactoferrin, cortisol, and DHEA are altered in individuals with periodontitis (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B28" ref-type="bibr">28</xref>), our study is the first to report a significant interrelationship among these biomarkers. Specifically, we observed that lactoferrin levels correlate with cortisol and DHEA levels in individuals with periodontitis, an association that is not present in healthy subjects. Moreover, our findings show that the abundance of <italic toggle="yes">P. gingivalis</italic> in saliva correlated with lactoferrin, cortisol and cortisol/DHEA ratio. We also observed that periodontal variables were positively correlated with salivary lactoferrin, cortisol, DHEA and <italic toggle="yes">P. gingivalis</italic>. Altogether, these findings suggest a functional interaction between the innate immune response and the neuroendocrine axis in the context of periodontitis, offering a new perspective on the pathophysiological mechanisms of the disease.</p><p>The oral microbiome in healthy individuals remains in a constant balance. However, in some cases this balance can become altered, deriving in a pathogenic environment that can contribute to the appearance of oral diseases, such as periodontitis (<xref rid="B42" ref-type="bibr">42</xref>). Periodontitis is described as a periodontal dysbiosis resulting from an altered inflammatory environment and a change in microbiota that benefits and amplifies the inflammatory response with a microbiome activity that destroys host tissues through enzymes and inflammatory mediators (<xref rid="B43" ref-type="bibr">43</xref>). Among the odontopathogenic bacteria involved in gum diseases, <italic toggle="yes">P. gingivalis</italic>, orchestrates the development of periodontal disease by converting a benign microbial community into a dysbiotic one (<xref rid="B30" ref-type="bibr">30</xref>). <italic toggle="yes">P. gingivalis</italic> causes a deregulated immune response due to virulence factors and molecular patterns associated with damage, leading pathogenic dysbiosis and hyperinflammation associated with secretion of proinflammatory cytokines and loss of homeostasis, which leads to connective tissue damage, tooth attachment loss and periodontitis (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>).</p><p>Lactoferrin plays a crucial role in the innate immune system, exhibiting well-known antimicrobial effects against various bacteria, fungi, and viruses (<xref rid="B46" ref-type="bibr">46</xref>). In particular, salivary lactoferrin contributes to maintaining symbiosis between the host and microbiome by regulating the oral microbiota (<xref rid="B47" ref-type="bibr">47</xref>). It was documented that lactoferrin inhibits the proteinase activity of <italic toggle="yes">P. gingivalis</italic>, specifically the inhibition of the virulence factor gingipain (<xref rid="B48" ref-type="bibr">48</xref>). In our present study lactoferrin levels are increased in saliva samples from patients with periodontitis, accordingly with previous studies (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). It is important to note that lactoferrin is also synthesized by neutrophils that are recruited in inflammatory processes and secreting secondary granules containing lactoferrin (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>). And increased neutrophil infiltration has been widely documented in patients with periodontitis (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>). Here, we propose that, in addition to salivary glands secretion, increased salivary lactoferrin levels in periodontal condition could be released from recruited neutrophils, based on the strong correlation we found between salivary lactoferrin and subgingival levels of <italic toggle="yes">P. gingivalis</italic>. Lactoferrin is found in saliva but also in gingival crevicular fluid (<xref rid="B48" ref-type="bibr">48</xref>). Gingival crevicular fluid is derived primarily from microvascular leakage (<xref rid="B55" ref-type="bibr">55</xref>), so neutrophils can enter the gingival crevice (<xref rid="B56" ref-type="bibr">56</xref>). Thus, <italic toggle="yes">P. gingivalis</italic>, that resides predominantly in subgingival biofilms (<xref rid="B57" ref-type="bibr">57</xref>), could facilitate the entry of neutrophils from the blood and therefore, the salivary levels of neutrophil-derived lactoferrin.</p><p>In periodontal disease it has been reported that stress-markers, including cortisol and DHEA, compromise immune response, affecting oral microbiome (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B58" ref-type="bibr">58</xref>). Since the main source of salivary lactoferrin is the salivary glands, which are closely linked to the HPA control (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B59" ref-type="bibr">59</xref>), we suggest that stress-mediated risen cortisol and DHEA expression can indirectly induce greater secretion of lactoferrin into saliva mediated by salivary gland upregulation. Our findings also revealed a significant correlation between salivary levels of cortisol and <italic toggle="yes">P. gingivalis</italic>, according to a previous study (<xref rid="B60" ref-type="bibr">60</xref>). Cortisol has been suggested to modify composition of subgingival biofilms. Particularly, cortisol was able to significantly increase <italic toggle="yes">P. gingivalis</italic> growth in culture (<xref rid="B27" ref-type="bibr">27</xref>). Altogether, we suggest that the high levels of lactoferrin found in our present study can be explained by increased secretion from both molecular mechanisms: HPA-mediated salivary gland activation and infiltrated neutrophils into the gingival crevicular fluid, probably as a compensatory mechanism to recover oral homeostasis. However, since neither total protein levels protein levels nor the ratio lactoferrin/total protein varied significantly between the periodontal disease group and the control group, we propose that the elevated salivary lactoferrin levels were not due to increased production by the salivary glands but to the release from infiltrated neutrophils. In any case, further studies will be needed to demonstrate this hypothesis.</p><p>In our study, salivary lactoferrin levels were positively correlated with periodontal variables, including BoP PPD, CAL, and PI. These results were consistent with previously reported findings although only the correlation of lactoferrin with BoP and PPD was described (<xref rid="B12" ref-type="bibr">12</xref>). Our results extend and demonstrate that salivary lactoferrin positively correlated with CAL, and PI. Notably, salivary lactoferrin was only correlated with bleeding in the periodontal disease group, which would support our hypothesis that high levels of lactoferrin found in saliva from periodontal disease patients can be explained by neutrophil infiltration due to microvascular leakage. Our study also confirmed that salivary cortisol and DHEA levels were correlated with BoP PPD, CAL, and PI, confirming but also expanding additional findings. Meanwhile previous studies have reported correlations between salivary cortisol and periodontal clinical parameters (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B61" ref-type="bibr">61</xref>), no data was found related to salivary DHEA correlations.</p><p>Additionally, we found that salivary and subgingival abundance of <italic toggle="yes">P. gingivalis</italic> was positively correlated with BoP, but, specifically, subgingival <italic toggle="yes">P. gingivalis</italic> also correlated with PPD, CAL, and PI. Since <italic toggle="yes">P. gingivalis</italic> colonizes predominantly subgingival biofilms as periodontal disease risk factor (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>), higher subgingival <italic toggle="yes">P. gingivalis</italic> may drive the tissue destruction in periodontal disease patients. The correlation between periodontal parameters and <italic toggle="yes">P. gingivalis</italic> abundance has been described in individuals hospitalized in the intensive care unit, who underwent a complete periodontal examination and microbiological sampling, and showing positive correlation with BoP and PPD (<xref rid="B64" ref-type="bibr">64</xref>).</p><p>This study had several limitations. First, this is a case-control study with its analysis restricted to a specific age range, however, age and sex are confounding variables that could influence. Second, the sample size in our study (n = 20 per group) may limit the analysis of correlations. Thus, further studies will be needed that apply stratification that allows the study population to be divided into age groups, and to evaluate neuropsychological variables and other clinical confounders. Additionally, further investigations are required to clarify the source of increased salivary lactoferrin levels in periodontal condition, including the role of infiltrated neutrophils from microvascular leakage and HPA-mediated salivary gland regulation.</p><p>In conclusion, our data indicates that salivary lactoferrin appears to be associated with stress-related hormones cortisol and DHEA, and abundance of <italic toggle="yes">P. gingivalis</italic> in periodontal disease patients. Furthermore, we found intercorrelations between these biochemical markers and clinical periodontal parameters highlighting the multifactorial feature of periodontal disease associated with oral dysbiosis and the progressive damage of the tooth-supporting tissue. This provides important information about the influence of both local and systemic factors and supports that periodontitis influences not only oral bacterial composition, but also salivary lactoferrin and stress-related hormones with potential effects for other diseases, such as AD, where lactoferrin levels are seriously altered.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank all the participants in this study for their support and dedication to this research.</p></ack><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The original contributions presented in the study are publicly available. Or All data are available in the main text. The original sequencing data was obtained from Buetas et al. 2024 available in the SRA repository with the accession number PRJNA933120.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>The studies involving humans were approved by Ethical Committee from the University of Valencia (ref. 1601392). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>DA: Investigation, Methodology, Software, Writing &#8211; original draft. EB: Investigation, Methodology, Writing &#8211; review &amp; editing. SGE: Methodology, Writing &#8211; review &amp; editing. DR: Methodology, Writing &#8211; original draft. LC: Investigation, Methodology, Writing &#8211; original draft. CM: Investigation, Supervision, Writing &#8211; original draft. AM: Investigation, Supervision, Writing &#8211; review &amp; editing. EC: Funding acquisition, Project administration, Supervision, Writing &#8211; original draft, Writing &#8211; review &amp; editing, Data curation, Investigation, Resources.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassebaum</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Bernab&#233;</surname><given-names>E</given-names></name><name name-style="western"><surname>Dahiya</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhandari</surname><given-names>B</given-names></name><name name-style="western"><surname>Murray</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Marcenes</surname><given-names>W</given-names></name></person-group>. <article-title>Global burden of severe periodontitis in 1990-2010: A systematic review and meta-regression</article-title>. <source>J Dent Res</source>. (<year>2014</year>) <volume>93</volume>:<page-range>1045&#8211;53</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0022034514552491</pub-id>, PMID: <pub-id pub-id-type="pmid">25261053</pub-id><pub-id pub-id-type="pmcid">PMC4293771</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajishengallis</surname><given-names>G</given-names></name><name name-style="western"><surname>Chavakis</surname><given-names>T</given-names></name><name name-style="western"><surname>Lambris</surname><given-names>JD</given-names></name></person-group>. <article-title>Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy</article-title>. <source>Periodontol 2000</source>. (<year>2020</year>) <volume>84</volume>:<fpage>14</fpage>&#8211;<lpage>34</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/prd.12331</pub-id>, PMID: <pub-id pub-id-type="pmid">32844416</pub-id><pub-id pub-id-type="pmcid">PMC7457922</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sansores-Espa&#241;a</surname><given-names>LD</given-names></name><name name-style="western"><surname>Melgar-Rodr&#237;guez</surname><given-names>S</given-names></name><name name-style="western"><surname>Olivares-Sagredo</surname><given-names>K</given-names></name><name name-style="western"><surname>Cafferata</surname><given-names>EA</given-names></name><name name-style="western"><surname>Mart&#237;nez-Aguilar</surname><given-names>VM</given-names></name><name name-style="western"><surname>Vernal</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Oral-gut-brain axis in experimental models of periodontitis: associating gut dysbiosis with neurodegenerative diseases</article-title>. <source>Front Aging</source>. (<year>2021</year>) <volume>2</volume>:<elocation-id>781582</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fragi.2021.781582</pub-id>, PMID: <pub-id pub-id-type="pmid">35822001</pub-id><pub-id pub-id-type="pmcid">PMC9261337</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantarci</surname><given-names>A</given-names></name><name name-style="western"><surname>Tognoni</surname><given-names>CM</given-names></name><name name-style="western"><surname>Yaghmoor</surname><given-names>W</given-names></name><name name-style="western"><surname>Marghalani</surname><given-names>A</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>D</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>JY</given-names></name><etal/></person-group>. <article-title>Microglial response to experimental periodontitis in a murine model of alzheimer&#8217;s disease</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>18561</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-020-75517-4</pub-id>, PMID: <pub-id pub-id-type="pmid">33122702</pub-id><pub-id pub-id-type="pmcid">PMC7596239</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mysak</surname><given-names>J</given-names></name><name name-style="western"><surname>Podzimek</surname><given-names>S</given-names></name><name name-style="western"><surname>Sommerova</surname><given-names>P</given-names></name><name name-style="western"><surname>Lyuya-Mi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bartova</surname><given-names>J</given-names></name><name name-style="western"><surname>Janatova</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Porphyromonas gingivalis: major periodontopathic pathogen overview</article-title>. <source>J Immunol Res</source>. (<year>2014</year>) <volume>2014</volume>:<elocation-id>476068</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2014/476068</pub-id>, PMID: <pub-id pub-id-type="pmid">24741603</pub-id><pub-id pub-id-type="pmcid">PMC3984870</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damgaard</surname><given-names>C</given-names></name><name name-style="western"><surname>Danielsen</surname><given-names>AK</given-names></name><name name-style="western"><surname>Enevold</surname><given-names>C</given-names></name><name name-style="western"><surname>Massarenti</surname><given-names>L</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Holmstrup</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Porphyromonas gingivalis in saliva associates with chronic and aggressive periodontitis</article-title>. <source>J Oral Microbiol</source>. (<year>2019</year>) <volume>11</volume>:<elocation-id>1653123</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1080/20002297.2019.1653123</pub-id>, PMID: <pub-id pub-id-type="pmid">31489129</pub-id><pub-id pub-id-type="pmcid">PMC6713147</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bostanci</surname><given-names>N</given-names></name><name name-style="western"><surname>Belibasakis</surname><given-names>GN</given-names></name></person-group>. <article-title>Porphyromonas gingivalis: an invasive and evasive opportunistic oral pathogen</article-title>. <source>FEMS Microbiol Lett</source>. (<year>2012</year>) <volume>333</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1574-6968.2012.02579.x</pub-id>, PMID: <pub-id pub-id-type="pmid">22530835</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haririan</surname><given-names>H</given-names></name><name name-style="western"><surname>Andrukhov</surname><given-names>O</given-names></name><name name-style="western"><surname>Bertl</surname><given-names>K</given-names></name><name name-style="western"><surname>Lettner</surname><given-names>S</given-names></name><name name-style="western"><surname>Kierstein</surname><given-names>S</given-names></name><name name-style="western"><surname>Moritz</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Microbial analysis of subgingival plaque samples compared to that of whole saliva in patients with periodontitis</article-title>. <source>J Periodontol</source>. (<year>2014</year>) <volume>85</volume>:<page-range>819&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1902/jop.2013.130306</pub-id>, PMID: <pub-id pub-id-type="pmid">24144271</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nickles</surname><given-names>K</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>S</given-names></name><name name-style="western"><surname>R&#246;llke</surname><given-names>L</given-names></name><name name-style="western"><surname>Dannewitz</surname><given-names>B</given-names></name><name name-style="western"><surname>Eickholz</surname><given-names>P</given-names></name></person-group>. <article-title>Comparison of two different sampling methods for subgingival plaque: subgingival paper points or mouthrinse sample</article-title>? <source>J Periodontol</source>. (<year>2017</year>) <volume>88</volume>:<fpage>399</fpage>&#8211;<lpage>406</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1902/jop.2016.160249</pub-id>, PMID: <pub-id pub-id-type="pmid">27786617</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorr</surname><given-names>SU</given-names></name><name name-style="western"><surname>Abdolhosseini</surname><given-names>M</given-names></name></person-group>. <article-title>Antimicrobial peptides and periodontal disease</article-title>. <source>J Clin Periodontol</source>. (<year>2011</year>) <volume>38 Suppl 11</volume>:<page-range>126&#8211;41</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1600-051X.2010.01664.x</pub-id>, PMID: <pub-id pub-id-type="pmid">21323710</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komine</surname><given-names>K</given-names></name><name name-style="western"><surname>Kuroishi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ozawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Komine</surname><given-names>Y</given-names></name><name name-style="western"><surname>Minami</surname><given-names>T</given-names></name><name name-style="western"><surname>Shimauchi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Cleaved inflammatory lactoferrin peptides in parotid saliva of periodontitis patients</article-title>. <source>Mol Immunol</source>. (<year>2007</year>) <volume>44</volume>:<page-range>1498&#8211;508</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.molimm.2006.09.003</pub-id>, PMID: <pub-id pub-id-type="pmid">17030385</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glimvall</surname><given-names>P</given-names></name><name name-style="western"><surname>Wickstr&#246;m</surname><given-names>C</given-names></name><name name-style="western"><surname>Jansson</surname><given-names>H</given-names></name></person-group>. <article-title>Elevated levels of salivary lactoferrin, a marker for chronic periodontitis</article-title>? <source>J Periodontal Res</source>. (<year>2012</year>) <volume>47</volume>:<page-range>655&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1600-0765.2012.01479.x</pub-id>, PMID: <pub-id pub-id-type="pmid">22471324</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramenzoni</surname><given-names>LL</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>D</given-names></name><name name-style="western"><surname>Solderer</surname><given-names>A</given-names></name><name name-style="western"><surname>Wiedemeier</surname><given-names>D</given-names></name><name name-style="western"><surname>Attin</surname><given-names>T</given-names></name><name name-style="western"><surname>Schmidlin</surname><given-names>PR</given-names></name></person-group>. <article-title>Origin of mmp-8 and lactoferrin levels from gingival crevicular fluid, salivary glands and whole saliva</article-title>. <source>BMC Oral Health</source>. (<year>2021</year>) <volume>21</volume>:<fpage>385</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12903-021-01743-5</pub-id>, PMID: <pub-id pub-id-type="pmid">34353321</pub-id><pub-id pub-id-type="pmcid">PMC8340507</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adonogianaki</surname><given-names>E</given-names></name><name name-style="western"><surname>Moughal</surname><given-names>NA</given-names></name><name name-style="western"><surname>Kinane</surname><given-names>DF</given-names></name></person-group>. <article-title>Lactoferrin in the gingival crevice as a marker of polymorphonuclear leucocytes in periodontal diseases</article-title>. <source>J Clin Periodontol</source>. (<year>1993</year>) <volume>20</volume>:<fpage>26</fpage>&#8211;<lpage>31</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1600-051x.1993.tb01755.x</pub-id>, PMID: <pub-id pub-id-type="pmid">8421112</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berlutti</surname><given-names>F</given-names></name><name name-style="western"><surname>Pilloni</surname><given-names>A</given-names></name><name name-style="western"><surname>Pietropaoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Polimeni</surname><given-names>A</given-names></name><name name-style="western"><surname>Valenti</surname><given-names>P</given-names></name></person-group>. <article-title>Lactoferrin and oral diseases: current status and perspective in periodontitis</article-title>. <source>Ann Stomatol (Roma)</source>. (<year>2011</year>) <volume>2</volume>:<page-range>10&#8211;8</page-range>., PMID: <pub-id pub-id-type="pmid">22545184</pub-id><pub-id pub-id-type="pmcid">PMC3314318</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reseco</surname><given-names>L</given-names></name><name name-style="western"><surname>Atienza</surname><given-names>M</given-names></name><name name-style="western"><surname>Fernandez-Alvarez</surname><given-names>M</given-names></name><name name-style="western"><surname>Carro</surname><given-names>E</given-names></name><name name-style="western"><surname>Cantero</surname><given-names>JL</given-names></name></person-group>. <article-title>Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging</article-title>. <source>Alzheimers Res Ther</source>. (<year>2021</year>) <volume>13</volume>:<fpage>150</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13195-021-00891-8</pub-id>, PMID: <pub-id pub-id-type="pmid">34488875</pub-id><pub-id pub-id-type="pmcid">PMC8422723</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carro</surname><given-names>E</given-names></name><name name-style="western"><surname>Bartolom&#233;</surname><given-names>F</given-names></name><name name-style="western"><surname>Bermejo-Pareja</surname><given-names>F</given-names></name><name name-style="western"><surname>Villarejo-Galende</surname><given-names>A</given-names></name><name name-style="western"><surname>Molina</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Early diagnosis of mild cognitive impairment and alzheimer&#8217;s disease based on salivary lactoferrin</article-title>. <source>Alzheimers Dement (Amst)</source>. (<year>2017</year>) <volume>8</volume>:<page-range>131&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.dadm.2017.04.002</pub-id>, PMID: <pub-id pub-id-type="pmid">28649597</pub-id><pub-id pub-id-type="pmcid">PMC5470603</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antequera</surname><given-names>D</given-names></name><name name-style="western"><surname>Carrero</surname><given-names>L</given-names></name><name name-style="western"><surname>Gonzalez-Sanchez</surname><given-names>M</given-names></name><name name-style="western"><surname>Cantero</surname><given-names>JL</given-names></name><name name-style="western"><surname>Orive</surname><given-names>G</given-names></name><name name-style="western"><surname>Municio</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Reduced salivary lactoferrin levels in early-onset alzheimer&#8217;s disease</article-title>. <source>Aging Dis</source>. (<year>2024</year>) <volume>15</volume>:<page-range>945&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.14336/ad.2023.0819</pub-id>, PMID: <pub-id pub-id-type="pmid">37815910</pub-id><pub-id pub-id-type="pmcid">PMC11081168</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-S&#225;nchez</surname><given-names>M</given-names></name><name name-style="western"><surname>Bartolome</surname><given-names>F</given-names></name><name name-style="western"><surname>Antequera</surname><given-names>D</given-names></name><name name-style="western"><surname>Puertas-Mart&#237;n</surname><given-names>V</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>P</given-names></name><name name-style="western"><surname>G&#243;mez-Grande</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Decreased salivary lactoferrin levels are specific to alzheimer&#8217;s disease</article-title>. <source>EBioMedicine</source>. (<year>2020</year>) <volume>57</volume>:<elocation-id>102834</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102834</pub-id>, PMID: <pub-id pub-id-type="pmid">32586758</pub-id><pub-id pub-id-type="pmcid">PMC7378957</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papacosta</surname><given-names>E</given-names></name><name name-style="western"><surname>Nassis</surname><given-names>GP</given-names></name></person-group>. <article-title>Saliva as a tool for monitoring steroid, peptide and immune markers in sport and exercise science</article-title>. <source>J Sci Med Sport</source>. (<year>2011</year>) <volume>14</volume>:<page-range>424&#8211;34</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jsams.2011.03.004</pub-id>, PMID: <pub-id pub-id-type="pmid">21474377</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proctor</surname><given-names>GB</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>GH</given-names></name></person-group>. <article-title>Regulation of salivary gland function by autonomic nerves</article-title>. <source>Auton Neurosci</source>. (<year>2007</year>) <volume>133</volume>:<fpage>3</fpage>&#8211;<lpage>18</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.autneu.2006.10.006</pub-id>, PMID: <pub-id pub-id-type="pmid">17157080</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antequera</surname><given-names>D</given-names></name><name name-style="western"><surname>Moneo</surname><given-names>D</given-names></name><name name-style="western"><surname>Carrero</surname><given-names>L</given-names></name><name name-style="western"><surname>Bartolome</surname><given-names>F</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I</given-names></name><name name-style="western"><surname>Proctor</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Salivary lactoferrin expression in a mouse model of alzheimer&#8217;s disease</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>749468</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.749468</pub-id>, PMID: <pub-id pub-id-type="pmid">34659251</pub-id><pub-id pub-id-type="pmcid">PMC8514982</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knight</surname><given-names>ET</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Faggion</surname><given-names>CM</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Cullinan</surname><given-names>MP</given-names></name></person-group>. <article-title>Risk factors that may modify the innate and adaptive immune responses in periodontal diseases</article-title>. <source>Periodontol 2000</source>. (<year>2016</year>) <volume>71</volume>:<fpage>22</fpage>&#8211;<lpage>51</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/prd.12110</pub-id>, PMID: <pub-id pub-id-type="pmid">27045429</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunz-Ebrecht</surname><given-names>SR</given-names></name><name name-style="western"><surname>Mohamed-Ali</surname><given-names>V</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Kirschbaum</surname><given-names>C</given-names></name><name name-style="western"><surname>Steptoe</surname><given-names>A</given-names></name></person-group>. <article-title>Cortisol responses to mild psychological stress are inversely associated with proinflammatory cytokines</article-title>. <source>Brain Behav Immun</source>. (<year>2003</year>) <volume>17</volume>:<page-range>373&#8211;83</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0889-1591(03)00029-1</pub-id>, PMID: <pub-id pub-id-type="pmid">12946659</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basson</surname><given-names>R</given-names></name><name name-style="western"><surname>O&#8217;Loughlin</surname><given-names>JI</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Young</surname><given-names>AH</given-names></name><name name-style="western"><surname>Bodnar</surname><given-names>T</given-names></name><name name-style="western"><surname>Brotto</surname><given-names>LA</given-names></name></person-group>. <article-title>Dehydroepiandrosterone and cortisol as markers of hpa axis dysregulation in women with low sexual desire</article-title>. <source>Psychoneuroendocrinology</source>. (<year>2019</year>) <volume>104</volume>:<page-range>259&#8211;68</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.psyneuen.2019.03.001</pub-id>, PMID: <pub-id pub-id-type="pmid">30909007</pub-id><pub-id pub-id-type="pmcid">PMC7343293</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yost</surname><given-names>S</given-names></name><name name-style="western"><surname>Duran-Pinedo</surname><given-names>AE</given-names></name><name name-style="western"><surname>Teles</surname><given-names>R</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>K</given-names></name><name name-style="western"><surname>Frias-Lopez</surname><given-names>J</given-names></name></person-group>. <article-title>Functional signatures of oral dysbiosis during periodontitis progression revealed by microbial metatranscriptome analysis</article-title>. <source>Genome Med</source>. (<year>2015</year>) <volume>7</volume>:<fpage>27</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13073-015-0153-3</pub-id>, PMID: <pub-id pub-id-type="pmid">25918553</pub-id><pub-id pub-id-type="pmcid">PMC4410737</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akcal&#305;</surname><given-names>A</given-names></name><name name-style="western"><surname>Huck</surname><given-names>O</given-names></name><name name-style="western"><surname>Buduneli</surname><given-names>N</given-names></name><name name-style="western"><surname>Davideau</surname><given-names>JL</given-names></name><name name-style="western"><surname>K&#246;se</surname><given-names>T</given-names></name><name name-style="western"><surname>Tenenbaum</surname><given-names>H</given-names></name></person-group>. <article-title>Exposure of porphyromonas gingivalis to cortisol increases bacterial growth</article-title>. <source>Arch Oral Biol</source>. (<year>2014</year>) <volume>59</volume>:<page-range>30&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.archoralbio.2013.09.003</pub-id>, PMID: <pub-id pub-id-type="pmid">24200466</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>YH</given-names></name><name name-style="western"><surname>Suk</surname><given-names>C</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SI</given-names></name><name name-style="western"><surname>Hong</surname><given-names>JY</given-names></name></person-group>. <article-title>Salivary cortisol, dehydroepiandrosterone, and chromogranin a levels in patients with gingivitis and periodontitis and a novel biomarker for psychological stress</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1147739</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fendo.2023.1147739</pub-id>, PMID: <pub-id pub-id-type="pmid">37113482</pub-id><pub-id pub-id-type="pmcid">PMC10126469</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubar</surname><given-names>M</given-names></name><name name-style="western"><surname>Clerc-Urm&#232;s</surname><given-names>I</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>C</given-names></name><name name-style="western"><surname>Cl&#233;ment</surname><given-names>C</given-names></name><name name-style="western"><surname>Alauzet</surname><given-names>C</given-names></name><name name-style="western"><surname>Bisson</surname><given-names>C</given-names></name></person-group>. <article-title>Relations of Psychosocial Factors and Cortisol with Periodontal and Bacterial Parameters: A Prospective Clinical Study in 30 Patients with Periodontitis before and after Non-Surgical Treatment</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2020</year>) <volume>17</volume>:<fpage>7651</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijerph17207651</pub-id>, PMID: <pub-id pub-id-type="pmid">33092182</pub-id><pub-id pub-id-type="pmcid">PMC7588876</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajishengallis</surname><given-names>G</given-names></name><name name-style="western"><surname>Darveau</surname><given-names>RP</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>MA</given-names></name></person-group>. <article-title>The keystone-pathogen hypothesis</article-title>. <source>Nat Rev Microbiol</source>. (<year>2012</year>) <volume>10</volume>:<page-range>717&#8211;25</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrmicro2873</pub-id>, PMID: <pub-id pub-id-type="pmid">22941505</pub-id><pub-id pub-id-type="pmcid">PMC3498498</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>C</given-names></name><name name-style="western"><surname>Round</surname><given-names>JL</given-names></name></person-group>. <article-title>Defining dysbiosis and its influence on host immunity and disease</article-title>. <source>Cell Microbiol</source>. (<year>2014</year>) <volume>16</volume>:<page-range>1024&#8211;33</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/cmi.12308</pub-id>, PMID: <pub-id pub-id-type="pmid">24798552</pub-id><pub-id pub-id-type="pmcid">PMC4143175</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>C</given-names></name><name name-style="western"><surname>Dilthey</surname><given-names>A</given-names></name><name name-style="western"><surname>Finzer</surname><given-names>P</given-names></name></person-group>. <article-title>The role of microbiome-host interactions in the development of alzheimer&#180;S disease</article-title>. <source>Front Cell Infect Microbiol</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>1151021</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcimb.2023.1151021</pub-id>, PMID: <pub-id pub-id-type="pmid">37333848</pub-id><pub-id pub-id-type="pmcid">PMC10272569</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faridvand</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nozari</surname><given-names>S</given-names></name><name name-style="western"><surname>Asoudeh-Fard</surname><given-names>A</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>MA</given-names></name><name name-style="western"><surname>Pezeshkian</surname><given-names>M</given-names></name><name name-style="western"><surname>Safaie</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Bovine lactoferrin ameliorates antioxidant esterase activity and 8-isoprostane levels in high-cholesterol-diet fed rats</article-title>. <source>Int J Vitam Nutr Res</source>. (<year>2017</year>) <volume>87</volume>:<page-range>201&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1024/0300-9831/a000516</pub-id>, PMID: <pub-id pub-id-type="pmid">30789809</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lynge Pedersen</surname><given-names>AM</given-names></name><name name-style="western"><surname>Belstr&#248;m</surname><given-names>D</given-names></name></person-group>. <article-title>The role of natural salivary defences in maintaining a healthy oral microbiota</article-title>. <source>J Dent</source>. (<year>2019</year>) <volume>80 Suppl 1</volume>:<fpage>S3</fpage>&#8211;<lpage>s12</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jdent.2018.08.010</pub-id>, PMID: <pub-id pub-id-type="pmid">30696553</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Haley</surname><given-names>KP</given-names></name><name name-style="western"><surname>Francis</surname><given-names>JD</given-names></name><name name-style="western"><surname>Guevara</surname><given-names>MA</given-names></name><name name-style="western"><surname>Doster</surname><given-names>RS</given-names></name><name name-style="western"><surname>Craft</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>The innate immune glycoprotein lactoferrin represses the helicobacter pylori cag type iv secretion system</article-title>. <source>Chembiochem</source>. (<year>2021</year>) <volume>22</volume>:<page-range>2783&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/cbic.202100249</pub-id>, PMID: <pub-id pub-id-type="pmid">34169626</pub-id><pub-id pub-id-type="pmcid">PMC8560179</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puddu</surname><given-names>P</given-names></name><name name-style="western"><surname>Latorre</surname><given-names>D</given-names></name><name name-style="western"><surname>Carollo</surname><given-names>M</given-names></name><name name-style="western"><surname>Catizone</surname><given-names>A</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>G</given-names></name><name name-style="western"><surname>Valenti</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Bovine lactoferrin counteracts toll-like receptor mediated activation signals in antigen presenting cells</article-title>. <source>PloS One</source>. (<year>2011</year>) <volume>6</volume>:<fpage>e22504</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0022504</pub-id>, PMID: <pub-id pub-id-type="pmid">21799877</pub-id><pub-id pub-id-type="pmcid">PMC3143167</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tonetti</surname><given-names>MS</given-names></name><name name-style="western"><surname>Greenwell</surname><given-names>H</given-names></name><name name-style="western"><surname>Kornman</surname><given-names>KS</given-names></name></person-group>. <article-title>Staging and grading of periodontitis: framework and proposal of a new classification and case definition</article-title>. <source>J Periodontol</source>. (<year>2018</year>) <volume>89 Suppl 1</volume>:<page-range>S159&#8211;s72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jper.18-0006</pub-id>, PMID: <pub-id pub-id-type="pmid">29926952</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim&#243;n-Soro</surname><given-names>A</given-names></name><name name-style="western"><surname>Tom&#225;s</surname><given-names>I</given-names></name><name name-style="western"><surname>Cabrera-Rubio</surname><given-names>R</given-names></name><name name-style="western"><surname>Catalan</surname><given-names>MD</given-names></name><name name-style="western"><surname>Nyvad</surname><given-names>B</given-names></name><name name-style="western"><surname>Mira</surname><given-names>A</given-names></name></person-group>. <article-title>Microbial geography of the oral cavity</article-title>. <source>J Dent Res</source>. (<year>2013</year>) <volume>92</volume>:<page-range>616&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0022034513488119</pub-id>, PMID: <pub-id pub-id-type="pmid">23674263</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buetas</surname><given-names>E</given-names></name><name name-style="western"><surname>Jord&#225;n-L&#243;pez</surname><given-names>M</given-names></name><name name-style="western"><surname>L&#243;pez-Rold&#225;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Mira</surname><given-names>A</given-names></name><name name-style="western"><surname>Carda-Di&#233;guez</surname><given-names>M</given-names></name></person-group>. <article-title>Impact of periodontitis on the leakage of oral bacteria to the gut</article-title>. <source>J Dent Res</source>. (<year>2024</year>) <volume>103</volume>:<page-range>289&#8211;97</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/00220345231221709</pub-id>, PMID: <pub-id pub-id-type="pmid">38193290</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callahan</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J</given-names></name><name name-style="western"><surname>Heiner</surname><given-names>C</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S</given-names></name><name name-style="western"><surname>Theriot</surname><given-names>CM</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>High-throughput amplicon sequencing of the full-length 16s rrna gene with single-nucleotide resolution</article-title>. <source>Nucleic Acids Res</source>. (<year>2019</year>) <volume>47</volume>:<fpage>e103</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gkz569</pub-id>, PMID: <pub-id pub-id-type="pmid">31269198</pub-id><pub-id pub-id-type="pmcid">PMC6765137</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLaren</surname><given-names>MR</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>BJ</given-names></name></person-group>. <article-title>Silva 138.1 prokaryotic SSU taxonomic training data formatted for DADA2</article-title>. (<year>2021</year>). doi:&#160;<pub-id pub-id-type="doi">10.5281/ZENODO.4587955</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsha</surname><given-names>TE</given-names></name><name name-style="western"><surname>Prince</surname><given-names>Y</given-names></name><name name-style="western"><surname>Davids</surname><given-names>S</given-names></name><name name-style="western"><surname>Chikte</surname><given-names>U</given-names></name><name name-style="western"><surname>Erasmus</surname><given-names>RT</given-names></name><name name-style="western"><surname>Kengne</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Oral microbiome signatures in diabetes mellitus and periodontal disease</article-title>. <source>J Dent Res</source>. (<year>2020</year>) <volume>99</volume>:<page-range>658&#8211;65</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0022034520913818</pub-id>, PMID: <pub-id pub-id-type="pmid">32298191</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamont</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Koo</surname><given-names>H</given-names></name><name name-style="western"><surname>Hajishengallis</surname><given-names>G</given-names></name></person-group>. <article-title>The oral microbiota: dynamic communities and host interactions</article-title>. <source>Nat Rev Microbiol</source>. (<year>2018</year>) <volume>16</volume>:<page-range>745&#8211;59</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41579-018-0089-x</pub-id>, PMID: <pub-id pub-id-type="pmid">30301974</pub-id><pub-id pub-id-type="pmcid">PMC6278837</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darveau</surname><given-names>RP</given-names></name></person-group>. <article-title>Periodontitis: A polymicrobial disruption of host homeostasis</article-title>. <source>Nat Rev Microbiol</source>. (<year>2010</year>) <volume>8</volume>:<page-range>481&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrmicro2337</pub-id>, PMID: <pub-id pub-id-type="pmid">20514045</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilian</surname><given-names>M</given-names></name><name name-style="western"><surname>Chapple</surname><given-names>IL</given-names></name><name name-style="western"><surname>Hannig</surname><given-names>M</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>PD</given-names></name><name name-style="western"><surname>Meuric</surname><given-names>V</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>The oral microbiome - an update for oral healthcare professionals</article-title>. <source>Br Dent J</source>. (<year>2016</year>) <volume>221</volume>:<page-range>657&#8211;66</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/sj.bdj.2016.865</pub-id>, PMID: <pub-id pub-id-type="pmid">27857087</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Timilsena</surname><given-names>YP</given-names></name><name name-style="western"><surname>Blanch</surname><given-names>E</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>B</given-names></name></person-group>. <article-title>Lactoferrin: structure, function, denaturation and digestion</article-title>. <source>Crit Rev Food Sci Nutr</source>. (<year>2019</year>) <volume>59</volume>:<page-range>580&#8211;96</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/10408398.2017.1381583</pub-id>, PMID: <pub-id pub-id-type="pmid">28933602</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruzel</surname><given-names>ML</given-names></name><name name-style="western"><surname>Zimecki</surname><given-names>M</given-names></name><name name-style="western"><surname>Actor</surname><given-names>JK</given-names></name></person-group>. <article-title>Lactoferrin in a context of inflammation-induced pathology</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<elocation-id>1438</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.01438</pub-id>, PMID: <pub-id pub-id-type="pmid">29163511</pub-id><pub-id pub-id-type="pmcid">PMC5681489</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dashper</surname><given-names>SG</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Veith</surname><given-names>PD</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YY</given-names></name><name name-style="western"><surname>Toh</surname><given-names>EC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>SW</given-names></name><etal/></person-group>. <article-title>Lactoferrin inhibits porphyromonas gingivalis proteinases and has sustained biofilm inhibitory activity</article-title>. <source>Antimicrob Agents Chemother</source>. (<year>2012</year>) <volume>56</volume>:<page-range>1548&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/aac.05100-11</pub-id>, PMID: <pub-id pub-id-type="pmid">22214780</pub-id><pub-id pub-id-type="pmcid">PMC3294922</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salazar</surname><given-names>MG</given-names></name><name name-style="western"><surname>Jehmlich</surname><given-names>N</given-names></name><name name-style="western"><surname>Murr</surname><given-names>A</given-names></name><name name-style="western"><surname>Dhople</surname><given-names>VM</given-names></name><name name-style="western"><surname>Holtfreter</surname><given-names>B</given-names></name><name name-style="western"><surname>Hammer</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Identification of periodontitis associated changes in the proteome of whole human saliva by mass spectrometric analysis</article-title>. <source>J Clin Periodontol</source>. (<year>2013</year>) <volume>40</volume>:<page-range>825&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/jcpe.12130</pub-id>, PMID: <pub-id pub-id-type="pmid">23790309</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramenzoni</surname><given-names>LL</given-names></name><name name-style="western"><surname>Lehner</surname><given-names>MP</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>ME</given-names></name><name name-style="western"><surname>Wiedemeier</surname><given-names>D</given-names></name><name name-style="western"><surname>Attin</surname><given-names>T</given-names></name><name name-style="western"><surname>Schmidlin</surname><given-names>PR</given-names></name></person-group>. <article-title>Oral diagnostic methods for the detection of periodontal disease</article-title>. <source>Diagn (Basel)</source>. (<year>2021</year>) <volume>11</volume>:<fpage>571</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/diagnostics11030571</pub-id>, PMID: <pub-id pub-id-type="pmid">33810094</pub-id><pub-id pub-id-type="pmcid">PMC8005070</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soehnlein</surname><given-names>O</given-names></name></person-group>. <article-title>An elegant defense: how neutrophils shape the immune response</article-title>. <source>Trends Immunol</source>. (<year>2009</year>) <volume>30</volume>:<page-range>511&#8211;2</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.it.2009.07.002</pub-id>, PMID: <pub-id pub-id-type="pmid">19709929</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lepanto</surname><given-names>MS</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>L</given-names></name><name name-style="western"><surname>Paesano</surname><given-names>R</given-names></name><name name-style="western"><surname>Valenti</surname><given-names>P</given-names></name><name name-style="western"><surname>Cutone</surname><given-names>A</given-names></name></person-group>. <article-title>Lactoferrin in aseptic and septic inflammation</article-title>. <source>Molecules</source>. (<year>2019</year>) <volume>24</volume>:<fpage>1323</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/molecules24071323</pub-id>, PMID: <pub-id pub-id-type="pmid">30987256</pub-id><pub-id pub-id-type="pmcid">PMC6480387</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landzberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Doering</surname><given-names>H</given-names></name><name name-style="western"><surname>Aboodi</surname><given-names>GM</given-names></name><name name-style="western"><surname>Tenenbaum</surname><given-names>HC</given-names></name><name name-style="western"><surname>Glogauer</surname><given-names>M</given-names></name></person-group>. <article-title>Quantifying oral inflammatory load: oral neutrophil counts in periodontal health and disease</article-title>. <source>J Periodontal Res</source>. (<year>2015</year>) <volume>50</volume>:<page-range>330&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/jre.12211</pub-id>, PMID: <pub-id pub-id-type="pmid">25040400</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>DW</given-names></name><name name-style="western"><surname>Greenwell-Wild</surname><given-names>T</given-names></name><name name-style="western"><surname>Brenchley</surname><given-names>L</given-names></name><name name-style="western"><surname>Dutzan</surname><given-names>N</given-names></name><name name-style="western"><surname>Overmiller</surname><given-names>A</given-names></name><name name-style="western"><surname>Sawaya</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Human oral mucosa cell atlas reveals a stromal-neutrophil axis regulating tissue immunity</article-title>. <source>Cell</source>. (<year>2021</year>) <volume>184</volume>:<fpage>4090</fpage>&#8211;<lpage>104.e15</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2021.05.013</pub-id>, PMID: <pub-id pub-id-type="pmid">34129837</pub-id><pub-id pub-id-type="pmcid">PMC8359928</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbarao</surname><given-names>KC</given-names></name><name name-style="western"><surname>Nattuthurai</surname><given-names>GS</given-names></name><name name-style="western"><surname>Sundararajan</surname><given-names>SK</given-names></name><name name-style="western"><surname>Sujith</surname><given-names>I</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>J</given-names></name><name name-style="western"><surname>Syedshah</surname><given-names>YP</given-names></name></person-group>. <article-title>Gingival crevicular fluid: an overview</article-title>. <source>J Pharm Bioallied Sci</source>. (<year>2019</year>) <volume>11</volume>:<page-range>S135&#8211;s9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4103/jpbs.Jpbs_56_19</pub-id>, PMID: <pub-id pub-id-type="pmid">31198325</pub-id><pub-id pub-id-type="pmcid">PMC6555362</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>HM</given-names></name><name name-style="western"><surname>Yonel</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kantarci</surname><given-names>A</given-names></name><name name-style="western"><surname>Grant</surname><given-names>MM</given-names></name><name name-style="western"><surname>Chapple</surname><given-names>ILC</given-names></name></person-group>. <article-title>Impact of gingivitis on circulating neutrophil reactivity and gingival crevicular fluid inflammatory proteins</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2022</year>) <volume>19</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijerph19106339</pub-id>, PMID: <pub-id pub-id-type="pmid">35627876</pub-id><pub-id pub-id-type="pmcid">PMC9141451</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yilmaz</surname><given-names>&#214;</given-names></name></person-group>. <article-title>The chronicles of porphyromonas gingivalis: the microbium, the human oral epithelium and their interplay</article-title>. <source>Microbiol (Reading)</source>. (<year>2008</year>) <volume>154</volume>:<page-range>2897&#8211;903</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1099/mic.0.2008/021220-0</pub-id>, PMID: <pub-id pub-id-type="pmid">18832296</pub-id><pub-id pub-id-type="pmcid">PMC2639765</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duran-Pinedo</surname><given-names>AE</given-names></name><name name-style="western"><surname>Solbiati</surname><given-names>J</given-names></name><name name-style="western"><surname>Frias-Lopez</surname><given-names>J</given-names></name></person-group>. <article-title>The effect of the stress hormone cortisol on the metatranscriptome of the oral microbiome</article-title>. <source>NPJ Biofilms Microbiomes</source>. (<year>2018</year>) <volume>4</volume>:<fpage>25</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41522-018-0068-z</pub-id>, PMID: <pub-id pub-id-type="pmid">30345066</pub-id><pub-id pub-id-type="pmcid">PMC6194028</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proctor</surname><given-names>GB</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>GH</given-names></name></person-group>. <article-title>Salivary secretion: mechanism and neural regulation</article-title>. <source>Monogr Oral Sci</source>. (<year>2014</year>) <volume>24</volume>:<fpage>14</fpage>&#8211;<lpage>29</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1159/000358781</pub-id>, PMID: <pub-id pub-id-type="pmid">24862591</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ardila</surname><given-names>CM</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>IC</given-names></name></person-group>. <article-title>Association of porphyromonas gingivalis with high levels of stress-induced hormone cortisol in chronic periodontitis patients</article-title>. <source>J Investig Clin Dent</source>. (<year>2016</year>) <volume>7</volume>:<page-range>361&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/jicd.12175</pub-id>, PMID: <pub-id pub-id-type="pmid">26194628</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botelho</surname><given-names>J</given-names></name><name name-style="western"><surname>MaChado</surname><given-names>V</given-names></name><name name-style="western"><surname>Mascarenhas</surname><given-names>P</given-names></name><name name-style="western"><surname>Rua</surname><given-names>J</given-names></name><name name-style="western"><surname>Alves</surname><given-names>R</given-names></name><name name-style="western"><surname>Cavacas</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Stress, salivary cortisol and periodontitis: A systematic review and meta-analysis of observational studies</article-title>. <source>Arch Oral Biol</source>. (<year>2018</year>) <volume>96</volume>:<fpage>58</fpage>&#8211;<lpage>65</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.archoralbio.2018.08.016</pub-id>, PMID: <pub-id pub-id-type="pmid">30189327</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinney</surname><given-names>JS</given-names></name><name name-style="western"><surname>Morelli</surname><given-names>T</given-names></name><name name-style="western"><surname>Braun</surname><given-names>T</given-names></name><name name-style="western"><surname>Ramseier</surname><given-names>CA</given-names></name><name name-style="western"><surname>Herr</surname><given-names>AE</given-names></name><name name-style="western"><surname>Sugai</surname><given-names>JV</given-names></name><etal/></person-group>. <article-title>Saliva/pathogen biomarker signatures and periodontal disease progression</article-title>. <source>J Dent Res</source>. (<year>2011</year>) <volume>90</volume>:<page-range>752&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0022034511399908</pub-id>, PMID: <pub-id pub-id-type="pmid">21406610</pub-id><pub-id pub-id-type="pmcid">PMC3144122</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liljestrand</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gursoy</surname><given-names>UK</given-names></name><name name-style="western"><surname>Hyv&#228;rinen</surname><given-names>K</given-names></name><name name-style="western"><surname>Sorsa</surname><given-names>T</given-names></name><name name-style="western"><surname>Suominen</surname><given-names>AL</given-names></name><name name-style="western"><surname>K&#246;n&#246;nen</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Combining salivary pathogen and serum antibody levels improves their diagnostic ability in detection of periodontitis</article-title>. <source>J Periodontol</source>. (<year>2014</year>) <volume>85</volume>:<page-range>123&#8211;31</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1902/jop.2013.130030</pub-id>, PMID: <pub-id pub-id-type="pmid">23646849</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ara&#250;jo</surname><given-names>MM</given-names></name><name name-style="western"><surname>Albuquerque</surname><given-names>BN</given-names></name><name name-style="western"><surname>Cota</surname><given-names>LOM</given-names></name><name name-style="western"><surname>Cortelli</surname><given-names>SC</given-names></name><name name-style="western"><surname>Cortelli</surname><given-names>JR</given-names></name><name name-style="western"><surname>Costa</surname><given-names>FO</given-names></name></person-group>. <article-title>Periodontitis and periodontopathogens in individuals hospitalized in the intensive care unit: A case-control study</article-title>. <source>Braz Dent J</source>. (<year>2019</year>) <volume>30</volume>:<page-range>342&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1590/0103-6440201902480</pub-id>, PMID: <pub-id pub-id-type="pmid">31340223</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurol</journal-id><journal-id journal-id-type="iso-abbrev">J Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Journal of Neurology</journal-title></journal-title-group><issn pub-type="ppub">0340-5354</issn><issn pub-type="epub">1432-1459</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12500819</article-id><article-id pub-id-type="pmcid-ver">PMC12500819.1</article-id><article-id pub-id-type="pmcaid">12500819</article-id><article-id pub-id-type="pmcaiid">12500819</article-id><article-id pub-id-type="pmid">41051527</article-id><article-id pub-id-type="doi">10.1007/s00415-025-13428-y</article-id><article-id pub-id-type="publisher-id">13428</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Communication</subject></subj-group></article-categories><title-group><article-title>Alpha-internexin as a brain-specific neurodegeneration marker: development and validation of a novel CSF assay</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3343-7351</contrib-id><name name-style="western"><surname>Meda</surname><given-names initials="FJ">Francisco J.</given-names></name><address><email>francisco.meda@gu.se</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dittrich</surname><given-names initials="A">Anna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Skoog</surname><given-names initials="I">Ingmar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kern</surname><given-names initials="S">Silke</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leckey</surname><given-names initials="C">Claire</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wild</surname><given-names initials="EJ">Edward J.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Paterson</surname><given-names initials="RW">Ross W.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brinkmalm</surname><given-names initials="G">Gunnar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Andreasson</surname><given-names initials="U">Ulf</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blennow</surname><given-names initials="K">Kaj</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zetterberg</surname><given-names initials="H">Henrik</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kvartsberg</surname><given-names initials="H">Hlin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tm6cn81</institution-id><institution-id institution-id-type="GRID">grid.8761.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9919 9582</institution-id><institution>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, </institution><institution>The Sahlgrenska Academy at the University of Gothenburg, </institution></institution-wrap>M&#246;lndal, Sweden </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tm6cn81</institution-id><institution-id institution-id-type="GRID">grid.8761.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9919 9582</institution-id><institution>Sahlgrenska Academy, University of Gothenburg, Neuropsychiatric Epidemiology Unit, </institution></institution-wrap>Gothenburg, Sweden </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04vgqjj36</institution-id><institution-id institution-id-type="GRID">grid.1649.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9445 082X</institution-id><institution>Sahlgrenska University Hospital, Department of Neuropsychiatry, </institution></institution-wrap>M&#246;lndal, Sweden </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02wedp412</institution-id><institution-id institution-id-type="GRID">grid.511435.7</institution-id><institution-id institution-id-type="ISNI">0000 0005 0281 4208</institution-id><institution>UK Dementia Research Institute at University College London, </institution></institution-wrap>London, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>UCL Huntington&#8217;s Disease Centre, Institute of Neurology, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04vgqjj36</institution-id><institution-id institution-id-type="GRID">grid.1649.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9445 082X</institution-id><institution>Clinical Neurochemistry Laboratory, </institution><institution>Sahlgrenska University Hospital, </institution></institution-wrap>M&#246;lndal, Sweden </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00q4vv597</institution-id><institution-id institution-id-type="GRID">grid.24515.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1450</institution-id><institution>Hong Kong Center for Neurodegenerative Diseases, </institution><institution>HKCeND, </institution></institution-wrap>Hong Kong, China </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01y2jtd41</institution-id><institution-id institution-id-type="GRID">grid.14003.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2167 3675</institution-id><institution>Wisconsin Alzheimer&#8217;s Disease Research Center, School of Medicine and Public Health, </institution><institution>University of Wisconsin, </institution></institution-wrap>Madison, WI USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03ydkyb10</institution-id><institution-id institution-id-type="GRID">grid.28803.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 0701 8607</institution-id><institution>Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, </institution><institution>University of Wisconsin, </institution></institution-wrap>Madison, WI USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>Department of Neurodegenerative Disease, Dementia Research Centre, </institution><institution>UCL Institute of Neurology, Queen Square, </institution></institution-wrap>London, UK </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05j873a45</institution-id><institution-id institution-id-type="GRID">grid.464869.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9288 3664</institution-id><institution>Centre for Brain Research, </institution><institution>Indian Institute of Science, </institution></institution-wrap>Bangalore, India </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>272</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498445</issue-id><elocation-id>676</elocation-id><history><date date-type="received"><day>25</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>22</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="415_2025_Article_13428.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Alpha-internexin (AINX) is a type IV intermediate filament alongside the neurofilament triplet proteins and periferin. Despite its homologies, the key difference is that AINX is central nervous system-specific. The purpose of this study was to develop an immunoassay for cerebrospinal fluid (CSF) AINX, quantify it in patients with neurodegenerative diseases, and compare its diagnostic performance with neurofilament light (NfL).</p></sec><sec><title>Methods</title><p id="Par2">Monoclonal antibodies were generated and characterized by immunoprecipitation followed by mass spectrometry and ELISA, for specificity to the target analyte and cross-reactivity. Single molecule array (Simoa) technology was the selected platform for assay development. The assay was validated according to pre-established parameters and AINX performance as a biomarker was tested in two independent cohorts (Gothenburg and University College London).</p></sec><sec><title>Results</title><p id="Par3">Two highly specific antibodies were generated (B15 and Ina1) and used to develop a robust assay in all analytical validation parameters tested. The quantitative range of the assay was 0.137&#8211;140&#160;pg/mL. In the Gothenburg cohort, AINX and NfL showed similar diagnostic performance, but the correlation between biomarkers was diagnosis dependent. In the University College London cohort, AINX and NfL showed similar trends across the different neurodegenerative diseases, with strong correlation between markers.</p></sec><sec><title>Conclusions</title><p id="Par4">We developed a highly sensitive and specific immunoassay for AINX in CSF. AINX showed similar diagnostic performance and high correlation with CSF NfL. Further research should focus on describing its role in specific disorders, as well as evaluate its potential as a blood-based biomarker.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00415-025-13428-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alpha-internexin</kwd><kwd>Neurofilaments</kwd><kwd>Immunoassay</kwd><kwd>Cerebrospinal fluid</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010665</institution-id><institution>H2020 Marie Sk&#322;odowska-Curie Actions</institution></institution-wrap></funding-source><award-id>860197</award-id><principal-award-recipient><name name-style="western"><surname>Zetterberg</surname><given-names>Henrik</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsr&#229;det</institution></institution-wrap></funding-source><award-id>#2023-00356</award-id><award-id>#2022-01018</award-id><award-id>#2019-02397</award-id><award-id>#2017-00915</award-id><award-id>#2022-00732</award-id><principal-award-recipient><name name-style="western"><surname>Blennow</surname><given-names>Kaj</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>Henrik</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>University of Gothenburg</institution></funding-source></award-group><open-access><p>Open access funding provided by University of Gothenburg.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Alpha-internexin (AINX) is a 66&#160;kDa protein, similar in structure to the neurofilament triplet proteins (NFTPs), neurofilament light (NfL), neurofilament medium (NfM), and neurofilament heavy (NfH) with a conserved mid coiled-coil rod domain, flanked by an N-terminal head and C-terminus tail domain making it a part of the type IV intermediate filament family [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. It is mainly expressed in the developing brain where it is a key factor in intermediate filament formation [<xref ref-type="bibr" rid="CR3">3</xref>]. With its ability to homo-oligomerize, similarly to neurofilament light (NfL), AINX creates the backbone for intermediate filament formation [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Studies suggest that AINX exists in similar abundance as the NFTPs and with relatively fixed stoichiometry of 2:1 (NfL:AINX) in rat optic nerve with similar turnover rates [<xref ref-type="bibr" rid="CR6">6</xref>], and in mouse olfactory bulb at the embryonic and post-natal stages [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par6">AINX is present across the brain, with especially high expression in cerebellar granule cells processes [<xref ref-type="bibr" rid="CR8">8</xref>]. Recent case studies reported distinct AINX immunoreactivity throughout the brain, including more pronounced reactivity in entorhinal cortex, amygdala, superior temporal gyrus, globus pallidus, and locus coeruleus [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Outside the brain, it is only reported to be expressed at RNA and protein level in endocrine tissues more specifically the pituitary and adrenal glands [<xref ref-type="bibr" rid="CR11">11</xref>], and different types of neuroendocrine tumors, with lower levels of AINX being associated with advanced stage of pancreatic neuroendocrine tumors [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par7">Despite being involved in the building of the neuronal filament network in the developing brain, knockout of AINX in mice does not lead to abnormal phenotypes, with NfL taking over most of its functions, thus not interfering with the normal brain development [<xref ref-type="bibr" rid="CR13">13</xref>]. In disease, AINX is present in the inclusion bodies of neuronal intermediate filament inclusion disease, together with the NFTPs [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par8">Out of all the NFTPs, NfL is the most established biomarker for general neurodegeneration providing an indirect measure of axonal damage in biofluids, such as blood and cerebrospinal fluid (CSF) [<xref ref-type="bibr" rid="CR16">16</xref>]. Several studies have described and quantified NfL either in CSF or plasma using different assays on different platforms (ELISA, Simoa, mass spectrometry) [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>]. Despite its similarities to NfL, AINX has one major difference from the other intermediate filament proteins; it is central nervous system (CNS)-specific [<xref ref-type="bibr" rid="CR6">6</xref>]. Previous studies show by SDS-PAGE and immunoblotting that, in mice, AINX is present in the corpus callosum, optic nerve, and spinal cord, but not in the sciatic nerve [<xref ref-type="bibr" rid="CR19">19</xref>]. This opens the possibility for a biomarker specific for CNS neurodegeneration.</p><p id="Par9">With this study, we intended to fill an important gap in the understanding of AINX in biofluids, by developing monoclonal antibodies and generating an immunoassay using the Simoa platform for its detection in CSF. We undertook an initial examination of the assay&#8217;s performance in healthy controls and patients with different neurodegenerative diseases and compared our findings to NfL levels in CSF.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Antibody development</title><p id="Par10">Antibodies were generated by the immunization of mice with recombinant AINX peptides targeting the coil domain of the protein (aa 100&#8211;150 and aa 186&#8211;208). These peptides target the regions where there is the least sequence homology with the NFTPs. After that, titers were tested, the spleen was removed, and B cells fused with the myeloma cell line SP2/0 following standard procedures. After screening the cell media for AINX antibodies, the clones that reacted to the immunizing peptides were grown, subcloned, and stored in liquid nitrogen. Antibody purification was performed in a Hitrap protein G column (GE Healthcare) according to the manufacturer&#8217;s instructions. The generated antibodies are referred to as Ina1 (aa&#160;100-150) and B15 (aa&#160;186-208). B15 was initially generated as an IgM, but due to the unpredictable binding characteristics of a pentameric structure antibody, prone to agglomeration that might influence the final protein measurement [<xref ref-type="bibr" rid="CR20">20</xref>], it was sequenced, the heavy chained was changed to IgG1, and it was expressed recombinantly as an IgG.</p></sec><sec id="Sec4"><title>Antibody specificity by enzyme-linked immunosorbent assay</title><p id="Par11">Direct ELISA setup was used to assess antibody cross-reactivity. Scaling molar concentrations (0.01563&#8211;1.526e-5&#160;pmol) of AINX89-499 (in-house AINX recombinant protein, 0.01&#8211;7.2&#160;ng/mL) and in-house NfL (0.01&#8211;9.77&#160;ng/mL), NfM (0.02&#8211;16.1&#160;ng/mL), and NfH (0.02&#8211;17.5&#160;ng/mL) extracted from bovine tissue in bicarbonate buffer (50&#160;mM NaHCO<sub>3</sub>, pH 9.6) were directly coated on 96-well microtiter plates and incubated over-night at 4&#160;&#176;C (100&#160;&#956;L/well). Both antibodies were applied at a concentration of 0.5&#160;&#181;g/mL and secondary anti-mouse IgG-horse radish peroxidase (HRP) linked antibody was used to identify protein-antibody binding. Following a 2.5&#160;h incubation period at room temperature (RT), 3,3&#8217;,5,5&#8217;-Tetramethylbenzidine (TMB ONE, Kem En Tech Nordic; 100 &#956;L/well) was added to act as substrate and generate a colorimetric signal. Finally, after 30&#160;min incubating in the dark, the reaction was stopped with 0.2&#160;M H<sub>2</sub>SO<sub>4</sub> (100 &#956;L/well), and the absorbance measured at 450&#160;nm (with 650&#160;nm reference) using an ELISA plate reader (Sunrise, Tecan Trading AG). For sandwich ELISA, a similar protocol was used, changing the plate coating to 1&#160;&#956;g/mL B15 IgG. After over-night incubation, the analytes (NfL, NfH and AINX) were added in serial dilutions (0.305&#8211;5000&#160;pg/mL) and incubated for 3&#160;h followed by addition of 1&#160;&#956;g/mL Ina1 detector. After the addition of secondary anti-mouse IgG-HRP, all steps were equal as previously described.</p></sec><sec id="Sec5"><title>Immunoprecipitation</title><p id="Par12">The antibodies were characterized by immunoprecipitation (IP) of sodium dodecyl sulfate (SDS) soluble brain extracts (Supplementary data <xref rid="MOESM1" ref-type="media">1</xref>, extraction protocol adapted from previous work [<xref ref-type="bibr" rid="CR21">21</xref>]) as well as recombinant protein (AINX89&#8211;499, in-house, adapted from previous protocol [<xref ref-type="bibr" rid="CR22">22</xref>]), followed by mass spectrometry detection. Ten milligrams of the SDS soluble fraction of human brain protein, previously extracted, and 2&#160;pmol of recombinant AINX89-499 protein were thawed and used to perform AINX extraction by IP. Both antibodies were coated on beads (Dynabeads M-280 sheep anti-mouse IgG, Thermo Fisher Scientific) using 8&#160;&#181;g/50&#160;&#181;L of beads and incubated for 1&#160;h at RT followed by a 1&#160;h incubation with Rotiblock (Carl Roth) and 3 washes with phosphate-buffered saline (PBS). Samples were diluted to the appropriate concentration, and incubated together with 50 &#181;L of antibody-bound beads in 0.2% (v/v) Triton X-100 for 1&#160;h. Sample volume was reduced to 1&#160;ml and transferred to a KingFisher magnetic particle processor (Thermo Fisher Scientific). The process consists of serial washing of the protein bound to beads with PBS 0.2% TritonX-100, PBS, ammonium bicarbonate (AMBIC, 50&#160;mM), and elution of the bound protein in 0.5% (v/v) formic acid (FA). After the samples were speed-vac-dried and resuspended in AMBIC, tryptic digestion was performed by adding 35&#160;ng of trypsin (sequencing grade, Promega) and incubated over-night at 37&#160;&#176;C. After 16&#160;h, proteolysis was quenched with 0.1% (v/v) trifluoroacetic acid, samples speed-vac-dried, and stored at &#8722;20&#160;&#176;C until further analysis.</p></sec><sec id="Sec6"><title>Liquid chromatography&#8211;tandem mass spectrometry</title><p id="Par13">Nanoflow liquid chromatography coupled to electrospray ionization hybrid quadrupole-orbitrap tandem mass spectrometry (Dionex Ultimate 3000 system and Q Exactive, both Thermo Fisher Scientific) was performed in a similar way as described previously [<xref ref-type="bibr" rid="CR23">23</xref>]. Samples reconstituted in 7 &#181;L 8% FA/8% acetonitrile in water (v/v/v) were loaded onto an Acclaim PepMap 100 C18 trap column (length: 20&#160;mm; inner diameter: 7&#160;&#956;m; particle size: 3&#160;&#956;m; pore size: 100&#160;&#197;) for online desalting, and subsequently onto a reversed-phase Acclaim PepMap RSLC column (length: 150&#160;mm, inner diameter: 75&#160;&#956;m; particle size: 2&#160;&#956;m; pore size: 100&#160;&#197;) for separation (both Thermo Fisher Scientific). Mobile phases were 0.1% FA in water (v/v) (A) and 0.1% FA/84% acetonitrile in water (v/v/v) (B). Separation was performed at a flow rate of 300 nL/min using a linear gradient of 3&#8211;40% B for 50&#160;min at 30&#160;&#176;C. The mass spectrometer was operated in positive ion mode and set to acquire spectra between m/z 350 and 1800. Mass spectrometry and tandem mass spectrometry acquisitions were both obtained at a resolution setting of 70,000 using 1 microscan. Tandem mass spectrometry acquisitions were obtained using higher-energy collisional dissociation fragmentation using a normalized collision energy setting of 25, target values of 106, and maximum injection time of 250&#160;ms. Database search was performed with Mascot Deamon (v2.6.0) using Mascot Distiller (v2.6.3.0) for isotope and charge deconvolution and Mascot Database (v2.6.1) to search against the Uniprot database. All fragment mass spectra were also evaluated manually.</p></sec><sec id="Sec7"><title>AINX immunoassay development</title><p id="Par14">The immunoassay was developed on the ultra-sensitive Simoa HD-X Analyzer (Quanterix). B15 antibody was bound to dyed magnetic beads (Quanterix), used as the capture antibody and Ina1 was biotinylated (Thermo Fisher) and used as detector antibody. In-house AINX89-499 recombinant protein was used as calibrator for the assay. Calibrator, detector, and samples were diluted in homebrew diluent (Quanterix) with added 10 ug/mL of TRUBlock (Meridian Bioscience).</p><p id="Par15">All samples used for validation procedures were obtained from the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#246;lndal, Sweden, pooled, aliquoted, and kept at &#8722;80&#160;&#176;C. Before analysis, samples were thawed at RT and vortexed at 2000&#160;rpm for 30&#160;s. Validation procedures were performed as per previous published research [<xref ref-type="bibr" rid="CR24">24</xref>] and clinical measurements obtained in a blinded and randomized way at the University of Gothenburg.</p></sec><sec id="Sec8"><title>Validation procedures</title><p id="Par16">De-identified CSF samples from the clinical routine at the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital were used to make pools for all optimization and validation steps except for sample stability, where four fresh de-identified CSF samples were used for each validation parameter.</p></sec><sec id="Sec9"><title>Repeatability and intermediate precision</title><p id="Par17">CSF from de-identified patients was screened for AINX and pooled into two batches with distinct concentrations. The first pool (~27&#160;pg/mL) was used as high concentration quality control (QC) and the second pool (~2&#160;pg/mL) was used as low concentration QC. Both samples were run in duplicates five times on five different days.</p></sec><sec id="Sec10"><title>Parallelism/spike recovery</title><p id="Par18">For parallelism testing, four de-identified samples with concentration between 5.56 and 100&#160;pg/mL were serial diluted up to 32-fold in analysis. For spike recovery, 5 samples were aliquoted 4 times and spiked with 3 different concentrations of recombinant protein calibrator (final theoretical concentration of analyte: 1.75, 3, or 7&#160;pg/mL) in a ratio of 1-part spike, 6-part sample before appropriate dilution. To the last aliquot, the same volume of sample diluent was added. Both validation parameters were accepted when the deviation from the mean was less than 15%.</p></sec><sec id="Sec11"><title>Measurement range</title><p id="Par19">The measuring range was defined, considering data from five different calibration curves from five runs performed at unique time points, using 4-parameter logistic regression with 1/Y<sup>2</sup> weighting. This definition was based on calculated concentrations of AINX in CSF, and when the relative deviation from the expected concentration in the calibration curve was below 15%. Lower limit of quantification (LLOQ) was determined by testing <italic toggle="yes">n</italic>&#8201;=&#8201;16 blanks (sample diluent) and calculated based on the result of 10 standard deviations above the mean signal of the blanks.</p></sec><sec id="Sec12"><title>Sample stability</title><p id="Par20">Three types of conditions for sample stability were tested: freeze/thaw cycles, RT, and 4&#160;&#176;C. All samples were collected fresh from clinical routine at the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital and aliquoted for different purposes. In short, for freeze/thaw cycling, four samples were aliquoted six times where five aliquots underwent 1&#8211;5 cycles with one kept at &#8722;80&#160;&#176;C to use as reference. For each cycle, samples were thawed for 1.5&#160;h, vortexed, lid opened, and put back at &#8722;80&#160;&#176;C until the next freeze/thaw cycle. When the required number of cycles was achieved, the samples were kept at &#8722;80&#160;&#176;C until further analysis.</p><p id="Par21">For RT and 4&#160;&#176;C stability, the procedure was the same, CSF was aliquoted six times, and samples were left on a bench exposed to daylight or in the fridge up to 1&#160;week. After each corresponding exposure period, the samples were stored at &#8722;80&#160;&#176;C until further analysis.</p></sec><sec id="Sec13"><title>Blood interference</title><p id="Par22">To evaluate potential interference of blood leaking into CSF, four de-identified CSF samples were divided into four aliquots. Fresh blood was collected and diluted in NaCl (154&#160;mM) before spiking (1-part blood, 19-part CSF) three aliquots from each individual in different volume/volume concentrations (0.1; 0.02; 0.004%). The remaining aliquots had the same volume of NaCl added and acted as the reference. After spiking or addition of NaCl buffer, samples were vortexed and centrifuged 10&#160;min at 4000&#160;g, and supernatants were collected and stored at &#8722;80&#160;&#176;C until analysis.</p></sec><sec id="Sec14"><title>Study participants</title><p id="Par23">In this study, two cohorts were included. The Gothenburg cohort included Alzheimer&#8217;s Disease (AD) patient samples (<italic toggle="yes">n</italic>&#8201;=&#8201;20) obtained from the H70 Clinical Studies at Sahlgrenska University Hospital, and cognitively healthy controls (<italic toggle="yes">n</italic>&#8201;=&#8201;20) from the Gothenburg H70 Birth Cohort Study at the University of Gothenburg (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par24">The University College London, Institute of Neurology (UCL ION) cohort consisted in healthy controls (<italic toggle="yes">n</italic>&#8201;=&#8201;5), AD (<italic toggle="yes">n</italic>&#8201;=&#8201;15), corticobasal syndrome (CBS) (<italic toggle="yes">n</italic>&#8201;=&#8201;4), Huntington&#8217;s disease (HD) (<italic toggle="yes">n</italic>&#8201;=&#8201;9), semantic dementia (SD) (<italic toggle="yes">n</italic>&#8201;=&#8201;5), dementia with Lewy bodies (DLB) (<italic toggle="yes">n</italic>&#8201;=&#8201;18), multiple sclerosis (MS) (<italic toggle="yes">n</italic>&#8201;=&#8201;9), and behavioral variant frontotemporal dementia (bvFTD) (<italic toggle="yes">n</italic>&#8201;=&#8201;2) with patient recruitment, sample collection, and patient diagnosis as previously described [<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec15"><title>Statistical analysis</title><p id="Par25">Analysis of covariance (ANCOVA) followed by post hoc Bonferroni test was used to evaluate comparisons between groups in both cohorts. Spearman correlations between NfL and AINX levels were used in both datasets. <italic toggle="yes">P</italic> values lower than 0.05 were considered significant. In the UCL ION cohort, bvFTD was excluded from all statistical analysis due to limited sample size (<italic toggle="yes">n</italic>&#8201;=&#8201;2). ANCOVA was performed using IBM SPSS Statistics software (v.29.0.1.1), with all plots and Spearman correlations made&#160;using GraphPad Prism (v10.4.1).</p></sec></sec><sec id="Sec16"><title>Results</title><sec id="Sec17"><title>Developed antibodies are specific for the target analyte</title><p id="Par26">After immunoprecipitation of SDS brain homogenates with both antibodies, liquid chromatography&#8211;mass spectrometry showed good coverage of tryptic peptides from the target analyte AINX (B15&#8212;41% and Ina1&#8212;85%). Besides this, B15 showed very little cross-reactivity with other neurofilament species, while Ina1 was less specific, showing some neurofilament homologous peptides (Supplementary data 2). However, cross-reactivity testing performed using ELISA against recombinant AINX and bovine-purified NFTPs verified that both antibodies react to AINX, but not with any NFTP, with absorbance values neighboring the blank measurement independently of concentration (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A-B). Sandwich ELISA setup with the most specific antibody as capture (B15 IgG) and Ina1 as detector yielded similar results, proving the analyte specificity of the antibodies in this setup. (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>C).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Reaction of alpha-internexin antibodies, <bold>A)</bold> B15 IgG, <bold>B)</bold> Ina1, and <bold>C)</bold> sandwich setup with B15 IgG as capture and Ina1 as detector, to different concentrations of neurofilament proteins. Dotted lines represent mean OD value of the blanks. Orange inverted triangles represent reaction to alpha-internexin recombinant protein (AINX89-499), green circles represent reaction to bovine neurofilament light, blue squares represent reaction to bovine neurofilament medium, and red triangles represents reaction to bovine neurofilament heavy. OD, optical density</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="415_2025_13428_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec18"><title>Method validation parameters show a sensitive and robust assay for CSF AINX</title><p id="Par27">Repeatability for samples with different concentrations stayed below 3.4% for samples with mean concentration of 27.6&#160;pg/mL (high control) and 2.7% for samples with mean concentration of 2.01&#160;pg/mL (low control). Intermediate precision stayed below 4.5% for the high control and 10.4% for the low control (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). CSF AINX was stable at room temperature and 4&#160;&#176;C up to a week and withstood up to five freeze thaw cycles (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A-C). Parallelism exhibited stability in calculated concentrations up to 32-fold dilution (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>D). Based on average sample concentrations, the selected dilution for the assay was set at two-fold. Measurement range was established as a 10-point calibration curve ranging from 0.137 to 140&#160;pg/mL. Deviations from expected concentrations were calculated for all points and stayed between &#8722;7.2% and 8.1% (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>E). Spike recovery with three different spike concentrations (1.75, 3.5, 7&#160;pg/mL) showed good recovery averaging on 102, 96.1, and 93.4%, respectively to the spike concentration (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>F). Calculated from <italic toggle="yes">n</italic>&#8201;=&#8201;16 blank measurements, the LLOQ of this assay was determined to be 0.113&#160;pg/mL (data not shown). The range of the assay was established to be between the highest point in the calibration curve (ULOQ&#8201;=&#8201;140&#160;pg/mL) and the lowest that was still above LLOQ (0.137&#160;pg/mL). Furthermore, blood contamination into CSF did not interfere with AINX concentrations, with fluctuations between &#8722;12.0 and 7.20% (Supplementary data 3).
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Repeatability and intermediate precision of CSF alpha-internexin detected by the developed Simoa assay</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1">Repeatability</th><th align="left" colspan="2" rowspan="1">Intermediate precision</th></tr><tr><th align="left" colspan="1" rowspan="1">Sample dilution 1:2</th><th align="left" colspan="1" rowspan="1">Mean concentration (pg/mL)</th><th align="left" colspan="1" rowspan="1">N</th><th align="left" colspan="1" rowspan="1">CVr (%)</th><th align="left" colspan="1" rowspan="1">SDr</th><th align="left" colspan="1" rowspan="1">CVrw (%)</th><th align="left" colspan="1" rowspan="1">SDrw</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">High control CSF</td><td char="." align="char" colspan="1" rowspan="1">27.6</td><td align="left" colspan="1" rowspan="1">5</td><td char="." align="char" colspan="1" rowspan="1">3.4</td><td char="." align="char" colspan="1" rowspan="1">0.95</td><td char="." align="char" colspan="1" rowspan="1">4.5</td><td char="." align="char" colspan="1" rowspan="1">1.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Low control CSF</td><td char="." align="char" colspan="1" rowspan="1">2.01</td><td align="left" colspan="1" rowspan="1">5</td><td char="." align="char" colspan="1" rowspan="1">2.7</td><td char="." align="char" colspan="1" rowspan="1">0.05</td><td char="." align="char" colspan="1" rowspan="1">10.4</td><td char="." align="char" colspan="1" rowspan="1">0.21</td></tr></tbody></table><table-wrap-foot><p>CSF, cerebrospinal fluid; CV, coefficient of variation; SD, standard deviation; r, repeatability; rw, intermediate precision</p></table-wrap-foot></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Validation parameters. <bold>A)</bold> Freeze/thaw cycle endurance, stability at <bold>B)</bold> 4&#160;&#176;C and <bold>C)</bold> room temperature. This data is plotted as percentage difference from mean. <bold>D)</bold> Parallelism, calculated concentrations of samples diluted until 32-fold, <bold>E)</bold> percentage change from expected concentration in 5 different calibration curves with defined range between 0.137 and 140&#160;pg/mL, and <bold>F)</bold> spike recovery between 102 and 93.4%. Dotted lines indicate 15% uncertainty limit. Concentrations annotated in&#160;the plots represent initial concentrations of the samples tested</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="415_2025_13428_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec19"><title>Alpha-internexin shows distinct characteristics compared to neurofilament light</title><p id="Par28">The Gothenburg cohort was used as a discovery cohort where the performance of AINX and NfL as biomarkers was compared in 20 controls (Ctrl) and 20 AD samples. AINX significantly separated Ctrl from AD (<italic toggle="yes">p</italic>&#8201;=&#8201;0.012) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). Similarly, NfL also significantly distinguishes Ctrl from AD (<italic toggle="yes">p</italic>&#8201;=&#8201;0.001) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B) with relative comparisons between the biomarkers showing the same trend. The absolute concentrations of AINX were much lower compared to NfL, within the single digit pg/mL (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Receiver-operating characteristics (ROC) analysis was used to evaluate case&#8211;control discrimination. NfL had better accuracy to differentiate AD from Ctrl AUC&#8201;=&#8201;0.85 (95% CI 0.71&#8211;0.98) than AINX AUC&#8201;=&#8201;0.77 (95% CI 0.63&#8211;0.91), while NfL/AINX ratio did not improve the diagnostic performance AUC&#8201;=&#8201;0.76 (95% CI 0.71&#8211;0.98) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C).&#65279;<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Alpha-internexin and neurofilament light concentrations (pg/mL) in the Gothenburg cohort. Boxplots represent median and IQR for <bold>A)</bold> alpha-internexin and <bold>B)</bold> neurofilament light by diagnosis group. Dashed line represents AINX assay LLOQ. <bold>C)</bold> Receiver-operating characteristics curves for AINX, NfL and NfL/AINX to discriminate between Ctrl and AD. Spearman correlations between alpha-internexin and neurofilament light in <bold>D)</bold> the whole cohort, <bold>E)</bold> the control group, and <bold>F)</bold> the Alzheimer&#8217;s group. Group comparisons made using age- and sex-adjusted analysis of covariance with Bonferroni post hoc test. Full lines represent fitted linear regression and dotted lines represent 95% confidence intervals. IQR, interquartile range; AUC, area under the curve; Ctrl, controls (<italic toggle="yes">n</italic>&#8201;=&#8201;20); AD, Alzheimer&#8217;s disease (<italic toggle="yes">n</italic>&#8201;=&#8201;20); AINX, alpha-internexin; NfL, neurofilament light; LLOQ, lower limit of quantification; r, Spearman correlation coefficient</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="415_2025_13428_Fig3_HTML.jpg"/></fig><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Demographics of both cohorts, Simoa AINX and NfL levels in pg/mL</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Gothenburg cohort</th><th align="left" colspan="1" rowspan="1">Age at LP, mean (SD)</th><th align="left" colspan="1" rowspan="1">male %</th><th align="left" colspan="1" rowspan="1">Simoa AINX pg/mL median (IQR)</th><th align="left" colspan="1" rowspan="1">CSF NfL pg/mL median (IQR)</th><th align="left" colspan="1" rowspan="1">Simoa AINX pg/mL mean (95% CI)</th><th align="left" colspan="1" rowspan="1">CSF NfL pg/mL mean (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Healthy controls (<italic toggle="yes">n</italic>&#8201;=&#8201;20)</td><td align="left" colspan="1" rowspan="1">70<sup>a</sup></td><td align="left" colspan="1" rowspan="1">58</td><td align="left" colspan="1" rowspan="1"><bold>1.811</bold> (1.577&#8211;2.483)</td><td align="left" colspan="1" rowspan="1"><bold>791</bold> (640&#8212;912)</td><td align="left" colspan="1" rowspan="1"><bold>1.784</bold><sup>c</sup> (0.818&#8211;2.749)</td><td align="left" colspan="1" rowspan="1"><bold>873</bold><sup>c</sup> (489&#8211;1247)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alzheimer's disease (<italic toggle="yes">n</italic>&#8201;=&#8201;20)</td><td align="left" colspan="1" rowspan="1">59.6 (9.24)</td><td align="left" colspan="1" rowspan="1">67</td><td align="left" colspan="1" rowspan="1"><bold>2.570</bold> (1.968&#8211;4.069)</td><td align="left" colspan="1" rowspan="1"><bold>1240</bold> (1078&#8212;2358)</td><td align="left" colspan="1" rowspan="1"><bold>3.613</bold><sup>c</sup> (2.648&#8211;4.578)</td><td align="left" colspan="1" rowspan="1"><bold>1832</bold><sup>c</sup> (1447&#8211;2216)</td></tr><tr><td align="left" colspan="1" rowspan="1">UCL ION cohort</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Simoa CSF NfL pg/mL median (IQR)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Simoa CSF NfL pg/mL mean (95% CI)</td></tr><tr><td align="left" colspan="1" rowspan="1">Healthy controls (<italic toggle="yes">n</italic>&#8201;=&#8201;5)</td><td align="left" colspan="1" rowspan="1">64.7 (6.26)</td><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1"><bold>0.7027</bold> (0.4187&#8212;1.962)</td><td align="left" colspan="1" rowspan="1"><bold>636.9</bold> (438.9&#8212;991.3)</td><td align="left" colspan="1" rowspan="1"><bold>1.134</bold><sup>d</sup> (&#8722;0.617&#8211;2.885)</td><td align="left" colspan="1" rowspan="1"><bold>665.4</bold><sup>d</sup> (&#8722;11.30&#8211;1342)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alzheimer's disease (<italic toggle="yes">n</italic>&#8201;=&#8201;15)</td><td align="left" colspan="1" rowspan="1">59.6 (9.24)</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1"><bold>3.225</bold> (1.846&#8212;5.282)</td><td align="left" colspan="1" rowspan="1"><bold>1007</bold> (700&#8212;1317)</td><td align="left" colspan="1" rowspan="1"><bold>3.633</bold><sup>d</sup> (2.580&#8211;4.685)</td><td align="left" colspan="1" rowspan="1"><bold>1135</bold><sup>d</sup> (727.7&#8211;1541)</td></tr><tr><td align="left" colspan="1" rowspan="1">Huntington's disease (<italic toggle="yes">n</italic>&#8201;=&#8201;9)</td><td align="left" colspan="1" rowspan="1">53.4 (9.07)</td><td align="left" colspan="1" rowspan="1">66</td><td align="left" colspan="1" rowspan="1"><bold>5.463</bold> (3.187&#8212;7.297)</td><td align="left" colspan="1" rowspan="1"><bold>2632</bold> (2086&#8212;3243)</td><td align="left" colspan="1" rowspan="1"><bold>5.537</bold><sup>d</sup> (4.112&#8211;6.963)</td><td align="left" colspan="1" rowspan="1"><bold>2552</bold><sup>d</sup> (2001&#8211;3103)</td></tr><tr><td align="left" colspan="1" rowspan="1">Corticobasal syndrome (<italic toggle="yes">n</italic>&#8201;=&#8201;4)</td><td align="left" colspan="1" rowspan="1">61.3 (8.97)</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1"><bold>3.143</bold> (2.916&#8212;7.746)</td><td align="left" colspan="1" rowspan="1"><bold>1368</bold> (1072&#8212;2698)</td><td align="left" colspan="1" rowspan="1"><bold>4.614</bold><sup>d</sup> (1.381&#8211;7.213)</td><td align="left" colspan="1" rowspan="1"><bold>1707</bold><sup>a</sup> (952.9&#8211;2462)</td></tr><tr><td align="left" colspan="1" rowspan="1">Semantic dementia (<italic toggle="yes">n</italic>&#8201;=&#8201;5)</td><td align="left" colspan="1" rowspan="1">62.0 (8.40)</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1"><bold>4.010</bold> (2.603&#8212;5.471)</td><td align="left" colspan="1" rowspan="1"><bold>1213</bold> (937.8&#8212;1873)</td><td align="left" colspan="1" rowspan="1"><bold>4.076</bold><sup>d</sup> (2.298&#8211;5.854)</td><td align="left" colspan="1" rowspan="1"><bold>1371</bold><sup>d</sup> (684.2&#8211;2058)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dementia with Lewy bodies (<italic toggle="yes">n</italic>&#8201;=&#8201;18)</td><td align="left" colspan="1" rowspan="1">66.0 (8.26)</td><td align="left" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1"><bold>1.738</bold> (1.096&#8212;3.796)</td><td align="left" colspan="1" rowspan="1"><bold>860.5</bold> (696.8&#8212;1084)</td><td align="left" colspan="1" rowspan="1"><bold>2.241</bold><sup>d</sup> (1.266&#8211;3.216)</td><td align="left" colspan="1" rowspan="1"><bold>969.5</bold><sup>d</sup> (592.7&#8211;2462</td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple sclerosis (<italic toggle="yes">n</italic>&#8201;=&#8201;9)</td><td align="left" colspan="1" rowspan="1">55.8 (7.39)</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1"><bold>0.7871</bold> (0.4253&#8212;1.023)</td><td align="left" colspan="1" rowspan="1"><bold>616.1</bold> (511.8&#8212;762.0)</td><td align="left" colspan="1" rowspan="1"><bold>0.870</bold><sup>d</sup> (&#8722;0.531&#8211;2.271)</td><td align="left" colspan="1" rowspan="1"><bold>659.2</bold><sup>d</sup> (117.7&#8211;1201)</td></tr><tr><td align="left" colspan="1" rowspan="1">bvFTD (<italic toggle="yes">n</italic>&#8201;=&#8201;2)</td><td align="left" colspan="1" rowspan="1">50.0 (7.80)</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1"><bold>4.167</bold><sup>b</sup></td><td align="left" colspan="1" rowspan="1"><bold>3240</bold><sup>b</sup></td><td align="left" colspan="1" rowspan="1"><sup>b</sup></td><td align="left" colspan="1" rowspan="1"><sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>Bold values represent each group median and mean biomarker concentrations,&#160;respectively.&#160;LP, Lumbar puncture; SD, Standard deviation; AINX, Alpha-internexin; IQR, Interquartile range; CSF, Cerebrospinal fluid; NfL, Neurofilament light; bvFTD, Behavioral variant Frontotemporal Dementia; CI, confidence intervals</p><p><sup>a</sup>All patients were 70&#160;years old</p><p><sup>b</sup>Excluded from analysis</p><p><sup>c</sup>After analysis of covariance, with covariates at the following values: age&#8201;=&#8201;61.45, sex&#8201;=&#8201;0.6818</p><p><sup>d</sup>After analysis of covariance, with covariates at the following values: age&#8201;=&#8201;68.43, sex&#8201;=&#8201;0.6250</p></table-wrap-foot></table-wrap></p><p id="Par29">However, when looking at correlations, despite the correlation coefficient being similar in all comparisons (AINX/NfL <italic toggle="yes">r</italic>&#8201;=&#8201;0.430, NfL/AINX Ctrl, <italic toggle="yes">r</italic>&#8201;=&#8201;0.357 and NfL/AINX AD, <italic toggle="yes">r</italic>&#8201;=&#8201;0.436), we can see a spread in values responsible for lower correlation values (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>D). When we separate the samples between Ctrl and AD, the correlations are lower&#160;and non-significant in Ctrl (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>E-F).</p></sec><sec id="Sec20"><title>Alpha-internexin performs similarly to NfL across neurodegenerative disease</title><p id="Par30">To further investigate the importance of AINX across neurodegenerative diseases, the UCL ION cohort was used to compare AINX levels in the neurodegenerative disease spectrum.</p><p id="Par31">The highest NfL levels were seen in HD patients, where they were significantly higher than Ctrl, MS, DLB, and AD (HD vs Ctrl, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001; vs MS, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; vs DLB, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001; vs AD, <italic toggle="yes">p</italic>&#8201;=&#8201;0.006) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A). AINX levels showed a similar pattern: significantly higher in HD compared to Ctrl and MS (HD vs Ctrl, <italic toggle="yes">p</italic>&#8201;=&#8201;0.006; vs MS <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Additionally, AINX was higher in MS than AD patients (<italic toggle="yes">p</italic>&#8201;=&#8201;0.019) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>, Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B).<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Alpha-internexin and neurofilament light concentrations (pg/mL) in the UCL ION cohort. Boxplots represent median and IQR of <bold>A)</bold> AINX and <bold>B)</bold> NfL concentrations across diagnosis groups. Dashed line represents AINX assay LLOQ. <bold>C)</bold> Spearman correlation between AINX and NfL in the whole data set. P values from the group comparisons made using age- and sex-adjusted analysis of covariance with Bonferroni post hoc test are shown above the lines. Full line represents fitted linear regression and dotted lines represent 95% confidence interval. IQR, interquartile range; Ctrl, controls; AD, Alzheimer&#8217;s Disease (<italic toggle="yes">n</italic>&#8201;=&#8201;15); HD, Huntington&#8217;s Disease (<italic toggle="yes">n</italic>&#8201;=&#8201;9); CBS, corticobasal syndrome (<italic toggle="yes">n</italic>&#8201;=&#8201;4); SD, semantic dementia (<italic toggle="yes">n</italic>&#8201;=&#8201;5); DLB, dementia with Lewy bodies (<italic toggle="yes">n</italic>&#8201;=&#8201;18); MS, multiple sclerosis (<italic toggle="yes">n</italic>&#8201;=&#8201;9); bvFTD: behavioral variant frontotemporal dementia (<italic toggle="yes">n</italic>&#8201;=&#8201;2); AINX, alpha-internexin; NfL, neurofilament light; LLOQ, lower limit of quantification</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="415_2025_13428_Fig4_HTML.jpg"/></fig></p><p id="Par32">Comparing the distribution of both biomarkers between groups, we found that the disease distribution of the samples across groups followed the same trend. Spearman rank correlations were used to determine the relationship between NfL and AINX in the whole cohort as well as between individual diagnosis groups. Correlations as a whole showed little variance and strong positive correlation between the two biomarkers, independently of disease diagnosis (<italic toggle="yes">r</italic>&#8201;=&#8201;0.8895, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>C). However, splitting the correlations based on disease diagnosis showed that, while most groups had high correlation coefficients (Ctrl, r&#8201;=&#8201;1.00; AD, r&#8201;=&#8201;0.910; HD, r&#8201;=&#8201;1.00; CBS, r&#8201;=&#8201;1.00; SD, r&#8201;=&#8201;0.900), pushing the whole correlation coefficient up, DLB and MS have slightly lower coefficients (DLB, r&#8201;=&#8201;0.762; MS, r&#8201;=&#8201;0.683) (Supplementary data 4). Diving into DLB specifically, in this cohort, correlations between these two biomarkers clearly generate two distinct groups with varying concentrations of AINX, but consistent NfL, something that can also be seen in the DLB group in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A</p></sec></sec><sec id="Sec21"><title>Discussion</title><p id="Par33">We have shown that AINX is measurable in CSF and is elevated across the spectrum of neurodegenerative diseases. Starting from monoclonal antibody generation, and confirmed reactivity with AINX, we then developed a novel Simoa immunoassay for its quantification.</p><p id="Par34">Overall, validation parameters show a robust and stable assay with variabilities within and between plates well below 15% and an analytical range that allows for detection of the low abundant target analyte. The assay is also flexible enough to allow for sample dilution up to 32-fold and to recover spiked material with almost 100% accuracy. When investigating analyte stability, neither multiple freeze/thaw cycles nor storage at different temperatures (RT and 4&#160;&#176;C) affected calculated concentrations. Furthermore, we tested whether blood contamination would interfere with the accurate measurement of the analyte when, for example, CSF gets contaminated during the lumbar puncture procedure. This proved not to be the case, expanding the potential utility of this assay to acute injury conditions where blood infiltrates the subarachnoid space like subarachnoid hemorrhage or traumatic brain injury, where a CNS-specific neurofilament biomarker might provide insightful information [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par35">Being the first immunoassay to accurately detect this analyte in biofluids, there are no reference materials or methods to compare it with. As such, the closest associated protein either in sequence homology or proved functionality is NfL [<xref ref-type="bibr" rid="CR30">30</xref>]. In this study, NfL was used as reference biomarker for correlations and to assess the potential value of AINX in the context of neurodegeneration biomarkers. This protein recognized as the fourth intermediate filament and being specifically located in the CNS has been, until now, mainly identified by imaging techniques like immunohistochemistry and western blotting, with a small part of prior studies showing its presence in human tissues or fluids [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par36">The Gothenburg cohort results show, in a simple comparison between participants with AD and cognitively healthy individuals, the low abundance of AINX in CSF, and the similarities to NfL when it comes to biomarker performance, the latter having been proven multiple times to be a marker for general neurodegeneration [<xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref>]. In this study, the lower CSF level of AINX compared to NfL, reflects, to some extent, the predicted lower abundance of AINX, as an early intermediate filament, being replaced and complemented by the NFTPs as the brain matures [<xref ref-type="bibr" rid="CR4">4</xref>]. However, this might also, to some extent, be caused by differences when determining the concentration of the calibrators for each assay.</p><p id="Par37">We hypothesize that, unlike NfL, AINX specifically reflects brain-derived neurodegeneration due to being a CNS-specific protein [<xref ref-type="bibr" rid="CR19">19</xref>]. Accordingly, it would of course be of interest to compare levels in diseases affecting only the peripheral nervous system (e.g., chronic inflammatory demyelinating polyneuropathy, or Guillain&#8211;Barr&#233; syndrome) with those affecting peripheral and central nerves (e.g., FTD/amyotrophic lateral sclerosis) as well as research further on conditions such as those examined in this initial study.</p><p id="Par38">Interestingly, when comparing both proteins concentrations, another factor differentiated AINX expression from NfL. There were individual samples, mostly from the AD group, deviating from the correlation line, where NfL was higher independently of AINX. We theorize that AINX might be differentially expressed across the brain, as shown in previous case studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. From the Human Protein Atlas website, we can see that AINX RNA, although expressed in all brain regions, is especially enriched in the parietal lobe, postcentral gyrus [<xref ref-type="bibr" rid="CR35">35</xref>]. For NfL, a study has shown that it is mostly associated with frontal lobe atrophy [<xref ref-type="bibr" rid="CR36">36</xref>]. These types of analysis need to be done in future studies, to explore our differential expression theory. For example, immunostaining of brain tissue with well-characterized disease progression with our AINX specific antibodies will help to clarify these findings, as will quantification in larger AD cohorts with a broader spread of disease severities supported by MRI and PET neuroimaging, including defined genetic causes.</p><p id="Par39">The UCL ION cohort gives a general idea of the CSF levels of both proteins across diseases and broadly reaffirmed that AINX and NfL showed similar distribution among diseases, albeit with some key differences. However, the possibility of drawing detailed inter-disease comparisons is limited by the low sample size in each disease. For instance, MS patients showed similar median levels of both AINX and NfL compared to Ctrl. Changes in NfL have been proven to occur depending on disease staging [<xref ref-type="bibr" rid="CR37">37</xref>], data that is not available for interpretation in our cohort. Also, due to an extremely low number of individuals, bvFTD was excluded from any statistical analysis (<italic toggle="yes">n</italic>&#8201;=&#8201;2). Finally, the DLB group showed a two-cluster pattern for AINX, but not NfL.</p><p id="Par40">There are reports on the performance of NfL to distinguish multiple system atrophy from Lewy Body synucleinopathies [<xref ref-type="bibr" rid="CR38">38</xref>]. Studies have also shown increased levels of NfL between DLB patients with and without concomitant AD pathology (A+&#8201;T+&#8201;vs A-&#160;T-) [<xref ref-type="bibr" rid="CR39">39</xref>]. Evaluating AINX in targeted DLB cohorts with defined disease staging and biomarker data might prove useful in respect of differential diagnosis. The correlation between both biomarkers was overall good, without large differences between groups.</p><p id="Par41">This study has some limitations. One of the generated antibodies (Ina1) has a certain degree of cross-reactivity shown in the IP-MS experiments, despite not showing in the ELISA. This might prove impactful in a more sensitive platform like Simoa. However, the assay is still robust, and this issue is solved using the most sensitive antibody as capture in the sandwich layout. The UCL ION cohort has a relatively small number of samples per disease group, which may limit statistical power, though the findings in the groupwise analysis are striking despite the small sample size. Despite this dataset providing a valuable overview of AINX detection and distribution across a range of neurodegenerative conditions, further validation is needed to properly determine clinical application and implementation of AINX. Studying differential diagnosis, case&#8211;control discrimination or disease monitoring will be the next steps toward identification of AINX clinical utility together with comparisons with other neurodegeneration biomarkers, data that should be available in future well-powered studies.</p><p id="Par42">This research highlights that AINX is present at low concentration and can be reliably detected in CSF and adult brain tissue using a novel and robust immunoassay. Furthermore, CSF AINX is elevated in several neurodegenerative diseases, indicating its potential as a novel biomarker. Future developments aimed at characterizing AINX in larger and well-defined cohorts, as well as extend the assay reach to blood, will be essential to truly identify the role of this biomarker in the neurodegenerative disease spectrum.</p></sec><sec id="Sec22" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="415_2025_13428_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file1 (PDF 264 KB)</p></caption></media></supplementary-material></p></sec></body><back><ack><title>Acknowledgements</title><p>Special acknowledgement to Jonathan Schott who holds the ethical permits and significantly contributed to the creation of the UCL ION cohort. The authors thank all study participants for contributing their valuable time and effort, without which this study would not have been possible.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>FJM contributed to the study design, acquisition, interpretation of data and drafting the manuscript. AD, IS, and SK characterized participants, provided the samples from the Gothenburg cohort, and revised the manuscript. CL and RWP provided the samples from the UCL ION cohort and revised the manuscript. EJW contributed to recruitment and sample collection from HD patients and controls from the UCL ION cohort and revision of the manuscript. GB contributed with the mass spectrometry analysis, drafting and revising the manuscript. UA contributed to the data analysis and revised the manuscript. KB contributed to the development of the monoclonal antibodies, study design, and revised the manuscript. HZ and HK contributed to the study design, data analysis, joint supervision, and drafting of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by University of Gothenburg. AD was financed by the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (ALFGBG-984092).</p><p>H2020 Marie Sk&#322;odowska-Curie Actions, 860197, Henrik Zetterberg, Vetenskapsr&#229;det, #2023-00356, Henrik Zetterberg, #2022-01018, Henrik Zetterberg, #2019-02397, Henrik Zetterberg, #2017-00915, Kaj Blennow, #2022-00732, Kaj Blennow.</p><p>SK was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (ALFGBG-1005471, ALFGBG-965923, ALFGBG-81392, and ALF GBG-771071). The Alzheimerfonden (AF-842471, AF-737641, AF-929959, and AF-939825). The Swedish Research Council (2019&#8211;02075 and 2019-02075_15), Stiftelsen Psykiatriska Forskningsfonden, and The Swedish Brain Foundation FO2024-0097.</p><p>RWP is supported by the Q Charitable trust and the NIHR UCL Queen Square BRC.</p><p>EJW is supported by CHDI Foundation and European Huntington&#8217;s Disease network.</p><p>KB is supported by the Swedish Research Council (#2017&#8211;00915 and #2022&#8211;00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hj&#228;rnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130, and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466&#8211;236), the Alzheimer&#8217;s Association 2021 Zenith Award (ZEN-21&#8211;848,495), the Alzheimer&#8217;s Association 2022&#8211;2025 Grant (SG-23&#8211;1,038,904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen R&#246;nstr&#246;ms Stiftelse, Stockholm, Sweden, and an anonymous philanthropist and donor.</p><p>HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023&#8211;00356, #2022&#8211;01018, and #2019&#8211;02397), the European Union&#8217;s Horizon Europe research and innovation program under Grant Agreement No. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809&#8211;2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21&#8211;831,376-C, #ADSF-21&#8211;831,381-C, #ADSF-21&#8211;831,377-C, and #ADSF-24&#8211;1,284,328-C), the European Partnership on Metrology, co-financed from the European Union&#8217;s Horizon Europe Research and Innovation Program and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer&#8217;s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen R&#246;nstr&#246;ms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen f&#246;r Gamla Tj&#228;narinnor, Hj&#228;rnfonden, Sweden (#FO2022-0270), the European Union&#8217;s Horizon 2020 Research and Innovation Program under the Marie Sk&#322;odowska-Curie Grant Agreement No. 860197 (MIRIADE), the European Union Joint Program&#8211;Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interests</title><p id="Par43">SK has served at scientific advisory boards, speaker, and/or as consultant for Roche, Eli Lilly, Geras Solutions, Optoceutics, Biogen, Eisai, Merry Life, Triolab, Novo Nordisk, and Bioarctic, unrelated to present study content.</p><p id="Par44">EJW reports consultancy/advisory board memberships with Alnylam, Annexon, Remix Therapeutics, Hoffman La Roche Ltd, Ionis Pharmaceuticals, PTC Therapeutics, Skyhawk Therapeutics, Takeda, Teitur Trophics, Triplet Therapeutics, Uniqure, Wave Life Sciences, and Vico Therapeutics. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London.</p><p id="Par45">KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sunbird Bio, Sanofi, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.</p><p id="Par46">HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp &amp; Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of MicThera (outside submitted work).</p><p id="Par47">FJM, AD, IS, CL, GB, UA, and HK have no competing interests to declare that are relevant to the content of this article.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par48">All participants provided written informed consent at enrollment including consent to publication. In the Gothenburg cohort, the H70 Clinical Studies was approved by the Ethical Review Authority in Sweden (ID: 2019&#8211;04024) and the Gothenburg H70 Birth Cohort Study was approved by the Regional Ethical Review Board in Gothenburg, Sweden (ID: 869&#8211;13). In the UCL ION cohort, dementia participants provided informed written consent (ethical permit 12/LO/1504). Ethical approval for HD patients was granted by the London Camberwell St Giles Ethics Committee (ref: 186932), for MS patients by the Scotland A Research Ethics Committee (REC: 13/SS/0007), and for healthy controls by the Hampstead Ethics Committee (ref: 19/LO/0913). Animal use for antibody production was approved by the Gothenburg's Animal Experimentation Ethics Committee (ID: 003795). This study complies with the Declaration of Helsinki.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pachter</surname><given-names>JS</given-names></name><name name-style="western"><surname>Liem</surname><given-names>RK</given-names></name></person-group><article-title>alpha-Internexin, a 66-kD intermediate filament-binding protein from mammalian central nervous tissues.</article-title><source>J Cell Biol</source><year>1985</year><volume>101</volume><fpage>1316</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1083/jcb.101.4.1316</pub-id><pub-id pub-id-type="pmid">2413040</pub-id><pub-id pub-id-type="pmcid">PMC2113898</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Pachter JS, Liem RK (1985) alpha-Internexin, a 66-kD intermediate filament-binding protein from mammalian central nervous tissues. J Cell Biol 101:1316&#8211;1322. 10.1083/jcb.101.4.1316<pub-id pub-id-type="pmid">2413040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.101.4.1316</pub-id><pub-id pub-id-type="pmcid">PMC2113898</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiu</surname><given-names>FC</given-names></name><etal/></person-group><article-title>Characterization of a novel 66 kd subunit of mammalian neurofilaments</article-title><source>Neuron</source><year>1989</year><volume>2</volume><fpage>1435</fpage><lpage>1445</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(89)90189-x</pub-id><pub-id pub-id-type="pmid">2516728</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Chiu FC et al (1989) Characterization of a novel 66 kd subunit of mammalian neurofilaments. Neuron 2:1435&#8211;1445. 10.1016/0896-6273(89)90189-x<pub-id pub-id-type="pmid">2516728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0896-6273(89)90189-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Liem</surname><given-names>RK</given-names></name></person-group><article-title>Alpha-internexin and peripherin: expression, assembly, functions, and roles in disease</article-title><source>Methods Enzymol</source><year>2016</year><volume>568</volume><fpage>477</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2015.09.012</pub-id><pub-id pub-id-type="pmid">26795481</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Zhao J, Liem RK (2016) Alpha-internexin and peripherin: expression, assembly, functions, and roles in disease. Methods Enzymol 568:477&#8211;507. 10.1016/bs.mie.2015.09.012<pub-id pub-id-type="pmid">26795481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.mie.2015.09.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>MP</given-names></name><name name-style="western"><surname>Chin</surname><given-names>SS</given-names></name><name name-style="western"><surname>Fliegner</surname><given-names>KH</given-names></name><name name-style="western"><surname>Liem</surname><given-names>RK</given-names></name></person-group><article-title>Alpha-internexin, a novel neuronal intermediate filament protein, precedes the low molecular weight neurofilament protein (NF-L) in the developing rat brain</article-title><source>J Neurosci</source><year>1990</year><volume>10</volume><fpage>2735</fpage><lpage>2748</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.10-08-02735.1990</pub-id><pub-id pub-id-type="pmid">2201753</pub-id><pub-id pub-id-type="pmcid">PMC6570287</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kaplan MP, Chin SS, Fliegner KH, Liem RK (1990) Alpha-internexin, a novel neuronal intermediate filament protein, precedes the low molecular weight neurofilament protein (NF-L) in the developing rat brain. J Neurosci 10:2735&#8211;2748. 10.1523/JNEUROSCI.10-08-02735.1990<pub-id pub-id-type="pmid">2201753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.10-08-02735.1990</pub-id><pub-id pub-id-type="pmcid">PMC6570287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ching</surname><given-names>GY</given-names></name><name name-style="western"><surname>Liem</surname><given-names>RK</given-names></name></person-group><article-title>Roles of head and tail domains in alpha-internexin's self-assembly and coassembly with the neurofilament triplet proteins</article-title><source>J Cell Sci</source><year>1998</year><volume>111</volume><issue>Pt 3</issue><fpage>321</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1242/jcs.111.3.321</pub-id><pub-id pub-id-type="pmid">9427681</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ching GY, Liem RK (1998) Roles of head and tail domains in alpha-internexin&#8217;s self-assembly and coassembly with the neurofilament triplet proteins. J Cell Sci 111(Pt 3):321&#8211;333. 10.1242/jcs.111.3.321<pub-id pub-id-type="pmid">9427681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/jcs.111.3.321</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Alpha-internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>10006</fpage><lpage>10019</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2580-06.2006</pub-id><pub-id pub-id-type="pmid">17005864</pub-id><pub-id pub-id-type="pmcid">PMC6674481</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Yuan A et al (2006) Alpha-internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS. J Neurosci 26:10006&#8211;10019. 10.1523/JNEUROSCI.2580-06.2006<pub-id pub-id-type="pmid">17005864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2580-06.2006</pub-id><pub-id pub-id-type="pmcid">PMC6674481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chien</surname><given-names>C-L</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T-H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>K-S</given-names></name></person-group><article-title>Distribution of neuronal intermediate filament proteins in the developing mouse olfactory system</article-title><source>J Neurosci Res</source><year>1998</year><volume>54</volume><fpage>353</fpage><lpage>363</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1097-4547(19981101)54:3&amp;#x0003c;353::Aid-jnr6&amp;#x0003e;3.0.Co;2-6</pub-id><pub-id pub-id-type="pmid">9819140</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Chien C-L, Lee T-H, Lu K-S (1998) Distribution of neuronal intermediate filament proteins in the developing mouse olfactory system. J Neurosci Res 54:353&#8211;363. 10.1002/(sici)1097-4547(19981101)54:3%3c353::Aid-jnr6%3e3.0.Co;2-6<pub-id pub-id-type="pmid">9819140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-4547(19981101)54:3&lt;353::AID-JNR6&gt;3.0.CO;2-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fliegner</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>MP</given-names></name><name name-style="western"><surname>Wood</surname><given-names>TL</given-names></name><name name-style="western"><surname>Pintar</surname><given-names>JE</given-names></name><name name-style="western"><surname>Liem</surname><given-names>RK</given-names></name></person-group><article-title>Expression of the gene for the neuronal intermediate filament protein &#945;&#8208;internexin coincides with the onset of neuronal differentiation in the developing rat nervous system</article-title><source>J Comp Neurol</source><year>1994</year><volume>342</volume><fpage>161</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1002/cne.903420202</pub-id><pub-id pub-id-type="pmid">8201029</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Fliegner KH, Kaplan MP, Wood TL, Pintar JE, Liem RK (1994) Expression of the gene for the neuronal intermediate filament protein &#945;&#8208;internexin coincides with the onset of neuronal differentiation in the developing rat nervous system. J Comp Neurol 342:161&#8211;173. 10.1002/cne.903420202<pub-id pub-id-type="pmid">8201029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cne.903420202</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koga</surname><given-names>S</given-names></name><etal/></person-group><article-title>Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: ftld with mixed tau, TDP-43 and FUS pathologies</article-title><source>Acta Neuropathol Commun</source><year>2023</year><volume>11</volume><fpage>109</fpage><pub-id pub-id-type="doi">10.1186/s40478-023-01611-z</pub-id><pub-id pub-id-type="pmid">37415197</pub-id><pub-id pub-id-type="pmcid">PMC10324204</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Koga S et al (2023) Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: ftld with mixed tau, TDP-43 and FUS pathologies. Acta Neuropathol Commun 11:109. 10.1186/s40478-023-01611-z<pub-id pub-id-type="pmid">37415197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-023-01611-z</pub-id><pub-id pub-id-type="pmcid">PMC10324204</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murakami</surname><given-names>A</given-names></name><etal/></person-group><article-title>An autopsy case report of neuronal intermediate filament inclusion disease presenting with predominantly upper motor neuron features</article-title><source>Neuropathology</source><year>2021</year><volume>41</volume><fpage>357</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1111/neup.12741</pub-id><pub-id pub-id-type="pmid">34309938</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Murakami A et al (2021) An autopsy case report of neuronal intermediate filament inclusion disease presenting with predominantly upper motor neuron features. Neuropathology 41:357&#8211;365. 10.1111/neup.12741<pub-id pub-id-type="pmid">34309938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/neup.12741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schult</surname><given-names>D</given-names></name><etal/></person-group><article-title>Expression pattern of neuronal intermediate filament alpha-internexin in anterior pituitary gland and related tumors</article-title><source>Pituitary</source><year>2015</year><volume>18</volume><fpage>465</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1007/s11102-014-0597-2</pub-id><pub-id pub-id-type="pmid">25236435</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Schult D et al (2015) Expression pattern of neuronal intermediate filament alpha-internexin in anterior pituitary gland and related tumors. Pituitary 18:465&#8211;473. 10.1007/s11102-014-0597-2<pub-id pub-id-type="pmid">25236435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11102-014-0597-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><etal/></person-group><article-title>alpha-Internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness</article-title><source>J Clin Endocrinol Metab</source><year>2014</year><volume>99</volume><fpage>E786</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-2874</pub-id><pub-id pub-id-type="pmid">24483152</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Liu B et al (2014) alpha-Internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness. J Clin Endocrinol Metab 99:E786-795. 10.1210/jc.2013-2874<pub-id pub-id-type="pmid">24483152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2013-2874</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levavasseur</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Julien</surname><given-names>JP</given-names></name></person-group><article-title>No requirement of alpha-internexin for nervous system development and for radial growth of axons</article-title><source>Brain Res Mol Brain Res</source><year>1999</year><volume>69</volume><fpage>104</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/s0169-328x(99)00104-7</pub-id><pub-id pub-id-type="pmid">10350642</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Levavasseur F, Zhu Q, Julien JP (1999) No requirement of alpha-internexin for nervous system development and for radial growth of axons. Brain Res Mol Brain Res 69:104&#8211;112. 10.1016/s0169-328x(99)00104-7<pub-id pub-id-type="pmid">10350642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-328x(99)00104-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cairns</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease</article-title><source>Am J Pathol</source><year>2004</year><volume>164</volume><fpage>2153</fpage><lpage>2161</lpage><pub-id pub-id-type="doi">10.1016/s0002-9440(10)63773-x</pub-id><pub-id pub-id-type="pmid">15161649</pub-id><pub-id pub-id-type="pmcid">PMC1615782</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Cairns NJ et al (2004) Alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol 164:2153&#8211;2161. 10.1016/s0002-9440(10)63773-x<pub-id pub-id-type="pmid">15161649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9440(10)63773-x</pub-id><pub-id pub-id-type="pmcid">PMC1615782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bieniek</surname><given-names>KF</given-names></name><name name-style="western"><surname>Josephs</surname><given-names>KA</given-names></name><name name-style="western"><surname>Lin</surname><given-names>WL</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></name></person-group><article-title>Neuronal intermediate filament inclusion disease may be incorrectly classified as a subtype of FTLD-FUS</article-title><source>Free Neuropathol</source><year>2020</year><pub-id pub-id-type="doi">10.17879/freeneuropathology-2020-2639</pub-id><pub-id pub-id-type="pmid">34386806</pub-id><pub-id pub-id-type="pmcid">PMC8356202</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Bieniek KF, Josephs KA, Lin WL, Dickson DW (2020) Neuronal intermediate filament inclusion disease may be incorrectly classified as a subtype of FTLD-FUS. Free Neuropathol. 10.17879/freeneuropathology-2020-2639<pub-id pub-id-type="pmid">34386806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17879/freeneuropathology-2020-2639</pub-id><pub-id pub-id-type="pmcid">PMC8356202</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaetani</surname><given-names>L</given-names></name><etal/></person-group><article-title>Neurofilament light chain as a biomarker in neurological disorders</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2019</year><volume>90</volume><fpage>870</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2018-320106</pub-id><pub-id pub-id-type="pmid">30967444</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Gaetani L et al (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90:870&#8211;881. 10.1136/jnnp-2018-320106<pub-id pub-id-type="pmid">30967444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2018-320106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaetani</surname><given-names>L</given-names></name><etal/></person-group><article-title>A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation</article-title><source>Alzheimers Res Ther</source><year>2018</year><pub-id pub-id-type="doi">10.1186/s13195-018-0339-1</pub-id><pub-id pub-id-type="pmid">29370869</pub-id><pub-id pub-id-type="pmcid">PMC6389166</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Gaetani L et al (2018) A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther. 10.1186/s13195-018-0339-1<pub-id pub-id-type="pmid">29370869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-018-0339-1</pub-id><pub-id pub-id-type="pmcid">PMC6389166</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Budelier</surname><given-names>MM</given-names></name><etal/></person-group><article-title>A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's disease</article-title><source>Brain Commun</source><year>2022</year><volume>4</volume><fpage>fcac045</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcac045</pub-id><pub-id pub-id-type="pmid">35415607</pub-id><pub-id pub-id-type="pmcid">PMC8994116</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Budelier MM et al (2022) A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer&#8217;s disease. Brain Commun 4:fcac045. 10.1093/braincomms/fcac045<pub-id pub-id-type="pmid">35415607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcac045</pub-id><pub-id pub-id-type="pmcid">PMC8994116</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>8501</fpage><lpage>8508</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1081-12.2012</pub-id><pub-id pub-id-type="pmid">22723690</pub-id><pub-id pub-id-type="pmcid">PMC3405552</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Yuan A et al (2012) Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J Neurosci 32:8501&#8211;8508. 10.1523/JNEUROSCI.1081-12.2012<pub-id pub-id-type="pmid">22723690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1081-12.2012</pub-id><pub-id pub-id-type="pmcid">PMC3405552</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchner</surname><given-names>J</given-names></name><name name-style="western"><surname>Sitia</surname><given-names>R</given-names></name><name name-style="western"><surname>Svilenov</surname><given-names>HL</given-names></name></person-group><article-title>Understanding IgM structure and biology to engineer new antibody therapeutics</article-title><source>BioDrugs</source><year>2025</year><volume>39</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1007/s40259-025-00720-6</pub-id><pub-id pub-id-type="pmid">40237925</pub-id><pub-id pub-id-type="pmcid">PMC12031937</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Buchner J, Sitia R, Svilenov HL (2025) Understanding IgM structure and biology to engineer new antibody therapeutics. BioDrugs 39:347&#8211;357. 10.1007/s40259-025-00720-6<pub-id pub-id-type="pmid">40237925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40259-025-00720-6</pub-id><pub-id pub-id-type="pmcid">PMC12031937</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahara</surname><given-names>N</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>T</given-names></name></person-group><article-title>Biochemical properties of pathology-related Tau species in Tauopathy brains: an extraction protocol for Tau oligomers and aggregates</article-title><source>Methods Mol Biol</source><year>2018</year><volume>1779</volume><fpage>435</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7816-8_26</pub-id><pub-id pub-id-type="pmid">29886548</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Sahara N, Kimura T (2018) Biochemical properties of pathology-related Tau species in Tauopathy brains: an extraction protocol for Tau oligomers and aggregates. Methods Mol Biol 1779:435&#8211;445. 10.1007/978-1-4939-7816-8_26<pub-id pub-id-type="pmid">29886548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-7816-8_26</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorsell</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease</article-title><source>Brain Res</source><year>2010</year><volume>1362</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2010.09.073</pub-id><pub-id pub-id-type="pmid">20875798</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Thorsell A et al (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer&#8217;s disease. Brain Res 1362:13&#8211;22. 10.1016/j.brainres.2010.09.073<pub-id pub-id-type="pmid">20875798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2010.09.073</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinkmalm</surname><given-names>G</given-names></name><etal/></person-group><article-title>An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid</article-title><source>J Mass Spectrom</source><year>2012</year><volume>47</volume><fpage>591</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1002/jms.2987</pub-id><pub-id pub-id-type="pmid">22576872</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Brinkmalm G et al (2012) An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. J Mass Spectrom 47:591&#8211;603. 10.1002/jms.2987<pub-id pub-id-type="pmid">22576872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jms.2987</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreasson</surname><given-names>U</given-names></name><etal/></person-group><article-title>A practical guide to immunoassay method validation</article-title><source>Front Neurol</source><year>2015</year><volume>6</volume><fpage>179</fpage><pub-id pub-id-type="doi">10.3389/fneur.2015.00179</pub-id><pub-id pub-id-type="pmid">26347708</pub-id><pub-id pub-id-type="pmcid">PMC4541289</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Andreasson U et al (2015) A practical guide to immunoassay method validation. Front Neurol 6:179. 10.3389/fneur.2015.00179<pub-id pub-id-type="pmid">26347708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2015.00179</pub-id><pub-id pub-id-type="pmcid">PMC4541289</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rydberg Sterner</surname><given-names>T</given-names></name><etal/></person-group><article-title>The Gothenburg H70 birth cohort study 2014&#8211;16: design, methods and study population</article-title><source>Eur J Epidemiol</source><year>2019</year><volume>34</volume><fpage>191</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1007/s10654-018-0459-8</pub-id><pub-id pub-id-type="pmid">30421322</pub-id><pub-id pub-id-type="pmcid">PMC6373310</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Rydberg Sterner T et al (2019) The Gothenburg H70 birth cohort study 2014&#8211;16: design, methods and study population. Eur J Epidemiol 34:191&#8211;209. 10.1007/s10654-018-0459-8<pub-id pub-id-type="pmid">30421322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-018-0459-8</pub-id><pub-id pub-id-type="pmcid">PMC6373310</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dittrich</surname><given-names>A</given-names></name><etal/></person-group><article-title>Evaluation of two plasma-based proteotyping assays against APOE epsilon4 genotyping in a memory clinic setting: The Gothenburg H70 Clinical Studies</article-title><source>Alzheimers Dement</source><year>2025</year><volume>21</volume><fpage>e14610</fpage><pub-id pub-id-type="doi">10.1002/alz.14610</pub-id><pub-id pub-id-type="pmid">39988952</pub-id><pub-id pub-id-type="pmcid">PMC11847986</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Dittrich A et al (2025) Evaluation of two plasma-based proteotyping assays against APOE epsilon4 genotyping in a memory clinic setting: The Gothenburg H70 Clinical Studies. Alzheimers Dement 21:e14610. 10.1002/alz.14610<pub-id pub-id-type="pmid">39988952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14610</pub-id><pub-id pub-id-type="pmcid">PMC11847986</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leckey</surname><given-names>CA</given-names></name><etal/></person-group><article-title>CSF neurofilament light chain profiling and quantitation in neurological diseases</article-title><source>Brain Commun</source><year>2024</year><volume>6</volume><fpage>fcae132</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcae132</pub-id><pub-id pub-id-type="pmid">38707707</pub-id><pub-id pub-id-type="pmcid">PMC11069115</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Leckey CA et al (2024) CSF neurofilament light chain profiling and quantitation in neurological diseases. Brain Commun 6:fcae132. 10.1093/braincomms/fcae132<pub-id pub-id-type="pmid">38707707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcae132</pub-id><pub-id pub-id-type="pmcid">PMC11069115</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claassen</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>S</given-names></name></person-group><article-title>Spontaneous subarachnoid haemorrhage</article-title><source>Lancet</source><year>2022</year><volume>400</volume><fpage>846</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00938-2</pub-id><pub-id pub-id-type="pmid">35985353</pub-id><pub-id pub-id-type="pmcid">PMC9987649</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Claassen J, Park S (2022) Spontaneous subarachnoid haemorrhage. Lancet 400:846&#8211;862. 10.1016/S0140-6736(22)00938-2<pub-id pub-id-type="pmid">35985353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(22)00938-2</pub-id><pub-id pub-id-type="pmcid">PMC9987649</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>KK</given-names></name><etal/></person-group><article-title>An update on diagnostic and prognostic biomarkers for traumatic brain injury</article-title><source>Expert Rev Mol Diagn</source><year>2018</year><volume>18</volume><fpage>165</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1080/14737159.2018.1428089</pub-id><pub-id pub-id-type="pmid">29338452</pub-id><pub-id pub-id-type="pmcid">PMC6359936</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Wang KK et al (2018) An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn 18:165&#8211;180. 10.1080/14737159.2018.1428089<pub-id pub-id-type="pmid">29338452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737159.2018.1428089</pub-id><pub-id pub-id-type="pmcid">PMC6359936</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>A</given-names></name><name name-style="western"><surname>Rao</surname><given-names>MV</given-names></name><name name-style="western"><surname>Veeranna</surname></name><name name-style="western"><surname>Nixon</surname><given-names>RA</given-names></name></person-group><article-title>Neurofilaments and Neurofilament Proteins in Health and Disease</article-title><source>Cold Spring Harb Perspect Biol</source><year>2017</year><pub-id pub-id-type="doi">10.1101/cshperspect.a018309</pub-id><pub-id pub-id-type="pmid">28373358</pub-id><pub-id pub-id-type="pmcid">PMC5378049</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Yuan A, Rao MV, Veeranna, Nixon RA (2017) Neurofilaments and Neurofilament Proteins in Health and Disease. Cold Spring Harb Perspect Biol. 10.1101/cshperspect.a018309<pub-id pub-id-type="pmid">28373358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a018309</pub-id><pub-id pub-id-type="pmcid">PMC5378049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cairns</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases</article-title><source>Acta Neuropathol</source><year>2004</year><volume>108</volume><fpage>213</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1007/s00401-004-0882-7</pub-id><pub-id pub-id-type="pmid">15170578</pub-id><pub-id pub-id-type="pmcid">PMC3516855</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Cairns NJ et al (2004) alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol 108:213&#8211;223. 10.1007/s00401-004-0882-7<pub-id pub-id-type="pmid">15170578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-004-0882-7</pub-id><pub-id pub-id-type="pmcid">PMC3516855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bridel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis</article-title><source>JAMA Neurol</source><year>2019</year><volume>76</volume><fpage>1035</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2019.1534</pub-id><pub-id pub-id-type="pmid">31206160</pub-id><pub-id pub-id-type="pmcid">PMC6580449</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bridel C et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 76:1035&#8211;1048. 10.1001/jamaneurol.2019.1534<pub-id pub-id-type="pmid">31206160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.1534</pub-id><pub-id pub-id-type="pmcid">PMC6580449</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verde</surname><given-names>F</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name><name name-style="western"><surname>Silani</surname><given-names>V</given-names></name></person-group><article-title>Neurofilament light chain as biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia</article-title><source>Front Neurosci</source><year>2021</year><volume>15</volume><fpage>679199</fpage><pub-id pub-id-type="doi">10.3389/fnins.2021.679199</pub-id><pub-id pub-id-type="pmid">34234641</pub-id><pub-id pub-id-type="pmcid">PMC8255624</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Verde F, Otto M, Silani V (2021) Neurofilament light chain as biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front Neurosci 15:679199. 10.3389/fnins.2021.679199<pub-id pub-id-type="pmid">34234641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2021.679199</pub-id><pub-id pub-id-type="pmcid">PMC8255624</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration</article-title><source>Neuron</source><year>2016</year><volume>91</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.06.030</pub-id><pub-id pub-id-type="pmid">27387643</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Zetterberg H (2016) Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron 91:1&#8211;3. 10.1016/j.neuron.2016.06.030<pub-id pub-id-type="pmid">27387643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2016.06.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other"><italic toggle="yes">Human Protein Atlas, INA Brain RNA expression</italic>, &lt;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.proteinatlas.org/ENSG00000148798-INA/brain">https://www.proteinatlas.org/ENSG00000148798-INA/brain</ext-link>&gt; (2025).</mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oeckl</surname><given-names>P</given-names></name><etal/></person-group><article-title>Relationship of serum beta-synuclein with blood biomarkers and brain atrophy</article-title><source>Alzheimers Dement</source><year>2023</year><volume>19</volume><fpage>1358</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1002/alz.12790</pub-id><pub-id pub-id-type="pmid">36129098</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Oeckl P et al (2023) Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. Alzheimers Dement 19:1358&#8211;1371. 10.1002/alz.12790<pub-id pub-id-type="pmid">36129098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malmestrom</surname><given-names>C</given-names></name><name name-style="western"><surname>Haghighi</surname><given-names>S</given-names></name><name name-style="western"><surname>Rosengren</surname><given-names>L</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>O</given-names></name><name name-style="western"><surname>Lycke</surname><given-names>J</given-names></name></person-group><article-title>Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS</article-title><source>Neurology</source><year>2003</year><volume>61</volume><fpage>1720</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000098880.19793.b6</pub-id><pub-id pub-id-type="pmid">14694036</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J (2003) Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 61:1720&#8211;1725. 10.1212/01.wnl.0000098880.19793.b6<pub-id pub-id-type="pmid">14694036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000098880.19793.b6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>W</given-names></name><etal/></person-group><article-title>Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies</article-title><source>Ann Neurol</source><year>2020</year><volume>88</volume><fpage>503</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1002/ana.25824</pub-id><pub-id pub-id-type="pmid">32557811</pub-id><pub-id pub-id-type="pmcid">PMC7719613</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Singer W et al (2020) Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies. Ann Neurol 88:503&#8211;512. 10.1002/ana.25824<pub-id pub-id-type="pmid">32557811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25824</pub-id><pub-id pub-id-type="pmcid">PMC7719613</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barba</surname><given-names>L</given-names></name><etal/></person-group><article-title>Csf synaptic biomarkers in AT(N)-based subgroups of Lewy body disease</article-title><source>Neurology</source><year>2023</year><volume>101</volume><fpage>e50</fpage><lpage>e62</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000207371</pub-id><pub-id pub-id-type="pmid">37188538</pub-id><pub-id pub-id-type="pmcid">PMC10351307</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Barba L et al (2023) Csf synaptic biomarkers in AT(N)-based subgroups of Lewy body disease. Neurology 101:e50&#8211;e62. 10.1212/WNL.0000000000207371<pub-id pub-id-type="pmid">37188538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000207371</pub-id><pub-id pub-id-type="pmcid">PMC10351307</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis Rep</journal-id><journal-id journal-id-type="iso-abbrev">J Alzheimers Dis Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3553</journal-id><journal-id journal-id-type="pmc-domain">jadr</journal-id><journal-id journal-id-type="publisher-id">ALR</journal-id><journal-title-group><journal-title>Journal of Alzheimer's Disease Reports</journal-title></journal-title-group><issn pub-type="epub">2542-4823</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501456</article-id><article-id pub-id-type="pmcid-ver">PMC12501456.1</article-id><article-id pub-id-type="pmcaid">12501456</article-id><article-id pub-id-type="pmcaiid">12501456</article-id><article-id pub-id-type="doi">10.1177/25424823251385589</article-id><article-id pub-id-type="publisher-id">10.1177_25424823251385589</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0837-9345</contrib-id><name name-style="western"><surname>Niu</surname><given-names initials="L">Li</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff1-25424823251385589" ref-type="aff">1</xref><xref rid="fn1-25424823251385589" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-2411-4988</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="Y">Yubo</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff2-25424823251385589" ref-type="aff">2</xref><xref rid="fn1-25424823251385589" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9310-8998</contrib-id><name name-style="western"><surname>Wu</surname><given-names initials="H">Hao</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff2-25424823251385589" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="L">Liping</given-names></name><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff3-25424823251385589" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jin</given-names></name><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff4-25424823251385589" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lu</surname><given-names initials="F">Fan</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff5-25424823251385589" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-7485-8544</contrib-id><name name-style="western"><surname>Zhao</surname><given-names initials="G">Guoqing</given-names></name><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff6-25424823251385589" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jia</surname><given-names initials="F">Fengfeng</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff7-25424823251385589" ref-type="aff">7</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5338-7825</contrib-id><name name-style="western"><surname>Zhu</surname><given-names initials="J">Jianjun</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff2-25424823251385589" ref-type="aff">2</xref><xref rid="corresp2-25424823251385589" ref-type="corresp"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9785-6056</contrib-id><name name-style="western"><surname>Liu</surname><given-names initials="M">Ming</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff2-25424823251385589" ref-type="aff">2</xref><xref rid="corresp1-25424823251385589" ref-type="corresp"/></contrib></contrib-group><aff id="aff1-25424823251385589">
<label>1</label>Department of Pathophysiology, School of Basic Medical Science, <institution-wrap><institution-id institution-id-type="Ringgold">74648</institution-id><institution content-type="university">Shanxi Medical University</institution></institution-wrap>, Taiyuan, China</aff><aff id="aff2-25424823251385589">
<label>2</label>Department of Medical Cell Biology and Genetics, School of Basic Medical Science, Shanxi Medical University, Taiyuan, China</aff><aff id="aff3-25424823251385589">
<label>3</label>Department of Pathology, <institution-wrap><institution-id institution-id-type="Ringgold">159431</institution-id><institution content-type="university">Shanxi Provincial People's Hospital</institution></institution-wrap>, Taiyuan, China</aff><aff id="aff4-25424823251385589">
<label>4</label>Department of Hepatology, <institution-wrap><institution-id institution-id-type="Ringgold">159431</institution-id><institution content-type="university">Shanxi Provincial People's Hospital</institution></institution-wrap>, Taiyuan, China</aff><aff id="aff5-25424823251385589">
<label>5</label>Department of Neurology, Shanxi Coal Central Hospital, Taiyuan, China</aff><aff id="aff6-25424823251385589">
<label>6</label>Department of Basic Medicine, School of Basic Medical Science, <institution-wrap><institution-id institution-id-type="Ringgold">74648</institution-id><institution content-type="university">Shanxi Medical University</institution></institution-wrap>, Taiyuan, China</aff><aff id="aff7-25424823251385589">
<label>7</label>Department of Corporate Services, Taiyuan Technology Transfer Promotion Center, Taiyuan, China</aff><author-notes><fn fn-type="equal" id="fn1-25424823251385589"><label>#</label><p>These authors contributed equally to this work.</p></fn><corresp id="corresp1-25424823251385589">Ming Liu, Department of Medical Cell Biology and Genetics, Shanxi Medical University, No. 56, Xinjian south road, Taiyuan 030001, Shanxi Province, China. 
Email: <email>lium0421@163.com</email></corresp><corresp id="corresp2-25424823251385589">Jianjun Zhu, Department of Medical Cell Biology and Genetics, Shanxi Medical University, No. 56, Xinjian south road, Taiyuan 030001, Shanxi Province, China. 
Email: <email>scdx007@163.com</email></corresp></author-notes><pub-date pub-type="epub"><day>6</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2025</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">482990</issue-id><elocation-id>25424823251385589</elocation-id><history><date date-type="received"><day>17</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_25424823251385589.pdf"/><abstract><sec><title>Background</title><p>Neuroinflammation represents a central pathological mechanism in Alzheimer's disease (AD). Lipopolysaccharide (LPS) is a potent inducer of neuroinflammation and demonstrates elevated circulating levels in AD patients.</p></sec><sec><title>Objective</title><p>This study aims to investigate the genetic association between serum LPS activity level, inflammatory proteins and AD.</p></sec><sec><title>Methods</title><p>A two-sample mendelian randomization (MR) analysis was performed to explore the causal effect of serum LPS activity level and 91 inflammatory proteins on AD, including 1, 260, 136 sporadic AD and 2, 838, 825 familial AD patients, respectively. Meta-analysis was conducted on multiple datasets to determine statistically significant results that was initially observed in one dataset.</p></sec><sec><title>Results</title><p>Serum LPS activity level is a risk factor for early onset sporadic AD with OR&#8201;=&#8201;1.392, 95% CI: 1.038&#8211;1.869. In most other sporadic AD datasets, LPS shows a trend of increasing the risk of AD onset. After meta-analysis in 10 independent datasets, no association between LPS and sporadic AD was observed. In most familial AD datasets, LPS level demonstrated a trend of decreasing AD risk in MR analysis, however, meta-analysis of the combined 8 datasets showed no statistically significant difference. Two inflammatory proteins, AXIN1 and IL-1 alpha, were identified as significant risk factors for sporadic AD.</p></sec><sec><title>Conclusions</title><p>This study suggested that serum LPS activity level may present a risk effect in early onset sporadic AD. Two inflammatory proteins AXIN1 and IL-1 alpha were associated with the risk of sporadic AD. These findings provide a new perspective for the early diagnosis and treatment of sporadic and familial AD.</p></sec></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>inflammatory proteins</kwd><kwd>lipopolysaccharide</kwd><kwd>Mendelian randomization</kwd><kwd>meta-analysis</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-25424823251385589"><funding-source id="funding1-25424823251385589"><institution-wrap><institution>Applied Basic Research Project of Shanxi Province, China</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100019447</institution-id></institution-wrap></funding-source><award-id rid="funding1-25424823251385589">No. 20210302123319</award-id></award-group><award-group id="award2-25424823251385589"><funding-source id="funding2-25424823251385589"><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id rid="funding2-25424823251385589">No.81902513</award-id></award-group><award-group id="award3-25424823251385589"><funding-source id="funding3-25424823251385589"><institution-wrap><institution>Science Research Start-up fund for doctor of Shanxi Medical University</institution></institution-wrap></funding-source><award-id rid="funding3-25424823251385589">XD1808</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-25424823251385589"><title>Introduction</title><p>Alzheimer's disease (AD), recognized as the leading cause of neurodegenerative disease, is marked by increase of hyperphosphorylated tau (pTau) and aggregation of amyloid-&#946; (A&#946;).<sup>
<xref rid="bibr1-25424823251385589" ref-type="bibr">1</xref>
</sup> AD spans a continuum from cognitively normal to mild cognitive impairment and dementia, emphasizing AD progression over several years.<sup>
<xref rid="bibr2-25424823251385589" ref-type="bibr">2</xref>
</sup> Statistics reveal that approximately one in nine individuals aged 65 and older, or 10.8%, suffer from AD in Americans.<sup>
<xref rid="bibr3-25424823251385589" ref-type="bibr">3</xref>
</sup> In 2019, AD was recognized as the sixth leading cause of death in the United States, with 121,499 fatalities attributed to the condition.<sup>
<xref rid="bibr4-25424823251385589" ref-type="bibr">4</xref>
</sup> It was estimated, the prevalence of AD will reach three times higher worldwide by 2050 when diagnosing based on biological indicators.<sup>
<xref rid="bibr2-25424823251385589" ref-type="bibr">2</xref>
</sup> These data underscore the profound impact of this neurodegenerative disorder on the aging demographic. However, the pathogenesis underlying AD are not fully understood.</p><p>Risk factors of AD encompass age, genetic mutations or variants, traumatic brain injury, diabetes and infections.<sup>
<xref rid="bibr1-25424823251385589" ref-type="bibr">1</xref>
</sup> AD can be divided into sporadic and familial types, accounting for 95% and 5% respectively. Sporadic AD with an age of onset at 60&#8211;65 years account 90% AD are late-onset AD (LOAD).<sup>
<xref rid="bibr5-25424823251385589" ref-type="bibr">5</xref>
</sup>
<italic toggle="yes">APOE4</italic> allele is a strongest genetic risk factor of LOAD, which can promote A&#946; aggregation and affect tau pathogenesis.<sup><xref rid="bibr6-25424823251385589" ref-type="bibr">6</xref>,<xref rid="bibr7-25424823251385589" ref-type="bibr">7</xref></sup> Familial AD is primarily caused by mutations of amyloid precursor protein (<italic toggle="yes">APP</italic>), presenilin 1 (<italic toggle="yes">PSEN1</italic>), and presenilin 2 (<italic toggle="yes">PSEN2</italic>), and mutation carriers exhibited higher levels of A&#946; deposition, decreased metabolism, and cortical thinning compared to non-carriers.<sup>
<xref rid="bibr8-25424823251385589" ref-type="bibr">8</xref>
</sup> In addition, genome-wide association studies (GWAS) have identified plenty of AD associated genes, which can increase the AD susceptibility, indicating the critical role of genetic factors in the onset and progression of AD.<sup><xref rid="bibr9-25424823251385589" ref-type="bibr">9</xref><xref rid="bibr10-25424823251385589" ref-type="bibr"/><xref rid="bibr11-25424823251385589" ref-type="bibr"/>&#8211;<xref rid="bibr12-25424823251385589" ref-type="bibr">12</xref></sup></p><p>Brain infection is another major risk factor for AD.<sup>
<xref rid="bibr1-25424823251385589" ref-type="bibr">1</xref>
</sup> Persistent neuroinflammation triggered by various infectious agents can facilitate the initiation and advancement of AD.<sup>
<xref rid="bibr13-25424823251385589" ref-type="bibr">13</xref>
</sup> Bacterial such as <italic toggle="yes">porphyromonas gingivalis</italic>, can harm cells utilizing their lipopolysaccharides (LPS) by combining with Toll-like receptors (TLRs), thereby inducing the secretion of pro-inflammatory cytokines to damage the neurons.<sup>
<xref rid="bibr14-25424823251385589" ref-type="bibr">14</xref>
</sup> Activation of microglia and astrocytes are involved in both neuroprotective (M2-phenotype microglia and A2-phenotype astrocytes) and neurotoxic (M1-phenotype microglia and A1-phenotype astrocytes) functions.<sup><xref rid="bibr1-25424823251385589" ref-type="bibr">1</xref>,<xref rid="bibr15-25424823251385589" ref-type="bibr">15</xref></sup> During the development of AD, the continuous chronic activation of microglia by A&#946; will lead to a long-lived inflammation through producing extensive cytokines, thereby promoting the progress of AD.<sup>
<xref rid="bibr16-25424823251385589" ref-type="bibr">16</xref>
</sup> A1-type astrocytes activated by LPS and IFN-&#947; show a decrease in phagocytic ability and dysregulation of synaptic function.<sup>
<xref rid="bibr15-25424823251385589" ref-type="bibr">15</xref>
</sup> Additionally, pro-inflammatory microglia can activate pro-inflammatory astrocytes by releasing inflammatory factors such as IL-1&#945;, IL-1&#946;, TNF-&#945;, result in a secondary inflammatory response.<sup>
<xref rid="bibr15-25424823251385589" ref-type="bibr">15</xref>
</sup> Therefore, targeting the pathways driven by microglia and astrocytes could inhibit neuroinflammation to intervene the progression of AD.<sup>
<xref rid="bibr17-25424823251385589" ref-type="bibr">17</xref>
</sup></p><p>Neuroinflammation is one of the characteristics of brain tissue in AD.<sup>
<xref rid="bibr2-25424823251385589" ref-type="bibr">2</xref>
</sup> LPS, commonly referred to as endotoxin, is a significant virulence factor of a cell-envelope component from gram-negative bacteria. Studies reported that LPS endotoxin levels in blood are higher in AD patients than in normal individuals.<sup><xref rid="bibr18-25424823251385589" ref-type="bibr">18</xref>,<xref rid="bibr19-25424823251385589" ref-type="bibr">19</xref></sup> LPS can induce neuroinflammation in the brain, and the immunomodulatory itaconate can reduce the inflammation by downregulating levels of inflammatory mediators.<sup>
<xref rid="bibr20-25424823251385589" ref-type="bibr">20</xref>
</sup> Neuroinflammatory biomarkers have the potential to achieve personalized treatment for AD by anti-neuroinflammatory therapy.<sup>
<xref rid="bibr21-25424823251385589" ref-type="bibr">21</xref>
</sup> However, detecting early-stage AD in clinical settings is difficult, as symptoms are frequently overlooked as routine aspects of aging by both patients and healthcare providers. Therefore, it is necessity to screen and identify potential novel biomarkers in AD's earliest stages in order to promote disease improvement and the development of secondary prevention therapies before symptoms appear.<sup>
<xref rid="bibr22-25424823251385589" ref-type="bibr">22</xref>
</sup> It is well established that LPS can induce neuroinflammation; however, there is a lack of research on whether populations susceptible to blood LPS level are at an increased risk for neuroinflammation-related diseases such as AD. Furthermore, the causal relationship between the multitude of inflammatory factors implicated in the pathogenesis of AD and the disease itself remains poorly understood.</p><p>Mendelian randomization (MR) studies can estimate the unconfounded causal effect.<sup>
<xref rid="bibr23-25424823251385589" ref-type="bibr">23</xref>
</sup> In this study, a two-sample reverse MR analysis was employed to elucidate the causal relationship between LPS/inflammatory factors and AD. Our research is poised to facilitate advancements in early detection, accelerate drug discovery, and refine personalized therapeutic strategies for both sporadic and familial AD.</p></sec><sec sec-type="methods" id="section2-25424823251385589"><title>Methods</title><sec id="section2A-25424823251385589"><title>Data availability and sources</title><p>All data used in this study are publicly available from GWAS databases. LPS related dataset (ebi-a-GCST90032674: the quantification of LPS activity in serum) was obtained from the Integrative Epidemiology Unit (IEU) OpenGWAS database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://gwas.mrcieu.ac.uk/datasets/" ext-link-type="uri">https://gwas.mrcieu.ac.uk/datasets/</ext-link>).</p><p>The sporadic AD related 10 datasets in this study were from two databases: the GWAS catalog database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/gwas/" ext-link-type="uri">https://www.ebi.ac.uk/gwas/</ext-link>) including five datasets: ebi-a-GCST002245 (late onset), ebi-a-GCST90027158, ieu-a-824, ieu-b-2. ieu-b-5067 and the Finnish database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.finngen.fi/en/access_results" ext-link-type="uri">https://www.finngen.fi/en/access_results</ext-link>) including five datasets: finngen_R10_AD_AM_EXMORE (atypical or mixed), finngen_R10_AD_EO_EXMORE (early onset), finngen_R10_AD_LO_EXMORE (late onset), finngen_R10_AD_U_EXMORE, and finngen_R10_G6_ALZHEIMER.</p><p>The datasets related to AD with a family history was drawn from the IEU OpenGWAS database including eight datasets: ebi-a-GCST005920, ebi-a-GCST005921, ebi-a-GCST005923, ebi-a-GCST90012877, ebi-a-GCST90012878, ukb-a-210, ukb-b-14043, ukb-b-14699.</p><p>Inflammatory factor-related datasets were obtained from the GWAS catalog database including dataset from GCST90274758 to GCST90274848 [PMID:37563310]. Plasma levels of 91 inflammatory proteins in European populations (Sweden, Denmark, United Kingdom, Germany, Estonia and Croatia) were tested using genome-wide genotyping array technology.</p><p>Ethical approval was not required for this study, as we used the results of publicly available GWAS analyses. The information of these datasets was list in <xref rid="table1-25424823251385589" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="table1-25424823251385589" orientation="portrait"><label>Table 1.</label><caption><p>Information of the exposure and outcome datasets in this study.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251385589-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Source</th><th align="left" rowspan="1" colspan="1">Ethnicity</th><th align="left" rowspan="1" colspan="1">Sample size</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Exposure</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Serum lipopolysaccharide activity</td><td rowspan="1" colspan="1">ebi-a-GCST90032674</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">11,296</td></tr><tr><td rowspan="1" colspan="1">Inflammatory factor</td><td rowspan="1" colspan="1">GCST90274758&#8211;GCST90274848(91)</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">1585</td></tr><tr><td rowspan="1" colspan="1">Outcome</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Alzheimer's disease (late onset)</td><td rowspan="1" colspan="1">ebi-a-GCST002245</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">55,134</td></tr><tr><td rowspan="1" colspan="1">Alzheimer's disease</td><td rowspan="1" colspan="1">ebi-a-GCST90027158</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">487,511</td></tr><tr><td rowspan="1" colspan="1">Alzheimer's disease</td><td rowspan="1" colspan="1">ieu-a-824</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">1489</td></tr><tr><td rowspan="1" colspan="1">Alzheimer's disease</td><td rowspan="1" colspan="1">ieu-b-2</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">63,926</td></tr><tr><td rowspan="1" colspan="1">Alzheimer's disease</td><td rowspan="1" colspan="1">ieu-b-5067</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">488,285</td></tr><tr><td rowspan="1" colspan="1">Alzheimer disease (Atypical or mixed)</td><td rowspan="1" colspan="1">finngen_R10_AD_AM_EXMORE</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">25,390</td></tr><tr><td rowspan="1" colspan="1">Alzheimer disease (Early onset)</td><td rowspan="1" colspan="1">finngen_R10_AD_EO_EXMORE</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">16,730</td></tr><tr><td rowspan="1" colspan="1">Alzheimer disease (Late onset)</td><td rowspan="1" colspan="1">finngen_R10_AD_LO_EXMORE</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">26,920</td></tr><tr><td rowspan="1" colspan="1">Alzheimer disease (undefined)</td><td rowspan="1" colspan="1">finngen_R10_AD_U_EXMORE</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">5062</td></tr><tr><td rowspan="1" colspan="1">Alzheimer disease</td><td rowspan="1" colspan="1">finngen_R10_G6_ALZHEIMER</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">89,689</td></tr><tr><td rowspan="1" colspan="1">Paternal history of Alzheimer's disease</td><td rowspan="1" colspan="1">ebi-a-GCST005920</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">260,279</td></tr><tr><td rowspan="1" colspan="1">Family history of Alzheimer's disease</td><td rowspan="1" colspan="1">ebi-a-GCST005921</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">314,278</td></tr><tr><td rowspan="1" colspan="1">Maternal history of Alzheimer's disease</td><td rowspan="1" colspan="1">ebi-a-GCST005923</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">288,676</td></tr><tr><td rowspan="1" colspan="1">Alzheimer's disease or family history of Alzheimer's disease</td><td rowspan="1" colspan="1">ebi-a-GCST90012877</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">472,868</td></tr><tr><td rowspan="1" colspan="1">Family history of Alzheimer's disease</td><td rowspan="1" colspan="1">ebi-a-GCST90012878</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">408,942</td></tr><tr><td rowspan="1" colspan="1">Illnesses of mother: Alzheimer's disease/dementia</td><td rowspan="1" colspan="1">ukb-a-210</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">308,780</td></tr><tr><td rowspan="1" colspan="1">Illnesses of siblings: Alzheimer's disease/dementia</td><td rowspan="1" colspan="1">ukb-b-14043</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">361,264</td></tr><tr><td rowspan="1" colspan="1">Illnesses of mother: Alzheimer's disease/dementia</td><td rowspan="1" colspan="1">ukb-b-14699</td><td rowspan="1" colspan="1">European</td><td rowspan="1" colspan="1">423,738</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="section2B-25424823251385589"><title>Selection of genetic instrumental variables</title><p>Single nucleotide polymorphisms (SNPs) are used as instrumental variables (IVs) for exposure and outcome. A relatively rigorous screening criteria was used to identify eligible SNPs for subsequent analyses. First, SNPs should be strongly associated with exposures with genome-wide significance levels of <italic toggle="yes">p</italic>&#8201;&lt;&#8201;1&#8201;&#215;&#8201;10<sup>&#8722;5</sup>. Second, to avoid biased results due to linkage disequilibrium (LD), the minimal linkage disequilibrium (r<sup>2</sup>&#8201;&lt;&#8201;0.001) were identified within the 10,000&#8197;kb range from GWAS, SNPs in the range of 10,000&#8197;kb with r<sup>2&#8201;</sup>&gt;&#8201;0.001 were filtered out. Third, IVs with <italic toggle="yes">F</italic> value&#8201;&lt;&#8201;10 were defined as weak IVs and were removed for subsequent analysis. For IVs of serum LPS levels selection, when clump_kb&#8201;=&#8201;5000, clump_r2&#8201;=&#8201;0.01 and <italic toggle="yes">p</italic>&#8201;&lt;&#8201;1&#8201;&#215;&#8201;10<sup>&#8722;5</sup> runs, only one SNP reach the specification. To increase the number of SNPs, IVs of serum LPS levels were selected by using <italic toggle="yes">p</italic>&#8201;&lt;&#8201;1&#8201;&#215;&#8201;10<sup>&#8722;5</sup> and <italic toggle="yes">F</italic> value&#8201;&gt;&#8201;10 criterion.</p></sec><sec id="section2C-25424823251385589"><title>Statistical analysis</title><sec id="section2C1-25424823251385589"><title>Mendelian randomization analysis</title><p>In this study, we used five MR methods to estimate the causal effect of exposure on outcome, namely MR Egger regression, Weighted median, Inverse-Variance Weighted MR, Simple mode and Weighted mode. &#8220;TwoSampleMR&#8221; package, &#8220;VariantAnnotation&#8221; package and &#8220;gwasglue&#8221; package of R (version 4.3.2) were performed for two-sample MR analysis. Among them, IVW is the most widely used method in MR analysis, which can provide a more accurate estimation of causal effects through inverse variance weighting. In our study, a <italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05 of IVW method was considered have statistical differences. We used a leave-one-out sensitivity, MR-Egger and Cochran's Q test analysis to assess whether the results were potentially biased by genetic pleiotropy and data heterogeneity. A <italic toggle="yes">p</italic>-value &gt;0.05 was considered no genetic pleiotropy and data heterogeneity. When there is a contradiction between the result of MR-Egger and IVW methods, MR-Egger and Cochran's Q test were used to determine which result was adopted. If the intercept term of MR Egger intercept test is significant (<italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05), indicating the existence of directional pleiotropy, IVW results may be biased, and we prioritized the MR Egger result as the primary finding. Conversely, both Cochran's Q test and MR Egger intercept test are not significant (<italic toggle="yes">p</italic>-value&#8201;&gt;&#8201;0.05), IVW results were used.</p></sec><sec id="section2C2-25424823251385589"><title>FDR correction</title><p>The False Discovery Rate (FDR) is the proportion of multiple hypothesis tests that are misreported as true associations. &#8220;pacman&#8221; package was used for FDR adjustment in MR analysis between inflammatory proteins and AD. All statistically significant associations were FDR corrected with adjusted <italic toggle="yes">p</italic>-values&#8201;&lt;&#8201;0.05.</p></sec><sec id="section2C3-25424823251385589"><title>Meta-analysis</title><p>Since the outcome data in this study was from different datasets, in order to estimate causality more accurately and improve the statistical power, we integrate the results by performing a meta-analysis using &#8220;meta&#8221; package. By combining meta-analysis and MR methods, the associations between genotypes and phenotypes were explored more comprehensively to improve the credibility and accuracy of this paper. Furthermore, we performed funnel plot analysis to evaluate potential bias in the MR findings obtained from the different AD datasets.</p></sec></sec></sec><sec sec-type="results" id="section3-25424823251385589"><title>Results</title><sec id="section3A-25424823251385589"><title>Overview of this study</title><p><xref rid="fig1-25424823251385589" ref-type="fig">Figure 1</xref> summarized the simple study flow and results. In this study, the serum LPS activity level and 91 inflammation proteins were used as exposure factors, sporadic AD and familial AD were used as outcome to conduct a two-sample MR analysis, respectively. For the positive results in any dataset, in order to increase statistical power value, meta-analysis was performed in all sporadic AD or familial AD patients. Our results indicate that LPS levels have risk effect on early onset sporadic AD, and there was no causal effect of LPS levels on both sporadic AD and familial AD patients after meta-analysis. Two inflammatory factors AXIN1 and IL1 have casual effect on risk of sporadic AD, and no inflammatory factors have association with familial AD after meta-analysis.</p><fig position="float" id="fig1-25424823251385589" orientation="portrait"><label>Figure 1.</label><caption><p>Flowchart of the study. The serum LPS activity level and 91 inflammation proteins were used as exposure factors, sporadic AD and familial AD were used as outcome to conduct a two-sample MR analysis, respectively. After heterogeneity and pleiotropy test, meta-analysis was performed. LPS levels have risk effect on early onset sporadic AD, and there was no causal effect of LPS levels on both sporadic AD and familial AD patients after meta-analysis. 17 inflammatory factors were identified have causal effect on sporadic AD. Two inflammatory factors AXIN1 and IL1 have casual effect on risk of sporadic AD, and no inflammatory factors have association with familial AD after meta-analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251385589-fig1.jpg"/></fig></sec><sec id="section3B-25424823251385589"><title>Causal effect of LPS on sporadic AD</title><p>After removing weak IVs (<italic toggle="yes">F</italic>&#8201;&lt;&#8201;10), the final number of SNPs associated with the serum LPS activity level with <italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;1&#8201;&#215;&#8201;10<sup>&#8722;5</sup> was 71 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251385589" ext-link-type="uri">Supplemental Table 1</ext-link>). The MR result showed there were statistical differences in five datasets (finngen_R10_AD_EO_EXMORE, finngen_R10_G6_AD_WIDE, finngen_R10_G6_ALZHEIMER, ebi-a-GCST90027158, and ieu-b-5067) with <italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05 using IVW method, however, no dataset with same OR value direction in all five MR methods (<xref rid="fig2-25424823251385589" ref-type="fig">Figure 2</xref>). We determined whether the IVW or MR Egger results could be used for the next meta-analysis by using sensitivity analysis including heterogeneity and pleiotropy tests (<xref rid="table2-25424823251385589" ref-type="table">Table 2</xref>). And the result of MR Egger with OR&#8201;=&#8201;1.392 (95%CI: 1.038&#8211;1.869) indicated that serum LPS levels were a risk factor for early-onset AD. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251385589" ext-link-type="uri">Supplemental Figure 1</ext-link> showed the forest plot, scatter plot, funnel plot and leave-one-out analysis of LPS level IVs with causal effect on early-onset sporadic AD (finngen_R10_AD_EO_EXMORE). We then performed a meta-analysis using IVW or Egger results selected in the previous step in all outcome datasets. The meta-analysis result of heterogeneity test showed that the <italic toggle="yes">p</italic> value&#8201;&gt;&#8201;0.05 and I<sup>2</sup>&#8201;=&#8201;18.1%, which means there is not a significant heterogeneity among these data. The result of common effects model (OR&#8201;=&#8201;1.000, 95% CI: 1.000&#8211;1.001) is used. That is, LPS activity level didn&#8217;t exhibit a causal effect on sporadic AD (<xref rid="fig3-25424823251385589" ref-type="fig">Figure 3</xref>). The detailed MR results of LPS activity level in sporadic AD were list in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251385589" ext-link-type="uri">Supplemental Table 2</ext-link>.</p><fig position="float" id="fig2-25424823251385589" orientation="portrait"><label>Figure 2.</label><caption><p>The effect of the serum LPS activity levels on sporadic AD. Effect of serum LPS activity levels on sporadic AD in 10 different outcome datasets. nsnp: number of single nucleotide polymorphisms; OR: odds ratio; CI: confidence interval; FDR: false discovery rate.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251385589-fig2.jpg"/></fig><fig position="float" id="fig3-25424823251385589" orientation="portrait"><label>Figure 3.</label><caption><p>Meta-analysis result of MR results between serum LPS activity levels and sporadic AD. Above is a forest chart and below is a funnel chart to eliminate data bias.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251385589-fig3.jpg"/></fig><table-wrap position="float" id="table2-25424823251385589" orientation="portrait"><label>Table 2.</label><caption><p>Heterogeneity and pleiotropy analysis of MR analysis between LPS and AD, and the MR results selection.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251385589-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">AD datasets</th><th align="left" colspan="2" rowspan="1">Heterogenity</th><th align="left" colspan="3" rowspan="1">MR-Egger intercept</th><th align="left" colspan="3" rowspan="1">MR result</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Q</th><th align="left" rowspan="1" colspan="1">Q-pvalue</th><th align="left" rowspan="1" colspan="1">Egger_intercept</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" rowspan="1" colspan="1">OR(95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" rowspan="1" colspan="1">result selection</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ebi-a-GCST002245</td><td rowspan="1" colspan="1">13.229</td><td rowspan="1" colspan="1">1.000</td><td rowspan="1" colspan="1">&#8722;0.004</td><td rowspan="1" colspan="1">0.005</td><td rowspan="1" colspan="1">0.390</td><td rowspan="1" colspan="1">1.004 (0.940 to 1.073)</td><td rowspan="1" colspan="1">0.896</td><td rowspan="1" colspan="1">Inverse variance weighted</td></tr><tr><td rowspan="1" colspan="1">ebi-a-GCST90027158</td><td rowspan="1" colspan="1">681.749</td><td rowspan="1" colspan="1">0.485</td><td rowspan="1" colspan="1">&#8722;0.006</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.012</td><td rowspan="1" colspan="1">1.012 (0.963 to 1.063)</td><td rowspan="1" colspan="1">0.641</td><td rowspan="1" colspan="1">MR Egger</td></tr><tr><td rowspan="1" colspan="1">ieu-a-824</td><td rowspan="1" colspan="1">0.136</td><td rowspan="1" colspan="1">0.998</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">1.128</td><td rowspan="1" colspan="1">0.998</td><td rowspan="1" colspan="1">1.053 (0.320 to 3.466)</td><td rowspan="1" colspan="1">0.932</td><td rowspan="1" colspan="1">Inverse variance weighted</td></tr><tr><td rowspan="1" colspan="1">ieu-b-2</td><td rowspan="1" colspan="1">31.850</td><td rowspan="1" colspan="1">0.965</td><td rowspan="1" colspan="1">0.004</td><td rowspan="1" colspan="1">0.004</td><td rowspan="1" colspan="1">0.382</td><td rowspan="1" colspan="1">0.984 (0.929 to 1.043)</td><td rowspan="1" colspan="1">0.984</td><td rowspan="1" colspan="1">Inverse variance weighted</td></tr><tr><td rowspan="1" colspan="1">ieu-b-5067</td><td rowspan="1" colspan="1">37.684</td><td rowspan="1" colspan="1">0.964</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">0.343</td><td rowspan="1" colspan="1">1.000 (1.000 to 1.001)</td><td rowspan="1" colspan="1">
<bold>0</bold>
<bold>.</bold>
<bold>035</bold>
</td><td rowspan="1" colspan="1">Inverse variance weighted</td></tr><tr><td rowspan="1" colspan="1">finngen_R10_AD_AM_EXMORE</td><td rowspan="1" colspan="1">42.156</td><td rowspan="1" colspan="1">0.952</td><td rowspan="1" colspan="1">&#8722;0.020</td><td rowspan="1" colspan="1">0.011</td><td rowspan="1" colspan="1">0.082</td><td rowspan="1" colspan="1">0.935 (0.820 to 1.065)</td><td rowspan="1" colspan="1">0.312</td><td rowspan="1" colspan="1">Inverse variance weighted</td></tr><tr><td rowspan="1" colspan="1">finngen_R10_AD_EO_EXMORE</td><td rowspan="1" colspan="1">50.446</td><td rowspan="1" colspan="1">0.749</td><td rowspan="1" colspan="1">&#8722;0.065</td><td rowspan="1" colspan="1">0.014</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">1.392 (1.038 to 1.869)</td><td rowspan="1" colspan="1">
<bold>0</bold>
<bold>.</bold>
<bold>031</bold>
</td><td rowspan="1" colspan="1">MR Egger</td></tr><tr><td rowspan="1" colspan="1">finngen_R10_AD_LO_EXMORE</td><td rowspan="1" colspan="1">74.026</td><td rowspan="1" colspan="1">0.090</td><td rowspan="1" colspan="1">&#8722;0.021</td><td rowspan="1" colspan="1">0.007</td><td rowspan="1" colspan="1">0.005</td><td rowspan="1" colspan="1">0.917 (0.837 to 1.004)</td><td rowspan="1" colspan="1">0.061</td><td rowspan="1" colspan="1">Inverse variance weighted</td></tr><tr><td rowspan="1" colspan="1">finngen_R10_AD_U_EXMORE</td><td rowspan="1" colspan="1">41.938</td><td rowspan="1" colspan="1">0. 944</td><td rowspan="1" colspan="1">&#8722;0.077</td><td rowspan="1" colspan="1">0.025</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">1.534 (0.895 to 2.630)</td><td rowspan="1" colspan="1">0.125</td><td rowspan="1" colspan="1">MR Egger</td></tr><tr><td rowspan="1" colspan="1">finngen_R10_G6_ALZHEIMER</td><td rowspan="1" colspan="1">29.193</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">&#8722;0.015</td><td rowspan="1" colspan="1">0.005</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1">1.035 (0.921 to 1.162)</td><td rowspan="1" colspan="1">0.567</td><td rowspan="1" colspan="1">MR Egger</td></tr><tr><td rowspan="1" colspan="1">ebi-a-GCST005920</td><td rowspan="1" colspan="1">55.444</td><td rowspan="1" colspan="1">0.245</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">0..053</td><td rowspan="1" colspan="1">1.013 (0.986 to 1.040)</td><td rowspan="1" colspan="1">0.348</td><td rowspan="1" colspan="1">Inverse variance weighted</td></tr><tr><td rowspan="1" colspan="1">ebi-a-GCST005921</td><td rowspan="1" colspan="1">53.832</td><td rowspan="1" colspan="1">0.261</td><td rowspan="1" colspan="1">0.007</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.991 (0.971 to 1.011)</td><td rowspan="1" colspan="1">0.382</td><td rowspan="1" colspan="1">MR Egger</td></tr><tr><td rowspan="1" colspan="1">ebi-a-GCST005923</td><td rowspan="1" colspan="1">37.543</td><td rowspan="1" colspan="1">0.861</td><td rowspan="1" colspan="1">0.007</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1">0.991 (0.967 to 1.015)</td><td rowspan="1" colspan="1">0.470</td><td rowspan="1" colspan="1">MR Egger</td></tr><tr><td rowspan="1" colspan="1">ebi-a-GCST90012877</td><td rowspan="1" colspan="1">38.122</td><td rowspan="1" colspan="1">0.974</td><td rowspan="1" colspan="1">0.008</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">0.004</td><td rowspan="1" colspan="1">0.952 (0.898 to 1.008)</td><td rowspan="1" colspan="1">0.099</td><td rowspan="1" colspan="1">MR Egger</td></tr><tr><td rowspan="1" colspan="1">ebi-a-GCST90012878</td><td rowspan="1" colspan="1">4.462</td><td rowspan="1" colspan="1">0.276</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1">0.997 (0.992 to 1.001)</td><td rowspan="1" colspan="1">0.152</td><td rowspan="1" colspan="1">MR Egger</td></tr><tr><td rowspan="1" colspan="1">ukb-a-210</td><td rowspan="1" colspan="1">60.529</td><td rowspan="1" colspan="1">0.252</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">0.048</td><td rowspan="1" colspan="1">1.001 (0.996 to 1.005)</td><td rowspan="1" colspan="1">0.815</td><td rowspan="1" colspan="1">MR Egger</td></tr><tr><td rowspan="1" colspan="1">ukb-b-14043</td><td rowspan="1" colspan="1">9.599</td><td rowspan="1" colspan="1">0.998</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">0.239</td><td rowspan="1" colspan="1">0.998 (0.997 to 1.000)</td><td rowspan="1" colspan="1">
<bold>0</bold>
<bold>.</bold>
<bold>011</bold>
</td><td rowspan="1" colspan="1">Inverse variance weighted</td></tr><tr><td rowspan="1" colspan="1">ukb-b-14699</td><td rowspan="1" colspan="1">41.296</td><td rowspan="1" colspan="1">0.898</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">0.246</td><td rowspan="1" colspan="1">1.001 (0.999 to 1.004)</td><td rowspan="1" colspan="1">0.227</td><td rowspan="1" colspan="1">Inverse variance weighted</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="section3C-25424823251385589"><title>Causal effect of LPS on familial AD</title><p>We also performed MR analysis with LPS as the exposure factor and familial AD as the outcome. <xref rid="fig4-25424823251385589" ref-type="fig">Figure 4</xref> showed there were 2 datasets (ukb-b-14043 and ukb-a-210) with <italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.05 in the IVW method. Among them, there was only ukb-a-210 with the consistent direction of OR value in 5 MR methods, and the OR value was 1.004 (95% CI: 1.000&#8211;1.007, <italic toggle="yes">p</italic>&#8201;=&#8201;0.003), however, there was pleiotropy in ukb-a-210 (<italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05 of egger intercept test). Meta-analysis was conducted after heterogeneity and pleiotropy tests (<xref rid="table2-25424823251385589" ref-type="table">Table 2</xref>). Meta-analysis results showed that <italic toggle="yes">p</italic> value &gt;0.05, I<sup>2</sup>&#8201;=&#8201;38.3% (I<sup>2</sup>&#8201;&gt;&#8201;50%), suggesting no heterogeneity among these datasets. The common effect model was adopted with OR&#8201;=&#8201;0.999, 95% CI: 0.998&#8211;1.000, no statistical differences were observed (<xref rid="fig5-25424823251385589" ref-type="fig">Figure 5</xref>). Therefore, LPS activity level were not considered to be a risk factor for familial AD. However, LPS activity level showed the opposite effects in sporadic (potential risk effect) and familial AD (potential protective effects). The detailed MR results of LPS activity level in familial AD were list in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251385589" ext-link-type="uri">Supplemental Table 3</ext-link>.</p><fig position="float" id="fig4-25424823251385589" orientation="portrait"><label>Figure 4.</label><caption><p>The effect of the serum LPS activity levels on familial AD. Effect of serum LPS activity levels on familial AD in 8 different outcome datasets. nsnp: number of single nucleotide polymorphisms; OR: odds ratio; CI: confidence interval; FDR: false discovery rate.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251385589-fig4.jpg"/></fig><fig position="float" id="fig5-25424823251385589" orientation="portrait"><label>Figure 5.</label><caption><p>Meta-analysis result of MR results between serum LPS activity levels and familial AD. Above is a forest chart and below is a funnel chart to eliminate data bias.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251385589-fig5.jpg"/></fig></sec><sec id="section3D-25424823251385589"><title>Causal effect of 91 inflammatory proteins on sporadic AD</title><p>Chronic inflammation is one of the risk factors for the onset of AD. Therefore, we simultaneously explored the causal relationship between 91 inflammatory proteins and AD. After removing SNPs exist LD (kb&#8201;=&#8201;1000, r<sup>2</sup>&#8201;=&#8201;0.001) and weak IVs (<italic toggle="yes">F</italic>&#8201;&lt;&#8201;10), the final number of SNPs associated with 91 inflammatory proteins with <italic toggle="yes">p</italic>-value &lt;1&#8201;&#215;&#8201;10<sup>&#8722;5</sup> was 2726. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251385589" ext-link-type="uri">Supplemental Table 4</ext-link> showed the information of selected 2726 IVs of 91 inflammatory proteins. The results showed, after FDR correction of <italic toggle="yes">p</italic>-value, 10 inflammatory proteins (ARTN, AXIN1, CX3CL1, CXCL9, IFN-gamma, IL-1 alpha, IL5, SIRT2, TNFSF14 and TSLP) were associated with the risk of sporadic AD with OR value from 1.082 to 1.809, while 7 inflammatory proteins (CCL25, CCL4, CSF-1, FGF-19, IL-10, IL-10RA, and IL-12B) were negatively associated with the risk of sporadic AD with OR value from 0.952 to 0.611, which suggesting their protective role in sporadic AD (<xref rid="fig6-25424823251385589" ref-type="fig">Figure 6</xref>). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251385589" ext-link-type="uri">Supplemental Figure 2</ext-link> is the forest plot, scatter plot, funnel plot and leave-one-out analysis of identified inflammatory proteins IVs with causal effect on sporadic AD. MR Egger and Cochran's Q test suggest no heterogeneity and horizontal pleiotropy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251385589" ext-link-type="uri">Supplemental Table 5</ext-link>). Then these 17 inflammatory proteins were selected for meta-analysis using all sporadic AD datasets, respectively. The meta-analysis validated 2 inflammatory proteins (AXIN1 and IL-1 alpha) were positively associated with the risk of sporadic AD, with the OR&#8201;=&#8201;1.08, 95% IC (1.02&#8211;1.14) and OR&#8201;=&#8201;1.09, 95% IC (1.03&#8211;1.15), respectively (<xref rid="fig7-25424823251385589" ref-type="fig">Figure 7</xref>). The detailed MR results of inflammatory proteins in sporadic AD were list in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251385589" ext-link-type="uri">Supplemental Table 6</ext-link>.</p><fig position="float" id="fig6-25424823251385589" orientation="portrait"><label>Figure 6.</label><caption><p>The causal effect of inflammatory proteins on sporadic AD. Causal effect of 17 inflammatory proteins on sporadic AD in different outcome datasets. nsnp: number of single nucleotide polymorphisms; OR: odds ratio; CI: confidence interval; FDR: false discovery rate.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251385589-fig6.jpg"/></fig><fig position="float" id="fig7-25424823251385589" orientation="portrait"><label>Figure 7.</label><caption><p>Meta-analysis result of MR results between inflammatory proteins and sporadic AD. Above are forest charts of AXIN1 and IL 1 alpha, and below are the corresponding funnel charts to eliminate data bias.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251385589-fig7.jpg"/></fig></sec><sec id="section3E-25424823251385589"><title>Causal effect of 91 inflammatory factors on familial AD</title><p>For familial AD, LIF and AXIN1 showed playing weak risk roles with OR&#8201;=&#8201;1.004 and 1.005 (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) in outcome dataset ukb-b-14699, respectively. However, after FDR correction, no causal association was found between any of the 91 inflammatory proteins and 8 familial AD datasets (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251385589" ext-link-type="uri">Supplemental Table 7</ext-link>).</p></sec></sec><sec sec-type="discussion" id="section4-25424823251385589"><title>Discussion</title><p>The gram-negative bacteria and their LPS significantly contribute to the pathogenesis of AD. However, the causal relationship between serum LPS activity level and the risk of AD has not been established. LPS often promotes the occurrence and development of AD through chronic inflammation, which is also a known risk factor for AD. In this study, we systematically analyzed the causal effects of serum LPS activity level and 91 circulating inflammatory proteins on AD (in both 1, 260, 136 sporadic and 2, 838, 825 familial AD samples) using a two-sample MR method and meta-analysis. The results showed that serum LPS activity level was as a risk factor for early onset sporadic AD, and a potential protective factor for familial AD. Two inflammatory proteins AXIN1 and IL-1 alpha have risk causal effects on sporadic AD. For familial AD, no inflammatory proteins were found to be associated with AD after meta-analysis. To our knowledge, this is the first study to investigate the causal effects between LPS and AD and to identify the opposite effects of serum LPS activity levels on sporadic and familial AD. These findings may provide a new perspective for the early diagnosis and treatment of AD.</p><p>LPS in the gut can translocate into the systemic circulation via dysfunction of the intestinal barrier, causing low-grade endotoxaemia.<sup>
<xref rid="bibr24-25424823251385589" ref-type="bibr">24</xref>
</sup> Elevated levels of LPS in the blood and brain may promote microglial activation, amyloid and tau pathology changes, those were the pathological mechanism of AD.<sup>
<xref rid="bibr25-25424823251385589" ref-type="bibr">25</xref>
</sup> Delivering a small amount of LPS to healthy volunteers can establish a human LPS inflammatory response model to study early human inflammation.<sup>
<xref rid="bibr26-25424823251385589" ref-type="bibr">26</xref>
</sup> However, unexpectedly, in our study, serum LPS activity level only showed weak risk effect on early onset sporadic AD. The LPS-related GWAS dataset has been used to prove the association between genetic loci of serum lipopolysaccharide activity and contact activation pathway, vasoactivity, and lipoprotein metabolism, which have causal effect on thromboembolism and stroke.<sup>
<xref rid="bibr27-25424823251385589" ref-type="bibr">27</xref>
</sup> That is to say the LPS-related GWAS dataset we have selected can be used for causal risk analysis of diseases. And, in our study, in familial AD patients, the same analysis was performed and the result showed that there is a potential negative correlation of the serum LPS activity level with the risk of AD. In the meta-analysis, the OR values of serum LPS activity level in multiple familial AD datasets are skewed towards the left, although the final result was not statistically significant (<xref rid="fig5-25424823251385589" ref-type="fig">Figure 5</xref>). The opposite effect of serum LPS activity level on sporadic and familial AD is an important finding of this study. We speculated the low concentration serum LPS may not be sufficient to cause the occurrence of AD, both in sporadic and familial AD patients. Mizobuchi et al. reviewed that high-dose lipopolysaccharide is an inflammatory inducer while low-dose lipopolysaccharide is an immunomodulator, and their study demonstrated oral lipopolysaccharide can reduce AD pathology.<sup>
<xref rid="bibr28-25424823251385589" ref-type="bibr">28</xref>
</sup> So, in our research results, serum LPS activity level was found to be a weak potential risk factor against sporadic AD. However, familial AD has clear heritability, mainly caused by mutations in <italic toggle="yes">APP</italic>, <italic toggle="yes">PSEN1</italic>, and <italic toggle="yes">PSEN2</italic> genes. Maybe, serum LPS activity may exert immunomodulatory effects against hereditary pathogenesis, potentially conferring a protective role in the onset of familial AD.</p><p>The role of neuroinflammation in AD progression is increasingly supported by evidence and inflammation signaling pathways has become a potential target for the prevention of this neurodegenerative condition.<sup><xref rid="bibr29-25424823251385589" ref-type="bibr">29</xref><xref rid="bibr30-25424823251385589" ref-type="bibr"/>&#8211;<xref rid="bibr31-25424823251385589" ref-type="bibr">31</xref></sup> In this study, through the combination of GWAS and meta-analysis in a large population, we ultimately identified two circulating inflammatory factors closely associated with the risk of sporadic AD, AXIN1 and IL-1 alpha. It has been clarified that protein encoded by AXIN1 can suppress Wnt signaling and regulates the stabilization of beta-catenin.<sup><xref rid="bibr32-25424823251385589" ref-type="bibr">32</xref>,<xref rid="bibr33-25424823251385589" ref-type="bibr">33</xref></sup> While Wnt-&#946;-catenin signaling serves as a protective mechanism against AD, and a prolonged disruption of Wnt signaling function could contribute to the A&#946;-related neurodegeneration.<sup><xref rid="bibr34-25424823251385589" ref-type="bibr">34</xref>,<xref rid="bibr35-25424823251385589" ref-type="bibr">35</xref></sup> Restoring or activating Wnt/&#946;-catenin pathway may be a potential treatment strategy for AD.<sup><xref rid="bibr36-25424823251385589" ref-type="bibr">36</xref>,<xref rid="bibr37-25424823251385589" ref-type="bibr">37</xref></sup> Our research demonstrated a direct causal relationship between AXIN1 and AD, which provided significant scientific value for treatment of sporadic AD based on the Wnt signaling. Additionally, in the recent MR research, AXIN1 was proved as a risk factor for AD, which consistent with our findings despite differences in research strategies and datasets.<sup>
<xref rid="bibr38-25424823251385589" ref-type="bibr">38</xref>
</sup> In familial AD, AXIN1 also showed weak risk effect before FDR correction. The association between AXIN1 and familial AD is worth exploring in larger samples in the future.</p><p>Interleukin-1 alpha (IL-1 alpha) is another inflammatory protein associated with the risk of sporadic AD in our study. Du et al. reported the association between IL-1 alpha (&#8722;889) allele 2 polymorphism and later-onset AD with OR&#8201;=&#8201;7.2 in homozygotes.<sup>
<xref rid="bibr39-25424823251385589" ref-type="bibr">39</xref>
</sup> Murphy et al. found that IL-1 alpha (&#8722;889) 2 allele demonstrated accelerate the rate of cognitive decline in AD.<sup>
<xref rid="bibr40-25424823251385589" ref-type="bibr">40</xref>
</sup> The homozygous IL-1 alpha T/T genotype was also showed association with AD onset age.<sup>
<xref rid="bibr41-25424823251385589" ref-type="bibr">41</xref>
</sup> Of course, there have also been some negative results reported in the study of the association between IL-1 and AD, considering it to be due to the different study populations.<sup>
<xref rid="bibr42-25424823251385589" ref-type="bibr">42</xref>
</sup> A meta-analysis data from 32 case-control studies suggested the association between IL-1 alpha &#8722;889C/T polymorphism and AD, though subgroup analysis revealed the robust associations in Caucasian populations but not in Asians.<sup>
<xref rid="bibr43-25424823251385589" ref-type="bibr">43</xref>
</sup> A standard and cumulative meta-analysis found rs1800587 of IL-1 alpha polymorphism was significantly associated with higher AD risk in Caucasian compared with Asians. The observed ethnic differences may reflect low statistical power in Asian subgroups. Maybe future large-scale multi-ethnic studies using standardized methods could confirm these findings and uncover the association between genetic variations of IL-1 alpha and AD across populations.</p><p>While this study provides novel insights into the association between serum LPS activity or inflammatory proteins and AD risk, three key limitations warrant consideration. First, in the selection of genetic IVs in exposure factor serum LPS activity, due to too few IVs after removing the LD SNPs, the filtering criteria are only constrained by p-values and F value. SNPs associated with the serum LPS activity level with <italic toggle="yes">p</italic>-value &lt;1&#8201;&#215;&#8201;10<sup>&#8722;5</sup> was only 71. Despite all this, only weak risk effect of the serum LPS activity level on early onset sporadic AD and potential protective effect on familial AD were observed. Second, since the existing dataset limitation, the study population is only limited to the European population and restricts generalizability, studies in multi-ethnic populations are recommended. Third, the meta-analysis relied exclusively on IVW method results, potentially introducing residual bias even after adjustments for heterogeneity and pleiotropy. Despite these limitations, this represents the most comprehensive MR study to date integrating meta-analytic approaches to investigate serum LPS and inflammatory proteins as risk factors for AD.</p><sec sec-type="conclusions" id="section5-25424823251385589"><title>Conclusions</title><p>In summary, evidence from this large-scale cohort MR combined with meta-analysis study suggested that serum LPS activity level may present an opposite effect in sporadic and familial AD: protective effect on sporadic AD and potential risk effect on familial AD. Only two inflammatory proteins AXIN1 and IL-1 alpha were observed as risk factors in sporadic AD. These findings provide a new perspective for the early diagnosis and treatment of sporadic and familial AD. Further studies in multi-ethnic populations are recommended to confirm our conclusions.</p></sec></sec><sec sec-type="supplementary-material" id="section6-25424823251385589"><title>Supplemental Material</title><supplementary-material id="suppl1-25424823251385589" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-xlsx-1-alr-10.1177_25424823251385589 - Supplemental material for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-xlsx-1-alr-10.1177_25424823251385589.xlsx" position="float" orientation="portrait"/><p>Supplemental material, sj-xlsx-1-alr-10.1177_25424823251385589 for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort by Li Niu, Yubo Li, Hao Wu, Liping Zhao, Jin Zhang, Fan Lu, Guoqing Zhao, Fengfeng Jia, Jianjun Zhu and Ming Liu in Journal of Alzheimer's Disease Reports</p></supplementary-material><supplementary-material id="suppl2-25424823251385589" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-xlsx-2-alr-10.1177_25424823251385589 - Supplemental material for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-xlsx-2-alr-10.1177_25424823251385589.xlsx" position="float" orientation="portrait"/><p>Supplemental material, sj-xlsx-2-alr-10.1177_25424823251385589 for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort by Li Niu, Yubo Li, Hao Wu, Liping Zhao, Jin Zhang, Fan Lu, Guoqing Zhao, Fengfeng Jia, Jianjun Zhu and Ming Liu in Journal of Alzheimer's Disease Reports</p></supplementary-material><supplementary-material id="suppl3-25424823251385589" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-xlsx-3-alr-10.1177_25424823251385589 - Supplemental material for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-xlsx-3-alr-10.1177_25424823251385589.xlsx" position="float" orientation="portrait"/><p>Supplemental material, sj-xlsx-3-alr-10.1177_25424823251385589 for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort by Li Niu, Yubo Li, Hao Wu, Liping Zhao, Jin Zhang, Fan Lu, Guoqing Zhao, Fengfeng Jia, Jianjun Zhu and Ming Liu in Journal of Alzheimer's Disease Reports</p></supplementary-material><supplementary-material id="suppl4-25424823251385589" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-xlsx-4-alr-10.1177_25424823251385589 - Supplemental material for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-xlsx-4-alr-10.1177_25424823251385589.xlsx" position="float" orientation="portrait"/><p>Supplemental material, sj-xlsx-4-alr-10.1177_25424823251385589 for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort by Li Niu, Yubo Li, Hao Wu, Liping Zhao, Jin Zhang, Fan Lu, Guoqing Zhao, Fengfeng Jia, Jianjun Zhu and Ming Liu in Journal of Alzheimer's Disease Reports</p></supplementary-material><supplementary-material id="suppl5-25424823251385589" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-xlsx-5-alr-10.1177_25424823251385589 - Supplemental material for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-xlsx-5-alr-10.1177_25424823251385589.xlsx" position="float" orientation="portrait"/><p>Supplemental material, sj-xlsx-5-alr-10.1177_25424823251385589 for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort by Li Niu, Yubo Li, Hao Wu, Liping Zhao, Jin Zhang, Fan Lu, Guoqing Zhao, Fengfeng Jia, Jianjun Zhu and Ming Liu in Journal of Alzheimer's Disease Reports</p></supplementary-material><supplementary-material id="suppl6-25424823251385589" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-xlsx-6-alr-10.1177_25424823251385589 - Supplemental material for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-xlsx-6-alr-10.1177_25424823251385589.xlsx" position="float" orientation="portrait"/><p>Supplemental material, sj-xlsx-6-alr-10.1177_25424823251385589 for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort by Li Niu, Yubo Li, Hao Wu, Liping Zhao, Jin Zhang, Fan Lu, Guoqing Zhao, Fengfeng Jia, Jianjun Zhu and Ming Liu in Journal of Alzheimer's Disease Reports</p></supplementary-material><supplementary-material id="suppl7-25424823251385589" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-xlsx-7-alr-10.1177_25424823251385589 - Supplemental material for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-xlsx-7-alr-10.1177_25424823251385589.xlsx" position="float" orientation="portrait"/><p>Supplemental material, sj-xlsx-7-alr-10.1177_25424823251385589 for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort by Li Niu, Yubo Li, Hao Wu, Liping Zhao, Jin Zhang, Fan Lu, Guoqing Zhao, Fengfeng Jia, Jianjun Zhu and Ming Liu in Journal of Alzheimer's Disease Reports</p></supplementary-material><supplementary-material id="suppl8-25424823251385589" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-8-alr-10.1177_25424823251385589 - Supplemental material for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-docx-8-alr-10.1177_25424823251385589.docx" position="float" orientation="portrait"/><p>Supplemental material, sj-docx-8-alr-10.1177_25424823251385589 for Causal effect of serum lipopolysaccharide activity levels and inflammatory proteins on Alzheimer's disease: A Mendelian randomization study combined with meta-analysis in a large-scale cohort by Li Niu, Yubo Li, Hao Wu, Liping Zhao, Jin Zhang, Fan Lu, Guoqing Zhao, Fengfeng Jia, Jianjun Zhu and Ming Liu in Journal of Alzheimer's Disease Reports</p></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>We sincerely thank the researchers and participants of the original GWAS studies for their contributions. We also acknowledge the data platforms and consortiums for their efforts in collecting, curating, and sharing these valuable data.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Li Niu <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-0837-9345" ext-link-type="uri">https://orcid.org/0000-0003-0837-9345</ext-link></p><p>Yubo Li <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0002-2411-4988" ext-link-type="uri">https://orcid.org/0009-0002-2411-4988</ext-link></p><p>Hao Wu <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-9310-8998" ext-link-type="uri">https://orcid.org/0000-0002-9310-8998</ext-link></p><p>Guoqing Zhao <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0003-7485-8544" ext-link-type="uri">https://orcid.org/0009-0003-7485-8544</ext-link></p><p>Jianjun Zhu <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-5338-7825" ext-link-type="uri">https://orcid.org/0000-0001-5338-7825</ext-link></p><p>Ming Liu <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-9785-6056" ext-link-type="uri">https://orcid.org/0000-0001-9785-6056</ext-link></p></fn><fn fn-type="other"><p><bold>Ethical considerations:</bold> The publicly available databases including the Finngen database and IEU open GWAS database were used in this study and ethics approval and consent to participate were obtained in these studies.</p></fn><fn fn-type="other"><p><bold>Consent to participate:</bold> Not applicable</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> Not applicable</p></fn><fn fn-type="con"><p><bold>Author contribution(s):</bold>
<bold>Li Niu:</bold> Conceptualization; Formal analysis; Writing &#8211; original draft; Writing &#8211; review &amp; editing.</p><p><bold>Yubo Li:</bold> Data curation; Methodology; Writing &#8211; original draft; Writing &#8211; review &amp; editing.</p><p><bold>Hao Wu:</bold> Data curation; Resources; Writing &#8211; review &amp; editing.</p><p><bold>Liping Zhao:</bold> Validation; Writing &#8211; review &amp; editing.</p><p><bold>Jin Zhang:</bold> Validation; Writing &#8211; review &amp; editing.</p><p><bold>Fan Lu:</bold> Writing &#8211; review &amp; editing.</p><p><bold>Guoqing Zhao:</bold> Validation; Writing &#8211; review &amp; editing.</p><p><bold>Fengfeng Jia:</bold> Writing &#8211; review &amp; editing.</p><p><bold>Jianjun Zhu:</bold> Conceptualization; Validation; Writing &#8211; original draft; Writing &#8211; review &amp; editing.</p><p><bold>Ming Liu:</bold> Conceptualization; Project administration; Supervision; Writing &#8211; original draft.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by National Natural Science Foundation of China (No.81902513), Applied Basic Research Project of Shanxi Province (No. 20210302123319, 20210302124376 and 202103021224228), and Science Research Start-up fund for doctor of Shanxi Medical University (XD1808, BS03201603).</p></fn><fn fn-type="COI-statement"><p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="other"><p><bold>Data availability statement:</bold> The datasets from the Finngen database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.finngen.fi/en/access_results" ext-link-type="uri">https://www.finngen.fi/en/access_results</ext-link>) and the publicly available IEU open GWAS database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://gwas.mrcieu.ac.uk/" ext-link-type="uri">https://gwas.mrcieu.ac.uk/</ext-link>) were downloaded to analysis. The original analysis data can be checked in Supplementary Material of the article.</p></fn><fn fn-type="other"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-25424823251385589"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>E</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JZ</given-names></name></person-group>. <article-title>Updates in Alzheimer's disease: from basic research to diagnosis and therapies</article-title>. <source>Transl Neurodegener</source><year>2024</year>; <volume>13</volume>: <fpage>45</fpage>.<pub-id pub-id-type="pmid">39232848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-024-00432-x</pub-id><pub-id pub-id-type="pmcid">PMC11373277</pub-id></mixed-citation></ref><ref id="bibr2-25424823251385589"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Alzheimer's disease</article-title>. <source>Lancet</source><year>2021</year>; <volume>397</volume>: <fpage>1577</fpage>&#8211;<lpage>1590</lpage>.<pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32205-4</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></mixed-citation></ref><ref id="bibr3-25424823251385589"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajan</surname><given-names>KB</given-names></name><name name-style="western"><surname>Weuve</surname><given-names>J</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></name></person-group>, <etal>et al.</etal><article-title>Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020&#8211;2060)</article-title>. <source>Alzheimers Dement</source><year>2021</year>; <volume>17</volume>: <fpage>1966</fpage>&#8211;<lpage>1975</lpage>.<pub-id pub-id-type="pmid">34043283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12362</pub-id><pub-id pub-id-type="pmcid">PMC9013315</pub-id></mixed-citation></ref><ref id="bibr4-25424823251385589"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Alzheimer's Association</collab></person-group>. <article-title>2023 Alzheimer's disease facts and figures</article-title>. <source>Alzheimers Dement</source><year>2023</year>; <volume>19</volume>: <fpage>1598</fpage>&#8211;<lpage>1695</lpage>.<pub-id pub-id-type="pmid">36918389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13016</pub-id></mixed-citation></ref><ref id="bibr5-25424823251385589"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamurthy</surname><given-names>HK</given-names></name><name name-style="western"><surname>Jayaraman</surname><given-names>V</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>An overview of the genes and biomarkers in Alzheimer's disease</article-title>. <source>Ageing Res Rev</source><year>2024</year>; <volume>104</volume>: <fpage>102599</fpage>.<pub-id pub-id-type="pmid">39612989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2024.102599</pub-id></mixed-citation></ref><ref id="bibr6-25424823251385589"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Cho</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>APOE epsilon4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer's disease</article-title>. <source>Transl Neurodegener</source><year>2022</year>; <volume>11</volume>: <fpage>45</fpage>.<pub-id pub-id-type="pmid">36284363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-022-00319-9</pub-id><pub-id pub-id-type="pmcid">PMC9594913</pub-id></mixed-citation></ref><ref id="bibr7-25424823251385589"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Liddelow</surname><given-names>SA</given-names></name></person-group>, <etal>et al.</etal><article-title>Apoe4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy</article-title>. <source>Nature</source><year>2017</year>; <volume>549</volume>: <fpage>523</fpage>&#8211;<lpage>527</lpage>.<pub-id pub-id-type="pmid">28959956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature24016</pub-id><pub-id pub-id-type="pmcid">PMC5641217</pub-id></mixed-citation></ref><ref id="bibr8-25424823251385589"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>BA</given-names></name><name name-style="western"><surname>Blazey</surname><given-names>TM</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study</article-title>. <source>Lancet Neurol</source><year>2018</year>; <volume>17</volume>: <fpage>241</fpage>&#8211;<lpage>250</lpage>.<pub-id pub-id-type="pmid">29397305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(18)30028-0</pub-id><pub-id pub-id-type="pmcid">PMC5816717</pub-id></mixed-citation></ref><ref id="bibr9-25424823251385589"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunasekaran</surname><given-names>TI</given-names></name><name name-style="western"><surname>Reyes-Dumeyer</surname><given-names>D</given-names></name><name name-style="western"><surname>Faber</surname><given-names>KM</given-names></name></person-group>, <etal>et al.</etal><article-title>Missense and loss-of-function variants at GWAS loci in familial Alzheimer's disease</article-title>. <source>Alzheimers Dement</source><year>2024</year>; <volume>20</volume>: <fpage>7580</fpage>&#8211;<lpage>7594</lpage>.<pub-id pub-id-type="pmid">39233587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14221</pub-id><pub-id pub-id-type="pmcid">PMC11567820</pub-id></mixed-citation></ref><ref id="bibr10-25424823251385589"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertram</surname><given-names>L</given-names></name><name name-style="western"><surname>Lange</surname><given-names>C</given-names></name><name name-style="western"><surname>Mullin</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE</article-title>. <source>Am J Hum Genet</source><year>2008</year>; <volume>83</volume>: <fpage>623</fpage>&#8211;<lpage>632</lpage>.<pub-id pub-id-type="pmid">18976728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2008.10.008</pub-id><pub-id pub-id-type="pmcid">PMC2668052</pub-id></mixed-citation></ref><ref id="bibr11-25424823251385589"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seshadri</surname><given-names>S</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>AL</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></name></person-group>, <etal>et al.</etal><article-title>Genome-wide analysis of genetic loci associated with Alzheimer disease</article-title>. <source>JAMA</source><year>2010</year>; <volume>303</volume>: <fpage>1832</fpage>&#8211;<lpage>1840</lpage>.<pub-id pub-id-type="pmid">20460622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2010.574</pub-id><pub-id pub-id-type="pmcid">PMC2989531</pub-id></mixed-citation></ref><ref id="bibr12-25424823251385589"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Es</surname><given-names>MA</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>LH</given-names></name></person-group>. <article-title>Alzheimer's disease beyond APOE</article-title>. <source>Nat Genet</source><year>2009</year>; <volume>41</volume>: <fpage>1047</fpage>&#8211;<lpage>1048</lpage>.<pub-id pub-id-type="pmid">19786950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng1009-1047</pub-id></mixed-citation></ref><ref id="bibr13-25424823251385589"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganz</surname><given-names>T</given-names></name><name name-style="western"><surname>Fainstein</surname><given-names>N</given-names></name><name name-style="western"><surname>Ben-Hur</surname><given-names>T</given-names></name></person-group>. <article-title>When the infectious environment meets the AD brain</article-title>. <source>Mol Neurodegener</source><year>2022</year>; <volume>17</volume>: <fpage>53</fpage>.<pub-id pub-id-type="pmid">35986296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-022-00559-3</pub-id><pub-id pub-id-type="pmcid">PMC9388962</pub-id></mixed-citation></ref><ref id="bibr14-25424823251385589"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominy</surname><given-names>SS</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>C</given-names></name><name name-style="western"><surname>Ermini</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>Porphyromonas gingivalis in Alzheimer's disease brains: evidence for disease causation and treatment with small-molecule inhibitors</article-title>. <source>Sci Adv</source><year>2019</year>; <volume>5</volume>: <comment>eaau3333</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.aau3333</pub-id><pub-id pub-id-type="pmcid">PMC6357742</pub-id><pub-id pub-id-type="pmid">30746447</pub-id></mixed-citation></ref><ref id="bibr15-25424823251385589"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>HS</given-names></name><name name-style="western"><surname>Koh</surname><given-names>SH</given-names></name></person-group>. <article-title>Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes</article-title>. <source>Transl Neurodegener</source><year>2020</year>; <volume>9</volume>: <fpage>42</fpage>.<pub-id pub-id-type="pmid">33239064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-020-00221-2</pub-id><pub-id pub-id-type="pmcid">PMC7689983</pub-id></mixed-citation></ref><ref id="bibr16-25424823251385589"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name></person-group>. <article-title>Microglia polarization from M1 to M2 in neurodegenerative diseases</article-title>. <source>Front Aging Neurosci</source><year>2022</year>; <volume>14</volume>: <fpage>815347</fpage>.<pub-id pub-id-type="pmid">35250543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.815347</pub-id><pub-id pub-id-type="pmcid">PMC8888930</pub-id></mixed-citation></ref><ref id="bibr17-25424823251385589"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>D</given-names></name></person-group>. <article-title>Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease</article-title>. <source>J Neuroinflammation</source><year>2022</year>; <volume>19</volume>: <fpage>206</fpage>.<pub-id pub-id-type="pmid">35978311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02565-0</pub-id><pub-id pub-id-type="pmcid">PMC9382837</pub-id></mixed-citation></ref><ref id="bibr18-25424823251385589"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez-Tapia</surname><given-names>M</given-names></name><name name-style="western"><surname>Mimenza-Alvarado</surname><given-names>A</given-names></name><name name-style="western"><surname>Granados-Dominguez</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>The gut microbiota-brain axis during aging, mild cognitive impairment and dementia: role of tau protein, beta-amyloid and LPS in serum and curli protein in stool</article-title>. <source>Nutrients</source><year>2023</year>; <volume>15</volume>: <fpage>932</fpage>.<pub-id pub-id-type="pmid">36839291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu15040932</pub-id><pub-id pub-id-type="pmcid">PMC9961602</pub-id></mixed-citation></ref><ref id="bibr19-25424823251385589"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreadou</surname><given-names>EG</given-names></name><name name-style="western"><surname>Katsipis</surname><given-names>G</given-names></name><name name-style="western"><surname>Tsolaki</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Involvement and relationship of bacterial lipopolysaccharides and cyclooxygenases levels in Alzheimer's disease and mild cognitive impairment patients</article-title>. <source>J Neuroimmunol</source><year>2021</year>; <volume>357</volume>: <fpage>577561</fpage>.<pub-id pub-id-type="pmid">34091099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2021.577561</pub-id></mixed-citation></ref><ref id="bibr20-25424823251385589"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohm</surname><given-names>M</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>S</given-names></name><name name-style="western"><surname>Lonnemann</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>The potential therapeutic role of itaconate and mesaconate on the detrimental effects of LPS-induced neuroinflammation in the brain</article-title>. <source>J Neuroinflammation</source><year>2024</year>; <volume>21</volume>: <fpage>207</fpage>.<pub-id pub-id-type="pmid">39164713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03188-3</pub-id><pub-id pub-id-type="pmcid">PMC11337794</pub-id></mixed-citation></ref><ref id="bibr21-25424823251385589"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lista</surname><given-names>S</given-names></name><name name-style="western"><surname>Imbimbo</surname><given-names>BP</given-names></name><name name-style="western"><surname>Grasso</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?</article-title><source>J Neuroinflammation</source><year>2024</year>; <volume>21</volume>: <fpage>187</fpage>.<pub-id pub-id-type="pmid">39080712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03163-y</pub-id><pub-id pub-id-type="pmcid">PMC11289964</pub-id></mixed-citation></ref><ref id="bibr22-25424823251385589"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdul Manap</surname><given-names>AS</given-names></name><name name-style="western"><surname>Almadodi</surname><given-names>R</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Alzheimer's disease: a review on the current trends of the effective diagnosis and therapeutics</article-title>. <source>Front Aging Neurosci</source><year>2024</year>; <volume>16</volume>: <fpage>1429211</fpage>.<pub-id pub-id-type="pmid">39185459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2024.1429211</pub-id><pub-id pub-id-type="pmcid">PMC11341404</pub-id></mixed-citation></ref><ref id="bibr23-25424823251385589"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ference</surname><given-names>BA</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>MV</given-names></name><name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name></person-group>. <article-title>Using Mendelian randomization to improve the design of randomized trials</article-title>. <source>Cold Spring Harb Perspect Med</source><year>2021</year>; <volume>11</volume>: <comment>a040980</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a040980</pub-id><pub-id pub-id-type="pmcid">PMC8247560</pub-id><pub-id pub-id-type="pmid">33431510</pub-id></mixed-citation></ref><ref id="bibr24-25424823251385589"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Violi</surname><given-names>F</given-names></name><name name-style="western"><surname>Cammisotto</surname><given-names>V</given-names></name><name name-style="western"><surname>Bartimoccia</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease</article-title>. <source>Nat Rev Cardiol</source><year>2023</year>; <volume>20</volume>: <fpage>24</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">35840742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-022-00737-2</pub-id><pub-id pub-id-type="pmcid">PMC9284488</pub-id></mixed-citation></ref><ref id="bibr25-25424823251385589"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>GC</given-names></name><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name></person-group>. <article-title>The endotoxin hypothesis of Alzheimer's disease</article-title>. <source>Mol Neurodegener</source><year>2024</year>; <volume>19</volume>: <fpage>30</fpage>.<pub-id pub-id-type="pmid">38561809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-024-00722-y</pub-id><pub-id pub-id-type="pmcid">PMC10983749</pub-id></mixed-citation></ref><ref id="bibr26-25424823251385589"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>D</given-names></name><name name-style="western"><surname>Barr</surname><given-names>LC</given-names></name><name name-style="western"><surname>Wiscombe</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation</article-title>. <source>Eur Respir J</source><year>2020</year>; <volume>56</volume>: <fpage>1901298</fpage>.<pub-id pub-id-type="pmid">32299854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.01298-2019</pub-id></mixed-citation></ref><ref id="bibr27-25424823251385589"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leskela</surname><given-names>J</given-names></name><name name-style="western"><surname>Toppila</surname><given-names>I</given-names></name><name name-style="western"><surname>Harma</surname><given-names>MA</given-names></name></person-group>, <etal>et al.</etal><article-title>Genetic profile of endotoxemia reveals an association with thromboembolism and stroke</article-title>. <source>J Am Heart Assoc</source><year>2021</year>; <volume>10</volume>: <comment>e022482</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.121.022482</pub-id><pub-id pub-id-type="pmcid">PMC8751832</pub-id><pub-id pub-id-type="pmid">34668383</pub-id></mixed-citation></ref><ref id="bibr28-25424823251385589"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizobuchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Soma</surname><given-names>GI</given-names></name></person-group>. <article-title>Low-dose lipopolysaccharide as an immune regulator for homeostasis maintenance in the central nervous system through transformation to neuroprotective microglia</article-title>. <source>Neural Regen Res</source><year>2021</year>; <volume>16</volume>: <fpage>1928</fpage>&#8211;<lpage>1934</lpage>.<pub-id pub-id-type="pmid">33642362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1673-5374.308067</pub-id><pub-id pub-id-type="pmcid">PMC8343302</pub-id></mixed-citation></ref><ref id="bibr29-25424823251385589"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradburn</surname><given-names>S</given-names></name><name name-style="western"><surname>Murgatroyd</surname><given-names>C</given-names></name><name name-style="western"><surname>Ray</surname><given-names>N</given-names></name></person-group>. <article-title>Neuroinflammation in mild cognitive impairment and Alzheimer's disease: a meta-analysis</article-title>. <source>Ageing Res Rev</source><year>2019</year>; <volume>50</volume>: <fpage>1</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">30610927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2019.01.002</pub-id></mixed-citation></ref><ref id="bibr30-25424823251385589"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almutary</surname><given-names>AG</given-names></name><name name-style="western"><surname>Begum</surname><given-names>MY</given-names></name><name name-style="western"><surname>Kyada</surname><given-names>AK</given-names></name></person-group>, <etal>et al.</etal><article-title>Inflammatory signaling pathways in Alzheimer's disease: mechanistic insights and possible therapeutic interventions</article-title>. <source>Ageing Res Rev</source><year>2025</year>; <volume>104</volume>: <fpage>102548</fpage>.<pub-id pub-id-type="pmid">39419399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2024.102548</pub-id></mixed-citation></ref><ref id="bibr31-25424823251385589"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botella Lucena</surname><given-names>P</given-names></name><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name></person-group>. <article-title>Inflammatory aspects of Alzheimer's disease</article-title>. <source>Acta Neuropathol</source><year>2024</year>; <volume>148</volume>: <fpage>31</fpage>.<pub-id pub-id-type="pmid">39196440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-024-02790-2</pub-id></mixed-citation></ref><ref id="bibr32-25424823251385589"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name><name name-style="western"><surname>Fagotto</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>The mouse fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation</article-title>. <source>Cell</source><year>1997</year>; <volume>90</volume>: <fpage>181</fpage>&#8211;<lpage>192</lpage>.<pub-id pub-id-type="pmid">9230313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0092-8674(00)80324-4</pub-id></mixed-citation></ref><ref id="bibr33-25424823251385589"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishida</surname><given-names>S</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin</article-title>. <source>J Biol Chem</source><year>1998</year>; <volume>273</volume>: <fpage>10823</fpage>&#8211;<lpage>10826</lpage>.<pub-id pub-id-type="pmid">9556553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.273.18.10823</pub-id></mixed-citation></ref><ref id="bibr34-25424823251385589"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>T</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Osteocyte-derived sclerostin impairs cognitive function during ageing and Alzheimer's disease progression</article-title>. <source>Nat Metab</source><year>2024</year>; <volume>6</volume>: <fpage>531</fpage>&#8211;<lpage>549</lpage>.<pub-id pub-id-type="pmid">38409606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-024-00989-x</pub-id></mixed-citation></ref><ref id="bibr35-25424823251385589"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inestrosa</surname><given-names>NC</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>EM</given-names></name></person-group>. <article-title>The role of Wnt signaling in neuronal dysfunction in Alzheimer's disease</article-title>. <source>Mol Neurodegener</source><year>2008</year>; <volume>3</volume>: <fpage>9</fpage>.<pub-id pub-id-type="pmid">18652670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1750-1326-3-9</pub-id><pub-id pub-id-type="pmcid">PMC2515306</pub-id></mixed-citation></ref><ref id="bibr36-25424823251385589"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Activation of Wnt/beta-catenin pathway mitigates blood-brain barrier dysfunction in Alzheimer's disease</article-title>. <source>Brain</source><year>2022</year>; <volume>145</volume>: <fpage>4474</fpage>&#8211;<lpage>4488</lpage>.<pub-id pub-id-type="pmid">35788280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awac236</pub-id><pub-id pub-id-type="pmcid">PMC9762951</pub-id></mixed-citation></ref><ref id="bibr37-25424823251385589"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Inhibition of CXXC5 function rescues Alzheimer's disease phenotypes by restoring Wnt/beta-catenin signaling pathway</article-title>. <source>Pharmacol Res</source><year>2023</year>; <volume>194</volume>: <fpage>106836</fpage>.<pub-id pub-id-type="pmid">37355147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2023.106836</pub-id></mixed-citation></ref><ref id="bibr38-25424823251385589"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Gong</surname><given-names>W</given-names></name></person-group>, <etal>et al.</etal><article-title>Exploring the bidirectional relationships between Alzheimer's disease and cerebral small vessel disease: insights from Mendelian randomization</article-title>. <source>J Stroke Cerebrovasc Dis</source><year>2025</year>; <volume>34</volume>: <fpage>108259</fpage>.<pub-id pub-id-type="pmid">39929297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jstrokecerebrovasdis.2025.108259</pub-id></mixed-citation></ref><ref id="bibr39-25424823251385589"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dodel</surname><given-names>RC</given-names></name><name name-style="western"><surname>Eastwood</surname><given-names>BJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Association of an interleukin 1 alpha polymorphism with Alzheimer's disease</article-title>. <source>Neurology</source><year>2000</year>; <volume>55</volume>: <fpage>480</fpage>&#8211;<lpage>483</lpage>.<pub-id pub-id-type="pmid">10953177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.55.4.480</pub-id></mixed-citation></ref><ref id="bibr40-25424823251385589"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>GM</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Claassen</surname><given-names>JD</given-names></name><name name-style="western"><surname>DeVoss</surname><given-names>JJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha &#8722;889 *1 allele</article-title>. <source>Neurology</source><year>2001</year>; <volume>56</volume>: <fpage>1595</fpage>&#8211;<lpage>1597</lpage>.<pub-id pub-id-type="pmid">11402127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.56.11.1595</pub-id></mixed-citation></ref><ref id="bibr41-25424823251385589"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grimaldi</surname><given-names>LM</given-names></name><name name-style="western"><surname>Casadei</surname><given-names>VM</given-names></name><name name-style="western"><surname>Ferri</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism</article-title>. <source>Ann Neurol</source><year>2000</year>; <volume>47</volume>: <fpage>361</fpage>&#8211;<lpage>365</lpage>.<pub-id pub-id-type="pmid">10716256</pub-id></mixed-citation></ref><ref id="bibr42-25424823251385589"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ki</surname><given-names>CS</given-names></name><name name-style="western"><surname>Na</surname><given-names>DL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DK</given-names></name></person-group>, <etal>et al.</etal><article-title>Lack of association of the interleukin-1alpha gene polymorphism with Alzheimer's disease in a Korean population</article-title>. <source>Ann Neurol</source><year>2001</year>; <volume>49</volume>: <fpage>817</fpage>&#8211;<lpage>818</lpage>.<pub-id pub-id-type="pmid">11409441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.1067</pub-id></mixed-citation></ref><ref id="bibr43-25424823251385589"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>X</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name></person-group>, <etal>et al.</etal><article-title>Interleukin-1A &#8722;889C/T polymorphism and risk of Alzheimer's disease: a meta-analysis based on 32 case-control studies</article-title>. <source>J Neurol</source><year>2012</year>; <volume>259</volume>: <fpage>1519</fpage>&#8211;<lpage>1529</lpage>.<pub-id pub-id-type="pmid">22234841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-011-6381-6</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501329</article-id><article-id pub-id-type="pmcid-ver">PMC12501329.1</article-id><article-id pub-id-type="pmcaid">12501329</article-id><article-id pub-id-type="pmcaiid">12501329</article-id><article-id pub-id-type="pmid">40912996</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100337</article-id><article-id pub-id-type="pii">S2274-5807(25)00279-1</article-id><article-id pub-id-type="publisher-id">100337</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Greeley</surname><given-names initials="D">David</given-names></name><email>nwn@me.com</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Nash</surname><given-names initials="M">Marshall</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Herskowitz</surname><given-names initials="B">Brad</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Kim</surname><given-names initials="F">Fred</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Rock</surname><given-names initials="J">James</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Prins</surname><given-names initials="N">Neils</given-names></name><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Kim</surname><given-names initials="S">SangYun</given-names></name><xref rid="aff0006" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Xi</surname><given-names initials="T">Tianyang</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0009"><name name-style="western"><surname>Busam</surname><given-names initials="JA">Jonathan A.</given-names></name><xref rid="aff0007" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Tete</surname><given-names initials="B">Benoit</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0011"><name name-style="western"><surname>Choung</surname><given-names initials="JJ">Jai Jun</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0012"><name name-style="western"><surname>Sha</surname><given-names initials="SJ">Sharon J.</given-names></name><xref rid="aff0008" ref-type="aff">h</xref></contrib><aff id="aff0001"><label>a</label>Northwest Neurological, PLLC, Spokane WA USA</aff><aff id="aff0002"><label>b</label>NeuroStudies, Decatur GA USA</aff><aff id="aff0003"><label>c</label>The Neurology Group, Miami FL USA</aff><aff id="aff0004"><label>d</label>AriBio Co., Ltd., San Diego CA USA</aff><aff id="aff0005"><label>e</label>Brain Research Center, Amsterdam, Netherlands</aff><aff id="aff0006"><label>f</label>Department of Neurology, Seoul National University College of Medicine and Clinical Neuroscience Center, Gyeonggi-do, Republic of Korea</aff><aff id="aff0007"><label>g</label>Geisel School of Medicine, Dartmouth University, Hanover NH USA</aff><aff id="aff0008"><label>h</label>Stanford Neuroscience Health Center, Stanford University, Palo Alto CA USA</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author. <email>nwn@me.com</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>9</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100337</elocation-id><history><date date-type="received"><day>3</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>7</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>9</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><sec><title>Background</title><p>AR1001 is a phosphodiesterase-5 inhibitor that produces improved cognitive performance and reduces amyloid-&#946; and phosphorylated tau burdens in preclinical models of Alzheimer&#8217;s disease (AD).</p></sec><sec><title>Objectives</title><p>To evaluate the safety and efficacy of AR1001 in participants with mild-to-moderate Alzheimer&#8217;s disease (AD).</p></sec><sec><title>Design</title><p>Randomized, double-blind, placebo-controlled phase 2 trial conducted at 21 sites in the United States.</p></sec><sec><title>Participants</title><p>Adults aged 55&#8211;80 years with mild-to-moderate dementia as determined by National Institutes of Aging-Alzheimer&#8217;s Association (NIA-AA) stage 4 or 5 and Mini-mental State Exam (MMSE) score 16-26.</p></sec><sec><title>Intervention</title><p>Once daily oral administration of placebo, 10 mg AR1001, or 30 mg AR1001 for 26 weeks followed by 26 weeks optional extension.</p></sec><sec><title>Measurements</title><p>Co-primary efficacy endpoints were changes from baseline at Week 26 in Alzheimer&#8217;s Disease Assessment Scale-cognitive subscale (ADAS-Cog 13) and Alzheimer&#8217;s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). Secondary endpoints included measures of cognition, daily living, and depression. Levels of plasma biomarkers pTau-181, pTau-217, A&#946;42/40 ratio, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) were also examined.</p></sec><sec><title>Results</title><p>A total of 210 participants were enrolled and 82% completed 26 weeks of treatment. AR1001 10 mg and 30 mg were well-tolerated with a similar safety profile compared to placebo. After 26 weeks, there were no differences in ADAS-Cog13, ADCS-CGIC, or in secondary efficacy endpoints between groups. Levels of plasma biomarkers pTau-181, pTau-217, and GFAP were improved in the 30 mg AR1001 group compared to placebo.</p></sec><sec><title>Conclusion</title><p>AR1001 was safe and well tolerated. Although primary efficacy endpoints were not met after 26 weeks of treatment, participants receiving 30 mg AR1001 showed favorable changes in AD-related plasma biomarkers compared to placebo.</p></sec><sec><title>Trial registration</title><p>clinicaltrials.gov; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03625622">NCT03625622</ext-link></p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Phosphodiesterase-5 inhibitor</kwd><kwd>AR1001</kwd><kwd>Mirodenafil</kwd><kwd>p-tau181</kwd><kwd>Alzheimer's disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><title>Introduction</title><p id="para0010">Alzheimer&#8217;s disease (AD) is the most common cause of dementia, accounting for 60&#8211;70% of cases [<xref rid="bib0001" ref-type="bibr">1</xref>]. According to the World Health Organization, more than 55 million people worldwide had dementia in 2021, with 10 million new cases per year, at a cost expected to reach $2.8 trillion USD per year globally by 2030 [<xref rid="bib0001" ref-type="bibr">1</xref>]. There are no medications or therapies that can arrest AD-related neurodegeneration and cognitive decline, creating a need for treatment options that at a minimum maintain quality of life for AD patients.</p><p id="para0011">It is widely believed that the pathogenesis of AD is multifactorial, involving genetic factors [<xref rid="bib0002" ref-type="bibr">2</xref>], cholinergic dysfunction [<xref rid="bib0003" ref-type="bibr">3</xref>,<xref rid="bib0004" ref-type="bibr">4</xref>], amyloid plaque formation [<xref rid="bib0005" ref-type="bibr">5</xref>], tau aggregation [<xref rid="bib0006" ref-type="bibr">6</xref>,<xref rid="bib0007" ref-type="bibr">7</xref>], inflammation [<xref rid="bib0008" ref-type="bibr">8</xref>,<xref rid="bib0009" ref-type="bibr">9</xref>], and oxidative stress [<xref rid="bib0010" ref-type="bibr">10</xref>]. Monoclonal antibodies that target cerebral amyloid have recently received FDA approval for the treatment of early AD based on improvements in cognitive measures and reduction in amyloid burden compared to placebo, although targeting amyloid alone does not appear to be sufficient to prevent disease progression [<xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>]. A polypharmacological approach that targets multiple pathogenic pathways may hold promise [<xref rid="bib0014" ref-type="bibr">[14]</xref>, <xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>]. The development of safe and easily administered medicines would provide additional treatment options to patients, particularly those who are at risk for amyloid-related imaging abnormalities (ARIA) from monoclonal antibody therapy, such as ApoE4 homozygotes, patients with cerebral amyloid angiopathy, and patients taking concomitant antithrombotic or thrombolytic medication.</p><p id="para0012">Phosphodiesterase-5 (PDE5) inhibitors, which include sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis), have been widely used for the treatment of erectile dysfunction (ED) and pulmonary arterial hypertension (PAH), and have extensive clinical and safety data. PDE5 inhibitors increase cellular levels of cyclic GMP (cGMP), which activates protein kinase G (PKG) and its downstream effectors including cyclic adenosine monophosphate responsive element binding protein (CREB) and phosphatidylinositol 3-kinase (PI3K)/Akt. CREB has been linked to preservation of neuronal signaling and synaptic plasticity, and Akt activation protects neurons through inhibition of glycogen synthase kinase 3&#946; and reduced phosphorylation of Tau [<xref rid="bib0018" ref-type="bibr">18</xref>].</p><p id="para0013">Preclinical studies of PDE5 inhibitors in cell and animal models of neurodegenerative diseases support a role in neuroprotective and anti-inflammatory processes. In pluripotent stem cells derived from AD patients, sildenafil treatment reduced hyperphosphorylated Tau levels and enhanced neurite outgrowth [<xref rid="bib0019" ref-type="bibr">19</xref>]. Treatment with sildenafil and tadalafil reduced expression of pro-inflammatory cytokines, reduced apoptosis and autophagy, increased neurogenesis, and ameliorated cognitive and behavioral deficits in rodent models of neurodegenerative diseases including AD (reviewed in [<xref rid="bib0018" ref-type="bibr">18</xref>,<xref rid="bib0020" ref-type="bibr">20</xref>,<xref rid="bib0021" ref-type="bibr">21</xref>].</p><p id="para0014">AR1001 (mirodenafil) is a phosphodiesterase 5 (PDE5) inhibitor approved in South Korea as Mvix&#174; for treatment of erectile dysfunction. It is a highly potent inhibitor of PDE5, with an IC&#8325;&#8320; of 0.34 nM and 30-fold greater selectivity against PDE5 than PDE6 (IC<sub>50</sub>= 10.2 nM) [<xref rid="bib0022" ref-type="bibr">22</xref>]. In neuroblastoma SH-SY5Y cells treated with the toxic amyloid form A&#946;42, administration of mirodenafil reduced levels of A&#946; and markers of apoptosis (cleaved caspase-3 and poly ADP-ribose polymerase), and increased levels of the autophagy marker p62 [<xref rid="bib0023" ref-type="bibr">23</xref>]. In the APP-C105 and ApoE4 knock-in transgenic mouse models of AD, mirodenafil-treated mice showed significant improvements in cognitive performance compared to control animals, had lower levels of A&#946;42 and phosphorylated Tau, and had improved cerebrovascular perfusion and tight junction gene expression [<xref rid="bib0024" ref-type="bibr">24</xref>]. A recent study also showed that mirodenafil significantly improved sensorimotor and cognitive recovery and reduced the amount of degenerative and apoptotic cell neurons in experimental models of stroke [<xref rid="bib0025" ref-type="bibr">25</xref>]. Mirodenafil has been shown to penetrate the blood-brain barrier, as levels of <sup>14</sup>C[mirodenafil] were present in the brains of rats [<xref rid="bib0026" ref-type="bibr">26</xref>].</p><p id="para0015">Due to the potent inhibition of PDE5 by AR1001, its blood-brain barrier penetration, and its amelioration of AD pathology and symptoms in preclinical models, AR1001 was evaluated in a Phase 2 study in patients with mild-to-moderate AD to determine its safety and preliminary efficacy.</p></sec><sec id="sec0002"><title>Methods</title><sec id="sec0003"><title>Trial conduct and oversight</title><p id="para0016">AR1001-ADP2-US01 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03625622">NCT03625622</ext-link>) was a 26-week, Phase 2, randomized, placebo-controlled, double-blinded study conducted across 21 sites in the United States from January 2019 to June 2021. All procedures were performed in compliance with the protocol, provisions in the Declaration of Helsinki, regulations of the United States Food and Drug Administration, and guidelines of Good Clinical Practice as outlined by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. WCG Institutional Review Board approved the study protocol and amendments. The privacy rights of human subjects were observed and informed consent was obtained from all participants and/or caregivers. The trial was sponsored by AriBio.</p></sec><sec id="sec0004"><title>Study participants</title><p id="para0017">Key eligibility criteria were 55-80 years of age, clinical staging 4 or 5 by 2011 NIA-AA criteria, and MMSE score between 16 and 26 (<xref rid="fig0001" ref-type="fig">Fig. 1A</xref>). Study participants were required to have an MRI or CT scan after the onset of dementia symptoms that showed findings consistent with a diagnosis of AD at the time of the study, without clinically significant comorbid pathologies.<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Trial Design Summary and Patient Disposition</bold>. (A) Schematic of the 26-week randomized, placebo-controlled treatment phase and optional 26-week extension. Participants were randomized 1:1:1 to receive placebo, AR1001 10 mg, or AR1001 30 mg QD. Participants originally on placebo were re-randomized to 10 mg or 30 mg AR1001 in the extension phase. (B) CONSORT diagram showing participant flow, completion, and discontinuation rates across treatment and extension phases.</p></caption><alt-text id="alt0005">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="para0018">FDA-approved Alzheimer&#8217;s disease medications (donepezil, rivastigmine, galantamine, memantine, or combinations of these [<xref rid="bib0027" ref-type="bibr">27</xref>]) were allowed if doses were stable for at least 3 months at the time of study enrollment.</p><p id="para0019">ApoE4 proteotypic status was determined using Lumipulse <italic toggle="yes">G</italic> ApoE4 and Lumipulse <italic toggle="yes">G</italic> Pan-ApoE protein assays.</p></sec><sec id="sec0005"><title>Randomization and intervention</title><p id="para0020">Eligible patients were randomized 1:1:1 with a randomization block size of 6 to receive a daily oral dose of placebo, 10 mg AR1001, or 30 mg AR1001 for 26 weeks. The study was double blinded to participant and investigator. Upon completion of the 26-week treatment phase, participants were given the option to continue for an additional 26-week extension phase. Participants assigned to AR1001 for the treatment phase continued at the same dose in the extension phase, and participants assigned to placebo were rerandomized 1:1 with a block size of 2 to receive 10 mg or 30 mg AR1001 (<xref rid="fig0001" ref-type="fig">Fig. 1A</xref>).</p></sec><sec id="sec0006"><title>Endpoints and assessments</title><p id="para0021">The co-primary efficacy endpoints were 1) change from baseline to Week 26 in the 13-item Alzheimer&#8217;s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog 13), with scores ranging from 0 (no impairment) to 85; and 2) change from baseline to Week 26 in the Alzheimer&#8217;s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), a 7-point scale that evaluates improvement or worsening of AD symptoms. Secondary efficacy endpoints included changes from baseline to Week 26 in MMSE-2, Neuropsychiatric Inventory (NPI), Geriatric Depression Scale (GDS), and Quality of Life in Alzheimer&#8217;s Disease (QOL-AD) (<xref rid="fig0001" ref-type="fig">Fig. 1A</xref>).</p><p id="para0022">Plasma samples for analysis of putative AD biomarkers pTau-181, pTau-217, A&#946;42/40 ratio, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) were collected from consented participants in 10 ml EDTA tubes, centrifuged, and stored frozen in 1 ml aliquots. Plasma samples were diluted 4&#215; and run in duplicate. The mean of duplicates for each sample was determined and included in the analysis if the coefficient of variation was &lt; 25%. Plasma levels of pTau-181 were quantified using the Simoa Human pTau-181 Advantage V2 Kit (Quanterix). Plasma pTau-217 was quantified using Lumipulse&#174; G pTau 217 kit (Fujirebio, Malvern, PA). Plasma levels of GFAP, A&#946;42/40 ratio, and NfL were quantified using the Simoa Neurology 4-Plex E Advantage Kit (Quanterix). pTau-217 was quantified using Lumipulse&#174; G pTau 217 kit (Fujirebio, Malvern, PA).</p><p id="para0023">Investigators reported adverse events using MedDRA Version 24.0 based on assessments of patient symptoms, vital signs, physical examinations, electrocardiography (ECG) readings, clinical laboratory tests (hematology, blood chemistry, and urinalysis), and the Columbia Suicide Severity Rating Scale (C-SSRS) [<xref rid="bib0028" ref-type="bibr">28</xref>].</p><p id="para0024">Cognitive and safety assessments were conducted at baseline (Week 0) and during the treatment phase at Weeks 4, 13, and 26, along with a safety phone call at Week 20. During the extension phase, cognitive and safety assessments were conducted at Weeks 30, 39, and 52, with a safety phone call at Week 46. A safety follow-up visit was conducted 2 weeks after the last dose of study drug (<xref rid="fig0001" ref-type="fig">Fig. 1A</xref>).</p></sec><sec id="sec0007"><title>Statistical methodology</title><p id="para0025">Efficacy outcomes were analyzed in the Intent-to-Treat (ITT) population, which included participants who took at least one dose of study drug and had at least one post-dose efficacy measurement. Descriptive statistics were used to summarize continuous variables by treatment group. For the primary analysis, the change from baseline in ADAS-Cog 13 at Week 26 was analyzed with an ANCOVA model including the factor of treatment and the Baseline ADAS-Cog 13 result as a covariate. No repeated measures were included in the model. For the co-primary endpoints, the overall Type I error of 0.05 was controlled using the Holm step-down procedure [<xref rid="bib0029" ref-type="bibr">29</xref>]. To reject the null hypothesis that AR1001 was not different from placebo with respect to changes from baseline in ADAS-Cog 13 and ADCS-CGIC at Week 26, both co-primary endpoints needed to show statistical significance. Similar ANCOVA models were used to analyze secondary outcomes at Week 26.</p><p id="para0026">Biomarker analyses evaluated changes from baseline to Week 26 in pTau-181, pTau-217, A&#946; 42/40 ratio, GFAP, and NfL, with independent samples tests for comparisons between treatment groups and placebo.</p><p id="para0027">Safety outcomes were summarized overall and by the treatment group to which patients were randomized. Outcomes were further classified by severity, seriousness, and relation to the study drug. Descriptive statistics were used to describe the data.</p><p id="para0028">Post-hoc analyses were performed in participants in the top tertile of baseline pTau-181 levels (corresponding to &gt; 5.0 pg/mL) and corresponding lower two tertiles using Mann-Whitney U tests to compare between groups.</p><sec id="sec0008"><title>Sample size calculation</title><p id="para0029">The population of 210 participants was selected based on an assumed 20% drop-out rate that would yield an evaluable sample size of 168 patients, providing the trial with 80% power to show that the AR1001 treatment groups altered disease progression compared to placebo by a 2-point difference at Week 26 in the group means of ADAS-Cog 13 scores, with an overall standard deviation of 6.7 points. For ADCS-CGIC, a 0.35 difference in group means can be detected as statistically significant with a sample size of 58 participants per group assuming the change from baseline in ADCS-CGIC has an overall standard deviation of 1.2 points [<xref rid="bib0030" ref-type="bibr">30</xref>].</p></sec></sec></sec><sec id="sec0009"><title>Results</title><sec id="sec0010"><title>Trial population</title><p id="para0030">The completion rate for the 26-week treatment phase was 78.6% in the placebo group, 87.1% in the 10 mg AR1001 group, and 81.4% in the 30 mg AR1001 group. Of the 173 participants who completed the treatment phase, 141 continued to the optional extension phase. The completion rate for participants entering the extension phase was 81.5% (115/141) (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>B).</p><p id="para0031">The mean age of participants was 70.6 years, and the population was 65.7% female (<xref rid="tbl0001" ref-type="table">Table 1</xref>). The racial and ethnic makeup of participants who were enrolled included 13.3% African-American and 20.0% Latino or Hispanic participants.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Baseline demographics and clinical characteristics of participants by treatment group.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Characteristic</th><th valign="top" colspan="1" rowspan="1">Placebo<break/>(N = 70)</th><th valign="top" colspan="1" rowspan="1">AR1001 10 mg<break/>(N = 70)</th><th valign="top" colspan="1" rowspan="1">AR1001 30 mg<break/>(N = 70)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Age (years), mean (SD)</td><td valign="top" colspan="1" rowspan="1">70.4 (5.5)</td><td valign="top" colspan="1" rowspan="1">70.9 (6.5)</td><td valign="top" colspan="1" rowspan="1">70.4 (6.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><underline>Gender, n (%)</underline></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Female</td><td valign="top" colspan="1" rowspan="1">48 (68.6)</td><td valign="top" colspan="1" rowspan="1">43 (61.4)</td><td valign="top" colspan="1" rowspan="1">47 (67.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Male</td><td valign="top" colspan="1" rowspan="1">22 (31.4)</td><td valign="top" colspan="1" rowspan="1">27 (38.6)</td><td valign="top" colspan="1" rowspan="1">23 (32.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><underline>Race/Ethnicity, n (%)</underline></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Black or African American</td><td valign="top" colspan="1" rowspan="1">12 (17.1)</td><td valign="top" colspan="1" rowspan="1">8 (11.4)</td><td valign="top" colspan="1" rowspan="1">8 (11.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;White</td><td valign="top" colspan="1" rowspan="1">58 (82.9)</td><td valign="top" colspan="1" rowspan="1">60 (85.7)</td><td valign="top" colspan="1" rowspan="1">62 (88.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Other</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">2 (2.8)</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Hispanic or Latino ethnicity, n (%)</td><td valign="top" colspan="1" rowspan="1">13 (18.6)</td><td valign="top" colspan="1" rowspan="1">13 (18.6)</td><td valign="top" colspan="1" rowspan="1">16 (22.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>), mean (SD)</td><td valign="top" colspan="1" rowspan="1">28.1 (5.5)</td><td valign="top" colspan="1" rowspan="1">29.6 (7.0)</td><td valign="top" colspan="1" rowspan="1">28.7 (6.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Ongoing AD treatment<xref rid="tb1fn1" ref-type="table-fn">*</xref>, n (%)</td><td valign="top" colspan="1" rowspan="1">36 (51.4)</td><td valign="top" colspan="1" rowspan="1">40 (57.1)</td><td valign="top" colspan="1" rowspan="1">46 (65.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><underline>Baseline cognitive impairment, n (%)</underline></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Mild (MMSE-2 &#8805; 21)</td><td valign="top" colspan="1" rowspan="1">52 (74.3)</td><td valign="top" colspan="1" rowspan="1">44 (62.9)</td><td valign="top" colspan="1" rowspan="1">37 (52.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Moderate (MMSE-2 of 16&#8211;20)</td><td valign="top" colspan="1" rowspan="1">18 (25.7)</td><td valign="top" colspan="1" rowspan="1">26 (37.1)</td><td valign="top" colspan="1" rowspan="1">33 (47.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><underline>ApoE4 Status, n</underline></td><td valign="top" colspan="1" rowspan="1">62</td><td valign="top" colspan="1" rowspan="1">59</td><td valign="top" colspan="1" rowspan="1">60</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Homozygous, n (%)</td><td valign="top" colspan="1" rowspan="1">6 (9.7)</td><td valign="top" colspan="1" rowspan="1">11 (18.6)</td><td valign="top" colspan="1" rowspan="1">10 (16.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Heterozygous, n (%)</td><td valign="top" colspan="1" rowspan="1">30 (48.4)</td><td valign="top" colspan="1" rowspan="1">18 (30.5)</td><td valign="top" colspan="1" rowspan="1">29 (48.3)</td></tr></tbody></table><table-wrap-foot><fn id="tb1fn1"><label>&#8270;</label><p id="notep0001">Ongoing AD treatment indicates concomitant administration of an approved medication for Alzheimer&#8217;s disease (donepezil, rivastigmine, galantamine, or memantine) at a stable dose.</p><p id="notep0002">Abbreviations: AD: Alzheimer&#8217;s disease; ApoE4: apolipoprotein E4; BMI: body mass index; MMSE-2: Mini-mental Status Examination, 2<sup>nd</sup> Edition; SD: standard deviation</p></fn></table-wrap-foot></table-wrap></p><p id="para0032">Of 181 participants tested for ApoE4 status, 27 (14.9%) were homozygous and 77 (42.5%) were heterozygous, an overall ApoE4 carrier rate of 57.4%. ApoE4 carrier status was broadly balanced across groups; however, the proportion of ApoE4 homozygotes was lower in the placebo group (9.7%) compared to the AR1001 10 mg (18.6%) and 30 mg (16.7%) groups (<xref rid="tbl0001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec0011"><title>Safety assessments</title><p id="para0033">During the 26-week placebo-controlled treatment phase, AR1001 at 10 and 30 mg had similar adverse event profiles compared to placebo (<xref rid="tbl0002" ref-type="table">Table 2</xref>). There was one serious adverse event of syncope in the 30 mg AR1001 group that was considered related to study treatment. One participant in the 10 mg AR1001 group died due to a serious adverse event of COVID-19 that was not considered related to study treatment. Fourteen participants had adverse events that led to treatment discontinuation, with no notable differences in discontinuations between treatment groups. All adverse events considered related to treatment intervention were graded as mild or moderate (Grade 1 or 2) in severity. The most common adverse events during the treatment phase, occurring in 5% or more of participants in any treatment group, were fall, nausea, headache, urinary tract infection, dizziness, and arthralgia (<xref rid="tbl0002" ref-type="table">Table 2</xref>).<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Summary of adverse events during the 26-week treatment and extension phases.</p></caption><alt-text id="alt0002">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="left" valign="top" rowspan="1"><bold>Treatment phase (Weeks 1-26)</bold><hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1">Event, n (%)</th><th valign="top" colspan="1" rowspan="1">Placebo<break/>(N = 70)</th><th valign="top" colspan="1" rowspan="1">AR1001 10 mg<break/>(N = 70)</th><th valign="top" colspan="1" rowspan="1">AR1001 30 mg<break/>(N = 70)</th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">n (%)</th><th valign="top" colspan="1" rowspan="1">n (%)</th><th valign="top" colspan="1" rowspan="1">n (%)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">42 (60.0)</td><td valign="top" colspan="1" rowspan="1">39 (55.7)</td><td valign="top" colspan="1" rowspan="1">47 (67.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adverse event related to study drug</td><td valign="top" colspan="1" rowspan="1">13 (18.6)</td><td valign="top" colspan="1" rowspan="1">4 (5.7)</td><td valign="top" colspan="1" rowspan="1">7 (10.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Grade 1 (mild)</td><td valign="top" colspan="1" rowspan="1">8 (11.4)</td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Grade 2 (moderate)</td><td valign="top" colspan="1" rowspan="1">5 (7.1)</td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td><td valign="top" colspan="1" rowspan="1">5 (7.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8805; Grade 3 (severe)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any serious adverse event</td><td valign="top" colspan="1" rowspan="1">6 (8.6)</td><td valign="top" colspan="1" rowspan="1">6 (8.6)</td><td valign="top" colspan="1" rowspan="1">8 (11.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse event related to study treatment</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">1 (1.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Death</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">1 (1.4)</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1">Death related to study treatment</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adverse event leading to treatment discontinuation</td><td valign="top" colspan="1" rowspan="1">7 (10.0)</td><td valign="top" colspan="1" rowspan="1">3 (4.3)</td><td valign="top" colspan="1" rowspan="1">4 (5.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adverse event leading to study discontinuation</td><td valign="top" colspan="1" rowspan="1">6 (8.6)</td><td valign="top" colspan="1" rowspan="1">3 (4.3)</td><td valign="top" colspan="1" rowspan="1">4 (5.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adverse events in clinical laboratory parameters</td><td valign="top" colspan="1" rowspan="1">9 (12.9)</td><td valign="top" colspan="1" rowspan="1">12 (17.1)</td><td valign="top" colspan="1" rowspan="1">15 (21.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><underline>Visual disorders</underline></td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"><underline>Adverse events &#8805;5% in any group</underline></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Fall</td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td><td valign="top" colspan="1" rowspan="1">5 (7.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Nausea</td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td><td valign="top" colspan="1" rowspan="1">1 (1.4)</td><td valign="top" colspan="1" rowspan="1">5 (7.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Headache</td><td valign="top" colspan="1" rowspan="1">3 (4.3)</td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td><td valign="top" colspan="1" rowspan="1">4 (5.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Urinary tract infection</td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td><td valign="top" colspan="1" rowspan="1">4 (5.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Dizziness</td><td valign="top" colspan="1" rowspan="1">5 (7.1)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">1 (1.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Arthralgia</td><td valign="top" colspan="1" rowspan="1">5 (7.1)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="left" valign="top" rowspan="1"><bold>Extension Phase (Weeks 26-52)</bold><hr/></th></tr><tr><th align="left" valign="top" colspan="1" rowspan="1">Event, n (%)</th><th valign="top" colspan="1" rowspan="1">10 mg AR1001<break/>(N = 73)<xref rid="tb2fn1" ref-type="table-fn">*</xref></th><th valign="top" colspan="1" rowspan="1">30 mg AR1001<break/>(N = 68)<xref rid="tb2fn1" ref-type="table-fn">*</xref></th></tr><tr><th align="left" valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">n (%)</th><th valign="top" colspan="1" rowspan="1">n (%)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">38 (52.1)</td><td valign="top" colspan="1" rowspan="1">33 (48.5)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Adverse event related to study drug</td><td valign="top" colspan="1" rowspan="1">4 (5.5)</td><td valign="top" colspan="1" rowspan="1">6 (8.8)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#160;Grade 1 (mild)</td><td valign="top" colspan="1" rowspan="1">2 (2.7)</td><td valign="top" colspan="1" rowspan="1">6 (8.8)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#160;Grade 2 (moderate)</td><td valign="top" colspan="1" rowspan="1">2 (2.7)</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#160;&#8805; Grade 3 (severe)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Any serious adverse event</td><td valign="top" colspan="1" rowspan="1">2 (2.7)</td><td valign="top" colspan="1" rowspan="1">2 (2.9)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Serious adverse event related to study treatment</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Deaths</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Adverse event leading to treatment discontinuation</td><td valign="top" colspan="1" rowspan="1">3 (4.3)</td><td valign="top" colspan="1" rowspan="1">4 (5.7)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Adverse event leading to study discontinuation</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Adverse events in clinical laboratory parameters</td><td valign="top" colspan="1" rowspan="1">10 (13.7)</td><td valign="top" colspan="1" rowspan="1">9 (13.2)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"><underline>Visual disorders</underline></td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">1 (1.5)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"><underline>Adverse events for &#8805;5% of patients in any group</underline></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#160;Urinary tract infection</td><td valign="top" colspan="1" rowspan="1">6 (8.2)</td><td valign="top" colspan="1" rowspan="1">3 (4.4)</td></tr></tbody></table><table-wrap-foot><fn id="tb2fn1"><label>&#8270;</label><p id="notep0003">Participants who received placebo during the treatment phase and opted to continue to the extension phase were randomized to receive 10 mg AR1001 (n=19) or 30 mg AR1001 (n=20). These participants were included in the extension phase safety analysis along with participants who continued their AR1001 treatment from the treatment phase.</p><p id="notep0004">Abbreviations: AE: adverse event; SAE: serious adverse event.</p></fn></table-wrap-foot></table-wrap></p><p id="para0034">Visual disturbances have been reported with sildenafil [<xref rid="bib0035" ref-type="bibr">35</xref>] and are attributed to its inhibition of PDE6 in the retina [<xref rid="bib0023" ref-type="bibr">23</xref>]. Mirodenafil has also been shown to inhibit PDE6 [<xref rid="bib0022" ref-type="bibr">22</xref>]. However, no clinically significant ocular safety signals were identified in this study. Two participants in the placebo group and no participants in AR1001 groups reported adverse events related to visual impairment during the treatment phase. In the extension phase, one participant in the 30 mg AR1001 group reported an adverse event of double vision (diplopia), which was assessed as mild by the investigator (<xref rid="tbl0002" ref-type="table">Table 2</xref>) (data not shown).</p><p id="para0035">During the extension phase, in which placebo participants were randomized to receive 10 or 30 mg AR1001, there were no Grade 3 or higher adverse events, serious adverse events, or study discontinuations related to study treatment. The only adverse event occurring in 5% or more of participants in either the 10 mg or 30 mg AR1001 groups during the extension phase was urinary tract infection (<xref rid="tbl0002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec0012"><title>Efficacy assessments</title><p id="para0036">For the co-primary efficacy endpoint of ADAS-Cog 13, least square mean change from baseline was not statistically different for 10 mg AR1001 vs placebo or 30 mg AR1001 vs placebo at Week 26 (<xref rid="tbl0003" ref-type="table">Table 3</xref>). There was a moderate placebo response that resulted in an ADAS-Cog13 improvement of 2.2 points at Weeks 13 and 1.3 points at Week 26 (<xref rid="fig0002" ref-type="fig">Fig. 2A</xref>).<table-wrap position="float" id="tbl0003" orientation="portrait"><label>Table 3</label><caption><p>Summary of primary and secondary efficacy endpoints at week 26.</p></caption><alt-text id="alt0003">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Placebo</th><th valign="top" colspan="1" rowspan="1">10 mg AR1001</th><th valign="top" colspan="1" rowspan="1">30 mg AR1001</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1"><underline>Primary Efficacy Endpoints</underline></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">ADAS-Cog-13</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants<xref rid="tb3fn1" ref-type="table-fn">*</xref></td><td valign="top" colspan="1" rowspan="1">51</td><td valign="top" colspan="1" rowspan="1">59</td><td valign="top" colspan="1" rowspan="1">57</td></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">24.2 (10.0)</td><td valign="top" colspan="1" rowspan="1">25.5 (9.4)</td><td valign="top" colspan="1" rowspan="1">26.8 (11.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM change from baseline (95% CI)<sup>#</sup></td><td valign="top" colspan="1" rowspan="1">-1.3 (-3.4, 0.7)</td><td valign="top" colspan="1" rowspan="1">-1.7 (-3.6, 0.2)</td><td valign="top" colspan="1" rowspan="1">-0.2 (-2.2, 1.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">-0.4</td><td valign="top" colspan="1" rowspan="1">1.1</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">.81</td><td valign="top" colspan="1" rowspan="1">.45</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">ADCS-CGIC</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants</td><td valign="top" colspan="1" rowspan="1">52</td><td valign="top" colspan="1" rowspan="1">58</td><td valign="top" colspan="1" rowspan="1">57</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM (95% CI)</td><td valign="top" colspan="1" rowspan="1">4.3 (4.0, 4.5)</td><td valign="top" colspan="1" rowspan="1">4.2 (4.0, 4.4)</td><td valign="top" colspan="1" rowspan="1">4.3 (4.1, 4.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">-0.1</td><td valign="top" colspan="1" rowspan="1">0.03</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">.57</td><td valign="top" colspan="1" rowspan="1">.88</td></tr><tr><td valign="top" colspan="1" rowspan="1"><underline>Secondary Efficacy Endpoints</underline></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">MMSE-BV</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants</td><td valign="top" colspan="1" rowspan="1">52</td><td valign="top" colspan="1" rowspan="1">59</td><td valign="top" colspan="1" rowspan="1">56</td></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">11.8 (2.6)</td><td valign="top" colspan="1" rowspan="1">11.2 (2.7)</td><td valign="top" colspan="1" rowspan="1">10.4 (2.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">-0.4 (-1.0, 0.2)</td><td valign="top" colspan="1" rowspan="1">-0.03 (-0.6, 0.5)</td><td valign="top" colspan="1" rowspan="1">0.07 (-0.5, 0.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.38</td><td valign="top" colspan="1" rowspan="1">0.48</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">.36</td><td valign="top" colspan="1" rowspan="1">.27</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">MMSE-SV</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants</td><td valign="top" colspan="1" rowspan="1">52</td><td valign="top" colspan="1" rowspan="1">59</td><td valign="top" colspan="1" rowspan="1">56</td></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">22.5 (3.8)</td><td valign="top" colspan="1" rowspan="1">21.8 (3.8)</td><td valign="top" colspan="1" rowspan="1">20.6 (3.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">-0.2 (-1.1, 0.6)</td><td valign="top" colspan="1" rowspan="1">-0.1 (-0.9, 0.7)</td><td valign="top" colspan="1" rowspan="1">-0.2 (-1.0, 0.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.12</td><td valign="top" colspan="1" rowspan="1">0.10</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">.83</td><td valign="top" colspan="1" rowspan="1">.87</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">NPI</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants</td><td valign="top" colspan="1" rowspan="1">51</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">56</td></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">7.7 (10.2)</td><td valign="top" colspan="1" rowspan="1">7.8 (9.0)</td><td valign="top" colspan="1" rowspan="1">7.9 (9.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">-2.5 (-4.6, -0.4)</td><td valign="top" colspan="1" rowspan="1">-1.7 (-3.6, 0.3)</td><td valign="top" colspan="1" rowspan="1">-0.6 (-2.6, 1.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.8</td><td valign="top" colspan="1" rowspan="1">1.9</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">.58</td><td valign="top" colspan="1" rowspan="1">.21</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">GDS</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants</td><td valign="top" colspan="1" rowspan="1">51</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">57</td></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">2.7 (2.2)</td><td valign="top" colspan="1" rowspan="1">2.3 (2.4)</td><td valign="top" colspan="1" rowspan="1">2.7 (2.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">-0.58 (-1.1, 0)</td><td valign="top" colspan="1" rowspan="1">-0.03 (-0.5, 0.5)</td><td valign="top" colspan="1" rowspan="1">-0.36 (-0.9, 0.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.55</td><td valign="top" colspan="1" rowspan="1">0.22</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">.16</td><td valign="top" colspan="1" rowspan="1">.56</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">QOL-AD: FV</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants</td><td valign="top" colspan="1" rowspan="1">51</td><td valign="top" colspan="1" rowspan="1">58</td><td valign="top" colspan="1" rowspan="1">57</td></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">34.5 (5.3)</td><td valign="top" colspan="1" rowspan="1">34.9 (6.8)</td><td valign="top" colspan="1" rowspan="1">34.9 (6.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">1.1 (-0.2, 2.4)</td><td valign="top" colspan="1" rowspan="1">0.9 (-0.2, 2.4)</td><td valign="top" colspan="1" rowspan="1">0.5 (-0.7, 1.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">-0.14</td><td valign="top" colspan="1" rowspan="1">-0.55</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">.88</td><td valign="top" colspan="1" rowspan="1">.54</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">QOL-AD: PV</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">59</td><td valign="top" colspan="1" rowspan="1">57</td></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">37.7 (6.0)</td><td valign="top" colspan="1" rowspan="1">38.6 (6.6)</td><td valign="top" colspan="1" rowspan="1">38.5 (6.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">0.17 (-1.1, 1.4)</td><td valign="top" colspan="1" rowspan="1">0.23 (-0.9, 1.4)</td><td valign="top" colspan="1" rowspan="1">0.36 (-0.8, 1.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1">LSM difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.07</td><td valign="top" colspan="1" rowspan="1">0.19</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">.94</td><td valign="top" colspan="1" rowspan="1">.82</td></tr></tbody></table><table-wrap-foot><fn id="tb3fn1"><label>&#8270;</label><p id="notep0005">Number of participants refers to participants evaluated at Week 26.</p><p id="notep0006">Abbreviations: ADAS-Cog13: Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognitive Subscale 13; ADCS-CGIC: Alzheimer&#8217;s Disease Cooperative Study-Clinical Global Impression of Change; CI: confidence interval; GDS: Geriatric Depression Scale; LSM: least square mean; MMSE-2: BV: Mini-mental Status Examination, 2nd Edition: Brief Version; MMSE-2: SV: Mini-mental Status Examination, 2nd Edition: Standard Version; NPI: Neuropsychiatric Inventory; QOL-AD: FV: Quality of Life in Alzheimer&#8217;s Disease: Family Version; QOL-AD: PV: Quality of Life in Alzheimer&#8217;s Disease: participant version; SD: standard deviation.</p></fn></table-wrap-foot></table-wrap><fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>Co-primary and secondary endpoints changes from baseline at Week 26 during the treatment phase.</bold> (A) Change from baseline in co-primary endpoint, ADAS-Cog13 total score at Weeks 13 and 26. Values on time axis are shifted slightly for ease of reading. (B) Distribution of co-primary endpoint, ADCS-CGIC scores at Week 26, reflecting clinician-rated change in global functioning. (C) Least squares (LS) mean difference (95% CI) from placebo for secondary endpoints at Week 26. Negative values are plotted for GDS and NPI to maintain directions.</p><p><italic toggle="yes">Abbreviations</italic>: ADAS-Cog13: Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognitive Subscale 13; ADCS-CGIC: Alzheimer&#8217;s Disease Cooperative Study-Clinical Global Impression of Change; CI: confidence interval; GDS: Geriatric Depression Scale; LS: least squares; MMSE-2: BV: Mini-mental Status Examination, 2nd Edition: Brief Version; MMSE-2: SV: Mini-mental Status Examination, 2nd Edition: Standard Version; NPI: Neuropsychiatric Inventory; QOL-AD: FV: Quality of Life in Alzheimer&#8217;s Disease: Family Version; QOL-AD: PV: Quality of Life in Alzheimer&#8217;s Disease: Participant Version; SE: standard error.</p></caption><alt-text id="alt0006">Fig 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="para0037">Pairwise comparisons for the co-primary efficacy endpoint of ADCS-CGIC were not statistically different for 10 mg or 30 mg AR1001 vs placebo (<xref rid="tbl0003" ref-type="table">Table 3</xref>). Nearly half of participants (49.7%) across groups were evaluated by investigators as having no change in cognitive performance after 26 weeks of treatment (Score = 4); 28.6% were evaluated as having minimal worsening (Score = 5), and 10.9% had minimal improvement (Score = 3). The remaining participants had moderate worsening/improvement or marked worsening (<xref rid="fig0002" ref-type="fig">Fig. 2B</xref>).</p><p id="para0038">Evaluation of secondary efficacy endpoints of MMSE-2, NPI, GDS, and QOL-AD found no statistically significant differences between placebo and AR1001 treatment groups 30 mg AR1001 (<xref rid="tbl0003" ref-type="table">Table 3</xref>). The mean changes from baseline for secondary endpoints in the 10 mg and 30 mg AR1001 treatment groups are compared to placebo in <xref rid="fig0002" ref-type="fig">Fig. 2C</xref>.</p></sec><sec id="sec0013"><title>Post-hoc biomarker analysis</title><p id="para0039">Plasma samples were collected for analysis of biomarkers pTau-181, pTau-217, A&#946;42/40 ratio, GFAP, and NfL. Participants on placebo had worsening mean change from baseline at Week 26 for pTau-181, pTau-217, GFAP, and NfL. In contrast, participants on 30 mg AR1001 had improved mean change from baseline at Week 26 for the same biomarkers (<xref rid="tbl0004" ref-type="table">Table 4</xref>). There were no appreciable changes in A&#946;42/40 ratio observed in any group. Between-group comparisons showed statistically significant improvements (p &lt; .05) in the 30 mg AR1001 group compared with placebo for pTau-181, pTau-217, and GFAP (<xref rid="tbl0004" ref-type="table">Table 4</xref>). Although the difference in NfL did not reach statistical significance (p = .052), the direction of effect favored AR1001. A Forest plot of the mean percentage difference from placebo in biomarker levels in 10 mg and 30 mg AR1001 groups is shown in <xref rid="fig0003" ref-type="fig">Fig. 3</xref>. Variability was high in the biomarker assays, nevertheless the difference in mean change from baseline between the 30 mg AR1001 group and placebo supports a potential biomarker effect of AR1001 on tau and glial markers.<table-wrap position="float" id="tbl0004" orientation="portrait"><label>Table 4</label><caption><p>Summary of biomarker results at week 26.</p></caption><alt-text id="alt0004">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Placebo</th><th valign="top" colspan="1" rowspan="1">10 mg AR1001</th><th valign="top" colspan="1" rowspan="1">30 mg AR1001</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">pTau-181 (pg/mL)</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">4.24 (2.16)</td><td valign="top" colspan="1" rowspan="1">4.65 (2.43)</td><td valign="top" colspan="1" rowspan="1">4.65 (2.66)</td></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants evaluated<xref rid="tb4fn1" ref-type="table-fn">*</xref></td><td valign="top" colspan="1" rowspan="1">41</td><td valign="top" colspan="1" rowspan="1">51</td><td valign="top" colspan="1" rowspan="1">45</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">0.31 (-0.09, 0.70)</td><td valign="top" colspan="1" rowspan="1">-0.29 (-0.85, 0.26)</td><td valign="top" colspan="1" rowspan="1">-0.46 (-1.04, 0.12)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">-0.60</td><td valign="top" colspan="1" rowspan="1">-0.77</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.093</td><td valign="top" colspan="1" rowspan="1">0.034</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">pTau-217 (pg/mL)</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">0.622 (0.609)</td><td valign="top" colspan="1" rowspan="1">0.632 (0.531)</td><td valign="top" colspan="1" rowspan="1">0.734 (0.744)</td></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants evaluated</td><td valign="top" colspan="1" rowspan="1">40</td><td valign="top" colspan="1" rowspan="1">51</td><td valign="top" colspan="1" rowspan="1">42</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">0.037 (-0.104, 0.162)</td><td valign="top" colspan="1" rowspan="1">0.020 (-0.112, 0.123)</td><td valign="top" colspan="1" rowspan="1">-0.118 (-0.223, -0.037)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">-0.017</td><td valign="top" colspan="1" rowspan="1">-0.155</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">.530</td><td valign="top" colspan="1" rowspan="1">.009</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">A&#946;42/40 ratio</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">0.084 (0.014)</td><td valign="top" colspan="1" rowspan="1">0.086 (0.016)</td><td valign="top" colspan="1" rowspan="1">0.089 (0.041)</td></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants evaluated</td><td valign="top" colspan="1" rowspan="1">40</td><td valign="top" colspan="1" rowspan="1">49</td><td valign="top" colspan="1" rowspan="1">41</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">0 (-0.004, 0.003)</td><td valign="top" colspan="1" rowspan="1">0.001 (-0.001, 0.005)</td><td valign="top" colspan="1" rowspan="1">0.001 (-0.003, 0.004)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.001</td><td valign="top" colspan="1" rowspan="1">0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.483</td><td valign="top" colspan="1" rowspan="1">0.932</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">GFAP (pg/mL)</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">255.7 (107.8)</td><td valign="top" colspan="1" rowspan="1">259.2 (118.6)</td><td valign="top" colspan="1" rowspan="1">256.6 (113.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants evaluated</td><td valign="top" colspan="1" rowspan="1">41</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">45</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">23.9 (-3.8, 51.6)</td><td valign="top" colspan="1" rowspan="1">11.9 (-14.0, 37.8)</td><td valign="top" colspan="1" rowspan="1">-7.0 (-26.2, 12.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">-12.0</td><td valign="top" colspan="1" rowspan="1">-30.9</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.393</td><td valign="top" colspan="1" rowspan="1">0.042</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">NfL (pg/mL)</italic></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline value (SD)</td><td valign="top" colspan="1" rowspan="1">29.4 (16.5)</td><td valign="top" colspan="1" rowspan="1">28.0 (14.6)</td><td valign="top" colspan="1" rowspan="1">33.2 (38.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1">No. participants evaluated</td><td valign="top" colspan="1" rowspan="1">41</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">45</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean change from baseline (95% CI)</td><td valign="top" colspan="1" rowspan="1">1.06 (-2.69, 4.82)</td><td valign="top" colspan="1" rowspan="1">0.95 (-2.69, 4.59)</td><td valign="top" colspan="1" rowspan="1">-6.65 (-19.09, 5.79)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mean difference vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">-0.25</td><td valign="top" colspan="1" rowspan="1">-1.6</td></tr><tr><td valign="top" colspan="1" rowspan="1">P value vs. placebo</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">.473</td><td valign="top" colspan="1" rowspan="1">.052</td></tr></tbody></table><table-wrap-foot><fn id="tb4fn1"><label>&#8270;</label><p id="notep0007">Number of participants refers to participants evaluated at Week 26.</p><p id="notep0008">Abbreviations: A&#946;: amyloid beta; CI: confidence interval; GFAP: glial fibrillary acidic protein; NfL: neurofilament light chain; SD: standard deviation</p></fn></table-wrap-foot></table-wrap><fig id="fig0003" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Changes in Plasma Biomarkers at Week 26.</p><p>Forest plot of percent difference in change from baseline at Week 26 for plasma biomarkers comparing AR1001 treatment groups to placebo. &#8224;p &lt; .05 for 30 mg vs placebo by Mann-Whitney U test. Negative values are plotted for A&#946;42/40 ratio to reflect direction of improvement.</p><p><italic toggle="yes">Abbreviations</italic>: A&#946;: amyloid beta; GFAP: glial fibrillary acidic protein; NfL: neurofilament light chain.</p></caption><alt-text id="alt0007">Fig 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0003" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><sec id="sec0014"><title>Baseline pTau-181 post-hoc subgroup analyses</title><p id="para0040">At the time of the trial, NIA-AA criteria did not require biomarker confirmation of cerebral amyloid in clinical trials. In basing eligibility on cognitive measures (e.g., MMSE), there was a possibility that the population had mixed AD and non-AD forms of dementia. To select for participants with a likelihood of having AD, we performed post-hoc analyses on participants in the top tertile of baseline pTau-181 (corresponding to &#8805; 5.0 pg/mL), along with the corresponding lower two tertiles (pTau-181 &lt; 5.0 pg/mL). pTau-181has been shown to correlate with cerebral amyloid PET [<xref rid="bib0031" ref-type="bibr">31</xref>]. A similar post-hoc tertile analysis was used to analyze donanemab and baseline tau PET [<xref rid="bib0032" ref-type="bibr">32</xref>].</p><p id="para0041">Participants taking placebo in the high pTau-181 cohort showed worsening performance in ADAS-Cog-13 (<xref rid="fig0004" ref-type="fig">Fig. 4A</xref>) and ADCS-CGIC (<xref rid="fig0004" ref-type="fig">Fig. 4B</xref>) at Week 26, whereas participants in the lower pTau-181 cohort had improved cognitive performance. These data support a scenario in which higher pTau-181 correlates with more rapid AD progression [<xref rid="bib0033" ref-type="bibr">33</xref>].<fig id="fig0004" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Primary Efficacy Outcomes Stratified by Baseline Plasma pTau-181 Levels.</p><p>Change from baseline in (A) ADAS-Cog13 and (B) ADCS-CGIC at Week 26 in participants with the highest tertile of baseline pTau-181 (&#8805; 5.0 pg/ml) and in the corresponding lower two-thirds tertiles (&lt; 5.0 pg/ml).</p><p><italic toggle="yes">Abbreviations:</italic> ADAS-Cog13: Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognitive Subscale 13; ADCS-CGIC: Alzheimer&#8217;s Disease Cooperative Study &#8211; Clinician Global Impression of Change; SE: standard error.</p></caption><alt-text id="alt0008">Fig 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0004" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="para0042">Participants in the high pTau-181 cohort treated with AR1001 had slower cognitive decline in ADAS-Cog13 and ADCS-CGIC relative to participants treated with placebo (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>), though sample sizes were small and the study was not powered to detect a statistical difference.</p></sec></sec></sec><sec id="sec0015"><title>Discussion</title><p id="para0043">This Phase 2 study aimed to evaluate the safety and preliminary efficacy of AR1001 in patients with mild-to-moderate AD dementia. Oral AR1001 at 10 or 30 mg once daily was well-tolerated, with a safety profile similar to that of placebo and few serious or severe adverse events related to treatment over 52 weeks. Although visual disturbances are a known side effect of other PDE5 inhibitors [<xref rid="bib0034" ref-type="bibr">34</xref>], no meaningful ocular safety concerns were identified with AR1001 in the Phase 2 trial. This favorable ocular safety profile may be attributed to the lower dose of AR1001 used in this trial relative to doses for erectile dysfunction, and the 30-fold higher selectivity of AR1001 for PDE5 over PDE6 [<xref rid="bib0022" ref-type="bibr">22</xref>]. Although post-treatment MRI was not performed to assess ARIA, no ARIA-like symptoms or serious adverse events were observed. This suggests that AR1001 may represent a viable treatment option for genetically at-risk individuals who may not tolerate or qualify for anti-amyloid therapies, including ApoE4 homozygotes.</p><p id="para0044">The completion rate in both the 26-week treatment phase and 26-week extension phase was 82%, suggesting the drug was well tolerated and low burden to use. The favorable safety profile of AR1001 and easy-to-use oral administration are strengths of this treatment.</p><p id="para0045">The study did not meet the co-primary endpoints as measured by ADAS-Cog 13 and ADCS-CGIC or secondary endpoints through 26 weeks of treatment. The placebo group improved in ADAS-Cog13 and was mostly unchanged in ADCS-CGIC at Week 26. A positive placebo response was also found in a second AD clinical trial after 26 weeks treatment [<xref rid="bib0035" ref-type="bibr">35</xref>], suggesting that the placebo effect may be present in short-duration AD trials. As this was the first trial of AR1001 in AD patients, the duration was kept to 26 weeks by FDA to first determine the drug&#8217;s safety. An extension phase was later approved and implemented to provide additional safety information.</p><p id="para0046">In post-hoc analyses, differences were observed between 30 mg AR1001 and placebo in change from baseline in levels of plasma AD biomarkers pTau-181, pTau-217, and GFAP. The biomarker findings are consistent with effects observed in preclinical models of AD in which treatment with AR1001 and other PDE5 inhibitors resulted in lower levels of toxic A&#946; and phosphorylated Tau[<xref rid="bib0018" ref-type="bibr">18</xref>,<xref rid="bib0023" ref-type="bibr">23</xref>].</p><p id="para0047">A limitation of the study was the possible heterogeneity of the population, which may have included participants with both Alzheimer&#8217;s and non-Alzheimer&#8217;s dementias. The use of biomarkers to determine cerebral amyloid was not required by NIA-AA criteria at the time of the trial [<xref rid="bib0036" ref-type="bibr">36</xref>]. The possible inclusion of participants with other types of dementia is supported by the lower level of participants who were ApoE4 positive (57%) compared to other AD trials that required amyloid positivity, which had ApoE4 carriers in the range of 65-70% [<xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>,<xref rid="bib0037" ref-type="bibr">37</xref>].</p><p id="para0048">The 30 mg AR1001 dose is currently being examined compared to placebo in a 52-week Phase 3 trial, POLARIS-AD (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05531526">NCT05531526</ext-link>) in participants with biomarker-confirmed AD, NIA-AA Stage 3 or 4, and MMSE &#8805; 20. The sample size for the Phase 3 trial is planned to be at approximately 1500 participants, and biomarker confirmation of AD is required by cerebrospinal fluid or PET scan. The primary endpoint is change from baseline after 52 weeks in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB), which has been used in other Phase 3 AD registration trials [<xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>,<xref rid="bib0037" ref-type="bibr">37</xref>] and is considered more sensitive to changes in cognition in early AD than the primary endpoints used in this study [<xref rid="bib0038" ref-type="bibr">38</xref>]. The POLARIS-AD Phase 3 trial will thus provide a more definitive evaluation of AR1001 effects in early AD patients.</p></sec><sec id="sec0016"><title>Conclusions</title><p id="para0049">This Phase 2 study was designed to evaluate the safety and preliminary efficacy of AR1001 for the treatment of mild to moderate AD. AR1001 treatment was well-tolerated and safe. The trial did not meet its primary or secondary endpoints for efficacy after 26 weeks of treatment. There were improvements in levels of pTau-181, pTau-217, and GFAP biomarkers in the 30 mg group compared to placebo.</p></sec><sec id="sec0016a"><title>CRediT authorship contribution statement</title><p id="para0049a"><bold>David Greeley:</bold> Writing &#8211; review &amp; editing, Investigation, Formal analysis, Conceptualization. <bold>Marshall Nash:</bold> Writing &#8211; review &amp; editing, Project administration, Investigation. <bold>Brad Herskowitz:</bold> Writing &#8211; review &amp; editing, Project administration, Methodology, Investigation. <bold>Fred Kim:</bold> Writing &#8211; review &amp; editing, Resources, Project administration, Funding acquisition, Formal analysis, Conceptualization. <bold>James Rock:</bold> Writing &#8211; review &amp; editing, Project administration, Formal analysis, Conceptualization. <bold>Neils Prins:</bold> Project administration, Methodology, Investigation. <bold>SangYun Kim:</bold> Writing &#8211; review &amp; editing, Visualization, Formal analysis. <bold>Tianyang Xi:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Project administration, Formal analysis. <bold>Jonathan A. Busam:</bold> Writing &#8211; review &amp; editing, Investigation. <bold>Benoit Tete:</bold> Methodology, Investigation. <bold>Jai Jun Choung:</bold> Writing &#8211; review &amp; editing, Resources, Project administration, Methodology, Funding acquisition, Formal analysis, Conceptualization. <bold>Sharon J. Sha:</bold> Writing &#8211; review &amp; editing, Project administration, Methodology, Formal analysis.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0052">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:</p><p id="para0053">David Greeley reports financial support was provided by Aribio Co., Ltd. Marshall Nash reports financial support was provided by Aribio Co., Ltd. Brad Herskowitz reports financial support was provided by Aribio Co., Ltd. Sharon J. Sha reports financial support was provided by Aribio Co., Ltd. Neils Prins reports financial support was provided by Aribio Co., Ltd. Jonathan A. Busam reports financial support was provided by Aribio Co., Ltd. Benoit Tete reports financial support was provided by Aribio Co., Ltd. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><mixed-citation publication-type="other" id="sbref0001">WHO. Fact sheets of dementia 2021 [updated 2017. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/dementia" id="interref0002">https://www.who.int/news-room/fact-sheets/detail/dementia</ext-link>.</mixed-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Tanzi</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Bertram</surname><given-names>L.</given-names></name></person-group><article-title>New frontiers in Alzheimer's disease genetics</article-title><source>Neuron</source><volume>32</volume><issue>2</issue><year>2001</year><fpage>181</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">11683989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0896-6273(01)00476-7</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Snape</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wilcock</surname><given-names>G.K.</given-names></name></person-group><article-title>The cholinergic hypothesis of Alzheimer's disease: a review of progress</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>66</volume><issue>2</issue><year>1999</year><fpage>137</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">10071091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.66.2.137</pub-id><pub-id pub-id-type="pmcid">PMC1736202</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mesulam</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Cuello</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>The cholinergic system in the pathophysiology and treatment of Alzheimer's disease</article-title><source>Brain</source><volume>141</volume><issue>7</issue><year>2018</year><fpage>1917</fpage><lpage>1933</lpage><pub-id pub-id-type="pmid">29850777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awy132</pub-id><pub-id pub-id-type="pmcid">PMC6022632</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J.</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer's disease at 25 years</article-title><source>EMBO Mol Med</source><volume>8</volume><issue>6</issue><year>2016</year><fpage>595</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">27025652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201606210</pub-id><pub-id pub-id-type="pmcid">PMC4888851</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Small</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Duff</surname><given-names>K.</given-names></name></person-group><article-title>Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis</article-title><source>Neuron</source><volume>60</volume><issue>4</issue><year>2008</year><fpage>534</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">19038212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2008.11.007</pub-id><pub-id pub-id-type="pmcid">PMC2692134</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Arnsten</surname><given-names>A.F.T.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Del Tredici</surname><given-names>K.</given-names></name><name name-style="western"><surname>Braak</surname><given-names>H.</given-names></name></person-group><article-title>Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease</article-title><source>Alzheimers Dement</source><volume>17</volume><issue>1</issue><year>2021</year><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">33075193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12192</pub-id><pub-id pub-id-type="pmcid">PMC7983919</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Kinney</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Bemiller</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Murtishaw</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>Inflammation as a central mechanism in Alzheimer's disease</article-title><source>Alzheimers Dement (N Y)</source><volume>4</volume><year>2018</year><fpage>575</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">30406177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2018.06.014</pub-id><pub-id pub-id-type="pmcid">PMC6214864</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Zotova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kalaria</surname><given-names>R.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boche</surname><given-names>D.</given-names></name></person-group><article-title>Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy</article-title><source>Alzheimer Res Ther</source><volume>2</volume><issue>1</issue><year>2010</year><fpage>1</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/alzrt24</pub-id><pub-id pub-id-type="pmcid">PMC2874260</pub-id><pub-id pub-id-type="pmid">20122289</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Markesbery</surname><given-names>W.R.</given-names></name></person-group><article-title>Oxidative stress hypothesis in Alzheimer's disease</article-title><source>Free Radic Biol Med</source><volume>23</volume><issue>1</issue><year>1997</year><fpage>134</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">9165306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0891-5849(96)00629-6</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Lecanemab in early Alzheimer's disease</article-title><source>N Engl J Med</source><volume>388</volume><issue>1</issue><year>2023</year><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial</article-title><source>JAMA</source><volume>330</volume><issue>6</issue><year>2023</year><fpage>512</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Budd Haeberlein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Two randomized phase 3 studies of aducanumab in early Alzheimer's disease</article-title><source>J Prev Alzheimer Dis</source><volume>9</volume><issue>2</issue><year>2022</year><fpage>197</fpage><lpage>210</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2022.30</pub-id><pub-id pub-id-type="pmid">35542991</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Cavalli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Minarini</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Multi-target-directed ligands to combat neurodegenerative diseases</article-title><source>J Med Chem</source><volume>51</volume><issue>3</issue><year>2008</year><fpage>347</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">18181565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm7009364</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Albertini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salerno</surname><given-names>A.</given-names></name><name name-style="western"><surname>de</surname><given-names>S.ena M.urteira</given-names></name><name name-style="western"><surname>Pinheiro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>M.L.</given-names></name></person-group><article-title>From combinations to multitarget-directed ligands: a continuum in Alzheimer's disease polypharmacology</article-title><source>Med Res Rev</source><volume>41</volume><issue>5</issue><year>2021</year><fpage>2606</fpage><lpage>2633</lpage><pub-id pub-id-type="pmid">32557696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.21699</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Boche</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>J.A.R.</given-names></name></person-group><article-title>Invited review - understanding cause and effect in Alzheimer's pathophysiology: implications for clinical trials</article-title><source>Neuropathol Appl Neurobiol</source><volume>46</volume><issue>7</issue><year>2020</year><fpage>623</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">32643143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nan.12642</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Proschak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stark</surname><given-names>H.</given-names></name><name name-style="western"><surname>Merk</surname><given-names>D.</given-names></name></person-group><article-title>Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds</article-title><source>J Med Chem</source><volume>62</volume><issue>2</issue><year>2019</year><fpage>420</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">30035545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.8b00760</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Zuccarello</surname><given-names>E.</given-names></name><name name-style="western"><surname>Acquarone</surname><given-names>E.</given-names></name><name name-style="western"><surname>Calcagno</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease</article-title><source>Biochem Pharmacol</source><volume>176</volume><year>2020</year><object-id pub-id-type="publisher-id">113818</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2020.113818</pub-id><pub-id pub-id-type="pmcid">PMC7263960</pub-id><pub-id pub-id-type="pmid">31978378</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease</article-title><source>Nat Aging</source><volume>1</volume><issue>12</issue><year>2021</year><fpage>1175</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">35572351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-021-00138-z</pub-id><pub-id pub-id-type="pmcid">PMC9097949</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>F.</given-names></name><name name-style="western"><surname>Song</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Choung</surname><given-names>J.J.</given-names></name></person-group><article-title>Polypharmacological potential of phosphodiesterase 5 inhibitors for the treatment of neurocognitive disorders</article-title><source>Aging Dis</source><volume>15</volume><issue>5</issue><year>2024</year><fpage>2008</fpage><lpage>2014</lpage><pub-id pub-id-type="pmid">38270120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2023.1129</pub-id><pub-id pub-id-type="pmcid">PMC11346399</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Crescioli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paronetto</surname><given-names>M.P.</given-names></name></person-group><article-title>The emerging role of phosphodiesterase 5 inhibition in neurological disorders: the state of the art</article-title><source>Cells</source><volume>13</volume><issue>20</issue><year>2024</year><fpage>1720</fpage><pub-id pub-id-type="pmid">39451238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells13201720</pub-id><pub-id pub-id-type="pmcid">PMC11506759</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H.-I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-K.</given-names></name></person-group><article-title>Synthesis of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazin1-ylsulfonyl]-2-n-propoxyphenyl}-7-n-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]-[2-14C]pyrimidin-4-one . 2HCl (14C-SK3530. 2 HCl)</article-title><source>J Label Compd Radiopharm</source><volume>49</volume><year>2006</year><fpage>1141</fpage><lpage>1149</lpage></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions</article-title><source>Alzheimer Res Ther</source><volume>14</volume><issue>1</issue><year>2022</year><fpage>92</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01034-3</pub-id><pub-id pub-id-type="pmcid">PMC9264543</pub-id><pub-id pub-id-type="pmid">35804462</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Mirodenafil improves cognitive function by reducing microglial activation and blood&#8211;brain barrier permeability in ApoE4 KI mice</article-title><source>Front Aging Neurosci</source><volume>17</volume><year>2025</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2025.1579411</pub-id><pub-id pub-id-type="pmcid">PMC12119498</pub-id><pub-id pub-id-type="pmid">40443793</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>F.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Therapeutic effects of mirodenafil, a phosphodiesterase 5 inhibitor, on stroke models in rats</article-title><source>Neurotherapeutics</source><year>2024</year><object-id pub-id-type="publisher-id">e00463</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurot.2024.e00463</pub-id><pub-id pub-id-type="pmcid">PMC11742844</pub-id><pub-id pub-id-type="pmid">39393981</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Im</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.H.</given-names></name></person-group><article-title>Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats</article-title><source>Acta Pharmacol Sin</source><volume>28</volume><issue>8</issue><year>2007</year><fpage>1247</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">17640490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1745-7254.2007.00611.x</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Lleo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Growdon</surname><given-names>J.H.</given-names></name></person-group><article-title>Current pharmacotherapy for Alzheimer's disease</article-title><source>Annu Rev Med</source><volume>57</volume><year>2006</year><fpage>513</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">16409164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.med.57.121304.131442</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Posner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults</article-title><source>Am J Psychiatry</source><volume>168</volume><issue>12</issue><year>2011</year><fpage>1266</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">22193671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2011.10111704</pub-id><pub-id pub-id-type="pmcid">PMC3893686</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Holm</surname><given-names>S.</given-names></name></person-group><article-title>A simple sequentially rejective multiple test procedure</article-title><source>Scandinav J Statist</source><volume>6</volume><year>1979</year><fpage>65</fpage><lpage>70</lpage></element-citation></ref><ref id="bib0030"><label>30</label><mixed-citation publication-type="other" id="sbref0030">FDA. Approval Package for Exelon Transdermal Patch. 2012.</mixed-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Wiste</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Algeciras-Schimnich</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Predicting amyloid PET and tau PET stages with plasma biomarkers</article-title><source>Brain</source><volume>146</volume><issue>5</issue><year>2023</year><fpage>2029</fpage><lpage>2044</lpage><pub-id pub-id-type="pmid">36789483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad042</pub-id><pub-id pub-id-type="pmcid">PMC10151195</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><mixed-citation publication-type="other" id="sbref0032">Mintun MA, eds. Donanemab slows progression of early symptomatic alzheimer's disease in Phase 2 proof of concept trial. AD/PD; 2021; Vienna.</mixed-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Plasma P-tau181 in Alzheimer&#8217;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#8217;s dementia</article-title><source>Nat Med</source><volume>26</volume><issue>3</issue><year>2020</year><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">32123385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0755-1</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Aus&#243;</surname><given-names>E.</given-names></name><name name-style="western"><surname>G&#243;mez-Vicente</surname><given-names>V.</given-names></name><name name-style="western"><surname>Esquiva</surname><given-names>G.</given-names></name></person-group><article-title>Visual side effects linked to sildenafil consumption: an update</article-title><source>Biomedicines</source><volume>9</volume><issue>3</issue><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines9030291</pub-id><pub-id pub-id-type="pmcid">PMC7998971</pub-id><pub-id pub-id-type="pmid">33809319</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><mixed-citation publication-type="other" id="sbref0035">Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer&#8217;s Disease [press release]. September 03, 2024 2024.</mixed-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><etal/></person-group><article-title>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease</article-title><source>Alzheimer Dement</source><volume>14</volume><issue>4</issue><year>2018</year><fpage>535</fpage><lpage>562</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id><pub-id pub-id-type="pmid">29653606</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Bateman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Two phase 3 trials of gantenerumab in early Alzheimer's disease</article-title><source>N Engl J Med</source><volume>389</volume><issue>20</issue><year>2023</year><fpage>1862</fpage><lpage>1876</lpage><pub-id pub-id-type="pmid">37966285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2304430</pub-id><pub-id pub-id-type="pmcid">PMC10794000</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Lansdall</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>McDougall</surname><given-names>F.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer's disease</article-title><source>J Prev Alzheimer Dis</source><volume>10</volume><issue>1</issue><year>2023</year><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2022.102</pub-id><pub-id pub-id-type="pmid">36641605</pub-id></element-citation></ref></ref-list><sec id="sec0022" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0050a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
<supplementary-material content-type="local-data" id="ecom0002" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.pdf" position="float" orientation="portrait"><alt-text>Image, application 2</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><sec id="sec0017"><title>Acknowledgments</title><p id="para0054">We thank all study participants, their families and caregivers for their significant support of this research study. We thank the following site investigators and the raters, staff and vendors who worked with the patients and helped collect, transport, and analyze samples: James L Andersen, Meridien Research &#8211; Lakeland; Deborah Burke, Meridien Research &#8211; Tampa; James Cain, FMC Science; Robert M Carlile, Palmetto Clinical Research; John Duffy, Syrentis Clinical Research; Ira Goodman, Accelerated Enrollment Solutions; Sinikka Liisa Green, Advanced Clinical Research; David Greeley, Kingfisher Cooperative, LLC; Carl Griffin, Lynn Health Science Institute; Brad Herskowitz, The Neurology Research Group; Eva-Maria Huerich, Meridien Research &#8211; Maitland; Artem Kaplan, New York Neurology Associates; Judith Kirstein, Advanced Clinical Research &#8211; Banning; Gigi Lefebvre, Meridien Research &#8211; St. Petersburg; Evelyn Lopez-Brignoni, IMIC, Inc.; Marshall Nash, NeuroStudies, LLC; Barbara E Rizzardi, Advanced Clinical Research &#8211; West Jordan; Mark Turner, Advanced Clinical Research &#8211; Boise; Douglas Young, Northern California Research; Simon Farrow Wake Research &#8211; CRCNV. PharmaScribe, LLC provided editorial assistance in the preparation of the figures and the manuscript, with financial support from AriBio.</p></sec><sec id="sec0018"><title>Funding</title><p id="para0055">The study was funded by <funding-source id="gs0001">AriBio Co., Ltd.</funding-source>, which contributed to the design of the study, analysis, and interpretation of the data, and preparation of the manuscript, with support from external vendors.</p></sec><sec id="sec0020"><title>Author disclosures</title><p id="para0057">DG, MN, BH and BT are the PIs or staff at top-enrolling study sites. NP, SS, SYK and JAB consult for AriBio. FK, JR, TX and JJC are full-time employees and/or shareholders of AriBio. The remaining authors declare no conflicts of interest. Artificial intelligence was not used in the preparation of this manuscript.</p></sec></ack><fn-group><fn id="sec0021" fn-type="supplementary-material"><p id="para0010a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100337" id="interref0001">doi:10.1016/j.tjpad.2025.100337</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501340</article-id><article-id pub-id-type="pmcid-ver">PMC12501340.1</article-id><article-id pub-id-type="pmcaid">12501340</article-id><article-id pub-id-type="pmcaiid">12501340</article-id><article-id pub-id-type="pmid">40701901</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100274</article-id><article-id pub-id-type="pii">S2274-5807(25)00217-1</article-id><article-id pub-id-type="publisher-id">100274</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Organ-specific proteomic aging and cognitive performance: Implications for risk prediction of Alzheimer&#8217;s disease and related dementias in older adults</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Kang</surname><given-names initials="S">Sujin</given-names></name><email>sujin.kang@imperial.ac.uk</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Baker</surname><given-names initials="S">Susan</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Hayhoe</surname><given-names initials="B">Benedict</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Price</surname><given-names initials="G">Geraint</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Novak</surname><given-names initials="G">Gerald</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Wong</surname><given-names initials="J">Janice</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Middleton</surname><given-names initials="L">Lefkos</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Robinson</surname><given-names initials="O">Oliver</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0005" ref-type="aff">e</xref></contrib><aff id="aff0001"><label>a</label>Ageing &amp; Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, UK</aff><aff id="aff0002"><label>b</label>Formerly Janssen Research &amp; Development, USA</aff><aff id="aff0003"><label>c</label>Division of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK</aff><aff id="aff0004"><label>d</label>Johnson &amp; Johnson, Cambridge, MA 02142, USA</aff><aff id="aff0005"><label>e</label>MRC Centre for Environment &amp; Health, Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author. <email>sujin.kang@imperial.ac.uk</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>7</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100274</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>5</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><sec><title>Background and objectives</title><p>Biological aging, characterized by cellular and molecular changes, may play a key role in neurodegenerative diseases. While recent proteomic advancements have introduced new aging clocks, widespread validation remains necessary. This study evaluated organ-specific and cognition-enriched proteomic clocks in relation to chronological age and cognitive change.</p></sec><sec><title>Methods</title><p>We analyzed plasma proteomic data from the CHARIOT PRO SubStudy (<italic toggle="yes">N</italic> = 409), measured using the SomaScan assay (version 4.1) at four time points over three years (months 0, 12, 24, and 36). Using published proteomic organ age weights, we calculated conventional, organ-specific, and cognition-enriched biological ages and compared them with chronological age. Adjusted multilevel regression analyses assessed associations between baseline proteomic AgeGaps (biological&#8722;chronological age differences) and cognitive performance over 54 months.</p></sec><sec><title>Results</title><p>The cohort (mean age: 71.8 &#177; 5.5 years; 50.1 % female) showed moderate to strong correlations between proteomic ages and chronological age (<italic toggle="yes">r</italic> = 0.37&#8211;0.80; MAE = 4.2&#8211;2.7). Over three years, AgeGaps increased across the conventional, organismal, muscle, liver, artery, and immune systems, ranging from 2.1 &#177; 1.9 to 1.0 &#177; 2.3 years. The artery AgeGap was most strongly associated with cognitive decline, with conventional and organismal AgeGaps showing similar patterns. Higher baseline AgeGap z-scores (i.e., greater biological age) in the artery and brain were associated with poorer cognition, as measured by the Repeatable Battery for the Assessment of Neuropsychological Status Total Scores (Coeff. &#8722;3.0, 95 % CI: &#8722;3.4, &#8722;2.5; and &#8722;1.1, 95 % CI: &#8722;1.5, &#8722;0.6) and the Preclinical Alzheimer's Cognitive Composite (Coeff. &#8722;0.5, 95 % CI: &#8722;0.6, &#8722;0.4; and &#8722;0.14, 95 % CI: &#8722;0.3, &#8722;0.03).</p></sec><sec><title>Conclusions</title><p>These findings highlight the interplay between neurological function and cardiovascular aging in cognitive decline. Organ-specific biological age assessments may aid in the early detection of age-related changes, informing personalized interventions. Our study underscores the importance of proteomic aging signatures in elucidating Alzheimer&#8217;s disease mechanisms and other neurodegenerative conditions, advocating for an integrated approach to brain and cardiovascular health.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Organ-specific aging</kwd><kwd>Proteomics</kwd><kwd>Biological age</kwd><kwd>Cognitive changes</kwd><kwd>Longitudinal validation</kwd><kwd>Multilevel models</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0005">Understanding biological aging and its implications for neurodegenerative disease risk is crucial in an era of increased population aging. As the global population continues to age, the prevalence of neurodegenerative diseases is expected to rise, posing significant public health challenges [<xref rid="bib0001" ref-type="bibr">1</xref>]. Biological aging, defined as the cellular and molecular changes associated with aging, may significantly influence the onset and progression of neurodegenerative diseases [<xref rid="bib0002" ref-type="bibr">2</xref>,<xref rid="bib0003" ref-type="bibr">3</xref>]. Understanding the hierarchical relationships and interconnected time courses of molecular (such as DNA, proteins, and other cellular components), phenotypic (physical traits or characteristics), and functional domains of aging is critical for advancing aging research [<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0005" ref-type="bibr">5</xref>]. By clarifying these relationships, researchers can enhance the translational potential of their findings, paving the way for effective interventions that reduce the impact of the most common sporadic form of Alzheimer&#8217;s disease (AD) and other age-related neurodegenerative diseases.</p><p id="para0006">Plasma-based, high-throughput proteomic assays, including the Olink and aptamer-based Somalogic platforms, have emerged as powerful tools for predicting common diseases across diverse populations [<xref rid="bib0006" ref-type="bibr">6</xref>,<xref rid="bib0007" ref-type="bibr">7</xref>]. These assays provide robust biochemical aging signatures that enable early disease detection and advance biological discovery of age-related pathways and therapeutic targets [<xref rid="bib0008" ref-type="bibr">8</xref>,<xref rid="bib0009" ref-type="bibr">9</xref>]. Notably, the Olink platform in the UK Biobank identified plasma proteins strongly associated with dementia risk, highlighting the potential of proteomics in predicting and managing age-related diseases [<xref rid="bib0010" ref-type="bibr">10</xref>]. In parallel, researchers have constructed proteomic aging clocks (PACs), multivariable models highly predictive of chronological age, that model age as a biological process [<xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>, <xref rid="bib0014" ref-type="bibr">[14]</xref>]. Predicted proteomic age, relative to chronological age, has been associated with mortality risk [<xref rid="bib0007" ref-type="bibr">7</xref>,<xref rid="bib0011" ref-type="bibr">11</xref>,<xref rid="bib0015" ref-type="bibr">15</xref>,<xref rid="bib0016" ref-type="bibr">16</xref>], age-related phenotypes [<xref rid="bib0007" ref-type="bibr">7</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>] and disease including AD and dementia [<xref rid="bib0015" ref-type="bibr">15</xref>], suggesting their utility for the assessment of biological age.</p><p id="para0007">To understand heterogeneity in aging across organ systems, Oh <italic toggle="yes">et al</italic>. (2023) trained a conventional, an &#8220;organismal&#8221;, and 11 organ-specific PACs using plasma SomaScan-based proteomics among 1398 healthy controls in the Knight Alzheimer&#8217;s Disease Research Center (Knight-ADRC) study. The conventional clock was trained using all available aptamers, while the organ PACs were trained using proteins putatively annotated to their organ sources, based on differences between organs in gene expression levels [<xref rid="bib0017" ref-type="bibr">17</xref>]. The organismal PAC was trained exclusively on organ-nonspecific proteins. Notably increased organ aging was associated with greater mortality risk and certain organ-specific diseases were related to greater aging of those organs [<xref rid="bib0017" ref-type="bibr">17</xref>]. The authors further trained cognition-enriched PACs by tuning the training process to prioritize age-related proteins, which are also enriched for cognition, using the global Clinical Dementia Rating (CDR) assessed across the Knight-ADRC cohort. They found that the cognition-enriched brain PAC strongly predicted progression to AD independently of age, genetic risk, and plasma pTau-181 in the Knight-ADRC cohort [<xref rid="bib0017" ref-type="bibr">17</xref>]. These findings emphasize the value of using organ-specific aging models to address age-related health issues, though their efficacy and applicability across diverse populations remain unexplored [<xref rid="bib0018" ref-type="bibr">18</xref>]. Further research is needed to enhance the accuracy and clinical relevance of PACs, particularly in relation to organ-specific aging and cognitive decline [<xref rid="bib0018" ref-type="bibr">18</xref>]. Systematic validation of aging biomarkers is crucial for their clinical translation and may accelerate their integration into gerotherapeutic trials, enabling personalized interventions to prevent age-related diseases and promote healthier aging trajectories [<xref rid="bib0019" ref-type="bibr">19</xref>].</p><p id="para0008">Our study aimed to address these gaps by assessing organ-specific and cognition-enriched aging clocks, in relation to cognitive performance. Using the proteomic organ age weights from Oh <italic toggle="yes">et al</italic>. (2023), we calculated conventional, organ-specific, and cognition-enriched biological ages of participants in the UK Cognitive Health in Ageing Register: Investigational, Observational, and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy. Among cognitively healthy older adults, we examined how biological age, as measured by these clocks, relates to cognitive performance, which was assessed through a series of cognitive tests.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><sec id="sec0003"><label>2.1</label><title>Study population</title><p id="para0009">This study focused on subcohort data from the Cognitive Health in Ageing Register: Investigational, Observational, and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort Study (PRO) SubStudy [<xref rid="bib0020" ref-type="bibr">20</xref>]. The CHARIOT-PRO SubStudy, initiated in 2015, is a prospective cohort study focused on cognitively unimpaired (CU) older participants to evaluate factors and markers of risk for developing mild cognitive impairment and dementia associated with AD. A total of 2644 consenting CU individuals were screened. After comprehensive clinical, cognitive, and brain magnetic resonance imaging (MRI) assessments to exclude ineligible cases, 1373 individuals underwent amyloid beta (A&#946;) status determination via positron emission tomography (PET) and/or cerebrospinal fluid (CSF) A&#946;<sub>42</sub> assays. The aim was to enroll approximately equal numbers of participants with elevated and non-elevated A&#946; levels into the longitudinal study. This study included six-monthly clinical and cognitive evaluations, annual biological sample collection, and an optional extension period with additional neuroimaging studies (structural and functional MRI, and up to three yearly tau PET scans) from 2021 to 2024 (<bold><italic toggle="yes">Supplementary Fig. 1</italic></bold>). The study (REGISTRYALZ0001) was approved by the London &#8211; Central Research Ethics Committee (REC); reference: 15/LO/0711, date of REC opinion: 12 June 2015.</p></sec><sec id="sec0004"><label>2.2</label><title>Proteomic data</title><p id="para0010">Ethylenediaminetetraacetic acid (EDTA)-plasma samples from the CHARIOT PRO SubStudy at the Imperial College London site, collected for 409 participants, were measured at up to four time points over three years using SomaLogic SomaScan assay (version 4.1), covering 7335 aptamers [<xref rid="bib0021" ref-type="bibr">21</xref>]. The data underwent standardization processes, including hybridization and median signal normalization, to ensure consistent results [<xref rid="bib0021" ref-type="bibr">21</xref>]. A total of 1439 samples were analyzed, with 10 excluded due to quality criteria. Adaptive Normalization by Maximum Likelihood (ANML) was used for normalization [<xref rid="bib0022" ref-type="bibr">22</xref>], and plate calibration was performed to account for variability. Batch effects were assessed using exploratory principal component analysis (PCA) by examining the association of the top two components with plate ID and sample age to ensure no substantial variation. Quality control measures ensured the reliability of the results, with most samples passing the set criteria for calibration and normalization [<xref rid="bib0023" ref-type="bibr">23</xref>]. Outlier values (6.1 %) were imputed using Singular Value Decomposition (SVD). Extreme values (z-score threshold of <inline-formula><mml:math id="M1" altimg="si2.svg"><mml:mo>&#177;</mml:mo></mml:math></inline-formula>2) were set to missing, initialized to the mean, and then SVD was performed to decompose the data [<xref rid="bib0024" ref-type="bibr">24</xref>]. This approach reduced the impact of extreme values, minimizing bias and ensuring more reliable results for consistent downstream analysis. The data were reconstructed with factors capturing approximately 90 % of the covariance [<xref rid="bib0025" ref-type="bibr">25</xref>] and iterated until values stabilized, with imputed extremes reverted if necessary. Both original and imputed proteomic data were used for the organ age calculation.</p></sec><sec id="sec0005"><label>2.3</label><title>Proteomic age calculation</title><p id="para0011">We calculated the PACs based on the model weights provided by Oh <italic toggle="yes">et al</italic>. (2023) [<xref rid="bib0017" ref-type="bibr">17</xref>], using the <italic toggle="yes">organage</italic> package in Python and the associated GitHub repository (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/hamiltonoh/organage" id="interref0001">https://github.com/hamiltonoh/organage</ext-link>). We included 11 organ-specific aging models, as well as the conventional, organismal (non&#8211;organ-specific proteins), and cognition-enriched models. AgeGap is defined as a measure of an individual&#8217;s biological age relative to same-age peers, based on their molecular profile. AgeGaps were generated using the <italic toggle="yes">organage</italic> package by subtracting the predicted age based on each PAC from the LOWESS fit between predicted and chronological age (PAC-predicted age <inline-formula><mml:math id="M2" altimg="si3.svg"><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mspace width="0.33em"/><mml:msub><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi mathvariant="italic">lowess</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>); that is, a positive AgeGap indicates a biologically older age in the CHARIOT PRO SubStudy. AgeGaps were expressed as z-scores (i.e., standardized units in years) to facilitate comparisons across different PACs.</p></sec><sec id="sec0006"><label>2.4</label><title>Clinical characteristics</title><p id="para0012">Medical history data were either self-reported or retrieved from participants&#8217; general practitioners' medical records. Details of medical history, including hypertension determined by systolic blood pressure (SBP) and diastolic blood pressure (DBP) (assessed at screening and classified using the National Institute for Health and Care Excellence Stage 2 Hypertension, based on the lower values of repeated measurements [<xref rid="bib0026" ref-type="bibr">26</xref>]), type 2 diabetes, body mass index (BMI), ongoing cardiovascular disease, triglycerides, low-density lipoprotein (LDL) cholesterol, hemoglobin, C-reactive protein, sodium, and creatinine, were collected during the screening phase. In addition, other sociodemographic information including age, sex, ethnicity, marital status, educational attainment (i.e., below or above a bachelor&#8217;s degree level), and family history of dementia suggestive of AD (at least one first-degree relative) were collected.</p><sec id="sec0007"><label>2.4.1</label><title>A&#946; status classification and APOE genotyping</title><p id="para0013">Most participants underwent A&#946; positron emission tomography (PET) imaging, while approximately 10 % opted for a lumbar puncture for CSF analysis. CSF samples were tested using the Meso Scale Discovery triplex (A&#946;<sub>38</sub>/<sub>40</sub>/<sub>42</sub>), with A&#946; positivity (+) classified based on CSF A&#946;<sub>1&#8211;42</sub> (&lt;600 ng/L) and A&#946;<sub>42/40</sub> ratio (&lt;0.89). Brain PET A&#946;+ was determined using the standardized uptake value ratio (SUVR) with three F18-labeled A&#946; tracers, namely florbetapir, flutemetamol, and florbetaben, using cut-off values of &gt;1.14, &gt;1.21, and &gt;1.20, respectively, referenced to the whole cerebellum [<xref rid="bib0027" ref-type="bibr">27</xref>,<xref rid="bib0028" ref-type="bibr">28</xref>]. APOE &#949;4 carrier status was determined using standardized procedures for extracting genomic DNA, utilizing commercially available kits (QIAgen QIAsymphony DSP DNA Mini Kits or Promega Maxwell RSC Whole Blood DNA Kit). In this study, participants were categorized as either &#949;4 non-carriers (&#949;2/&#949;2, &#949;2/&#949;3, and &#949;3/&#949;3) or &#949;4 carriers (&#949;2/&#949;4, &#949;3/&#949;4, and &#949;4/&#949;4).</p></sec></sec><sec id="sec0008"><label>2.5</label><title>Cognitive and functional measures</title><p id="para0014">Multiple cognitive and functional measurements were used to monitor trajectories longitudinally at six- or twelve-month intervals [<xref rid="bib0015" ref-type="bibr">15</xref>] over a 54-month period. The cognitive measures were routinely administered in person, with remote delivery permitted during the COVID-19 pandemic. The remote assessment completion rates for the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Preclinical Alzheimer&#8217;s Cognitive Composite (PACC) ranged from 25 to 179 participants (9.3 % to 53.5 %) across assessment months 18/21 to 54. Fifty-four participants completed additional assessments as part of a neuroimaging study conducted after month 54 but prior to month 60 and were included in the analysis. &#8220;Month &gt;54&#8221; refers to the visit date of these assessments (<bold><italic toggle="yes">Supplementary Fig. 2</italic></bold><italic toggle="yes">;</italic>
<bold><italic toggle="yes">Supplementary Fig. 3</italic></bold>).</p><sec id="sec0009"><label>2.5.1</label><title>Repeatable battery for the assessment of neuropsychological status (RBANS)</title><p id="para0015">The RBANS is a 20- to 25-minute battery developed for cognitive assessment, detection, and characterization of dementia, as well as neuropsychological screening [<xref rid="bib0029" ref-type="bibr">29</xref>]. The RBANS includes 12 subtests that measure five indices: Immediate Memory Index, Visuospatial/Constructional Index, Language Index, Attention Index, and Delayed Memory Index, all of which were included in the analyses to support more detailed clinical interpretation. The sum of index scores is converted into a Total Scale Score using a mapping table. The Total Scale Score is a norm-based t-score, age-adjusted to a distribution with a mean of 100 and a standard deviation (SD) of 15, with higher scores indicating better cognitive function relative to age-matched peers [<xref rid="bib0028" ref-type="bibr">28</xref>,<xref rid="bib0030" ref-type="bibr">30</xref>]. The possible score ranges for the RBANS are 40 to 154 for domain indices and 40 to 160 for the Total Scale Score [<xref rid="bib0029" ref-type="bibr">29</xref>].</p></sec><sec id="sec0010"><label>2.5.2</label><title>The preclinical Alzheimer's cognitive composite (PACC)</title><p id="para0016">The PACC is a composite of four components, each z-score&#8211;transformed: (1) Free and Cued Selective Reminding Test (FCSRT) Immediate Recall (IR) Free + Total Recall Score, (2) Wechsler Memory Scale (WMS01)-Logical Memory II, (3) Wechsler Adult Intelligence Scale (WAIS&#8211;01) &#8211; Total Correct Responses in 120 s, and (4) Mini-Mental State Examination (MMSE) Total (Raw) [<xref rid="bib0028" ref-type="bibr">28</xref>]. Each component score was converted to a z-score based on the mean and SD of the baseline sample, and the z-scores were then summed to create the composite standardized PACC score [<xref rid="bib0031" ref-type="bibr">31</xref>].</p></sec><sec id="sec0011"><label>2.5.3</label><title>The Alzheimer's disease cooperative study prevention-activities of daily living-participant (ADCS-ADL-Participant) and ADCS-ADL-Study partner</title><p id="para0017">The ADCS-ADL was developed during the ADCS Prevention Instruments Trial and consists of 15 subjectively rated questions related to activities of daily living and 5 questions assessing physical functioning [<xref rid="bib0032" ref-type="bibr">32</xref>]. This scale can be completed either by the participant (self-rating) or by a study partner, such as a caregiver or family member, who is familiar with the individual, with the two responses treated as separate measures. A higher score on the ADCS-ADL indicates better overall functioning and independence in daily activities and physical tasks. The 23-item scale includes 6 Basic Activities of Daily Living (BADL) items and 17 Instrumental Activities of Daily Living (IADL) items, giving a total score from 0 to 78, with lower scores reflecting poorer functioning [<xref rid="bib0032" ref-type="bibr">32</xref>,<xref rid="bib0033" ref-type="bibr">33</xref>].</p></sec><sec id="sec0012"><label>2.5.4</label><title>Clinical dementia rating (CDR)-Global score (GS)</title><p id="para0018">The CDR (Clinical Dementia Rating) has been used as a global clinical staging measure in several AD trials. The CDR yields categorical ratings based on six subscales: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care [<xref rid="bib0034" ref-type="bibr">34</xref>]. Each subscale is rated from 0 to 3, and these are combined into a global score of 0, 0.5, 1, 2, or 3, with 0 indicating normal cognition. In the CHARIOT PRO SubStudy, a global score of 0 was required at baseline and reassessed at 12, 24, 36, 42, 54, and post-month 54 visits.</p></sec></sec><sec id="sec0013"><label>2.6</label><title>Statistical analysis</title><p id="para0019">Fisher&#8217;s exact test and the Wilcoxon rank-sum test were used to assess the significance of A&#946; pathology at baseline in relation to covariates. Cross-sectional Spearman's rank correlation coefficients were used to examine associations between baseline AgeGap z-score and chronological age. Cross-sectional and longitudinal analyses of predicted age versus chronological age were conducted. For participants without data at month 36, the maximum available month was used to calculate the difference from month 0. Participants with data from only one time point were excluded.</p></sec><sec id="sec0014"><label>2.7</label><title>Organ-specific baseline AgeGap z-score</title><p id="para0020">We employed a multilevel mixed-effects linear regression (with random effect ID) to assess associations between baseline AgeGap z-scores and cognition and functional scores, using 500 bootstrap replications [<xref rid="bib0035" ref-type="bibr">35</xref>]. This approach accounts for within-subject correlations in repeated measures, with time included as a fixed effect to control for the learning effect and model changes over time:<disp-formula id="ueqn0001"><mml:math id="M3" altimg="si4.svg"><mml:mrow><mml:mrow><mml:mo stretchy="true">{</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:msub><mml:mi>X</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>Z</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mtd></mml:mtr></mml:mtable><mml:mo stretchy="true">}</mml:mo></mml:mrow><mml:mspace width="4.pt"/><mml:mo>&#8764;</mml:mo><mml:mspace width="4.pt"/><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mtd><mml:mtd><mml:mrow><mml:msub><mml:mi>&#961;</mml:mi><mml:mi mathvariant="italic">xz</mml:mi></mml:msub><mml:msub><mml:mi>&#963;</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:msub><mml:mi>&#963;</mml:mi><mml:mi>z</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>&#961;</mml:mi><mml:mi mathvariant="italic">xz</mml:mi></mml:msub><mml:msub><mml:mi>&#963;</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:msub><mml:mi>&#963;</mml:mi><mml:mi>z</mml:mi></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mtd></mml:mtr></mml:mtable><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="ueqn0002"><label>(2)</label><mml:math id="M4" altimg="si5.svg"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="italic">Base</mml:mi><mml:mi mathvariant="italic">line</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="italic">AgeG</mml:mi><mml:mi mathvariant="italic">ap</mml:mi><mml:mspace width="0.33em"/><mml:mi>z</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="italic">score</mml:mi><mml:mo>_</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mspace width="4.pt"/><mml:mo linebreak="goodbreak">=</mml:mo><mml:mspace width="4.pt"/><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mspace width="4.pt"/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mspace width="4.pt"/><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi mathvariant="italic">Sex</mml:mi><mml:mo>_</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mspace width="4.pt"/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mspace width="4.pt"/><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mi>Z</mml:mi><mml:mrow><mml:mi mathvariant="italic">Base</mml:mi><mml:mi mathvariant="italic">line</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="italic">Age</mml:mi><mml:mo>_</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mspace width="4.pt"/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mspace width="4.pt"/><mml:msub><mml:mo>&#8712;</mml:mo><mml:mi>C</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="ueqn0003"><label>(3)</label><mml:math id="M5" altimg="si6.svg"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi mathvariant="italic">Cogn</mml:mi><mml:mi mathvariant="italic">ition</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="italic">score</mml:mi><mml:mo>_</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mspace width="4.pt"/><mml:mo linebreak="goodbreak">=</mml:mo><mml:mspace width="4.pt"/><mml:msub><mml:mi>&#952;</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mspace width="4.pt"/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mspace width="4.pt"/><mml:msub><mml:mi>&#952;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="italic">Base</mml:mi><mml:mi mathvariant="italic">line</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="italic">AgeG</mml:mi><mml:mi mathvariant="italic">ap</mml:mi><mml:mspace width="0.33em"/><mml:mi>z</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="italic">score</mml:mi><mml:mo>_</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mspace width="4.pt"/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mspace width="4.pt"/><mml:msub><mml:mi>&#952;</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi mathvariant="italic">Time</mml:mi><mml:mspace width="0.33em"/><mml:mi mathvariant="italic">point</mml:mi><mml:mo>_</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mspace width="4.pt"/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mspace width="4.pt"/><mml:msub><mml:mi>&#947;</mml:mi><mml:mi>Y</mml:mi></mml:msub><mml:mspace width="4.pt"/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mspace width="4.pt"/><mml:msub><mml:mo>&#8712;</mml:mo><mml:mi>Y</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><italic toggle="yes">where</italic>, <inline-formula><mml:math id="M6" altimg="si7.svg"><mml:mi>&#963;</mml:mi></mml:math></inline-formula> is the variance; <inline-formula><mml:math id="M7" altimg="si8.svg"><mml:msub><mml:mi>&#952;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math></inline-formula> is the target estimand and fixed effect parameter; <inline-formula><mml:math id="M8" altimg="si9.svg"><mml:mi>&#947;</mml:mi></mml:math></inline-formula> is random effect variance; <inline-formula><mml:math id="M9" altimg="si10.svg"><mml:mo>&#8712;</mml:mo></mml:math></inline-formula> is residual variance</p><p id="para0022">Chronological baseline age was included in the model to yield unbiased estimates of the association between each organ-specific baseline AgeGap z-score and the outcome [<xref rid="bib0036" ref-type="bibr">36</xref>]. Additional covariates (X), i.e., time point and sex, which are also associated with the outcome, were included. Bootstrapping was used to resample the data and assess variability, reducing the potential impact of non-normal learning effects on the test statistics. Multiple testing correction was done using the Benjamani&#8211;Hochberg (BH) method and the significance threshold was a 5 % false discovery rate (i.e. q-value).</p><p id="para0023">Clinical and sociodemographic exposures were also included in the fully adjusted models. Backward-elimination procedures, clinical significance, and log-likelihood (a measure of goodness of fit) were used to select terms for the final multivariate model across the organ. Estimates from multilevel mixed-effects linear regressions were reported alongside pooled estimates within subgroups, and heterogeneity was assessed using the I-squared (I&#178;) statistic [<xref rid="bib0037" ref-type="bibr">37</xref>]. Subgroup analyses stratified by A&#946; (+/<inline-formula><mml:math id="M10" altimg="si11.svg"><mml:mo>&#8722;</mml:mo></mml:math></inline-formula>) and APOE (carrier/non-carrier) status were conducted separately to examine the associations between AgeGap z-score and cognitive functioning. Additionally, interaction term analyses were performed for AgeGap z-score with either A&#946; or APOE carrier status to assess their combined effect on cognitive functioning. To account for practice effects, cognitive scores over time were modeled using multilevel mixed-effects linear regression with 500 bootstrap replications. The residuals were then regressed on baseline AgeGap z-scores using the same model, adjusting for covariates, including time point, age, and sex. Anaconda Jupyter Notebook (version 6.5.4) was used for implementing Python scripting for organ age calculation. Statistical analyses were conducted using Stata/SE 17 and using R (version 4.3.0).</p></sec></sec><sec id="sec0015"><label>3</label><title>Results</title><sec id="sec0016"><label>3.1</label><title>Study participants</title><p id="para0024">PACs were calculated for 409 participants. The study sample had an average age of 71.8 (SD 5.5), consisting of 205 females (50.1 %). It was predominantly of White ethnicity (95.6 %), with 59.7 % holding a bachelor's degree or a higher qualification. Approximately 45.2 % of the cohort had a BMI within the normal range (18.5 to &lt; 25), 67.2 % had a family history of dementia (at least one first-degree relative), 50.3 % tested positive for A&#946;, and 38.1 % were carriers of APOE &#949;4 at screening (<xref rid="tbl0001" ref-type="table">Table 1</xref>). The average baseline conventional AgeGap (years, non-standardized) was &#8722;0.32 (SD 2.9), while the average baseline brain AgeGap was &#8722;0.04 (SD 3.2) (<xref rid="tbl0001" ref-type="table">Table 1</xref>). The baseline brain AgeGap z-score showed a medium Spearman&#8217;s correlation with conventional, organismal, liver, adipose, and immune systems (&#961; <inline-formula><mml:math id="M11" altimg="si12.svg"><mml:mo>&#8805;</mml:mo></mml:math></inline-formula>0.4), and artery, heart, and pancreas (0.3); intestine, muscle, and lung (0.2) showed a small effect size [<xref rid="bib0038" ref-type="bibr">38</xref>] (<bold><italic toggle="yes">Supplementary Fig. 4</italic></bold>). Most participants remained at a CDR-GS of 0, but 83 progressed to a score of 0.5 at least once, indicating possible mild cognitive impairment. Of these, 26 reached a score of 0.5 at their final study visit, while 57 had reached a 0.5 score earlier; 43 of the latter subsequently reverted to a score of 0. Two participants progressed to a score of 1, suggesting possible early-stage dementia.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Baseline demographic characteristics of the participants.</p></caption><alt-text id="alt0006">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="left" valign="top" rowspan="1">Participants' characteristics</th><th valign="top" colspan="1" rowspan="1">Total (<italic toggle="yes">N</italic> = 409)</th><th valign="top" colspan="1" rowspan="1">A&#946; Negative (<italic toggle="yes">N</italic> = 203)</th><th valign="top" colspan="1" rowspan="1">A&#946; Positive (<italic toggle="yes">N</italic> = 206)</th></tr></thead><tbody><tr><td colspan="2" align="left" valign="top" rowspan="1">Chronological Age, yrs<xref rid="tb1fn2" ref-type="table-fn">&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 409</td><td valign="top" colspan="1" rowspan="1">71.8 (5.5)</td><td valign="top" colspan="1" rowspan="1">70.9 (5.2)</td><td valign="top" colspan="1" rowspan="1">72.6 (5.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Predicted Age,yrs, mean (SD)</td><td valign="top" colspan="1" rowspan="1">Lung</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 409</td><td valign="top" colspan="1" rowspan="1">74.5 (2.3)</td><td valign="top" colspan="1" rowspan="1">74.4 (2.4)</td><td valign="top" colspan="1" rowspan="1">74.6 (2.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Intestine</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">72.9 (2.8)</td><td valign="top" colspan="1" rowspan="1">72.6 (2.9)</td><td valign="top" colspan="1" rowspan="1">73.3 (2.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Brain</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">72.4 (3.5)</td><td valign="top" colspan="1" rowspan="1">72.3 (3.6)</td><td valign="top" colspan="1" rowspan="1">72.5 (3.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Adipose</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">72.5 (3.0)</td><td valign="top" colspan="1" rowspan="1">72.2 (3.2)</td><td valign="top" colspan="1" rowspan="1">72.8 (2.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Organismal</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">72.3 (4.4)</td><td valign="top" colspan="1" rowspan="1">71.5 (4.2)</td><td valign="top" colspan="1" rowspan="1">73.1 (4.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Conventional</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">72.1 (4.4)</td><td valign="top" colspan="1" rowspan="1">71.3 (4.2)</td><td valign="top" colspan="1" rowspan="1">72.9 (4.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Artery</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">72.2 (2.4)</td><td valign="top" colspan="1" rowspan="1">72.1 (2.5)</td><td valign="top" colspan="1" rowspan="1">72.4 (2.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Heart</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">71.7 (3.1)</td><td valign="top" colspan="1" rowspan="1">71.4 (2.9)</td><td valign="top" colspan="1" rowspan="1">72.0 (3.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Immune</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">71.4 (3.8)</td><td valign="top" colspan="1" rowspan="1">71.0 (3.8)</td><td valign="top" colspan="1" rowspan="1">71.9 (3.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Pancreas</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">71.9 (2.9)</td><td valign="top" colspan="1" rowspan="1">71.7 (2.9)</td><td valign="top" colspan="1" rowspan="1">72.0 (2.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Kidney</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">72.5 (1.6)</td><td valign="top" colspan="1" rowspan="1">72.4 (1.7)</td><td valign="top" colspan="1" rowspan="1">72.5 (1.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Liver</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">70.7 (4.0)</td><td valign="top" colspan="1" rowspan="1">70.2 (3.9)</td><td valign="top" colspan="1" rowspan="1">71.2 (4.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Muscle</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">70.8 (3.2)</td><td valign="top" colspan="1" rowspan="1">70.3 (3.1)</td><td valign="top" colspan="1" rowspan="1">71.2 (3.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Baseline AgeGap (years, non-standardized), mean (SD)</td><td valign="top" colspan="1" rowspan="1">Lung<xref rid="tb1fn5" ref-type="table-fn">&#167;</xref></td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 409</td><td valign="top" colspan="1" rowspan="1">1.62 (2.3)</td><td valign="top" colspan="1" rowspan="1">1.67 (2.4)</td><td valign="top" colspan="1" rowspan="1">1.56 (2.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Intestine<xref rid="tb1fn5" ref-type="table-fn">&#167;</xref></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.06 (2.9)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.08 (3)</td><td valign="top" colspan="1" rowspan="1">0.19 (2.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Brain</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;0.04 (3.2)</td><td valign="top" colspan="1" rowspan="1">0.27 (3.1)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.34 (3.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Adipose</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;0.04 (3)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.05 (3.1)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.04 (3)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Organismal</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;0.12 (3)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.21 (2.7)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.03 (3.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Conventional</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;0.32 (2.9)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.39 (2.6)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.24 (3.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Artery</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;0.4 (2.4)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.33 (2.4)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.47 (2.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Heart</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;0.75 (2.9)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.75 (2.7)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.75 (3.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Immune</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;0.97 (3.3)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.99 (3.3)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.95 (3.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Pancreas</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;0.82 (2.8)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.78 (2.9)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.85 (2.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Kidney</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;0.62 (1.6)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.61 (1.6)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.63 (1.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Liver</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;1.75 (3.4)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.79 (3.3)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.71 (3.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Muscle</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;1.89 (3.1)</td><td valign="top" colspan="1" rowspan="1">&#8722;2.07 (2.8)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.72 (3.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Cognitive functioning<xref rid="tb1fn4" ref-type="table-fn">&#8225;</xref>, mean (SD)</td><td valign="top" colspan="1" rowspan="1">PACC (Standardized)<xref rid="tb1fn1" ref-type="table-fn">*</xref></td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 407; range &#8722;8.52 &#8764; 6.59</td><td valign="top" colspan="1" rowspan="1">&#8722;0.2 (2.7)</td><td valign="top" colspan="1" rowspan="1">0.2 (2.8)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.5 (2.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">RBANS total (Derived)</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 406; range 69 &#8764; 147</td><td valign="top" colspan="1" rowspan="1">106.1 (12.4)</td><td valign="top" colspan="1" rowspan="1">106.7 (12.3)</td><td valign="top" colspan="1" rowspan="1">105.6 (12.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">ADCS-ADL-Participant</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 408; range 26 &#8764; 45</td><td valign="top" colspan="1" rowspan="1">42.4 (3.0)</td><td valign="top" colspan="1" rowspan="1">42.7 (2.8)</td><td valign="top" colspan="1" rowspan="1">42.2 (3.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">ADCS-ADL-Study Partner</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 408; range 15 &#8764; 45</td><td valign="top" colspan="1" rowspan="1">41.6 (4.2)</td><td valign="top" colspan="1" rowspan="1">41.5 (4.5)</td><td valign="top" colspan="1" rowspan="1">41.6 (3.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sociodemographic, N ( %)</td><td valign="top" colspan="1" rowspan="1">Sex</td><td valign="top" colspan="1" rowspan="1">Female (<italic toggle="yes">N</italic> = 205)</td><td valign="top" colspan="1" rowspan="1">205 (50.1)</td><td valign="top" colspan="1" rowspan="1">106 (52.2)</td><td valign="top" colspan="1" rowspan="1">99 (48.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Male (<italic toggle="yes">N</italic> = 204)</td><td valign="top" colspan="1" rowspan="1">204 (49.9)</td><td valign="top" colspan="1" rowspan="1">97 (47.8)</td><td valign="top" colspan="1" rowspan="1">107 (51.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Ethnicity</td><td valign="top" colspan="1" rowspan="1">White</td><td valign="top" colspan="1" rowspan="1">391 (95.6)</td><td valign="top" colspan="1" rowspan="1">191 (94.1)</td><td valign="top" colspan="1" rowspan="1">200 (97.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Other (Asian, Other, Multiple, Unknown)</td><td valign="top" colspan="1" rowspan="1">18 (4.4)</td><td valign="top" colspan="1" rowspan="1">12 (5.9)</td><td valign="top" colspan="1" rowspan="1">6 (2.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Marital Status</td><td valign="top" colspan="1" rowspan="1">Married</td><td valign="top" colspan="1" rowspan="1">275 (67.2)</td><td valign="top" colspan="1" rowspan="1">131 (64.5)</td><td valign="top" colspan="1" rowspan="1">144 (69.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Other (Widowed/Single/Divorced/ Separated)</td><td valign="top" colspan="1" rowspan="1">133 (32.5)</td><td valign="top" colspan="1" rowspan="1">71 (35.0)</td><td valign="top" colspan="1" rowspan="1">62 (30.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Missing</td><td valign="top" colspan="1" rowspan="1">1 (0.2)</td><td valign="top" colspan="1" rowspan="1">1 (0.5)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Highest Education</td><td valign="top" colspan="1" rowspan="1">Below a Bachelor's degree</td><td valign="top" colspan="1" rowspan="1">165 (40.3)</td><td valign="top" colspan="1" rowspan="1">85 (41.9)</td><td valign="top" colspan="1" rowspan="1">80 (38.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Bachelor&#8217;s degree or higher</td><td valign="top" colspan="1" rowspan="1">244 (59.7)</td><td valign="top" colspan="1" rowspan="1">118 (58.1)</td><td valign="top" colspan="1" rowspan="1">126 (61.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Family history of dementia</td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">134 (32.8)</td><td valign="top" colspan="1" rowspan="1">57 (28.1)</td><td valign="top" colspan="1" rowspan="1">77 (37.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">275 (67.2)</td><td valign="top" colspan="1" rowspan="1">146 (71.9)</td><td valign="top" colspan="1" rowspan="1">129 (62.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1">APOE Genotyping, N ( %)</td><td valign="top" colspan="1" rowspan="1">APOE &#949;4<xref rid="tb1fn2" ref-type="table-fn">&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">None</td><td valign="top" colspan="1" rowspan="1">253 (61.9)</td><td valign="top" colspan="1" rowspan="1">156 (76.9)</td><td valign="top" colspan="1" rowspan="1">97 (47.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Heterozygous (&#949;2/&#949;4 or &#949;3/&#949;4)</td><td valign="top" colspan="1" rowspan="1">143 (35)</td><td valign="top" colspan="1" rowspan="1">46 (22.7)</td><td valign="top" colspan="1" rowspan="1">97 (47.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Homozygous(&#949;4/&#949;4)</td><td valign="top" colspan="1" rowspan="1">13 (3.2)</td><td valign="top" colspan="1" rowspan="1">1 (0.49)</td><td valign="top" colspan="1" rowspan="1">12 (5.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">APOE &#949;4<xref rid="tb1fn2" ref-type="table-fn">&#8270;&#8270;</xref></td><td valign="top" colspan="1" rowspan="1">Non-carrier</td><td valign="top" colspan="1" rowspan="1">253 (61.9)</td><td valign="top" colspan="1" rowspan="1">156 (76.9)</td><td valign="top" colspan="1" rowspan="1">97 (47.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Carrier</td><td valign="top" colspan="1" rowspan="1">156 (38.1)</td><td valign="top" colspan="1" rowspan="1">47 (23.2)</td><td valign="top" colspan="1" rowspan="1">109 (52.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Clinical Measures, N ( %)</td><td valign="top" colspan="1" rowspan="1">BMI</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 407</td><td valign="top" colspan="1" rowspan="1">26.2 (4.3)</td><td valign="top" colspan="1" rowspan="1">26.3 (4.5)</td><td valign="top" colspan="1" rowspan="1">26.1 (4.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Missing</td><td valign="top" colspan="1" rowspan="1">2 (0.5)</td><td valign="top" colspan="1" rowspan="1">1 (0.5)</td><td valign="top" colspan="1" rowspan="1">1 (0.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Waist Circumference for Females (cm) <xref rid="tb1fn6" ref-type="table-fn">||</xref></td><td valign="top" colspan="1" rowspan="1">Low risk (&lt; 80)</td><td valign="top" colspan="1" rowspan="1">41 (20)</td><td valign="top" colspan="1" rowspan="1">24 (22.6)</td><td valign="top" colspan="1" rowspan="1">17 (17.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">High risk (80&#8211;88)</td><td valign="top" colspan="1" rowspan="1">61 (29.8)</td><td valign="top" colspan="1" rowspan="1">32 (30.2)</td><td valign="top" colspan="1" rowspan="1">29 (29.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Very high risk (&gt;88)</td><td valign="top" colspan="1" rowspan="1">96 (46.8)</td><td valign="top" colspan="1" rowspan="1">46 (43.4)</td><td valign="top" colspan="1" rowspan="1">50 (50.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Missing</td><td valign="top" colspan="1" rowspan="1">7 (3.4)</td><td valign="top" colspan="1" rowspan="1">4 (3.8)</td><td valign="top" colspan="1" rowspan="1">3 (3)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Waist Circumference for Males (cm) <xref rid="tb1fn6" ref-type="table-fn">||</xref></td><td valign="top" colspan="1" rowspan="1">Low risk (&lt; 94)</td><td valign="top" colspan="1" rowspan="1">89 (43.6)</td><td valign="top" colspan="1" rowspan="1">35 (36.1)</td><td valign="top" colspan="1" rowspan="1">54 (50.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">High risk (94&#8211;102)</td><td valign="top" colspan="1" rowspan="1">65 (31.9)</td><td valign="top" colspan="1" rowspan="1">31 (32)</td><td valign="top" colspan="1" rowspan="1">34 (31.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Very high risk (&gt;102)</td><td valign="top" colspan="1" rowspan="1">47 (23)</td><td valign="top" colspan="1" rowspan="1">29 (29.9)</td><td valign="top" colspan="1" rowspan="1">18 (16.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Missing</td><td valign="top" colspan="1" rowspan="1">3 (1.5)</td><td valign="top" colspan="1" rowspan="1">2 (2.1)</td><td valign="top" colspan="1" rowspan="1">1 (0.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Hypertension<xref rid="tb1fn3" ref-type="table-fn">&#8224;</xref></td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">285 (69.7)</td><td valign="top" colspan="1" rowspan="1">147 (72.4)</td><td valign="top" colspan="1" rowspan="1">138 (67)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">124 (30.3)</td><td valign="top" colspan="1" rowspan="1">56 (27.6)</td><td valign="top" colspan="1" rowspan="1">68 (33)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Cardiovascular disease (ongoing)</td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">183 (44.7)</td><td valign="top" colspan="1" rowspan="1">97 (47.8)</td><td valign="top" colspan="1" rowspan="1">86 (41.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">226 (55.3)</td><td valign="top" colspan="1" rowspan="1">106 (52.2)</td><td valign="top" colspan="1" rowspan="1">120 (58.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Clinical Measures, mean (SD)</td><td valign="top" colspan="1" rowspan="1">SBP</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 409</td><td valign="top" colspan="1" rowspan="1">139.9 (17.3)</td><td valign="top" colspan="1" rowspan="1">139 (17)</td><td valign="top" colspan="1" rowspan="1">140.7 (17.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">DBP</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 409</td><td valign="top" colspan="1" rowspan="1">78.9 (10)</td><td valign="top" colspan="1" rowspan="1">79 (10.1)</td><td valign="top" colspan="1" rowspan="1">78.7 (9.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Triglycerides</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 408</td><td valign="top" colspan="1" rowspan="1">1.3 (0.6)</td><td valign="top" colspan="1" rowspan="1">1.4 (0.7)</td><td valign="top" colspan="1" rowspan="1">1.3 (0.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">LDL Cholesterol</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 407</td><td valign="top" colspan="1" rowspan="1">3.0 (1.0)</td><td valign="top" colspan="1" rowspan="1">3.0 (1.0)</td><td valign="top" colspan="1" rowspan="1">3.0 (1.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">C Reactive Protein</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 409</td><td valign="top" colspan="1" rowspan="1">1.7 (2.9)</td><td valign="top" colspan="1" rowspan="1">1.7 (2.2)</td><td valign="top" colspan="1" rowspan="1">1.7 (3.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Sodium</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 408</td><td valign="top" colspan="1" rowspan="1">138.6 (2.5)</td><td valign="top" colspan="1" rowspan="1">138.5 (2.5)</td><td valign="top" colspan="1" rowspan="1">138.7 (2.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Creatinine</td><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> = 408</td><td valign="top" colspan="1" rowspan="1">76.0 (15.3)</td><td valign="top" colspan="1" rowspan="1">75.4 (14.8)</td><td valign="top" colspan="1" rowspan="1">76.6 (15.8)</td></tr></tbody></table><table-wrap-foot><fn id="tb1fn1"><label>&#8270;</label><p id="notep0001">&lt; 0.05.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn2"><label>&#8270;&#8270;</label><p id="notep0002">&lt; 0.001.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn3"><label>&#8224;</label><p id="notep0003">Medical History plus NHS UK: Stage 2 - 160/100 mmHg and 180/120 mmHg in the clinic.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn4"><label>&#8225;</label><p id="notep0004">At baseline, CDR-SB = 0 (<italic toggle="yes">N</italic> = 408).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn5"><label>&#167;</label><p id="notep0005">Positive AgeGap indicates that the biological age is greater than the chronological age.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn6"><label>||</label><p id="notep0006">Waist circumference categories, based on World Health Organization (WHO) guidelines, indicate the risk of cardiometabolic diseases (Note: Consultation, W.E., Waist circumference and waist-hip ratio. Report of a WHO Expert Consultation. Geneva: World Health Organization, 2008. 2008: pp. 8&#8211;11).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0017"><label>3.2</label><title>Predicted age versus chronological age</title><p id="para0025">Proteomic ages of conventional, organismal, immune, liver, brain, cognition-enriched brain, muscle, and artery demonstrated moderate to strong cross-sectional correlations with chronological age (r = 0.37 to 0.80) and mean absolute errors (MAEs) of 4.2 to 2.7 years (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>(a) and (b)). The mean change in predicted age from baseline to the final longitudinal sampling point (month 36) was 2.4 years (SD = 0.7), suggesting longitudinal, organ-specific age changes. All clocks tested, except for adipose, brain, and cognition-enriched brain, showed significant mean increases in predicted age over the follow-up period (<xref rid="fig0001" ref-type="fig">Fig. 1</xref><italic toggle="yes">(c)</italic>). Longitudinal predicted age versus chronological age (<italic toggle="yes">N</italic> = 384), stratified by A&#946; pathology at screening, is presented in <bold><italic toggle="yes">Supplementary Fig. 5</italic></bold>; similar changes were observed between A&#946;<inline-formula><mml:math id="M12" altimg="si13.svg"><mml:mo>+</mml:mo></mml:math></inline-formula> and A&#946;<inline-formula><mml:math id="M13" altimg="si11.svg"><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mspace width="0.33em"/></mml:mrow></mml:math></inline-formula> groups. The correlation ranges for the original proteomic data, without outlier imputation, were slightly lower for conventional, organismal, immune, liver, brain, muscle, and artery ages (with correlation values of 0.34 to 0.77; corresponding MAEs of 4.2 to 2.8), <bold><italic toggle="yes">Supplementary Fig. 6(a)</italic></bold>.<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>(a) Organ-specific Biological Age. We estimated the 11 organ-specific aging models, along with conventional and organismal (non-organ-specific proteins) models, in the CHARIOT PRO SubStudy (<italic toggle="yes">N</italic> = 409) using plasma proteomic data measured over three years; (b) Cross-sectional predicted age versus chronological age (all months, <italic toggle="yes">N</italic> = 1274); (c) Change in predicted age versus change in chronological age over longitudinal follow-up (<italic toggle="yes">N</italic> = 384).</p></caption><alt-text id="alt0001">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec0018"><label>3.3</label><title>Baseline AgeGap z-score and cognitive functioning</title><p id="para0026">The overall trends for the RBANS total score and the PACC showed an increase (coefficient (Coeff.) 2.88, 95 % CI: 2.5, 3.2, and 0.47, 95 % CI: 0.4, 0.6) between baseline and the end of study, indicating improved performance, likely due to a learning or practice effect over time (<bold><italic toggle="yes">Supplementary Fig. 7</italic></bold>). The overall trends for the Visuospatial/Constructional Index Score, Immediate Memory Index Score, and Delayed Memory Index Score also indicated improved cognitive functioning during the study. In contrast, the Attentional Index remained stable, while the Language Index (Coeff. &#8722;0.53, 95 % CI: &#8722;1.0, &#8722;0.06) showed an overall decline from baseline to end of study (<bold><italic toggle="yes">Supplementary Fig. 3</italic></bold>). Sensitivity analyses focused on remote cognitive assessments showed very similar patterns for the RBANS total score, indices, and the PACC, indicating that visit mode had little effect on results (<bold><italic toggle="yes">Supplementary Fig. 2</italic></bold>).</p><p id="para0027">Greater baseline organ AgeGap z-scores of conventional, organismal, immune, brain, and artery were associated with poorer cognition after correction for false discovery rate (FDR), as measured by RBANS total score (<xref rid="fig0002" ref-type="fig">Fig. 2</xref><italic toggle="yes">(a)</italic>). The conventional AgeGap was associated with a 0.97-point decrease in the RBANS total score over follow-up for each SD increase in AgeGap z-score (Coeff. &#8722;0.97, 95 % CI: &#8722;1.32, &#8722;0.62). The largest effects were observed for the artery AgeGap z-score, which was associated with a 2.95 decrease in the RBANS total score (Coeff. &#8722;2.95, 95 % CI: &#8722;3.42, &#8722;2.48), while the brain AgeGap z-score was associated with a 1.1-point decrease in the RBANS total score. Generally, similar patterns of association were observed with the PACC, <xref rid="fig0002" ref-type="fig">Fig. 2</xref><italic toggle="yes">(b)</italic>, although the conventional and organismal AgeGaps were not associated with the PACC and we additionally observed associations with the pancreas, lung and intestine AgeGaps. Cognition-enriched AgeGaps generally showed similar associations with the PACC and the RBANS total score, and did not strengthen observed associations over their respective age-gaps trained solely on chronological age.<fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Coefficient of the baseline AgeGap z-score regarding (a) RBANS total score (<italic toggle="yes">N</italic> = 409) and (b) PACC (<italic toggle="yes">N</italic> = 409), using multilevel mixed-effects linear regression with 500 bootstrap replications, adjusted for time point, chronological age, and sex; (c) RBANS (<italic toggle="yes">N</italic> = 400), additionally adjusted for A&#946;, APOE &#949;4, family history of dementia, education, hypertension, BMI, hemoglobin, LDL, triglycerides, and sodium; and (d) PACC (<italic toggle="yes">N</italic> = 400), additionally adjusted for A&#946;, APOE &#949;4, family history of dementia, education, marital status, BMI, hemoglobin, and LDL.</p></caption><alt-text id="alt0002">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="para0028">Adjustment for additional significant covariates, including A&#946; and APOE &#949;4 status, generally had minimal effects on the estimates, except for the brain AgeGaps, where associations were attenuated to no longer be statistically significant for the RBANS total score (Coeff. &#8722;0.6, 95 % CI: &#8722;1.1, &#8722;0.1, <xref rid="fig0002" ref-type="fig">Fig. 2</xref><italic toggle="yes">(c)</italic>) and the PACC (Coeff. &#8722;0.1, 95 % CI: &#8722;0.2, &#8722;0.02, <xref rid="fig0002" ref-type="fig">Fig. 2</xref><italic toggle="yes">(d)</italic>).</p><p id="para0029">In sensitivity analyses, using the same adjustment covariates for the PACC score as in the RBANS analysis yielded similar results. Model coefficients are presented in <bold><italic toggle="yes">Supplementary Fig. 8</italic></bold>. Family history of dementia and higher education were associated with better performance, while being male and A&#946;+ were associated with poorer performance across both scores. APOE &#949;4 non-carrier status was associated with higher PACC scores. Furthermore, a sensitivity analysis using the non-outlier imputed proteomic data showed very similar associations between AgeGap z-scores, <bold><italic toggle="yes">Supplementary Fig. 6(b)</italic></bold>.</p><p id="para0030">Results remained consistent after controlling for learning or practice effects through residualization of cognitive scores (<bold><italic toggle="yes">Supplementary Fig. 9</italic></bold>).</p><p id="para0031"><bold><italic toggle="yes">Supplementary Fig. 10</italic></bold> shows AgeGap associations with RBANS indices. The artery AgeGap z-score was most strongly associated across all RBANS indices, ranging from a reduction of 1.10 points for the Delayed Memory Index (Coeff. &#8722;1.10, 95 % CI: &#8722;1.57, &#8722;0.63) to a reduction of 2.63 points for the Language Index (Coeff. &#8722;2.63, 95 % CI: &#8722;3.19, &#8722;2.07). The conventional AgeGap z-score was most strongly associated with the Visuospatial/Constructional Index (Coeff. &#8722;1.98, 95 % CI: &#8722;2.13, &#8722;1.24). Greater baseline brain AgeGap z-scores were associated with poorer cognition, as measured by the RBANS Attentional Index (Coeff. &#8722;1.5, 95 % CI: &#8722;2.0, &#8722;1.0), the Language Index (Coeff. &#8722;1.4, 95 % CI: &#8722;1.8, &#8722;0.9), and the Visuospatial/Constructional Index (Coeff. &#8722;0.6, 95 % CI: &#8722;1.1, 0). In contrast, the RBANS Immediate Memory Index (Coeff. &#8722;0.3, 95 % CI: &#8722;0.8, 0.2), and Delayed Memory Index (Coeff. &#8722;0.3, 95 % CI: &#8722;0.7, 0.1) showed a tendency toward poorer cognition over the study period.</p></sec><sec id="sec0019"><label>3.4</label><title>Effect modification by AD risk factors</title><p id="para0032">In subgroup analysis, stratified by A&#946; status, stronger negative associations between AgeGap and RBANS total score were observed in the A&#946; positive subgroup for many of the PACs (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><italic toggle="yes">(a)</italic>), and effect modification by A&#946; status was supported by significant (q value &lt;0.001) interaction terms (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><italic toggle="yes">(c)</italic>). For instance, a greater baseline brain AgeGap z-score was associated with a 1.6-point decline in the RBANS total score (Coeff. &#8722;1.6, 95 % CI: &#8722;2.2, &#8722;1) with A&#946;+ pathology, but showed no significant association in the A&#946;-negative group (Coeff. &#8722;0.5, 95 % CI: &#8722;1.2, 0.1). There was no statistically significant interaction between A&#946; pathology and the conventional, organismal, immune or artery PACs (<italic toggle="yes">q</italic> &gt; 0.05).<fig id="fig0003" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Coefficient of the baseline AgeGap z-score associated with the decline in the RBANS total score for A&#946; and APOE &#949;4 status. Models were adjusted for time point, chronological age, and sex. (a) and (b) represent subgroup analyses, while (c) and (d) present interaction term analyses with the baseline AgeGap z-score and A&#946;+ or APOE &#949;4 carrier status.</p></caption><alt-text id="alt0003">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0003" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="para0033">Upon stratification by APOE &#949;4 carrier status, associations between conventional and organismal AgeGap z-scores and the RBANS total score were apparent only among APOE &#949;4 non-carriers, and negative associations with the artery AgeGap z-score were stronger among non-carriers (Coeff. &#8722;3.7 (95 % CI: &#8722;4.2, &#8722;3.1) (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><italic toggle="yes">(b)</italic>). Interaction term analysis confirmed significant interactions between these PACs and APOE &#949;4 carrier status (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><italic toggle="yes">(d)</italic>). Conversely, while negative associations with the brain and immune PACs were stronger among APOE &#949;4 carriers (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><italic toggle="yes">(b)</italic>), the interaction terms were not significant after FDR correction (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><italic toggle="yes">(d)</italic>). Notably, the artery was significantly associated with a lower RBANS total score across all A&#946; status and APOE &#949;4 carrier strata.</p><p id="para0034">As the RBANS Language Index showed an overall decline from baseline to before month 60 (<bold><italic toggle="yes">Supplementary Fig. 3</italic></bold>), we examined stratifications for further risk factors specifically for this index. Combined effects under the fixed-effect model, assuming a common true effect size for the organs and using the I&#178; statistic to indicate variability across organs, demonstrated that organs were strongly associated with lower RBANS Language Index in high-risk groups of BMI <inline-formula><mml:math id="M14" altimg="si12.svg"><mml:mo>&#8805;</mml:mo></mml:math></inline-formula>30 (classified as obese [<xref rid="bib0039" ref-type="bibr">39</xref>], Coeff. &#8722;1.7, 95 % CI: &#8722;2, &#8722;1.3), hypertension (Coeff. &#8722;1.0, 95 % CI: &#8722;1.3, &#8722;0.8), and education below a bachelor's degree (Coeff. &#8722;1.2, 95 % CI: &#8722;1.5, &#8722;1.0) (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>).<fig id="fig0004" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Coefficient of the baseline AgeGap z-score associated with the decline in the RBANS Language Index for (a) BMI<inline-formula><mml:math id="M15" altimg="si1.svg"><mml:mrow><mml:mrow><mml:mspace width="0.33em"/></mml:mrow><mml:mo>&#8805;</mml:mo></mml:mrow></mml:math></inline-formula>30, (b) hypertension, and (c) education level below a bachelor's degree. Models were adjusted for time point, chronological age, and sex.</p></caption><alt-text id="alt0004">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0004" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec0020"><label>3.5</label><title>Baseline AgeGap z-score and functional aging</title><p id="para0035">The overall trend for ADCS-ADL-Participant remained stable (<xref rid="fig0005" ref-type="fig">Fig. 5</xref><italic toggle="yes">(a)</italic>, Coeff. 0.02, 95 % CI: &#8722;0.1, 0.2), but the ADCS-ADL-Study Partner score declined (<xref rid="fig0005" ref-type="fig">Fig. 5</xref><italic toggle="yes">(b)</italic>, Coeff. &#8722;0.39, 95 % CI: &#8722;0.6, &#8722;0.2) over the course of the study, as shown by multilevel mixed-effects linear regressions. Greater baseline liver, artery, and muscle AgeGap z-scores were associated with poorer functioning and independence in performing daily activities and physical tasks, as measured by the ADCS-ADL-Participant score. For instance, the artery AgeGap z-score was associated with a 0.4-point reduction (Coeff. &#8722;0.41, 95 % CI: &#8722;0.6, &#8722;0.2) in ADCS-ADL-Participant score over the course of the study. Only the cognition-enriched brain AgeGap was significantly associated with ADCS-ADL-Study Partner scores, as reported by the study partner, with a 0.5-point reduction per unit change in AgeGap z-score (Coeff. &#8722;0.49, 95 % CI: &#8722;0.8, &#8722;0.2).<fig id="fig0005" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Coefficient of (a) ADCS-ADL-Participant and (b) ADCS-ADL-Study Partner, using multilevel mixed-effects linear regression with 500 bootstrap replications; coefficient of the baseline AgeGap z-score with respect to (c) ADCS-ADL-Participant and (d) ADCS-ADL-Study Partner, adjusted for time point, chronological age, and sex.</p></caption><alt-text id="alt0005">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0005" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></sec></sec><sec id="sec0021"><label>4</label><title>Discussion</title><p id="para0036">We applied proteomic aging clocks to assess biological age, both overall and specifically for organ systems, using SomaScan proteomics within the CHARIOT PRO SubStudy cohort. Proteomic ages of conventional, organismal, immune, liver, brain, muscle, artery, and heart demonstrated moderate to strong cross-sectional correlations with chronological age. Conventional, organismal, muscle, liver, artery, and immune proteomic ages increased as expected over three years, tracking changes in chronological age. Greater baseline AgeGap z-scores for conventional, organismal, immune, brain, and artery models were associated with poorer cognitive performance, as measured by the RBANS total score. Significant associations between immune and artery AgeGap z-scores and the PACC, as an alternative cognitive assessment battery, were also observed. This suggests that individuals with higher deviations in AgeGap across multiple organ systems tend to experience greater loss of cognitive functioning over time. The AgeGap metric likely reflects the discrepancy between biological and chronological age, with accelerated aging in these organs correlating with poorer cognitive outcomes. These findings highlight the multisystem contributions to cognition, emphasizing that cognitive decline is not solely brain-related but also influenced by vascular (artery), immune, and systemic (organismal) aging processes.</p><p id="para0037">Artery age was most strongly associated with cognitive decline. Aging arteries undergo stiffening and structural changes, leading to higher blood pressure and reduced blood flow, which impair oxygen and nutrient delivery to the brain. This is particularly relevant due to the role of systolic hypertension and endothelial dysfunction, which contribute to cognitive decline and increase the risk of conditions such as vascular dementia [<xref rid="bib0040" ref-type="bibr">40</xref>]. In contrast, ADCS-ADL results suggested that functional impairment may involve additional factors beyond those driving cognitive decline. Notably, liver, arterial, and muscle-related factors also played a role in ADCS-ADL outcomes, highlighting the multifactorial nature of functional decline. This underscores the importance of considering both vascular and systemic influences when evaluating functional impairment.</p><p id="para0038">Only the cognition-enriched brain AgeGap z-score was associated with the ADCS-ADL-Study Partner score, suggesting that further investigation is needed to explore its role in the progression of functional decline. This underscores the importance of including study partners in assessments to provide a more comprehensive understanding of cognitive decline [<xref rid="bib0041" ref-type="bibr">41</xref>]. Our study observed interactions between proteomic aging patterns and risk factors for cognition, with different effects noted in high-risk groups for A&#946;+ pathology, APOE &#949;4 carriers, obesity, hypertension, and education. These patterns highlight important associations that will inform ongoing investigations into cognitive outcomes in vulnerable populations. Specifically, the effects of A&#946;+ pathology and APOE &#949;4 carrier status were significant, with differing patterns of association with cognitive outcomes. These findings suggest that these AD markers may play a critical role in understanding the broader context of cognition.</p><sec id="sec0022"><label>4.1</label><title>Proteomic aging clocks and neurodegeneration</title><p id="para0039">Our study investigated the application of proteomic aging clocks to AD and other age-related neurodegenerative diseases, focusing on their potential as biomarkers for cognitive health assessment. The observed strong-to-moderate correlation between organ-specific biological ages and chronological age suggests that proteomic data may help identify individuals at risk for neurodegenerative diseases, such as Alzheimer's, before cognitive decline becomes clinically apparent. Previous research supports this, including the cognition-optimized aging model by Oh et al. (2003), which was trained using the CDR-GS), feature importance for biological aging (FIBA) and brain-specific proteins. In the Knight-ADRC cohort, the Cognition-Brain AgeGap showed a stronger association with AD [<xref rid="bib0017" ref-type="bibr">17</xref>]. However, in our study, cognition-enriched clocks did not significantly contribute to the findings, likely due to differences in the CDR status of the study population. Argentieri et al. (2004) tested the associations between Olink-based proteomic age and incidence of 18 chronic diseases, finding the strongest associations with AD and dementia [<xref rid="bib0015" ref-type="bibr">15</xref>]. Casanova et al. (2024) further demonstrated that MRI-based brain age correlates with cognitive health, aging, risks for mortality, and chronic diseases, while also having a significant impact on the proteome [<xref rid="bib0042" ref-type="bibr">42</xref>]. This aligns with our findings, where the AgeGap measures significantly correlated with neurodegeneration, reinforcing their potential for early detection and monitoring. Recent advancements in the UK Biobank highlight how multi-organ aging processes contribute to neurodegenerative risk [<xref rid="bib0043" ref-type="bibr">43</xref>]. Identifying proteins associated with the brain AgeGap opens new research directions into brain aging and neurodegenerative diseases [<xref rid="bib0042" ref-type="bibr">42</xref>].</p></sec><sec id="sec0023"><label>4.2</label><title>Future directions</title><p id="para0040">Our findings suggest that proteomic aging signatures may reflect broader systemic and vascular aging processes beyond APOE &#949;4 and amyloid, tau, and neurodegeneration (ATN), complementing traditional biomarkers and offering insights into cognitive vulnerability [<xref rid="bib0014" ref-type="bibr">14</xref>]. These signals may also capture APOE-independent aging processes and help identify at-risk individuals without a genetic predisposition. The weaker associations observed in APOE &#949;4 carriers may result from ceiling effects or reduced variability caused by the strong genetic influence [<xref rid="bib0044" ref-type="bibr">44</xref>], underscoring the need for future research on the role of aging clocks across genetic subgroups and within established AD pathways to improve risk prediction and mechanistic insight.</p><p id="para0041">This aligns with research identifying plasma proteomic signatures such as GDF-15 and NT-pro-BNP as predictors of morbidity and longevity, highlighting the value of proteomic clocks in aging research [<xref rid="bib0008" ref-type="bibr">8</xref>]. Building on this, we explore organ-specific biomarkers for early neurodegenerative disease detection. Our findings support the role of proteomic aging models in assessing organ age and identifying individuals at risk for cognitive decline, though effect sizes were small, requiring further refinement and validation. Future research should standardize methodologies, ensure biomarker reliability, and integrate multi-omics for broader clinical use, particularly in memory clinics and primary care, to improve targeted interventions <xref rid="bib0029" ref-type="bibr">[29]</xref>, <xref rid="bib0045" ref-type="bibr">[45]</xref>.</p><p id="para0042">Our data, along with findings from other studies, suggest that proteomic age can be tracked longitudinally, enabling the modeling of individual aging trajectories and the early detection of deviations. Although these clocks were trained on cross-sectional data, they show promise in longitudinal applications. However, limitations such as dropout bias and neurobiological variability must be considered. Investigating discordant or dynamic biological aging trajectories may provide valuable insights into aging heterogeneity and its relationship to disease risk, thereby improving the sensitivity of aging clocks in distinguishing pathological from healthy aging [<xref rid="bib0046" ref-type="bibr">46</xref>]. To fully realize this potential, longitudinal studies must address proteomic changes over time and account for batch effects [<xref rid="bib0047" ref-type="bibr">47</xref>], while the standardization of biomarker analyses is essential for cross-study comparisons. Artificial intelligence and machine learning offer promising tools for biomarker discovery and aging therapeutics, although challenges related to data diversity, model robustness, and ethical considerations remain [<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0048" ref-type="bibr">48</xref>]. In addition, a deeper understanding of how organ health influences dementia risk, and how organ function can mitigate this risk, is crucial for translating these insights into clinical practice [<xref rid="bib0049" ref-type="bibr">49</xref>]. To advance clinical utility, future efforts should prioritize refining biomarker panels, incorporating measures of biological resilience, conducting age-adjusted analyses, validating these tools across diverse populations and care settings [<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0050" ref-type="bibr">50</xref>], and addressing challenges in proteomic assays, such as orthogonal validation and absolute quantification.</p><p id="para0043">Integrating biological age assessments into clinical workflows could transform early diagnosis and management, aligning with the NHS England Dementia Diagnostic and Treatment Pathway (2024) [<xref rid="bib0051" ref-type="bibr">51</xref>]. Further exploration of arterial health&#8217;s influence on cognitive function may reveal novel strategies for prevention and intervention, emphasizing the importance of regular screening, lifestyle modification, and risk factor monitoring. Ultimately, this line of research may support improved patient classification, management, and clinical care across age groups without prior treatment.</p><p id="para0044">Advancements in biological age assessments and proteomic technologies offer deeper insights into aging and age-related diseases, enabling targeted interventions [<xref rid="bib0004" ref-type="bibr">4</xref>]. Trials like the Targeting Aging by Metformin (TAME), focused on modifying biological age, could enhance preventive measures in aging populations [<xref rid="bib0052" ref-type="bibr">52</xref>]. Studies suggest that a multibiomarker index of biological age correlates more strongly with worsening depressive symptoms and mortality than chronological age [<xref rid="bib0053" ref-type="bibr">53</xref>,<xref rid="bib0054" ref-type="bibr">54</xref>], reinforcing the advantage of multifaceted biomarkers over single markers. These findings contribute to understanding AD, particularly in early detection and intervention, though direct application to early AD diagnosis may be premature.</p><sec id="sec0024"><label>4.2.1</label><title>Strengths and limitations</title><p id="para0045">Our study leverages proteomic data to assess organ aging, providing in-depth insights into aging processes compared to traditional aging clocks or clinical markers. Protein annotations in organ-specific aging clocks remain putative, reflecting uncertainties regarding blood-brain barrier permeability and its role in neurodegeneration [<xref rid="bib0055" ref-type="bibr">55</xref>]. A key strength is the use of repeated protein measures, enabling the testing of clock performance in a longitudinal setting. The CHARIOT PRO SubStudy benefits from high-quality clinical data, regular assessments, and standard study monitoring, including compliance checks, source verification, and quality assurance audits [<xref rid="bib0020" ref-type="bibr">20</xref>]. The inclusion of multiple cognitive assessments strengthens evaluation accuracy and reduces measurement bias. By modeling and removing practice effects from cognitive scores, we demonstrated that the outcomes are robust, with learning effects likely minimal.</p><p id="para0046">Cross-sectional and longitudinal analyses were validated using multiple analytic methods, including multilevel mixed-effects linear regression with bootstrap inference. Our well-characterized cohort of cognitively healthy older adults (96 % White European), with relatively favorable sociodemographic conditions, facilitates early biomarker investigation but limits the inclusion of individuals with extreme organ-specific biological discrepancies. Suhre et al. (2017) reported that common medications can affect the plasma proteome [<xref rid="bib0056" ref-type="bibr">56</xref>]. Although medication data were unavailable, we examined the impact of baseline medical conditions and clinical variables on AgeGaps. Associations were generally limited, except for lung- and kidney-related histories. However, unmeasured factors such as lifestyle, genetics, and complex interactions may obscure true relationships [<xref rid="bib0057" ref-type="bibr">57</xref>]. Future studies in larger and more diverse cohorts are warranted to clarify these links. Additionally, the absence of full genetic data limited control for population structure via genetic principal components. Enriching A&#946;-positive individuals enables a focused examination of AD-related processes but may limit result applicability to diverse aging populations [<xref rid="bib0058" ref-type="bibr">58</xref>]. Future studies should address demographic constraints to enhance external validity, including external validation using multi-cohort datasets, such as those from the Global Neurodegeneration Proteomics Consortium (GNPC).</p></sec></sec><sec id="sec0025"><label>4.3</label><title>Conclusion</title><p id="para0047">Assessing organ-specific biological age holds significant potential for early detection of age-related changes, including neurocognitive decline, and supports preventive and treatment-based personalized interventions. Our study underscores the importance of understanding proteomic aging patterns and their impact on cognitive health. Conventional, organismal, immune, and brain organ ages demonstrated their importance, with arterial age showing the strongest association with cognitive decline.</p><p id="para0048">Proteomic approaches in aging research hold promise for improving health outcomes and healthcare practices. By distinguishing biological from chronological age, leveraging advanced analytical methods, and addressing existing challenges, we can develop more effective aging interventions. The focus on organ-specific biological age in this study highlights its potential to predict age-related cognitive decline and enable personalized approaches to prevention, diagnosis, and management, ultimately reducing the burden of age-related disease and improving health expectancy.</p></sec></sec><sec id="sec0026"><title>Funding</title><p id="para0049">The CHARIOT PRO SubStudy was made possible through funding from Janssen Research &amp; Development, LLC, Merck, Takeda, and Gates Ventures to Imperial College London. SK received support as an NIHR ARC Dementia Fellow (NIHR200180), and OR was supported by a UKRI Future Leaders Fellowship (MR/S03532X/1, MR/Y02012X/1). LTM has received funding (to the institution) from Janssen Research &amp; Development, LLC, Merck &amp; Co., Inc., Takeda, Gates Ventures, NIHR, UKRI, and the Davos Alzheimer&#8217;s Collaborative (DAC).</p></sec><sec id="sec0026a"><title>CRediT authorship contribution statement</title><p id="para0049a"><bold>Sujin Kang:</bold> Writing &#8211; review &amp; editing, Visualization, Software, Formal analysis, Conceptualization, Writing &#8211; original draft, Validation, Methodology, Data curation. <bold>Susan Baker:</bold> Data curation. <bold>Benedict Hayhoe:</bold> Writing &#8211; review &amp; editing. <bold>Geraint Price:</bold> Writing &#8211; review &amp; editing. <bold>Gerald Novak:</bold> Writing &#8211; review &amp; editing. <bold>Janice Wong:</bold> Writing &#8211; review &amp; editing. <bold>Lefkos Middleton:</bold> Writing &#8211; review &amp; editing, Funding acquisition, Resources. <bold>Oliver Robinson:</bold> Supervision, Methodology, Writing &#8211; review &amp; editing, Resources, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of conflicting interest</title><p id="para0052">The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Beard</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>The World report on ageing and health: a policy framework for healthy ageing</article-title><source>Lancet</source><volume>387</volume><issue>10033</issue><year>2016</year><fpage>2145</fpage><lpage>2154</lpage><pub-id pub-id-type="pmid">26520231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)00516-4</pub-id><pub-id pub-id-type="pmcid">PMC4848186</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Aging and aging-related diseases: from molecular mechanisms to interventions and treatments</article-title><source>Signal Transd Targeted Therapy</source><volume>7</volume><issue>1</issue><year>2022</year><fpage>391</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-01251-0</pub-id><pub-id pub-id-type="pmcid">PMC9755275</pub-id><pub-id pub-id-type="pmid">36522308</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Gonzales</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Biological aging processes underlying cognitive decline and neurodegenerative disease</article-title><source>J Clin Invest</source><issue>10</issue><year>2022</year><fpage>132</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI158453</pub-id><pub-id pub-id-type="pmcid">PMC9106343</pub-id><pub-id pub-id-type="pmid">35575089</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Ferrucci</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Time and the metrics of aging</article-title><source>Circ Res</source><volume>123</volume><issue>7</issue><year>2018</year><fpage>740</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">30355074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.118.312816</pub-id><pub-id pub-id-type="pmcid">PMC6205734</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Maudsley</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Bioinformatic approaches to metabolic pathways analysis</article-title><source>Signal Transd Protocols</source><year>2011</year><fpage>99</fpage><lpage>130</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-61779-160-4_5</pub-id><pub-id pub-id-type="pmcid">PMC4698828</pub-id><pub-id pub-id-type="pmid">21870222</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Maretty</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Proteomic changes upon treatment with semaglutide in individuals with obesity</article-title><source>Nat Med</source><volume>31</volume><issue>1</issue><year>2025</year><fpage>267</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">39753963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03355-2</pub-id><pub-id pub-id-type="pmcid">PMC11750704</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="book" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>H.S.-H.</given-names></name></person-group><part-title>Deciphering human aging and neurodegeneration with large-scale fluid proteomics</part-title><year>2024</year><publisher-name>Stanford University</publisher-name></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Methods and clinical biomarker discovery for targeted proteomics using Olink technology</article-title><source>Proteomics &#8211; Clin Appl,</source><volume>18</volume><issue>5</issue><year>2024</year><object-id pub-id-type="publisher-id">2300233</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prca.202300233</pub-id><pub-id pub-id-type="pmid">38726756</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Austin</surname><given-names>T.R.</given-names></name><etal/></person-group><article-title>A plasma protein-based risk score to predict hip fractures</article-title><source>Nature Aging (Albany NY)</source><volume>4</volume><issue>8</issue><year>2024</year><fpage>1064</fpage><lpage>1075</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-024-00639-7</pub-id><pub-id pub-id-type="pmcid">PMC11333168</pub-id><pub-id pub-id-type="pmid">38802582</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Plasma proteomic profiles predict future dementia in healthy adults</article-title><source>Nature Aging (Albany NY)</source><volume>4</volume><issue>2</issue><year>2024</year><fpage>247</fpage><lpage>260</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00565-0</pub-id><pub-id pub-id-type="pmid">38347190</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Plasma proteomic signature of age in healthy humans</article-title><source>Aging (Albany NY) Cell</source><volume>17</volume><issue>5</issue><year>2018</year><object-id pub-id-type="publisher-id">e12799</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.12799</pub-id><pub-id pub-id-type="pmcid">PMC6156492</pub-id><pub-id pub-id-type="pmid">29992704</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>C.-L.</given-names></name><etal/></person-group><article-title>Proteomic aging clock (PAC) predicts age-related outcomes in middle-aged and older adults</article-title><source>Aging (Albany NY) Cell</source><volume>23</volume><issue>8</issue><year>2024</year><object-id pub-id-type="publisher-id">e14195</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.14195</pub-id><pub-id pub-id-type="pmcid">PMC11320350</pub-id><pub-id pub-id-type="pmid">38747160</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Sathyan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Plasma proteomic profile of age, health span, and all-cause mortality in older adults</article-title><source>Aging (Albany NY) Cell</source><volume>19</volume><issue>11</issue><year>2020</year><object-id pub-id-type="publisher-id">e13250</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13250</pub-id><pub-id pub-id-type="pmcid">PMC7681045</pub-id><pub-id pub-id-type="pmid">33089916</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Lehallier</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Undulating changes in human plasma proteome profiles across the lifespan</article-title><source>Nat Med</source><volume>25</volume><issue>12</issue><year>2019</year><fpage>1843</fpage><lpage>1850</lpage><pub-id pub-id-type="pmid">31806903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-019-0673-2</pub-id><pub-id pub-id-type="pmcid">PMC7062043</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Argentieri</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Proteomic aging clock predicts mortality and risk of common age-related diseases in diverse populations</article-title><source>Nat Med</source><year>2024</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">39117878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03164-7</pub-id><pub-id pub-id-type="pmcid">PMC11405266</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Plasma proteomic biomarker signature of age predicts health and life span</article-title><source>eLife</source><year>2020</year><fpage>9</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.61073</pub-id><pub-id pub-id-type="pmcid">PMC7723412</pub-id><pub-id pub-id-type="pmid">33210602</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>H.S.-H.</given-names></name><etal/></person-group><article-title>Organ aging signatures in the plasma proteome track health and disease</article-title><source>Nature</source><volume>624</volume><issue>7990</issue><year>2023</year><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">38057571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06802-1</pub-id><pub-id pub-id-type="pmcid">PMC10700136</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Rutledge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name></person-group><article-title>Measuring biological age using omics data</article-title><source>Nat Rev Genet</source><volume>23</volume><issue>12</issue><year>2022</year><fpage>715</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">35715611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-022-00511-7</pub-id><pub-id pub-id-type="pmcid">PMC10048602</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Moqri</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Validation of biomarkers of aging</article-title><source>Nat Med</source><volume>30</volume><issue>2</issue><year>2024</year><fpage>360</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">38355974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02784-9</pub-id><pub-id pub-id-type="pmcid">PMC11090477</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Lefkos Middleton</surname><given-names>M.K.</given-names></name></person-group><article-title>Cognitive health in ageing register: investigational, observational, and Trial studies in dementia research (CHARIOT): prospective readiness cOhort study(PRO) - clinical protocol</article-title><source>Janssen Research &amp; Development</source><year>2022</year></element-citation></ref><ref id="bib0021"><label>21</label><mixed-citation publication-type="other" id="sbref0021">SomaLogic, I. SomaScan&#174; Assay v4.1. 2022 (SL00000572 Rev 4: 2022&#8211;01).</mixed-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Plasma proteomic signature of human longevity</article-title><source>Aging (Albany NY) Cell</source><volume>23</volume><issue>6</issue><year>2024</year><object-id pub-id-type="publisher-id">e14136</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.14136</pub-id><pub-id pub-id-type="pmcid">PMC11166369</pub-id><pub-id pub-id-type="pmid">38440820</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="book" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>SomaLogic</surname><given-names>I.</given-names></name></person-group><part-title>SomaScan&#174; quality statement</part-title><year>2021</year><publisher-name>SomaLogic, Inc</publisher-name></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Karpievitch</surname><given-names>Y.V.</given-names></name><etal/></person-group><article-title>Normalization of peak intensities in bottom-up MS-based proteomics using singular value decomposition</article-title><source>Bioinformatics</source><volume>25</volume><issue>19</issue><year>2009</year><fpage>2573</fpage><lpage>2580</lpage><pub-id pub-id-type="pmid">19602524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btp426</pub-id><pub-id pub-id-type="pmcid">PMC2752608</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="book" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Jolliffe</surname><given-names>I.T.</given-names></name></person-group><part-title>Principal component analysis for special types of data</part-title><year>2002</year><publisher-name>Springer</publisher-name></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="book" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Health</surname><given-names>N.I.f.</given-names></name><name name-style="western"><surname>Excellence</surname><given-names>C.</given-names></name></person-group><part-title>Hypertension in adults: diagnosis and management</part-title><year>2019</year><publisher-name>National Institute for Health and Care Excellence (UK)</publisher-name><publisher-loc>London</publisher-loc></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Pannee</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Reference measurement procedure for CSF amyloid beta (A&#946;)(1-42) and the CSF a&#946;(1-42) /a&#946;(1-40) ratio - a cross-validation study against amyloid PET</article-title><source>J Neurochem</source><volume>139</volume><issue>4</issue><year>2016</year><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">27579672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.13838</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Udeh-Momoh</surname><given-names>C.T.</given-names></name><etal/></person-group><article-title>Protocol of the cognitive health in ageing Register: investigational, observational and Trial studies in dementia research (CHARIOT): prospective readiness cOhort (PRO) SubStudy</article-title><source>BMJ Open</source><volume>11</volume><issue>6</issue><year>2021</year><object-id pub-id-type="publisher-id">e043114</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2020-043114</pub-id><pub-id pub-id-type="pmcid">PMC8230926</pub-id><pub-id pub-id-type="pmid">34168021</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="book" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Randolph</surname><given-names>C.</given-names></name></person-group><part-title>Repeatable battery for the assessment of neuropsychological status (RBANS)</part-title><year>1998</year><publisher-name>Psychological Corporation</publisher-name><publisher-loc>San Antonio, TX</publisher-loc></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Randolph</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity</article-title><source>J Clin Exp Neuropsychol</source><volume>20</volume><issue>3</issue><year>1998</year><fpage>310</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">9845158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1076/jcen.20.3.310.823</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Bransby</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Sensitivity of a preclinical Alzheimer&#8217;s Cognitive composite (PACC) to amyloid &#946; load in preclinical Alzheimer&#8217;s disease</article-title><source>J Clin Exp Neuropsychol</source><volume>41</volume><issue>6</issue><year>2019</year><fpage>591</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">30924399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13803395.2019.1593949</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="book" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Galasko</surname><given-names>D.</given-names></name><etal/></person-group><series>ADCS prevention instrument project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials</series><volume>20</volume><year>2006</year><publisher-name>Alzheimer Disease &amp; Associated Disorders</publisher-name><fpage>S152</fpage><lpage>S169</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.wad.0000213873.25053.2b</pub-id><pub-id pub-id-type="pmid">17135809</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><mixed-citation publication-type="other" id="sbref0033">Malm, T., 8th Kuopio Alzheimer Symposium: from translational research to biomarkers, treatment and prevention strategies. 2018.</mixed-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>J.C.</given-names></name></person-group><article-title>Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type</article-title><source>Int Psychogeriatr</source><volume>9</volume><issue>S1</issue><year>1997</year><fpage>173</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">9447441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/s1041610297004870</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="book" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Searle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cassella</surname><given-names>G.</given-names></name><name name-style="western"><surname>McCullouch</surname><given-names>C.</given-names></name></person-group><part-title>Variance components</part-title><year>1992</year><publisher-name>Jonh Wiley-Sons</publisher-name><publisher-loc>New-York</publisher-loc><pub-id pub-id-type="doi">10.1002/9780470316856</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Krieger</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Use of correct and incorrect methods of accounting for age in studies of epigenetic accelerated aging: implications and recommendations for best practices</article-title><source>Am J Epidemiol</source><volume>192</volume><issue>5</issue><year>2023</year><fpage>800</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">36721372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwad025</pub-id><pub-id pub-id-type="pmcid">PMC10160768</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Migliavaca</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Meta-analysis of prevalence: statistic and how to deal with heterogeneity</article-title><source>Res Synth Methods</source><volume>13</volume><issue>3</issue><year>2022</year><fpage>363</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">35088937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jrsm.1547</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="book" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>J.</given-names></name></person-group><part-title>Statistical power analysis for the behavioral sciences</part-title><year>1988</year><publisher-name>L. Erlbaum Associates</publisher-name></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Organization</surname><given-names>W.H.</given-names></name></person-group><source>Obesity: preventing and managing the global epidemic: report of a WHO consultation</source><year>2000</year><pub-id pub-id-type="pmid">11234459</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>L.J.</given-names></name></person-group><article-title>Functional, structural and proteomic effects of ageing in resistance arteries</article-title><source>Int J Mol Sci</source><volume>25</volume><issue>5</issue><year>2024</year><fpage>2601</fpage><pub-id pub-id-type="pmid">38473847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25052601</pub-id><pub-id pub-id-type="pmcid">PMC10932216</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Munro</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>Longitudinal trajectories of participant-and study partner-rated cognitive decline, in relation to Alzheimer&#8217;s disease biomarkers and mood symptoms</article-title><source>Front (Boulder) Front Aging Neurosci</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">806432</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.806432</pub-id><pub-id pub-id-type="pmcid">PMC8841868</pub-id><pub-id pub-id-type="pmid">35173601</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Casanova</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Associations of plasma proteomics and age-related outcomes with brain age in a diverse cohort</article-title><source>Gero Sci</source><volume>46</volume><issue>4</issue><year>2024</year><fpage>3861</fpage><lpage>3873</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11357-024-01112-4</pub-id><pub-id pub-id-type="pmcid">PMC11226584</pub-id><pub-id pub-id-type="pmid">38438772</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Prattichizzo</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Organ-specific biological clocks: ageotyping for personalized anti-aging medicine</article-title><source>Ageing Res Rev</source><volume>96</volume><year>2024</year><object-id pub-id-type="publisher-id">102253</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2024.102253</pub-id><pub-id pub-id-type="pmid">38447609</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Apolipoprotein E &#603;4&#8211;related effects on cognition are limited to the Alzheimer&#8217;s disease spectrum</article-title><source>Geroscience</source><volume>44</volume><issue>1</issue><year>2022</year><fpage>195</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">34591236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11357-021-00450-x</pub-id><pub-id pub-id-type="pmcid">PMC8811053</pub-id></element-citation></ref><ref id="bib0045"><label>45</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Galkin</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Biohorology and biomarkers of aging: current state-of-the-art, challenges and opportunities</article-title><source>Ageing Res Rev</source><volume>60</volume><year>2020</year><object-id pub-id-type="publisher-id">101050</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2020.101050</pub-id><pub-id pub-id-type="pmid">32272169</pub-id></element-citation></ref><ref id="bib0046"><label>46</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Shaaban</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>Discordant biological and chronological age: implications for cognitive decline and frailty</article-title><source>J Gerontol: Series A</source><volume>78</volume><issue>11</issue><year>2023</year><fpage>2152</fpage><lpage>2161</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glad174</pub-id><pub-id pub-id-type="pmcid">PMC10613009</pub-id><pub-id pub-id-type="pmid">37480573</pub-id></element-citation></ref><ref id="bib0047"><label>47</label><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Suhre</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>B.W.</given-names></name></person-group><article-title>Promises and challenges of populational proteomics in health and disease</article-title><source>Mol Cell Proteomics</source><volume>23</volume><issue>7</issue><year>2024</year><object-id pub-id-type="publisher-id">100786</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcpro.2024.100786</pub-id><pub-id pub-id-type="pmcid">PMC11193116</pub-id><pub-id pub-id-type="pmid">38761890</pub-id></element-citation></ref><ref id="bib0048"><label>48</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Ubaida-Mohien</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Proteomics and epidemiological models of Human aging</article-title><source>Front Physiol</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">674013</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2021.674013</pub-id><pub-id pub-id-type="pmcid">PMC8202502</pub-id><pub-id pub-id-type="pmid">34135771</pub-id></element-citation></ref><ref id="bib0049"><label>49</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>E.E.</given-names></name><etal/></person-group><article-title>Systemic determinants of brain health in ageing</article-title><source>Nat Rev Neurol</source><year>2024</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-024-01016-z</pub-id><pub-id pub-id-type="pmcid">PMC11926994</pub-id><pub-id pub-id-type="pmid">39375564</pub-id></element-citation></ref><ref id="bib0050"><label>50</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Plasma protein patterns as comprehensive indicators of health</article-title><source>Nat Med</source><volume>25</volume><issue>12</issue><year>2019</year><fpage>1851</fpage><lpage>1857</lpage><pub-id pub-id-type="pmid">31792462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-019-0665-2</pub-id><pub-id pub-id-type="pmcid">PMC6922049</pub-id></element-citation></ref><ref id="bib0051"><label>51</label><element-citation publication-type="book" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Claire Murdoch</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Health</surname><given-names>Mental</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>John</given-names></name></person-group><part-title>National director of specialised commissioning, dementia programme and preparation for new alzheimer&#8217;s disease modifying treatments</part-title><year>2024</year><publisher-name>NHS England</publisher-name></element-citation></ref><ref id="bib0052"><label>52</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gubbi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barzilai</surname><given-names>N.</given-names></name></person-group><article-title>Benefits of metformin in attenuating the hallmarks of</article-title><source>Aging. Cell Metabolism</source><volume>32</volume><issue>1</issue><year>2020</year><fpage>15</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">32333835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2020.04.001</pub-id><pub-id pub-id-type="pmcid">PMC7347426</pub-id></element-citation></ref><ref id="bib0053"><label>53</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Biological age, not chronological age, is associated with late-life depression</article-title><source>J Gerontol: Series A</source><volume>73</volume><issue>10</issue><year>2017</year><fpage>1370</fpage><lpage>1376</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glx162</pub-id><pub-id pub-id-type="pmcid">PMC6132120</pub-id><pub-id pub-id-type="pmid">28958059</pub-id></element-citation></ref><ref id="bib0054"><label>54</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>M.E.</given-names></name></person-group><article-title>Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age?</article-title><source>J Gerontol A Biol Sci Med Sci</source><volume>68</volume><issue>6</issue><year>2013</year><fpage>667</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">23213031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/gls233</pub-id><pub-id pub-id-type="pmcid">PMC3660119</pub-id></element-citation></ref><ref id="bib0055"><label>55</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Pluvinage</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name></person-group><article-title>Systemic factors as mediators of brain homeostasis, ageing and neurodegeneration</article-title><source>Nat Rev Neurosci</source><volume>21</volume><issue>2</issue><year>2020</year><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">31913356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41583-019-0255-9</pub-id></element-citation></ref><ref id="bib0056"><label>56</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Suhre</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Connecting genetic risk to disease end points through the human blood plasma proteome</article-title><source>Nat Commun</source><volume>8</volume><issue>1</issue><year>2017</year><object-id pub-id-type="publisher-id">14357</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms14357</pub-id><pub-id pub-id-type="pmcid">PMC5333359</pub-id><pub-id pub-id-type="pmid">28240269</pub-id></element-citation></ref><ref id="bib0057"><label>57</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Seals</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Justice</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>LaRocca</surname><given-names>T.J.</given-names></name></person-group><article-title>Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity</article-title><source>J. Physiol. (Lond.)</source><volume>594</volume><issue>8</issue><year>2016</year><fpage>2001</fpage><lpage>2024</lpage><pub-id pub-id-type="pmid">25639909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/jphysiol.2014.282665</pub-id><pub-id pub-id-type="pmcid">PMC4933122</pub-id></element-citation></ref><ref id="bib0058"><label>58</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>W.J.</given-names></name><etal/></person-group><article-title>Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum</article-title><source>JAMA Neurol</source><volume>79</volume><issue>3</issue><year>2022</year><fpage>228</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">35099509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2021.5216</pub-id><pub-id pub-id-type="pmcid">PMC12138908</pub-id></element-citation></ref></ref-list><sec id="sec0029" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0050a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgements</title><p id="para0053">The authors wish to thank the participants who continue to volunteer their time and commitment to the CHARIOT PRO SubStudy. We also extend our thanks to the clinical, research, and operational staff for their assistance in collecting biological, cognitive, and other clinical data. We are grateful to Janssen Pharmaceuticals for their financial and technical support throughout the study, and for funding of the Somascan assays. We also thank to Merck, Takeda, and Gates Ventures for their financial support, which enabled the study extension and the neuroimaging sub-study in years 2021 to 2024. We appreciate the support of the National Institute for Health Research (NIHR) under the Applied Health Research (ARC) programme for North West London. This article presents independent research commissioned by the NIHR under ARC Northwest London. The views expressed in this publication are those of the authors and not necessarily those of the funders, NHS, the NIHR, or the Department of Health.</p></ack><fn-group><fn id="sec0028" fn-type="supplementary-material"><p id="para0005a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100274" id="interref0002">doi:10.1016/j.tjpad.2025.100274</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501337</article-id><article-id pub-id-type="pmcid-ver">PMC12501337.1</article-id><article-id pub-id-type="pmcaid">12501337</article-id><article-id pub-id-type="pmcaiid">12501337</article-id><article-id pub-id-type="pmid">40817009</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100323</article-id><article-id pub-id-type="pii">S2274-5807(25)00266-3</article-id><article-id pub-id-type="publisher-id">100323</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group></article-categories><title-group><article-title>A novel early imaging biomarker for glymphatic function: Cerebral cortical arterial pulsatility index from 2-Minute phase-contrast MRI</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>You</surname><given-names initials="SH">Sung-Hye</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Kim</surname><given-names initials="B">Byungjun</given-names></name><email>bj1492.kim@gmail.com</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Hwang</surname><given-names initials="M">Moonjung</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Yang</surname><given-names initials="KS">Kyung-Sook</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Park</surname><given-names initials="HW">Hye-Won</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Kim</surname><given-names initials="I">InSeong</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Kim</surname><given-names initials="S">SuGil</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Kim</surname><given-names initials="KM">Kyung Min</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0009"><name name-style="western"><surname>Kim</surname><given-names initials="BK">Bo Kyu</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Shin</surname><given-names initials="JH">Jae Ho</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><aff id="aff0001"><label>a</label>Department of Radiology, Anam Hospital, Korea University College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</aff><aff id="aff0002"><label>b</label>Department of Biostatistics, Korea University College of Medicine, Republic of Korea</aff><aff id="aff0003"><label>c</label>Siemens Healthineers, Republic of Korea</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author. <email>bj1492.kim@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>8</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100323</elocation-id><history><date date-type="received"><day>11</day><month>6</month><year>2025</year></date><date date-type="rev-recd"><day>22</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><sec><title>Background</title><p>Arterial pulsatility is one of the driving forces of glymphatic flow.</p></sec><sec><title>Objectives</title><p>To evaluate the feasibility of the pulsatility index (PI) of cortical arteries in the centrum semiovale (PI<sub>CSO</sub>) as a novel non-invasive imaging biomarker for Alzheimer&#8217;s disease (AD) in the context of glymphatic function.</p></sec><sec><title>Design</title><p>Retrospective cross-sectional study.</p></sec><sec><title>Setting</title><p>Single tertiary academic center equipped with both 3.0 T MRI systems.</p></sec><sec><title>Participants</title><p>A total of 160 individuals were enrolled: 50 healthy volunteers, 46 cognitively normal controls, and 64 AD patients who underwent diffusion tensor imaging (DTI) and 2D phase-contrast MRI.</p></sec><sec><title>Measurements</title><p>Diffusion Tensor Imaging Analysis along the Perivascular Space (DTI-ALPS) index and PI<sub>CSO</sub> were assessed using 2D phase-contrast MRI. Correlations with age, DTI-ALPS index, and Mini-Mental State Examination (MMSE) scores were analyzed.</p></sec><sec><title>Results</title><p>PI<sub>CSO</sub> was significantly higher in the AD group than those in healthy volunteers (P&lt;0.001) and cognitively normal aging (P=0.001) groups. PI<sub>CSO</sub> correlated positively with age (rho=0.613, P&lt;0.001) and negatively with both the DTI-ALPS index (rho=-0.439, P&lt;0.001) and MMSE scores (rho=-0.486, P&lt;0.001) in total group.</p></sec><sec><title>Conclusion</title><p>PI<sub>CSO</sub> derived from 2D phase-contrast 3.0T MRI may serve as a novel imaging biomarker for Alzheimer&#8217;s disease in relation to glymphatic function.</p></sec></abstract><abstract abstract-type="graphical" id="abs0002"><title>Graphical abstract</title><p><fig id="fig0005" position="anchor" orientation="portrait"><alt-text id="alttx001">Image, graphical abstract</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0005" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>2D Phase-contrast MRI</kwd><kwd>Pulsatility index</kwd><kwd>Glymphatics</kwd><kwd>Alzheimer&#8217;s disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="para9001">
<def-list><title>Abbreviations</title><def-item><term id="dt0001">AD</term><def><p id="para0009">Alzheimer&#8217;s disease</p></def></def-item><def-item><term id="dt0002">CDR-SB</term><def><p id="para0010">clinical dementia rating sum of boxes</p></def></def-item><def-item><term id="dt0003">CSO</term><def><p id="para0011">centrum semiovale</p></def></def-item><def-item><term id="dt0004">DTI-ALPS</term><def><p id="para0012">diffusion tensor image analysis along the perivascular space</p></def></def-item><def-item><term id="dt0005">MMSE</term><def><p id="para0013">Mini-Mental State Examination</p></def></def-item><def-item><term id="dt0006">PI</term><def><p id="para0014">pulsatility index</p></def></def-item><def-item><term id="dt0007">PI<sub>CSO</sub></term><def><p id="para0015">pulsatility index of cortical artery in centrum semiovale level</p></def></def-item><def-item><term id="dt0008">SNSB-II</term><def><p id="para0016">Seoul Neuropsychological Screening Battery-II</p></def></def-item><def-item><term id="dt0009">PC-MRI</term><def><p id="para0017">phase-contrast magnetic resonance imaging</p></def></def-item></def-list>
</p><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0018">Over the past two decades, several studies have proposed that cerebral small vessel pathologies may negatively impact on cognitive function [<xref rid="bib0001" ref-type="bibr">[1]</xref>, <xref rid="bib0002" ref-type="bibr">[2]</xref>, <xref rid="bib0003" ref-type="bibr">[3]</xref>, <xref rid="bib0004" ref-type="bibr">[4]</xref>], and related imaging parameters have attracted attention as early imaging biomarkers of neurodegeneration [<xref rid="bib0005" ref-type="bibr">[5]</xref>, <xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>]. Recently, several studies have demonstrated a correlation between cerebral arterial wall stiffness and cognitive impairment [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0008" ref-type="bibr">[8]</xref>, <xref rid="bib0009" ref-type="bibr">[9]</xref>, <xref rid="bib0010" ref-type="bibr">[10]</xref>]. Although the exact underlying mechanism remains unclear, one plausible explanation is that the pulsation of small perforating arteries plays a crucial role as a driving force for glymphatic flow [<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0011" ref-type="bibr">11</xref>,<xref rid="bib0012" ref-type="bibr">12</xref>]. Reduced clearance of amyloid-beta due to impaired glymphatic flow resulting from vascular stiffness may increase the risk of Alzheimer&#8217;s disease (AD) [<xref rid="bib0011" ref-type="bibr">11</xref>].</p><p id="para0019">While MRI following intrathecal contrast administration or serial imaging after intravenous contrast injection represents the most accurate method for assessing glymphatic function, the inherent invasiveness of these approaches has spurred increasing interest in the development of non-invasive MR-based alternatives. To date, the Diffusion Tensor Image Analysis along the Perivascular Space (DTI-ALPS) index, which reflects perivascular glymphatic flow, has been the most thoroughly investigated and has shown potential as an indirect imaging biomarker for estimating glymphatic function [<xref rid="bib0013" ref-type="bibr">13</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>]. In addition, several other advanced imaging sequences have been explored, targeting various aspects of the glymphatic system, including cerebrospinal fluid (CSF) flow, CSF production, aquaporin-4 (AQP4) channel activity, and meningeal lymphatic vessels [<xref rid="bib0013" ref-type="bibr">[13]</xref>, <xref rid="bib0014" ref-type="bibr">[14]</xref>, <xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>]. However, studies on glymphatic function in relation to arterial pulsation are limited. Phase-contrast magnetic resonance imaging (PC-MRI) is a widely used technique that measures flow velocity by detecting phase shifts induced by bipolar gradients [<xref rid="bib0006" ref-type="bibr">6</xref>]. The pulsatility index (PI), derived from blood flow curves, serves as an indirect indicator of vascular wall stiffness [<xref rid="bib0007" ref-type="bibr">7</xref>,<xref rid="bib0018" ref-type="bibr">18</xref>,<xref rid="bib0019" ref-type="bibr">19</xref>]. Thus, PI can theoretically be considered a glymphatic parameter in terms of the vascular driving force for glymphatic flow. Since impaired pulsatility may hinder glymphatic clearance, a lower PI could be associated with increased risk for Alzheimer&#8217;s disease and may therefore be hypothesized to be lower in the AD group.</p><p id="para0020">Nevertheless, owing to technical challenges in measuring phase shifts in small cerebral arteries, most previous PC-MRI studies on these vessels have been conducted using 7.0 T MRI [<xref rid="bib0020" ref-type="bibr">[20]</xref>, <xref rid="bib0021" ref-type="bibr">[21]</xref>, <xref rid="bib0022" ref-type="bibr">[22]</xref>, <xref rid="bib0023" ref-type="bibr">[23]</xref>, <xref rid="bib0024" ref-type="bibr">[24]</xref>, <xref rid="bib0025" ref-type="bibr">[25]</xref>, <xref rid="bib0026" ref-type="bibr">[26]</xref>, <xref rid="bib0027" ref-type="bibr">[27]</xref>, <xref rid="bib0028" ref-type="bibr">[28]</xref>]. These studies have established correlations between PI and factors such as age, intracerebral hemorrhage, hypertension, and number of perivascular spaces [<xref rid="bib0021" ref-type="bibr">[21]</xref>, <xref rid="bib0022" ref-type="bibr">[22]</xref>, <xref rid="bib0023" ref-type="bibr">[23]</xref>, <xref rid="bib0024" ref-type="bibr">[24]</xref>,<xref rid="bib0027" ref-type="bibr">27</xref>]. Given the limited accessibility of 7.0 T MRI in routine clinical practice, a few studies attempted to apply PC-MRI for cerebral arteries using 3.0 T MRI [<xref rid="bib0029" ref-type="bibr">29</xref>,<xref rid="bib0030" ref-type="bibr">30</xref>]. One study performed 3.0 T PC-MRI on the proximal internal carotid artery to reveal its correlation with cognitive impairment [<xref rid="bib0005" ref-type="bibr">5</xref>], while recent studies have explored the feasibility of using 3.0 T MRI to obtain the PI in perforating arteries within the centrum semiovale (CSO) and basal ganglia (BG) [<xref rid="bib0029" ref-type="bibr">29</xref>,<xref rid="bib0030" ref-type="bibr">30</xref>].</p><p id="para0021">In addition to demonstrating the feasibility of measuring the PI of cortical arteries using 3.0 T PC-MRI, the potential association between PI and AD, particularly in the context of glymphatic function, has not yet been investigated. Therefore, this study aimed to evaluate whether the PI of cortical arteries at the centrum semiovale level (PI<sub>CSO</sub>), derived from 3.0 T MRI, could serve as a novel, non-invasive imaging biomarker for AD in relation to glymphatic function.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><sec id="sec0003"><label>2.1</label><title>Patient selection 1: healthy volunteer (HV) group</title><p id="para0022">This prospective, single-center study was approved by the institutional review board of Korea University Anam Hospital, and informed consent was obtained from all participants. From October 2022 to December 2022, 54 healthy volunteers were enrolled and underwent 3.0 T MRI using the Magnetom Vida (Siemens Healthineers, Erlangen, Germany) (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>). The imaging protocol included three-dimensional (3D) T1-weighted imaging (T1WI), PC-MRI, and diffusion tensor imaging (DTI) sequences. Four participants were excluded due to inadequate image quality for analysis. Demographic and clinical data, including age, sex, and Mini-Mental State Examination (MMSE) scores, were collected.<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study design. Note: SNSB-II = Seoul Neuropsychological Screening Battery-II.</p></caption><alt-text id="alt0002">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec0004"><label>2.2</label><title>Patient selection 2: Neurodegeneration screening group</title><p id="para0023">This single-center, retrospective study was approved by the institutional review board of the same institution, and the requirement for informed consent was waived because of the retrospective nature of this study. From June 2023 to May 2025, a total of 484 participants underwent 3.0T brain MRI as part of a neurodegeneration screening protocol, and 239 individuals who performing both DTI and 2D PC-MRI were eligible for further analysis (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>). Among them, forty-three participants were excluded due to abnormal MRI findings, including brain tumor (n = 3), normal pressure hydrocephalus (n = 19), frontotemporal dementia (n = 6), sequelae of previous trauma (n = 6), and chronic infarction (n = 9). The remaining participants (n = 196) were classified into two groups: cognitively normal aging (MMSE 28&#8211;30, n = 53) and suspected cognitive impairment (MMSE &#8804; 27, n = 143). In the cognitively normal (CN) group, seven participants were excluded due to inadequate image quality, resulting in 46 subjects for final analysis. In the suspected cognitive impairment group, 79 participants were excluded for the following reasons: inadequate image quality (n = 8), no completion of Seoul Neuropsychological Screening Battery-II (SNSB-II) (n = 22), diagnosed with a condition other than dementia in SNSB-II (n=8), absence of amyloid PET imaging (n = 21), or negative amyloid PET results (n = 20). Ultimately, 64 participants with positive amyloid PET findings and consistent SNSB-II results were classified as having Alzheimer&#8217;s disease based on the diagnostic criteria for AD as defined by the 2011 National Institute on Aging&#8211;Alzheimer&#8217;s Association (NIA-AA) guidelines [<xref rid="bib0031" ref-type="bibr">31</xref>]. The following clinical information related to cognitive impairment was collected: age, sex, MMSE score, APOE4 genotyping results, years of education, presence of hypertension or type 2 diabetes, and SNSB-II results.</p></sec><sec id="sec0005"><label>2.3</label><title>Imaging acquisition</title><p id="para0024">MRI was performed with 3.0 T MRI scanners (Magnetom Vida, Prisma_fit, Magnetom Skyra [Siemens Healthineers, Erlangen, Germany]; Signa Premier [GE Healthcare, Milwaukee, WI, USA]; Ingenia Elition X [Philips Healthcare, Best, Netherlands]) with 64-channel head coils. The specific MRI parameters of DTI and PC-MRI sequences are listed in Supplementary Table 1. A peripheral pulse oximeter was used for cardiac gating. The target slice for PI<sub>CSO</sub> was positioned 15 mm above the upper margin of the corpus callosum body.</p></sec><sec id="sec0006"><label>2.4</label><title>Imaging analysis</title><p id="para0025">Glymphatic function was assessed using two main indices: the DTI-ALPS index for perivascular glymphatic flow and PI for the driving force of glymphatic flow (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>). The DTI-ALPS index was calculated using DTI data, while the PI was derived from 2D PC-MRI.<fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Measurement of Diffusion Tensor Image Analysis along the Perivascular Space (DTI-ALPS) index and pulsatility index (PI).</p></caption><alt-text id="alt0003">Fig 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec0007"><label>2.5</label><title>Parameter for perivascular glymphatic flow: DTI-ALPS index</title><p id="para0026">The DTI-ALPS index, which reflects perivascular glymphatic flow, was measured under the hypothesis that it may be reduced in AD. The DTI-ALPS index was calculated using the following formula proposed by Taoka et al. (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>):<disp-formula id="ueqn0001"><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mi>D</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi><mml:mspace width="0.33em"/><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mspace width="0.33em"/><mml:mi>A</mml:mi><mml:mi>L</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:mspace width="0.33em"/><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mspace width="0.33em"/><mml:mo linebreak="goodbreak">=</mml:mo><mml:mspace width="0.33em"/><mml:mfrac><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mspace width="0.33em"/><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>D</mml:mi><mml:mi>x</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.33em"/><mml:mi>D</mml:mi><mml:mi>x</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mspace width="0.33em"/><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>D</mml:mi><mml:mi>y</mml:mi><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.33em"/><mml:mi>D</mml:mi><mml:mi>z</mml:mi><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>Three preprocessing steps were performed before calculating the DTI-ALPS index. For perivascular glymphatic flow, the DTI-ALPS index was used. The analysis began with preprocessing of the DTI data using MRTrix3. This preprocessing included denoising, unringing, and eddy current correction to enhance the quality of the diffusion data. Next, the preprocessed data were fitted using the FMRIB Software Library to create diffusion maps, specifically, the Dxx, Dyy, and Dzz maps, which represent the diffusion coefficients along the x-, y-, and z-axes, respectively. These steps were performed on individual datasets. Following fitting, fractional anisotropy (FA) maps were normalized using a template (JHU-ICBM-FA-1 mm.nii.gz) through both linear and non-linear registration processes, ensuring that the diffusion data were aligned to a common space for accurate comparison. Regions of interest (ROIs) were then extracted based on specific anatomical landmarks. The DTI-ALPS index was calculated by measuring the mean diffusivity along the projection and association fibers. The ALPS index was determined as the ratio of the mean (Dxproj, Dyassoc) to mean (Dzassoc). The resulting ALPS index values from the right and left hemispheres were averaged to obtain a mean value for each participant.</p></sec><sec id="sec0008"><label>2.6</label><title>Parameter for arterial wall stiffness: pulsatility index</title><p id="para0027">The PI, reflecting arterial wall stiffness, was calculated as a potential imaging biomarker of glymphatic function, representing the driving force of CSF flow into the brain interstitial space, under the hypothesis that it may be elevated in AD. The PI<sub>CSO</sub> was derived from PC-MRI data using Circle Cardiovascular Imaging software (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>). The PI was calculated using the following formula based on the flow velocity curve: Pulsatility Index (PI) = <inline-formula><mml:math id="M2" altimg="si2.svg"><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:mi>V</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi><mml:mspace width="0.33em"/><mml:mo>&#8722;</mml:mo><mml:mspace width="0.33em"/><mml:mi>V</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>V</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:mfrac><mml:mrow><mml:mo>|</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, where V<sub>max</sub> is the maximum velocity, V<sub>min</sub> is the minimum velocity, and V<sub>mean</sub> is the mean velocity of blood flow. The ROIs were placed on four cortical arteries&#8212;distal branches of the anterior cerebral artery&#8212;at the CSO level (PI<sub>CSO</sub> 1: right medial frontal area; PI<sub>CSO</sub> 2: left medial frontal area; PI<sub>CSO</sub> 3: right medial parietal area; PI<sub>CSO</sub> 4: left medial parietal area) to identify the artery coursing most orthogonally to the axial imaging plane at this level. Four ROIs were manually placed on the magnitude images showing the highest signal intensity with a round shape, and the mean PI<sub>CSO</sub> was calculated from the values of four ROIs.</p></sec><sec id="sec0009"><label>2.7</label><title>Statistical analysis</title><p id="para0028">Statistical analyses were performed using MedCalc version 19.5.3 (MedCalc Software, Mariakerke, Belgium). Continuous variables were tested for normality using the Shapiro&#8211;Wilk test and were found to have non-normal distributions; hence, they were presented as median and interquartile range (IQR). Categorical variables were expressed as frequencies and percentages. Group comparisons among HV, CN, and AD groups were conducted using the Kruskal&#8211;Wallis H test for continuous variables and the chi-square test for categorical variables. For post-hoc analyses of continuous variables, Dunn&#8217;s test was applied to assess pairwise differences between groups. A P value less than 0.05 was considered statistically significant. The reliability of PI<sub>CSO</sub> measurements data was evaluated using the intraclass correlation coefficient among the four ROIs. Spearman&#8217;s rank correlation coefficient (rho) was used to evaluate the associations between the PI<sub>CSO</sub>, age, MMSE scores, and the DTI-ALPS index. Correlation analyses were performed in the overall cohort and within each diagnostic subgroup (HV, CN, and AD). Ninety-five percent confidence intervals (95% CI) were calculated for correlation coefficients.</p></sec></sec><sec id="sec0010"><label>3</label><title>Results</title><sec id="sec0011"><label>3.1</label><title>Patients</title><p id="para0029">The baseline characteristics of the HV, CN, and AD groups are presented in <xref rid="tbl0001" ref-type="table">Table 1</xref>. A total of 160 participants were included in the final analysis: 50 HV, 46 CN, and 64 patients with AD. There was a significant difference in age across the groups (P &lt; 0.001), with HV being significantly younger than both CN and AD groups (both P &lt; 0.001), while no significant difference was observed between CN and AD (P = 0.980). MMSE scores were significantly lower in the AD group compared to both HV and CN groups (both P &lt; 0.001).<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Patient characteristics.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Healthy volunteer (HV)<break/>(n = 50)</th><th valign="top" colspan="1" rowspan="1">Cognitively normal aging (CN)<break/>(n = 46)</th><th valign="top" colspan="1" rowspan="1">Alzheimer&#8217;s disease (AD)<break/>(n = 64)</th><th valign="top" colspan="1" rowspan="1">P value</th><th valign="top" colspan="1" rowspan="1">HV vs. CN<xref rid="tb1fn2" ref-type="table-fn">b</xref></th><th valign="top" colspan="1" rowspan="1">HV vs. AD<xref rid="tb1fn2" ref-type="table-fn">b</xref></th><th valign="top" colspan="1" rowspan="1">CN vs. AD<xref rid="tb1fn2" ref-type="table-fn">b</xref></th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Age<xref rid="tb1fn1" ref-type="table-fn">a</xref><sup>,</sup><xref rid="tb1fn2" ref-type="table-fn">b</xref></td><td valign="top" colspan="1" rowspan="1">43.000<break/>[34.000;55.000]</td><td valign="top" colspan="1" rowspan="1">78.000<break/>[68.000;83.000]</td><td valign="top" colspan="1" rowspan="1">80.000<break/>[73.000;83.000]</td><td valign="top" colspan="1" rowspan="1">&lt;0.001<xref rid="tb1fn4" ref-type="table-fn">d</xref></td><td valign="top" colspan="1" rowspan="1">&lt;0.001</td><td valign="top" colspan="1" rowspan="1">&lt;0.001</td><td valign="top" colspan="1" rowspan="1">0.980</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sex, female<xref rid="tb1fn3" ref-type="table-fn">c</xref></td><td valign="top" colspan="1" rowspan="1">26 (52.000%)</td><td valign="top" colspan="1" rowspan="1">27 (58.696%)</td><td valign="top" colspan="1" rowspan="1">41 (64.062%)</td><td valign="top" colspan="1" rowspan="1">0.431<xref rid="tb1fn4" ref-type="table-fn">d</xref></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">MMSE, total score<xref rid="tb1fn1" ref-type="table-fn">a</xref><sup>,</sup><xref rid="tb1fn2" ref-type="table-fn">b</xref></td><td valign="top" colspan="1" rowspan="1">29.000<break/>[29.000;30.000]</td><td valign="top" colspan="1" rowspan="1">28.000<break/>[28.000;30.000]</td><td valign="top" colspan="1" rowspan="1">25.000<break/>[22.000;27.000]</td><td valign="top" colspan="1" rowspan="1">&lt;0.001<xref rid="tb1fn4" ref-type="table-fn">d</xref></td><td valign="top" colspan="1" rowspan="1">0.126</td><td valign="top" colspan="1" rowspan="1">&lt;0.001</td><td valign="top" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">APOE4 status (No. of &#400;4)<xref rid="tb1fn3" ref-type="table-fn">c</xref></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.248<sup>e</sup></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">50 (100.000%)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">33 (71.739%)</td><td valign="top" colspan="1" rowspan="1">39 (60.938%)</td><td colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">11 (23.913%)</td><td valign="top" colspan="1" rowspan="1">23 (35.938%)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">2 (4.348%)</td><td valign="top" colspan="1" rowspan="1">1 (1.562%)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Education (y)<xref rid="tb1fn1" ref-type="table-fn">a</xref></td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">12.000<break/>[8.000;16.000]</td><td valign="top" colspan="1" rowspan="1">9.000<break/>[6.000;15.000]</td><td valign="top" colspan="1" rowspan="1">0.049<xref rid="tb1fn5" ref-type="table-fn">e</xref></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Hypertension<xref rid="tb1fn1" ref-type="table-fn">a</xref><sup>,</sup><xref rid="tb1fn3" ref-type="table-fn">c</xref></td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">26 (56.522%)</td><td valign="top" colspan="1" rowspan="1">29 (45.312%)</td><td valign="top" colspan="1" rowspan="1">0.248<xref rid="tb1fn5" ref-type="table-fn">e</xref></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Type 2 diabetes mellitus<xref rid="tb1fn1" ref-type="table-fn">a</xref><sup>,</sup><xref rid="tb1fn3" ref-type="table-fn">c</xref></td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">16 (34.783%)</td><td valign="top" colspan="1" rowspan="1">22 (34.375%)</td><td valign="top" colspan="1" rowspan="1">0.864<xref rid="tb1fn5" ref-type="table-fn">e</xref></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Neuropsychologic assessment (SNSB-II)</td></tr><tr><td valign="top" colspan="1" rowspan="1">CDR-SB<xref rid="tb1fn1" ref-type="table-fn">a</xref></td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">1.500<break/>[0.500;3.000]</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">SGDS<xref rid="tb1fn1" ref-type="table-fn">a</xref></td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">4.000<break/>[1.500;8.000]</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Barthel-ADL<xref rid="tb1fn1" ref-type="table-fn">a</xref></td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">20.000<break/>[20.000;20.000]</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">GDS<xref rid="tb1fn1" ref-type="table-fn">a</xref></td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">NA</td><td valign="top" colspan="1" rowspan="1">3.000<break/>[3.000;4.000]</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Note. MMSE = Mini-Mental State Examination; APOE4 = apolipoprotein E &#400;4 allele; SNSB-II = Seoul Neuropsychological Screening Battery-II; CDR-SB = Clinical dementia Rating Sum of Boxes; SGDS = Short Version of the Geriatric Depression Scale; Barthel-ADL = Barthel-Activities of Daily Living; GDS = Global Deterioration Scale</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn1"><label>a</label><p id="notep0002">Data are presented as median [interquartile range] owing to their non-normal distribution.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn2"><label>b</label><p id="notep0003">Group comparisons were performed using the Kruskal-Wallis H test, followed by Dunn&#8217;s post-hoc test as a post-hoc analysis</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn3"><label>c</label><p id="notep0004">Chi-square test</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn4"><label>d</label><p id="notep0005">P value among the three groups</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn5"><label>e</label><p id="notep0006">P value between the second and third groups</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0012"><label>3.2</label><title>Comparison of DTI-ALPS index and PI<sub>CSO</sub> among the three groups</title><p id="para0030">As presented in Supplementary Table 2 and <xref rid="fig0003" ref-type="fig">Fig. 3</xref>, there were significant differences in both the DTI-ALPS index and PI<sub>CSO</sub> among the three groups (both P &lt; 0.001). The DTI-ALPS index was highest in HV (median [IQR], 1.392 [1.350;1.429]), followed by CN (median [IQR], 1.305 [1.270;1.380]), and lowest in the AD group (1.280 [1.215;1.330]). Post-hoc analysis revealed that the AD group showed significantly lower DTI-ALPS values compared to both HV (P &lt; 0.001) and CN (P = 0.026). Conversely, PI<sub>CSO</sub> was significantly elevated in the AD group (median [IQR], 1.115 [0.930;1.270]) compared to CN (median [IQR], 0.875 [0.770;1.030], P = 0.001) and HV (median [IQR], 0.490 [0.410;0.540], P &lt; 0.001). Regarding the reliability of PI<sub>CSO</sub>, the intraclass correlation coefficient among the 4 ROIs was 0.786 (95% CI, 0.726 to 0.835).<fig id="fig0003" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Comparison of Diffusion Tensor Image Analysis along the Perivascular Space (DTI-ALPS) index and pulsatility index (PI) among the healthy volunteers, cognitively normal, and Alzheimer&#8217;s disease groups. Note: In this box-and-Whisker plot, the green box represents the interquartile range (IQR), the horizontal line inside the box indicates the median, the red square shows the mean, and the blue bars denote the 95% confidence interval of the mean. Whiskers extend to the minimum and maximum values within 1.5&#215;IQR, and orange circles indicate outliers. *indicates P &lt; 0.05.</p></caption><alt-text id="alt0004">Fig 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0003" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec0013"><label>3.3</label><title>Correlation of PI<sub>CSO</sub> with age, MMSE score, and DTI-ALPS index</title><p id="para0031">Supplementary Table 3 and <xref rid="fig0004" ref-type="fig">Fig. 4</xref> shows the correlation between PI<sub>CSO</sub> with age, MMSE score, and DTI-ALPS index. In the total cohort (N = 160), PI<sub>CSO</sub> showed a positive correlation with age (rho = 0.613, P &lt; 0.001), and negative correlations with MMSE score (rho = &#8211;0.486, P &lt; 0.001) and DTI-ALPS index (rho = &#8211;0.439, P &lt; 0.001). In the non-AD group (HV + CN; n = 96), PI<sub>CSO</sub> was significantly correlated with age (&#961; = 0.575, 95% CI: 0.423&#8211;0.695, P &lt; 0.001), negatively correlated with MMSE score (&#961; = &#8211;0.273, 95% CI: &#8211;0.449 to &#8211;0.076, P = 0.007), and with DTI-ALPS index (&#961; = &#8211;0.319, 95% CI: &#8211;0.488 to &#8211;0.126, P = 0.002). In the AD group (n = 64), no significant correlations were observed between PICSO and age (&#961; = 0.094, <italic toggle="yes">P</italic> = 0.462), MMSE score (&#961; = 0.067, <italic toggle="yes">P</italic> = 0.597), or DTI-ALPS index (&#961; = 0.067, <italic toggle="yes">P</italic> = 0.601).<fig id="fig0004" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Correlation of pulsatility index (PI) with age, Mini-Mental State Examination (MMSE) score, and Diffusion Tensor Image Analysis along the Perivascular Space (DTI-ALPS) index. Note: Each dot represents an individual participant. The solid blue line indicates the linear regression fit, with shaded areas representing the 95% confidence interval. The dashed orange lines indicate the 95% prediction interval. Linear regression equations, Spearman&#8217;s correlation coefficients (rho), and P-values are provided in each panel.</p></caption><alt-text id="alt0005">Fig 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0004" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec></sec><sec id="sec0014"><label>4</label><title>Discussion</title><p id="para0032">The key findings of our study are as follows: (1) PI<sub>CSO</sub> was significantly higher in the AD group compared to CN and HV groups. (2) PI<sub>CSO</sub> exhibited a positive correlation with age and a negative correlation with both the DTI-ALPS index and MMSE scores.</p><sec id="sec0015"><label>4.1</label><title>PI<sub>CSO</sub>, glymphatic function, and AD</title><p id="para0033">In our study, PI<sub>CSO</sub> was significantly higher in the AD group. Additionally, it was negatively correlated with the DTI-ALPS index and MMSE score. One potential mechanism underlying the correlation between elevated PI<sub>CSO</sub> and AD is that increased vascular wall stiffness reduces the pulsatile force driving glymphatic flow, leading to the accumulation of cerebral metabolic waste products, such as amyloid-beta, which in turn contributes to AD. Concurrently, amyloid-beta deposition within the perivascular space may increase vascular stiffness, creating a vicious cycle that exacerbates vascular wall damage and stiffening. The DTI-ALPS index has been established as a glymphatic biomarker in previous studies. The positive correlation observed between the DTI-ALPS index and PI<sub>CSO</sub> suggests that this new index may serve as a novel, non-invasive imaging biomarker for Alzheimer&#8217;s disease in the context of glymphatic dysfunction. Furthermore, in the future, PI<sub>CSO</sub> might serve as a potential monitoring marker for treatments targeting amyloid-beta, such as monoclonal antibody therapies like lecanemab, as perivascular amyloid-beta deposition could increase vascular stiffness.</p></sec><sec id="sec0016"><label>4.2</label><title>PI<sub>CSO</sub> and endothelial dysfunction</title><p id="para0034">Elevated PI<sub>CSO</sub> may also be linked to endothelial dysfunction, a pathological process that contributes to cognitive decline via vascular dementia-related mechanisms [<xref rid="bib0021" ref-type="bibr">21</xref>,<xref rid="bib0032" ref-type="bibr">32</xref>]. In younger individuals, cerebral small arteries maintain proper endothelial function and vascular compliance, effectively dampening the transmission of cardiac pulsation from the aortic artery [<xref rid="bib0026" ref-type="bibr">26</xref>,<xref rid="bib0033" ref-type="bibr">33</xref>]. This compensation reduces the exposure of small cerebral vessels to hemodynamic stress and endothelial damage [<xref rid="bib0026" ref-type="bibr">26</xref>]. However, with aging and the accumulation of cardiovascular risk factors, such as hypertension, endothelial dysfunction and vascular stiffness progressively develop [<xref rid="bib0024" ref-type="bibr">24</xref>]. Loss of smooth muscle cells, endothelial damage, lipohyalinosis, and fibrinoid necrosis contribute to functional abnormalities and mechanical stiffening of the arterial wall through increased collagen fiber synthesis. Thus, cerebrovascular flow imaging has the potential to serve as an early biomarker for detecting small vessel dysfunction before more advanced parenchymal changes, such as white matter hyperintensity or brain atrophy, become apparent.</p></sec><sec id="sec0017"><label>4.3</label><title>Comparison of PI in 3.0 T vs. 7.0 T MRI</title><p id="para0035">The degree of phase-shifting in MRI is influenced by gradient performance [<xref rid="bib0006" ref-type="bibr">6</xref>]. As a result, most previous studies using PC-MRI for small cerebral arteries were conducted using 7.0 T MRI [<xref rid="bib0023" ref-type="bibr">23</xref>]. However, given that ultra-high-field MRI is primarily limited to research settings, evaluating the feasibility of 3.0 T MRI is crucial for broader clinical applications. Although the vascular detection sensitivity of 3.0 T MRI is approximately five times lower than that of 7.0 T MRI for phase-contrast imaging [<xref rid="bib0019" ref-type="bibr">19</xref>], a previous study demonstrated that PI measurements are feasible at 3.0 T [<xref rid="bib0029" ref-type="bibr">29</xref>]. In that study, no direct correlation between 3.0 T and 7.0 T MRI in terms of flow velocity and PI values was established because 3.0 T MRI is only capable of detecting relatively larger arteries. Consistent with previous research, our study also identified the feasibility of PI measurement in 3.0T MRI. Considering accessibility, measuring PI using 3.0 T MRI showed potential as a good alternative to 7.0 T MRI.</p></sec><sec id="sec0018"><label>4.4</label><title>Cortical artery vs. perforating artery as a target vessel</title><p id="para0036">In our study, we selected cortical arteries at the CSO level rather than perforating arteries for two reasons: [<xref rid="bib0001" ref-type="bibr">1</xref>] the manual detection of perforating arteries in 3.0 T MRI was expected to have low reliability due to poor signal intensity, and [<xref rid="bib0002" ref-type="bibr">2</xref>] PI values reflect not only the compliance of the targeted vessel but also that of downstream smaller vascular structures [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0025" ref-type="bibr">25</xref>,<xref rid="bib0033" ref-type="bibr">33</xref>]. Fortunately, PI<sub>CSO</sub> from cortical vessels correlated well with the DTI-ALPS index and MMSE scores in 3.0 T MRI. This suggests that cortical artery-based PI measurement in 3.0 T MRI may be feasible alternative to perforating artery-based measurements in 7.0 T MRI.</p></sec><sec id="sec0019"><label>4.5</label><title>PI Measurement Using 2D vs. 4D PC-MRI</title><p id="para0037">Recent studies have explored the use of 4D PC-MRI for PI calculation across multiple intracranial arteries [<xref rid="bib0033" ref-type="bibr">33</xref>,<xref rid="bib0034" ref-type="bibr">34</xref>]. This technique offers several advantages, such as the ability to assess any desired artery and measure additional parameters, including the damping index and pulse wave velocity [<xref rid="bib0006" ref-type="bibr">6</xref>,<xref rid="bib0033" ref-type="bibr">33</xref>,<xref rid="bib0034" ref-type="bibr">34</xref>]. However, 4D PC-MRI requires a scan time of approximately 10 min and involves complex post-processing [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0006" ref-type="bibr">6</xref>,<xref rid="bib0033" ref-type="bibr">33</xref>]. Furthermore, its application is limited to selected MRI scanners, and a critical drawback is its reduced feasibility for assessing small vessels owing to its low spatial resolution and high VENC values required for covering a diverse range of arteries [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0006" ref-type="bibr">6</xref>]. In contrast, 2D PC-MRI is available on all commercial MRI scanners, has a significantly shorter scan time (approximately 2&#8211;3 min), and requires simpler post-processing. Given these advantages, 2D PC-MRI at the CSO level may be more suitable than whole-brain 4D PC-MRI for evaluating glymphatic function.</p></sec><sec id="sec0020"><label>4.6</label><title>Limitations</title><p id="para0038">This study had several limitations. <bold>First,</bold> it was a single-center study with a relatively small sample size. Future prospective multicenter studies with larger cohorts are required to validate our findings. <bold>Second,</bold> we could not evaluate the correlation of PI<sub>CSO</sub> with other more comprehensive and accurate methods to reflect glymphatic function such as MRI after intrathecal contrast injection or repeated MRI after intravenous contrast injection due to its invasiveness and inconvenience of the patients. Although the usefulness of DTI-ALPS index is evaluated in many previous studies and the most widely applied to evaluate the perivascular glymphatic flow due to its non-invasiveness and convenience, further animal study or using repeated MRI is warranted to obtain more firm evidence for this new parameter. <bold>Third,</bold> given that amyloid PET-CT was not performed in the HV and CN groups, the possibility of including participants with subclinical Alzheimer&#8217;s disease cannot be excluded. As our institution does not routinely perform amyloid PET-CT in individuals without clinical evidence of cognitive impairment, direct comparison was not feasible. Further prospective studies involving amyloid PET-CT in these populations are warranted. <bold>Fourth</bold>, we selected four cortical arteries at the CSO level rather than performing whole-artery segmentation. A previous study reported that single round-shaped artery selection is more accurate than whole-artery segmentation because data from obliquely scanned arteries are inaccurate in 2D PC-MRI [<xref rid="bib0028" ref-type="bibr">28</xref>]. Thus, we manually selected the most round-shaped high-signal-intensity vessel. This method is intuitive, does not require a special post-processing algorithm, and showed good agreement among the four vessels in terms of PI values. However, further study is required to compare the accuracy between four-vessel selection and whole-vessel segmentation methods. <bold>Fifth,</bold> in the non-AD group, two distinct participant profiles were present. The HV group tended to be significantly younger, as participants were recruited based on their eligibility to undergo simultaneous 7.0T MRI, in order to conduct a preliminary assessment of the feasibility of 2D phase-contrast MRI at 3.0T. In contrast, the CN group included relatively older individuals, reflecting the nature of their recruitment for neurodegeneration evaluation. This heterogeneity across groups may introduce ambiguity in the interpretation of the study findings. Therefore, future comparative studies should include a more representative control group, such as individuals undergoing brain MRI as part of routine health screening.</p></sec></sec><sec id="sec0021"><label>5</label><title>Conclusion</title><p id="para0039">PI<sub>CSO</sub>, derived from 2D phase-contrast imaging in 3.0 T MRI, shows promise as a potential non-invasive imaging biomarker for AD in the context of glymphatic function.</p></sec><sec id="sec0022"><title>Funding</title><p id="para9002">
<list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#8226;</label><p id="para0040">This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT, Ministry of Science and ICT) (Grant No. RS-2023-00209819)</p></list-item><list-item id="celistitem0002"><label>&#8226;</label><p id="para0041">This research was supported by a grant of the Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &amp; Welfare, Republic of Korea (grant number: RS-2022-KH129293)</p></list-item><list-item id="celistitem0003"><label>&#8226;</label><p id="para0042">This work was supported by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health &amp; Welfare, the Ministry of Food and Drug Safety) (Project Number: 1711138003, Grant No. RS-2020-KD000041)</p></list-item></list>
</p><p id="para0043">The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; in the preparation of the manuscript; or in the review or approval of the manuscript.</p></sec><sec id="sec0022a"><title>CRediT authorship contribution statement</title><p id="para0043a"><bold>Sung-Hye You:</bold> Writing &#8211; original draft, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. <bold>Byungjun Kim:</bold> Writing &#8211; review &amp; editing, Methodology, Investigation, Funding acquisition, Data curation, Conceptualization. <bold>Moonjung Hwang:</bold> Writing &#8211; review &amp; editing, Investigation, Formal analysis, Data curation. <bold>Kyung-Sook Yang:</bold> Methodology, Formal analysis. <bold>Hye-Won Park:</bold> Writing &#8211; review &amp; editing, Formal analysis, Data curation. <bold>InSeong Kim:</bold> Software. <bold>SuGil Kim:</bold> Software. <bold>Kyung Min Kim:</bold> Investigation. <bold>Bo Kyu Kim:</bold> Writing &#8211; review &amp; editing, Data curation. <bold>Jae Ho Shin:</bold> Writing &#8211; review &amp; editing, Data curation.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0046">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>De la Torre</surname><given-names>J.</given-names></name></person-group><article-title>Impaired brain microcirculation may trigger Alzheimer's disease</article-title><source>Neurosci Biobehav Rev</source><volume>18</volume><year>1994</year><fpage>397</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">7984357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0149-7634(94)90052-3</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Knopman</surname><given-names>D.</given-names></name></person-group><article-title>Cerebrovascular disease and dementia</article-title><source>Br J Radiol</source><volume>80</volume><year>2007</year><fpage>S121</fpage><lpage>S127</lpage><pub-id pub-id-type="pmid">18445742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1259/bjr/75681080</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Roher</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Esh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kokjohn</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name></person-group><article-title>Atherosclerosis of cerebral arteries in Alzheimer disease</article-title><source>Stroke</source><volume>35</volume><year>2004</year><fpage>2623</fpage><lpage>2627</lpage><pub-id pub-id-type="pmid">15375298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.STR.0000143317.70478.b3</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><mixed-citation publication-type="other" id="sbref0004">Tormos A, Tal&#233;ns Visconti R, P&#233;rez Garrido S, Rius P&#233;rez S. Vascular pathology: cause or effect in Alzheimer disease? 2018.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nrl.2015.07.010</pub-id><pub-id pub-id-type="pmid">26385017</pub-id></mixed-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Pahlavian</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Cerebroarterial pulsatility and resistivity indices are associated with cognitive impairment and white matter hyperintensity in elderly subjects: A phase-contrast MRI study</article-title><source>J Cereb Blood Flow Metab</source><volume>41</volume><year>2021</year><fpage>670</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">32501154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0271678X20927101</pub-id><pub-id pub-id-type="pmcid">PMC7922759</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Wymer</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>W.F.</given-names><suffix>III</suffix></name><name name-style="western"><surname>VK</surname><given-names>Bhatia</given-names></name></person-group><article-title>Phase-contrast MRI: physics, techniques, and clinical applications</article-title><source>Radiographics</source><volume>40</volume><year>2020</year><fpage>122</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">31917664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/rg.2020190039</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name></person-group><article-title>Visualizing cerebral small vessel degeneration during aging and diseases using magnetic resonance imaging</article-title><source>J Magn Reson Imaging</source><volume>58</volume><year>2023</year><fpage>1323</fpage><lpage>1337</lpage><pub-id pub-id-type="pmid">37052571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.28736</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Tomek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Urbanov&#225;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hort</surname><given-names>J.</given-names></name></person-group><article-title>Utility of transcranial ultrasound in predicting Alzheimer's disease risk</article-title><source>J Alzheimers Dis</source><volume>42</volume><year>2014</year><fpage>S365</fpage><lpage>S374</lpage><pub-id pub-id-type="pmid">25298200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-141803</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>C-P</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P-C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P-N</given-names></name></person-group><article-title>Cerebral artery pulsatility is associated with cognitive impairment and predicts dementia in individuals with subjective memory decline or mild cognitive impairment</article-title><source>J Alzheimers Dis</source><volume>60</volume><year>2017</year><fpage>625</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">28826186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170349</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>J-S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>H-M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y-S</given-names></name></person-group><article-title>The correlation between cerebral arterial pulsatility and cognitive dysfunction in Alzheimer's disease patients</article-title><source>J Neurol Sci</source><volume>373</volume><year>2017</year><fpage>285</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">28131207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2017.01.001</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Nedergaard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>S.A.</given-names></name></person-group><article-title>Glymphatic failure as a final common pathway to dementia</article-title><source>Science (1979)</source><volume>370</volume><year>2020</year><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb8739</pub-id><pub-id pub-id-type="pmcid">PMC8186542</pub-id><pub-id pub-id-type="pmid">33004510</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Kiviniemi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Korhonen</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Ultra-fast magnetic resonance encephalography of physiological brain activity&#8211;glymphatic pulsation mechanisms?</article-title><source>J Cereb Blood Flow Metab</source><volume>36</volume><year>2016</year><fpage>1033</fpage><lpage>1045</lpage><pub-id pub-id-type="pmid">26690495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0271678X15622047</pub-id><pub-id pub-id-type="pmcid">PMC4908626</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Taoka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nakamichi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nakane</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Naganawa</surname><given-names>S.</given-names></name></person-group><article-title>Diffusion tensor image analysis along the perivascular space (DTI-ALPS): revisiting the meaning and significance of the method</article-title><source>Magn Reson Med Sci</source><volume>23</volume><year>2024</year><fpage>268</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">38569866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2463/mrms.rev.2023-0175</pub-id><pub-id pub-id-type="pmcid">PMC11234944</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Naganawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taoka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kawamura</surname><given-names>M.</given-names></name></person-group><article-title>The glymphatic system in humans: investigations with magnetic resonance imaging</article-title><source>Invest Radiol</source><volume>59</volume><year>2024</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">36897826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/RLI.0000000000000969</pub-id><pub-id pub-id-type="pmcid">PMC11805491</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H-J</given-names></name><name name-style="western"><surname>Yim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>W-J</given-names></name></person-group><article-title>Choroid plexus volume and permeability at brain MRI within the Alzheimer disease clinical spectrum</article-title><source>Radiology</source><volume>304</volume><year>2022</year><fpage>635</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">35579521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.212400</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Measurement of blood&#8211;brain barrier water exchange rate using diffusion-prepared and multi-echo arterial spin labelling: comparison of quantitative values and age dependence</article-title><source>NMR Biomed</source><volume>37</volume><year>2024</year><fpage>e5256</fpage><pub-id pub-id-type="pmid">39252500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/nbm.5256</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>R-E</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S-H</given-names></name></person-group><article-title>Non-invasive flow mapping of parasagittal meningeal lymphatics using 2D interslice flow saturation MRI</article-title><source>Fluids Barriers CNS</source><volume>20</volume><year>2023</year><fpage>37</fpage><pub-id pub-id-type="pmid">37237402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-023-00446-z</pub-id><pub-id pub-id-type="pmcid">PMC10224581</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Webb</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Simoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mazzucco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuker</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>U.</given-names></name><name name-style="western"><surname>Rothwell</surname><given-names>P.M.</given-names></name></person-group><article-title>Increased cerebral arterial pulsatility in patients with leukoaraiosis: arterial stiffness enhances transmission of aortic pulsatility</article-title><source>Stroke</source><volume>43</volume><year>2012</year><fpage>2631</fpage><lpage>2636</lpage><pub-id pub-id-type="pmid">22923446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.112.655837</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Van Den Brink</surname><given-names>H.</given-names></name><name name-style="western"><surname>Doubal</surname><given-names>F.N.</given-names></name><name name-style="western"><surname>Duering</surname><given-names>M.</given-names></name></person-group><article-title>Advanced MRI in cerebral small vessel disease</article-title><source>Int J Stroke</source><volume>18</volume><year>2023</year><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">35311609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17474930221091879</pub-id><pub-id pub-id-type="pmcid">PMC9806457</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Arts</surname><given-names>T.</given-names></name><name name-style="western"><surname>Siero</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Biessels</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Zwanenburg</surname><given-names>J.J.</given-names></name></person-group><article-title>Automated assessment of cerebral arterial perforator function on 7T MRI</article-title><source>J Magn Reson Imaging</source><volume>53</volume><year>2021</year><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">32810376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.27304</pub-id><pub-id pub-id-type="pmcid">PMC7754489</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Geurts</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Zwanenburg</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Klijn</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Luijten</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Biessels</surname><given-names>G.J.</given-names></name></person-group><article-title>Higher pulsatility in cerebral perforating arteries in patients with small vessel disease related stroke, a 7T MRI study</article-title><source>Stroke</source><volume>50</volume><year>2019</year><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">30580730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.118.022516</pub-id><pub-id pub-id-type="pmcid">PMC6314503</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>van den Kerkhof</surname><given-names>M.</given-names></name><name name-style="western"><surname>van der Thiel</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>van Oostenbrugge</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Impaired damping of cerebral blood flow velocity pulsatility is associated with the number of perivascular spaces as measured with 7T MRI</article-title><source>J Cereb Blood Flow Metab</source><volume>43</volume><year>2023</year><fpage>937</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">36704826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0271678X231153374</pub-id><pub-id pub-id-type="pmcid">PMC10196747</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Zong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name></person-group><article-title>Quantitative phase contrast MRI of penetrating arteries in centrum semiovale at 7T</article-title><source>Neuroimage</source><volume>195</volume><year>2019</year><fpage>463</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">30935910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2019.03.059</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Perosa</surname><given-names>V.</given-names></name><name name-style="western"><surname>Arts</surname><given-names>T.</given-names></name><name name-style="western"><surname>Assmann</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pulsatility index in the basal ganglia arteries increases with age in elderly with and without cerebral small vessel disease</article-title><source>Am J Neuroradiol</source><volume>43</volume><year>2022</year><fpage>540</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">35332021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A7450</pub-id><pub-id pub-id-type="pmcid">PMC8993201</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Onkenhout</surname><given-names>L.</given-names></name><name name-style="western"><surname>Arts</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ferro</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Perforating artery flow velocity and pulsatility in patients with carotid occlusive disease. A 7 tesla MRI study</article-title><source>Cereb Circ - Cogn Behav</source><volume>3</volume><year>2022</year><object-id pub-id-type="publisher-id">100143</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cccb.2022.100143</pub-id><pub-id pub-id-type="pmcid">PMC9616320</pub-id><pub-id pub-id-type="pmid">36324413</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Arts</surname><given-names>T.</given-names></name><name name-style="western"><surname>Onkenhout</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Amier</surname><given-names>R.P.</given-names></name><etal/></person-group><article-title>Non-invasive assessment of damping of blood flow velocity pulsatility in cerebral arteries with MRI</article-title><source>J Magn Reson Imaging</source><volume>55</volume><year>2022</year><fpage>1785</fpage><lpage>1794</lpage><pub-id pub-id-type="pmid">34792263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.27989</pub-id><pub-id pub-id-type="pmcid">PMC9298760</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>van den Kerkhof</surname><given-names>M.</given-names></name><name name-style="western"><surname>van der Thiel</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Postma</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>Hypertension correlates with stronger blood flow pulsatility in small perforating cerebral arteries assessed with 7 tesla magnetic resonance imaging</article-title><source>Hypertension</source><volume>80</volume><year>2023</year><fpage>802</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">36722349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.122.19866</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>van den Kerkhof</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>van Oostenbrugge</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Backes</surname><given-names>W.H.</given-names></name></person-group><article-title>1D versus 3D blood flow velocity and pulsatility measurements of lenticulostriate arteries at 7T MRI</article-title><source>Magn Reson Imaging</source><volume>96</volume><year>2023</year><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">36473545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mri.2022.12.005</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Arts</surname><given-names>T.</given-names></name><name name-style="western"><surname>Meijs</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Grotenhuis</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Velocity and pulsatility measures in the perforating arteries of the basal ganglia at 3T MRI in reference to 7T MRI</article-title><source>Front Neurosci</source><volume>15</volume><year>2021</year><object-id pub-id-type="publisher-id">665480</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2021.665480</pub-id><pub-id pub-id-type="pmcid">PMC8107291</pub-id><pub-id pub-id-type="pmid">33981198</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>van Tuijl</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Ruigrok</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Biessels</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Velthuis</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Zwanenburg</surname><given-names>J.J.</given-names></name></person-group><article-title>Reliability of velocity pulsatility in small vessels on 3tesla mri in the basal ganglia: A test&#8211;retest study. Magnetic resonance materials in physics</article-title><source>Biol Med</source><volume>36</volume><year>2023</year><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10334-022-01042-2</pub-id><pub-id pub-id-type="pmcid">PMC9992040</pub-id><pub-id pub-id-type="pmid">36166103</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>McKhann</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Chertkow</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title><source>Alzheimer's &amp; dementia</source><volume>7</volume><year>2011</year><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.005</pub-id><pub-id pub-id-type="pmcid">PMC3312024</pub-id><pub-id pub-id-type="pmid">21514250</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Thrippleton</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wardlaw</surname><given-names>J.M.</given-names></name></person-group><article-title>Intracranial pulsatility in patients with cerebral small vessel disease: a systematic review</article-title><source>Clin Sci</source><volume>132</volume><year>2018</year><fpage>157</fpage><lpage>171</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/CS20171280</pub-id><pub-id pub-id-type="pmid">29229867</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>W&#229;hlin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eklund</surname><given-names>A.</given-names></name><name name-style="western"><surname>Malm</surname><given-names>J.</given-names></name></person-group><article-title>4D flow MRI hemodynamic biomarkers for cerebrovascular diseases</article-title><source>J Intern Med</source><volume>291</volume><year>2022</year><fpage>115</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">34813112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/joim.13392</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Peret</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jonaitis</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Normative cerebral hemodynamics in middle-aged and older adults using 4D flow MRI: initial analysis of vascular aging</article-title><source>Radiology</source><volume>307</volume><year>2023</year><object-id pub-id-type="publisher-id">e222685</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.222685</pub-id><pub-id pub-id-type="pmcid">PMC10140641</pub-id><pub-id pub-id-type="pmid">36943077</pub-id></element-citation></ref></ref-list><sec id="sec0024" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0044a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgements</title><p id="para0045">None.</p></ack><fn-group><fn id="sec0023" fn-type="supplementary-material"><p id="para0009a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100323" id="interref0001">doi:10.1016/j.tjpad.2025.100323</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501331</article-id><article-id pub-id-type="pmcid-ver">PMC12501331.1</article-id><article-id pub-id-type="pmcaid">12501331</article-id><article-id pub-id-type="pmcaiid">12501331</article-id><article-id pub-id-type="pmid">40885682</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100364</article-id><article-id pub-id-type="pii">S2274-5807(25)00306-1</article-id><article-id pub-id-type="publisher-id">100364</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">APOE</italic> &#949;4-related differences in brain structure, function, and connectivity at midlife: A scoping review</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Lissaman</surname><given-names initials="R">Rikki</given-names></name><email>rikki.lissaman@mail.mcgill.ca</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Anjum</surname><given-names initials="S">Sidra</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Quaiattini</surname><given-names initials="A">Andrea</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Rajah</surname><given-names initials="MN">M. Natasha</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0005" ref-type="aff">e</xref></contrib><aff id="aff0001"><label>a</label>Department of Psychiatry, McGill University, Montreal, QC, Canada</aff><aff id="aff0002"><label>b</label>Department of Psychology, Royal Holloway, University of London, Egham, Surrey, UK</aff><aff id="aff0003"><label>c</label>Centre for Addiction and Mental Health, Toronto, ON, Canada</aff><aff id="aff0004"><label>d</label>Schulich Library of Physical Sciences, Life Sciences, and Engineering, McGill University, QC, Canada</aff><aff id="aff0005"><label>e</label>Department of Psychology, Toronto Metropolitan University, Toronto, ON, Canada</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author at: Department of Psychiatry, McGill University, Montreal, QC, Canada. <email>rikki.lissaman@mail.mcgill.ca</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>29</day><month>8</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100364</elocation-id><history><date date-type="received"><day>15</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>20</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract abstract-type="author-highlights" id="abs0001"><title>Highlights</title><p><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#8226;</label><p id="para0001">We review <italic toggle="yes">APOE</italic> &#949;4-related differences in the middle-aged brain.</p></list-item><list-item id="celistitem0002"><label>&#8226;</label><p id="para0002">Current research provides little evidence of robust differences.</p></list-item><list-item id="celistitem0003"><label>&#8226;</label><p id="para0003">Small, non-representative samples were prominent.</p></list-item><list-item id="celistitem0004"><label>&#8226;</label><p id="para0004">Few studies considered the role of sex-specific factors or ethnocultural diversity.</p></list-item></list></p></abstract><abstract id="abs0002"><sec><title>Background</title><p>The apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 allele is a major genetic risk factor for late-onset Alzheimer&#8217;s disease (AD), yet there is little consensus about how and when the allele exerts its influence on the brain.</p></sec><sec><title>Methods</title><p>In this scoping review, we synthesized research examining <italic toggle="yes">APOE</italic> &#949;4-related differences on MRI-derived measures of brain structure, function, and connectivity in cognitively unimpaired, middle-aged adults (aged 40&#8211;65 years). Four online databases (Ovid MEDLINE, Ovid Embase, Ovid PsycINFO, Scopus) were searched on July 11, 2024, and forward/backward reference searching was conducted on identified studies. We extracted data on sample characteristics, methods, and key <italic toggle="yes">APOE</italic> &#949;4-related results.</p></sec><sec><title>Results</title><p>Our pre-registered search strategy identified 30 relevant studies. Overall, we found little evidence of robust, consistent differences between <italic toggle="yes">APOE</italic> &#949;4 carriers and non-carriers at midlife, especially in relation to brain structure. However, among the studies identified, small samples were common, and limited consideration was afforded to factors such as sex and ethnocultural diversity.</p></sec><sec><title>Conclusion</title><p>Overall, the existing literature indicates that <italic toggle="yes">APOE</italic> &#949;4 exerts little, if any, influence on brain structure at midlife, while differences in brain function and connectivity remain poorly characterized.</p></sec></abstract><abstract abstract-type="graphical" id="abs0003"><title>Graphical abstract</title><p><fig id="fig0003" position="anchor" orientation="portrait"><alt-text id="alttx001">Image, graphical abstract</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0003" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Apolipoprotein E</kwd><kwd>Midlife</kwd><kwd>Brain structure</kwd><kwd>Brain function</kwd><kwd>Structural connectivity</kwd><kwd>Functional connectivity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0009">The human apolipoprotein E (<italic toggle="yes">APOE</italic>) gene, located on chromosome 19, encodes a multi-functional protein, APOE, originally identified for its role in lipid metabolism [<xref rid="bib0060" ref-type="bibr">1</xref>,<xref rid="bib0061" ref-type="bibr">2</xref>]. There are three common allelic variants of the <italic toggle="yes">APOE</italic> gene: &#949;2, &#949;3, and &#949;4. The APOE protein isoforms produced by these three alleles differ in their amino acid sequences at only two positions [<xref rid="bib0077" ref-type="bibr">3</xref>,<xref rid="bib0094" ref-type="bibr">4</xref>]. Although small, these single amino acid differences alter the structure and function of APOE <xref rid="bib0061" ref-type="bibr">[2]</xref>, <xref rid="bib0042" ref-type="bibr">[5]</xref> and, in turn, have significant implications for an individual&#8217;s risk of developing late-onset Alzheimer&#8217;s disease (AD; [<xref rid="bib0009" ref-type="bibr">6</xref>]). Relative to the most common <italic toggle="yes">APOE</italic> genotype (&#949;3/&#949;3), possession of the &#949;4 allele is associated with a &#8764;2- to 4-fold and &#8764;8- to-12-fold increase in AD risk among heterozygote and homozygotes, respectively [<xref rid="bib0003" ref-type="bibr">7</xref>,<xref rid="bib0023" ref-type="bibr">8</xref>]. Estimates of lifetime risk for AD, as opposed to odds ratios, indicate that the risk conferred by <italic toggle="yes">APOE</italic> &#949;4 is closer in magnitude to major genes in Mendelian diseases than to genetic loci identified through genome-wide association studies [<xref rid="bib0033" ref-type="bibr">9</xref>]. <italic toggle="yes">APOE</italic> &#949;4 is also strongly associated with earlier and more advanced accumulation of amyloid-&#946; [<xref rid="bib0045" ref-type="bibr">[10]</xref>, <xref rid="bib0046" ref-type="bibr">[11]</xref>, <xref rid="bib0084" ref-type="bibr">[12]</xref>], a cardinal pathological feature of AD [<xref rid="bib0012" ref-type="bibr">13</xref>]. Accordingly, although not all <italic toggle="yes">APOE</italic> &#949;4 carriers ultimately develop AD, the allele is widely recognized as a major genetic risk factor for late-onset AD.</p><p id="para0010">Given the <italic toggle="yes">APOE</italic> &#949;4-AD link, there is considerable research interest in understanding how and when the allele exerts its influence on the brain. To this end, magnetic resonance imaging (MRI) &#8211; a non-invasive imaging modality capable of evaluating brain structure, function, and connectivity in vivo &#8211; has been widely adopted. To date, however, results have been mixed. Among older adults, <italic toggle="yes">APOE</italic> &#949;4 has been associated with lower gray matter volume in regions implicated in AD, most notably the hippocampus, although findings are not consistent (e.g., [<xref rid="bib0041" ref-type="bibr">[14]</xref>, <xref rid="bib0052" ref-type="bibr">[15]</xref>, <xref rid="bib0058" ref-type="bibr">[16]</xref>]; for reviews, see [<xref rid="bib0008" ref-type="bibr">17</xref>,<xref rid="bib0031" ref-type="bibr">18</xref>]). Studies using diffusion MRI to probe <italic toggle="yes">APOE</italic> &#949;4-related differences in the microstructural properties of white matter &#8211; the brain&#8217;s structural connections &#8211; have likewise produced heterogenous findings, both in terms of the presence/absence of differences and the tracts implicated (e.g., <xref rid="bib0052" ref-type="bibr">[15]</xref>, <xref rid="bib0005" ref-type="bibr">[19]</xref>, <xref rid="bib0038" ref-type="bibr">[20]</xref>, <xref rid="bib0039" ref-type="bibr">[21]</xref>, <xref rid="bib0059" ref-type="bibr">[22]</xref>). In terms of brain function, task-evoked functional MRI (fMRI) studies utilising episodic memory paradigms have reported higher and lower activation levels in older &#949;4 carriers compared to non-carriers, as well as null effects [<xref rid="bib0062" ref-type="bibr">23</xref>]. To account for these inconsistencies, some researchers have turned to the prodromal hypothesis [<xref rid="bib0030" ref-type="bibr">24</xref>,<xref rid="bib0083" ref-type="bibr">25</xref>], which posits that &#949;4-related differences in brain health and cognition emerge late in life (&#8764;65+ years), fueled by greater levels of AD pathology (e.g., amyloid-&#946;) among &#949;4 carriers who will ultimately develop AD [<xref rid="bib0070" ref-type="bibr">26</xref>]. According to this perspective, inconsistencies between studies may be driven by the incidental inclusion (or exclusion) of older &#949;4 carriers in the prodromal phase of AD.</p><p id="para0011">However, <italic toggle="yes">APOE</italic> &#949;4-related differences in brain structure, function, and connectivity have been observed much earlier in the adult lifespan, decades prior to the onset of significant levels of AD pathology. For instance, several studies have reported that young adult &#949;4 carriers compared to non-carriers exhibit higher levels of functional activation and connectivity, especially in AD-vulnerable regions such as the hippocampus and posteromedial cortex <xref rid="bib0011" ref-type="bibr">[27]</xref>, <xref rid="bib0025" ref-type="bibr">[28]</xref>, <xref rid="bib0026" ref-type="bibr">[29]</xref>, <xref rid="bib0040" ref-type="bibr">[30]</xref>, <xref rid="bib0051" ref-type="bibr">[31]</xref>, <xref rid="bib0082" ref-type="bibr">[32]</xref>. Recent work has further reported an association between heightened memory-related activation in posteromedial cortex and subsequent amyloid-&#946; burden in older &#949;4 carriers [<xref rid="bib0027" ref-type="bibr">33</xref>]. Such findings have led some to propose lifespan accounts, whereby <italic toggle="yes">APOE</italic> &#949;4 induces a prolonged pattern of &#8220;hyperactivation&#8221;, maintained throughout early-/mid-adulthood, predisposing specific brain networks to the accumulation of AD pathology [<xref rid="bib0010" ref-type="bibr">34</xref>,<xref rid="bib0044" ref-type="bibr">35</xref>]. Other researchers, however, have argued that neural differences in early adulthood may be independent of <italic toggle="yes">APOE</italic> &#949;4&#8217;s role in AD <xref rid="bib0073" ref-type="bibr">[36]</xref>, <xref rid="bib0087" ref-type="bibr">[37]</xref>, <xref rid="bib0088" ref-type="bibr">[38]</xref>. Proponents of the antagonistic pleiotropy hypothesis [<xref rid="bib0037" ref-type="bibr">39</xref>,<xref rid="bib0092" ref-type="bibr">40</xref>], for example, argue that possession of the &#949;4 allele is evolutionary advantageous in early life but detrimental in later life. In this context, heightened levels of activation among young adult &#949;4 carriers are considered beneficial, unrelated to later AD risk [<xref rid="bib0070" ref-type="bibr">26</xref>]. It is currently unclear whether these benefits are maintained into midlife, as some have suggested (e.g., [<xref rid="bib0097" ref-type="bibr">41</xref>]), or whether midlife represents a transition period characterized by minimal &#949;4-related differences as the allele&#8217;s influence shifts from advantageous to disadvantageous [<xref rid="bib0081" ref-type="bibr">42</xref>].</p><p id="para0012">Despite this, little is currently known about <italic toggle="yes">APOE</italic> &#949;4-related differences in the brain at midlife. Although historically understudied, midlife &#8211; broadly defined as ages 40 to 65 years &#8211; is increasingly recognized as a pivotal point in the adult lifespan, shaping both normal and pathological brain health trajectories <xref rid="bib0013" ref-type="bibr">[43]</xref>, <xref rid="bib0055" ref-type="bibr">[44]</xref>. Many factors, both biological (e.g., menopause) and lifestyle (e.g., physical exercise, diet), contribute to the importance of this period and its impact on the brain and cognition <xref rid="bib0053" ref-type="bibr">[45]</xref>, <xref rid="bib0075" ref-type="bibr">[46]</xref>, <xref rid="bib0086" ref-type="bibr">[47]</xref>. Nevertheless, it remains to be seen whether midlife also marks a transition point for the influence of <italic toggle="yes">APOE</italic> &#949;4. In terms of cognition, findings to date have been mixed, providing little evidence of a well-defined cognitive profile associated with <italic toggle="yes">APOE</italic> &#949;4 at midlife [<xref rid="bib0054" ref-type="bibr">48</xref>]. However, this does not preclude the presence of neural differences. For instance, lifespan accounts specifically argue that while <italic toggle="yes">APOE</italic> &#949;4-related &#8220;hyperactivation&#8221; is present throughout midlife, it is a precursor to later life cognitive decline [<xref rid="bib0010" ref-type="bibr">34</xref>,<xref rid="bib0044" ref-type="bibr">35</xref>]. To assess such possibilities and inform our understanding of when and how <italic toggle="yes">APOE</italic> &#949;4 influences the brain, a comprehensive review of the extant literature is warranted. To our knowledge, only one review has specifically targeted midlife [<xref rid="bib0036" ref-type="bibr">49</xref>], yet the authors did not incorporate a lower age cut-off, leading to the inclusion of many studies containing younger adults, complicating interpretation.</p><p id="para0013">In this scoping review, we attempt to address this knowledge gap. Our primary aim was to systematically summarize what is currently known about <italic toggle="yes">APOE</italic> &#949;4-related differences on MRI-derived measures of brain structure, function, and connectivity in cognitively unimpaired, middle-aged adults (aged 40&#8211;65 years). Our secondary aim was to summarize the methods used to date, highlighting potential issues and outstanding questions for future research.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><p id="para0014">We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist [<xref rid="bib0090" ref-type="bibr">50</xref>] to ensure this scoping review was transparently and clearly described. Ethical approval was not required.</p><sec id="sec0003"><label>2.1</label><title>Protocol and registration</title><p id="para0015">Our protocol was developed a priori and pre-registered on the Open Science Framework (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.17605/OSF.IO/5S4K9" id="interref0001">https://doi.org/10.17605/OSF.IO/5S4K9</ext-link>). No substantive deviations were made. However, during screening, we encountered studies that led us to add additional details, clarifying our approach. All such clarifications are provided in the relevant sections below.</p></sec><sec id="sec0004"><label>2.2</label><title>Information sources and search strategy</title><p id="para0016">The search strategy was developed for Ovid MEDLINE by a subject librarian (A.Q.) working alongside a member of the review team (R.L.). Once finalized, the search strategy was translated to Ovid Embase, Ovid PsycINFO, and Scopus. A combination of text-word and controlled vocabulary terms were used to target key concepts of interest: <italic toggle="yes">APOE</italic> and MRI-derived measures of brain structure, function, and connectivity. To maximize inclusivity, search terms related to midlife were not included. Instead, we screened studies for relevance. To limit the number of publications requiring screening, however, we included a term to remove animal only studies, where possible.</p><p id="para0017">All searches were run on July 11, 2024. No language limits were applied. The full search strategy is provided in the Supplementary Material. For completeness, we also performed forward and backward reference searching of studies that passed full-text review. Forward reference searching was performed using Scopus and restricted to studies published on or before July 11, 2024.</p></sec><sec id="sec0005"><label>2.3</label><title>Eligibility criteria</title><p id="para0018">All studies identified in our searches were assessed against multi-stage eligibility criteria. First, studies had to be published in a peer-reviewed journal. Owing to the language proficiency of the authors, studies also had to be written in English. Second, studies had to include a distinct group of cognitively unimpaired, middle-aged adults. For this review, we define &#8220;cognitively unimpaired&#8221; as the absence of participants with neurological/psychiatric disorders and &#8220;middle-aged adults&#8221; as those aged between 40 and 65 years [<xref rid="bib0013" ref-type="bibr">43</xref>]. To meet this age criterion, studies had to explicitly state the age range of the included participants or the age range used for (initial) recruitment. In addition, if studies included more than one age group, they had to include an <italic toggle="yes">APOE</italic> &#949;4 comparison within the middle-aged group. Third, studies had to use MRI to examine brain structure, function, or connectivity. For this review, &#8220;structure&#8221; refers to volumetric and/or cortical thickness measures derived from structural MRI, whereas &#8220;function&#8221; refers to task-evoked BOLD signal change (i.e., activation/deactivation), assessed using fMRI. We use the term &#8220;connectivity&#8221; to refer to the temporal synchronicity of the BOLD fMRI signal across regions during task or rest (i.e., task-based or resting-state functional connectivity) and diffusion MRI-derived measures assessing the microstructural properties of white matter (i.e., structural connectivity). We thus excluded studies using MRI methods that do not assess these neural properties, as well as non-MRI methods. This ensured that we covered studies examining the neural properties of interest at a broadly similar spatial and temporal scale. Fourth, studies had to directly compare a group of <italic toggle="yes">APOE</italic> &#949;4 carriers to one or more groups of non-carriers. We did not include studies that adopted genome-wide association-like analyses, whereby associations with many single nucleotide polymorphisms in/near the <italic toggle="yes">APOE</italic> locus were examined. Moreover, if studies incorporated other factors (e.g., family history of dementia), we included them only if one of two conditions were met: (1) a formal statistical comparison between a carrier and non-carrier group at the same level of the other variable was presented (e.g., <italic toggle="yes">APOE</italic> &#949;4 carriers with a positive family history of dementia vs. <italic toggle="yes">APOE</italic> &#949;4 non-carriers with a positive family history of dementia); (2) a &#8220;main effect&#8221; of <italic toggle="yes">APOE</italic> &#949;4 was reported from the statistical model. It was not enough to adjust for <italic toggle="yes">APOE</italic> &#949;4 carrier status.</p></sec><sec id="sec0006"><label>2.4</label><title>Screening and data extraction</title><p id="para0019">Our search results were uploaded into Covidence (Veritas Health Innovation, Melbourne, Australia) for title and abstract screening. This screening step was performed independently by two reviewers (R.L., S.A.) who adopted a liberal approach, excluding studies only if there was evidence that they did not meet our stated eligibility criteria. For example, if a study abstract did not include an age range, we initially included it (if other criteria were satisfied). Disagreements were discussed and, where necessary, submitted to a third reviewer (M.N.R.) for mediation. All studies that passed this initial step were then subject to full-text review, again completed independently by two reviewers (R.L., S.A.) and mediated by a third (M.N.R). This step was performed more conservatively. For example, if a study passed title and abstract screening due to lack of evidence (e.g., no age range in the abstract), it was excluded during full-text review if the age range was either (a) not specified in the methods or (b) incompatible with our definition of midlife.</p><p id="para0020">Data from studies that passed full-text review were extracted by one reviewer (R.L.) using a project-specific Microsoft Excel spreadsheet. The extracted data included general publication information (e.g., title, publication year), methods (e.g., cross-sectional/longitudinal design, imaging modalities used), sample characteristics (e.g., sample size), and key <italic toggle="yes">APOE</italic> &#949;4-related results.</p></sec><sec id="sec0007"><label>2.5</label><title>Synthesis of results</title><p id="para0021">Studies were grouped according to whether they assessed brain structure, function, or connectivity. We initially planned to include separate structural and functional connectivity sections. However, due to the small number of studies using diffusion MRI, we instead grouped these studies together. Note that studies adopting a multi-modal approach were included in more than one category. Moreover, given the variable statistical methods and corresponding <italic toggle="yes">p</italic>-value thresholds used across studies, we discuss results according to the methods used in each study, as done elsewhere [<xref rid="bib0089" ref-type="bibr">51</xref>].</p></sec></sec><sec id="sec0008"><label>3</label><title>Results</title><sec id="sec0009"><label>3.1</label><title>Search results</title><p id="para0022">A PRISMA flow diagram outlining our search results is provided in <xref rid="fig0001" ref-type="fig">Fig. 1</xref>. After removing duplicates, our initial searches yielded 7092 studies. Of these, 6932 were excluded during title and abstract screening, leaving 160 studies for full-text review. In total, 135 studies were subsequently excluded. Reasons for exclusion were: age range not reported (<italic toggle="yes">n</italic> = 62); age range did not fall between 40 and 65 years (<italic toggle="yes">n</italic> = 61); lack of relevant <italic toggle="yes">APOE</italic> &#949;4 comparison (<italic toggle="yes">n</italic> = 11); did not use neuroimaging modality of interest (<italic toggle="yes">n</italic> = 1). Given the large number of studies excluded for failing to report an age range, we conducted a follow-up analysis to estimate the age range for these studies. As shown in the Supplementary Material, only one of the 62 studies reported values potentially consistent with a range between 40 and 65 years, suggesting our age criteria were appropriate for this midlife-specific review. The reference lists of the remaining 25 studies were then scanned, leading to the identification of three additional studies <xref rid="bib0057" ref-type="bibr">[52]</xref>, <xref rid="bib0063" ref-type="bibr">[53]</xref>, <xref rid="bib0069" ref-type="bibr">[54]</xref>. All three studies included relevant <italic toggle="yes">APOE</italic> &#949;4-related analyses, even though <italic toggle="yes">APOE</italic> was not mentioned in the title or abstract. Forward reference searching, performed in Scopus, led to the identification of two further studies [<xref rid="bib0068" ref-type="bibr">55</xref>,<xref rid="bib0071" ref-type="bibr">56</xref>]. These studies likewise did not mention <italic toggle="yes">APOE</italic> &#949;4 in the title or abstract. In total, therefore, we identified 30 studies eligible for this scoping review.<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>PRISMA flow diagram for the scoping review.</p></caption><alt-text id="alt0004">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec0010"><label>3.2</label><title>Study characteristics</title><p id="para0023">Among the 30 studies identified, 25 focused on brain structure (83.3 %), 10 focused on brain function (33.3 %), and 7 focused on brain structural/functional connectivity (23.3 %). These numbers do not sum to 30 as more than a third of the included studies were multi-modal (<italic toggle="yes">n</italic> = 11, 36.7 %). Collapsed across modality, most studies (<italic toggle="yes">n</italic> = 25, 83.3 %) adopted a cross-sectional design or reported only cross-sectional analyses of <italic toggle="yes">APOE</italic> &#949;4. In terms of sample size, substantial variability was evident. Median total sample size across studies was 92.5 (range = 32&#8211;611). When separated according to the neural properties examined, however, we found that studies focused on structure tended to include larger samples (<italic toggle="yes">Mdn</italic> = 122) than those focused on function (<italic toggle="yes">Mdn</italic> = 52) or connectivity (<italic toggle="yes">Mdn</italic> = 46). Surprisingly, we found little evidence to indicate that sample sizes had increased over the last two decades (Supplementary Figure 1).</p><p id="para0024">Variability was also evident in the age range of participants (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>). For instance, while all but one study [<xref rid="bib0007" ref-type="bibr">57</xref>] included individuals aged 50&#8211;55 years, those aged 40&#8211;55 and 60&#8211;65 years were less consistently included. In terms of geography, we found that most studies were conducted in North America (<italic toggle="yes">n</italic> = 17, 56.7 %) and Europe (<italic toggle="yes">n</italic> = 12, 40 %), although one study was conducted in Oceania (<italic toggle="yes">n</italic> = 1, 3.3 %). None of the studies included were conducted in Africa, Asia, or South America. Furthermore, only 8 studies provided information on the racial/ethnic composition of the included participants <xref rid="bib0071" ref-type="bibr">[56]</xref>, <xref rid="bib0028" ref-type="bibr">[58]</xref>, <xref rid="bib0029" ref-type="bibr">[59]</xref>, <xref rid="bib0065" ref-type="bibr">[60]</xref>, <xref rid="bib0066" ref-type="bibr">[61]</xref>, <xref rid="bib0072" ref-type="bibr">[62]</xref>, <xref rid="bib0074" ref-type="bibr">[63]</xref>, <xref rid="bib0080" ref-type="bibr">[64]</xref>. The reported values demonstrate that most of the participants (&#8805; 75 %) identified as white or &#8220;Caucasian&#8221;.<fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Age range in midlife <italic toggle="yes">APOE</italic> &#949;4 studies. Studies are listed by first author name and year of publication, arranged alphabetically. Circles represent minimum and maximum age values, while lines represent the full range. The ranges shown here reflect the full age range of the included participants or, if not available, the age range used for recruitment.</p></caption><alt-text id="alt0005">Fig 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="para0025">Almost all studies included here were mixed-sex<xref rid="cit_1" ref-type="fn">1</xref> studies (<italic toggle="yes">n</italic> = 27, 90 %). Among the three single-sex studies, two focused on males <xref rid="bib0074" ref-type="bibr">[63]</xref>, <xref rid="bib0024" ref-type="bibr">[65]</xref> and one focused on females [<xref rid="bib0066" ref-type="bibr">61</xref>]. Notably, excluding one study that did not report figures for sex [<xref rid="bib0078" ref-type="bibr">66</xref>], all mixed-sex studies included more females than males. It was surprising, therefore, that only four studies in this midlife review mentioned menopause. Of these, two discussed menopause in their discussion <xref rid="bib0065" ref-type="bibr">[60]</xref>, <xref rid="bib0020" ref-type="bibr">[67]</xref>, one reported the number of (self-reported) menopausal females in the sample but did not collect further details [<xref rid="bib0076" ref-type="bibr">68</xref>], and one (female-only) study reported the number of pre-, peri&#8209;, and post-menopausal females included, while examining associations between gonadotropins and neuroimaging biomarkers [<xref rid="bib0066" ref-type="bibr">61</xref>]. None of the studies examined the potential link between <italic toggle="yes">APOE</italic> &#949;4-related differences and menopausal status, despite the skew toward females.</p></sec><sec id="sec0011"><label>3.3</label><title>Brain structure</title><p id="para0027"><xref rid="tbl0001" ref-type="table">Table 1</xref> provides an overview of the 25 studies that examined differences in brain structure between midlife <italic toggle="yes">APOE</italic> &#949;4 carriers and non-carriers. Most of these studies focused on volumetric measures, although some examined cortical thickness. Whole-brain analyses tended to use voxel-based morphometry, but others analyzed global/whole-brain measures (e.g., total grey matter volume). Region of interest (ROI) analyses were heavily focused on the hippocampus. Of the 19 studies reporting an ROI analysis, 17 (89.5 %) included the hippocampus as an ROI, while 10 (52.9 %) included the hippocampus as the only ROI.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Summary of studies examining <italic toggle="yes">APOE</italic> &#949;4-related differences in brain structure at midlife.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Study</th><th valign="top" colspan="1" rowspan="1">Sample <italic toggle="yes">N</italic></th><th valign="top" colspan="1" rowspan="1">Age range</th><th valign="top" colspan="1" rowspan="1">Design</th><th valign="top" colspan="1" rowspan="1">Analytical approach</th><th valign="top" colspan="1" rowspan="1">Key <italic toggle="yes">APOE</italic> &#949;4 result(s)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Cherbuin et al. [<xref rid="bib0007" ref-type="bibr">57</xref>]</td><td valign="top" colspan="1" rowspan="1">331 (89 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">60&#8211;64</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (hippocampus, amygdala)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in total GM or WM volume<break/>(2) No difference in ROI volumes<break/>(3) No difference in whole-brain VBM analysis</td></tr><tr><td valign="top" colspan="1" rowspan="1">Dounavi et al. [<xref rid="bib0017" ref-type="bibr">69</xref>]</td><td valign="top" colspan="1" rowspan="1">180 (67 &#949;4+) / 156 (59 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;59</td><td valign="top" colspan="1" rowspan="1">Longitudinal</td><td valign="top" colspan="1" rowspan="1">ROI (hippocampus + subfields)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in hippocampal volume at baseline or two-year follow-up<break/>(2) Lower molecular layer volume at baseline in &#949;4+</td></tr><tr><td valign="top" colspan="1" rowspan="1">Dounavi et al. [<xref rid="bib0018" ref-type="bibr">70</xref>]</td><td valign="top" colspan="1" rowspan="1">600 (233 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;59</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (hippocampus + subfields, assorted subcortical structures)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in ROI volumes<break/>(2) No difference in cortical thickness</td></tr><tr><td valign="top" colspan="1" rowspan="1">Dowell et al. [<xref rid="bib0019" ref-type="bibr">71</xref>]</td><td valign="top" colspan="1" rowspan="1">37 (17 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">43&#8211;58</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (parahippocampus, cuneus, anterior cingulate, precuneus, posterior cingulate, hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in ROI (WM) volumes<break/>(2) Thicker parahippocampal cortex in &#949;4+</td></tr><tr><td valign="top" colspan="1" rowspan="1">Evans et al. [<xref rid="bib0022" ref-type="bibr">72</xref>]</td><td valign="top" colspan="1" rowspan="1">32 (16 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">45&#8211;55</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in hippocampal volume</td></tr><tr><td valign="top" colspan="1" rowspan="1">Fennema-Notestine et al. [<xref rid="bib0024" ref-type="bibr">65</xref>]</td><td valign="top" colspan="1" rowspan="1">482 (125 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">51&#8211;59</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (assorted medial temporal, lateral temporal, and frontal regions)</td><td valign="top" colspan="1" rowspan="1">(1) Thinner frontal cortices in &#949;4+<break/>(2) Thicker fusiform cortex in &#949;4+</td></tr><tr><td valign="top" colspan="1" rowspan="1">Goveas et al. [<xref rid="bib0034" ref-type="bibr">73</xref>]</td><td valign="top" colspan="1" rowspan="1">46 (20 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">44&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) No difference in whole-brain VBM analysis</td></tr><tr><td valign="top" colspan="1" rowspan="1">Johnson et al. [<xref rid="bib0048" ref-type="bibr">74</xref>]</td><td valign="top" colspan="1" rowspan="1">132 (48 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) No difference in whole-brain VBM analysis</td></tr><tr><td valign="top" colspan="1" rowspan="1">Johnson et al. [<xref rid="bib0047" ref-type="bibr">75</xref>]</td><td valign="top" colspan="1" rowspan="1">110 (39 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) No difference in whole-brain VBM analysis</td></tr><tr><td valign="top" colspan="1" rowspan="1">Li et al. [<xref rid="bib0056" ref-type="bibr">76</xref>]</td><td valign="top" colspan="1" rowspan="1">46 (20 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">44&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in whole-brain VBM analysis<break/>(2) No difference in hippocampal volume</td></tr><tr><td valign="top" colspan="1" rowspan="1">Liu et al. [<xref rid="bib0057" ref-type="bibr">52</xref>]</td><td valign="top" colspan="1" rowspan="1">160 (61 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;59</td><td valign="top" colspan="1" rowspan="1">Longitudinal</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) No difference in total GM or WM volume at baseline or two-year follow-up<break/>(2) No difference in total cortical thickness</td></tr><tr><td valign="top" colspan="1" rowspan="1">McKeever et al. [<xref rid="bib0063" ref-type="bibr">53</xref>]</td><td valign="top" colspan="1" rowspan="1">150 (57 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;59</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (hippocampal subfields)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in hippocampal subfield volumes</td></tr><tr><td valign="top" colspan="1" rowspan="1">Nemes et al. [<xref rid="bib0065" ref-type="bibr">60</xref>]</td><td valign="top" colspan="1" rowspan="1">77 (33&#8314; &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;64</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in whole-brain VBM analyses (males or females, respectively)<break/>(2) No difference in hippocampal volume</td></tr><tr><td valign="top" colspan="1" rowspan="1">Nerattini et al. [<xref rid="bib0066" ref-type="bibr">61</xref>]</td><td valign="top" colspan="1" rowspan="1">191 (86&#8314; &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (frontal regions)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in frontal GM volume</td></tr><tr><td valign="top" colspan="1" rowspan="1">Newton et al. [<xref rid="bib0068" ref-type="bibr">55</xref>]</td><td valign="top" colspan="1" rowspan="1">53 (18 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;59</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (entorhinal cortex + subregions, hippocampal subfields, retrosplenial cortex, posterior cingulate)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in ROI volumes</td></tr><tr><td valign="top" colspan="1" rowspan="1">O'Brien et al. <xref rid="bib0069" ref-type="bibr">[54]</xref></td><td valign="top" colspan="1" rowspan="1">165 (64 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;59</td><td valign="top" colspan="1" rowspan="1">Longitudinal</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) No difference in brain volume change</td></tr><tr><td valign="top" colspan="1" rowspan="1">Okonkwo et al. [<xref rid="bib0072" ref-type="bibr">62</xref>]</td><td valign="top" colspan="1" rowspan="1">108 (35 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Longitudinal</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (posterior cingulate, hippocampus, parahippocampal gyrus, amygdala)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in ROI-restricted VBM analysis at baseline or four-year follow-up<break/>(2) Lower right middle temporal gyrus GM density in &#949;4+ (exploratory whole-brain VBM analysis)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Okonkwo et al. [<xref rid="bib0071" ref-type="bibr">56</xref>]</td><td valign="top" colspan="1" rowspan="1">122 (48&#8314; &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in hippocampal volume</td></tr><tr><td valign="top" colspan="1" rowspan="1">Panizzon et al. [<xref rid="bib0074" ref-type="bibr">63</xref>]</td><td valign="top" colspan="1" rowspan="1">375 (94&#8314; &#949;4+)</td><td valign="top" colspan="1" rowspan="1">51&#8211;59</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) Lower hippocampal volume in &#949;4+ (only when <italic toggle="yes">APOE</italic>-testosterone interaction present)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Rajah et al. [<xref rid="bib0076" ref-type="bibr">68</xref>]</td><td valign="top" colspan="1" rowspan="1">49 (11 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">41&#8211;58</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in hippocampal volume</td></tr><tr><td valign="top" colspan="1" rowspan="1">Reiman et al. [<xref rid="bib0078" ref-type="bibr">66</xref>]</td><td valign="top" colspan="1" rowspan="1">33 (11 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">50&#8211;62</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in hippocampal volume<break/>(2) No difference in left-right asymmetry of hippocampal volume</td></tr><tr><td valign="top" colspan="1" rowspan="1">Ritchie et al. [<xref rid="bib0080" ref-type="bibr">64</xref>]</td><td valign="top" colspan="1" rowspan="1">208 (75&#8314; &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;59</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in total brain volume of whole-brain grey matter<break/>(2) No difference in hippocampal volume</td></tr><tr><td valign="top" colspan="1" rowspan="1">Shah et al. <xref rid="bib98" ref-type="bibr">[77]</xref></td><td valign="top" colspan="1" rowspan="1">611 (235 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;59</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (thalamus + subregions)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in thalamus volume<break/>(2) No difference in thalamic subregion volumes</td></tr><tr><td valign="top" colspan="1" rowspan="1">Trivedi et al. [<xref rid="bib0091" ref-type="bibr">78</xref>]</td><td valign="top" colspan="1" rowspan="1">40 (23 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (medial temporal lobe)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in ROI-restricted VBM analysis</td></tr><tr><td valign="top" colspan="1" rowspan="1">Xu et al. [<xref rid="bib0095" ref-type="bibr">79</xref>]</td><td valign="top" colspan="1" rowspan="1">74 (33 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) No difference in whole-brain VBM analysis</td></tr></tbody></table><table-wrap-foot><fn id="spara004"><p><italic toggle="yes">Note</italic>. Sample <italic toggle="yes">N</italic> reflects the total number of cognitively healthy middle-aged participants reportedly included in relevant <italic toggle="yes">APOE</italic> &#949;4 analyses. The number of <italic toggle="yes">APOE</italic> &#949;4 carriers (&#949;4+) is provided in parentheses. Age range is reported in years and reflects the stated age range of the included participants or, if unavailable, the age range used for (initial) recruitment. We did not differentiate between studies adopting different definitions of <italic toggle="yes">APOE</italic> &#949;4+ (e.g., &#949;3/&#949;4 vs. &#949;3/&#949;4 + &#949;4/&#949;4). For studies with multiple groups (e.g., FH+/&#949;4+, FH-/&#949;4+, etc.), we summed across carrier/non-carrier groups. For studies reporting the percentage of <italic toggle="yes">APOE</italic> &#949;4 carriers, we used the reported sample sizes to calculate values and, where necessary, rounded to the nearest whole number (indicated by &#8314;). Design reflects the cross-sectional or longitudinal nature of the <italic toggle="yes">APOE</italic> &#949;4 analysis and not necessarily the overall design of the study.</p></fn><fn id="spara005"><p>Abbreviations: <italic toggle="yes">APOE</italic> = apolipoprotein-E; FH = family history of dementia; GM = grey matter; ROI = region of interest; VBM = voxel-based morphometry; WM = white matter.</p></fn></table-wrap-foot></table-wrap></p><p id="para0028">Among the 25 studies reviewed, 20 (80 %) did not observe a statistically significant difference between <italic toggle="yes">APOE</italic> &#949;4 carriers and non-carriers. While null findings were prominent in studies employing voxel-based morphometry, studies examining whole-brain and ROI-specific measures of volume and cortical thickness also reported null findings (<xref rid="tbl0001" ref-type="table">Table 1</xref>). Moreover, even among the 5 studies reporting at least one significant <italic toggle="yes">APOE</italic> &#949;4-related difference <xref rid="bib0072" ref-type="bibr">[62]</xref>, <xref rid="bib0074" ref-type="bibr">[63]</xref>, <xref rid="bib0024" ref-type="bibr">[65]</xref>, <xref rid="bib0017" ref-type="bibr">[69]</xref>, <xref rid="bib0019" ref-type="bibr">[71]</xref>, no consistent pattern was evident. For instance, in a single-sex (male-only) study, Fennema-Notestine et al. [<xref rid="bib0024" ref-type="bibr">65</xref>] reported that &#949;4 carriers possessed thinner frontal cortices but thicker fusiform cortices than &#949;4 non-carriers. However, no such differences were observed in the thickness of parahippocampal cortex, despite another study reporting &#949;4-related differences in this region at midlife [<xref rid="bib0019" ref-type="bibr">71</xref>]. Fennama-Notestine et al. also observed no difference in hippocampal volume, consistent with most midlife studies reviewed here, but inconsistent with a study conducted on participants from the same male-only cohort [<xref rid="bib0074" ref-type="bibr">63</xref>]. That said, the negative influence of <italic toggle="yes">APOE</italic> &#949;4 on hippocampal volume in the latter study was only evident when the interaction between the allele and testosterone was included in the statistical model [<xref rid="bib0074" ref-type="bibr">63</xref>].</p><p id="para0029">The focus on the whole hippocampus and not its subfields may also explain the lack of &#949;4-related differences in studies targeting this structure. While terminology varies, it is generally accepted that the hippocampus includes distinct subfields: the cornu ammonis fields, dentate gyrus, and subiculum [<xref rid="bib0043" ref-type="bibr">80</xref>]. There is evidence to suggest that these subfields are differentially impacted in the early stages of AD [<xref rid="bib0096" ref-type="bibr">81</xref>] and thus differences between <italic toggle="yes">APOE</italic> &#949;4 carriers and non-carriers may likewise be present earlier in the lifespan. Accordingly, by averaging across subfields, it is possible that important differences were missed. This view is partially supported by findings from Dounavi et al. [<xref rid="bib0017" ref-type="bibr">69</xref>] who reported that the volume of the hippocampal molecular layer, but not other hippocampal subfields, was lower in &#949;4 carriers. However, the same group failed to replicate this result in a subsequent study adopting a different method for the automated segmentation and processing of hippocampal subfields [<xref rid="bib0018" ref-type="bibr">70</xref>]. Additionally, two other studies featured in this review &#8211; one including manual segmentation of hippocampal subfields at 3T [<xref rid="bib0063" ref-type="bibr">53</xref>], one including semi-automated segmentation of hippocampal subfields at 7T [<xref rid="bib0068" ref-type="bibr">55</xref>] &#8211; failed to identify &#949;4-related differences.</p></sec><sec id="sec0012"><label>3.4</label><title>Brain function</title><p id="para0030"><xref rid="tbl0002" ref-type="table">Table 2</xref> provides an overview of the 10 midlife studies that used fMRI to examine <italic toggle="yes">APOE</italic> &#949;4-related differences on brain function. Analytical approaches varied across studies: four adopted whole-brain analyses (40 %), two adopted ROI-specific analyses (20 %), and four conducted mixed analyses (40 %). As with studies of brain structure, ROI-specific analyses often focused on the hippocampus and medial temporal lobe, although other regions (e.g., posterior cingulate cortex) were also examined. Interestingly, many of these midlife fMRI studies (<italic toggle="yes">n</italic> = 7, 70 %) reported at least one significant difference between &#949;4 carriers and non-carriers, but variability was present.<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Summary of studies examining <italic toggle="yes">APOE</italic> &#949;4-related differences in brain function at midlife.</p></caption><alt-text id="alt0002">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Study</th><th valign="top" colspan="1" rowspan="1">Sample <italic toggle="yes">N</italic></th><th valign="top" colspan="1" rowspan="1">Age range</th><th valign="top" colspan="1" rowspan="1">Design</th><th valign="top" colspan="1" rowspan="1">Task(s)</th><th valign="top" colspan="1" rowspan="1">Analytical approach</th><th valign="top" colspan="1" rowspan="1">Key <italic toggle="yes">APOE</italic> &#949;4 result(s)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Evans et al. [<xref rid="bib0020" ref-type="bibr">67</xref>]</td><td valign="top" colspan="1" rowspan="1">36 (17 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">43&#8211;58</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Covert attention</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (hippocampus, extrastriate visual areas, inferior parietal areas, anterior cingulate areas, right middle frontal areas)</td><td valign="top" colspan="1" rowspan="1">(1) Lower activation in extrastriate cortex independent of cue type (valid, invalid) among &#949;4+</td></tr><tr><td valign="top" colspan="1" rowspan="1">Evans et al. [<xref rid="bib0021" ref-type="bibr">82</xref>]</td><td valign="top" colspan="1" rowspan="1">40 (19 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">43&#8211;58</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Prospective memory, covert attention</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (hippocampus, superior parietal areas)</td><td valign="top" colspan="1" rowspan="1">(1) Lower activation in extrastriate cortex and right superior parietal lobule during prospective memory trials among &#949;4+ <break/>(2) No difference in activation for validity effect (valid trial mean RTs - invalid trial mean RTs) on covert attention task</td></tr><tr><td valign="top" colspan="1" rowspan="1">Evans et al. [<xref rid="bib0022" ref-type="bibr">72</xref>]</td><td valign="top" colspan="1" rowspan="1">32 (16 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">45&#8211;55</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Old/new recognition</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (hippocampus, parahippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in activation for subsequent memory effects<break/>(2) Greater activation in left hippocampus (subiculum) for remembered vs. forgotten items in &#949;4- but not &#949;4+</td></tr><tr><td valign="top" colspan="1" rowspan="1">Johnson et al. [<xref rid="bib0048" ref-type="bibr">74</xref>]</td><td valign="top" colspan="1" rowspan="1">132 (48 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Old/new recognition</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) No difference in activation for novelty effect (new &gt; old)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Johnson et al. [<xref rid="bib0047" ref-type="bibr">75</xref>]</td><td valign="top" colspan="1" rowspan="1">110 (39 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Self-appraisal</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) Greater activation for referential self-appraisal in left superior frontal gyrus, left anterior cingulate, and retrosplenial areas among &#949;4+ with negative FH<break/>(2) No difference in activation for referential self-appraisal (restricted to regions not showing interaction)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Newton et al. [<xref rid="bib0068" ref-type="bibr">55</xref>]</td><td valign="top" colspan="1" rowspan="1">53 (18 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;59</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Spatial memory</td><td valign="top" colspan="1" rowspan="1">ROI (posteromedial entorhinal cortex)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in grid cell-like activation</td></tr><tr><td valign="top" colspan="1" rowspan="1">Okonkwo et al. [<xref rid="bib0071" ref-type="bibr">56</xref>]</td><td valign="top" colspan="1" rowspan="1">122 (48&#8314; &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Old/new recognition</td><td valign="top" colspan="1" rowspan="1">ROI (precuneus, posterior cingulate)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in activation for familiarity effect (old &gt; new)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Rajah et al. [<xref rid="bib0076" ref-type="bibr">68</xref>]</td><td valign="top" colspan="1" rowspan="1">51 (11 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">41&#8211;58</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Spatial context memory</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) Greater activation in right hippocampus during low-load encoding among &#949;4+ with positive FH<break/>(2) Greater encoding-related activation and lower retrieval related activation in fusiform cortex among &#949;4+ with positive FH</td></tr><tr><td valign="top" colspan="1" rowspan="1">Trivedi et al. [<xref rid="bib0091" ref-type="bibr">78</xref>]</td><td valign="top" colspan="1" rowspan="1">40 (23 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Old/new recognition</td><td valign="top" colspan="1" rowspan="1">Whole-brain &amp; ROI (medial temporal lobe)</td><td valign="top" colspan="1" rowspan="1">(1) Lower activation for novelty effect (new &gt; old) in right hippocampus among &#949;4+<break/>(2) No difference in activation for familiarity effect (old &gt; new)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Xu et al. [<xref rid="bib0095" ref-type="bibr">79</xref>]</td><td valign="top" colspan="1" rowspan="1">74 (33 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Old/new recognition</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) Lower activation for familiarity effect (old &gt; new) in left dorsal posterior cingulate/precuneus among &#949;4+<break/>(2) Lower activation for faces (old or new) in left anterior cingulate gyrus among &#949;4+</td></tr></tbody></table><table-wrap-foot><fn><p><italic toggle="yes">Note</italic>. Sample <italic toggle="yes">N</italic> reflects the total number of cognitively healthy middle-aged participants reportedly included in relevant <italic toggle="yes">APOE</italic> &#949;4 analyses. The number of <italic toggle="yes">APOE</italic> &#949;4 carriers (&#949;4+) is provided in parentheses. Age range is reported in years and reflects the stated age range of the included participants or, if unavailable, the age range used for (initial) recruitment. We did not differentiate between studies adopting different definitions of <italic toggle="yes">APOE</italic> &#949;4+ (e.g., &#949;3/&#949;4 vs. &#949;3/&#949;4 + &#949;4/&#949;4). For studies with multiple groups (e.g., FH+/&#949;4+, FH-/&#949;4+, etc.), we summed across carrier/non-carrier groups. For studies reporting the percentage of <italic toggle="yes">APOE</italic> &#949;4 carriers, we used the reported sample sizes to calculate values and, where necessary, rounded to the nearest whole number (indicated by &#8314;). Design reflects the cross-sectional or longitudinal nature of the <italic toggle="yes">APOE</italic> &#949;4 analysis and not necessarily the overall design of the study. For Task, we used our own labels and not necessarily those provided by the authors. This helps to highlight commonalities across studies, where they exist. Abbreviations: <italic toggle="yes">APOE</italic> = apolipoprotein-E; FH = family history of dementia; ROI = region of interest; RTs = reaction times.</p></fn></table-wrap-foot></table-wrap></p><p id="para0031">Given the <italic toggle="yes">APOE</italic> &#949;4-AD link, it is unsurprising that most tasks were memory-related (<italic toggle="yes">n</italic> = 8, 72.7 %). Old/new recognition memory tasks were the most common (<italic toggle="yes">n</italic> = 5). Results from these studies were inconclusive and sometimes contradictory. For instance, while Johnson et al. [<xref rid="bib0048" ref-type="bibr">74</xref>] did not observe <italic toggle="yes">APOE</italic> &#949;4-related differences in novelty-related activation, Trivedi et al. [<xref rid="bib0091" ref-type="bibr">78</xref>] reported lower novelty-related activation in the right hippocampus among &#949;4 carriers relative to &#949;4 non-carriers. Further, when examining familiarity-related activation, Trivedi et al. [<xref rid="bib0091" ref-type="bibr">78</xref>] did not identify differences related to <italic toggle="yes">APOE</italic> &#949;4 (see also [<xref rid="bib0071" ref-type="bibr">56</xref>]), despite another study reporting lower activation among &#949;4 carriers (relative to &#949;4 non-carriers) in left dorsal posterior cingulate cortex/precuneus [<xref rid="bib0095" ref-type="bibr">79</xref>]. Finally, while Evans et al. [<xref rid="bib0022" ref-type="bibr">72</xref>] did not detect a significant <italic toggle="yes">APOE</italic> &#949;4 group difference, they did find that non-carriers &#8211; but not &#949;4 carriers &#8211; exhibited greater activation in left hippocampus at encoding for remembered vs. forgotten items. Caution is warranted, however, as this was the only study to examine activation during the encoding phase of an old/new recognition task.</p><p id="para0032">Nonetheless, differences in encoding-related activation between those with and without &#949;4 have been reported in another midlife memory study, albeit using a different paradigm. Rajah et al. [<xref rid="bib0076" ref-type="bibr">68</xref>] used a spatial context memory task and scanned participants at encoding and retrieval. At encoding, participants viewed photographs of faces presented to the left or right of fixation and were required to remember the item and its location. At retrieval, participants were asked to indicate which face they previously saw on the left or right, depending on the cue. The number of items was manipulated, producing low- and high-load conditions. The authors reported greater activation in the right hippocampus during low-load encoding among &#949;4 carriers with a family history of AD relative to &#949;4 non-carriers with a family history of AD, as well as those without either risk factor. The authors also observed that, among participants with a family history of AD, possession of the &#949;4 allele was related to differential activation of fusiform cortex during encoding and retrieval.</p><p id="para0033">In a separate study, Newton et al. [<xref rid="bib0068" ref-type="bibr">55</xref>] used a spatial memory task to explore the association between AD risk factors, including <italic toggle="yes">APOE</italic> &#949;4, and grid cell-like activation in posteromedial entorhinal cortex. Using ultra-high resolution (7T) MRI, the authors scanned participants from the PREVENT Dementia cohort [<xref rid="bib0079" ref-type="bibr">83</xref>] while they watched videos of themselves passively navigate through a three-dimensional room containing seven everyday items. Participants were instructed to learn the locations of these items, which changed across videos. The walls of the room, each decorated with items, did not change, providing orientation clues. At the end of each video, participants were presented with three images of each item &#8211; one in the correct location, two in incorrect locations &#8211; and asked to identify the correct one. For this review, the crucial finding was that <italic toggle="yes">APOE</italic> &#949;4 alone was not associated with grid cell-like activation in posteromedial entorhinal cortex. While this task differed substantially to that use by Rajah et al. [<xref rid="bib0076" ref-type="bibr">68</xref>], it is notable that only one of these studies identified an &#949;4 effect at midlife, despite both tasks requiring participants to identify the spatial location of previously seen items.</p><p id="para0034">The final memory-related task focused on prospective memory: remembering to perform a future planned action [<xref rid="bib0021" ref-type="bibr">82</xref>]. In this study, participants were presented with playing cards, presented sequentially. They were required to press a button if the suit was hearts or spades (sort trials) but withhold their response if the suit was clubs or diamonds (withhold trials). While doing so, participants also had to remember to press a different button if the card was a seven regardless of the suit (prospective memory trial). The authors observed an association between <italic toggle="yes">APOE</italic> &#949;4 and activation evoked by this task but only on prospective memory trials. Specifically, during prospective memory trials, <italic toggle="yes">APOE</italic> &#949;4 carriers were found to exhibit lower levels of activation than non-carriers in extrastriate cortex and the right superior parietal lobe.</p><p id="para0035"><italic toggle="yes">APOE</italic> &#949;4-related differences in extrastriate cortex function have also been reported using a non-mnemonic paradigm, potentially suggesting that the allele has a detrimental impact on aspects of the visual system at midlife. Evans et al. [<xref rid="bib0020" ref-type="bibr">67</xref>] used a covert attention task in which participants were asked to indicate whether an item appeared on the left or right of screen following a cue, which was predictive of item location (valid cue) or not (invalid cue). Evans et al. found that &#949;4 carriers demonstrated lower activation than non-carriers in extrastriate cortex independent of cue type (valid, invalid). However, in a subsequent study, the same group failed to observe differences in activation between groups when using the exact same covert attention task [<xref rid="bib0021" ref-type="bibr">82</xref>]. Accordingly, given the lack of internal replication, it is unclear whether differences in extrastriate cortex function are robust.</p><p id="para0036">While nearly all tasks used to explore <italic toggle="yes">APOE</italic> &#949;4&#8217;s influence at midlife were memory- or attention-related, Johnson et al. [<xref rid="bib0047" ref-type="bibr">75</xref>] used a metacognitive self-appraisal task. In this paradigm, a series of adjectives were presented, and participants were asked to indicate whether the adjectives described their own traits/abilities (self-referential condition) or were of positive valence (non-referential condition). The authors did not identify <italic toggle="yes">APOE</italic> &#949;4-related differences, but their analysis was restricted to regions not showing an interaction between the allele and family history of AD. Despite not being the primary focus of this review, Johnson et al. did find that &#949;4 carriers without a family history of AD showed greater activation for referential self-appraisal in left superior frontal gyrus, left anterior cingulate, and retrosplenial areas in left superior frontal gyrus, left anterior cingulate gyrus, and retrosplenial cortex relative to all other groups. Yet, while differences between &#949;4 carriers/non-carriers without a family history of AD could point to an allele-specific impact at midlife, the lack of difference between &#949;4 carriers/non-carriers with a family history of AD complicates this interpretation.</p></sec><sec id="sec0013"><label>3.5</label><title>Brain connectivity</title><p id="para0037"><xref rid="tbl0003" ref-type="table">Table 3</xref> provides an overview of the seven midlife studies that examined differences in brain connectivity between middle-aged <italic toggle="yes">APOE</italic> &#949;4 carriers and non-carriers. Five reported significant &#949;4-related differences, representing a majority (71.4 %). However, the methods and, in turn, the form of connectivity probed varied across studies. One study used diffusion MRI [<xref rid="bib0022" ref-type="bibr">72</xref>], three studies used resting-state fMRI [<xref rid="bib0019" ref-type="bibr">71</xref>,<xref rid="bib0034" ref-type="bibr">73</xref>,<xref rid="bib0056" ref-type="bibr">76</xref>], while an additional three studies used some combination of the two [<xref rid="bib0028" ref-type="bibr">58</xref>,<xref rid="bib0029" ref-type="bibr">59</xref>,<xref rid="bib0049" ref-type="bibr">84</xref>].<table-wrap position="float" id="tbl0003" orientation="portrait"><label>Table 3</label><caption><p>Summary of studies examining <italic toggle="yes">APOE</italic> &#949;4-related differences in brain structural/functional connectivity at midlife.</p></caption><alt-text id="alt0003">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Study</th><th valign="top" colspan="1" rowspan="1">Sample <italic toggle="yes">N</italic></th><th valign="top" colspan="1" rowspan="1">Age range</th><th valign="top" colspan="1" rowspan="1">Design</th><th valign="top" colspan="1" rowspan="1">Analytical approach</th><th valign="top" colspan="1" rowspan="1">Key <italic toggle="yes">APOE</italic> &#949;4 result(s)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Dowell et al. [<xref rid="bib0019" ref-type="bibr">71</xref>]</td><td valign="top" colspan="1" rowspan="1">37 (17 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">43&#8211;58</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) No difference in 8 resting-state networks</td></tr><tr><td valign="top" colspan="1" rowspan="1">Evans et al. [<xref rid="bib0022" ref-type="bibr">72</xref>]</td><td valign="top" colspan="1" rowspan="1">32 (16 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">45&#8211;55</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) No difference in hippocampal ODI</td></tr><tr><td valign="top" colspan="1" rowspan="1">Fortel et al. [<xref rid="bib0028" ref-type="bibr">58</xref>]</td><td valign="top" colspan="1" rowspan="1">76 (38 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;60</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) Global shift toward hyper-excitation in rs-SC among female (but not male) &#949;4+<break/>(2) Lower tolerance to network dysfunction among female (but not male) &#949;4+</td></tr><tr><td valign="top" colspan="1" rowspan="1">Fortel et al. [<xref rid="bib0029" ref-type="bibr">59</xref>]</td><td valign="top" colspan="1" rowspan="1">76 (38 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;60</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) Global shift toward hyper-excitation in rs-SC among &#949;4+<break/>(2) Shift toward hyper-excitation across several ROIs comprising the rs-SC among female (but not male) &#949;4+, starting at age 50</td></tr><tr><td valign="top" colspan="1" rowspan="1">Goveas et al. [<xref rid="bib0034" ref-type="bibr">73</xref>]</td><td valign="top" colspan="1" rowspan="1">46 (20 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">44&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (DMN: posterior cingulate, ECN: dorsolateral prefrontal cortex, SN: orbital anterior insula)</td><td valign="top" colspan="1" rowspan="1">(1) Lower DMN connectivity among &#949;4+<break/>(2) Lower ECN connectivity among &#949;4+<break/>(3) Greater SN connectivity among &#949;4+</td></tr><tr><td valign="top" colspan="1" rowspan="1">Korthauer et al. [<xref rid="bib0049" ref-type="bibr">84</xref>]</td><td valign="top" colspan="1" rowspan="1">76 (38 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">40&#8211;60</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">Whole-brain</td><td valign="top" colspan="1" rowspan="1">(1) Lower global and local efficiency in rs-SC among &#949;4+<break/>(2) Greater betweenness centrality of right putamen and right thalamus, as well as greater participation coefficient of the right thalamus, in rs-SC among &#949;4+<break/>(3) Lower betweenness centrality of left lateral orbitofrontal cortex and left superior temporal gyrus, as well as lower participation coefficient of the left lateral orbitofrontal cortex and left superior frontal cortex, in rs-SC among &#949;4+<break/>(4) In targeted failure analysis, greater resilience evident in &#949;4+ until 10 % of hubs removed, then lower resilience as central nodes removed</td></tr><tr><td valign="top" colspan="1" rowspan="1">Li et al. [<xref rid="bib0056" ref-type="bibr">76</xref>]</td><td valign="top" colspan="1" rowspan="1">46 (20 &#949;4+)</td><td valign="top" colspan="1" rowspan="1">44&#8211;65</td><td valign="top" colspan="1" rowspan="1">Cross-sectional</td><td valign="top" colspan="1" rowspan="1">ROI (hippocampus)</td><td valign="top" colspan="1" rowspan="1">(1) Lower functional connectivity between hippocampus and various regions (caudate, thalamus, posterior cingulate, superior frontal gyrus, lentiform nucleus, medial frontal gyrus, insula, anterior cingulate corte, culmen of cerebellum) among &#949;4+</td></tr></tbody></table><table-wrap-foot><fn id="spara009"><p><italic toggle="yes">Note</italic>. Sample <italic toggle="yes">N</italic> reflects the total number of cognitively healthy middle-aged participants reportedly included in relevant <italic toggle="yes">APOE</italic> &#949;4 analyses. The number of <italic toggle="yes">APOE</italic> &#949;4 carriers (&#949;4+) is provided in parentheses. Age range is reported in years and reflects the stated age range of the included participants or, if unavailable, the age range used for (initial) recruitment. We did not differentiate between studies adopting different definitions of <italic toggle="yes">APOE</italic> &#949;4+ (e.g., &#949;3/&#949;4 vs. &#949;3/&#949;4 + &#949;4/&#949;4). For studies with multiple groups (e.g., FH+/&#949;4+, FH-/&#949;4+, etc.), we summed across carrier/non-carrier groups. For studies reporting the percentage of <italic toggle="yes">APOE</italic> &#949;4 carriers, we used the reported sample sizes to calculate values and, where necessary, rounded to the nearest whole number (indicated by &#8314;). Design reflects the cross-sectional or longitudinal nature of the <italic toggle="yes">APOE</italic> &#949;4 analysis and not necessarily the overall design of the study.</p></fn><fn id="spara010"><p>Abbreviations: <italic toggle="yes">APOE</italic> = apolipoprotein-E; DMN = default mode network; ECN = executive control network; FH = family history of dementia; ODI = orientation dispersion index; ROI = region of interest; rs-SC = resting-state structural connectome; SN = salience network.</p></fn></table-wrap-foot></table-wrap></p><p id="para0038">The study to exclusively use diffusion MRI did so to examine <italic toggle="yes">APOE</italic> &#949;4-related differences in bilateral hippocampal microstructure, assessed via the orientation dispersion index (ODI; [<xref rid="bib0022" ref-type="bibr">72</xref>]). However, the authors found that &#949;4 carriers and non-carriers did not differ in bilateral hippocampal ODI. Nevertheless, Evans et al. did observe a difference between groups in the association between hippocampal ODI and old/new recognition memory, with a positive trend evident only for &#949;4 non-carriers. It is possible, therefore, that <italic toggle="yes">APOE</italic> &#949;4 may not impact the microstructural properties of the hippocampus but may impact how these properties relate to and support memory.</p><p id="para0039">Among the three studies to exclusively use resting-state fMRI, there was variation in the analytical methods used. Goveas et al. [<xref rid="bib0034" ref-type="bibr">73</xref>] and Li et al. [<xref rid="bib0056" ref-type="bibr">76</xref>] both conducted seed-based analyses, examining differences in functional connectivity associated with specific regions. Goveas et al. focused on core components of different resting-state functional networks: posterior cingulate cortex (default mode network), dorsolateral prefrontal cortex (executive control network), and orbital anterior insula (salience network). Li et al., conversely, focused on the hippocampus. Despite this, both studies reported patterns of lower functional connectivity among &#949;4 carriers relative to non-carriers; Goveas et al. identified this pattern within the default mode and executive control networks, while Li et al. identified this pattern between the hippocampus and several regions. The exception was that of the salience network, where Goveas et al. identified increased connectivity among &#949;4 carriers relative to non-carriers. By contrast, Dowell et al. [<xref rid="bib0019" ref-type="bibr">71</xref>] used independent components analysis to identify resting-state networks and test for <italic toggle="yes">APOE</italic> &#949;4-related differences. Although the authors identified eight such networks, including the default mode and executive control networks, no carrier/non-carrier differences were evident in their midlife sample. This contradicts the results reported by Goveas et al., raising questions about the role of methodological choices.</p><p id="para0040">Three studies have adopted an alternative approach, combining both diffusion MRI and resting-state fMRI [<xref rid="bib0028" ref-type="bibr">58</xref>,<xref rid="bib0029" ref-type="bibr">59</xref>,<xref rid="bib0049" ref-type="bibr">84</xref>]. For example, Korthauer et al. [<xref rid="bib0049" ref-type="bibr">84</xref>] extracted graph theoretical properties from three networks &#8211; a functional network derived from resting-state fMRI, a structural network derived from diffusion MRI, and an integrated functional-structural network (the &#8220;resting-state structural connectome&#8221;) &#8211; and then examined differences between middle-aged <italic toggle="yes">APOE</italic> &#949;4 carriers and non-carriers. While the authors did not find differences in the properties of the functional and structural networks, they observed differences in the resting-state structural connectome. Specifically, they found that &#949;4 carriers exhibited lower levels of global and local efficiency in this combined network. Korthauer et al. also reported differences in the properties of hub networks and lower resilience to node failure, especially once more than 10 % of hubs were removed. These results highlight the potential utility of combining resting-state fMRI and diffusion MRI to probe connectivity and indicate that such an approach may reveal subtle <italic toggle="yes">APOE</italic> &#949;4-related differences at midlife. Concordantly, two further studies have demonstrated that <italic toggle="yes">APOE</italic> &#949;4 carriers, in particular female <italic toggle="yes">APOE</italic> &#949;4 carriers, exhibit a global shift towards hyper-excitation in the resting-state structural connectome [<xref rid="bib0029" ref-type="bibr">59</xref>] and a lower tolerance to network dysfunction [<xref rid="bib0028" ref-type="bibr">58</xref>] at midlife.</p></sec></sec><sec id="sec0014"><label>4</label><title>Discussion</title><sec id="sec0015"><label>4.1</label><title>Summary of findings</title><p id="para0041">In this scoping review, we synthesized research examining <italic toggle="yes">APOE</italic> &#949;4-related differences in brain structure, function, and connectivity at midlife. The reviewed MRI studies provide little evidence to indicate that middle-aged <italic toggle="yes">APOE</italic> &#949;4 carriers exhibit consistent differences in brain structure relative to non-carriers. Variation in study design, analytical approach, and outcome measure do not appear to offer a coherent explanation for these null findings. Among studies assessing brain function and connectivity, <italic toggle="yes">APOE</italic> &#949;4-related differences were more commonly reported. However, there was marked variation in the regions/networks implicated and the direction of the reported differences. The neural profile of <italic toggle="yes">APOE</italic> &#949;4 at midlife thus remains poorly characterized.</p><p id="para0042">The absence of robust, consistent differences in the reviewed studies may reflect a genuine lack of <italic toggle="yes">APOE</italic> &#949;4-related differences in the brain at midlife. Such an explanation is consistent with the prodromal hypothesis, which proposes that &#949;4-related differences in the brain and cognition emerge relatively late in the adult lifespan, driven by the heightened burden of AD pathology among &#949;4 carriers who will go on to develop the disease [<xref rid="bib0030" ref-type="bibr">24</xref>,<xref rid="bib0083" ref-type="bibr">25</xref>]. In this light, it is perhaps unsurprising that the reviewed studies reported many null findings. However, the lack of a distinct neural profile among middle-aged <italic toggle="yes">APOE</italic> &#949;4 carriers is also arguably consistent with the antagonistic pleiotropy hypothesis [<xref rid="bib0037" ref-type="bibr">39</xref>,<xref rid="bib0092" ref-type="bibr">40</xref>]. Although some <italic toggle="yes">APOE</italic> studies have claimed to identify examples of antagonistic pleiotropy in midlife (e.g., [<xref rid="bib0097" ref-type="bibr">41</xref>]), the hypothesis &#8211; as originally stated &#8211; predicts subtle differences, if any, at midlife, as the allele&#8217;s influence shifts from advantageous to disadvantageous <xref rid="bib0081" ref-type="bibr">[42]</xref>, <xref rid="bib0035" ref-type="bibr">[85]</xref>. It follows, therefore, that the reviewed studies do not necessarily provide evidence that <italic toggle="yes">APOE</italic> &#949;4-related differences are driven entirely by pathology. Longitudinal studies are needed to determine whether midlife differences in MRI-based measures, if present, are related to prodromal AD, a necessary step for the development of imaging biomarkers [<xref rid="bib0070" ref-type="bibr">26</xref>].</p><p id="para0043">It is less clear how lifespan accounts can explain the results from the reviewed studies. These accounts propose that the <italic toggle="yes">APOE</italic> &#949;4 allele induces a prolonged pattern of hyperactivation that is present across early- and mid-life, predisposing vulnerable brain networks to AD pathology and later dysfunction [<xref rid="bib0010" ref-type="bibr">34</xref>,<xref rid="bib0044" ref-type="bibr">35</xref>]. Yet, consistent with a review of studies on older adults [<xref rid="bib0062" ref-type="bibr">23</xref>], the reported differences in patterns of task-evoked fMRI activation were extremely mixed. In fact, of the 10 fMRI studies identified, only two observed greater activation in middle-aged <italic toggle="yes">APOE</italic> &#949;4 carriers compared to non-carriers <xref rid="bib0076" ref-type="bibr">[68]</xref>, <xref rid="bib0047" ref-type="bibr">[75]</xref>. Four studies even reported the opposite pattern, linking <italic toggle="yes">APOE</italic> &#949;4 with lower levels of task-evoked activation <xref rid="bib0020" ref-type="bibr">[67]</xref>, <xref rid="bib0091" ref-type="bibr">[78]</xref>, <xref rid="bib0095" ref-type="bibr">[79]</xref>, <xref rid="bib0021" ref-type="bibr">[82]</xref>. While the use of different paradigms and stimuli place constraints on comparability across studies, it is nevertheless challenging to reconcile these findings with claims that fMRI hyperactivation observed in young, at-risk adults (e.g., [<xref rid="bib0026" ref-type="bibr">29</xref>]) is maintained into midlife.</p><p id="para0044">Another possibility is that the &#949;4 allele impacts brain health at midlife through alternative mechanisms. For example, <italic toggle="yes">APOE</italic> &#949;4 has been associated with cerebrovascular dysfunction in aging and AD, including alterations in cerebral blood flow and blood-brain barrier integrity <xref rid="bib0073" ref-type="bibr">[36]</xref>, <xref rid="bib0006" ref-type="bibr">[86]</xref>. Differences between &#949;4 carriers and non-carriers in these vascular mechanisms have likewise been observed in studies of young and middle-aged adults <xref rid="bib0001" ref-type="bibr">[87]</xref>, <xref rid="bib0015" ref-type="bibr">[88]</xref>, <xref rid="bib0016" ref-type="bibr">[89]</xref>, <xref rid="bib0085" ref-type="bibr">[90]</xref>. Such findings suggest that <italic toggle="yes">APOE</italic> &#949;4&#8217;s influence on the cerebrovascular system is more prominent than its influence on brain structure, function, or connectivity. Consistent with this notion, one large cross-sectional study of late middle-aged and older adults reported that <italic toggle="yes">APOE</italic> &#949;4 was associated with greater white matter hyperintensity volumes, an indicator of poorer cerebrovascular health, but not gray matter volume or white matter microstructure [<xref rid="bib0058" ref-type="bibr">16</xref>]. Together, these findings provide evidence that <italic toggle="yes">APOE</italic> &#949;4 is linked to midlife brain health but, crucially, not in the neural properties targeted in this scoping review.</p><p id="para0045">A variety of methodological issues could have influenced the results reported, however, contributing to a lack of &#949;4-related differences in brain structure and/or variability in &#949;4-related differences in brain function/connectivity. One prominent issue is the widespread use of small samples, which limits statistical power and increases the likelihood of missing a true &#8220;effect&#8221; (i.e., a Type II error) [<xref rid="bib0004" ref-type="bibr">91</xref>]. In the reviewed studies, the median total sample size was 92.5, which is comparable to <italic toggle="yes">APOE</italic> &#949;4-related studies in young adults (<italic toggle="yes">Mdn</italic> = 62; [<xref rid="bib0050" ref-type="bibr">92</xref>]) but provides insufficient power to reliably detect small effects. This is relevant here as effect sizes associated with common genetic variants on neuroimaging outcomes are typically small [<xref rid="bib0064" ref-type="bibr">93</xref>]. While <italic toggle="yes">APOE</italic> &#949;4 may represent an exception to this rule, a recent study of &#8764;43,000 late middle-aged and older adults casts some doubt on this [<xref rid="bib0039" ref-type="bibr">21</xref>]. It is possible, therefore, that <italic toggle="yes">APOE</italic> &#949;4 does influence brain structure, function, and/or connectivity at midlife, but most studies were simply underpowered to detect it.</p><p id="para0046">Another methodological issue was the lack of consideration for the roles of sex and ethnocultural diversity. Regarding sex, we found that most studies included more females than males, some to a greater extent that others, but few actively explored the influence of sex or sex-related factors. Indeed, only four studies identified in this review even mentioned menopause, despite the focus on midlife. This was surprising as the <italic toggle="yes">APOE</italic> &#949;4 allele has long been shown to have a greater impact on AD risk among females [<xref rid="bib0023" ref-type="bibr">8</xref>], especially among those aged 60&#8211;75 years [<xref rid="bib0002" ref-type="bibr">94</xref>,<xref rid="bib0067" ref-type="bibr">95</xref>], potentially underpinned by estrogen-<italic toggle="yes">APOE</italic> interactions [<xref rid="bib0032" ref-type="bibr">96</xref>,<xref rid="bib0093" ref-type="bibr">97</xref>]. Regarding ethnocultural diversity, we found that few studies reported the racial/ethnic breakdown of their samples. Among those that did, there was a clear skew towards white or &#8220;Caucasian&#8221; individuals. Although unsurprising given the broader cognitive neuroscience literature, the lack of studies including non-white individuals limits the generalizability of results <xref rid="bib0014" ref-type="bibr">[98]</xref>. This is particularly problematic for research on <italic toggle="yes">APOE</italic>, as evidence suggests that the association between the &#949;4 allele and AD risk varies as a function of race/ethnicity <xref rid="bib0003" ref-type="bibr">[7]</xref>, <xref rid="bib0023" ref-type="bibr">[8]</xref>, <xref rid="bib0002" ref-type="bibr">[94]</xref>. Given this, we cannot rule out the possibility that inconsistencies across studies were partly related to the differential composition of the participants, both in terms of sex and ethnocultural diversity, as well as other health factors (e.g., hormone replacement therapy, body mass index, hypertension). Future research would greatly benefit from the inclusion of more diverse midlife samples, as well as a greater consideration of menopause and related factors.</p></sec><sec id="sec0016"><label>4.2</label><title>Limitations</title><p id="para0047">Our scoping review has some limitations that should be considered. First, we focused exclusively on studies published in peer-reviewed journals. It is thus possible that we missed relevant research, which may be available as pre-prints, conference proceedings, or dissertations. If publication bias was present, our focus on peer-reviewed studies may have resulted in the over-representation of work reporting significant <italic toggle="yes">APOE</italic> &#949;4-related differences. However, the studies reviewed &#8211; many reporting null findings &#8211; cast some doubt on this. Second, our scoping review included studies published as of July 11, 2024. Although this is an unavoidable feature of reviews, we may have missed relevant work published since this date. Third, we included studies only if the age range was reported and, crucially, if it fell between 40&#8211;65 years, a common definition of midlife [<xref rid="bib0013" ref-type="bibr">43</xref>]. While we identified 30 studies meeting this criterion, this led to the exclusion of several studies that claimed to focus on midlife. In this regard, our approach arguably placed a greater emphasis on specificity than sensitivity (although see Supplementary Material).</p></sec></sec><sec id="sec0017"><label>5</label><title>Conclusions</title><p id="para0048">The <italic toggle="yes">APOE</italic> &#949;4 allele is a major genetic risk factor for late-onset Alzheimer&#8217;s disease, yet its influence on the middle-aged brain is not well characterized. In this scoping review, we aimed to address this by synthesizing research examining &#949;4-related differences on MRI-derived measures of brain structure, function, and connectivity among middle-aged adults. While the current literature is dominated by small, non-representative samples, the available evidence suggests that <italic toggle="yes">APOE</italic> &#949;4 carriers and non-carriers do not exhibit robust, consistent differences at midlife. This is especially true for measures of brain structure, although the allele&#8217;s influence on brain function and connectivity remains poorly delineated.</p></sec><sec id="sec0018"><title>Funding</title><p id="para0049">This work was supported by Canada Research Chairs Program CRC-2022&#8211;00,240, CIHR Sex &amp; Gender Research Chair GS9&#8211;171,369, and NSERC Discovery Grant RGPIN-2018&#8211;05,761 awarded to M. N. Rajah, and a Canadian Consortium on Neurodegeneration in Aging (CCNA) &#8211; Women, Sex, Gender, &amp; Dementia (WSGD) Postdoctoral Fellowship awarded to R. Lissaman.</p></sec><sec id="sec0019"><title>Declaration of generative AI and AI-assisted technologies in the writing process</title><p id="para0050">During the preparation of this work, the first author (R. Lissaman) used ChatGPT to rephrase limited sections of text, with the aim of improving manuscript readability. After using this tool/service, the author reviewed and edited the content as needed and takes full responsibility for the content of the published article.</p></sec><sec id="sec0019a"><title>CRediT authorship contribution statement</title><p id="para0050a"><bold>Rikki Lissaman:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. <bold>Sidra Anjum:</bold> Writing &#8211; review &amp; editing, Investigation, Formal analysis. <bold>Andrea Quaiattini:</bold> Resources, Methodology. <bold>M. Natasha Rajah:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Methodology, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0053">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0060"><label>1</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Mahley</surname><given-names>R.W.</given-names></name></person-group><article-title>Apolipoprotein E: cholesterol transport protein with expanding role in cell biology</article-title><source>Science</source><volume>240</volume><issue>4852</issue><year>1988</year><fpage>622</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1126/science.3283935</pub-id><pub-id pub-id-type="pmid">3283935</pub-id></element-citation></ref><ref id="bib0061"><label>2</label><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name name-style="western"><surname>Mahley</surname><given-names>R.W.</given-names></name></person-group><article-title>Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders</article-title><source>J Mol Med</source><volume>94</volume><issue>7</issue><year>2016</year><fpage>739</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1007/s00109-016-1427-y</pub-id><pub-id pub-id-type="pmid">27277824</pub-id><pub-id pub-id-type="pmcid">PMC4921111</pub-id></element-citation></ref><ref id="bib0077"><label>3</label><element-citation publication-type="journal" id="sbref0077"><person-group person-group-type="author"><name name-style="western"><surname>Rall</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Weisgraber</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Mahley</surname><given-names>R.W.</given-names></name></person-group><article-title>Human apolipoprotein E. The complete amino acid sequence</article-title><source>J Biol Chem</source><volume>257</volume><issue>8</issue><year>1982</year><fpage>4171</fpage><lpage>4178</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)34702-1</pub-id><pub-id pub-id-type="pmid">7068630</pub-id></element-citation></ref><ref id="bib0094"><label>4</label><element-citation publication-type="journal" id="sbref0094"><person-group person-group-type="author"><name name-style="western"><surname>Weisgraber</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Rall</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Mahley</surname><given-names>R.W.</given-names></name></person-group><article-title>Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms</article-title><source>J Biol Chem</source><volume>256</volume><issue>17</issue><year>1981</year><fpage>9077</fpage><lpage>9083</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(19)52510-8</pub-id><pub-id pub-id-type="pmid">7263700</pub-id></element-citation></ref><ref id="bib0042"><label>5</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mahley</surname><given-names>R.W.</given-names></name></person-group><article-title>Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer&#8217;s diseases</article-title><source>Neurobiol Dis</source><volume>72</volume><year>2014</year><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.08.025</pub-id><pub-id pub-id-type="pmid">25173806</pub-id><pub-id pub-id-type="pmcid">PMC4253862</pub-id></element-citation></ref><ref id="bib0009"><label>6</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Corder</surname><given-names>E.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strittmatter</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schmechel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gaskell</surname><given-names>P.</given-names></name><name name-style="western"><surname>Small</surname><given-names>G.</given-names></name><name name-style="western"><surname>Roses</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haines</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pericak-Vance</surname><given-names>M.</given-names></name></person-group><article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#8217;s disease in late onset families</article-title><source>Science</source><volume>261</volume><issue>5123</issue><year>1993</year><fpage>921</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1126/science.8346443</pub-id><pub-id pub-id-type="pmid">8346443</pub-id></element-citation></ref><ref id="bib0003"><label>7</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Belloy</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Napolioni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Greicius</surname><given-names>M.D.</given-names></name></person-group><article-title>A quarter century of APOE and Alzheimer&#8217;s disease: progress to date and the path forward</article-title><source>Neuron</source><volume>101</volume><issue>5</issue><year>2019</year><fpage>820</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.01.056</pub-id><pub-id pub-id-type="pmid">30844401</pub-id><pub-id pub-id-type="pmcid">PMC6407643</pub-id></element-citation></ref><ref id="bib0023"><label>8</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Farrer</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Cupples</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Haines</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kukull</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Mayeux</surname><given-names>R.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Pericak-Vance</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Risch</surname><given-names>N.</given-names></name><name name-style="western"><surname>van Duijn</surname><given-names>C.M.</given-names></name></person-group><article-title>Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis</article-title><source>JAMA</source><volume>278</volume><issue>16</issue><year>1997</year><fpage>1349</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1001/jama.1997.03550160069041</pub-id><pub-id pub-id-type="pmid">9343467</pub-id></element-citation></ref><ref id="bib0033"><label>9</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Genin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hannequin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wallon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sleegers</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hiltunen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Combarros</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bullido</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Engelborghs</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Deyn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Berr</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pasquier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tognoni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fi&#233;vet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brouwers</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bettens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Arosio</surname><given-names>B.</given-names></name><name name-style="western"><surname>Coto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Del Zompo</surname><given-names>M.</given-names></name><x xml:space="preserve">&#8230;</x><name name-style="western"><surname>Campion</surname><given-names>D.</given-names></name></person-group><article-title><italic toggle="yes">APOE</italic> and Alzheimer disease: a major gene with semi-dominant inheritance</article-title><source>Mol Psychiatry</source><volume>16</volume><issue>9</issue><year>2011</year><fpage>903</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1038/mp.2011.52</pub-id><pub-id pub-id-type="pmid">21556001</pub-id><pub-id pub-id-type="pmcid">PMC3162068</pub-id></element-citation></ref><ref id="bib0045"><label>10</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tijms</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Vos</surname><given-names>S.J.B.</given-names></name><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>P.J.</given-names></name></person-group><article-title>Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum</article-title><source>JAMA Neurol</source><volume>79</volume><issue>3</issue><year>2022</year><fpage>228</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2021.5216</pub-id><pub-id pub-id-type="pmid">35099509</pub-id><pub-id pub-id-type="pmcid">PMC12138908</pub-id></element-citation></ref><ref id="bib0046"><label>11</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Knol</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Tijms</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verhey</surname><given-names>F.R.J.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Aalten</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aarsland</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alcolea</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>M.</given-names></name><name name-style="western"><surname>Almdahl</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Baldeiras</surname><given-names>I.</given-names></name><name name-style="western"><surname>Barthel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Berckel</surname><given-names>B.N.M.van</given-names></name><name name-style="western"><surname>Bibeau</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>D.J.</given-names></name><x xml:space="preserve">&#8230;</x><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name></person-group><article-title>Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis</article-title><source>JAMA</source><volume>313</volume><issue>19</issue><year>2015</year><fpage>1924</fpage><lpage>1938</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.4668</pub-id><pub-id pub-id-type="pmid">25988462</pub-id><pub-id pub-id-type="pmcid">PMC4486209</pub-id></element-citation></ref><ref id="bib0084"><label>12</label><element-citation publication-type="journal" id="sbref0084"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Yaari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Holdridge</surname><given-names>K.</given-names></name><name name-style="western"><surname>Siemers</surname><given-names>E.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name></person-group><article-title>Association of factors with elevated amyloid burden in clinically normal older individuals</article-title><source>JAMA Neurol</source><volume>77</volume><issue>6</issue><year>2020</year><fpage>735</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2020.0387</pub-id><pub-id pub-id-type="pmid">32250387</pub-id><pub-id pub-id-type="pmcid">PMC7136861</pub-id></element-citation></ref><ref id="bib0012"><label>13</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>DeTure</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name></person-group><article-title>The neuropathological diagnosis of Alzheimer&#8217;s disease</article-title><source>Mol Neurodegener</source><volume>14</volume><year>2019</year><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s13024-019-0333-5</pub-id><pub-id pub-id-type="pmid">31375134</pub-id><pub-id pub-id-type="pmcid">PMC6679484</pub-id></element-citation></ref><ref id="bib0041"><label>14</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Honea</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Vidoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harsha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>J.M.</given-names></name></person-group><article-title>Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study</article-title><source>J Alzheimer&#8217;s Dis: JAD</source><volume>18</volume><issue>3</issue><year>2009</year><fpage>553</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.3233/JAD-2009-1163</pub-id><pub-id pub-id-type="pmid">19584447</pub-id><pub-id pub-id-type="pmcid">PMC2892293</pub-id></element-citation></ref><ref id="bib0052"><label>15</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Lacey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gawryluk</surname><given-names>J.R.</given-names></name></person-group><article-title>Impact of APOE-&#949; alleles on brain structure and cognitive function in healthy older adults: a VBM and DTI replication study</article-title><source>PLOS ONE</source><volume>19</volume><issue>4</issue><year>2024</year><object-id pub-id-type="publisher-id">e0292576</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0292576</pub-id><pub-id pub-id-type="pmcid">PMC11025752</pub-id><pub-id pub-id-type="pmid">38635499</pub-id></element-citation></ref><ref id="bib0058"><label>16</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Lyall</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Lyall</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Celis-Morales</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J.</given-names></name><name name-style="western"><surname>Strawbridge</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sattar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Cavanagh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deary</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Pell</surname><given-names>J.P.</given-names></name></person-group><article-title>Association between <italic toggle="yes">APOE</italic> e4 and white matter hyperintensity volume, but not total brain volume or white matter integrity</article-title><source>Brain Imaging Behav</source><volume>14</volume><year>2019</year><fpage>1468</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1007/s11682-019-00069-9</pub-id><pub-id pub-id-type="pmcid">PMC7572345</pub-id><pub-id pub-id-type="pmid">30903549</pub-id></element-citation></ref><ref id="bib0008"><label>17</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Cherbuin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name></person-group><article-title>Neuroimaging and <italic toggle="yes">APOE</italic> genotype: a systematic qualitative review</article-title><source>Dement Geriatr Cogn Disord</source><volume>24</volume><issue>5</issue><year>2007</year><fpage>348</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1159/000109150</pub-id><pub-id pub-id-type="pmid">17911980</pub-id></element-citation></ref><ref id="bib0031"><label>18</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Fouquet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Besson</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Gonneaud</surname><given-names>J.</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G.</given-names></name></person-group><article-title>Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan</article-title><source>Neuropsychol Rev</source><volume>24</volume><issue>3</issue><year>2014</year><fpage>290</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1007/s11065-014-9263-8</pub-id><pub-id pub-id-type="pmid">25146994</pub-id></element-citation></ref><ref id="bib0005"><label>19</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Cavedo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lista</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rojkova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chiesa</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Houot</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brueggen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blautzik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bokde</surname><given-names>A.L.W.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pouwels</surname><given-names>P.J.W.</given-names></name><name name-style="western"><surname>Teipel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name></person-group><article-title>Disrupted white matter structural networks in healthy older adult <italic toggle="yes">APOE</italic> &#949;4 carriers &#8211; An international multicenter DTI study</article-title><source>Neuroscience</source><volume>357</volume><year>2017</year><fpage>119</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.05.048</pub-id><pub-id pub-id-type="pmid">28596117</pub-id></element-citation></ref><ref id="bib0038"><label>20</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Heise</surname><given-names>V.</given-names></name><name name-style="western"><surname>Filippini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ebmeier</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>MacKay</surname><given-names>C.E.</given-names></name></person-group><article-title>The <italic toggle="yes">APOE</italic> &#603;4 allele modulates brain white matter integrity in healthy adults</article-title><source>Mol Psychiatry</source><volume>16</volume><issue>9</issue><year>2011</year><fpage>908</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1038/mp.2010.90</pub-id><pub-id pub-id-type="pmid">20820167</pub-id></element-citation></ref><ref id="bib0039"><label>21</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Heise</surname><given-names>V.</given-names></name><name name-style="western"><surname>Offer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whiteley</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Armitage</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Parish</surname><given-names>S.</given-names></name></person-group><article-title>A comprehensive analysis of <italic toggle="yes">APOE</italic> genotype effects on human brain structure in the UK Biobank</article-title><source>Transl Psychiatry</source><volume>14</volume><issue>1</issue><year>2024</year><fpage>143</fpage><pub-id pub-id-type="doi">10.1038/s41398-024-02848-5</pub-id><pub-id pub-id-type="pmid">38472178</pub-id><pub-id pub-id-type="pmcid">PMC10933274</pub-id></element-citation></ref><ref id="bib0059"><label>22</label><element-citation publication-type="journal" id="sbref0059"><person-group person-group-type="author"><name name-style="western"><surname>Lyall</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Bastin</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Mu&#241;oz Maniega</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Roses</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Vald&#233;s Hern&#225;ndez</surname><given-names>M.</given-names></name><name name-style="western"><surname>del</surname><given-names>C.</given-names></name><name name-style="western"><surname>Royle</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Starr</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Porteous</surname><given-names>David.J.</given-names></name><name name-style="western"><surname>Wardlaw</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Deary</surname><given-names>I.J.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease susceptibility genes <italic toggle="yes">APOE</italic> and <italic toggle="yes">TOMM40</italic>, and brain white matter integrity in the Lothian Birth Cohort 1936</article-title><source>Neurobiol Aging</source><volume>35</volume><issue>6</issue><year>2014</year><fpage>1513</fpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.01.006</pub-id><comment>e25-1513.e33</comment><pub-id pub-id-type="pmcid">PMC3969262</pub-id><pub-id pub-id-type="pmid">24508314</pub-id></element-citation></ref><ref id="bib0062"><label>23</label><element-citation publication-type="journal" id="sbref0062"><person-group person-group-type="author"><name name-style="western"><surname>McDonough</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Festini</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>M.M.</given-names></name></person-group><article-title>Risk for Alzheimer&#8217;s disease: a review of long-term episodic memory encoding and retrieval fMRI studies</article-title><source>Ageing Res Rev</source><volume>62</volume><year>2020</year><object-id pub-id-type="publisher-id">101133</object-id><pub-id pub-id-type="doi">10.1016/j.arr.2020.101133</pub-id><pub-id pub-id-type="pmid">32717407</pub-id></element-citation></ref><ref id="bib0030"><label>24</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Albrecht</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Savage</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lautenschlager</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Maruff</surname><given-names>P.</given-names></name><name name-style="western"><surname>Szoeke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Taddei</surname><given-names>K.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Ames</surname><given-names>D.</given-names></name><name name-style="western"><surname>Research Group</surname><given-names>A.I.B.L.</given-names></name></person-group><article-title>Lack of reliable evidence for a distinctive &#949;4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study</article-title><source>Brain</source><volume>136</volume><issue>7</issue><year>2013</year><fpage>2201</fpage><lpage>2216</lpage><pub-id pub-id-type="doi">10.1093/brain/awt127</pub-id><pub-id pub-id-type="pmid">23737466</pub-id></element-citation></ref><ref id="bib0083"><label>25</label><element-citation publication-type="journal" id="sbref0083"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Bohac</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Waring</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Kokmen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tangalos</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Ivnik</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R.C.</given-names></name></person-group><article-title>Apolipoprotein E genotype influences cognitive &#8220;phenotype&#8221; in patients with Alzheimer&#8217;s disease but not in healthy control subjects</article-title><source>Neurology</source><volume>50</volume><issue>2</issue><year>1998</year><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1212/wnl.50.2.355</pub-id><pub-id pub-id-type="pmid">9484353</pub-id></element-citation></ref><ref id="bib0070"><label>26</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Donoghue</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Zamboni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nobre</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C.E.</given-names></name></person-group><article-title>APOE genotype and cognition in healthy individuals at-risk of Alzheimer&#8217;s disease: a review</article-title><source>Cortex</source><volume>104</volume><year>2018</year><fpage>103</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.cortex.2018.03.025</pub-id><pub-id pub-id-type="pmid">29800787</pub-id></element-citation></ref><ref id="bib0011"><label>27</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Dennis</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Browndyke</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Stokes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Need</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Welsh-Bohmer</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Cabeza</surname><given-names>R.</given-names></name></person-group><article-title>Temporal lobe functional activity and connectivity in young adult <italic toggle="yes">APOE</italic> &#949;4 carriers</article-title><source>Alzheimer&#8217;s Dement</source><volume>6</volume><issue>4</issue><year>2010</year><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2009.07.003</pub-id><pub-id pub-id-type="pmid">19744893</pub-id><pub-id pub-id-type="pmcid">PMC2891943</pub-id></element-citation></ref><ref id="bib0025"><label>28</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Filbey</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Slack</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Sunderland</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.M.</given-names></name></person-group><article-title>Functional magnetic resonance imaging and magnetoencephalography differences associated with APOE&#949;4 in young healthy adults</article-title><source>NeuroReport</source><volume>17</volume><issue>15</issue><year>2006</year><fpage>1585</fpage><pub-id pub-id-type="doi">10.1097/01.wnr.0000234745.27571.d1</pub-id><pub-id pub-id-type="pmid">17001273</pub-id></element-citation></ref><ref id="bib0026"><label>29</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Filippini</surname><given-names>N.</given-names></name><name name-style="western"><surname>MacIntosh</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Hough</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C.E.</given-names></name></person-group><article-title>Distinct patterns of brain activity in young carriers of the <italic toggle="yes">APOE</italic>-&#949;4 allele</article-title><source>Proc Natl Acad Sci</source><volume>106</volume><issue>17</issue><year>2009</year><fpage>7209</fpage><lpage>7214</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811879106</pub-id><pub-id pub-id-type="pmid">19357304</pub-id><pub-id pub-id-type="pmcid">PMC2678478</pub-id></element-citation></ref><ref id="bib0040"><label>30</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Hodgetts</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Shine</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>H.</given-names></name><name name-style="western"><surname>Postans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>K.S.</given-names></name></person-group><article-title>Increased posterior default mode network activity and structural connectivity in young adult <italic toggle="yes">APOE</italic>-&#949;4 carriers: a multimodal imaging investigation</article-title><source>Neurobiol Aging</source><volume>73</volume><year>2019</year><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.08.026</pub-id><pub-id pub-id-type="pmid">30339963</pub-id><pub-id pub-id-type="pmcid">PMC6261847</pub-id></element-citation></ref><ref id="bib0051"><label>31</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Kunz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schr&#246;der</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Montag</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lachmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sariyska</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stirnberg</surname><given-names>R.</given-names></name><name name-style="western"><surname>St&#246;cker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Messing-Floeter</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Fell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Doeller</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Axmacher</surname><given-names>N.</given-names></name></person-group><article-title>Reduced grid-cell&#8211;like representations in adults at genetic risk for Alzheimer&#8217;s disease</article-title><source>Science</source><volume>350</volume><issue>6259</issue><year>2015</year><fpage>430</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1126/science.aac8128</pub-id><pub-id pub-id-type="pmid">26494756</pub-id></element-citation></ref><ref id="bib0082"><label>32</label><element-citation publication-type="journal" id="sbref0082"><person-group person-group-type="author"><name name-style="western"><surname>Shine</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Hodgetts</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Postans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>K.S.</given-names></name></person-group><article-title>APOE-&#949;4 selectively modulates posteromedial cortex activity during scene perception and short-term memory in young healthy adults</article-title><source>Sci Rep</source><volume>5</volume><year>2015</year><object-id pub-id-type="publisher-id">16322</object-id><pub-id pub-id-type="doi">10.1038/srep16322</pub-id><pub-id pub-id-type="pmcid">PMC4639783</pub-id><pub-id pub-id-type="pmid">26552581</pub-id></element-citation></ref><ref id="bib0027"><label>33</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Molloy</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Binette</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Vockert</surname><given-names>N.</given-names></name><name name-style="western"><surname>Marquardt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pilar</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Kreissl</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Remz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tremblay-Mercier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rajah</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Villeneuve</surname><given-names>S.</given-names></name><name name-style="western"><surname>Group</surname><given-names>P.-A.R.</given-names></name><name name-style="western"><surname>Maass</surname><given-names>A.</given-names></name></person-group><article-title>Precuneus activity during retrieval is positively associated with amyloid burden in cognitively normal older <italic toggle="yes">APOE</italic>4 carriers</article-title><source>J Neurosci</source><volume>45</volume><issue>6</issue><year>2025</year><object-id pub-id-type="publisher-id">e1408242024</object-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1408-24.2024</pub-id><pub-id pub-id-type="pmcid">PMC11800745</pub-id><pub-id pub-id-type="pmid">39788739</pub-id></element-citation></ref><ref id="bib0010"><label>34</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Corriveau-Lecavalier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Molloy</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Maass</surname><given-names>A.</given-names></name></person-group><article-title>Cerebral hyperactivation across the Alzheimer&#8217;s disease pathological cascade</article-title><source>Brain Commun</source><volume>6</volume><issue>6</issue><year>2024</year><fpage>fcae376</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcae376</pub-id><pub-id pub-id-type="pmid">39513091</pub-id><pub-id pub-id-type="pmcid">PMC11542485</pub-id></element-citation></ref><ref id="bib0044"><label>35</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Jagust</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Mormino</surname><given-names>E.C.</given-names></name></person-group><article-title>Lifespan brain activity, &#946;-amyloid, and Alzheimer&#8217;s disease</article-title><source>Trends Cogn Sci (Regul Ed)</source><volume>15</volume><issue>11</issue><year>2011</year><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.tics.2011.09.004</pub-id><pub-id pub-id-type="pmcid">PMC3206968</pub-id><pub-id pub-id-type="pmid">21983147</pub-id></element-citation></ref><ref id="bib0073"><label>36</label><element-citation publication-type="journal" id="sbref0073"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Huentelman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>L.</given-names></name></person-group><article-title>More than just risk for Alzheimer&#8217;s disease: <italic toggle="yes">APOE</italic> &#949;4&#8217;s impact on the aging brain</article-title><source>Trends Neurosci</source><volume>46</volume><issue>9</issue><year>2023</year><fpage>750</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2023.06.003</pub-id><pub-id pub-id-type="pmid">37460334</pub-id></element-citation></ref><ref id="bib0087"><label>37</label><element-citation publication-type="journal" id="sbref0087"><person-group person-group-type="author"><name name-style="western"><surname>Trachtenberg</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Filippini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cheeseman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duff</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Neville</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Ebmeier</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Karpe</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C.E.</given-names></name></person-group><article-title>The effects of APOE on brain activity do not simply reflect the risk of Alzheimer&#8217;s disease</article-title><source>Neurobiol Aging</source><volume>33</volume><issue>3</issue><year>2012</year><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.11.011</pub-id><comment>618.e1-618.e13</comment><pub-id pub-id-type="pmid">21232817</pub-id></element-citation></ref><ref id="bib0088"><label>38</label><element-citation publication-type="journal" id="sbref0088"><person-group person-group-type="author"><name name-style="western"><surname>Trachtenberg</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Filippini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ebmeier</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Karpe</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C.E.</given-names></name></person-group><article-title>The effects of <italic toggle="yes">APOE</italic> on the functional architecture of the resting brain</article-title><source>NeuroImage</source><volume>59</volume><issue>1</issue><year>2012</year><fpage>565</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.07.059</pub-id><pub-id pub-id-type="pmid">21851856</pub-id></element-citation></ref><ref id="bib0037"><label>39</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Bondi</surname><given-names>M.W.</given-names></name></person-group><article-title>Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis</article-title><source>Alzheimer&#8217;s Dement</source><volume>4</volume><issue>4</issue><year>2008</year><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2008.02.006</pub-id><pub-id pub-id-type="pmid">18631975</pub-id></element-citation></ref><ref id="bib0092"><label>40</label><element-citation publication-type="journal" id="sbref0092"><person-group person-group-type="author"><name name-style="western"><surname>Tuminello</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.D.</given-names></name></person-group><article-title>The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations</article-title><source>Int J Alzheimer&#8217;s Dis</source><volume>2011</volume><year>2011</year><object-id pub-id-type="publisher-id">726197</object-id><pub-id pub-id-type="doi">10.4061/2011/726197</pub-id><pub-id pub-id-type="pmcid">PMC3056453</pub-id><pub-id pub-id-type="pmid">21423560</pub-id></element-citation></ref><ref id="bib0097"><label>41</label><element-citation publication-type="journal" id="sbref0097"><person-group person-group-type="author"><name name-style="western"><surname>Zokaei</surname><given-names>N.</given-names></name><name name-style="western"><surname>Giehl</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sillence</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neville</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Karpe</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nobre</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Husain</surname><given-names>M.</given-names></name></person-group><article-title>Sex and APOE: a memory advantage in male APOE &#949;4 carriers in midlife</article-title><source>Cortex</source><volume>88</volume><year>2017</year><fpage>98</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.cortex.2016.12.016</pub-id><pub-id pub-id-type="pmid">28086184</pub-id><pub-id pub-id-type="pmcid">PMC5333781</pub-id></element-citation></ref><ref id="bib0081"><label>42</label><element-citation publication-type="journal" id="sbref0081"><person-group person-group-type="author"><name name-style="western"><surname>Salvato</surname><given-names>G.</given-names></name></person-group><article-title>Does apolipoprotein E genotype influence cognition in middle-aged individuals?</article-title><source>Curr, Opin, Neurol</source><volume>28</volume><issue>6</issue><year>2015</year><fpage>612</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1097/WCO.0000000000000262</pub-id><pub-id pub-id-type="pmid">26402402</pub-id></element-citation></ref><ref id="bib0013"><label>43</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Dohm-Hansen</surname><given-names>S.</given-names></name><name name-style="western"><surname>English</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fitzsimons</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Lucassen</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>Y.M.</given-names></name></person-group><article-title>The &#8220;middle-aging&#8221; brain</article-title><source>Trends Neurosci</source><volume>47</volume><issue>4</issue><year>2024</year><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2024.02.001</pub-id><pub-id pub-id-type="pmid">38508906</pub-id></element-citation></ref><ref id="bib0055"><label>44</label><element-citation publication-type="book" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>LaPlume</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Lissaman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kearley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rajah</surname><given-names>M.N.</given-names></name></person-group><part-title>Brain health and episodic memory function at midlife: exploring the effects of sex differences and menopause status</part-title><comment>editor</comment><person-group person-group-type="editor"><name name-style="western"><surname>Grafman</surname><given-names>J.H.</given-names></name></person-group><source>Encyclopedia of the human brain</source><edition>2nd ed.</edition><year>2025</year><publisher-name>Elsevier</publisher-name><fpage>95</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-820480-1.00179-0</pub-id></element-citation></ref><ref id="bib0053"><label>45</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>Lachman</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Teshale</surname><given-names>S.</given-names></name><name name-style="western"><surname>Agrigoroaei</surname><given-names>S.</given-names></name></person-group><article-title>Midlife as a pivotal period in the life course: balancing growth and decline at the crossroads of youth and old age</article-title><source>Int J Behav Dev</source><volume>39</volume><issue>1</issue><year>2015</year><fpage>20</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1177/0165025414533223</pub-id><pub-id pub-id-type="pmid">25580043</pub-id><pub-id pub-id-type="pmcid">PMC4286887</pub-id></element-citation></ref><ref id="bib0075"><label>46</label><element-citation publication-type="book" id="sbref0075"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Festini</surname><given-names>S.B.</given-names></name></person-group><part-title>The middle-aged brain: a cognitive neuroscience perspective</part-title><comment>editors</comment><person-group person-group-type="editor"><name name-style="western"><surname>Cabeza</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nyberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D.C.</given-names></name></person-group><source>Cognitive neuroscience of aging: linking cognitive and cerebral aging</source><edition>2nd Ed</edition><year>2016</year><publisher-name>Oxford University Press</publisher-name><fpage>363</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1093/acprof:oso/9780199372935.003.0015</pub-id></element-citation></ref><ref id="bib0086"><label>47</label><element-citation publication-type="journal" id="sbref0086"><person-group person-group-type="author"><name name-style="western"><surname>Thurston</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Castle</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>C.J.</given-names></name></person-group><article-title>Menopause as a biological and psychological transition</article-title><source>Nat Rev Psychol</source><year>2025</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s44159-025-00463-9</pub-id></element-citation></ref><ref id="bib0054"><label>48</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Lancaster</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tabet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rusted</surname><given-names>J.</given-names></name></person-group><article-title>The elusive nature of APOE &#949;4 in mid-adulthood: understanding the cognitive profile</article-title><source>J Int Neuropsychol Soc</source><volume>23</volume><issue>3</issue><year>2017</year><fpage>239</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1017/S1355617716000990</pub-id><pub-id pub-id-type="pmid">28059047</pub-id></element-citation></ref><ref id="bib0036"><label>49</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Habib</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gabel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.</given-names></name><name name-style="western"><surname>Waldman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.T.</given-names></name></person-group><article-title>Functional neuroimaging findings in healthy middle-aged adults at risk of Alzheimer&#8217;s disease</article-title><source>Ageing Res Rev</source><volume>36</volume><year>2017</year><fpage>88</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2017.03.004</pub-id><pub-id pub-id-type="pmid">28342882</pub-id></element-citation></ref><ref id="bib0090"><label>50</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name name-style="western"><surname>Tricco</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Lillie</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zarin</surname><given-names>W.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Colquhoun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Levac</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>M.D.J.</given-names></name><name name-style="western"><surname>Horsley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weeks</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hempel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akl</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hartling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aldcroft</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Garritty</surname><given-names>C.</given-names></name><x xml:space="preserve">&#8230;</x><name name-style="western"><surname>Straus</surname><given-names>S.E.</given-names></name></person-group><article-title>PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation</article-title><source>Ann, Intern, Med</source><volume>169</volume><issue>7</issue><year>2018</year><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.7326/M18-0850</pub-id><pub-id pub-id-type="pmid">30178033</pub-id></element-citation></ref><ref id="bib0089"><label>51</label><element-citation publication-type="journal" id="sbref0089"><person-group person-group-type="author"><name name-style="western"><surname>Trachtenberg</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Filippini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C.E.</given-names></name></person-group><article-title>The effects of APOE-&#949;4 on the BOLD response</article-title><source>Neurobiol Aging</source><volume>33</volume><issue>2</issue><year>2012</year><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.03.009</pub-id><pub-id pub-id-type="pmid">20409610</pub-id></element-citation></ref><ref id="bib0057"><label>52</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dounavi</surname><given-names>M.-E.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Muniz-Terrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.T.</given-names></name></person-group><article-title>Higher midlife CAIDE score is associated with increased brain atrophy in a cohort of cognitively healthy middle-aged individuals</article-title><source>J Neurol</source><volume>268</volume><issue>5</issue><year>2021</year><fpage>1962</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.1007/s00415-020-10383-8</pub-id><pub-id pub-id-type="pmid">33423129</pub-id><pub-id pub-id-type="pmcid">PMC8068701</pub-id></element-citation></ref><ref id="bib0063"><label>53</label><element-citation publication-type="journal" id="sbref0063"><person-group person-group-type="author"><name name-style="western"><surname>McKeever</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paris</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Waldman</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>K.</given-names></name><name name-style="western"><surname>Busza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carriere</surname><given-names>I.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name></person-group><article-title>Hippocampal subfield volumes in middle-aged adults at risk of dementia</article-title><source>J Alzheimer&#8217;s Dis</source><volume>75</volume><issue>4</issue><year>2020</year><fpage>1211</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.3233/JAD-200238</pub-id><pub-id pub-id-type="pmid">32417786</pub-id></element-citation></ref><ref id="bib0069"><label>54</label><element-citation publication-type="journal" id="sbref0069"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Firbank</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>K.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name></person-group><article-title>Association between midlife dementia risk factors and longitudinal brain atrophy: the PREVENT-dementia study</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>91</volume><issue>2</issue><year>2020</year><fpage>158</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2019-321652</pub-id><pub-id pub-id-type="pmid">31806724</pub-id></element-citation></ref><ref id="bib0068"><label>55</label><element-citation publication-type="journal" id="sbref0068"><person-group person-group-type="author"><name name-style="western"><surname>Newton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pope</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rua</surname><given-names>C.</given-names></name><name name-style="western"><surname>Henson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Stangl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dounavi</surname><given-names>M.-E.</given-names></name><name name-style="western"><surname>Castegnaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koychev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wolbers</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D.</given-names></name></person-group><article-title>Entorhinal-based path integration selectively predicts midlife risk of Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement</source><volume>20</volume><issue>4</issue><year>2024</year><fpage>2779</fpage><lpage>2793</lpage><pub-id pub-id-type="doi">10.1002/alz.13733</pub-id><pub-id pub-id-type="pmid">38421123</pub-id><pub-id pub-id-type="pmcid">PMC11032581</pub-id></element-citation></ref><ref id="bib0071"><label>56</label><element-citation publication-type="journal" id="sbref0071"><person-group person-group-type="author"><name name-style="western"><surname>Okonkwo</surname><given-names>O.C.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Koscik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jonaitis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Dowling</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Bendlin</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>LaRue</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Barnhart</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Murali</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Carlsson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sager</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Christian</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name></person-group><article-title>Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer&#8217;s disease</article-title><source>J Int Neuropsychol Soc</source><volume>20</volume><issue>4</issue><year>2014</year><fpage>422</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1017/S1355617714000113</pub-id><pub-id pub-id-type="pmid">24621494</pub-id><pub-id pub-id-type="pmcid">PMC4103611</pub-id></element-citation></ref><ref id="bib0007"><label>57</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Cherbuin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Maller</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Meslin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Easteal</surname><given-names>S.</given-names></name></person-group><article-title>Total and regional gray matter volume is not related to <italic toggle="yes">APOE*E4</italic> status in a community sample of middle-aged individuals</article-title><source>J Gerontol: A</source><volume>63</volume><issue>5</issue><year>2008</year><fpage>501</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1093/gerona/63.5.501</pub-id><pub-id pub-id-type="pmid">18511754</pub-id></element-citation></ref><ref id="bib0028"><label>58</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Fortel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korthauer</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ajilore</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sidiropoulos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Driscoll</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schonfeld</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leow</surname><given-names>A.</given-names></name></person-group><article-title>Inferring excitation-inhibition dynamics using a maximum entropy model unifying brain structure and function</article-title><source>Netw Neurosci</source><volume>6</volume><issue>2</issue><year>2022</year><fpage>420</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1162/netn_a_00220</pub-id><pub-id pub-id-type="pmid">35733430</pub-id><pub-id pub-id-type="pmcid">PMC9205431</pub-id></element-citation></ref><ref id="bib0029"><label>59</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Fortel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Korthauer</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Morrissey</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ajilore</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wolfson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Driscoll</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schonfeld</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leow</surname><given-names>A.</given-names></name></person-group><article-title>Connectome signatures of hyperexcitation in cognitively intact middle-aged female APOE-&#949;4 carriers</article-title><source>Cereb Cortex</source><volume>30</volume><issue>12</issue><year>2020</year><fpage>6350</fpage><lpage>6362</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhaa190</pub-id><pub-id pub-id-type="pmid">32662517</pub-id><pub-id pub-id-type="pmcid">PMC7609923</pub-id></element-citation></ref><ref id="bib0065"><label>60</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Nemes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Logan</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Manchella</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Mundada</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Polsinelli</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hammers</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Foroud</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Nudelman</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Eloyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iaccarino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dorsant-Ard&#243;n</surname><given-names>V.</given-names></name><name name-style="western"><surname>Taurone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thangarajah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dage</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grinberg</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names><suffix>Jr.</suffix></name><x xml:space="preserve">&#8230;</x><name name-style="western"><surname>Leads</surname><given-names>C.</given-names></name></person-group><article-title>Sex and <italic toggle="yes">APOE &#949;4</italic> carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement</source><volume>19</volume><issue>S9</issue><year>2023</year><fpage>S49</fpage><lpage>S63</lpage><pub-id pub-id-type="doi">10.1002/alz.13403</pub-id><pub-id pub-id-type="pmid">37496307</pub-id><pub-id pub-id-type="pmcid">PMC10811272</pub-id></element-citation></ref><ref id="bib0066"><label>61</label><element-citation publication-type="journal" id="sbref0066"><person-group person-group-type="author"><name name-style="western"><surname>Nerattini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rubino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jett</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boneu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zarate</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carlton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Loeb-Zeitlin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Havryliuk</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pahlajani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berti</surname><given-names>V.</given-names></name><name name-style="western"><surname>Christos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fink</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dyke</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Brinton</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Mosconi</surname><given-names>L.</given-names></name></person-group><article-title>Elevated gonadotropin levels are associated with increased biomarker risk of Alzheimer&#8217;s disease in midlife women</article-title><source>Front Dement</source><volume>2</volume><year>2023</year><object-id pub-id-type="publisher-id">1303256</object-id><pub-id pub-id-type="doi">10.3389/frdem.2023.1303256</pub-id><pub-id pub-id-type="pmcid">PMC11108587</pub-id><pub-id pub-id-type="pmid">38774256</pub-id></element-citation></ref><ref id="bib0072"><label>62</label><element-citation publication-type="journal" id="sbref0072"><person-group person-group-type="author"><name name-style="western"><surname>Okonkwo</surname><given-names>O.C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dowling</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Bendlin</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>LaRue</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Koscik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jonaitis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Carlsson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sager</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name></person-group><article-title>Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults</article-title><source>Neurology</source><volume>78</volume><issue>22</issue><year>2012</year><fpage>1769</fpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182583047</pub-id><pub-id pub-id-type="pmid">22592366</pub-id><pub-id pub-id-type="pmcid">PMC3359586</pub-id></element-citation></ref><ref id="bib0074"><label>63</label><element-citation publication-type="journal" id="sbref0074"><person-group person-group-type="author"><name name-style="western"><surname>Panizzon</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hauger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dale</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Eaves</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Eyler</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fennema-Notestine</surname><given-names>C.</given-names></name><name name-style="western"><surname>Franz</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Jak</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Neale</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Prom-Wormley</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Seidman</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Tsuang</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Xian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kremen</surname><given-names>W.S.</given-names></name></person-group><article-title>Testosterone modifies the effect of <italic toggle="yes">APOE</italic> genotype on hippocampal volume in middle-aged men</article-title><source>Neurology</source><volume>75</volume><issue>10</issue><year>2010</year><fpage>874</fpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f11deb</pub-id><pub-id pub-id-type="pmid">20819998</pub-id><pub-id pub-id-type="pmcid">PMC2938973</pub-id></element-citation></ref><ref id="bib0080"><label>64</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carri&#232;re</surname><given-names>I.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Lovestone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name></person-group><article-title>The midlife cognitive profiles of adults at high risk of late-onset Alzheimer&#8217;s disease: the PREVENT study</article-title><source>Alzheimer&#8217;s Dement</source><volume>13</volume><issue>10</issue><year>2017</year><fpage>1089</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2017.02.008</pub-id><pub-id pub-id-type="pmid">28365321</pub-id></element-citation></ref><ref id="bib0024"><label>65</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Fennema-Notestine</surname><given-names>C.</given-names></name><name name-style="western"><surname>Panizzon</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Eyler</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Franz</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Jak</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Jernigan</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Neale</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Seidman</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Tsuang</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Xian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dale</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kremen</surname><given-names>W.S.</given-names></name></person-group><article-title>Presence of ApoE &#949;4 allele associated with thinner frontal cortex in middle age</article-title><source>J Alzheimer&#8217;s Dis</source><volume>26</volume><issue>Suppl 3</issue><year>2011</year><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.3233/JAD-2011-0002</pub-id><pub-id pub-id-type="pmid">21971450</pub-id><pub-id pub-id-type="pmcid">PMC3302177</pub-id></element-citation></ref><ref id="bib0078"><label>66</label><element-citation publication-type="journal" id="sbref0078"><person-group person-group-type="author"><name name-style="western"><surname>Reiman</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Uecker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caselli</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bandy</surname><given-names>D.</given-names></name><name name-style="western"><surname>De Leon</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>De Santi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Convit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thibodeau</surname><given-names>S.N.</given-names></name></person-group><article-title>Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer&#8217;s disease</article-title><source>Ann, Neurol</source><volume>44</volume><issue>2</issue><year>1998</year><fpage>288</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1002/ana.410440226</pub-id><pub-id pub-id-type="pmid">9708558</pub-id></element-citation></ref><ref id="bib0020"><label>67</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dowell</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Tabet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tofts</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>King</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rusted</surname><given-names>J.M.</given-names></name></person-group><article-title>Nicotine effects on attentional reorienting in mid-age adults, and interactions with apolipoprotein E status</article-title><source>J Psychopharmacol</source><volume>27</volume><issue>11</issue><year>2013</year><fpage>1007</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1177/0269881113499828</pub-id><pub-id pub-id-type="pmid">23958867</pub-id></element-citation></ref><ref id="bib0076"><label>68</label><element-citation publication-type="journal" id="sbref0076"><person-group person-group-type="author"><name name-style="western"><surname>Rajah</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>L.M.K.</given-names></name><name name-style="western"><surname>Ankudowich</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Swierkot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chakravarty</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Naumova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pruessner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Joober</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pasvanis</surname><given-names>S.</given-names></name></person-group><article-title>Family history and APOE4 risk for Alzheimer&#8217;s disease impact the neural correlates of episodic memory by early midlife</article-title><source>NeuroImage: Clin</source><volume>14</volume><year>2017</year><fpage>760</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/j.nicl.2017.03.016</pub-id><pub-id pub-id-type="pmid">28413778</pub-id><pub-id pub-id-type="pmcid">PMC5385589</pub-id></element-citation></ref><ref id="bib0017"><label>69</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Dounavi</surname><given-names>M.-E.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>O&#8217; Brien</surname><given-names>J.T.</given-names></name></person-group><article-title>Volumetric alterations in the hippocampal subfields of subjects at increased risk of dementia</article-title><source>Neurobiol Aging</source><volume>91</volume><year>2020</year><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2020.03.006</pub-id><pub-id pub-id-type="pmid">32311609</pub-id></element-citation></ref><ref id="bib0018"><label>70</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Dounavi</surname><given-names>M.-E.</given-names></name><name name-style="western"><surname>Newton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Low</surname><given-names>A.</given-names></name><name name-style="western"><surname>Muniz-Terrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Naci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Koychev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.T.</given-names></name></person-group><article-title>Macrostructural brain alterations at midlife are connected to cardiovascular and not inherited risk of future dementia: the PREVENT-dementia study</article-title><source>J Neurol</source><volume>269</volume><issue>8</issue><year>2022</year><fpage>4299</fpage><lpage>4309</lpage><pub-id pub-id-type="doi">10.1007/s00415-022-11061-7</pub-id><pub-id pub-id-type="pmid">35279756</pub-id><pub-id pub-id-type="pmcid">PMC9294019</pub-id></element-citation></ref><ref id="bib0019"><label>71</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Dowell</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Tofts</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>King</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Tabet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rusted</surname><given-names>J.M.</given-names></name></person-group><article-title>Structural and resting-state MRI detects regional brain differences in young and mid-age healthy APOE-e4 carriers compared with non-APOE-e4 carriers</article-title><source>NMR Biomed</source><volume>29</volume><issue>5</issue><year>2016</year><fpage>614</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1002/nbm.3502</pub-id><pub-id pub-id-type="pmid">26929040</pub-id></element-citation></ref><ref id="bib0022"><label>72</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Dowell</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Prowse</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tabet</surname><given-names>N.</given-names></name><name name-style="western"><surname>King</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Rusted</surname><given-names>J.M.</given-names></name></person-group><article-title>Mid age <italic toggle="yes">APOE</italic> &#949;4 carriers show memory-related functional differences and disrupted structure-function relationships in hippocampal regions</article-title><source>Sci Rep</source><volume>10</volume><year>2020</year><fpage>3110</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-59272-0</pub-id><pub-id pub-id-type="pmid">32080211</pub-id><pub-id pub-id-type="pmcid">PMC7033211</pub-id></element-citation></ref><ref id="bib0034"><label>73</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Goveas</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Franczak</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Antuono</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.-J.</given-names></name></person-group><article-title>Functional network endophenotypes unravel the effects of apolipoprotein E epsilon 4 in middle-aged adults</article-title><source>PLOS ONE</source><volume>8</volume><issue>2</issue><year>2013</year><object-id pub-id-type="publisher-id">e55902</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0055902</pub-id><pub-id pub-id-type="pmcid">PMC3570545</pub-id><pub-id pub-id-type="pmid">23424640</pub-id></element-citation></ref><ref id="bib0048"><label>74</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ries</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Torgerson</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Carlsson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Sager</surname><given-names>M.A.</given-names></name></person-group><article-title>The influence of Alzheimer disease family history and apolipoprotein E &#949;4 on mesial temporal lobe activation</article-title><source>J Neurosci</source><volume>26</volume><issue>22</issue><year>2006</year><fpage>6069</fpage><lpage>6076</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0959-06.2006</pub-id><pub-id pub-id-type="pmid">16738250</pub-id><pub-id pub-id-type="pmcid">PMC2684824</pub-id></element-citation></ref><ref id="bib0047"><label>75</label><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Ries</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Carlsson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Gleason</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sager</surname><given-names>M.A.</given-names></name></person-group><article-title>Effect of Alzheimer disease risk on brain function during self-appraisal in healthy middle-aged adults</article-title><source>Arch Gen Psychiatry</source><volume>64</volume><issue>10</issue><year>2007</year><fpage>1163</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.64.10.1163</pub-id><pub-id pub-id-type="pmid">17909128</pub-id><pub-id pub-id-type="pmcid">PMC2650497</pub-id></element-citation></ref><ref id="bib0056"><label>76</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Antuono</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Franczak</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Goveas</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.-J.</given-names></name></person-group><article-title>Aberrant functional connectivity in Papez circuit correlates with memory performance in cognitively intact middle-aged <italic toggle="yes">APOE</italic>4 carriers</article-title><source>Cortex</source><volume>57</volume><year>2014</year><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.cortex.2014.04.006</pub-id><pub-id pub-id-type="pmid">24905971</pub-id><pub-id pub-id-type="pmcid">PMC4448757</pub-id></element-citation></ref><ref id="bib98"><label>77</label><element-citation publication-type="journal" id="optTWgc3lbHrn"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Dounavi</surname><given-names>M.-E.</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Naci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Koychev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.T.</given-names></name></person-group><article-title>Dementia risk and thalamic nuclei volumetry in healthy midlife adults: The PREVENT Dementia study</article-title><source>Brain Commun</source><volume>6</volume><issue>2</issue><year>2024</year><fpage>fcae046</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcae046</pub-id><pub-id pub-id-type="pmid">38444908</pub-id><pub-id pub-id-type="pmcid">PMC10914447</pub-id></element-citation></ref><ref id="bib0091"><label>78</label><element-citation publication-type="journal" id="sbref0091"><person-group person-group-type="author"><name name-style="western"><surname>Trivedi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Ries</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Torgerson</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Sager</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name></person-group><article-title>Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer&#8217;s Disease: a cross-sectional study</article-title><source>BMC Med</source><volume>4</volume><year>2006</year><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1741-7015-4-1</pub-id><pub-id pub-id-type="pmid">16412236</pub-id><pub-id pub-id-type="pmcid">PMC1373642</pub-id></element-citation></ref><ref id="bib0095"><label>79</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mclaren</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Ries</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Bendlin</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Sager</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Atwood</surname><given-names>C.</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name></person-group><article-title>The influence of parental history of Alzheimer&#8217;s disease and apolipoprotein E 4 on the BOLD signal during recognition memory</article-title><source>Brain</source><volume>132</volume><issue>2</issue><year>2009</year><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1093/brain/awn254</pub-id><pub-id pub-id-type="pmid">18829694</pub-id><pub-id pub-id-type="pmcid">PMC2724919</pub-id></element-citation></ref><ref id="bib0043"><label>80</label><element-citation publication-type="book" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Insausti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>D.G.</given-names></name></person-group><part-title>Chapter 24&#8212;Hippocampal formation</part-title><comment>editors</comment><person-group person-group-type="editor"><name name-style="western"><surname>Mai</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Paxinos</surname><given-names>G.</given-names></name></person-group><source>The human nervous system</source><edition>3rd Ed.</edition><year>2012</year><publisher-name>Academic Press</publisher-name><fpage>896</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-374236-0.10024-0</pub-id></element-citation></ref><ref id="bib0096"><label>81</label><element-citation publication-type="journal" id="sbref0096"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>P.N.E.</given-names></name><name name-style="western"><surname>Estarellas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coomans</surname><given-names>E.</given-names></name><name name-style="western"><surname>Srikrishna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beaumont</surname><given-names>H.</given-names></name><name name-style="western"><surname>Maass</surname><given-names>A.</given-names></name><name name-style="western"><surname>Venkataraman</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Lissaman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jim&#233;nez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Betts</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>McGlinchey</surname><given-names>E.</given-names></name><name name-style="western"><surname>Berron</surname><given-names>D.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Sch&#246;ll</surname><given-names>M.</given-names></name></person-group><article-title>Imaging biomarkers in neurodegeneration: current and future practices</article-title><source>Alzheimer&#8217;s Res Ther</source><volume>12</volume><issue>1</issue><year>2020</year><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s13195-020-00612-7</pub-id><pub-id pub-id-type="pmid">32340618</pub-id><pub-id pub-id-type="pmcid">PMC7187531</pub-id></element-citation></ref><ref id="bib0021"><label>82</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dowell</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Tabet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tofts</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>King</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Rusted</surname><given-names>J.M.</given-names></name></person-group><article-title>Cognitive and neural signatures of the APOE E4 allele in mid-aged adults</article-title><source>Neurobiol Aging</source><volume>35</volume><issue>7</issue><year>2014</year><fpage>1615</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.01.145</pub-id><pub-id pub-id-type="pmid">24582638</pub-id><pub-id pub-id-type="pmcid">PMC4001126</pub-id></element-citation></ref><ref id="bib0079"><label>83</label><element-citation publication-type="journal" id="sbref0079"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Bridgeman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>S.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Danso</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Dounavi</surname><given-names>M.-E.</given-names></name><name name-style="western"><surname>Carriere</surname><given-names>I.</given-names></name><name name-style="western"><surname>Driscoll</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hillary</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koychev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Naci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Low</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Manson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marioni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>L.</given-names></name><x xml:space="preserve">&#8230;</x><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name></person-group><article-title>The PREVENT dementia programme: baseline demographic, lifestyle, imaging and cognitive data from a midlife cohort study investigating risk factors for dementia</article-title><source>Brain Commun</source><volume>6</volume><issue>3</issue><year>2024</year><fpage>fcae189</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcae189</pub-id><pub-id pub-id-type="pmid">38863576</pub-id><pub-id pub-id-type="pmcid">PMC11166176</pub-id></element-citation></ref><ref id="bib0049"><label>84</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Korthauer</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ajilore</surname><given-names>O.</given-names></name><name name-style="western"><surname>Leow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Driscoll</surname><given-names>I.</given-names></name></person-group><article-title>Disrupted topology of the resting state structural connectome in middle-aged APOE &#949;4 carriers</article-title><source>NeuroImage</source><volume>178</volume><year>2018</year><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2018.05.052</pub-id><pub-id pub-id-type="pmid">29803958</pub-id><pub-id pub-id-type="pmcid">PMC6249680</pub-id></element-citation></ref><ref id="bib0035"><label>85</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Guidotti Breting</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Tuminello</surname><given-names>E.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.D.</given-names></name></person-group><article-title>Functional neuroimaging studies in normal aging</article-title><source>In: Pardon, M.-C. &amp; Bondi, M.W., editors. Behavioral neurobiology of aging Springer</source><year>2012</year><fpage>91</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1007/7854_2011_13</pub-id><pub-id pub-id-type="pmid">21751096</pub-id></element-citation></ref><ref id="bib0006"><label>86</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.</given-names></name><name name-style="western"><surname>He</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name></person-group><article-title>The vascular contribution of apolipoprotein E to Alzheimer&#8217;s disease</article-title><source>Brain</source><volume>147</volume><issue>9</issue><year>2024</year><fpage>2946</fpage><lpage>2965</lpage><pub-id pub-id-type="doi">10.1093/brain/awae156</pub-id><pub-id pub-id-type="pmid">38748848</pub-id></element-citation></ref><ref id="bib0001"><label>87</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Alruwais</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Rusted</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Tabet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dowell</surname><given-names>N.G.</given-names></name></person-group><article-title>Evidence of emerging BBB changes in mid-age apolipoprotein E epsilon-4 carriers</article-title><source>Brain Behav</source><volume>12</volume><issue>12</issue><year>2022</year><fpage>e2806</fpage><pub-id pub-id-type="doi">10.1002/brb3.2806</pub-id><pub-id pub-id-type="pmid">36408825</pub-id><pub-id pub-id-type="pmcid">PMC9759141</pub-id></element-citation></ref><ref id="bib0015"><label>88</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Dounavi</surname><given-names>M.-E.</given-names></name><name name-style="western"><surname>Low</surname><given-names>A.</given-names></name><name name-style="western"><surname>McKiernan</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Muniz-Terrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.T.</given-names></name></person-group><article-title>Evidence of cerebral hemodynamic dysregulation in middle-aged APOE &#949;4 carriers: the PREVENT-dementia study</article-title><source>J Cereb Blood Flow Metab</source><volume>41</volume><issue>11</issue><year>2021</year><fpage>2844</fpage><lpage>2855</lpage><pub-id pub-id-type="doi">10.1177/0271678X211020863</pub-id><pub-id pub-id-type="pmid">34078163</pub-id><pub-id pub-id-type="pmcid">PMC8543665</pub-id></element-citation></ref><ref id="bib0016"><label>89</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Dounavi</surname><given-names>M.-E.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Swann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Low</surname><given-names>A.</given-names></name><name name-style="western"><surname>Muniz-Terrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>McKeever</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pope</surname><given-names>M.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Naci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koychev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.T.</given-names></name></person-group><article-title>Differential association of cerebral blood flow and anisocytosis in APOE &#949;4 carriers at midlife</article-title><source>J Cereb Blood Flow Metab</source><volume>43</volume><issue>10</issue><year>2023</year><fpage>1672</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1177/0271678X231173587</pub-id><pub-id pub-id-type="pmid">37132287</pub-id><pub-id pub-id-type="pmcid">PMC10581239</pub-id></element-citation></ref><ref id="bib0085"><label>90</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name name-style="western"><surname>Suri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Germuska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tunbridge</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Ebmeier</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Bulte</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Filippini</surname><given-names>N.</given-names></name></person-group><article-title>Reduced cerebrovascular reactivity in young adults carrying the <italic toggle="yes">APOE</italic> &#949;4 allele</article-title><source>Alzheimer&#8217;s Dement</source><volume>11</volume><year>2015</year><pub-id pub-id-type="doi">10.1016/j.jalz.2014.05.1755</pub-id><comment>6648-657.e1</comment><pub-id pub-id-type="pmid">25160043</pub-id></element-citation></ref><ref id="bib0004"><label>91</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Button</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>J.P.A.</given-names></name><name name-style="western"><surname>Mokrysz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nosek</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Flint</surname><given-names>J.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>E.S.J.</given-names></name><name name-style="western"><surname>Munaf&#242;</surname><given-names>M.R.</given-names></name></person-group><article-title>Power failure: why small sample size undermines the reliability of neuroscience</article-title><source>Nat Rev Neurosci</source><volume>14</volume><issue>5</issue><year>2013</year><pub-id pub-id-type="doi">10.1038/nrn3475</pub-id><comment>Article 5</comment><pub-id pub-id-type="pmid">23571845</pub-id></element-citation></ref><ref id="bib0050"><label>92</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Kucikova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Reinecke</surname><given-names>P.</given-names></name><name name-style="western"><surname>Madden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tappin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dounavi</surname><given-names>M.-E.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name></person-group><article-title>The effects of <italic toggle="yes">APOEe4</italic> allele on cerebral structure, function, and related interactions with cognition in young adults</article-title><source>Ageing Res Rev</source><volume>101</volume><year>2024</year><object-id pub-id-type="publisher-id">102510</object-id><pub-id pub-id-type="doi">10.1016/j.arr.2024.102510</pub-id><pub-id pub-id-type="pmid">39326705</pub-id></element-citation></ref><ref id="bib0064"><label>93</label><element-citation publication-type="journal" id="sbref0064"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>K.J.</given-names></name></person-group><article-title>Neurogenomics &#8211; Towards a more rigorous science</article-title><source>Eur J Neurosci</source><volume>47</volume><issue>2</issue><year>2017</year><fpage>109</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1111/ejn.13801</pub-id><pub-id pub-id-type="pmid">29230896</pub-id></element-citation></ref><ref id="bib0002"><label>94</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Belloy</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Le Guen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cuccaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farrer</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Napolioni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Greicius</surname><given-names>M.D.</given-names></name></person-group><article-title><italic toggle="yes">APOE</italic> genotype and Alzheimer disease risk across age, sex, and population ancestry</article-title><source>JAMA Neurol</source><year>2023</year><pub-id pub-id-type="doi">10.1001/jamaneurol.2023.3599</pub-id><pub-id pub-id-type="pmcid">PMC10628838</pub-id><pub-id pub-id-type="pmid">37930705</pub-id></element-citation></ref><ref id="bib0067"><label>95</label><element-citation publication-type="journal" id="sbref0067"><person-group person-group-type="author"><name name-style="western"><surname>Neu</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Pa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kukull</surname><given-names>W.</given-names></name><name name-style="western"><surname>Beekly</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kuzma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gangadharan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>K.</given-names></name><name name-style="western"><surname>Arneric</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Redolfi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Orlandi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Au</surname><given-names>R.</given-names></name><name name-style="western"><surname>Devine</surname><given-names>S.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>S.</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name><x xml:space="preserve">&#8230;</x><name name-style="western"><surname>Toga</surname><given-names>A.W.</given-names></name></person-group><article-title>Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis</article-title><source>JAMA Neurol</source><volume>74</volume><issue>10</issue><year>2017</year><fpage>1178</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2017.2188</pub-id><pub-id pub-id-type="pmid">28846757</pub-id><pub-id pub-id-type="pmcid">PMC5759346</pub-id></element-citation></ref><ref id="bib0032"><label>96</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Gamache</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chiba-Falek</surname><given-names>O.</given-names></name></person-group><article-title>Sex-dependent effect of <italic toggle="yes">APOE</italic> on Alzheimer&#8217;s disease and other age-related neurodegenerative disorders</article-title><source>Dis Model Mech</source><volume>13</volume><issue>8</issue><year>2020</year><object-id pub-id-type="publisher-id">dmm045211</object-id><pub-id pub-id-type="doi">10.1242/dmm.045211</pub-id><pub-id pub-id-type="pmcid">PMC7473656</pub-id><pub-id pub-id-type="pmid">32859588</pub-id></element-citation></ref><ref id="bib0093"><label>97</label><element-citation publication-type="journal" id="sbref0093"><person-group person-group-type="author"><name name-style="western"><surname>Valencia-Olvera</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Maldonado Weng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>A.</given-names></name><name name-style="western"><surname>LaDu</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Pike</surname><given-names>C.J.</given-names></name></person-group><article-title>Role of estrogen in women&#8217;s Alzheimer&#8217;s disease risk as modified by <italic toggle="yes">APOE</italic></article-title><source>J Neuroendocr</source><volume>35</volume><issue>2</issue><year>2023</year><object-id pub-id-type="publisher-id">e13209</object-id><pub-id pub-id-type="doi">10.1111/jne.13209</pub-id><pub-id pub-id-type="pmcid">PMC10049970</pub-id><pub-id pub-id-type="pmid">36420620</pub-id></element-citation></ref><ref id="bib0014"><label>98</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Dotson</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>A.</given-names></name></person-group><article-title>The importance of diversity in cognitive neuroscience</article-title><source>Ann N Y Acad Sci</source><volume>1464</volume><issue>1</issue><year>2020</year><fpage>181</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1111/nyas.14268</pub-id><pub-id pub-id-type="pmid">31663150</pub-id></element-citation></ref></ref-list><sec id="sec0022" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0052a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgements</title><p id="para0054">We are grateful to our respective institutions for their support.</p></ack><fn-group><fn id="sec0021" fn-type="supplementary-material"><p id="para0009a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100364" id="interref0002">doi:10.1016/j.tjpad.2025.100364</ext-link>.</p></fn></fn-group><fn-group><fn id="cit_1"><label>1</label><p id="notep0001">The terms &#8220;sex&#8221; and &#8220;gender&#8221; were used somewhat interchangeable in the reviewed studies. For consistency, we use the term sex throughout this scoping review. Further, as the included studies overwhelmingly used self-report to categorize individuals as male/female or man/woman, we also use terms such as &#8220;mixed-sex studies&#8221; and &#8220;single-sex studies&#8221;. This reflects the state of the literature, which has hitherto largely ignored intersex individuals, as well as transgender and gender non-binary individuals.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Arch Psychiatry Clin Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Eur Arch Psychiatry Clin Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>European Archives of Psychiatry and Clinical Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">0940-1334</issn><issn pub-type="epub">1433-8491</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12500809</article-id><article-id pub-id-type="pmcid-ver">PMC12500809.1</article-id><article-id pub-id-type="pmcaid">12500809</article-id><article-id pub-id-type="pmcaiid">12500809</article-id><article-id pub-id-type="pmid">38976049</article-id><article-id pub-id-type="doi">10.1007/s00406-024-01843-7</article-id><article-id pub-id-type="publisher-id">1843</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Neurosteroids and translocator protein 18&#160;kDa (TSPO) ligands as novel treatment options in depression</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2177-3884</contrib-id><name name-style="western"><surname>Riebel</surname><given-names initials="M">Marco</given-names></name><address><email>Marco.Riebel@medbo.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brunner</surname><given-names initials="LM">Lisa-Marie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nothdurfter</surname><given-names initials="C">Caroline</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wein</surname><given-names initials="S">Simon</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schwarzbach</surname><given-names initials="J">Jens</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liere</surname><given-names initials="P">Philippe</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schumacher</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rupprecht</surname><given-names initials="R">Rainer</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01eezs655</institution-id><institution-id institution-id-type="GRID">grid.7727.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 5763</institution-id><institution>Department of Psychiatry and Psychotherapy, </institution><institution>University Regensburg, </institution></institution-wrap>Universit&#228;tsstrasse 84, 93053 Regensburg, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05c9p1x46</institution-id><institution-id institution-id-type="GRID">grid.413784.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 7253</institution-id><institution>U1195 Inserm and University Paris-Saclay, Le Kremlin-Bic&#234;tre, </institution></institution-wrap>Paris, 94276 France </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>275</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">498445</issue-id><fpage>1581</fpage><lpage>1591</lpage><history><date date-type="received"><day>29</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>6</day><month>6</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="406_2024_Article_1843.pdf"/><abstract id="Abs1"><p id="Par1">Recently, the gamma-aminobutyric acid (GABA) system has come into focus for the treatment of anxiety, postpartum depression, and major depressive disorder. Endogenous 3&#945;-reduced steroids such as allopregnanolone are potent positive allosteric modulators of GABA<sub>A</sub> receptors and have been known for decades. Current industry developments and first approvals by the U.S. food and drug administration (FDA) for the treatment of postpartum depression with exogenous analogues of these steroids represent a major step forward in the field. 3&#945;-reduced steroids target both synaptic and extrasynaptic GABA<sub>A</sub> receptors, unlike benzodiazepines, which bind to synaptic receptors. The first FDA-approved 3&#945;-reduced steroid for postpartum depression is brexanolone, an intravenous formulation of allopregnanolone. It has been shown to provide rapid relief of depressive symptoms. An orally available 3&#945;-reduced steroid is zuranolone, which also received FDA approval in 2023 for the treatment of postpartum depression. Although a number of studies have been conducted, the efficacy data were not sufficient to achieve approval of zuranolone in major depressive disorder by the FDA in 2023. The most prominent side effects of these 3&#945;-reduced steroids are somnolence, dizziness and headache. In addition to the issue of efficacy, it should be noted that current data limit the use of these compounds to two weeks. An alternative to exogenous 3&#945;-reduced steroids may be the use of substances that induce endogenous neurosteroidogenesis, such as the translocator protein 18&#160;kDa (TSPO) ligand etifoxine. TSPO has been extensively studied for its role in steroidogenesis, in addition to other functions such as anti-inflammatory and neuroregenerative properties. Currently, etifoxine is the only clinically available TSPO ligand in France for the treatment of anxiety disorders. Studies are underway to evaluate its antidepressant potential. Hopefully, neurosteroid research will lead to the development of fast-acting antidepressants.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Neurosteroids</kwd><kwd>TSPO</kwd><kwd>Depression</kwd><kwd>Treatment</kwd><kwd>GABA<sub>A</sub> receptor</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#228;t Regensburg (3161)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par12">Major depressive disorder (MDD) is a serious condition with a high 12-month prevalence of about 6% and a lifetime incidence of about 16% [<xref ref-type="bibr" rid="CR1">1</xref>]. Unmet needs include the limited efficacy of antidepressants, particularly their slow onset of action. Most antidepressants commonly described in depression are believed to compensate for monoaminergic and anticholinergic neurotransmitter shifts [<xref ref-type="bibr" rid="CR2">2</xref>], but it takes several weeks for a clinically meaningful onset of action to occur. Thus, there is a need for rapid-acting antidepressants using novel pharmacologic targets. For example, ketamine has been shown to induce relatively rapid but short-lasting improvement in depressive symptoms via the glutamate system [<xref ref-type="bibr" rid="CR3">3</xref>]. Benzodiazepines are comparably fast-acting and widely used anxiolytic compounds [<xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>]. However, side effects such as tolerance development and abuse liability limit their use for medium- and long-term treatment [<xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>]. Benzodiazepines do not have sustained antidepressant properties [<xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, other treatment options, that produce rapid antidepressant and/or anxiolytic effects without the side effects of benzodiazepines are needed for the treatment of affective disorders. Most of the available antidepressants are based on the concept of monoamine reuptake inhibition, e.g., selective serotonin reuptake inhibitor (SSRIs). Recently, however, the GABAergic system has come into focus with the industrial development of GABAergic steroids as novel treatment options for postpartum depression and major depressive disorder. Moreover, given the discrete signs of neuroinflammation in depression as revealed by positron emission tomography (PET) studies for the translocator protein 18&#160;kDa (TSPO) and the ability of TSPO ligands to promote endogenous steroidogenesis [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], TSPO ligands may represent an interesting alternative to the administration of exogenous steroids.</p><p id="Par13">Therefore, we discuss below recent developments in the treatment of depression and postpartum depression using GABAergic steroids in relation to their mechanism of action and in relation to TSPO ligands.</p><sec id="Sec2"><title>Steroids: synthesis and mechanisms of action</title><p id="Par14">Steroids present in the brain originate from both steroidogenic tissues, e.g., the adrenal cortex and also from a local synthesis [<xref ref-type="bibr" rid="CR12">12</xref>]. Cholesterol is a substrate for the translocator protein 18&#160;kDa (TSPO), which serves as a channel to transport cholesterol into the mitochondrial matrix [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. There, steroids are formed from cholesterol (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par15">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Neurosteroidogenic pathway and therapeutic compounds. Left panel: 3&#945;-reduced steroids are metabolites of progesterone. Their synthesis is catalyzed by the 5&#945;-reductase and the 3&#945;-hydroxysteroid oxidoreductase. The activity of the 3&#945;-hydroxysteroid oxidoreductase may work both towards reduction and oxidation [<xref ref-type="bibr" rid="CR92">92</xref>]. Right panel: Molecule structure of brexanolone and zuranolone. Brexanolone is an intravenous formulation of 3&#945;, 5&#945;-tetrahydroprogesterone (3&#945;, 5&#945;-THP, allopregnanolone). Zuranolone is a synthetic modification of allopregnanolone and can be administered orally [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Brexanolone and zuranolone are approved by FDA for the treatment of postpartum depression, while zuranolone is still under investigation for major depressive disorder (MDD) and eventually for anxiety disorders</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e289" position="float" orientation="portrait" xlink:href="406_2024_1843_Fig1_HTML.jpg"/></fig>
</p><p id="Par16">An initial steroid is pregnenolone, which is converted to progesterone and deoxycorticosterone. These steroids are further reduced via the 5&#945;-reductase and then by the 3&#945;-hydroxysteroid oxidoreductase that works in both directions [<xref ref-type="bibr" rid="CR12">12</xref>] to produce 3&#945;-reduced steroids, such as allopregnanolone and 3&#945;,5&#945;-tetrahydrodeoxycorticosterone (3&#945;5&#945;-THDOC), that are positive allosteric modulators of GABA<sub>A</sub> receptors. Steroid binding occurs mainly at &#223;-subunit interfaces [<xref ref-type="bibr" rid="CR15">15</xref>], whereas the benzodiazepine binding site is determined by the differential composition of &#945;-subunits [<xref ref-type="bibr" rid="CR16">16</xref>], thereby enhancing GABA-gated chloride currents. GABA<sub>A</sub> receptors can be differentiated into synaptic and extrasynaptic GABA<sub>A</sub> receptors. Synaptic GABA<sub>A</sub> receptors, which are targeted by benzodiazepines and 3&#945;-reduced steroids, show a widespread expression profile and mediate a phasic inhibition. Extrasynaptic GABA<sub>A</sub> receptors, however, are targeted by 3&#945;-reduced steroids and confer tonic inhibition with a more region-specific expression profile [<xref ref-type="bibr" rid="CR17">17</xref>] (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). As 3&#945;-reduced steroids target both synaptic and extrasynaptic GABA<sub>A</sub> receptors [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>], this may contribute to their unique pharmacological profile. It is also noteworthy that while benzodiazepines prolong the fast phasic postsynaptic response of &#947;2 subunit-containing GABA<sub>A</sub> receptors, 3&#945;-reduced steroids additionally evoke a tonic persistent inhibitory response involving extrasynaptic GABA<sub>A</sub> receptors containing the &#948; subunit [<xref ref-type="bibr" rid="CR21">21</xref>]. These differential effects on the time course and peak amplitude of GABA-evoked chloride currents may explain the differences in efficacy and side effect profile between 3&#945;-reduced steroids and benzodiazepines.</p><p id="Par17">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Mechanism of action of etifoxine. Upper box: Molecule structure of etifoxine. Etifoxine has a dual mode of action. It is a TSPO ligand and promotes neurosteroidogenesis, which in turn modulate GABA<sub>A</sub> receptors, but also directly modulates &#945;2 and &#945;3 containing GABA<sub>A</sub> receptors (gray dotted arrows). It is approved in France for adjustment anxiety disorders and under investigation for the treatment of depression by our group. Lower boxes: GABA<sub>A</sub> receptors are expressed both at synaptic and extrasynaptic sites with different expression patterns and physiological and pharmacological properties. While benzodiazepines target only synaptic receptors, neurosteroids modulate both synaptic and extrasynaptic receptors, which may explain their distinct clinical profile</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e350" position="float" orientation="portrait" xlink:href="406_2024_1843_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec3"><title>Neurosteroids in depression</title><p id="Par18">Studies investigating the composition of neurosteroids in depressed patients are rather rare. First clinical studies reported reduced levels of 3&#945;-reduced steroids in corticospinal fluid and plasma of depressed patients and a subsequent increase following SSRI treatment [<xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref>]. These findings are in line with molecular data showing that SSRIs or mirtazapine may increase concentrations of 3&#945;-reduced steroids through shifting the activity of the 3&#945;-hydroxysteroid oxidoreductase towards the reductive direction (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. This mechanism may contribute to the antidepressant and anxiolytic effects of these compounds. Moreover, following medication with different antidepressants we found an increase in 3&#946;-reduced steroids, which exert functional antagonistic properties [<xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref>]. To investigate whether these changes in neurosteroid composition more likely reflect clinical response patterns, we did a series of studies with nonpharmacological treatments of depression such as sleep deprivation [<xref ref-type="bibr" rid="CR27">27</xref>], repetitive transcranial magnetic stimulation [<xref ref-type="bibr" rid="CR28">28</xref>] and electroconvulsive therapy [<xref ref-type="bibr" rid="CR29">29</xref>]. However, none of these treatments affected neurosteroid composition independent of treatment response. On the other hand, treatment with mirtazapine normalized the altered neurosteroid pattern in both responders and non-responders to treatment, suggesting a pharmacological effect via neurosteroidogenic enzymes [<xref ref-type="bibr" rid="CR26">26</xref>]. Another study suggested alterations in neurosteroid composition also in perinatal depression [<xref ref-type="bibr" rid="CR30">30</xref>]. Interestingly, in patients with premenstrual dysphoric disorder (PMDD), the sensitivity of exogenously administered allopregnanolone was shown to be dependent on the menstrual cycle [<xref ref-type="bibr" rid="CR31">31</xref>]. Although 3&#945;-reduced steroids are altered in depression, these changes are far less pronounced than in postpartum depression and conflicting results have been reported on the relationship between hormonal changes and symptom onset [<xref ref-type="bibr" rid="CR32">32</xref>]. Although the reported findings of alterations in neurosteroid composition are subtle and only few studies are available, there is a good rationale for the therapeutic use of either exogenous or endogenous neurosteroids in affective disorders, which may provide a basis for novel treatment options.</p></sec><sec id="Sec4"><title>Therapeutic effects of 3&#945;-reduced steroids</title><p id="Par19">Although 3&#945;-reduced steroids and their behavioral properties have been known for decades, only recently industrial efforts have been undertaken to put these molecules forward as therapeutic agents. The first neurosteroid to receive approval for the treatment of postpartum depression by the FDA is brexanolone [<xref ref-type="bibr" rid="CR33">33</xref>]. The formula of brexanolone is identical to that of the naturally occurring allopregnanolone (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). It is a special preparation for intravenous application, that should be administered for 60&#160;h [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. In these two studies, a rapid, clinically meaningful antidepressant effect was observed that persisted throughout the study period of 30 days. The most common adverse effects were dizziness and headache. These findings were replicated in the HUMMINGBIRD clinical program with rapid improvement of depressive, anxiety and insomnia symptoms [<xref ref-type="bibr" rid="CR36">36</xref>]. A post-marketing survey revealed no serious safety concerns for brexanolone, with sedation being the most serious side effect [<xref ref-type="bibr" rid="CR37">37</xref>]. From a pathophysiological perspective the administration of 3&#945;-reduced steroids such as brexanolone may alleviate affective symptoms in postpartum depression [<xref ref-type="bibr" rid="CR11">11</xref>]. After parturition, progesterone and its 3&#945;-reduced metabolites show an enormous decline, which may cause affective symptoms and may be alleviated by exogenous administration of 3&#945;-reduced steroids [<xref ref-type="bibr" rid="CR5">5</xref>]. Thus, neurosteroid replacement may be directly related to the pathophysiology of postpartum depression. However, a practical inconvenience of brexanolone is the 60-hour intravenous infusion. An oral medication was needed and was introduced with zuranolone (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>), which solves the problem of administration. In 2023, zuranolone was approved by the FDA for the treatment of postpartum depression [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. It was shown that zuranolone produced a reduction in depressive symptoms within 15 days of treatment that lasted until day 45 [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. In addition, zuranolone improved sleep patterns in a model of insomnia in healthy volunteers [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. In these studies, side effects of zuranolone were similar to those of brexanolone (headache, dizziness, and somnolence). The approval of two 3a-reduced steroids for postpartum depression represents a major breakthrough in the treatment of this mental disorder.</p><p id="Par20">A series of studies have been conducted to further study the efficacy of zuranolone in major depressive disorder. Zuranolone significantly improved depressive symptoms within 15 days of treatment when compared to placebo [<xref ref-type="bibr" rid="CR42">42</xref>] and increased patient-reported quality of life within this time frame [<xref ref-type="bibr" rid="CR43">43</xref>]. In addition, a recent meta-analysis pointed towards a beneficial effect of zuranolone within two weeks of treatment [<xref ref-type="bibr" rid="CR44">44</xref>]. Several follow-up studies have been published recently. A study with 50&#160;mg zuranolone was able to reproduce the superiority over placebo on day 15 in reducing the Hamilton Depression Scale (HAM-D) score with the first signs of onset already on day 3 [<xref ref-type="bibr" rid="CR45">45</xref>]. However, in the so-called MOUNTAIN study, zuranolone did not meet its primary endpoint at a dose of 30&#160;mg on day 15 of treatment [<xref ref-type="bibr" rid="CR46">46</xref>]. In the SHORELINE study, an open-label phase 3 trial, repeated treatment courses were offered as needed, with responders requiring fewer than two treatment courses during one year of follow-up [<xref ref-type="bibr" rid="CR47">47</xref>]. Another recent meta-analysis suggested antidepressant and anxiolytic efficacy of zuranolone with an optimal dose of 30&#160;mg, with an increased risk of side effects with increasing the dose [<xref ref-type="bibr" rid="CR48">48</xref>]. It is noteworthy, however, that in contrast to postpartum depression, zuranolone has not been approved for major depressive disorder. Concerns have been raised about limited efficacy, incompatibility with breastfeeding, putative impairment of psychomotor function, and potential for abuse [<xref ref-type="bibr" rid="CR49">49</xref>]. Other issues that need to be evaluated include how long the effects of zuranolone can be maintained after treatment is discontinued, whether zuranolone can really work as an interval therapy requiring only short treatment intervals of 14 days, thereby changing the course of the disease without the need for maintenance or relapse medications, and whether zuranolone can be administered for a longer period of time in relation to side effects. So far, headache, somnolence and dizziness are the most prominent side effects within a two-week treatment. The side effect profile over longer treatment periods remains to be determined. It will be of great interest to see what the future potential of zuranolone in the treatment of major depressive disorder will be.</p></sec><sec id="Sec5"><title>Structure and function of TSPO</title><p id="Par21">An alternative to the administration of exogenous 3a-reduced steroids is the promotion of endogenous neurosteroidogenesis. Much research has focused on the translocator protein 18&#160;kDa (TSPO), suggesting it as a promising candidate for endogenous steroid formation. The following section on the structure and function of TSPO is taken in part from a recent review by our group in the same journal and presented again here for reasons of clarity [<xref ref-type="bibr" rid="CR11">11</xref>]. The translocator protein 18&#160;kDa (TSPO) is a 169 amino acid comprising protein of the outer mitochondrial membrane (OMM) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], which is associated with other proteins residing in the OMM such as voltage-dependent anion channel (VDAC), but also with cytosolic proteins, e.g., the steroidogenic acute regulatory protein (StAR) and proteins of the inner mitochondrial membrane (IMM), such as the adenine nucleotide transporter (ANT) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. TSPO mediates numerous biological functions such as mitochondrial cholesterol transport, porphyrin transport and heme synthesis, apoptosis, cell proliferation, and transport of ions and metabolites [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Although TSPO is particularly abundant in steroid producing tissues it can be found substantially also in the brain, liver, heart, and the immune system. The broad range of expression and its pleiotropic functional properties render TSPO an interesting target for many disease areas [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Currently, the exact role of TSPO for steroidogenesis has been challenged by studies in various knock-out mice [<xref ref-type="bibr" rid="CR51">51</xref>&#8211;<xref ref-type="bibr" rid="CR53">53</xref>], where steroidogenesis remains unaffected by TSPO knockout.</p><p id="Par22">Nevertheless, TSPO ligands exert numerous functions including anti-inflammatory properties, which on the one hand offer a much broader pharmacological profile but on the other hand should be considered when developing TSPO ligands for therapeutic purposes both in terms of clinical and side effects. Recently, some TSPO ligands, such as the benzodiazepine diazepam (which also has some affinity for TSPO [<xref ref-type="bibr" rid="CR14">14</xref>]), have been shown to activate synaptic pruning, leading to increased synaptic C1q deposition, removal of excitatory synapses, microglial phagocytosis of synaptic proteins, and decline in cognitive function [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Such findings of impaired cognitive function, which may be due to a loss of hippocampal and cortical excitatory synapses, may provide an explanation for why certain benzodiazepines, such as diazepam, may cause cognitive impairment in humans. On the other hand, a recent study showed that the TSPO ligand XBD173 prevented the amyloid &#946;-induced neurotoxicity and dendritic spine loss and even exerted precognitive effects in a mouse model of Alzheimer&#8217;s disease [<xref ref-type="bibr" rid="CR55">55</xref>]. Thus, the question of whether TSPO ligands may have beneficial or even detrimental effects on cognition and in neurodegenerative disorders warrants further investigation.</p></sec><sec id="Sec6"><title>TSPO ligands in the treatment of anxiety and depression</title><p id="Par23">TSPO expression and activity [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>] play an important role for psychiatric disorders and their treatment. A variety of studies have investigated the expression of TSPO in stress-related disorders [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. These studies investigated either the expression of TSPO mRNA in peripheral mononuclear cells, the binding characteristics of the TSPO ligand PK11195 to platelet membranes, or protein expression in thrombocytes [<xref ref-type="bibr" rid="CR58">58</xref>&#8211;<xref ref-type="bibr" rid="CR60">60</xref>]. Meanwhile, various PET studies reported increased TSPO expression in depression [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>] and obsessive-compulsive disorder [<xref ref-type="bibr" rid="CR63">63</xref>]. Recently, it has been suggested that TSPO PET imaging may even predict the clinical response to celecoxib treatment in major depression [<xref ref-type="bibr" rid="CR64">64</xref>], thereby highlighting the potential of TSPO ligands as personalized approaches both in diagnostics and for selecting treatment procedures in relation to their outcome. In patients suffering from PTSD, it has been shown that higher C-reactive protein (CRP) levels are associated with lower prefrontal-limbic TSPO availability and PTSD severity [<xref ref-type="bibr" rid="CR65">65</xref>]. Moreover, in neurodegenerative disorders, such as Alzheimer&#180;s disease but also in depression with cognitive impairment, upregulation of TSPO labeling has been reported in PET studies [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. However, TSPO expression should not unequivocally be considered as a marker of neuroinflammation, since also neuronal activation may increase TSPO levels [<xref ref-type="bibr" rid="CR67">67</xref>]. These findings suggest that TSPO ligands exert antidepressant effects through their anti-inflammatory properties. Moreover, TSPO gene variants, such as the rs6971 Ala147Thr polymorphism, which affects ligand binding and cholesterol uptake, should be considered in clinical studies when assessing TSPO binding or function. For example, both bipolar disorder and diurnal cortisol rhythm in bipolar disorder have been linked to this TSPO polymorphism [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>].</p><p id="Par24">Various TSPO ligands may display anxiolytic or putative antidepressant properties in rodents [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. In a translational study, our group showed that the selective TSPO ligand XBD173 enhanced GABAergic neurotransmission in brain slices via the induction of neurosteroidogenesis and effectively reduced the number of pharmacologically induced panic attacks in rodents in the absence of sedation [<xref ref-type="bibr" rid="CR70">70</xref>]. Moreover, XBD173 displayed anti-panic and anxiolytic efficacy in humans using an experimental anxiety paradigm involving a challenge with cholecystokinin tetrapeptide (CCK-4). Whereas the benzodiazepine alprazolam caused sedation and withdrawal symptoms after only 7 days of treatment, these were absent in the XBD173-treated subjects. Recent molecular studies using global or neuronal TSPO knockout mice further dissected the role of neuronal TSPO for modulating anxiety- and depression-related behavior and the effects of XBD173 [<xref ref-type="bibr" rid="CR57">57</xref>]. A recent animal study suggested that the TSPO ligand AC-5216 (XBD173) may exert rapid antidepressant and memory enhancing effects [<xref ref-type="bibr" rid="CR71">71</xref>]. The capability of TSPO ligands to exert anxiolytic and antidepressant effects has also been demonstrated for other novel TSPO ligands such as YL-IPAo8 in a rat model of postpartum depression [<xref ref-type="bibr" rid="CR72">72</xref>] or the antagonistic ligand ONO-2952 [<xref ref-type="bibr" rid="CR73">73</xref>]. Therefore, TSPO represents a promising target for the development of fast-acting anxiolytics and antidepressants with a favorable side effect profile.</p><p id="Par25">Currently, the only clinically available TSPO ligand is etifoxine (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>), which is approved in France. Etifoxine has a dual mode of action, as it targets TSPO but also directly &#945;2 and &#945;3 containing GABA<sub>A</sub> receptors [<xref ref-type="bibr" rid="CR74">74</xref>]. Initial clinical studies with etifoxine have provided first evidence for a clinical anxiolytic effect, which showed comparable efficacy to the benzodiazepine lorazepam in patients suffering from adjustment disorders with anxiety [<xref ref-type="bibr" rid="CR75">75</xref>]. The anxiolytic effects of etifoxine comparable to clonazepam have recently been confirmed in a randomized controlled double-blind clinical trial in patients with anxiety disorders [<xref ref-type="bibr" rid="CR76">76</xref>]. At the cellular level, we have characterized the effects of etifoxine in comparison to benzodiazepines regarding neurosteroidogenesis [<xref ref-type="bibr" rid="CR56">56</xref>]. Moreover, our group recently described differential effects of etifoxine and alprazolam on hypothalamic-pituitary-adrenal (HPA) axis activity in the Trier Social Stress Test in Virtual Reality (VR-TSST) [<xref ref-type="bibr" rid="CR77">77</xref>]. Furthermore, we recently showed that etifoxine but not alprazolam reduced the fear-potentiated startle in comparison to placebo in an experimental threat paradigm in healthy volunteers [<xref ref-type="bibr" rid="CR78">78</xref>]. However, the brain circuits underlying the anxiolytic and/or anti-stress effects of TSPO ligands have not been identified so far. Therefore, we conducted a double blinded within-design study with healthy male volunteers to address this issue. In this study, we could also show differential effects of etifoxine and alprazolam on GABAergic function as assessed by double-pulse transcranial magnetic stimulation (TMS) [<xref ref-type="bibr" rid="CR79">79</xref>] and subtle effects on microbiome composition [<xref ref-type="bibr" rid="CR80">80</xref>]. To address the question of whether etifoxine may affect peripheral steroid concentrations, steroid profiles were obtained in plasma in a subset of study participants which are reported below.</p></sec><sec id="Sec7"><title>Steroid plasma profile following treatment with etifoxine</title><p id="Par26">The study population of 36 male participants between the ages of 18 and 55 years was screened by a physician for the absence of physical and psychiatric disorders by physical examination and the German version of the Mini-International Neuropsychiatric Interview (M.I.N.I.) [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Study population and design are described in more detail elsewhere [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. The trial was registered at the European Clinical Trials Register (EudraCT number: 2018-002181-40) and at the German Register of Clinical Studies (DRKS-ID: DRKS00020267) and approved by the ethics committee of University of Regensburg and the German Federal Institute for Drugs and Medical Devices (BfArM). All participants gave their written informed consent. Throughout the experiment, participants were required to abstain from alcohol, driving, and the use of heavy machinery. The order of medication intake was pseudo-randomly assigned - placebo, alprazolam (1.5&#160;mg/d in 3 doses of 0.5&#160;mg) and etifoxine (150&#160;mg/d in 3 doses of 50&#160;mg) for 5 days each, with a washout period of at least 7 days between medications. Due to the complexity and expense of the steroid analysis, only placebo and etifoxine samples from 25 subjects were complete and could be analyzed. These were collected on day 5, 60&#160;min after the 12:00 midday medication intake (placebo or etifoxine). Steroid profiles were determined by means of a highly specific and sensitive gas chromatography coupled to tandem mass spectrometry analysis as described previously [<xref ref-type="bibr" rid="CR53">53</xref>]. A two-sided t-test was performed between etifoxine and placebo samples per neurosteroid using a bootstrapped (k&#8201;=&#8201;10,000) null distribution generated from the study data.</p><p id="Par28">Figure <xref rid="Fig3" ref-type="fig">3</xref> (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>) shows peripheral plasma levels of pregnenolone (PREG), progesterone (PROG), 5&#945;-dihydroprogesterone (5&#945;-DHP), 3&#945;,5&#945;-tetrahydroprogesterone (3&#945;,5&#945;-THP, allopregnanolone), 5&#945;-dihydrodeoxycorticosterone (5&#945;-DHDOC), and 3&#945;,5&#945;-tetrahydrodeoxycorticosterone (3&#945;,5&#945;-THDOC) on a logarithmic scale (absolute values are provided in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par27">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Steroid profile in plasma following administration of etifoxine and placebo in healthy male volunteers. Steroid concentrations in ng/ml are shown logarithmized on the y axis. Error bars indicate 95% confidence intervals. No significant effect of the etifoxine on plasma steroids was detectable. PREG: pregnenolone, PROG: progesterone, 5&#945;-DHP: 5&#945;-dihydrodroprogesterone, 3&#945;,5&#945;-THP: 3&#945;,5&#945;-tetrahydroprogesterone, 5&#945;-DHDOC: 5&#945;-dihydrodeoxycorticosterone, 3&#945;,5&#945;-THDOC: 3&#945;,5&#945;-tetrahydrodeoxycorticosterone</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e698" position="float" orientation="portrait" xlink:href="406_2024_1843_Fig3_HTML.jpg"/></fig>
</p><p id="Par29">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Steroid profile in plasma following administration of etifoxine and placebo in healthy male volunteers. Mean and standard deviation of steroid concentrations in ng/ml. PREG: pregnenolone, PROG: progesterone, 5&#945;-DHP: 5&#945;-dihydrodroprogesterone, 3&#945;,5&#945;-THP: 3&#945;,5&#945;-tetrahydroprogesterone, 5&#945;-DHDOC: 5&#945;-dihydrodeoxycorticosterone, 3&#945;,5&#945;-THDOC: 3&#945;,5&#945;-tetrahydrodeoxycorticosterone</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">neurosteroid</th><th align="left" colspan="1" rowspan="1">medication</th><th align="left" colspan="1" rowspan="1">mean [ng/ml]</th><th align="left" colspan="1" rowspan="1">standard deviation</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">PREG</td><td align="left" colspan="1" rowspan="1">Etifoxine</td><td char="." align="char" colspan="1" rowspan="1">5.222</td><td char="." align="char" colspan="1" rowspan="1">2.486</td></tr><tr><td align="left" colspan="1" rowspan="1">Placebo</td><td char="." align="char" colspan="1" rowspan="1">5.832</td><td char="." align="char" colspan="1" rowspan="1">2.730</td></tr><tr><td align="left" rowspan="2" colspan="1">PROG</td><td align="left" colspan="1" rowspan="1">Etifoxine</td><td char="." align="char" colspan="1" rowspan="1">0.178</td><td char="." align="char" colspan="1" rowspan="1">0.103</td></tr><tr><td align="left" colspan="1" rowspan="1">Placebo</td><td char="." align="char" colspan="1" rowspan="1">0.148</td><td char="." align="char" colspan="1" rowspan="1">0.095</td></tr><tr><td align="left" rowspan="2" colspan="1">5&#945;-DHP</td><td align="left" colspan="1" rowspan="1">Etifoxine</td><td char="." align="char" colspan="1" rowspan="1">0.249</td><td char="." align="char" colspan="1" rowspan="1">0.128</td></tr><tr><td align="left" colspan="1" rowspan="1">Placebo</td><td char="." align="char" colspan="1" rowspan="1">0.317</td><td char="." align="char" colspan="1" rowspan="1">0.162</td></tr><tr><td align="left" rowspan="2" colspan="1">3&#945;,5&#945;-THP</td><td align="left" colspan="1" rowspan="1">Etifoxine</td><td char="." align="char" colspan="1" rowspan="1">0.183</td><td char="." align="char" colspan="1" rowspan="1">0.227</td></tr><tr><td align="left" colspan="1" rowspan="1">Placebo</td><td char="." align="char" colspan="1" rowspan="1">0.190</td><td char="." align="char" colspan="1" rowspan="1">0.131</td></tr><tr><td align="left" rowspan="2" colspan="1">5&#945;-DHDOC</td><td align="left" colspan="1" rowspan="1">Etifoxine</td><td char="." align="char" colspan="1" rowspan="1">0.328</td><td char="." align="char" colspan="1" rowspan="1">0.403</td></tr><tr><td align="left" colspan="1" rowspan="1">Placebo</td><td char="." align="char" colspan="1" rowspan="1">0.264</td><td char="." align="char" colspan="1" rowspan="1">0.646</td></tr><tr><td align="left" rowspan="2" colspan="1">3&#945;,5&#945;-THDOC</td><td align="left" colspan="1" rowspan="1">Etifoxine</td><td char="." align="char" colspan="1" rowspan="1">0.061</td><td char="." align="char" colspan="1" rowspan="1">0.035</td></tr><tr><td align="left" colspan="1" rowspan="1">Placebo</td><td char="." align="char" colspan="1" rowspan="1">0.056</td><td char="." align="char" colspan="1" rowspan="1">0.044</td></tr></tbody></table></table-wrap>
</p><p id="Par30">In this clinical study, no effects of etifoxine were detected in the plasma of male volunteers. This is in contrast to findings in rats, where etifoxine caused increases in progesterone and 3&#945;-reduced steroids in both brain and plasma [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>] as well as in cellular systems [<xref ref-type="bibr" rid="CR56">56</xref>]. Presumed differences in tissue-specific enzymatic machinery and between rats and humans preclude further conclusions. A part of the steroid pool, like allopregnanolone, is mainly formed in peripheral glands [<xref ref-type="bibr" rid="CR85">85</xref>], whereas neuronal tissue provides enzymes such as the 5&#945;-reductase and 3&#945;-hydroxysteroid dehydrogenase to synthesize meaningful local concentrations of neurosteroids [<xref ref-type="bibr" rid="CR85">85</xref>&#8211;<xref ref-type="bibr" rid="CR87">87</xref>]. In rats, plasma levels are not fully correlated and much lower compared to their levels in neural tissue [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. Although these findings seem to weaken the role of peripheral plasma levels of neurosteroids as sensitive clinical biomarkers, measurable differences in plasma levels of specific neurosteroids could still be an important marker of pathological conditions with or without reflecting localized brain processes [<xref ref-type="bibr" rid="CR90">90</xref>]. Ongoing clinical research in our group aims to study the sensitivity of peripheral steroid levels to therapeutic manipulation, e.g. by etifoxine treatment under pathological conditions [<xref ref-type="bibr" rid="CR91">91</xref>].</p></sec><sec id="Sec8"><title>Etifoxine and GABAkines in the treatment of depression</title><p id="Par31">Because TSPO ligands may induce neurosteroidogenesis, they may represent an alternative approach to exogenously applied 3&#945;-reduced steroids such as brexanolone or zuranolone in the treatment of postpartum depression or major depressive disorder. As outlined above, our group is currently performing a first proof of concept study assessing the potential of etifoxine as adjunct treatment in depression in relation to neuroimaging and microbiome parameters. Moreover, modifications of the etifoxine molecule, such as the GABAkine GRX-917 [<xref ref-type="bibr" rid="CR92">92</xref>], may provide TSPO ligands with improved pharmacokinetic properties. It is noteworthy that side effects such as sedation, tolerance development and abuse liability, which are typical for benzodiazepines, have not been reported for TSPO ligands so far, which further supports their investigation as a novel treatment option.</p><p id="Par32">Conclusion and outlook.</p><p id="Par33">The neurosteroid field is known for decades. However, it has recently gained considerable interest due to industrial efforts, e.g., by SAGE/Biogen, to develop 3&#945;-reduced steroids such as brexanolone and zuranolone as novel therapeutic agents for affective disorders. With respect to postpartum depression, it is quite clear that the dramatic drop in progesterone after childbirth leads to a corresponding drop in 3&#945;-reduced steroids, which may contribute to the psychopathology of postpartum depression. As a clinical consequence, the administration of exogenous 3&#945;-reduced steroids has a solid pathophysiological rationale. In fact, the portfolio of studies presented has led to the approval of brexanolone and zuranolone for the treatment of postpartum depression. The situation is less clear in major depressive disorder. Although subtle changes in neurosteroid composition have been reported in major depressive disorder and anxiety disorders, and antidepressants have been shown to interfere with neurosteroidogenic enzymes, the magnitude of alterations is only marginal compared to postpartum depression. Nevertheless, it is intriguing that the study portfolio presented by SAGE/Biogen suggests a rapid antidepressant potential of zuranolone also in major depressive disorder. However, zuranolone has not been approved by the FDA for major depressive disorder due to several concerns that need to be addressed. According to the authors, the following questions should be addressed: What will be the side-effect profile after a more prolonged administration beyond 14 days? Will there be abuse liability or tolerance effects? What will be the efficacy over a longer period of time? Will these agents find their place as a monotherapy or as adjuncts to standard antidepressants? Will interval therapy become a novel treatment regimen? Moreover, the induction of endogenous neurosteroidogenesis via TSPO ligands such as etifoxine or derivatives may be an interesting alternative approach. Will these two approaches provide similar clinical effects, or will there be a different clinical profile given the broad spectrum of action of TSPO ligands? In conclusion, it is encouraging that the progress made in the field of neurosteroids and TSPO has now opened the door to new treatment options. Hopefully, these will find their way as alternative strategies to existing pharmacological and non-pharmacological treatments for affective disorders.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>This work has been supported by the German Research Foundation (Deutsche Forschungsgemeinschaft) (DFG), project number 422179811 to RR, CN and JS.</p></ack><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethical standards</title><p id="Par39">All clinical studies have been approved by the local ethics committee and have been performed in accordanve with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par40">The other authors declare that they have no conflict of interest.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par41">RR has received consultancy honoraria from SAGE/Biogen and GABA Therapeutics.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malhi</surname><given-names>GS</given-names></name><name name-style="western"><surname>Mann</surname><given-names>JJ</given-names></name></person-group><article-title>Depression.</article-title><source>The Lancet</source><year>2018</year><volume>392</volume><fpage>2299</fpage><lpage>2312</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31948-2</pub-id><pub-id pub-id-type="pmid">30396512</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Malhi GS, Mann JJ (2018) Depression. The Lancet 392:2299&#8211;2312. 10.1016/S0140-6736(18)31948-2<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)31948-2</pub-id><pub-id pub-id-type="pmid">30396512</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Analysis of Time-Course, Dose-Effect, and influencing factors of antidepressants in the treatment of Acute adult patients with Major Depression</article-title><source>Int J Neuropsychopharmacol</source><year>2020</year><volume>23</volume><fpage>76</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1093/ijnp/pyz062</pub-id><pub-id pub-id-type="pmid">31774497</pub-id><pub-id pub-id-type="pmcid">PMC7094001</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Cheng Q, Huang J, Xu L, Li Y, Li H, Shen Y, Zheng Q, Li L (2020) Analysis of Time-Course, Dose-Effect, and influencing factors of antidepressants in the treatment of Acute adult patients with Major Depression. Int J Neuropsychopharmacol 23:76&#8211;87. 10.1093/ijnp/pyz062<pub-id pub-id-type="pmid">31774497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ijnp/pyz062</pub-id><pub-id pub-id-type="pmcid">PMC7094001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kritzer</surname><given-names>M</given-names></name></person-group><article-title>Ketamine for treatment of mood disorders and suicidality: a narrative review of recent progress</article-title><source>Ann Clin Psychiatry</source><year>2021</year><volume>33</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.12788/acp.0048</pub-id><pub-id pub-id-type="pmid">35166663</pub-id><pub-id pub-id-type="pmcid">PMC9044467</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Kritzer M (2021) Ketamine for treatment of mood disorders and suicidality: a narrative review of recent progress. Ann Clin Psychiatry 33:4. 10.12788/acp.0048<pub-id pub-id-type="pmid">35166663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12788/acp.0048</pub-id><pub-id pub-id-type="pmcid">PMC9044467</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;iz-V&#225;zquez</surname><given-names>O</given-names></name><name name-style="western"><surname>Gracia-Garc&#237;a</surname><given-names>P</given-names></name><name name-style="western"><surname>Ubillos-Landa</surname><given-names>S</given-names></name><name name-style="western"><surname>Puente-Mart&#237;nez</surname><given-names>A</given-names></name><name name-style="western"><surname>Casado-Yusta</surname><given-names>S</given-names></name><name name-style="western"><surname>Olaya</surname><given-names>B</given-names></name><name name-style="western"><surname>Santab&#225;rbara</surname><given-names>J</given-names></name></person-group><article-title>Depression as a risk factor for Alzheimer&#8217;s Disease: a systematic review of longitudinal Meta-analyses</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><fpage>1809</fpage><pub-id pub-id-type="doi">10.3390/jcm10091809</pub-id><pub-id pub-id-type="pmid">33919227</pub-id><pub-id pub-id-type="pmcid">PMC8122638</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">S&#225;iz-V&#225;zquez O, Gracia-Garc&#237;a P, Ubillos-Landa S, Puente-Mart&#237;nez A, Casado-Yusta S, Olaya B, Santab&#225;rbara J (2021) Depression as a risk factor for Alzheimer&#8217;s Disease: a systematic review of longitudinal Meta-analyses. J Clin Med 10:1809. 10.3390/jcm10091809<pub-id pub-id-type="pmid">33919227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10091809</pub-id><pub-id pub-id-type="pmcid">PMC8122638</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Wetzel</surname><given-names>CH</given-names></name><name name-style="western"><surname>Dorostkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Herms</surname><given-names>J</given-names></name><name name-style="western"><surname>Albert</surname><given-names>NL</given-names></name><name name-style="western"><surname>Schwarzbach</surname><given-names>J</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>ID</given-names></name></person-group><article-title>Translocator protein (18&#160;kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders?</article-title><source>Mol Psychiatry</source><year>2022</year><volume>27</volume><fpage>2918</fpage><lpage>2926</lpage><pub-id pub-id-type="doi">10.1038/s41380-022-01561-3</pub-id><pub-id pub-id-type="pmid">35444254</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Rupprecht R, Wetzel CH, Dorostkar M, Herms J, Albert NL, Schwarzbach J, Schumacher M, Neumann ID (2022) Translocator protein (18&#160;kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders? Mol Psychiatry 27:2918&#8211;2926. 10.1038/s41380-022-01561-3<pub-id pub-id-type="pmid">35444254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-022-01561-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edinoff</surname><given-names>AN</given-names></name><name name-style="western"><surname>Nix</surname><given-names>CA</given-names></name><name name-style="western"><surname>Hollier</surname><given-names>J</given-names></name><name name-style="western"><surname>Sagrera</surname><given-names>CE</given-names></name><name name-style="western"><surname>Delacroix</surname><given-names>BM</given-names></name><name name-style="western"><surname>Abubakar</surname><given-names>T</given-names></name><name name-style="western"><surname>Cornett</surname><given-names>EM</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>AD</given-names></name></person-group><article-title>Benzodiazepines: uses, dangers, and clinical considerations</article-title><source>Neurol Int</source><year>2021</year><volume>13</volume><fpage>594</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.3390/neurolint13040059</pub-id><pub-id pub-id-type="pmid">34842811</pub-id><pub-id pub-id-type="pmcid">PMC8629021</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Edinoff AN, Nix CA, Hollier J, Sagrera CE, Delacroix BM, Abubakar T, Cornett EM, Kaye AM, Kaye AD (2021) Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int 13:594&#8211;607. 10.3390/neurolint13040059<pub-id pub-id-type="pmid">34842811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/neurolint13040059</pub-id><pub-id pub-id-type="pmcid">PMC8629021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pariente</surname><given-names>A</given-names></name><name name-style="western"><surname>De Gage</surname><given-names>SB</given-names></name><name name-style="western"><surname>Moore</surname><given-names>N</given-names></name><name name-style="western"><surname>B&#233;gaud</surname><given-names>B</given-names></name></person-group><article-title>The benzodiazepine&#8211;dementia disorders Link: current state of knowledge</article-title><source>CNS Drugs</source><year>2016</year><volume>30</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s40263-015-0305-4</pub-id><pub-id pub-id-type="pmid">26715389</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Pariente A, De Gage SB, Moore N, B&#233;gaud B (2016) The benzodiazepine&#8211;dementia disorders Link: current state of knowledge. CNS Drugs 30:1&#8211;7. 10.1007/s40263-015-0305-4<pub-id pub-id-type="pmid">26715389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40263-015-0305-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barker</surname><given-names>M</given-names></name></person-group><article-title>Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis</article-title><source>Arch Clin Neuropsychol</source><year>2004</year><volume>19</volume><fpage>437</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/S0887-6177(03)00096-9</pub-id><pub-id pub-id-type="pmid">15033227</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Barker M (2004) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 19:437&#8211;454. 10.1016/S0887-6177(03)00096-9<pub-id pub-id-type="pmid">15033227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0887-6177(03)00096-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furukawa</surname><given-names>TA</given-names></name><name name-style="western"><surname>Streiner</surname><given-names>D</given-names></name><name name-style="western"><surname>Young</surname><given-names>LT</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>Y</given-names></name></person-group><article-title>Antidepressants plus benzodiazepines for major depression</article-title><source>Cochrane Database Syst Rev</source><year>2001</year><pub-id pub-id-type="doi">10.1002/14651858.CD001026</pub-id><pub-id pub-id-type="pmid">31158298</pub-id><pub-id pub-id-type="pmcid">PMC6546439</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Furukawa TA, Streiner D, Young LT, Kinoshita Y (2001) Antidepressants plus benzodiazepines for major depression. Cochrane Database Syst Rev. 10.1002/14651858.CD001026<pub-id pub-id-type="pmid">31158298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD001026.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6546439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takeshima</surname><given-names>N</given-names></name><name name-style="western"><surname>Hayasaka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tajika</surname><given-names>A</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>N</given-names></name><name name-style="western"><surname>Streiner</surname><given-names>D</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>TA</given-names></name></person-group><article-title>Antidepressants plus benzodiazepines for adults with major depression</article-title><source>Cochrane Database Syst Rev</source><year>2019</year><pub-id pub-id-type="doi">10.1002/14651858.CD001026.pub2</pub-id><pub-id pub-id-type="pmid">31158298</pub-id><pub-id pub-id-type="pmcid">PMC6546439</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, Furukawa TA (2019) Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. 10.1002/14651858.CD001026.pub2<pub-id pub-id-type="pmid">31158298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD001026.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6546439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kufner</surname><given-names>M</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>LM</given-names></name><name name-style="western"><surname>Nothdurfter</surname><given-names>C</given-names></name><name name-style="western"><surname>Wein</surname><given-names>S</given-names></name><name name-style="western"><surname>Schwarzbach</surname><given-names>J</given-names></name><name name-style="western"><surname>Puig</surname><given-names>X</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>C</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G</given-names></name></person-group><article-title>Neurosteroids and translocator protein 18&#160;kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>2022</year><volume>273</volume><fpage>1477</fpage><lpage>1487</lpage><pub-id pub-id-type="doi">10.1007/s00406-022-01532-3</pub-id><pub-id pub-id-type="pmid">36574032</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Rupprecht R, Pradhan AK, Kufner M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Puig X, Rupprecht C, Rammes G (2022) Neurosteroids and translocator protein 18&#160;kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options. Eur Arch Psychiatry Clin Neurosci 273:1477&#8211;1487. 10.1007/s00406-022-01532-3<pub-id pub-id-type="pmid">36574032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00406-022-01532-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F</given-names></name></person-group><article-title>Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives</article-title><source>Trends Neurosci</source><year>1999</year><volume>22</volume><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/S0166-2236(99)01399-5</pub-id><pub-id pub-id-type="pmid">10441302</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Rupprecht R, Holsboer F (1999) Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 22:410&#8211;416. 10.1016/S0166-2236(99)01399-5<pub-id pub-id-type="pmid">10441302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0166-2236(99)01399-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papadopoulos</surname><given-names>V</given-names></name><name name-style="western"><surname>Baraldi</surname><given-names>M</given-names></name><name name-style="western"><surname>Guilarte</surname><given-names>TR</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>TB</given-names></name><name name-style="western"><surname>Lacap&#232;re</surname><given-names>J-J</given-names></name><name name-style="western"><surname>Lindemann</surname><given-names>P</given-names></name><name name-style="western"><surname>Norenberg</surname><given-names>MD</given-names></name><name name-style="western"><surname>Nutt</surname><given-names>D</given-names></name><name name-style="western"><surname>Weizman</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M-R</given-names></name><name name-style="western"><surname>Gavish</surname><given-names>M</given-names></name></person-group><article-title>Translocator protein (18&#160;kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function</article-title><source>Trends Pharmacol Sci</source><year>2006</year><volume>27</volume><fpage>402</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2006.06.005</pub-id><pub-id pub-id-type="pmid">16822554</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacap&#232;re J-J, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang M-R, Gavish M (2006) Translocator protein (18&#160;kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27:402&#8211;409. 10.1016/j.tips.2006.06.005<pub-id pub-id-type="pmid">16822554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2006.06.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>V</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G</given-names></name><name name-style="western"><surname>Baghai</surname><given-names>TC</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J</given-names></name><name name-style="western"><surname>Akula</surname><given-names>N</given-names></name><name name-style="western"><surname>Groyer</surname><given-names>G</given-names></name><name name-style="western"><surname>Adams</surname><given-names>D</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>M</given-names></name></person-group><article-title>Translocator protein (18&#160;kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders</article-title><source>Nat Rev Drug Discov</source><year>2010</year><volume>9</volume><fpage>971</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1038/nrd3295</pub-id><pub-id pub-id-type="pmid">21119734</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M (2010) Translocator protein (18&#160;kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 9:971&#8211;988. 10.1038/nrd3295<pub-id pub-id-type="pmid">21119734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd3295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z-W</given-names></name><name name-style="western"><surname>Bracamontes</surname><given-names>JR</given-names></name><name name-style="western"><surname>Budelier</surname><given-names>MM</given-names></name><name name-style="western"><surname>Germann</surname><given-names>AL</given-names></name><name name-style="western"><surname>Shin</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Kathiresan</surname><given-names>K</given-names></name><name name-style="western"><surname>Qian</surname><given-names>M-X</given-names></name><name name-style="western"><surname>Manion</surname><given-names>B</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>WWL</given-names></name><name name-style="western"><surname>Reichert</surname><given-names>DE</given-names></name><name name-style="western"><surname>Akk</surname><given-names>G</given-names></name><name name-style="western"><surname>Covey</surname><given-names>DF</given-names></name><name name-style="western"><surname>Evers</surname><given-names>AS</given-names></name></person-group><article-title>Multiple functional neurosteroid binding sites on GABAA receptors</article-title><source>PLOS Biol</source><year>2019</year><volume>17</volume><fpage>e3000157</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.3000157</pub-id><pub-id pub-id-type="pmid">30845142</pub-id><pub-id pub-id-type="pmcid">PMC6424464</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Chen Z-W, Bracamontes JR, Budelier MM, Germann AL, Shin DJ, Kathiresan K, Qian M-X, Manion B, Cheng WWL, Reichert DE, Akk G, Covey DF, Evers AS (2019) Multiple functional neurosteroid binding sites on GABAA receptors. PLOS Biol 17:e3000157. 10.1371/journal.pbio.3000157<pub-id pub-id-type="pmid">30845142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.3000157</pub-id><pub-id pub-id-type="pmcid">PMC6424464</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudolph</surname><given-names>U</given-names></name><name name-style="western"><surname>Crestani</surname><given-names>F</given-names></name><name name-style="western"><surname>Benke</surname><given-names>D</given-names></name><name name-style="western"><surname>Br&#252;nig</surname><given-names>I</given-names></name><name name-style="western"><surname>Benson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Fritschy</surname><given-names>J-M</given-names></name><name name-style="western"><surname>Martin</surname><given-names>JR</given-names></name><name name-style="western"><surname>Bluethmann</surname><given-names>H</given-names></name><name name-style="western"><surname>M&#246;hler</surname><given-names>H</given-names></name></person-group><article-title>Benzodiazepine actions mediated by specific &#947;-aminobutyric acidA receptor subtypes</article-title><source>Nature</source><year>1999</year><volume>401</volume><fpage>796</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1038/44579</pub-id><pub-id pub-id-type="pmid">10548105</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Rudolph U, Crestani F, Benke D, Br&#252;nig I, Benson JA, Fritschy J-M, Martin JR, Bluethmann H, M&#246;hler H (1999) Benzodiazepine actions mediated by specific &#947;-aminobutyric acidA receptor subtypes. Nature 401:796&#8211;800. 10.1038/44579<pub-id pub-id-type="pmid">10548105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/44579</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luscher</surname><given-names>B</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>JL</given-names></name><name name-style="western"><surname>Rudolph</surname><given-names>U</given-names></name><name name-style="western"><surname>Sibille</surname><given-names>E</given-names></name></person-group><article-title>GABAA receptors as targets for treating affective and cognitive symptoms of depression</article-title><source>Trends Pharmacol Sci</source><year>2023</year><volume>44</volume><fpage>586</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2023.06.009</pub-id><pub-id pub-id-type="pmid">37543478</pub-id><pub-id pub-id-type="pmcid">PMC10511219</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Luscher B, Maguire JL, Rudolph U, Sibille E (2023) GABAA receptors as targets for treating affective and cognitive symptoms of depression. Trends Pharmacol Sci 44:586&#8211;600. 10.1016/j.tips.2023.06.009<pub-id pub-id-type="pmid">37543478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2023.06.009</pub-id><pub-id pub-id-type="pmcid">PMC10511219</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locci</surname><given-names>A</given-names></name><name name-style="western"><surname>Pinna</surname><given-names>G</given-names></name></person-group><article-title>Neurosteroid biosynthesis down-regulation and changes in GABA <sub>A</sub> receptor subunit composition: a <italic toggle="yes">biomarker axis</italic> in stress&#8208;induced cognitive and emotional impairment</article-title><source>Br J Pharmacol</source><year>2017</year><volume>174</volume><fpage>3226</fpage><lpage>3241</lpage><pub-id pub-id-type="doi">10.1111/bph.13843</pub-id><pub-id pub-id-type="pmid">28456011</pub-id><pub-id pub-id-type="pmcid">PMC5595768</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Locci A, Pinna G (2017) Neurosteroid biosynthesis down-regulation and changes in GABA <sub>A</sub> receptor subunit composition: a <italic toggle="yes">biomarker axis</italic> in stress&#8208;induced cognitive and emotional impairment. Br J Pharmacol 174:3226&#8211;3241. 10.1111/bph.13843<pub-id pub-id-type="pmid">28456011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.13843</pub-id><pub-id pub-id-type="pmcid">PMC5595768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>SM</given-names></name><name name-style="western"><surname>Pinna</surname><given-names>G</given-names></name><name name-style="western"><surname>Guidotti</surname><given-names>A</given-names></name></person-group><article-title>Allopregnanolone: from molecular pathophysiology to therapeutics. A historical perspective</article-title><source>Neurobiol Stress</source><year>2020</year><volume>12</volume><fpage>100215</fpage><pub-id pub-id-type="doi">10.1016/j.ynstr.2020.100215</pub-id><pub-id pub-id-type="pmid">32435665</pub-id><pub-id pub-id-type="pmcid">PMC7231972</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Paul SM, Pinna G, Guidotti A (2020) Allopregnanolone: from molecular pathophysiology to therapeutics. A historical perspective. Neurobiol Stress 12:100215. 10.1016/j.ynstr.2020.100215<pub-id pub-id-type="pmid">32435665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ynstr.2020.100215</pub-id><pub-id pub-id-type="pmcid">PMC7231972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Althaus</surname><given-names>AL</given-names></name><name name-style="western"><surname>Ackley</surname><given-names>MA</given-names></name><name name-style="western"><surname>Belfort</surname><given-names>GM</given-names></name><name name-style="western"><surname>Gee</surname><given-names>SM</given-names></name><name name-style="western"><surname>Dai</surname><given-names>J</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>DP</given-names></name><name name-style="western"><surname>Kazdoba</surname><given-names>TM</given-names></name><name name-style="western"><surname>Modgil</surname><given-names>A</given-names></name><name name-style="western"><surname>Davies</surname><given-names>PA</given-names></name><name name-style="western"><surname>Moss</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Salituro</surname><given-names>FG</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>RS</given-names></name><name name-style="western"><surname>Robichaud</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Quirk</surname><given-names>MC</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>JJ</given-names></name></person-group><article-title>Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator</article-title><source>Neuropharmacology</source><year>2020</year><volume>181</volume><fpage>108333</fpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2020.108333</pub-id><pub-id pub-id-type="pmid">32976892</pub-id><pub-id pub-id-type="pmcid">PMC8265595</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Althaus AL, Ackley MA, Belfort GM, Gee SM, Dai J, Nguyen DP, Kazdoba TM, Modgil A, Davies PA, Moss SJ, Salituro FG, Hoffmann E, Hammond RS, Robichaud AJ, Quirk MC, Doherty JJ (2020) Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator. Neuropharmacology 181:108333. 10.1016/j.neuropharm.2020.108333<pub-id pub-id-type="pmid">32976892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2020.108333</pub-id><pub-id pub-id-type="pmcid">PMC8265595</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zorumski</surname><given-names>CF</given-names></name><name name-style="western"><surname>Paul</surname><given-names>SM</given-names></name><name name-style="western"><surname>Izumi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Covey</surname><given-names>DF</given-names></name><name name-style="western"><surname>Mennerick</surname><given-names>S</given-names></name></person-group><article-title>Neurosteroids, stress and depression: potential therapeutic opportunities</article-title><source>Neurosci Biobehav Rev</source><year>2013</year><volume>37</volume><fpage>109</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2012.10.005</pub-id><pub-id pub-id-type="pmid">23085210</pub-id><pub-id pub-id-type="pmcid">PMC3591791</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S (2013) Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev 37:109&#8211;122. 10.1016/j.neubiorev.2012.10.005<pub-id pub-id-type="pmid">23085210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2012.10.005</pub-id><pub-id pub-id-type="pmcid">PMC3591791</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romeo</surname><given-names>E</given-names></name><name name-style="western"><surname>Str&#246;hle</surname><given-names>A</given-names></name><name name-style="western"><surname>Spalletta</surname><given-names>G</given-names></name><name name-style="western"><surname>Michele</surname><given-names>FD</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>B</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>A</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name></person-group><article-title>Effects of antidepressant treatment on neuroactive steroids in Major Depression</article-title><source>Am J Psychiatry</source><year>1998</year><volume>155</volume><fpage>910</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1176/ajp.155.7.910</pub-id><pub-id pub-id-type="pmid">9659856</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Romeo E, Str&#246;hle A, Spalletta G, Michele FD, Hermann B, Holsboer F, Pasini A, Rupprecht R (1998) Effects of antidepressant treatment on neuroactive steroids in Major Depression. Am J Psychiatry 155:910&#8211;913. 10.1176/ajp.155.7.910<pub-id pub-id-type="pmid">9659856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/ajp.155.7.910</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uzunova</surname><given-names>V</given-names></name><name name-style="western"><surname>Sheline</surname><given-names>Y</given-names></name><name name-style="western"><surname>Davis</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rasmusson</surname><given-names>A</given-names></name><name name-style="western"><surname>Uzunov</surname><given-names>DP</given-names></name><name name-style="western"><surname>Costa</surname><given-names>E</given-names></name><name name-style="western"><surname>Guidotti</surname><given-names>A</given-names></name></person-group><article-title>Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine</article-title><source>Proc Natl Acad Sci</source><year>1998</year><volume>95</volume><fpage>3239</fpage><lpage>3244</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.6.3239</pub-id><pub-id pub-id-type="pmid">9501247</pub-id><pub-id pub-id-type="pmcid">PMC19726</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci 95:3239&#8211;3244. 10.1073/pnas.95.6.3239<pub-id pub-id-type="pmid">9501247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.95.6.3239</pub-id><pub-id pub-id-type="pmcid">PMC19726</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Str&#246;hle</surname><given-names>A</given-names></name><name name-style="western"><surname>Romeo</surname><given-names>E</given-names></name><name name-style="western"><surname>Di Michele</surname><given-names>F</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>A</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>B</given-names></name><name name-style="western"><surname>Gajewsky</surname><given-names>G</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name></person-group><article-title>Induced panic attacks Shift &#947;-Aminobutyric acid type a receptor Modulatory Neuroactive Steroid Composition in patients with panic disorder: preliminary results</article-title><source>Arch Gen Psychiatry</source><year>2003</year><volume>60</volume><fpage>161</fpage><pub-id pub-id-type="doi">10.1001/archpsyc.60.2.161</pub-id><pub-id pub-id-type="pmid">12578433</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Str&#246;hle A, Romeo E, Di Michele F, Pasini A, Hermann B, Gajewsky G, Holsboer F, Rupprecht R (2003) Induced panic attacks Shift &#947;-Aminobutyric acid type a receptor Modulatory Neuroactive Steroid Composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 60:161. 10.1001/archpsyc.60.2.161<pub-id pub-id-type="pmid">12578433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archpsyc.60.2.161</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffin</surname><given-names>LD</given-names></name><name name-style="western"><surname>Mellon</surname><given-names>SH</given-names></name></person-group><article-title>Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes</article-title><source>Proc Natl Acad Sci</source><year>1999</year><volume>96</volume><fpage>13512</fpage><lpage>13517</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.23.13512</pub-id><pub-id pub-id-type="pmid">10557352</pub-id><pub-id pub-id-type="pmcid">PMC23979</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Griffin LD, Mellon SH (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci 96:13512&#8211;13517. 10.1073/pnas.96.23.13512<pub-id pub-id-type="pmid">10557352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.96.23.13512</pub-id><pub-id pub-id-type="pmcid">PMC23979</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#252;le</surname><given-names>C</given-names></name><name name-style="western"><surname>Romeo</surname><given-names>E</given-names></name><name name-style="western"><surname>Uzunov</surname><given-names>DP</given-names></name><name name-style="western"><surname>Eser</surname><given-names>D</given-names></name><name name-style="western"><surname>Di Michele</surname><given-names>F</given-names></name><name name-style="western"><surname>Baghai</surname><given-names>TC</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>A</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>M</given-names></name><name name-style="western"><surname>Kempter</surname><given-names>H</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name></person-group><article-title>Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3&#945;-hydroxysteroid dehydrogenase activity</article-title><source>Mol Psychiatry</source><year>2006</year><volume>11</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4001782</pub-id><pub-id pub-id-type="pmid">16344854</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Sch&#252;le C, Romeo E, Uzunov DP, Eser D, Di Michele F, Baghai TC, Pasini A, Schwarz M, Kempter H, Rupprecht R (2006) Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3&#945;-hydroxysteroid dehydrogenase activity. Mol Psychiatry 11:261&#8211;272. 10.1038/sj.mp.4001782<pub-id pub-id-type="pmid">16344854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.mp.4001782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#252;le</surname><given-names>C</given-names></name><name name-style="western"><surname>di Michele</surname><given-names>F</given-names></name><name name-style="western"><surname>Baghai</surname><given-names>T</given-names></name><name name-style="western"><surname>Romeo</surname><given-names>E</given-names></name><name name-style="western"><surname>Bernardi</surname><given-names>G</given-names></name><name name-style="western"><surname>Zwanzger</surname><given-names>P</given-names></name><name name-style="western"><surname>Padberg</surname><given-names>F</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>A</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name></person-group><article-title>Influence of sleep deprivation major depression on neuroactive steroids in major depression</article-title><source>Neuropsychopharmacology</source><year>2003</year><volume>28</volume><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300084</pub-id><pub-id pub-id-type="pmid">12629540</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Sch&#252;le C, di Michele F, Baghai T, Romeo E, Bernardi G, Zwanzger P, Padberg F, Pasini A, Rupprecht R (2003) Influence of sleep deprivation major depression on neuroactive steroids in major depression. Neuropsychopharmacology 28:577&#8211;581<pub-id pub-id-type="pmid">12629540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.npp.1300084</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padberg</surname><given-names>F</given-names></name></person-group><article-title>Plasma concentrations of neuroactive steroids before and after Repetitive Transcranial Magnetic Stimulation (rTMS) in Major Depression</article-title><source>Neuropsychopharmacology</source><year>2002</year><volume>27</volume><fpage>874</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(02)00355-X</pub-id><pub-id pub-id-type="pmid">12431862</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Padberg F (2002) Plasma concentrations of neuroactive steroids before and after Repetitive Transcranial Magnetic Stimulation (rTMS) in Major Depression. Neuropsychopharmacology 27:874&#8211;878. 10.1016/S0893-133X(02)00355-X<pub-id pub-id-type="pmid">12431862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0893-133X(02)00355-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baghai</surname><given-names>TC</given-names></name><name name-style="western"><surname>Di Michele</surname><given-names>F</given-names></name><name name-style="western"><surname>Sch&#252;le</surname><given-names>C</given-names></name><name name-style="western"><surname>Eser</surname><given-names>D</given-names></name><name name-style="western"><surname>Zwanzger</surname><given-names>P</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>A</given-names></name><name name-style="western"><surname>Romeo</surname><given-names>E</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name></person-group><article-title>Plasma concentrations of neuroactive steroids before and after Electroconvulsive Therapy in Major Depression</article-title><source>Neuropsychopharmacology</source><year>2005</year><volume>30</volume><fpage>1181</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300684</pub-id><pub-id pub-id-type="pmid">15702138</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Baghai TC, Di Michele F, Sch&#252;le C, Eser D, Zwanzger P, Pasini A, Romeo E, Rupprecht R (2005) Plasma concentrations of neuroactive steroids before and after Electroconvulsive Therapy in Major Depression. Neuropsychopharmacology 30:1181&#8211;1186. 10.1038/sj.npp.1300684<pub-id pub-id-type="pmid">15702138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.npp.1300684</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deligiannidis</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kroll-Desrosiers</surname><given-names>AR</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dubuke</surname><given-names>ML</given-names></name><name name-style="western"><surname>Shaffer</surname><given-names>SA</given-names></name></person-group><article-title>Longitudinal proneuroactive and neuroactive steroid profiles in medication-free women with, without and at-risk for perinatal depression: a liquid chromatography-tandem mass spectrometry analysis</article-title><source>Psychoneuroendocrinology</source><year>2020</year><volume>121</volume><fpage>104827</fpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2020.104827</pub-id><pub-id pub-id-type="pmid">32828068</pub-id><pub-id pub-id-type="pmcid">PMC7572700</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Deligiannidis KM, Kroll-Desrosiers AR, Tan Y, Dubuke ML, Shaffer SA (2020) Longitudinal proneuroactive and neuroactive steroid profiles in medication-free women with, without and at-risk for perinatal depression: a liquid chromatography-tandem mass spectrometry analysis. Psychoneuroendocrinology 121:104827. 10.1016/j.psyneuen.2020.104827<pub-id pub-id-type="pmid">32828068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2020.104827</pub-id><pub-id pub-id-type="pmcid">PMC7572700</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timby</surname><given-names>E</given-names></name><name name-style="western"><surname>B&#228;ckstr&#246;m</surname><given-names>T</given-names></name><name name-style="western"><surname>Nyberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Stenlund</surname><given-names>H</given-names></name><name name-style="western"><surname>Wihlb&#228;ck</surname><given-names>A-CN</given-names></name><name name-style="western"><surname>Bixo</surname><given-names>M</given-names></name></person-group><article-title>Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls&#8212;a pilot study</article-title><source>Psychopharmacology</source><year>2016</year><volume>233</volume><fpage>2109</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.1007/s00213-016-4258-1</pub-id><pub-id pub-id-type="pmid">26960697</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Timby E, B&#228;ckstr&#246;m T, Nyberg S, Stenlund H, Wihlb&#228;ck A-CN, Bixo M (2016) Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls&#8212;a pilot study. Psychopharmacology 233:2109&#8211;2117. 10.1007/s00213-016-4258-1<pub-id pub-id-type="pmid">26960697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-016-4258-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walton</surname><given-names>N</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>J</given-names></name></person-group><article-title>Allopregnanolone-based treatments for postpartum depression: Why/how do they work?</article-title><source>Neurobiol Stress</source><year>2019</year><volume>11</volume><fpage>100198</fpage><pub-id pub-id-type="doi">10.1016/j.ynstr.2019.100198</pub-id><pub-id pub-id-type="pmid">31709278</pub-id><pub-id pub-id-type="pmcid">PMC6838978</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Walton N, Maguire J (2019) Allopregnanolone-based treatments for postpartum depression: Why/how do they work? Neurobiol Stress 11:100198. 10.1016/j.ynstr.2019.100198<pub-id pub-id-type="pmid">31709278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ynstr.2019.100198</pub-id><pub-id pub-id-type="pmcid">PMC6838978</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powell</surname><given-names>JG</given-names></name><name name-style="western"><surname>Garland</surname><given-names>S</given-names></name><name name-style="western"><surname>Preston</surname><given-names>K</given-names></name><name name-style="western"><surname>Piszczatoski</surname><given-names>C</given-names></name></person-group><article-title>Brexanolone (Zulresso): finally, an FDA-Approved treatment for Postpartum Depression</article-title><source>Ann Pharmacother</source><year>2020</year><volume>54</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1177/1060028019873320</pub-id><pub-id pub-id-type="pmid">31476884</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Powell JG, Garland S, Preston K, Piszczatoski C (2020) Brexanolone (Zulresso): finally, an FDA-Approved treatment for Postpartum Depression. Ann Pharmacother 54:157&#8211;163. 10.1177/1060028019873320<pub-id pub-id-type="pmid">31476884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1060028019873320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanes</surname><given-names>S</given-names></name><name name-style="western"><surname>Colquhoun</surname><given-names>H</given-names></name><name name-style="western"><surname>Gunduz-Bruce</surname><given-names>H</given-names></name><name name-style="western"><surname>Raines</surname><given-names>S</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>R</given-names></name><name name-style="western"><surname>Schacterle</surname><given-names>A</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>J</given-names></name><name name-style="western"><surname>Epperson</surname><given-names>CN</given-names></name><name name-style="western"><surname>Deligiannidis</surname><given-names>KM</given-names></name><name name-style="western"><surname>Riesenberg</surname><given-names>R</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Rubinow</surname><given-names>D</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>J</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S</given-names></name><name name-style="western"><surname>Meltzer-Brody</surname><given-names>S</given-names></name></person-group><article-title>Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>480</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31264-3</pub-id><pub-id pub-id-type="pmid">28619476</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, Doherty J, Epperson CN, Deligiannidis KM, Riesenberg R, Hoffmann E, Rubinow D, Jonas J, Paul S, Meltzer-Brody S (2017) Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 390:480&#8211;489. 10.1016/S0140-6736(17)31264-3<pub-id pub-id-type="pmid">28619476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)31264-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meltzer-Brody</surname><given-names>S</given-names></name><name name-style="western"><surname>Colquhoun</surname><given-names>H</given-names></name><name name-style="western"><surname>Riesenberg</surname><given-names>R</given-names></name><name name-style="western"><surname>Epperson</surname><given-names>CN</given-names></name><name name-style="western"><surname>Deligiannidis</surname><given-names>KM</given-names></name><name name-style="western"><surname>Rubinow</surname><given-names>DR</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Sankoh</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Clemson</surname><given-names>C</given-names></name><name name-style="western"><surname>Schacterle</surname><given-names>A</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>J</given-names></name><name name-style="western"><surname>Kanes</surname><given-names>S</given-names></name></person-group><article-title>Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>1058</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31551-4</pub-id><pub-id pub-id-type="pmid">30177236</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh AJ, Clemson C, Schacterle A, Jonas J, Kanes S (2018) Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 392:1058&#8211;1070. 10.1016/S0140-6736(18)31551-4<pub-id pub-id-type="pmid">30177236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)31551-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epperson</surname><given-names>CN</given-names></name><name name-style="western"><surname>Rubinow</surname><given-names>DR</given-names></name><name name-style="western"><surname>Meltzer-Brody</surname><given-names>S</given-names></name><name name-style="western"><surname>Deligiannidis</surname><given-names>KM</given-names></name><name name-style="western"><surname>Riesenberg</surname><given-names>R</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>AD</given-names></name><name name-style="western"><surname>Bankole</surname><given-names>K</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M-Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C</given-names></name><name name-style="western"><surname>Kanes</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Lasser</surname><given-names>R</given-names></name></person-group><article-title>Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program</article-title><source>J Affect Disord</source><year>2023</year><volume>320</volume><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2022.09.143</pub-id><pub-id pub-id-type="pmid">36191643</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Epperson CN, Rubinow DR, Meltzer-Brody S, Deligiannidis KM, Riesenberg R, Krystal AD, Bankole K, Huang M-Y, Li H, Brown C, Kanes SJ, Lasser R (2023) Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J Affect Disord 320:353&#8211;359. 10.1016/j.jad.2022.09.143<pub-id pub-id-type="pmid">36191643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2022.09.143</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garafola</surname><given-names>S</given-names></name><name name-style="western"><surname>Shiferaw</surname><given-names>E</given-names></name><name name-style="western"><surname>Dev</surname><given-names>V</given-names></name></person-group><article-title>Safety of Brexanolone in adults with Postpartum Depression: Postmarketing Surveillance Data</article-title><source>Drugs - Real World Outcomes</source><year>2023</year><volume>10</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1007/s40801-023-00372-4</pub-id><pub-id pub-id-type="pmid">37280463</pub-id><pub-id pub-id-type="pmcid">PMC10491550</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Garafola S, Shiferaw E, Dev V (2023) Safety of Brexanolone in adults with Postpartum Depression: Postmarketing Surveillance Data. Drugs - Real World Outcomes 10:351&#8211;356. 10.1007/s40801-023-00372-4<pub-id pub-id-type="pmid">37280463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40801-023-00372-4</pub-id><pub-id pub-id-type="pmcid">PMC10491550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heo</surname><given-names>Y-A</given-names></name></person-group><article-title>Zuranolone: first approval</article-title><source>Drugs</source><year>2023</year><volume>83</volume><fpage>1559</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1007/s40265-023-01953-x</pub-id><pub-id pub-id-type="pmid">37882942</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Heo Y-A (2023) Zuranolone: first approval. Drugs 83:1559&#8211;1567. 10.1007/s40265-023-01953-x<pub-id pub-id-type="pmid">37882942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-023-01953-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>KN</given-names></name><name name-style="western"><surname>Vogl</surname><given-names>CM</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>LA</given-names></name></person-group><article-title>Zuranolone: the first FDA-Approved oral treatment option for Postpartum Depression</article-title><source>Ann Pharmacother</source><year>2023</year><volume>0</volume><fpage>0</fpage><pub-id pub-id-type="doi">10.1177/10600280231204953</pub-id><pub-id pub-id-type="pmid">37876133</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Barnes KN, Vogl CM, Nelson LA (2023) Zuranolone: the first FDA-Approved oral treatment option for Postpartum Depression. Ann Pharmacother 0:0. 10.1177/10600280231204953<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/10600280231204953</pub-id><pub-id pub-id-type="pmid">37876133</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deligiannidis</surname><given-names>KM</given-names></name><name name-style="western"><surname>Meltzer-Brody</surname><given-names>S</given-names></name><name name-style="western"><surname>Gunduz-Bruce</surname><given-names>H</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>J</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Sankoh</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Silber</surname><given-names>C</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>AD</given-names></name><name name-style="western"><surname>Werneburg</surname><given-names>B</given-names></name><name name-style="western"><surname>Kanes</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Lasser</surname><given-names>R</given-names></name></person-group><article-title>Effect of Zuranolone vs Placebo in Postpartum Depression: a Randomized Clinical Trial</article-title><source>JAMA Psychiatry</source><year>2021</year><volume>78</volume><fpage>951</fpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2021.1559</pub-id><pub-id pub-id-type="pmid">34190962</pub-id><pub-id pub-id-type="pmcid">PMC8246337</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, Sankoh AJ, Silber C, Campbell AD, Werneburg B, Kanes SJ, Lasser R (2021) Effect of Zuranolone vs Placebo in Postpartum Depression: a Randomized Clinical Trial. JAMA Psychiatry 78:951. 10.1001/jamapsychiatry.2021.1559<pub-id pub-id-type="pmid">34190962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2021.1559</pub-id><pub-id pub-id-type="pmcid">PMC8246337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bullock</surname><given-names>A</given-names></name><name name-style="western"><surname>Gunduz-Bruce</surname><given-names>H</given-names></name><name name-style="western"><surname>Zammit</surname><given-names>GK</given-names></name><name name-style="western"><surname>Qin</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Sankoh</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Silber</surname><given-names>C</given-names></name><name name-style="western"><surname>Kanes</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>J</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>J</given-names></name></person-group><article-title>A phase 1 double&#8208;blind, placebo&#8208;controlled study of zuranolone (SAGE&#8208;217) in a phase advance model of insomnia in healthy adults</article-title><source>Hum Psychopharmacol Clin Exp</source><year>2022</year><volume>37</volume><fpage>e2806</fpage><pub-id pub-id-type="doi">10.1002/hup.2806</pub-id><pub-id pub-id-type="pmcid">PMC9286466</pub-id><pub-id pub-id-type="pmid">34352138</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Bullock A, Gunduz-Bruce H, Zammit GK, Qin M, Li H, Sankoh AJ, Silber C, Kanes SJ, Jonas J, Doherty J (2022) A phase 1 double&#8208;blind, placebo&#8208;controlled study of zuranolone (SAGE&#8208;217) in a phase advance model of insomnia in healthy adults. Hum Psychopharmacol Clin Exp 37:e2806. 10.1002/hup.2806<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hup.2806</pub-id><pub-id pub-id-type="pmcid">PMC9286466</pub-id><pub-id pub-id-type="pmid">34352138</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunduz-Bruce</surname><given-names>H</given-names></name><name name-style="western"><surname>Silber</surname><given-names>C</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>I</given-names></name><name name-style="western"><surname>Rothschild</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Riesenberg</surname><given-names>R</given-names></name><name name-style="western"><surname>Sankoh</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Lasser</surname><given-names>R</given-names></name><name name-style="western"><surname>Zorumski</surname><given-names>CF</given-names></name><name name-style="western"><surname>Rubinow</surname><given-names>DR</given-names></name><name name-style="western"><surname>Paul</surname><given-names>SM</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>J</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kanes</surname><given-names>SJ</given-names></name></person-group><article-title>Trial of SAGE-217 in patients with major depressive disorder</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><fpage>903</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1815981</pub-id><pub-id pub-id-type="pmid">31483961</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, Li H, Lasser R, Zorumski CF, Rubinow DR, Paul SM, Jonas J, Doherty JJ, Kanes SJ (2019) Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 381:903&#8211;911. 10.1056/NEJMoa1815981<pub-id pub-id-type="pmid">31483961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1815981</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suthoff</surname><given-names>E</given-names></name><name name-style="western"><surname>Kosinski</surname><given-names>M</given-names></name><name name-style="western"><surname>Arnaud</surname><given-names>A</given-names></name><name name-style="western"><surname>Hodgkins</surname><given-names>P</given-names></name><name name-style="western"><surname>Gunduz-Bruce</surname><given-names>H</given-names></name><name name-style="western"><surname>Lasser</surname><given-names>R</given-names></name><name name-style="western"><surname>Silber</surname><given-names>C</given-names></name><name name-style="western"><surname>Sankoh</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Werneburg</surname><given-names>B</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>J</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>J</given-names></name><name name-style="western"><surname>Kanes</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Bonthapally</surname><given-names>V</given-names></name></person-group><article-title>Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder</article-title><source>J Affect Disord</source><year>2022</year><volume>308</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2022.03.068</pub-id><pub-id pub-id-type="pmid">35378149</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Suthoff E, Kosinski M, Arnaud A, Hodgkins P, Gunduz-Bruce H, Lasser R, Silber C, Sankoh AJ, Li H, Werneburg B, Jonas J, Doherty J, Kanes SJ, Bonthapally V (2022) Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder. J Affect Disord 308:19&#8211;26. 10.1016/j.jad.2022.03.068<pub-id pub-id-type="pmid">35378149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2022.03.068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnaud</surname><given-names>A</given-names></name><name name-style="western"><surname>Suthoff</surname><given-names>E</given-names></name><name name-style="western"><surname>Stenson</surname><given-names>K</given-names></name><name name-style="western"><surname>Werneburg</surname><given-names>B</given-names></name><name name-style="western"><surname>Hodgkins</surname><given-names>P</given-names></name><name name-style="western"><surname>Bonthapally</surname><given-names>V</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>J</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>K</given-names></name><name name-style="western"><surname>O&#8217;Day</surname><given-names>K</given-names></name></person-group><article-title>Number needed to treat and Number needed to harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder</article-title><source>J Affect Disord</source><year>2021</year><volume>285</volume><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2021.02.027</pub-id><pub-id pub-id-type="pmid">33640861</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Arnaud A, Suthoff E, Stenson K, Werneburg B, Hodgkins P, Bonthapally V, Jonas J, Meyer K, O&#8217;Day K (2021) Number needed to treat and Number needed to harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. J Affect Disord 285:112&#8211;119. 10.1016/j.jad.2021.02.027<pub-id pub-id-type="pmid">33640861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2021.02.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clayton</surname><given-names>AH</given-names></name><name name-style="western"><surname>Lasser</surname><given-names>R</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>SV</given-names></name><name name-style="western"><surname>Iosifescu</surname><given-names>DV</given-names></name><name name-style="western"><surname>Jung</surname><given-names>J</given-names></name><name name-style="western"><surname>Kotecha</surname><given-names>M</given-names></name><name name-style="western"><surname>Forrestal</surname><given-names>F</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>J</given-names></name><name name-style="western"><surname>Kanes</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>J</given-names></name></person-group><article-title>Zuranolone for the treatment of adults with major depressive disorder: a Randomized, Placebo-Controlled phase 3 trial</article-title><source>Am J Psychiatry</source><year>2023</year><volume>180</volume><fpage>676</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.20220459</pub-id><pub-id pub-id-type="pmid">37132201</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Clayton AH, Lasser R, Parikh SV, Iosifescu DV, Jung J, Kotecha M, Forrestal F, Jonas J, Kanes SJ, Doherty J (2023) Zuranolone for the treatment of adults with major depressive disorder: a Randomized, Placebo-Controlled phase 3 trial. Am J Psychiatry 180:676&#8211;684. 10.1176/appi.ajp.20220459<pub-id pub-id-type="pmid">37132201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.20220459</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clayton</surname><given-names>AH</given-names></name><name name-style="western"><surname>Lasser</surname><given-names>R</given-names></name><name name-style="western"><surname>Nandy</surname><given-names>I</given-names></name><name name-style="western"><surname>Sankoh</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>J</given-names></name><name name-style="western"><surname>Kanes</surname><given-names>SJ</given-names></name></person-group><article-title>Zuranolone in major depressive disorder: results from MOUNTAIN&#8212;A phase 3, Multicenter, Double-Blind, randomized, Placebo&#8208;Controlled Trial</article-title><source>J Clin Psychiatry</source><year>2023</year><volume>84</volume><fpage>22m14445</fpage><pub-id pub-id-type="doi">10.4088/JCP.22m14445</pub-id><pub-id pub-id-type="pmid">36811520</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Clayton AH, Lasser R, Nandy I, Sankoh AJ, Jonas J, Kanes SJ (2023) Zuranolone in major depressive disorder: results from MOUNTAIN&#8212;A phase 3, Multicenter, Double-Blind, randomized, Placebo&#8208;Controlled Trial. J Clin Psychiatry 84:22m14445. 10.4088/JCP.22m14445<pub-id pub-id-type="pmid">36811520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/JCP.22m14445</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutler</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Mattingly</surname><given-names>GW</given-names></name><name name-style="western"><surname>Kornstein</surname><given-names>SG</given-names></name><name name-style="western"><surname>Aaronson</surname><given-names>ST</given-names></name><name name-style="western"><surname>Lasser</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Rana</surname><given-names>N</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C</given-names></name><name name-style="western"><surname>Levin</surname><given-names>S</given-names></name><name name-style="western"><surname>Miller</surname><given-names>C</given-names></name><name name-style="western"><surname>Kotecha</surname><given-names>M</given-names></name><name name-style="western"><surname>Forrestal</surname><given-names>F</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>J</given-names></name></person-group><article-title>Long-term safety and efficacy of initial and repeat treatment courses with zuranolone in adult patients with major depressive disorder: interim results from the Open-Label, phase 3 SHORELINE Study</article-title><source>J Clin Psychiatry</source><year>2023</year><volume>85</volume><fpage>23m14845</fpage><pub-id pub-id-type="doi">10.4088/JCP.23m14845</pub-id><pub-id pub-id-type="pmid">38153320</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Cutler AJ, Mattingly GW, Kornstein SG, Aaronson ST, Lasser R, Zhang H, Rana N, Brown C, Levin S, Miller C, Kotecha M, Forrestal F, Doherty J (2023) Long-term safety and efficacy of initial and repeat treatment courses with zuranolone in adult patients with major depressive disorder: interim results from the Open-Label, phase 3 SHORELINE Study. J Clin Psychiatry 85:23m14845. 10.4088/JCP.23m14845<pub-id pub-id-type="pmid">38153320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/JCP.23m14845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y-W</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Y-K</given-names></name><name name-style="western"><surname>Hung</surname><given-names>K-C</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C-S</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>P-T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P-Y</given-names></name><name name-style="western"><surname>Chia-Cheng Lai</surname><given-names>E</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C-W</given-names></name></person-group><article-title>Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses</article-title><source>eClinicalMedicine</source><year>2023</year><volume>66</volume><fpage>102308</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.102308</pub-id><pub-id pub-id-type="pmid">38045802</pub-id><pub-id pub-id-type="pmcid">PMC10690540</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Lin Y-W, Tu Y-K, Hung K-C, Liang C-S, Tseng P-T, Lin P-Y, Chia-Cheng Lai E, Hsu C-W (2023) Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses. eClinicalMedicine 66:102308. 10.1016/j.eclinm.2023.102308<pub-id pub-id-type="pmid">38045802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.102308</pub-id><pub-id pub-id-type="pmcid">PMC10690540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>V</given-names></name><name name-style="western"><surname>Allely</surname><given-names>D</given-names></name></person-group><article-title>Concerns that may limit the utility of Zuranolone</article-title><source>JAMA</source><year>2024</year><volume>331</volume><fpage>105</fpage><pub-id pub-id-type="doi">10.1001/jama.2023.26103</pub-id><pub-id pub-id-type="pmid">38100400</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Prasad V, Allely D (2024) Concerns that may limit the utility of Zuranolone. JAMA 331:105. 10.1001/jama.2023.26103<pub-id pub-id-type="pmid">38100400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.26103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>C</given-names></name><name name-style="western"><surname>Di Benedetto</surname><given-names>B</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G</given-names></name></person-group><article-title>Neuroinflammation and psychiatric disorders: relevance of C1q, translocator protein (18&#160;kDa) (TSPO), and neurosteroids</article-title><source>World J Biol Psychiatry</source><year>2022</year><volume>23</volume><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1080/15622975.2021.1961503</pub-id><pub-id pub-id-type="pmid">34320915</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Rupprecht R, Rupprecht C, Di Benedetto B, Rammes G (2022) Neuroinflammation and psychiatric disorders: relevance of C1q, translocator protein (18&#160;kDa) (TSPO), and neurosteroids. World J Biol Psychiatry 23:257&#8211;263. 10.1080/15622975.2021.1961503<pub-id pub-id-type="pmid">34320915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15622975.2021.1961503</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>J</given-names></name><name name-style="western"><surname>Campioli</surname><given-names>E</given-names></name><name name-style="western"><surname>Midzak</surname><given-names>A</given-names></name><name name-style="western"><surname>Culty</surname><given-names>M</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>V</given-names></name></person-group><article-title>Conditional steroidogenic cell-targeted deletion of TSPO unveils a crucial role in viability and hormone-dependent steroid formation</article-title><source>Proc Natl Acad Sci</source><year>2015</year><volume>112</volume><fpage>7261</fpage><lpage>7266</lpage><pub-id pub-id-type="doi">10.1073/pnas.1502670112</pub-id><pub-id pub-id-type="pmid">26039990</pub-id><pub-id pub-id-type="pmcid">PMC4466704</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Fan J, Campioli E, Midzak A, Culty M, Papadopoulos V (2015) Conditional steroidogenic cell-targeted deletion of TSPO unveils a crucial role in viability and hormone-dependent steroid formation. Proc Natl Acad Sci 112:7261&#8211;7266. 10.1073/pnas.1502670112<pub-id pub-id-type="pmid">26039990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1502670112</pub-id><pub-id pub-id-type="pmcid">PMC4466704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selvaraj</surname><given-names>V</given-names></name><name name-style="western"><surname>Stocco</surname><given-names>DM</given-names></name><name name-style="western"><surname>Tu</surname><given-names>LN</given-names></name></person-group><article-title>Minireview: Translocator Protein (TSPO) and steroidogenesis: a reappraisal</article-title><source>Mol Endocrinol</source><year>2015</year><volume>29</volume><fpage>490</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1210/me.2015-1033</pub-id><pub-id pub-id-type="pmid">25730708</pub-id><pub-id pub-id-type="pmcid">PMC4399280</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Selvaraj V, Stocco DM, Tu LN (2015) Minireview: Translocator Protein (TSPO) and steroidogenesis: a reappraisal. Mol Endocrinol 29:490&#8211;501. 10.1210/me.2015-1033<pub-id pub-id-type="pmid">25730708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/me.2015-1033</pub-id><pub-id pub-id-type="pmcid">PMC4399280</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liere</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G-J</given-names></name><name name-style="western"><surname>Pianos</surname><given-names>A</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Banati</surname><given-names>RB</given-names></name><name name-style="western"><surname>Akwa</surname><given-names>Y</given-names></name></person-group><article-title>The Comprehensive Steroidome in Complete TSPO/PBR knockout mice under basal conditions</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>2474</fpage><pub-id pub-id-type="doi">10.3390/ijms24032474</pub-id><pub-id pub-id-type="pmid">36768796</pub-id><pub-id pub-id-type="pmcid">PMC9916858</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Liere P, Liu G-J, Pianos A, Middleton RJ, Banati RB, Akwa Y (2023) The Comprehensive Steroidome in Complete TSPO/PBR knockout mice under basal conditions. Int J Mol Sci 24:2474. 10.3390/ijms24032474<pub-id pub-id-type="pmid">36768796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24032474</pub-id><pub-id pub-id-type="pmcid">PMC9916858</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cui</surname><given-names>M</given-names></name><name name-style="western"><surname>Ochs</surname><given-names>K</given-names></name><name name-style="western"><surname>Brendel</surname><given-names>M</given-names></name><name name-style="western"><surname>Str&#252;bing</surname><given-names>FL</given-names></name><name name-style="western"><surname>Briel</surname><given-names>N</given-names></name><name name-style="western"><surname>Eckenweber</surname><given-names>F</given-names></name><name name-style="western"><surname>Zou</surname><given-names>C</given-names></name><name name-style="western"><surname>Banati</surname><given-names>RB</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G-J</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Rudolph</surname><given-names>U</given-names></name><name name-style="western"><surname>Zeilhofer</surname><given-names>HU</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G</given-names></name><name name-style="western"><surname>Herms</surname><given-names>J</given-names></name><name name-style="western"><surname>Dorostkar</surname><given-names>MM</given-names></name></person-group><article-title>Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18&#160;kDa translocator protein (TSPO)</article-title><source>Nat Neurosci</source><year>2022</year><volume>25</volume><fpage>317</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1038/s41593-022-01013-9</pub-id><pub-id pub-id-type="pmid">35228700</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Shi Y, Cui M, Ochs K, Brendel M, Str&#252;bing FL, Briel N, Eckenweber F, Zou C, Banati RB, Liu G-J, Middleton RJ, Rupprecht R, Rudolph U, Zeilhofer HU, Rammes G, Herms J, Dorostkar MM (2022) Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18&#160;kDa translocator protein (TSPO). Nat Neurosci 25:317&#8211;329. 10.1038/s41593-022-01013-9<pub-id pub-id-type="pmid">35228700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-022-01013-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pradhan</surname><given-names>AK</given-names></name><name name-style="western"><surname>Neum&#252;ller</surname><given-names>T</given-names></name><name name-style="western"><surname>Klug</surname><given-names>C</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>S</given-names></name><name name-style="western"><surname>Schlegel</surname><given-names>M</given-names></name><name name-style="western"><surname>Ballmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Tartler</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Pianos</surname><given-names>A</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>MS</given-names></name><name name-style="western"><surname>Liere</surname><given-names>P</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Kreuzer</surname><given-names>M</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G</given-names></name></person-group><article-title>Chronic administration of XBD173 ameliorates cognitive deficits and neuropathology via 18&#160;kDa translocator protein (TSPO) in a mouse model of Alzheimer&#8217;s disease</article-title><source>Transl Psychiatry</source><year>2023</year><volume>13</volume><fpage>332</fpage><pub-id pub-id-type="doi">10.1038/s41398-023-02630-z</pub-id><pub-id pub-id-type="pmid">37891168</pub-id><pub-id pub-id-type="pmcid">PMC10611770</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Pradhan AK, Neum&#252;ller T, Klug C, Fuchs S, Schlegel M, Ballmann M, Tartler KJ, Pianos A, Garcia MS, Liere P, Schumacher M, Kreuzer M, Rupprecht R, Rammes G (2023) Chronic administration of XBD173 ameliorates cognitive deficits and neuropathology via 18&#160;kDa translocator protein (TSPO) in a mouse model of Alzheimer&#8217;s disease. Transl Psychiatry 13:332. 10.1038/s41398-023-02630-z<pub-id pub-id-type="pmid">37891168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-023-02630-z</pub-id><pub-id pub-id-type="pmcid">PMC10611770</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>L</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>A</given-names></name><name name-style="western"><surname>Melchner</surname><given-names>D</given-names></name><name name-style="western"><surname>Hallof-Buestrich</surname><given-names>H</given-names></name><name name-style="western"><surname>Stoertebecker</surname><given-names>P</given-names></name><name name-style="western"><surname>Haen</surname><given-names>E</given-names></name><name name-style="western"><surname>Kreutz</surname><given-names>M</given-names></name><name name-style="western"><surname>Sarubin</surname><given-names>N</given-names></name><name name-style="western"><surname>Milenkovic</surname><given-names>V</given-names></name><name name-style="western"><surname>Wetzel</surname><given-names>C</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Nothdurfter</surname><given-names>C</given-names></name></person-group><article-title>Enhancing Neurosteroid synthesis &#8211; relationship to the Pharmacology of Translocator protein (18&#160;kDa) (TSPO) ligands and benzodiazepines</article-title><source>Pharmacopsychiatry</source><year>2015</year><volume>48</volume><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1398507</pub-id><pub-id pub-id-type="pmid">25654303</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Wolf L, Bauer A, Melchner D, Hallof-Buestrich H, Stoertebecker P, Haen E, Kreutz M, Sarubin N, Milenkovic V, Wetzel C, Rupprecht R, Nothdurfter C (2015) Enhancing Neurosteroid synthesis &#8211; relationship to the Pharmacology of Translocator protein (18&#160;kDa) (TSPO) ligands and benzodiazepines. Pharmacopsychiatry 48:72&#8211;77. 10.1055/s-0034-1398507<pub-id pub-id-type="pmid">25654303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0034-1398507</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barron</surname><given-names>AM</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>S</given-names></name><name name-style="western"><surname>Kito</surname><given-names>S</given-names></name><name name-style="western"><surname>Suhara</surname><given-names>T</given-names></name><name name-style="western"><surname>Ji</surname><given-names>B</given-names></name></person-group><article-title>Regulation of anxiety and depression by mitochondrial translocator protein-mediated steroidogenesis: the role of neurons</article-title><source>Mol Neurobiol</source><year>2021</year><volume>58</volume><fpage>550</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1007/s12035-020-02136-5</pub-id><pub-id pub-id-type="pmid">32989676</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Barron AM, Higuchi M, Hattori S, Kito S, Suhara T, Ji B (2021) Regulation of anxiety and depression by mitochondrial translocator protein-mediated steroidogenesis: the role of neurons. Mol Neurobiol 58:550&#8211;563. 10.1007/s12035-020-02136-5<pub-id pub-id-type="pmid">32989676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-020-02136-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pini</surname><given-names>S</given-names></name><name name-style="western"><surname>Martini</surname><given-names>C</given-names></name><name name-style="western"><surname>Abelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Muti</surname><given-names>M</given-names></name><name name-style="western"><surname>Gesi</surname><given-names>C</given-names></name><name name-style="western"><surname>Montali</surname><given-names>M</given-names></name><name name-style="western"><surname>Chelli</surname><given-names>B</given-names></name><name name-style="western"><surname>Lucacchini</surname><given-names>A</given-names></name><name name-style="western"><surname>Cassano</surname><given-names>GB</given-names></name></person-group><article-title>Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms</article-title><source>Psychopharmacology</source><year>2005</year><volume>181</volume><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1007/s00213-005-2247-x</pub-id><pub-id pub-id-type="pmid">15830231</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Pini S, Martini C, Abelli M, Muti M, Gesi C, Montali M, Chelli B, Lucacchini A, Cassano GB (2005) Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. Psychopharmacology 181:407&#8211;411. 10.1007/s00213-005-2247-x<pub-id pub-id-type="pmid">15830231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-005-2247-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Chelli</surname><given-names>B</given-names></name><name name-style="western"><surname>Costa</surname><given-names>B</given-names></name><name name-style="western"><surname>Lari</surname><given-names>L</given-names></name><name name-style="western"><surname>Cardini</surname><given-names>A</given-names></name><name name-style="western"><surname>Gesi</surname><given-names>C</given-names></name><name name-style="western"><surname>Muti</surname><given-names>M</given-names></name><name name-style="western"><surname>Lucacchini</surname><given-names>A</given-names></name><name name-style="western"><surname>Martini</surname><given-names>C</given-names></name><name name-style="western"><surname>Cassano</surname><given-names>GB</given-names></name><name name-style="western"><surname>Pini</surname><given-names>S</given-names></name></person-group><article-title>Reductions in platelet 18-kDa Translocator Protein Density Are Associated with adult separation anxiety in patients with bipolar disorder</article-title><source>Neuropsychobiology</source><year>2010</year><volume>62</volume><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1159/000315440</pub-id><pub-id pub-id-type="pmid">20523081</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Abelli M, Chelli B, Costa B, Lari L, Cardini A, Gesi C, Muti M, Lucacchini A, Martini C, Cassano GB, Pini S (2010) Reductions in platelet 18-kDa Translocator Protein Density Are Associated with adult separation anxiety in patients with bipolar disorder. Neuropsychobiology 62:98&#8211;103. 10.1159/000315440<pub-id pub-id-type="pmid">20523081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000315440</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarubin</surname><given-names>N</given-names></name><name name-style="western"><surname>Baghai</surname><given-names>T</given-names></name><name name-style="western"><surname>Lima-Ojeda</surname><given-names>J</given-names></name><name name-style="western"><surname>Melchner</surname><given-names>D</given-names></name><name name-style="western"><surname>Hallof-Buestrich</surname><given-names>H</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>L</given-names></name><name name-style="western"><surname>Hilbert</surname><given-names>S</given-names></name><name name-style="western"><surname>Milenkovic</surname><given-names>V</given-names></name><name name-style="western"><surname>Wetzel</surname><given-names>C</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Nothdurfter</surname><given-names>C</given-names></name></person-group><article-title>Translocator Protein (TSPO) expression in platelets of depressed patients decreases during antidepressant therapy</article-title><source>Pharmacopsychiatry</source><year>2016</year><volume>49</volume><fpage>204</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1055/s-0042-107795</pub-id><pub-id pub-id-type="pmid">27276366</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Sarubin N, Baghai T, Lima-Ojeda J, Melchner D, Hallof-Buestrich H, Wolf L, Hilbert S, Milenkovic V, Wetzel C, Rupprecht R, Nothdurfter C (2016) Translocator Protein (TSPO) expression in platelets of depressed patients decreases during antidepressant therapy. Pharmacopsychiatry 49:204&#8211;209. 10.1055/s-0042-107795<pub-id pub-id-type="pmid">27276366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0042-107795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Setiawan</surname><given-names>E</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>AA</given-names></name><name name-style="western"><surname>Mizrahi</surname><given-names>R</given-names></name><name name-style="western"><surname>Rusjan</surname><given-names>PM</given-names></name><name name-style="western"><surname>Miler</surname><given-names>L</given-names></name><name name-style="western"><surname>Rajkowska</surname><given-names>G</given-names></name><name name-style="western"><surname>Suridjan</surname><given-names>I</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>JL</given-names></name><name name-style="western"><surname>Rekkas</surname><given-names>PV</given-names></name><name name-style="western"><surname>Houle</surname><given-names>S</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>JH</given-names></name></person-group><article-title>Role of Translocator Protein Density, a marker of Neuroinflammation, in the Brain during Major depressive episodes</article-title><source>JAMA Psychiatry</source><year>2015</year><volume>72</volume><fpage>268</fpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.2427</pub-id><pub-id pub-id-type="pmid">25629589</pub-id><pub-id pub-id-type="pmcid">PMC4836849</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, Suridjan I, Kennedy JL, Rekkas PV, Houle S, Meyer JH (2015) Role of Translocator Protein Density, a marker of Neuroinflammation, in the Brain during Major depressive episodes. JAMA Psychiatry 72:268. 10.1001/jamapsychiatry.2014.2427<pub-id pub-id-type="pmid">25629589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2014.2427</pub-id><pub-id pub-id-type="pmcid">PMC4836849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Sagar</surname><given-names>AP</given-names></name><name name-style="western"><surname>K&#233;ri</surname><given-names>S</given-names></name></person-group><article-title>Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder</article-title><source>J Affect Disord</source><year>2018</year><volume>241</volume><fpage>305</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2018.08.021</pub-id><pub-id pub-id-type="pmid">30142589</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Li H, Sagar AP, K&#233;ri S (2018) Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder. J Affect Disord 241:305&#8211;310. 10.1016/j.jad.2018.08.021<pub-id pub-id-type="pmid">30142589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2018.08.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attwells</surname><given-names>S</given-names></name><name name-style="western"><surname>Setiawan</surname><given-names>E</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>AA</given-names></name><name name-style="western"><surname>Rusjan</surname><given-names>PM</given-names></name><name name-style="western"><surname>Mizrahi</surname><given-names>R</given-names></name><name name-style="western"><surname>Miler</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Richter</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>A</given-names></name><name name-style="western"><surname>Kish</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Houle</surname><given-names>S</given-names></name><name name-style="western"><surname>Ravindran</surname><given-names>L</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>JH</given-names></name></person-group><article-title>Inflammation in the neurocircuitry of obsessive-compulsive disorder</article-title><source>JAMA Psychiatry</source><year>2017</year><volume>74</volume><fpage>833</fpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2017.1567</pub-id><pub-id pub-id-type="pmid">28636705</pub-id><pub-id pub-id-type="pmcid">PMC5710556</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, Xu C, Richter MA, Kahn A, Kish SJ, Houle S, Ravindran L, Meyer JH (2017) Inflammation in the neurocircuitry of obsessive-compulsive disorder. JAMA Psychiatry 74:833. 10.1001/jamapsychiatry.2017.1567<pub-id pub-id-type="pmid">28636705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2017.1567</pub-id><pub-id pub-id-type="pmcid">PMC5710556</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attwells</surname><given-names>S</given-names></name><name name-style="western"><surname>Setiawan</surname><given-names>E</given-names></name><name name-style="western"><surname>Rusjan</surname><given-names>PM</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Hutton</surname><given-names>C</given-names></name><name name-style="western"><surname>Rafiei</surname><given-names>D</given-names></name><name name-style="western"><surname>Varughese</surname><given-names>B</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>A</given-names></name><name name-style="western"><surname>Kish</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Vasdev</surname><given-names>N</given-names></name><name name-style="western"><surname>Houle</surname><given-names>S</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>JH</given-names></name></person-group><article-title>Translocator protein distribution volume predicts reduction of symptoms during open-label trial of Celecoxib in Major Depressive Disorder</article-title><source>Biol Psychiatry</source><year>2020</year><volume>88</volume><fpage>649</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2020.03.007</pub-id><pub-id pub-id-type="pmid">32402468</pub-id><pub-id pub-id-type="pmcid">PMC11878442</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Attwells S, Setiawan E, Rusjan PM, Xu C, Hutton C, Rafiei D, Varughese B, Kahn A, Kish SJ, Vasdev N, Houle S, Meyer JH (2020) Translocator protein distribution volume predicts reduction of symptoms during open-label trial of Celecoxib in Major Depressive Disorder. Biol Psychiatry 88:649&#8211;656. 10.1016/j.biopsych.2020.03.007<pub-id pub-id-type="pmid">32402468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2020.03.007</pub-id><pub-id pub-id-type="pmcid">PMC11878442</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>S</given-names></name><name name-style="western"><surname>Hilmer</surname><given-names>AT</given-names></name><name name-style="western"><surname>Girgenti</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Rusowicz</surname><given-names>A</given-names></name><name name-style="western"><surname>Kapinos</surname><given-names>M</given-names></name><name name-style="western"><surname>Nabuls</surname><given-names>N</given-names></name></person-group><article-title>PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transctriptional studies</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>2360</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15930-5</pub-id><pub-id pub-id-type="pmid">32398677</pub-id><pub-id pub-id-type="pmcid">PMC7217830</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Bhatt S, Hilmer AT, Girgenti MJ, Rusowicz A, Kapinos M, Nabuls N (2020) PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transctriptional studies. Nat Commun 11:2360. 10.1038/s41467-020-15930-5<pub-id pub-id-type="pmid">32398677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-15930-5</pub-id><pub-id pub-id-type="pmcid">PMC7217830</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Tournier BB, Tsartsalis S, Ceyzeriat K, Garibotto V, Millet P (2020) In vivo TSPO signal and neuroinflammation in Alzheimer&#180;s disease. Cells 9:1941. 10.3390/cells9091941<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9091941</pub-id><pub-id pub-id-type="pmcid">PMC7565089</pub-id><pub-id pub-id-type="pmid">32839410</pub-id></mixed-citation></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Notter</surname><given-names>T</given-names></name><name name-style="western"><surname>Schalbetter</surname><given-names>SM</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>NE</given-names></name><name name-style="western"><surname>Mattei</surname><given-names>D</given-names></name><name name-style="western"><surname>Richetto</surname><given-names>J</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>U</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J</given-names></name></person-group><article-title>Neuronal activity increases translocator protein (TSPO) levels</article-title><source>Mol Psychiatry</source><year>2021</year><volume>26</volume><fpage>2025</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1038/s41380-020-0745-1</pub-id><pub-id pub-id-type="pmid">32398717</pub-id><pub-id pub-id-type="pmcid">PMC8440208</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Notter T, Schalbetter SM, Clifton NE, Mattei D, Richetto J, Thomas K, Meyer U, Hall J (2021) Neuronal activity increases translocator protein (TSPO) levels. Mol Psychiatry 26:2025&#8211;2037. 10.1038/s41380-020-0745-1<pub-id pub-id-type="pmid">32398717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-020-0745-1</pub-id><pub-id pub-id-type="pmcid">PMC8440208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colasanti</surname><given-names>A</given-names></name><name name-style="western"><surname>Owen</surname><given-names>DR</given-names></name><name name-style="western"><surname>Grozeva</surname><given-names>D</given-names></name><name name-style="western"><surname>Rabiner</surname><given-names>EA</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>PM</given-names></name><name name-style="western"><surname>Craddock</surname><given-names>N</given-names></name><name name-style="western"><surname>Young</surname><given-names>AH</given-names></name></person-group><article-title>Bipolar disorder is associated with the rs6971 polymorphism in the gene encoding 18&#160;kDa translocator protein (TSPO)</article-title><source>Psychoneuroendocrinology</source><year>2013</year><volume>38</volume><fpage>2826</fpage><lpage>2829</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2013.07.007</pub-id><pub-id pub-id-type="pmid">23942012</pub-id><pub-id pub-id-type="pmcid">PMC3820042</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Colasanti A, Owen DR, Grozeva D, Rabiner EA, Matthews PM, Craddock N, Young AH (2013) Bipolar disorder is associated with the rs6971 polymorphism in the gene encoding 18&#160;kDa translocator protein (TSPO). Psychoneuroendocrinology 38:2826&#8211;2829. 10.1016/j.psyneuen.2013.07.007<pub-id pub-id-type="pmid">23942012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2013.07.007</pub-id><pub-id pub-id-type="pmcid">PMC3820042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prossin</surname><given-names>AR</given-names></name><name name-style="western"><surname>Chandler</surname><given-names>M</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>KA</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>EF</given-names></name><name name-style="western"><surname>Kamali</surname><given-names>M</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>V</given-names></name><name name-style="western"><surname>Z&#246;llner</surname><given-names>S</given-names></name><name name-style="western"><surname>Dantzer</surname><given-names>R</given-names></name><name name-style="western"><surname>McInnis</surname><given-names>MG</given-names></name></person-group><article-title>Functional TSPO polymorphism predicts variance in the diurnal cortisol rhythm in bipolar disorder</article-title><source>Psychoneuroendocrinology</source><year>2018</year><volume>89</volume><fpage>194</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2018.01.013</pub-id><pub-id pub-id-type="pmid">29414032</pub-id><pub-id pub-id-type="pmcid">PMC6048960</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Prossin AR, Chandler M, Ryan KA, Saunders EF, Kamali M, Papadopoulos V, Z&#246;llner S, Dantzer R, McInnis MG (2018) Functional TSPO polymorphism predicts variance in the diurnal cortisol rhythm in bipolar disorder. Psychoneuroendocrinology 89:194&#8211;202. 10.1016/j.psyneuen.2018.01.013<pub-id pub-id-type="pmid">29414032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2018.01.013</pub-id><pub-id pub-id-type="pmcid">PMC6048960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G</given-names></name><name name-style="western"><surname>Eser</surname><given-names>D</given-names></name><name name-style="western"><surname>Baghai</surname><given-names>TC</given-names></name><name name-style="western"><surname>Sch&#252;le</surname><given-names>C</given-names></name><name name-style="western"><surname>Nothdurfter</surname><given-names>C</given-names></name><name name-style="western"><surname>Troxler</surname><given-names>T</given-names></name><name name-style="western"><surname>Gentsch</surname><given-names>C</given-names></name><name name-style="western"><surname>Kalkman</surname><given-names>HO</given-names></name><name name-style="western"><surname>Chaperon</surname><given-names>F</given-names></name><name name-style="western"><surname>Uzunov</surname><given-names>V</given-names></name><name name-style="western"><surname>McAllister</surname><given-names>KH</given-names></name><name name-style="western"><surname>Bertaina-Anglade</surname><given-names>V</given-names></name><name name-style="western"><surname>La Rochelle</surname><given-names>CD</given-names></name><name name-style="western"><surname>Tuerck</surname><given-names>D</given-names></name><name name-style="western"><surname>Floesser</surname><given-names>A</given-names></name><name name-style="western"><surname>Kiese</surname><given-names>B</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Landgraf</surname><given-names>R</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F</given-names></name><name name-style="western"><surname>Kucher</surname><given-names>K</given-names></name></person-group><article-title>Translocator Protein (18 kD) as target for Anxiolytics without Benzodiazepine-Like Side effects</article-title><source>Science</source><year>2009</year><volume>325</volume><fpage>490</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1126/science.1175055</pub-id><pub-id pub-id-type="pmid">19541954</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Rupprecht R, Rammes G, Eser D, Baghai TC, Sch&#252;le C, Nothdurfter C, Troxler T, Gentsch C, Kalkman HO, Chaperon F, Uzunov V, McAllister KH, Bertaina-Anglade V, La Rochelle CD, Tuerck D, Floesser A, Kiese B, Schumacher M, Landgraf R, Holsboer F, Kucher K (2009) Translocator Protein (18 kD) as target for Anxiolytics without Benzodiazepine-Like Side effects. Science 325:490&#8211;493. 10.1126/science.1175055<pub-id pub-id-type="pmid">19541954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1175055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yao</surname><given-names>RM</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ding</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Sun</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Ran</surname><given-names>YH</given-names></name></person-group><article-title>Translocator protein-mediated fast-onset antidepressant-like and memory-enhancing effects in chronically stressed mice</article-title><source>J Psychopharmacol</source><year>2020</year><volume>34</volume><fpage>441</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1177/0269881119896304</pub-id><pub-id pub-id-type="pmid">31913078</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Shang C, Yao RM, Guo Y, Ding ZC, Sun LJ, Ran YH (2020) Translocator protein-mediated fast-onset antidepressant-like and memory-enhancing effects in chronically stressed mice. J Psychopharmacol 34:441&#8211;451. 10.1177/0269881119896304<pub-id pub-id-type="pmid">31913078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0269881119896304</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>P</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M-L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y-Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y-Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y-F</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W-Z</given-names></name></person-group><article-title>Anxiolytic and anti-depressive like effects of Translocator protein (18&#160;kDa) Ligand YL-IPA08 in a rat model of Postpartum Depression</article-title><source>Neurochem Res</source><year>2020</year><volume>45</volume><fpage>1746</fpage><lpage>1757</lpage><pub-id pub-id-type="doi">10.1007/s11064-020-03036-9</pub-id><pub-id pub-id-type="pmid">32383026</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Ren P, Ma L, Wang J-Y, Guo H, Sun L, Gao M-L, Liu Y-Z, Ma Y-Q, Li Y-F, Guo W-Z (2020) Anxiolytic and anti-depressive like effects of Translocator protein (18&#160;kDa) Ligand YL-IPA08 in a rat model of Postpartum Depression. Neurochem Res 45:1746&#8211;1757. 10.1007/s11064-020-03036-9<pub-id pub-id-type="pmid">32383026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-020-03036-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nozaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Ito</surname><given-names>H</given-names></name><name name-style="western"><surname>Ohgidani</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamawaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>EH</given-names></name><name name-style="western"><surname>Kitajima</surname><given-names>T</given-names></name><name name-style="western"><surname>Katsumata</surname><given-names>S</given-names></name><name name-style="western"><surname>Yamawaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Kato</surname><given-names>TA</given-names></name><name name-style="western"><surname>Aizawa</surname><given-names>H</given-names></name></person-group><article-title>Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress</article-title><source>Neuropharmacology</source><year>2020</year><volume>162</volume><fpage>107835</fpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.107835</pub-id><pub-id pub-id-type="pmid">31682855</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Nozaki K, Ito H, Ohgidani M, Yamawaki Y, Sahin EH, Kitajima T, Katsumata S, Yamawaki S, Kato TA, Aizawa H (2020) Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress. Neuropharmacology 162:107835. 10.1016/j.neuropharm.2019.107835<pub-id pub-id-type="pmid">31682855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2019.107835</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattei</surname><given-names>C</given-names></name><name name-style="western"><surname>Taly</surname><given-names>A</given-names></name><name name-style="western"><surname>Soualah</surname><given-names>Z</given-names></name><name name-style="western"><surname>Saulais</surname><given-names>O</given-names></name><name name-style="western"><surname>Henrion</surname><given-names>D</given-names></name><name name-style="western"><surname>Gu&#233;rineau</surname><given-names>NC</given-names></name><name name-style="western"><surname>Verleye</surname><given-names>M</given-names></name><name name-style="western"><surname>Legros</surname><given-names>C</given-names></name></person-group><article-title>Involvement of the GABAA receptor &#945; subunit in the mode of action of etifoxine</article-title><source>Pharmacol Res</source><year>2019</year><volume>145</volume><fpage>104250</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.04.034</pub-id><pub-id pub-id-type="pmid">31059790</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Mattei C, Taly A, Soualah Z, Saulais O, Henrion D, Gu&#233;rineau NC, Verleye M, Legros C (2019) Involvement of the GABAA receptor &#945; subunit in the mode of action of etifoxine. Pharmacol Res 145:104250. 10.1016/j.phrs.2019.04.034<pub-id pub-id-type="pmid">31059790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2019.04.034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>N</given-names></name><name name-style="western"><surname>Fakra</surname><given-names>E</given-names></name><name name-style="western"><surname>Pradel</surname><given-names>V</given-names></name><name name-style="western"><surname>Jouve</surname><given-names>E</given-names></name><name name-style="western"><surname>Alquier</surname><given-names>C</given-names></name><name name-style="western"><surname>Guern</surname><given-names>ME</given-names></name></person-group><article-title>Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice</article-title><source>Hum Psychopharmacol</source><year>2006</year><volume>21</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1002/hup.757</pub-id><pub-id pub-id-type="pmid">16625522</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Guern ME (2006) Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 21:139&#8211;149. 10.1002/hup.757<pub-id pub-id-type="pmid">16625522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hup.757</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vicente</surname><given-names>B</given-names></name><name name-style="western"><surname>Saldicia</surname><given-names>S</given-names></name><name name-style="western"><surname>Hormazabal</surname><given-names>N</given-names></name><name name-style="western"><surname>Bustos</surname><given-names>C</given-names></name><name name-style="western"><surname>Rubi</surname><given-names>P</given-names></name></person-group><article-title>Etifoxine is non-inferior than clonazepam for the reduction of anxiety disorders: a randomized, double blind, non-inferiority trial</article-title><source>Psychopharmacology</source><year>2020</year><volume>237</volume><fpage>3357</fpage><lpage>3367</lpage><pub-id pub-id-type="doi">10.1007/s00213-020-05617-6</pub-id><pub-id pub-id-type="pmid">33009629</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Vicente B, Saldicia S, Hormazabal N, Bustos C, Rubi P (2020) Etifoxine is non-inferior than clonazepam for the reduction of anxiety disorders: a randomized, double blind, non-inferiority trial. Psychopharmacology 237:3357&#8211;3367. 10.1007/s00213-020-05617-6<pub-id pub-id-type="pmid">33009629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-020-05617-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahr</surname><given-names>LM</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>F</given-names></name><name name-style="western"><surname>Weigl</surname><given-names>J</given-names></name><name name-style="western"><surname>Weber</surname><given-names>K</given-names></name><name name-style="western"><surname>Melchner</surname><given-names>D</given-names></name><name name-style="western"><surname>D&#246;rfelt</surname><given-names>A</given-names></name></person-group><article-title>Dissociation of endocrine responses to the Trier social stress test in virtual reality (VR-TSST) by the benzodiazepine alprazolam and the translocator protein 18&#160;kDa (TSPO) ligand etifoxine</article-title><source>Psychoneuroendocrinology</source><year>2021</year><volume>124</volume><fpage>105100</fpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2020.105100</pub-id><pub-id pub-id-type="pmid">33338971</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Bahr LM, Maurer F, Weigl J, Weber K, Melchner D, D&#246;rfelt A (2021) Dissociation of endocrine responses to the Trier social stress test in virtual reality (VR-TSST) by the benzodiazepine alprazolam and the translocator protein 18&#160;kDa (TSPO) ligand etifoxine. Psychoneuroendocrinology 124:105100. 10.1016/j.psyneuen.2020.105100<pub-id pub-id-type="pmid">33338971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2020.105100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunner</surname><given-names>LM</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>F</given-names></name><name name-style="western"><surname>Weber</surname><given-names>K</given-names></name><name name-style="western"><surname>Weigl</surname><given-names>J</given-names></name><name name-style="western"><surname>Milenkovic</surname><given-names>VM</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Nothdurfter</surname><given-names>C</given-names></name><name name-style="western"><surname>M&#252;hlberger</surname><given-names>A</given-names></name></person-group><article-title>Differential effects of the translocator protein 18&#160;kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment</article-title><source>Psychopharmacology</source><year>2022</year><volume>1</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/S00213-022-06111-X/FIGURES/3</pub-id><pub-id pub-id-type="pmcid">PMC9205810</pub-id><pub-id pub-id-type="pmid">35278124</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Brunner LM, Maurer F, Weber K, Weigl J, Milenkovic VM, Rupprecht R, Nothdurfter C, M&#252;hlberger A (2022) Differential effects of the translocator protein 18&#160;kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment. Psychopharmacology 1:1&#8211;12. 10.1007/S00213-022-06111-X/FIGURES/3<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-022-06111-x</pub-id><pub-id pub-id-type="pmcid">PMC9205810</pub-id><pub-id pub-id-type="pmid">35278124</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riebel</surname><given-names>M</given-names></name><name name-style="western"><surname>Von Pappenheim</surname><given-names>B</given-names></name><name name-style="western"><surname>Kanig</surname><given-names>C</given-names></name><name name-style="western"><surname>Nothdurfter</surname><given-names>C</given-names></name><name name-style="western"><surname>Wetter</surname><given-names>TC</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Schwarzbach</surname><given-names>J</given-names></name></person-group><article-title>GABAergic effects of Etifoxine and Alprazolam assessed by double pulse TMS</article-title><source>Pharmacopsychiatry</source><year>2023</year><volume>56</volume><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1055/a-2078-4823</pub-id><pub-id pub-id-type="pmid">37220781</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Riebel M, Von Pappenheim B, Kanig C, Nothdurfter C, Wetter TC, Rupprecht R, Schwarzbach J (2023) GABAergic effects of Etifoxine and Alprazolam assessed by double pulse TMS. Pharmacopsychiatry 56:154&#8211;161. 10.1055/a-2078-4823<pub-id pub-id-type="pmid">37220781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-2078-4823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manook</surname><given-names>A</given-names></name><name name-style="western"><surname>Baghai</surname><given-names>TC</given-names></name><name name-style="western"><surname>Riebel</surname><given-names>M</given-names></name><name name-style="western"><surname>Nothdurfter</surname><given-names>C</given-names></name><name name-style="western"><surname>Schwarzbach</surname><given-names>JV</given-names></name><name name-style="western"><surname>Gessner</surname><given-names>A</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Hiergeist</surname><given-names>A</given-names></name></person-group><article-title>Short-term effects of etifoxine on human gut microbiome in healthy men</article-title><source>Front Neurosci</source><year>2023</year><volume>17</volume><fpage>1188847</fpage><pub-id pub-id-type="doi">10.3389/fnins.2023.1188847</pub-id><pub-id pub-id-type="pmid">38075272</pub-id><pub-id pub-id-type="pmcid">PMC10704910</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Manook A, Baghai TC, Riebel M, Nothdurfter C, Schwarzbach JV, Gessner A, Rupprecht R, Hiergeist A (2023) Short-term effects of etifoxine on human gut microbiome in healthy men. Front Neurosci 17:1188847. 10.3389/fnins.2023.1188847<pub-id pub-id-type="pmid">38075272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1188847</pub-id><pub-id pub-id-type="pmcid">PMC10704910</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lecrubier</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>D</given-names></name><name name-style="western"><surname>Weiller</surname><given-names>E</given-names></name><name name-style="western"><surname>Amorim</surname><given-names>P</given-names></name><name name-style="western"><surname>Bonora</surname><given-names>I</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>KH</given-names></name><name name-style="western"><surname>Janavs</surname><given-names>J</given-names></name><name name-style="western"><surname>Dunbar</surname><given-names>G</given-names></name></person-group><article-title>The Mini International Neuropsychiatric interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI</article-title><source>Eur Psychiatry</source><year>1997</year><volume>12</volume><fpage>224</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/S0924-9338(97)83296-8</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar G (1997) The Mini International Neuropsychiatric interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12:224&#8211;231. 10.1016/S0924-9338(97)83296-8</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="other">Ackenheil M, Stotz-Ingenlath G, Dietz-Bauer R, Vossen A (1999) MINI mini international neuropsychiatric interview, German version 5.0. 0 DSM IV. Munich Psychiatr Univ Clin</mixed-citation></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verleye</surname><given-names>M</given-names></name><name name-style="western"><surname>Akwa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liere</surname><given-names>P</given-names></name><name name-style="western"><surname>Ladurelle</surname><given-names>N</given-names></name><name name-style="western"><surname>Pianos</surname><given-names>A</given-names></name><name name-style="western"><surname>Eychenne</surname><given-names>B</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Gillardin</surname><given-names>J-M</given-names></name></person-group><article-title>The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain</article-title><source>Pharmacol Biochem Behav</source><year>2005</year><volume>82</volume><fpage>712</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2005.11.013</pub-id><pub-id pub-id-type="pmid">16388839</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Verleye M, Akwa Y, Liere P, Ladurelle N, Pianos A, Eychenne B, Schumacher M, Gillardin J-M (2005) The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behav 82:712&#8211;720. 10.1016/j.pbb.2005.11.013<pub-id pub-id-type="pmid">16388839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pbb.2005.11.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liere</surname><given-names>P</given-names></name><name name-style="western"><surname>Pianos</surname><given-names>A</given-names></name><name name-style="western"><surname>Oudinet</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Akwa</surname><given-names>Y</given-names></name></person-group><article-title>Differential effects of the 18-kDa translocator protein (TSPO) ligand etifoxine on steroidogenesis in rat brain, plasma and steroidogenic glands: pharmacodynamic studies</article-title><source>Psychoneuroendocrinology</source><year>2017</year><volume>83</volume><fpage>122</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2017.05.022</pub-id><pub-id pub-id-type="pmid">28609670</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Liere P, Pianos A, Oudinet J-P, Schumacher M, Akwa Y (2017) Differential effects of the 18-kDa translocator protein (TSPO) ligand etifoxine on steroidogenesis in rat brain, plasma and steroidogenic glands: pharmacodynamic studies. Psychoneuroendocrinology 83:122&#8211;134. 10.1016/j.psyneuen.2017.05.022<pub-id pub-id-type="pmid">28609670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2017.05.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kancheva</surname><given-names>L</given-names></name><name name-style="western"><surname>Hill</surname><given-names>M</given-names></name><name name-style="western"><surname>V&#269;el&#225;kov&#225;</surname><given-names>H</given-names></name><name name-style="western"><surname>Vrb&#237;kov&#225;</surname><given-names>J</given-names></name><name name-style="western"><surname>Pelik&#225;nov&#225;</surname><given-names>T</given-names></name><name name-style="western"><surname>St&#225;rka</surname><given-names>L</given-names></name></person-group><article-title>The identification and simultaneous quantification of neuroactive androstane steroids and their polar conjugates in the serum of adult men, using gas chromatography&#8211;mass spectrometry</article-title><source>Steroids</source><year>2007</year><volume>72</volume><fpage>792</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.steroids.2007.06.006</pub-id><pub-id pub-id-type="pmid">17716701</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Kancheva L, Hill M, V&#269;el&#225;kov&#225; H, Vrb&#237;kov&#225; J, Pelik&#225;nov&#225; T, St&#225;rka L (2007) The identification and simultaneous quantification of neuroactive androstane steroids and their polar conjugates in the serum of adult men, using gas chromatography&#8211;mass spectrometry. Steroids 72:792&#8211;801. 10.1016/j.steroids.2007.06.006<pub-id pub-id-type="pmid">17716701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.steroids.2007.06.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baulieu</surname><given-names>E</given-names></name></person-group><article-title>Neurosteroids: of the nervous system, by the nervous system, for the nervous system</article-title><source>Recent Prog Horm Res</source><year>1997</year><volume>52</volume><fpage>1</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">9238846</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Baulieu E (1997) Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 52:1&#8211;32 PMID: 9238846<pub-id pub-id-type="pmid">9238846</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoffel-Wagner</surname><given-names>B</given-names></name></person-group><article-title>Neurosteroid biosynthesis in the human brain and its clinical implications</article-title><source>Ann N Y Acad Sci</source><year>2003</year><volume>1007</volume><fpage>64</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1196/annals.1286.007</pub-id><pub-id pub-id-type="pmid">14993041</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Stoffel-Wagner B (2003) Neurosteroid biosynthesis in the human brain and its clinical implications. Ann N Y Acad Sci 1007:64&#8211;78. 10.1196/annals.1286.007<pub-id pub-id-type="pmid">14993041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1286.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caruso</surname><given-names>D</given-names></name><name name-style="western"><surname>Scurati</surname><given-names>S</given-names></name><name name-style="western"><surname>Maschi</surname><given-names>O</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>L</given-names></name><name name-style="western"><surname>Roglio</surname><given-names>I</given-names></name><name name-style="western"><surname>Giatti</surname><given-names>S</given-names></name><name name-style="western"><surname>Garcia-Segura</surname><given-names>LM</given-names></name><name name-style="western"><surname>Melcangi</surname><given-names>RC</given-names></name></person-group><article-title>Evaluation of neuroactive steroid levels by liquid chromatography&#8211;tandem mass spectrometry in central and peripheral nervous system: Effect of diabetes</article-title><source>Neurochem Int</source><year>2008</year><volume>52</volume><fpage>560</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2007.06.004</pub-id><pub-id pub-id-type="pmid">17686551</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Caruso D, Scurati S, Maschi O, De Angelis L, Roglio I, Giatti S, Garcia-Segura LM, Melcangi RC (2008) Evaluation of neuroactive steroid levels by liquid chromatography&#8211;tandem mass spectrometry in central and peripheral nervous system: Effect of diabetes. Neurochem Int 52:560&#8211;568. 10.1016/j.neuint.2007.06.004<pub-id pub-id-type="pmid">17686551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuint.2007.06.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caruso</surname><given-names>D</given-names></name><name name-style="western"><surname>Pesaresi</surname><given-names>M</given-names></name><name name-style="western"><surname>Abbiati</surname><given-names>F</given-names></name><name name-style="western"><surname>Calabrese</surname><given-names>D</given-names></name><name name-style="western"><surname>Giatti</surname><given-names>S</given-names></name><name name-style="western"><surname>Garcia-Segura</surname><given-names>LM</given-names></name><name name-style="western"><surname>Melcangi</surname><given-names>RC</given-names></name></person-group><article-title>Comparison of plasma and cerebrospinal fluid levels of neuroactive steroids with their brain, spinal cord and peripheral nerve levels in male and female rats</article-title><source>Psychoneuroendocrinology</source><year>2013</year><volume>38</volume><fpage>2278</fpage><lpage>2290</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2013.04.016</pub-id><pub-id pub-id-type="pmid">23706961</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Caruso D, Pesaresi M, Abbiati F, Calabrese D, Giatti S, Garcia-Segura LM, Melcangi RC (2013) Comparison of plasma and cerebrospinal fluid levels of neuroactive steroids with their brain, spinal cord and peripheral nerve levels in male and female rats. Psychoneuroendocrinology 38:2278&#8211;2290. 10.1016/j.psyneuen.2013.04.016<pub-id pub-id-type="pmid">23706961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2013.04.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kancheva</surname><given-names>R</given-names></name><name name-style="western"><surname>Hill</surname><given-names>M</given-names></name><name name-style="western"><surname>Nov&#225;k</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chrastina</surname><given-names>J</given-names></name><name name-style="western"><surname>Kancheva</surname><given-names>L</given-names></name><name name-style="western"><surname>St&#225;rka</surname><given-names>L</given-names></name></person-group><article-title>Neuroactive steroids in periphery and cerebrospinal fluid</article-title><source>Neuroscience</source><year>2011</year><volume>191</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.05.054</pub-id><pub-id pub-id-type="pmid">21641969</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Kancheva R, Hill M, Nov&#225;k Z, Chrastina J, Kancheva L, St&#225;rka L (2011) Neuroactive steroids in periphery and cerebrospinal fluid. Neuroscience 191:22&#8211;27. 10.1016/j.neuroscience.2011.05.054<pub-id pub-id-type="pmid">21641969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2011.05.054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunner</surname><given-names>L-M</given-names></name><name name-style="western"><surname>Riebel</surname><given-names>M</given-names></name><name name-style="western"><surname>Wein</surname><given-names>S</given-names></name><name name-style="western"><surname>Koller</surname><given-names>M</given-names></name><name name-style="western"><surname>Zeman</surname><given-names>F</given-names></name><name name-style="western"><surname>Huppertz</surname><given-names>G</given-names></name><name name-style="western"><surname>Emmer</surname><given-names>T</given-names></name><name name-style="western"><surname>Eberhardt</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schwarzbach</surname><given-names>J</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Nothdurfter</surname><given-names>C</given-names></name></person-group><article-title>The translocator protein 18&#160;kDa ligand etifoxine in the treatment of depressive disorders&#8212;a double-blind, randomized, placebo-controlled proof-of-concept study</article-title><source>Trials</source><year>2024</year><volume>25</volume><fpage>274</fpage><pub-id pub-id-type="doi">10.1186/s13063-024-08120-x</pub-id><pub-id pub-id-type="pmid">38650030</pub-id><pub-id pub-id-type="pmcid">PMC11034134</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Brunner L-M, Riebel M, Wein S, Koller M, Zeman F, Huppertz G, Emmer T, Eberhardt Y, Schwarzbach J, Rupprecht R, Nothdurfter C (2024) The translocator protein 18&#160;kDa ligand etifoxine in the treatment of depressive disorders&#8212;a double-blind, randomized, placebo-controlled proof-of-concept study. Trials 25:274. 10.1186/s13063-024-08120-x<pub-id pub-id-type="pmid">38650030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13063-024-08120-x</pub-id><pub-id pub-id-type="pmcid">PMC11034134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witkin</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lippa</surname><given-names>A</given-names></name><name name-style="western"><surname>Smith</surname><given-names>JL</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name><name name-style="western"><surname>Ping</surname><given-names>X</given-names></name><name name-style="western"><surname>Biggerstaff</surname><given-names>A</given-names></name></person-group><article-title>The imidazodiazepine, KRM-II-81: an example of a newly emerging generations of GABAkines for neurological and psychiatric disorders</article-title><source>Phamacol Biochem Behav</source><year>2022</year><volume>213</volume><fpage>173321</fpage><pub-id pub-id-type="doi">10.1016/j.pbb.2021.173321</pub-id><pub-id pub-id-type="pmid">35041859</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Witkin JM, Lippa A, Smith JL, Jin X, Ping X, Biggerstaff A (2022) The imidazodiazepine, KRM-II-81: an example of a newly emerging generations of GABAkines for neurological and psychiatric disorders. Phamacol Biochem Behav 213:173321. 10.1016/j.pbb.2021.173321<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pbb.2021.173321</pub-id><pub-id pub-id-type="pmid">35041859</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501323</article-id><article-id pub-id-type="pmcid-ver">PMC12501323.1</article-id><article-id pub-id-type="pmcaid">12501323</article-id><article-id pub-id-type="pmcaiid">12501323</article-id><article-id pub-id-type="pmid">40713245</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100312</article-id><article-id pub-id-type="pii">S2274-5807(25)00255-9</article-id><article-id pub-id-type="publisher-id">100312</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group></article-categories><title-group><article-title>Dietary sugar intake, genetic susceptibility, and risk of dementia: A prospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>An</surname><given-names initials="Y">Yu</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Cao</surname><given-names initials="L">Limin</given-names></name><xref rid="aff0002" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Zheng</surname><given-names initials="G">Gang</given-names></name><xref rid="aff0003" ref-type="aff">c</xref><xref rid="aff0004" ref-type="aff">d</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yashu</given-names></name><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Yang</surname><given-names initials="H">Honghao</given-names></name><xref rid="aff0003" ref-type="aff">c</xref><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Chen</surname><given-names initials="L">Liangkai</given-names></name><xref rid="aff0006" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Zhao</surname><given-names initials="Y">Yuhong</given-names></name><xref rid="aff0003" ref-type="aff">c</xref><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xiaopeng</given-names></name><email>xiaopeng.zhang@bjmu.edu.cn</email><xref rid="aff0007" ref-type="aff">g</xref><xref rid="cor0002" ref-type="corresp">&#8270;&#8270;</xref></contrib><contrib contrib-type="author" id="au0009"><name name-style="western"><surname>Xia</surname><given-names initials="Y">Yang</given-names></name><email>xytmu507@126.com</email><xref rid="aff0003" ref-type="aff">c</xref><xref rid="aff0004" ref-type="aff">d</xref><xref rid="PC_aff2R8WJCpGYp" ref-type="aff">h</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><aff id="aff0001"><label>a</label>Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, 100020, Beijing, China</aff><aff id="aff0002"><label>b</label>The Third Central Hospital of Tianjin, No. 83, Jin Tang Road, Tianjin, 300070, China</aff><aff id="aff0003"><label>c</label>Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, No. 36, San Hao Street, Shenyang, Liaoning, 110004, China</aff><aff id="aff0004"><label>d</label>Liaoning Key Laboratory of Precision Medical Research on Major Chronic Disease, Shenyang, No. 36, San Hao Street, Shenyang, Liaoning, 110004, China</aff><aff id="aff0005"><label>e</label>Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, No. 36, San Hao Street, Shenyang, Liaoning, 110004, China</aff><aff id="aff0006"><label>f</label>Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No. 13, Hang Kong Road, 430030, Wuhan, China</aff><aff id="aff0007"><label>g</label>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital and Institute, Beijing 100142, China</aff><aff id="PC_aff2R8WJCpGYp"><label>h</label>Department of Data Center, Shengjing Hospital of China Medical University, Shenyang, No. 36, San Hao Street, Shenyang, Liaoning, 110004, China.</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author at: Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, No. 36, San Hao Street, Shenyang, Liaoning, 110004, China. <email>xytmu507@126.com</email></corresp><corresp id="cor0002"><label>&#8270;&#8270;</label>Corresponding author at: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital and Institute, Beijing 100142, China. <email>xiaopeng.zhang@bjmu.edu.cn</email></corresp><fn id="fn1"><label>1</label><p id="notep0001">These three authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>7</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100312</elocation-id><history><date date-type="received"><day>29</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>6</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><title>Abstracts</title><sec><title>Background</title><p>Sugar intake has been identified as a risk factor for incident dementia; however, the role of genetic susceptibility in such association remains unclear.</p></sec><sec><title>Methods</title><p>This cohort study involved 158,408 participants from the UK Biobank to explore the effect of genetic susceptibility on the association between dietary sugar intake and dementia risk. Data on sugar intake were evaluated using repeated web-based 24-hour dietary recalls. Polygenic risk scores (PRS) for sugar metabolism (Triglyceride Glucose, TyG), gut microbiota, and disease susceptibility (Alzheimer's disease) were generated based on genome-wide association studies.</p></sec><sec><title>Results</title><p>Over a median follow-up period of 9.94 years, 1,219 dementia cases (0.7%) were documented. There were significant positive dose-response relationships between sugar intake and dementia risk (non-free sugar: HR, 95% CI, <sub>Quartile 4</sub> vs. <sub>Quartile 1</sub> = 1.26, 1.04&#8211;1.52; free sugar: 1.43, 1.20&#8211;1.70). Genetic susceptibility, including TyG-PRS, gut microbiota, and disease susceptibility, showed a combined effect on the association between sugar intake and dementia risk. Notably, significant interactions were observed between sugar intake, PRS for <italic toggle="yes">Ruminococcaceae UCG-014</italic> and dementia, as well as between free sugar, PRS for <italic toggle="yes">Oscillospira</italic> and dementia. Participants with lower PRS of <italic toggle="yes">Ruminococcaceae UCG-014</italic>, or higher PRS of <italic toggle="yes">Oscillospira</italic>, posed a higher risk of dementia due to sugar intake.</p></sec><sec><title>Conclusion</title><p>Both free and non-free sugar intake are independent risk factors for dementia incidence. The role of genetic susceptibility among such association cannot be ignored. These results underscore the importance of personalized nutritional interventions targeting both dietary habits and genetic risk profiles in dementia prevention strategies.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Dementia</kwd><kwd>Non-free sugar intake</kwd><kwd>Genetic susceptibility</kwd><kwd>Gut microbiota</kwd><kwd>Cohort</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Background</title><p id="para0006">Dementia poses a great global health challenge, currently affecting 55 million individuals with approximately 10 million new cases annually [<xref rid="bib0001" ref-type="bibr">1</xref>]. By 2050, this number is projected to rise to 152 million [<xref rid="bib0002" ref-type="bibr">2</xref>]. With the aging population, the prevalence of dementia is expected to double approximately every five years between 2019 and 2050, particularly among individuals aged 85 years and above [<xref rid="bib0002" ref-type="bibr">2</xref>], making it one of the leading contributors of disability and dependency among older adults [<xref rid="bib0003" ref-type="bibr">3</xref>]. Despite recent advances in the treatment of Alzheimer's disease (AD) showing clinical potential [<xref rid="bib0004" ref-type="bibr">4</xref>], primary prevention through dietary regulation remains critical [<xref rid="bib0005" ref-type="bibr">5</xref>].</p><p id="para0007">Excessive intake of sugar, particularly free sugar (all monosaccharides and disaccharides added to foods by manufacturers, cooks, or consumers, as well as sugars occurring naturally in honey, syrups, and unsweetened fruit juices), has been linked to an increased incidence of noncommunicable diseases such as obesity, diabetes [<xref rid="bib0006" ref-type="bibr">6</xref>], and neurodegenerative disorders [<xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>, <xref rid="bib0009" ref-type="bibr">[9]</xref>, <xref rid="bib0010" ref-type="bibr">[10]</xref>]. Moreover, intake of non-free sugar has also been reported to have adverse effects on dementia [<xref rid="bib0010" ref-type="bibr">10</xref>], despite its demonstrated benefits for cardiovascular diseases (CVDs) [<xref rid="bib0011" ref-type="bibr">11</xref>] and reduction of liver fat [<xref rid="bib0012" ref-type="bibr">12</xref>]. Furthermore, the gut microbiota-brain axis (GMBA) has emerged as a potential target for modulating brain health [<xref rid="bib0013" ref-type="bibr">13</xref>]. The "gut microbiome" is the largest repository of microbes in the human body, containing about 10<sup>14</sup> species [<xref rid="bib0014" ref-type="bibr">14</xref>]. These gut microbes play important roles in physiological homeostasis and metabolism, promoting the development of the immune system, vitamin production, and nutrient absorption, and have been demonstrated to be involved in the onset of neurodegenerative diseases (such as glucose and fat metabolism and insulin sensitivity) [<xref rid="bib0015" ref-type="bibr">15</xref>,<xref rid="bib0016" ref-type="bibr">16</xref>].</p><p id="para0008">On the other hand, it has been widely accepted that dementia develops at the complex intersection of environmental factors and inherited predisposition [<xref rid="bib0017" ref-type="bibr">17</xref>]. Research from Genome-Wide Association Studies (GWASs) has recently identified a growing number of genetic variations associated with the risk of dementia, with heritability estimates spanning 13 %&#8722;80 % across different populations [<xref rid="bib0018" ref-type="bibr">18</xref>]. Notably, emerging evidence has demonstrated that a favorable lifestyle is associated with a decreased risk of dementia among individuals with high genetic risk [<xref rid="bib0019" ref-type="bibr">19</xref>]. Therefore, exploring modifiable risk factors for dementia needs to consider an individual&#8217;s inherent genetic susceptibility. However, limited studies reported the role of disease susceptibility among the association between sugar intake and dementia risk. What&#8217;s more, the genetic susceptibility of sugar metabolism and gut microbiota may also influence the risk of dementia, along with sugar intake.</p><p id="para0009">To address these knowledge gaps, the current study aimed to prospectively explore the long-term associations of both non-free sugar and free sugar intake with dementia risk, and furtherly investigated whether genetic susceptibility of sugar metabolism, gut microbiota, and disease susceptibility play a role in such association based on the UK Biobank, a large-scale prospective cohort study involving approximately half million participants.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><sec id="sec0003"><label>2.1</label><title>Study design and population</title><p id="para0010">The UK Biobank is an extensive cohort involving over 500,000 individuals aged 37&#8211;73 years from across England, Scotland, and Wales. The detailed information about the structure and demographics of the UK Biobank can be found in previous studies [<xref rid="bib0020" ref-type="bibr">20</xref>,<xref rid="bib0021" ref-type="bibr">21</xref>].</p><p id="para0011">In the current cohort study, a dietary questionnaire with credible energy intake (defined as &gt;0&#8211;20 MJ/day for males, &gt;0&#8211;18 MJ/day for females) was considered valid [<xref rid="bib0022" ref-type="bibr">22</xref>]. The baseline was defined as the time when participants completed the first valid 24-hour recall dietary questionnaire. Among 210,433 participants who had at least one valid 24-hour recall dietary assessment, we excluded (1) those who had dementia at baseline (<italic toggle="yes">n</italic> = 94) and (2) those with missing data on covariates (<italic toggle="yes">n</italic> = 51,931). Finally, 158,408 participants remained in the final analysis (<xref rid="fig0001" ref-type="fig">Fig 1</xref>).<fig id="fig0001" position="float" orientation="portrait"><label>Fig 1</label><caption><p>Flowchart for the selection of the study population.</p><p><italic toggle="yes">Abbreviations:</italic> BMI, body mass index; TDI, Townsend Deprivation Index.</p></caption><alt-text id="alt0001">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec0004"><label>2.2</label><title>Assessment of sugar intake</title><p id="para0012">The Oxford WebQ questionnaire, an online tool for assessing dietary intake over a 24-hour period, was utilized to collect dietary information [<xref rid="bib0023" ref-type="bibr">23</xref>]. The initial round was conducted for participants recruited between 2009 and 2010 at assessment centers. Individuals who submitted a verifiable email address during the recruitment process were subsequently extended an invitation to partake in 24-hour dietary evaluations spanning from February 2011 to April 2012. The intake of non-free sugar, free sugar, and other nutrients was derived from the average of &#8805; one (maximum of five) 24-hour dietary assessments, calculated by multiplying the content of food items and beverages by the frequency of intake using UK Nutrient Databank food composition tables [<xref rid="bib0023" ref-type="bibr">23</xref>]. The primary exposure of interest was the percentage of total energy intake from non-free sugar and free sugar. For further analyses, the percentages were categorized into quartiles.</p></sec><sec id="sec0005"><label>2.3</label><title>Assessment of dementia</title><p id="para0013">Dementia cases were identified by the Hospital Episode Statistics for England, Scottish Morbidity Records for Scotland, and Patient Episode Database for Wales. The incident and prevalent dementia cases were determined by utilizing International Classification of Diseases, 10th Revision (ICD-10) (F00, F000, F001, F002, F009, G30, G300, G301, G308, G309, F01, F010, F011, F012, F013, F018, F019, I673, F020, G310, A810, F02, F021, F022, F023, F024, F028, F03, F051, F106, G311, G318), present in hospital inpatient data and death registry records. The identification of dementia-related deaths was accomplished by linking the data to the death registry. The follow-up time was analyzed starting at the baseline date and ending at the dementia diagnosis, censoring date, or death (up to May 2021), whichever came first.</p></sec><sec id="sec0006"><label>2.4</label><title>The polygenic risk score (PRS) for sugar metabolism and gut microbiota</title><p id="para0014">The triglyceride-glucose (TyG) index represents a robust surrogate marker for evaluating insulin resistance (IR) and overall glucose metabolism, calculated through the logarithmic transformation of fasting triglyceride (TG) and fasting plasma glucose (FPG) concentrations. This composite biomarker has demonstrated significant clinical utility in predicting the development of metabolic dysregulation and associated pathological consequences. Thus, we built a weighted polygenic risk score as an instrumental variable for TyG using independent genetic variants (linkage disequilibrium R<sup>2</sup> &lt; 0.2 and a 500 kb clustering window) with <italic toggle="yes">P</italic> &lt; 5 &#215; 10<sup>&#8722;8</sup> at a genome-wide level in large numbers of individuals from European-descent populations [<xref rid="bib0024" ref-type="bibr">24</xref>]. Overall, 192 genetic variants were selected, and 21 SNPs were excluded due to a high R<sup>2</sup>. The remaining 171 SNPs were all independent of each other (i.e. linkage equilibrium) and were used to construct the PRS. The PRS for each participant was calculated by summing the number of risk alleles and was weighted by the corresponding effect size (<italic toggle="yes">&#946;</italic>-coefficients) derived from the GWAS study. The following equation was applied: <inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mi>S</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>S</mml:mi><mml:mi>N</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>S</mml:mi><mml:mi>N</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo linebreak="goodbreak">+</mml:mo><mml:mo>&#8943;</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>S</mml:mi><mml:mi>N</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> [<xref rid="bib0025" ref-type="bibr">25</xref>]. The characteristics of the SNPs associated with sugar metabolism were listed in <bold>Supplementary Table 1</bold>.</p><p id="para0015">The PRS for gut microbiota was derived from the largest GWAS meta-analysis published to date conducted by the MiBioGen consortium [<xref rid="bib0026" ref-type="bibr">26</xref>]. The study coordinated 16S rRNA gene sequencing profiles and genotyping data from 24 cohorts. Most participants were of European ancestry (<italic toggle="yes">N</italic> = 13,266). Among them, the taxonomic level of genus was the lowest; 131 genera (including 12 unknown genera) were identified, and the average abundance was more than 1 %. We built weighted PRS for genus-level gut microbes using independent genetic variants (linkage disequilibrium R<sup>2</sup> &lt; 0.001 and a 10,000&#8201;kb clustering window) with <italic toggle="yes">P</italic> &lt; 1 &#215; 10<sup>&#8211;5</sup> at a genome-wide level in large numbers of individuals from European-descent populations. Single-nucleotide polymorphisms (SNPs) with a minor allele frequency of &lt; 0.01, ambiguous SNPs with non-concordant alleles, and palindromic SNPs were excluded. The remaining SNPs were all independent of each other (i.e., linkage equilibrium) and were used to construct the PRS. The PRS for each participant was calculated by summing the number of risk alleles and was weighted by the corresponding effect size (&#946;-coefficients) derived from the GWAS study. The following equation was applied: <inline-formula><mml:math id="M2" altimg="si1.svg"><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mi>S</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>S</mml:mi><mml:mi>N</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>S</mml:mi><mml:mi>N</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo linebreak="goodbreak">+</mml:mo><mml:mo>&#8943;</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>S</mml:mi><mml:mi>N</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> [<xref rid="bib0025" ref-type="bibr">25</xref>]. The characteristics of the SNPs associated with genus-level gut microbes were listed in <bold>Supplementary Table 2</bold>.</p></sec><sec id="sec0007"><label>2.5</label><title>Assessment of covariates</title><p id="para0016">Potential confounding variables were evaluated using the baseline questionnaire, which included information on comorbidities, demographics, physical, lifestyle characteristics, and family history of dementia. The identification of previous occurrences of comorbidities, including cardiovascular disease, diabetes, and hypertension, was based on either the self-reporting of medical conditions or the utilization of ICD-10 codes in hospital inpatient records. Standardized techniques were employed to gather physical measurements and biological specimens, and these procedures have been previously described and validated [<xref rid="bib0027" ref-type="bibr">27</xref>]. Demographic, physical, and lifestyle characteristics, including age, sex, race, education level, average total household income before tax, Townsend Deprivation Index (TDI), smoking status, alcohol drinking status, and family history of dementia, were all collected by self-administered touchscreen survey and interview at recruitment. Physical activity was evaluated in metabolic equivalent (MET) minutes per week for all activities using a short-form international physical activity questionnaire [<xref rid="bib0028" ref-type="bibr">28</xref>]. Anthropometric indices (e.g., height and weight) were calculated by trained and experienced staff during the initial visit at the assessment center. Body mass index (BMI) was calculated by weight in kilograms divided by the square of height in meters.</p></sec><sec id="sec0008"><label>2.6</label><title>Statistical analyses</title><p id="para0017">The baseline characteristics of participants were described by the highest and lowest quartiles of the percentage of energy intake of non-free sugar and free sugar. Continuous and categorical variables were expressed as means (standard deviations) and numbers (proportions), respectively. The cause-specific competing risk model was performed to determine the hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of non-free and free sugar intake with dementia risk, while treating deaths before dementia development as competing risks and censoring. The linear trend was tested by using the median values of each quartile for non-free and free sugar intake (per 5 % energy increase) as continuous values. Restricted cubic splines were performed to flexibly model the associations between non-free and free sugar intake (continuous variables) and dementia risk, and the minimum Akaike information criterion was used to choose optimal knots. The reference point was 10 % of total energy intake for non-free and free sugar following World Health Organization guidelines [<xref rid="bib0029" ref-type="bibr">29</xref>]. Three sets of models were fitted. Model 1 was the crude model. Model 2 was adjusted for age at recruitment (years), sex (male, female), race (white, non-white), education (college or university degree, high school, below), average total household income before tax (&lt; &#163;18,000, &#163;18,000&#8211;&#163;52,000, &#8805; &#163;52,000), TDI (continuous), physical activity (MET, continuous), tobacco intake status (never, previous, and current), alcohol intake status (never, previous, and current), protein and fat intake (percentage of energy intake), and total energy intake (kcal/day, continuous). Model 3 was additionally adjusted for variables in model 2, plus hypertension history (yes, no), diabetes history (yes, no), CVD history (yes, no), and family history of dementia (yes, no). Model 3 was also mutually adjusted for non-free sugar intake and free sugar intake.</p><p id="para0018">To examine potential modifying effects, we additionally repeated analyses stratified by age (&lt; 60 or &#8805; 60 years), sex (male or female), BMI (&lt; 25 or &#8805; 25 kg/m<sup>2</sup>), physical activity (below or above the median value), history of diabetes (yes or no), and history of hypertension (yes or no). <italic toggle="yes">P</italic>-value for interactions between these stratifying factors and sugar intake were calculated by entering their multiplication terms in model 3. The robustness of our findings was examined in sensitivity analyses by (i) excluding dementia cases within the first 2 years of follow-up to reduce the possibility of reverse causation; (ii) restricting to participants who had completed &#8805; 2 dietary assessments to minimize the effects of random error and within-person variability; (iii) using absolute intake of non-free and free sugar (g/day) as exposures; (iv) using the ratio dividing non-free sugar intake or free sugar intake by total carbohydrate intake (%) as exposures; and (v) using Fine and Gray&#8217;s model to estimate the sub-distribution HRs (95% CIs) of incident dementia with the intake of sugar.</p><p id="para0019">Furthermore, we investigated the PRS of sugar metabolism, gut microbiota, and disease susceptibility of dementia in the association between sugar intake and incident dementia, respectively. To explore the role of microbiota abundance on the association of sugar intake and dementia risk, valid data were selected from 119 kinds of gut microbiota&#8217;s PRS with false discovery rate (FDR) estimation [<xref rid="bib0030" ref-type="bibr">30</xref>,<xref rid="bib0031" ref-type="bibr">31</xref>]. As reported elsewhere, we additionally considered the PRS of total relative abundance of gut microbial taxa [<xref rid="bib0032" ref-type="bibr">32</xref>] as a covariate in the sensitivity analysis. Finally, the modifying effects of the valid gut microbiota&#8217;s PRS on the association between sugar intake and dementia risk were assessed. To assess for modifying effects between the disease susceptibility and the intake of non-free and free sugars on dementia risk, the standard released version of PRS for AD from the UK-Biobank was used to evaluate the disease susceptibility. Detailed information on the PRS can be found elsewhere [<xref rid="bib0033" ref-type="bibr">33</xref>].</p><p id="para0020">The analyses were stratified by PRS (TyG-PRS, gut microbial-PRS, or dementia-PRS) categories (high PRS: &#8805; median value; low PRS: &lt; median value), and the product term of non-free or free sugar with PRS was included in the multivariate-adjusted models. To further evaluate the joint associations of sugar (non-free or free) intake and genetic susceptibility, we classified participants into eight groups according to the categories of PRS and the quartiles of sugar intake. The HRs (95% CIs) of incident dementia in different groups were estimated and compared to those with low risk of PRS and in the lowest quartile of sugar intake. The HRs (95% CIs) were estimated using Model 3 and further adjusted for the first 10 genetic principal components and the genotyping batch.</p><p id="para0021">All statistical analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). Two-sided <italic toggle="yes">P</italic> values &lt; 0.05 were recognized as statistically significant.</p></sec></sec><sec id="sec0009"><label>3</label><title>Results</title><sec id="sec0010"><label>3.1</label><title>Characteristics of participants</title><p id="para0022">After a median follow-up period of 9.94 years, a total of 1,219 dementia cases were documented among 158,408 dementia-free participants. Participant characteristics based on the lowest and highest quartiles of non-free and free sugar intake are presented in <xref rid="tbl0001" ref-type="table">Table 1</xref><bold>.</bold> The findings revealed that individuals with elevated levels of non-free sugar intake were more likely to be women, older, experiencing higher levels of deprivation, having higher levels of education and income, non-smokers, and showing higher carbohydrate intake but lower fat, protein, and total energy intake. In contrast, participants with higher intake of free sugar tended to be younger men, experiencing higher levels of deprivation, possessing lower levels of education and higher levels of income, as well as smokers. Additionally, they showed higher total energy and carbohydrate intake, but lower fat and protein intake.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics according to the lowest and highest quartiles of non-free sugar and free sugars intake (<italic toggle="yes">n</italic> = 158,408).</p></caption><alt-text id="alt0004">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="top" colspan="1"><bold>Characteristics</bold></th><th rowspan="2" align="left" valign="top" colspan="1"><bold>Total</bold></th><th colspan="2" align="left" valign="top" rowspan="1"><bold>Non-free sugar intake</bold><hr/></th><th colspan="2" align="left" valign="top" rowspan="1"><bold>Free sugar intake</bold><hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1"><bold>Quartile 1</bold></th><th valign="top" colspan="1" rowspan="1"><bold>Quartile 4</bold></th><th valign="top" colspan="1" rowspan="1"><bold>Quartile 1</bold></th><th valign="top" colspan="1" rowspan="1"><bold>Quartile 4</bold></th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">No. of participants</td><td valign="top" colspan="1" rowspan="1">158,408</td><td valign="top" colspan="1" rowspan="1">39,602</td><td valign="top" colspan="1" rowspan="1">39,602</td><td valign="top" colspan="1" rowspan="1">39,602</td><td valign="top" colspan="1" rowspan="1">39,602</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intake of sugars of interest (% energy intake)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">6.3 (1.7)</td><td valign="top" colspan="1" rowspan="1">21.3 (5.0)</td><td valign="top" colspan="1" rowspan="1">5.4 (1.9)</td><td valign="top" colspan="1" rowspan="1">19.3 (4.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sociodemographic factors</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Age at recruitment (years)</td><td valign="top" colspan="1" rowspan="1">55.7 (8.0)</td><td valign="top" colspan="1" rowspan="1">53.8 (8.1)</td><td valign="top" colspan="1" rowspan="1">57.1 (7.6)</td><td valign="top" colspan="1" rowspan="1">55.9 (7.8)</td><td valign="top" colspan="1" rowspan="1">55.2 (8.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Female sex, n (%)</td><td valign="top" colspan="1" rowspan="1">82,304 (52.0)</td><td valign="top" colspan="1" rowspan="1">15,021 (37.9)</td><td valign="top" colspan="1" rowspan="1">26,392 (66.6)</td><td valign="top" colspan="1" rowspan="1">23,585 (59.6)</td><td valign="top" colspan="1" rowspan="1">17,430 (44.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;White ethnicity, n (%)</td><td valign="top" colspan="1" rowspan="1">144,248 (91.1)</td><td valign="top" colspan="1" rowspan="1">36,157 (91.3)</td><td valign="top" colspan="1" rowspan="1">35,675 (90.1)</td><td valign="top" colspan="1" rowspan="1">35,578 (89.8)</td><td valign="top" colspan="1" rowspan="1">36,010 (90.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Townsend deprivation index</td><td valign="top" colspan="1" rowspan="1">&#8722;1.6 (2.9)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.3 (3.0)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.7 (2.8)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.5 (2.9)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.4 (3.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;College or university degree, n (%)</td><td valign="top" colspan="1" rowspan="1">24,950 (15.8)</td><td valign="top" colspan="1" rowspan="1">5493 (13.9)</td><td valign="top" colspan="1" rowspan="1">6577 (16.6)</td><td valign="top" colspan="1" rowspan="1">6702 (16.9)</td><td valign="top" colspan="1" rowspan="1">5581 (14.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Income &#8805; 52,000 EUR, n (%)</td><td valign="top" colspan="1" rowspan="1">23,194 (14.6)</td><td valign="top" colspan="1" rowspan="1">5396 (13.6)</td><td valign="top" colspan="1" rowspan="1">6648 (16.8)</td><td valign="top" colspan="1" rowspan="1">5730 (14.5)</td><td valign="top" colspan="1" rowspan="1">6807 (17.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Lifestyle and dietary information</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;BMI (kg/m<sup>2</sup>)</td><td valign="top" colspan="1" rowspan="1">26.9 (4.6)</td><td valign="top" colspan="1" rowspan="1">27.5 (4.6)</td><td valign="top" colspan="1" rowspan="1">26.6 (4.6)</td><td valign="top" colspan="1" rowspan="1">27.1 (4.8)</td><td valign="top" colspan="1" rowspan="1">26.9 (4.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Current smoker, n (%)</td><td valign="top" colspan="1" rowspan="1">12,488 (7.9)</td><td valign="top" colspan="1" rowspan="1">5328 (13.5)</td><td valign="top" colspan="1" rowspan="1">1811 (4.6)</td><td valign="top" colspan="1" rowspan="1">2992 (7.6)</td><td valign="top" colspan="1" rowspan="1">4185 (10.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Current alcohol drinker, n (%)</td><td valign="top" colspan="1" rowspan="1">149,264 (94.2)</td><td valign="top" colspan="1" rowspan="1">37,981 (95.9)</td><td valign="top" colspan="1" rowspan="1">36,157 (91.3)</td><td valign="top" colspan="1" rowspan="1">37,374 (94.4)</td><td valign="top" colspan="1" rowspan="1">36,458 (92.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Physical activity (MET min/wk)</td><td valign="top" colspan="1" rowspan="1">964.8 (1009.4)</td><td valign="top" colspan="1" rowspan="1">926.1 (1023.8)</td><td valign="top" colspan="1" rowspan="1">1035.4 (1027.0)</td><td valign="top" colspan="1" rowspan="1">957.1 (991.5)</td><td valign="top" colspan="1" rowspan="1">1001.5 (1067.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Total carbohydrate intake (% energy intake)</td><td valign="top" colspan="1" rowspan="1">50.2 (8.5)</td><td valign="top" colspan="1" rowspan="1">45.2 (8.7)</td><td valign="top" colspan="1" rowspan="1">55.5 (7.5)</td><td valign="top" colspan="1" rowspan="1">47.1 (9.5)</td><td valign="top" colspan="1" rowspan="1">54.0 (7.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Total fat intake (% energy intake)</td><td valign="top" colspan="1" rowspan="1">30.9 (6.6)</td><td valign="top" colspan="1" rowspan="1">33.0 (7.0)</td><td valign="top" colspan="1" rowspan="1">27.7 (6.1)</td><td valign="top" colspan="1" rowspan="1">31.9 (7.3)</td><td valign="top" colspan="1" rowspan="1">29.4 (6.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Total protein intake (% energy intake)</td><td valign="top" colspan="1" rowspan="1">16.2 (3.6)</td><td valign="top" colspan="1" rowspan="1">15.6 (3.8)</td><td valign="top" colspan="1" rowspan="1">16.9 (3.9)</td><td valign="top" colspan="1" rowspan="1">17.9 (4.2)</td><td valign="top" colspan="1" rowspan="1">14.6 (3.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Total energy intake (kal/day)</td><td valign="top" colspan="1" rowspan="1">8669.4 (2395.8)</td><td valign="top" colspan="1" rowspan="1">9312.1 (2623.3)</td><td valign="top" colspan="1" rowspan="1">7769.5 (2160.1)</td><td valign="top" colspan="1" rowspan="1">8090.7 (2345.4)</td><td valign="top" colspan="1" rowspan="1">8948.0 (2528.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Comorbidity, n (%)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Cardiovascular disease</td><td valign="top" colspan="1" rowspan="1">6776 (4.3)</td><td valign="top" colspan="1" rowspan="1">1804 (4.6)</td><td valign="top" colspan="1" rowspan="1">1718 (4.3)</td><td valign="top" colspan="1" rowspan="1">1742 (4.4)</td><td valign="top" colspan="1" rowspan="1">1869 (4.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Hypertension</td><td valign="top" colspan="1" rowspan="1">81,326 (51.3)</td><td valign="top" colspan="1" rowspan="1">20,503 (51.8)</td><td valign="top" colspan="1" rowspan="1">20,389 (51.5)</td><td valign="top" colspan="1" rowspan="1">20,460 (51.7)</td><td valign="top" colspan="1" rowspan="1">20,377 (51.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Diabetes</td><td valign="top" colspan="1" rowspan="1">8442 (5.3)</td><td valign="top" colspan="1" rowspan="1">2093 (5.3)</td><td valign="top" colspan="1" rowspan="1">2104 (5.3)</td><td valign="top" colspan="1" rowspan="1">3262 (8.2)</td><td valign="top" colspan="1" rowspan="1">1522 (3.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Laboratory indicators</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;LDL&#8209;C (mmol/L)</td><td valign="top" colspan="1" rowspan="1">3.5 (0.8)</td><td valign="top" colspan="1" rowspan="1">3.6 (0.8)</td><td valign="top" colspan="1" rowspan="1">3.5 (0.9)</td><td valign="top" colspan="1" rowspan="1">3.5 (0.9)</td><td valign="top" colspan="1" rowspan="1">3.6 (0.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;HDL&#8209;C (mmol/L)</td><td valign="top" colspan="1" rowspan="1">1.5 (0.4)</td><td valign="top" colspan="1" rowspan="1">1.4 (0.4)</td><td valign="top" colspan="1" rowspan="1">1.5 (0.4)</td><td valign="top" colspan="1" rowspan="1">1.5 (0.4)</td><td valign="top" colspan="1" rowspan="1">1.4 (0.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Triglycerides (mmol/L)</td><td valign="top" colspan="1" rowspan="1">1.7 (1.0)</td><td valign="top" colspan="1" rowspan="1">1.8 (1.1)</td><td valign="top" colspan="1" rowspan="1">1.6 (0.9)</td><td valign="top" colspan="1" rowspan="1">1.6 (1.0)</td><td valign="top" colspan="1" rowspan="1">1.8 (1.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Family history of dementia</td><td valign="top" colspan="1" rowspan="1">20,543 (13.0)</td><td valign="top" colspan="1" rowspan="1">4565 (11.5)</td><td valign="top" colspan="1" rowspan="1">5526 (14.0)</td><td valign="top" colspan="1" rowspan="1">5143 (13.0)</td><td valign="top" colspan="1" rowspan="1">4920 (12.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Incident dementia</td><td valign="top" colspan="1" rowspan="1">1219 (0.8)</td><td valign="top" colspan="1" rowspan="1">241 (0.6)</td><td valign="top" colspan="1" rowspan="1">369 (0.9)</td><td valign="top" colspan="1" rowspan="1">280 (0.7)</td><td valign="top" colspan="1" rowspan="1">366 (0.9)</td></tr></tbody></table><table-wrap-foot><fn><p><italic toggle="yes">Abbreviations:</italic> BMI, body mass index; hs-CRP, high-sensitive C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MET, metabolic equivalent task; Q, quartile. Numbers are presented as means (standard deviation) unless otherwise specified as numbers (%).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0011"><label>3.2</label><title>Association between dietary sugar intake and incident dementia</title><p id="para0023">In the multivariable cause-specific competing risk model, both non-free sugar and free sugar intake were positively associated with the risk of incident dementia (both <italic toggle="yes">P</italic> for trend &lt; 0.01) (<xref rid="tbl0002" ref-type="table">Table 2</xref>). Compared with participants in the lowest quartile of non-free and free sugar intake, those in the highest quartile had adjusted HRs (95% CIs) 1.26 (1.04, 1.52) and 1.43 (1.20, 1.70) for dementia, respectively. The adjusted HRs (95% CIs) for dementia per 5 % increase in energy from non-free and free sugar intake were 1.10 (1.04, 1.16) and 1.16 (1.10, 1.23), respectively. Moreover, using a restricted cubic spline curve, there was no evidence for a nonlinear association between non-free sugar intake and dementia risk (<bold>Supplementary Fig 1A</bold>). Conversely, a significant nonlinear relationship (<italic toggle="yes">P</italic> for nonlinearity = 0.038) was observed for free sugar intake and incident dementia risk (<bold>Supplementary Fig 1B</bold>). The risk of dementia remained relatively flat until free sugars constituted approximately 10 % of total energy, after which it started to increase rapidly. In the sensitivity analyses, the results were generally consistent with the main results when we (i) included BMI as a covariate (<bold>Supplementary Table 3</bold>); (ii) excluded dementia cases within the first 2 years of follow-up (<bold>Supplementary Table 4</bold>); (iii) restricted the analysis to participants who had completed &#8805; 2 dietary assessments (<bold>Supplementary Table 5</bold>); (iv) used absolute intake of free and non-free sugar (g/day) as exposures (<bold>Supplementary Table 6</bold>); (v) used the ratio by dividing free sugar intake or non-free sugar intake by total carbohydrate intake (%) as exposures (<bold>Supplementary Table 7</bold>); and (vi) used Fine and Gray&#8217;s model instead of the cause-specific competing risk model (<bold>Supplementary Table 9</bold>).<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Associations of non-free and free sugars consumption with incident dementia (<italic toggle="yes">n</italic> = 158,408) <xref rid="tb2fn1" ref-type="table-fn">a.</xref></p></caption><alt-text id="alt0005">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="top" colspan="1"><bold>Sugar intake</bold></th><th rowspan="2" align="left" valign="top" colspan="1"><bold>Cases (%)</bold></th><th valign="top" colspan="1" rowspan="1"><bold>Model 1</bold><xref rid="tb2fn3" ref-type="table-fn">c</xref></th><th valign="top" colspan="1" rowspan="1"><bold>Model 2</bold><xref rid="tb2fn4" ref-type="table-fn">d</xref></th><th valign="top" colspan="1" rowspan="1"><bold>Model 3</bold><xref rid="tb2fn5" ref-type="table-fn">e</xref></th></tr><tr><th valign="top" colspan="1" rowspan="1"><bold>HR (95% CI)</bold></th><th valign="top" colspan="1" rowspan="1"><bold>HR (95% CI)</bold></th><th valign="top" colspan="1" rowspan="1"><bold>HR (95% CI)</bold></th></tr></thead><tbody><tr><td colspan="5" align="left" valign="top" rowspan="1"><bold>Non-free sugar intakes (% energy intake)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Quartile</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&lt;8.62 %</td><td valign="top" colspan="1" rowspan="1">241 (0.61)</td><td valign="top" colspan="1" rowspan="1">Reference</td><td valign="top" colspan="1" rowspan="1">Reference</td><td valign="top" colspan="1" rowspan="1">Reference</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8805;8.62 % and &lt;12.11 %</td><td valign="top" colspan="1" rowspan="1">279 (0.70)</td><td valign="top" colspan="1" rowspan="1">1.15 (0.97, 1.36)</td><td valign="top" colspan="1" rowspan="1">1.00 (0.84, 1.19)</td><td valign="top" colspan="1" rowspan="1">1.02 (0.85, 1.21)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8805;12.11 % and &lt;16.32 %</td><td valign="top" colspan="1" rowspan="1">330 (0.83)</td><td valign="top" colspan="1" rowspan="1">1.35 (1.15, 1.60)</td><td valign="top" colspan="1" rowspan="1">1.12 (0.94, 1.33)</td><td valign="top" colspan="1" rowspan="1">1.14 (0.96, 1.36)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8805;16.32 %</td><td valign="top" colspan="1" rowspan="1">369 (0.93)</td><td valign="top" colspan="1" rowspan="1">1.50 (1.28, 1.76)</td><td valign="top" colspan="1" rowspan="1">1.22 (1.01, 1.47)</td><td valign="top" colspan="1" rowspan="1">1.26 (1.04, 1.52)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold><italic toggle="yes">P</italic>-trend</bold><xref rid="tb2fn2" ref-type="table-fn">b</xref></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&lt;0.0001</td><td valign="top" colspan="1" rowspan="1">0.02</td><td valign="top" colspan="1" rowspan="1">&lt; 0.01</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Continuous (per 5% energy increase)</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">1.12 (1.08, 1.17)</td><td valign="top" colspan="1" rowspan="1">1.09 (1.03, 1.15)</td><td valign="top" colspan="1" rowspan="1">1.10 (1.04, 1.16)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Free sugar intakes (% energy intake)</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Quartile</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&lt;7.87 %</td><td valign="top" colspan="1" rowspan="1">280 (0.71)</td><td valign="top" colspan="1" rowspan="1">Reference</td><td valign="top" colspan="1" rowspan="1">Reference</td><td valign="top" colspan="1" rowspan="1">Reference</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#8805;7.87 % and &lt;11.08 %</td><td valign="top" colspan="1" rowspan="1">279 (0.70)</td><td valign="top" colspan="1" rowspan="1">1.00 (0.84. 1.18)</td><td valign="top" colspan="1" rowspan="1">1.03 (0.87, 1.22)</td><td valign="top" colspan="1" rowspan="1">1.06 (0.90, 1.26)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#8805;11.08 % and &lt;14.78 %</td><td valign="top" colspan="1" rowspan="1">294 (0.74)</td><td valign="top" colspan="1" rowspan="1">1.05 (0.89, 1.24)</td><td valign="top" colspan="1" rowspan="1">1.07 (0.90, 1.26)</td><td valign="top" colspan="1" rowspan="1">1.11 (0.94, 1.32)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#8805;14.78 %</td><td valign="top" colspan="1" rowspan="1">366 (0.92)</td><td valign="top" colspan="1" rowspan="1">1.31 (1.12, 1.53)</td><td valign="top" colspan="1" rowspan="1">1.36 (1.14, 1.62)</td><td valign="top" colspan="1" rowspan="1">1.43 (1.20, 1.70)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold><italic toggle="yes">P</italic>-trend</bold><xref rid="tb2fn2" ref-type="table-fn">b</xref></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&lt;0.001</td><td valign="top" colspan="1" rowspan="1">&lt;0.001</td><td valign="top" colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Continuous (per 5 % energy increase)</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">1.11 (1.06, 1.16)</td><td valign="top" colspan="1" rowspan="1">1.15 (1.09, 1.21)</td><td valign="top" colspan="1" rowspan="1">1.16 (1.10, 1.23)</td></tr></tbody></table><table-wrap-foot><fn><p><italic toggle="yes">Abbreviations:</italic> CIs, confidence intervals; HRs, hazard ratios.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb2fn1"><label>a</label><p id="notep0004">HRs and 95 % CIs were calculated by the cause-specific competing risk model.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb2fn2"><label>b</label><p id="notep0005">Test for trend based on variables containing the median value for each quartile.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb2fn3"><label>c</label><p id="notep0006">Model 1 was the crude model.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb2fn4"><label>d</label><p id="notep0007">Model 2 was adjusted for age at recruitment, sex, race, education level, average total household income before tax, Townsend Deprivation Index, physical activity, alcohol consumption status, smoking status, intakes of protein and fat (percentage of energy intake), and total energy intake.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb2fn5"><label>e</label><p id="notep0008">Model 3 was adjusted for Model 2 + history of hypertension, diabetes, and cardiovascular diseases, and family history of dementia (free sugar intake or non-free sugar intake were mutually adjusted for each other).</p></fn></table-wrap-foot></table-wrap></p><p id="para0024">No significant heterogeneity across the majority of prespecified subgroups for the association of sugar intake with dementia was observed (<italic toggle="yes">P</italic> for interactions &gt; 0.05 for most stratification factors) <bold>(Supplementary Table 9)</bold>. However, a significant interaction between free sugar intake and age (<italic toggle="yes">P</italic> for interaction = 0.04) was noted. The positive association of dementia risk with free sugar intake was slightly more pronounced among younger participants (&#8804; 60 years).</p></sec><sec id="sec0012"><label>3.3</label><title>Association between dietary sugar intake, genetic susceptibility, and incident dementia</title><p id="para0025">As shown in <bold>Supplementary Fig 2</bold>, there were no significant interaction effects between sugar intake and the TyG-PRS (both <italic toggle="yes">P</italic> for interaction &gt; 0.05) on dementia risk. In the joint association analysis, the highest hazard of dementia was observed among participants with high TyG-PRS and in the highest quartile of sugar intake, with HRs (95% CIs) of 1.45 (1.13, 1.86) for non-free sugar and 1.92 (1.50, 2.44) for free sugar intake <bold>(Supplementary Fig 3)</bold>.</p><p id="para0026">Then, we investigated the modifying effect of gut microbiota on the association of dementia risk with sugar intake. As outlined in <bold>Supplementary Table 10</bold>, increased risk of dementia was positively associated with <italic toggle="yes">Oscillospira</italic> PRS, but negatively linked to PRS of <italic toggle="yes">Ruminococcaceae UCG-014</italic> with adjustment of FDR. Moreover, as listed in <xref rid="fig0002" ref-type="fig">Fig 2</xref>, a significant interaction effect was only observed between free sugar intake and PRS of <italic toggle="yes">Oscillospira</italic> (<italic toggle="yes">P</italic> for interaction = 0.03); in other words, individuals with high PRS of <italic toggle="yes">Oscillospira</italic> were more likely to develop dementia with HRs (95% CIs) of 1.59 (1.25, 2.02). On the contrary, there were significant interaction effects of <italic toggle="yes">Ruminococcaceae UCG-014</italic>-PRS on the associations between non-free sugar and free sugar intake and dementia risk (both <italic toggle="yes">P</italic> for interaction &lt; 0.05). Those with high PRS of <italic toggle="yes">Ruminococcaceae UCG-014</italic> showed an increased risk of dementia (HRs, 95% CIs: 1.68, 1.25&#8211;2.25 for non-free sugar intake; 1.61, 1.23&#8211;2.09 for free sugar intake). In the joint association analysis, the highest hazard of dementia was observed among participants with high PRS of <italic toggle="yes">Oscillospira</italic> and in the highest quartile of sugar intake, with HRs (95% CIs) of 1.34 (1.04, 1.72) for non-free sugar and 1.73 (1.37, 2.19) for free sugar intake (<xref rid="fig0003" ref-type="fig">Fig 3</xref><bold>A</bold>). However, for <italic toggle="yes">Ruminococcaceae UCG-014</italic>, the highest hazard of dementia was observed among participants with low PRS of <italic toggle="yes">Ruminococcaceae UCG-014</italic> and in the highest quartile of sugar intake, with HRs (95% CIs) of 1.80 (1.38, 2.36) for non-free sugar and 1.64 (1.29, 2.09) for free sugar intake (<xref rid="fig0003" ref-type="fig">Fig 3</xref><bold>B</bold>). After additionally adjusting for the total relative abundance of gut microbial taxa, the results were still consistent with the main results (data not shown).<fig id="fig0002" position="float" orientation="portrait"><label>Fig 2</label><caption><p>Associations of sugar intake with incident dementia according to PRS of gut microbial (<italic toggle="yes">n</italic> = 158,408).</p><p><italic toggle="yes">Abbreviations:</italic> CIs, confidence intervals; HRs, hazard ratios; PRS, polygenic risk score.</p><p>HRs and 95 % CIs were calculated by the cause-specific competing risk model with adjustments for age at recruitment, sex, ethnicity, education level, average total household income before tax, Townsend Deprivation Index, physical activity, alcohol intake status, smoking status, intakes of protein and fat (percentage of energy intake), total energy intake, history of hypertension, diabetes, and cardiovascular diseases, and family history of dementia.</p></caption><alt-text id="alt0002">Fig 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig><fig id="fig0003" position="float" orientation="portrait"><label>Fig 3</label><caption><p>Joint associations of sugar intake and <italic toggle="yes">Oscillospira-PRS</italic> (A) or <italic toggle="yes">Ruminococcaceae UCG-014</italic> -PRS (B) with incident dementia (<italic toggle="yes">n</italic> = 158,408).</p><p><italic toggle="yes">Abbreviations:</italic> CIs, confidence intervals; HRs, hazard ratios; PRS, polygenic risk score.</p><p>HRs and 95% CIs were calculated by the cause-specific competing risk model with adjustments for age at recruitment, sex, ethnicity, education level, average total household income before tax, Townsend Deprivation Index, physical activity, alcohol intake status, smoking status, intakes of protein and fat (percentage of energy intake), total energy intake, history of hypertension, diabetes, and cardiovascular diseases, and family history of dementia.</p></caption><alt-text id="alt0003">Fig 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0003" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="para0027">The positive association between disease susceptibility and dementia risk was confirmed in <bold>Supplementary Table 11.</bold> Compared with participants with low dementia-PRS (&lt; median value), those with high dementia-PRS (&#8805; median value) had an adjusted HR (95% CI) of 2.30 (2.03, 2.60) for dementia. The associations of sugar intake with incident dementia according to dementia-PRS are presented in <bold>Supplementary Fig 4</bold>. There was a significant interaction effect of dementia-PRS on the associations between non-free sugar intake and dementia risk (<italic toggle="yes">P</italic> for interaction = 0.04). The positive association between non-free sugar intake and dementia risk was observed only in the high dementia-PRS subgroup (<italic toggle="yes">P</italic> for trend &lt; 0.01), but not in the low dementia-PRS subgroup (<italic toggle="yes">P</italic> for trend = 0.13). However, intake of free sugar was positively associated with risk of dementia in both high and low dementia-PRS subgroups, with no significant interaction of dementia-PRS detected (<italic toggle="yes">P</italic> for interaction = 0.37). In the joint association analysis, the highest hazard of dementia was observed among participants with high dementia-PRS and in the highest quartile of sugar intake, with HRs (95% CIs) of 2.59 (1.99, 2.38) for non-free sugar and 3.09 (2.38, 4.00) for free sugar intake <bold>(Supplementary Fig 5)</bold>.</p></sec></sec><sec id="sec0013"><label>4</label><title>Discussion</title><p id="para0028">In the current cohort study of 158,408 participants from the UK Biobank, we found that there is a synergistic effect of dietary sugar intake and genetic susceptibility on incident dementia. This comprehensive analysis incorporated three dimensions of genetic susceptibility: sugar metabolism, gut microbiota (represented by <italic toggle="yes">Ruminococcaceae UCG-014</italic> and <italic toggle="yes">Oscillospira</italic> PRS), and disease susceptibility. Intriguingly, we provided the first evidence that individuals with high TyG-PRS, as well as with low PRS of <italic toggle="yes">Ruminococcaceae UCG-014</italic> or high PRS of <italic toggle="yes">Oscillospira</italic>, demonstrate substantially heightened dementia risk when consuming high-sugar diets.</p><p id="para0029">Sugar intake, particularly free sugar intake, has been identified as a risk factor for the onset and progression of dementia. Evidence from the United States Women&#8217;s Health Initiative-Dietary Modification Trial and the Rush Memory and Aging Project both reported a significant association between excessive total sugar intake and dementia [<xref rid="bib0034" ref-type="bibr">34</xref>,<xref rid="bib0035" ref-type="bibr">35</xref>]. Specifically, an increase of 10 <italic toggle="yes">g</italic> per day in total sugar intake was associated with a 1.3 %&#8211;1.4 % elevated risk of AD [<xref rid="bib0035" ref-type="bibr">35</xref>]. Studies from the United States community-based Framingham Heart Study have further supported the closely association between dementia risk and higher intake of sugar in beverages (HR: 2.80; 95% CI: 2.24, 3.50) [<xref rid="bib0036" ref-type="bibr">36</xref>] and artificially sweetened soft drinks (HR: 2.20; 95% CI: 1.09, 4.45) [<xref rid="bib0008" ref-type="bibr">8</xref>]. Another study based on 186,622 UK Biobank participants revealed a &#8220;J-shaped&#8221; association between increased sugar intake and dementia risk, with the HR-nadir observed at 9 % total energy [<xref rid="bib0010" ref-type="bibr">10</xref>]. However, to the best of our knowledge, only one study from the UK reported a linear-shaped association between non-free sugar intake and dementia risk [<xref rid="bib0010" ref-type="bibr">10</xref>], consistent with our findings. Subgroup analyses confirmed these associations remained robust after adjustment for demographic and lifestyle covariates, though the free sugar-dementia link exhibited particular prominence in younger adults (&#8804; 60 years), likely reflecting their greater consumption of processed sweets and beverages. Contrary to prevailing assumptions about non-free sugars' protective effects against cardiovascular disease [<xref rid="bib0011" ref-type="bibr">11</xref>,<xref rid="bib0037" ref-type="bibr">37</xref>], our data underscore their underappreciated neurocognitive risks.</p><p id="para0030">The pathophysiological mechanisms underlying sugar-induced neurodegeneration remain incompletely characterized but appear multifaceted. Free sugars include all monosaccharides and disaccharides added to foods by the manufacturer, cook, or consumer, plus sugars naturally present in honey, syrups, and unsweetened fruit juices. Non-free sugars are made up of all sugars excluded from the definition of free sugars, mostly naturally occurring in fruit, vegetables, and dairy products, which are enclosed within plant cell walls or the food matrix, requiring chewing or digestion in the intestines to be gradually released [<xref rid="bib0038" ref-type="bibr">38</xref>]. Because free sugars are not encapsulated by the cell walls, they can quickly enter the bloodstream and exert effects. On the one hand, studies have demonstrated that the brain, as the most energy-hungry organ, relies heavily on a quarter-pound daily supply of glucose to produce the ATP necessary for its function [<xref rid="bib0039" ref-type="bibr">39</xref>]. Animal models of dementia have revealed that excessive intake of fructose, present in refined sugars such as sucrose and high-fructose corn syrup, may contribute to dementia by increasing central neuronal insulin resistance and amyloid deposition, a factor linked to AD [<xref rid="bib0040" ref-type="bibr">40</xref>,<xref rid="bib0041" ref-type="bibr">41</xref>]. On the other hand, dementia, including AD, is essentially an age-related disease where excessive sugar intake may accelerate cellular aging through inflammatory responses and oxidative stresses [<xref rid="bib0042" ref-type="bibr">42</xref>]. Despite the absence of a chemical difference between non-free sugars and free sugars, further studies are needed to elucidate the underlying mechanisms.</p><p id="para0031">In addition, our findings suggested that genetic susceptibility is also an important factor influencing the effect of sugar intake on dementia. In the present study, we first explored it from three related aspects: sugar metabolism, gut microbiota, and disease susceptibility. The TyG Index is an economical and effective diagnostic tool for several medical conditions. It not only reflects underlying insulin resistance but is also considered a key factor in several metabolic disorders (including dementia) [<xref rid="bib0043" ref-type="bibr">43</xref>]. Published meta-analyses have demonstrated that the TyG Index is associated with an increased risk of dementia [<xref rid="bib0043" ref-type="bibr">43</xref>,<xref rid="bib0044" ref-type="bibr">44</xref>]. Consistently, we found that individuals who consumed more sugar in their diet and had a high PRS of TyG are more likely to develop dementia.</p><p id="para0032">Then, we explored the interaction effect of dementia-PRS on such associations. There was no significant interaction between dementia-PRS and free sugar, but an interacting effect of dementia-PRS was observed in the association between non-free sugar intake and dementia risk. Specifically, individuals with high dementia-PRS showed an increased dementia risk with non-free sugar intake. Moreover, the joint effect analysis revealed that the highest hazard of dementia was observed in individuals with high AD-PRS and the highest intake of free sugar or non-free sugar intake. These results strongly suggest the importance of controlling the quantity of free sugar and non-free sugar intake, especially for individuals with a high hereditary risk of dementia.</p><p id="para0033">More importantly, mounting evidence underscores the pivotal role of dietary patterns in modulating gut microbial ecology, with profound implications for disease pathogenesis [<xref rid="bib0045" ref-type="bibr">45</xref>]. At the gut level, sugar and elevated blood sugar strongly influence the gut microbiota and gut barrier by increasing permeability and susceptibility to infection [<xref rid="bib0046" ref-type="bibr">46</xref>]. Evidence from both human and animal studies has revealed that the intake of non-caloric artificial sweeteners (a type of free sugar) enhances the risk of glucose intolerance by influencing the composition and function of the microbiota [<xref rid="bib0047" ref-type="bibr">47</xref>]. Another animal study reported that the intake of sugary drinks during adolescence leads to alterations in the gut microbiota, including an elevated abundance of two species in the genus <italic toggle="yes">Parabacteroides</italic> (<italic toggle="yes">P. distasonis</italic> and <italic toggle="yes">P. johnsonii</italic>), which are inversely associated with hippocampal function [<xref rid="bib0048" ref-type="bibr">48</xref>]. However, according to 119 kinds of gut microbial-PRS, we found that different gut microbial show inconsistent effects on dementia. The <italic toggle="yes">Oscillospira</italic> emerged as a significant risk factor, whereas <italic toggle="yes">Ruminococcaceae UCG-014</italic> demonstrated protective effects. Both microbial PRS scores exhibited interactive effects with dietary sugar consumption on dementia risk. The paradoxical nature of <italic toggle="yes">Oscillospira</italic> warrants particular attention - while recognized as a butyrate producer and potential next-generation probiotic candidate [<xref rid="bib0049" ref-type="bibr">49</xref>], this bacterium has been implicated in the pathogenesis of type 2 diabetes [<xref rid="bib0050" ref-type="bibr">50</xref>], Parkinson&#8217;s disease [<xref rid="bib0051" ref-type="bibr">51</xref>], and dementia [<xref rid="bib0052" ref-type="bibr">52</xref>]. Supporting our findings, animal models indicate that <italic toggle="yes">Oscillospira</italic> enrichment predicts activation of the farnesoid X receptor pathway, a known dementia risk factor [<xref rid="bib0052" ref-type="bibr">52</xref>]. In contrast, although <italic toggle="yes">Ruminococcaceae UCG-014</italic>&#8242;s anti-obesity properties are well-documented [<xref rid="bib0053" ref-type="bibr">53</xref>], its neuroprotective potential remains unexplored. We hypothesize that this bacterium may confer cognitive benefits through enhanced dietary fiber fermentation, yielding butyrate and other neuroprotective short-chain fatty acids that mitigate <italic toggle="yes">&#946;</italic>-amyloid accumulation and neuroinflammation [<xref rid="bib0054" ref-type="bibr">[54]</xref>, <xref rid="bib0055" ref-type="bibr">[55]</xref>, <xref rid="bib0056" ref-type="bibr">[56]</xref>]. Interestingly, it should be noted that <italic toggle="yes">Ruminococcaceae UCG-014</italic> and <italic toggle="yes">Oscillospira</italic> belong to the same genus <italic toggle="yes">Firmicute</italic> - <italic toggle="yes">Clostridia</italic> &#8211; <italic toggle="yes">Ruminococcaceae</italic>, which makes the two exhibit some similar physiological functions. Although previous evidence has shown that high sugar intake could reduce the abundance of <italic toggle="yes">Ruminococcaceae UCG-014</italic> and <italic toggle="yes">Oscillospira</italic> in the intestine, thereby inhibiting butyric acid production and affecting cognitive function [<xref rid="bib0057" ref-type="bibr">57</xref>,<xref rid="bib0058" ref-type="bibr">58</xref>]. However, the differential responses of <italic toggle="yes">Ruminococcaceae UCG-014</italic> and <italic toggle="yes">Oscillospira</italic> on the association between dietary sugar intake and dementia demonstrated that beyond dietary modulation of microbial abundance, the host's genetically determined microbial functional capacity represents an independent and critical determinant of neurological outcomes. This finding fundamentally advances our understanding of diet-microbiome-brain interactions by emphasizing the need to consider both environmental exposures and host genetic factors in predictive models of neurodegeneration.</p><p id="para0034">To the best of our knowledge, this study represents the first exploration of the association between non-free sugar intake, genetic factors, and incident dementia within a large and representative cohort. Comprehensive subgroup and sensitivity analyses further confirmed the robustness of the findings. Besides, based on previous studies, limiting the intake of free sugars is good for health [<xref rid="bib0059" ref-type="bibr">59</xref>], while the harmful effects of non-free sugar intake on health are not clear. Our findings, therefore, have important public health value, offering new insights to prompt a re-evaluation of the potential role of non-free sugar intake. Last but not least, our findings indicate that the influence of genetic susceptibility on the association between dietary sugar intake and dementia may help identify the high-risk population and investigate the potential therapeutic target for mitigating the onset of dementia.</p><p id="para0035">Several potential limitations should be acknowledged. First, reliance on self-reported data regarding dietary patterns may introduce information bias. To address this, we mitigated the issue by utilizing the average dietary assessment of each individual over a 24-hour period and further excluding implausible intake. Second, due to the inherent limitations of an observational study design, residual confounders could not be eliminated, although we did adjust for several potential confounders. Third, this study primarily focused on the impact of the types of sugar intake on dementia risk, and it remains unclear whether there are distinctions between non-free and free sugars in specific forms, such as solid and liquid. Therefore, further research is still warranted. Fourth, the UK Biobank consists largely of relatively healthy, affluent individuals who are predominantly white. As a result, our findings may not be generalizable to the entire population. Fifth, given the fact that feces are difficult to preserve and collect, the UK Biobank does not include fecal samples in the research design; the PRS we calculated could not represent the real profile of gut microbiota. Finally, our findings provide clues for slowing the development of dementia by improving the gut microbiota through diet, but given that the effects of various foods on the gut microbiota are not fully understood, we cannot make exact food recommendations.</p></sec><sec id="sec0014"><label>5</label><title>Conclusions</title><p id="para0036">In summary, both non-free sugar and free sugar intake are risk factors for the incidence of dementia, suggesting that intake of non-free sugars should also be limited. What&#8217;s more, genetic susceptibility may play a pivotal role in the association between dementia risk and dietary sugar intake.<def-list><title>Abbreviations</title><def-item><term id="dt0001">AD</term><def><p id="para0037">Alzheimer&#8217;s disease</p></def></def-item><def-item><term id="dt0002">BMI</term><def><p id="para0038">Body mass index</p></def></def-item><def-item><term id="dt0003">CI</term><def><p id="para0039">confidence interval</p></def></def-item><def-item><term id="dt0004">CVD</term><def><p id="para0040">cardiovascular disease</p></def></def-item><def-item><term id="dt0005">HR</term><def><p id="para0041">hazard ratio</p></def></def-item><def-item><term id="dt0006">ICD</term><def><p id="para0042">International Classification of Diseases</p></def></def-item><def-item><term id="dt0007">MET</term><def><p id="para0043">metabolic equivalent</p></def></def-item><def-item><term id="dt0008">PRS</term><def><p id="para0044">polygenic risk score</p></def></def-item><def-item><term id="dt0009">TDI</term><def><p id="para0045">Townsend Deprivation Index</p></def></def-item></def-list></p></sec><sec id="sec0015"><title>Ethics approval and consent to participant</title><p id="para0046">The study protocol of the UK Biobank has been approved by the North West Multi-Center Research&#8217;s Ethics Committee (REC reference: NW/0382) and conducted in accordance with the principles of the Declaration of Helsinki. All individuals provided written informed consent prior to recruitment.</p></sec><sec id="sec0016"><title>Consent for publication</title><p id="para0047">Not applicable</p></sec><sec sec-type="data-availability" id="sec0017"><title>Availability of data and materials</title><p id="para0048">Data are available in a public, open access repository. This research has been conducted using the UK Biobank Resource under Application Number 63,454. The UK Biobank data are available on application to the UK Biobank (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ukbiobank.ac.uk/" id="interref0001">www.ukbiobank.ac.uk/</ext-link>).</p></sec><sec id="sec0018"><title>Funding</title><p id="para0049">This work was supported by the Young Elite Scientists Sponsorship Program by China Association for Science and Technology [grant number 2020QNRC001 to Yang Xia and Yu An, 2024-2026QNRC001 to Xiaopeng Zhang], the LiaoNing Revitalization Talents Program [grant number XLYC2203168 to Yang Xia], the Beijing Hospitals Authority Youth Programme [grant number QML20230301 to Yu An], and Tianjin Natural Science Foundation [grant number 23JCQNJC01830 to Limin Cao). The funders had no role in the conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.</p></sec><sec sec-type="supplementary-material" id="sec0019"><title>Supplementary Material</title><p id="para0050"><bold>Supplementary Table 1.</bold> Characteristics of the SNPs associated with genus-level TyG.</p><p id="para0051"><bold>Supplementary Table 2.</bold> Characteristics of the SNPs associated with genus-level gut microbes.</p><p id="para0052"><bold>Supplementary Fig 1.</bold> Restricted cubic splines of the associations of dementia risk with non-free sugar (A) and sugar (B) intake.</p><p id="para0053"><bold>Supplementary Table 3.</bold> Sensitivity analysis of the associations between non-free and free sugar intake and incident dementia with including BMI as a covariate (<italic toggle="yes">n</italic> = 158,408) <sup>a</sup></p><p id="para0054"><bold>Supplementary Table 4.</bold> Associations of non-free and free sugar intake with incident dementia by excluding participants with less than two years of follow-up (<italic toggle="yes">n</italic> = 157,541) <sup>a</sup>.</p><p id="para0055"><bold>Supplementary Table 5.</bold> Associations of non-free and free sugar intake with incident dementia by excluding participants with less than two dietary assessments (<italic toggle="yes">n</italic> = 97,821) <sup>a</sup>.</p><p id="para0056"><bold>Supplementary Table 6.</bold> Associations of absolute non-free and free sugar intake with incident dementia (<italic toggle="yes">n</italic> = 158,408) <sup>a</sup>.</p><p id="para0057"><bold>Supplementary Table 7.</bold> Associations of non-free and free sugar to carbohydrates intake ratio with incident dementia (<italic toggle="yes">n</italic> = 158,408) <sup>a</sup>.</p><p id="para0058"><bold>Supplementary Table 8.</bold> Associations of non-free and free sugar intake with incident dementia using the sub-distribution competing risk model (<italic toggle="yes">n</italic> = 158,408) <sup>a</sup>.</p><p id="para0059"><bold>Supplementary Table 9.</bold> Subgroup analyses for the associations of non-free sugar and free sugars intakes ( % energy intake) with incident dementia (<italic toggle="yes">n</italic> = 158,408) <sup>a</sup>.</p><p id="para0060"><bold>Supplementary Fig 2.</bold> Associations of sugar intake with incident dementia according to the PRS of TyG (<italic toggle="yes">n</italic> = 158,408).</p><p id="para0061"><bold>Supplementary Fig 3.</bold> Joint associations of sugar intake and the PRS of TyG with incident dementia (<italic toggle="yes">n</italic> = 158,408).</p><p id="para0062"><bold>Supplementary Table 10.</bold> Associations between genetic risk of gut microbial and incident dementia (<italic toggle="yes">n</italic> = 158,408)</p><p id="para0063"><bold>Supplementary Table 11.</bold> Associations between genetic risk of dementia and incident dementia (<italic toggle="yes">n</italic> = 158,408).</p><p id="para0064"><bold>Supplementary Fig 4.</bold> Associations of sugar intake with incident dementia according to genetic risk (<italic toggle="yes">n</italic> = 158,408).</p><p id="para0065"><bold>Supplementary Fig 5.</bold> Joint associations of sugar intake and genetic risk with incident dementia (<italic toggle="yes">n</italic> = 158,408).</p></sec><sec id="sec0019a"><title>CRediT authorship contribution statement</title><p id="para0065a"><bold>Yu An:</bold> Project administration, Investigation, Funding acquisition. <bold>Limin Cao:</bold> Writing &#8211; original draft, Software, Funding acquisition, Conceptualization. <bold>Gang Zheng:</bold> Resources, Methodology, Formal analysis. <bold>Yashu Liu:</bold> Visualization, Methodology, Investigation. <bold>Honghao Yang:</bold> Methodology, Investigation. <bold>Liangkai Chen:</bold> Resources, Data curation. <bold>Yuhong Zhao:</bold> Resources, Conceptualization. <bold>Xiaopeng Zhang:</bold> Writing &#8211; review &amp; editing, Funding acquisition. <bold>Yang Xia:</bold> Writing &#8211; review &amp; editing, Validation, Funding acquisition, Data curation, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0067">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="book" id="sbref0001"><part-title>Dementia</part-title><year>2023</year><publisher-name>World Health Organizaiton</publisher-name><comment>[Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/dementia" id="interref0003">https://www.who.int/news-room/fact-sheets/detail/dementia</ext-link></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet Public Health</source><volume>7</volume><issue>2</issue><year>2022</year><fpage>e105</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.1016/s2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="book" id="sbref0003"><person-group person-group-type="author"><collab>WHO</collab></person-group><part-title>Global status report on the public health response to dementia</part-title><year>2021</year><publisher-name>WHO</publisher-name><comment>[Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cdn.who.int/media/docs/default-source/mental-health/dementia/who_dementia-infographic_2021-09-23_dv.pdf?sfvrsn=d9ecdc14_3" id="interref0004">https://cdn.who.int/media/docs/default-source/mental-health/dementia/who_dementia-infographic_2021-09-23_dv.pdf?sfvrsn=d9ecdc14_3</ext-link></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reyderman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Froelich</surname><given-names>L.</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dhadda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Irizarry</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Iwatsubo</surname><given-names>T.</given-names></name></person-group><article-title>Lecanemab in early Alzheimer's disease</article-title><source>New Engl J Med</source><volume>388</volume><issue>1</issue><year>2023</year><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2212948</pub-id><pub-id pub-id-type="pmid">36449413</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Jennings</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cunnane</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Minihane</surname><given-names>A.M.</given-names></name></person-group><article-title>Can nutrition support healthy cognitive ageing and reduce dementia risk?</article-title><source>BMJ</source><volume>369</volume><year>2020</year><fpage>m2269</fpage><pub-id pub-id-type="doi">10.1136/bmj.m2269</pub-id><pub-id pub-id-type="pmid">32591407</pub-id><pub-id pub-id-type="pmcid">PMC7318880</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Arnone</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chabot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heba</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>K&#246;kten</surname><given-names>T.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hansmannel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dreumont</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ananthakrishnan</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Quilliot</surname><given-names>D.</given-names></name><name name-style="western"><surname>Peyrin-Biroulet</surname><given-names>L.</given-names></name></person-group><article-title>Sugars and gastrointestinal health</article-title><source>Clin Gastroenterol Hepatol</source><volume>20</volume><issue>9</issue><year>2022</year><fpage>1912</fpage><lpage>1924.e1917</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2021.12.011</pub-id><pub-id pub-id-type="pmid">34902573</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>J.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lodge</surname><given-names>J.K.</given-names></name></person-group><article-title>Associations between free sugar intake and markers of health in the UK population: an analysis of the National Diet and Nutrition Survey rolling programme</article-title><source>Br J Nutr</source><volume>128</volume><issue>2</issue><year>2022</year><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1017/s0007114521002981</pub-id><pub-id pub-id-type="pmid">34369329</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Pase</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Himali</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Aparicio</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Satizabal</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Seshadri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jacques</surname><given-names>P.F.</given-names></name></person-group><article-title>Sugar- and artificially sweetened beverages and the risks of incident stroke and dementia: a prospective cohort study</article-title><source>Stroke</source><volume>48</volume><issue>5</issue><year>2017</year><fpage>1139</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1161/strokeaha.116.016027</pub-id><pub-id pub-id-type="pmid">28428346</pub-id><pub-id pub-id-type="pmcid">PMC5405737</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Pase</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Himali</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Jacques</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>DeCarli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Satizabal</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Aparicio</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Seshadri</surname><given-names>S.</given-names></name></person-group><article-title>Sugary beverage intake and preclinical Alzheimer's disease in the community</article-title><source>Alzheimer's Dement</source><volume>13</volume><issue>9</issue><year>2017</year><fpage>955</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2017.01.024</pub-id><pub-id pub-id-type="pmid">28274718</pub-id><pub-id pub-id-type="pmcid">PMC6820519</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Schaefer</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eichner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fasshauer</surname><given-names>M.</given-names></name></person-group><article-title>Association of sugar intake from different sources with incident dementia in the prospective cohort of UK Biobank participants</article-title><source>Nutr J</source><volume>22</volume><issue>1</issue><year>2023</year><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s12937-023-00871-8</pub-id><pub-id pub-id-type="pmid">37661278</pub-id><pub-id pub-id-type="pmcid">PMC10476309</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>T.Y.N.</given-names></name><name name-style="western"><surname>Watling</surname><given-names>C.Z.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piernas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Papier</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Key</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Perez-Cornago</surname><given-names>A.</given-names></name></person-group><article-title>Associations between types and sources of dietary carbohydrates and cardiovascular disease risk: a prospective cohort study of UK Biobank participants</article-title><source>BMC Med</source><volume>21</volume><issue>1</issue><year>2023</year><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s12916-022-02712-7</pub-id><pub-id pub-id-type="pmid">36782209</pub-id><pub-id pub-id-type="pmcid">PMC9926727</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Orliacq</surname><given-names>J.</given-names></name><name name-style="western"><surname>P&#233;rez-Cornago</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parry</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Koutoukidis</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>J.L.</given-names></name></person-group><article-title>Associations between types and sources of dietary carbohydrates and liver fat: a UK Biobank study</article-title><source>BMC Med</source><volume>21</volume><issue>1</issue><year>2023</year><fpage>444</fpage><pub-id pub-id-type="doi">10.1186/s12916-023-03135-8</pub-id><pub-id pub-id-type="pmid">37968623</pub-id><pub-id pub-id-type="pmcid">PMC10652437</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hyun</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Mook-Jung</surname><given-names>I.</given-names></name></person-group><article-title>Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model</article-title><source>Gut</source><volume>69</volume><issue>2</issue><year>2020</year><fpage>283</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-317431</pub-id><pub-id pub-id-type="pmid">31471351</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Alkasir</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name></person-group><article-title>Human gut microbiota: the links with dementia development</article-title><source>Protein Cell</source><volume>8</volume><issue>2</issue><year>2017</year><fpage>90</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1007/s13238-016-0338-6</pub-id><pub-id pub-id-type="pmid">27866330</pub-id><pub-id pub-id-type="pmcid">PMC5291774</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.L.</given-names></name></person-group><article-title>Gut microbiota and dysbiosis in Alzheimer's disease: implications for pathogenesis and treatment</article-title><source>Mol Neurobiol</source><volume>57</volume><issue>12</issue><year>2020</year><fpage>5026</fpage><lpage>5043</lpage><pub-id pub-id-type="doi">10.1007/s12035-020-02073-3</pub-id><pub-id pub-id-type="pmid">32829453</pub-id><pub-id pub-id-type="pmcid">PMC7541367</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Varesi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pierella</surname><given-names>E.</given-names></name><name name-style="western"><surname>Romeo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Piccini</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bj&#248;rklund</surname><given-names>G.</given-names></name><name name-style="western"><surname>Oppong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ricevuti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chirumbolo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pascale</surname><given-names>A.</given-names></name></person-group><article-title>The potential role of gut microbiota in Alzheimer's disease: from diagnosis to treatment</article-title><source>Nutrients</source><volume>14</volume><issue>3</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/nu14030668</pub-id><pub-id pub-id-type="pmcid">PMC8840394</pub-id><pub-id pub-id-type="pmid">35277027</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Hebert</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Weuve</surname><given-names>J.</given-names></name><name name-style="western"><surname>Scherr</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.A.</given-names></name></person-group><article-title>Alzheimer disease in the United States (2010-2050) estimated using the 2010 census</article-title><source>Neurology</source><volume>80</volume><issue>19</issue><year>2013</year><fpage>1778</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31828726f5</pub-id><pub-id pub-id-type="pmid">23390181</pub-id><pub-id pub-id-type="pmcid">PMC3719424</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Anttila</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bulik-Sullivan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Finucane</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Bras</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Escott-Price</surname><given-names>V.</given-names></name><name name-style="western"><surname>Falcone</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Gormley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patsopoulos</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Ripke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Turley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grenier-Boley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chouraki</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kamatani</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Berr</surname><given-names>C.</given-names></name><name name-style="western"><surname>Letenneur</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hannequin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Amouyel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deleuze</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Duron</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vardarajan</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Reitz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goate</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Huentelman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kamboh</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Rogaeva</surname><given-names>E.</given-names></name><name name-style="western"><surname>St George-Hyslop</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hakonarson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kukull</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Farrer</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Demirci</surname><given-names>F.Y.</given-names></name><name name-style="western"><surname>Head</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hulette</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Jicha</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Kauwe</surname><given-names>J.S.K.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Leverenz</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Levey</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Pankratz</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Sonnen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Van Deerlin</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Van Eldik</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Harold</surname><given-names>D.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rubinsztein</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Bayer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsolaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Proitsi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Owen</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Mead</surname><given-names>S.</given-names></name><name name-style="western"><surname>Passmore</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>K.</given-names></name><name name-style="western"><surname>N&#246;then</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Rossor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lupton</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kornhuber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>B.</given-names></name><name name-style="western"><surname>McQuillin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Chalabi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bis</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seshadri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>K.</given-names></name><name name-style="western"><surname>van der Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>De Jager</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Geschwind</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Riemenschneider</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riedel-Heller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rotter</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Ransmayr</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Cruchaga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alegret</surname><given-names>M.</given-names></name><name name-style="western"><surname>Winsvold</surname><given-names>B.</given-names></name><name name-style="western"><surname>Palta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Farh</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Cuenca-Leon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Furlotte</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kurth</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ligthart</surname><given-names>L.</given-names></name><name name-style="western"><surname>Terwindt</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Freilinger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ran</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Borck</surname><given-names>G.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>H.H.H.</given-names></name><name name-style="western"><surname>Lehtim&#228;ki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wedenoja</surname><given-names>J.</given-names></name><name name-style="western"><surname>Buring</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Sch&#252;rks</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hrafnsdottir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hottenga</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Penninx</surname><given-names>B.</given-names></name><name name-style="western"><surname>Artto</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kaunisto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Veps&#228;l&#228;inen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Kurki</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>H&#228;m&#228;l&#228;inen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sandor</surname><given-names>C.</given-names></name><name name-style="western"><surname>Webber</surname><given-names>C.</given-names></name><name name-style="western"><surname>Muller-Myhsok</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salomaa</surname><given-names>V.</given-names></name><name name-style="western"><surname>Loehrer</surname><given-names>E.</given-names></name><name name-style="western"><surname>G&#246;bel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Macaya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pozo-Rosich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Werge</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kaprio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Metspalu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kubisch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Belin</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>van den Maagdenberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zwart</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Boomsma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Olesen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chasman</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Nyholt</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Avbersek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baum</surname><given-names>L.</given-names></name><name name-style="western"><surname>Berkovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bradfield</surname><given-names>J.</given-names></name><name name-style="western"><surname>Buono</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Catarino</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Cossette</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Jonghe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Depondt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dlugos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ferraro</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>French</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hjalgrim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jamnadas-Khoda</surname><given-names>J.</given-names></name><name name-style="western"><surname>K&#228;lvi&#228;inen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kunz</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Lerche</surname><given-names>H.</given-names></name><name name-style="western"><surname>Leu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lindhout</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lowenstein</surname><given-names>D.</given-names></name><name name-style="western"><surname>McCormack</surname><given-names>M.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Molloy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>K.</given-names></name><name name-style="western"><surname>Privitera</surname><given-names>M.</given-names></name><name name-style="western"><surname>Radtke</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ruppert</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schachter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schankin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scheffer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schoch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sisodiya</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>M.</given-names></name><name name-style="western"><surname>Striano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Surges</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Visscher</surname><given-names>F.</given-names></name><name name-style="western"><surname>Whelan</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Zara</surname><given-names>F.</given-names></name><name name-style="western"><surname>Heinzen</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Marson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>F.</given-names></name><name name-style="western"><surname>Stroink</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zimprich</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gasser</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heutink</surname><given-names>P.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ryten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Pulit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bevan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holliday</surname><given-names>E.</given-names></name><name name-style="western"><surname>Attia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Battey</surname><given-names>T.</given-names></name><name name-style="western"><surname>Boncoraglio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thijs</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rothwell</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sudlow</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vicente</surname><given-names>A.</given-names></name><name name-style="western"><surname>Markus</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kourkoulis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raffeld</surname><given-names>M.</given-names></name><name name-style="western"><surname>Silliman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boraska Perica</surname><given-names>V.</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Huckins</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>William Rayner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Gratacos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rybakowski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Keski-Rahkonen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Raevuori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Reichborn-Kjennerud</surname><given-names>T.</given-names></name><name name-style="western"><surname>Monteleone</surname><given-names>P.</given-names></name><name name-style="western"><surname>Karwautz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mannik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>O'Toole</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Trace</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>O.S.P.</given-names></name><name name-style="western"><surname>Helder</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Ehrlich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Herpertz-Dahlmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Danner</surname><given-names>U.N.</given-names></name><name name-style="western"><surname>van Elburg</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Clementi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Forzan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Docampo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lissowska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tortorella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maj</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonidakis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tziouvas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Papezova</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yilmaz</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cohen-Woods</surname><given-names>S.</given-names></name><name name-style="western"><surname>Herms</surname><given-names>S.</given-names></name><name name-style="western"><surname>Juli&#224;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rabionet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dick</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Ripatti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andreassen</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Espeseth</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lundervold</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Steen</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Aschauer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schosser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alfredsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Padyukov</surname><given-names>L.</given-names></name><name name-style="western"><surname>Halmi</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Strober</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bergen</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>W.</given-names></name><name name-style="western"><surname>Szatkiewicz</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Cormand</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ramos-Quiroga</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>S&#225;nchez-Mora</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ribas&#233;s</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hervas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arranz</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Haavik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zayats</surname><given-names>T.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dempfle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rothenberger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuntsi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oades</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Banaschewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Franke</surname><given-names>B.</given-names></name><name name-style="western"><surname>Buitelaar</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Arias Vasquez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Reif</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lesch</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Freitag</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rivero</surname><given-names>O.</given-names></name><name name-style="western"><surname>Palmason</surname><given-names>H.</given-names></name><name name-style="western"><surname>Romanos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rietschel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Witt</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Dalsgaard</surname><given-names>S.</given-names></name><name name-style="western"><surname>B&#248;rglum</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Waldman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wilmot</surname><given-names>B.</given-names></name><name name-style="western"><surname>Molly</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bau</surname><given-names>C.H.D.</given-names></name><name name-style="western"><surname>Crosbie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schachar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Loo</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>McGough</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Grevet</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Medland</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Bacchelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Battaglia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Betancur</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cantor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Celestino-Soper</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Rubeis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duque</surname><given-names>F.</given-names></name><name name-style="western"><surname>Green</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klauck</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Leboyer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levitt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maestrini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mane</surname><given-names>S.</given-names></name><name name-style="western"><surname>De-Luca</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Parr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Regan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reichenberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sandin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vorstman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wassink</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wijsman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>E.</given-names></name><name name-style="western"><surname>Santangelo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Delorme</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rog&#233;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Magalhaes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arking</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Strohmaier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>K.</given-names></name><name name-style="western"><surname>Melle</surname><given-names>I.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blackwood</surname><given-names>D.</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bergen</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Schalling</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jamain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maaser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Reinbold</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Fullerton</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Guzman-Parra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mayoral</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schofield</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Cichon</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#252;hleisen</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Gershon</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>J.</given-names></name><name name-style="western"><surname>Potash</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Zandi</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Craddock</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ferrier</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Alda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rouleau</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Turecki</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ophoff</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pato</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anjorin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>E.</given-names></name><name name-style="western"><surname>Leber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Czerski</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Cruceanu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Posthuma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Andlauer</surname><given-names>T.F.M.</given-names></name><name name-style="western"><surname>Forstner</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Streit</surname><given-names>F.</given-names></name><name name-style="western"><surname>Baune</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Air</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sinnamon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wray</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>MacIntyre</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Porteous</surname><given-names>D.</given-names></name><name name-style="western"><surname>Homuth</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grove</surname><given-names>J.</given-names></name><name name-style="western"><surname>Middeldorp</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hickie</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pergadia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Geus</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>E.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.S.</given-names></name><name name-style="western"><surname>Nauck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schoevers</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Beekman</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Viktorin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barr</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Bedoya-Berrio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bienvenu</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Brentani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Camarena</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cappi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cath</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cavallini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cusi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Darrow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Denys</surname><given-names>D.</given-names></name><name name-style="western"><surname>Derks</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Figee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Freimer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grados</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hirschtritt</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Hoekstra</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huyser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Illmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jenike</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuperman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leventhal</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lochner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lyon</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Macciardi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Madruga-Garrido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Malaty</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Maras</surname><given-names>A.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>L.</given-names></name><name name-style="western"><surname>Miguel</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Mir</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nestadt</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nicolini</surname><given-names>H.</given-names></name><name name-style="western"><surname>Okun</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Pakstis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paschou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Piacentini</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pittenger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Plessen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ramensky</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Reus</surname><given-names>V.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Riddle</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Roessner</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ros&#225;rio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Sandor</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Tsetsos</surname><given-names>F.</given-names></name><name name-style="western"><surname>Van Nieuwerburgh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weatherall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wendland</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Wolanczyk</surname><given-names>T.</given-names></name><name name-style="western"><surname>Worbe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Goes</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nestadt</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Grabe</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Depienne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Konkashbaev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lanzagorta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Valencia-Duarte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bramon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Buccola</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cahn</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Crespo-Facorro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>M.</given-names></name><name name-style="western"><surname>DeLisi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dinan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Donohoe</surname><given-names>G.</given-names></name><name name-style="western"><surname>Drapeau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hougaard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Karachanak-Yankova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khrunin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klovins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ku&#269;inskas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lee Chee Keong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Limborska</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loughland</surname><given-names>C.</given-names></name><name name-style="western"><surname>L&#246;nnqvist</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maher</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mattheisen</surname><given-names>M.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>C.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Nenadic</surname><given-names>I.</given-names></name><name name-style="western"><surname>van Os</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pantelis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petryshen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Quested</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roussos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Schall</surname><given-names>U.</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Sim</surname><given-names>K.</given-names></name><name name-style="western"><surname>So</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>St&#246;gmann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toncheva</surname><given-names>D.</given-names></name><name name-style="western"><surname>Waddington</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cloninger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gejman</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Henskens</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mattingsdal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>R.</given-names></name><name name-style="western"><surname>Webb</surname><given-names>B.</given-names></name><name name-style="western"><surname>Breen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Churchhouse</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bulik</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Daly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dichgans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Faraone</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Guerreiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Holmans</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kendler</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Koeleman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Price</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sklar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>N.W.</given-names></name><name name-style="western"><surname>Cotsapas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palotie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Smoller</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rosand</surname><given-names>J.</given-names></name><name name-style="western"><surname>Corvin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neale</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Schott</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Anney</surname><given-names>R.</given-names></name><name name-style="western"><surname>Elia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grigoroiu-Serbanescu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edenberg</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>R.</given-names></name></person-group><article-title>Analysis of shared heritability in common disorders of the brain</article-title><source>Science</source><volume>360</volume><issue>6395</issue><year>2018</year><pub-id pub-id-type="doi">10.1126/science.aap8757</pub-id><pub-id pub-id-type="pmcid">PMC6097237</pub-id><pub-id pub-id-type="pmid">29930110</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Lourida</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hannon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Littlejohns</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Langa</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Hypp&#246;nen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kuzma</surname><given-names>E.</given-names></name><name name-style="western"><surname>Llewellyn</surname><given-names>D.J.</given-names></name></person-group><article-title>Association of lifestyle and genetic risk with incidence of dementia</article-title><source>JAMA</source><volume>322</volume><issue>5</issue><year>2019</year><fpage>430</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.9879</pub-id><pub-id pub-id-type="pmid">31302669</pub-id><pub-id pub-id-type="pmcid">PMC6628594</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Fry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Littlejohns</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Sudlow</surname><given-names>C.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>N.</given-names></name><name name-style="western"><surname>Adamska</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sprosen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>N.E</given-names></name></person-group><article-title>Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population</article-title><source>Am J Epidemiol</source><volume>186</volume><issue>9</issue><year>2017</year><fpage>1026</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1093/aje/kwx246</pub-id><pub-id pub-id-type="pmid">28641372</pub-id><pub-id pub-id-type="pmcid">PMC5860371</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Sudlow</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gallacher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Beral</surname><given-names>V.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>P.</given-names></name><name name-style="western"><surname>Danesh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Downey</surname><given-names>P.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>P.</given-names></name><name name-style="western"><surname>Green</surname><given-names>J.</given-names></name><name name-style="western"><surname>Landray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Silman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sprosen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Peakman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>R.</given-names></name></person-group><article-title>UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age</article-title><source>PLoS Med</source><volume>12</volume><issue>3</issue><year>2015</year><object-id pub-id-type="publisher-id">e1001779</object-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001779</pub-id><pub-id pub-id-type="pmcid">PMC4380465</pub-id><pub-id pub-id-type="pmid">25826379</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Freedman</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Commins</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Moler</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Arab</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baer</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kipnis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Midthune</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moshfegh</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Neuhouser</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Prentice</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Schatzkin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spiegelman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Subar</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Tinker</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Willett</surname><given-names>W.</given-names></name></person-group><article-title>Pooled results from 5 validation studies of dietary self-report instruments using recovery biomarkers for energy and protein intake</article-title><source>Am J Epidemiol</source><volume>180</volume><issue>2</issue><year>2014</year><fpage>172</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1093/aje/kwu116</pub-id><pub-id pub-id-type="pmid">24918187</pub-id><pub-id pub-id-type="pmcid">PMC4082341</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Cornago</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Young</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Uden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>C.</given-names></name><name name-style="western"><surname>Piernas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Key</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lentjes</surname><given-names>M.</given-names></name></person-group><article-title>Description of the updated nutrition calculation of the Oxford WebQ questionnaire and comparison with the previous version among 207,144 participants in UK Biobank</article-title><source>Eur J Nutr</source><volume>60</volume><issue>7</issue><year>2021</year><fpage>4019</fpage><lpage>4030</lpage><pub-id pub-id-type="doi">10.1007/s00394-021-02558-4</pub-id><pub-id pub-id-type="pmid">33956230</pub-id><pub-id pub-id-type="pmcid">PMC8437868</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Association of triglyceride glucose index with stroke: from two large cohort studies and Mendelian randomization analysis</article-title><source>Int J Surg</source><volume>110</volume><issue>9</issue><year>2024</year><fpage>5409</fpage><lpage>5416</lpage><pub-id pub-id-type="doi">10.1097/js9.0000000000001795</pub-id><pub-id pub-id-type="pmid">38896856</pub-id><pub-id pub-id-type="pmcid">PMC11392123</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Vassos</surname><given-names>E.</given-names></name></person-group><article-title>Polygenic risk scores: from research tools to clinical instruments</article-title><source>Genome Med</source><volume>12</volume><issue>1</issue><year>2020</year><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s13073-020-00742-5</pub-id><pub-id pub-id-type="pmid">32423490</pub-id><pub-id pub-id-type="pmcid">PMC7236300</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Kurilshikov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medina-Gomez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bacigalupe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Radjabzadeh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Demirkan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Le Roy</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Raygoza Garay</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Finnicum</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhernakova</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Bonder</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>F.</given-names></name><name name-style="western"><surname>R&#252;hlemann</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Turpin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>L&#252;ll</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barkan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Fornage</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szopinska-Tokov</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wallen</surname><given-names>Z.D.</given-names></name><name name-style="western"><surname>Borisevich</surname><given-names>D.</given-names></name><name name-style="western"><surname>Agreus</surname><given-names>L.</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bedrani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Bisgaard</surname><given-names>H.</given-names></name><name name-style="western"><surname>Boehnke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boomsma</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Burk</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Claringbould</surname><given-names>A.</given-names></name><name name-style="western"><surname>Croitoru</surname><given-names>K.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>van Duijn</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Duijts</surname><given-names>L.</given-names></name><name name-style="western"><surname>Falony</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name><name name-style="western"><surname>van der Graaf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Homuth</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Ijzerman</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jaddoe</surname><given-names>V.W.V.</given-names></name><name name-style="western"><surname>Joossens</surname><given-names>M.</given-names></name><name name-style="western"><surname>J&#248;rgensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Keszthelyi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R.</given-names></name><name name-style="western"><surname>Laakso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laudes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Launer</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Lieb</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lusis</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Masclee</surname><given-names>A.A.M.</given-names></name><name name-style="western"><surname>Moll</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Mujagic</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qibin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Rothschild</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Steves</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Thorsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Timpson</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Tito</surname><given-names>R.Y.</given-names></name><name name-style="western"><surname>Vieira-Silva</surname><given-names>S.</given-names></name><name name-style="western"><surname>V&#246;lker</surname><given-names>U.</given-names></name><name name-style="western"><surname>V&#246;lzke</surname><given-names>H.</given-names></name><name name-style="western"><surname>V&#245;sa</surname><given-names>U.</given-names></name><name name-style="western"><surname>Wade</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>F.U.</given-names></name><name name-style="western"><surname>Weissbrod</surname><given-names>O.</given-names></name><name name-style="western"><surname>Westra</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Willemsen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Payami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jonkers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arias Vasquez</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Geus</surname><given-names>E.J.C.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Stokholm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Org</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wijmenga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Uitterlinden</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Rivadeneira</surname><given-names>F.</given-names></name><name name-style="western"><surname>Franke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lerch</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Franke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sanna</surname><given-names>S.</given-names></name><name name-style="western"><surname>D'Amato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Kraaij</surname><given-names>R.</given-names></name><name name-style="western"><surname>Raes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhernakova</surname><given-names>A.</given-names></name></person-group><article-title>Large-scale association analyses identify host factors influencing human gut microbiome composition</article-title><source>Nat Genet</source><volume>53</volume><issue>2</issue><year>2021</year><fpage>156</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-00763-1</pub-id><pub-id pub-id-type="pmid">33462485</pub-id><pub-id pub-id-type="pmcid">PMC8515199</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>R.</given-names></name></person-group><article-title>What makes UK Biobank special?</article-title><source>Lancet</source><volume>379</volume><issue>9822</issue><year>2012</year><fpage>1173</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60404-8</pub-id><pub-id pub-id-type="pmid">22463865</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bradbury</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Key</surname><given-names>T.J.</given-names></name></person-group><article-title>Physical activity in relation to body size and composition in women in UK Biobank</article-title><source>Ann Epidemiol</source><volume>25</volume><issue>6</issue><year>2015</year><fpage>406</fpage><lpage>413.e406</lpage><pub-id pub-id-type="doi">10.1016/j.annepidem.2015.01.015</pub-id><pub-id pub-id-type="pmid">25749558</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="book" id="sbref0029"><part-title>Guideline: sugars intake for adults and children</part-title><year>2015</year><publisher-name>WHO Guidelines Approved by the Guidelines Review Committee</publisher-name><publisher-loc>Geneva</publisher-loc><pub-id pub-id-type="pmid">25905159</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Audic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Claverie</surname><given-names>J.M.</given-names></name></person-group><article-title>The significance of digital gene expression profiles</article-title><source>Genome Res.</source><volume>7</volume><issue>10</issue><year>1997</year><fpage>986</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1101/gr.7.10.986</pub-id><pub-id pub-id-type="pmid">9331369</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Benjamini</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yekutieli</surname><given-names>D.</given-names></name></person-group><article-title>The control of the false discovery rate in multiple testing under dependency</article-title><source>Ann Stat</source><volume>29</volume><issue>4</issue><year>2001</year></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Sugar types, genetic predictors of the gut microbiome, and the risk of chronic kidney disease: a prospective cohort study</article-title><source>Food Funct</source><volume>15</volume><issue>9</issue><year>2024</year><fpage>4925</fpage><lpage>4935</lpage><pub-id pub-id-type="doi">10.1039/d4fo00724g</pub-id><pub-id pub-id-type="pmid">38601989</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>D.</given-names></name><name name-style="western"><surname>Selzam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peneva</surname><given-names>I.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tarran</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Beard</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Riveros-Mckay</surname><given-names>F.</given-names></name><name name-style="western"><surname>Giner-Delgado</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Seth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>J.</given-names></name><name name-style="western"><surname>Futema</surname><given-names>M.</given-names></name><name name-style="western"><surname>Consortium</surname><given-names>G.E.R.</given-names></name><name name-style="western"><surname>McVean</surname><given-names>G.</given-names></name><name name-style="western"><surname>Plagnol</surname><given-names>V.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weale</surname><given-names>M.E.</given-names></name></person-group><article-title>UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits</article-title><source>medRxiv</source><year>2022</year><pub-id pub-id-type="doi">10.1101/2022.06.16.22276246</pub-id><comment>2022.2006.2016.22276246</comment><pub-id pub-id-type="pmcid">PMC11410272</pub-id><pub-id pub-id-type="pmid">39292644</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Leurgans</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>T.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dhana</surname><given-names>K.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Halloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Rajan</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name></person-group><article-title>Dietary sugar intake associated with a higher risk of dementia in community-dwelling older adults</article-title><source>J Alzheimer's Dis</source><volume>95</volume><issue>4</issue><year>2023</year><fpage>1417</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.3233/jad-230013</pub-id><pub-id pub-id-type="pmid">37694364</pub-id><pub-id pub-id-type="pmcid">PMC10921393</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Volpe</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Van Bockstaele</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Eisen</surname><given-names>H.J.</given-names></name></person-group><article-title>Dietary sugar intake and risk of Alzheimer's disease in older women</article-title><source>Nutr Neurosci</source><volume>25</volume><issue>11</issue><year>2022</year><fpage>2302</fpage><lpage>2313</lpage><pub-id pub-id-type="doi">10.1080/1028415x.2021.1959099</pub-id><pub-id pub-id-type="pmid">34328409</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name></person-group><article-title>Sugar in Beverage and the Risk of Incident Dementia, Alzheimer's Disease and Stroke: a Prospective Cohort Study</article-title><source>J Prev Alzheimers Dis</source><volume>8</volume><issue>2</issue><year>2021</year><fpage>188</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.14283/jpad.2020.62</pub-id><pub-id pub-id-type="pmid">33569566</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Petocz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Duve</surname><given-names>E.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cassettari</surname><given-names>T.</given-names></name><name name-style="western"><surname>Blumfield</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fayet-Moore</surname><given-names>F.</given-names></name></person-group><article-title>The Effect of Replacing Refined Grains with Whole Grains on Cardiovascular Risk Factors: a Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Clinical Recommendation</article-title><source>J Acad Nutr Diet</source><volume>120</volume><issue>11</issue><year>2020</year><fpage>1859</fpage><lpage>1883.e1831</lpage><pub-id pub-id-type="doi">10.1016/j.jand.2020.06.021</pub-id><pub-id pub-id-type="pmid">32933853</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Swan</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Bush</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>L.B.</given-names></name></person-group><article-title>A definition of free sugars for the UK</article-title><source>Public Health Nutr</source><volume>21</volume><issue>9</issue><year>2018</year><fpage>1636</fpage><lpage>1638</lpage><pub-id pub-id-type="doi">10.1017/S136898001800085X</pub-id><pub-id pub-id-type="pmid">29587886</pub-id><pub-id pub-id-type="pmcid">PMC5962881</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Iadecola</surname><given-names>C.</given-names></name></person-group><article-title>Sugar and Alzheimer's disease: a bittersweet truth</article-title><source>Nat Neurosci</source><volume>18</volume><issue>4</issue><year>2015</year><fpage>477</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1038/nn.3986</pub-id><pub-id pub-id-type="pmid">25811474</pub-id><pub-id pub-id-type="pmcid">PMC4731873</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease</article-title><source>J Biol Chem</source><volume>282</volume><issue>50</issue><year>2007</year><fpage>36275</fpage><lpage>36282</lpage><pub-id pub-id-type="doi">10.1074/jbc.M703561200</pub-id><pub-id pub-id-type="pmid">17942401</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Mielke</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Taghibiglou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Adeli</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.T.</given-names></name></person-group><article-title>A biochemical and functional characterization of diet-induced brain insulin resistance</article-title><source>J Neurochem</source><volume>93</volume><issue>6</issue><year>2005</year><fpage>1568</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03155.x</pub-id><pub-id pub-id-type="pmid">15935073</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>van Deursen</surname><given-names>J.M.</given-names></name></person-group><article-title>The role of senescent cells in ageing</article-title><source>Nature</source><volume>509</volume><issue>7501</issue><year>2014</year><fpage>439</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1038/nature13193</pub-id><pub-id pub-id-type="pmid">24848057</pub-id><pub-id pub-id-type="pmcid">PMC4214092</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Nayak</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Kuriyakose</surname><given-names>D.</given-names></name><name name-style="western"><surname>Polisetty</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ameen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bonu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shetty</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ulrich</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Letafatkar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keivanlou</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Nobakht</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alotaibi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hassanipour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amini-Salehi</surname><given-names>E.</given-names></name></person-group><article-title>Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis</article-title><source>Cardiovasc Diabetol</source><volume>23</volume><issue>1</issue><year>2024</year><fpage>310</fpage><pub-id pub-id-type="doi">10.1186/s12933-024-02392-y</pub-id><pub-id pub-id-type="pmid">39180024</pub-id><pub-id pub-id-type="pmcid">PMC11344391</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>Association between the triglyceride glucose index and cognitive impairment and dementia: a meta-analysis</article-title><source>Front Aging Neurosci</source><volume>15</volume><year>2023</year><object-id pub-id-type="publisher-id">1278730</object-id><pub-id pub-id-type="doi">10.3389/fnagi.2023.1278730</pub-id><pub-id pub-id-type="pmcid">PMC10757637</pub-id><pub-id pub-id-type="pmid">38161596</pub-id></element-citation></ref><ref id="bib0045"><label>45</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Valdes</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>T.D.</given-names></name></person-group><article-title>Role of the gut microbiota in nutrition and health</article-title><source>BMJ</source><volume>361</volume><year>2018</year><fpage>k2179</fpage><pub-id pub-id-type="doi">10.1136/bmj.k2179</pub-id><pub-id pub-id-type="pmid">29899036</pub-id><pub-id pub-id-type="pmcid">PMC6000740</pub-id></element-citation></ref><ref id="bib0046"><label>46</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Thaiss</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grosheva</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Soffer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blacher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Braverman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tengeler</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Barak</surname><given-names>O.</given-names></name><name name-style="western"><surname>Elazar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ben-Zeev</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lehavi-Regev</surname><given-names>D.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Pevsner-Fischer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gertler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Halpern</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Harmelin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aamar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Serradas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grosfeld</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>H.</given-names></name><name name-style="western"><surname>Geiger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Elinav</surname><given-names>E.</given-names></name></person-group><article-title>Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection</article-title><source>Science</source><volume>359</volume><issue>6382</issue><year>2018</year><fpage>1376</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1126/science.aar3318</pub-id><pub-id pub-id-type="pmid">29519916</pub-id></element-citation></ref><ref id="bib0047"><label>47</label><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Suez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Korem</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zeevi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zilberman-Schapira</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thaiss</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Maza</surname><given-names>O.</given-names></name><name name-style="western"><surname>Israeli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zmora</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gilad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weinberger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuperman</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Harmelin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolodkin-Gal</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>H.</given-names></name><name name-style="western"><surname>Halpern</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Elinav</surname><given-names>E.</given-names></name></person-group><article-title>Artificial sweeteners induce glucose intolerance by altering the gut microbiota</article-title><source>Nature</source><volume>514</volume><issue>7521</issue><year>2014</year><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nature13793</pub-id><pub-id pub-id-type="pmid">25231862</pub-id></element-citation></ref><ref id="bib0048"><label>48</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Noble</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Schade</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Suarez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>de</surname><given-names>La</given-names></name><name name-style="western"><surname>Serre</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Kanoski</surname><given-names>S.E.</given-names></name></person-group><article-title>Gut microbial taxa elevated by dietary sugar disrupt memory function</article-title><source>Transl Psychiatry</source><volume>11</volume><issue>1</issue><year>2021</year><fpage>194</fpage><pub-id pub-id-type="doi">10.1038/s41398-021-01309-7</pub-id><pub-id pub-id-type="pmid">33790226</pub-id><pub-id pub-id-type="pmcid">PMC8012713</pub-id></element-citation></ref><ref id="bib0049"><label>49</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name></person-group><article-title>Oscillospira - a candidate for the next-generation probiotics</article-title><source>Gut microbes</source><volume>13</volume><issue>1</issue><year>2021</year><object-id pub-id-type="publisher-id">1987783</object-id><pub-id pub-id-type="doi">10.1080/19490976.2021.1987783</pub-id><pub-id pub-id-type="pmcid">PMC8547878</pub-id><pub-id pub-id-type="pmid">34693878</pub-id></element-citation></ref><ref id="bib0050"><label>50</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>R.</given-names></name></person-group><article-title>Effects of oat &#946;-glucan, oat resistant starch, and the whole oat flour on insulin resistance, inflammation, and gut microbiota in high-fat-diet-induced type 2 diabetic rats</article-title><source>J Funct Foods</source><volume>69</volume><year>2020</year><object-id pub-id-type="publisher-id">103939</object-id><pub-id pub-id-type="doi">10.1016/j.jff.2020.103939</pub-id></element-citation></ref><ref id="bib0051"><label>51</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name></person-group><article-title>Altered gut microbiota in Parkinson's disease patients/healthy spouses and its association with clinical features</article-title><source>Parkinsonism Relat Disord</source><volume>81</volume><year>2020</year><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2020.10.034</pub-id><pub-id pub-id-type="pmid">33099131</pub-id></element-citation></ref><ref id="bib0052"><label>52</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.Y.</given-names></name></person-group><article-title>Uncovering the gut-liver axis biomarkers for predicting metabolic burden in mice</article-title><source>Nutrients</source><volume>15</volume><issue>15</issue><year>2023</year><pub-id pub-id-type="doi">10.3390/nu15153406</pub-id><pub-id pub-id-type="pmcid">PMC10421148</pub-id><pub-id pub-id-type="pmid">37571345</pub-id></element-citation></ref><ref id="bib0053"><label>53</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gui</surname><given-names>S.</given-names></name></person-group><article-title>Amelioration of obesity and inflammation by polysaccharide from unripe fruits of raspberry via gut microbiota regulation</article-title><source>Int J Biol Macromol</source><volume>261</volume><issue>Pt 2</issue><year>2024</year><object-id pub-id-type="publisher-id">129825</object-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.129825</pub-id><pub-id pub-id-type="pmid">38309402</pub-id></element-citation></ref><ref id="bib0054"><label>54</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Effect of clostridium butyricum against microglia-mediated neuroinflammation in Alzheimer's disease via regulating gut microbiota and metabolites butyrate</article-title><source>Mol Nutr Food Res</source><volume>64</volume><issue>2</issue><year>2020</year><object-id pub-id-type="publisher-id">e1900636</object-id><pub-id pub-id-type="doi">10.1002/mnfr.201900636</pub-id><pub-id pub-id-type="pmid">31835282</pub-id></element-citation></ref><ref id="bib0055"><label>55</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Fecal microbiota transplantation alleviated Alzheimer's disease-like pathogenesis in APP/PS1 transgenic mice</article-title><source>Transl Psychiatry</source><volume>9</volume><issue>1</issue><year>2019</year><fpage>189</fpage><pub-id pub-id-type="doi">10.1038/s41398-019-0525-3</pub-id><pub-id pub-id-type="pmid">31383855</pub-id><pub-id pub-id-type="pmcid">PMC6683152</pub-id></element-citation></ref><ref id="bib0056"><label>56</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.J.</given-names></name></person-group><article-title>Gut microbiota, circulating cytokines and dementia: a Mendelian randomization study</article-title><source>J Neuroinflammation</source><volume>21</volume><issue>1</issue><year>2024</year><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s12974-023-02999-0</pub-id><pub-id pub-id-type="pmid">38178103</pub-id><pub-id pub-id-type="pmcid">PMC10765696</pub-id></element-citation></ref><ref id="bib0057"><label>57</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Fructose stimulated colonic arginine and proline metabolism dysbiosis, altered microbiota and aggravated intestinal barrier dysfunction in DSS-induced colitis rats</article-title><source>Nutrients</source><volume>15</volume><issue>3</issue><year>2023</year><pub-id pub-id-type="doi">10.3390/nu15030782</pub-id><pub-id pub-id-type="pmcid">PMC9921751</pub-id><pub-id pub-id-type="pmid">36771488</pub-id></element-citation></ref><ref id="bib0058"><label>58</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Tiffany</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Mahan</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Kellom</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>A.W.L.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Masson</surname><given-names>H.L.P.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Marco</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Eloe-Fadrosh</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Turnbaugh</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>B&#228;umler</surname><given-names>A.J.</given-names></name></person-group><article-title>High fat intake sustains sorbitol intolerance after antibiotic-mediated Clostridia depletion from the gut microbiota</article-title><source>Cell</source><volume>187</volume><issue>5</issue><year>2024</year><fpage>1191</fpage><lpage>1205.e1115</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2024.01.029</pub-id><pub-id pub-id-type="pmid">38366592</pub-id><pub-id pub-id-type="pmcid">PMC11023689</pub-id></element-citation></ref><ref id="bib0059"><label>59</label><element-citation publication-type="book" id="sbref0059"><person-group person-group-type="author"><collab>WHO Guidelines Approved by the Guidelines Review Committee</collab></person-group><series>Guideline: sugars intake for adults and children</series><volume>2015</volume><year>2015</year><publisher-name>World Health Organization Copyright &#169; World Health Organization</publisher-name><publisher-loc>Geneva</publisher-loc></element-citation></ref></ref-list><sec id="sec0021" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0066a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgements</title><p id="para0068">We are grateful to all participants and staff in the UK Biobank Study.</p></ack><fn-group><fn id="sec0020" fn-type="supplementary-material"><p id="para0006a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100312" id="interref0002">doi:10.1016/j.tjpad.2025.100312</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="imm70010" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Immunology</journal-id><journal-id journal-id-type="iso-abbrev">Immunology</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">IMM</journal-id><journal-title-group><journal-title>Immunology</journal-title></journal-title-group><issn pub-type="ppub">0019-2805</issn><issn pub-type="epub">1365-2567</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12500389</article-id><article-id pub-id-type="pmcid-ver">PMC12500389.1</article-id><article-id pub-id-type="pmcaid">12500389</article-id><article-id pub-id-type="pmcaiid">12500389</article-id><article-id pub-id-type="pmid">40563231</article-id><article-id pub-id-type="doi">10.1111/imm.70010</article-id><article-id pub-id-type="publisher-id">IMM70010</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Palmitoylethanolamide (<styled-content style="fixed-case" toggle="no">PEA</styled-content>) Induces an Increase in Spleen Regulatory T Cells, Reduces <styled-content style="fixed-case" toggle="no">CD8</styled-content>
<sup>+</sup> Cells and <styled-content style="fixed-case" toggle="no">TNF</styled-content>&#8208;&#945; Levels in Target Organs, and Protects Mice From Graft&#8208;Versus&#8208;Host Disease&#8208;Related Mortality Through <styled-content style="fixed-case" toggle="no">PPAR</styled-content> Activation Without Compromising the Graft&#8208;Versus&#8208;Tumour Response</article-title></title-group><contrib-group><contrib id="imm70010-cr-0001" contrib-type="author"><name name-style="western"><surname>Berg</surname><given-names initials="BB">B&#225;rbara Bet&#244;nico</given-names></name><xref rid="imm70010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="imm70010-cr-0002" contrib-type="author"><name name-style="western"><surname>Campos</surname><given-names initials="ZDT">Zara Desiree Tonidandel</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-1280-4532</contrib-id><xref rid="imm70010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="imm70010-cr-0003" contrib-type="author"><name name-style="western"><surname>Ruggio</surname><given-names initials="GMF">Gioconda Muniz Fiorenza</given-names></name><xref rid="imm70010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="imm70010-cr-0004" contrib-type="author"><name name-style="western"><surname>Linhares</surname><given-names initials="AFS">Ana Fl&#225;via Santos</given-names></name><xref rid="imm70010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="imm70010-cr-0005" contrib-type="author"><name name-style="western"><surname>Rezende</surname><given-names initials="BM">B&#225;rbara Maximino</given-names></name><xref rid="imm70010-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="imm70010-cr-0006" contrib-type="author"><name name-style="western"><surname>de Assis Cau</surname><given-names initials="SB">St&#234;fany Bruno</given-names></name><xref rid="imm70010-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="imm70010-cr-0007" contrib-type="author"><name name-style="western"><surname>Romero</surname><given-names initials="TRL">Thiago Roberto Lima</given-names></name><xref rid="imm70010-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="imm70010-cr-0008" contrib-type="author"><name name-style="western"><surname>Teixeira</surname><given-names initials="MM">Mauro Martins</given-names></name><xref rid="imm70010-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="imm70010-cr-0009" contrib-type="author"><name name-style="western"><surname>Pinho</surname><given-names initials="V">Vanessa</given-names></name><xref rid="imm70010-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="imm70010-cr-0010" contrib-type="author" corresp="yes"><name name-style="western"><surname>Miranda Castor</surname><given-names initials="MG">Marina Gomes</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4129-8715</contrib-id><xref rid="imm70010-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>marinacastor@ufmg.br</email></address></contrib></contrib-group><aff id="imm70010-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Graduate Program in Biological Sciences: Physiology and Pharmacology</named-content>
<institution>Federal University of Minas Gerais</institution>
<city>Belo Horizonte</city>
<country country="BR">Brazil</country>
</aff><aff id="imm70010-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Nursing, School of Nursing</named-content>
<institution>Federal University of Minas Gerais</institution>
<city>Belo Horizonte</city>
<country country="BR">Brazil</country>
</aff><aff id="imm70010-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacology</named-content>
<institution>Federal University of Minas Gerais</institution>
<city>Belo Horizonte</city>
<country country="BR">Brazil</country>
</aff><aff id="imm70010-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Biochemistry and Immunology</named-content>
<institution>Federal University of Minas Gerais</institution>
<city>Belo Horizonte</city>
<country country="BR">Brazil</country>
</aff><aff id="imm70010-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Morphology, Institute of Biological Sciences</named-content>
<institution>Federal University of Minas Gerais</institution>
<city>Belo Horizonte</city>
<country country="BR">Brazil</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Marina Gomes Miranda Castor (<email>marinacastor@ufmg.br</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2025</year></pub-date><volume>176</volume><issue seq="100">3</issue><issue-id pub-id-type="pmc-issue-id">498441</issue-id><issue-id pub-id-type="doi">10.1111/imm.v176.3</issue-id><fpage>385</fpage><lpage>402</lpage><history><date date-type="rev-recd"><day>30</day><month>4</month><year>2025</year></date><date date-type="received"><day>08</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Immunology</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="IMM-176-385.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:IMM-176-385.pdf"/><abstract><title>ABSTRACT</title><p>Graft&#8208;versus&#8208;host disease (GVHD), a secondary complication of bone marrow transplantation, leads to the development of a systemic inflammatory illness in the host, resulting in high mortality and morbidity. Current therapies lack prophylactic effectiveness and often fail to achieve an optimal immunological balance between inflammation and immunosuppression. In this study, we investigated the effects of palmitoylethanolamide (PEA), an endocannabinoid&#8208;like lipid mediator with extensively documented anti&#8208;inflammatory, analgesic, antimicrobial, immunomodulatory, and neuroprotective effects, on the complex pathology of GVHD. Treatment with PEA reduced clinical disease severity in GVHD mice, leading to an 80% increase in survival rates. Additionally, PEA created an immunoregulatory environment in the spleen by reducing the activation of CD3<sup>+</sup>CD4<sup>+</sup> cells. In the intestine, PEA protected against damage, reduced the number of CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> cells, and suppressed the activation of CD3<sup>+</sup>CD8<sup>+</sup> cells. PEA also decreased the levels of TNF&#8208;&#945; in the intestine and increased IL&#8208;10 production. Furthermore, in the liver, PEA treatment reduced the number of CD8<sup>+</sup> cells, the activation of CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> cells, and TNF&#8208;&#945; levels. The effect of PEA on survival was dependent on Peroxisome Proliferator&#8208;activated receptor gamma (PPAR&#8208;&#947;) activation but did not rely on cannabinoid (CB) receptors activation. In addition to GVHD protection, PEA treatment did not interfere in the graft&#8208;versus&#8208;tumour response. These results demonstrate the therapeutic potential of PEA as a promising option for the treatment of GVHD, balancing inflammation and immunosuppression, and improving both survival and clinical outcomes.</p></abstract><abstract abstract-type="graphical"><p>Effect of Palmitoylethanolamide (PEA) in a murine model of graft&#8208;versus&#8208;host disease (GVHD). Following an allogeneic transplant from C57BL/6J donors to BALB/c recipients, PEA treatment improved survival, alleviated clinical symptoms, and protected target organs in GVHD&#8208;affected mice.<boxed-text position="anchor" content-type="graphic" id="imm70010-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="IMM-176-385-g003.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="imm70010-kwd-0001">endocannabinoids</kwd><kwd id="imm70010-kwd-0002">graft&#8208;versus&#8208;host disease</kwd><kwd id="imm70010-kwd-0003">inflammation</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico</institution><institution-id institution-id-type="doi">10.13039/501100003593</institution-id></institution-wrap></funding-source><award-id>306923&#8208;2021&#8208;1</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado de Minas Gerais</institution><institution-id institution-id-type="doi">10.13039/501100004901</institution-id></institution-wrap></funding-source><award-id>APQ&#8208;01307&#8208;14</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Pr&#243;&#8208;Reitoria de Pesquisa, Universidade Federal de Minas Gerais</institution><institution-id institution-id-type="doi">10.13039/501100007375</institution-id></institution-wrap></funding-source><award-id>307&#8208;05/2016</award-id></award-group></funding-group><counts><fig-count count="9"/><table-count count="0"/><page-count count="18"/><word-count count="12600"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:06.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="imm70010-cit-1001"><string-name name-style="western"><given-names>B. B.</given-names><surname>Berg</surname></string-name>, <string-name name-style="western"><given-names>Z. D. T.</given-names><surname>Campos</surname></string-name>, <string-name name-style="western"><given-names>G. M. F.</given-names><surname>Ruggio</surname></string-name>, et al., &#8220;<article-title>Palmitoylethanolamide (<styled-content style="fixed-case" toggle="no">PEA</styled-content>) Induces an Increase in Spleen Regulatory T Cells, Reduces <styled-content style="fixed-case" toggle="no">CD8</styled-content>
<sup>+</sup> Cells and <styled-content style="fixed-case" toggle="no">TNF</styled-content>&#8208;&#945; Levels in Target Organs, and Protects Mice From Graft&#8208;Versus&#8208;Host Disease&#8208;Related Mortality Through <styled-content style="fixed-case" toggle="no">PPAR</styled-content> Activation Without Compromising the Graft&#8208;Versus&#8208;Tumour Response</article-title>,&#8221; <source>Immunology</source><volume>176</volume>, no. <issue>3</issue> (<year>2025</year>): <fpage>385</fpage>&#8211;<lpage>402</lpage>, <pub-id pub-id-type="doi">10.1111/imm.70010</pub-id>.<pub-id pub-id-type="pmcid">PMC12500389</pub-id><pub-id pub-id-type="pmid">40563231</pub-id></mixed-citation>
</p><fn-group id="imm70010-ntgp-0001"><fn fn-type="funding" id="imm70010-note-0001"><p>
<bold>Funding:</bold> This work was supported by Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico, 306923&#8208;2021&#8208;1, Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado de Minas Gerais (APQ&#8208;01307&#8208;14), Pr&#243;&#8208;Reitoria de Pesquisa, Universidade Federal de Minas Gerais, 307&#8208;05/2016.</p></fn></fn-group></notes></front><body id="imm70010-body-0001"><def-list list-content="abbreviations" id="imm70010-dl-0001"><title>Abbreviations</title><def-item><term id="imm70010-li-0001">&#916;9&#8208;THC</term><def id="imm70010-li-0002"><p>delta&#8208;9&#8208;tetrahidrocanabinol</p></def></def-item><def-item><term id="imm70010-li-0003">AEA</term><def id="imm70010-li-0004"><p>arachidonoyl ethanolamine/anandamide</p></def></def-item><def-item><term id="imm70010-li-0005">CB<sub>1</sub>
</term><def id="imm70010-li-0006"><p>cannabinoid receptor type 1</p></def></def-item><def-item><term id="imm70010-li-0007">CB<sub>2</sub>
</term><def id="imm70010-li-0008"><p>cannabinoid receptor type 2</p></def></def-item><def-item><term id="imm70010-li-0009">CBD&#8211;</term><def id="imm70010-li-0010"><p>cannabidiol</p></def></def-item><def-item><term id="imm70010-li-0011">CCL</term><def id="imm70010-li-0012"><p>C&#8208;C motif chemokine ligand</p></def></def-item><def-item><term id="imm70010-li-0013">DMSO</term><def id="imm70010-li-0014"><p>dimethyl sulfoxide</p></def></def-item><def-item><term id="imm70010-li-0015">ECS</term><def id="imm70010-li-0016"><p>endocannabinoid system</p></def></def-item><def-item><term id="imm70010-li-0017">ELISA</term><def id="imm70010-li-0018"><p>enzyme&#8208;linked immunosorbent assay</p></def></def-item><def-item><term id="imm70010-li-0019">FACS</term><def id="imm70010-li-0020"><p>fluorescence&#8208;activated cell sorting</p></def></def-item><def-item><term id="imm70010-li-0021">FITC</term><def id="imm70010-li-0022"><p>fluorescein isothiocyanate</p></def></def-item><def-item><term id="imm70010-li-0023">Fox</term><def id="imm70010-li-0024"><p>forkhead box</p></def></def-item><def-item><term id="imm70010-li-0025">GFP</term><def id="imm70010-li-0026"><p>green fluorescence protein</p></def></def-item><def-item><term id="imm70010-li-0027">GPCR</term><def id="imm70010-li-0028"><p>G protein&#8208;coupled receptors</p></def></def-item><def-item><term id="imm70010-li-0029">GVHD</term><def id="imm70010-li-0030"><p>graft&#8208;versus&#8208;host disease</p></def></def-item><def-item><term id="imm70010-li-0031">GVT</term><def id="imm70010-li-0032"><p>graft&#8208;versus&#8208;tumour</p></def></def-item><def-item><term id="imm70010-li-0033">G&#947;</term><def id="imm70010-li-0034"><p>grey (unit of ionising radiation)</p></def></def-item><def-item><term id="imm70010-li-0035">H&amp;E</term><def id="imm70010-li-0036"><p>haematoxylin and eosin</p></def></def-item><def-item><term id="imm70010-li-0037">H2&#8208;Db</term><def id="imm70010-li-0038"><p>MHC Class I Allele B</p></def></def-item><def-item><term id="imm70010-li-0039">H2&#8208;Dd</term><def id="imm70010-li-0040"><p>MHC Class I Allele D</p></def></def-item><def-item><term id="imm70010-li-0041">HSCs</term><def id="imm70010-li-0042"><p>haematopoietic stem cells</p></def></def-item><def-item><term id="imm70010-li-0043">HSCT</term><def id="imm70010-li-0044"><p>haematopoietic stem cell transplantation</p></def></def-item><def-item><term id="imm70010-li-0045">i.v.</term><def id="imm70010-li-0046"><p>intravenous</p></def></def-item><def-item><term id="imm70010-li-0047">ICAM&#8208;1</term><def id="imm70010-li-0048"><p>intercellular adhesion molecule 1</p></def></def-item><def-item><term id="imm70010-li-0049">IFN&#947;</term><def id="imm70010-li-0050"><p>interferon &#947;</p></def></def-item><def-item><term id="imm70010-li-0051">IL</term><def id="imm70010-li-0052"><p>interleukin</p></def></def-item><def-item><term id="imm70010-li-0053">MFI</term><def id="imm70010-li-0054"><p>mean fluorescence intensity</p></def></def-item><def-item><term id="imm70010-li-0055">MHC</term><def id="imm70010-li-0056"><p>major histocompatibility complex</p></def></def-item><def-item><term id="imm70010-li-0057">NAEs</term><def id="imm70010-li-0058"><p>N&#8208;acylethanolamines</p></def></def-item><def-item><term id="imm70010-li-0059">PE</term><def id="imm70010-li-0060"><p>phycoerythrin</p></def></def-item><def-item><term id="imm70010-li-0061">PEA</term><def id="imm70010-li-0062"><p>palmitoylethanolamide</p></def></def-item><def-item><term id="imm70010-li-0063">PerCP</term><def id="imm70010-li-0064"><p>peridinin&#8208;chlorophyll&#8208;protein</p></def></def-item><def-item><term id="imm70010-li-0065">TNF&#945;</term><def id="imm70010-li-0066"><p>tumour necrosis factor &#945;</p></def></def-item></def-list><sec id="imm70010-sec-0001"><label>1</label><title>Introduction</title><p>Haematopoietic stem cells (HSCs) are a class of transplantable tissue with significant regenerative capacity, primarily due to their ability to differentiate into various haematopoietic lineage components following appropriate stimulation. This capacity allows for the reconstitution of haematopoiesis by replacing the recipient's damaged cells with healthy donor cells [<xref rid="imm70010-bib-0001" ref-type="bibr">1</xref>]. Among the various transplantation approaches, allogeneic transplantation is particularly notable. The efficacy of allogeneic haematopoietic stem cell transplantation (HSCT) is largely attributed to the graft&#8208;versus&#8208;tumour (GVT) effect [<xref rid="imm70010-bib-0002" ref-type="bibr">2</xref>]. This occurs when transplanted allogeneic CD4<sup>+</sup> T cells, through the secretion of interferon&#8208;&#947; (IFN&#8208;&#947;), enhance the proliferation and activation of cytotoxic CD8<sup>+</sup> T cells, which then recognise and eliminate residual tumour cells in the host, thereby suppressing tumour growth [<xref rid="imm70010-bib-0003" ref-type="bibr">3</xref>]. Consequently, patients with hematologic malignancies benefit from eradicating residual cancer cells and preventing disease relapse [<xref rid="imm70010-bib-0004" ref-type="bibr">4</xref>].</p><p>However, the therapeutic success of allogeneic HSCT is often compromised by graft&#8208;versus&#8208;host disease (GVHD), a severe complication arising from genetic disparities between donor and recipient [<xref rid="imm70010-bib-0005" ref-type="bibr">5</xref>]. GVHD is characterised by a hyperinflammatory response, extensive tissue damage, and a cytokine storm, primarily involving the gastrointestinal tract, liver, skin, and lungs [<xref rid="imm70010-bib-0006" ref-type="bibr">6</xref>]. This condition is the leading cause of non&#8208;relapse mortality post&#8208;transplantation [<xref rid="imm70010-bib-0007" ref-type="bibr">7</xref>], and it contributes to clinicians' hesitancy to pursue this therapeutic approach [<xref rid="imm70010-bib-0008" ref-type="bibr">8</xref>].</p><p>The disease occurs due to the activation of T lymphocytes, which are triggered by antigen&#8208;presenting cells (APCs) that recognise disparities between the donor and recipient cells, including both residual recipient cells and those derived from the transplanted marrow [<xref rid="imm70010-bib-0009" ref-type="bibr">9</xref>]. This cross&#8208;presentation occurs via MHC&#8208;I for CD8<sup>+</sup> T cells and MHC&#8208;II for cells such as CD4<sup>+</sup> T lymphocytes [<xref rid="imm70010-bib-0010" ref-type="bibr">10</xref>]. Consequently, the expansion of cytotoxic effector alloreactive T cells, accompanied by a cytokine storm and the subsequent migration of these cells to target organs, perpetuates the inflammatory response and characterises the early stages of GVHD [<xref rid="imm70010-bib-0011" ref-type="bibr">11</xref>, <xref rid="imm70010-bib-0012" ref-type="bibr">12</xref>].</p><p>Despite ongoing advances in medicine, the primary treatment for this disease remains prolonged use of immunosuppressants and corticosteroids [<xref rid="imm70010-bib-0012" ref-type="bibr">12</xref>, <xref rid="imm70010-bib-0013" ref-type="bibr">13</xref>]. Approximately 60% of patients treated with corticosteroids become tolerant to the therapy and develop steroid&#8208;refractory GVHD, which has a survival rate of 30% to 40% [<xref rid="imm70010-bib-0014" ref-type="bibr">14</xref>]. Immunosuppressants are also used prophylactically and during the conditioning regimen. This includes drugs such as alemtuzumab, an anti&#8208;CD52 antibody [<xref rid="imm70010-bib-0015" ref-type="bibr">15</xref>, <xref rid="imm70010-bib-0016" ref-type="bibr">16</xref>], and other agents like sirolimus [<xref rid="imm70010-bib-0017" ref-type="bibr">17</xref>], cyclosporine [<xref rid="imm70010-bib-0018" ref-type="bibr">18</xref>] or tacrolimus [<xref rid="imm70010-bib-0019" ref-type="bibr">19</xref>].</p><p>New therapies have been proposed complementary to corticosteroid use and potential replacements, such as CAR&#8208;T cells or monoclonal antibodies like Inolimomab (CD25). CAR&#8208;T cells are genetically modified cells that express chimeric antigens, enabling them to target specific receptors and cell types to reduce the inflammatory response [<xref rid="imm70010-bib-0020" ref-type="bibr">20</xref>]. The main drawback of this therapy, as well as that of monoclonal antibody therapy, is the high toxicity, with potential complications including cytokine release syndrome and neurological syndromes triggered by immune effector cells [<xref rid="imm70010-bib-0021" ref-type="bibr">21</xref>, <xref rid="imm70010-bib-0022" ref-type="bibr">22</xref>]. Moreover, despite these effects, there remains a risk of GVHD, in which case corticosteroid use reverts to being the standard therapy [<xref rid="imm70010-bib-0023" ref-type="bibr">23</xref>].</p><p>In this context, therapies based on molecules with known immunomodulatory effects become interesting therapeutic targets. The pharmacological activities of PEA were first described in the mid&#8208;1950s when Ganley and Robinson (1958) reported the initial evidence of anti&#8208;inflammatory activity, identifying therapeutic properties in anaphylaxis. In 1971, the first report suggested that this exogenous compound could be helpful in the management of arthritis [<xref rid="imm70010-bib-0024" ref-type="bibr">24</xref>]. Currently, the literature provides evidence for its use as an immunomodulator [<xref rid="imm70010-bib-0025" ref-type="bibr">25</xref>], in analgesia [<xref rid="imm70010-bib-0026" ref-type="bibr">26</xref>], in the management of hypersensitivity [<xref rid="imm70010-bib-0025" ref-type="bibr">25</xref>], in alterations of central nervous system activities such as Alzheimer's disease [<xref rid="imm70010-bib-0027" ref-type="bibr">27</xref>], multiple sclerosis [<xref rid="imm70010-bib-0028" ref-type="bibr">28</xref>], and in sciatic nerve injuries [<xref rid="imm70010-bib-0029" ref-type="bibr">29</xref>]. Additionally, PEA shows significant potential as an anti&#8208;inflammatory agent [<xref rid="imm70010-bib-0030" ref-type="bibr">30</xref>].</p><p>Studies have demonstrated that PEA exhibits activity on the CB<sub>2</sub> receptor, playing an antinociceptive in&#160;vivo [<xref rid="imm70010-bib-0031" ref-type="bibr">31</xref>] and neuroprotective role in&#160;vitro [<xref rid="imm70010-bib-0032" ref-type="bibr">32</xref>], as well as on the colonic CB1 receptor as an anti&#8208;inflammatory agent [<xref rid="imm70010-bib-0033" ref-type="bibr">33</xref>]. Furthermore, this lipid compound also promotes an increase in the concentration of AEA, thereby enhancing its action [<xref rid="imm70010-bib-0034" ref-type="bibr">34</xref>]. In addition, PEA acts by receptors such as PPARs [<xref rid="imm70010-bib-0035" ref-type="bibr">35</xref>, <xref rid="imm70010-bib-0036" ref-type="bibr">36</xref>]. These therapeutic targets underscore the potential of PEA as an anti&#8208;inflammatory and immunomodulatory tool [<xref rid="imm70010-bib-0037" ref-type="bibr">37</xref>].</p><p>In this context, the present study aims to investigate the therapeutic use of PEA in the inflammatory response associated with murine GVHD, as well as the correlation of its effects with its pharmacological targets.</p></sec><sec sec-type="methods" id="imm70010-sec-0002"><label>2</label><title>Methods</title><sec id="imm70010-sec-0003"><label>2.1</label><title>Animals</title><p>BALB&#8208;c mice, ranging from 8 to 12&#8201;weeks of age, were our research subjects. Both C57BL/6J and BALB&#8208;c mice were used as bone marrow and splenocyte donors for the disease induction and control groups, respectively. The mice were provided by the Center of Bioterism of the Federal University of Minas Gerais, Belo Horizonte, Brazil, or the Ren&#233; Rachou Research Center of the Oswaldo Cruz Foundation, Belo Horizonte, Brazil. The animals were housed in controlled conditions under a 12&#8201;h light&#8211;dark cycle at a temperature of 25&#176;C&#8201;&#177;&#8201;2&#176;C, with food and water available ad&#160;libitum. All procedures performed were approved by the Ethics Committee on Animal Experimentation of the Federal University of Minas Gerais under protocol number 203/2021. The experiments were carried out following the guidelines of the Guide for the Care and Use of Laboratory Animals and were in accordance with the Animal Research: Reporting of In&#160;Vivo Experiments (ARRIVE) guidelines.</p></sec><sec id="imm70010-sec-0004"><label>2.2</label><title>Disease Induction</title><p>Using gamma radiation, BALB/c mice were subjected to two doses of 3.5&#8201;Gy for bone marrow ablation. Subsequently, these mice received 3 &#215;&#8201;10<sup>7</sup> splenocytes and 1 &#215;&#8201;10<sup>7</sup> bone marrow cells intravenously, either from an allogeneic C57BL/6J donor, thereby developing GVHD, or from syngeneic BALB/c mice, which did not develop the disease. All mice were administered ciprofloxacin for the first 7&#8201;days post&#8208;transplant to prevent secondary infections [<xref rid="imm70010-bib-0038" ref-type="bibr">38</xref>, <xref rid="imm70010-bib-0039" ref-type="bibr">39</xref>]. Following the transplant, the mice were monitored every 2&#8201;days using a standard clinical scoring system that evaluated and scored parameters such as hunching, activity, fur loss and texture, weight loss, skin integrity, and diarrhoea. The scoring scale varied according to clinical manifestations: 0&#8201;=&#8201;normal; 0.5&#8201;=&#8201;slight alteration; 1&#8201;=&#8201;minor alteration; 1.5&#8201;=&#8201;moderate alteration; and 2&#8201;=&#8201;severe alteration. To minimise animal suffering, a standardised cut&#8208;off level of 10 points was implemented [<xref rid="imm70010-bib-0010" ref-type="bibr">10</xref>, <xref rid="imm70010-bib-0038" ref-type="bibr">38</xref>, <xref rid="imm70010-bib-0040" ref-type="bibr">40</xref>, <xref rid="imm70010-bib-0041" ref-type="bibr">41</xref>].</p></sec><sec id="imm70010-sec-0005"><label>2.3</label><title>Pharmacological Treatments</title><p>Allogeneic transplanted mice received 1, 5 or 10&#8201;mg of PEA (Cayman Chemical Company, Michigan, USA) or its vehicle (1,25% of ethanol + 1,25% DMSO In PBS1X). The participation of CB1 and CB2 was assessed by treatment with 1&#8201;mg/kg of their respective Antagonist AM251 (Tocris, Sellex, Sao Paulo, SP, Brazil) or selective inverse agonists AM630 (Tocris, Sellex, Sao Paulo, SP, Brazil). Participation of PPAR&#8208;&#947; receptor was verified by the PPAR&#8208;&#947; antagonist GW 9662: 2&#8208;chloro&#8208;5&#8208;nitrobenzanilide, dose of 1&#8201;mg/kg, dissolved in 2.5% DMSO in PBS1x. Brand: Tocris, Sellex, S&#227;o Paulo, SP, Brazil. One hour before the treatment with target agonists, and both their vehicles consisted of 2.5% DMSO in PBS&#8208;1x. All drugs were administered daily by intraperitoneal injection starting 2&#8201;h before bone marrow ablation and continuing for the duration of the protocols. The dose of AM251, AM630 and GW9662 were in accordance with previous studies [<xref rid="imm70010-bib-0038" ref-type="bibr">38</xref>, <xref rid="imm70010-bib-0042" ref-type="bibr">42</xref>, <xref rid="imm70010-bib-0043" ref-type="bibr">43</xref>].</p></sec><sec id="imm70010-sec-0006"><label>2.4</label><title>Histopathological Analysis</title><p>Seven days after transplantation, the mice were euthanized and their livers and intestines were collected and fixed in formaldehyde before being paraffinised and stained with Hematoxylin and Eosin (H&amp;E) (Abcam, Cambridge, MA, USA). Regions of the jejunum&#8211;ileum and the full extension of the liver were blindly analysed by a pathologist under an optical microscope (Olympus BX51, Tokyo, Japan) based on the following scoring system. In the jejunum&#8211;ileum, the scoring system assigned numerical values according to changes observed in the mucosa (0&#8201;=&#8201;no alterations, 1&#8201;=&#8201;reactive alterations, 2&#8201;=&#8201;loss of architecture, 3&#8201;=&#8201;nuclear changes and hyperplasia without ulceration or loss of goblet cells, 4&#8201;=&#8201;nuclear changes and hyperplasia with ulceration and/or loss of goblet cells). Lamina propria as well as muscular and serosa layers were scored according to the presence of inflammatory infiltrate (0&#8201;=&#8201;absent, 1&#8201;=&#8201;discrete cellular infiltrate, 2&#8201;=&#8201;moderate cellular infiltrate with or without swelling, 3&#8201;=&#8201;severe inflammatory infiltrate with villous enlargement, swelling, and congestion in the lamina propria; 4&#8201;=&#8201;ischemic necrosis and intense inflammatory infiltration mainly in muscular and serosa layers, 5&#8201;=&#8201;ischemic necrosis and intense inflammatory infiltration with generalised loss of architecture). The sum of the individual results was used as the general score of the animal, with a maximum index of nine points.</p><p>For the liver, degenerative alterations in the parenchyma were enumerated as 0&#8201;=&#8201;normal, 1&#8201;=&#8201;discrete vacuolization of the cytoplasm and focal eosinophilia, 2&#8201;=&#8201;diffuse vacuolization and alterations in hepatocyte and nucleus morphology, and 3&#8201;=&#8201;necrosis and diffuse vacuolization, alterations in hepatocyte morphology, and the nucleus. Inflammatory infiltration was scored as: 0&#8201;=&#8201;none, 1&#8201;=&#8201;discrete infiltration in the periportal area, 2&#8201;=&#8201;discrete or moderate presence of periportal and intralobular cellular infiltration, and 3&#8201;=&#8201;accentuated cellular infiltration in periportal and intralobular regions. The sum of the values gave the mice's total score, which was a maximum index of six points.</p></sec><sec id="imm70010-sec-0007"><label>2.5</label><title>Enzyme&#8208;Linked Immunosorbent Assay (<styled-content style="fixed-case" toggle="no">ELISA</styled-content>)</title><p>Mice were euthanized on the seventh day after transplantation. A 100&#8201;mg sample from the liver and intestine was collected and processed for ELISA assay. The concentrations of the cytokines CCL2, CCL3, CCL5, IL&#8208;10, TNF&#8208;&#945;, and IFN&#8208;&#947; were measured according to the manufacturer's instructions (R&amp;D Systems, Minneapolis, MN, USA) at a wavelength of 490&#8201;nm using a spectrophotometer (Agilent BioTek ELx808 Absorbance Reader, Agilent Technologies, Barueri, SP, Brazil).</p></sec><sec id="imm70010-sec-0008"><label>2.6</label><title>Flow Cytometry</title><p>Panels of gate strategy of Lymphocyte subtypes and their specific markers were provided in Figures&#160;<xref rid="imm70010-supitem-0001" ref-type="supplementary-material">S1</xref> and <xref rid="imm70010-supitem-0001" ref-type="supplementary-material">S2</xref>. Tissue samples from the bone marrow (Figure&#160;<xref rid="imm70010-supitem-0003" ref-type="supplementary-material">S3</xref>), spleen (Figure&#160;<xref rid="imm70010-supitem-0004" ref-type="supplementary-material">S4</xref>), intestine (Figure&#160;<xref rid="imm70010-supitem-0005" ref-type="supplementary-material">S5</xref>), and liver (Figure&#160;<xref rid="imm70010-supitem-0006" ref-type="supplementary-material">S6</xref>) were collected and processed on Day 7 according to the protocol described by Berg et&#160;al. [<xref rid="imm70010-bib-0038" ref-type="bibr">38</xref>]. The number of cells was counted using a Neubauer chamber, and a total of 1 &#215;&#8201;10<sup>6</sup> cells were stained with the following antibodies: CD3 (Pacific Blue [RRID&#8208;17&#8208;A2], BioLegend, San Diego, USA), CD4 (PE&#8208;Cy7 [RRID&#8208;RM45], BioLegend), CD8 (FITC [RRID&#8208;53&#8208;6.7], BioLegend), CD25 (allophycocyanin [RRID&#8208;PC61], BioLegend), and CD28 (PE&#8208;A [RRID&#8208;37.51], BioLegend), FoxP3 (PE&#8208;A [RRID&#8208;MF14], BioLegend), and CD62L (allophycocyanin [MEL&#8208;14 Biolegend]). For the evaluation of the chimerism process, we used H2&#8208;Db (AlexaFluor 647 [RRID&#8208;KH95], BioLegend) and H2&#8208;Dd (PE [RRID&#8208;34,212], BioLegend) as markers in the bone marrow and spleen. A total of 1 million events were considered for each sample and tracked using a BD FACSCanto II cytometer (New Jersey, USA) and further analysed using FlowJo V10 software (BD Immunocytometry Systems, San Jose, USA). H2&#8208;Db and H2&#8208;Dd are MHC class I alloantigens expressed on all nucleated cells from mice that express either of these haplotypes, namely C57BL/6 and BALB&#8208;c mice, respectively. These alloantigens are involved in CD3/TCR T cell antigen presentation.</p></sec><sec id="imm70010-sec-0009"><label>2.7</label><title>GVT</title><p>GVHD was induced in the Balb/c mice as described in Section&#160;<xref rid="imm70010-sec-0004" ref-type="sec">2.2</xref>. At the GVHD induction, the mice received murine mastocytoma P815<sup>+</sup> cells i.v. (H&#8208;2d, American Type Culture Collection, Rockville, MD&#8212;RRID TIB&#8208;64) transduced with the EF1aGFP vector (National Institute of Cancer, Rio de Janeiro, Brasil) in a concentration of 1 &#215;&#8201;10<sup>5</sup> cells. Mice were treated with vehicle or PEA for 7&#8201;days. The lymph nodes (mesenteric and inguinal) were processed for FACS analysis by Flow Cytometry (FacsScaibur). The number of tumour cells was evaluated by the percentage of GFP+ fluorescence.</p></sec><sec id="imm70010-sec-0010"><label>2.8</label><title>Statistical Analysis</title><p>Data was analysed using GraphPad Prism 8.0.2 software. Normality was assessed by the Shapiro&#8211;Wilk test, and outliers were determined using Grubb's test (<italic toggle="yes">&#945;</italic>&#8201;=&#8201;0.05). Differences between vehicle and PEA treated groups were determined by the Unpaired parametric Two&#8208;tailed Student's <italic toggle="yes">t</italic> test (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Differences in survival curves were determined based on the log&#8208;rank (Mantel&#8211;Cox) test (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). For the clinical score, two&#8208;way ANOVA with Bonferroni's multiple comparison test was used for statistical hypothesis testing (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05).</p></sec></sec><sec sec-type="results" id="imm70010-sec-0011"><label>3</label><title>Results</title><p>BALB&#8208;c mice received the transplant from syngeneic (BALB&#8208;c) or allogeneic (C57BL/6J) donor mice. As expected, the recipients of allogeneic transplants developed GVHD (Figure&#160;<xref rid="imm70010-fig-0001" ref-type="fig">1A</xref>), which was the focus of the study. The GVHD mice were treated with the target drugs from the day of disease induction until either the seventh day (for mice euthanized for analysis) or until mortality (for mice undergoing mortality evaluation). The mice were closely observed, and their clinical scores were recorded to assess their overall health and well&#8208;being throughout the study. PEA 5 and 10&#8201;mg/kg increased survival at 80% compared to vehicle&#8208;treated mice (Figure&#160;<xref rid="imm70010-fig-0001" ref-type="fig">1B</xref>) and reduced clinical signs of murine GVHD (Figure&#160;<xref rid="imm70010-fig-0001" ref-type="fig">1C</xref>).</p><fig position="float" fig-type="FIGURE" id="imm70010-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Evaluation of PEA treatment on survival and clinical parameters of acute murine Graft&#8208;versus&#8208;host disease. (A) Procedure of disease induction, previously irradiated BALB&#8208;c mice received either allogeneic or syngeneic splenocytes (3 &#215;&#8201;10<sup>7</sup>) and bone marrow cells (1 &#215;&#8201;10<sup>7</sup>), thus developing or not GVHD, respectively. GVHD occurs due to differences in MHC I from BALB&#8208;c (H2&#8208;Dd) and C57BL/6J (H2&#8208;Db) mice. (B) Percentage of survival of mice receiving daily treatment of PEA 1&#8201;mg/kg (orange line), PEA 5&#8201;mg/kg (green line), PEA 10&#8201;mg/kg (black line), compared to vehicle (red line) (#) or (*) compared to syngeneic transplanted (blue line) mice. (C) Clinical score of mice receiving daily treatment of PEA 1&#8201;mg/kg (orange line), PEA 5&#8201;mg/kg (green line), PEA 10&#8201;mg/kg (black line), compared to vehicle (red line) (#) compared to syngeneic transplanted (blue line) (*) mice. <italic toggle="yes">n</italic>&#8201;=&#8201;10 for all groups and in all experiments. Treatment was performed from Day 0 until the end of the experiment. Survival was verified by Log&#8208;rank (Mantel&#8208;Cox) test and groups were considered different only when <italic toggle="yes">p</italic> value was &lt;&#8201;0.05. Two&#8208;way ANOVA with Bonferroni's multiple comparisons test was used to compare the clinical scores of groups, and they were considered different only when <italic toggle="yes">p</italic> value was &lt;&#8201;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="IMM-176-385-g002.jpg"/></fig><sec id="imm70010-sec-0012"><label>3.1</label><title>
<styled-content style="fixed-case" toggle="no">PEA</styled-content> Treatment Did Not Change the Engraftment Process</title><p>Bone marrow and spleen, 7&#8201;days after transplantation, were analysed using flow cytometry to verify if transplanted bone marrow cells had successfully transmigrated and colonised lymphoid organs. In both organs, we analysed the presence of BALB&#8208;c MHC&#8208;1 marker (H2&#8208;Dd) and C57BL/6J MHC&#8208;1 (H2&#8208;Db). In allogeneic transplanted mice, it is crucial to find a predominance of H2&#8208;Db. Treatment with PEA did not interfere with the engraftment process in bone marrow, and hence we found a predominance of H2&#8208;Db (99.01% in the vehicle and 99.80% in PEA) over H2&#8208;Dd (0.99% in the vehicle and 0.20% in PEA) (Figures&#160;<xref rid="imm70010-fig-0002" ref-type="fig">2A</xref> and <xref rid="imm70010-supitem-0001" ref-type="supplementary-material">S1</xref>). In the spleen, the same predominance of H2&#8208;Db (92.85% in the vehicle and 96.52% in PEA) over H2&#8208;Dd (7.15% in the vehicle and 3.48% in PEA) was found (Figures&#160;<xref rid="imm70010-fig-0002" ref-type="fig">2B</xref> and <xref rid="imm70010-supitem-0002" ref-type="supplementary-material">S2</xref>).</p><fig position="float" fig-type="FIGURE" id="imm70010-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Evaluation of PEA treatment on engraftment process and chimerism in BALB&#8208;c recipient mice. Schematic representation of the bone marrow and spleen engraftment process. The presence of mice MHC I H2&#8208;Dd (BALB&#8208;c) and H2&#8208;Db (C57BL/6J) was verified by flow cytometry in bone marrow cells (A) and in spleen cells from Vehicle or PEA treated mice, 7&#8201;days after transplantation. The unpaired parametric two&#8208;tailed Student's <italic toggle="yes">t</italic> test was used to assess differences between Vehicle and AEA, the groups were considered significantly different when <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 (<italic toggle="yes">n</italic>&#8201;=&#8201;5 in all groups). Next, lymphocytes populations were analysed by flow cytometry, identifying (C) Number of CD3<sup>+</sup> lymphocytes. (D) Number of CD3<sup>+</sup>CD4<sup>+</sup> lymphocytes. (E) Number of CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes. (F) Number of CD4<sup>+</sup>CD25<sup>+</sup> lymphocytes. (G) Number of CD4<sup>+</sup>CD25<sup>+</sup> FoxP3<sup>+</sup> lymphocytes. (H) Mean fluorescence intensity (MFI) of CD4<sup>+</sup>CD25<sup>+</sup> FoxP3+. (I) MFI of CD28 in CD3<sup>+</sup>CD4<sup>+</sup> lymphocytes. (J) MFI of CD28 in CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes. (K) MFI of CD3<sup>+</sup>CD4<sup>+</sup> CD62L<sup>high</sup> lymphocytes. (L) MFI of CD3<sup>+</sup>CD4<sup>+</sup> CD62L<sup>low</sup> lymphocytes. (M) MFI of CD3<sup>+</sup>CD8<sup>+</sup> CD62L<sup>high</sup> lymphocytes. (N) MFI of CD3<sup>+</sup>CD8<sup>+</sup> CD62L<sup>low</sup> lymphocytes. Treatment was performed from Day 0 until the end of the experiment. Groups were considered significantly different when <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, compared to allogeneic group treated with vehicle. Assessed by unpaired parametric two&#8208;tailed Student's <italic toggle="yes">t</italic> test (<italic toggle="yes">n</italic>&#8201;=&#8201;5 in all groups).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="IMM-176-385-g001.jpg"/></fig></sec><sec id="imm70010-sec-0013"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">PEA</styled-content> Increased <styled-content style="fixed-case" toggle="no">CD3</styled-content>
<sup>+</sup>
<styled-content style="fixed-case" toggle="no">CD4</styled-content>
<sup>+</sup>
<styled-content style="fixed-case" toggle="no">FOXP3</styled-content>
<sup>+</sup> Cells and Reduced Activation of <styled-content style="fixed-case" toggle="no">CD3</styled-content>
<sup>+</sup>
<styled-content style="fixed-case" toggle="no">CD4</styled-content>
<sup>+</sup> Cells in the Spleen of <styled-content style="fixed-case" toggle="no">GVHD</styled-content> Mice</title><p>The cellular populations in the spleen were evaluated to verify if the allogeneic transplant or treatment with PEA led to differences in cellular populations. The number of CD3<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> was increased in the vehicle when compared to the syngeneic group, but there was no difference between the vehicle and the PEA&#8208;treated group (Figure&#160;<xref rid="imm70010-fig-0002" ref-type="fig">2C&#8211;E</xref>). Concerning the number of CD4<sup>+</sup>CD25<sup>+</sup> cells and CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> cells, treatment with PEA increased these populations and increased the mean fluorescence intensity of FoxP3<sup>+</sup> cells compared to vehicle treated mice (Figure&#160;<xref rid="imm70010-fig-0002" ref-type="fig">2F&#8211;H</xref>). Regarding lymphocyte activation status, marked by MFI of CD28, PEA treatment reduced the MFI of CD28 in the CD3<sup>+</sup>CD4<sup>+</sup> cells compared to vehicle treated mice (Figure&#160;<xref rid="imm70010-fig-0002" ref-type="fig">2I</xref>). However, no difference was found between groups regarding CD3<sup>+</sup>CD8<sup>+</sup>CD28 cells (Figure&#160;<xref rid="imm70010-fig-0002" ref-type="fig">2J</xref>). The profile of effector or memory T cells was verified by a CD62L marker in the spleen. Treatment with PEA did not alter the CD3<sup>+</sup>CD4<sup>+</sup>CD62L<sup>low</sup>, effector memory T cells and CD3<sup>+</sup>CD4<sup>+</sup>CD62L<sup>high</sup> central memory T cells, nor CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>low</sup> or CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>high</sup> populations in the spleen, compared to the vehicle group (Figure&#160;<xref rid="imm70010-fig-0002" ref-type="fig">2K&#8211;N</xref>).</p></sec><sec id="imm70010-sec-0014"><label>3.3</label><title>
<styled-content style="fixed-case" toggle="no">PEA</styled-content> Reduced the Number of <styled-content style="fixed-case" toggle="no">CD3</styled-content>
<sup>+</sup>
<styled-content style="fixed-case" toggle="no">CD4</styled-content>
<sup>+</sup> and <styled-content style="fixed-case" toggle="no">CD3</styled-content>
<sup>+</sup>
<styled-content style="fixed-case" toggle="no">CD8</styled-content>
<sup>+</sup> Cells and the Activation of CD3<sup>+</sup>CD8<sup>+</sup> in the Intestine, Reducing Damage, <styled-content style="fixed-case" toggle="no">TNF</styled-content>&#8208;&#945; Levels and Increasing the Anti&#8208;Inflammatory Cytokine <styled-content style="fixed-case" toggle="no">IL</styled-content>&#8208;10 in the Intestine of <styled-content style="fixed-case" toggle="no">GVHD</styled-content> Mice</title><p>The number of CD3<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells was increased in the vehicle group when compared to the syngeneic group (Figure&#160;<xref rid="imm70010-fig-0003" ref-type="fig">3A&#8211;C</xref>). PEA treatment led to a reduction in the number of these cells when compared to the vehicle group. Regarding the activation, CD3<sup>+</sup>CD8<sup>+</sup> cells were more activated in the vehicle group compared to syngeneic, but treatment with PEA reduced the MFI of CD28 in the CD3<sup>+</sup>CD8<sup>+</sup> cells (Figure&#160;<xref rid="imm70010-fig-0003" ref-type="fig">3E</xref>). Although the number of CD4<sup>+</sup>CD25<sup>+</sup> cells and the number of regulatory T cells, stained by CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup>, were lower in the PEA treated group compared to vehicle (Figure&#160;<xref rid="imm70010-fig-0003" ref-type="fig">3F,G</xref>), the activation of CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> measured by MFI (H) PAE enhance the fluorescence to Foxp3 compared to vehicle treated group. There was no difference between the CD3<sup>+</sup>CD4<sup>+</sup>CD62L<sup>high</sup>, CD3<sup>+</sup>CD4<sup>+</sup>CD62L<sup>low</sup>, CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>high</sup> and CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>low</sup> in the syngeneic compared to the vehicle or the vehicle compared to the PEA treated group (Figure&#160;<xref rid="imm70010-fig-0003" ref-type="fig">3I&#8211;L</xref>).</p><fig position="float" fig-type="FIGURE" id="imm70010-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>PEA reduces CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> cells infiltration and activation in the intestine of GVHD mice. The number and profile of infiltrated cells in the intestine were analysed through flow cytometry. (A) CD3<sup>+</sup>, (B) CD3<sup>+</sup>CD4<sup>+</sup> and (C) CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes, (MFI) of CD28 was assessed in (D) CD3<sup>+</sup>CD4<sup>+</sup> and (E) CD3<sup>+</sup>CD8<sup>+</sup> cells. Furthermore, the number of (F) CD4<sup>+</sup>CD25<sup>+</sup> cells and the (G) CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> cells and the (H) MFI of CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> were investigated. The profile of effector or central memory cells was also investigated in T cells (I) CD3<sup>+</sup>CD4<sup>+</sup>CD62L<sup>high</sup>, (J) CD3<sup>+</sup>CD4<sup>+</sup>CD62L<sup>low</sup>, (K) CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>high</sup> and (L) CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>low</sup>. Treatment was performed from Day 0 until the end of the experiment. Groups were considered significantly different when <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, compared to the allogeneic group. Assessed by unpaired parametric two&#8208;tailed Student's <italic toggle="yes">t</italic> test, (<italic toggle="yes">n</italic>&#8201;=&#8201;5 in all groups).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="IMM-176-385-g008.jpg"/></fig><p>For histopathological analysis, a blind examination of small intestine slices, stained with H&amp;E, was conducted by a pathologist. The vehicle group presented alteration and loss of crypt architecture and epithelium with moderate edema and hyperemia and increased infiltration of mononuclear cells when compared to the syngeneic transplanted group. Treatment with PEA reduced inflammatory infiltration and preserved crypt architecture, thus protecting the intestine (Figure&#160;<xref rid="imm70010-fig-0004" ref-type="fig">4A&#8211;D</xref>). Additionally, the levels of pro&#8208;inflammatory cytokines and chemokines in the intestine were investigated. The vehicle group had an increase in CCL2, CCL3, TNF&#8208;&#945; and IFN&#8208;&#947; when compared to the syngeneic group. Treatment with PEA reduced the concentration of TNF&#8208;&#945; and did not alter CCL2, CCL3 or IFN&#8208;&#947; levels in the intestine. No alteration was observed in the levels of CCL5 (Figure&#160;<xref rid="imm70010-fig-0004" ref-type="fig">4E&#8211;I</xref>). However, the levels of IL&#8208;10 were increased by treatment with PEA (Figure&#160;<xref rid="imm70010-fig-0004" ref-type="fig">4J</xref>).</p><fig position="float" fig-type="FIGURE" id="imm70010-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>PEA protects the intestine by reducing damage and increasing IL&#8208;10. Slices of intestine of the syngeneic group and allogeneic recipient mice treated with vehicle or PEA (A&#8211;C) on the 7th day after disease induction, were fixated and stained with H&amp;E for analysis of their (D) histopathological score. Samples of the intestines were collected, processed and the ELISA assay was performed, and the concentration of the chemokines (E) TNF&#8208;&#945;, (F) IFN&#8208;&#947;, and (G) IL&#8208;10 and the cytokines (H) CCL2, (I) CCL3 and (J) CCL5 were verified. Treatment was performed from Day 0 until the end of the experiment. Groups were considered significantly different when <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, compared to the allogeneic group. Assessed by unpaired parametric two&#8208;tailed Student's <italic toggle="yes">t</italic> test (<italic toggle="yes">n</italic>&#8201;=&#8201;8&#8211;9 for the histopathological score <italic toggle="yes">n</italic>&#8201;=&#8201;5 for the quantification of Inflammatory mediators). The <italic toggle="yes">N</italic> for the histopathological score was result of two experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="IMM-176-385-g009.jpg"/></fig></sec><sec id="imm70010-sec-0015"><label>3.4</label><title>Treatment With <styled-content style="fixed-case" toggle="no">PEA</styled-content> Reduced Infiltration of <styled-content style="fixed-case" toggle="no">CD3</styled-content>
<sup>+</sup>
<styled-content style="fixed-case" toggle="no">CD8</styled-content>
<sup>+</sup> Cells, Activation of <styled-content style="fixed-case" toggle="no">CD3</styled-content>
<sup>+</sup>
<styled-content style="fixed-case" toggle="no">CD4</styled-content>
<sup>+</sup> and <styled-content style="fixed-case" toggle="no">CD3</styled-content>
<sup>+</sup>
<styled-content style="fixed-case" toggle="no">CD8</styled-content>
<sup>+</sup>, <styled-content style="fixed-case" toggle="no">TNF</styled-content>&#8208;&#945; Levels, and Damage in the Liver of <styled-content style="fixed-case" toggle="no">GVHD</styled-content> Mice</title><p>Flow cytometry was also performed to evaluate the inflammatory infiltrate and profile of infiltrated cells into the liver on the 7th day after disease induction. There were no alterations in the number of CD3<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup> cells between the vehicle and the treated group (Figure&#160;<xref rid="imm70010-fig-0005" ref-type="fig">5A,B</xref>). Still, the number of CD3<sup>+</sup>CD8<sup>+</sup> cells and activation of CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> cells, measured by MFI of CD28, were reduced in mice treated with PEA compared to vehicle (Figure&#160;<xref rid="imm70010-fig-0005" ref-type="fig">5C&#8211;E</xref>). No changes were&#160;observed regarding the number of CD4<sup>+</sup>CD25<sup>+</sup> or FoxP3 cells, neither in the MFI of FoxP3 or in the CD3<sup>+</sup>CD4<sup>+</sup>CD62L<sup>high</sup>, CD3<sup>+</sup>CD4<sup>+</sup>CD62L<sup>low</sup>, CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>high</sup> and CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>low</sup> comparing vehicle and PEA treated group (Figure&#160;<xref rid="imm70010-fig-0005" ref-type="fig">5F&#8211;L</xref>). In liver slices, a pathological analysis found alterations in cellular morphology and diffuse vacuolization with infiltration in periportal and intralobular regions in the vehicle group compared to syngeneic transplanted mice. Treatment with PEA reduced inflammatory infiltrate and damage protecting the liver of GVHD mice (Figure&#160;<xref rid="imm70010-fig-0006" ref-type="fig">6A&#8211;D</xref>) and corroborating the histological findings, the&#160;levels of TNF&#8208;&#945; were reduced in the GVHD mice treated with PEA compared to vehicles (Figure&#160;<xref rid="imm70010-fig-0006" ref-type="fig">6E</xref>). Treatment with PEA did not alter the levels of IFN&#8208;&#947; and IL&#8208;10, nor did chemokines&#160;levels when contrasted with the vehicle group (Figure&#160;<xref rid="imm70010-fig-0006" ref-type="fig">6F&#8211;J</xref>).</p><fig position="float" fig-type="FIGURE" id="imm70010-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>PEA reduced CD3<sup>+</sup>CD8<sup>+</sup> cells and activation of CD3<sup>+</sup>CD8<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup> cells in the liver. The lymphocytic profile was investigated by flow cytometry, determining the number of (A) CD3<sup>+</sup>, (B) CD3<sup>+</sup>CD4<sup>+</sup> and (C) CD3<sup>+</sup>CD8<sup>+</sup>, and the MFI of CD28 in (D) CD3<sup>+</sup>CD4+ and (E) CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes. The number of (F) CD4<sup>+</sup>CD25<sup>+</sup> cells and (G) CD4<sup>+</sup>CD25<sup>+</sup>FoxP3, and MFI of CD4<sup>+</sup>CD25<sup>+</sup>FoxP3. The profile of effector or central memory cells was also investigated in T cells (H) CD3<sup>+</sup>CD4<sup>+</sup>CD62L<sup>high</sup>, (I) CD3<sup>+</sup>CD4<sup>+</sup>CD62L<sup>low</sup>, (J) CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>high</sup> and (K) CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>low</sup>. Treatment was performed from Day 0 until the end of the experiment. Groups were considered significantly different when <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, compared to allogeneic group. Assessed by unpaired parametric two&#8208;tailed Student's <italic toggle="yes">t</italic> test (<italic toggle="yes">n</italic>&#8201;=&#8201;5 in all groups).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="IMM-176-385-g004.jpg"/></fig><fig position="float" fig-type="FIGURE" id="imm70010-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Treatment with PEA reduced damage and TNF&#8208;&#945; levels in the liver of mice subjected to GVHD. H&amp;E&#8208;stained slices of liver from the syngeneic group, and from allogeneic recipient mice treated with vehicle or PEA were examined (A&#8211;C). The &#8594; indicates inflammatory infiltrate. (D) Histopathological scores of the groups were then compared. The concentrations of cytokines and chemokines were evaluated (E) TNF&#8208;&#945;, (F) IFN&#8208;&#947;, (G) IL&#8208;10, (H) CCL2, (I) CCL3 and (J) CCL5. Treatment was performed from Day 0 until the end of the experiment. Groups were considered significantly different when <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, compared to the allogeneic group. Assessed by unpaired parametric two&#8208;tailed Student's <italic toggle="yes">t</italic> test (<italic toggle="yes">n</italic>&#8201;=&#8201;9 for the histopathological score <italic toggle="yes">n</italic>&#8201;=&#8201;5 for the quantification of Inflammatory mediators). The <italic toggle="yes">N</italic> for the histopathological score was result of two experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="IMM-176-385-g006.jpg"/></fig></sec><sec id="imm70010-sec-0016"><label>3.5</label><title>The Protective Effect of <styled-content style="fixed-case" toggle="no">PEA</styled-content> on Mice Submitted to Experimental Graft&#8208;Versus&#8208;Host Disease Was Dependent on <styled-content style="fixed-case" toggle="no">PPAR</styled-content>&#8208;&#947; Activation</title><p>The receptor by which PEA reduces GVHD and increases survival was investigated. The first receptors evaluated were the cannabinoids, CB<sub>1</sub> and CB<sub>2</sub>. The antagonist of the CB<sub>1</sub> receptor, AM251, or the inverse agonist of the CB<sub>2</sub> receptor was administered to mice at the GVHD induction and 1&#8201;h before PEA treatment. The treatment with AM251, AM630 and PEA was performed every 24&#8201;h until the end of the experiment (Figure&#160;<xref rid="imm70010-fig-0007" ref-type="fig">7A</xref>). The occupation of the CB<sub>1</sub> receptor or CB<sub>2</sub> receptor&#160;did not alter the protective effect of PEA on mice submitted to experimental GVHD (Figure&#160;<xref rid="imm70010-fig-0007" ref-type="fig">7B</xref>). However, the same protocol was repeated to evaluate the PPAR&#8208;&#947; receptor. The antagonist of PPAR&#8208;&#947;, GW9662, was administered to mice submitted to experimental GVHD at the GVHD induction until the end of the experiment, once a day, and before PEA treatment (Figure&#160;<xref rid="imm70010-fig-0007" ref-type="fig">7C</xref>). The occupation of the PPAR&#8208;&#947; receptor by GW9662 eliminated the protection of PEA treatment on GVHD mice (Figure&#160;<xref rid="imm70010-fig-0007" ref-type="fig">7D</xref>).</p><fig position="float" fig-type="FIGURE" id="imm70010-fig-0007" orientation="portrait"><label>FIGURE 7</label><caption><p>Receptors involved in the effect of PEA treatment on survival of mice submitted to Graft&#8208;versus&#8208;host disease. (A) Procedure of disease induction, previously irradiated BALB&#8208;c mice received either allogeneic or syngeneic splenocytes (3 &#215;&#8201;10<sup>7</sup>) and bone marrow cells (1 &#215;&#8201;10<sup>7</sup>), thus developing or not GVHD, respectively. GVHD occurs due to differences in MHC I from BALB&#8208;c (H2&#8208;Dd) and C57BL/6J (H2&#8208;Db) mice. GVHD mice received treatment with AM251 or AM630 1&#8201;h before PEA treatment. (B) Percentage of survival of mice receiving daily treatment of PEA 5&#8201;mg/kg (green line), AM251 1&#8201;mg/kg&#8201;+&#8201;PEA 5&#8201;mg/kg (dashed black line) and AM630 1&#8201;mg/kg&#8201;+&#8201;PEA (1&#8201;mg/kg) (continuous black line) *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 compared to vehicle (red line). (C) Procedure of disease induction. GVHD mice received treatment with GW9662 1&#8201;h before PEA treatment. (D) Percentage of survival of mice receiving daily treatment of PEA 5&#8201;mg/kg (green line), GW9662 1&#8201;mg/kg&#8201;+&#8201;PEA 5&#8201;mg/kg (dashed black line) *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 compared to vehicle and <sup>#</sup>
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 compared to PEA treatment alone. <italic toggle="yes">n</italic>&#8201;=&#8201;10 results from two different experiments. Treatment was performed from Day 0 until the end of the experiment. Survival was verified by Log&#8208;rank (Mantel&#8208;Cox) test and groups were considered different only when <italic toggle="yes">p</italic> value was &lt;&#8201;0,05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-15" orientation="portrait" xlink:href="IMM-176-385-g007.jpg"/></fig></sec><sec id="imm70010-sec-0017"><label>3.6</label><title>Treatment With <styled-content style="fixed-case" toggle="no">PEA</styled-content> Reduced Overall Graft&#8208;Versus&#8208;Host Disease Without Interfering in GVT Response</title><p>On the same day as disease induction, mice were injected with P815GFP+ tumour cells. After 7&#8201;days, their immune response was evaluated using flow cytometry. The control group received only tumour cells and a syngeneic transplant, showing an increase in P815GFP+ cells in the lymph nodes, indicating tumour progression. The vehicle group, which received tumour cells along with allogeneic bone marrow and splenocytes, exhibited a reduction in GFP+ tumour cells compared to the control group. Similarly, PEA treatment did not disrupt the allograft's anti&#8208;tumour response, as tumour presence in the lymph nodes of PEA&#8208;treated mice was significantly reduced compared to the tumour syngeneic group, preserving the GVT effect (Figure&#160;<xref rid="imm70010-fig-0008" ref-type="fig">8</xref>).</p><fig position="float" fig-type="FIGURE" id="imm70010-fig-0008" orientation="portrait"><label>FIGURE 8</label><caption><p>Flow Cytometry of mice lymph nodes, 7&#8201;days after disease induction and P815&#8208;GFP+ cells transplant. GVHD was induced by bone marrow cells and splenocytes transplantation. On Day 0 of disease induction 1 &#215;&#8201;10<sup>5</sup> P815&#8208;GFP<sup>+</sup> cells were injected i.v. Treatment with PEA did not alter the GVT effect. (A) Frequency of P815&#8208;GFP+ cells were represented in dispersion graphs next to flow cytometry shards; <italic toggle="yes">n</italic>&#8201;=&#8201;5 for all groups. *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 compared to GVHD group alone. <sup>#</sup>
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 compared to tumour group alone. (B) Representative photo of P815&#8208;GFP+ cells on the lymph nodes of mice. The lymph nodes were removed and the cells extracted for cytospin centrifugation and stained with DAPI for the nuclei visualisation. P815&#8208;GFP<sup>+</sup> cells are pointed by the arrows.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-17" orientation="portrait" xlink:href="IMM-176-385-g005.jpg"/></fig></sec></sec><sec sec-type="discussion" id="imm70010-sec-0018"><label>4</label><title>Discussion</title><p>PEA, N&#8208;hexadecanoylethanolamide, is an endocannabinoid lipid mediator belonging to the N&#8208;acylethanolamine phospholipid family [<xref rid="imm70010-bib-0044" ref-type="bibr">44</xref>]. PEA demonstrates significant therapeutic potential for inflammation, primarily due to its ability to modulate the immune system. Therefore, PEA was utilised as a therapeutic strategy in mice subjected to an experimental model of GVHD. In an allogeneic transplantation model, BALB/c mice received spleen and bone marrow cells from C57 mice. Our GVHD model has been widely recognised in the literature as a robust model for drug screening due to its high mortality rate, and protection from death in this model could serve as the first evidence of a promising therapy [<xref rid="imm70010-bib-0045" ref-type="bibr">45</xref>]. Treatment with PEA at doses of 5 or 10&#8201;mg/kg reduced the clinical GVHD score from the 12th day after disease induction and almost entirely reduced mortality.</p><p>The therapeutic action of PEA has previously been demonstrated in experimental models of Alzheimer's disease, where PEA improved learning and memory due to its anti&#8208;inflammatory and neuroprotective effects [<xref rid="imm70010-bib-0046" ref-type="bibr">46</xref>]. A similar observation was made by D'Agostino et&#160;al., where PEA, by activating PPAR receptors, reduced oxidative stress in the central nervous system (CNS), improving learning in mice subjected to an experimental Alzheimer's disease model [<xref rid="imm70010-bib-0047" ref-type="bibr">47</xref>]. PEA has also been tested as a therapeutic strategy for osteoarthritis in rats, where it reduced edema, cartilage degradation, and the production of pro&#8208;inflammatory mediators. The same effect was observed in mice by Impellizzeri et&#160;al. [<xref rid="imm70010-bib-0048" ref-type="bibr">48</xref>]. The therapeutic potential of PEA was further demonstrated by Borelli et&#160;al., using an experimental colitis model in mice, where PEA reduced intestinal injury and stimulated epithelial regeneration [<xref rid="imm70010-bib-0033" ref-type="bibr">33</xref>].</p><p>In human studies, treatment with PEA has been effective in improving the clinical condition of patients with amyotrophic lateral sclerosis, as evidenced by electromyography analysis and pulmonary function assessment [<xref rid="imm70010-bib-0049" ref-type="bibr">49</xref>]. It also showed efficacy in treating acute mania, where PEA combination therapy demonstrated a reduction in YMRS scores, indicating an improvement in manic symptoms and overall clinical status during acute manic episodes [<xref rid="imm70010-bib-0050" ref-type="bibr">50</xref>]. Furthermore, in patients with COVID&#8208;19, PEA reduced systemic inflammation, oxidative stress, and modulated the coagulation cascade, leading to an improvement in the patients' clinical condition [<xref rid="imm70010-bib-0051" ref-type="bibr">51</xref>].</p><p>The data presented above corroborate our findings, showing the potential of PEA as an anti&#8208;inflammatory and immunomodulatory tool and the importance of further investigating the mechanisms underlying its actions.</p><p>Then, a flow cytometer was used to assess the effect of PEA on the engraftment process. After bone marrow transplantation, the engraftment of the new marrow in the transplant host is necessary. This engraftment is fundamental to the integration and functioning of a new transplanted immune system [<xref rid="imm70010-bib-0052" ref-type="bibr">52</xref>]. Failure in bone marrow or lymphoid organ engraftment leads to transplant failure, which is a pivotal reason for discontinuing trials of a drug considered as a therapy for GVHD [<xref rid="imm70010-bib-0053" ref-type="bibr">53</xref>]. Our results demonstrate that PEA does not interfere with this process as evaluated in the bone marrow and spleen. Our analysis of the lymphocytic profile in the spleen supports our findings on the preservation of the engraftment process. The presence of thriving cells in the spleen after transplantation indicates a functioning immune system, which is essential for preventing opportunistic infections unrelated to the transplant that could negatively impact survival [<xref rid="imm70010-bib-0054" ref-type="bibr">54</xref>].</p><p>The spleen is a central lymphoid organ involved in the pathogenesis of GVHD, driving immune cell activation and expansion before their migration to target organs [<xref rid="imm70010-bib-0055" ref-type="bibr">55</xref>]. In this context, it is important to control the activation of effector cells against host antigens without interfering with their activation against tumour cells, thereby maintaining the Graft&#8208;versus&#8208;Leukaemia (GVL) effect. The enhancement of regulatory T cells (Tregs) has been extensively demonstrated as an efficient therapy for GVHD, both in humans and mice, by creating this balance between GVHD and GVL [<xref rid="imm70010-bib-0056" ref-type="bibr">56</xref>, <xref rid="imm70010-bib-0057" ref-type="bibr">57</xref>, <xref rid="imm70010-bib-0058" ref-type="bibr">58</xref>]. The expansion of Tregs in the spleen was sufficient to prolong the survival of mice experiencing lethal acute GVHD while maintaining responsiveness to third&#8208;party alloantigens and leukaemia cells [<xref rid="imm70010-bib-0059" ref-type="bibr">59</xref>]. Interestingly, PEA fosters this regulatory environment in the spleen, increasing the number of CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> cells and the mean fluorescence intensity (MFI) for FoxP3<sup>+</sup> while reducing the activation of CD3<sup>+</sup>CD4<sup>+</sup> cells, as evidenced by a decrease in MFI for CD28<sup>+</sup>, a co&#8208;stimulatory molecule crucial for antigen presentation and clonal expansion of T cells [<xref rid="imm70010-bib-0060" ref-type="bibr">60</xref>].</p><p>Damage to the gastrointestinal tract is a major cause of morbidity and mortality in GVHD, primarily attributable to T cell&#8208;mediated inflammation. Preserving intestinal integrity is crucial for maintaining nutrient absorption and preventing microbiota transmigration [<xref rid="imm70010-bib-0061" ref-type="bibr">61</xref>]. Treatment with PEA effectively reduced tissue damage, inflammatory infiltrates, and preserved intestinal architecture. Regarding the inflammatory infiltrate, there was a reduction in the number of CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> cells, which were found to be less activated, as assessed by CD28 expression. Previous studies from our group have shown that the presence of activated lymphocytes in the intestines is a major contributor to intestinal injury [<xref rid="imm70010-bib-0040" ref-type="bibr">40</xref>, <xref rid="imm70010-bib-0041" ref-type="bibr">41</xref>, <xref rid="imm70010-bib-0060" ref-type="bibr">60</xref>, <xref rid="imm70010-bib-0062" ref-type="bibr">62</xref>]. Additionally, this issue has been extensively discussed in the GVHD literature, and it is now widely accepted that the presence and activation of CD3<sup>+</sup>CD8<sup>+</sup> cells drive intestinal injury in GVHD [<xref rid="imm70010-bib-0063" ref-type="bibr">63</xref>, <xref rid="imm70010-bib-0064" ref-type="bibr">64</xref>, <xref rid="imm70010-bib-0065" ref-type="bibr">65</xref>, <xref rid="imm70010-bib-0066" ref-type="bibr">66</xref>, <xref rid="imm70010-bib-0067" ref-type="bibr">67</xref>].</p><p>Similarly, CD3<sup>+</sup>CD4<sup>+</sup> infiltration in the gastrointestinal tract initiates Th1&#8208;mediated proinflammatory cytokine production, exacerbates pathological damage, and increases mortality [<xref rid="imm70010-bib-0068" ref-type="bibr">68</xref>]. In most murine models, CD4<sup>+</sup> T cells are critical to the induction of GVHD, either by producing IL&#8208;2, which mediates robust allospecific CD8<sup>+</sup> T&#8208;cell proliferation, or by generating effector proteins such as TNF&#8208;&#945; [<xref rid="imm70010-bib-0069" ref-type="bibr">69</xref>].</p><p>For CD4<sup>+</sup> and CD8<sup>+</sup> T cells, PEA treatment reduced the upregulation of CD28 expression. CD28 is well characterised as the most effective co&#8208;stimulatory molecule expressed by na&#239;ve and activated T cells. Co&#8208;stimulation through CD28 regulates multiple aspects of T cell function, including cytokine secretion, proliferation, and cell survival [<xref rid="imm70010-bib-0070" ref-type="bibr">70</xref>, <xref rid="imm70010-bib-0071" ref-type="bibr">71</xref>]. Moreover, the CD28 signal, which is responsible for T cell activation [<xref rid="imm70010-bib-0072" ref-type="bibr">72</xref>, <xref rid="imm70010-bib-0073" ref-type="bibr">73</xref>, <xref rid="imm70010-bib-0074" ref-type="bibr">74</xref>, <xref rid="imm70010-bib-0075" ref-type="bibr">75</xref>], can be enhanced by TNF&#8208;&#945; [<xref rid="imm70010-bib-0076" ref-type="bibr">76</xref>, <xref rid="imm70010-bib-0077" ref-type="bibr">77</xref>].</p><p>Using CD28&#8208;deficient mice, it was demonstrated that CD28 co&#8208;stimulation plays a critical role in the development of GVHD [<xref rid="imm70010-bib-0060" ref-type="bibr">60</xref>, <xref rid="imm70010-bib-0078" ref-type="bibr">78</xref>, <xref rid="imm70010-bib-0079" ref-type="bibr">79</xref>], and CD28 blockade ameliorated GVHD mediated by both CD4<sup>+</sup> and CD8<sup>+</sup> T cells [<xref rid="imm70010-bib-0080" ref-type="bibr">80</xref>, <xref rid="imm70010-bib-0081" ref-type="bibr">81</xref>]. In CD4<sup>+</sup> cells, CD28 signalling positively regulated T cell responses to alloantigens and supported GVHD development in an additive or synergistic manner by reinforcing the CD8<sup>+</sup> effector response. Its blockade resulted in the suppression of GVHD [<xref rid="imm70010-bib-0060" ref-type="bibr">60</xref>]. Additionally, Nurieva et&#160;al. showed that in the absence of positive co&#8208;stimulation mediated by CD28, negative co&#8208;stimulatory molecules, including CTLA&#8208;4 and PD&#8208;1, actively instruct T cells to develop into tolerant cells, characterised by inactivation of intrinsic signalling and transcriptional programmes [<xref rid="imm70010-bib-0082" ref-type="bibr">82</xref>].</p><p>In addition to reducing the expression of co&#8208;stimulatory molecules critical for T cell activation, treatment with PEA increased the fluorescence intensity of FoxP3 in CD4<sup>+</sup>CD25<sup>+</sup> cells, thereby promoting immune response regulation, including within the intestine.</p><p>The anti&#8208;inflammatory activity of PEA was also demonstrated by Wang et&#160;al., 2014 and their research group using a radiation&#8208;induced intestinal inflammation model [<xref rid="imm70010-bib-0083" ref-type="bibr">83</xref>]. The treatment led to improvements at the lesion site, including a reduction in overall radiation&#8208;induced structural damage, intestinal wall thickness, collagen deposition, and neutrophil influx in irradiated intestinal areas.</p><p>Similar results were observed in the context of colitis, a type of intestinal inflammation. Borrelli et&#160;al. demonstrated the anti&#8208;inflammatory potential of PEA in an experimental mouse model, which resulted in reduced edema and erosion areas, leukocyte infiltration, and intestinal permeability while also stimulating colonic cell regeneration [<xref rid="imm70010-bib-0033" ref-type="bibr">33</xref>]. According to the authors, these effects involved the action of CB<sub>2</sub>, GPR55, and PPAR&#945; receptors [<xref rid="imm70010-bib-0033" ref-type="bibr">33</xref>]. Additionally, Peritore et&#160;al., using a PEA/Pol&#8208;co compound that combines PEA with polydatin, a fatty acid derivative, to treat murine colitis, observed anti&#8208;inflammatory activity, improved clinical signs, reduced pro&#8208;inflammatory cytokines IL&#8208;1&#946; and TNF&#8208;&#945;, myeloperoxidase (MPO), malondialdehyde (MDA), nitrotyrosine expression, PARP protein, ICAM&#8208;1 and P&#8208;selectin, as well as increased levels of SIRT&#8208;1, heme oxygenase 1 (HO&#8208;1) expression and Nrf2 [<xref rid="imm70010-bib-0084" ref-type="bibr">84</xref>]. This protective effect was not species&#8208;dependent, as evidenced by the anti&#8208;inflammatory effect of PEA&#8208;OXA observed in an experimental zebrafish model of colitis, as reported by Di Paola et&#160;al. [<xref rid="imm70010-bib-0085" ref-type="bibr">85</xref>]. The compound was found to reduce intestinal damage, mucus production, and the expression of inflammatory and endoplasmic reticulum stress&#8208;related genes.</p><p>TNF&#8208;&#945; is a major inflammatory cytokine associated with damage in GVHD target organs, and its control is crucial for promoting protection in GVHD&#8208;affected mice [<xref rid="imm70010-bib-0086" ref-type="bibr">86</xref>]. PEA treatment reduced TNF&#8208;&#945; levels in the intestines of GVHD mice and promoted an increase in IL&#8208;10.</p><p>The effect of PEA on TNF&#8208;&#945; production has been demonstrated in previous studies. Using a spinal cord injury model, Genovese et&#160;al., showed that intraperitoneal administration of PEA in mice reduced neutrophil infiltration and TNF&#8208;&#945; levels, improving functional deficits [<xref rid="imm70010-bib-0087" ref-type="bibr">87</xref>]. Similar results were observed by Paterniti et&#160;al., who showed that the reduction in neutrophil infiltration and TNF&#8208;&#945; levels was related to the activation of PPAR receptors by PEA [<xref rid="imm70010-bib-0042" ref-type="bibr">42</xref>]. Other studies have shown that PEA treatment can reduce neural injury by controlling TNF&#8208;&#945; levels [<xref rid="imm70010-bib-0029" ref-type="bibr">29</xref>, <xref rid="imm70010-bib-0088" ref-type="bibr">88</xref>, <xref rid="imm70010-bib-0089" ref-type="bibr">89</xref>, <xref rid="imm70010-bib-0090" ref-type="bibr">90</xref>].</p><p>The reduction of TNF&#8208;&#945; levels by PEA treatment was also observed by Petrosino et&#160;al. using a rat paw edema model and neuropathic and inflammatory pain models, respectively [<xref rid="imm70010-bib-0044" ref-type="bibr">44</xref>, <xref rid="imm70010-bib-0091" ref-type="bibr">91</xref>]. De Filippis et&#160;al. demonstrated similar effects in a model of chronic granulomatous inflammation in rats, and Impellizzeri et&#160;al. observed these effects in the treatment of inflammatory arthritis in induced mice [<xref rid="imm70010-bib-0048" ref-type="bibr">48</xref>, <xref rid="imm70010-bib-0092" ref-type="bibr">92</xref>]. Most of these studies suggested that reducing NF&#8208;&#954;B by PEA is a key step in lowering TNF&#8208;&#945;.</p><p>Another vital cytokine to consider in the inflammatory response associated with GVHD is IL&#8208;10. IL&#8208;10 is a regulatory interleukin associated with protective roles and has been linked to a reduction in disease severity in humans [<xref rid="imm70010-bib-0093" ref-type="bibr">93</xref>]. Impellizzieri et&#160;al. demonstrated the ability of PEA to increase IL&#8208;10 levels and positively regulate the antioxidant response in a vascular dementia model in mice [<xref rid="imm70010-bib-0094" ref-type="bibr">94</xref>]. Additionally, Wang et&#160;al. observed that PEA could inhibit pathways controlling mast cell&#8208;derived cellular immune responses and enhance the anti&#8208;inflammatory signalling of IL&#8208;6 and IL&#8208;10 in the intestines of mice exposed to radiation [<xref rid="imm70010-bib-0083" ref-type="bibr">83</xref>].</p><p>The source of IL&#8208;10 in our model remains undetermined. However, we hypothesise that Treg cells (FoxP3<sup>+</sup>) play a crucial role in IL&#8208;10 production, as described by Berg et&#160;al. [<xref rid="imm70010-bib-0038" ref-type="bibr">38</xref>, <xref rid="imm70010-bib-0043" ref-type="bibr">43</xref>]. Although PEA treatment reduced the overall T cell population in the intestine, the intensity of FoxP3 fluorescence, measured by mean fluorescence intensity (MFI), was enhanced. The expression of the transcription factor FoxP3 is essential for the regulatory activity of Tregs. Thus, after treatment with PEA, this population could be responsible for IL&#8208;10 production.</p><p>In the liver, a similar protective profile was observed, with reduced CD3<sup>+</sup>CD8<sup>+</sup> infiltration and decreased activation of both CD3<sup>+</sup>CD8<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup> T cells, as assessed by the MFI of CD28. This finding is consistent with the observed reduction in TNF&#8208;&#945; secretion, similar to the effects seen in the intestine. Panoskaltsis&#8208;Mortari et&#160;al. found that liver involvement in GVHD typically occurs after intestinal damage, with T cells first migrating to and damaging the intestine before being recruited to the liver [<xref rid="imm70010-bib-0055" ref-type="bibr">55</xref>]. The protective role of PEA in the liver was demonstrated by Hu et&#160;al. in a mouse model of non&#8208;alcoholic steatohepatitis (NASH) [<xref rid="imm70010-bib-0095" ref-type="bibr">95</xref>]. Treatment with PEA attenuated the progression of NASH, alleviated oxidative stress, and reduced the expression of genes related to lipid metabolism and inflammatory mediators, such as iNOS, TNF&#8208;&#945;, CCL5, CCL2 and the activation of the NALRP3 inflammasome [<xref rid="imm70010-bib-0095" ref-type="bibr">95</xref>]. The authors attributed the effects of PEA to the activation of PPAR receptors.</p><p>Although the anti&#8208;inflammatory and immunomodulatory effects of PEA are extensively described in the literature, studies exploring its mechanisms of action and therapeutic activity are scarce. Therefore, we evaluated which receptor might be involved in the observed protection against mortality in mice subjected to GVHD. Our results indicate that the protective effect of PEA can be entirely abolished by antagonism of the PPAR&#8208;&#947; receptor, while the same is not observed with antagonism of CB receptors.</p><p>In a nociception model induced by formalin injection, Calignano et&#160;al. discussed that the effects of PEA, which are dependent on CB<sub>2</sub> receptors, might result from the potentiation of AEA, which would bind to CB<sub>2</sub> [<xref rid="imm70010-bib-0096" ref-type="bibr">96</xref>]. In an inflammatory hyperalgesia model induced by carrageenan injection, Jhaveri et&#160;al. described this potentiation effect as the &#8216;entourage effect&#8217;, a term that elucidates the synergistic interaction between cannabinoids [<xref rid="imm70010-bib-0097" ref-type="bibr">97</xref>]. Therefore, PEA could enhance both the concentration and effects of endogenous AEA. In a previous study, our group demonstrated that AEA treatment reduced the mortality of mice subjected to the experimental GVHD model, and this effect was associated with CB<sub>2</sub> receptor activation [<xref rid="imm70010-bib-0043" ref-type="bibr">43</xref>]. Consequently, one of our study's hypotheses was that PEA could increase AEA concentrations, thereby improving the survival of mice experimentally subjected to GVHD. However, when cannabinoid receptors were blocked with their antagonists or inverse agonists, PEA continued to exert its effect on survival, indicating that this effect was not directly associated with CB receptors.</p><p>In previous studies, it was observed that &#916;9&#8208;THC and CBD, which share the same molecular formula, behave differently in their interactions with cannabinoid receptors [<xref rid="imm70010-bib-0038" ref-type="bibr">38</xref>, <xref rid="imm70010-bib-0098" ref-type="bibr">98</xref>]. Similarly, despite their high molecular similarity, we observed that AEA and PEA exhibited distinct interactions with cannabinoid receptors in relation to the increased survival of animals with GVHD, with AEA being dependent on CB<sub>2</sub>. Conversely, due to the observed PEA effect being similar to the AEA, the antagonism of the CB<sub>2</sub> does not interfere with survival.</p><p>Moreover, PEA displays a certain degree of pharmacological promiscuity, capable of interacting with various receptors beyond cannabinoid receptors. Some examples include the vanilloid receptor type 1, PPARs, 5HT receptors, GPRs, among others [<xref rid="imm70010-bib-0099" ref-type="bibr">99</xref>, <xref rid="imm70010-bib-0100" ref-type="bibr">100</xref>, <xref rid="imm70010-bib-0101" ref-type="bibr">101</xref>]. In this context, PEA has been extensively studied for its interaction with PPAR, a nuclear receptor that plays a crucial role in regulating inflammation and various metabolic processes. Prior treatment of GVHD mice with the PPAR&#8208;&#947; antagonist, GW9662, completely abolished the protective effect of PEA on survival rates.</p><p>The anti&#8208;inflammatory and neuroprotective properties of PEA administration have been demonstrated by Paterniti et&#160;al. using a spinal cord injury model in mice [<xref rid="imm70010-bib-0042" ref-type="bibr">42</xref>]. PEA restored physiological levels of TNF&#8208;&#945; and IL&#8208;1&#946;, but the genetic absence of PPAR&#8208;&#945; or the use of PPAR&#8208;&#948; or PPAR&#8208;&#947; antagonists reversed the reduction induced by PEA. PEA also attenuated iNOS expression and restored PPAR&#8208;&#947; and PPAR&#8208;&#948; levels in the spinal cord [<xref rid="imm70010-bib-0042" ref-type="bibr">42</xref>]. In another study using a mouse model of intracerebral haemorrhage (ICH), intraperitoneal administration of PEA exhibited anti&#8208;inflammatory activity, improved neurological and motor function, and attenuated NF&#8208;&#954;B, IL&#8208;1&#946;, and TNF&#8208;&#945;. This mechanism was correlated with PPAR receptors [<xref rid="imm70010-bib-0102" ref-type="bibr">102</xref>].</p><p>The importance of the PPAR&#8208;&#947; receptor in GVHD was previously demonstrated through the protection of target organs and reduction in the production of inflammatory mediators in mice with GVHD subjected to treatment with the PPAR&#8208;&#947; agonist, rosiglitazone [<xref rid="imm70010-bib-0103" ref-type="bibr">103</xref>]. The interaction of PEA with the PPAR&#8208;&#947; receptor producing anti&#8208;inflammatory, analgesic, and immunomodulatory effects has been previously demonstrated in several different experimental models, such as neuropathic pain [<xref rid="imm70010-bib-0104" ref-type="bibr">104</xref>], in tumour cell apoptosis [<xref rid="imm70010-bib-0105" ref-type="bibr">105</xref>], in models of multiple sclerosis, spinal cord trauma [<xref rid="imm70010-bib-0042" ref-type="bibr">42</xref>] and in intestinal inflammation induced by ischemia and reperfusion [<xref rid="imm70010-bib-0106" ref-type="bibr">106</xref>].</p><p>The GVT effect appears after allogeneic HSCT and is dependent on allogeneic donor cells that can eliminate residual malignant cells. This anti&#8208;tumour effect is known as GVL or GVT. It is a critical factor in the medical decision to proceed with HSCT as a therapeutic option. It is important to note that, despite the higher likelihood of developing GVHD, allogeneic transplantation provides a stronger GVL effect than other transplantation types [<xref rid="imm70010-bib-0107" ref-type="bibr">107</xref>]. Therefore, an ideal therapy for patients with GVHD would involve the use of drugs that modulate, rather than suppress, the inflammatory response, thus balancing GVL and GVHD [<xref rid="imm70010-bib-0108" ref-type="bibr">108</xref>]. In our experimental model of GVHD, treatment with PEA was able to abrogate the allogeneic response against the target organ but preserves the GVT response observed in the lymph nodes of GVHD mice injected with tumour cells.</p><p>The GVL experiment indicated that PEA treatment did not interfere with the response of allogeneic donor lymphocytes to tumour cells injected into mice. This effect is significant when considering potential pharmacological treatment for GVHD. Although PEA reduced tumour cell proliferation in mice that did not receive allogeneic transplantation, its antitumour effect was not the focus of our study. Further experiments should be conducted to confirm this. However, Pagano et&#160;al., showed that PEA could inhibit the proliferation, migration, and cell cycle of colon cancer cells studied in&#160;vitro and in&#160;vivo [<xref rid="imm70010-bib-0109" ref-type="bibr">109</xref>]. Interestingly, PPAR receptors are also involved in the mechanism of action of PEA on the tumour. PEA&#8208;induced cell cycle arrest in the G2/M phase, possibly through cyclin B1/CDK1 upregulation and induced DNA fragmentation. In addition, Camoglio et&#160;al., have investigated the effect of PEA treatment on human neuroblastoma SH&#8208;SY5Y cells, resulting in o increased apoptotic cell death marked by the cleavage of caspase 3 and poly&#8208;(ADP ribose) polymerase (PARP) alongside a decrease in survivin and IKB&#945; levels. Treatment of SH&#8208;SY5Y culture with PEA also increased p38 MAP kinase phosphorylation and programmed death&#8208;ligand 1 (PD&#8208;L1) expression in full cell lysate and surface membranes [<xref rid="imm70010-bib-0110" ref-type="bibr">110</xref>]. In this way, PEA could reduce the proliferation of P815 mastocitoma cells in our model.</p><p>The balance between the effector and regulatory components of the immune system also influences the severity of GVHD. The absence of regulatory cell populations has been shown to exacerbate GVHD severity [<xref rid="imm70010-bib-0111" ref-type="bibr">111</xref>, <xref rid="imm70010-bib-0112" ref-type="bibr">112</xref>], indicating that counterregulatory mechanisms are active during GVHD. However, they are often insufficient to prevent or mitigate the disease [<xref rid="imm70010-bib-0113" ref-type="bibr">113</xref>]. PEA treatment established this regulatory environment by increasing the number of regulatory cells in target organs and elevating IL&#8208;10 levels. It also reduced effector T cells and damaged the intestine and liver. However, effector T cells from the donor are crucial for an effective response against tumours. This response should be preserved when promising therapy is proposed. Despite PEA reducing GVHD, it did not alter the GVT response, demonstrating its potential as an alternative therapy for GVHD.</p></sec><sec sec-type="conclusions" id="imm70010-sec-0019"><label>5</label><title>Conclusion</title><p>The present study demonstrated that PEA treatment increased survival and reduced clinical scores in mice subjected to GVHD. PEA treatment did not interfere with engraftment in the spleen and bone marrow. Still, intriguingly, it increased the number of T regulatory cells and the intensity of Foxp3 expression while reducing the expression of the co&#8208;stimulatory molecule CD28 in CD3<sup>+</sup>CD4<sup>+</sup> cells. In the intestine, PEA treatment reduced the infiltration of CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> cells, and the CD3<sup>+</sup>CD8<sup>+</sup> cells also exhibited reduced CD28 expression intensity. Although the number of T regulatory cells decreased, the intensity of Foxp3 fluorescence increased in the intestines of mice treated with PEA. Accordingly, the levels of TNF&#8208;&#945; were reduced, and the IL&#8208;10 levels were increased in the intestines of mice treated with PEA. In the liver, PEA treatment reduced the infiltration of CD3<sup>+</sup>CD8<sup>+</sup> cells and the co&#8208;stimulatory CD28 expression in CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> cells, as well as TNF&#8208;&#945; levels and tissue damage. The effect of PEA on the survival of GVHD mice was dependent on PPAR&#8208;&#947; activation but did not rely on CB receptor activation.</p></sec><sec id="imm70010-sec-0021"><title>Author Contributions</title><p>B.B.B., A.F.S.L., Z.D.T.C., and G.M.F.R., performed experiment. B.B.B., B.M.R., and M.G.M.C, analysed results and drew figures. S.B.A.C., T.R.L.R., V.P., and M.M.T. contributed to the experimental design, with drugs and reagents and analytic tools. B.B.B. and M.G.M.C., designed the research and wrote the paper.</p></sec><sec sec-type="COI-statement" id="imm70010-sec-0022"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="imm70010-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S1.</bold> Gating strategy. (A) Initial sample separated by granularity and size. (B) Separation of single cells within the granulocyte population. (C) Separation of single cells within the monocyte population. (D) Separation of single cells within the lymphocyte population. (E) Identification of the CD3<sup>+</sup> cell population. (F) Identification of the CD4<sup>+</sup> and CD8<sup>+</sup> cell populations.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMM-176-385-s005.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="imm70010-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S2.</bold> FoxP3 analysis. (A) Initial sample of intestinal cells with total lymphocyte selection. (B) Identification of CD4<sup>+</sup> and CD25<sup>+</sup> cell populations. (C&#8212;D) Mean fluorescence intensity of FoxP3 cells within the CD4<sup>+</sup> CD25<sup>+</sup> cell population.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMM-176-385-s004.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="imm70010-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S3.</bold> Flow cytometry analysis of bone marrow engraftment. Representative histogram of H2&#8208;Db and H2&#8208;Dd expression in bone marrow cells. Seven days after transplant, bone marrow was proceeded to flow cytometry analysis. Frequency of H2&#8208;Db and H2&#8208;Dd was accessed by specific surface markers.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMM-176-385-s006.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="imm70010-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S4.</bold> Flow cytometry analysis of spleen, seven days after disease induction. Analysis of cell surface markers, such as CD3, CD4, CD8 and the activation marker CD28 and CD62l. CD4, CD25 and FoxP3 to characterise T regulatory lymphocytes.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMM-176-385-s003.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="imm70010-supitem-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S5.</bold> Flow cytometry analysis of intestine, seven days after disease induction. Analysis of cell surface markers, such as CD3, CD4, CD8 and the activation marker CD28 and CD62l. CD4, CD25 and FoxP3 to characterise T regulatory lymphocytes.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMM-176-385-s001.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="imm70010-supitem-0006" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S6.</bold> Flow cytometry analysis of liver, seven days after disease induction. Analysis of cell surface markers, such as CD3, CD4, CD8 and the activation marker CD28 and CD62l. CD4, CD25 and FoxP3 to characterise T regulatory lymphocytes.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMM-176-385-s002.jpg" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="imm70010-sec-0020"><title>Acknowledgements</title><p>This work was supported by grants from Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal do Ensino Superior: Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico PQ (Grant 306923&#8208;2021&#8208;1), Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado de Minas Gerais (Grant APQ&#8208;01307&#8208;14), and Pr&#243;&#8208;Reitoria de Pesquisa da UFMG (Grant 307&#8208;05/2016). We wish to acknowledge Fernanda Trindade Madeira Araujo from the Ren&#233; Rachou Institute/Oswaldo Cruz Foundation for providing mice for our experiments. Furthermore, we thank the Gama Irradiation Lab of the Centro de Desenvolvimento da Tecnologia Nuclear.</p></ack><sec sec-type="data-availability" id="imm70010-sec-0024"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="imm70010-bibl-0001"><title>References</title><ref id="imm70010-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="imm70010-cit-0001"><string-name name-style="western"><given-names>S.</given-names><surname>Ghimire</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Weber</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Mavin</surname></string-name>, <string-name name-style="western"><given-names>X. N.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Dickinson</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Holler</surname></string-name>, &#8220;<article-title>Pathophysiology of GvHD and Other HSCT&#8208;Related Major Complications</article-title>,&#8221; <source>Frontiers in Immunology</source><volume>8</volume> (<year>2017</year>): <elocation-id>79</elocation-id>.<pub-id pub-id-type="pmid">28373870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.00079</pub-id><pub-id pub-id-type="pmcid">PMC5357769</pub-id></mixed-citation></ref><ref id="imm70010-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="imm70010-cit-0002"><string-name name-style="western"><given-names>K.</given-names><surname>Riesner</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Jacobi</surname></string-name>, et&#160;al., &#8220;<article-title>Initiation of Acute Graft&#8208;Versus&#8208;Host Disease by Angiogenesis</article-title>,&#8221; <source>Blood</source><volume>129</volume>, no. <issue>14</issue> (<year>2017</year>): <fpage>2021</fpage>&#8211;<lpage>2032</lpage>.<pub-id pub-id-type="pmid">28096092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2016-08-736314</pub-id></mixed-citation></ref><ref id="imm70010-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="imm70010-cit-0003"><string-name name-style="western"><given-names>Q.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Tong</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>IFN&#8208;&#947; Mediates Graft&#8208;Versus&#8208;Breast Cancer Effects via Enhancing Cytotoxic T Lymphocyte Activity</article-title>,&#8221; <source>Experimental and Therapeutic Medicine</source><volume>8</volume>, no. <issue>2</issue> (<year>2014</year>): <fpage>347</fpage>&#8211;<lpage>354</lpage>.<pub-id pub-id-type="pmid">25009582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2014.1760</pub-id><pub-id pub-id-type="pmcid">PMC4079438</pub-id></mixed-citation></ref><ref id="imm70010-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="imm70010-cit-0004"><string-name name-style="western"><given-names>A.</given-names><surname>Elhage</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Sligar</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Cuthbertson</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Watson</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Sluyter</surname></string-name>, &#8220;<article-title>Insights Into Mechanisms of Graft&#8208;Versus&#8208;Host Disease Through Humanised Mouse Models</article-title>,&#8221; <source>Bioscience Reports</source><volume>42</volume>, no. <issue>9</issue> (<year>2022</year>): <elocation-id>BSR20211986</elocation-id>.<pub-id pub-id-type="pmid">35993192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20211986</pub-id><pub-id pub-id-type="pmcid">PMC9446388</pub-id></mixed-citation></ref><ref id="imm70010-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="imm70010-cit-0005"><string-name name-style="western"><given-names>J. L.</given-names><surname>Ferrara</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Levine</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Reddy</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Holler</surname></string-name>, &#8220;<article-title>Graft&#8208;Versus&#8208;Host Disease</article-title>,&#8221; <source>Lancet</source><volume>373</volume>, no. <issue>9674</issue> (<year>2009</year>): <fpage>1550</fpage>&#8211;<lpage>1561</lpage>.<pub-id pub-id-type="pmid">19282026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(09)60237-3</pub-id><pub-id pub-id-type="pmcid">PMC2735047</pub-id></mixed-citation></ref><ref id="imm70010-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="imm70010-cit-0006"><string-name name-style="western"><given-names>H. M.</given-names><surname>Shulman</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Cardona</surname></string-name>, <string-name name-style="western"><given-names>J. K.</given-names><surname>Greenson</surname></string-name>, et&#160;al., &#8220;<article-title>NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft&#8208;Versus&#8208;Host Disease: II. The 2014 Pathology Working Group Report</article-title>,&#8221; <source>Biology of Blood and Marrow Transplantation</source><volume>21</volume>, no. <issue>4</issue> (<year>2015</year>): <fpage>589</fpage>&#8211;<lpage>603</lpage>.<pub-id pub-id-type="pmid">25639770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2014.12.031</pub-id><pub-id pub-id-type="pmcid">PMC4359636</pub-id></mixed-citation></ref><ref id="imm70010-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="imm70010-cit-0007"><string-name name-style="western"><given-names>H.</given-names><surname>Major&#8208;Monfried</surname></string-name>, <string-name name-style="western"><given-names>A. S.</given-names><surname>Renteria</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Pawarode</surname></string-name>, et&#160;al., &#8220;<article-title>MAGIC Biomarkers Predict Long&#8208;Term Outcomes for Steroid&#8208;Resistant Acute GVHD</article-title>,&#8221; <source>Blood</source><volume>131</volume>, no. <issue>25</issue> (<year>2018</year>): <fpage>2846</fpage>&#8211;<lpage>2855</lpage>.<pub-id pub-id-type="pmid">29545329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2018-01-822957</pub-id><pub-id pub-id-type="pmcid">PMC6014357</pub-id></mixed-citation></ref><ref id="imm70010-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="imm70010-cit-0008"><string-name name-style="western"><given-names>M.</given-names><surname>Barton&#8208;Burke</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Dwinell</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Kafkas</surname></string-name>, et&#160;al., &#8220;<article-title>Graft&#8208;Versus&#8208;Host Disease: A Complex Long&#8208;Term Side Effect of Hematopoietic Stem Cell Transplant</article-title>,&#8221; <source>Oncology (Williston Park, N.Y.)</source><volume>22</volume>, no. <issue>11 Suppl Nurse Ed</issue> (<year>2008</year>): <fpage>31</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">19856578</pub-id></mixed-citation></ref><ref id="imm70010-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="imm70010-cit-0009"><string-name name-style="western"><given-names>C. A.</given-names><surname>Wysocki</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Panoskaltsis&#8208;Mortari</surname></string-name>, <string-name name-style="western"><given-names>B. R.</given-names><surname>Blazar</surname></string-name>, and <string-name name-style="western"><given-names>J. S.</given-names><surname>Serody</surname></string-name>, &#8220;<article-title>Leukocyte Migration and Graft&#8208;Versus&#8208;Host Disease</article-title>,&#8221; <source>Blood</source><volume>105</volume>, no. <issue>11</issue> (<year>2005</year>): <fpage>4191</fpage>&#8211;<lpage>4199</lpage>.<pub-id pub-id-type="pmid">15701715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2004-12-4726</pub-id><pub-id pub-id-type="pmcid">PMC1895033</pub-id></mixed-citation></ref><ref id="imm70010-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="imm70010-cit-0010"><string-name name-style="western"><given-names>M. A.</given-names><surname>Schroeder</surname></string-name> and <string-name name-style="western"><given-names>J. F.</given-names><surname>DiPersio</surname></string-name>, &#8220;<article-title>Mouse Models of Graft&#8208;Versus&#8208;Host Disease: Advances and Limitations</article-title>,&#8221; <source>Disease Models &amp; Mechanisms</source><volume>4</volume>, no. <issue>3</issue> (<year>2011</year>): <fpage>318</fpage>&#8211;<lpage>333</lpage>.<pub-id pub-id-type="pmid">21558065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dmm.006668</pub-id><pub-id pub-id-type="pmcid">PMC3097454</pub-id></mixed-citation></ref><ref id="imm70010-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="imm70010-cit-0011"><string-name name-style="western"><given-names>F.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Hu</surname></string-name>, et&#160;al., &#8220;<article-title>Risk Factors for Graft&#8208;Versus&#8208;Host Disease After Transplantation of Hematopoietic Stem Cells From Unrelated Donors in the China Marrow Donor Program</article-title>,&#8221; <source>Annals of Transplantation</source><volume>22</volume> (<year>2017</year>): <fpage>384</fpage>&#8211;<lpage>401</lpage>.<pub-id pub-id-type="pmid">28652564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/AOT.902805</pub-id><pub-id pub-id-type="pmcid">PMC6248289</pub-id></mixed-citation></ref><ref id="imm70010-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="imm70010-cit-0012"><string-name name-style="western"><given-names>M. P.</given-names><surname>Devetten</surname></string-name> and <string-name name-style="western"><given-names>J. M.</given-names><surname>Vose</surname></string-name>, &#8220;<article-title>Graft&#8208;Versus&#8208;Host Disease: How to Translate New Insights Into New Therapeutic Strategies</article-title>,&#8221; <source>Biology of Blood and Marrow Transplantation</source><volume>10</volume>, no. <issue>12</issue> (<year>2004</year>): <fpage>815</fpage>&#8211;<lpage>825</lpage>.<pub-id pub-id-type="pmid">15570250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2004.10.005</pub-id></mixed-citation></ref><ref id="imm70010-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="imm70010-cit-0013"><string-name name-style="western"><given-names>M. O.</given-names><surname>Jamil</surname></string-name> and <string-name name-style="western"><given-names>S.</given-names><surname>Mineishi</surname></string-name>, &#8220;<article-title>State&#8208;Of&#8208;The&#8208;Art Acute and Chronic GVHD Treatment</article-title>,&#8221; <source>International Journal of Hematology</source><volume>101</volume>, no. <issue>5</issue> (<year>2015</year>): <fpage>452</fpage>&#8211;<lpage>466</lpage>.<pub-id pub-id-type="pmid">25864189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12185-015-1785-1</pub-id></mixed-citation></ref><ref id="imm70010-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="imm70010-cit-0014"><string-name name-style="western"><given-names>A.</given-names><surname>Xhaard</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Rocha</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Bueno</surname></string-name>, et&#160;al., &#8220;<article-title>Steroid&#8208;Refractory Acute GVHD: Lack of Long&#8208;Term Improved Survival Using New Generation Anticytokine Treatment</article-title>,&#8221; <source>Biology of Blood and Marrow Transplantation</source><volume>18</volume>, no. <issue>3</issue> (<year>2012</year>): <fpage>406</fpage>&#8211;<lpage>413</lpage>.<pub-id pub-id-type="pmid">21736868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2011.06.012</pub-id></mixed-citation></ref><ref id="imm70010-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="imm70010-cit-0015"><string-name name-style="western"><given-names>C. B.</given-names><surname>Resende</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Rezende</surname></string-name>, <string-name name-style="western"><given-names>P. T.</given-names><surname>Bernardes</surname></string-name>, et&#160;al., &#8220;<article-title>Alemtuzumab as Graft&#8208;Versus&#8208;Host Disease (GVHD) Prophylaxis Strategy in a Developing Country: Lower Rate of Acute GVHD, Increased Risk of Cytomegalovirus Reactivation</article-title>,&#8221; <source>Brazilian Journal of Medical and Biological Research</source><volume>50</volume>, no. <issue>2</issue> (<year>2017</year>): <elocation-id>e5566</elocation-id>.<pub-id pub-id-type="pmid">28198910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/1414-431X20165566</pub-id><pub-id pub-id-type="pmcid">PMC5343562</pub-id></mixed-citation></ref><ref id="imm70010-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="imm70010-cit-0016"><string-name name-style="western"><given-names>G. M.</given-names><surname>Teixeira</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Bittencourt</surname></string-name>, <string-name name-style="western"><given-names>A. V.</given-names><surname>de Macedo</surname></string-name>, <string-name name-style="western"><given-names>G. H.</given-names><surname>Martinho</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Colosimo</surname></string-name>, and <string-name name-style="western"><given-names>S. M.</given-names><surname>Rezende</surname></string-name>, &#8220;<article-title>Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country</article-title>,&#8221; <source>PLoS One</source><volume>10</volume>, no. <issue>9</issue> (<year>2015</year>): <elocation-id>e0137390</elocation-id>.<pub-id pub-id-type="pmid">26394228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0137390</pub-id><pub-id pub-id-type="pmcid">PMC4578937</pub-id></mixed-citation></ref><ref id="imm70010-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="imm70010-cit-0017"><string-name name-style="western"><given-names>B. M.</given-names><surname>Sandmaier</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Kornblit</surname></string-name>, <string-name name-style="western"><given-names>B. E.</given-names><surname>Storer</surname></string-name>, et&#160;al., &#8220;<article-title>Addition of Sirolimus to Standard Cyclosporine Plus Mycophenolate Mofetil&#8208;Based Graft&#8208;Versus&#8208;Host Disease Prophylaxis for Patients After Unrelated Non&#8208;Myeloablative Haemopoietic Stem Cell Transplantation: A Multicentre, Randomised, Phase 3 Trial</article-title>,&#8221; <source>Lancet Haematol</source><volume>6</volume>, no. <issue>8</issue> (<year>2019</year>): <fpage>e409</fpage>&#8211;<lpage>e418</lpage>.<pub-id pub-id-type="pmid">31248843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2352-3026(19)30088-2</pub-id><pub-id pub-id-type="pmcid">PMC6686903</pub-id></mixed-citation></ref><ref id="imm70010-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="imm70010-cit-0018"><string-name name-style="western"><given-names>R.</given-names><surname>Zeiser</surname></string-name> and <string-name name-style="western"><given-names>B. R.</given-names><surname>Blazar</surname></string-name>, &#8220;<article-title>Acute Graft&#8208;Versus&#8208;Host Disease&#8212;Biologic Process, Prevention, and Therapy</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>377</volume>, no. <issue>22</issue> (<year>2017</year>): <fpage>2167</fpage>&#8211;<lpage>2179</lpage>.<pub-id pub-id-type="pmid">29171820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1609337</pub-id><pub-id pub-id-type="pmcid">PMC6034180</pub-id></mixed-citation></ref><ref id="imm70010-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="imm70010-cit-0019"><string-name name-style="western"><given-names>A.</given-names><surname>Ganetsky</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Shah</surname></string-name>, <string-name name-style="western"><given-names>T. A.</given-names><surname>Miano</surname></string-name>, et&#160;al., &#8220;<article-title>Higher Tacrolimus Concentrations Early After Transplant Reduce the Risk of Acute GvHD in Reduced&#8208;Intensity Allogeneic Stem Cell Transplantation</article-title>,&#8221; <source>Bone Marrow Transplantation</source><volume>51</volume>, no. <issue>4</issue> (<year>2016</year>): <fpage>568</fpage>&#8211;<lpage>572</lpage>.<pub-id pub-id-type="pmid">26691423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bmt.2015.323</pub-id><pub-id pub-id-type="pmcid">PMC5775750</pub-id></mixed-citation></ref><ref id="imm70010-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="imm70010-cit-0020"><string-name name-style="western"><given-names>K.</given-names><surname>Sanber</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Savani</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Jain</surname></string-name>, &#8220;<article-title>Graft&#8208;Versus&#8208;Host Disease Risk After Chimeric Antigen Receptor T&#8208;Cell Therapy: The Diametric Opposition of T Cells</article-title>,&#8221; <source>British Journal of Haematology</source><volume>195</volume>, no. <issue>5</issue> (<year>2021</year>): <fpage>660</fpage>&#8211;<lpage>668</lpage>.<pub-id pub-id-type="pmid">34036558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjh.17544</pub-id></mixed-citation></ref><ref id="imm70010-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="imm70010-cit-0021"><string-name name-style="western"><given-names>D. W.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>B. D.</given-names><surname>Santomasso</surname></string-name>, <string-name name-style="western"><given-names>F. L.</given-names><surname>Locke</surname></string-name>, et&#160;al., &#8220;<article-title>ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated With Immune Effector Cells</article-title>,&#8221; <source>Biology of Blood and Marrow Transplantation</source><volume>25</volume>, no. <issue>4</issue> (<year>2019</year>): <fpage>625</fpage>&#8211;<lpage>638</lpage>.<pub-id pub-id-type="pmid">30592986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2018.12.758</pub-id><pub-id pub-id-type="pmcid">PMC12180426</pub-id></mixed-citation></ref><ref id="imm70010-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="imm70010-cit-0022"><string-name name-style="western"><given-names>S. J.</given-names><surname>Schuster</surname></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Bishop</surname></string-name>, <string-name name-style="western"><given-names>C. S.</given-names><surname>Tam</surname></string-name>, et&#160;al., &#8220;<article-title>Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B&#8208;Cell Lymphoma</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>380</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>45</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">30501490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1804980</pub-id></mixed-citation></ref><ref id="imm70010-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="imm70010-cit-0023"><string-name name-style="western"><given-names>F.</given-names><surname>Anwer</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Shaukat</surname></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Zahid</surname></string-name>, et&#160;al., &#8220;<article-title>Donor Origin CAR T Cells: Graft Versus Malignancy Effect Without GVHD, a Systematic Review</article-title>,&#8221; <source>Immunotherapy</source><volume>9</volume>, no. <issue>2</issue> (<year>2017</year>): <fpage>123</fpage>&#8211;<lpage>130</lpage>.<pub-id pub-id-type="pmid">28128714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/imt-2016-0127</pub-id><pub-id pub-id-type="pmcid">PMC5827793</pub-id></mixed-citation></ref><ref id="imm70010-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="imm70010-cit-0024"><string-name name-style="western"><given-names>F.</given-names><surname>Perl&#237;k</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Raskov&#225;</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Elis</surname></string-name>, &#8220;<article-title>Anti&#8208;Inflammatory Properties of N(2&#8208;Hydroxyethyl) Palmitamide</article-title>,&#8221; <source>Acta Physiologica Academiae Scientiarum Hungaricae</source><volume>39</volume>, no. <issue>4</issue> (<year>1971</year>): <fpage>395</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="pmid">5119194</pub-id></mixed-citation></ref><ref id="imm70010-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="imm70010-cit-0025"><string-name name-style="western"><given-names>F.</given-names><surname>Roviezzo</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Rossi</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Caiazzo</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide Supplementation During Sensitization Prevents Airway Allergic Symptoms in the Mouse</article-title>,&#8221; <source>Frontiers in Pharmacology</source><volume>8</volume> (<year>2017</year>): <fpage>857</fpage>.<pub-id pub-id-type="pmid">29311913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2017.00857</pub-id><pub-id pub-id-type="pmcid">PMC5732963</pub-id></mixed-citation></ref><ref id="imm70010-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="imm70010-cit-0026"><string-name name-style="western"><given-names>R.</given-names><surname>Siracusa</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Fusco</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cordaro</surname></string-name>, et&#160;al., &#8220;<article-title>The Protective Effects of Pre&#8208; and Post&#8208;Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>21</volume>, no. <issue>20</issue> (<year>2020</year>): <elocation-id>7700</elocation-id>.<pub-id pub-id-type="pmid">33080989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21207700</pub-id><pub-id pub-id-type="pmcid">PMC7589788</pub-id></mixed-citation></ref><ref id="imm70010-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="imm70010-cit-0027"><string-name name-style="western"><given-names>V.</given-names><surname>D'Antongiovanni</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Pellegrini</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Antonioli</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer's Disease</article-title>,&#8221; <source>Frontiers in Pharmacology</source><volume>12</volume> (<year>2021</year>): <elocation-id>748021</elocation-id>.<pub-id pub-id-type="pmid">34658885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.748021</pub-id><pub-id pub-id-type="pmcid">PMC8511319</pub-id></mixed-citation></ref><ref id="imm70010-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="imm70010-cit-0028"><string-name name-style="western"><given-names>G.</given-names><surname>Contarini</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Franceschini</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Facci</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Barbierato</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Giusti</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Zusso</surname></string-name>, &#8220;<article-title>A Co&#8208;Ultramicronized Palmitoylethanolamide/Luteolin Composite Mitigates Clinical Score and Disease&#8208;Relevant Molecular Markers in a Mouse Model of Experimental Autoimmune Encephalomyelitis</article-title>,&#8221; <source>Journal of Neuroinflammation</source><volume>16</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>126</fpage>.<pub-id pub-id-type="pmid">31221190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-019-1514-4</pub-id><pub-id pub-id-type="pmcid">PMC6587257</pub-id></mixed-citation></ref><ref id="imm70010-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="imm70010-cit-0029"><string-name name-style="western"><given-names>E.</given-names><surname>Gugliandolo</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>D'Amico</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cordaro</surname></string-name>, et&#160;al., &#8220;<article-title>Effect of PEA&#8208;OXA on Neuropathic Pain and Functional Recovery After Sciatic Nerve Crush</article-title>,&#8221; <source>Journal of Neuroinflammation</source><volume>15</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>264</fpage>.<pub-id pub-id-type="pmid">30217164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-018-1303-5</pub-id><pub-id pub-id-type="pmcid">PMC6137737</pub-id></mixed-citation></ref><ref id="imm70010-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="imm70010-cit-0030"><string-name name-style="western"><given-names>P.</given-names><surname>Clayton</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hill</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Bogoda</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Subah</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Venkatesh</surname></string-name>, &#8220;<article-title>Palmitoylethanolamide: A Natural Compound for Health Management</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume>, no. <issue>10</issue> (<year>2021</year>): <elocation-id>5305</elocation-id>.<pub-id pub-id-type="pmid">34069940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22105305</pub-id><pub-id pub-id-type="pmcid">PMC8157570</pub-id></mixed-citation></ref><ref id="imm70010-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="imm70010-cit-0031"><string-name name-style="western"><given-names>T. R.</given-names><surname>Romero</surname></string-name>, <string-name name-style="western"><given-names>L. C.</given-names><surname>Resende</surname></string-name>, <string-name name-style="western"><given-names>L. S.</given-names><surname>Guzzo</surname></string-name>, and <string-name name-style="western"><given-names>I. D.</given-names><surname>Duarte</surname></string-name>, &#8220;<article-title>CB1 and CB2 Cannabinoid Receptor Agonists Induce Peripheral Antinociception by Activation of the Endogenous Noradrenergic System</article-title>,&#8221; <source>Anesthesia and Analgesia</source><volume>116</volume>, no. <issue>2</issue> (<year>2013</year>): <fpage>463</fpage>&#8211;<lpage>472</lpage>.<pub-id pub-id-type="pmid">23302980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0b013e3182707859</pub-id></mixed-citation></ref><ref id="imm70010-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="imm70010-cit-0032"><string-name name-style="western"><given-names>A.</given-names><surname>D'Aloia</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Molteni</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Gullo</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective Effects</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume>, no. <issue>6</issue> (<year>2021</year>): <fpage>3054</fpage>.<pub-id pub-id-type="pmid">33802689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22063054</pub-id><pub-id pub-id-type="pmcid">PMC8002502</pub-id></mixed-citation></ref><ref id="imm70010-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="imm70010-cit-0033"><string-name name-style="western"><given-names>F.</given-names><surname>Borrelli</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Romano</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Petrosino</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide, a Naturally Occurring Lipid, Is an Orally Effective Intestinal Anti&#8208;Inflammatory Agent</article-title>,&#8221; <source>British Journal of Pharmacology</source><volume>172</volume>, no. <issue>1</issue> (<year>2015</year>): <fpage>142</fpage>&#8211;<lpage>158</lpage>.<pub-id pub-id-type="pmid">25205418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.12907</pub-id><pub-id pub-id-type="pmcid">PMC4280974</pub-id></mixed-citation></ref><ref id="imm70010-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="imm70010-cit-0034"><string-name name-style="western"><given-names>S.</given-names><surname>Petrosino</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Palazzo</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>de Novellis</surname></string-name>, et&#160;al., &#8220;<article-title>Changes in Spinal and Supraspinal Endocannabinoid Levels in Neuropathic Rats</article-title>,&#8221; <source>Neuropharmacology</source><volume>52</volume>, no. <issue>2</issue> (<year>2007</year>): <fpage>415</fpage>&#8211;<lpage>422</lpage>.<pub-id pub-id-type="pmid">17011598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2006.08.011</pub-id></mixed-citation></ref><ref id="imm70010-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="imm70010-cit-0035"><string-name name-style="western"><given-names>S.</given-names><surname>Petrosino</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Iuvone</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Di Marzo</surname></string-name>, &#8220;<article-title>N&#8208;Palmitoyl&#8208;Ethanolamine: Biochemistry and New Therapeutic Opportunities</article-title>,&#8221; <source>Biochimie</source><volume>92</volume>, no. <issue>6</issue> (<year>2010</year>): <fpage>724</fpage>&#8211;<lpage>727</lpage>.<pub-id pub-id-type="pmid">20096327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biochi.2010.01.006</pub-id></mixed-citation></ref><ref id="imm70010-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="imm70010-cit-0036"><string-name name-style="western"><given-names>L.</given-names><surname>Rankin</surname></string-name> and <string-name name-style="western"><given-names>C. J.</given-names><surname>Fowler</surname></string-name>, &#8220;<article-title>The Basal Pharmacology of Palmitoylethanolamide</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>21</volume>, no. <issue>21</issue> (<year>2020</year>): <elocation-id>7942</elocation-id>.<pub-id pub-id-type="pmid">33114698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21217942</pub-id><pub-id pub-id-type="pmcid">PMC7662788</pub-id></mixed-citation></ref><ref id="imm70010-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="imm70010-cit-0037"><string-name name-style="western"><given-names>P.</given-names><surname>Rinne</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Guillamat&#8208;Prats</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Rami</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation</article-title>,&#8221; <source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>38</volume>, no. <issue>11</issue> (<year>2018</year>): <fpage>2562</fpage>&#8211;<lpage>2575</lpage>.<pub-id pub-id-type="pmid">30354245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.118.311185</pub-id></mixed-citation></ref><ref id="imm70010-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="imm70010-cit-0038"><string-name name-style="western"><given-names>B. B.</given-names><surname>Berg</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Soares</surname></string-name>, <string-name name-style="western"><given-names>I. R.</given-names><surname>Paiva</surname></string-name>, et&#160;al., &#8220;<article-title>Cannabidiol Enhances Intestinal Cannabinoid Receptor Type 2 Receptor Expression and Activation Increasing Regulatory T Cells and Reduces Murine Acute Graft&#8208;Versus&#8208;Host Disease Without Interfering With the Graft&#8208;Versus&#8208;Leukemia Response</article-title>,&#8221; <source>Journal of Pharmacology and Experimental Therapeutics</source><volume>377</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>273</fpage>&#8211;<lpage>283</lpage>.<pub-id pub-id-type="pmid">33658314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.120.000479</pub-id></mixed-citation></ref><ref id="imm70010-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="imm70010-cit-0039"><string-name name-style="western"><given-names>W. O.</given-names><surname>B&#246;cher</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Marcus</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Shakarchy</surname></string-name>, et&#160;al., &#8220;<article-title>Antigen&#8208;Specific B and T Cells in Human/Mouse Radiation Chimera Following Immunization In&#160;Vivo</article-title>,&#8221; <source>Immunology</source><volume>96</volume>, no. <issue>4</issue> (<year>1999</year>): <fpage>634</fpage>&#8211;<lpage>641</lpage>.<pub-id pub-id-type="pmid">10233752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2567.1999.00704.x</pub-id><pub-id pub-id-type="pmcid">PMC2326778</pub-id></mixed-citation></ref><ref id="imm70010-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="imm70010-cit-0040"><string-name name-style="western"><given-names>M. G.</given-names><surname>Castor</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Rezende</surname></string-name>, <string-name name-style="western"><given-names>C. B.</given-names><surname>Resende</surname></string-name>, et&#160;al., &#8220;<article-title>Platelet&#8208;Activating Factor Receptor Plays a Role in the Pathogenesis of Graft&#8208;Versus&#8208;Host Disease by Regulating Leukocyte Recruitment, Tissue Injury, and Lethality</article-title>,&#8221; <source>Journal of Leukocyte Biology</source><volume>91</volume>, no. <issue>4</issue> (<year>2012</year>): <fpage>629</fpage>&#8211;<lpage>639</lpage>.<pub-id pub-id-type="pmid">22301794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.1111561</pub-id></mixed-citation></ref><ref id="imm70010-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="imm70010-cit-0041"><string-name name-style="western"><given-names>M. G.</given-names><surname>Castor</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Rezende</surname></string-name>, <string-name name-style="western"><given-names>P. T.</given-names><surname>Bernardes</surname></string-name>, et&#160;al., &#8220;<article-title>PI3K&#947; Controls Leukocyte Recruitment, Tissue Injury, and Lethality in a Model of Graft&#8208;Versus&#8208;Host Disease in Mice</article-title>,&#8221; <source>Journal of Leukocyte Biology</source><volume>89</volume>, no. <issue>6</issue> (<year>2011</year>): <fpage>955</fpage>&#8211;<lpage>964</lpage>.<pub-id pub-id-type="pmid">21402770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.0810464</pub-id></mixed-citation></ref><ref id="imm70010-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="imm70010-cit-0042"><string-name name-style="western"><given-names>I.</given-names><surname>Paterniti</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Impellizzeri</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Crupi</surname></string-name>, et&#160;al., &#8220;<article-title>Molecular Evidence for the Involvement of PPAR&#8208;&#948; and PPAR&#8208;&#947; in Anti&#8208;Inflammatory and Neuroprotective Activities of Palmitoylethanolamide After Spinal Cord Trauma</article-title>,&#8221; <source>Journal of Neuroinflammation</source><volume>10</volume> (<year>2013</year>): <elocation-id>20</elocation-id>.<pub-id pub-id-type="pmid">23374874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-2094-10-20</pub-id><pub-id pub-id-type="pmcid">PMC3579707</pub-id></mixed-citation></ref><ref id="imm70010-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="imm70010-cit-0043"><string-name name-style="western"><given-names>B. B.</given-names><surname>Berg</surname></string-name>, <string-name name-style="western"><given-names>A. F. S.</given-names><surname>Linhares</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Martins</surname></string-name>, et&#160;al., &#8220;<article-title>Anandamide Reduces the Migration of Lymphocytes to the Intestine by CB2 Activation and Reduces TNF&#8208;&#945; in the Target Organs, Protecting Mice From Graft&#8208;Versus&#8208;Host Disease</article-title>,&#8221; <source>European Journal of Pharmacology</source><volume>956</volume> (<year>2023</year>): <elocation-id>175932</elocation-id>.<pub-id pub-id-type="pmid">37536622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2023.175932</pub-id></mixed-citation></ref><ref id="imm70010-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="imm70010-cit-0044"><string-name name-style="western"><given-names>S.</given-names><surname>Petrosino</surname></string-name> and <string-name name-style="western"><given-names>V.</given-names><surname>Di Marzo</surname></string-name>, &#8220;<article-title>The Pharmacology of Palmitoylethanolamide and First Data on the Therapeutic Efficacy of Some of Its New Formulations</article-title>,&#8221; <source>British Journal of Pharmacology</source><volume>174</volume>, no. <issue>11</issue> (<year>2017</year>): <fpage>1349</fpage>&#8211;<lpage>1365</lpage>.<pub-id pub-id-type="pmid">27539936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.13580</pub-id><pub-id pub-id-type="pmcid">PMC5429331</pub-id></mixed-citation></ref><ref id="imm70010-bib-0045"><label>45</label><mixed-citation publication-type="book" id="imm70010-cit-0045"><string-name name-style="western"><given-names>V.</given-names><surname>di Marzo</surname></string-name> and <string-name name-style="western"><given-names>S. D.</given-names><surname>Skaper</surname></string-name>, &#8220;<part-title>Editorial (Hot Topic: Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a Pleiotropic Anti&#8208;Inflammatory Lipid Mediator)</part-title>,&#8221; in <source>Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a Pleiotropic Anti&#8208;Inflammatory Lipid Mediator</source>, vol. <volume>12</volume> (<publisher-name>United Arab Emirates</publisher-name>, <year>2013</year>), <fpage>4</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871527311312010004</pub-id><pub-id pub-id-type="pmid">23394521</pub-id></mixed-citation></ref><ref id="imm70010-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="imm70010-cit-0046"><string-name name-style="western"><given-names>C.</given-names><surname>Scuderi</surname></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Bronzuoli</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Facchinetti</surname></string-name>, et&#160;al., &#8220;<article-title>Ultramicronized Palmitoylethanolamide Rescues Learning and Memory Impairments in a Triple Transgenic Mouse Model of Alzheimer's Disease by Exerting Anti&#8208;Inflammatory and Neuroprotective Effects</article-title>,&#8221; <source>Translational Psychiatry</source><volume>8</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>32</fpage>.<pub-id pub-id-type="pmid">29382825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-017-0076-4</pub-id><pub-id pub-id-type="pmcid">PMC5802581</pub-id></mixed-citation></ref><ref id="imm70010-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="imm70010-cit-0047"><string-name name-style="western"><given-names>G.</given-names><surname>D'Agostino</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Russo</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Avagliano</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Cristiano</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Meli</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Calignano</surname></string-name>, &#8220;<article-title>Palmitoylethanolamide Protects Against the Amyloid&#8208;&#946;25&#8208;35&#8208;Induced Learning and Memory Impairment in Mice, an Experimental Model of Alzheimer Disease</article-title>,&#8221; <source>Neuropsychopharmacology</source><volume>37</volume>, no. <issue>7</issue> (<year>2012</year>): <fpage>1784</fpage>&#8211;<lpage>1792</lpage>.<pub-id pub-id-type="pmid">22414817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2012.25</pub-id><pub-id pub-id-type="pmcid">PMC3358748</pub-id></mixed-citation></ref><ref id="imm70010-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="imm70010-cit-0048"><string-name name-style="western"><given-names>D.</given-names><surname>Impellizzeri</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Esposito</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Di Paola</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide and Luteolin Ameliorate Development of Arthritis Caused by Injection of Collagen Type II in Mice</article-title>,&#8221; <source>Arthritis Research &amp; Therapy</source><volume>15</volume>, no. <issue>6</issue> (<year>2013</year>): <fpage>R192</fpage>.<pub-id pub-id-type="pmid">24246048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/ar4382</pub-id><pub-id pub-id-type="pmcid">PMC3978572</pub-id></mixed-citation></ref><ref id="imm70010-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="imm70010-cit-0049"><string-name name-style="western"><given-names>S.</given-names><surname>Clemente</surname></string-name>, &#8220;<article-title>Amyotrophic Lateral Sclerosis Treatment With Ultramicronized Palmitoylethanolamide: A Case Report</article-title>,&#8221; <source>CNS &amp; Neurological Disorders Drug Targets</source><volume>11</volume>, no. <issue>7</issue> (<year>2012</year>): <fpage>933</fpage>&#8211;<lpage>936</lpage>.<pub-id pub-id-type="pmid">22998138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871527311201070933</pub-id></mixed-citation></ref><ref id="imm70010-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="imm70010-cit-0050"><string-name name-style="western"><given-names>T.</given-names><surname>Abedini</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Hosseyni</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Ghannadi</surname></string-name>, et&#160;al., &#8220;<article-title>Efficacy and Safety of Palmitoylethanolamide as an Adjunctive Treatment for Acute Mania: A Randomized, Double&#8208;Blind, Placebo&#8208;Controlled Trial</article-title>,&#8221; <source>Psychiatry and Clinical Neurosciences</source><volume>76</volume>, no. <issue>10</issue> (<year>2022</year>): <fpage>505</fpage>&#8211;<lpage>511</lpage>.<pub-id pub-id-type="pmid">35737597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcn.13441</pub-id></mixed-citation></ref><ref id="imm70010-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="imm70010-cit-0051"><string-name name-style="western"><given-names>M.</given-names><surname>Albanese</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Marrone</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Paolino</surname></string-name>, et&#160;al., &#8220;<article-title>Effects of Ultramicronized Palmitoylethanolamide (UM&#8208;PEA) in COVID&#8208;19 Early Stages: A Case&#8208;Control Study</article-title>,&#8221; <source>Pharmaceuticals (Basel)</source><volume>15</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>253</fpage>.<pub-id pub-id-type="pmid">35215365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph15020253</pub-id><pub-id pub-id-type="pmcid">PMC8878249</pub-id></mixed-citation></ref><ref id="imm70010-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="imm70010-cit-0052"><string-name name-style="western"><given-names>J. H.</given-names><surname>Antin</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Childs</surname></string-name>, <string-name name-style="western"><given-names>A. H.</given-names><surname>Filipovich</surname></string-name>, et&#160;al., &#8220;<article-title>Establishment of Complete and Mixed Donor Chimerism After Allogeneic Lymphohematopoietic Transplantation: Recommendations From a Workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation</article-title>,&#8221; <source>Biology of Blood and Marrow Transplantation</source><volume>7</volume>, no. <issue>9</issue> (<year>2001</year>): <fpage>473</fpage>&#8211;<lpage>485</lpage>.<pub-id pub-id-type="pmid">11669214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/bbmt.2001.v7.pm11669214</pub-id></mixed-citation></ref><ref id="imm70010-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="imm70010-cit-0053"><string-name name-style="western"><given-names>F.</given-names><surname>Khan</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Agarwal</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Agrawal</surname></string-name>, &#8220;<article-title>Significance of Chimerism in Hematopoietic Stem Cell Transplantation: New Variations on an Old Theme</article-title>,&#8221; <source>Bone Marrow Transplantation</source><volume>34</volume>, no. <issue>1</issue> (<year>2004</year>): <fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">15156163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bmt.1704525</pub-id></mixed-citation></ref><ref id="imm70010-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="imm70010-cit-0054"><string-name name-style="western"><given-names>R.</given-names><surname>Admiraal</surname></string-name>, <string-name name-style="western"><given-names>C. C. H.</given-names><surname>de Koning</surname></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Lindemans</surname></string-name>, et&#160;al., &#8220;<article-title>Viral Reactivations and Associated Outcomes in the Context of Immune Reconstitution After Pediatric Hematopoietic Cell Transplantation</article-title>,&#8221; <source>Journal of Allergy and Clinical Immunology</source><volume>140</volume>, no. <issue>6</issue> (<year>2017</year>): <fpage>1643</fpage>&#8211;<lpage>1650</lpage>.<pub-id pub-id-type="pmid">28392330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2016.12.992</pub-id></mixed-citation></ref><ref id="imm70010-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="imm70010-cit-0055"><string-name name-style="western"><given-names>A.</given-names><surname>Panoskaltsis&#8208;Mortari</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Price</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Hermanson</surname></string-name>, et&#160;al., &#8220;<article-title>In Vivo Imaging of Graft&#8208;Versus&#8208;Host&#8208;Disease in Mice</article-title>,&#8221; <source>Blood</source><volume>103</volume>, no. <issue>9</issue> (<year>2004</year>): <fpage>3590</fpage>&#8211;<lpage>3598</lpage>.<pub-id pub-id-type="pmid">14715632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2003-08-2827</pub-id></mixed-citation></ref><ref id="imm70010-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="imm70010-cit-0056"><string-name name-style="western"><given-names>G.</given-names><surname>Soci&#233;</surname></string-name> and <string-name name-style="western"><given-names>B. R.</given-names><surname>Blazar</surname></string-name>, &#8220;<article-title>Acute Graft&#8208;Versus&#8208;Host Disease: From the Bench to the Bedside</article-title>,&#8221; <source>Blood</source><volume>114</volume>, no. <issue>20</issue> (<year>2009</year>): <fpage>4327</fpage>&#8211;<lpage>4336</lpage>.<pub-id pub-id-type="pmid">19713461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2009-06-204669</pub-id><pub-id pub-id-type="pmcid">PMC2777122</pub-id></mixed-citation></ref><ref id="imm70010-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="imm70010-cit-0057"><string-name name-style="western"><given-names>C. G.</given-names><surname>Brunstein</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Miller</surname></string-name>, <string-name name-style="western"><given-names>D. H.</given-names><surname>McKenna</surname></string-name>, et&#160;al., &#8220;<article-title>Umbilical Cord Blood&#8208;Derived T Regulatory Cells to Prevent GVHD: Kinetics, Toxicity Profile, and Clinical Effect</article-title>,&#8221; <source>Blood</source><volume>127</volume>, no. <issue>8</issue> (<year>2016</year>): <fpage>1044</fpage>&#8211;<lpage>1051</lpage>.<pub-id pub-id-type="pmid">26563133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2015-06-653667</pub-id><pub-id pub-id-type="pmcid">PMC4768428</pub-id></mixed-citation></ref><ref id="imm70010-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="imm70010-cit-0058"><string-name name-style="western"><given-names>A.</given-names><surname>Meyer</surname></string-name> and <string-name name-style="western"><given-names>D. M.</given-names><surname>Kofler</surname></string-name>, &#8220;<article-title>Failure of a T Cell Regulator: CD6 Contributes to the Aggravation of Autoimmune Inflammation</article-title>,&#8221; <source>Cellular &amp; Molecular Immunology</source><volume>16</volume>, no. <issue>9</issue> (<year>2019</year>): <fpage>733</fpage>&#8211;<lpage>734</lpage>.<pub-id pub-id-type="pmid">30002450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-018-0089-9</pub-id><pub-id pub-id-type="pmcid">PMC6804726</pub-id></mixed-citation></ref><ref id="imm70010-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="imm70010-cit-0059"><string-name name-style="western"><given-names>O.</given-names><surname>Duramad</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Laysang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Ishii</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Namikawa</surname></string-name>, &#8220;<article-title>Pharmacologic Expansion of Donor&#8208;Derived, Naturally Occurring CD4(+)Foxp3(+) Regulatory T Cells Reduces Acute Graft&#8208;Versus&#8208;Host Disease Lethality Without Abrogating the Graft&#8208;Versus&#8208;Leukemia Effect in Murine Models</article-title>,&#8221; <source>Biology of Blood and Marrow Transplantation</source><volume>17</volume>, no. <issue>8</issue> (<year>2011</year>): <fpage>1154</fpage>&#8211;<lpage>1168</lpage>.<pub-id pub-id-type="pmid">21145405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2010.11.022</pub-id></mixed-citation></ref><ref id="imm70010-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="imm70010-cit-0060"><string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Semple</surname></string-name>, <string-name name-style="western"><given-names>W. K.</given-names><surname>Suh</surname></string-name>, et&#160;al., &#8220;<article-title>Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft&#8208;Versus&#8208;Host Disease in Mice</article-title>,&#8221; <source>Biology of Blood and Marrow Transplantation</source><volume>17</volume>, no. <issue>7</issue> (<year>2011</year>): <fpage>962</fpage>&#8211;<lpage>969</lpage>.<pub-id pub-id-type="pmid">21447398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2011.01.018</pub-id><pub-id pub-id-type="pmcid">PMC3131782</pub-id></mixed-citation></ref><ref id="imm70010-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="imm70010-cit-0061"><string-name name-style="western"><given-names>J. U.</given-names><surname>Peled</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Hanash</surname></string-name>, and <string-name name-style="western"><given-names>R. R.</given-names><surname>Jenq</surname></string-name>, &#8220;<article-title>Role of the Intestinal Mucosa in Acute Gastrointestinal GVHD</article-title>,&#8221; <source>Hematology. American Society of Hematology. Education Program</source><volume>2016</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>119</fpage>&#8211;<lpage>127</lpage>.<pub-id pub-id-type="pmid">27913470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/asheducation-2016.1.119</pub-id><pub-id pub-id-type="pmcid">PMC5575743</pub-id></mixed-citation></ref><ref id="imm70010-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="imm70010-cit-0062"><string-name name-style="western"><given-names>M. G.</given-names><surname>Castor</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Rezende</surname></string-name>, <string-name name-style="western"><given-names>C. B.</given-names><surname>Resende</surname></string-name>, et&#160;al., &#8220;<article-title>The CCL3/Macrophage Inflammatory Protein&#8208;1alpha&#8208;Binding Protein Evasin&#8208;1 Protects From Graft&#8208;Versus&#8208;Host Disease but Does Not Modify Graft&#8208;Versus&#8208;Leukemia in Mice</article-title>,&#8221; <source>Journal of Immunology (Baltimore, Md.: 1950)</source><volume>184</volume>, no. <issue>5</issue> (<year>2010</year>): <fpage>2646</fpage>&#8211;<lpage>2654</lpage>.<pub-id pub-id-type="pmid">20100934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0902614</pub-id></mixed-citation></ref><ref id="imm70010-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="imm70010-cit-0063"><string-name name-style="western"><given-names>R.</given-names><surname>Korngold</surname></string-name> and <string-name name-style="western"><given-names>J.</given-names><surname>Sprent</surname></string-name>, &#8220;<article-title>Lethal Graft&#8208;Versus&#8208;Host Disease After Bone Marrow Transplantation Across Minor Histocompatibility Barriers in Mice. Prevention by Removing Mature T Cells From Marrow</article-title>,&#8221; <source>Journal of Experimental Medicine</source><volume>148</volume>, no. <issue>6</issue> (<year>1978</year>): <fpage>1687</fpage>&#8211;<lpage>1698</lpage>.<pub-id pub-id-type="pmid">363972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.148.6.1687</pub-id><pub-id pub-id-type="pmcid">PMC2185109</pub-id></mixed-citation></ref><ref id="imm70010-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="imm70010-cit-0064"><string-name name-style="western"><given-names>D. L.</given-names><surname>Thiele</surname></string-name>, <string-name name-style="western"><given-names>M. L.</given-names><surname>Eigenbrodt</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Bryde</surname></string-name>, <string-name name-style="western"><given-names>E. H.</given-names><surname>Eigenbrodt</surname></string-name>, and <string-name name-style="western"><given-names>P. E.</given-names><surname>Lipsky</surname></string-name>, &#8220;<article-title>Intestinal Graft&#8208;Versus&#8208;Host Disease Is Initiated by Donor T Cells Distinct From Classic Cytotoxic T Lymphocytes</article-title>,&#8221; <source>Journal of Clinical Investigation</source><volume>84</volume>, no. <issue>6</issue> (<year>1989</year>): <fpage>1947</fpage>&#8211;<lpage>1956</lpage>.<pub-id pub-id-type="pmid">2531761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI114383</pub-id><pub-id pub-id-type="pmcid">PMC304076</pub-id></mixed-citation></ref><ref id="imm70010-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="imm70010-cit-0065"><string-name name-style="western"><given-names>D.</given-names><surname>Guy&#8208;Grand</surname></string-name> and <string-name name-style="western"><given-names>P.</given-names><surname>Vassalli</surname></string-name>, &#8220;<article-title>Gut Injury in Mouse Graft&#8208;Versus&#8208;Host Reaction. Study of Its Occurrence and Mechanisms</article-title>,&#8221; <source>Journal of Clinical Investigation</source><volume>77</volume>, no. <issue>5</issue> (<year>1986</year>): <fpage>1584</fpage>&#8211;<lpage>1595</lpage>.<pub-id pub-id-type="pmid">3486193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI112474</pub-id><pub-id pub-id-type="pmcid">PMC424562</pub-id></mixed-citation></ref><ref id="imm70010-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="imm70010-cit-0066"><string-name name-style="western"><given-names>M.</given-names><surname>Murai</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yoneyama</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Harada</surname></string-name>, et&#160;al., &#8220;<article-title>Active Participation of CCR5(+)CD8(+) T Lymphocytes in the Pathogenesis of Liver Injury in Graft&#8208;Versus&#8208;Host Disease</article-title>,&#8221; <source>Journal of Clinical Investigation</source><volume>104</volume>, no. <issue>1</issue> (<year>1999</year>): <fpage>49</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">10393698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI6642</pub-id><pub-id pub-id-type="pmcid">PMC408408</pub-id></mixed-citation></ref><ref id="imm70010-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="imm70010-cit-0067"><string-name name-style="western"><given-names>J. M.</given-names><surname>El&#8208;Hayek</surname></string-name>, <string-name name-style="western"><given-names>T. E.</given-names><surname>Rogers</surname></string-name>, and <string-name name-style="western"><given-names>G. R.</given-names><surname>Brown</surname></string-name>, &#8220;<article-title>The Role of TNF in Hepatic Histopathological Manifestations and Hepatic CD8+ T Cell Alloresponses in Murine MHC Class I Disparate GVHD</article-title>,&#8221; <source>Journal of Leukocyte Biology</source><volume>78</volume>, no. <issue>4</issue> (<year>2005</year>): <fpage>1001</fpage>&#8211;<lpage>1007</lpage>.<pub-id pub-id-type="pmid">16081594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.1204730</pub-id></mixed-citation></ref><ref id="imm70010-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="imm70010-cit-0068"><string-name name-style="western"><given-names>W.</given-names><surname>Krenger</surname></string-name> and <string-name name-style="western"><given-names>J. L.</given-names><surname>Ferrara</surname></string-name>, &#8220;<article-title>Graft&#8208;Versus&#8208;Host Disease and the Th1/Th2 Paradigm</article-title>,&#8221; <source>Immunologic Research</source><volume>15</volume>, no. <issue>1</issue> (<year>1996</year>): <fpage>50</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">8739565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02918284</pub-id></mixed-citation></ref><ref id="imm70010-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="imm70010-cit-0069"><string-name name-style="western"><given-names>J. M.</given-names><surname>Coghill</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sarantopoulos</surname></string-name>, <string-name name-style="western"><given-names>T. P.</given-names><surname>Moran</surname></string-name>, <string-name name-style="western"><given-names>W. J.</given-names><surname>Murphy</surname></string-name>, <string-name name-style="western"><given-names>B. R.</given-names><surname>Blazar</surname></string-name>, and <string-name name-style="western"><given-names>J. S.</given-names><surname>Serody</surname></string-name>, &#8220;<article-title>Effector CD4+ T Cells, the Cytokines They Generate, and GVHD: Something Old and Something New</article-title>,&#8221; <source>Blood</source><volume>117</volume>, no. <issue>12</issue> (<year>2011</year>): <fpage>3268</fpage>&#8211;<lpage>3276</lpage>.<pub-id pub-id-type="pmid">21245483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2010-12-290403</pub-id><pub-id pub-id-type="pmcid">PMC3069668</pub-id></mixed-citation></ref><ref id="imm70010-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="imm70010-cit-0070"><string-name name-style="western"><given-names>M. L.</given-names><surname>Alegre</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Frauwirth</surname></string-name>, and <string-name name-style="western"><given-names>C. B.</given-names><surname>Thompson</surname></string-name>, &#8220;<article-title>T&#8208;Cell Regulation by CD28 and CTLA&#8208;4</article-title>,&#8221; <source>Nature Reviews. Immunology</source><volume>1</volume>, no. <issue>3</issue> (<year>2001</year>): <fpage>220</fpage>&#8211;<lpage>228</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35105024</pub-id><pub-id pub-id-type="pmid">11905831</pub-id></mixed-citation></ref><ref id="imm70010-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="imm70010-cit-0071"><string-name name-style="western"><given-names>B.</given-names><surname>Salomon</surname></string-name> and <string-name name-style="western"><given-names>J. A.</given-names><surname>Bluestone</surname></string-name>, &#8220;<article-title>Complexities of CD28/B7: CTLA&#8208;4 Costimulatory Pathways in Autoimmunity and Transplantation</article-title>,&#8221; <source>Annual Review of Immunology</source><volume>19</volume> (<year>2001</year>): <fpage>225</fpage>&#8211;<lpage>252</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.immunol.19.1.225</pub-id><pub-id pub-id-type="pmid">11244036</pub-id></mixed-citation></ref><ref id="imm70010-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="imm70010-cit-0072"><string-name name-style="western"><given-names>A. J.</given-names><surname>Coyle</surname></string-name> and <string-name name-style="western"><given-names>J. C.</given-names><surname>Gutierrez&#8208;Ramos</surname></string-name>, &#8220;<article-title>The Expanding B7 Superfamily: Increasing Complexity in Costimulatory Signals Regulating T Cell Function</article-title>,&#8221; <source>Nature Immunology</source><volume>2</volume>, no. <issue>3</issue> (<year>2001</year>): <fpage>203</fpage>&#8211;<lpage>209</lpage>.<pub-id pub-id-type="pmid">11224518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/85251</pub-id></mixed-citation></ref><ref id="imm70010-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="imm70010-cit-0073"><string-name name-style="western"><given-names>J. A.</given-names><surname>Gonzalo</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Tian</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Delaney</surname></string-name>, et&#160;al., &#8220;<article-title>ICOS Is Critical for T Helper Cell&#8208;Mediated Lung Mucosal Inflammatory Responses</article-title>,&#8221; <source>Nature Immunology</source><volume>2</volume>, no. <issue>7</issue> (<year>2001</year>): <fpage>597</fpage>&#8211;<lpage>604</lpage>.<pub-id pub-id-type="pmid">11429543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/89739</pub-id></mixed-citation></ref><ref id="imm70010-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="imm70010-cit-0074"><string-name name-style="western"><given-names>E.</given-names><surname>Ozkaynak</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Shemmeri</surname></string-name>, et&#160;al., &#8220;<article-title>Importance of ICOS&#8208;B7RP&#8208;1 Costimulation in Acute and Chronic Allograft Rejection</article-title>,&#8221; <source>Nature Immunology</source><volume>2</volume>, no. <issue>7</issue> (<year>2001</year>): <fpage>591</fpage>&#8211;<lpage>596</lpage>.<pub-id pub-id-type="pmid">11429542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/89731</pub-id></mixed-citation></ref><ref id="imm70010-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="imm70010-cit-0075"><string-name name-style="western"><given-names>J. B.</given-names><surname>Rottman</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Tonra</surname></string-name>, et&#160;al., &#8220;<article-title>The Costimulatory Molecule ICOS Plays an Important Role in the Immunopathogenesis of EAE</article-title>,&#8221; <source>Nature Immunology</source><volume>2</volume>, no. <issue>7</issue> (<year>2001</year>): <fpage>605</fpage>&#8211;<lpage>611</lpage>.<pub-id pub-id-type="pmid">11429544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/89750</pub-id></mixed-citation></ref><ref id="imm70010-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="imm70010-cit-0076"><string-name name-style="western"><given-names>M. M.</given-names><surname>Swallow</surname></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Wallin</surname></string-name>, and <string-name name-style="western"><given-names>W. C.</given-names><surname>Sha</surname></string-name>, &#8220;<article-title>B7h, a Novel Costimulatory Homolog of B7.1 and B7.2, Is Induced by TNFalpha</article-title>,&#8221; <source>Immunity</source><volume>11</volume>, no. <issue>4</issue> (<year>1999</year>): <fpage>423</fpage>&#8211;<lpage>432</lpage>.<pub-id pub-id-type="pmid">10549624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1074-7613(00)80117-x</pub-id></mixed-citation></ref><ref id="imm70010-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="imm70010-cit-0077"><string-name name-style="western"><given-names>S. K.</given-names><surname>Yoshinaga</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Whoriskey</surname></string-name>, <string-name name-style="western"><given-names>S. D.</given-names><surname>Khare</surname></string-name>, et&#160;al., &#8220;<article-title>T&#8208;Cell Co&#8208;Stimulation Through B7RP&#8208;1 and ICOS</article-title>,&#8221; <source>Nature</source><volume>402</volume>, no. <issue>6763</issue> (<year>1999</year>): <fpage>827</fpage>&#8211;<lpage>832</lpage>.<pub-id pub-id-type="pmid">10617205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/45582</pub-id></mixed-citation></ref><ref id="imm70010-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="imm70010-cit-0078"><string-name name-style="western"><given-names>B. R.</given-names><surname>Blazar</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Taylor</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Panoskaltsis&#8208;Mortari</surname></string-name>, <string-name name-style="western"><given-names>A. H.</given-names><surname>Sharpe</surname></string-name>, and <string-name name-style="western"><given-names>D. A.</given-names><surname>Vallera</surname></string-name>, &#8220;<article-title>Opposing Roles of CD28:B7 and CTLA&#8208;4:B7 Pathways in Regulating In&#160;Vivo Alloresponses in Murine Recipients of MHC Disparate T Cells</article-title>,&#8221; <source>Journal of Immunology</source><volume>162</volume>, no. <issue>11</issue> (<year>1999</year>): <fpage>6368</fpage>&#8211;<lpage>6377</lpage>.<pub-id pub-id-type="pmid">10352249</pub-id></mixed-citation></ref><ref id="imm70010-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="imm70010-cit-0079"><string-name name-style="western"><given-names>X. Z.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>P. J.</given-names><surname>Martin</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Anasetti</surname></string-name>, &#8220;<article-title>Role of CD28 in Acute Graft&#8208;Versus&#8208;Host Disease</article-title>,&#8221; <source>Blood</source><volume>92</volume>, no. <issue>8</issue> (<year>1998</year>): <fpage>2963</fpage>&#8211;<lpage>2970</lpage>.<pub-id pub-id-type="pmid">9763584</pub-id></mixed-citation></ref><ref id="imm70010-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="imm70010-cit-0080"><string-name name-style="western"><given-names>V. M.</given-names><surname>Hubbard</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Eng</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ramirez&#8208;Montagut</surname></string-name>, et&#160;al., &#8220;<article-title>Absence of Inducible Costimulator on Alloreactive T Cells Reduces Graft Versus Host Disease and Induces Th2 Deviation</article-title>,&#8221; <source>Blood</source><volume>106</volume>, no. <issue>9</issue> (<year>2005</year>): <fpage>3285</fpage>&#8211;<lpage>3292</lpage>.<pub-id pub-id-type="pmid">15956289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2005-01-0410</pub-id><pub-id pub-id-type="pmcid">PMC1895338</pub-id></mixed-citation></ref><ref id="imm70010-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="imm70010-cit-0081"><string-name name-style="western"><given-names>P. A.</given-names><surname>Taylor</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Panoskaltsis&#8208;Mortari</surname></string-name>, <string-name name-style="western"><given-names>G. J.</given-names><surname>Freeman</surname></string-name>, et&#160;al., &#8220;<article-title>Targeting of Inducible Costimulator (ICOS) Expressed on Alloreactive T Cells Down&#8208;Regulates Graft&#8208;Versus&#8208;Host Disease (GVHD) and Facilitates Engraftment of Allogeneic Bone Marrow (BM)</article-title>,&#8221; <source>Blood</source><volume>105</volume>, no. <issue>8</issue> (<year>2005</year>): <fpage>3372</fpage>&#8211;<lpage>3380</lpage>.<pub-id pub-id-type="pmid">15618467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2004-10-3869</pub-id></mixed-citation></ref><ref id="imm70010-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="imm70010-cit-0082"><string-name name-style="western"><given-names>R.</given-names><surname>Nurieva</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Thomas</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Nguyen</surname></string-name>, et&#160;al., &#8220;<article-title>T&#8208;Cell Tolerance or Function Is Determined by Combinatorial Costimulatory Signals</article-title>,&#8221; <source>EMBO Journal</source><volume>25</volume>, no. <issue>11</issue> (<year>2006</year>): <fpage>2623</fpage>&#8211;<lpage>2633</lpage>.<pub-id pub-id-type="pmid">16724117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.emboj.7601146</pub-id><pub-id pub-id-type="pmcid">PMC1478197</pub-id></mixed-citation></ref><ref id="imm70010-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="imm70010-cit-0083"><string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zheng</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Kulkarni</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide Regulates Development of Intestinal Radiation Injury in a Mast Cell&#8208;Dependent Manner</article-title>,&#8221; <source>Digestive Diseases and Sciences</source><volume>59</volume>, no. <issue>11</issue> (<year>2014</year>): <fpage>2693</fpage>&#8211;<lpage>2703</lpage>.<pub-id pub-id-type="pmid">24848354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-014-3212-5</pub-id><pub-id pub-id-type="pmcid">PMC4213290</pub-id></mixed-citation></ref><ref id="imm70010-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="imm70010-cit-0084"><string-name name-style="western"><given-names>A. F.</given-names><surname>Peritore</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>D'Amico</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Siracusa</surname></string-name>, et&#160;al., &#8220;<article-title>Management of Acute Lung Injury: Palmitoylethanolamide as a New Approach</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume>, no. <issue>11</issue> (<year>2021</year>): <elocation-id>5533</elocation-id>.<pub-id pub-id-type="pmid">34073872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22115533</pub-id><pub-id pub-id-type="pmcid">PMC8197255</pub-id></mixed-citation></ref><ref id="imm70010-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="imm70010-cit-0085"><string-name name-style="western"><given-names>D.</given-names><surname>Di Paola</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Natale</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Iaria</surname></string-name>, et&#160;al., &#8220;<article-title>Intestinal Disorder in Zebrafish Larvae (<italic toggle="yes">Danio Rerio</italic>): The Protective Action of N&#8208;Palmitoylethanolamide&#8208;Oxazoline</article-title>,&#8221; <source>Life (Basel)</source><volume>12</volume>, no. <issue>1</issue> (<year>2022</year>): <elocation-id>125</elocation-id>.<pub-id pub-id-type="pmid">35054518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life12010125</pub-id><pub-id pub-id-type="pmcid">PMC8778351</pub-id></mixed-citation></ref><ref id="imm70010-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="imm70010-cit-0086"><string-name name-style="western"><given-names>J. E.</given-names><surname>Levine</surname></string-name>, &#8220;<article-title>Implications of TNF&#8208;&#945; in the Pathogenesis and Management of GVHD</article-title>,&#8221; <source>International Journal of Hematology</source><volume>93</volume>, no. <issue>5</issue> (<year>2011</year>): <fpage>571</fpage>&#8211;<lpage>577</lpage>.<pub-id pub-id-type="pmid">21384095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12185-011-0803-1</pub-id><pub-id pub-id-type="pmcid">PMC3488873</pub-id></mixed-citation></ref><ref id="imm70010-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="imm70010-cit-0087"><string-name name-style="western"><given-names>T.</given-names><surname>Genovese</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Esposito</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Mazzon</surname></string-name>, et&#160;al., &#8220;<article-title>Effects of Palmitoylethanolamide on Signaling Pathways Implicated in the Development of Spinal Cord Injury</article-title>,&#8221; <source>Journal of Pharmacology and Experimental Therapeutics</source><volume>326</volume>, no. <issue>1</issue> (<year>2008</year>): <fpage>12</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">18367664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.108.136903</pub-id></mixed-citation></ref><ref id="imm70010-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="imm70010-cit-0088"><string-name name-style="western"><given-names>C.</given-names><surname>Scuderi</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Esposito</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Blasio</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide Counteracts Reactive Astrogliosis Induced by &#946;&#8208;Amyloid Peptide</article-title>,&#8221; <source>Journal of Cellular and Molecular Medicine</source><volume>15</volume>, no. <issue>12</issue> (<year>2011</year>): <fpage>2664</fpage>&#8211;<lpage>2674</lpage>.<pub-id pub-id-type="pmid">21255263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1582-4934.2011.01267.x</pub-id><pub-id pub-id-type="pmcid">PMC4373435</pub-id></mixed-citation></ref><ref id="imm70010-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="imm70010-cit-0089"><string-name name-style="western"><given-names>R.</given-names><surname>Fusco</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Scuto</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cordaro</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide&#8208;Oxazoline Protects Against Middle Cerebral Artery Occlusion Injury in Diabetic Rats by Regulating the SIRT1 Pathway</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>20</volume>, no. <issue>19</issue> (<year>2019</year>): <elocation-id>4845</elocation-id>.<pub-id pub-id-type="pmid">31569558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20194845</pub-id><pub-id pub-id-type="pmcid">PMC6801841</pub-id></mixed-citation></ref><ref id="imm70010-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="imm70010-cit-0090"><string-name name-style="western"><given-names>U.</given-names><surname>Hohmann</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pelzer</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Kleine</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Hohmann</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ghadban</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Dehghani</surname></string-name>, &#8220;<article-title>Opposite Effects of Neuroprotective Cannabinoids, Palmitoylethanolamide, and 2&#8208;Arachidonoylglycerol on Function and Morphology of Microglia</article-title>,&#8221; <source>Frontiers in Neuroscience</source><volume>13</volume> (<year>2019</year>): <fpage>1180</fpage>.<pub-id pub-id-type="pmid">31787870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2019.01180</pub-id><pub-id pub-id-type="pmcid">PMC6853843</pub-id></mixed-citation></ref><ref id="imm70010-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="imm70010-cit-0091"><string-name name-style="western"><given-names>S.</given-names><surname>Petrosino</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cordaro</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Verde</surname></string-name>, et&#160;al., &#8220;<article-title>Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti&#8208;Hyperalgesic Effect</article-title>,&#8221; <source>Frontiers in Pharmacology</source><volume>9</volume> (<year>2018</year>): <fpage>249</fpage>.<pub-id pub-id-type="pmid">29615912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2018.00249</pub-id><pub-id pub-id-type="pmcid">PMC5870042</pub-id></mixed-citation></ref><ref id="imm70010-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="imm70010-cit-0092"><string-name name-style="western"><given-names>D.</given-names><surname>De Filippis</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Luongo</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cipriano</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide Reduces Granuloma&#8208;Induced Hyperalgesia by Modulation of Mast Cell Activation in Rats</article-title>,&#8221; <source>Molecular Pain</source><volume>7</volume> (<year>2011</year>): <elocation-id>3</elocation-id>.<pub-id pub-id-type="pmid">21219627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1744-8069-7-3</pub-id><pub-id pub-id-type="pmcid">PMC3034677</pub-id></mixed-citation></ref><ref id="imm70010-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="imm70010-cit-0093"><string-name name-style="western"><given-names>J.</given-names><surname>Rozmus</surname></string-name>, <string-name name-style="western"><given-names>K. R.</given-names><surname>Schultz</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Wynne</surname></string-name>, et&#160;al., &#8220;<article-title>Early and Late Extensive Chronic Graft&#8208;Versus&#8208;Host Disease in Children Is Characterized by Different Th1/Th2 Cytokine Profiles: Findings of the Children's Oncology Group Study ASCT0031</article-title>,&#8221; <source>Biology of Blood and Marrow Transplantation</source><volume>17</volume>, no. <issue>12</issue> (<year>2011</year>): <fpage>1804</fpage>&#8211;<lpage>1813</lpage>.<pub-id pub-id-type="pmid">21669298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2011.05.011</pub-id><pub-id pub-id-type="pmcid">PMC3190042</pub-id></mixed-citation></ref><ref id="imm70010-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="imm70010-cit-0094"><string-name name-style="western"><given-names>D.</given-names><surname>Impellizzeri</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Siracusa</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cordaro</surname></string-name>, et&#160;al., &#8220;<article-title>N&#8208;Palmitoylethanolamine&#8208;Oxazoline (PEA&#8208;OXA): A New Therapeutic Strategy to Reduce Neuroinflammation, Oxidative Stress Associated to Vascular Dementia in an Experimental Model of Repeated Bilateral Common Carotid Arteries Occlusion</article-title>,&#8221; <source>Neurobiology of Disease</source><volume>125</volume> (<year>2019</year>): <fpage>77</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">30660740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2019.01.007</pub-id></mixed-citation></ref><ref id="imm70010-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="imm70010-cit-0095"><string-name name-style="western"><given-names>J.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Ying</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Yao</surname></string-name>, et&#160;al., &#8220;<article-title>Micronized Palmitoylethanolamide Ameliorates Methionine&#8208; and Choline&#8208;Deficient Diet&#8208;Induced Nonalcoholic Steatohepatitis</article-title>,&#8221; <source>Frontiers in Pharmacology</source><volume>12</volume> (<year>2021</year>): <fpage>744483</fpage>.<pub-id pub-id-type="pmid">34712137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.744483</pub-id><pub-id pub-id-type="pmcid">PMC8546106</pub-id></mixed-citation></ref><ref id="imm70010-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="imm70010-cit-0096"><string-name name-style="western"><given-names>A.</given-names><surname>Calignano</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>La Rana</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Giuffrida</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Piomelli</surname></string-name>, &#8220;<article-title>Control of Pain Initiation by Endogenous Cannabinoids</article-title>,&#8221; <source>Nature</source><volume>394</volume>, no. <issue>6690</issue> (<year>1998</year>): <fpage>277</fpage>&#8211;<lpage>281</lpage>.<pub-id pub-id-type="pmid">9685157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/28393</pub-id></mixed-citation></ref><ref id="imm70010-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="imm70010-cit-0097"><string-name name-style="western"><given-names>M. D.</given-names><surname>Jhaveri</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Richardson</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Robinson</surname></string-name>, et&#160;al., &#8220;<article-title>Inhibition of Fatty Acid Amide Hydrolase and Cyclooxygenase&#8208;2 Increases Levels of Endocannabinoid Related Molecules and Produces Analgesia via Peroxisome Proliferator&#8208;Activated Receptor&#8208;Alpha in a Model of Inflammatory Pain</article-title>,&#8221; <source>Neuropharmacology</source><volume>55</volume>, no. <issue>1</issue> (<year>2008</year>): <fpage>85</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">18534634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2008.04.018</pub-id></mixed-citation></ref><ref id="imm70010-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="imm70010-cit-0098"><string-name name-style="western"><given-names>I.</given-names><surname>Galve&#8208;Roperh</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Chiurchi&#249;</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>D&#237;az&#8208;Alonso</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Bari</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Guzm&#225;n</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Maccarrone</surname></string-name>, &#8220;<article-title>Cannabinoid Receptor Signaling in Progenitor/Stem Cell Proliferation and Differentiation</article-title>,&#8221; <source>Progress in Lipid Research</source><volume>52</volume>, no. <issue>4</issue> (<year>2013</year>): <fpage>633</fpage>&#8211;<lpage>650</lpage>.<pub-id pub-id-type="pmid">24076098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.plipres.2013.05.004</pub-id></mixed-citation></ref><ref id="imm70010-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="imm70010-cit-0099"><string-name name-style="western"><given-names>R. G.</given-names><surname>Pertwee</surname></string-name> and <string-name name-style="western"><given-names>R. A.</given-names><surname>Ross</surname></string-name>, &#8220;<article-title>Cannabinoid Receptors and Their Ligands</article-title>,&#8221; <source>Prostaglandins, Leukotrienes, and Essential Fatty Acids</source><volume>66</volume>, no. <issue>2&#8211;3</issue> (<year>2002</year>): <fpage>101</fpage>&#8211;<lpage>121</lpage>.<pub-id pub-id-type="pmid">12052030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1054/plef.2001.0341</pub-id></mixed-citation></ref><ref id="imm70010-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="imm70010-cit-0100"><string-name name-style="western"><given-names>R. G.</given-names><surname>Pertwee</surname></string-name>, &#8220;<article-title>The Pharmacology of Cannabinoid Receptors and Their Ligands: An Overview</article-title>,&#8221; <source>International Journal of Obesity (London)</source><volume>30</volume>, no. <issue>Suppl 1</issue> (<year>2006</year>): <fpage>S13</fpage>&#8211;<lpage>S18</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.ijo.0803272</pub-id><pub-id pub-id-type="pmid">16570099</pub-id></mixed-citation></ref><ref id="imm70010-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="imm70010-cit-0101"><string-name name-style="western"><given-names>R. G.</given-names><surname>Pertwee</surname></string-name>, &#8220;<article-title>Endocannabinoids and Their Pharmacological Actions</article-title>,&#8221; <source>Handbook of Experimental Pharmacology</source><volume>231</volume> (<year>2015</year>): <fpage>1</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">26408156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-319-20825-1_1</pub-id></mixed-citation></ref><ref id="imm70010-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="imm70010-cit-0102"><string-name name-style="western"><given-names>G.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Fu</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide Ameliorates Neuroinflammation via Modulating PPAR&#8208;&#945; to Promote the Functional Outcome After Intracerebral Hemorrhage</article-title>,&#8221; <source>Neuroscience Letters</source><volume>781</volume> (<year>2022</year>): <elocation-id>136648</elocation-id>.<pub-id pub-id-type="pmid">35469820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2022.136648</pub-id></mixed-citation></ref><ref id="imm70010-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="imm70010-cit-0103"><string-name name-style="western"><given-names>E. K.</given-names><surname>Song</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Yim</surname></string-name>, <string-name name-style="western"><given-names>J. Y.</given-names><surname>Yim</surname></string-name>, et&#160;al., &#8220;<article-title>Rosiglitazone Prevents Graft&#8208;Versus&#8208;Host Disease (GVHD)</article-title>,&#8221; <source>Transplantation Immunology</source><volume>27</volume>, no. <issue>2&#8211;30</issue> (<year>2012</year>): <fpage>128</fpage>&#8211;<lpage>137</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trim.2012.09.001</pub-id><pub-id pub-id-type="pmid">22982856</pub-id></mixed-citation></ref><ref id="imm70010-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="imm70010-cit-0104"><string-name name-style="western"><given-names>B.</given-names><surname>Costa</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Comelli</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Bettoni</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Colleoni</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Giagnoni</surname></string-name>, &#8220;<article-title>The Endogenous Fatty Acid Amide, Palmitoylethanolamide, Has Anti&#8208;Allodynic and Anti&#8208;Hyperalgesic Effects in a Murine Model of Neuropathic Pain: Involvement of CB(1), TRPV1 and PPARgamma Receptors and Neurotrophic Factors</article-title>,&#8221; <source>Pain</source><volume>139</volume>, no. <issue>3</issue> (<year>2008</year>): <fpage>541</fpage>&#8211;<lpage>550</lpage>.<pub-id pub-id-type="pmid">18602217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2008.06.003</pub-id></mixed-citation></ref><ref id="imm70010-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="imm70010-cit-0105"><string-name name-style="western"><given-names>S. E.</given-names><surname>O'Sullivan</surname></string-name>, &#8220;<article-title>An Update on PPAR Activation by Cannabinoids</article-title>,&#8221; <source>British Journal of Pharmacology</source><volume>173</volume>, no. <issue>12</issue> (<year>2016</year>): <fpage>1899</fpage>&#8211;<lpage>1910</lpage>.<pub-id pub-id-type="pmid">27077495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.13497</pub-id><pub-id pub-id-type="pmcid">PMC4882496</pub-id></mixed-citation></ref><ref id="imm70010-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="imm70010-cit-0106"><string-name name-style="western"><given-names>R.</given-names><surname>Di Paola</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Impellizzeri</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Torre</surname></string-name>, et&#160;al., &#8220;<article-title>Effects of Palmitoylethanolamide on Intestinal Injury and Inflammation Caused by Ischemia&#8208;Reperfusion in Mice</article-title>,&#8221; <source>Journal of Leukocyte Biology</source><volume>91</volume>, no. <issue>6</issue> (<year>2012</year>): <fpage>911</fpage>&#8211;<lpage>920</lpage>.<pub-id pub-id-type="pmid">22469754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.0911485</pub-id></mixed-citation></ref><ref id="imm70010-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="imm70010-cit-0107"><string-name name-style="western"><given-names>H. J.</given-names><surname>Kolb</surname></string-name>, &#8220;<article-title>Graft&#8208;Versus&#8208;Leukemia Effects of Transplantation and Donor Lymphocytes</article-title>,&#8221; <source>Blood</source><volume>112</volume>, no. <issue>12</issue> (<year>2008</year>): <fpage>4371</fpage>&#8211;<lpage>4383</lpage>.<pub-id pub-id-type="pmid">19029455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2008-03-077974</pub-id></mixed-citation></ref><ref id="imm70010-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="imm70010-cit-0108"><string-name name-style="western"><given-names>K.</given-names><surname>van Besien</surname></string-name>, &#8220;<article-title>Allogeneic Transplantation for AML and MDS: GVL Versus GVHD and Disease Recurrence</article-title>,&#8221; <source>Hematology. American Society of Hematology. Education Program</source><volume>2013</volume> (<year>2013</year>): <fpage>56</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">24319163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/asheducation-2013.1.56</pub-id></mixed-citation></ref><ref id="imm70010-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="imm70010-cit-0109"><string-name name-style="western"><given-names>E.</given-names><surname>Pagano</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Venneri</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Lucariello</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylethanolamide Reduces Colon Cancer Cell Proliferation and Migration, Influences Tumor Cell Cycle and Exerts in Vivo Chemopreventive Effects</article-title>,&#8221; <source>Cancers</source><volume>13</volume>, no. <issue>8</issue> (<year>2021</year>): <elocation-id>1923</elocation-id>.<pub-id pub-id-type="pmid">33923494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13081923</pub-id><pub-id pub-id-type="pmcid">PMC8073478</pub-id></mixed-citation></ref><ref id="imm70010-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="imm70010-cit-0110"><string-name name-style="western"><given-names>C.</given-names><surname>Camoglio</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Balla</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Fadda</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Dedoni</surname></string-name>, &#8220;<article-title>Oleoylethanolamide and Palmitoylethanolamide Enhance IFN&#946;&#8208;Induced Apoptosis in Human Neuroblastoma SH&#8208;SY5Y Cells</article-title>,&#8221; <source>Molecules</source><volume>29</volume>, no. <issue>7</issue> (<year>2024</year>): <fpage>1592</fpage>.<pub-id pub-id-type="pmid">38611871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules29071592</pub-id><pub-id pub-id-type="pmcid">PMC11013881</pub-id></mixed-citation></ref><ref id="imm70010-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="imm70010-cit-0111"><string-name name-style="western"><given-names>P. A.</given-names><surname>Taylor</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Lees</surname></string-name>, and <string-name name-style="western"><given-names>B. R.</given-names><surname>Blazar</surname></string-name>, &#8220;<article-title>The Infusion of Ex&#160;Vivo Activated and Expanded CD4(+)CD25(+) Immune Regulatory Cells Inhibits Graft&#8208;Versus&#8208;Host Disease Lethality</article-title>,&#8221; <source>Blood</source><volume>99</volume>, no. <issue>10</issue> (<year>2002</year>): <fpage>3493</fpage>&#8211;<lpage>3499</lpage>.<pub-id pub-id-type="pmid">11986199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.v99.10.3493</pub-id></mixed-citation></ref><ref id="imm70010-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="imm70010-cit-0112"><string-name name-style="western"><given-names>D.</given-names><surname>Schneidawind</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Pierini</surname></string-name>, and <string-name name-style="western"><given-names>R. S.</given-names><surname>Negrin</surname></string-name>, &#8220;<article-title>Regulatory T Cells and Natural Killer T Cells for Modulation of GVHD Following Allogeneic Hematopoietic Cell Transplantation</article-title>,&#8221; <source>Blood</source><volume>122</volume>, no. <issue>18</issue> (<year>2013</year>): <fpage>3116</fpage>&#8211;<lpage>3121</lpage>.<pub-id pub-id-type="pmid">24068494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2013-08-453126</pub-id><pub-id pub-id-type="pmcid">PMC3814728</pub-id></mixed-citation></ref><ref id="imm70010-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="imm70010-cit-0113"><string-name name-style="western"><given-names>V.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Agle</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, et&#160;al., &#8220;<article-title>A Colitogenic Memory CD4+ T Cell Population Mediates Gastrointestinal Graft&#8208;Versus&#8208;Host Disease</article-title>,&#8221; <source>Journal of Clinical Investigation</source><volume>126</volume>, no. <issue>9</issue> (<year>2016</year>): <fpage>3541</fpage>&#8211;<lpage>3555</lpage>.<pub-id pub-id-type="pmid">27500496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI80874</pub-id><pub-id pub-id-type="pmcid">PMC5004941</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501339</article-id><article-id pub-id-type="pmcid-ver">PMC12501339.1</article-id><article-id pub-id-type="pmcaid">12501339</article-id><article-id pub-id-type="pmcaiid">12501339</article-id><article-id pub-id-type="pmid">40750514</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100294</article-id><article-id pub-id-type="pii">S2274-5807(25)00237-7</article-id><article-id pub-id-type="publisher-id">100294</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group></article-categories><title-group><article-title>Temporal associations of neuropsychiatric symptoms, demographics and amyloid with subsequent tau burden in older adults</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Aguilar-Dominguez</surname><given-names initials="P">Pablo</given-names></name><xref rid="fn1" ref-type="fn">#</xref><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Palpatzis</surname><given-names initials="E">Eleni</given-names></name><xref rid="fn1" ref-type="fn">#</xref><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Akinci</surname><given-names initials="M">Muge</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Canal-Garcia</surname><given-names initials="A">Anna</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Pereira</surname><given-names initials="JB">Joana B.</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Bejanin</surname><given-names initials="A">Alexandre</given-names></name><xref rid="fn2" ref-type="fn">1</xref><xref rid="aff0003" ref-type="aff">c</xref><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Arenaza-Urquijo</surname><given-names initials="EM">Eider M.</given-names></name><email>eider.arenaza@isglobal.org</email><xref rid="fn2" ref-type="fn">1</xref><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><on-behalf-of>for the Alzheimer&#8217;s Disease Neuroimaging Initiative</on-behalf-of><aff id="aff0001"><label>a</label>Barcelona Institute for Global Health (ISGlobal), Environment and Health over the Lifecourse programme. Barcelona, Spain</aff><aff id="aff0002"><label>b</label>University of Pompeu Fabra (UPF), Barcelona, Spain</aff><aff id="aff0003"><label>c</label>Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</aff><aff id="aff0004"><label>d</label>Division of Neuro, Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden</aff><aff id="aff0005"><label>e</label>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author. <email>eider.arenaza@isglobal.org</email></corresp><fn id="fn1"><label>#</label><p id="notep0001">Contributed equally, co-first authors.</p></fn><fn id="fn2"><label>1</label><p id="notep0002">Contributed equally, co-last authors.</p></fn></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>31</day><month>7</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100294</elocation-id><history><date date-type="received"><day>5</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>4</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>8</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><sec><title>Background</title><p>Psychiatric symptoms are increasingly recognized as early manifestations of Alzheimer&#8217;s disease (AD). These symptoms may reflect or contribute to underlying neurobiological changes, including tau burden, which represents more advanced AD pathology. Understanding factors associated with tau burden may help identify individuals at elevated risk and improve early detection strategies.</p></sec><sec><title>Objectives</title><p>To investigate the temporal relationships between neuropsychiatric symptoms, demographic factors, and tau burden, by examining amyloid (A&#946;)-dependent, -independent, and interactive associations.</p></sec><sec><title>Design</title><p>Retrospective cohort study.</p></sec><sec><title>Setting</title><p>Alzheimer&#8217;s Disease Neuroimaging Initiative.</p></sec><sec><title>Participants</title><p>We included 681 participants without dementia (mean age = 71.2 years, 51.8 % female).</p></sec><sec><title>Measurements</title><p>The participants underwent tau PET scanning with prior amyloid PET and Neuropsychiatric Inventory (NPI) interview assessments clustered around three time periods relative to tau PET: closest (0 &#8722; 2 years), mid (3 &#8722; 5 years), and furthest (6 &#8722; 8 years). Linear regression analyses, adjusting for age and APOE &#949;4 alleles, examined associations of NPI scores, sex, education, and their A&#946;-status interactions with tau burden.</p></sec><sec><title>Results</title><p>Higher total NPI scores up to 2 years prior to tau PET were associated with greater tau burden independently of A&#946; status, whereas anxiety symptoms demonstrated an A&#946;-dependent relationship with tau. (<italic toggle="yes">NPI: &#946;=0.117, 95 % CI: 0.049 to 0.185, p</italic><italic toggle="yes">=</italic><italic toggle="yes">0.001</italic>, Anxiety: <italic toggle="yes">&#946;=0.249, 95 % CI: 0.073 to 0.424, p</italic><italic toggle="yes">=</italic><italic toggle="yes">0.006</italic>). NPI measured up to 5 years prior to tau PET interacted with A&#946; on tau burden (0&#8211;2 years: <italic toggle="yes">&#946;=0.272, 95 % CI: 0.136 to 0.407, p</italic><italic toggle="yes">&lt;</italic><italic toggle="yes">0.001,</italic> 3&#8211;5 years: <italic toggle="yes">&#946;=0.336, 95 % CI: 0.127 to 0.544, p</italic><italic toggle="yes">=</italic><italic toggle="yes">0.002</italic>). Sex and education showed minimal associations with tau at uncorrected statistical levels.</p></sec><sec><title>Conclusions</title><p>Neuropsychiatric symptoms were associated with tau burden up to two years before tau sampling, independently of A&#946;, and interacted with A&#946; status up to five years prior, suggesting that neuropsychiatric symptoms are related to tau in the short term and may represent manifestations of advancing AD pathology. Demographic factors showed minimal associations. These findings highlight the importance of evaluating neuropsychiatric and anxiety symptoms as potential indicators of increased tau pathology.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Neuropsychiatric symptoms</kwd><kwd>Tau</kwd><kwd>Amyloid</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0011">Given the importance of treating individuals as early as possible in the Alzheimer&#8217;s disease (AD) process, there has been a growing emphasis on enrolling cognitively unimpaired (CU) individuals in clinical trials based on their positive amyloid-beta (A&#946;) status [<xref rid="bib0001" ref-type="bibr">1</xref>]. However, this approach runs the risk of including individuals who may not be at high risk of developing cognitive decline in the near future.</p><p id="para0012">This challenge stems from the differential relationships between AD pathologies and clinical outcomes. While cognitively unimpaired individuals can often present with a significant A&#946; PET burden, it is less likely that they display an extensive pattern of tau-PET deposition [<xref rid="bib0002" ref-type="bibr">2</xref>]. Indeed, clinical symptoms are more closely related to the location and extent of tau PET uptake rather than A&#946; PET [<xref rid="bib0002" ref-type="bibr">[2]</xref>, <xref rid="bib0003" ref-type="bibr">[3]</xref>, <xref rid="bib0004" ref-type="bibr">[4]</xref>]. Therefore, identifying factors that associate with advanced tau pathology, including in the context of existing A&#946;, is essential for designing successful clinical trials and developing preventive interventions [<xref rid="bib0005" ref-type="bibr">5</xref>].</p><p id="para0013">Factors influencing AD progression can be conceptualized as either modifiable or non-modifiable. Among non-modifiable factors, evidence suggests that sex influences AD pathology. Cognitively unimpaired females exhibit higher tau pathology compared to males, as evidenced by tau PET imaging [<xref rid="bib0006" ref-type="bibr">6</xref>,<xref rid="bib0007" ref-type="bibr">7</xref>] and post-mortem studies [<xref rid="bib0008" ref-type="bibr">8</xref>], while most studies have not found sex differences in A&#946; levels measured by PET [<xref rid="bib0007" ref-type="bibr">7</xref>] or CSF [<xref rid="bib0009" ref-type="bibr">9</xref>]. Among modifiable factors, which offer potential intervention opportunities, higher education has been linked to lower A&#946; in cognitively unimpaired older adults [<xref rid="bib0010" ref-type="bibr">10</xref>,<xref rid="bib0011" ref-type="bibr">11</xref>]. Similarly, neuropsychiatric symptoms, apart from being potential risk factors for AD progression [<xref rid="bib0012" ref-type="bibr">12</xref>], are also increasingly recognized as early manifestations of AD [<xref rid="bib0013" ref-type="bibr">13</xref>]. However, their role as early markers of pathophysiological progression in AD remains still somewhat unclear. Current evidence suggests neuropsychiatric symptoms may emerge at multiple stages of the AD <italic toggle="yes">continuum</italic>, with distinct temporal patterns for different symptom types. Depression, anxiety, and sleep disturbances can become prevalent in preclinical AD, while others, such as hallucinations and disinhibition, may manifest at later stages once AD diagnosis is established [<xref rid="bib0014" ref-type="bibr">14</xref>]. Symptoms of depression and anxiety have been observed in cognitively normal older adults with higher A&#946; levels [<xref rid="bib0015" ref-type="bibr">15</xref>,<xref rid="bib0016" ref-type="bibr">16</xref>]. However, the strongest associations appear to emerge as tau pathology develops, with neuropsychiatric symptoms showing more consistent relationships with tau burden in AD-vulnerable brain regions in the inferior temporal and entorhinal cortex independent of A&#946; pathology [<xref rid="bib0017" ref-type="bibr">17</xref>]. Similarly, various other neuropsychiatric symptoms have been associated with elevated tau PET levels across the AD <italic toggle="yes">continuum</italic> [<xref rid="bib0018" ref-type="bibr">18</xref>]. Importantly, studies suggest that neuropsychiatric symptoms may accelerate AD progression [<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0020" ref-type="bibr">20</xref>], highlighting the importance of identifying them.</p><p id="para0014">Beyond these individual effects, emerging evidence suggests that both modifiable and non-modifiable factors may interact with A&#946; to predict tau burden. For example, A&#946;-positive women show higher tau-PET deposition in medial and inferior-lateral temporal regions compared with A&#946;-positive men [<xref rid="bib0021" ref-type="bibr">21</xref>], and individuals carrying the APOE &#949;4 allele have an increased tau load in AD-vulnerable brain areas compared with non-carriers [<xref rid="bib0022" ref-type="bibr">22</xref>]. Similarly, among modifiable factors, A&#946;-positive individuals with lower stress-coping abilities exhibited higher levels of tau [<xref rid="bib0023" ref-type="bibr">23</xref>], suggesting that psychological factors may modulate tau pathology in the presence of existing A&#946; burden.</p><p id="para0015">Building on this research, our primary objective was to examine the temporal dynamics of study-partner reported neuropsychiatric symptoms and demographic factors with future tau burden across three time windows (0&#8211;2, 3&#8211;5, and 6&#8211;8 years) prior to tau acquisition in individuals without dementia, considering A&#946;-dependent, -independent and interactive effects. This approach allows to shed light on the temporal ordering of these relationships by comparing associations across different time intervals, which could aid in designing successful interventions and trials to delay AD progression [<xref rid="bib0024" ref-type="bibr">24</xref>].</p><p id="para0016">Based on previous evidence, we propose three hypotheses: (i) neuropsychiatric symptoms (total, anxiety, sleep disturbances and depression) will show stronger associations with concurrent tau burden (0&#8211;2 years) compared to long- term tau burden (3&#8211;8 years). This temporal pattern would be consistent with hypotheses suggesting that tau pathology and neuropsychiatric symptoms emerge concurrently; (ii) A&#946; status will moderate the relationship between neuropsychiatric symptoms and tau burden, such that the neuropsychiatric symptom-tau associations will be stronger in the presence of existing A&#946; pathology; (iii) female sex will exhibit higher tau burden and sex and education will interact with A&#946; status on tau burden.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><sec id="sec0003"><label>2.1</label><title>Study design and participants</title><p id="para0017">We conducted a retrospective analysis using longitudinal data (between 2015&#8211;2023) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (<underline>ClinicalTrials.gov</underline> registry numbers: ADNI GO: <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01078636">NCT01078636</ext-link></underline> (registration date: 2010&#8211;03&#8211;02); ADNI 2: <underline>NCT0123197</underline> (registration date: 2010&#8211;11&#8211;01); ADNI 3: <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02854033">NCT02854033</ext-link></underline> (registration date: 2016&#8211;08&#8211;03). The ADNI is a public-private longitudinal multicenter study aimed at developing biomarkers for the early detection and tracking of AD. Initiated in 2004, ADNI has significantly advanced AD research by facilitating global data sharing among researchers. Its primary objectives include early detection of AD, supporting interventions at pre-dementia stages, and maintaining an open data-access policy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.adni-info.org" id="interref0001">www.adni-info.org</ext-link>). The inclusion and exclusion criteria of ADNI can be found in the ADNI protocol (<underline>adni.loni.usc.edu)</underline>.</p><p id="para0018">For this study, we included 681 (427 cognitively unimpaired and 254 MCI) participants who met the following criteria: available cross-sectional tau PET data, and retrospective longitudinal data on A&#946; PET and NPI. Participants could not have a diagnosis of dementia at the time of their first A&#946; PET. Additionally, all participants provided demographic information such as sex and years of education, and underwent genetic testing for the APOE &#949;4 genotype when they were enrolled in ADNI. Information about the participant selection process can be found in the supplementary material (Figure S1).</p><p id="para0019">For each participant, we selected their latest available tau PET scan, which served as the reference point for our analysis. This maximized the backward time window, giving us more historical data, ensuring the most complete information available per participant. This single tau scan was the outcome of our subsequent analyses. Then we grouped the data into three time windows: 0&#8211;2 years, 3&#8211;5 years, and 6&#8211;8 years prior to the tau scan. If a participant had two or more visits within a time window, the one closest to the tau sample was used (Figure S2). The length of the time windows was chosen to maximize data availability and to approximate the average duration of clinical trials and intervention studies (&#8764;2 years) [<xref rid="bib0025" ref-type="bibr">25</xref>,<xref rid="bib0026" ref-type="bibr">26</xref>], making our findings more applicable to real-world intervention planning. For each window, we tested whether NPS, sex and education were associated with later tau pathology. We also examined whether amyloid status influenced these associations and whether amyloid interacted with NPS, sex and education.</p><p id="para0020">All methods and protocols followed ADNI&#8217;s ethical guidelines, which follow the standards of the institutional and/or national research committees as well as the 1964 Helsinki declaration and its later revisions. The ADNI study was approved by the institutional review boards of all the participating institutions. Written consent was obtained from all participants at each site before they were included. More details can be found at <underline>adni.loni.usc.edu</underline>. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.</p></sec><sec id="sec0004"><label>2.2</label><title>PET imaging and processing</title><p id="para0021">Participants&#8217; scans were acquired between 2015 and 2023. Details about the acquisition and analysis of [18]F-Florbetapir (FBP), and [18]F-Flortaucipir (FTP) images can be found at [<xref rid="bib0027" ref-type="bibr">27</xref>]. The PET images were pre-processed following ADNI guidelines. In brief, images were aligned, averaged, and reoriented before being interpolated to a standardized image and voxel size (160 &#215; 160 &#215; 96 dimensions, with each voxel measuring 1.5 &#215; 1.5 &#215; 1.5 mm in x, y, z). They were then smoothed to achieve a uniform 8 mm resolution at full width at half maximum. Regional Standardized Uptake Value Ratios (SUVRs) for both FTP and FBP were calculated by normalizing the regional uptake to a reference region.</p><p id="para0022"><italic toggle="yes">FTP</italic> PET images were acquired in four 5-minute frames between 50&#8211;70 min after injection (10.0 mCi &#177;10 %). The reference region used was the inferior cerebellum [<xref rid="bib0028" ref-type="bibr">28</xref>]. Continuous SUVRs from the composite Braak regions I/II, which represent the earliest stages of neurofibrillary tangle formation in the brain [<xref rid="bib0002" ref-type="bibr">2</xref>], were used as outcome.</p><p id="para0023"><italic toggle="yes">FBP</italic> PET images were acquired in four 5-minutes frames between 75&#8211;105 min after injection (10 mCi &#177;10 %). The reference region used was the whole cerebellum <xref rid="bib63" ref-type="bibr">29</xref>. The global SUVR was calculated using a composite region that included the frontal, parietal, cingulate, and temporal regions [<xref rid="bib0029" ref-type="bibr">30</xref>]. The SUVRs were then converted into Centiloid units by linear transformation using the PET tracer equations published for conversion [<xref rid="bib0030" ref-type="bibr">31</xref>]. Due to data distribution, subjects were then classified as A&#946; positive or negative using 20 CL as threshold [<xref rid="bib0031" ref-type="bibr">32</xref>].</p></sec><sec id="sec0005"><label>2.3</label><title>Neuropsychiatric symptoms and cognitive evaluation</title><p id="para0024">All participants&#8217; study-partners underwent the Neuropsychiatric Inventory interview, which is a reliable tool for assessing psychopathology [<xref rid="bib0032" ref-type="bibr">33</xref>]. It is based on interviews with qualified study partners to assess both the frequency and severity of symptoms such as delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability, apathy, and aberrant motor behavior. ADNI addressed potential bias from responses from relatives by conducting an interrater reliability assessment across various domains, confirming and maintaining an excellent level of agreement [<xref rid="bib0033" ref-type="bibr">34</xref>]. The NPI demonstrates satisfactory validity and reliability in outpatient settings, with strong content validity across all items and acceptable concurrent validity when compared to standard instruments for assessing NPS in neurologically impaired patients [<xref rid="bib0034" ref-type="bibr">35</xref>]. The total NPI score, which ranges from 0 to 144, is the sum of all scores from the individual domains. In our study, we focused on the total NPI score and sub-scores for depression [<xref rid="bib0035" ref-type="bibr">36</xref>], anxiety [<xref rid="bib0036" ref-type="bibr">37</xref>] and sleep as key predictors, as these have been linked to AD pathology or are considered risk factors for AD.</p><p id="para0025">Since the sub-scores for anxiety, sleep, and depression did not follow a normal distribution and showed limited variability (see Figure S3), we converted these variables to ordinal binary variables (1 for those with a score equal or higher to one; 0 for those with a score equal to zero), while the total NPI score was treated as a continuous variable.</p></sec><sec id="sec0006"><label>2.4</label><title>Demographic and genetic data</title><p id="para0026">The demographic variables included in the study were sex (female/male), and years of education (continuous variable). <italic toggle="yes">APOE</italic> genotyping was performed at the time of participant enrollment, where they were genotyped using DNA extracted by Cogenics from a 3 mL aliquot of EDTA blood. The genetic covariate included was the number of APOE &#949;4 alleles (0/1/2 as categorical ordered variable).</p></sec><sec id="sec0007"><label>2.5</label><title>Statistical analyses</title><p id="para0027">Demographic data were summarized as means (and standard deviations) for continuous variables and frequencies (and percentages) for categorical variables. Linear regression models were conducted to examine the association of tau burden in Braak I/II with total NPI score, depression, anxiety, sleep, sex, and years of education i) dependently, ii) independently and iii) in interaction with A&#946; status, adjusting for sex, education, age and number of APOE &#949;4 alleles. Main and interaction effects were considered significant at <italic toggle="yes">p</italic> &lt; 0.05 after correction for multiple comparisons with Bonferroni [<xref rid="bib0037" ref-type="bibr">38</xref>].</p><p id="para0028">The outcome variable used in the different linear models was tau burden in the Braak I/II region. The exposures were A&#946; status (positive/negative); NPI total scores; NPI sub-scores: anxiety, depression and sleep; sex; and years of education. Age, sex, education and APOE &#949;4 allele were considered in all the models. We tested the main effect of each variable of interest, the main effect of the variables of interest independent of A&#946; status, and the interaction between the variable of interest and A&#946; status.</p><p id="para0029">Models used:<disp-formula id="eqn0001"><label>(1)</label><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mi>B</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>a</mml:mi><mml:mi>k</mml:mi><mml:mrow/><mml:mi>I</mml:mi><mml:mo linebreak="goodbreak">/</mml:mo><mml:mi>I</mml:mi><mml:mi>I</mml:mi><mml:mrow/><mml:mi>S</mml:mi><mml:mi>U</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi><mml:mrow/><mml:mo>&#8764;</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>O</mml:mi><mml:mi>E</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:math></disp-formula><disp-formula id="eqn0002"><label>(2)</label><mml:math id="M2" altimg="si2.svg"><mml:mrow><mml:mi>B</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>a</mml:mi><mml:mi>k</mml:mi><mml:mrow/><mml:mi>I</mml:mi><mml:mo linebreak="goodbreak">/</mml:mo><mml:mi>I</mml:mi><mml:mi>I</mml:mi><mml:mrow/><mml:mi>S</mml:mi><mml:mi>U</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi><mml:mrow/><mml:mo>&#8764;</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>O</mml:mi><mml:mi>E</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>&#946;</mml:mi><mml:mrow/><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:math></disp-formula><disp-formula id="eqn0003"><label>(3)</label><mml:math id="M3" altimg="si3.svg"><mml:mrow><mml:mi>B</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>a</mml:mi><mml:mi>k</mml:mi><mml:mrow/><mml:mi>I</mml:mi><mml:mo linebreak="goodbreak">/</mml:mo><mml:mi>I</mml:mi><mml:mi>I</mml:mi><mml:mrow/><mml:mi>S</mml:mi><mml:mi>U</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi><mml:mrow/><mml:mo>&#8764;</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>O</mml:mi><mml:mi>E</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>&#946;</mml:mi><mml:mrow/><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mrow/><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow/><mml:mi>A</mml:mi><mml:mi>&#946;</mml:mi><mml:mrow/><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mo linebreak="goodbreak">*</mml:mo><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:math></disp-formula></p><p id="para0030">All models were run using exposures and A&#946;-PET data from different time windows (0&#8211;2 years, 3&#8211;5 years, and 6&#8211;8 years before tau PET scans) to examine how predictors at specific time points were associated with tau burden. Since education and sex are time-invariant, we opted to run models 1 and 2 for these variables using only the largest sample size available (i.e., closest time window). To examine whether amyloid positivity was driving any interactions in model 3, we additionally ran model 1 stratified by amyloid status.</p><p id="para0031">Further, we performed a <italic toggle="yes">post-hoc</italic> analysis to investigate whether neuropsychiatric symptoms (total NPI score) mediate the relationship between A&#946; status and tau burden. Specifically, we conducted mediation analyses across the three time windows, estimating the Average Causal Mediated Effect (ACME), Average Direct Effect (ADE), total effect, and proportion mediated. A nonparametric bootstrap procedure with 1000 simulations was used to derive 95 % confidence intervals and p-values. Mediation was considered significant at <italic toggle="yes">p</italic> &lt; 0.05. These analyses were performed using the R package <italic toggle="yes">mediation</italic>.</p><p id="para0032">All analyses were conducted using R (version 4.2.2).</p></sec></sec><sec id="sec0008"><label>3</label><title>Results</title><p id="para0033">A total of 681 participants were included. At the time of their first amyloid-PET, 427 participants were cognitively unimpaired and 254 had mild cognitive impairment (MCI). The mean age at baseline was 71.2 (SD = 6.71), 51.8 % of the participants were females and 36.4 % had at least one APOE &#949;4 allele. The mean Mini Mental State Evaluation (MMSE) score was 28.7 (SD = 1.52) and the mean years of education was 16.5 (SD = 2.48). Demographic data for baseline and all time windows are shown in <xref rid="tbl0001" ref-type="table">Table 1</xref>. Further information about the change in NPI status and diagnosis between time windows can be found in supplementary materials (Table S1).<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Demographic and clinical characteristics at baseline (first amyloid sample) for the participants included in the study.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th colspan="2" align="left" valign="top" rowspan="1">Baseline (First amyloid sample)<hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">mean (SD) / count ( %); range</th><th valign="top" colspan="1" rowspan="1">N</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Age</bold></td><td valign="top" colspan="1" rowspan="1">71.2 (6.71); (49.1&#8211;88.6)</td><td valign="top" colspan="1" rowspan="1">681</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sex</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">681</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>Male</bold></td><td valign="top" colspan="1" rowspan="1">328 (48.2 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>Female</bold></td><td valign="top" colspan="1" rowspan="1">353 (51.8 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Number of APOE &#949;4 alleles</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">681</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>0</bold></td><td valign="top" colspan="1" rowspan="1">433 (63.6 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>1</bold></td><td valign="top" colspan="1" rowspan="1">210 (30.8 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>2</bold></td><td valign="top" colspan="1" rowspan="1">38 (5.6 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Diagnosis</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">681</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>CN</bold></td><td valign="top" colspan="1" rowspan="1">427 (62.7 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>MCI</bold></td><td valign="top" colspan="1" rowspan="1">254 (37.3 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>AD</bold></td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education (years)</bold></td><td valign="top" colspan="1" rowspan="1">16.5 (2.48); (0&#8211;20)</td><td valign="top" colspan="1" rowspan="1">681</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>NPI</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>NPI total</bold></td><td valign="top" colspan="1" rowspan="1">2.21 (4.47); (0&#8211;43)</td><td valign="top" colspan="1" rowspan="1">681</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>Depression (negative)</bold></td><td valign="top" colspan="1" rowspan="1">586 (86.2 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>Anxiety (negative)</bold></td><td valign="top" colspan="1" rowspan="1">629 (92.5 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>Sleep (negative)</bold></td><td valign="top" colspan="1" rowspan="1">564 (82.9 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>MMSE</bold></td><td valign="top" colspan="1" rowspan="1">28.7 (1.52);(9&#8211;30)</td><td valign="top" colspan="1" rowspan="1">681</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Race</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">681</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>American Indian or Alaskan Native</bold></td><td valign="top" colspan="1" rowspan="1">2 (0.3 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>Asian</bold></td><td valign="top" colspan="1" rowspan="1">11 (1.6 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>Black or African American</bold></td><td valign="top" colspan="1" rowspan="1">33 (4.9 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>White</bold></td><td valign="top" colspan="1" rowspan="1">622 (91.3 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>More than one race</bold></td><td valign="top" colspan="1" rowspan="1">12 (1.8 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;<bold>Unknown</bold></td><td valign="top" colspan="1" rowspan="1">1 (0.2 %)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Time between amyloid and tau (months)</bold></td><td valign="top" colspan="1" rowspan="1">48.9 (44.9); (0&#8211;96)</td><td valign="top" colspan="1" rowspan="1">681</td></tr></tbody></table><table-wrap-foot><fn id="spara006"><p><italic toggle="yes">Note1.</italic> APOE4: number of alleles (0, 1 or 2). CN: Cognitively normal. MCI: Mild-Cognitive Impairment. NPI total: Neuropsychiatric Inventory total score. Education: measured in years of education. MMSE: Mini Mental State Examination. Baseline: time when participants were enrolled in ADNI.</p></fn><fn id="spara007"><p><italic toggle="yes">Note2.</italic> The possible range for NPI total score is 0&#8211;144. The possible range for MMSE is 0&#8211;30.</p></fn><fn id="spara008"><p><italic toggle="yes">Note 3.</italic> Data for each time window included in supplementary material (Table S8).</p></fn></table-wrap-foot></table-wrap></p><p id="para0034"><xref rid="fig0001" ref-type="fig">Fig. 1</xref> shows a summary of all the results from all the statistical analyses performed. The exact statistical values for these models can be found in supplementary materials (Table S2). Furthermore, for the sake of completeness, we are providing the statistical models with other neuropsychiatric symptoms in supplementary materials (Tables S3, S4 and S5).<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Forest plot showing the association of neuropsychiatric and demographic variables with subsequent tau PET burden. First column shows results for model 1 (Braak I/II &#8764; exposure + covariates), second column shows results for model 2 (model 1 including additionally A&#946;) and third column shows results for model 3 (model 2 including additionally the interaction A&#946;*exposure).</p></caption><alt-text id="alt0002">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/><attrib><italic toggle="yes">Note.</italic> Estimates (and 95 % CIs) of demographics and NPI scores at different time windows on subsequent tau-PET SUVR. All models were adjusted for APOE4 alleles and age; when necessary, sex and education were also included as covariates. Color code: Blue: p-value below 0.05 uncorrected. Green: p-value below 0.05 Bonferroni corrected. Grey: p-value above 0.05.</attrib></fig></p><sec id="sec0009"><label>3.1</label><title>Association of neuropsychiatric symptoms and demographics with tau burden</title><p id="para0035">Below, we summarize the findings from model 1, where we explored the associations between neuropsychiatric symptoms, sex and education with tau burden across the three previously defined time windows (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>, first column).</p><p id="para0036">We found that, after adjusting for age, sex, education and APOE &#949;4 carrier status, NPI total score (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>a) and anxiety (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>b) were significantly associated with tau burden only in the closest time window (<italic toggle="yes">NPI total score. 0&#8211;2 years: &#946; = 0.150, 95 % CI: 0.079 to 0.221, p</italic>
<italic toggle="yes">&lt;</italic>
<italic toggle="yes">0.001; Anxiety. 0&#8211;2 years: &#946; = 0.249, 95 % CI: 0.073 to 0.424, p</italic>
<italic toggle="yes">=</italic>
<italic toggle="yes">0.006</italic>).<fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Plots representing the association between tau PET SUVR in Braak I/II region neuropsychiatric symptoms in the 0&#8211;2 years time window. (A) Scatter plot representing the relationship between total NPI score and tau PET SUVR in Braak I/II. (B) Boxplot representing the association between Anxiety status and tau PET SUVR in Braak I/II.</p></caption><alt-text id="alt0003">Fig 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/><attrib><italic toggle="yes">Note:</italic> predicted values for tau PET SUVR were estimated from a linear regression model 1. Predictions were generated across the observed range of neuropsychiatric symptoms while holding covariates constant.</attrib></fig></p><p id="para0037">Further, we also observed that females showed higher tau burden compared with males at an uncorrected level (<italic toggle="yes">&#946; = 0.172, 95 % CI: 0.026 to 0.318, p</italic>
<italic toggle="yes">=</italic>
<italic toggle="yes">0.021, Uncorrected</italic>; Figure S4). No significant association was found with years of education.</p></sec><sec id="sec0010"><label>3.2</label><title>Amyloid-independent associations of neuropsychiatric symptoms and demographics with tau burden</title><p id="para0038">Here, we report the results corresponding to model 2, which builds on model 1 by additionally adjusting for A&#946;-status (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>, second column).</p><p id="para0039">After adjusting for A&#946;-status, the association between the NPI total score at the closest time window and tau PET remained unchanged (<italic toggle="yes">0&#8211;2 years: &#946; = 0.117, 95 % CI: 0.049 to 0.185, p</italic>
<italic toggle="yes">=</italic>
<italic toggle="yes">0.001</italic>). However, the association of anxiety with tau was attenuated and did not reach anymore significance. Similarly, the association between female sex and tau burden was not anymore significant after adjustment for A&#946;-status. Education remained non-significant.</p></sec><sec id="sec0011"><label>3.3</label><title>Interaction of neuropsychiatric symptoms and demographics with amyloid to explain tau burden on early tau accumulation regions</title><p id="para0040">This section presents the results corresponding to model 3, which examines the interactions between neuropsychiatric symptoms, sex and education with A&#946;-status on tau burden (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>, third column).</p><p id="para0041">Regarding neuropsychiatric symptoms, we found that in the two closest time windows, NPI total score interacted with A&#946;-status (<italic toggle="yes">Interactions: 0&#8211;2 years: &#946; = 0.272, 95 % CI: 0.136 to 0.407, p</italic>
<italic toggle="yes">&lt;</italic>
<italic toggle="yes">0.001; 3&#8211;5 years: &#946; = 0.336, 95 % CI: 0.127 to 0.544, p</italic>
<italic toggle="yes">=</italic>
<italic toggle="yes">0.002;</italic>
<xref rid="fig0003" ref-type="fig">Fig. 3</xref>). Stratified analyses by A&#946; status (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>) showed that, among A&#946; positive participants, a higher NPI total score was associated with higher tau burden (Figure S4, Table S6a).<fig id="fig0003" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Scatter plots representing interaction between NPI total score and A&#946; status on tau PET SUVR measured in Braak I/II region (A) Represents interaction in the 0&#8211;2 years time window between NPI total score and A&#946; status on tau PET SUVR measured in Braak I/II region; (B) represents the interaction in the 3&#8211;5 years time window between NPI total score and A&#946; status on tau PET SUVR measured in Braak I/II region.</p></caption><alt-text id="alt0004">Fig 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0003" position="float" orientation="portrait" xlink:href="gr3.jpg"/><attrib><italic toggle="yes">Note 1:</italic> to rule out the possibility that outliers were driving the interaction, we re-tested it after excluding NPI total values above 2.5 in <italic toggle="yes">A</italic>&#8722; individuals. The interaction remained significant. <italic toggle="yes">Note 2:</italic> predicted values for tau PET SUVR were estimated from model 3. Predictions were generated across the observed range of neuropsychiatric symptoms while holding covariates constant.</attrib></fig><fig id="fig0004" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Forest plot showing the association of demographic and neuropsychiatric variables with subsequent tau PET burden stratified by A&#946; status (model 1). The first plot shows results for A&#946; positive subjects. Second plot shows results for A&#946; negative subjects.</p></caption><alt-text id="alt0005">Fig 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0004" position="float" orientation="portrait" xlink:href="gr4.jpg"/><attrib><italic toggle="yes">Note.</italic> Estimates (and 95 % CIs) of demographics and NPI scores at different time windows on subsequent tau-PET SUVR. All models were corrected for APOE4 alleles and age, further in those necessary, sex and education was used as covariate as well. Color code: Blue: p-value below 0.05 uncorrected. Green: p-value below 0.05 Bonferroni corrected. Grey: p-value above 0.05</attrib></fig></p><p id="para0042">Similarly to NPI total score, sleep disturbances interacted with A&#946;-status, although at an uncorrected level (<italic toggle="yes">Interactions: 0&#8211;2 years: &#946; = 0.298, 95 % CI: 0.059 to 0.538, p</italic>
<italic toggle="yes">=</italic>
<italic toggle="yes">0.015, Uncorrected; 3&#8211;5 years: &#946; = 0.481, 95 % CI: 0.116 to 0.845, p</italic>
<italic toggle="yes">=</italic>
<italic toggle="yes">0.010, Uncorrected</italic>). Stratified analyses showed that among A&#946; negative participants, sleep disturbances were associated with lower tau burden (Figure S5, Table S6b).</p><p id="para0043">Regarding sex and education, A&#946;-status interacted with both variables at an uncorrected level (<italic toggle="yes">Interaction for sex: 3&#8211;5 years: &#946; = 0.428, 95 % CI: 0.061 to 0.795, p</italic>
<italic toggle="yes">=</italic>
<italic toggle="yes">0.022, Uncorrected; Interaction for education: 0&#8211;2 years: &#946; = &#8722;0.163, 95 % CI: &#8722;0.300 to &#8722;0.028, p</italic>
<italic toggle="yes">=</italic>
<italic toggle="yes">0.018, Uncorrected</italic>). Stratified analyses showed that female sex was associated with higher tau burden among A&#946; positive participants (Figure S6) while higher education was associated with higher tau burden among A&#946; negative participants (Figure S7).</p><p id="para0044">We further conducted a mediation analysis testing the mediating role of neuropsychiatric symptoms on the association between A&#946; status and tau burden. Results revealed a significant mediation effect in the 0&#8211;2 year window, with neuropsychiatric symptoms accounting for approximately 3 % of the effect of A&#946; on tau (<italic toggle="yes">ACME = 0.02, 95 % CI: 0.00 to 0.07, p</italic>
<italic toggle="yes">=</italic>
<italic toggle="yes">0.032; ADE = 0.74, 95 % CI: 0.57 to 0.91, p</italic>
<italic toggle="yes">&lt;</italic>
<italic toggle="yes">0.001; total effect = 0.76, 95 % CI: 0.59 to 0.94, p</italic>
<italic toggle="yes">&lt;</italic>
<italic toggle="yes">0.001; proportion mediated = 0.03, 95 % CI: 0.00 to 0.08, p</italic>
<italic toggle="yes">=</italic>
<italic toggle="yes">0.032</italic>; Table S7a). No significant mediation was observed in the remaining time windows (Tables S7b and S7c).</p></sec><sec id="sec0012"><label>3.4</label><title>Sensitivity analyses</title><p id="para0045">We conducted two sensitivity analyses to ensure the robustness of our findings. First, to ensure that our findings were not influenced by variability among the different samples used in each time window, we limited the sample to participants who had data at both the closest- and mid-time windows. We did not consider the furthest time window to preserve statistical power. The associations observed in the full cohort for A&#946; status-NPI interactions remained significant but attenuated slightly for the mid-time window (Figure S8). Associations of sex with tau and A&#946; status-sleep and A&#946; status-sex interactions became stronger in these analyses (Figure S8), while the associations of anxiety with tau burden and the A&#946; status-education interaction attenuated to non-significant. All other results remained consistent (Figure S8).</p><p id="para0046">In the second sensitivity analysis, we treated A&#946; as a continuous variable instead of a binary variable (A&#946; positive/negative). This approach aimed to more accurately capture the influence of A&#946; burden. The only significant interactions with A&#946; were: sex, education, and total NPI score, all observed in the closest time window (Figure S9).</p></sec></sec><sec id="sec0013"><label>4</label><title>Discussion</title><p id="para0047">In this retrospective cohort study of older adults, we examined the temporal associations between neuropsychiatric symptoms, demographic factors, and tau burden across different time windows. Our findings partially supported our hypotheses and revealed several key patterns. We found evidence of (i) a short-term association of total neuropsychiatric symptoms with tau burden, with and without adjusting for A&#946; status, and a short-term association of anxiety with tau burden when not adjusting for A&#946; status; (ii) a short- to mid-term interaction of total neuropsychiatric symptoms with A&#946; status on tau burden; (iii) low evidence for higher tau burden among females (only when not adjusting for A&#946;-status and at uncorrected level); and low evidence for interactions of sex and education with A&#946; status on subsequent tau burden (only at uncorrected levels).</p><p id="para0048">Our first hypothesis regarding stronger associations between neuropsychiatric symptoms and tau burden over shorter time intervals was partially supported. Higher total NPI scores were associated with greater tau PET burden in early AD-affected areas within the 2-year window independent of A&#946;-status. As expected, we did not observe associations beyond 2 years, suggesting that neuropsychiatric symptoms alone may not be a strong risk factor for AD pathology, like a clinical diagnosis of a psychiatric disease may be, as previous studies report an association between a previous depression diagnosis and higher AD risk [<xref rid="bib0038" ref-type="bibr">39</xref>]. The association within the 2-year window suggests neuropsychiatric symptoms may serve as early indicators of emerging tau pathology [<xref rid="bib0039" ref-type="bibr">40</xref>]. This interpretation is consistent with growing literature suggesting clinical manifestations and neuropsychiatric symptoms&#8217; close relationship with tau, particularly in early regions affected by AD [<xref rid="bib0017" ref-type="bibr">17</xref>,<xref rid="bib0018" ref-type="bibr">18</xref>,<xref rid="bib0040" ref-type="bibr">41</xref>], but little to no correlation with A&#946; [<xref rid="bib0018" ref-type="bibr">18</xref>,<xref rid="bib0041" ref-type="bibr">42</xref>]. Our findings are also in line with those of a recent study [<xref rid="bib0042" ref-type="bibr">43</xref>] showing that neuropsychiatric burden increased across Braak stages, and that individuals at later Braak stages showed further increases in symptoms over a 2-year period. These findings indicate that neuropsychiatric symptoms emerge early in the pathological process reflecting higher tau burden.</p><p id="para0049">The emergence of neuropsychiatric symptoms concurrently with tau may reflect the neuroanatomical vulnerability of circuits involved in emotional regulation, particularly the entorhinal cortex and its connections with the limbic system and default mode network [<xref rid="bib0040" ref-type="bibr">41</xref>]. Such regions are implicated in both early tau deposition and in affective processing [<xref rid="bib0040" ref-type="bibr">41</xref>,<xref rid="bib0043" ref-type="bibr">44</xref>]. Potential mechanisms for the A&#946;-independent association of tau burden with neuropsychiatric symptoms may include multiple pathways including neuroinflammatory processes, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, and vulnerability of medial temporal lobe structures to both emotional dysregulation and tau spread. Specifically, neuropsychiatric symptoms and chronic stress may activate the HPA axis, leading to elevated glucocorticoids, such as cortisol. Elevated cortisol levels can directly promote tau hyperphosphorylation and aggregation, while also triggering neuroinflammatory cascades in tau-vulnerable regions [<xref rid="bib0044" ref-type="bibr">45</xref>]. Moreover, emotional processing networks may be preferentially susceptible to tau deposition independent of A&#946;, consistent with studies reporting early tau in these regions in primary age-related tauopathy [<xref rid="bib0045" ref-type="bibr">46</xref>,<xref rid="bib0046" ref-type="bibr">47</xref>].</p><p id="para0050">Among specific symptoms, anxiety showed associations with tau burden when not adjusting for A&#946;-status within the 2-year window, aligning with previous findings of anxiety as an early AD manifestation [<xref rid="bib0047" ref-type="bibr">48</xref>,<xref rid="bib0048" ref-type="bibr">49</xref>]. However, these findings are not in line with those of a recent meta-analysis among cognitively unimpaired individuals, reporting no association of anxiety symptoms with AD biomarkers [<xref rid="bib0049" ref-type="bibr">50</xref>]. However, interpretation requires caution given our use of informant reports, which may require higher symptom thresholds compared to self-report measures. Other specific symptoms, including sleep disturbances and depression showed no main effects on tau burden, contrary to some previous studies using self-reported measures [<xref rid="bib0017" ref-type="bibr">17</xref>]. For example, a cross-sectional study, conducted on the Harvard Aging Brain Study cohort including cognitively unimpaired individuals, reported a modest association of self-reported depressive symptoms (measured with the Geriatric Depression Scale) with tau PET burden in early tau areas [<xref rid="bib0017" ref-type="bibr">17</xref>]. Another cross-sectional study using the Framingham Heart Study cohort in cognitively unimpaired middle-aged participants, reported no association between self-reported depressive symptoms (measured with the Center for Epidemiological Studies Depression Scale) and tau PET uptake in the overall sample, but an association of depressive symptoms with entorhinal and amygdalar tau only among APOE &#949;4 carriers [<xref rid="bib0050" ref-type="bibr">51</xref>]. The mixed findings regarding depressive symptoms and tau PET might be explained by different scales (self-reported vs informant-based) used in studies or research design (longitudinal vs cross-sectional).</p><p id="para0051">Our second hypothesis regarding A&#946;-status moderation was supported within a 5-year window, where A&#946;-positive individuals showed higher tau burden with higher neuropsychiatric symptoms compared to A&#946;-negative individuals. This was further supported by the post-hoc mediation analysis suggesting that total neuropsychiatric symptoms partially mediated the relationship between A&#946;-status and tau burden in the 0&#8211;2 years time window. While, to our knowledge, this is the first study examining such temporal relationships, previous studies have examined the interaction of NPS with A&#946; on cognition, but not on tau. One recent study did not find NPS to moderate the relationship of A&#946; with cognition cross-sectionally nor longitudinally [<xref rid="bib0051" ref-type="bibr">52</xref>], while another study showed higher A&#946; to interact with NPS to accelerate cognitive decline [<xref rid="bib0019" ref-type="bibr">19</xref>]. Several interpretations of the interaction found in the current study are possible: (i) the co-occurrence of neuropsychiatric symptoms and A&#946; positivity might identify individuals at a more advanced stage in the AD pathological continuum, (ii) A&#946; pathology might increase vulnerability to stress-related factors, consistent with studies showing that A&#946;-positive individuals with lower stress-coping abilities exhibit higher tau levels [<xref rid="bib0023" ref-type="bibr">23</xref>], or (iii) the presence of both neuropsychiatric symptoms and A&#946; might synergistically relate to tau burden patterns.</p><p id="para0052">We further found low evidence (at an uncorrected level) of an interaction of A&#946; with NPI sub-variable of sleep, assessed within 5 years before tau PET. Previous literature has shown sleep to interact with AD pathology on cortical volume among ADNI participants [<xref rid="bib0052" ref-type="bibr">53</xref>]. Our findings extend this by demonstrating that sleep disturbances interact with A&#946; status on tau burden, with A&#946; negative individuals driving this interaction. It is therefore possible that sleep disturbances modulate the effects of metabolic dysfunction of A&#946; and tau [<xref rid="bib0053" ref-type="bibr">54</xref>]. Future studies incorporating longitudinal tau PET imaging are needed to disentangle these potential mechanisms.</p><p id="para0053">Contrary to our third hypothesis, sex and education showed limited associations with tau burden. Despite extensive literature demonstrating sex-related tau vulnerability, we only observed sex-differences at an uncorrected level, such that females, compared with males, exhibited higher tau burden, but only when A&#946;-status was not adjusted for. Prior evidence shows that females exhibit higher tau pathology than males for equivalent cognitive performance [<xref rid="bib0021" ref-type="bibr">21</xref>,<xref rid="bib0054" ref-type="bibr">55</xref>,<xref rid="bib0055" ref-type="bibr">56</xref>]. This suggests that sex-related tau vulnerability may become more pronounced as cognitive decline emerges. We further observed an interaction at an uncorrected level of sex with A&#946; status on tau burden, when A&#946; was measured within 3 to 5 years before tau PET. These results serve as a replication of a previous study&#8217;s finding using TRIAD and ADNI data, which showed a sex-specific modulation of cortical A&#946; in tau phosphorylation among females across the clinical spectrum over time [<xref rid="bib0056" ref-type="bibr">57</xref>]. These sex-differences have been suggested to be explained by differential testosterone levels, protecting males against tau [<xref rid="bib0057" ref-type="bibr">58</xref>]. Our results, albeit weak, together with past literature suggest that, in general, females may have lower resistance to tau pathology which seems to be more driven by the presence of A&#946; among females, compared with males.</p><p id="para0054">Further, we found no main effects of education on tau burden. This is in line with previous studies indicating that years of education are associated with A&#946; [<xref rid="bib0011" ref-type="bibr">11</xref>], but not consistently with tau [<xref rid="bib0058" ref-type="bibr">59</xref>]. However, we showed, at an uncorrected level, that A&#946; and years of education measured within 2 years before PET assessment, interacted on tau burden. Stratified analyses revealed that this interaction may be driven by A&#946; negative individuals, where higher educational attainment was associated with greater tau burden. While seemingly counterintuitive, this is consistent with recent findings reporting a similar association of higher education being associated with greater tau levels among A&#946;-positive individuals [<xref rid="bib0059" ref-type="bibr">60</xref>]. This pattern may reflect education&#8217;s role in cognitive reserve, whereby individuals with higher educational attainment may tolerate greater underlying pathology without clinical expression [<xref rid="bib0060" ref-type="bibr">61</xref>]. This finding may also reflect selection given our sample&#8217;s high average educational attainment (mean = 16.5), or unmeasured socioeconomic or lifestyle factors that could promote tau accumulation (e.g., chronic occupational stress) associated with educational level. Overall, these results should be interpreted cautiously given the restricted educational variability of the sample, and warrant replication in future studies<italic toggle="yes">.</italic></p><p id="para0055">This study&#8217;s strengths include the use of a longitudinal biomarker cohort employing standardized assessments; PET scan collection protocols and meticulous data quality control; and the large sample size allowing for interaction analyses, including both cognitively unimpaired and MCI participants. The study also has several limitations. We used complete-case data within our study resulting in different sample sizes and statistical power across the time windows, limiting the comparison of results across time windows. Although our sensitivity analyses matching participants from the closest and mid time windows showed consistency across results, we advise caution on drawing conclusions regarding the furthest time window. While the NPI has been considered a valid and reliable tool [<xref rid="bib0061" ref-type="bibr">62</xref>], it was originally designed for informant reporting by caregivers of AD patients. Recent validation studies across ADNI and NACC cohorts have, however, demonstrated its reliability in MCI populations, particularly through validated subscales measuring clinically meaningful symptom clusters [<xref rid="bib0032" ref-type="bibr">33</xref>,<xref rid="bib0062" ref-type="bibr">63</xref>]. However, its application to cognitively unimpaired individuals might introduce bias, as informants might require a higher threshold of symptom severity before reporting symptoms compared to self-report measures. While we addressed some measurement limitations by binarizing the sub-NPI variables to account for floor effects, future studies might benefit from complementing NPI with self-report measures in cognitively unimpaired individuals. Additionally, the NPI uses retrospective informant rating (preceding month), introducing potential recall bias. Further, as ADNI employs rigorous exclusion criteria, including the exclusion of participants with pre-existing depression, our study's sample is not representative of the general population. Finally, as 91.4 % of the participants included in our study were of White ethnicity, the results are not generalizable to other populations at risk. Future research will benefit from replicating these results in other populations, potentially using a combination of assessment tools to capture the full spectrum of neuropsychiatric symptoms across the cognitive <italic toggle="yes">continuum</italic>.</p></sec><sec id="sec0014"><label>5</label><title>Conclusion</title><p id="para0056">This study reveals important temporal relationships between neuropsychiatric symptoms and AD pathology in older adults. Higher neuropsychiatric symptoms showed associations with tau burden primarily within short time intervals (0&#8211;2 years), and this association was modified by A&#946; status across short- and mid-term intervals (0&#8211;5 years). Among specific symptoms, anxiety was associated with tau burden only in models not adjusted for A&#946;, while other symptoms, as well as sex and education, showed weaker or non-significant associations. These temporal patterns suggest that neuropsychiatric symptoms might be concurrent manifestations of advancing AD pathology. Future longitudinal studies using both informant and self-report measures in diverse populations will be important for advancing our understanding of AD pathophysiology and developing more effective clinical strategies.</p></sec><sec id="sec0015"><title>Funding</title><p id="para0057">The research leading to these results has received funding by the <funding-source id="gs0001">Ajuntament de Barcelona</funding-source> (<award-id award-type="grant" rid="gs0001">23S06157&#8211;001</award-id>), <funding-source id="gs0002">Ministry of Science and Innovation</funding-source> (PID2019&#8211;111514RA-I00 &amp; PID2023-153362OB-I00) and the <funding-source id="gs0003">Alzheimer&#8217;s Association research</funding-source> grants (<award-id award-type="grant" rid="gs0003">AARG 2019-AARG-644,641</award-id>, <award-id award-type="grant" rid="gs0003">AARG2019-AARG-644,641-RAPID</award-id>), to EMA-U. EMA-U is supported by the <funding-source id="gs0004">Spanish Ministry of Science and Innovation&#8212;State Research Agency</funding-source> (<award-id award-type="grant" rid="gs0004">RYC2018&#8211;026,053-I</award-id>), co-funded by the <funding-source id="gs0005">European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation</funding-source> (<award-id award-type="grant" rid="gs0005">PRE2020&#8211;095,827</award-id>). AB acknowledges support from Instituto de Salud Carlos III and co-funded by the <funding-source id="gs0006">European Union through the Miguel Servet</funding-source> grant (<award-id award-type="grant" rid="gs0006">CP20/00,038</award-id>) and <funding-source id="gs0007">Fondo de Investigaciones Sanitario</funding-source> (<award-id award-type="grant" rid="gs0007">PI22/00,307</award-id>), the Alzheimer's Association (<award-id award-type="grant" rid="gs0007">AARG-22&#8211;923,680</award-id>) and the <funding-source id="gs0008">Ajuntament de Barcelona, in collaboration with Fundaci&#243; La Caixa</funding-source> (<award-id award-type="grant" rid="gs0008">23S06157&#8211;001</award-id>). The sponsor had no role in the design and conduct of the study; in the collection, analysis and interpretation of data; in the preparation of the manuscript; or in the review or approval of the manuscript.</p></sec><sec id="sec0016"><title>Declaration of generative AI and AI-assisted technologies in the writing process</title><p id="para0059">During the preparation of this work the authors used ChatGPT and Claude in order to support the writing of this manuscript. This tool was used for language improvement, grammar correction, and suggestions on phrasing. After using these tools/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.</p></sec><sec id="sec0016a"><title>CRediT authorship contribution statement</title><p id="para0059a"><bold>Pablo Aguilar-Dominguez:</bold> Writing &#8211; original draft, Methodology, Formal analysis, Data curation, Conceptualization. <bold>Eleni Palpatzis:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Conceptualization. <bold>Muge Akinci:</bold> Writing &#8211; review &amp; editing. <bold>Anna Canal-Garcia:</bold> Writing &#8211; review &amp; editing, Data curation. <bold>Joana B. Pereira:</bold> Writing &#8211; review &amp; editing. <bold>Alexandre Bejanin:</bold> Writing &#8211; review &amp; editing, Supervision, Methodology, Conceptualization. <bold>Eider M. Arenaza-Urquijo:</bold> Writing &#8211; review &amp; editing, Supervision, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0060">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Rentz</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>The A4 study: stopping AD before symptoms begin?</article-title><source>Sci Transl Med</source><volume>6</volume><issue>228</issue><year>2014</year><pub-id pub-id-type="doi">10.1126/SCITRANSLMED.3007941</pub-id><pub-id pub-id-type="pmcid">PMC4049292</pub-id><pub-id pub-id-type="pmid">24648338</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Wiste</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Botha</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The bivariate distribution of amyloid-&#946; and tau: relationship with established neurocognitive clinical syndromes</article-title><source>Brain</source><volume>142</volume><issue>10</issue><year>2019</year><fpage>3230</fpage><lpage>3242</lpage><pub-id pub-id-type="doi">10.1093/BRAIN/AWZ268</pub-id><pub-id pub-id-type="pmid">31501889</pub-id><pub-id pub-id-type="pmcid">PMC6763736</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schonhaut</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Sch&#246;ll</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#8217;s disease</article-title><source>Brain</source><volume>139</volume><issue>5</issue><year>2016</year><fpage>1551</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1093/BRAIN/AWW027</pub-id><pub-id pub-id-type="pmid">26962052</pub-id><pub-id pub-id-type="pmcid">PMC5006248</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Bejanin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schonhaut</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#8217;s disease</article-title><source>Brain</source><volume>140</volume><issue>12</issue><year>2017</year><fpage>3286</fpage><lpage>3300</lpage><pub-id pub-id-type="doi">10.1093/BRAIN/AWX243</pub-id><pub-id pub-id-type="pmid">29053874</pub-id><pub-id pub-id-type="pmcid">PMC5841139</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Arenaza-Urquijo</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Vemuri</surname><given-names>P.</given-names></name></person-group><article-title>Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies</article-title><source>Neurology</source><volume>90</volume><issue>15</issue><year>2018</year><fpage>695</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000005303</pub-id><pub-id pub-id-type="pmid">29592885</pub-id><pub-id pub-id-type="pmcid">PMC5894932</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.J.</given-names></name></person-group><article-title>Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults</article-title><source>Eur J Nucl Med Mol Imaging</source><volume>47</volume><issue>9</issue><year>2020</year><fpage>2155</fpage><lpage>2164</lpage><pub-id pub-id-type="doi">10.1007/S00259-019-04669-X</pub-id><pub-id pub-id-type="pmid">31915896</pub-id><pub-id pub-id-type="pmcid">PMC7338820</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Arenaza-Urquijo</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Casaletto</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Sex and gender differences in cognitive resilience to aging and Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement</source><volume>19</volume><year>2024</year><fpage>27</fpage><pub-id pub-id-type="doi">10.1002/ALZ.13844</pub-id><pub-id pub-id-type="pmcid">PMC11350140</pub-id><pub-id pub-id-type="pmid">38967222</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Liesinger</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Graff-Radford</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Duara</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Sex and age interact to determine clinicopathologic differences in Alzheimer&#8217;s disease</article-title><source>Acta Neuropathol</source><volume>136</volume><issue>6</issue><year>2018</year><fpage>873</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1007/S00401-018-1908-X</pub-id><pub-id pub-id-type="pmid">30219939</pub-id><pub-id pub-id-type="pmcid">PMC6280837</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Schoonenboom</surname><given-names>N.S.M.</given-names></name><name name-style="western"><surname>Pijnenburg</surname><given-names>Y.A.L.</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Amyloid &#946;(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease</article-title><source>Neurology</source><volume>62</volume><issue>9</issue><year>2004</year><fpage>1580</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000123249.58898.E0</pub-id><pub-id pub-id-type="pmid">15136685</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Gonneaud</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bedetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pichet Binette</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Association of education with A&#946; burden in preclinical familial and sporadic Alzheimer disease</article-title><source>Neurology</source><volume>95</volume><issue>11</issue><year>2020</year><fpage>e1554</fpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000010314</pub-id><pub-id pub-id-type="pmid">32759192</pub-id><pub-id pub-id-type="pmcid">PMC7713743</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Arenaza-Urquijo</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Bejanin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonneaud</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation</article-title><source>Neurobiol Aging</source><volume>59</volume><year>2017</year><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/J.NEUROBIOLAGING.2017.06.016</pub-id><pub-id pub-id-type="pmid">28764930</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.H.</given-names></name><etal/></person-group><article-title>Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment</article-title><source>J Alzheimers Dis</source><volume>58</volume><issue>4</issue><year>2017</year><fpage>1255</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.3233/JAD-170225</pub-id><pub-id pub-id-type="pmid">28550264</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Devanand</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huey</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>T.E.</given-names></name></person-group><article-title>Associations Between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias</article-title><source>JAMA Psychiatry</source><volume>79</volume><issue>4</issue><year>2022</year><fpage>359</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1001/JAMAPSYCHIATRY.2021.4363</pub-id><pub-id pub-id-type="pmid">35171235</pub-id><pub-id pub-id-type="pmcid">PMC8851371</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer&#8217;s disease: a systematic review of symptom-general and &#8211;specific lesion patterns</article-title><source>Mol Neurodegener</source><volume>16</volume><issue>1</issue><year>2021</year><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1186/S13024-021-00456-1</pub-id><comment>2021 161</comment><pub-id pub-id-type="pmid">34099005</pub-id><pub-id pub-id-type="pmcid">PMC8186099</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid amyloid-&#946; and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients</article-title><source>Alzheimers Res Ther</source><volume>16</volume><issue>1</issue><year>2024</year><pub-id pub-id-type="doi">10.1186/S13195-024-01434-7</pub-id><pub-id pub-id-type="pmcid">PMC10988961</pub-id><pub-id pub-id-type="pmid">38570794</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Donovan</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Locascio</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults</article-title><source>Am J Psychiatry</source><volume>175</volume><issue>6</issue><year>2018</year><fpage>530</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1176/APPI.AJP.2017.17040442</pub-id><pub-id pub-id-type="pmid">29325447</pub-id><pub-id pub-id-type="pmcid">PMC5988933</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Gatchel</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Locascio</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: a Pilot Study</article-title><source>J Alzheimers Dis</source><volume>59</volume><issue>3</issue><year>2017</year><fpage>975</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.3233/JAD-170001</pub-id><pub-id pub-id-type="pmid">28697559</pub-id><pub-id pub-id-type="pmcid">PMC5577564</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Tissot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Therriault</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pascoal</surname><given-names>T.A.</given-names></name><etal/></person-group><article-title>Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement Transl Res Clin Interv</source><volume>7</volume><issue>1</issue><year>2021</year><pub-id pub-id-type="doi">10.1002/TRC2.12154</pub-id><pub-id pub-id-type="pmcid">PMC8012244</pub-id><pub-id pub-id-type="pmid">33816761</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Pink</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krell-Roesch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Syrjanen</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Interactions Between Neuropsychiatric Symptoms and Alzheimer&#8217;s Disease Neuroimaging Biomarkers in Predicting Longitudinal Cognitive Decline</article-title><source>Psychiatr Res Clin Pract</source><volume>5</volume><issue>1</issue><year>2023</year><fpage>4</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1176/APPI.PRCP.20220036/ASSET/IMAGES/MEDIUM/RCP21057-FIG-0003.PNG</pub-id><pub-id pub-id-type="pmid">36909142</pub-id><pub-id pub-id-type="pmcid">PMC9997077</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Sharif</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>D.X.</given-names></name><name name-style="western"><surname>Bodnar</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Neuropsychiatric symptoms and progression to pathologically confirmed Alzheimer&#8217;s disease</article-title><source>Brain. Published online April</source><volume>25</volume><year>2025</year><pub-id pub-id-type="doi">10.1093/BRAIN/AWAF156</pub-id><pub-id pub-id-type="pmcid">PMC12493056</pub-id><pub-id pub-id-type="pmid">40279515</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>H.I.L.</given-names></name><etal/></person-group><article-title>Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline</article-title><source>Ann Neurol</source><volume>88</volume><issue>5</issue><year>2020</year><fpage>921</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1002/ANA.25878</pub-id><pub-id pub-id-type="pmid">32799367</pub-id><pub-id pub-id-type="pmcid">PMC7581543</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Therriault</surname><given-names>J.</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Pascoal</surname><given-names>T.A.</given-names></name><etal/></person-group><article-title>APOE&#949;4 potentiates the relationship between amyloid-&#946; and tau pathologies</article-title><source>Mol Psychiatry</source><volume>26</volume><issue>10</issue><year>2021</year><fpage>5977</fpage><lpage>5988</lpage><pub-id pub-id-type="doi">10.1038/S41380-020-0688-6</pub-id><pub-id pub-id-type="pmid">32161362</pub-id><pub-id pub-id-type="pmcid">PMC8758492</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Arenaza-Urquijo</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Przybelski</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>MacHulda</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults</article-title><source>Neurology</source><volume>94</volume><issue>15</issue><year>2020</year><fpage>e1571</fpage><lpage>e1579</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000008979</pub-id><pub-id pub-id-type="pmid">31964689</pub-id><pub-id pub-id-type="pmcid">PMC7251516</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Shcherbinin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>I.A.</given-names></name><etal/></person-group><article-title>Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement (New York, N Y)</source><volume>9</volume><issue>3</issue><year>2023</year><pub-id pub-id-type="doi">10.1002/TRC2.12415</pub-id><pub-id pub-id-type="pmcid">PMC10432878</pub-id><pub-id pub-id-type="pmid">37600216</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Espeland</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER)</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>2</issue><year>2024</year><fpage>769</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1002/alz.13365</pub-id><pub-id pub-id-type="pmid">37776210</pub-id><pub-id pub-id-type="pmcid">PMC10916955</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Florian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study</article-title><source>Brain</source><volume>146</volume><issue>6</issue><year>2023</year><fpage>2275</fpage><lpage>2284</lpage><pub-id pub-id-type="doi">10.1093/brain/awad024</pub-id><pub-id pub-id-type="pmid">36730056</pub-id><pub-id pub-id-type="pmcid">PMC10232284</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>SL</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>SN</given-names></name><name name-style="western"><surname>Price</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging</article-title><source>J Nucl Med</source><volume>58</volume><issue>2</issue><year>2017</year><fpage>332</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.2967/jnumed.116.175273</pub-id><pub-id pub-id-type="pmid">27587706</pub-id><pub-id pub-id-type="pmcid">PMC5288744</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Maass</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.J.</given-names></name></person-group><article-title>Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data</article-title><source>Data Br</source><volume>15</volume><year>2017</year><fpage>648</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1016/J.DIB.2017.10.024</pub-id><pub-id pub-id-type="pmcid">PMC5671473</pub-id><pub-id pub-id-type="pmid">29124088</pub-id></element-citation></ref><ref id="bib63"><label>29</label><element-citation publication-type="journal" id="optSiSQBcwCat"><person-group person-group-type="author"><name name-style="western"><surname>Landau</surname><given-names>SM</given-names></name><name name-style="western"><surname>Breault</surname><given-names>C</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Amyloid-&#946; imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods</article-title><source>J Nucl Med</source><volume>54</volume><issue>1</issue><year>2013</year><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.2967/jnumed.112.109009</pub-id><pub-id pub-id-type="pmid">23166389</pub-id><pub-id pub-id-type="pmcid">PMC3747730</pub-id></element-citation></ref><ref id="bib0029"><label>30</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Landau</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Fero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Measurement of Longitudinal &#946;-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios</article-title><source>J Nucl Med</source><volume>56</volume><issue>4</issue><year>2015</year><fpage>567</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.2967/JNUMED.114.148981</pub-id><pub-id pub-id-type="pmid">25745095</pub-id><pub-id pub-id-type="pmcid">PMC5313473</pub-id></element-citation></ref><ref id="bib0030"><label>31</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Klunk</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Price</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET</article-title><source>Alzheimers Dement</source><volume>11</volume><issue>1</issue><year>2015</year><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/J.JALZ.2014.07.003</pub-id><comment>e4</comment><pub-id pub-id-type="pmid">25443857</pub-id><pub-id pub-id-type="pmcid">PMC4300247</pub-id></element-citation></ref><ref id="bib0031"><label>32</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Royse</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Minhas</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lopresti</surname><given-names>B.J.</given-names></name><etal/></person-group><article-title>Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach</article-title><source>Alzheimer&#8217;s Res Ther</source><volume>13</volume><issue>1</issue><year>2021</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/S13195-021-00836-1</pub-id><comment>2021 131</comment><pub-id pub-id-type="pmid">33971965</pub-id><pub-id pub-id-type="pmcid">PMC8111744</pub-id></element-citation></ref><ref id="bib0032"><label>33</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name></person-group><article-title>The Neuropsychiatric Inventory: development and Applications</article-title><source>J Geriatr Psychiatry Neurol</source><volume>33</volume><issue>2</issue><year>2020</year><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1177/0891988719882102</pub-id><pub-id pub-id-type="pmid">32013737</pub-id><pub-id pub-id-type="pmcid">PMC8505128</pub-id></element-citation></ref><ref id="bib0033"><label>34</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.L.</given-names></name></person-group><article-title>The Neuropsychiatric Inventory: assessing psychopathology in dementia patients</article-title><source>Neurology</source><volume>48</volume><issue>5 SUPPL. 6</issue><year>1997</year><pub-id pub-id-type="doi">10.1212/WNL.48.5_SUPPL_6.10S</pub-id><pub-id pub-id-type="pmid">9153155</pub-id></element-citation></ref><ref id="bib0034"><label>35</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Mega</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rosenberg-Thompson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carusi</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Gornbein</surname><given-names>J.</given-names></name></person-group><article-title>The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia</article-title><source>Neurology</source><volume>44</volume><issue>12</issue><year>1994</year><fpage>2308</fpage><lpage>2314</lpage><pub-id pub-id-type="doi">10.1212/WNL.44.12.2308</pub-id><pub-id pub-id-type="pmid">7991117</pub-id></element-citation></ref><ref id="bib0035"><label>36</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;iz-V&#225;zquez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gracia-Garc&#237;a</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ubillos-Landa</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Depression as a Risk Factor for Alzheimer&#8217;s Disease: a Systematic Review of Longitudinal Meta-Analyses</article-title><source>J Clin Med</source><volume>10</volume><issue>9</issue><year>2021</year><fpage>1809</fpage><pub-id pub-id-type="doi">10.3390/JCM10091809</pub-id><pub-id pub-id-type="pmid">33919227</pub-id><pub-id pub-id-type="pmcid">PMC8122638</pub-id></element-citation></ref><ref id="bib0036"><label>37</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Pietrzak</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Neumeister</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Amyloid-&#946;, anxiety, and cognitive decline in preclinical alzheimer disease a multicenter, prospective cohort study</article-title><source>JAMA Psychiatry</source><volume>72</volume><issue>3</issue><year>2015</year><fpage>284</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.2476</pub-id><pub-id pub-id-type="pmid">25629787</pub-id></element-citation></ref><ref id="bib0037"><label>38</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>R.A.</given-names></name></person-group><article-title>When to use the Bonferroni correction</article-title><source>Ophthalmic Physiol Opt</source><volume>34</volume><issue>5</issue><year>2014</year><fpage>502</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1111/OPO.12131</pub-id><pub-id pub-id-type="pmid">24697967</pub-id></element-citation></ref><ref id="bib0038"><label>39</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Ownby</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Crocco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Acevedo</surname><given-names>A.</given-names></name><name name-style="western"><surname>John</surname><given-names>V.</given-names></name><name name-style="western"><surname>Loewenstein</surname><given-names>D.</given-names></name></person-group><article-title>Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis</article-title><source>Arch Gen Psychiatry</source><volume>63</volume><issue>5</issue><year>2006</year><fpage>530</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1001/ARCHPSYC.63.5.530</pub-id><pub-id pub-id-type="pmid">16651510</pub-id><pub-id pub-id-type="pmcid">PMC3530614</pub-id></element-citation></ref><ref id="bib0039"><label>40</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schonhaut</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Sch&#246;ll</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#8217;s disease</article-title><source>Brain</source><volume>139</volume><issue>5</issue><year>2016</year><fpage>1551</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1093/BRAIN/AWW027</pub-id><pub-id pub-id-type="pmid">26962052</pub-id><pub-id pub-id-type="pmcid">PMC5006248</pub-id></element-citation></ref><ref id="bib0040"><label>41</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Ehrenberg</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Suemoto</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Fran&#231;a Resende</surname><given-names>E.</given-names></name><name name-style="western"><surname>de</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer&#8217;s Disease</article-title><source>J Alzheimers Dis</source><volume>66</volume><issue>1</issue><year>2018</year><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.3233/JAD-180688</pub-id><pub-id pub-id-type="pmid">30223398</pub-id><pub-id pub-id-type="pmcid">PMC6381997</pub-id></element-citation></ref><ref id="bib0041"><label>42</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Krell-Roesch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vassilaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mielke</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Cortical &#946;-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging</article-title><source>Transl Psychiatry</source><volume>9</volume><issue>1</issue><year>2019</year><pub-id pub-id-type="doi">10.1038/s41398-019-0456-z</pub-id><pub-id pub-id-type="pmcid">PMC6438979</pub-id><pub-id pub-id-type="pmid">30923322</pub-id></element-citation></ref><ref id="bib0042"><label>43</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Macedo</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Therriault</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tissot</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Modeling the progression of neuropsychiatric symptoms in Alzheimer&#8217;s disease with PET-based Braak staging</article-title><source>Neurobiol Aging</source><volume>144</volume><year>2024</year><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/J.NEUROBIOLAGING.2024.09.009</pub-id><pub-id pub-id-type="pmid">39326302</pub-id></element-citation></ref><ref id="bib0043"><label>44</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Del Tredici</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Braak</surname><given-names>H.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.I.</given-names></name></person-group><article-title>Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer&#8217;s disease and PART</article-title><source>Acta Neuropathol</source><volume>136</volume><issue>1</issue><year>2018</year><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1007/S00401-018-1855-6</pub-id><pub-id pub-id-type="pmid">29752551</pub-id><pub-id pub-id-type="pmcid">PMC6015098</pub-id></element-citation></ref><ref id="bib0044"><label>45</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>El</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Neuroinflammation in Alzheimer&#8217;s Disease</article-title><source>Lancet Neurol</source><volume>14</volume><issue>4</issue><year>2015</year><fpage>388</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)70016-5</pub-id><pub-id pub-id-type="pmid">25792098</pub-id><pub-id pub-id-type="pmcid">PMC5909703</pub-id></element-citation></ref><ref id="bib0045"><label>46</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Crary</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Primary age-related tauopathy (PART): a common pathology associated with human aging</article-title><source>Acta Neuropathol</source><volume>128</volume><issue>6</issue><year>2014</year><fpage>755</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1007/S00401-014-1349-0</pub-id><pub-id pub-id-type="pmid">25348064</pub-id><pub-id pub-id-type="pmcid">PMC4257842</pub-id></element-citation></ref><ref id="bib0046"><label>47</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Maass</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.J.</given-names></name></person-group><article-title>Cortical tau deposition follows patterns of entorhinal functional connectivity in aging</article-title><source>Elife</source><volume>8</volume><year>2019</year><pub-id pub-id-type="doi">10.7554/ELIFE.49132</pub-id><pub-id pub-id-type="pmcid">PMC6764824</pub-id><pub-id pub-id-type="pmid">31475904</pub-id></element-citation></ref><ref id="bib0047"><label>48</label><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Johansson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stomrud</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lindberg</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Apathy and anxiety are early markers of Alzheimer&#8217;s disease</article-title><source>Neurobiol Aging</source><volume>85</volume><year>2020</year><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.10.008</pub-id><pub-id pub-id-type="pmid">31735378</pub-id></element-citation></ref><ref id="bib0048"><label>49</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Babulal</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Roe</surname><given-names>C.M.</given-names></name></person-group><article-title>Longitudinal Changes in Anger, Anxiety, and Fatigue Are Associated with Cerebrospinal Fluid Biomarkers of Alzheimer&#8217;s Disease</article-title><source>J Alzheimers Dis</source><volume>87</volume><issue>1</issue><year>2022</year><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.3233/JAD-215708</pub-id><pub-id pub-id-type="pmid">35253769</pub-id><pub-id pub-id-type="pmcid">PMC9086112</pub-id></element-citation></ref><ref id="bib0049"><label>50</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Demnitz-King</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saba</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Association between anxiety symptoms and Alzheimer&#8217;s disease biomarkers in cognitively healthy adults: a systematic review and meta-analysis</article-title><source>J Psychosom Res</source><volume>166</volume><year>2023</year><object-id pub-id-type="publisher-id">111159</object-id><pub-id pub-id-type="doi">10.1016/J.JPSYCHORES.2023.111159</pub-id><pub-id pub-id-type="pmid">36709611</pub-id></element-citation></ref><ref id="bib0050"><label>51</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Gonzales</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Samra</surname><given-names>J.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Association of Midlife Depressive Symptoms with Regional Amyloid-&#946; and Tau in the Framingham Heart Study</article-title><source>J Alzheimers Dis</source><volume>82</volume><issue>1</issue><year>2021</year><fpage>249</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.3233/JAD-210232</pub-id><pub-id pub-id-type="pmid">34024836</pub-id><pub-id pub-id-type="pmcid">PMC8900661</pub-id></element-citation></ref><ref id="bib0051"><label>52</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>De Vito</surname><given-names>A.N.</given-names></name><etal/></person-group><article-title>Parallel changes in cognition, neuropsychiatric symptoms, and amyloid in cognitively unimpaired older adults and those with mild cognitive impairment</article-title><source>Alzheimer's &amp; dementia: the journal of the Alzheimer's Association</source><volume>21</volume><issue>2</issue><year>2025</year><object-id pub-id-type="publisher-id">e14568</object-id><pub-id pub-id-type="doi">10.1002/alz.14568</pub-id><pub-id pub-id-type="pmcid">PMC11815203</pub-id><pub-id pub-id-type="pmid">39936256</pub-id></element-citation></ref><ref id="bib0052"><label>53</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer&#8217;s Disease Risks</article-title><source>J Alzheimers Dis</source><volume>87</volume><issue>4</issue><year>2022</year><fpage>1567</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.3233/JAD-215417</pub-id><pub-id pub-id-type="pmid">35491776</pub-id><pub-id pub-id-type="pmcid">PMC9644449</pub-id></element-citation></ref><ref id="bib0053"><label>54</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>Lucey</surname><given-names>B.P.</given-names></name></person-group><article-title>It&#8217;s complicated: the relationship between sleep and Alzheimer&#8217;s disease in humans</article-title><source>Neurobiol Dis</source><volume>144</volume><year>2020</year><object-id pub-id-type="publisher-id">105031</object-id><pub-id pub-id-type="doi">10.1016/J.NBD.2020.105031</pub-id><pub-id pub-id-type="pmcid">PMC7484285</pub-id><pub-id pub-id-type="pmid">32738506</pub-id></element-citation></ref><ref id="bib0054"><label>55</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Mormino</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Rabin</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults</article-title><source>JAMA Neurol</source><volume>76</volume><issue>5</issue><year>2019</year><fpage>542</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1001/JAMANEUROL.2018.4693</pub-id><pub-id pub-id-type="pmid">30715078</pub-id><pub-id pub-id-type="pmcid">PMC6515599</pub-id></element-citation></ref><ref id="bib0055"><label>56</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.J.</given-names></name></person-group><article-title>Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults</article-title><source>Eur J Nucl Med Mol Imaging</source><volume>47</volume><issue>9</issue><year>2020</year><fpage>2155</fpage><lpage>2164</lpage><pub-id pub-id-type="doi">10.1007/S00259-019-04669-X</pub-id><pub-id pub-id-type="pmid">31915896</pub-id><pub-id pub-id-type="pmcid">PMC7338820</pub-id></element-citation></ref><ref id="bib0056"><label>57</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y-T</given-names></name><name name-style="western"><surname>Therriault</surname><given-names>J.</given-names></name><name name-style="western"><surname>Servaes</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Sex-specific modulation of amyloid-&#946; on tau phosphorylation underlies faster tangle accumulation in females</article-title><source>Brain</source><volume>147</volume><issue>4</issue><year>2024</year><fpage>1497</fpage><lpage>1510</lpage><pub-id pub-id-type="doi">10.1093/BRAIN/AWAD397</pub-id><pub-id pub-id-type="pmid">37988283</pub-id><pub-id pub-id-type="pmcid">PMC10994548</pub-id></element-citation></ref><ref id="bib0057"><label>58</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Sundermann</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Panizzon</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>M.</given-names></name><name name-style="western"><surname>Galasko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>S.J.</given-names></name></person-group><article-title>Sex differences in Alzheimer&#8217;s-related Tau biomarkers and a mediating effect of testosterone</article-title><source>Biol Sex Differ</source><volume>11</volume><issue>1</issue><year>2020</year><pub-id pub-id-type="doi">10.1186/S13293-020-00310-X</pub-id><pub-id pub-id-type="pmcid">PMC7304096</pub-id><pub-id pub-id-type="pmid">32560743</pub-id></element-citation></ref><ref id="bib0058"><label>59</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Pichet Binette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vachon-Presseau</surname><given-names>&#201;</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer&#8217;s Disease</article-title><source>Biol Psychiatry</source><volume>89</volume><issue>8</issue><year>2021</year><fpage>776</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2020.01.023</pub-id><pub-id pub-id-type="pmid">32228870</pub-id><pub-id pub-id-type="pmcid">PMC7415608</pub-id></element-citation></ref><ref id="bib0059"><label>60</label><element-citation publication-type="journal" id="sbref0059"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Educational attainment, A&#946;, tau, and structural brain reserve in Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement</source><volume>21</volume><issue>2</issue><year>2025</year><object-id pub-id-type="publisher-id">e14400</object-id><pub-id pub-id-type="doi">10.1002/ALZ.14400</pub-id><pub-id pub-id-type="pmcid">PMC11848334</pub-id><pub-id pub-id-type="pmid">39854134</pub-id></element-citation></ref><ref id="bib0060"><label>61</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name></person-group><article-title>Cognitive reserve and Alzheimer disease</article-title><source>Alzheimer Dis Assoc Disord</source><volume>20</volume><issue>2</issue><year>2006</year><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1097/01.wad.0000213815.20177.19</pub-id><pub-id pub-id-type="pmid">16772747</pub-id></element-citation></ref><ref id="bib0061"><label>62</label><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>C.K.Y.</given-names></name></person-group><article-title>The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders</article-title><source>Clin Interv Aging</source><volume>9</volume><year>2014</year><fpage>1051</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.2147/CIA.S63504</pub-id><pub-id pub-id-type="pmid">25031530</pub-id><pub-id pub-id-type="pmcid">PMC4099101</pub-id></element-citation></ref><ref id="bib0062"><label>63</label><element-citation publication-type="journal" id="sbref0062"><person-group person-group-type="author"><name name-style="western"><surname>Trzepacz</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Subscale Validation of the Neuropsychiatric Inventory Questionnaire (NPI-Q): comparison of ADNI and NACC Cohorts</article-title><source>Am J Geriatr Psychiatry</source><volume>21</volume><issue>7</issue><year>2013</year><fpage>607</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/J.JAGP.2012.10.027</pub-id><pub-id pub-id-type="pmid">23602309</pub-id><pub-id pub-id-type="pmcid">PMC3913908</pub-id></element-citation></ref></ref-list><sec id="sec0018" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0058a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgments</title><p id="para0061">The data used for this paper were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) database (ht tp://adni.loni.usc.edu/). The investigators involved in ADNI contributed to its design and implementation and/or provided data but were not involved in the analysis or writing of this paper. Full list of ADNI investigators: htt p://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.</p></ack><fn-group><fn id="sec0017" fn-type="supplementary-material"><p id="para0011a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100294" id="interref0003">doi:10.1016/j.tjpad.2025.100294</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="pmc-domain-id">2786</journal-id><journal-id journal-id-type="pmc-domain">medicine</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12499709</article-id><article-id pub-id-type="pmcid-ver">PMC12499709.1</article-id><article-id pub-id-type="pmcaid">12499709</article-id><article-id pub-id-type="pmcaiid">12499709</article-id><article-id pub-id-type="pmid">41054094</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000044786</article-id><article-id pub-id-type="publisher-id">MD-D-25-03790</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>3200</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>Dose-response relationship between sleep duration and mediation of phenotypic age acceleration: A cross-sectional study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yujia</given-names></name><degrees>MEd</degrees><email>liuyujia929@outlook.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-7910-0130</contrib-id><name name-style="western"><surname>Qiao</surname><given-names initials="K">Kai</given-names></name><degrees>MEd</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Ministry of Basic Education, Inner Mongolia Minzu Preschool Education College, Ordos, China</aff><aff id="aff2"><label>b</label>Research Medical Center, Ordos Sports Vocational School, Ordos, China.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Kai Qiao, Ministry of Basic Education, Inner Mongolia Minzu Preschool Education College, No. 18, Houde Road, Tiexi Vocational Education Park, Dongsheng District, Ordos City 017000, Inner Mongolia Autonomous Region, China (e-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="qiaokai666@outlook.com">qiaokai666@outlook.com</email>).</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>03</day><month>10</month><year>2025</year></pub-date><volume>104</volume><issue>40</issue><issue-id pub-id-type="pmc-issue-id">498401</issue-id><elocation-id>e44786</elocation-id><history><date date-type="received"><day>20</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>25</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC)</ext-link>, where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medi-104-e44786.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medi-104-e44786.pdf"/><abstract><p>This study aimed to explore the dose-response relationship between sleep duration and phenotypic age acceleration (PhenoAgeAccel), as well as the potential impact of different sleep duration patterns on the biological aging process. Utilizing data from the National Health and Nutrition Examination Survey from 2001 to 2010, this cross-sectional study included 8992 adult participants. Sleep duration data were collected via self-report and categorized into &#8220;&lt;7 hours/day,&#8221; &#8220;7&#8211;9 hours/day,&#8221; and &#8220;&gt;9 hours/day&#8221; groups. PhenoAgeAccel was calculated by combining actual age with 9 biomarkers. Weighted generalized linear regression models and unrestricted cubic spline analyses were employed to examine the relationship between sleep duration and PhenoAgeAccel. Interaction effects were assessed to evaluate the influence of different demographic and health characteristics. In unadjusted analyses, the 7 to 9 hours/day sleep group showed a significant deceleration in phenotypic aging compared to the &lt;7 hours/day group (<italic toggle="yes">&#946;</italic>&#8197;=&#8197;&#8722;1.207, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.0001). However, this association was substantially attenuated and no longer statistically significant after full adjustment for demographic, lifestyle, and comorbidity factors. A significant nonlinear dose-response relationship was confirmed, with an inflection point at approximately 6.7 hours. Interaction effect tests revealed that this relationship was significantly influenced by an individual&#8217;s smoking and diabetes status (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01). This study suggests that moderate sleep duration of 7 to 9 hours/day is associated with a deceleration in phenotypic aging, with a critical inflection point for sleep and aging health at approximately 6.7 hours. Both insufficient and excessive sleep durations may be detrimental to slowing the aging process. The results of the interaction effect tests emphasize the need to consider individual smoking and diabetes status when developing targeted health interventions. These findings provide new insights into the complex relationship between sleep and biological aging, offering a scientific basis for public health guidance and the optimization of individual sleep habits. Future research should employ longitudinal designs and objective sleep monitoring tools to further explore the causal relationship and underlying mechanisms between sleep and biological aging.</p></abstract><kwd-group><kwd>aging</kwd><kwd>phenotypic age acceleration</kwd><kwd>sleep duration</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>In contemporary society, sleep issues have emerged as a global public health challenge, particularly concerning their impact on the aging process. It is well-established that sufficient and high-quality sleep is crucial for maintaining health and preventing premature aging. However, with the acceleration of life&#8217;s pace and increased societal pressures, an increasing number of individuals are experiencing the plight of insufficient sleep. Studies have shown that lack of sleep is closely associated with a variety of health problems, such as cardiovascular diseases, diabetes, obesity, and depression, all of which may accelerate the aging process of individuals.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup></p><p>Aging is a complex biological process involving changes in various physiological and molecular mechanisms. In recent years, phenotypic age acceleration (PhenoAgeAccel), as an important indicator for measuring the speed of an individual&#8217;s biological aging, has garnered widespread attention in the scientific community. PhenoAgeAccel predicts the speed of an individual&#8217;s biological aging by assessing age-related biomarkers, providing a new perspective for understanding individual health conditions. For instance, research by Chen et al<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> demonstrated that PhenoAgeAccel is positively associated with all-cause and specific-cause mortality in diabetes patients, highlighting the potential value of antiaging treatments in slowing disease progression; the study by Shadyab et al<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> emphasized the potential value of PhenoAgeAccel as a biomarker in assessing cognitive impairment and brain structure, as well as whether these associations are influenced by cardiovascular diseases.</p><p>The relationship between sleep and aging is particularly complex.<sup>[<xref rid="R4" ref-type="bibr">4</xref>&#8211;<xref rid="R7" ref-type="bibr">7</xref>]</sup> On one hand, changes in sleep quality and duration directly affect an individual&#8217;s physiological and psychological health, which may in turn accelerate the aging process. On the other hand, aging itself may affect sleep patterns, leading to the occurrence of sleep problems. Therefore, understanding the relationship between sleep and PhenoAgeAccel is crucial for developing effective public health strategies and interventions.</p><p>After an in-depth analysis of the key role of sleep duration in the biological aging process, we further explored the connection between sleep patterns and PhenoAgeAccel, as well as the importance of these factors in disease risk assessment and aging research. We recognize the significant potential of these indicators in revealing the subtle mechanisms of aging and in formulating effective health intervention strategies. However, despite some key findings, the dose-response relationship between sleep patterns and PhenoAgeAccel has not been fully clarified.</p><p>Thus, this study aims to delve into the relationship between sleep duration and PhenoAgeAccel and attempts to reveal the potential synergistic mechanisms between sleep patterns and the biological aging process. Our preliminary hypothesis is that there is a significant correlation between sleep duration and PhenoAgeAccel, suggesting that optimizing sleep patterns may contribute to slowing the process of biological aging.</p></sec><sec sec-type="methods"><title>2. Materials and methods</title><sec><title>2.1. Study subjects and data sources</title><p>This investigation utilized data from the National Health and Nutrition Examination Survey (NHANES) conducted between 2001 and 2010. Orchestrated by the Centers for Disease Control and Prevention (CDC), NHANES is a representative national survey designed to gauge the health and nutritional status of American adults and children. The cohort of participants was selected from the NHANES database, in alignment with the protocols recommended by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Administered every 2 years by the National Center for Health Statistics alongside the Centers for Disease Control and Prevention, the survey employs a complex, multi-stage probability sampling method to examine around 10,000 noninstitutionalized individuals from various US locales. Data collection involved household interviews and physical examinations, where participants answered questions related to demographic, socioeconomic, dietary, and health-related factors, and underwent assessments for medical, dental, and physiological-biochemical indicators.</p><p>In this study, a total of 8992 adults aged &#8805;20 were included in the final analysis after a rigorous screening process. This process primarily involved the exclusion of participants who did not meet the age criteria and those who failed to complete the requisite questionnaires and physical examinations. Data analysis was conducted using a complete case analysis approach. The detailed screening procedure is depicted in Figure <xref rid="F1" ref-type="fig">1</xref>. The NHANES survey data utilized in this study has undergone the necessary ethical approval, adhering to the principles of the Declaration of Helsinki.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Flowchart. This figure illustrates the detailed process of participant inclusion and exclusion criteria based on NHANES data. Participants who did not meet the age criteria and those who failed to complete the requisite questionnaires and physical examinations were excluded, leading to a final analytical sample of 8992 adults. NHANES = National Health and Nutrition Examination Survey.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e44786-g001.jpg"/></fig></sec><sec><title>2.2. Definition of the sleep time</title><p>In the NHANES dataset, the measurement of sleep duration was obtained through a questionnaire survey. Participants were asked, &#8220;How much do you usually sleep during a typical 24-hour period on weekdays or workdays?&#8221; This question aimed to capture their typical sleep habits. The response options ranged from 1 hour to 12 hours, with 12 hours representing a sleep duration of 12 hours or more. This self-reported sleep duration data were used to analyze the relationship between sleep and various health outcomes. In this study, sleep duration was categorized into &#8220;&lt;7 hours/day,&#8221; &#8220;7&#8211;9 hours/day,&#8221; and &#8220;&gt;9 hours/day&#8221; groups. This categorization helps in more accurately assessing the relationship between different durations of sleep and PhenoAgeAccel.</p></sec><sec><title>2.3. Definition of the PhenoAgeAccel</title><p>This study adopted a comprehensive approach to calculate an individual&#8217;s phenotypic age, based on pivotal research on phenotypic age.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> This method considers both chronological age and 9 key biomarkers, including albumin, creatinine, glucose, log-transformed C-reactive protein, percentage of lymphocytes, mean cell volume, red cell distribution width, alkaline phosphatase, and white blood cell count. The selection of these biomarkers was based on a Cox proportional hazards elastic net model for mortality, validated through 10-fold cross-validation. The study employed 2 Gompertz proportional hazards models to parameterize phenotypic age: one model incorporated all 10 selected variables, while the other considered only chronological age. This calculation method aids in a more precise assessment of an individual&#8217;s biological aging process.</p><p>Particular attention was given to PhenoAgeAccel, an indicator derived from the residuals of a linear regression analysis comparing phenotypic age against chronological age.<sup>[<xref rid="R9" ref-type="bibr">9</xref>&#8211;<xref rid="R13" ref-type="bibr">13</xref>]</sup> For instance, if 2 individuals of the same age display different levels of physiological health and vitality, leading one to appear younger and the other older due to health issues or poor lifestyle choices, their PhenoAgeAccel values would differ. As a lagging indicator, lower PhenoAgeAccel values signify a slower process of biological aging, offering a crucial perspective on the variance of an individual&#8217;s physiological state relative to their chronological age. The specific formula for PhenoAgeAccel is as follows:</p><disp-formula><mml:math id="M1" overflow="scroll"><mml:mstyle displaystyle="true"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mn>141.50</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>ln</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mo>&#8722;</mml:mo><mml:mn>0.00553</mml:mn><mml:mo>&#215;</mml:mo><mml:mi>ln</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mrow><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mn>0.09165</mml:mn></mml:mfrac></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:math></disp-formula><p>where xb&#8197;=&#8197;&#8722;19.907&#8197;&#8722;&#8197;0.0336&#8197;&#215;&#8197;albumin&#8197;+&#8197;0.0095&#8197;&#215;&#8197;creatinine&#8197;+&#8197;0.0195&#8197;&#215;&#8197;glucose&#8197;+&#8197;0.0954&#8197;&#215;&#8197;ln(CRP)&#8197;&#8722;&#8197;0.0120&#8197;&#215;&#8197;lymphocyte percent&#8197;+&#8197;0.0268&#8197;&#215;&#8197;mean cell volume&#8197;+&#8197;0.3356&#8197;&#215;&#8197;red cell distribution width&#8197;+&#8197;0.00188&#8197;&#215;&#8197;alkaline phosphatase&#8197;+&#8197;0.0554&#8197;&#215;&#8197;white blood cell count&#8197;+&#8197;0.0804&#8197;&#215;&#8197;chronological age.</p></sec><sec><title>2.4. Covariate</title><p>This investigation incorporated a variety of covariates for a comprehensive analysis, encompassing fundamental demographic information, lifestyle factors, and health status indicators. Demographic data included age, gender (male, female), race (Mexican American, non-Hispanic Black, non-Hispanic White, other), and education levels (less than high school, high school, beyond high school). Economic status was gauged through the poverty income ratio (PIR), comparing household or individual income against the poverty guidelines for the survey year (low income PIR&#8197;&#8804;&#8197;1.3, middle income 1.3&#8197;&lt;&#8197;PIR&#8197;&lt;&#8197;3.5, high income&#8197;&#8805;&#8197;3.5).</p><p>Lifestyle factors covered marital status (married/living with partner, single, widowed/divorced/separated), body mass index (BMI) classifications (&lt;25, 25&#8211;29.9, &#8805;30&#8201;kg/m<sup>2</sup>), smoking status (former smoker, nonsmoker, current smoker), and alcohol consumption habits (never, former, light, moderate, heavy). Physical activity was assessed through the typical time and energy expenditure in physical activities over the past week, including vigorous and moderate activities during work, commute, and leisure, quantified using metabolic equivalent of task (METs h/week) scores. Dietary quality was evaluated with the Healthy Eating Index-2020 (HEI-2020), measuring the alignment of an individual or group&#8217;s diet with the Dietary Guidelines for Americans issued by the US Department of Agriculture. The HEI-2020, updated to reflect current nutritional recommendations and dietary patterns, encompasses several components representing vital aspects of the diet such as fruits, vegetables, whole grains, dairy, proteins, the ratio of unsaturated to saturated fats, and intake of sodium and added sugars. The scoring system of HEI-2020 is quantitative, with a total score of 100 points, where higher scores indicate better dietary quality and greater adherence to the Dietary Guidelines for Americans.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup></p><p>Health status indicators included diagnostic criteria for hypertension, hyperlipidemia, and diabetes. Hypertension was determined based on physician diagnosis, antihypertensive medication usage, and blood pressure measurements (systolic &#8805;140&#8201;mm Hg or diastolic &#8805;90mm Hg). Hyperlipidemia diagnosis relied on lipid levels (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein) and the use of lipid-lowering medications. Diabetes assessment was based on physician diagnosis, levels of glycated hemoglobin, fasting glucose, and the use of antidiabetic medications. Cancer prevalence was determined by diagnoses from physicians or health professionals.</p></sec><sec sec-type="methods"><title>2.5. Statistical methods</title><p>This study meticulously adhered to the complex survey sampling procedures of the NHANES and computed complex sampling weights as per the analysis guidelines provided by NHANES. To ensure the national representativeness of the results, all statistical analyses were conducted using weighted data. Continuous variables were reported as means and their standard errors (mean&#8197;&#177;&#8197;SE), while categorical variables were presented as counts and their weighted percentages.</p><p>To assess the differences between groups, the study utilized 1-way analysis of variance for continuous variables and chi-square tests for categorical variables. Additionally, weighted generalized linear regression models were applied to examine the linear relationship between sleep duration and PhenoAgeAccel, with subgroup analyses conducted for gender to investigate the impact of sex differences on this relationship.</p><p>Furthermore, based on the outcomes of the linear regression models, this study employed restricted cubic splines to test for nonlinear trends between variables. To further validate the influence of control variables on the relationship between sleep duration and PhenoAgeAccel, these variables were incorporated into the interaction effect test models.</p><p>All statistical analyses were conducted with a 2-tailed <italic toggle="yes">P</italic>-value &lt;.05 considered statistically significant, and data processing and analysis were performed using R Studio (version 4.2.1, USA).</p></sec></sec><sec sec-type="results"><title>3. Result</title><sec><title>3.1. Baseline characteristics of the study population</title><p>Table <xref rid="T1" ref-type="table">1</xref> displays characteristics of the study population grouped by sleep duration within the 2001 to 2010 NHANES dataset, revealing significant differences in sleep duration and PhenoAgeAccel across different groups (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01). Significant variances were also observed in the distribution of gender, age, race, BMI, marital status, education level, PIR, smoking status, alcohol consumption, physical activity, dietary quality, diabetes, hypertension, and cancer across various sleep duration categories (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.0001). However, the distribution of hyperlipidemia did not show significant differences across the sleep groups (<italic toggle="yes">P</italic>&#8197;=&#8197;.84).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics of the study population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">&lt;7 hours/day</th><th align="center" rowspan="1" colspan="1">7&#8211;9 hours/day</th><th align="center" rowspan="1" colspan="1">&gt;9 hours/day</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">8992</td><td align="center" rowspan="1" colspan="1">3515</td><td align="center" rowspan="1" colspan="1">4915</td><td align="center" rowspan="1" colspan="1">562</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PhenoAgeAccel</td><td align="center" rowspan="1" colspan="1">&#8722;4.86 (0.08)</td><td align="center" rowspan="1" colspan="1">&#8722;3.57 (0.14)</td><td align="center" rowspan="1" colspan="1">&#8722;4.51 (0.13)</td><td align="center" rowspan="1" colspan="1">&#8722;5.08 (0.12)</td><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="center" rowspan="1" colspan="1">4179 (48.28)</td><td align="center" rowspan="1" colspan="1">1576 (45.63)</td><td align="center" rowspan="1" colspan="1">2318 (49.02)</td><td align="center" rowspan="1" colspan="1">285 (57.08)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="center" rowspan="1" colspan="1">4813 (51.72)</td><td align="center" rowspan="1" colspan="1">1939 (54.37)</td><td align="center" rowspan="1" colspan="1">2597 (50.98)</td><td align="center" rowspan="1" colspan="1">277 (42.92)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (yr), n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;20&#8211;29</td><td align="center" rowspan="1" colspan="1">1493 (17.87)</td><td align="center" rowspan="1" colspan="1">542 (17.02)</td><td align="center" rowspan="1" colspan="1">827 (17.84)</td><td align="center" rowspan="1" colspan="1">124 (23.33)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;30&#8211;39</td><td align="center" rowspan="1" colspan="1">1675 (19.48)</td><td align="center" rowspan="1" colspan="1">690 (20.60)</td><td align="center" rowspan="1" colspan="1">909 (19.28)</td><td align="center" rowspan="1" colspan="1">76 (14.62)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;40&#8211;49</td><td align="center" rowspan="1" colspan="1">1706 (22.21)</td><td align="center" rowspan="1" colspan="1">729 (24.11)</td><td align="center" rowspan="1" colspan="1">888 (21.14)</td><td align="center" rowspan="1" colspan="1">89 (21.28)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;50&#8211;59</td><td align="center" rowspan="1" colspan="1">1464 (19.98)</td><td align="center" rowspan="1" colspan="1">627 (20.82)</td><td align="center" rowspan="1" colspan="1">779 (20.27)</td><td align="center" rowspan="1" colspan="1">58 (11.94)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;60</td><td align="center" rowspan="1" colspan="1">2654 (20.46)</td><td align="center" rowspan="1" colspan="1">927 (17.45)</td><td align="center" rowspan="1" colspan="1">1512 (21.47)</td><td align="center" rowspan="1" colspan="1">215 (28.83)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Race, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-Hispanic White</td><td align="center" rowspan="1" colspan="1">4846 (75.15)</td><td align="center" rowspan="1" colspan="1">1602 (67.98)</td><td align="center" rowspan="1" colspan="1">2911 (79.44)</td><td align="center" rowspan="1" colspan="1">333 (76.18)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mexican American</td><td align="center" rowspan="1" colspan="1">1488 (6.87)</td><td align="center" rowspan="1" colspan="1">545 (6.81)</td><td align="center" rowspan="1" colspan="1">865 (7.01)</td><td align="center" rowspan="1" colspan="1">78 (5.92)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-Hispanic Black</td><td align="center" rowspan="1" colspan="1">1606 (9.14)</td><td align="center" rowspan="1" colspan="1">884 (14.18)</td><td align="center" rowspan="1" colspan="1">623 (5.93)</td><td align="center" rowspan="1" colspan="1">99 (10.27)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other race (including multi-racial and other Hispanic)</td><td align="center" rowspan="1" colspan="1">1052 (8.84)</td><td align="center" rowspan="1" colspan="1">484 (11.03)</td><td align="center" rowspan="1" colspan="1">516 (7.62)</td><td align="center" rowspan="1" colspan="1">52 (7.63)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>), n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;25</td><td align="center" rowspan="1" colspan="1">2683 (32.38)</td><td align="center" rowspan="1" colspan="1">936 (29.20)</td><td align="center" rowspan="1" colspan="1">1545 (33.52)</td><td align="center" rowspan="1" colspan="1">202 (40.38)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;25&#8211;29.9</td><td align="center" rowspan="1" colspan="1">3092 (33.71)</td><td align="center" rowspan="1" colspan="1">1178 (32.51)</td><td align="center" rowspan="1" colspan="1">1741 (34.78)</td><td align="center" rowspan="1" colspan="1">173 (30.38)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;30</td><td align="center" rowspan="1" colspan="1">3217 (33.91)</td><td align="center" rowspan="1" colspan="1">1401 (38.29)</td><td align="center" rowspan="1" colspan="1">1629 (31.70)</td><td align="center" rowspan="1" colspan="1">187 (29.23)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Marital status, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Married/living with partner</td><td align="center" rowspan="1" colspan="1">5713 (67.53)</td><td align="center" rowspan="1" colspan="1">2117 (64.34)</td><td align="center" rowspan="1" colspan="1">3266 (70.16)</td><td align="center" rowspan="1" colspan="1">330 (60.93)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Never married</td><td align="center" rowspan="1" colspan="1">1460 (15.82)</td><td align="center" rowspan="1" colspan="1">600 (16.57)</td><td align="center" rowspan="1" colspan="1">739 (14.72)</td><td align="center" rowspan="1" colspan="1">121 (22.25)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Widowed/divorced/separated</td><td align="center" rowspan="1" colspan="1">1819 (16.64)</td><td align="center" rowspan="1" colspan="1">798 (19.09)</td><td align="center" rowspan="1" colspan="1">910 (15.12)</td><td align="center" rowspan="1" colspan="1">111 (16.82)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Education level, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Below</td><td align="center" rowspan="1" colspan="1">2081 (14.79)</td><td align="center" rowspan="1" colspan="1">842 (16.26)</td><td align="center" rowspan="1" colspan="1">1090 (13.47)</td><td align="center" rowspan="1" colspan="1">149 (18.79)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;High school</td><td align="center" rowspan="1" colspan="1">2114 (23.24)</td><td align="center" rowspan="1" colspan="1">908 (26.59)</td><td align="center" rowspan="1" colspan="1">1071 (20.98)</td><td align="center" rowspan="1" colspan="1">135 (25.28)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Above</td><td align="center" rowspan="1" colspan="1">4797 (61.97)</td><td align="center" rowspan="1" colspan="1">1765 (57.15)</td><td align="center" rowspan="1" colspan="1">2754 (65.55)</td><td align="center" rowspan="1" colspan="1">278 (55.93)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Poverty to income ratio, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;1.3</td><td align="center" rowspan="1" colspan="1">2385 (16.57)</td><td align="center" rowspan="1" colspan="1">1025 (19.69)</td><td align="center" rowspan="1" colspan="1">1200 (14.23)</td><td align="center" rowspan="1" colspan="1">160 (20.78)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;1.3&#8211;3.49</td><td align="center" rowspan="1" colspan="1">3338 (33.90)</td><td align="center" rowspan="1" colspan="1">1319 (35.03)</td><td align="center" rowspan="1" colspan="1">1785 (32.75)</td><td align="center" rowspan="1" colspan="1">234 (38.46)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;3.5</td><td align="center" rowspan="1" colspan="1">3269 (49.53)</td><td align="center" rowspan="1" colspan="1">1171 (45.28)</td><td align="center" rowspan="1" colspan="1">1930 (53.02)</td><td align="center" rowspan="1" colspan="1">168 (40.76)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smoke status, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Former smoker</td><td align="center" rowspan="1" colspan="1">2313 (25.44)</td><td align="center" rowspan="1" colspan="1">825 (23.65)</td><td align="center" rowspan="1" colspan="1">1341 (26.81)</td><td align="center" rowspan="1" colspan="1">147 (22.80)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Nonsmoker</td><td align="center" rowspan="1" colspan="1">4648 (52.38)</td><td align="center" rowspan="1" colspan="1">1730 (48.46)</td><td align="center" rowspan="1" colspan="1">2646 (54.99)</td><td align="center" rowspan="1" colspan="1">272 (50.30)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Current smoker</td><td align="center" rowspan="1" colspan="1">2031 (22.18)</td><td align="center" rowspan="1" colspan="1">960 (27.88)</td><td align="center" rowspan="1" colspan="1">928 (18.20)</td><td align="center" rowspan="1" colspan="1">143 (26.90)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Alcohol status, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Former</td><td align="center" rowspan="1" colspan="1">1573 (14.54)</td><td align="center" rowspan="1" colspan="1">701 (16.74)</td><td align="center" rowspan="1" colspan="1">772 (13.12)</td><td align="center" rowspan="1" colspan="1">100 (15.26)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Never</td><td align="center" rowspan="1" colspan="1">992 (8.96)</td><td align="center" rowspan="1" colspan="1">372 (9.06)</td><td align="center" rowspan="1" colspan="1">541 (8.51)</td><td align="center" rowspan="1" colspan="1">79 (12.82)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mild</td><td align="center" rowspan="1" colspan="1">3021 (36.85)</td><td align="center" rowspan="1" colspan="1">1103 (34.43)</td><td align="center" rowspan="1" colspan="1">1740 (38.89)</td><td align="center" rowspan="1" colspan="1">178 (31.47)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Moderate</td><td align="center" rowspan="1" colspan="1">1424 (17.44)</td><td align="center" rowspan="1" colspan="1">541 (16.17)</td><td align="center" rowspan="1" colspan="1">799 (18.08)</td><td align="center" rowspan="1" colspan="1">84 (18.83)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Heavy</td><td align="center" rowspan="1" colspan="1">1982 (22.20)</td><td align="center" rowspan="1" colspan="1">798 (23.60)</td><td align="center" rowspan="1" colspan="1">1063 (21.40)</td><td align="center" rowspan="1" colspan="1">121 (21.62)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Physical activity (MET-min/wk), n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q1 [0.93, 700]</td><td align="center" rowspan="1" colspan="1">3005 (34.30)</td><td align="center" rowspan="1" colspan="1">1124 (32.20)</td><td align="center" rowspan="1" colspan="1">1677 (35.16)</td><td align="center" rowspan="1" colspan="1">204 (38.58)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q2 [700, 2880]</td><td align="center" rowspan="1" colspan="1">3070 (34.97)</td><td align="center" rowspan="1" colspan="1">1138 (32.61)</td><td align="center" rowspan="1" colspan="1">1724 (36.21)</td><td align="center" rowspan="1" colspan="1">208 (36.92)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q3 [2880, 55,440]</td><td align="center" rowspan="1" colspan="1">2917 (30.73)</td><td align="center" rowspan="1" colspan="1">1253 (35.18)</td><td align="center" rowspan="1" colspan="1">1514 (28.62)</td><td align="center" rowspan="1" colspan="1">150 (24.50)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Healthy eating index, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q1 [0, 44.31]</td><td align="center" rowspan="1" colspan="1">2998 (33.96)</td><td align="center" rowspan="1" colspan="1">1312 (38.94)</td><td align="center" rowspan="1" colspan="1">1495 (30.88)</td><td align="center" rowspan="1" colspan="1">191 (34.14)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q2 [44.31, 56.49]</td><td align="center" rowspan="1" colspan="1">2996 (33.53)</td><td align="center" rowspan="1" colspan="1">1180 (33.93)</td><td align="center" rowspan="1" colspan="1">1641 (33.63)</td><td align="center" rowspan="1" colspan="1">175 (30.09)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q3 [56.49, 96.11]</td><td align="center" rowspan="1" colspan="1">2998 (32.51)</td><td align="center" rowspan="1" colspan="1">1023 (27.13)</td><td align="center" rowspan="1" colspan="1">1779 (35.49)</td><td align="center" rowspan="1" colspan="1">196 (35.78)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.002</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">6876 (81.10)</td><td align="center" rowspan="1" colspan="1">2633 (79.00)</td><td align="center" rowspan="1" colspan="1">3828 (82.56)</td><td align="center" rowspan="1" colspan="1">415 (79.48)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">2116 (18.90)</td><td align="center" rowspan="1" colspan="1">882 (21.00)</td><td align="center" rowspan="1" colspan="1">1087 (17.44)</td><td align="center" rowspan="1" colspan="1">147 (20.52)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">5512 (65.86)</td><td align="center" rowspan="1" colspan="1">2052 (63.07)</td><td align="center" rowspan="1" colspan="1">3112 (67.65)</td><td align="center" rowspan="1" colspan="1">348 (65.06)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">3480 (34.14)</td><td align="center" rowspan="1" colspan="1">1463 (36.93)</td><td align="center" rowspan="1" colspan="1">1803 (32.35)</td><td align="center" rowspan="1" colspan="1">214 (34.94)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidemia, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.84</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">2461 (28.11)</td><td align="center" rowspan="1" colspan="1">973 (27.64)</td><td align="center" rowspan="1" colspan="1">1331 (28.35)</td><td align="center" rowspan="1" colspan="1">157 (28.64)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">6531 (71.89)</td><td align="center" rowspan="1" colspan="1">2542 (72.36)</td><td align="center" rowspan="1" colspan="1">3584 (71.65)</td><td align="center" rowspan="1" colspan="1">405 (71.36)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cancer, n (weighted %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">8189 (91.34)</td><td align="center" rowspan="1" colspan="1">3237 (92.31)</td><td align="center" rowspan="1" colspan="1">4458 (91.04)</td><td align="center" rowspan="1" colspan="1">494 (88.47)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">803 (8.66)</td><td align="center" rowspan="1" colspan="1">278 (7.69)</td><td align="center" rowspan="1" colspan="1">457 (8.96)</td><td align="center" rowspan="1" colspan="1">68 (11.53)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>The continuity variables involved in this study are expressed by means (standard error), and the categorical variables are expressed by actual quantities (weighted percentages). The 1-way ANOVA applies to continuity variables and Chi-square test applies to categorical variables.</p></fn><fn fn-type="other"><p>ANOVA = analysis of variance, MET = metabolic equivalent of task, Q1 = the first quartile, Q2 = the second quartile, Q3 = the third quartile.</p></fn></table-wrap-foot></table-wrap><p>Notably, the PhenoAgeAccel overlapping density plot illustrated in Figure <xref rid="F2" ref-type="fig">2</xref>. indicates that the distribution peak for the 7 to 9 hours/day sleep group is closer to the 0 point, suggesting that this group&#8217;s PhenoAgeAccel is closer to the average level (with less variability), implying a higher likelihood of actual age matching biological age. In contrast, the curves for the &lt;7 hours/day and &gt;9 hours/day sleep groups deviate further from the 0 point, indicating that the daily 7 to 9 hours sleep duration group tends to have a more concentrated distribution with less fluctuation in PhenoAgeAccel. This may imply that this range of sleep duration is more conducive to maintaining a health status that corresponds with actual age, thereby decelerating the biological aging process.</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Distribution of phenotypic age acceleration by sleep group. This figure shows the density distribution of phenotypic age acceleration for the 3 sleep duration groups (&lt;7 hours/day, 7&#8211;9 hours/day, and &gt;9 hours/day). The <italic toggle="yes">x</italic>-axis represents the PhenoAgeAccel value, and the <italic toggle="yes">y</italic>-axis represents the density of the participant distribution.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e44786-g002.jpg"/></fig></sec><sec><title>3.2. Association analysis between sleep time and PhenoAgeAccel in American adults</title><p>This study investigated the relationship between daily sleep duration and PhenoAgeAccel, with the results depicted in Figure <xref rid="F3" ref-type="fig">3</xref>. In the unadjusted Crude Model, the 7 to 9 hours/day sleep group exhibited a significant deceleration in phenotypic aging compared to the reference group with &lt;7 hours of sleep (<italic toggle="yes">&#946;</italic>&#8197;=&#8197;&#8722;1.207; 95% CI: &#8722;1.599, &#8722;0.815; <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.0001). After adjusting for key demographic and lifestyle factors in Model 1, this association remained statistically significant (<italic toggle="yes">&#946;</italic>&#8197;=&#8197;&#8722;0.373; 95% CI: &#8722;0.737, &#8722;0.009; <italic toggle="yes">P</italic>&#8197;=&#8197;.045). However, in the fully adjusted Model 2, the protective trend for the 7 to 9 hour group was attenuated and no longer statistically significant (<italic toggle="yes">&#946;</italic>&#8197;=&#8197;&#8722;0.251; <italic toggle="yes">P</italic>&#8197;=&#8197;.166). Meanwhile, the association between sleeping &gt;9 hours/day and accelerated phenotypic aging became evident after adjustments, reaching statistical significance in both Model 1 (<italic toggle="yes">P</italic>&#8197;=&#8197;.006) and Model 2 (<italic toggle="yes">P</italic>&#8197;=&#8197;.009).</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Association analysis between sleep duration and PhenoAgeAccel in American adults. This figure displays the association between sleep duration and PhenoAgeAccel. The forest plot (left) shows the regression coefficients (<italic toggle="yes">&#946;</italic>) and 95% confidence intervals (CIs) from 3 models: Crude Model (unadjusted); Model 1 (adjusted for age, sex, race, education, PIR, BMI, marital status, smoking status, alcohol consumption, physical activity, and HEI); and Model 2 (further adjusted for hypertension, hyperlipidemia, diabetes, and cancer). The curve on the right, analyzed using a restricted cubic spline (RCS), illustrates the nonlinear dose-response relationship; the solid line represents the estimated association, and the shaded area is the 95% CI. BMI = body mass index, HEI = Healthy Eating Index, PIR = poverty income ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e44786-g003.jpg"/></fig><p>The dose-response analysis confirmed a significant nonlinear, U-shaped relationship between sleep duration and PhenoAgeAccel (<italic toggle="yes">P</italic> for nonlinear&#8197;=&#8197;0.0001), with an inflection point at approximately 6.774 hours. This suggests that both insufficient and excessive sleep may be linked to accelerated biological aging.</p></sec><sec><title>3.3. Association analysis between sleep time and PhenoAgeAccel in American adults (gender subgroups)</title><p>In the male subgroup (Fig. <xref rid="F4" ref-type="fig">4</xref>), the analysis revealed a similar pattern. While a significant protective effect for the 7 to 9 hour sleep group was observed in the crude model (<italic toggle="yes">&#946;</italic>&#8197;=&#8197;&#8722;0.917; <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.001), this effect did not retain statistical significance after multivariate adjustments in Model 1 and Model 2. Conversely, sleeping more than 9 hours was associated with significantly accelerated aging in the fully adjusted Model 2 (<italic toggle="yes">&#946;</italic>&#8197;=&#8197;0.989; <italic toggle="yes">P</italic>&#8197;=&#8197;.044). The nonlinear curve for males showed an inflection point at 6.724 hours.</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Association analysis between sleep duration and PhenoAgeAccel in American adults (male). This figure displays the association between sleep duration and PhenoAgeAccel. The forest plot (left) shows the regression coefficients (<italic toggle="yes">&#946;</italic>) and 95% confidence intervals (CIs) from 3 models: Crude Model (unadjusted); Model 1 (adjusted for age, race, education, PIR, BMI, marital status, smoking status, alcohol consumption, physical activity, and HEI); and Model 2 (further adjusted for hypertension, hyperlipidemia, diabetes, and cancer). The curve on the right, analyzed using a restricted cubic spline (RCS), illustrates the nonlinear dose-response relationship; the solid line represents the estimated association, and the shaded area is the 95% CI. BMI = body mass index, HEI = Healthy Eating Index, PIR = poverty income ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e44786-g004.jpg"/></fig><p>In the female subgroup (Fig. <xref rid="F5" ref-type="fig">5</xref>), the protective association for the 7 to 9 hour sleep group appeared more pronounced. The effect was highly significant in the crude model (<italic toggle="yes">&#946;</italic>&#8197;=&#8197;&#8722;1.445; <italic toggle="yes">P</italic>&#8197;&lt;&#8197;.0001) and, after full adjustment in Model 2, showed a strong trend that approached statistical significance (<italic toggle="yes">&#946;</italic>&#8197;=&#8197;&#8722;0.401; <italic toggle="yes">P</italic>&#8197;=&#8197;.091). In contrast to males, sleeping &gt;9 hours was not significantly associated with accelerated aging in females in any of the models. The dose-response curve for females identified an inflection point at 6.623 hours.</p><fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>Association analysis between sleep duration and PhenoAgeAccel in American adults (female). This figure displays the association between sleep duration and PhenoAgeAccel. The forest plot (left) shows the regression coefficients (<italic toggle="yes">&#946;</italic>) and 95% confidence intervals (CIs) from 3 models: Crude Model (unadjusted); Model 1 (adjusted for age, race, education, PIR, BMI, marital status, smoking status, alcohol consumption, physical activity, and HEI); and Model 2 (further adjusted for hypertension, hyperlipidemia, diabetes, and cancer). The curve on the right, analyzed using a restricted cubic spline (RCS), illustrates the nonlinear dose-response relationship; the solid line represents the estimated association, and the shaded area is the 95% CI. BMI = body mass index, HEI = Healthy Eating Index, PIR = poverty income ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e44786-g005.jpg"/></fig></sec><sec><title>3.4. Interaction effect test</title><p>In this study, interaction effect tests were conducted to explore whether the relationship between sleep duration and PhenoAgeAccel was influenced by demographic and health-related characteristics such as gender, age, race, education level, economic status, BMI, marital status, smoking and drinking habits, physical activity, dietary quality, and chronic disease conditions. The results indicated that significant interaction effects were observed only among current smokers and individuals with diabetes (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01), with no such effects found in subgroups of other characteristics (Table <xref rid="T2" ref-type="table">2</xref>). This finding demonstrates the robustness of the relationship between sleep duration and PhenoAgeAccel across most subgroups. For smokers and individuals with diabetes, further specific interventions may be required to elucidate potential associations.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Interaction effect test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">&lt;7 hours/day</th><th align="center" rowspan="1" colspan="1">7&#8211;9 hours/day</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1">&gt;9 hours/day</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> for trend</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> for interaction</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.38</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.4 (&#8722;0.87, 0.07)</td><td align="center" rowspan="1" colspan="1">.09</td><td align="center" rowspan="1" colspan="1">0.63 (&#8722;0.29, 1.55)</td><td align="center" rowspan="1" colspan="1">.17</td><td align="center" rowspan="1" colspan="1">.94</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.16 (&#8722;0.60, 0.29)</td><td align="center" rowspan="1" colspan="1">.47</td><td align="center" rowspan="1" colspan="1">0.99 (0.03, 1.95)</td><td align="center" rowspan="1" colspan="1">.04</td><td align="center" rowspan="1" colspan="1">.49</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.31</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;20&#8211;29</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.92 (&#8722;1.61, &#8722;0.22)</td><td align="center" rowspan="1" colspan="1">.01</td><td align="center" rowspan="1" colspan="1">&#8722;0.52 (&#8722;1.45, 0.41)</td><td align="center" rowspan="1" colspan="1">.26</td><td align="center" rowspan="1" colspan="1">.04</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;30&#8211;39</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">0.23 (&#8722;0.34, 0.79)</td><td align="center" rowspan="1" colspan="1">.41</td><td align="center" rowspan="1" colspan="1">1.07 (&#8722;0.70, 2.84)</td><td align="center" rowspan="1" colspan="1">.22</td><td align="center" rowspan="1" colspan="1">.22</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;40&#8211;49</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.37 (&#8722;1.28, 0.53)</td><td align="center" rowspan="1" colspan="1">.4</td><td align="center" rowspan="1" colspan="1">0.62 (&#8722;0.86, 2.11)</td><td align="center" rowspan="1" colspan="1">.39</td><td align="center" rowspan="1" colspan="1">.84</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;50&#8211;59</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.43 (&#8722;1.50, 0.64)</td><td align="center" rowspan="1" colspan="1">.41</td><td align="center" rowspan="1" colspan="1">1.16 (&#8722;1.15, 3.47)</td><td align="center" rowspan="1" colspan="1">.31</td><td align="center" rowspan="1" colspan="1">.84</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;60</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">0.08 (&#8722;0.59, 0.74)</td><td align="center" rowspan="1" colspan="1">.81</td><td align="center" rowspan="1" colspan="1">1.68 (0.45, 2.91)</td><td align="center" rowspan="1" colspan="1">.01</td><td align="center" rowspan="1" colspan="1">.05</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.55</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-Hispanic White</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.37 (&#8722;0.85, 0.11)</td><td align="center" rowspan="1" colspan="1">.12</td><td align="center" rowspan="1" colspan="1">0.9 (0.13, 1.66)</td><td align="center" rowspan="1" colspan="1">.02</td><td align="center" rowspan="1" colspan="1">.86</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mexican American</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">0.26 (&#8722;0.42, 0.94)</td><td align="center" rowspan="1" colspan="1">.43</td><td align="center" rowspan="1" colspan="1">0.03 (&#8722;1.46, 1.52)</td><td align="center" rowspan="1" colspan="1">.97</td><td align="center" rowspan="1" colspan="1">.59</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-Hispanic Black</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.37 (&#8722;1.29, 0.55)</td><td align="center" rowspan="1" colspan="1">.41</td><td align="center" rowspan="1" colspan="1">0.87 (&#8722;1.75, 3.50)</td><td align="center" rowspan="1" colspan="1">.49</td><td align="center" rowspan="1" colspan="1">.92</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other race</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">0.29 (&#8722;0.87, 1.44)</td><td align="center" rowspan="1" colspan="1">.61</td><td align="center" rowspan="1" colspan="1">0.76 (&#8722;1.39, 2.90)</td><td align="center" rowspan="1" colspan="1">.46</td><td align="center" rowspan="1" colspan="1">.44</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Educational level</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.35</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Below</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.29 (&#8722;0.95, 0.38)</td><td align="center" rowspan="1" colspan="1">.37</td><td align="center" rowspan="1" colspan="1">0.17 (&#8722;0.87, 1.21)</td><td align="center" rowspan="1" colspan="1">.73</td><td align="center" rowspan="1" colspan="1">.71</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;High school</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.67 (&#8722;1.34, &#8722;0.01)</td><td align="center" rowspan="1" colspan="1">.05</td><td align="center" rowspan="1" colspan="1">1.03 (&#8722;0.50, 2.57)</td><td align="center" rowspan="1" colspan="1">.17</td><td align="center" rowspan="1" colspan="1">.79</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Above</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.06 (&#8722;0.51, 0.39)</td><td align="center" rowspan="1" colspan="1">.78</td><td align="center" rowspan="1" colspan="1">1.06 (0.12, 1.99)</td><td align="center" rowspan="1" colspan="1">.03</td><td align="center" rowspan="1" colspan="1">.28</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Poverty to income ratio</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.69</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;1.3</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.19 (&#8722;0.80, 0.41)</td><td align="center" rowspan="1" colspan="1">.51</td><td align="center" rowspan="1" colspan="1">0.22 (&#8722;0.68, 1.11)</td><td align="center" rowspan="1" colspan="1">.61</td><td align="center" rowspan="1" colspan="1">.88</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;1.3&#8211;3.49</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.14 (&#8722;0.73, 0.44)</td><td align="center" rowspan="1" colspan="1">.61</td><td align="center" rowspan="1" colspan="1">1.17 (0.21, 2.14)</td><td align="center" rowspan="1" colspan="1">.02</td><td align="center" rowspan="1" colspan="1">.28</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;3.5</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.27 (&#8722;0.80, 0.27)</td><td align="center" rowspan="1" colspan="1">.31</td><td align="center" rowspan="1" colspan="1">1.02 (&#8722;0.11, 2.15)</td><td align="center" rowspan="1" colspan="1">.07</td><td align="center" rowspan="1" colspan="1">.77</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.13</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;25</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.33 (&#8722;0.88, 0.22)</td><td align="center" rowspan="1" colspan="1">.22</td><td align="center" rowspan="1" colspan="1">0.26 (&#8722;0.71, 1.24)</td><td align="center" rowspan="1" colspan="1">.58</td><td align="center" rowspan="1" colspan="1">.76</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;25&#8211;29.9</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.03 (&#8722;0.63, 0.58)</td><td align="center" rowspan="1" colspan="1">.93</td><td align="center" rowspan="1" colspan="1">0.71 (&#8722;0.44, 1.86)</td><td align="center" rowspan="1" colspan="1">.21</td><td align="center" rowspan="1" colspan="1">.56</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;30</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.28 (&#8722;0.92, 0.36)</td><td align="center" rowspan="1" colspan="1">.37</td><td align="center" rowspan="1" colspan="1">2.1 (0.61, 3.60)</td><td align="center" rowspan="1" colspan="1">.01</td><td align="center" rowspan="1" colspan="1">.28</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Marital status</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Widowed/divorced/separated</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">0.05 (&#8722;0.86, 0.95)</td><td align="center" rowspan="1" colspan="1">.92</td><td align="center" rowspan="1" colspan="1">2.08 (0.35, 3.82)</td><td align="center" rowspan="1" colspan="1">.02</td><td align="center" rowspan="1" colspan="1">.14</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Never married</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;1.18 (&#8722;1.92, &#8722;0.45)</td><td align="center" rowspan="1" colspan="1">.004</td><td align="center" rowspan="1" colspan="1">&#8722;0.1 (&#8722;1.17, 0.97)</td><td align="center" rowspan="1" colspan="1">.84</td><td align="center" rowspan="1" colspan="1">.06</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Married/living with partner</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.13 (&#8722;0.54, 0.28)</td><td align="center" rowspan="1" colspan="1">.51</td><td align="center" rowspan="1" colspan="1">0.88 (0.19, 1.57)</td><td align="center" rowspan="1" colspan="1">.02</td><td align="center" rowspan="1" colspan="1">.41</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smoke status</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.04</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Former smoker</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.07 (&#8722;0.76, 0.63)</td><td align="center" rowspan="1" colspan="1">.84</td><td align="center" rowspan="1" colspan="1">1.62 (0.31, 2.93)</td><td align="center" rowspan="1" colspan="1">.02</td><td align="center" rowspan="1" colspan="1">.27</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Nonsmoker</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.19 (&#8722;0.66, 0.29)</td><td align="center" rowspan="1" colspan="1">.42</td><td align="center" rowspan="1" colspan="1">1.21 (0.32, 2.11)</td><td align="center" rowspan="1" colspan="1">.01</td><td align="center" rowspan="1" colspan="1">.3</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Current smoker</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.52 (&#8722;1.03, 0.00)</td><td align="center" rowspan="1" colspan="1">.05</td><td align="center" rowspan="1" colspan="1">&#8722;0.63 (&#8722;1.64, 0.38)</td><td align="center" rowspan="1" colspan="1">.21</td><td align="center" rowspan="1" colspan="1">.04</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Alcohol status</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.68</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Former</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.15 (&#8722;1.10, 0.79)</td><td align="center" rowspan="1" colspan="1">.73</td><td align="center" rowspan="1" colspan="1">1.57 (&#8722;0.75, 3.90)</td><td align="center" rowspan="1" colspan="1">.17</td><td align="center" rowspan="1" colspan="1">.46</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Never</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.59 (&#8722;1.77, 0.59)</td><td align="center" rowspan="1" colspan="1">.3</td><td align="center" rowspan="1" colspan="1">1.52 (&#8722;1.16, 4.19)</td><td align="center" rowspan="1" colspan="1">.25</td><td align="center" rowspan="1" colspan="1">.68</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mild</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.25 (&#8722;0.80, 0.30)</td><td align="center" rowspan="1" colspan="1">.35</td><td align="center" rowspan="1" colspan="1">0.69 (&#8722;0.30, 1.69)</td><td align="center" rowspan="1" colspan="1">.16</td><td align="center" rowspan="1" colspan="1">.96</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Moderate</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">0.21 (&#8722;0.61, 1.02)</td><td align="center" rowspan="1" colspan="1">.6</td><td align="center" rowspan="1" colspan="1">0.88 (&#8722;0.28, 2.04)</td><td align="center" rowspan="1" colspan="1">.13</td><td align="center" rowspan="1" colspan="1">.24</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Heavy</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.43 (&#8722;1.06, 0.20)</td><td align="center" rowspan="1" colspan="1">.17</td><td align="center" rowspan="1" colspan="1">0.25 (&#8722;0.76, 1.27)</td><td align="center" rowspan="1" colspan="1">.61</td><td align="center" rowspan="1" colspan="1">.48</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Physical activity</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.78</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q1</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.2 (&#8722;0.92, 0.52)</td><td align="center" rowspan="1" colspan="1">.56</td><td align="center" rowspan="1" colspan="1">0.93 (&#8722;0.14, 1.99)</td><td align="center" rowspan="1" colspan="1">.08</td><td align="center" rowspan="1" colspan="1">.58</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q2</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.4 (&#8722;1.01, 0.20)</td><td align="center" rowspan="1" colspan="1">.18</td><td align="center" rowspan="1" colspan="1">0.8 (&#8722;0.24, 1.84)</td><td align="center" rowspan="1" colspan="1">.12</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q3</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.01 (&#8722;0.54, 0.52)</td><td align="center" rowspan="1" colspan="1">.96</td><td align="center" rowspan="1" colspan="1">0.88 (&#8722;0.63, 2.39)</td><td align="center" rowspan="1" colspan="1">.24</td><td align="center" rowspan="1" colspan="1">.36</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Healthy eating index</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.67</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q1</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.3 (&#8722;0.93, 0.33)</td><td align="center" rowspan="1" colspan="1">.33</td><td align="center" rowspan="1" colspan="1">1.13 (&#8722;0.12, 2.37)</td><td align="center" rowspan="1" colspan="1">.07</td><td align="center" rowspan="1" colspan="1">.64</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q2</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.32 (&#8722;0.85, 0.20)</td><td align="center" rowspan="1" colspan="1">.21</td><td align="center" rowspan="1" colspan="1">0.29 (&#8722;0.90, 1.47)</td><td align="center" rowspan="1" colspan="1">.61</td><td align="center" rowspan="1" colspan="1">.63</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Q3</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.04 (&#8722;0.51, 0.44)</td><td align="center" rowspan="1" colspan="1">.87</td><td align="center" rowspan="1" colspan="1">1.28 (0.19, 2.38)</td><td align="center" rowspan="1" colspan="1">.02</td><td align="center" rowspan="1" colspan="1">.11</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.39 (&#8722;0.70, &#8722;0.08)</td><td align="center" rowspan="1" colspan="1">.02</td><td align="center" rowspan="1" colspan="1">0.25 (&#8722;0.48, 0.98)</td><td align="center" rowspan="1" colspan="1">.48</td><td align="center" rowspan="1" colspan="1">.3</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">0.33 (&#8722;0.67, 1.33)</td><td align="center" rowspan="1" colspan="1">.49</td><td align="center" rowspan="1" colspan="1">3.33 (1.73, 4.94)</td><td align="center" rowspan="1" colspan="1">&lt;.001</td><td align="center" rowspan="1" colspan="1">.01</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidemia</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.45</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.21 (&#8722;0.64, 0.21)</td><td align="center" rowspan="1" colspan="1">.31</td><td align="center" rowspan="1" colspan="1">1.19 (0.44, 1.94)</td><td align="center" rowspan="1" colspan="1">.004</td><td align="center" rowspan="1" colspan="1">.24</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.33 (&#8722;0.98, 0.33)</td><td align="center" rowspan="1" colspan="1">.31</td><td align="center" rowspan="1" colspan="1">0.12 (&#8722;1.27, 1.51)</td><td align="center" rowspan="1" colspan="1">.86</td><td align="center" rowspan="1" colspan="1">.62</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.29</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.15 (&#8722;0.85, 0.55)</td><td align="center" rowspan="1" colspan="1">.66</td><td align="center" rowspan="1" colspan="1">1.6 (0.58, 2.63)</td><td align="center" rowspan="1" colspan="1">.004</td><td align="center" rowspan="1" colspan="1">.2</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.28 (&#8722;0.72, 0.17)</td><td align="center" rowspan="1" colspan="1">.21</td><td align="center" rowspan="1" colspan="1">0.5 (&#8722;0.34, 1.34)</td><td align="center" rowspan="1" colspan="1">.22</td><td align="center" rowspan="1" colspan="1">.9</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cancer</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.59</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">0.64 (&#8722;0.65, 1.94)</td><td align="center" rowspan="1" colspan="1">.31</td><td align="center" rowspan="1" colspan="1">1.72 (&#8722;0.28, 3.72)</td><td align="center" rowspan="1" colspan="1">.09</td><td align="center" rowspan="1" colspan="1">.09</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">ref</td><td align="center" rowspan="1" colspan="1">&#8722;0.31 (&#8722;0.67, 0.06)</td><td align="center" rowspan="1" colspan="1">.09</td><td align="center" rowspan="1" colspan="1">0.79 (0.04, 1.54)</td><td align="center" rowspan="1" colspan="1">.04</td><td align="center" rowspan="1" colspan="1">.87</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Q1 = the first quartile, Q2 = the second quartile, Q3 = the third quartile, ref = reference.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>4. Discussion</title><p>This study delved into the dose-response relationship between sleep duration and PhenoAgeAccel, uncovering its nonlinear characteristics. Through a detailed analysis of NHANES data from 2001 to 2010, we discovered a significant positive association between daily sleep durations of 7 to 9 hours and deceleration in phenotypic aging, whereas sleep durations below or beyond this range were linked to accelerated phenotypic aging. This dose-response finding not only augments existing research on sleep and aging but also holds crucial implications for public health guidance and the optimization of individual sleep habits.</p><p>Particularly noteworthy is our identification of a critical inflection point (~6.7 hours/day) in the nonlinear model between sleep duration and PhenoAgeAccel, providing a more precise quantitative description of the relationship between sleep duration and biological aging. This finding underscores the pivotal role of moderate sleep in preventing the acceleration of biological aging, suggesting that both insufficient and excessive sleep could adversely affect health. Moreover, gender subgroup analysis further revealed variations in the dose-response effect across different gender groups, indicating the need to consider gender differences when devising targeted health interventions. Additionally, the results of the interaction effect tests suggest that an individual&#8217;s health status (such as smoking and diabetes status) may influence the dose-response relationship between sleep duration and PhenoAgeAccel, offering valuable insights for personalized medicine.</p><p>In delving deeper into the relationship between sleep and biological aging, our focus extends beyond the duration of sleep to understand the profound impact of sleep quality on physiological mechanisms. Recent studies have unveiled the intricate interplay between sleep and aging, providing new perspectives on this relationship.</p><p>Firstly, sleep is crucial for maintaining the stability and functionality of the nervous system. Research by Mander et al<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> demonstrated that adequate sleep facilitates the clearance of metabolic waste from the brain, including beta-amyloid proteins associated with Alzheimer disease, primarily during deep sleep stages through the so-called &#8220;glymphatic system,&#8221; aiding in brain health maintenance and cognitive function preservation. Secondly, sleep is closely linked to the body&#8217;s endocrine system. Studies by Knutson et al<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> have shown that insufficient or poor-quality sleep disrupts the normal secretion of hormones, including growth hormone, cortisol, and insulin. Hormonal imbalances not only affect energy metabolism but may also accelerate cellular aging and tissue damage, thereby promoting the process of biological aging.</p><p>Furthermore, sleep is intimately connected with immune system function. Research by Irwin<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> has shown that good sleep helps maintain immune system balance and enhances the body&#8217;s resistance to inflammation and infection. Conversely, sleep deprivation leads to increased inflammatory responses, which, over time, may accelerate the aging of cells and increase the risk of chronic diseases. Studies by Besedovsky et al<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> point out a bidirectional link between sleep and immunity. Activation of the immune system alters sleep patterns, which in turn affects the innate and adaptive parts of our defense system. Inflammatory responses induced by microbial challenges, depending on their magnitude and temporal course, can induce increases in sleep duration and intensity but may also lead to sleep disruption. Enhanced sleep during infection is considered a way to feedback to the immune system to promote host defense. In fact, sleep influences various immune parameters, associated with reduced infection risk, and can improve infection outcomes and vaccine responses. A possible mechanism supporting the immune-supportive effects of sleep is the induction of a hormone combination supportive of immune function. Moreover, research by Ibarra-Coronado et al<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup> suggests sleep is a significant regulator of immune responses. Thus, lack of sleep weakens immunity, increasing susceptibility to infections. For instance, shorter sleep durations are associated with increased risk of the common cold. The role of sleep in altering immune responses needs to be determined to understand how sleep deprivation increases susceptibility to viral, bacterial, and parasitic infections. Several explanations for increased susceptibility to infections after sleep deprivation, such as impaired lymphocyte mitotic proliferation, reduced HLA-DR expression, upregulation of CD14+, and alterations in CD4+ and CD8+ T lymphocytes, have been observed during partial sleep deprivation.</p><p>This study echoes the findings of Hahn et al, who discovered in a mouse model that adequate sleep significantly increased the number and functionality of classical monocytes in circulation and enhanced defense outcomes against bacterial infections, thereby improving survival rates. This suggests that sleep enhances the body&#8217;s early defense against infections by boosting the quantity and functionality of immune cells, possibly through the regulation of hormone levels and cytokine production related to the immune system. Moreover, the research by Christoffersson et al revealed the impact of acute sleep deprivation on neutrophils, the most abundant cell type in our immune system and the first line of defense against infection responses, in healthy young males. They found that sleep deprivation led to an increase in neutrophil count but impaired their functionality, such as reduced production of reactive oxygen species, potentially lowering the body&#8217;s defense capability against infections. These studies underscore the importance of sleep for biological health, especially in maintaining the balance and functionality of the immune system. While this research focuses on the relationship between sleep and biological aging, these studies provide insights into the effects of sleep on immune cells, indirectly supporting the crucial role of sleep in maintaining overall biological health, including delaying the aging process. These findings emphasize the importance of maintaining proper sleep patterns for promoting health and preventing disease, complementing the objectives of this study.</p><p>This research delved into the dose-response relationship between sleep duration and PhenoAgeAccel, revealing its nonlinear characteristics and finding that moderate sleep per day is significantly associated with a deceleration in the biological aging process. This discovery not only enriches existing research in the field of sleep and aging but also provides crucial scientific evidence for public health guidance and the optimization of individual sleep habits. The importance of moderate sleep extends beyond its role in regulating the immune system; it plays a key role in maintaining the balance of various physiological systems in the body. For instance, adequate sleep facilitates the clearance of metabolic waste from the brain, reduces the accumulation of proteins associated with neurodegenerative diseases,<sup>[<xref rid="R20" ref-type="bibr">20</xref>&#8211;<xref rid="R23" ref-type="bibr">23</xref>]</sup> and protects cognitive functions from damage. Additionally, moderate sleep balances the endocrine system, regulates hormone levels, and plays a vital role in emotional stability and metabolic health.<sup>[<xref rid="R24" ref-type="bibr">24</xref>&#8211;<xref rid="R26" ref-type="bibr">26</xref>]</sup> From the perspective of biological aging, moderate sleep supports the slowing of the aging process through various mechanisms, such as maintaining the effectiveness of DNA repair mechanisms, alleviating oxidative stress and inflammation, and influencing telomere length and cellular aging pathways. The combined effect of these mechanisms not only slows the accumulation of cellular damage and genetic mutations but also helps maintain the youthful state of cells and tissues, thereby extending healthy lifespan.<sup>[<xref rid="R27" ref-type="bibr">27</xref>&#8211;<xref rid="R31" ref-type="bibr">31</xref>]</sup> Furthermore, the interaction effects observed in this study for smoking and diabetes conditions may interact through shared physiological pathways, affecting sleep patterns and biological aging. For example, both smoking and diabetes are associated with endocrine changes that may disrupt sleep regulation mechanisms, leading to decreased sleep quality and changes in sleep duration, which in turn affect biological aging.</p><p>Therefore, moderate sleep should be viewed as an important public health strategy, capable of not only improving current quality of life but also laying the foundation for future health and longevity. Future research should delve deeper into the intrinsic connections between sleep and biological aging, exploring the specific mechanisms through which improved sleep quality can slow the aging process, providing a solid scientific basis for effective health interventions.</p><p>Despite providing valuable insights into the relationship between sleep duration and PhenoAgeAccel, this study has several limitations to note. First, due to its cross-sectional study design, causality cannot be established. Although we observed a significant association between sleep duration and PhenoAgeAccel, we cannot determine whether sleep patterns influence the biological aging process or vice versa. Second, sleep duration data was based on participants&#8217; self-reports, which may be subject to recall bias. Self-reported sleep duration may not be as accurate as objective sleep monitoring (such as polysomnography), potentially affecting our assessment of the relationship between sleep duration and PhenoAgeAccel. Furthermore, we did not thoroughly consider the impact of sleep quality, including sleep interruptions and depth, which are important factors affecting biological aging. Although we controlled for various potential confounders, including lifestyle, health status, and socioeconomic status, there may still be unobserved confounders. For example, genetic factors, long-term illness history, medication use, and environmental factors may also affect sleep patterns and the biological aging process, but these factors were not fully considered in the current study. Lastly, the sample of this study was drawn from the NHANES in the United States, and while representative, the results may not be entirely applicable to other countries and regions. Different cultural backgrounds, lifestyles, and social environments may influence the relationship between sleep patterns and biological aging. Despite these limitations, the findings of this study provide valuable insights into the relationship between sleep and biological aging, offering important references for future research directions and public health interventions. Future research should adopt longitudinal study designs, use objective sleep monitoring tools, and consider more potential influencing factors to further elucidate the causal relationships and mechanisms between sleep and biological aging.</p></sec><sec><title>5. Conclusion</title><p>This study suggests that moderate sleep duration of 7 to 9 hours/day is associated with a deceleration in phenotypic aging, with a critical inflection point for sleep and aging health at approximately 6.7 hours. Both insufficient and excessive sleep durations may be detrimental to slowing the aging process. The results of the interaction effect tests emphasize the need to consider individual smoking and diabetes status when developing targeted health interventions. These findings provide new insights into the complex relationship between sleep and biological aging, offering a scientific basis for public health guidance and the optimization of individual sleep habits. Future research should employ longitudinal designs and objective sleep monitoring tools to further explore the causal relationship and underlying mechanisms between sleep and biological aging.</p></sec><sec><title>Acknowledgments</title><p>The authors express their gratitude to the National Health and Nutrition Examination Survey (NHANES) for providing the public access data for this study. We also sincerely thank all the NHANES participants for their invaluable contributions, which made this research possible.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Yujia Liu, Kai Qiao.</p><p><bold>Data curation:</bold> Yujia Liu.</p><p><bold>Formal analysis:</bold> Yujia Liu, Kai Qiao.</p><p><bold>Methodology:</bold> Yujia Liu.</p><p><bold>Visualization:</bold> Yujia Liu.</p><p><bold>Writing &#8211; original draft:</bold> Kai Qiao.</p><p><bold>Writing &#8211; review &amp; editing:</bold> Kai Qiao.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>HEI-2020</term><def><p>Healthy Eating Index-2020</p></def></def-item><def-item><term>NHANES</term><def><p>National Health and Nutrition Examination Survey</p></def></def-item><def-item><term>PhenoAgeAccel</term><def><p>phenotypic age acceleration</p></def></def-item><def-item><term>PIR</term><def><p>poverty income ratio</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="other"><p>This study was a secondary analysis based on data from the National Health and Nutrition Examination Survey (NHANES) for the cycles 2001 to 2010. The survey protocols for NHANES were approved by the National Center for Health Statistics (NCHS) Research Ethics Review Board (ERB). Specifically, the data cycles from 2001 to 2004 were conducted under Protocol #98-12, and the cycles from 2005 to 2010 were conducted under Protocol #2005-06. All participants provided written informed consent. As this study used only publicly available and de-identified data, it was exempt from further institutional review board approval.</p></fn><fn fn-type="COI-statement"><p>The authors have no funding and conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are publicly available.</p></fn><fn fn-type="other"><p>How to cite this article: Liu Y, Qiao K. Dose-response relationship between sleep duration and mediation of phenotypic age acceleration: A cross-sectional study. Medicine 2025;104:40(e44786).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward-Caviness</surname><given-names>CK</given-names></name><name name-style="western"><surname>Russell</surname><given-names>AG</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Accelerated epigenetic age as a biomarker of cardiovascular sensitivity to traffic-related air pollution.</article-title><source>Aging (Albany NY)</source>. <year>2020</year>;<volume>12</volume>:<fpage>24141</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">33289704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.202341</pub-id><pub-id pub-id-type="pmcid">PMC7762491</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Biological ageing and the risks of all-cause and cause-specific mortality among people with diabetes: a prospective cohort study.</article-title><source>J Epidemiol Community Health</source>. <year>2022</year>;<volume>76</volume>:<fpage>771</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">35738895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jech-2022-219142</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shadyab</surname><given-names>AH</given-names></name><name name-style="western"><surname>McEvoy</surname><given-names>LK</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Association of epigenetic age acceleration with incident mild cognitive impairment and dementia among older women.</article-title><source>J Gerontol A Biol Sci Med Sci</source>. <year>2021</year>;<volume>77</volume>:<fpage>1239</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glab245</pub-id><pub-id pub-id-type="pmcid">PMC9159659</pub-id><pub-id pub-id-type="pmid">34417803</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raniti</surname><given-names>MB</given-names></name><name name-style="western"><surname>Allen</surname><given-names>NB</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Sleep duration and sleep quality: associations with depressive symptoms across adolescence.</article-title><source>Behav Sleep Med</source>. <year>2017</year>;<volume>15</volume>:<fpage>198</fpage>&#8211;<lpage>215</lpage>.<pub-id pub-id-type="pmid">26744783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15402002.2015.1120198</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chee</surname><given-names>MWL</given-names></name></person-group>. <article-title>Fragmented sleep and cortical thinning in old adults: time to wake up?</article-title><source>Sleep</source>. <year>2016</year>;<volume>39</volume>:<fpage>15</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26564137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5665/sleep.5306</pub-id><pub-id pub-id-type="pmcid">PMC4678335</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhi</surname><given-names>TF</given-names></name><name name-style="western"><surname>Sun</surname><given-names>XM</given-names></name><name name-style="western"><surname>Li</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>Associations of sleep duration and sleep quality with life satisfaction in elderly Chinese: the mediating role of depression.</article-title><source>Arch Gerontol Geriatr</source>. <year>2016</year>;<volume>65</volume>:<fpage>211</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">27100684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.archger.2016.03.023</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>JC</given-names></name><name name-style="western"><surname>Groeger</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>GH</given-names></name><name name-style="western"><surname>Dijk</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Chee</surname><given-names>MWL</given-names></name></person-group>. <article-title>Self-reported sleep duration and cognitive performance in older adults: a systematic review and meta-analysis.</article-title><source>Sleep Med</source>. <year>2016</year>;<volume>17</volume>:<fpage>87</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">26847980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sleep.2015.08.021</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>A</given-names></name><name name-style="western"><surname>Quach</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>An epigenetic biomarker of aging for lifespan and healthspan.</article-title><source>Aging (Albany NY)</source>. <year>2018</year>;<volume>10</volume>:<fpage>573</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">29676998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.101414</pub-id><pub-id pub-id-type="pmcid">PMC5940111</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><name name-style="western"><surname>Geng</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Dose-response relationship between leisure-time physical activity patterns and phenotypic age acceleration in American adults: a cross-sectional analysis.</article-title><source>J Exerc Sci Fit</source>. <year>2024</year>;<volume>22</volume>:<fpage>445</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">40276583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jesf.2024.09.005</pub-id><pub-id pub-id-type="pmcid">PMC12020996</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shang</surname><given-names>M</given-names></name></person-group>. <article-title>Dose-response relationship of dietary omega-3 fatty acids on slowing phenotypic age acceleration: a cross-sectional study.</article-title><source>Front Nutr</source>. <year>2024</year>;<volume>11</volume>:<fpage>1424156</fpage>.<pub-id pub-id-type="pmid">39296507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnut.2024.1424156</pub-id><pub-id pub-id-type="pmcid">PMC11409900</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>PL</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>S</given-names></name><name name-style="western"><surname>Crimmins</surname><given-names>E</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M</given-names></name></person-group>. <article-title>A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: a cohort study.</article-title><source>PLoS Med</source>. <year>2018</year>;<volume>15</volume>:<fpage>e1002718</fpage>.<pub-id pub-id-type="pmid">30596641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1002718</pub-id><pub-id pub-id-type="pmcid">PMC6312200</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qu</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Association between dietary and behavioral-based oxidative balance score and phenotypic age acceleration: a cross-sectional study of Americans.</article-title><source>Epidemiol Health</source>. <year>2024</year>;<volume>46</volume>:<fpage>e2024023</fpage>.<pub-id pub-id-type="pmid">38271958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4178/epih.e2024023</pub-id><pub-id pub-id-type="pmcid">PMC11176717</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Shang</surname><given-names>M</given-names></name></person-group>. <article-title>Dose response of leisure time physical activity and biological aging in type 2 diabetes: a cross sectional study.</article-title><source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>:<fpage>26253</fpage>.<pub-id pub-id-type="pmid">39482385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-77359-w</pub-id><pub-id pub-id-type="pmcid">PMC11528019</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reedy</surname><given-names>J</given-names></name><name name-style="western"><surname>Pannucci</surname><given-names>T</given-names></name><name name-style="western"><surname>Herrick</surname><given-names>K</given-names></name><name name-style="western"><surname>Lerman</surname><given-names>J</given-names></name><name name-style="western"><surname>Shams-White</surname><given-names>M</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>M</given-names></name></person-group>. <article-title>Healthy Eating Index protocol: review, update, and development process to reflect dietary guidance across the lifespan.</article-title><source>Curr Dev Nutr</source>. <year>2021</year>;<volume>5</volume>:<fpage>447</fpage>.</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mander</surname><given-names>BA</given-names></name><name name-style="western"><surname>Winer</surname><given-names>JR</given-names></name><name name-style="western"><surname>Walker</surname><given-names>MP</given-names></name></person-group>. <article-title>Sleep and human aging.</article-title><source>Neuron</source>. <year>2017</year>;<volume>94</volume>:<fpage>19</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">28384471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2017.02.004</pub-id><pub-id pub-id-type="pmcid">PMC5810920</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knutson</surname><given-names>KL</given-names></name><name name-style="western"><surname>Spiegel</surname><given-names>K</given-names></name><name name-style="western"><surname>Penev</surname><given-names>P</given-names></name><name name-style="western"><surname>Van Cauter</surname><given-names>E</given-names></name></person-group>. <article-title>The metabolic consequences of sleep deprivation.</article-title><source>Sleep Med Rev</source>. <year>2007</year>;<volume>11</volume>:<fpage>163</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">17442599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smrv.2007.01.002</pub-id><pub-id pub-id-type="pmcid">PMC1991337</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irwin</surname><given-names>MR</given-names></name></person-group>. <article-title>Sleep and inflammation: partners in sickness and in health.</article-title><source>Nat Rev Immunol</source>. <year>2019</year>;<volume>19</volume>:<fpage>702</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">31289370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-019-0190-z</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Besedovsky</surname><given-names>L</given-names></name><name name-style="western"><surname>Lange</surname><given-names>T</given-names></name><name name-style="western"><surname>Haack</surname><given-names>M</given-names></name></person-group>. <article-title>The sleep-immune crosstalk in health and disease.</article-title><source>Physiol Rev</source>. <year>2019</year>;<volume>99</volume>:<fpage>1325</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">30920354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00010.2018</pub-id><pub-id pub-id-type="pmcid">PMC6689741</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibarra-Coronado</surname><given-names>EG</given-names></name><name name-style="western"><surname>Pantale&#243;n-Mart&#237;nez</surname><given-names>AM</given-names></name><name name-style="western"><surname>Velazqu&#233;z-Moctezuma</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The bidirectional relationship between sleep and immunity against infections.</article-title><source>J Immunol Res</source>. <year>2015</year>;<volume>2015</volume>:<fpage>678164</fpage>.<pub-id pub-id-type="pmid">26417606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/678164</pub-id><pub-id pub-id-type="pmcid">PMC4568388</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrone</surname><given-names>CD</given-names></name><name name-style="western"><surname>Raghuraman</surname><given-names>R</given-names></name><name name-style="western"><surname>Hussaini</surname><given-names>SA</given-names></name><name name-style="western"><surname>Yu</surname><given-names>WH</given-names></name></person-group>. <article-title>Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer&#8217;s disease.</article-title><source>Mol Neurodegener</source>. <year>2023</year>;<volume>18</volume>:<fpage>27</fpage>.<pub-id pub-id-type="pmid">37085942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-023-00617-4</pub-id><pub-id pub-id-type="pmcid">PMC10119020</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hafycz</surname><given-names>JM</given-names></name><name name-style="western"><surname>Naidoo</surname><given-names>NN</given-names></name></person-group>. <article-title>Sleep, aging, and cellular health: aged-related changes in sleep and protein homeostasis converge in neurodegenerative diseases.</article-title><source>Front Aging Neurosci</source>. <year>2019</year>;<volume>11</volume>:<fpage>140</fpage>.<pub-id pub-id-type="pmid">31244649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2019.00140</pub-id><pub-id pub-id-type="pmcid">PMC6579877</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picchioni</surname><given-names>D</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>KC</given-names></name><name name-style="western"><surname>Loutaev</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Increased rates of brain protein synthesis during [N1,N2] sleep: L-[1-<sup>11</sup>C]leucine PET studies in human subjects.</article-title><source>J Cereb Blood Flow Metab</source>. <year>2023</year>;<volume>43</volume>:<fpage>59</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">36071616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0271678X221121873</pub-id><pub-id pub-id-type="pmcid">PMC9875345</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsiknia</surname><given-names>AA</given-names></name><name name-style="western"><surname>Parada</surname><given-names>H</given-names></name><name name-style="western"><surname>Banks</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Reas</surname><given-names>ET</given-names></name></person-group>. <article-title>Sleep quality and sleep duration predict brain microstructure among community-dwelling older adults.</article-title><source>Neurobiol Aging</source>. <year>2023</year>;<volume>125</volume>:<fpage>90</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">36871334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2023.02.001</pub-id><pub-id pub-id-type="pmcid">PMC10115563</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palamarchuk</surname><given-names>IS</given-names></name><name name-style="western"><surname>Slavich</surname><given-names>GM</given-names></name><name name-style="western"><surname>Vaillancourt</surname><given-names>T</given-names></name><name name-style="western"><surname>Rajji</surname><given-names>TK</given-names></name></person-group>. <article-title>Stress-related cellular pathophysiology as a crosstalk risk factor for neurocognitive and psychiatric disorders.</article-title><source>BMC Neurosci</source>. <year>2023</year>;<volume>24</volume>:<fpage>65</fpage>.<pub-id pub-id-type="pmid">38087196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12868-023-00831-2</pub-id><pub-id pub-id-type="pmcid">PMC10714507</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>F</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>AF</given-names></name><name name-style="western"><surname>Rungratanawanich</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Melatonin and autophagy in aging-related neurodegenerative diseases.</article-title><source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>:<fpage>7174</fpage>.<pub-id pub-id-type="pmid">32998479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21197174</pub-id><pub-id pub-id-type="pmcid">PMC7584015</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faggiano</surname><given-names>A</given-names></name><name name-style="western"><surname>Gherbesi</surname><given-names>E</given-names></name><name name-style="western"><surname>Avagimyan</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Melatonin mitigates oxidative damage induced by anthracycline: a systematic-review and meta-analysis of murine models.</article-title><source>Front Cardiovasc Med</source>. <year>2023</year>;<volume>10</volume>:<fpage>1289384</fpage>.<pub-id pub-id-type="pmid">38075951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2023.1289384</pub-id><pub-id pub-id-type="pmcid">PMC10701532</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mak</surname><given-names>MHC</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>A</given-names></name><name name-style="western"><surname>Horner</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Gaskell</surname><given-names>MG</given-names></name></person-group>. <article-title>A registered report testing the effect of sleep on Deese-Roediger-McDermott false memory: greater lure and veridical recall but fewer intrusions after sleep.</article-title><source>R Soc Open Sci</source>. <year>2023</year>;<volume>10</volume>:<fpage>220595</fpage>.<pub-id pub-id-type="pmid">38077219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rsos.220595</pub-id><pub-id pub-id-type="pmcid">PMC10698482</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>M</given-names></name><name name-style="western"><surname>Betriana</surname><given-names>F</given-names></name><name name-style="western"><surname>Tanioka</surname><given-names>R</given-names></name><name name-style="western"><surname>Osaka</surname><given-names>K</given-names></name><name name-style="western"><surname>Tanioka</surname><given-names>T</given-names></name><name name-style="western"><surname>Schoenhofer</surname><given-names>S</given-names></name></person-group>. <article-title>Balance of autonomic nervous activity, exercise, and sleep status in older adults: a review of the literature.</article-title><source>Int J Environ Res Public Health</source>. <year>2021</year>;<volume>18</volume>:<fpage>12896</fpage>.<pub-id pub-id-type="pmid">34948506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph182412896</pub-id><pub-id pub-id-type="pmcid">PMC8701130</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scullin</surname><given-names>MK</given-names></name><name name-style="western"><surname>Bliwise</surname><given-names>DL</given-names></name></person-group>. <article-title>Sleep, cognition, and normal aging: integrating a half century of multidisciplinary research.</article-title><source>Perspect Psychol Sci</source>. <year>2015</year>;<volume>10</volume>:<fpage>97</fpage>&#8211;<lpage>137</lpage>.<pub-id pub-id-type="pmid">25620997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1745691614556680</pub-id><pub-id pub-id-type="pmcid">PMC4302758</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chery</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Baral</surname><given-names>A</given-names></name><name name-style="western"><surname>Rolle</surname><given-names>LD</given-names></name><etal/></person-group>. <article-title>Depression, sleep health &amp; sociodemographic correlates in a nationwide survey: implications for depression treatment during the COVID-19.</article-title><source>Nat Sci Sleep</source>. <year>2024</year>;<volume>16</volume>:<fpage>17</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">38235481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NSS.S434148</pub-id><pub-id pub-id-type="pmcid">PMC10793117</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P</given-names></name><name name-style="western"><surname>Wei</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Gender- and age-specific associations of sleep duration and quality with cognitive impairment in community-dwelling older adults in Anhui Province, China.</article-title><source>Front Public Health</source>. <year>2023</year>;<volume>11</volume>:<fpage>1047025</fpage>.<pub-id pub-id-type="pmid">38249381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2023.1047025</pub-id><pub-id pub-id-type="pmcid">PMC10796606</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501348</article-id><article-id pub-id-type="pmcid-ver">PMC12501348.1</article-id><article-id pub-id-type="pmcaid">12501348</article-id><article-id pub-id-type="pmcaiid">12501348</article-id><article-id pub-id-type="pmid">40903313</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100333</article-id><article-id pub-id-type="pii">S2274-5807(25)00276-6</article-id><article-id pub-id-type="publisher-id">100333</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A critical review and classification of dementia risk assessment tools to inform dementia risk reduction</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Huque</surname><given-names initials="MH">Md Hamidul</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Eramudugolla</surname><given-names initials="R">Ranmalee</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Li</surname><given-names initials="M">Meiwei</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Kiely</surname><given-names initials="KM">Kim M.</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Peters</surname><given-names initials="R">Ruth</given-names></name><xref rid="aff0003" ref-type="aff">c</xref><xref rid="aff0005" ref-type="aff">e</xref><xref rid="aff0006" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Anstey</surname><given-names initials="KJ">Kaarin J.</given-names></name><email>k.anstey@unsw.edu.au</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="aff0003" ref-type="aff">c</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><aff id="aff0001"><label>a</label>School of Psychology, University of New South Wales, High St, Kensington, NSW 2052, Australia</aff><aff id="aff0002"><label>b</label>Neuroscience Research Australia, 139 Barker St, Randwick, NSW 2031, Australia</aff><aff id="aff0003"><label>c</label>UNSW Ageing Futures Institute, University of NSW, High St, Kensington, NSW 2052, Australia</aff><aff id="aff0004"><label>d</label>School of Mathematics and Applied Statistics, and, School of Social Sciences, University of Wollongong, Northfields Ave, Wollongong NSW 2500, Australia</aff><aff id="aff0005"><label>e</label>School of Public Health, University of New South Wales, High St, Kensington, NSW 2052, Australia</aff><aff id="aff0006"><label>f</label>The George Institute of Global Health, 300 Barangaroo Ave, Barangaroo NSW 2000, Australia</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author. Kaarin J. Anstey, School of Psychology, University of New South Wales, High St, Kensington NSW 2052, Australia. <email>k.anstey@unsw.edu.au</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>9</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100333</elocation-id><history><date date-type="received"><day>15</day><month>6</month><year>2025</year></date><date date-type="rev-recd"><day>4</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract abstract-type="author-highlights" id="abs0001"><title>Highlights</title><p><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#8226;</label><p id="para0001">This is the first study explaining heterogeneity in dementia risk score performance.</p></list-item><list-item id="celistitem0002"><label>&#8226;</label><p id="para0002">Of the 39 dementia risk scores analysed, the pooled AUC is about 0.7.</p></list-item><list-item id="celistitem0003"><label>&#8226;</label><p id="para0003">Few comparisons between risk scores used valid criteria or consistent exposure age.</p></list-item><list-item id="celistitem0004"><label>&#8226;</label><p id="para0004">AUCs are higher for development studies than validation studies, creating bias.</p></list-item><list-item id="celistitem0005"><label>&#8226;</label><p id="para0005">DemNCD, ANU-ADRI, CogDrisk, and LIBRA include most WHO-recommended risk factors.</p></list-item></list></p></abstract><abstract id="abs0002"><p>Addressing modifiable dementia risk factors requires reliable risk assessment methods. We aimed to synthesise knowledge on risk scores for all cause dementia, Alzheimer&#8217;s disease (AD) and vascular dementia, classify them according to target population, evaluate their content, cost, appropriateness of validation studies, and suitability for implementing risk reduction guidelines. A systematic search was conducted of PubMed, Cochrane Collaboration, ProQuest, Scopus, Embase, and PsycINFO databases using a pre-registered protocol. Data on risk factors, target population, predictive validity, cost, and alignment with WHO guidelines were extracted. Random-effects meta-analysis was performed. Of 45 risk scores identified, 29 were for all-cause dementia, including 11 based on late-life cohorts, 6 on midlife, and 7 covering mid to late-life. The pooled C-statistic across development and validation studies of dementia risk scores was 0.69 (95 % CI: 0.67, 0.71). Development study AUCs were higher than validation study AUCs and dropped from 0.74 to 0.66 for risk scores developed for clinical samples and from 0.79 to 0.71 for AD specific scores (which include functional indicators non-independent of disease). There were no validated risk scores for vascular dementia. Dem-NCD, CogDrisk, ANU-ADRI and LIBRA risk scores incorporated most WHO-recommended risk factors and demonstrated accuracy comparable to the overall pooled C-statistic. We conclude that across the field, there are methodological limitations relating to validation, and inappropriate comparison of tools designed for different purposes or target populations. However, there are now several validated, risk scores for all-cause dementia and AD that assess modifiable factors and offer cost-effective dementia risk assessment and risk reduction advice.</p></abstract><kwd-group id="keys0001"><title>Key words</title><kwd>Dementia risk</kwd><kwd>Prevention</kwd><kwd>Prediction</kwd><kwd>Meta-analysis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0006">Given the large projected increase in people with dementia due to population aging [<xref rid="bib0001" ref-type="bibr">[1]</xref>, <xref rid="bib0002" ref-type="bibr">[2]</xref>, <xref rid="bib0003" ref-type="bibr">[3]</xref>], there is an urgent need to reduce risk and delay or where possible, prevent cognitive decline. Current monoclonal antibody treatments for Alzheimer&#8217;s disease (AD) hold promise [<xref rid="bib0004" ref-type="bibr">4</xref>], but they are unlikely to be a panacea for preventing dementia in the short term. This is because most late-life dementia has multiple causes, and the drugs have modest effects, are expensive, and are accessible to a very small minority of patients [<xref rid="bib0004" ref-type="bibr">4</xref>]. Even in a future world where there are effective treatments for the diseases that cause dementia, it will be desirable to address modifiable risk factors that increase the risk of dementia, to optimise brain health, potentially prevent incident cases, and slow disease progression. Similar examples are currently available in the treatment of heart disease, where specialised treatments are available alongside population-level risk reduction strategies [<xref rid="bib0005" ref-type="bibr">5</xref>]. Therefore, addressing modifiable risk factors for dementia needs to be a key long-term and ideally, global strategy for promotion of brain health and prevention of dementia [<xref rid="bib0006" ref-type="bibr">6</xref>]. However, in order to provide risk reduction advice, it is necessary to have accurate and informative risk assessments [<xref rid="bib0007" ref-type="bibr">7</xref>].</p><p id="para0007">There is also now robust epidemiological evidence underpinning a large number of modifiable risk factors for dementia [<xref rid="bib0006" ref-type="bibr">6</xref>,<xref rid="bib0008" ref-type="bibr">8</xref>,<xref rid="bib0009" ref-type="bibr">9</xref>], and randomised controlled trial evidence of the benefits of risk modification for reducing cognitive decline [<xref rid="bib0010" ref-type="bibr">10</xref>], including clinical trial evidence that antihypertensive use is associated with reduced risk of dementia [<xref rid="bib0011" ref-type="bibr">11</xref>]. There has been a recent proliferation of models that combine risk factors to predict AD and dementia [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>]. Some of these models have been developed into practical tools that are available in digital or other formats for clinicians and the general public [<xref rid="bib0014" ref-type="bibr">[14]</xref>, <xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>], whilst the majority have remained as risk scores based on published statistical models but not translated for practical day-to-day use. While previous systematic reviews of dementia risk scores have reported on their discriminative performance only through narrative summaries [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>], key sources of variation, such as, the age at risk assessment, adherence to established guidelines, and the intended target population (e.g., clinical vs. community-based settings), have not been systematically explored. Moreover, prior reviews have not conducted a meta-analysis of discriminative properties of tools, or examined whether variations in the included risk factors contribute to differences in predictive accuracy across tools.</p><sec id="sec0002"><label>1.1</label><title>Establishing principles for tool comparison</title><p id="para0008">Previous studies have attempted to compare dementia risk tools, but often these comparisons fail to consider the specific purpose for which tools were designed or the population for which they were developed [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>,<xref rid="bib0017" ref-type="bibr">17</xref>,<xref rid="bib0018" ref-type="bibr">18</xref>]. Furthermore, evaluations of risk tools have often been approximations of those tools in datasets that do not contain well-defined risk factors, and sometimes they have not been informed by dementia epidemiology. As a result, comparisons are not meaningful or valid. For example, tools developed for midlife may be compared with tools designed for late-life [<xref rid="bib0017" ref-type="bibr">17</xref>]; tools intended for clinical settings, which involve blood biomarkers and imaging, may be compared with tools designed for public use online [<xref rid="bib0018" ref-type="bibr">18</xref>]; or tools may be evaluated on samples with an upper age limit lower than the age at which dementia is most prevalent [<xref rid="bib0019" ref-type="bibr">19</xref>]. The evaluation of risk tools that involve poor measurement of individual risk factors or that are not informed by dementia epidemiology can lead to &#8216;strawman&#8217; comparisons, and potentially inaccurate results and misleading interpretations.</p></sec><sec id="sec0003"><label>1.2</label><title>Need for a framework for describing and evaluating risk assessment tools for dementia</title><p id="para0009">To improve the quality of research in this field, there is a need for an accurate characterisation of the purpose of the dementia risk assessment tool, its target population (age, disease, cohort, location) and the environment in which it is designed for use. This will facilitate a valid comparison of tools that share similar characteristics and purpose. We conducted a systematic review of published risk tools for dementia and summarised their key characteristics to develop findings that would guide the application of risk assessment and guide future research.</p><p id="para0010">The aim of this review is to provide an overview of the published dementia risk assessment tools along with their characteristics and evaluate them according to cost, ease of administration, the degree to which they assess risk factors identified by the World Health Organisation guidelines [<xref rid="bib0010" ref-type="bibr">10</xref>], and to make recommendations for evaluating the utility of dementia risk assessment tools.</p></sec></sec><sec id="sec0004"><label>2</label><title>Methods</title><p id="para0011">The systematic review aimed to locate all relevant dementia risk assessment tools. An a priori protocol defining eligibility criteria, search strategy and outcome of interest was developed and was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42,023,392,435) and reported in accordance with the PRISMA checklist. The population, intervention, comparison, and outcome (PICO) framework to define eligibility criteria was given in the Supplementary Material: PICO Framework section.</p><sec id="sec0005"><label>2.1</label><title>Search strategy</title><p id="para0012">Databases PubMed and Cochrane Collaboration, ProQuest, Scopus, Embase, and PsycINFO were searched from inception to 19 February 2025. Reference lists of all papers identified were screened for other published papers. The following terms were used for PubMed: &#8220;risk tool*" OR "risk score*" OR "risk assessment*" OR "risk index" OR "risk indices" OR "risk model*&#8221;, &#8220;valid*" OR "develop*" OR "predict*&#8221; "dementia" OR "alzheimer's disease" OR "alzheimer disease", #1 AND #2 AND #3. Searches used for the other databases are reported in the Supplementary materials. The search was limited to articles published in English and in humans.</p></sec><sec id="sec0006"><label>2.2</label><title>Selection criteria</title><p id="para0013">The study inclusion criteria for this review were designed to ensure that all articles met the Oxford Centre for Evidence-Based Medicine Level of Evidence 1B (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cebm.net/" id="PC_linkBuPWlRgPIu">https://www.cebm.net/</ext-link> = 1025). Only articles that identified a specific dementia risk assessment tool (whether a risk score or another type) were included. These tools had to assess at least some modifiable behavioural factors. Hybrid tools assessing both behavioural and genetic factors were included, but purely genetic risk tools, such as polygenic risk scores, were excluded. Risk scores intended for specific clinical subgroups were allowed. The risk scores had to evaluate all-cause dementia (referred to as "dementia" throughout this review), Alzheimer's disease (AD), or vascular dementia (VaD) as an outcome. The article also had to report information on the validation of the tool and be the first instance of the validation of the tool in the specific type of population. A study could be included if it was validated on a new population, despite having prior validity data published on a different population. Both internal and external validation data were acceptable. Articles had to report a measure of predictive accuracy, such as the area under a receiver operating curve (ROC) curve in relation to dementia incidence, a c-statistic, or risk ratios.</p></sec><sec id="sec0007"><label>2.3</label><title>Abstract screening and article selection</title><p id="para0014">Citations downloaded into an EndNote reference database were screened in three stages (title, abstract and full text). The selected journal articles retrieved were examined by at least two of the authors (ML, RE, HH) and rated against the inclusion criteria. Abstracts and articles were discussed with the team (ML, RE, HH, KA) and reassessed where reviewers differed until a consensus was reached. Reference lists of included articles were also searched to identify additional studies for inclusion.</p></sec><sec id="sec0008"><label>2.4</label><title>Data extraction</title><p id="para0015">We distinguished between studies reporting the development of dementia risk assessment tools and studies validating risk assessment tools. For each tool, we sought to identify whether it had been validated, externally or internally, either in the original publication or in subsequent publications. External validation could comprise evaluation on a second independent sample, and internal validation could include, for example, a split sample with one part used to develop the tool and one for validation. For each validation study, we extracted data on assessed tools, cohorts used, settings, sample size, minimum and maximum age of the sample assessed, area under the curve (AUC) with 95 % confidence interval (CI), receiver operating characteristics (ROC), if available and the risks factors used in the assessment of the tool.</p></sec><sec id="sec0009"><label>2.5</label><title>Classification of tools</title><p id="para0016">To enable classification of tools we coded each one according to the age of assessment (mid-life: ages between 40 and 65, late-life: ages over 65, and mid to late-life: ages spanning between midlife and late-life), target assessment population (e.g. clinical population, general population), and outcome measure (dementia, AD, VaD and cognitive impairment).</p><p id="para0017">In addition, we coded the purpose of the tool, estimated the cost of implementation for each tool and rated the scalability. Costs for administration were based on equivalent costs for services (blood tests, MRI scans, etc.) in Australia. We also coded the risk factors included in each tool to allow for its classification in terms of content, implementation cost, and scalability as well as the extent to which they reflect WHO guidelines related to dementia risk reduction. Risk factors were also coded according to whether they were exogenous of dementia, or whether they could be classified as a &#8216;risk indicator&#8217;. A risk indicator is a variable that indicates cognitive decline or neurodegeneration and hence is not independent of the outcome [<xref rid="bib0020" ref-type="bibr">20</xref>]. Examples of risk indicators include memory tests and neuroimaging indices. Finally, we conducted an online search for each risk tool to locate evidence of implementation of the risk tools via apps or other media.</p></sec><sec id="sec0010"><label>2.6</label><title>Statistical analysis</title><p id="para0018">Pooled estimates of AUC for various risk scores assessing dementia, AD and VAD were obtained using a random-effect meta-analysis technique. For specific tools with sufficient data, we also calculated tool-specific pooled AUC values using the same method. The study-specific estimated AUCs were visualized through forest plots. Heterogeneity was examined by using the inconsistency index (I<sup>2</sup>) statistic. Subgroup analyses were conducted to explore sources of heterogeneity by calculating Cochran&#8217;s Q statistic. Publication bias was assessed visually using a funnel plot (log AUC against the standard error) using Stata version 16.1. Additionally, we performed a random effects meta-regression to quantify study design characteristics, especially the risk/protective factors, length of follow-ups, and influence on the AUC using R &#8220;metaphor&#8221; package (R version 4.4.0), adjusting for study and cohort specific random intercepts as well as the mean age of the study participants. When comparing risk scores, we assess the compatibility in terms of age, outcome, and sampling frame.</p></sec><sec id="sec0011"><label>2.7</label><title>Quality evaluation</title><p id="para0019">Studies were rated according to the Prediction model Risk Of Bias Assessment Tool (PROBAST) [<xref rid="bib0021" ref-type="bibr">21</xref>] by two independent researchers. PROBAST evaluates the risk of bias and applicability of primary studies that have developed and/or validated diagnostic or prognostic prediction models. Where consensus was not reached between the two assessors regarding PROBAST outcomes, a third reviewer acted as arbitrator.</p></sec></sec><sec id="sec0012"><label>3</label><title>Results</title><sec id="sec0013"><label>3.1</label><title>Included studies</title><p id="para0020"><xref rid="fig0001" ref-type="fig">Fig. 1</xref> illustrates the process of identifying articles with risk prediction tools and models. In total, 15,850 records were initially identified through searches from database and reference lists. After removing duplicates and title screening, 490 abstracts were screened for eligibility. Among them, 121 full-text articles were screened for eligibility. This resulted in 49 eligible studies with 45 risk scores that met study criteria for inclusion in the review. This includes studies originating from a diverse range of countries, including Australia, New Zealand, the United States, Canada, Finland, Germany, the United Kingdom, Sweden, Spain, Netherlands, Japan, Thailand, Singapore, and Taiwan.<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flowchart for the selection of studies in the systematic review.</p></caption><alt-text id="alt0004">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec0014"><label>3.2</label><title>Characteristics of dementia risk tools, their development and validation</title><sec id="sec0015"><label>3.2.1</label><title>Dementia risk scores according to age of assessment</title><p id="para0021"><xref rid="fig0002" ref-type="fig">Fig. 2</xref> presents a classification tree for all-cause dementia risk tools based on target population and key sample characteristics. This includes age of assessment (mid-life: ages between 40 and 65, late-life: ages over 65, and mid to late-life: ages spanning between midlife and late-life) for risk tools intended for community use and various predominant clinical characteristics in the development sample for clinical risk tools. Among the 45 risk scores identified in the current study, 6 risk scores were developed using midlife, 10 for midlife to late-life range, 14 for late-life, and 15 were based on clinical risk factor information. All midlife and midlife-late life studies and 48 % (14/29) of the late-life studies were sampled from a community-dwelling population. A majority of the risk scores 67 % (30/45) require clinical investigations to determine the risk scores. Four midlife risk scores: (i) CAIDE risk score [<xref rid="bib0022" ref-type="bibr">22</xref>], (ii) CAIDE midlife healthy diet index [<xref rid="bib0023" ref-type="bibr">23</xref>], (iii) Education and occupation-based midlife risk [<xref rid="bib0024" ref-type="bibr">24</xref>], and midlife primary care risk score [<xref rid="bib0025" ref-type="bibr">25</xref>] can be administered using self-reported risk information. In the mid-to-late life category, six risk scores (Australian National University Alzheimer's Disease Risk Index (ANU-ADRI) [<xref rid="bib0014" ref-type="bibr">14</xref>]; Cognitive Health and Dementia Risk Index (CogDrisk) [<xref rid="bib0015" ref-type="bibr">15</xref>]; CogDrisk for Alzheimer disease (CogDrisk-AD) [<xref rid="bib0015" ref-type="bibr">15</xref>]; LIfestyle for BRAin health (LIBRA) [<xref rid="bib0026" ref-type="bibr">26</xref>]; clinical dementia risk score prediction tool [<xref rid="bib0027" ref-type="bibr">27</xref>]; and SLAS risk index [<xref rid="bib0028" ref-type="bibr">28</xref>]), and in the late-life category, one late-life risk score (BDSI) [<xref rid="bib0029" ref-type="bibr">29</xref>] can be administered using self-reported risk information (see <xref rid="fig0002" ref-type="fig">Fig. 2</xref>).<fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Classification tree for risk tools according to age of risk exposure for development of the tool, setting, and type of administration.</p></caption><alt-text id="alt0005">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec0016"><label>3.2.2</label><title>Risk scores according to guidelines</title><p id="para0022"><xref rid="tbl0001" ref-type="table">Table 1</xref> reports the number of risk factors included in each of the risk scores according to the WHO guidelines for dementia [<xref rid="bib0010" ref-type="bibr">10</xref>]. Among the 12 risk factors identified in the guideline, the DemNCD incorporated the highest number of WHO identified risk factors (<italic toggle="yes">n</italic> = 11), followed by ANU-ADRI, LIBRA, CogDrisk and CogDrisk-AD, each including 10 risk factors. The &#8216;Risk scores for late-life dementia&#8217; [<xref rid="bib0030" ref-type="bibr">30</xref>], both midlife and late-life dementia risk models in primary care [<xref rid="bib0031" ref-type="bibr">31</xref>] and the &#8216;THIN health data algorithm&#8217; [<xref rid="bib0032" ref-type="bibr">32</xref>] each included seven risk factors identified in the WHO guideline. Five risk scores included four, three included three, two included only one risk factor, and seven of the risk scores included none of the WHO risk factors in the risk score development.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>The number of risk factors included in risk scores for which recommendations were made in the WHO guidelines.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><tbody><tr><td valign="top" colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0006" xlink:href="fx1.gif"><alt-text id="alt1">Image, table 1</alt-text></inline-graphic></td></tr></tbody></table></table-wrap></p></sec><sec id="sec0017"><label>3.2.3</label><title>Risk score according to the underlying population characteristics and outcome of interest</title><p id="para0023">Out of 45 risk scores, 29 risk scores were developed to predict the risk of all-cause dementia, 10 for AD, 5 for cardiovascular disease (CVD) and 1 for cognitive impairment (combining MCI and dementia) (see Supplementary Table 1). Of the 29 dementia risk scores, 24 were derived using community samples, including 11 based on late-life cohorts, 6 from midlife, and 7 utilizing a range of risk factors spanning from midlife to late-life. The remaining 5 risk scores were developed using clinical samples (Supplementary Table S1). The mean age of participants in the development sample for midlife risk scores ranges from 46 to 57 years, with follow-up durations varying from 21.5 years to 30 years. In contrast, the mean age ranges from midlife to late-life, late-life community sample and clinical samples are 56.3&#8211;67.9, 71.2&#8211;79.7 and 65.2&#8211;77.7, respectively. The mean follow-up durations for these groups are 0&#8211;14 years, 2&#8211;20 years and 0.5&#8211;9 years, respectively. One late-life risk tool, the mCAIDE [<xref rid="bib0033" ref-type="bibr">33</xref>] was developed using a cross-sectional study design to predict cognitive impairment. In addition, 4 midlife to late-life risk tools (ANU-ADRI, LIBRA, CogDrisk and CogDrisk-AD) were developed through evidence synthesis.</p></sec><sec id="sec0018"><label>3.2.4</label><title>Risk factor distribution in risk scores</title><p id="para0024">The number of risk factors included in each risk score varied, ranging from 5 to 31 risk factors in each tool, with a median of 8 risk factors (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>). <xref rid="tbl0002" ref-type="table">Table 2</xref> presents the distribution of risk and protective factors included in the development of these risk scores. Most of the risk scores included participants&#8217; age (84 %) followed by sex (64 %), diabetes (62 %), education (51 %), hypertension (53 %), depression (44 %), BMI/Obesity (40 %), dyslipidaemias (36 %), physical inactivity (36 %), measures of cognitive function (34 %), and smoking (33 %). Information on diet and APOE &#949;4 were included in 8 risk scores, while 4 risk scores required data from MRI and cognitive activity, and 3 risk scores needed information from pesticide exposures. Age was included in almost all AD risk scores (9 out of 10), whereas 23 out of 29 dementia risk scores included age. Notably, 10 dementia risk scores included cognitive function in the development, i.e., as part of the risk calculation, although cognitive function is an indicator of dementia rather than a risk factor.<fig id="fig0003" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Gopher chart of risk scores and their general composition.</p></caption><alt-text id="alt0006">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0003" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig><table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Distribution of risk and protective factors included in the development of these risk scores.</p></caption><alt-text id="alt0002">Table 2:</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1"/><th colspan="3" align="left" valign="top" rowspan="1">Outcome measures<hr/></th><th colspan="4" align="left" valign="top" rowspan="1">Age characteristics<hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1">Variables</th><th valign="top" colspan="1" rowspan="1">All risk scores<sup>&#8224;</sup></th><th valign="top" colspan="1" rowspan="1">Dementia</th><th valign="top" colspan="1" rowspan="1">AD</th><th valign="top" colspan="1" rowspan="1">CVD</th><th valign="top" colspan="1" rowspan="1">Midlife</th><th valign="top" colspan="1" rowspan="1">Midlife to late-life</th><th valign="top" colspan="1" rowspan="1">Late-life</th><th valign="top" colspan="1" rowspan="1">Clinical</th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 45 ( %)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 29 ( %)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 10 ( %)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 5 ( %)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 6 ( %)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 10 ( %)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 14 ( %)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">n</italic> = 15 ( %)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Age</td><td valign="top" colspan="1" rowspan="1">38 (84.4)</td><td valign="top" colspan="1" rowspan="1">23 (79.3)</td><td valign="top" colspan="1" rowspan="1">9 (90.0)</td><td valign="top" colspan="1" rowspan="1">5 (100.0)</td><td valign="top" colspan="1" rowspan="1">3 (50.0)</td><td valign="top" colspan="1" rowspan="1">9 (90.0)</td><td valign="top" colspan="1" rowspan="1">12 (85.7)</td><td valign="top" colspan="1" rowspan="1">14 (93.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sex</td><td valign="top" colspan="1" rowspan="1">29 (64.4)</td><td valign="top" colspan="1" rowspan="1">18 (62.1)</td><td valign="top" colspan="1" rowspan="1">7 (70.0)</td><td valign="top" colspan="1" rowspan="1">3 (60.0)</td><td valign="top" colspan="1" rowspan="1">3 (50.0)</td><td valign="top" colspan="1" rowspan="1">9 (90.0)</td><td valign="top" colspan="1" rowspan="1">9 (64.3)</td><td valign="top" colspan="1" rowspan="1">8 (53.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Education</td><td valign="top" colspan="1" rowspan="1">23 (51.1)</td><td valign="top" colspan="1" rowspan="1">14 (48.3)</td><td valign="top" colspan="1" rowspan="1">6 (60.0)</td><td valign="top" colspan="1" rowspan="1">2 (40.0)</td><td valign="top" colspan="1" rowspan="1">2 (33.3)</td><td valign="top" colspan="1" rowspan="1">8 (80.0)</td><td valign="top" colspan="1" rowspan="1">7 (50.0)</td><td valign="top" colspan="1" rowspan="1">6 (40.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Diabetes/Glucose</td><td valign="top" colspan="1" rowspan="1">25 (55.6)</td><td valign="top" colspan="1" rowspan="1">18 (62.1)</td><td valign="top" colspan="1" rowspan="1">4 (40.0)</td><td valign="top" colspan="1" rowspan="1">3 (60.0)</td><td valign="top" colspan="1" rowspan="1">4 (66.7)</td><td valign="top" colspan="1" rowspan="1">7 (70.0)</td><td valign="top" colspan="1" rowspan="1">8 (57.1)</td><td valign="top" colspan="1" rowspan="1">7 (46.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">BMI/Obesity</td><td valign="top" colspan="1" rowspan="1">18 (40.0)</td><td valign="top" colspan="1" rowspan="1">14 (48.3)</td><td valign="top" colspan="1" rowspan="1">3 (30.0)</td><td valign="top" colspan="1" rowspan="1">1 (20.0)</td><td valign="top" colspan="1" rowspan="1">4 (66.7)</td><td valign="top" colspan="1" rowspan="1">6 (60.0)</td><td valign="top" colspan="1" rowspan="1">6 (42.9)</td><td valign="top" colspan="1" rowspan="1">2 (13.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Hypertension</td><td valign="top" colspan="1" rowspan="1">24 (53.3)</td><td valign="top" colspan="1" rowspan="1">16 (55.2)</td><td valign="top" colspan="1" rowspan="1">5 (50.0)</td><td valign="top" colspan="1" rowspan="1">3 (60.0)</td><td valign="top" colspan="1" rowspan="1">4 (66.7)</td><td valign="top" colspan="1" rowspan="1">6 (60.0)</td><td valign="top" colspan="1" rowspan="1">3 (21.4)</td><td valign="top" colspan="1" rowspan="1">8 (53.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Cholesterol/HDL/LDL</td><td valign="top" colspan="1" rowspan="1">16 (35.6)</td><td valign="top" colspan="1" rowspan="1">12 (41.4)</td><td valign="top" colspan="1" rowspan="1">3 (30.0)</td><td valign="top" colspan="1" rowspan="1">1 (20.0)</td><td valign="top" colspan="1" rowspan="1">4 (66.7)</td><td valign="top" colspan="1" rowspan="1">6 (60.0)</td><td valign="top" colspan="1" rowspan="1">3 (21.4)</td><td valign="top" colspan="1" rowspan="1">3 (20.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Hearing loss</td><td valign="top" colspan="1" rowspan="1">4 (8.9)</td><td valign="top" colspan="1" rowspan="1">2 (6.9)</td><td valign="top" colspan="1" rowspan="1">1 (10.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">1 (10.0)</td><td valign="top" colspan="1" rowspan="1">3 (21.4)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sleep problem</td><td valign="top" colspan="1" rowspan="1">3 (6.7)</td><td valign="top" colspan="1" rowspan="1">3 (10.3)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">1 (10.0)</td><td valign="top" colspan="1" rowspan="1">1 (7.1)</td><td valign="top" colspan="1" rowspan="1">1 (6.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Traumatic Brain Injury (TBI)</td><td valign="top" colspan="1" rowspan="1">5 (11.1)</td><td valign="top" colspan="1" rowspan="1">3 (10.3)</td><td valign="top" colspan="1" rowspan="1">2 (20.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">3 (30.0)</td><td valign="top" colspan="1" rowspan="1">1 (7.1)</td><td valign="top" colspan="1" rowspan="1">1 (6.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Depression</td><td valign="top" colspan="1" rowspan="1">20 (44.4)</td><td valign="top" colspan="1" rowspan="1">14 (48.3)</td><td valign="top" colspan="1" rowspan="1">5 (50.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">7 (70.0)</td><td valign="top" colspan="1" rowspan="1">9 (64.3)</td><td valign="top" colspan="1" rowspan="1">4 (26.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Other medical conditions<sup>&#8225;</sup></td><td valign="top" colspan="1" rowspan="1">18 (40.0)</td><td valign="top" colspan="1" rowspan="1">12 (41.4)</td><td valign="top" colspan="1" rowspan="1">3 (30.0)</td><td valign="top" colspan="1" rowspan="1">3 (60.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">5 (50.0)</td><td valign="top" colspan="1" rowspan="1">6 (42.7)</td><td valign="top" colspan="1" rowspan="1">6 (40.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Physical activity</td><td valign="top" colspan="1" rowspan="1">16 (35.6)</td><td valign="top" colspan="1" rowspan="1">11 (37.9)</td><td valign="top" colspan="1" rowspan="1">4 (40.0)</td><td valign="top" colspan="1" rowspan="1">1 (20.0)</td><td valign="top" colspan="1" rowspan="1">3 (50.0)</td><td valign="top" colspan="1" rowspan="1">6 (60.0)</td><td valign="top" colspan="1" rowspan="1">5 (35.7)</td><td valign="top" colspan="1" rowspan="1">2 (13.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Cognitive function</td><td valign="top" colspan="1" rowspan="1">15 (33.5)</td><td valign="top" colspan="1" rowspan="1">10 (34.5)</td><td valign="top" colspan="1" rowspan="1">5 (50.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">1 (16.7)</td><td valign="top" colspan="1" rowspan="1">1 (10.0)</td><td valign="top" colspan="1" rowspan="1">7 (50.0)</td><td valign="top" colspan="1" rowspan="1">6 (40.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Smoking</td><td valign="top" colspan="1" rowspan="1">15 (33.3)</td><td valign="top" colspan="1" rowspan="1">9 (31.0)</td><td valign="top" colspan="1" rowspan="1">6 (60.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">2 (33.3)</td><td valign="top" colspan="1" rowspan="1">6 (60.0)</td><td valign="top" colspan="1" rowspan="1">5 (35.7)</td><td valign="top" colspan="1" rowspan="1">2 (13.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Diet</td><td valign="top" colspan="1" rowspan="1">8 (17.8)</td><td valign="top" colspan="1" rowspan="1">5 (17.2)</td><td valign="top" colspan="1" rowspan="1">3 (30.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">2 (33.3)</td><td valign="top" colspan="1" rowspan="1">4 (40.0)</td><td valign="top" colspan="1" rowspan="1">2 (14.3)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Social engagement</td><td valign="top" colspan="1" rowspan="1">9 (20.0)</td><td valign="top" colspan="1" rowspan="1">5 (17.2)</td><td valign="top" colspan="1" rowspan="1">4 (40.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">3 (30.0)</td><td valign="top" colspan="1" rowspan="1">5 (35.7)</td><td valign="top" colspan="1" rowspan="1">1 (6.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Alcohol</td><td valign="top" colspan="1" rowspan="1">8 (17.8)</td><td valign="top" colspan="1" rowspan="1">7 (24.1)</td><td valign="top" colspan="1" rowspan="1">1 (10.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">2 (33.3)</td><td valign="top" colspan="1" rowspan="1">2 (20.0)</td><td valign="top" colspan="1" rowspan="1">4 (28.6)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Cognitive engagement</td><td valign="top" colspan="1" rowspan="1">4 (8.9)</td><td valign="top" colspan="1" rowspan="1">2 (6.9)</td><td valign="top" colspan="1" rowspan="1">2 (20.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">3 (30.0)</td><td valign="top" colspan="1" rowspan="1">1 (7.1)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Apoe &#949;4</td><td valign="top" colspan="1" rowspan="1">8 (17.8)</td><td valign="top" colspan="1" rowspan="1">4 (13.8)</td><td valign="top" colspan="1" rowspan="1">4 (40.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">1 (16.7)</td><td valign="top" colspan="1" rowspan="1">1 (10.0)</td><td valign="top" colspan="1" rowspan="1">3 (21.4)</td><td valign="top" colspan="1" rowspan="1">3 (20.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">MRI</td><td valign="top" colspan="1" rowspan="1">4 (8.9)</td><td valign="top" colspan="1" rowspan="1">2 (6.9)</td><td valign="top" colspan="1" rowspan="1">1 (10.0)</td><td valign="top" colspan="1" rowspan="1">1 (20.0)</td><td valign="top" colspan="1" rowspan="1">1 (16.7)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">1 (7.1)</td><td valign="top" colspan="1" rowspan="1">2 (13.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Pesticides</td><td valign="top" colspan="1" rowspan="1">3 (6.7)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">3 (30.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">2 (20.0)</td><td valign="top" colspan="1" rowspan="1">1 (7.1)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td></tr></tbody></table><table-wrap-foot><fn id="spara008"><p>Note: *includes 29 scores for dementia, 10 for AD, 5 for CVD, and 1 for MCI/dementia.</p></fn><fn id="spara009"><p><sup>&#8225;</sup>Other medical condition includes wide range of medical condition such as stroke, Atrial Fibrillation, Coronary heart disease, Myocardial Infraction, Arthritis, cerebrovascular disease, cardiovascular disease, history of bypass surgery, Chronic Kidney disease, renal failure, Parkinson&#8217;s, cancer etc.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0019"><label>3.2.5</label><title>Characteristics of the validation of risk scores</title><p id="para0025">Supplementary Table 2 presents detailed characteristics of validation studies for various dementia risk scores. Sixteen risk prediction models (including 10 for dementia, 5 for AD, and 1 for CVD) were not validated using any internal or external validation samples. The remaining 29 risk prediction models were validated using 35 studies (with a range of 1 to 5 studies per model). Among the validated risk scores, CAIDE was validated on the highest number of external studies (validated in 5 studies), followed by LIBRA and ANU-ADRI, each validated in 4 studies. The CogDrisk, CogDrisk-AD, and the Framingham CVD risk scores were each validated in two studies. All other risk scores were validated in a single either external or internal study (Supplementary Table S2). The midlife risk prediction tool CAIDE was validated using data from midlife (2 studies), late-life (2 studies) and clinical samples (1 study). Similarly, the mid-to-late-life risk tool, LIBRA was validated using midlife (2 studies), mid-to-late-life (1 study) and late-life samples (3 studies). Although the ANU-ADRI risk tool was developed for risk assessment of AD, in addition to validation for AD (2 studies), it has been validated for dementia risk assessment using both late-life (2 studies) and mid-to-late-life risk information (1 study).</p></sec></sec><sec id="sec0020"><label>3.3</label><title>Meta-analysis of the predictive accuracy of the development and validation sample</title><p id="para0026">The mean age and length of follow-up, along with detailed sample characteristics for the development and validation of risk scores, are provided in Supplementary Table S1 and Supplementary Table S2, respectively. Pooled c-statistics (95 % CI) for various risk scores, based on both development and validation samples are presented using forest plots in <xref rid="fig0004" ref-type="fig">Fig. 4</xref> and Supplementary Figures S1-S6. The combined c-statistic (95 % CI) of all dementia risk scores in the validation and development sample is 0.69 (0.67, 0.71) (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>).<fig id="fig0004" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Forest plot of AUCs/C-statistics obtained from meta-analysis using all dementia risk scores.</p></caption><alt-text id="alt0007">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0004" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><sec id="sec0021"><label>3.3.1</label><title>Performance of midlife risk scores in predicting dementia risk</title><p id="para0027">The mean age of the development samples for midlife risk prediction scores ranged from 46 to 57 years, with follow-up durations from 8.3 to 31 years. Among the validation studies, three studies that validated midlife risk scores had follow-up intervals of 20 to 39 years [<xref rid="bib0024" ref-type="bibr">24</xref>,<xref rid="bib0030" ref-type="bibr">30</xref>,<xref rid="bib0034" ref-type="bibr">34</xref>], three had shorter follow-up periods of 0, 3.8, and 5 years. Out of the six midlife risk scores, three reported AUC with 95 % CI, yielding a pooled estimate of 0.71 (0.61, 0.83). Among these, the CAIDE, and the Education and occupation-based midlife risk score were validated externally, resulting an estimated c-statistic (95 % CI) of 0.63 (0.58, 0.68) (Supplementary Figure S1). Note that studies using midlife data [<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0024" ref-type="bibr">24</xref>,<xref rid="bib0035" ref-type="bibr">35</xref>] to validate midlife risk scores provided better c-statistics than those using late-life data [<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0025" ref-type="bibr">25</xref>,<xref rid="bib0036" ref-type="bibr">36</xref>,<xref rid="bib0037" ref-type="bibr">37</xref>].</p></sec><sec id="sec0022"><label>3.3.2</label><title>Performance of midlife to late-life risk scores in predicting dementia risk</title><p id="para0028">For mid-to-late-life risk models, the mean age of the development samples ranges from 56 to 68 years, with follow-up durations from 0 to 14 years. The mean age of validation samples for this category ranged from 57 to 74 years, with follow-up also from 0 to 14 years. Notably, four mid-to-late-life risk tools (ANU-ADRI, LIBRA, CogDrisk and CogDrisk-AD) were developed using evidence synthesis and validated across diverse cohorts, with mean participant ages ranging from 47.85 to 80 years and follow-up durations from 0 to 30 years. Apart from a cross-sectional study and a study with long follow-up (30 years), all other validation studies had follow-up ranges from 5 to 16 years.</p><p id="para0029">Among the 10 risk scores utilizing midlife to late-life risk factors, 6 were developed using cohort data, yielding a pooled c-statistic (95 % CI) of 0.79 (0.73, 0.85) (Supplementary Figure S1). Note that two of the three studies used to estimate the pooled estimate of the development sample were from the UK Biobank. The other UK Biobank study provides similar c-statistics but was not included in the meta-analysis due to the absence of a confidence interval for the c-statistic estimate in the study [<xref rid="bib0027" ref-type="bibr">27</xref>]. Only the UKBDRS risk score that was developed using cohort data was externally validated. The estimated c-statistics for the midlife to late-life tools (developed from cohorts and evidence synthesis) on the validation sample is 0.65 (0.60, 0.69). Although the LIBRA tool uses risk information from both midlife and late-life, it did not include non-modifiable risk factors such as age, sex and education, resulting in low c-statistics in validation. Moreover, studies that use midlife to late-life samples [<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0038" ref-type="bibr">38</xref>] for the validation of these risk tools exhibited better c-statistics compared to studies that used late-life samples (Supplementary Figure S1).</p></sec><sec id="sec0023"><label>3.3.3</label><title>Performance of late-life risk scores in predicting dementia risk</title><p id="para0030">For late-life risk scores, the mean age of the development sample ranged from 71 to 80 years, with follow-ups lasting 2 to 20 years. Mean participants&#8217; ages in the validation samples ranged from 57 to 76 years, with follow-up durations from 2 to 18 years. All of the community-dwelling samples used to validate late-life risk tools had follow-ups ranging from 5 to 10 years, except for the UK Biobank [<xref rid="bib0019" ref-type="bibr">19</xref>], Whitehall [<xref rid="bib0019" ref-type="bibr">19</xref>], and ROS cohorts [<xref rid="bib0039" ref-type="bibr">39</xref>]. Note that the UK Biobank includes participants from both midlife and late-life, however, the Whitehall study includes participants from midlife.</p><p id="para0031">Among the 14 late-life risk scores that were developed using late-life community samples, only 7 reported AUC/C-statistics for dementia in the development samples, resulting in pooled estimated c-statistics (95 % CI) 0.77 (0.75, 0.80). The pooled c-statistics (95 % CI) for the validation samples is 0.73 (0.69, 0.79) (Supplementary Figure S2).</p></sec><sec id="sec0024"><label>3.3.4</label><title>Performance of clinical risk scores in predicting dementia risk</title><p id="para0032">For the clinical risk scores, the mean age of the development samples ranged from 65 years to 80 years, with follow-up durations of 0.5 years to 12 years; validation sample ages ranged from 67.2 to 73.9 years, with follow-up durations of 2.91 to 12 years. Only two validation studies had follow-up durations of &lt;3 years.</p><p id="para0033">Among the 15 clinical risk scores, five were developed to estimate the risk prediction for all-cause dementia, 5 for AD, 4 for CVD, and 1 for VAD. Evidence on the performance of CVD risk for dementia risk tools is only available through validation studies. Of the clinical risk scores for dementia, one risk score did not report a confidence interval for AUC. The pooled c-statistics for the clinical risk scores for dementia in development samples were 0.74 (0.69, 0.79) and 0.66 (0.62, 0.71) in validation samples (Supplementary Figure S2). Risk scores that utilized a large number of clinical markers or registry data tended to result in higher AUCs.</p></sec><sec id="sec0025"><label>3.3.5</label><title>Performance of widely validated risk tools of dementia</title><p id="para0034">The performance of risk tools evaluated in multiple studies, such as CAIDE, LIBRA, ANU-ADRI, CogDrisk, and BDRM, is illustrated in Supplementary Figure S3. The pooled estimates for the CAIDE risk score in the validation sample is 0.60 (0.56, 0.64), with better performance observed in studies using midlife risk factors. The pooled c-statistic for LIBRA is 0.52 (0.50, 0.55), likely due to the exclusion of age, sex, and education. Both CogDrisk and ANU-ADRI demonstrated similar predictive performance, with pooled AUCs of 0.70 (0.68, 0.72) and 0.69 (0.68, 0.71), respectively. The Basic Dementia Risk Model (BDRM) [<xref rid="bib0040" ref-type="bibr">40</xref>] yielded a pooled c-statistics of 0.72 (0.70, 0.75), while the Late-Life Dementia Risk Index reported a pooled c-statistics of 0.72 (0.61, 0.85). Note that the BDRM risk tool includes indicators of both subjective memory decline and IADL.</p></sec><sec id="sec0026"><label>3.3.6</label><title>Subgroup analysis according to included risk factors</title><p id="para0035">Only a few studies incorporated APOE &#949;4, physical activity, cognitive activity, diet and cognitive function. Supplementary Figure S4 demonstrates that risk scores including APOE &#949;4 and cognitive function resulted in higher c-statistics - 0.74 (0.68, 0.80) for APOE &#949;4 and 0.73 (0.70, 0.76) for cognitive function - compared to the overall c-statistics 0.69 (0.67, 0.71). In contrast, studies that included physical activity or cognitive activity in risk prediction resulted in wide range AUCs.</p></sec><sec id="sec0027"><label>3.3.7</label><title>Alzheimer&#8217;s disease (AD) risk scores</title><p id="para0036">Supplementary Table S3 lists all AD risk factors considered in the development AD risk scores across community and clinical settings. AD risk scores from clinical settings predominantly utilized cognitive function and functional dependence indicators, while community-based AD risk scores incorporated a broader range of risk factors. The pooled c-statistics for the AD risk tools in development samples is 0.79 (0.76, 0.82) and it is 0.71(0.68, 0.75) in validation samples (Supplementary Figure S5). Among these, the ANU-ADRI and CogDrisk-AD have been validated in a number of studies, providing similar estimated pooled c-statistics (supplementary Figure S6). Of all the tools reviewed, these were the only ones to include environmental risk factors, namely exposure to pesticides.</p></sec><sec id="sec0028"><label>3.3.8</label><title>Vascular dementia (VaD) risk scores</title><p id="para0037">Only two studies presented risk scores for vascular dementia (VaD), one with clinical sample [<xref rid="bib0041" ref-type="bibr">41</xref>], and one using UK Biobank dataset [<xref rid="bib0042" ref-type="bibr">42</xref>] with AUCs (95 % CI) 0.76 (0.69, 0.83) and 0.85 (0.84, 0.87). However, none of these scores are validated.</p></sec><sec id="sec0029"><label>3.3.9</label><title>Contribution of various factors in the performance of dementia risk scores</title><p id="para0038">Length of follow-up, sample size, inclusion of certain covariates and prevalence of dementia in the sample all impact the performance of the tool and preclude direct comparison of AUCs between publications, we therefore conducted meta-regression to evaluate how the study design influences the reported AUC in the literature. <xref rid="tbl0003" ref-type="table">Table 3</xref> presents results from the meta-regression on the effect of including various risk factors on log (AUC) estimates for both community and clinical sample based risk scores. Our results showed that inclusion of BMI in risk scores for late life significantly increases AUC (average increase 26 %), on the contrary the inclusion of dyslipidaemia significantly decreases AUC (average decrease 26 %) in late life risk scores. Among all risk scores, age in risk scores increases AUCs (average increase 27 %&#8722;42 %) for community sample based dementia risk scores. Conversely, inclusion of physical activity in risk scores decreases AUCs (average decrease 12 %) for community sample based dementia risk scores, however, none of these estimates are statistically significant.<table-wrap position="float" id="tbl0003" orientation="portrait"><label>Table 3</label><caption><p>Meta regression analysis of log (AUC) associated with covariates in risk scores.</p></caption><alt-text id="alt0003">Table 3:</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th colspan="3" align="left" valign="top" rowspan="1">Community sample<hr/></th><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Clinical</th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th colspan="3" align="left" valign="top" rowspan="1">Dementia<hr/></th><th valign="top" colspan="1" rowspan="1">AD</th><th valign="top" colspan="1" rowspan="1">Dementia</th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">All sample<sup>&#8224;</sup></th><th valign="top" colspan="1" rowspan="1">Midlife to late-life</th><th valign="top" colspan="1" rowspan="1">Late life</th><th valign="top" colspan="1" rowspan="1">All sample<sup>&#8224;</sup></th><th valign="top" colspan="1" rowspan="1">All sample<sup>&#8224;</sup></th></tr><tr><th valign="top" colspan="1" rowspan="1">Variables</th><th valign="top" colspan="1" rowspan="1"><inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mi>&#946;</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>95</mml:mn><mml:mrow><mml:mo>%</mml:mo><mml:mspace width="0.33em"/><mml:mtext>CI</mml:mtext></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula></th><th valign="top" colspan="1" rowspan="1"><inline-formula><mml:math id="M2" altimg="si1.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mi>&#946;</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>95</mml:mn><mml:mrow><mml:mo>%</mml:mo><mml:mspace width="0.33em"/><mml:mtext>CI</mml:mtext></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula></th><th valign="top" colspan="1" rowspan="1"><inline-formula><mml:math id="M3" altimg="si1.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mi>&#946;</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>95</mml:mn><mml:mrow><mml:mo>%</mml:mo><mml:mspace width="0.33em"/><mml:mtext>CI</mml:mtext></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula></th><th valign="top" colspan="1" rowspan="1"><inline-formula><mml:math id="M4" altimg="si1.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mi>&#946;</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>95</mml:mn><mml:mrow><mml:mo>%</mml:mo><mml:mspace width="0.33em"/><mml:mtext>CI</mml:mtext></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula></th><th valign="top" colspan="1" rowspan="1"><inline-formula><mml:math id="M5" altimg="si1.svg"><mml:mrow><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mi>&#946;</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>95</mml:mn><mml:mrow><mml:mo>%</mml:mo><mml:mspace width="0.33em"/><mml:mtext>CI</mml:mtext></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula></th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Age</td><td valign="top" colspan="1" rowspan="1">1.27 (0.94, 1.72)</td><td valign="top" colspan="1" rowspan="1">1.41 (0.16, 12.31)</td><td valign="top" colspan="1" rowspan="1">1.42 (0.90, 2.23)</td><td valign="top" colspan="1" rowspan="1">1.05 (0.02, 5.86)</td><td valign="top" colspan="1" rowspan="1">0.93 (0.75, 1.16)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sex</td><td valign="top" colspan="1" rowspan="1">1.06 (0.86, 1.32)</td><td valign="top" colspan="1" rowspan="1">NAN</td><td valign="top" colspan="1" rowspan="1">1.11 (0.68, 1.80)</td><td valign="top" colspan="1" rowspan="1">0.91 (0.60, 1.39)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.67, 1.27)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Education</td><td valign="top" colspan="1" rowspan="1">0.97 (0.82, 1.15)</td><td valign="top" colspan="1" rowspan="1">0.98 (0.09, 11.06)</td><td valign="top" colspan="1" rowspan="1">0.87 (0.71, 1.08)</td><td valign="top" colspan="1" rowspan="1">1.30 (0.17, 9.80)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">APOE &#949;4</td><td valign="top" colspan="1" rowspan="1">1.10 (0.91, 1.34)</td><td valign="top" colspan="1" rowspan="1">1.22 (0.20, 7.62)</td><td valign="top" colspan="1" rowspan="1">1.03 (0.63, 1.70)</td><td valign="top" colspan="1" rowspan="1">0.99 (0.51, 1.91)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Hypertension</td><td valign="top" colspan="1" rowspan="1">1.03 (0.85, 1.25)</td><td valign="top" colspan="1" rowspan="1">1.05 (0.60, 1.83)</td><td valign="top" colspan="1" rowspan="1">0.95 (0.71, 1.28)</td><td valign="top" colspan="1" rowspan="1">0.85 (0.14, 5.04)</td><td valign="top" colspan="1" rowspan="1">1.20 (0.83,1.75)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Dyslipidemia</td><td valign="top" colspan="1" rowspan="1">0.92 (0.78, 1.08)</td><td valign="top" colspan="1" rowspan="1">1.03 (0.40, 2.68)</td><td valign="top" colspan="1" rowspan="1"><bold>0.74 (0.58, 0.96)</bold></td><td valign="top" colspan="1" rowspan="1">0.78 (0.01, 6.11)</td><td valign="top" colspan="1" rowspan="1">1.13 (0.84, 1.51)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Diabetes</td><td valign="top" colspan="1" rowspan="1">1.09 (0.85, 1.39)</td><td valign="top" colspan="1" rowspan="1">1.31 (0.09, 19.60)</td><td valign="top" colspan="1" rowspan="1">1.11 (0.76, 1.63)</td><td valign="top" colspan="1" rowspan="1">0.90 (0.08, 9.81)</td><td valign="top" colspan="1" rowspan="1">0.77 (0.62, 0.95)</td></tr><tr><td valign="top" colspan="1" rowspan="1">BMI/Obesity</td><td valign="top" colspan="1" rowspan="1">1.00 (0.87, 1.15)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.20, 4.28)</td><td valign="top" colspan="1" rowspan="1"><bold>1.26 (1.02, 1.55)</bold></td><td valign="top" colspan="1" rowspan="1">1.00 (0.29, 3.44)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Hearing loss</td><td valign="top" colspan="1" rowspan="1">1.01 (0.74, 1.38)</td><td valign="top" colspan="1" rowspan="1">NAN</td><td valign="top" colspan="1" rowspan="1">1.25 (0.80, 1.95)</td><td valign="top" colspan="1" rowspan="1">NAN</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sleep problem</td><td valign="top" colspan="1" rowspan="1">0.93 (0.67, 1.28)</td><td valign="top" colspan="1" rowspan="1">0.95 (0.33, 2.69)</td><td valign="top" colspan="1" rowspan="1">0.78 (0.46, 1.32)</td><td valign="top" colspan="1" rowspan="1">0.98 (0.21, 4.62)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Traumatic brain Injury</td><td valign="top" colspan="1" rowspan="1">1.03 (0.76, 1.39)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.42, 2.00)</td><td valign="top" colspan="1" rowspan="1">0.87 (0.59, 1.27)</td><td valign="top" colspan="1" rowspan="1">0.94 (0.20, 4.45)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Other medical condition<sup>&#8225;</sup></td><td valign="top" colspan="1" rowspan="1">1.01 (0.87, 1.19)</td><td valign="top" colspan="1" rowspan="1">1.04 (0.80, 1.35)</td><td valign="top" colspan="1" rowspan="1">1.03 (0.72, 1.49)</td><td valign="top" colspan="1" rowspan="1">1.00 (0.54, 184)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Cognition</td><td valign="top" colspan="1" rowspan="1">1.04 (0.83, 1.30)</td><td valign="top" colspan="1" rowspan="1">NAN</td><td valign="top" colspan="1" rowspan="1">1.02 (0.75, 1.38)</td><td valign="top" colspan="1" rowspan="1">1.17 (0.20, 7.02)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Social engagement</td><td valign="top" colspan="1" rowspan="1">0.99 (0.82, 1.20)</td><td valign="top" colspan="1" rowspan="1">0.98 (0.47, 2.06)</td><td valign="top" colspan="1" rowspan="1">1.06 (0.82, 1.37)</td><td valign="top" colspan="1" rowspan="1">1.00 (0.45, 2.24)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Cognitive engagement</td><td valign="top" colspan="1" rowspan="1">1.06 (0.75, 1.48)</td><td valign="top" colspan="1" rowspan="1">1.02 (0.29, 362)</td><td valign="top" colspan="1" rowspan="1">1.23 (0.75, 2.03)</td><td valign="top" colspan="1" rowspan="1">1.11 (0.62, 1.99)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Depression</td><td valign="top" colspan="1" rowspan="1">0.93 (0.74, 1.17)</td><td valign="top" colspan="1" rowspan="1">0.97 (0.22, 4.36)</td><td valign="top" colspan="1" rowspan="1">0.81 (0.59, 1.11)</td><td valign="top" colspan="1" rowspan="1">0.89 (0.20, 3.90)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Alcohol</td><td valign="top" colspan="1" rowspan="1">0.95 (0.75, 1.20)</td><td valign="top" colspan="1" rowspan="1">0.96 (0.59, 1.58)</td><td valign="top" colspan="1" rowspan="1">0.84 (0.54, 1.30)</td><td valign="top" colspan="1" rowspan="1">0.98 (0.39, 2.48)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Smoking status</td><td valign="top" colspan="1" rowspan="1">1.04 (0.87, 1.22)</td><td valign="top" colspan="1" rowspan="1">1.00 (0.03, 29.31)</td><td valign="top" colspan="1" rowspan="1">1.19 (0.92, 1.54)</td><td valign="top" colspan="1" rowspan="1">1.08 (0.22, 5.25)</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Physical activity</td><td valign="top" colspan="1" rowspan="1">0.88 (0.74, 1.04)</td><td valign="top" colspan="1" rowspan="1">1.08 (0.40, 2.89)</td><td valign="top" colspan="1" rowspan="1">0.94 (0.72, 1.21)</td><td valign="top" colspan="1" rowspan="1">NAN</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Diet</td><td valign="top" colspan="1" rowspan="1">1.12 (0.87, 1.45)</td><td valign="top" colspan="1" rowspan="1">1.07 (0.40, 2.84)</td><td valign="top" colspan="1" rowspan="1">1.21 (0.79, 1.86)</td><td valign="top" colspan="1" rowspan="1">NAN</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Follow-up duration</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">NAN</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">0&#8211;5 years</td><td valign="top" colspan="1" rowspan="1">Ref</td><td valign="top" colspan="1" rowspan="1">Ref</td><td valign="top" colspan="1" rowspan="1">Ref</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Ref</td></tr><tr><td valign="top" colspan="1" rowspan="1">6&#8211;10 years</td><td valign="top" colspan="1" rowspan="1">1.07 (0.89, 1.22)</td><td valign="top" colspan="1" rowspan="1">0.89 (0.15, 5.37)</td><td valign="top" colspan="1" rowspan="1">1.08 (0.86, 1.35)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">&gt;10 years</td><td valign="top" colspan="1" rowspan="1">1.03 (0.86, 1.22)</td><td valign="top" colspan="1" rowspan="1">NAN</td><td valign="top" colspan="1" rowspan="1">1.13 (0.91, 1.40)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Cohorts type</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Not included</td><td valign="top" colspan="1" rowspan="1">Not included</td><td valign="top" colspan="1" rowspan="1">NAN</td><td valign="top" colspan="1" rowspan="1">NAN</td></tr><tr><td valign="top" colspan="1" rowspan="1">Midlife</td><td valign="top" colspan="1" rowspan="1">Ref</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Midlife to late-life</td><td valign="top" colspan="1" rowspan="1">1.00 (0.86, 1.18)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Late-life</td><td valign="top" colspan="1" rowspan="1">0.88 (0.70, 1.11)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="spara011"><p>Note: *adjusted for mean age.gal.</p></fn><fn id="spara012"><p>&#8224;NAN: Not included in the final model as redundant.</p></fn><fn id="spara013"><p><sup>&#8225;</sup>Other medical condition includes wide range of medical condition such as stroke, Atrial Fibrillation, Coronary heart disease, Myocardial Infraction, Arthritis, cerebrovascular disease, cardiovascular disease, history of bypass surgery, Chronic Kidney disease, renal failure, Parkinson&#8217;s, cancer etc.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec0030"><label>3.4</label><title>Risk of bias assessment in dementia risk prediction models</title><p id="para0039">The risk of bias assessment using the Prediction model Risk of Bias Assessment Tool (PROBAST) is provided in Supplementary Table S4. The PROBAST tool evaluates studies across four domains for risk of bias and three domains for the applicability of the risk prediction model.</p><p id="para0040">Among the 49 studies included in this review, 41 (84 %) were classified as having a high risk of bias, five (10 %) as low risk, and three (6 %) as having an unclear risk of bias. Notably, biases related to participants, predictors, or outcomes were observed in only a subset of studies, whereas most of the high-risk classifications were due to issues in the analysis domain. Common sources of bias in analysis included: excluding participants from the final analysis; selecting predictors based on bivariate analysis with arbitrary p-value thresholds; improper handling of missing data or censoring; and failure to account for overfitting in model development.</p><p id="para0041">Of the five studies [<xref rid="bib0030" ref-type="bibr">30</xref>,<xref rid="bib0032" ref-type="bibr">32</xref>,<xref rid="bib0036" ref-type="bibr">36</xref>,<xref rid="bib0038" ref-type="bibr">38</xref>,<xref rid="bib0040" ref-type="bibr">40</xref>] assessed as having a low risk of bias, two involved both development and validation of risk scores, two were external validations of existing tools, and one focused solely on tool development. One study, which developed the RXDx Dementia Risk Score [<xref rid="bib0043" ref-type="bibr">43</xref>], provided insufficient information on the ascertainment of outcomes and predictors, and thus the risk of bias could not be assessed. Additionally, CogDrisk, CogDrisk-AD [<xref rid="bib0015" ref-type="bibr">15</xref>], and ANU-ADRI [<xref rid="bib0014" ref-type="bibr">14</xref>] were developed through evidence synthesis rather than primary cohort data. As a result, PROBAST&#8217;s cohort-specific bias domains were not applicable to these tools, leading to their classification as having unclear risk of bias.</p></sec><sec id="sec0031"><label>3.5</label><title>Administration of dementia risk tools</title><sec id="sec0032"><label>3.5.1</label><title>Information required for implementation</title><p id="para0042">Three midlife assessment tools could be administered by self-report [<xref rid="bib0022" ref-type="bibr">[22]</xref>, <xref rid="bib0023" ref-type="bibr">[23]</xref>, <xref rid="bib0024" ref-type="bibr">[24]</xref>], and the other midlife risk tools [<xref rid="bib0030" ref-type="bibr">30</xref>,<xref rid="bib0044" ref-type="bibr">44</xref>] required clinical tests such as clinical assessments, blood tests, and/or genotyping. Note that the CAIDE risk tool has two versions, one can be administered by self-report and the other requires genotyping. Of risk scores developed on midlife to late-life samples, seven could be administered purely by self-report [<xref rid="bib0014" ref-type="bibr">14</xref>,<xref rid="bib0015" ref-type="bibr">15</xref>,<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0026" ref-type="bibr">[26]</xref>, <xref rid="bib0027" ref-type="bibr">[27]</xref>, <xref rid="bib0028" ref-type="bibr">[28]</xref>,<xref rid="bib0045" ref-type="bibr">45</xref>], whereas five required clinical assessments and/or additional blood tests or imaging. Of the late-life risk tools, three could be administered using self-reported data [<xref rid="bib0029" ref-type="bibr">29</xref>,<xref rid="bib0032" ref-type="bibr">32</xref>,<xref rid="bib0046" ref-type="bibr">[46]</xref>, <xref rid="bib0047" ref-type="bibr">[47]</xref>, <xref rid="bib0048" ref-type="bibr">[48]</xref>, <xref rid="bib0049" ref-type="bibr">[49]</xref>]. Of the tools developed on clinical samples, all involved either clinical tests or administrative data. There were two derived from administrative databases [<xref rid="bib0050" ref-type="bibr">50</xref>,<xref rid="bib0051" ref-type="bibr">51</xref>], two required brain imaging [<xref rid="bib0041" ref-type="bibr">41</xref>,<xref rid="bib0052" ref-type="bibr">52</xref>]and several required blood tests.</p></sec><sec id="sec0033"><label>3.5.2</label><title>Economic cost and potential scalability</title><p id="para0043">The costs of dementia risk assessment varied from zero to approximately $939USD (<xref rid="fig0005" ref-type="fig">Fig. 5</xref>), noting that costs do not take into account the time of the participant (see supplementary Table S5) and are based on the Australian Medical Benefits Scheme rebates. These results give a broad indication of the relative cost of tools. Those involving MRIs and memory clinics were the most expensive. <xref rid="fig0003" ref-type="fig">Fig. 3</xref> shows the AUCs plotted against the cost of risk assessment tool. There appears to be no association between cost and predictive accuracy, although this figure does not take into account other factors such as length of follow-up or age.<fig id="fig0005" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Cost of tools plotted against AUC statistic. Note this does not take into account length of follow-up or the age distribution of samples, which may influence AUCs.</p></caption><alt-text id="alt0008">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0005" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></sec></sec></sec><sec id="sec0034"><label>4</label><title>Discussion</title><p id="para0044">This systematic review provides a comprehensive overview of 45 published dementia risk scores and critically evaluates their content, validation, cost, adherence to WHO guidelines, and generalisability. The meta-analysis revealed that the pooled estimate for the AUC of dementia risk scores is around 0.7. A new risk tool for dementia developed from 10 cohorts studies also provided similar pooled AUCs <xref rid="bib0045" ref-type="bibr">[45]</xref>. Moreover, we did not find greater predictive validity when including biomarkers, which may be expensive, in risk models that also included preventative risk factors. However, a recent study focusing only on biomarkers suggests higher AUCs for plasma biomarkers in predicting dementia [<xref rid="bib0054" ref-type="bibr">53</xref>], which needs further verification in independent studies. Plasma biomarkers of disease are inherently different from modifiable risk factors which are independent of disease processes, and risk scores comprised of plasma biomarkers may complement prevention focussed risk assessment.</p><p id="para0045">Our review identified a handful of dementia risk scores considered modifiable risk factors for dementia that are considered in the WHO guidelines. Two of the five midlife risk tools included information on age, sex, education, physical activity, diet, and smoking. A small number of late-life risk tools included modifiable risk factors such as physical inactivity, cognitive engagement, social engagement, and diet. Similarly, many midlife-to-late-life risk scores did not include information on diet, social engagement, or cognitive engagement. As a result, their effectiveness as risk monitoring tools for targeting strategies for delaying cognitive decline and dementia in late life may be questionable, as optimal social and cognitive engagement may help delay the progression of dementia. Risk scores that include modifiable risk factors <xref rid="bib0036" ref-type="bibr">[36]</xref>, <xref rid="bib0045" ref-type="bibr">[45]</xref>, are not only effective and inexpensive but also aligned with the factors identified by the WHO guidelines [<xref rid="bib0006" ref-type="bibr">6</xref>].</p><p id="para0046">There was also overlap with the risk factors identified in the Lancet Commission on Dementia [<xref rid="bib0006" ref-type="bibr">6</xref>]. Interestingly, 15 risk scores included high cholesterol, reflecting the evidence for this factor in the literature over a long period of time [<xref rid="bib0055" ref-type="bibr">54</xref>], despite it only being included in the most recent Lancet Commission list of key risk factors. Three studies included hearing loss despite the growing evidence of its role as a risk factor (although there is limited evidence at this stage of the benefits of intervention). No study included uncorrected vision loss [<xref rid="bib0006" ref-type="bibr">6</xref>]. Despite the importance of low education as a risk factor, only 50 % of late life risk tools, and 40 % of clinical tools included this but 80 % of midlife risk tools included education. This may reflect the emphasis on modifiable risk factors in the tools reviewed. While the Lancet Commission did not include an unhealthy diet in its of risk factors, the WHO did make recommendations for healthy diet reducing risk of cognitive decline and dementia and diet was included in 40 % of midlife risk tools, and 14.3 % of late-life risk tools. Overall these differences show that tools that measure modifiable risk factors will need to be updated as the evidence base continues to grow and clarify.</p><p id="para0047">Our results highlight that self-reported risk assessment tools (e.g., CAIDE, LIBRA, BDRM, CogDrisk, ANU-ADRI) are widely validated tools across diverse settings and exhibit good performance in the validation samples (see Supplementary Figure S3) [<xref rid="bib0035" ref-type="bibr">35</xref>,<xref rid="bib0036" ref-type="bibr">36</xref>,<xref rid="bib0056" ref-type="bibr">55</xref>,<xref rid="bib0057" ref-type="bibr">56</xref>]. The CogDrisk ANU-ADRI, and LIBRA were developed using evidence synthesis can only be evaluated through validation samples. Hence, these tools are often misrepresented when compared with others that are not fully aligned with their development principles or with dementia epidemiology. For example, the LIBRA score does not include effects of non-modifiable risk factors such as age, sex and education, and ANU-ADRI assumes a weight of zero for ages under 65. Hence, comparing these risk tools with other risk tools, which provide risk stratification based on age in midlife results in an invalid comparison. The CAIDE risk tool has been developed using age weights of midlife samples (age&lt;65). It is well known that age is a significant risk factor for dementia, and prevalence as well as incidence of dementia increase with increasing age [<xref rid="bib0058" ref-type="bibr">57</xref>]. Therefore, comparing CAIDE risk scores with other risk scores that were developed using late-life age weights can lead to misleading conclusions. All of the risk scores included in our review are specific to either midlife or late life. More recently, a midlife version of the CogDrisk tool, CogDrisk-ML [<xref rid="bib0059" ref-type="bibr">58</xref>], was developed, which can be used in combination with the original CogDrisk tool for late life. Together, these tools enable dementia risk prediction across the life course, from midlife to late life.</p><p id="para0048">The age at which risk factors are assessed is critical, prevalence of dementia increases with age [<xref rid="bib0058" ref-type="bibr">57</xref>], and the relevance of risk factors can change over the life course [<xref rid="bib0060" ref-type="bibr">59</xref>]. For example, hypertension, high BMI and serum cholesterol may not increase risk of dementia when they are observed in late-life [<xref rid="bib0008" ref-type="bibr">8</xref>]. Moreover, the salience of risk factors in the oldest old (adults aged over 85 years) is not well understood. Additionally, if follow-up periods do not extend into very old age, the true incidence of dementia in the population will not be established, as seen in the UK Biobank, where high AUCs can be attributed to age alone rather than the full model [<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0027" ref-type="bibr">27</xref>,<xref rid="bib0042" ref-type="bibr">42</xref>,<xref rid="bib0061" ref-type="bibr">[60]</xref>, <xref rid="bib0062" ref-type="bibr">[61]</xref>, <xref rid="bib0063" ref-type="bibr">[62]</xref>]. This is because the UK Biobank study includes samples from age 44 to 73, with a 14-year follow-up; hence, individuals in the upper age spectrum of this cohort experience dementia at a higher rate than participants in the lower age spectrum. As a result, in the UK Biobank, age alone has a higher predictive power for dementia than in other cohorts, which results in relatively higher AUCs. For example, previous report suggests that CogDrisk-AD and ANU-ADRI provide similar but moderate AUCs (AUC ranges from 0.65 to 0.72) for the prediction of AD when applied to the Rush Memory and Aging Project (MAP), the Cardiovascular Health Study Cognition Study (CHS-CS), and the Health and Retirement Study&#8211;Aging, Demographics and Memory Study (HRS-ADAMS) [<xref rid="bib0036" ref-type="bibr">36</xref>,<xref rid="bib0056" ref-type="bibr">55</xref>]. However, application of CogDrisk-AD on UK-Biobank data resulted an AUC of 0.856 [<xref rid="bib0064" ref-type="bibr">63</xref>]. Moreover, the recent Lancet commission report [<xref rid="bib0006" ref-type="bibr">6</xref>] estimated that up to 45 % of dementia cases are attributable to 14 modifiable risk factors. None of the risk scores reviewed here included all the risk factors identified in the Lancet Commission. Altogether, this raises the concern that AUCs for dementia risk scores exceeding 0.8 may be an artifact of exceptionally wide age ranges in cohorts or sample bias.</p><p id="para0049">In addition, we found that the inclusion of physical activity as a risk factor was associated with lower AUCs in community-based samples assessing dementia risk. Among the studies that included physical activity, only 7 % also incorporated a measure of cognitive function. In contrast, approximately 50 % of studies included cognitive assessments without considering physical activity. Since cognitive assessments are closely linked to dementia outcomes and often serve as direct indicators of the condition, these studies tended to report higher AUCs. As a result, the observed differences in model performance may be biased due to confounding by cognitive measures. Similarly, late-life studies that included dyslipidaemia as a risk factor were less likely to include cognitive assessments in their risk scores, which may have contributed to the lower AUCs observed in these studies compared to those that did not include dyslipidaemia. Notably, a slightly higher proportion of risk scores that included BMI or obesity measures also incorporated cognitive assessments and other medical conditions such as stroke, Atrial Fibrillation, heart disease, renal failure etc.. This highlights the importance of critically evaluating the components of risk scores when comparing their predictive performance.</p><p id="para0050">Our review had both strengths and limitations. To our knowledge, this is the most comprehensive review of dementia risk scores in terms of the domains that were evaluated. The review identified very few studies comparing different risk tools using valid criteria and consistent age of exposure. A strength is the finding of overall consistency in the effect sizes for dementia risk assessment tools identified throughout the review. We identified several methodological limitations in validation studies, including inappropriate age or exposure, age ranges and length of follow-up, and small sample sizes. The use of clinical samples introduces selection bias, which precludes generalisation to the population, unless a tool is externally validated on a population sample. Another observation was that inappropriate comparisons made in validation studies can lead to inaccurate or misleading conclusions (e.g. evaluating a tool developed for late-life, on the UK Biobank/Whitehall sample, which has a midlife sample) [<xref rid="bib0019" ref-type="bibr">19</xref>]. In our review, we included a relatively smaller number of studies compared to previous reviews [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>], reflecting our distinct objectives. Whereas prior reviews incorporated a larger number of studies using artificial intelligence (AI), machine learning (ML) algorithms, or clinical risk assessments, we focused specifically on models with greater potential for real-world implementation in guiding dementia risk reduction strategies. Many AI/ML-based models lack external validation, have limited transportability, and do not consistently outperform traditional statistical approaches [<xref rid="bib0012" ref-type="bibr">12</xref>]. Moreover, they often fail to offer actionable insights relevant to prevention, which is the central focus of our review. Similar to previous reviews [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>], we also found that a large number of risk scores were not validated using any internal or external datasets. Therefore, concerns remain regarding the heavy dependence on a single data source and the lack of sufficient validation in these models. Similar findings were also reported elsewhere [<xref rid="bib0052" ref-type="bibr">52</xref>]. Our risk of bias assessment reveals that only handful of risk scores are of low risk of bias which indicate severe methodological flaws, and need greater care for future development and validation of dementia risk assessment tools.</p><p id="para0051">In our review, we observed considerable variation in the number of risk factors included across different dementia risk tools. Therefore it might be interesting to explore whether including a greater number of risk factors, particularly those identified by the WHO or Lancet Commision leads to improved predictive performance. Addressing this question would require cohort datasets that include comprehensive information on all relevant risk factors and maintain consistent age distributions. We suggest that future studies explore this issue in greater detail.</p><p id="para0052">A key aspect of dementia risk tools that requires better definition is the purpose of the tool. Some risk tools were developed as statistical models without a clear plan for use in clinical practice. Others were developed for use in clinics and others for primary prevention and primary care. If the goal is to maximise statistical prediction, then the specific risk factors included (e.g. risk indicators) do not matter. However, if the tool has been developed with the aim of providing information for practical risk reduction, then it is essential that the tools include relevant factors that can effectively guide intervention.</p></sec><sec id="sec0035"><label>5</label><title>Conclusion</title><p id="para0053">Dementia is a major cause of disability and dependence in older adults, highlighting the urgent need to identify those at high risk early. Numerous dementia risk scores have been developed as statistical models, with a few being adapted into affordable risk assessment tools. Risk scores that include modifiable risk factors offer effective, inexpensive and valid risk assessment and align with dementia risk reduction guidelines, making them a practical approach for prevention.</p></sec><sec id="sec0036"><title>Source of funding</title><p id="para0055">This project is funded by NHMRC GNT1171279. KA is funded by ARC laureate Fellowship FL190100011.</p></sec><sec id="sec0037"><title>Author&#8217;s contribution</title><p id="para0056">KA developed the project, wrote the first draft and supervised the project. HH, RE and ML conducted systematic review of literature. HH and ML independently extracted the data. HH conducted the statistical analysis and drafted sections of the results. HH, RE, ML, and KA prepared figures and tables. KA, RP and KK obtained funding. All authors provided critical review and contribution to the draft.</p></sec><sec id="sec0037a"><title>CRediT authorship contribution statement</title><p id="para0056a"><bold>Md Hamidul Huque:</bold> Writing &#8211; review &amp; editing, Methodology, Formal analysis. <bold>Ranmalee Eramudugolla:</bold> Visualization, Formal analysis, Data curation. <bold>Meiwei Li:</bold> Visualization, Data curation. <bold>Kim M. Kiely:</bold> Funding acquisition. <bold>Ruth Peters:</bold> Funding acquisition. <bold>Kaarin J. Anstey:</bold> Writing &#8211; original draft, Supervision, Investigation, Funding acquisition, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0058">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadi-Abhari</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study</article-title><source>bmj</source><volume>358</volume><year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.j2856</pub-id><pub-id pub-id-type="pmcid">PMC5497174</pub-id><pub-id pub-id-type="pmid">28679494</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Dementia incidence trend in England and Wales, 2002&#8211;19, and projection for dementia burden to 2040: analysis of data from the English Longitudinal Study of Ageing</article-title><source>Lancet Public Health</source><volume>8</volume><issue>11</issue><year>2023</year><fpage>e859</fpage><lpage>e867</lpage><pub-id pub-id-type="pmid">37898518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-2667(23)00214-1</pub-id><pub-id pub-id-type="pmcid">PMC10958989</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Nakahori</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Future projections of the prevalence of dementia in Japan: results from the Toyama Dementia Survey</article-title><source>BMC Geriatr</source><volume>21</volume><year>2021</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">34702187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12877-021-02540-z</pub-id><pub-id pub-id-type="pmcid">PMC8546941</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Ebell</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of Alzheimer disease: a systematic review and meta-analysis</article-title><source>Ann. Fam. Med.</source><volume>22</volume><issue>1</issue><year>2024</year><fpage>50</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">38253509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1370/afm.3050</pub-id><pub-id pub-id-type="pmcid">PMC11233076</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A whole-population approach is required for dementia risk reduction</article-title><source>Lancet Healthy Longev.</source><volume>3</volume><issue>1</issue><year>2022</year><fpage>e6</fpage><lpage>e8</lpage><pub-id pub-id-type="pmid">36098322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-7568(21)00301-9</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission</article-title><source>Lancet</source><year>2024</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)01296-0</pub-id><pub-id pub-id-type="pmid">39096926</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Eramudugolla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>R.A.</given-names></name></person-group><article-title>Contributions of a risk assessment approach to the prevention of Alzheimer's disease and dementia</article-title><source>J. Alzheimer's Dis.</source><volume>42</volume><issue>s4</issue><year>2014</year><fpage>S463</fpage><lpage>S473</lpage><pub-id pub-id-type="pmid">25114084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-141248</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>A systematic review of meta-analyses that evaluate risk factors for dementia to evaluate the quantity, quality, and global representativeness of evidence</article-title><source>J. Alzheimer's Dis.</source><volume>70</volume><issue>s1</issue><year>2019</year><fpage>S165</fpage><lpage>S186</lpage><pub-id pub-id-type="pmid">31306123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-190181</pub-id><pub-id pub-id-type="pmcid">PMC6700718</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.-R.</given-names></name><etal/></person-group><article-title>Modifiable risk factors for incident dementia and cognitive impairment: an umbrella review of evidence</article-title><source>J Affect Disord</source><volume>314</volume><year>2022</year><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">35863541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2022.07.008</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><mixed-citation publication-type="other" id="sbref0010">World Health Organization, Risk reduction of cognitive decline and dementia: WHO guidelines. 2019.<pub-id pub-id-type="pmid">31219687</pub-id></mixed-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis</article-title><source>Eur. Heart J</source><volume>43</volume><issue>48</issue><year>2022</year><fpage>4980</fpage><lpage>4990</lpage><pub-id pub-id-type="pmid">36282295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehac584</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Brain</surname><given-names>J.</given-names></name><etal/></person-group><article-title>What&#8217;s new in dementia risk prediction modelling? An updated systematic review</article-title><source>Dement Geriatr Cogn Dis Extra</source><volume>14</volume><issue>1</issue><year>2024</year><fpage>49</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">39015518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000539744</pub-id><pub-id pub-id-type="pmcid">PMC11250535</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X.-H.</given-names></name><etal/></person-group><article-title>Models for predicting risk of dementia: a systematic review</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><volume>90</volume><issue>4</issue><year>2019</year><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">29954871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2018-318212</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Cherbuin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herath</surname><given-names>P.M.</given-names></name></person-group><article-title>Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention</article-title><source>Prev Sci</source><volume>14</volume><issue>4</issue><year>2013</year><fpage>411</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">23319292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11121-012-0313-2</pub-id><pub-id pub-id-type="pmcid">PMC3696462</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Development of the CogDrisk tool to assess risk factors for dementia</article-title><source>Alzheimers Dement (Amst)</source><volume>14</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">e12336</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12336</pub-id><pub-id pub-id-type="pmcid">PMC9275658</pub-id><pub-id pub-id-type="pmid">35845259</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Variation in real world dementia risk profiles in 6171 adults drawn from the Australian CogDrisk website according to demographic characteristics</article-title><source>medRxiv</source><volume>2025</volume><issue>07</issue><year>2025</year><comment>24.25332109</comment></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Licher</surname><given-names>S.</given-names></name><etal/></person-group><article-title>External validation of four dementia prediction models for use in the general community-dwelling population: a comparative analysis from the Rotterdam Study</article-title><source>Eur, J. Epidemiol</source><volume>33</volume><year>2018</year><fpage>645</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">29740780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-018-0403-y</pub-id><pub-id pub-id-type="pmcid">PMC6061119</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Reuben</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Improving risk indexes for Alzheimer&#8217;s disease and related dementias for use in midlife</article-title><source>Brain commun.</source><volume>4</volume><issue>5</issue><year>2022</year><fpage>fcac223</fpage><pub-id pub-id-type="pmid">36213312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcac223</pub-id><pub-id pub-id-type="pmcid">PMC9535507</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Anat&#252;rk</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Development and validation of a dementia risk score in the UK Biobank and Whitehall II cohorts</article-title><source>BMJ Ment. Health</source><volume>26</volume><issue>1</issue><year>2023</year><object-id pub-id-type="publisher-id">e300719</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjment-2023-300719</pub-id><pub-id pub-id-type="pmcid">PMC10577770</pub-id><pub-id pub-id-type="pmid">37603383</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Dementia risk scores and their role in the implementation of risk reduction guidelines</article-title><source>Front Neurol</source><volume>12</volume><year>2022</year><fpage>2436</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.765454</pub-id><pub-id pub-id-type="pmcid">PMC8764151</pub-id><pub-id pub-id-type="pmid">35058873</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Wolff</surname><given-names>R.F.</given-names></name><etal/></person-group><article-title>PROBAST: a tool to assess the risk of bias and applicability of prediction model studies</article-title><source>Ann, Intern, Med</source><volume>170</volume><issue>1</issue><year>2019</year><fpage>51</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">30596875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M18-1376</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study</article-title><source>Lancet Neurol</source><volume>5</volume><issue>9</issue><year>2006</year><fpage>735</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">16914401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(06)70537-3</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Eskelinen</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>Midlife healthy-diet index and late-life dementia and Alzheimer's disease</article-title><source>Dement Geriatr Cogn Dis Extra</source><volume>1</volume><issue>1</issue><year>2011</year><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">22163237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000327518</pub-id><pub-id pub-id-type="pmcid">PMC3199886</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Vuoksimaa</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Middle age self-report risk score predicts cognitive functioning and dementia in 20-40 years</article-title><source>Alzheimers Dement (Amst)</source><volume>4</volume><year>2016</year><fpage>118</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">27752535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2016.08.003</pub-id><pub-id pub-id-type="pmcid">PMC5061466</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Predicting mid-and late-life dementia risk in primary care: a prognostic study from a national health screening cohort</article-title><source>Psychiatry Res</source><volume>342</volume><year>2024</year><object-id pub-id-type="publisher-id">116237</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psychres.2024.116237</pub-id><pub-id pub-id-type="pmid">39476452</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Deckers</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies</article-title><source>Int J Geriatr Psychiatry</source><volume>30</volume><issue>3</issue><year>2015</year><fpage>234</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">25504093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.4245</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Development of a clinical risk score prediction tool for 5-, 9-, and 13-year risk of dementia</article-title><source>JAMA Netw Open</source><volume>5</volume><issue>11</issue><year>2022</year><object-id pub-id-type="publisher-id">e2242596</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.42596</pub-id><pub-id pub-id-type="pmcid">PMC9672974</pub-id><pub-id pub-id-type="pmid">36394871</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>T.P.</given-names></name><etal/></person-group><article-title>Development, validation and field evaluation of the Singapore Longitudinal Ageing Study (SLAS) Risk Index for prediction of mild cognitive impairment and dementia</article-title><source>J Prev Alzheimers Dis</source><volume>8</volume><issue>3</issue><year>2021</year><fpage>335</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">34101792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2021.19</pub-id><pub-id pub-id-type="pmcid">PMC12280715</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>D.E.</given-names></name><etal/></person-group><article-title>Development and validation of a brief dementia screening indicator for primary care</article-title><source>Alzheimers Dement</source><volume>10</volume><issue>6</issue><year>2014</year><fpage>656</fpage><lpage>665</lpage><comment>.e1</comment><pub-id pub-id-type="pmid">24491321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2013.11.006</pub-id><pub-id pub-id-type="pmcid">PMC4119094</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Ibarrondo</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Dementia risk score for a population in Southern Europe calculated using competing risk models</article-title><source>J Alzheimers Dis</source><volume>86</volume><issue>4</issue><year>2022</year><fpage>1751</fpage><lpage>1762</lpage><pub-id pub-id-type="pmid">35253747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215211</pub-id><pub-id pub-id-type="pmcid">PMC9108562</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Predicting mid- and late-life dementia risk in primary care: a prognostic study from a national health screening cohort</article-title><source>Psychiatry Res</source><volume>342</volume><year>2024</year><object-id pub-id-type="publisher-id">116237</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psychres.2024.116237</pub-id><pub-id pub-id-type="pmid">39476452</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Walters</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Predicting dementia risk in primary care: development and validation of the Dementia Risk Score using routinely collected data</article-title><source>BMC Med</source><volume>14</volume><issue>1</issue><year>2016</year><fpage>6</fpage><pub-id pub-id-type="pmid">26797096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-016-0549-y</pub-id><pub-id pub-id-type="pmcid">PMC4722622</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Tolea</surname><given-names>M.I.</given-names></name><etal/></person-group><article-title>A modified CAIDE risk score as a screening tool for cognitive impairment in older adults</article-title><source>J Alzheimers Dis</source><volume>82</volume><issue>4</issue><year>2021</year><fpage>1755</fpage><lpage>1768</lpage><pub-id pub-id-type="pmid">34219721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-210269</pub-id><pub-id pub-id-type="pmcid">PMC8483620</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Chosy</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>The CAIDE dementia risk Score and the Honolulu-Asia Aging Study</article-title><source>Dement Geriatr Cogn Disord</source><volume>48</volume><issue>3&#8211;4</issue><year>2019</year><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">31968337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000504801</pub-id><pub-id pub-id-type="pmcid">PMC9620982</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Exalto</surname><given-names>L.G.</given-names></name><etal/></person-group><article-title>Midlife risk score for the prediction of dementia four decades later</article-title><source>Alzheimers Dement</source><volume>10</volume><issue>5</issue><year>2014</year><fpage>562</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">24035147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2013.05.1772</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Huque</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>CogDrisk, ANU-ADRI, CAIDE, and LIBRA risk scores for estimating dementia risk</article-title><source>JAMA Netw Open</source><volume>6</volume><issue>8</issue><year>2023</year><object-id pub-id-type="publisher-id">e2331460</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.31460</pub-id><pub-id pub-id-type="pmcid">PMC10469268</pub-id><pub-id pub-id-type="pmid">37647064</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Stephan</surname><given-names>B.C.M.</given-names></name><etal/></person-group><article-title>Prediction of dementia risk in low-income and middle-income countries (the 10/66 Study): an independent external validation of existing models</article-title><source>Lancet Glob Health</source><volume>8</volume><issue>4</issue><year>2020</year><fpage>e524</fpage><lpage>e535</lpage><pub-id pub-id-type="pmid">32199121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(20)30062-0</pub-id><pub-id pub-id-type="pmcid">PMC7090906</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Kootar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Validation of the CogDrisk Instrument as predictive of dementia in four general community-dwelling populations</article-title><source>J Prev Alzheimers Dis</source><volume>10</volume><issue>3</issue><year>2023</year><fpage>478</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">37357288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2023.38</pub-id><pub-id pub-id-type="pmcid">PMC10449369</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Capuano</surname><given-names>A.W.</given-names></name><etal/></person-group><article-title>Derivation and validation of the Rapid Assessment of Dementia Risk (RADaR) for older adults</article-title><source>PLoS One</source><volume>17</volume><issue>3</issue><year>2022</year><object-id pub-id-type="publisher-id">e0265379</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0265379</pub-id><pub-id pub-id-type="pmcid">PMC8929636</pub-id><pub-id pub-id-type="pmid">35299231</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Licher</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Development and validation of a dementia risk prediction model in the general population: an analysis of three longitudinal studies</article-title><source>Am J Psychiatry</source><volume>176</volume><issue>7</issue><year>2019</year><fpage>543</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">30525906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2018.18050566</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Dharmasaroja</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Charernboon</surname><given-names>T.</given-names></name></person-group><article-title>Clinical risk score for predicting vascular dementia after ischemic stroke in Thailand</article-title><source>Stroke Res Treat</source><volume>2022</volume><year>2022</year><object-id pub-id-type="publisher-id">1600444</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/1600444</pub-id><pub-id pub-id-type="pmcid">PMC9529475</pub-id><pub-id pub-id-type="pmid">36199625</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.T.</given-names></name><etal/></person-group><article-title>Modified dementia risk score as a tool for the prediction of dementia: a prospective cohort study of 239745 participants</article-title><source>Transl Psychiatry</source><volume>12</volume><issue>1</issue><year>2022</year><fpage>509</fpage><pub-id pub-id-type="pmid">36496374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-022-02269-2</pub-id><pub-id pub-id-type="pmcid">PMC9741578</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>H.B.</given-names></name><etal/></person-group><article-title>Development and validation of the RxDx-Dementia risk index to predict dementia in patients with type 2 diabetes and hypertension</article-title><source>J Alzheimers Dis</source><volume>49</volume><issue>2</issue><year>2016</year><fpage>423</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">26519436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-150466</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Cardiovascular health metrics from mid- to late-life and risk of dementia: a population-based cohort study in Finland</article-title><source>PLoS Med</source><volume>17</volume><issue>12</issue><year>2020</year><object-id pub-id-type="publisher-id">e1003474</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1003474</pub-id><pub-id pub-id-type="pmcid">PMC7737898</pub-id><pub-id pub-id-type="pmid">33320852</pub-id></element-citation></ref><ref id="bib0045"><label>45</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Huque</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>A single risk assessment for the most common diseases of ageing, developed and validated on 10 cohort studies</article-title><source>BMC Med</source><volume>22</volume><issue>1</issue><year>2024</year><fpage>501</fpage><pub-id pub-id-type="pmid">39482675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-024-03711-6</pub-id><pub-id pub-id-type="pmcid">PMC11526665</pub-id></element-citation></ref><ref id="bib0046"><label>46</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Makino</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Development and validation of new screening tool for predicting dementia risk in community-dwelling older Japanese adults</article-title><source>J Transl Med</source><volume>19</volume><issue>1</issue><year>2021</year><fpage>448</fpage><pub-id pub-id-type="pmid">34702306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-021-03121-9</pub-id><pub-id pub-id-type="pmcid">PMC8549197</pub-id></element-citation></ref><ref id="bib0047"><label>47</label><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Santabarbara</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A novel score for predicting Alzheimer's Disease risk from late life psychopathological and health risk factors</article-title><source>Int J Env. Res Public Health</source><volume>18</volume><issue>4</issue><year>2021</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph18041802</pub-id><pub-id pub-id-type="pmcid">PMC7918511</pub-id><pub-id pub-id-type="pmid">33673250</pub-id></element-citation></ref><ref id="bib0048"><label>48</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Development and validation of the Florey Dementia Risk Score web-based tool to screen for Alzheimer's disease in primary care</article-title><source>eClinicalMedicine</source><volume>76</volume><year>2024</year><object-id pub-id-type="publisher-id">102834</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2024.102834</pub-id><pub-id pub-id-type="pmcid">PMC11426130</pub-id><pub-id pub-id-type="pmid">39328810</pub-id></element-citation></ref><ref id="bib0049"><label>49</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Social environment, lifestyle, and genetic predisposition with dementia risk: a long-term longitudinal study among older adults</article-title><source>J. Gerontol.: A</source><volume>79</volume><issue>7</issue><year>2024</year><fpage>glae128</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glae128</pub-id><pub-id pub-id-type="pmcid">PMC11184450</pub-id><pub-id pub-id-type="pmid">38733088</pub-id></element-citation></ref><ref id="bib0050"><label>50</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>T.C.</given-names></name><etal/></person-group><article-title>Development and validation of the dialysis dementia risk score: a retrospective, population-based, nested case-control study</article-title><source>Eur J Neurol</source><volume>29</volume><issue>1</issue><year>2022</year><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">34561939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.15123</pub-id><pub-id pub-id-type="pmcid">PMC9293339</pub-id></element-citation></ref><ref id="bib0051"><label>51</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.L.</given-names></name></person-group><article-title>Comparison of CHA(2)DS(2)-VASc and AHEAD scores for the prediction of incident dementia in patients hospitalized for heart failure: a nationwide cohort study</article-title><source>Intern Emerg Med</source><volume>14</volume><issue>3</issue><year>2019</year><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">30306322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11739-018-1961-4</pub-id></element-citation></ref><ref id="bib0052"><label>52</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>D.E.</given-names></name><etal/></person-group><article-title>A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease</article-title><source>Alzheimers Dement</source><volume>10</volume><issue>6</issue><year>2014</year><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">24495339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2013.12.014</pub-id><pub-id pub-id-type="pmcid">PMC4119093</pub-id></element-citation></ref><ref id="bib0054"><label>53</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Grande</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Blood-based biomarkers of Alzheimer&#8217;s disease and incident dementia in the community</article-title><source>Nat, Med</source><year>2025</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">40140622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-025-03605-x</pub-id><pub-id pub-id-type="pmcid">PMC12176656</pub-id></element-citation></ref><ref id="bib0055"><label>54</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Lipnicki</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Low</surname><given-names>L.-F.</given-names></name></person-group><article-title>Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis</article-title><source>Am J Geriatr Psychiatry</source><volume>16</volume><issue>5</issue><year>2008</year><fpage>343</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">18448847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JGP.0b013e31816b72d4</pub-id></element-citation></ref><ref id="bib0056"><label>55</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>A self-report risk index to predict occurrence of dementia in three independent cohorts of older adults: the ANU-ADRI</article-title><source>PLoS One</source><volume>9</volume><issue>1</issue><year>2014</year><object-id pub-id-type="publisher-id">e86141</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0086141</pub-id><pub-id pub-id-type="pmcid">PMC3900468</pub-id><pub-id pub-id-type="pmid">24465922</pub-id></element-citation></ref><ref id="bib0057"><label>56</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Ranson</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services&#8212;Part 2 of 6</article-title><source>Alzheimers Res Ther</source><volume>13</volume><issue>1</issue><year>2021</year><fpage>169</fpage><pub-id pub-id-type="pmid">34635138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-021-00895-4</pub-id><pub-id pub-id-type="pmcid">PMC8507172</pub-id></element-citation></ref><ref id="bib0058"><label>57</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Huque</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Could country-level factors explain sex differences in dementia incidence and prevalence? A systematic review and meta-analysis</article-title><source>J. Alzheimer's Dis.</source><issue>Preprint</issue><year>2022</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220724</pub-id><pub-id pub-id-type="pmcid">PMC9986694</pub-id><pub-id pub-id-type="pmid">36565114</pub-id></element-citation></ref><ref id="bib0059"><label>58</label><element-citation publication-type="journal" id="sbref0059"><person-group person-group-type="author"><name name-style="western"><surname>Huque</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Development of a midlife specific CogDrisk algorithm (CogDrisk-ML) to enable validated implementation of dementia risk assessment from midlife to late-life</article-title><source>Age Ageing 2025</source><volume>54</volume><issue>7</issue><year>2025</year><fpage>afaf201</fpage><pub-id pub-id-type="doi">10.1093/ageing/afaf201</pub-id><pub-id pub-id-type="pmcid">PMC12277239</pub-id><pub-id pub-id-type="pmid">40685637</pub-id></element-citation></ref><ref id="bib0060"><label>59</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Fayosse</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Risk prediction models for dementia: role of age and cardiometabolic risk factors</article-title><source>BMC Med</source><volume>18</volume><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">32423410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-020-01578-x</pub-id><pub-id pub-id-type="pmcid">PMC7236124</pub-id></element-citation></ref><ref id="bib0061"><label>60</label><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Plasma proteomic profiles predict future dementia in healthy adults</article-title><source>Nat. Aging</source><year>2024</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">38347190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00565-0</pub-id></element-citation></ref><ref id="bib0062"><label>61</label><element-citation publication-type="journal" id="sbref0062"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Plasma metabolomic profiles of dementia: a prospective study of 110,655 participants in the UK Biobank</article-title><source>BMC Med</source><volume>20</volume><issue>1</issue><year>2022</year><fpage>252</fpage><pub-id pub-id-type="pmid">35965319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-022-02449-3</pub-id><pub-id pub-id-type="pmcid">PMC9377110</pub-id></element-citation></ref><ref id="bib0063"><label>62</label><element-citation publication-type="journal" id="sbref0063"><person-group person-group-type="author"><name name-style="western"><surname>Kivim&#228;ki</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Estimating dementia risk using multifactorial prediction models</article-title><source>JAMA Netw. Open</source><volume>6</volume><issue>6</issue><year>2023</year><object-id pub-id-type="publisher-id">e2318132</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.18132</pub-id><pub-id pub-id-type="pmcid">PMC10265307</pub-id><pub-id pub-id-type="pmid">37310738</pub-id></element-citation></ref><ref id="bib0064"><label>63</label><element-citation publication-type="journal" id="sbref0064"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Plasma proteomics for risk prediction of Alzheimer's disease in the general population</article-title><source>Aging Cell</source><year>2024</year><object-id pub-id-type="publisher-id">e14330</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.14330</pub-id><pub-id pub-id-type="pmcid">PMC11634738</pub-id><pub-id pub-id-type="pmid">39252463</pub-id></element-citation></ref></ref-list><sec id="sec0039" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0054a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgement</title><p id="para0057">We thank Charlotte Harper-Cass for her assistance.</p></ack><fn-group><fn id="sec0038" fn-type="supplementary-material"><p id="para0006a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100333" id="interref0005">doi:10.1016/j.tjpad.2025.100333</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jnc70252" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurochem</journal-id><journal-id journal-id-type="iso-abbrev">J Neurochem</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">JNC</journal-id><journal-title-group><journal-title>Journal of Neurochemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-3042</issn><issn pub-type="epub">1471-4159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501489</article-id><article-id pub-id-type="pmcid-ver">PMC12501489.1</article-id><article-id pub-id-type="pmcaid">12501489</article-id><article-id pub-id-type="pmcaiid">12501489</article-id><article-id pub-id-type="pmid">41054216</article-id><article-id pub-id-type="doi">10.1111/jnc.70252</article-id><article-id pub-id-type="publisher-id">JNC70252</article-id><article-id pub-id-type="other">JNC-2025-0475.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Astrocytes as Metabolic Sensors Orchestrating Energy&#8208;Driven Brain Vulnerability in Alzheimer's Disease</article-title></title-group><contrib-group><contrib id="jnc70252-cr-0001" contrib-type="author"><name name-style="western"><surname>S&#225;nchez de Muniain</surname><given-names initials="L">Leyre</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-4487-935X</contrib-id><xref rid="jnc70252-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jnc70252-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jnc70252-cr-0002" contrib-type="author"><name name-style="western"><surname>Escalada</surname><given-names initials="P">Paula</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-5164-9410</contrib-id><xref rid="jnc70252-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jnc70252-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jnc70252-cr-0003" contrib-type="author"><name name-style="western"><surname>Ram&#237;rez</surname><given-names initials="MJ">Mar&#237;a J.</given-names></name><xref rid="jnc70252-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jnc70252-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jnc70252-cr-0004" contrib-type="author" corresp="yes"><name name-style="western"><surname>Solas</surname><given-names initials="M">Maite</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7670-3237</contrib-id><xref rid="jnc70252-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jnc70252-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>msolaszu@unav.es</email></address></contrib></contrib-group><aff id="jnc70252-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmaceutical Sciences</named-content>
<institution>University of Navarra</institution>
<city>Pamplona</city>
<country country="ES">Spain</country>
</aff><aff id="jnc70252-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>IdiSNA, Navarra Institute for Health Research</institution>
<city>Pamplona</city>
<country country="ES">Spain</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Maite Solas (<email>msolaszu@unav.es</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2025</year></pub-date><volume>169</volume><issue seq="150">10</issue><issue-id pub-id-type="pmc-issue-id">498441</issue-id><issue-id pub-id-type="doi">10.1111/jnc.v169.10</issue-id><elocation-id>e70252</elocation-id><history><date date-type="rev-recd"><day>12</day><month>9</month><year>2025</year></date><date date-type="received"><day>08</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Journal of Neurochemistry</italic> published by John Wiley &amp; Sons Ltd on behalf of International Society for Neurochemistry.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JNC-169-0.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:JNC-169-0.pdf"/><abstract><title>ABSTRACT</title><p>Alzheimer's disease (AD), the leading neurodegenerative disorder linked to aging, emerges within a paradoxical metabolic landscape. Despite rising cellular energy demands due to accumulated damage and stress, overall energy expenditure remains stable or declines with age. The brain, acting as the central regulator, responds to hypermetabolic signals from aged tissues by activating energy&#8208;conserving mechanisms. In this scenario, astrocytes, strategically located between blood vessels and neurons, play a pivotal role as energy sensors, adapting to systemic stress and modulating brain metabolism. This review explores how astrocytes undergo metabolic reprogramming in the early stages, potentially becoming maladaptive over time, fueling neuroinflammation, oxidative stress, and accelerating AD. By understanding astrocyte energetics, we uncover new avenues for biomarkers and therapies that could transform AD treatment.</p><p>
<boxed-text position="anchor" content-type="graphic" id="jnc70252-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="JNC-169-0-g004.jpg"/></boxed-text>
</p></abstract><abstract abstract-type="graphical"><p>Alzheimer's disease unfolds within a paradoxical metabolic milieu, where rising cellular energy demands contrast with declining systemic expenditure. Astrocytes, strategically located at the neurovascular interface, act as metabolic sentinels that dynamically reprogram their glycolytic and oxidative pathways in response to aging and peripheral hypermetabolic cues. Evidence supports a biphasic trajectory: an early, neuroprotective hypermetabolic state followed by a late hypometabolic decline that undermines neuronal support. This dynamic astrocytic metabolism offers distinct therapeutic windows to modulate neuroinflammation and preserve cognitive function.<boxed-text position="anchor" content-type="graphic" id="jnc70252-blkfxd-0002" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="JNC-169-0-g002.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jnc70252-kwd-0001">aging</kwd><kwd id="jnc70252-kwd-0002">allostasis</kwd><kwd id="jnc70252-kwd-0003">glycolysis</kwd><kwd id="jnc70252-kwd-0004">hypermetabolism</kwd><kwd id="jnc70252-kwd-0005">neurodegeneration</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>MCIN/AEI/10.13039/501100011033</institution></institution-wrap></funding-source><award-id>PID2021&#8208;128737NB&#8208;I00</award-id></award-group></funding-group><counts><fig-count count="6"/><table-count count="0"/><page-count count="17"/><word-count count="13900"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jnc70252-cit-1001"><string-name name-style="western"><surname>S&#225;nchez de Muniain</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Escalada</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Ram&#237;rez</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Solas</surname></string-name>. <year>2025</year>. &#8220;<article-title>Astrocytes as Metabolic Sensors Orchestrating Energy&#8208;Driven Brain Vulnerability in Alzheimer's Disease</article-title>.&#8221; <source>Journal of Neurochemistry</source><volume>169</volume>, no. <issue>10</issue>: <elocation-id>e70252</elocation-id>. <pub-id pub-id-type="doi">10.1111/jnc.70252</pub-id>.<pub-id pub-id-type="pmid">41054216</pub-id></mixed-citation>
</p><fn-group id="jnc70252-ntgp-0001"><fn fn-type="funding" id="jnc70252-note-0001"><p>
<bold>Funding:</bold> This work was supported by MCIN/AEI/10.13039/501100011033, PID2021&#8208;128737NB&#8208;I00.</p></fn></fn-group></notes></front><body id="jnc70252-body-0001"><def-list list-content="abbreviations" id="jnc70252-dl-0001"><title>Abbreviations</title><def-item><term id="jnc70252-li-0001">[11C]BU99008</term><def id="jnc70252-li-0002"><p>PET radiotracer targeting imidazoline2&#8208;binding sites</p></def></def-item><def-item><term id="jnc70252-li-0003">[18F]FDG&#8208;PET</term><def id="jnc70252-li-0004"><p>Fluorodeoxyglucose positron emission tomography (18F&#8208;labeled)</p></def></def-item><def-item><term id="jnc70252-li-0005">AD</term><def id="jnc70252-li-0006"><p>Alzheimer's disease</p></def></def-item><def-item><term id="jnc70252-li-0007">AGEs</term><def id="jnc70252-li-0008"><p>advanced glycation end&#8208;products</p></def></def-item><def-item><term id="jnc70252-li-0009">APP</term><def id="jnc70252-li-0010"><p>amyloid precursor protein</p></def></def-item><def-item><term id="jnc70252-li-0011">ATP</term><def id="jnc70252-li-0012"><p>adenosine triphosphate</p></def></def-item><def-item><term id="jnc70252-li-0013">A&#946;</term><def id="jnc70252-li-0014"><p>amyloid beta</p></def></def-item><def-item><term id="jnc70252-li-0015">BBB</term><def id="jnc70252-li-0016"><p>blood&#8211;brain barrier</p></def></def-item><def-item><term id="jnc70252-li-0017">BEC</term><def id="jnc70252-li-0018"><p>brain&#8211;body energy conservation</p></def></def-item><def-item><term id="jnc70252-li-0019">Ca<sup>2+</sup>
</term><def id="jnc70252-li-0020"><p>calcium</p></def></def-item><def-item><term id="jnc70252-li-0021">CNS</term><def id="jnc70252-li-0022"><p>central nervous system</p></def></def-item><def-item><term id="jnc70252-li-0023">CSF</term><def id="jnc70252-li-0024"><p>Cerebrospinal fluid</p></def></def-item><def-item><term id="jnc70252-li-0025">DED</term><def id="jnc70252-li-0026"><p>Deuterium&#8208;labeled radiotracer (in [11C]DED PET imaging)</p></def></def-item><def-item><term id="jnc70252-li-0027">ETC</term><def id="jnc70252-li-0028"><p>electron transport chain</p></def></def-item><def-item><term id="jnc70252-li-0029">FAO</term><def id="jnc70252-li-0030"><p>fatty acid oxidation</p></def></def-item><def-item><term id="jnc70252-li-0031">FDG&#8208;PET</term><def id="jnc70252-li-0032"><p>Fluorodeoxyglucose positron emission tomography</p></def></def-item><def-item><term id="jnc70252-li-0033">GFAP</term><def id="jnc70252-li-0034"><p>glial fibrillary acidic protein</p></def></def-item><def-item><term id="jnc70252-li-0035">Glx</term><def id="jnc70252-li-0036"><p>glutamate + glutamine</p></def></def-item><def-item><term id="jnc70252-li-0037">GR</term><def id="jnc70252-li-0038"><p>glucocorticoid receptor</p></def></def-item><def-item><term id="jnc70252-li-0039">GSH</term><def id="jnc70252-li-0040"><p>glutathione reduced form</p></def></def-item><def-item><term id="jnc70252-li-0041">HIF1</term><def id="jnc70252-li-0042"><p>Hypoxia&#8208;inducible factor 1</p></def></def-item><def-item><term id="jnc70252-li-0043">HPA</term><def id="jnc70252-li-0044"><p>hypothalamic&#8211;pituitary&#8211;adrenal</p></def></def-item><def-item><term id="jnc70252-li-0045">KBs</term><def id="jnc70252-li-0046"><p>ketone bodies</p></def></def-item><def-item><term id="jnc70252-li-0047">LD</term><def id="jnc70252-li-0048"><p>lipid droplet</p></def></def-item><def-item><term id="jnc70252-li-0049">MAO&#8208;B</term><def id="jnc70252-li-0050"><p>Monoamine oxidase B</p></def></def-item><def-item><term id="jnc70252-li-0051">MCI</term><def id="jnc70252-li-0052"><p>mild cognitive impairment</p></def></def-item><def-item><term id="jnc70252-li-0053">MeS</term><def id="jnc70252-li-0054"><p>metabolic syndrome</p></def></def-item><def-item><term id="jnc70252-li-0055">MRI</term><def id="jnc70252-li-0056"><p>magnetic resonance imaging</p></def></def-item><def-item><term id="jnc70252-li-0057">mROS</term><def id="jnc70252-li-0058"><p>mitochondrial reactive oxygen species</p></def></def-item><def-item><term id="jnc70252-li-0059">MRS</term><def id="jnc70252-li-0060"><p>magnetic resonance spectroscopy</p></def></def-item><def-item><term id="jnc70252-li-0061">mtDNA</term><def id="jnc70252-li-0062"><p>mitochondrial DNA</p></def></def-item><def-item><term id="jnc70252-li-0063">Nf&#8208;&#954;B</term><def id="jnc70252-li-0064"><p>nuclear factor kappa&#8208;light&#8208;chain&#8208;enhancer of activated B cells</p></def></def-item><def-item><term id="jnc70252-li-0065">NO</term><def id="jnc70252-li-0066"><p>nitric oxide</p></def></def-item><def-item><term id="jnc70252-li-0067">NRF2</term><def id="jnc70252-li-0068"><p>nuclear factor erythroid 2&#8208;related factor 2</p></def></def-item><def-item><term id="jnc70252-li-0069">OxPhos</term><def id="jnc70252-li-0070"><p>oxidative phosphorylation</p></def></def-item><def-item><term id="jnc70252-li-0071">PET</term><def id="jnc70252-li-0072"><p>positron emission tomography</p></def></def-item><def-item><term id="jnc70252-li-0073">PGE2</term><def id="jnc70252-li-0074"><p>Prostaglandin E2</p></def></def-item><def-item><term id="jnc70252-li-0075">ROS</term><def id="jnc70252-li-0076"><p>reactive oxygen species</p></def></def-item><def-item><term id="jnc70252-li-0077">SASP</term><def id="jnc70252-li-0078"><p>senescence&#8208;associated secretory phenotype</p></def></def-item><def-item><term id="jnc70252-li-0079">STAT3</term><def id="jnc70252-li-0080"><p>signal transducer and activator of transcription 3</p></def></def-item><def-item><term id="jnc70252-li-0081">T2DM</term><def id="jnc70252-li-0082"><p>type 2 diabetes mellitus</p></def></def-item><def-item><term id="jnc70252-li-0083">Tau</term><def id="jnc70252-li-0084"><p>tau protein</p></def></def-item></def-list><sec id="jnc70252-sec-0001"><label>1</label><title>Reprogramming Energy Sensing in the Aging Brain: The Astrocytic Link to Alzheimer's Disease</title><p>Aging, the main risk factor for Alzheimer's disease (AD), entails seemingly paradoxical shifts in energy metabolism (L&#243;pez&#8208;Ot&#237;n et&#160;al.&#160;<xref rid="jnc70252-bib-0121" ref-type="bibr">2016</xref>; Moqri et&#160;al.&#160;<xref rid="jnc70252-bib-0027" ref-type="bibr">2023</xref>; Kaeberlein et&#160;al.&#160;<xref rid="jnc70252-bib-0103" ref-type="bibr">2015</xref>; L&#243;pez&#8208;Ot&#237;n et&#160;al.&#160;<xref rid="jnc70252-bib-0120" ref-type="bibr">2023</xref>; Wiley and Campisi&#160;<xref rid="jnc70252-bib-0216" ref-type="bibr">2021</xref>). While the accumulation of molecular damage increases cellular energy demands, overall energy expenditure at the whole&#8208;body level remains stable or even declines with age (Moldakozhayev and Gladyshev&#160;<xref rid="jnc70252-bib-0136" ref-type="bibr">2023</xref>; Sturm, Bobba&#8208;Alves, et&#160;al.&#160;<xref rid="jnc70252-bib-0198" ref-type="bibr">2023</xref>; Bobba&#8208;Alves et&#160;al.&#160;<xref rid="jnc70252-bib-0031" ref-type="bibr">2022</xref>; Wordsworth et&#160;al.&#160;<xref rid="jnc70252-bib-0219" ref-type="bibr">2023</xref>). This apparent contradiction can be explained by positioning the brain as the central mediator in the organism's energy economy. As somatic tissues accumulate damage over time, they activate energy&#8208;intensive stress responses&#8212;<italic toggle="yes">hypermetabolism</italic>&#8212;, and aging or senescent cells release cytokines or other factors signaling elevated cellular energy needs to the brain (de Magalh&#227;es&#160;<xref rid="jnc70252-bib-0055" ref-type="bibr">2024</xref>). In response, the brain initiates energy conservation mechanisms to manage the reduced energy budget. These mechanisms suppress lower&#8208;priority processes (Ferrucci et&#160;al.&#160;<xref rid="jnc70252-bib-0069" ref-type="bibr">2018</xref>), resulting in symptoms like fatigue, physical inactivity, diminished sensory capacities, immune changes, hormonal alterations, and brain atrophy that could lead to neurodegenerative diseases such as AD (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>) (Figure&#160;<xref rid="jnc70252-fig-0001" ref-type="fig">1</xref>). In this scenario, a pivotal question arises: <italic toggle="yes">which cells in the brain are responsible for sensing this hypermetabolic state?</italic> Due to their adaptive nature and strategic location, interfacing with both blood vessels and neurons, <italic toggle="yes">astrocytes</italic> are key in integrating and transmitting peripheral signals to central neuronal networks in the brain (Garc&#237;a&#8208;C&#225;ceres et&#160;al.&#160;<xref rid="jnc70252-bib-0078" ref-type="bibr">2019</xref>; Clasadonte and Prevot&#160;<xref rid="jnc70252-bib-0045" ref-type="bibr">2018</xref>; Chowen et&#160;al.&#160;<xref rid="jnc70252-bib-0043" ref-type="bibr">2016</xref>). Thus, the present proposal postulates that <italic toggle="yes">astrocytes</italic> are the <italic toggle="yes">primary energy sensors in the brain</italic> and the key drivers of the <italic toggle="yes">adaptive processes</italic> underpinning the aging&#8208;induced hypermetabolic state and playing a central role in neurodegeneration (Figure&#160;<xref rid="jnc70252-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="jnc70252-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Central control of hypermetabolic signals in aging. Astrocytes act as central energy sensors in the brain, detecting hypermetabolic states induced by aging. By integrating peripheral signals, they drive adaptive energy conservation processes, linking increased cellular energy demands to brain atrophy and neurodegeneration in Alzheimer's disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="JNC-169-0-g001.jpg"/></fig><p>Astrocytes monitor and integrate signals related to cellular energy demands and relay this information to support the brain's adaptive energy management strategies. Indeed, astrocytes undergo significant morphological, molecular, and functional changes in response to central nervous system (CNS) pathologies such as stroke, infections, epilepsy, and AD (Escartin et&#160;al.&#160;<xref rid="jnc70252-bib-0064" ref-type="bibr">2021</xref>). They are abundant in regions with amyloid&#8208;&#946; (A&#946;) or tau pathology, contributing to neuronal damage by releasing inflammatory cytokines, nitric oxide (NO), and reactive oxygen species (ROS) (Bezzi et&#160;al.&#160;<xref rid="jnc70252-bib-0025" ref-type="bibr">2001</xref>; Lemoine et&#160;al.&#160;<xref rid="jnc70252-bib-0113" ref-type="bibr">2017</xref>). Known as reactive astrocytes, they exhibit diverse, pathology&#8208;specific states (Escartin et&#160;al.&#160;<xref rid="jnc70252-bib-0064" ref-type="bibr">2021</xref>), which can be protective or harmful depending on the context (Liddelow et&#160;al.&#160;<xref rid="jnc70252-bib-0116" ref-type="bibr">2017</xref>; Diaz&#8208;Castro et&#160;al.&#160;<xref rid="jnc70252-bib-0057" ref-type="bibr">2019</xref>; Smith et&#160;al.&#160;<xref rid="jnc70252-bib-0192" ref-type="bibr">2020</xref>; Sanmarco et&#160;al.&#160;<xref rid="jnc70252-bib-0175" ref-type="bibr">2021</xref>; Wheeler et&#160;al.&#160;<xref rid="jnc70252-bib-0213" ref-type="bibr">2020</xref>; Hasel et&#160;al.&#160;<xref rid="jnc70252-bib-0086" ref-type="bibr">2021</xref>; Chun et&#160;al.&#160;<xref rid="jnc70252-bib-0044" ref-type="bibr">2020</xref>; O'Shea et&#160;al.&#160;<xref rid="jnc70252-bib-0146" ref-type="bibr">2024</xref>). These states are marked by <italic toggle="yes">metabolic and functional adaptations</italic>, such as <italic toggle="yes">changes in glycolytic and lipid metabolism</italic>, critical for <italic toggle="yes">meeting increased energy demands</italic> (Morita et&#160;al.&#160;<xref rid="jnc70252-bib-0137" ref-type="bibr">2019</xref>; Xiong et&#160;al.&#160;<xref rid="jnc70252-bib-0220" ref-type="bibr">2022</xref>).</p><p>In this context, the present review aims to delineate the factors that may drive peripheral hypermetabolism, how astrocytes are capable of sensing this altered energetic state and, in turn, become hypermetabolic themselves. This astrocytic hypermetabolism at the cellular level involves increased glucose uptake, glycolysis, and lactate export to neurons; molecularly, it features upregulation of glucose transporters, glycolytic enzymes, and signaling pathways like adenosine&#8208;cAMP; physiologically, it results in elevated energy support to neurons, greater extracellular lactate, and dynamic responses to intense neural activity or CNS stress. This initial metabolic reprogramming appears to serve an <italic toggle="yes">allostatic purpose</italic>&#8212;the process by which the body attempts to achieve stability through physiological or behavioral change&#8212;in response to sustained energetic demands. However, over time, this hypermetabolic shift may lead to <italic toggle="yes">astrocytic exhaustion</italic>, promoting a hypometabolic stage, exacerbating neurodegenerative processes and precipitating the onset or progression of pathologies such as AD. Therefore, this review seeks to underscore the pivotal role of astrocytes as <italic toggle="yes">central energy sensors</italic> within the brain, capable of extensive metabolic adaptation, and undergoing distinct metabolic phases throughout the course of AD. Understanding these transitions not only highlights the astrocyte's <italic toggle="yes">dynamic role</italic> in disease progression but may also open new avenues for the development of stage&#8208;specific biomarkers and targeted therapies aimed at selectively modulating astrocytic energetics.</p></sec><sec id="jnc70252-sec-0002"><label>2</label><title>Risk Factors Driving Metabolic Dysregulation in Alzheimer's Disease</title><p>AD is a neurodegenerative condition influenced by multiple risk factors, ranging from genetic variants to environmental and non&#8208;genetic factors, all of which are linked to the onset and/or progression of the disease (Soria et&#160;al.&#160;<xref rid="jnc70252-bib-0193" ref-type="bibr">2019</xref>; Ballard et&#160;al.&#160;<xref rid="jnc70252-bib-0016" ref-type="bibr">2011</xref>). Among the many pathways involved, <italic toggle="yes">energy metabolism emerges as a key axis</italic> in the early stages of AD, impacting both cerebral and peripheral energy regulation. Factors such as aging, metabolic syndrome, chronic inflammation, or stress converge to disrupt systemic metabolic equilibrium and create a hypermetabolic environment that often precedes evident and noticeable cognitive decline (Figure&#160;<xref rid="jnc70252-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="FIGURE" id="jnc70252-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Metabolic risk factors for AD. AD is a multifactorial neurodegenerative disorder wherein genetic, environmental, and non&#8208;genetic factors converge to disrupt energy metabolism from the earliest stages of pathogenesis. Aging, metabolic syndrome, mitochondrial dysfunction, and chronic stress synergistically promote a systemic hypermetabolic state that often precedes overt cognitive decline. These factors contribute to the accumulation of molecular damage, cellular senescence, chronic low&#8208;grade inflammation (inflammaging), blood&#8211;brain barrier disruption, and impaired central insulin signaling, collectively undermining cerebral and systemic energy homeostasis and facilitating the progression of AD. AD, Alzheimer's disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="JNC-169-0-g003.jpg"/></fig><sec id="jnc70252-sec-0003"><label>2.1</label><title>Aging</title><p>
<italic toggle="yes">Aging</italic>, the decline in capacity and performance experienced by an individual over the years (Ferrucci et&#160;al.&#160;<xref rid="jnc70252-bib-0069" ref-type="bibr">2018</xref>), is considered the <italic toggle="yes">predominant risk factor</italic> for AD, with its incidence doubling every 5&#8201;years after age 65, and 50% of individuals aged 85 or older suffering from the disease (Ballard et&#160;al.&#160;<xref rid="jnc70252-bib-0016" ref-type="bibr">2011</xref>; Ferreira et&#160;al.&#160;<xref rid="jnc70252-bib-0068" ref-type="bibr">2014</xref>; Liu&#160;<xref rid="jnc70252-bib-0119" ref-type="bibr">2022</xref>).</p><p>Recent research has overturned the traditional view of aging cells being metabolically inactive. It has been demonstrated that aging cells and tissues become <italic toggle="yes">hypermetabolic</italic>, consuming increasing amounts of energy (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>; Gems&#160;<xref rid="jnc70252-bib-0080" ref-type="bibr">2022</xref>). As somatic tissues accumulate <italic toggle="yes">molecular damage</italic> over time&#8212;telomere shortening, mutations in autosomal genes and mitochondrial DNA (mtDNA), and mislocation of nuclear and mtDNA fragments (Gladyshev et&#160;al.&#160;<xref rid="jnc70252-bib-0081" ref-type="bibr">2021</xref>; Yousefzadeh et&#160;al.&#160;<xref rid="jnc70252-bib-0226" ref-type="bibr">2021</xref>; Whittemore et&#160;al.&#160;<xref rid="jnc70252-bib-0214" ref-type="bibr">2019</xref>; Zhang et&#160;al.&#160;<xref rid="jnc70252-bib-0231" ref-type="bibr">2017</xref>)&#8212;aging cells activate conserved stress responses that, although aimed at survival, ultimately contribute to hypermetabolism (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>; Bobba&#8208;Alves et&#160;al.&#160;<xref rid="jnc70252-bib-0032" ref-type="bibr">2023</xref>).</p><p>These <italic toggle="yes">stress</italic> responses culminate in a state known as <italic toggle="yes">cellular senescence</italic>, where cells undergo permanent cell cycle arrest (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>; Birch and Gil&#160;<xref rid="jnc70252-bib-0028" ref-type="bibr">2020</xref>; Sikora et&#160;al.&#160;<xref rid="jnc70252-bib-0189" ref-type="bibr">2014</xref>). This phenomenon, first identified by Leonard Hayflick and Paul Moorhead and termed the &#8220;Hayflick limit&#8221;, was crucial for understanding the aging of cells and their role in age&#8208;related diseases (Salama et&#160;al.&#160;<xref rid="jnc70252-bib-0173" ref-type="bibr">2014</xref>). Although senescent cells stop dividing, they remain metabolically active and secrete bioactive molecules (termed senescence &#8208;associated secretory phenotype, SASP), creating a chronic low&#8208;grade inflammatory state known as <italic toggle="yes">inflammaging</italic> (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>; Birch and Gil&#160;<xref rid="jnc70252-bib-0028" ref-type="bibr">2020</xref>; Salama et&#160;al.&#160;<xref rid="jnc70252-bib-0173" ref-type="bibr">2014</xref>; Franceschi and Campisi&#160;<xref rid="jnc70252-bib-0073" ref-type="bibr">2014</xref>). In other words, although senescent cells are no longer capable of dividing, they remain metabolically active and continue to influence the surrounding tissue through the secretion of these inflammatory molecules and the upregulation of several energetically costly processes.</p><p>Numerous findings support this existing <italic toggle="yes">correlation between age&#8208; and/or senescence&#8208;associated cellular hypermetabolism</italic>. When comparing fibroblasts from centenarian individuals to fibroblasts from young donors, it was found that aged cells exhibit increased protein content per cell and 47% higher mitochondrial mass, characteristics generally associated with increased cellular energy demand and oxidative phosphorylation (OxPhos) activity (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>; Sgarbi et&#160;al.&#160;<xref rid="jnc70252-bib-0182" ref-type="bibr">2014</xref>). Longitudinal studies reveal that as fibroblasts approach senescence, their energy demand and mitochondrial DNA content increase markedly, partially due to SASP&#8208;related cytokine secretion (Sturm et&#160;al.&#160;<xref rid="jnc70252-bib-0200" ref-type="bibr">2022</xref>). Moreover, interventions that reduce protein synthesis or ribosomal RNA production can alleviate hypermetabolism and extend lifespan (Takauji et&#160;al.&#160;<xref rid="jnc70252-bib-0201" ref-type="bibr">2016</xref>; Sharifi et&#160;al.&#160;<xref rid="jnc70252-bib-0183" ref-type="bibr">2024</xref>).</p><p>In this scenario, mounting evidence indicates that the accumulation of senescent cells and their associated signaling plays a crucial role in aging and, therefore, in <italic toggle="yes">age&#8208;related diseases</italic>, including <italic toggle="yes">AD</italic> (Liu&#160;<xref rid="jnc70252-bib-0119" ref-type="bibr">2022</xref>; Sikora et&#160;al.&#160;<xref rid="jnc70252-bib-0189" ref-type="bibr">2014</xref>). In fact, both A&#946; and tau pathologies have been demonstrated to be potent inducers of cellular senescence (Liu&#160;<xref rid="jnc70252-bib-0119" ref-type="bibr">2022</xref>; Baker and Petersen&#160;<xref rid="jnc70252-bib-0015" ref-type="bibr">2018</xref>), and senescent cells have been detected in AD brains and mouse models (Baker and Petersen&#160;<xref rid="jnc70252-bib-0015" ref-type="bibr">2018</xref>; Bhat et&#160;al.&#160;<xref rid="jnc70252-bib-0026" ref-type="bibr">2012</xref>; Musi et&#160;al.&#160;<xref rid="jnc70252-bib-0140" ref-type="bibr">2018</xref>). The removal of senescent cells in AD models reduces A&#946; load and tauopathy and improves cognition, suggesting that cellular senescence not only contributes to A&#946; and tau accumulation (Zhang et&#160;al.&#160;<xref rid="jnc70252-bib-0230" ref-type="bibr">2019</xref>) but also reinforces the <italic toggle="yes">hypermetabolic state that could trigger neurodegeneration</italic>.</p></sec><sec id="jnc70252-sec-0004"><label>2.2</label><title>Mitochondrial Dysfunction</title><p>Mitochondria are crucial for ATP production through <italic toggle="yes">OxPhos</italic>, an essential process for maintaining cellular energy homeostasis (Jang et&#160;al.&#160;<xref rid="jnc70252-bib-0097" ref-type="bibr">2018</xref>; Cunnane et&#160;al.&#160;<xref rid="jnc70252-bib-0052" ref-type="bibr">2020</xref>). Mitochondrial dysfunction has long been linked to the aging process and neurodegenerative disorders like AD (Zong et&#160;al.&#160;<xref rid="jnc70252-bib-0233" ref-type="bibr">2024</xref>; Michailidis et&#160;al.&#160;<xref rid="jnc70252-bib-0133" ref-type="bibr">2022</xref>; Yin et&#160;al.&#160;<xref rid="jnc70252-bib-0225" ref-type="bibr">2016</xref>).</p><p>
<italic toggle="yes">Aging</italic> is characterized by the accumulation of mitochondrial damage, caused by <italic toggle="yes">oxidative stress</italic> (Yin et&#160;al.&#160;<xref rid="jnc70252-bib-0225" ref-type="bibr">2016</xref>; Kang et&#160;al.&#160;<xref rid="jnc70252-bib-0104" ref-type="bibr">2017</xref>), <italic toggle="yes">decreased mitochondrial biogenesis, and mtDNA mutations</italic> (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>; Kang et&#160;al.&#160;<xref rid="jnc70252-bib-0104" ref-type="bibr">2017</xref>), driving oxidative damage and energy exhaustion. In animal models, such as mice with mutations in mtDNA polymerase gamma, mitochondrial content and electron transport chain (ETC) activity decrease, leading to apoptotic activation (Trifunovic et&#160;al.&#160;<xref rid="jnc70252-bib-0203" ref-type="bibr">2004</xref>), reduced energy production, and increased reactive oxygen species (ROS). This supports the free radical theory of aging, where mitochondrial oxidants contribute to age&#8208;related damage (Wickens&#160;<xref rid="jnc70252-bib-0215" ref-type="bibr">2001</xref>). The resulting energy deficit promotes cellular senescence, metabolic reprogramming, and reduced stress responses, contributing to tissue decline (Kang et&#160;al.&#160;<xref rid="jnc70252-bib-0104" ref-type="bibr">2017</xref>).</p><p>However, mitochondrial dysfunction and OxPhos deficiency are not always linked to constant energy depletion. Patients with primary mitochondrial OxPhos defects often exhibit <italic toggle="yes">hypermetabolism</italic>&#8212;increased resting energy expenditure&#8212;as a compensatory response (Naia et&#160;al.&#160;<xref rid="jnc70252-bib-0141" ref-type="bibr">2023</xref>; Sturm, Karan, et&#160;al.&#160;<xref rid="jnc70252-bib-0199" ref-type="bibr">2023</xref>). A study found that disrupting OxPhos doubles energy expenditure, suggesting the body compensates by increasing metabolism. Rather than depleting energy, OxPhos&#8208;deficient cells experience reductive stress, activating the <italic toggle="yes">integrated stress response</italic> and other transcriptional programs. This hypermetabolic state, though initially compensatory, <italic toggle="yes">shortens lifespan</italic> in cells, animal models, and humans (Sturm, Karan, et&#160;al.&#160;<xref rid="jnc70252-bib-0199" ref-type="bibr">2023</xref>).</p><p>This connection between mitochondrial dysfunction and hypermetabolism is critical for understanding AD, long associated with OxPhos deficiency (Birnbaum et&#160;al.&#160;<xref rid="jnc70252-bib-0029" ref-type="bibr">2018</xref>; Dentoni et&#160;al.&#160;<xref rid="jnc70252-bib-0056" ref-type="bibr">2022</xref>). Postmortem studies show downregulation of nuclear&#8208;encoded OxPhos genes, especially in complex IV, contributing to energy deficits in AD (Yin et&#160;al.&#160;<xref rid="jnc70252-bib-0225" ref-type="bibr">2016</xref>). Interestingly, in mild cognitive impairment (MCI), a prodromal stage of AD, there is <italic toggle="yes">upregulation of OxPhos</italic> genes in complexes I, III, and IV, suggesting an early compensatory mechanism aimed at meeting the increased energy demands of the brain during the early stages of the disease (Mastroeni et&#160;al.&#160;<xref rid="jnc70252-bib-0126" ref-type="bibr">2017</xref>; Ashraf et&#160;al.&#160;<xref rid="jnc70252-bib-0012" ref-type="bibr">2015</xref>). APP knock&#8208;in mouse models also exhibit early mitochondrial hyperactivity before severe symptoms arise, particularly in brain regions like the hippocampus (Naia et&#160;al.&#160;<xref rid="jnc70252-bib-0141" ref-type="bibr">2023</xref>). This <italic toggle="yes">early hypermetabolism</italic> may help sustain energy production initially but is followed by neuroinflammation, autophagic decline, and synaptic dysfunction, which drives cognitive decline as the disease progresses (Naia et&#160;al.&#160;<xref rid="jnc70252-bib-0141" ref-type="bibr">2023</xref>).</p><p>In summary, mitochondrial dysfunction plays a pivotal role in both aging and AD. While OxPhos deficiency is traditionally associated with energy depletion and neurodegeneration, new evidence suggests that <italic toggle="yes">early stages</italic> of AD are characterized by a temporary upregulation of OxPhos and a state of hypermetabolism (Ashraf et&#160;al.&#160;<xref rid="jnc70252-bib-0012" ref-type="bibr">2015</xref>). This compensatory response fails as the disease progresses, leading to the hypometabolic state that contributes to the neurodegeneration and cognitive decline seen in <italic toggle="yes">later stages</italic> of the disease.</p></sec><sec id="jnc70252-sec-0005"><label>2.3</label><title>Metabolic Syndrome</title><p>The risk of developing AD is markedly elevated under conditions of systemic metabolic dysregulation (Cunnane et&#160;al.&#160;<xref rid="jnc70252-bib-0052" ref-type="bibr">2020</xref>), particularly in the presence of metabolic syndrome (MeS)&#8212;a cluster of interrelated conditions including obesity, hypertension, hyperlipidemia, and type 2 diabetes mellitus (T2DM) (Ezkurdia et&#160;al.&#160;<xref rid="jnc70252-bib-0066" ref-type="bibr">2023</xref>; Frisardi et&#160;al.&#160;<xref rid="jnc70252-bib-0074" ref-type="bibr">2010</xref>). These peripheral metabolic disorders act synergistically to create a pro&#8208;inflammatory, pro&#8208;oxidative, and <italic toggle="yes">energetically compromised environment</italic> that ultimately affects brain health.</p><p>
<italic toggle="yes">Obesity</italic>, particularly in midlife, has been consistently associated with an increased risk of dementia (Kang et&#160;al.&#160;<xref rid="jnc70252-bib-0104" ref-type="bibr">2017</xref>; Xu et&#160;al.&#160;<xref rid="jnc70252-bib-0221" ref-type="bibr">2011</xref>): excess adipose tissue releases adipokines and other inflammatory mediators that can cross the blood&#8211;brain barrier (BBB), promoting <italic toggle="yes">neuroinflammation</italic> and further <italic toggle="yes">metabolic disruption</italic> within the CNS (Ezkurdia et&#160;al.&#160;<xref rid="jnc70252-bib-0066" ref-type="bibr">2023</xref>; Elias et&#160;al.&#160;<xref rid="jnc70252-bib-0062" ref-type="bibr">2005</xref>; Ouchi et&#160;al.&#160;<xref rid="jnc70252-bib-0147" ref-type="bibr">2011</xref>; Lee et&#160;al.&#160;<xref rid="jnc70252-bib-0112" ref-type="bibr">2019</xref>). Obesity also increases the risk of insulin resistance and T2DM, compounding its negative effects on brain function (Kang et&#160;al.&#160;<xref rid="jnc70252-bib-0104" ref-type="bibr">2017</xref>; Ezkurdia et&#160;al.&#160;<xref rid="jnc70252-bib-0066" ref-type="bibr">2023</xref>).</p><p>
<italic toggle="yes">Hypertension</italic>, another key MeS component, contributes to AD through vascular and metabolic pathways. It induces <italic toggle="yes">cerebral vasculature changes</italic>&#8212;such as hypoperfusion, ischemia, and BBB breakdown&#8212;that facilitate A&#946; accumulation and upregulate proteins like presenilin (Ezkurdia et&#160;al.&#160;<xref rid="jnc70252-bib-0066" ref-type="bibr">2023</xref>; Lennon et&#160;al.&#160;<xref rid="jnc70252-bib-0114" ref-type="bibr">2021</xref>; Skoog and Gustafson&#160;<xref rid="jnc70252-bib-0190" ref-type="bibr">2006</xref>). Longitudinal studies have shown that midlife hypertension significantly increases the risk of both AD and vascular dementia (Skoog et&#160;al.&#160;<xref rid="jnc70252-bib-0191" ref-type="bibr">1996</xref>; Staessen et&#160;al.&#160;<xref rid="jnc70252-bib-0194" ref-type="bibr">2007</xref>), whereas late&#8208;life hypertension effects appear more variable. Furthermore, hypertension promotes systemic vascular damage and inflammation, exacerbating metabolic dysfunction (Ezkurdia et&#160;al.&#160;<xref rid="jnc70252-bib-0066" ref-type="bibr">2023</xref>; Frisardi et&#160;al.&#160;<xref rid="jnc70252-bib-0074" ref-type="bibr">2010</xref>).</p><p>
<italic toggle="yes">Hyperlipidemia</italic>, particularly hypercholesterolemia, is another metabolic factor contributing to AD. Elevated cholesterol correlates with increased A&#946; deposition, Tau hyperphosphorylation, neuroinflammation, and cognitive deficits (Ezkurdia et&#160;al.&#160;<xref rid="jnc70252-bib-0066" ref-type="bibr">2023</xref>; Popp et&#160;al.&#160;<xref rid="jnc70252-bib-0157" ref-type="bibr">2013</xref>; Xue&#8208;Shan et&#160;al.&#160;<xref rid="jnc70252-bib-0222" ref-type="bibr">2016</xref>; Ricciarelli et&#160;al.&#160;<xref rid="jnc70252-bib-0165" ref-type="bibr">2012</xref>; Ullrich et&#160;al.&#160;<xref rid="jnc70252-bib-0206" ref-type="bibr">2010</xref>). Altered lipid metabolism also allows free fatty acids to enter the brain, fueling <italic toggle="yes">inflammation and insulin resistance</italic>. High&#8208;fat diets promote AD&#8208;like changes, whereas diets rich in polyunsaturated fatty acids like docosahexaenoic acid show protective effects (Karmi et&#160;al.&#160;<xref rid="jnc70252-bib-0106" ref-type="bibr">2010</xref>; Cole et&#160;al.&#160;<xref rid="jnc70252-bib-0047" ref-type="bibr">2010</xref>).</p><p>
<italic toggle="yes">T2DM</italic> presents one of the most compelling metabolic links to AD, with strong evidence supporting a bidirectional relationship (Michailidis et&#160;al.&#160;<xref rid="jnc70252-bib-0133" ref-type="bibr">2022</xref>; Ezkurdia et&#160;al.&#160;<xref rid="jnc70252-bib-0066" ref-type="bibr">2023</xref>; Arnold et&#160;al.&#160;<xref rid="jnc70252-bib-0011" ref-type="bibr">2018</xref>; Vieira et&#160;al.&#160;<xref rid="jnc70252-bib-0209" ref-type="bibr">2018</xref>). Shared mechanisms include insulin resistance, <italic toggle="yes">impaired glucose metabolism</italic>, oxidative stress, and chronic inflammation (Ezkurdia et&#160;al.&#160;<xref rid="jnc70252-bib-0066" ref-type="bibr">2023</xref>; Li et&#160;al.&#160;<xref rid="jnc70252-bib-0115" ref-type="bibr">2015</xref>). In the brain, disrupted insulin signaling contributes to synaptic dysfunction and neuronal death. Furthermore, amyloidogenic protein accumulation&#8212;A&#946; in AD and amylin in T2DM&#8212;occurs in both the pancreas and brain, suggesting overlapping toxic pathways (Michailidis et&#160;al.&#160;<xref rid="jnc70252-bib-0133" ref-type="bibr">2022</xref>; Vieira et&#160;al.&#160;<xref rid="jnc70252-bib-0209" ref-type="bibr">2018</xref>; Gabbouj et&#160;al.&#160;<xref rid="jnc70252-bib-0076" ref-type="bibr">2019</xref>; S&#281;dzikowska and Szablewski&#160;<xref rid="jnc70252-bib-0179" ref-type="bibr">2021</xref>; Steen et&#160;al.&#160;<xref rid="jnc70252-bib-0197" ref-type="bibr">2005</xref>; Steculorum et&#160;al.&#160;<xref rid="jnc70252-bib-0195" ref-type="bibr">2014</xref>; Bosco et&#160;al.&#160;<xref rid="jnc70252-bib-0034" ref-type="bibr">2011</xref>). <italic toggle="yes">Hyperglycemia</italic> and advanced glycation end&#8208;products (AGEs) further damage vasculature and promote neuroinflammation (Ezkurdia et&#160;al.&#160;<xref rid="jnc70252-bib-0066" ref-type="bibr">2023</xref>; Li et&#160;al.&#160;<xref rid="jnc70252-bib-0115" ref-type="bibr">2015</xref>).</p><p>Collectively, these metabolic conditions generate a sustained <italic toggle="yes">bioenergetic imbalance</italic> that compromises CNS integrity. Through mechanisms such as BBB disruption, chronic inflammation, oxidative stress, and impaired insulin signaling, they facilitate the accumulation of neurotoxic proteins and disturb neuronal homeostasis. As a result, peripheral metabolic dysfunctions not only serve as risk factors but also <italic toggle="yes">actively drive and exacerbate</italic> the neurodegenerative cascade observed in AD, highlighting the need for integrative strategies that address both systemic and brain&#8208;specific <italic toggle="yes">metabolic health</italic>.</p></sec><sec id="jnc70252-sec-0006"><label>2.4</label><title>Stress</title><p>Stress is a complex physiological and psychological response aimed at promoting <italic toggle="yes">allostasis</italic> to adapt to real or perceived threats, involving the nervous, endocrine, and immune systems (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>; Picard et&#160;al.&#160;<xref rid="jnc70252-bib-0155" ref-type="bibr">2018</xref>). While short&#8208;term stress responses are crucial for survival, chronic stress leads to <italic toggle="yes">allostatic load</italic>&#8212;the cumulative progressive deterioration of the body and brain (Bobba&#8208;Alves et&#160;al.&#160;<xref rid="jnc70252-bib-0031" ref-type="bibr">2022</xref>; Picard et&#160;al.&#160;<xref rid="jnc70252-bib-0155" ref-type="bibr">2018</xref>)&#8212;profoundly impacting health by accelerating aging, causing metabolic dysregulation, and increasing susceptibility to neurodegenerative diseases, including AD (Bobba&#8208;Alves et&#160;al.&#160;<xref rid="jnc70252-bib-0032" ref-type="bibr">2023</xref>).</p><p>Longitudinal studies show that individuals with high chronic stress have a 2.7&#8208;fold increased risk of developing AD (Wilson et&#160;al.&#160;<xref rid="jnc70252-bib-0217" ref-type="bibr">2006</xref>; Ricci et&#160;al.&#160;<xref rid="jnc70252-bib-0164" ref-type="bibr">2012</xref>). Psychosocial stressors like loneliness are linked to accelerated cognitive decline and doubled dementia risk (Ricci et&#160;al.&#160;<xref rid="jnc70252-bib-0164" ref-type="bibr">2012</xref>; Wilson et&#160;al.&#160;<xref rid="jnc70252-bib-0218" ref-type="bibr">2007</xref>). Moreover, stress&#8208;related psychiatric conditions such as depression and anxiety further contribute to cognitive deterioration and may act as early signs of neurodegeneration (Mej&#237;a et&#160;al.&#160;<xref rid="jnc70252-bib-0131" ref-type="bibr">2003</xref>).</p><p>The physiological stress response rapidly activates the sympathetic nervous system and the hypothalamic&#8211;pituitary&#8211;adrenal (HPA) axis, resulting in the release of catecholamines and <italic toggle="yes">glucocorticoids</italic> (Ricci et&#160;al.&#160;<xref rid="jnc70252-bib-0164" ref-type="bibr">2012</xref>; Lyons et&#160;al.&#160;<xref rid="jnc70252-bib-0123" ref-type="bibr">2023</xref>). Catecholamines elevate cardiovascular output and energy mobilization, while <italic toggle="yes">glucocorticoids regulate metabolism</italic> (Picard et&#160;al.&#160;<xref rid="jnc70252-bib-0155" ref-type="bibr">2018</xref>; Ricci et&#160;al.&#160;<xref rid="jnc70252-bib-0164" ref-type="bibr">2012</xref>).</p><p>Glucocorticoids are essential for energy homeostasis, acting as <italic toggle="yes">key metabolic regulators</italic> by mobilizing energy substrates such as glucose, lipids, and amino acids to ensure an adequate energy supply during stress. Their <italic toggle="yes">hyperglycemic</italic> action is mediated by the activation of the glucocorticoid receptor (GR) in various tissues. In the liver, they stimulate gluconeogenesis, <italic toggle="yes">increasing glucose production</italic> and release into circulation. Meanwhile, in muscle and adipose tissue, they impair insulin signaling, reducing glucose uptake and promoting insulin resistance (Picard et&#160;al.&#160;<xref rid="jnc70252-bib-0155" ref-type="bibr">2018</xref>). However, while this mechanism ensures glucose availability for critical organs like the brain during stress, prolonged or excessive exposure to glucocorticoids contributes to an excessive allostatic load, disrupting multiple physiological processes and leading to <italic toggle="yes">metabolic dysfunction</italic> (Bobba&#8208;Alves et&#160;al.&#160;<xref rid="jnc70252-bib-0031" ref-type="bibr">2022</xref>; Bobba&#8208;Alves et&#160;al.&#160;<xref rid="jnc70252-bib-0032" ref-type="bibr">2023</xref>; Picard et&#160;al.&#160;<xref rid="jnc70252-bib-0155" ref-type="bibr">2018</xref>; McEwen and Gianaros&#160;<xref rid="jnc70252-bib-0129" ref-type="bibr">2010</xref>).</p><p>In the brain, chronic glucocorticoid exposure severely affects the hippocampus, rich in GR (McEwen&#160;<xref rid="jnc70252-bib-0128" ref-type="bibr">2007</xref>). Hippocampal <italic toggle="yes">atrophy</italic>, linked to chronic elevated glucocorticoid levels, is consistently observed in stress&#8208;related disorders and early AD stages (McEwen and Gianaros&#160;<xref rid="jnc70252-bib-0129" ref-type="bibr">2010</xref>). Functional consequences include disrupted synaptic plasticity, reduced neurogenesis, and dendritic atrophy, impairing learning and cognitive flexibility (McEwen and Gianaros&#160;<xref rid="jnc70252-bib-0129" ref-type="bibr">2010</xref>; McEwen&#160;<xref rid="jnc70252-bib-0128" ref-type="bibr">2007</xref>). Additionally, hippocampal dysfunction weakens the negative feedback on the HPA axis, prolonging stress responses and exacerbating cognitive decline (McEwen and Gianaros&#160;<xref rid="jnc70252-bib-0129" ref-type="bibr">2010</xref>; McEwen&#160;<xref rid="jnc70252-bib-0128" ref-type="bibr">2007</xref>; Cohen et&#160;al.&#160;<xref rid="jnc70252-bib-0046" ref-type="bibr">2012</xref>; Sapolsky et&#160;al.&#160;<xref rid="jnc70252-bib-0176" ref-type="bibr">1986</xref>; McEwen&#160;<xref rid="jnc70252-bib-0127" ref-type="bibr">1992</xref>).</p><p>Chronic glucocorticoid exposure also intertwines with <italic toggle="yes">key aging processes</italic> (Lyons et&#160;al.&#160;<xref rid="jnc70252-bib-0123" ref-type="bibr">2023</xref>; Polsky et&#160;al.&#160;<xref rid="jnc70252-bib-0156" ref-type="bibr">2022</xref>). It increases oxidative stress, mitochondrial dysfunction, and cellular senescence, making neurons more vulnerable to damage. Furthermore, it induces brain <italic toggle="yes">insulin resistance</italic>, impairing glucose uptake and synaptic activity, thereby linking metabolic dysfunction directly to A&#946; and tau accumulation (Ezkurdia et&#160;al.&#160;<xref rid="jnc70252-bib-0066" ref-type="bibr">2023</xref>; S&#281;dzikowska and Szablewski&#160;<xref rid="jnc70252-bib-0179" ref-type="bibr">2021</xref>; Steculorum et&#160;al.&#160;<xref rid="jnc70252-bib-0195" ref-type="bibr">2014</xref>).</p><p>Simultaneously, chronic stress triggers the release of <italic toggle="yes">pro&#8208;inflammatory cytokines</italic> such as IL&#8208;6, TNF&#8208;&#945;, and IL&#8208;1&#946;, promoting <italic toggle="yes">inflammaging</italic> (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>; Ricci et&#160;al.&#160;<xref rid="jnc70252-bib-0164" ref-type="bibr">2012</xref>; Lyons et&#160;al.&#160;<xref rid="jnc70252-bib-0123" ref-type="bibr">2023</xref>; Polsky et&#160;al.&#160;<xref rid="jnc70252-bib-0156" ref-type="bibr">2022</xref>). This environment intensifies oxidative damage, disrupts synapses, and promotes neurotoxic protein accumulation, all contributing to AD pathology.</p><p>Overall, chronic stress imposes a <italic toggle="yes">sustained hypermetabolic state in peripheral tissues</italic>, leading to <italic toggle="yes">systemic metabolic dysregulation</italic> that profoundly impacts <italic toggle="yes">brain function</italic>. The <italic toggle="yes">brain&#8211;body energy conservation (BEC) model</italic> provides an insightful framework for understanding how stress&#8208;driven hypermetabolism forces energy trade&#8208;offs, ultimately impairing brain health (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>). Severe biological and psychosocial stressors trigger a metabolic shift that prioritizes immediate survival over long&#8208;term maintenance, repair, and cognitive function. Under prolonged stress, allostasis promotes adaptive changes, but at a cost: energy reserves are redirected toward survival, undermining long&#8208;term brain health. This shift contributes to insulin resistance, mitochondrial dysfunction, cellular senescence, neuroinflammation, and other hallmarks of aging, all of which are closely linked to the progression of AD.</p></sec></sec><sec id="jnc70252-sec-0007"><label>3</label><title>Sex Differences in Alzheimer's Disease Risk Factors</title><p>Women bear a substantially greater lifetime risk of Alzheimer's disease (AD) than men (21.2% vs. 11.6% at age 65) (Hebert et&#160;al.&#160;<xref rid="jnc70252-bib-0089" ref-type="bibr">2013</xref>; Ch&#234;ne et&#160;al.&#160;<xref rid="jnc70252-bib-0042" ref-type="bibr">2015</xref>; Alzheimer's Association&#160;<xref rid="jnc70252-bib-0006" ref-type="bibr">2022</xref>), a difference only partly attributable to longevity and instead reflecting complex hormonal, genetic, vascular, and lifestyle interactions. Female&#8208;specific factors such as pregnancy complications and menopause contribute significantly: a history of preeclampsia increases the likelihood of mild cognitive impairment (MCI), vascular dementia, and AD (Andolf et&#160;al.&#160;<xref rid="jnc70252-bib-0008" ref-type="bibr">2020</xref>; Basit et&#160;al.&#160;<xref rid="jnc70252-bib-0021" ref-type="bibr">2018</xref>; Fields et&#160;al.&#160;<xref rid="jnc70252-bib-0070" ref-type="bibr">2017</xref>), and early menopause (before 45&#8201;years, natural or surgical) is similarly linked to elevated risk (Coppus et&#160;al.&#160;<xref rid="jnc70252-bib-0049" ref-type="bibr">2010</xref>; Phung et&#160;al.&#160;<xref rid="jnc70252-bib-0154" ref-type="bibr">2010</xref>; Rocca et&#160;al.&#160;<xref rid="jnc70252-bib-0169" ref-type="bibr">2021</xref>; Rocca et&#160;al.&#160;<xref rid="jnc70252-bib-0168" ref-type="bibr">2007</xref>). The Women's Health Initiative Memory Study reported a doubling of all&#8208;cause dementia with combined conjugated equine estrogen and medroxyprogesterone acetate therapy compared to placebo, whereas estrogen alone showed no such effect (Shumaker et&#160;al.&#160;<xref rid="jnc70252-bib-0186" ref-type="bibr">2004</xref>; Shumaker et&#160;al.&#160;<xref rid="jnc70252-bib-0187" ref-type="bibr">2003</xref>). Subsequent trials underscore the importance of timing, suggesting that hormone therapy initiated within 5&#8201;years of menopause is cognitively neutral, whereas prolonged use (&#8805;&#8201;5&#8201;years) may increase risk (Espeland et&#160;al.&#160;<xref rid="jnc70252-bib-0065" ref-type="bibr">2013</xref>; Gleason et&#160;al.&#160;<xref rid="jnc70252-bib-0082" ref-type="bibr">2015</xref>; Henderson et&#160;al.&#160;<xref rid="jnc70252-bib-0090" ref-type="bibr">2016</xref>). In contrast, evidence regarding cognitive consequences of age&#8208;related testosterone decline in men remains sparse and inconclusive (Feldman et&#160;al.&#160;<xref rid="jnc70252-bib-0067" ref-type="bibr">2002</xref>; Holland et&#160;al.&#160;<xref rid="jnc70252-bib-0091" ref-type="bibr">2011</xref>; Jayadevappa et&#160;al.&#160;<xref rid="jnc70252-bib-0098" ref-type="bibr">2019</xref>).</p><p>Genetically, the apolipoprotein E &#949;4 allele remains the strongest common risk factor for late&#8208;onset AD (Carmona et&#160;al.&#160;<xref rid="jnc70252-bib-0038" ref-type="bibr">2018</xref>; Huang and Mahley&#160;<xref rid="jnc70252-bib-0092" ref-type="bibr">2014</xref>; Liu et&#160;al.&#160;<xref rid="jnc70252-bib-0117" ref-type="bibr">2013</xref>), with female &#949;4 carriers experiencing both greater risk and earlier onset than male carriers, particularly between 65 and 75&#8201;years (Neu et&#160;al.&#160;<xref rid="jnc70252-bib-0142" ref-type="bibr">2017</xref>). Cardiometabolic and vascular factors&#8212;including hypertension, hyperlipidemia, obesity, and diabetes&#8212;are strongly associated with AD pathogenesis (Barnes and Yaffe&#160;<xref rid="jnc70252-bib-0020" ref-type="bibr">2011</xref>; Ritchie et&#160;al.&#160;<xref rid="jnc70252-bib-0166" ref-type="bibr">2015</xref>; Mielke et&#160;al.&#160;<xref rid="jnc70252-bib-0134" ref-type="bibr">2007</xref>; Profenno et&#160;al.&#160;<xref rid="jnc70252-bib-0159" ref-type="bibr">2010</xref>); although men show higher midlife prevalence, women with comparable vascular risk profiles exhibit greater cognitive decline and higher rates of diabetes&#8208;related cardiovascular complications (Azad et&#160;al.&#160;<xref rid="jnc70252-bib-0013" ref-type="bibr">2007</xref>; Bairey Merz et&#160;al.&#160;<xref rid="jnc70252-bib-0014" ref-type="bibr">2006</xref>; Huo et&#160;al.&#160;<xref rid="jnc70252-bib-0093" ref-type="bibr">2022</xref>).</p><p>Neuropsychiatric and lifestyle variables further modify sex differences. Depression, nearly twice as prevalent in women, is variably linked to AD risk (Goldstein et&#160;al.&#160;<xref rid="jnc70252-bib-0083" ref-type="bibr">2014</xref>; Kessler et&#160;al.&#160;<xref rid="jnc70252-bib-0107" ref-type="bibr">1993</xref>; Dal Forno et&#160;al.&#160;<xref rid="jnc70252-bib-0053" ref-type="bibr">2005</xref>; Goveas et&#160;al.&#160;<xref rid="jnc70252-bib-0084" ref-type="bibr">2011</xref>; Invernizzi et&#160;al.&#160;<xref rid="jnc70252-bib-0095" ref-type="bibr">2021</xref>); historically lower educational attainment among women reduces cognitive reserve (Baumgart et&#160;al.&#160;<xref rid="jnc70252-bib-0022" ref-type="bibr">2015</xref>); and sustained physical activity confers stronger cognitive protection in older women than in men (Barha, Davis, et&#160;al.&#160;<xref rid="jnc70252-bib-0018" ref-type="bibr">2017</xref>; Barha, Hsiung, et&#160;al.&#160;<xref rid="jnc70252-bib-0019" ref-type="bibr">2017</xref>; Barha et&#160;al.&#160;<xref rid="jnc70252-bib-0017" ref-type="bibr">2020</xref>). Additional sex&#8208;specific vulnerabilities include poorer outcomes after traumatic brain injury (Perry et&#160;al.&#160;<xref rid="jnc70252-bib-0153" ref-type="bibr">2016</xref>; Hasselgren et&#160;al.&#160;<xref rid="jnc70252-bib-0087" ref-type="bibr">2020</xref>; Kim et&#160;al.&#160;<xref rid="jnc70252-bib-0108" ref-type="bibr">2015</xref>), heightened sleep disruption around menopause&#8212;associated with increased amyloid burden (Sateia&#160;<xref rid="jnc70252-bib-0177" ref-type="bibr">2014</xref>; Bombois et&#160;al.&#160;<xref rid="jnc70252-bib-0033" ref-type="bibr">2010</xref>; Ju et&#160;al.&#160;<xref rid="jnc70252-bib-0101" ref-type="bibr">2014</xref>; Yaffe et&#160;al.&#160;<xref rid="jnc70252-bib-0223" ref-type="bibr">2011</xref>; Bixler et&#160;al.&#160;<xref rid="jnc70252-bib-0030" ref-type="bibr">2001</xref>; Ju et&#160;al.&#160;<xref rid="jnc70252-bib-0102" ref-type="bibr">2017</xref>)&#8212;and dietary influences, with Western dietary patterns and high intake of saturated fat and red meat more strongly tied to AD in men than in women (Tangney et&#160;al.&#160;<xref rid="jnc70252-bib-0202" ref-type="bibr">2009</xref>; D'Amico et&#160;al.&#160;<xref rid="jnc70252-bib-0054" ref-type="bibr">2020</xref>; Niu et&#160;al.&#160;<xref rid="jnc70252-bib-0143" ref-type="bibr">2017</xref>).</p><p>Collectively, these findings demonstrate that female biology, particularly hormonal transitions and the interaction with APOE &#949;4, combined with differential cardiovascular and lifestyle risk profiles, confer a distinct and amplified vulnerability to AD relative to men.</p></sec><sec id="jnc70252-sec-0008"><label>4</label><title>Metabolic Dysregulation of Astrocytes in Early Stages of Alzheimer's Disease</title><p>Astrocytes occupy a strategic position in the brain, contacting both vasculature and neural cells (Oberheim et&#160;al.&#160;<xref rid="jnc70252-bib-0144" ref-type="bibr">2009</xref>). This unique localization enables them to act as <italic toggle="yes">metabolic integrators of peripheral signals</italic> (Zhang et&#160;al.&#160;<xref rid="jnc70252-bib-0232" ref-type="bibr">2023</xref>), regulate glucose and lipid homeostasis, and dynamically <italic toggle="yes">reprogram metabolism</italic> to meet energy demands (Morita et&#160;al.&#160;<xref rid="jnc70252-bib-0137" ref-type="bibr">2019</xref>).</p><p>Basally, astrocytes show <italic toggle="yes">higher glycolysis</italic> and lower OxPhos than neurons (Itoh et&#160;al.&#160;<xref rid="jnc70252-bib-0096" ref-type="bibr">2003</xref>; Bouzier&#8208;Sore et&#160;al.&#160;<xref rid="jnc70252-bib-0035" ref-type="bibr">2006</xref>), reflected in their higher glycolytic enzyme and transporter expression. Most glucose undergoes glycolysis to <italic toggle="yes">lactate</italic>, released extracellularly (Pellerin and Magistretti&#160;<xref rid="jnc70252-bib-0152" ref-type="bibr">1994</xref>; Serres et&#160;al.&#160;<xref rid="jnc70252-bib-0181" ref-type="bibr">2005</xref>; Lovatt et&#160;al.&#160;<xref rid="jnc70252-bib-0122" ref-type="bibr">2007</xref>). Neurons use this lactate to fuel OxPhos and support synaptic activity. However, during activation, neurons prefer direct glucose oxidation (D&#237;az&#8208;Garc&#237;a et&#160;al.&#160;<xref rid="jnc70252-bib-0058" ref-type="bibr">2017</xref>). Astrocytes also store glucose as glycogen to supply energy during neuronal activity.</p><sec id="jnc70252-sec-0009"><label>4.1</label><title>Glycolytic Changes in Astrocytes During <styled-content style="fixed-case" toggle="no">AD</styled-content>
</title><p>In pathology, astrocytes undergo morphological, molecular, functional, and <italic toggle="yes">metabolic remodeling</italic>, leading to <italic toggle="yes">reactive states</italic> (Cal&#236; et&#160;al.&#160;<xref rid="jnc70252-bib-0037" ref-type="bibr">2024</xref>). These changes may support energetically demanding conditions but can also disrupt the balance between neuro&#8208;supportive and neurotoxic properties (Patani et&#160;al.&#160;<xref rid="jnc70252-bib-0150" ref-type="bibr">2023</xref>), contributing to <italic toggle="yes">disease progression</italic> in a <italic toggle="yes">context&#8208;dependent</italic> manner.</p><p>
<italic toggle="yes">Astrocytic metabolic adaptations</italic> may be <italic toggle="yes">shaped</italic> not only by intrinsic brain pathology but also by <italic toggle="yes">peripheral metabolic disturbances</italic>, as observed in early AD stages (Figure&#160;<xref rid="jnc70252-fig-0003" ref-type="fig">3</xref>). A <italic toggle="yes">pro&#8208;inflammatory response</italic> occurs early in AD (Steele and Robinson&#160;<xref rid="jnc70252-bib-0196" ref-type="bibr">2012</xref>), potentially due to accumulated molecular and cellular damage, increasing whole&#8208;body energy expenditure and leading to <italic toggle="yes">hypermetabolism</italic> (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>), as explained above. Cytokines and peripheral immune cells activate microglia, which release ATP and inflammatory mediators like IL&#8208;1, TNF&#945;, and PGE2, subsequently activating <italic toggle="yes">astrocytes</italic> via Nf&#8208;&#954;B pathways (Bezzi et&#160;al.&#160;<xref rid="jnc70252-bib-0025" ref-type="bibr">2001</xref>; Steele and Robinson&#160;<xref rid="jnc70252-bib-0196" ref-type="bibr">2012</xref>; Agulhon et&#160;al.&#160;<xref rid="jnc70252-bib-0002" ref-type="bibr">2012</xref>; Price et&#160;al.&#160;<xref rid="jnc70252-bib-0158" ref-type="bibr">2021</xref>; Adamu et&#160;al.&#160;<xref rid="jnc70252-bib-0001" ref-type="bibr">2024</xref>). Activated reactive astrocytes further propagate inflammation through <italic toggle="yes">increased Ca</italic>
<sup>
<italic toggle="yes">2+</italic>
</sup>
<italic toggle="yes">waves</italic> and cytokine secretion. While acute inflammation and oxidative stress can be resolved, <italic toggle="yes">sustained</italic> responses in neurodegenerative diseases like AD contribute to chronic inflammation, excitotoxicity, and neuronal degeneration (Price et&#160;al.&#160;<xref rid="jnc70252-bib-0158" ref-type="bibr">2021</xref>; McQuade and Blurton&#8208;Jones&#160;<xref rid="jnc70252-bib-0130" ref-type="bibr">2019</xref>).</p><fig position="float" fig-type="FIGURE" id="jnc70252-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Astrocytic metabolic reprogramming at early AD stages. Astrocytes play a critical metabolic role in the brain by integrating vascular and neuronal signals, regulating glucose and lipid homeostasis, and dynamically adjusting metabolism to meet energy demands. Under basal conditions, astrocytes favor glycolysis over oxidative phosphorylation (OxPhos), producing lactate to support neuronal function. During Alzheimer's disease (AD) progression, astrocytes undergo metabolic reprogramming characterized by enhanced glycolysis, mitochondrial dysfunction, and impaired lipid metabolism. Initially, increased glycolysis helps sustain neuronal activity under stress; however, chronic shifts contribute to neuroinflammation, oxidative stress, and neurodegeneration. ATP, Adenosine triphosphate; KBs, Ketone bodies; mROS, Mitochondrial reactive oxygen species; OxPhos, Oxidative phosphorylation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="JNC-169-0-g005.jpg"/></fig><p>
<italic toggle="yes">Astrocytes upregulate glycolysis</italic> to sustain energy demands during <italic toggle="yes">early</italic> AD pathology (Cal&#236; et&#160;al.&#160;<xref rid="jnc70252-bib-0037" ref-type="bibr">2024</xref>). Increased glycolysis produces <italic toggle="yes">L&#8208;lactate and ATP</italic> to support neurons when OxPhos is impaired (Morita et&#160;al.&#160;<xref rid="jnc70252-bib-0137" ref-type="bibr">2019</xref>; Fu et&#160;al.&#160;<xref rid="jnc70252-bib-0075" ref-type="bibr">2015</xref>). Reactive astrocytes boost glycolysis to maintain ATP necessary for neuronal survival (Motori et&#160;al.&#160;<xref rid="jnc70252-bib-0138" ref-type="bibr">2013</xref>; Almeida et&#160;al.&#160;<xref rid="jnc70252-bib-0005" ref-type="bibr">2001</xref>). Indeed, an initial rise in GFAP expression correlates with elevated glycolytic enzyme levels before A&#946; deposition (Escartin et&#160;al.&#160;<xref rid="jnc70252-bib-0064" ref-type="bibr">2021</xref>; Fu et&#160;al.&#160;<xref rid="jnc70252-bib-0075" ref-type="bibr">2015</xref>; Kumar et&#160;al.&#160;<xref rid="jnc70252-bib-0109" ref-type="bibr">2023</xref>), with glycolytic activation overlapping areas prone to amyloid accumulation (Vlassenko et&#160;al.&#160;<xref rid="jnc70252-bib-0210" ref-type="bibr">2010</xref>).</p><p>While hypometabolism has traditionally been emphasized in descriptions of AD progression, increasing attention has been directed toward the pathophysiological role of brain hypermetabolism (Rae et&#160;al.&#160;<xref rid="jnc70252-bib-0162" ref-type="bibr">2024</xref>; Corriveau&#8208;Lecavalier et&#160;al.&#160;<xref rid="jnc70252-bib-0050" ref-type="bibr">2024</xref>). Evidence suggests that increased glial metabolism is detectable in prodromal AD stages and could serve as an early biomarker. Reactive astrocytes can display higher glucose consumption and lactate release (Pamies et&#160;al.&#160;<xref rid="jnc70252-bib-0148" ref-type="bibr">2021</xref>; Salvad&#243; et&#160;al.&#160;<xref rid="jnc70252-bib-0174" ref-type="bibr">2022</xref>), and astrocytes incubated with A&#946; show increased glucose uptake, upregulation of the GLUT1 glucose transporter, and larger glycogen reserves (Bentivegna et&#160;al.&#160;<xref rid="jnc70252-bib-0023" ref-type="bibr">2025</xref>). Plasma GFAP levels have been associated with higher cerebral glucose consumption and early amyloid deposition (Salvad&#243; et&#160;al.&#160;<xref rid="jnc70252-bib-0174" ref-type="bibr">2022</xref>), while CSF lactate levels are elevated early in AD, reflecting enhanced astrocytic glycolysis (Zebhauser et&#160;al.&#160;<xref rid="jnc70252-bib-0228" ref-type="bibr">2022</xref>). Although lactate is a primary neuronal fuel, excessive astrocytic lactate release may be detrimental. Regional brain lactate levels, as a proxy of neuronal activity, correlate with local amyloid burden (Bero et&#160;al.&#160;<xref rid="jnc70252-bib-0024" ref-type="bibr">2011</xref>), suggesting that increased glycolysis in AD may potentiate amyloid pathogenic effects. Longitudinal studies of autosomal AD patients indicate that astrogliosis and enhanced glucose metabolism are early events that precede overt amyloid pathology and cognitive impairment by many years (Carter, Chiotis, et&#160;al.&#160;<xref rid="jnc70252-bib-0039" ref-type="bibr">2019</xref>; Fontana et&#160;al.&#160;<xref rid="jnc70252-bib-0071" ref-type="bibr">2023</xref>).</p><p>However, chronic glycolytic reprogramming may become maladaptive. For instance, in T2DM, insulin resistance activates <italic toggle="yes">GSK3&#946;</italic>, promoting Tau hyperphosphorylation and neurofibrillary tangle formation (Michailidis et&#160;al.&#160;<xref rid="jnc70252-bib-0133" ref-type="bibr">2022</xref>). Increased GSK3&#946; activity may also <italic toggle="yes">enhance glycogen synthesis</italic> and accumulation, as seen in conditions like ischemic stroke (Cai et&#160;al.&#160;<xref rid="jnc70252-bib-0036" ref-type="bibr">2020</xref>).</p><p>Thus, while astrocytic glycolysis initially supports neuronal function, prolonged metabolic shifts may fuel neuroinflammation and accelerate AD progression, acting as a &#8220;double&#8208;edged sword&#8221; (Morita et&#160;al.&#160;<xref rid="jnc70252-bib-0137" ref-type="bibr">2019</xref>; Cal&#236; et&#160;al.&#160;<xref rid="jnc70252-bib-0037" ref-type="bibr">2024</xref>).</p></sec><sec id="jnc70252-sec-0010"><label>4.2</label><title>Mitochondrial Changes in Astrocytes During <styled-content style="fixed-case" toggle="no">AD</styled-content>
</title><p>Although astrocytes primarily rely on glycolysis (Bouzier&#8208;Sore et&#160;al.&#160;<xref rid="jnc70252-bib-0035" ref-type="bibr">2006</xref>; Vicente&#8208;Guti&#233;rrez et&#160;al.&#160;<xref rid="jnc70252-bib-0208" ref-type="bibr">2021</xref>), they can activate <italic toggle="yes">mitochondrial OxPhos</italic> under high energy demand (Liu et&#160;al.&#160;<xref rid="jnc70252-bib-0118" ref-type="bibr">2024</xref>). Mitochondrial respiration accounts for <italic toggle="yes">20% of the brain's energy consumption</italic>, highlighting the role of astrocytic OxPhos in brain energy homeostasis. While early studies showed that the loss of astrocytic mitochondrial function did not induce neurodegeneration in mice (Edmond et&#160;al.&#160;<xref rid="jnc70252-bib-0061" ref-type="bibr">1985</xref>), more recent evidence emphasizes its importance for neuronal health (Cal&#236; et&#160;al.&#160;<xref rid="jnc70252-bib-0037" ref-type="bibr">2024</xref>; Zehnder et&#160;al.&#160;<xref rid="jnc70252-bib-0229" ref-type="bibr">2021</xref>).</p><p>Emerging evidence suggests <italic toggle="yes">mitochondrial dysfunction appears early</italic> in AD, with <italic toggle="yes">reduced</italic> OxPhos, decreased ATP, reduced ROS, and disturbed mitochondrial homeostasis (Wang et&#160;al.&#160;<xref rid="jnc70252-bib-0211" ref-type="bibr">2020</xref>). Whether it is a primary or secondary event after A&#946; accumulation remains unclear, but it is a key hallmark that precedes clinical onset (Wang et&#160;al.&#160;<xref rid="jnc70252-bib-0211" ref-type="bibr">2020</xref>).</p><p>Under physiological conditions, astrocytes generate high amounts of mitochondrial ROS (<italic toggle="yes">mROS</italic>), which activate <italic toggle="yes">HIF1</italic> (supporting glycolysis) and <italic toggle="yes">NRF2</italic> (promoting reduced glutathione &#8208;<italic toggle="yes">GSH</italic>&#8208; synthesis) (Jimenez&#8208;Blasco et&#160;al.&#160;<xref rid="jnc70252-bib-0099" ref-type="bibr">2023</xref>). Neurons, poor mROS producers, depend on astrocyte&#8208;derived GSH (Jimenez&#8208;Blasco et&#160;al.&#160;<xref rid="jnc70252-bib-0099" ref-type="bibr">2023</xref>; Rodr&#237;guez&#8208;Giraldo et&#160;al.&#160;<xref rid="jnc70252-bib-0170" ref-type="bibr">2022</xref>) for survival.</p><p>However, in AD, increased A&#946; disrupts mitochondrial function and calcium homeostasis (Patil et&#160;al.&#160;<xref rid="jnc70252-bib-0151" ref-type="bibr">2023</xref>). Reduced astrocytic OxPhos <italic toggle="yes">lowers mROS and GSH</italic> production, impairing neuronal protection (Jimenez&#8208;Blasco et&#160;al.&#160;<xref rid="jnc70252-bib-0099" ref-type="bibr">2023</xref>). Consequently, astrocytes shift toward a <italic toggle="yes">glycolytic, low&#8208;OxPhos phenotype</italic>, initially adaptive but ultimately exacerbating neuroinflammation and oxidative stress in early AD.</p></sec><sec id="jnc70252-sec-0011"><label>4.3</label><title>Lipid Metabolism Changes in Astrocytes During <styled-content style="fixed-case" toggle="no">AD</styled-content>
</title><p>Although astrocytic mitochondria show <italic toggle="yes">low OxPhos</italic> activity and ATP production, they are <italic toggle="yes">crucial</italic> for <italic toggle="yes">lipid homeostasis</italic> and brain protection against lipotoxicity. Impaired astrocytic OxPhos disrupts lipid metabolism, increases susceptibility to fatty acid&#8208;induced oxidative stress, promotes astrocyte activation, and contributes to neurodegeneration (Mi et&#160;al.&#160;<xref rid="jnc70252-bib-0132" ref-type="bibr">2023</xref>).</p><p>In AD brains, early <italic toggle="yes">mitochondrial dysfunction</italic> impairs fatty acid oxidation (<italic toggle="yes">FAO</italic>), leading to lipid droplet (LD) accumulation, lipid peroxidation, and oxidative stress (Shichkova et&#160;al.&#160;<xref rid="jnc70252-bib-0185" ref-type="bibr">2024</xref>; Conte et&#160;al.&#160;<xref rid="jnc70252-bib-0048" ref-type="bibr">2021</xref>). A mechanism proposed by Mi et&#160;al. (Mi et&#160;al.&#160;<xref rid="jnc70252-bib-0132" ref-type="bibr">2023</xref>) suggests that fatty acid overload exceeding OxPhos capacity leads to <italic toggle="yes">acetyl&#8208;CoA</italic> accumulation, activating <italic toggle="yes">STAT3</italic> and astrocyte reactivity. Additionally, failed astrocytic lipid clearance forces neurons to upregulate FAO, despite their limited antioxidant defenses, resulting in lipid peroxidation, ROS buildup, and cognitive decline (Mi et&#160;al.&#160;<xref rid="jnc70252-bib-0132" ref-type="bibr">2023</xref>).</p><p>Astrocytes generate <italic toggle="yes">ketone bodies</italic> (<italic toggle="yes">KBs</italic>) through &#946;&#8208;oxidation during <italic toggle="yes">prolonged starvation</italic> (Zhang et&#160;al.&#160;<xref rid="jnc70252-bib-0232" ref-type="bibr">2023</xref>; Le Foll and Levin&#160;<xref rid="jnc70252-bib-0111" ref-type="bibr">2016</xref>). In AD, <italic toggle="yes">disrupted astrocytic FAO reduces KB production</italic>, depriving neurons of alternative ATP sources and impairing synaptic function. Although a metabolic <italic toggle="yes">shift</italic> from glycolysis to ketogenesis occurs in AD (Yao et&#160;al.&#160;<xref rid="jnc70252-bib-0224" ref-type="bibr">2011</xref>; Iglesias et&#160;al.&#160;<xref rid="jnc70252-bib-0094" ref-type="bibr">2017</xref>), failure to adapt worsens mitochondrial dysfunction and oxidative stress.</p><p>Considering this, it can be argued that the reactive astrocyte response to neurodegenerative diseases involves <italic toggle="yes">enhanced glucose metabolism to produce lactate</italic>. However, when this process is <italic toggle="yes">disrupted, fatty acids are metabolized to produce KBs</italic>. If astrocytes are unable to compensate for damage&#8208;induced mitochondrial dysfunction through lactate and KB production, the onset of neurodegenerative diseases, such as AD, occurs (Iglesias et&#160;al.&#160;<xref rid="jnc70252-bib-0094" ref-type="bibr">2017</xref>).</p><p>
<italic toggle="yes">Hypercholesterolemia</italic> increases AD risk by promoting A&#946; aggregation (Popp et&#160;al.&#160;<xref rid="jnc70252-bib-0157" ref-type="bibr">2013</xref>). Astrocytes are the main brain cholesterol producers modulating neuroinflammation. However, chronic <italic toggle="yes">inflammation elevates cholesterol</italic>, forming <italic toggle="yes">lipid rafts</italic> that favor A&#946; deposition, Tau hyperphosphorylation, and cognitive impairment (Ricciarelli et&#160;al.&#160;<xref rid="jnc70252-bib-0165" ref-type="bibr">2012</xref>; Ullrich et&#160;al.&#160;<xref rid="jnc70252-bib-0206" ref-type="bibr">2010</xref>; Wang et&#160;al.&#160;<xref rid="jnc70252-bib-0212" ref-type="bibr">2022</xref>). Reducing astrocytic cholesterol synthesis could decrease cytokine production and mitigate AD progression (Wang et&#160;al.&#160;<xref rid="jnc70252-bib-0212" ref-type="bibr">2022</xref>).</p><p>Moreover, the <italic toggle="yes">APOE4</italic> variant heightens AD risk. ApoE binds A&#946; and regulates its clearance; however, APOE4 increases neuronal LDs, which astrocytes clear inefficiently, impairing FAO and leading to toxic LD buildup. This results in calcium dysregulation, ROS production, and inflammatory cytokine release, disrupting astrocytic support for neurons (Sienski et&#160;al.&#160;<xref rid="jnc70252-bib-0188" ref-type="bibr">2021</xref>; Qi et&#160;al.&#160;<xref rid="jnc70252-bib-0160" ref-type="bibr">2021</xref>).</p></sec></sec><sec id="jnc70252-sec-0012"><label>5</label><title>Astrocytic Biomarkers in Alzheimer's Disease</title><p>Sensitive and specific biomarkers exist for classical AD pathology, including A&#946; and tau in CSF or via PET, and neurodegeneration via [<sup>18</sup>F]FDG&#8208;PET or structural MRI. However, astrocytes are not yet integrated into these biomarker frameworks due to a paucity of specific in&#160;vivo markers (Carter, Herholz, et&#160;al.&#160;<xref rid="jnc70252-bib-0040" ref-type="bibr">2019</xref>). Fluid biomarkers such as GFAP, S100B, and YKL&#8208;40 can be measured in CSF and blood, with GFAP correlating with dementia severity (Salvad&#243; et&#160;al.&#160;<xref rid="jnc70252-bib-0174" ref-type="bibr">2022</xref>; Zebhauser et&#160;al.&#160;<xref rid="jnc70252-bib-0228" ref-type="bibr">2022</xref>). Yet, these biomarkers lack the sensitivity and specificity to distinguish early astrocytic changes from normal aging or other dementias. CSF d&#8208;serine, elevated in probable AD, and YKL&#8208;40, overexpressed in a subset of astrocytes, reflect astrocytic responses but require further validation (Carter, Herholz, et&#160;al.&#160;<xref rid="jnc70252-bib-0040" ref-type="bibr">2019</xref>; Madeira et&#160;al.&#160;<xref rid="jnc70252-bib-0124" ref-type="bibr">2015</xref>; Querol&#8208;Vilaseca et&#160;al.&#160;<xref rid="jnc70252-bib-0161" ref-type="bibr">2017</xref>; Rathcke and Vestergaard&#160;<xref rid="jnc70252-bib-0163" ref-type="bibr">2009</xref>; Alcolea et&#160;al.&#160;<xref rid="jnc70252-bib-0003" ref-type="bibr">2014</xref>; Craig&#8208;Schapiro et&#160;al.&#160;<xref rid="jnc70252-bib-0051" ref-type="bibr">2010</xref>; Alcolea et&#160;al.&#160;<xref rid="jnc70252-bib-0004" ref-type="bibr">2015</xref>; Antonell et&#160;al.&#160;<xref rid="jnc70252-bib-0009" ref-type="bibr">2014</xref>).</p><p>Neuroimaging approaches offer complementary strategies. PET radiotracers such as [<sup>11</sup>C]DED and [<sup>11</sup>C]BU99008 allow in&#160;vivo quantification of astrocyte reactivity, targeting MAO&#8208;B and imidazoline 2&#8208;binding sites, respectively, and show early alterations in autosomal dominant AD decades before symptom onset (Fowler et&#160;al.&#160;<xref rid="jnc70252-bib-0072" ref-type="bibr">1995</xref>; Tyacke et&#160;al.&#160;<xref rid="jnc70252-bib-0204" ref-type="bibr">2012</xref>; Engler et&#160;al.&#160;<xref rid="jnc70252-bib-0063" ref-type="bibr">2003</xref>; Johansson et&#160;al.&#160;<xref rid="jnc70252-bib-0100" ref-type="bibr">2007</xref>; Kumlien et&#160;al.&#160;<xref rid="jnc70252-bib-0110" ref-type="bibr">2001</xref>; Olsen et&#160;al.&#160;<xref rid="jnc70252-bib-0145" ref-type="bibr">2018</xref>; Rodriguez&#8208;Vieitez et&#160;al.&#160;<xref rid="jnc70252-bib-0171" ref-type="bibr">2015</xref>; Carter et&#160;al.&#160;<xref rid="jnc70252-bib-0041" ref-type="bibr">2012</xref>; Sch&#246;ll et&#160;al.&#160;<xref rid="jnc70252-bib-0178" ref-type="bibr">2015</xref>; Rodriguez&#8208;Vieitez et&#160;al.&#160;<xref rid="jnc70252-bib-0172" ref-type="bibr">2016</xref>; Parker et&#160;al.&#160;<xref rid="jnc70252-bib-0149" ref-type="bibr">2014</xref>; Tyacke et&#160;al.&#160;<xref rid="jnc70252-bib-0205" ref-type="bibr">2018</xref>). MRI&#8208;based methods, including [<sup>1</sup>H]&#8208;magnetic resonance spectroscopy (MRS), can assess astrocyte&#8208;enriched metabolites like myo&#8208;inositol and Glx (glutamate + glutamine), providing indirect measures of astrocytic metabolic function (Harris et&#160;al.&#160;<xref rid="jnc70252-bib-0085" ref-type="bibr">2015</xref>; Gao and Barker&#160;<xref rid="jnc70252-bib-0077" ref-type="bibr">2014</xref>; Hattori et&#160;al.&#160;<xref rid="jnc70252-bib-0088" ref-type="bibr">2002</xref>; Kantarci et&#160;al.&#160;<xref rid="jnc70252-bib-0105" ref-type="bibr">2003</xref>; Murray et&#160;al.&#160;<xref rid="jnc70252-bib-0139" ref-type="bibr">2014</xref>). Despite these advances, in&#160;vivo imaging biomarkers remain limited by specificity, and none have been validated for early clinical diagnosis in sporadic AD.</p><p>Overall, developing sensitive and specific astrocyte biomarkers&#8212;ideally detectable in peripheral fluids or via widely accessible imaging modalities&#8212;remains a critical need. Such tools could enable earlier detection of astrocytic metabolic dysfunction, facilitate monitoring of disease progression, and provide outcome measures for interventions targeting astrocyte metabolism in AD (Carter, Herholz, et&#160;al.&#160;<xref rid="jnc70252-bib-0040" ref-type="bibr">2019</xref>).</p></sec><sec id="jnc70252-sec-0013"><label>6</label><title>Navigating the Astrocytic Metabolic Continuum in Alzheimer's Disease: Implications for Pathogenesis and Therapy</title><p>AD emerges within a <italic toggle="yes">paradoxical metabolic landscape</italic> (L&#243;pez&#8208;Ot&#237;n et&#160;al.&#160;<xref rid="jnc70252-bib-0121" ref-type="bibr">2016</xref>; Moqri et&#160;al.&#160;<xref rid="jnc70252-bib-0027" ref-type="bibr">2023</xref>; Kaeberlein et&#160;al.&#160;<xref rid="jnc70252-bib-0103" ref-type="bibr">2015</xref>; L&#243;pez&#8208;Ot&#237;n et&#160;al.&#160;<xref rid="jnc70252-bib-0120" ref-type="bibr">2023</xref>; Wiley and Campisi&#160;<xref rid="jnc70252-bib-0216" ref-type="bibr">2021</xref>) wherein increasing cellular energy demands coexist with declining systemic energy expenditure (Moldakozhayev and Gladyshev&#160;<xref rid="jnc70252-bib-0136" ref-type="bibr">2023</xref>; Sturm, Bobba&#8208;Alves, et&#160;al.&#160;<xref rid="jnc70252-bib-0198" ref-type="bibr">2023</xref>; Bobba&#8208;Alves et&#160;al.&#160;<xref rid="jnc70252-bib-0031" ref-type="bibr">2022</xref>; Wordsworth et&#160;al.&#160;<xref rid="jnc70252-bib-0219" ref-type="bibr">2023</xref>). This contradiction underscores the brain's pivotal role as the central regulator of organismal energy homeostasis. In the face of peripheral hypermetabolic signals (de Magalh&#227;es&#160;<xref rid="jnc70252-bib-0055" ref-type="bibr">2024</xref>), the brain initiates energy&#8208;conserving strategies aimed at maintaining homeostasis, prioritizing critical neuronal and cognitive functions while curtailing others (Ferrucci et&#160;al.&#160;<xref rid="jnc70252-bib-0069" ref-type="bibr">2018</xref>). These adaptations, although protective in intent, may contribute over time to neuroendocrine dysfunction, immunosenescence, fatigue, brain atrophy, and ultimately, neurodegeneration (Shaulson et&#160;al.&#160;<xref rid="jnc70252-bib-0184" ref-type="bibr">2024</xref>).</p><p>Astrocytes, positioned at the neurovascular interface, function as <italic toggle="yes">key metabolic sentinels</italic>. Beyond their classical roles, astrocytes dynamically recalibrate their metabolism in response to local and systemic cues (Garc&#237;a&#8208;C&#225;ceres et&#160;al.&#160;<xref rid="jnc70252-bib-0078" ref-type="bibr">2019</xref>; Clasadonte and Prevot&#160;<xref rid="jnc70252-bib-0045" ref-type="bibr">2018</xref>; Chowen et&#160;al.&#160;<xref rid="jnc70252-bib-0043" ref-type="bibr">2016</xref>). In AD, reactive astrocytes undergo profound metabolic reprogramming (Escartin et&#160;al.&#160;<xref rid="jnc70252-bib-0064" ref-type="bibr">2021</xref>)&#8212;altering glycolytic flux, oxidative metabolism, and lipid handling&#8212;to support neuronal survival and modulate neuroinflammation (Morita et&#160;al.&#160;<xref rid="jnc70252-bib-0137" ref-type="bibr">2019</xref>; Xiong et&#160;al.&#160;<xref rid="jnc70252-bib-0220" ref-type="bibr">2022</xref>).</p><p>A compelling body of evidence now points to the existence of <italic toggle="yes">two temporally and functionally distinct astrocytic metabolic phases across the course of AD</italic> (Figure&#160;<xref rid="jnc70252-fig-0004" ref-type="fig">4</xref>). In prodromal and early symptomatic stages, astrocytes exhibit a <italic toggle="yes">hypermetabolic phenotype</italic> (Magistretti and Allaman&#160;<xref rid="jnc70252-bib-0125" ref-type="bibr">2018</xref>), characterized by increased glycolysis and augmented ATP and L&#8208;lactate production. This adaptation, corroborated by FDG&#8208;PET imaging and studies in transgenic models, appears to be neuroprotective, sustaining synaptic function amid neuronal stress (Dienel and Cruz&#160;<xref rid="jnc70252-bib-0060" ref-type="bibr">2016</xref>; Dienel&#160;<xref rid="jnc70252-bib-0059" ref-type="bibr">2019</xref>). However, prolonged glycolysis exacerbates neuroinflammation (Robb et&#160;al.&#160;<xref rid="jnc70252-bib-0167" ref-type="bibr">2020</xref>; Pamies et&#160;al.&#160;<xref rid="jnc70252-bib-0148" ref-type="bibr">2021</xref>), suggesting that early astrocytic hypermetabolism, though initially compensatory, may <italic toggle="yes">ultimately drive disease acceleration</italic>. Notably, spatial overlap between regions of glycolytic upregulation and amyloid deposition suggests that early metabolic reprogramming may not merely reflect an epiphenomenon but could actively modulate disease trajectory.</p><fig position="float" fig-type="FIGURE" id="jnc70252-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Schematic representation of postulated hypothesis. Astrocytic metabolic reprogramming plays dual roles in neurodegeneration, balancing neuroprotection and neurotoxicity depending on the stage and context of the disease. While early hypermetabolic states may accelerate disease progression, later hypometabolic adaptations could offer protective benefits initially but could end up inducing neuronal dysfunction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="JNC-169-0-g006.jpg"/></fig><p>As AD progresses into more advanced stages, a <italic toggle="yes">second, contrasting astrocytic state emerges</italic>&#8212;a <italic toggle="yes">hypometabolic phenotype</italic>, marked by diminished glycolytic activity, glycogen depletion, and reduced lactate output (Yu et&#160;al.&#160;<xref rid="jnc70252-bib-0227" ref-type="bibr">1995</xref>; Gavillet et&#160;al.&#160;<xref rid="jnc70252-bib-0079" ref-type="bibr">2008</xref>; V&#233;ga et&#160;al.&#160;<xref rid="jnc70252-bib-0207" ref-type="bibr">2002</xref>). This downregulation may represent a compensatory mechanism aimed at dampening chronic inflammation and reducing glial&#8208;driven excitotoxicity but simultaneously undermines neuronal support, exacerbating synaptic and cognitive decline. Single&#8208;cell transcriptomics corroborate this model, revealing early upregulation and late&#8208;stage attenuation of glycolytic and mitochondrial gene expression (Serrano&#8208;Pozo et&#160;al.&#160;<xref rid="jnc70252-bib-0180" ref-type="bibr">2024</xref>). Thus, the astrocytic metabolic landscape in AD is <italic toggle="yes">not static but dynamic</italic>, encompassing an early hyperfunctional phase followed by a late hypoenergetic decline (Figure&#160;<xref rid="jnc70252-fig-0004" ref-type="fig">4</xref>).</p><p>The implications of these findings are far&#8208;reaching. They suggest the existence of <italic toggle="yes">two distinct therapeutic windows</italic> in the course of AD: one in which <italic toggle="yes">attenuating early astrocytic hypermetabolism</italic> could prevent the cascade of neuroinflammation and synaptic stress that precipitates neurodegeneration (Ardanaz et&#160;al.&#160;<xref rid="jnc70252-bib-0010" ref-type="bibr">2024</xref>); and a second, in which reviving astrocytic metabolism in late stages may restore metabolic support to failing neurons. Intriguingly, while promising efforts have begun to explore strategies to boost astrocytic metabolism in late AD&#8212;with some evidence of functional recovery (Minhas et&#160;al.&#160;<xref rid="jnc70252-bib-0135" ref-type="bibr">2024</xref>)&#8212;to our knowledge, no studies to date have definitively addressed whether dampening the initial metabolic surge could forestall disease onset or progression. This remains a critical and uncharted frontier in AD research.</p><p>In light of these insights, several pivotal questions emerge for future investigation:
<list list-type="bullet" id="jnc70252-list-0001"><list-item id="jnc70252-li-0087"><p>How do temporal shifts in astrocyte metabolism influence AD progression at the molecular, cellular, and systems level?</p></list-item><list-item id="jnc70252-li-0088"><p>Which metabolic pathways are most susceptible to dysregulation in early versus late reactive astrocytes?</p></list-item><list-item id="jnc70252-li-0089"><p>How can the balance between protective and detrimental astrocytic metabolic responses be therapeutically modulated?</p></list-item><list-item id="jnc70252-li-0090"><p>What are the mechanistic links between astrocytic heterogeneity, metabolic phenotype, and disease vulnerability across different brain regions?</p></list-item><list-item id="jnc70252-li-0091"><p>Can we leverage spatial and single&#8208;cell metabolomics to identify new metabolic subtypes of reactive astrocytes, and how do these interact with neuronal circuits under stress?</p></list-item></list>
</p><p>Addressing these challenges requires a multidimensional approach, integrating molecular, genetic, imaging, and computational tools to unravel the metabolic logic of reactive astrocytes in AD. The ability of astrocytes to sense, integrate, and respond to energy demands&#8212;both locally and systemically&#8212;places them at the nexus of neurodegenerative vulnerability and resilience. As such, astrocytic metabolism is not merely a consequence of pathology but a potential driver and modulator of disease. By harnessing this adaptive plasticity, novel therapeutic strategies may emerge&#8212;ones that modulate astrocytic energy sensing and metabolic programming to delay onset, mitigate progression, and ultimately alter the course of AD and related disorders.</p></sec><sec id="jnc70252-sec-0014"><label>7</label><title>Concluding Remarks</title><p>Astrocytic metabolism emerges as a critical yet underappreciated component in the pathophysiological landscape of AD. In the present review, we propose a dynamic, biphasic trajectory wherein astrocytes initially engage in a hypermetabolic response aimed at sustaining neuronal function, followed by a hypometabolic collapse that deprives neurons of essential metabolic support. This metabolic plasticity, while initially protective, may ultimately contribute to neuroinflammation, synaptic failure, and disease progression.</p><p>Crucially, astrocytes act <italic toggle="yes">not only as metabolic buffers</italic> but also as active <italic toggle="yes">transducers of peripheral cues into central nervous system responses</italic>, positioning them as <italic toggle="yes">key modulators of neurodegenerative vulnerability</italic>. Their unique anatomical and functional attributes&#8212;such as glucose sensing, energy redistribution, and immune regulation&#8212;underscore their potential as both early biomarkers and therapeutic targets.</p><p>Understanding the temporal and mechanistic nuances of astrocytic metabolic reprogramming is therefore essential. It opens up the possibility of tailored, stage&#8208;specific interventions: early modulation to prevent pathological overactivation, and late&#8208;stage support to restore metabolic resilience.</p><p>Ultimately, reframing AD as a disorder not only of neuronal dysfunction but also of <italic toggle="yes">astrocytic metabolic dysregulation</italic> may lead to a new generation of therapeutic strategies&#8212;ones that harness the adaptive capacities of astrocytes to reshape disease trajectories and promote brain resilience.</p></sec><sec id="jnc70252-sec-0020"><title>Author Contributions</title><p>
<bold>Leyre S&#225;nchez de Muniain:</bold> conceptualization, writing &#8211; original draft. <bold>Paula Escalada:</bold> conceptualization, writing &#8211; original draft. <bold>Mar&#237;a J. Ram&#237;rez:</bold> conceptualization, writing &#8211; review and editing. <bold>Maite Solas:</bold> conceptualization, funding acquisition, writing &#8211; original draft, writing &#8211; review and editing, visualization, formal analysis, supervision.</p></sec><sec sec-type="conclusions" id="jnc70252-sec-0016"><title>Consent</title><p>&#8220;Informed consent was achieved for all subjects, and the experiments were approved by the local ethics committee.&#8221;</p></sec><sec sec-type="COI-statement" id="jnc70252-sec-0017"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="peer-review" id="jnc70252-sec-0021"><title>Peer Review</title><p>The peer review history for this article is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/jnc.70252" ext-link-type="uri">https://www.webofscience.com/api/gateway/wos/peer&#8208;review/10.1111/jnc.70252</ext-link>.</p></sec></body><back><ack id="jnc70252-sec-0015"><title>Acknowledgments</title><p>This work was funded by MCIN/AEI/<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.13039/501100011033" ext-link-type="uri">10.13039/501100011033</ext-link> and by &#8220;ERDF A way of making Europe&#8221; (PID2021&#8208;128737NB&#8208;I00). L.SdM. and P.E. are supported by an FPU (Formaci&#243;n de Profesorado Universitario) fellowship from the Spanish Ministry of Universities (FPU24/00007 and FPU23/02644 respectively). All figures have been created in BioRender.</p></ack><sec sec-type="data-availability" id="jnc70252-sec-0019"><title>Data Availability Statement</title><p>Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.</p></sec><ref-list content-type="cited-references" id="jnc70252-bibl-0001"><title>References</title><ref id="jnc70252-bib-0001"><mixed-citation publication-type="journal" id="jnc70252-cit-0001"><string-name name-style="western"><surname>Adamu</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Gao</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Xue</surname></string-name>. <year>2024</year>. &#8220;<article-title>The Role of Neuroinflammation in Neurodegenerative Diseases: Current Understanding and Future Therapeutic Targets</article-title>.&#8221; <source>Frontiers in Aging Neuroscience</source><volume>16</volume>: <elocation-id>1347987</elocation-id>.<pub-id pub-id-type="pmid">38681666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2024.1347987</pub-id><pub-id pub-id-type="pmcid">PMC11045904</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0002"><mixed-citation publication-type="journal" id="jnc70252-cit-0002"><string-name name-style="western"><surname>Agulhon</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>M.&#8208;Y.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Murphy</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Myers</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Lauderdale</surname></string-name>, and <string-name name-style="western"><given-names>T. A.</given-names><surname>Fiacco</surname></string-name>. <year>2012</year>. &#8220;<article-title>Calcium Signaling and Gliotransmission in Normal vs. Reactive Astrocytes</article-title>.&#8221; <source>Frontiers in Pharmacology</source><volume>3</volume>: <elocation-id>139</elocation-id>.<pub-id pub-id-type="pmid">22811669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2012.00139</pub-id><pub-id pub-id-type="pmcid">PMC3395812</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0003"><mixed-citation publication-type="journal" id="jnc70252-cit-0003"><string-name name-style="western"><surname>Alcolea</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Carmona&#8208;Iragui</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Su&#225;rez&#8208;Calvet</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Relationship Between &#946;&#8208;Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease</article-title>.&#8221; <source>Journal of Alzheimer's Disease</source><volume>42</volume>: <fpage>157</fpage>&#8211;<lpage>167</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-140240</pub-id><pub-id pub-id-type="pmid">24820015</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0004"><mixed-citation publication-type="journal" id="jnc70252-cit-0004"><string-name name-style="western"><surname>Alcolea</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Mart&#237;nez&#8208;Lage</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>S&#225;nchez&#8208;Juan</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Amyloid Precursor Protein Metabolism and Inflammation Markers in Preclinical Alzheimer Disease</article-title>.&#8221; <source>Neurology</source><volume>85</volume>: <fpage>626</fpage>&#8211;<lpage>633</lpage>.<pub-id pub-id-type="pmid">26180139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000001859</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0005"><mixed-citation publication-type="journal" id="jnc70252-cit-0005"><string-name name-style="western"><surname>Almeida</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Almeida</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>Bola&#241;os</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Moncada</surname></string-name>. <year>2001</year>. &#8220;<article-title>Different Responses of Astrocytes and Neurons to Nitric Oxide: The Role of Glycolytically Generated ATP in Astrocyte Protection</article-title>.&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>98</volume>: <fpage>15294</fpage>&#8211;<lpage>15299</lpage>.<pub-id pub-id-type="pmid">11742096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.261560998</pub-id><pub-id pub-id-type="pmcid">PMC65023</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0006"><mixed-citation publication-type="book" id="jnc70252-cit-0006"><collab collab-type="authors">Alzheimer's Association</collab>
. <year>2022</year>. <source>2022 Alzheimer's Disease Facts and Figures</source>. <publisher-name>Alzheimer's &amp; Dementia</publisher-name>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12638</pub-id><pub-id pub-id-type="pmid">35289055</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0008"><mixed-citation publication-type="journal" id="jnc70252-cit-0008"><string-name name-style="western"><surname>Andolf</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Bladh</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>M&#246;ller</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Sydsj&#246;</surname></string-name>. <year>2020</year>. &#8220;<article-title>Prior Placental Bed Disorders and Later Dementia: A Retrospective Swedish Register&#8208;Based Cohort Study</article-title>.&#8221; <source>BJOG</source><volume>127</volume>: <fpage>1090</fpage>&#8211;<lpage>1099</lpage>.<pub-id pub-id-type="pmid">32145044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1471-0528.16201</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0009"><mixed-citation publication-type="journal" id="jnc70252-cit-0009"><string-name name-style="western"><surname>Antonell</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Mansilla</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Rami</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Cerebrospinal Fluid Level of YKL&#8208;40 Protein in Preclinical and Prodromal Alzheimer's Disease</article-title>.&#8221; <source>Journal of Alzheimer's Disease</source><volume>42</volume>: <fpage>901</fpage>&#8211;<lpage>908</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-140624</pub-id><pub-id pub-id-type="pmid">25024322</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0010"><mixed-citation publication-type="journal" id="jnc70252-cit-0010"><string-name name-style="western"><surname>Ardanaz</surname>, <given-names>C. G.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>de la Cruz</surname></string-name>, <string-name name-style="western"><given-names>P. S.</given-names><surname>Minhas</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Astrocytic GLUT1 Reduction Paradoxically Improves Central and Peripheral Glucose Homeostasis</article-title>.&#8221; <source>Science Advances</source><volume>10</volume>: <elocation-id>eadp1115</elocation-id>.<pub-id pub-id-type="pmid">39423276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adp1115</pub-id><pub-id pub-id-type="pmcid">PMC11488540</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0011"><mixed-citation publication-type="journal" id="jnc70252-cit-0011"><string-name name-style="western"><surname>Arnold</surname>, <given-names>S. E.</given-names></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Arvanitakis</surname></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Macauley&#8208;Rambach</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Brain Insulin Resistance in Type 2 Diabetes and Alzheimer Disease: Concepts and Conundrums</article-title>.&#8221; <source>Nature Reviews. Neurology</source><volume>14</volume>: <fpage>168</fpage>&#8211;<lpage>181</lpage>.<pub-id pub-id-type="pmid">29377010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2017.185</pub-id><pub-id pub-id-type="pmcid">PMC6098968</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0012"><mixed-citation publication-type="journal" id="jnc70252-cit-0012"><string-name name-style="western"><surname>Ashraf</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Brooks</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Edison</surname></string-name>. <year>2015</year>. &#8220;<article-title>Cortical Hypermetabolism in MCI Subjects: A Compensatory Mechanism?</article-title>&#8221; <source>European Journal of Nuclear Medicine and Molecular Imaging</source><volume>42</volume>: <fpage>447</fpage>&#8211;<lpage>458</lpage>.<pub-id pub-id-type="pmid">25267349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-014-2919-z</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0013"><mixed-citation publication-type="journal" id="jnc70252-cit-0013"><string-name name-style="western"><surname>Azad</surname>, <given-names>N. A.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Al Bugami</surname></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Loy&#8208;English</surname></string-name>. <year>2007</year>. &#8220;<article-title>Gender Differences in Dementia Risk Factors</article-title>.&#8221; <source>Gender Medicine</source><volume>4</volume>: <fpage>120</fpage>&#8211;<lpage>129</lpage>.<pub-id pub-id-type="pmid">17707846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1550-8579(07)80026-x</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0014"><mixed-citation publication-type="journal" id="jnc70252-cit-0014"><string-name name-style="western"><surname>Bairey Merz</surname>, <given-names>C. N.</given-names></string-name>, <string-name name-style="western"><given-names>L. J.</given-names><surname>Shaw</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Reis</surname></string-name>, et&#160;al. <year>2006</year>. &#8220;<article-title>Insights From the NHLBI&#8208;Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: Gender Differences in Presentation, Diagnosis, and Outcome With Regard to Gender&#8208;Based Pathophysiology of Atherosclerosis and Macrovascular and Microvascular Coronary Disease</article-title>.&#8221; <source>Journal of the American College of Cardiology</source><volume>47</volume>: <fpage>S21</fpage>&#8211;<lpage>S29</lpage>.<pub-id pub-id-type="pmid">16458167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2004.12.084</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0015"><mixed-citation publication-type="journal" id="jnc70252-cit-0015"><string-name name-style="western"><surname>Baker</surname>, <given-names>D. J.</given-names></string-name>, and <string-name name-style="western"><given-names>R. C.</given-names><surname>Petersen</surname></string-name>. <year>2018</year>. &#8220;<article-title>Cellular Senescence in Brain Aging and Neurodegenerative Diseases: Evidence and Perspectives</article-title>.&#8221; <source>Journal of Clinical Investigation</source><volume>128</volume>: <fpage>1208</fpage>&#8211;<lpage>1216</lpage>.<pub-id pub-id-type="pmid">29457783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI95145</pub-id><pub-id pub-id-type="pmcid">PMC5873891</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0016"><mixed-citation publication-type="journal" id="jnc70252-cit-0016"><string-name name-style="western"><surname>Ballard</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Gauthier</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Corbett</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Brayne</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Aarsland</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Jones</surname></string-name>. <year>2011</year>. &#8220;<article-title>Alzheimer's Disease</article-title>.&#8221; <source>Lancet</source><volume>377</volume>: <fpage>1019</fpage>&#8211;<lpage>1031</lpage>.<pub-id pub-id-type="pmid">21371747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(10)61349-9</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0017"><mixed-citation publication-type="journal" id="jnc70252-cit-0017"><string-name name-style="western"><surname>Barha</surname>, <given-names>C. K.</given-names></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Best</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Rosano</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Yaffe</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Catov</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Liu&#8208;Ambrose</surname></string-name>. <year>2020</year>. &#8220;<article-title>Sex&#8208;Specific Relationship Between Long&#8208;Term Maintenance of Physical Activity and Cognition in the Health ABC Study: Potential Role of Hippocampal and Dorsolateral Prefrontal Cortex Volume</article-title>.&#8221; <source>Journals of Gerontology. Series A, Biological Sciences and Medical Sciences</source><volume>75</volume>: <fpage>764</fpage>&#8211;<lpage>770</lpage>.<pub-id pub-id-type="pmid">30958523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glz093</pub-id><pub-id pub-id-type="pmcid">PMC7931854</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0018"><mixed-citation publication-type="journal" id="jnc70252-cit-0018"><string-name name-style="western"><surname>Barha</surname>, <given-names>C. K.</given-names></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Davis</surname></string-name>, <string-name name-style="western"><given-names>R. S.</given-names><surname>Falck</surname></string-name>, <string-name name-style="western"><given-names>L. S.</given-names><surname>Nagamatsu</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Liu&#8208;Ambrose</surname></string-name>. <year>2017</year>. &#8220;<article-title>Sex Differences in Exercise Efficacy to Improve Cognition: A Systematic Review and Meta&#8208;Analysis of Randomized Controlled Trials in Older Humans</article-title>.&#8221; <source>Frontiers in Neuroendocrinology</source><volume>46</volume>: <fpage>71</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">28442274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yfrne.2017.04.002</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0019"><mixed-citation publication-type="journal" id="jnc70252-cit-0019"><string-name name-style="western"><surname>Barha</surname>, <given-names>C. K.</given-names></string-name>, <string-name name-style="western"><given-names>G.&#8208;Y. R.</given-names><surname>Hsiung</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Best</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Sex Difference in Aerobic Exercise Efficacy to Improve Cognition in Older Adults With Vascular Cognitive Impairment: Secondary Analysis of a Randomized Controlled Trial</article-title>.&#8221; <source>Journal of Alzheimer's Disease</source><volume>60</volume>: <fpage>1397</fpage>&#8211;<lpage>1410</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170221</pub-id><pub-id pub-id-type="pmid">29036816</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0020"><mixed-citation publication-type="journal" id="jnc70252-cit-0020"><string-name name-style="western"><surname>Barnes</surname>, <given-names>D. E.</given-names></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Yaffe</surname></string-name>. <year>2011</year>. &#8220;<article-title>The Projected Effect of Risk Factor Reduction on Alzheimer's Disease Prevalence</article-title>.&#8221; <source>Lancet Neurology</source><volume>10</volume>: <fpage>819</fpage>&#8211;<lpage>828</lpage>.<pub-id pub-id-type="pmid">21775213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(11)70072-2</pub-id><pub-id pub-id-type="pmcid">PMC3647614</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0021"><mixed-citation publication-type="journal" id="jnc70252-cit-0021"><string-name name-style="western"><surname>Basit</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wohlfahrt</surname></string-name>, and <string-name name-style="western"><given-names>H. A.</given-names><surname>Boyd</surname></string-name>. <year>2018</year>. &#8220;<article-title>Pre&#8208;Eclampsia and Risk of Dementia Later in Life: Nationwide Cohort Study</article-title>.&#8221; <source>BMJ (Clinical Research Ed.)</source><volume>363</volume>: <elocation-id>k4109</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.k4109</pub-id><pub-id pub-id-type="pmcid">PMC6191824</pub-id><pub-id pub-id-type="pmid">30333106</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0022"><mixed-citation publication-type="journal" id="jnc70252-cit-0022"><string-name name-style="western"><surname>Baumgart</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>H. M.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>M. C.</given-names><surname>Carrillo</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Fazio</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Kim</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Johns</surname></string-name>. <year>2015</year>. &#8220;<article-title>Summary of the Evidence on Modifiable Risk Factors for Cognitive Decline and Dementia: A Population&#8208;Based Perspective</article-title>.&#8221; <source>Alzheimers Dement</source><volume>11</volume>: <fpage>718</fpage>&#8211;<lpage>726</lpage>.<pub-id pub-id-type="pmid">26045020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2015.05.016</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0023"><mixed-citation publication-type="book" id="jnc70252-cit-0023"><string-name name-style="western"><surname>Bentivegna</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Pomilio</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Bellotto</surname></string-name>, et&#160;al. <year>2025</year>. <source>Amyloid Beta Regulates Astrocytic Glucose Metabolism and Insulin Signaling in Experimental Models of Alzheimer's Disease</source>. <publisher-name>Aging Dis</publisher-name>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2025.0484</pub-id><pub-id pub-id-type="pmid">40768640</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0024"><mixed-citation publication-type="journal" id="jnc70252-cit-0024"><string-name name-style="western"><surname>Bero</surname>, <given-names>A. W.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Yan</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Roh</surname></string-name>, et&#160;al. <year>2011</year>. &#8220;<article-title>Neuronal Activity Regulates the Regional Vulnerability to Amyloid&#8208;&#946; Deposition</article-title>.&#8221; <source>Nature Neuroscience</source><volume>14</volume>: <fpage>750</fpage>&#8211;<lpage>756</lpage>.<pub-id pub-id-type="pmid">21532579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.2801</pub-id><pub-id pub-id-type="pmcid">PMC3102784</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0025"><mixed-citation publication-type="journal" id="jnc70252-cit-0025"><string-name name-style="western"><surname>Bezzi</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Domercq</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Brambilla</surname></string-name>, et&#160;al. <year>2001</year>. &#8220;<article-title>CXCR4&#8208;Activated Astrocyte Glutamate Release via TNFalpha: Amplification by Microglia Triggers Neurotoxicity</article-title>.&#8221; <source>Nature Neuroscience</source><volume>4</volume>: <fpage>702</fpage>&#8211;<lpage>710</lpage>.<pub-id pub-id-type="pmid">11426226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/89490</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0026"><mixed-citation publication-type="journal" id="jnc70252-cit-0026"><string-name name-style="western"><surname>Bhat</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>E. P.</given-names><surname>Crowe</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bitto</surname></string-name>, et&#160;al. <year>2012</year>. &#8220;<article-title>Astrocyte Senescence as a Component of Alzheimer's Disease</article-title>.&#8221; <source>PLoS One</source><volume>7</volume>: <elocation-id>e45069</elocation-id>.<pub-id pub-id-type="pmid">22984612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0045069</pub-id><pub-id pub-id-type="pmcid">PMC3440417</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0028"><mixed-citation publication-type="journal" id="jnc70252-cit-0028"><string-name name-style="western"><surname>Birch</surname>, <given-names>J.</given-names></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Gil</surname></string-name>. <year>2020</year>. &#8220;<article-title>Senescence and the SASP: Many Therapeutic Avenues</article-title>.&#8221; <source>Genes &amp; Development</source><volume>34</volume>: <fpage>1565</fpage>&#8211;<lpage>1576</lpage>.<pub-id pub-id-type="pmid">33262144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.343129.120</pub-id><pub-id pub-id-type="pmcid">PMC7706700</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0029"><mixed-citation publication-type="journal" id="jnc70252-cit-0029"><string-name name-style="western"><surname>Birnbaum</surname>, <given-names>J. H.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Wanner</surname></string-name>, <string-name name-style="western"><given-names>A. F.</given-names><surname>Gietl</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Oxidative Stress and Altered Mitochondrial Protein Expression in the Absence of Amyloid&#8208;&#946; and Tau Pathology in iPSC&#8208;Derived Neurons From Sporadic Alzheimer's Disease Patients</article-title>.&#8221; <source>Stem Cell Research</source><volume>27</volume>: <fpage>121</fpage>&#8211;<lpage>130</lpage>.<pub-id pub-id-type="pmid">29414602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scr.2018.01.019</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0030"><mixed-citation publication-type="journal" id="jnc70252-cit-0030"><string-name name-style="western"><surname>Bixler</surname>, <given-names>E. O.</given-names></string-name>, <string-name name-style="western"><given-names>A. N.</given-names><surname>Vgontzas</surname></string-name>, <string-name name-style="western"><given-names>H. M.</given-names><surname>Lin</surname></string-name>, et&#160;al. <year>2001</year>. &#8220;<article-title>Prevalence of Sleep&#8208;Disordered Breathing in Women: Effects of Gender</article-title>.&#8221; <source>American Journal of Respiratory and Critical Care Medicine</source><volume>163</volume>: <fpage>608</fpage>&#8211;<lpage>613</lpage>.<pub-id pub-id-type="pmid">11254512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/ajrccm.163.3.9911064</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0031"><mixed-citation publication-type="journal" id="jnc70252-cit-0031"><string-name name-style="western"><surname>Bobba&#8208;Alves</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>R.&#8208;P.</given-names><surname>Juster</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Picard</surname></string-name>. <year>2022</year>. &#8220;<article-title>The Energetic Cost of Allostasis and Allostatic Load</article-title>.&#8221; <source>Psychoneuroendocrinology</source><volume>146</volume>: <elocation-id>105951</elocation-id>.<pub-id pub-id-type="pmid">36302295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2022.105951</pub-id><pub-id pub-id-type="pmcid">PMC10082134</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0032"><mixed-citation publication-type="journal" id="jnc70252-cit-0032"><string-name name-style="western"><surname>Bobba&#8208;Alves</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Sturm</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lin</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Cellular Allostatic Load Is Linked to Increased Energy Expenditure and Accelerated Biological Aging</article-title>.&#8221; <source>Psychoneuroendocrinology</source><volume>155</volume>: <elocation-id>106322</elocation-id>.<pub-id pub-id-type="pmid">37423094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2023.106322</pub-id><pub-id pub-id-type="pmcid">PMC10528419</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0033"><mixed-citation publication-type="journal" id="jnc70252-cit-0033"><string-name name-style="western"><surname>Bombois</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Derambure</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Pasquier</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Monaca</surname></string-name>. <year>2010</year>. &#8220;<article-title>Sleep Disorders in Aging and Dementia</article-title>.&#8221; <source>Journal of Nutrition, Health &amp; Aging</source><volume>14</volume>: <fpage>212</fpage>&#8211;<lpage>217</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12603-010-0052-7</pub-id><pub-id pub-id-type="pmid">20191256</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0034"><mixed-citation publication-type="journal" id="jnc70252-cit-0034"><string-name name-style="western"><surname>Bosco</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Fava</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Plastino</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Montalcini</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Pujia</surname></string-name>. <year>2011</year>. &#8220;<article-title>Possible Implications of Insulin Resistance and Glucose Metabolism in Alzheimer's Disease Pathogenesis</article-title>.&#8221; <source>Journal of Cellular and Molecular Medicine</source><volume>15</volume>: <fpage>1807</fpage>&#8211;<lpage>1821</lpage>.<pub-id pub-id-type="pmid">21435176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1582-4934.2011.01318.x</pub-id><pub-id pub-id-type="pmcid">PMC3918038</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0035"><mixed-citation publication-type="journal" id="jnc70252-cit-0035"><string-name name-style="western"><surname>Bouzier&#8208;Sore</surname>, <given-names>A.&#8208;K.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Voisin</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Bouchaud</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Bezancon</surname></string-name>, <string-name name-style="western"><given-names>J.&#8208;M.</given-names><surname>Franconi</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Pellerin</surname></string-name>. <year>2006</year>. &#8220;<article-title>Competition Between Glucose and Lactate as Oxidative Energy Substrates in Both Neurons and Astrocytes: A Comparative NMR Study</article-title>.&#8221; <source>European Journal of Neuroscience</source><volume>24</volume>: <fpage>1687</fpage>&#8211;<lpage>1694</lpage>.<pub-id pub-id-type="pmid">17004932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1460-9568.2006.05056.x</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0036"><mixed-citation publication-type="journal" id="jnc70252-cit-0036"><string-name name-style="western"><surname>Cai</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Fan</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Glycogenolysis Is Crucial for Astrocytic Glycogen Accumulation and Brain Damage After Reperfusion in Ischemic Stroke</article-title>.&#8221; <source>IScience</source><volume>23</volume>: <elocation-id>101136</elocation-id>.<pub-id pub-id-type="pmid">32446205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2020.101136</pub-id><pub-id pub-id-type="pmcid">PMC7240195</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0037"><mixed-citation publication-type="journal" id="jnc70252-cit-0037"><string-name name-style="western"><surname>Cal&#236;</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Cantando</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Veloz</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Metabolic Reprogramming of Astrocytes in Pathological Conditions: Implications for Neurodegenerative Diseases</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>25</volume>: <fpage>8922</fpage>.<pub-id pub-id-type="pmid">39201607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25168922</pub-id><pub-id pub-id-type="pmcid">PMC11354244</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0038"><mixed-citation publication-type="journal" id="jnc70252-cit-0038"><string-name name-style="western"><surname>Carmona</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Hardy</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Guerreiro</surname></string-name>. <year>2018</year>. &#8220;<article-title>The Genetic Landscape of Alzheimer Disease</article-title>.&#8221; <source>Handbook of Clinical Neurology</source><volume>148</volume>: <fpage>395</fpage>&#8211;<lpage>408</lpage>.<pub-id pub-id-type="pmid">29478590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-444-64076-5.00026-0</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0039"><mixed-citation publication-type="journal" id="jnc70252-cit-0039"><string-name name-style="western"><surname>Carter</surname>, <given-names>S. F.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Chiotis</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Nordberg</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Rodriguez&#8208;Vieitez</surname></string-name>. <year>2019</year>. &#8220;<article-title>Longitudinal Association Between Astrocyte Function and Glucose Metabolism in Autosomal Dominant Alzheimer's Disease</article-title>.&#8221; <source>European Journal of Nuclear Medicine and Molecular Imaging</source><volume>46</volume>: <fpage>348</fpage>&#8211;<lpage>356</lpage>.<pub-id pub-id-type="pmid">30515545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-018-4217-7</pub-id><pub-id pub-id-type="pmcid">PMC6333721</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0040"><mixed-citation publication-type="journal" id="jnc70252-cit-0040"><string-name name-style="western"><surname>Carter</surname>, <given-names>S. F.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Herholz</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Rosa&#8208;Neto</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Pellerin</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Nordberg</surname></string-name>, and <string-name name-style="western"><given-names>E. R.</given-names><surname>Zimmer</surname></string-name>. <year>2019</year>. &#8220;<article-title>Astrocyte Biomarkers in Alzheimer's Disease</article-title>.&#8221; <source>Trends in Molecular Medicine</source><volume>25</volume>: <fpage>77</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">30611668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2018.11.006</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0041"><mixed-citation publication-type="journal" id="jnc70252-cit-0041"><string-name name-style="western"><surname>Carter</surname>, <given-names>S. F.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Sch&#246;ll</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Almkvist</surname></string-name>, et&#160;al. <year>2012</year>. &#8220;<article-title>Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C&#8208;Deuterium&#8208;L&#8208;Deprenyl: A Multitracer PET Paradigm Combining 11C&#8208;Pittsburgh Compound B and 18F&#8208;FDG</article-title>.&#8221; <source>Journal of Nuclear Medicine</source><volume>53</volume>: <fpage>37</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">22213821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.110.087031</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0042"><mixed-citation publication-type="journal" id="jnc70252-cit-0042"><string-name name-style="western"><surname>Ch&#234;ne</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Beiser</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Au</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Gender and Incidence of Dementia in the Framingham Heart Study From Mid&#8208;Adult Life</article-title>.&#8221; <source>Alzheimers Dement</source><volume>11</volume>: <fpage>310</fpage>&#8211;<lpage>320</lpage>.<pub-id pub-id-type="pmid">24418058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2013.10.005</pub-id><pub-id pub-id-type="pmcid">PMC4092061</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0043"><mixed-citation publication-type="journal" id="jnc70252-cit-0043"><string-name name-style="western"><surname>Chowen</surname>, <given-names>J. A.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Argente&#8208;Ariz&#243;n</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Freire&#8208;Regatillo</surname></string-name>, <string-name name-style="western"><given-names>L. M.</given-names><surname>Frago</surname></string-name>, <string-name name-style="western"><given-names>T. L.</given-names><surname>Horvath</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Argente</surname></string-name>. <year>2016</year>. &#8220;<article-title>The Role of Astrocytes in the Hypothalamic Response and Adaptation to Metabolic Signals</article-title>.&#8221; <source>Progress in Neurobiology</source><volume>144</volume>: <fpage>68</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">27000556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2016.03.001</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0044"><mixed-citation publication-type="journal" id="jnc70252-cit-0044"><string-name name-style="western"><surname>Chun</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Im</surname></string-name>, <string-name name-style="western"><given-names>Y. J.</given-names><surname>Kang</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Severe Reactive Astrocytes Precipitate Pathological Hallmarks of Alzheimer's Disease via H<sub>2</sub>O<sub>2</sub>&#8208; Production</article-title>.&#8221; <source>Nature Neuroscience</source><volume>23</volume>: <fpage>1555</fpage>&#8211;<lpage>1566</lpage>.<pub-id pub-id-type="pmid">33199896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-020-00735-y</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0045"><mixed-citation publication-type="journal" id="jnc70252-cit-0045"><string-name name-style="western"><surname>Clasadonte</surname>, <given-names>J.</given-names></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Prevot</surname></string-name>. <year>2018</year>. &#8220;<article-title>The Special Relationship: Glia&#8208;Neuron Interactions in the Neuroendocrine Hypothalamus</article-title>.&#8221; <source>Nature Reviews. Endocrinology</source><volume>14</volume>: <fpage>25</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrendo.2017.124</pub-id><pub-id pub-id-type="pmid">29076504</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0046"><mixed-citation publication-type="journal" id="jnc70252-cit-0046"><string-name name-style="western"><surname>Cohen</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Janicki&#8208;Deverts</surname></string-name>, <string-name name-style="western"><given-names>W. J.</given-names><surname>Doyle</surname></string-name>, et&#160;al. <year>2012</year>. &#8220;<article-title>Chronic Stress, Glucocorticoid Receptor Resistance, Inflammation, and Disease Risk</article-title>.&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>109</volume>: <fpage>5995</fpage>&#8211;<lpage>5999</lpage>.<pub-id pub-id-type="pmid">22474371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1118355109</pub-id><pub-id pub-id-type="pmcid">PMC3341031</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0047"><mixed-citation publication-type="journal" id="jnc70252-cit-0047"><string-name name-style="western"><surname>Cole</surname>, <given-names>G. M.</given-names></string-name>, <string-name name-style="western"><given-names>Q.&#8208;L.</given-names><surname>Ma</surname></string-name>, and <string-name name-style="western"><given-names>S. A.</given-names><surname>Frautschy</surname></string-name>. <year>2010</year>. &#8220;<article-title>Dietary Fatty Acids and the Aging Brain</article-title>.&#8221; <source>Nutrition Reviews</source><volume>68</volume>, no. <issue>Suppl 2</issue>: <fpage>S102</fpage>&#8211;<lpage>S111</lpage>.<pub-id pub-id-type="pmid">21091943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1753-4887.2010.00345.x</pub-id><pub-id pub-id-type="pmcid">PMC4019000</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0048"><mixed-citation publication-type="journal" id="jnc70252-cit-0048"><string-name name-style="western"><surname>Conte</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Sabbatinelli</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Chiariello</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Disease&#8208;Specific Plasma Levels of Mitokines FGF21, GDF15, and Humanin in Type II Diabetes and Alzheimer's Disease in Comparison With Healthy Aging</article-title>.&#8221; <source>Geroscience</source><volume>43</volume>: <fpage>985</fpage>&#8211;<lpage>1001</lpage>.<pub-id pub-id-type="pmid">33131010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11357-020-00287-w</pub-id><pub-id pub-id-type="pmcid">PMC8110619</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0049"><mixed-citation publication-type="journal" id="jnc70252-cit-0049"><string-name name-style="western"><surname>Coppus</surname>, <given-names>A. M. W.</given-names></string-name>, <string-name name-style="western"><given-names>H. M.</given-names><surname>Evenhuis</surname></string-name>, <string-name name-style="western"><given-names>G.&#8208;J.</given-names><surname>Verberne</surname></string-name>, et&#160;al. <year>2010</year>. &#8220;<article-title>Early Age at Menopause Is Associated With Increased Risk of Dementia and Mortality in Women With Down Syndrome</article-title>.&#8221; <source>Journal of Alzheimer's Disease</source><volume>19</volume>: <fpage>545</fpage>&#8211;<lpage>550</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2010-1247</pub-id><pub-id pub-id-type="pmid">20110600</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0050"><mixed-citation publication-type="journal" id="jnc70252-cit-0050"><string-name name-style="western"><surname>Corriveau&#8208;Lecavalier</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>J. N.</given-names><surname>Adams</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Fischer</surname></string-name>, <string-name name-style="western"><given-names>E. N.</given-names><surname>Molloy</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Maass</surname></string-name>. <year>2024</year>. &#8220;<article-title>Cerebral Hyperactivation Across the Alzheimer's Disease Pathological Cascade</article-title>.&#8221; <source>Brain Communications</source><volume>6</volume>: <elocation-id>fcae376</elocation-id>.<pub-id pub-id-type="pmid">39513091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcae376</pub-id><pub-id pub-id-type="pmcid">PMC11542485</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0051"><mixed-citation publication-type="journal" id="jnc70252-cit-0051"><string-name name-style="western"><surname>Craig&#8208;Schapiro</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Perrin</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Roe</surname></string-name>, et&#160;al. <year>2010</year>. &#8220;<article-title>YKL&#8208;40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease</article-title>.&#8221; <source>Biological Psychiatry</source><volume>68</volume>: <fpage>903</fpage>&#8211;<lpage>912</lpage>.<pub-id pub-id-type="pmid">21035623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2010.08.025</pub-id><pub-id pub-id-type="pmcid">PMC3011944</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0052"><mixed-citation publication-type="journal" id="jnc70252-cit-0052"><string-name name-style="western"><surname>Cunnane</surname>, <given-names>S. C.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Trushina</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Morland</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Brain Energy Rescue: An Emerging Therapeutic Concept for Neurodegenerative Disorders of Ageing</article-title>.&#8221; <source>Nature Reviews. Drug Discovery</source><volume>19</volume>: <fpage>609</fpage>&#8211;<lpage>633</lpage>.<pub-id pub-id-type="pmid">32709961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-020-0072-x</pub-id><pub-id pub-id-type="pmcid">PMC7948516</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0053"><mixed-citation publication-type="journal" id="jnc70252-cit-0053"><string-name name-style="western"><surname>Dal Forno</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>M. T.</given-names><surname>Palermo</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Donohue</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Karagiozis</surname></string-name>, <string-name name-style="western"><given-names>A. B.</given-names><surname>Zonderman</surname></string-name>, and <string-name name-style="western"><given-names>C. H.</given-names><surname>Kawas</surname></string-name>. <year>2005</year>. &#8220;<article-title>Depressive Symptoms, Sex, and Risk for Alzheimer's Disease</article-title>.&#8221; <source>Annals of Neurology</source><volume>57</volume>: <fpage>381</fpage>&#8211;<lpage>387</lpage>.<pub-id pub-id-type="pmid">15732103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.20405</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0054"><mixed-citation publication-type="journal" id="jnc70252-cit-0054"><string-name name-style="western"><surname>D'Amico</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Parrott</surname></string-name>, <string-name name-style="western"><given-names>C. E.</given-names><surname>Greenwood</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Sex Differences in the Relationship Between Dietary Pattern Adherence and Cognitive Function Among Older Adults: Findings From the NuAge Study</article-title>.&#8221; <source>Nutrition Journal</source><volume>19</volume>: <elocation-id>58</elocation-id>.<pub-id pub-id-type="pmid">32563260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12937-020-00575-3</pub-id><pub-id pub-id-type="pmcid">PMC7306140</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0055"><mixed-citation publication-type="journal" id="jnc70252-cit-0055"><string-name name-style="western"><surname>de Magalh&#227;es</surname>, <given-names>J. P.</given-names></string-name><year>2024</year>. &#8220;<article-title>Cellular Senescence in Normal Physiology</article-title>.&#8221; <source>Science</source><volume>384</volume>: <fpage>1300</fpage>&#8211;<lpage>1301</lpage>.<pub-id pub-id-type="pmid">38900869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adj7050</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0056"><mixed-citation publication-type="journal" id="jnc70252-cit-0056"><string-name name-style="western"><surname>Dentoni</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Naia</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Portal</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Mitochondrial Alterations in Neurons Derived From the Murine AppNL&#8208;F Knock&#8208;In Model of Alzheimer's Disease</article-title>.&#8221; <source>Journal of Alzheimer's Disease</source><volume>90</volume>: <fpage>565</fpage>&#8211;<lpage>583</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220383</pub-id><pub-id pub-id-type="pmcid">PMC9697055</pub-id><pub-id pub-id-type="pmid">36155507</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0057"><mixed-citation publication-type="journal" id="jnc70252-cit-0057"><string-name name-style="western"><surname>Diaz&#8208;Castro</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Gangwani</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Coppola</surname></string-name>, and <string-name name-style="western"><given-names>B. S.</given-names><surname>Khakh</surname></string-name>. <year>2019</year>. &#8220;<article-title>Astrocyte Molecular Signatures in Huntington's Disease</article-title>.&#8221; <source>Science Translational Medicine</source><volume>11</volume>: <elocation-id>eaaw8546</elocation-id>.<pub-id pub-id-type="pmid">31619545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aaw8546</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0058"><mixed-citation publication-type="journal" id="jnc70252-cit-0058"><string-name name-style="western"><surname>D&#237;az&#8208;Garc&#237;a</surname>, <given-names>C. M.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Mongeon</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Lahmann</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Koveal</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zucker</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Yellen</surname></string-name>. <year>2017</year>. &#8220;<article-title>Neuronal Stimulation Triggers Neuronal Glycolysis and Not Lactate Uptake</article-title>.&#8221; <source>Cell Metabolism</source><volume>26</volume>: <fpage>361</fpage>&#8211;<lpage>374.e4</lpage>.<pub-id pub-id-type="pmid">28768175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2017.06.021</pub-id><pub-id pub-id-type="pmcid">PMC5559896</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0059"><mixed-citation publication-type="journal" id="jnc70252-cit-0059"><string-name name-style="western"><surname>Dienel</surname>, <given-names>G. A.</given-names></string-name><year>2019</year>. &#8220;<article-title>Brain Glucose Metabolism: Integration of Energetics With Function</article-title>.&#8221; <source>Physiological Reviews</source><volume>99</volume>: <fpage>949</fpage>&#8211;<lpage>1045</lpage>.<pub-id pub-id-type="pmid">30565508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00062.2017</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0060"><mixed-citation publication-type="journal" id="jnc70252-cit-0060"><string-name name-style="western"><surname>Dienel</surname>, <given-names>G. A.</given-names></string-name>, and <string-name name-style="western"><given-names>N. F.</given-names><surname>Cruz</surname></string-name>. <year>2016</year>. &#8220;<article-title>Aerobic Glycolysis During Brain Activation: Adrenergic Regulation and Influence of Norepinephrine on Astrocytic Metabolism</article-title>.&#8221; <source>Journal of Neurochemistry</source><volume>138</volume>: <fpage>14</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">27166428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.13630</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0061"><mixed-citation publication-type="journal" id="jnc70252-cit-0061"><string-name name-style="western"><surname>Edmond</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Auestad</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Robbins</surname></string-name>, and <string-name name-style="western"><given-names>J. D.</given-names><surname>Bergstrom</surname></string-name>. <year>1985</year>. &#8220;<article-title>Ketone Body Metabolism in the Neonate: Development and the Effect of Diet</article-title>.&#8221; <source>Federation Proceedings</source><volume>44</volume>: <fpage>2359</fpage>&#8211;<lpage>2364</lpage>.<pub-id pub-id-type="pmid">3884392</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0062"><mixed-citation publication-type="journal" id="jnc70252-cit-0062"><string-name name-style="western"><surname>Elias</surname>, <given-names>M. F.</given-names></string-name>, <string-name name-style="western"><given-names>P. K.</given-names><surname>Elias</surname></string-name>, <string-name name-style="western"><given-names>L. M.</given-names><surname>Sullivan</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Wolf</surname></string-name>, and <string-name name-style="western"><given-names>R. B.</given-names><surname>D'Agostino</surname></string-name>. <year>2005</year>. &#8220;<article-title>Obesity, Diabetes and Cognitive Deficit: The Framingham Heart Study</article-title>.&#8221; <source>Neurobiology of Aging</source><volume>26</volume>, no. <issue>Suppl 1</issue>: <fpage>11</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">16223549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2005.08.019</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0063"><mixed-citation publication-type="journal" id="jnc70252-cit-0063"><string-name name-style="western"><surname>Engler</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>P. O.</given-names><surname>Lundberg</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Ekbom</surname></string-name>, et&#160;al. <year>2003</year>. &#8220;<article-title>Multitracer Study With Positron Emission Tomography in Creutzfeldt&#8208;Jakob Disease</article-title>.&#8221; <source>European Journal of Nuclear Medicine and Molecular Imaging</source><volume>30</volume>: <fpage>85</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">12483414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-002-1008-x</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0064"><mixed-citation publication-type="journal" id="jnc70252-cit-0064"><string-name name-style="western"><surname>Escartin</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Galea</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Lakatos</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Reactive Astrocyte Nomenclature, Definitions, and Future Directions</article-title>.&#8221; <source>Nature Neuroscience</source><volume>24</volume>: <fpage>312</fpage>&#8211;<lpage>325</lpage>.<pub-id pub-id-type="pmid">33589835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-020-00783-4</pub-id><pub-id pub-id-type="pmcid">PMC8007081</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0065"><mixed-citation publication-type="journal" id="jnc70252-cit-0065"><string-name name-style="western"><surname>Espeland</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Shumaker</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Leng</surname></string-name>, et&#160;al. <year>2013</year>. &#8220;<article-title>Long&#8208;Term Effects on Cognitive Function of Postmenopausal Hormone Therapy Prescribed to Women Aged 50 to 55&#8201;Years</article-title>.&#8221; <source>JAMA Internal Medicine</source><volume>173</volume>: <fpage>1429</fpage>&#8211;<lpage>1436</lpage>.<pub-id pub-id-type="pmid">23797469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2013.7727</pub-id><pub-id pub-id-type="pmcid">PMC3844547</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0066"><mixed-citation publication-type="journal" id="jnc70252-cit-0066"><string-name name-style="western"><surname>Ezkurdia</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Ram&#237;rez</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Solas</surname></string-name>. <year>2023</year>. &#8220;<article-title>Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: A Focus on Insulin Resistance</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>24</volume>: <elocation-id>4354</elocation-id>.<pub-id pub-id-type="pmid">36901787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24054354</pub-id><pub-id pub-id-type="pmcid">PMC10001958</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0067"><mixed-citation publication-type="journal" id="jnc70252-cit-0067"><string-name name-style="western"><surname>Feldman</surname>, <given-names>H. A.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Longcope</surname></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Derby</surname></string-name>, et&#160;al. <year>2002</year>. &#8220;<article-title>Age Trends in the Level of Serum Testosterone and Other Hormones in Middle&#8208;Aged Men: Longitudinal Results From the Massachusetts Male Aging Study</article-title>.&#8221; <source>Journal of Clinical Endocrinology and Metabolism</source><volume>87</volume>: <fpage>589</fpage>&#8211;<lpage>598</lpage>.<pub-id pub-id-type="pmid">11836290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem.87.2.8201</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0068"><mixed-citation publication-type="journal" id="jnc70252-cit-0068"><string-name name-style="western"><surname>Ferreira</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Perestelo&#8208;P&#233;rez</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Westman</surname></string-name>, <string-name name-style="western"><given-names>L.&#8208;O.</given-names><surname>Wahlund</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Sarr&#237;a</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Serrano&#8208;Aguilar</surname></string-name>. <year>2014</year>. &#8220;<article-title>Meta&#8208;Review of CSF Core Biomarkers in Alzheimer's Disease: The State&#8208;Of&#8208;The&#8208;Art After the New Revised Diagnostic Criteria</article-title>.&#8221; <source>Frontiers in Aging Neuroscience</source><volume>6</volume>: <elocation-id>47</elocation-id>.<pub-id pub-id-type="pmid">24715863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2014.00047</pub-id><pub-id pub-id-type="pmcid">PMC3970033</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0069"><mixed-citation publication-type="journal" id="jnc70252-cit-0069"><string-name name-style="western"><surname>Ferrucci</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Levine</surname></string-name>, <string-name name-style="western"><given-names>P.&#8208;L.</given-names><surname>Kuo</surname></string-name>, and <string-name name-style="western"><given-names>E. M.</given-names><surname>Simonsick</surname></string-name>. <year>2018</year>. &#8220;<article-title>Time and the Metrics of Aging</article-title>.&#8221; <source>Circulation Research</source><volume>123</volume>: <fpage>740</fpage>&#8211;<lpage>744</lpage>.<pub-id pub-id-type="pmid">30355074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.118.312816</pub-id><pub-id pub-id-type="pmcid">PMC6205734</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0070"><mixed-citation publication-type="journal" id="jnc70252-cit-0070"><string-name name-style="western"><surname>Fields</surname>, <given-names>J. A.</given-names></string-name>, <string-name name-style="western"><given-names>V. D.</given-names><surname>Garovic</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Mielke</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Preeclampsia and Cognitive Impairment Later in Life</article-title>.&#8221; <source>American Journal of Obstetrics and Gynecology</source><volume>217</volume>: <fpage>74.e1</fpage>&#8211;<lpage>74.e11</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2017.03.008</pub-id><pub-id pub-id-type="pmcid">PMC5615406</pub-id><pub-id pub-id-type="pmid">28322777</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0071"><mixed-citation publication-type="journal" id="jnc70252-cit-0071"><string-name name-style="western"><surname>Fontana</surname>, <given-names>I. C.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Scarpa</surname></string-name>, <string-name name-style="western"><given-names>M.&#8208;L.</given-names><surname>Malarte</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Astrocyte Signature in Alzheimer's Disease Continuum Through a Multi&#8208;PET Tracer Imaging Perspective</article-title>.&#8221; <source>Cells</source><volume>12</volume>: <elocation-id>1469</elocation-id>.<pub-id pub-id-type="pmid">37296589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12111469</pub-id><pub-id pub-id-type="pmcid">PMC10253101</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0072"><mixed-citation publication-type="journal" id="jnc70252-cit-0072"><string-name name-style="western"><surname>Fowler</surname>, <given-names>J. S.</given-names></string-name>, <string-name name-style="western"><given-names>G. J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Logan</surname></string-name>, et&#160;al. <year>1995</year>. &#8220;<article-title>Selective Reduction of Radiotracer Trapping by Deuterium Substitution: Comparison of Carbon&#8208;11&#8208;L&#8208;Deprenyl and Carbon&#8208;11&#8208;Deprenyl&#8208;D2 for MAO B Mapping</article-title>.&#8221; <source>Journal of Nuclear Medicine</source><volume>36</volume>: <fpage>1255</fpage>&#8211;<lpage>1262</lpage>.<pub-id pub-id-type="pmid">7790952</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0073"><mixed-citation publication-type="journal" id="jnc70252-cit-0073"><string-name name-style="western"><surname>Franceschi</surname>, <given-names>C.</given-names></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Campisi</surname></string-name>. <year>2014</year>. &#8220;<article-title>Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age&#8208;Associated Diseases</article-title>.&#8221; <source>Journals of Gerontology. Series A, Biological Sciences and Medical Sciences</source><volume>69</volume>, no. <issue>Suppl 1</issue>: <fpage>S4</fpage>&#8211;<lpage>S9</lpage>.<pub-id pub-id-type="pmid">24833586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glu057</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0074"><mixed-citation publication-type="journal" id="jnc70252-cit-0074"><string-name name-style="western"><surname>Frisardi</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Solfrizzi</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Seripa</surname></string-name>, et&#160;al. <year>2010</year>. &#8220;<article-title>Metabolic&#8208;Cognitive Syndrome: A Cross&#8208;Talk Between Metabolic Syndrome and Alzheimer's Disease</article-title>.&#8221; <source>Ageing Research Reviews</source><volume>9</volume>: <fpage>399</fpage>&#8211;<lpage>417</lpage>.<pub-id pub-id-type="pmid">20444434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2010.04.007</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0075"><mixed-citation publication-type="journal" id="jnc70252-cit-0075"><string-name name-style="western"><surname>Fu</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Westaway</surname></string-name>, and <string-name name-style="western"><given-names>J. H.</given-names><surname>Jhamandas</surname></string-name>. <year>2015</year>. &#8220;<article-title>Bioenergetic Mechanisms in Astrocytes May Contribute to Amyloid Plaque Deposition and Toxicity</article-title>.&#8221; <source>Journal of Biological Chemistry</source><volume>290</volume>: <fpage>12504</fpage>&#8211;<lpage>12513</lpage>.<pub-id pub-id-type="pmid">25814669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M114.618157</pub-id><pub-id pub-id-type="pmcid">PMC4432272</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0076"><mixed-citation publication-type="journal" id="jnc70252-cit-0076"><string-name name-style="western"><surname>Gabbouj</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ryh&#228;nen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Marttinen</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>Altered Insulin Signaling in Alzheimer's Disease Brain&#8212;Special Emphasis on PI3K&#8208;Akt Pathway</article-title>.&#8221; <source>Frontiers in Neuroscience</source><volume>13</volume>: <fpage>629</fpage>.<pub-id pub-id-type="pmid">31275108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2019.00629</pub-id><pub-id pub-id-type="pmcid">PMC6591470</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0077"><mixed-citation publication-type="journal" id="jnc70252-cit-0077"><string-name name-style="western"><surname>Gao</surname>, <given-names>F.</given-names></string-name>, and <string-name name-style="western"><given-names>P. B.</given-names><surname>Barker</surname></string-name>. <year>2014</year>. &#8220;<article-title>Various MRS Application Tools for Alzheimer Disease and Mild Cognitive Impairment</article-title>.&#8221; <source>AJNR. American Journal of Neuroradiology</source><volume>35</volume>: <fpage>S4</fpage>&#8211;<lpage>S11</lpage>.<pub-id pub-id-type="pmid">24742809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A3944</pub-id><pub-id pub-id-type="pmcid">PMC4401041</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0078"><mixed-citation publication-type="journal" id="jnc70252-cit-0078"><string-name name-style="western"><surname>Garc&#237;a&#8208;C&#225;ceres</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Balland</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Prevot</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>Role of Astrocytes, Microglia, and Tanycytes in Brain Control of Systemic Metabolism</article-title>.&#8221; <source>Nature Neuroscience</source><volume>22</volume>: <fpage>7</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">30531847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-018-0286-y</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0079"><mixed-citation publication-type="journal" id="jnc70252-cit-0079"><string-name name-style="western"><surname>Gavillet</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Allaman</surname></string-name>, and <string-name name-style="western"><given-names>P. J.</given-names><surname>Magistretti</surname></string-name>. <year>2008</year>. &#8220;<article-title>Modulation of Astrocytic Metabolic Phenotype by Proinflammatory Cytokines</article-title>.&#8221; <source>Glia</source><volume>56</volume>: <fpage>975</fpage>&#8211;<lpage>989</lpage>.<pub-id pub-id-type="pmid">18383346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.20671</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0080"><mixed-citation publication-type="journal" id="jnc70252-cit-0080"><string-name name-style="western"><surname>Gems</surname>, <given-names>D.</given-names></string-name><year>2022</year>. &#8220;<article-title>The Hyperfunction Theory: An Emerging Paradigm for the Biology of Aging</article-title>.&#8221; <source>Ageing Research Reviews</source><volume>74</volume>: <elocation-id>101557</elocation-id>.<pub-id pub-id-type="pmid">34990845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2021.101557</pub-id><pub-id pub-id-type="pmcid">PMC7612201</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0081"><mixed-citation publication-type="journal" id="jnc70252-cit-0081"><string-name name-style="western"><surname>Gladyshev</surname>, <given-names>V. N.</given-names></string-name>, <string-name name-style="western"><given-names>S. B.</given-names><surname>Kritchevsky</surname></string-name>, <string-name name-style="western"><given-names>S. G.</given-names><surname>Clarke</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Molecular Damage in Aging</article-title>.&#8221; <source>Nature Aging</source><volume>1</volume>: <fpage>1096</fpage>&#8211;<lpage>1106</lpage>.<pub-id pub-id-type="pmid">36846190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-021-00150-3</pub-id><pub-id pub-id-type="pmcid">PMC9957516</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0082"><mixed-citation publication-type="journal" id="jnc70252-cit-0082"><string-name name-style="western"><surname>Gleason</surname>, <given-names>C. E.</given-names></string-name>, <string-name name-style="western"><given-names>N. M.</given-names><surname>Dowling</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Wharton</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings From the Randomized, Controlled KEEPS&#8208;Cognitive and Affective Study</article-title>.&#8221; <source>PLoS Medicine</source><volume>12</volume>: <elocation-id>e1001833</elocation-id>.<pub-id pub-id-type="pmid">26035291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1001833</pub-id><pub-id pub-id-type="pmcid">PMC4452757</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0083"><mixed-citation publication-type="journal" id="jnc70252-cit-0083"><string-name name-style="western"><surname>Goldstein</surname>, <given-names>J. M.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Holsen</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Handa</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Tobet</surname></string-name>. <year>2014</year>. &#8220;<article-title>Fetal Hormonal Programming of Sex Differences in Depression: Linking Women's Mental Health With Sex Differences in the Brain Across the Lifespan</article-title>.&#8221; <source>Frontiers in Neuroscience</source><volume>8</volume>: <elocation-id>247</elocation-id>.<pub-id pub-id-type="pmid">25249929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2014.00247</pub-id><pub-id pub-id-type="pmcid">PMC4157606</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0084"><mixed-citation publication-type="journal" id="jnc70252-cit-0084"><string-name name-style="western"><surname>Goveas</surname>, <given-names>J. S.</given-names></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Espeland</surname></string-name>, <string-name name-style="western"><given-names>N. F.</given-names><surname>Woods</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wassertheil&#8208;Smoller</surname></string-name>, and <string-name name-style="western"><given-names>J. M.</given-names><surname>Kotchen</surname></string-name>. <year>2011</year>. &#8220;<article-title>Depressive Symptoms and Incidence of Mild Cognitive Impairment and Probable Dementia in Elderly Women: The Women's Health Initiative Memory Study</article-title>.&#8221; <source>Journal of the American Geriatrics Society</source><volume>59</volume>: <fpage>57</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">21226676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.2010.03233.x</pub-id><pub-id pub-id-type="pmcid">PMC7716777</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0085"><mixed-citation publication-type="journal" id="jnc70252-cit-0085"><string-name name-style="western"><surname>Harris</surname>, <given-names>J. L.</given-names></string-name>, <string-name name-style="western"><given-names>I.&#8208;Y.</given-names><surname>Choi</surname></string-name>, and <string-name name-style="western"><given-names>W. M.</given-names><surname>Brooks</surname></string-name>. <year>2015</year>. &#8220;<article-title>Probing Astrocyte Metabolism In&#160;Vivo: Proton Magnetic Resonance Spectroscopy in the Injured and Aging Brain</article-title>.&#8221; <source>Frontiers in Aging Neuroscience</source><volume>7</volume>: <elocation-id>202</elocation-id>.<pub-id pub-id-type="pmid">26578948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2015.00202</pub-id><pub-id pub-id-type="pmcid">PMC4623195</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0086"><mixed-citation publication-type="journal" id="jnc70252-cit-0086"><string-name name-style="western"><surname>Hasel</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>I. V. L.</given-names><surname>Rose</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Sadick</surname></string-name>, <string-name name-style="western"><given-names>R. D.</given-names><surname>Kim</surname></string-name>, and <string-name name-style="western"><given-names>S. A.</given-names><surname>Liddelow</surname></string-name>. <year>2021</year>. &#8220;<article-title>Neuroinflammatory Astrocyte Subtypes in the Mouse Brain</article-title>.&#8221; <source>Nature Neuroscience</source><volume>24</volume>: <fpage>1475</fpage>&#8211;<lpage>1487</lpage>.<pub-id pub-id-type="pmid">34413515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-021-00905-6</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0087"><mixed-citation publication-type="journal" id="jnc70252-cit-0087"><string-name name-style="western"><surname>Hasselgren</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Ekbrand</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Haller&#246;d</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Sex Differences in Dementia: On the Potentially Mediating Effects of Educational Attainment and Experiences of Psychological Distress</article-title>.&#8221; <source>BMC Psychiatry</source><volume>20</volume>: <elocation-id>434</elocation-id>.<pub-id pub-id-type="pmid">32887574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12888-020-02820-9</pub-id><pub-id pub-id-type="pmcid">PMC7487622</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0088"><mixed-citation publication-type="journal" id="jnc70252-cit-0088"><string-name name-style="western"><surname>Hattori</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Abe</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sakoda</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Sawada</surname></string-name>. <year>2002</year>. &#8220;<article-title>Proton MR Spectroscopic Study at 3 Tesla on Glutamate/Glutamine in Alzheimer's Disease</article-title>.&#8221; <source>Neuroreport</source><volume>13</volume>: <fpage>183</fpage>&#8211;<lpage>186</lpage>.<pub-id pub-id-type="pmid">11924885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00001756-200201210-00041</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0089"><mixed-citation publication-type="journal" id="jnc70252-cit-0089"><string-name name-style="western"><surname>Hebert</surname>, <given-names>L. E.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Weuve</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Scherr</surname></string-name>, and <string-name name-style="western"><given-names>D. A.</given-names><surname>Evans</surname></string-name>. <year>2013</year>. &#8220;<article-title>Alzheimer Disease in the United States (2010&#8208;2050) Estimated Using the 2010 Census</article-title>.&#8221; <source>Neurology</source><volume>80</volume>: <fpage>1778</fpage>&#8211;<lpage>1783</lpage>.<pub-id pub-id-type="pmid">23390181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e31828726f5</pub-id><pub-id pub-id-type="pmcid">PMC3719424</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0090"><mixed-citation publication-type="journal" id="jnc70252-cit-0090"><string-name name-style="western"><surname>Henderson</surname>, <given-names>V. W.</given-names></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>St John</surname></string-name>, <string-name name-style="western"><given-names>H. N.</given-names><surname>Hodis</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Cognitive Effects of Estradiol After Menopause: A Randomized Trial of the Timing Hypothesis</article-title>.&#8221; <source>Neurology</source><volume>87</volume>: <fpage>699</fpage>&#8211;<lpage>708</lpage>.<pub-id pub-id-type="pmid">27421538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000002980</pub-id><pub-id pub-id-type="pmcid">PMC4999165</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0091"><mixed-citation publication-type="journal" id="jnc70252-cit-0091"><string-name name-style="western"><surname>Holland</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bandelow</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Hogervorst</surname></string-name>. <year>2011</year>. &#8220;<article-title>Testosterone Levels and Cognition in Elderly Men: A Review</article-title>.&#8221; <source>Maturitas</source><volume>69</volume>: <fpage>322</fpage>&#8211;<lpage>337</lpage>.<pub-id pub-id-type="pmid">21696899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.maturitas.2011.05.012</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0092"><mixed-citation publication-type="journal" id="jnc70252-cit-0092"><string-name name-style="western"><surname>Huang</surname>, <given-names>Y.</given-names></string-name>, and <string-name name-style="western"><given-names>R. W.</given-names><surname>Mahley</surname></string-name>. <year>2014</year>. &#8220;<article-title>Apolipoprotein E: Structure and Function in Lipid Metabolism, Neurobiology, and Alzheimer's Diseases</article-title>.&#8221; <source>Neurobiology of Disease</source><volume>72</volume>: <fpage>3</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">25173806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2014.08.025</pub-id><pub-id pub-id-type="pmcid">PMC4253862</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0093"><mixed-citation publication-type="journal" id="jnc70252-cit-0093"><string-name name-style="western"><surname>Huo</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Vemuri</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Graff&#8208;Radford</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Sex Differences in the Association Between Midlife Cardiovascular Conditions or Risk Factors With Midlife Cognitive Decline</article-title>.&#8221; <source>Neurology</source><volume>98</volume>: <fpage>e623</fpage>&#8211;<lpage>e632</lpage>.<pub-id pub-id-type="pmid">34987078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000013174</pub-id><pub-id pub-id-type="pmcid">PMC8829960</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0094"><mixed-citation publication-type="journal" id="jnc70252-cit-0094"><string-name name-style="western"><surname>Iglesias</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Morales</surname></string-name>, and <string-name name-style="western"><given-names>G. E.</given-names><surname>Barreto</surname></string-name>. <year>2017</year>. &#8220;<article-title>Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs</article-title>.&#8221; <source>Molecular Neurobiology</source><volume>54</volume>: <fpage>2518</fpage>&#8211;<lpage>2538</lpage>.<pub-id pub-id-type="pmid">26984740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-016-9833-2</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0095"><mixed-citation publication-type="journal" id="jnc70252-cit-0095"><string-name name-style="western"><surname>Invernizzi</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Simoes Loureiro</surname></string-name>, <string-name name-style="western"><given-names>K. G.</given-names><surname>Kandana Arachchige</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Lefebvre</surname></string-name>. <year>2021</year>. &#8220;<article-title>Late&#8208;Life Depression, Cognitive Impairment, and Relationship With Alzheimer's Disease</article-title>.&#8221; <source>Dementia and Geriatric Cognitive Disorders</source><volume>50</volume>: <fpage>414</fpage>&#8211;<lpage>424</lpage>.<pub-id pub-id-type="pmid">34823241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000519453</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0096"><mixed-citation publication-type="journal" id="jnc70252-cit-0096"><string-name name-style="western"><surname>Itoh</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Esaki</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Shimoji</surname></string-name>, et&#160;al. <year>2003</year>. &#8220;<article-title>Dichloroacetate Effects on Glucose and Lactate Oxidation by Neurons and Astroglia In&#160;Vitro and on Glucose Utilization by Brain In&#160;Vivo</article-title>.&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>100</volume>: <fpage>4879</fpage>&#8211;<lpage>4884</lpage>.<pub-id pub-id-type="pmid">12668764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0831078100</pub-id><pub-id pub-id-type="pmcid">PMC153649</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0097"><mixed-citation publication-type="journal" id="jnc70252-cit-0097"><string-name name-style="western"><surname>Jang</surname>, <given-names>J. Y.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Blum</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Liu</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Finkel</surname></string-name>. <year>2018</year>. &#8220;<article-title>The Role of Mitochondria in Aging</article-title>.&#8221; <source>Journal of Clinical Investigation</source><volume>128</volume>: <fpage>3662</fpage>&#8211;<lpage>3670</lpage>.<pub-id pub-id-type="pmid">30059016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI120842</pub-id><pub-id pub-id-type="pmcid">PMC6118639</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0098"><mixed-citation publication-type="journal" id="jnc70252-cit-0098"><string-name name-style="western"><surname>Jayadevappa</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chhatre</surname></string-name>, <string-name name-style="western"><given-names>S. B.</given-names><surname>Malkowicz</surname></string-name>, <string-name name-style="western"><given-names>R. B.</given-names><surname>Parikh</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Guzzo</surname></string-name>, and <string-name name-style="western"><given-names>A. J.</given-names><surname>Wein</surname></string-name>. <year>2019</year>. &#8220;<article-title>Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer</article-title>.&#8221; <source>JAMA Network Open</source><volume>2</volume>: <elocation-id>e196562</elocation-id>.<pub-id pub-id-type="pmid">31268539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2019.6562</pub-id><pub-id pub-id-type="pmcid">PMC6613289</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0099"><mixed-citation publication-type="journal" id="jnc70252-cit-0099"><string-name name-style="western"><surname>Jimenez&#8208;Blasco</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Almeida</surname></string-name>, and <string-name name-style="western"><given-names>J. P.</given-names><surname>Bola&#241;os</surname></string-name>. <year>2023</year>. &#8220;<article-title>Brightness and Shadows of Mitochondrial ROS in the Brain</article-title>.&#8221; <source>Neurobiology of Disease</source><volume>184</volume>: <elocation-id>106199</elocation-id>.<pub-id pub-id-type="pmid">37321421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2023.106199</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0100"><mixed-citation publication-type="journal" id="jnc70252-cit-0100"><string-name name-style="western"><surname>Johansson</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Engler</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Blomquist</surname></string-name>, et&#160;al. <year>2007</year>. &#8220;<article-title>Evidence for Astrocytosis in ALS Demonstrated by [11C](L)&#8208;Deprenyl&#8208;D2 PET</article-title>.&#8221; <source>Journal of the Neurological Sciences</source><volume>255</volume>: <fpage>17</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">17346749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2007.01.057</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0101"><mixed-citation publication-type="journal" id="jnc70252-cit-0101"><string-name name-style="western"><surname>Ju</surname>, <given-names>Y.&#8208;E. S.</given-names></string-name>, <string-name name-style="western"><given-names>B. P.</given-names><surname>Lucey</surname></string-name>, and <string-name name-style="western"><given-names>D. M.</given-names><surname>Holtzman</surname></string-name>. <year>2014</year>. &#8220;<article-title>Sleep and Alzheimer Disease Pathology&#8212;A Bidirectional Relationship</article-title>.&#8221; <source>Nature Reviews. Neurology</source><volume>10</volume>: <fpage>115</fpage>&#8211;<lpage>119</lpage>.<pub-id pub-id-type="pmid">24366271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2013.269</pub-id><pub-id pub-id-type="pmcid">PMC3979317</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0102"><mixed-citation publication-type="journal" id="jnc70252-cit-0102"><string-name name-style="western"><surname>Ju</surname>, <given-names>Y.&#8208;E. S.</given-names></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>Ooms</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Sutphen</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Slow Wave Sleep Disruption Increases Cerebrospinal Fluid Amyloid&#8208;&#946; Levels</article-title>.&#8221; <source>Brain</source><volume>140</volume>: <fpage>2104</fpage>&#8211;<lpage>2111</lpage>.<pub-id pub-id-type="pmid">28899014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awx148</pub-id><pub-id pub-id-type="pmcid">PMC5790144</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0103"><mixed-citation publication-type="journal" id="jnc70252-cit-0103"><string-name name-style="western"><surname>Kaeberlein</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>P. S.</given-names><surname>Rabinovitch</surname></string-name>, and <string-name name-style="western"><given-names>G. M.</given-names><surname>Martin</surname></string-name>. <year>2015</year>. &#8220;<article-title>Healthy Aging: The Ultimate Preventative Medicine</article-title>.&#8221; <source>Science</source><volume>350</volume>: <fpage>1191</fpage>&#8211;<lpage>1193</lpage>.<pub-id pub-id-type="pmid">26785476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad3267</pub-id><pub-id pub-id-type="pmcid">PMC4793924</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0104"><mixed-citation publication-type="journal" id="jnc70252-cit-0104"><string-name name-style="western"><surname>Kang</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>Y. H.</given-names><surname>Lee</surname></string-name>, and <string-name name-style="western"><given-names>J. E.</given-names><surname>Lee</surname></string-name>. <year>2017</year>. &#8220;<article-title>Metabolism&#8208;Centric Overview of the Pathogenesis of Alzheimer's Disease</article-title>.&#8221; <source>Yonsei Medical Journal</source><volume>58</volume>: <fpage>479</fpage>&#8211;<lpage>488</lpage>.<pub-id pub-id-type="pmid">28332351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3349/ymj.2017.58.3.479</pub-id><pub-id pub-id-type="pmcid">PMC5368131</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0105"><mixed-citation publication-type="journal" id="jnc70252-cit-0105"><string-name name-style="western"><surname>Kantarci</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Reynolds</surname></string-name>, <string-name name-style="western"><given-names>R. C.</given-names><surname>Petersen</surname></string-name>, et&#160;al. <year>2003</year>. &#8220;<article-title>Proton MR Spectroscopy in Mild Cognitive Impairment and Alzheimer Disease: Comparison of 1.5 and 3 T</article-title>.&#8221; <source>AJNR. American Journal of Neuroradiology</source><volume>24</volume>: <fpage>843</fpage>&#8211;<lpage>849</lpage>.<pub-id pub-id-type="pmid">12748083</pub-id><pub-id pub-id-type="pmcid">PMC7975780</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0106"><mixed-citation publication-type="journal" id="jnc70252-cit-0106"><string-name name-style="western"><surname>Karmi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Iozzo</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Viljanen</surname></string-name>, et&#160;al. <year>2010</year>. &#8220;<article-title>Increased Brain Fatty Acid Uptake in Metabolic Syndrome</article-title>.&#8221; <source>Diabetes</source><volume>59</volume>: <fpage>2171</fpage>&#8211;<lpage>2177</lpage>.<pub-id pub-id-type="pmid">20566663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db09-0138</pub-id><pub-id pub-id-type="pmcid">PMC2927939</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0107"><mixed-citation publication-type="journal" id="jnc70252-cit-0107"><string-name name-style="western"><surname>Kessler</surname>, <given-names>R. C.</given-names></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>McGonagle</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Swartz</surname></string-name>, <string-name name-style="western"><given-names>D. G.</given-names><surname>Blazer</surname></string-name>, and <string-name name-style="western"><given-names>C. B.</given-names><surname>Nelson</surname></string-name>. <year>1993</year>. &#8220;<article-title>Sex and Depression in the National Comorbidity Survey. I: Lifetime Prevalence, Chronicity and Recurrence</article-title>.&#8221; <source>Journal of Affective Disorders</source><volume>29</volume>: <fpage>85</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">8300981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-0327(93)90026-g</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0108"><mixed-citation publication-type="journal" id="jnc70252-cit-0108"><string-name name-style="western"><surname>Kim</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kim</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Gender Differences in Risk Factors for Transition From Mild Cognitive Impairment to Alzheimer's Disease: A CREDOS Study</article-title>.&#8221; <source>Comprehensive Psychiatry</source><volume>62</volume>: <fpage>114</fpage>&#8211;<lpage>122</lpage>.<pub-id pub-id-type="pmid">26343475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.comppsych.2015.07.002</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0109"><mixed-citation publication-type="journal" id="jnc70252-cit-0109"><string-name name-style="western"><surname>Kumar</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>I. C.</given-names><surname>Fontana</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Nordberg</surname></string-name>. <year>2023</year>. &#8220;<article-title>Reactive Astrogliosis: A Friend or Foe in the Pathogenesis of Alzheimer's Disease</article-title>.&#8221; <source>Journal of Neurochemistry</source><volume>164</volume>: <fpage>309</fpage>&#8211;<lpage>324</lpage>.<pub-id pub-id-type="pmid">34931315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.15565</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0110"><mixed-citation publication-type="journal" id="jnc70252-cit-0110"><string-name name-style="western"><surname>Kumlien</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Nilsson</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Hagberg</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>L&#229;ngstr&#246;m</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Bergstr&#246;m</surname></string-name>. <year>2001</year>. &#8220;<article-title>PET With 11C&#8208;Deuterium&#8208;Deprenyl and 18F&#8208;FDG in Focal Epilepsy</article-title>.&#8221; <source>Acta Neurologica Scandinavica</source><volume>103</volume>: <fpage>360</fpage>&#8211;<lpage>366</lpage>.<pub-id pub-id-type="pmid">11421848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1600-0404.2001.103006360.x</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0111"><mixed-citation publication-type="journal" id="jnc70252-cit-0111"><string-name name-style="western"><surname>Le Foll</surname>, <given-names>C.</given-names></string-name>, and <string-name name-style="western"><given-names>B. E.</given-names><surname>Levin</surname></string-name>. <year>2016</year>. &#8220;<article-title>Fatty Acid&#8208;Induced Astrocyte Ketone Production and the Control of Food Intake</article-title>.&#8221; <source>American Journal of Physiology. Regulatory, Integrative and Comparative Physiology</source><volume>310</volume>: <fpage>R1186</fpage>&#8211;<lpage>R1192</lpage>.<pub-id pub-id-type="pmid">27122369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpregu.00113.2016</pub-id><pub-id pub-id-type="pmcid">PMC4935491</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0112"><mixed-citation publication-type="journal" id="jnc70252-cit-0112"><string-name name-style="western"><surname>Lee</surname>, <given-names>T. H.&#8208;Y.</given-names></string-name>, <string-name name-style="western"><given-names>K. K.&#8208;Y.</given-names><surname>Cheng</surname></string-name>, <string-name name-style="western"><given-names>R. L.&#8208;C.</given-names><surname>Hoo</surname></string-name>, <string-name name-style="western"><given-names>P. M.&#8208;F.</given-names><surname>Siu</surname></string-name>, and <string-name name-style="western"><given-names>S.&#8208;Y.</given-names><surname>Yau</surname></string-name>. <year>2019</year>. &#8220;<article-title>The Novel Perspectives of Adipokines on Brain Health</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>20</volume>: <elocation-id>5638</elocation-id>.<pub-id pub-id-type="pmid">31718027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20225638</pub-id><pub-id pub-id-type="pmcid">PMC6887733</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0113"><mixed-citation publication-type="journal" id="jnc70252-cit-0113"><string-name name-style="western"><surname>Lemoine</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Saint&#8208;Aubert</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Nennesmo</surname></string-name>, <string-name name-style="western"><given-names>P.&#8208;G.</given-names><surname>Gillberg</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Nordberg</surname></string-name>. <year>2017</year>. &#8220;<article-title>Cortical Laminar Tau Deposits and Activated Astrocytes in Alzheimer's Disease Visualised by 3H&#8208;THK5117 and 3H&#8208;Deprenyl Autoradiography</article-title>.&#8221; <source>Scientific Reports</source><volume>7</volume>: <elocation-id>45496</elocation-id>.<pub-id pub-id-type="pmid">28374768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep45496</pub-id><pub-id pub-id-type="pmcid">PMC5379625</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0114"><mixed-citation publication-type="journal" id="jnc70252-cit-0114"><string-name name-style="western"><surname>Lennon</surname>, <given-names>M. J.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Koncz</surname></string-name>, and <string-name name-style="western"><given-names>P. S.</given-names><surname>Sachdev</surname></string-name>. <year>2021</year>. &#8220;<article-title>Hypertension and Alzheimer's Disease: Is the Picture Any Clearer?</article-title>&#8221; <source>Current Opinion in Psychiatry</source><volume>34</volume>: <fpage>142</fpage>&#8211;<lpage>148</lpage>.<pub-id pub-id-type="pmid">33395097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/YCO.0000000000000684</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0115"><mixed-citation publication-type="journal" id="jnc70252-cit-0115"><string-name name-style="western"><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Song</surname></string-name>, and <string-name name-style="western"><given-names>S. X.</given-names><surname>Leng</surname></string-name>. <year>2015</year>. &#8220;<article-title>Link Between Type 2 Diabetes and Alzheimer's Disease: From Epidemiology to Mechanism and Treatment</article-title>.&#8221; <source>Clinical Interventions in Aging</source><volume>10</volume>: <fpage>549</fpage>&#8211;<lpage>560</lpage>.<pub-id pub-id-type="pmid">25792818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CIA.S74042</pub-id><pub-id pub-id-type="pmcid">PMC4360697</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0116"><mixed-citation publication-type="journal" id="jnc70252-cit-0116"><string-name name-style="western"><surname>Liddelow</surname>, <given-names>S. A.</given-names></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Guttenplan</surname></string-name>, <string-name name-style="western"><given-names>L. E.</given-names><surname>Clarke</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia</article-title>.&#8221; <source>Nature</source><volume>541</volume>: <fpage>481</fpage>&#8211;<lpage>487</lpage>.<pub-id pub-id-type="pmid">28099414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature21029</pub-id><pub-id pub-id-type="pmcid">PMC5404890</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0117"><mixed-citation publication-type="journal" id="jnc70252-cit-0117"><string-name name-style="western"><surname>Liu</surname>, <given-names>C.&#8208;C.</given-names></string-name>, <string-name name-style="western"><given-names>C.&#8208;C.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kanekiyo</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Xu</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Bu</surname></string-name>. <year>2013</year>. &#8220;<article-title>Apolipoprotein E and Alzheimer Disease: Risk, Mechanisms and Therapy</article-title>.&#8221; <source>Nature Reviews. Neurology</source><volume>9</volume>: <fpage>106</fpage>&#8211;<lpage>118</lpage>.<pub-id pub-id-type="pmid">23296339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2012.263</pub-id><pub-id pub-id-type="pmcid">PMC3726719</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0118"><mixed-citation publication-type="journal" id="jnc70252-cit-0118"><string-name name-style="western"><surname>Liu</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Li</surname></string-name>. <year>2024</year>. &#8220;<article-title>Regulation of Adult Neurogenesis: The Crucial Role of Astrocytic Mitochondria</article-title>.&#8221; <source>Frontiers in Molecular Neuroscience</source><volume>17</volume>: <elocation-id>1516119</elocation-id>.<pub-id pub-id-type="pmid">39649104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2024.1516119</pub-id><pub-id pub-id-type="pmcid">PMC11621070</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0119"><mixed-citation publication-type="journal" id="jnc70252-cit-0119"><string-name name-style="western"><surname>Liu</surname>, <given-names>R.&#8208;M.</given-names></string-name><year>2022</year>. &#8220;<article-title>Aging, Cellular Senescence, and Alzheimer's Disease</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>23</volume>: <elocation-id>1989</elocation-id>.<pub-id pub-id-type="pmid">35216123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23041989</pub-id><pub-id pub-id-type="pmcid">PMC8874507</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0120"><mixed-citation publication-type="journal" id="jnc70252-cit-0120"><string-name name-style="western"><surname>L&#243;pez&#8208;Ot&#237;n</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Blasco</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Partridge</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Serrano</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Kroemer</surname></string-name>. <year>2023</year>. &#8220;<article-title>Hallmarks of Aging: An Expanding Universe</article-title>.&#8221; <source>Cell</source><volume>186</volume>: <fpage>243</fpage>&#8211;<lpage>278</lpage>.<pub-id pub-id-type="pmid">36599349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.11.001</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0121"><mixed-citation publication-type="journal" id="jnc70252-cit-0121"><string-name name-style="western"><surname>L&#243;pez&#8208;Ot&#237;n</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Galluzzi</surname></string-name>, <string-name name-style="western"><given-names>J. M. P.</given-names><surname>Freije</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Madeo</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Kroemer</surname></string-name>. <year>2016</year>. &#8220;<article-title>Metabolic Control of Longevity</article-title>.&#8221; <source>Cell</source><volume>166</volume>: <fpage>802</fpage>&#8211;<lpage>821</lpage>.<pub-id pub-id-type="pmid">27518560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2016.07.031</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0122"><mixed-citation publication-type="journal" id="jnc70252-cit-0122"><string-name name-style="western"><surname>Lovatt</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Sonnewald</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Waagepetersen</surname></string-name>, et&#160;al. <year>2007</year>. &#8220;<article-title>The Transcriptome and Metabolic Gene Signature of Protoplasmic Astrocytes in the Adult Murine Cortex</article-title>.&#8221; <source>Journal of Neuroscience</source><volume>27</volume>: <fpage>12255</fpage>&#8211;<lpage>12266</lpage>.<pub-id pub-id-type="pmid">17989291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3404-07.2007</pub-id><pub-id pub-id-type="pmcid">PMC6673251</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0123"><mixed-citation publication-type="journal" id="jnc70252-cit-0123"><string-name name-style="western"><surname>Lyons</surname>, <given-names>C. E.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Razzoli</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Bartolomucci</surname></string-name>. <year>2023</year>. &#8220;<article-title>The Impact of Life Stress on Hallmarks of Aging and Accelerated Senescence: Connections in Sickness and in Health</article-title>.&#8221; <source>Neuroscience and Biobehavioral Reviews</source><volume>153</volume>: <elocation-id>105359</elocation-id>.<pub-id pub-id-type="pmid">37586578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2023.105359</pub-id><pub-id pub-id-type="pmcid">PMC10592082</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0124"><mixed-citation publication-type="journal" id="jnc70252-cit-0124"><string-name name-style="western"><surname>Madeira</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>M. V.</given-names><surname>Lourenco</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Vargas&#8208;Lopes</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>D&#8208;Serine Levels in Alzheimer's Disease: Implications for Novel Biomarker Development</article-title>.&#8221; <source>Translational Psychiatry</source><volume>5</volume>: <elocation-id>e561</elocation-id>.<pub-id pub-id-type="pmid">25942042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tp.2015.52</pub-id><pub-id pub-id-type="pmcid">PMC4471283</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0125"><mixed-citation publication-type="journal" id="jnc70252-cit-0125"><string-name name-style="western"><surname>Magistretti</surname>, <given-names>P. J.</given-names></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Allaman</surname></string-name>. <year>2018</year>. &#8220;<article-title>Lactate in the Brain: From Metabolic End&#8208;Product to Signalling Molecule</article-title>.&#8221; <source>Nature Reviews. Neuroscience</source><volume>19</volume>: <fpage>235</fpage>&#8211;<lpage>249</lpage>.<pub-id pub-id-type="pmid">29515192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn.2018.19</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0126"><mixed-citation publication-type="journal" id="jnc70252-cit-0126"><string-name name-style="western"><surname>Mastroeni</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>O. M.</given-names><surname>Khdour</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Delvaux</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Nuclear but Not Mitochondrial&#8208;Encoded Oxidative Phosphorylation Genes Are Altered in Aging, Mild Cognitive Impairment, and Alzheimer's Disease</article-title>.&#8221; <source>Alzheimers Dement</source><volume>13</volume>: <fpage>510</fpage>&#8211;<lpage>519</lpage>.<pub-id pub-id-type="pmid">27793643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.09.003</pub-id><pub-id pub-id-type="pmcid">PMC5967608</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0127"><mixed-citation publication-type="journal" id="jnc70252-cit-0127"><string-name name-style="western"><surname>McEwen</surname>, <given-names>B. S.</given-names></string-name><year>1992</year>. &#8220;<article-title>Re&#8208;Examination of the Glucocorticoid Hypothesis of Stress and Aging</article-title>.&#8221; <source>Progress in Brain Research</source><volume>93</volume>: <fpage>365</fpage>&#8211;<lpage>381</lpage>.<pub-id pub-id-type="pmid">1480759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0079-6123(08)64585-9</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0128"><mixed-citation publication-type="journal" id="jnc70252-cit-0128"><string-name name-style="western"><surname>McEwen</surname>, <given-names>B. S.</given-names></string-name><year>2007</year>. &#8220;<article-title>Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain</article-title>.&#8221; <source>Physiological Reviews</source><volume>87</volume>: <fpage>873</fpage>&#8211;<lpage>904</lpage>.<pub-id pub-id-type="pmid">17615391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00041.2006</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0129"><mixed-citation publication-type="journal" id="jnc70252-cit-0129"><string-name name-style="western"><surname>McEwen</surname>, <given-names>B. S.</given-names></string-name>, and <string-name name-style="western"><given-names>P. J.</given-names><surname>Gianaros</surname></string-name>. <year>2010</year>. &#8220;<article-title>Central Role of the Brain in Stress and Adaptation: Links to Socioeconomic Status, Health, and Disease</article-title>.&#8221; <source>Annals of the New York Academy of Sciences</source><volume>1186</volume>: <fpage>190</fpage>&#8211;<lpage>222</lpage>.<pub-id pub-id-type="pmid">20201874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1749-6632.2009.05331.x</pub-id><pub-id pub-id-type="pmcid">PMC2864527</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0130"><mixed-citation publication-type="journal" id="jnc70252-cit-0130"><string-name name-style="western"><surname>McQuade</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Blurton&#8208;Jones</surname></string-name>. <year>2019</year>. &#8220;<article-title>Microglia in Alzheimer's Disease: Exploring How Genetics and Phenotype Influence Risk</article-title>.&#8221; <source>Journal of Molecular Biology</source><volume>431</volume>: <fpage>1805</fpage>&#8211;<lpage>1817</lpage>.<pub-id pub-id-type="pmid">30738892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmb.2019.01.045</pub-id><pub-id pub-id-type="pmcid">PMC6475606</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0131"><mixed-citation publication-type="journal" id="jnc70252-cit-0131"><string-name name-style="western"><surname>Mej&#237;a</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Giraldo</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Pineda</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ardila</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Lopera</surname></string-name>. <year>2003</year>. &#8220;<article-title>Nongenetic Factors as Modifiers of the Age of Onset of Familial Alzheimer's Disease</article-title>.&#8221; <source>International Psychogeriatrics</source><volume>15</volume>: <fpage>337</fpage>&#8211;<lpage>349</lpage>.<pub-id pub-id-type="pmid">15000414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/s1041610203009591</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0132"><mixed-citation publication-type="journal" id="jnc70252-cit-0132"><string-name name-style="western"><surname>Mi</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Qi</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Vitali</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Loss of Fatty Acid Degradation by Astrocytic Mitochondria Triggers Neuroinflammation and Neurodegeneration</article-title>.&#8221; <source>Nature Metabolism</source><volume>5</volume>: <fpage>445</fpage>&#8211;<lpage>465</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00756-4</pub-id><pub-id pub-id-type="pmcid">PMC10202034</pub-id><pub-id pub-id-type="pmid">36959514</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0133"><mixed-citation publication-type="journal" id="jnc70252-cit-0133"><string-name name-style="western"><surname>Michailidis</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Moraitou</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Tata</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kalinderi</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Papamitsou</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Papaliagkas</surname></string-name>. <year>2022</year>. &#8220;<article-title>Alzheimer's Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms Between Alzheimer's Disease and Type 2 Diabetes</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>23</volume>: <elocation-id>2687</elocation-id>.<pub-id pub-id-type="pmid">35269827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23052687</pub-id><pub-id pub-id-type="pmcid">PMC8910482</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0134"><mixed-citation publication-type="journal" id="jnc70252-cit-0134"><string-name name-style="western"><surname>Mielke</surname>, <given-names>M. M.</given-names></string-name>, <string-name name-style="western"><given-names>P. B.</given-names><surname>Rosenberg</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Tschanz</surname></string-name>, et&#160;al. <year>2007</year>. &#8220;<article-title>Vascular Factors Predict Rate of Progression in Alzheimer Disease</article-title>.&#8221; <source>Neurology</source><volume>69</volume>: <fpage>1850</fpage>&#8211;<lpage>1858</lpage>.<pub-id pub-id-type="pmid">17984453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000279520.59792.fe</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0135"><mixed-citation publication-type="journal" id="jnc70252-cit-0135"><string-name name-style="western"><surname>Minhas</surname>, <given-names>P. S.</given-names></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Jones</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Latif&#8208;Hernandez</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Restoring Hippocampal Glucose Metabolism Rescues Cognition Across Alzheimer's Disease Pathologies</article-title>.&#8221; <source>Science</source><volume>385</volume>: <fpage>eabm6131</fpage>.<pub-id pub-id-type="pmid">39172838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abm6131</pub-id><pub-id pub-id-type="pmcid">PMC12313320</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0136"><mixed-citation publication-type="journal" id="jnc70252-cit-0136"><string-name name-style="western"><surname>Moldakozhayev</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><given-names>V. N.</given-names><surname>Gladyshev</surname></string-name>. <year>2023</year>. &#8220;<article-title>Metabolism, Homeostasis, and Aging</article-title>.&#8221; <source>Trends in Endocrinology and Metabolism</source><volume>34</volume>: <fpage>158</fpage>&#8211;<lpage>169</lpage>.<pub-id pub-id-type="pmid">36681595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2023.01.003</pub-id><pub-id pub-id-type="pmcid">PMC11096277</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0027"><mixed-citation publication-type="journal" id="jnc70252-cit-0027"><string-name name-style="western"><surname>Moqri</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Herzog</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Poganik</surname></string-name>, <collab collab-type="authors">Biomarkers of Aging Consortium</collab>
, et&#160;al. <year>2023</year>. &#8220;<article-title>Biomarkers of Aging for the Identification and Evaluation of Longevity Interventions</article-title>.&#8221; <source>Cell</source><volume>186</volume>: <fpage>3758</fpage>&#8211;<lpage>3775</lpage>.<pub-id pub-id-type="pmid">37657418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.08.003</pub-id><pub-id pub-id-type="pmcid">PMC11088934</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0137"><mixed-citation publication-type="journal" id="jnc70252-cit-0137"><string-name name-style="western"><surname>Morita</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Ikeshima&#8208;Kataoka</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Kreft</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Vardjan</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Zorec</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Noda</surname></string-name>. <year>2019</year>. &#8220;<article-title>Metabolic Plasticity of Astrocytes and Aging of the Brain</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>20</volume>: <elocation-id>941</elocation-id>.<pub-id pub-id-type="pmid">30795555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20040941</pub-id><pub-id pub-id-type="pmcid">PMC6413111</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0138"><mixed-citation publication-type="journal" id="jnc70252-cit-0138"><string-name name-style="western"><surname>Motori</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Puyal</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Toni</surname></string-name>, et&#160;al. <year>2013</year>. &#8220;<article-title>Inflammation&#8208;Induced Alteration of Astrocyte Mitochondrial Dynamics Requires Autophagy for Mitochondrial Network Maintenance</article-title>.&#8221; <source>Cell Metabolism</source><volume>18</volume>: <fpage>844</fpage>&#8211;<lpage>859</lpage>.<pub-id pub-id-type="pmid">24315370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2013.11.005</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0139"><mixed-citation publication-type="journal" id="jnc70252-cit-0139"><string-name name-style="western"><surname>Murray</surname>, <given-names>M. E.</given-names></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Przybelski</surname></string-name>, <string-name name-style="western"><given-names>T. G.</given-names><surname>Lesnick</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy</article-title>.&#8221; <source>Journal of Neuroscience</source><volume>34</volume>: <fpage>16247</fpage>&#8211;<lpage>16255</lpage>.<pub-id pub-id-type="pmid">25471565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2027-14.2014</pub-id><pub-id pub-id-type="pmcid">PMC4252542</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0140"><mixed-citation publication-type="journal" id="jnc70252-cit-0140"><string-name name-style="western"><surname>Musi</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Valentine</surname></string-name>, <string-name name-style="western"><given-names>K. R.</given-names><surname>Sickora</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Tau Protein Aggregation Is Associated With Cellular Senescence in the Brain</article-title>.&#8221; <source>Aging Cell</source><volume>17</volume>: <elocation-id>e12840</elocation-id>.<pub-id pub-id-type="pmid">30126037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.12840</pub-id><pub-id pub-id-type="pmcid">PMC6260915</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0141"><mixed-citation publication-type="journal" id="jnc70252-cit-0141"><string-name name-style="western"><surname>Naia</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Shimozawa</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Bereczki</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Mitochondrial Hypermetabolism Precedes Impaired Autophagy and Synaptic Disorganization in App Knock&#8208;In Alzheimer Mouse Models</article-title>.&#8221; <source>Molecular Psychiatry</source><volume>28</volume>: <fpage>3966</fpage>&#8211;<lpage>3981</lpage>.<pub-id pub-id-type="pmid">37907591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-023-02289-4</pub-id><pub-id pub-id-type="pmcid">PMC10730401</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0142"><mixed-citation publication-type="journal" id="jnc70252-cit-0142"><string-name name-style="western"><surname>Neu</surname>, <given-names>S. C.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Pa</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Kukull</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta&#8208;Analysis</article-title>.&#8221; <source>JAMA Neurology</source><volume>74</volume>: <fpage>1178</fpage>&#8211;<lpage>1189</lpage>.<pub-id pub-id-type="pmid">28846757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2017.2188</pub-id><pub-id pub-id-type="pmcid">PMC5759346</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0143"><mixed-citation publication-type="journal" id="jnc70252-cit-0143"><string-name name-style="western"><surname>Niu</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>&#193;lvarez&#8208;&#193;lvarez</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Guill&#233;n&#8208;Grima</surname></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Aguinaga&#8208;Ontoso</surname></string-name>. <year>2017</year>. &#8220;<article-title>Prevalence and Incidence of Alzheimer's Disease in Europe: A Meta&#8208;Analysis</article-title>.&#8221; <source>Neurolog&#237;a</source><volume>32</volume>: <fpage>523</fpage>&#8211;<lpage>532</lpage>.<pub-id pub-id-type="pmid">27130306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nrl.2016.02.016</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0144"><mixed-citation publication-type="journal" id="jnc70252-cit-0144"><string-name name-style="western"><surname>Oberheim</surname>, <given-names>N. A.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Takano</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Han</surname></string-name>, et&#160;al. <year>2009</year>. &#8220;<article-title>Uniquely Hominid Features of Adult Human Astrocytes</article-title>.&#8221; <source>Journal of Neuroscience</source><volume>29</volume>: <fpage>3276</fpage>&#8211;<lpage>3287</lpage>.<pub-id pub-id-type="pmid">19279265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.4707-08.2009</pub-id><pub-id pub-id-type="pmcid">PMC2819812</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0145"><mixed-citation publication-type="journal" id="jnc70252-cit-0145"><string-name name-style="western"><surname>Olsen</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Aguilar</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Sehlin</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Astroglial Responses to Amyloid&#8208;Beta Progression in a Mouse Model of Alzheimer's Disease</article-title>.&#8221; <source>Molecular Imaging and Biology</source><volume>20</volume>: <fpage>605</fpage>&#8211;<lpage>614</lpage>.<pub-id pub-id-type="pmid">29297157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11307-017-1153-z</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0146"><mixed-citation publication-type="journal" id="jnc70252-cit-0146"><string-name name-style="western"><surname>O'Shea</surname>, <given-names>T. M.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Ao</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wang</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Derivation and Transcriptional Reprogramming of Border&#8208;Forming Wound Repair Astrocytes After Spinal Cord Injury or Stroke in Mice</article-title>.&#8221; <source>Nature Neuroscience</source><volume>27</volume>: <fpage>1505</fpage>&#8211;<lpage>1521</lpage>.<pub-id pub-id-type="pmid">38907165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-024-01684-6</pub-id><pub-id pub-id-type="pmcid">PMC11303254</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0147"><mixed-citation publication-type="journal" id="jnc70252-cit-0147"><string-name name-style="western"><surname>Ouchi</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Parker</surname></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Lugus</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Walsh</surname></string-name>. <year>2011</year>. &#8220;<article-title>Adipokines in Inflammation and Metabolic Disease</article-title>.&#8221; <source>Nature Reviews. Immunology</source><volume>11</volume>: <fpage>85</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2921</pub-id><pub-id pub-id-type="pmcid">PMC3518031</pub-id><pub-id pub-id-type="pmid">21252989</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0148"><mixed-citation publication-type="journal" id="jnc70252-cit-0148"><string-name name-style="western"><surname>Pamies</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Sartori</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Schvartz</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Neuroinflammatory Response to TNF&#945; and IL1&#946; Cytokines Is Accompanied by an Increase in Glycolysis in Human Astrocytes In&#160;Vitro</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume>: <fpage>4065</fpage>.<pub-id pub-id-type="pmid">33920048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22084065</pub-id><pub-id pub-id-type="pmcid">PMC8071021</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0149"><mixed-citation publication-type="journal" id="jnc70252-cit-0149"><string-name name-style="western"><surname>Parker</surname>, <given-names>C. A.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Nabulsi</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Holden</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Evaluation of 11C&#8208;BU99008, a PET Ligand for the imidazoline2 Binding Sites in Rhesus Brain</article-title>.&#8221; <source>Journal of Nuclear Medicine</source><volume>55</volume>: <fpage>838</fpage>&#8211;<lpage>844</lpage>.<pub-id pub-id-type="pmid">24711648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.113.131854</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0150"><mixed-citation publication-type="journal" id="jnc70252-cit-0150"><string-name name-style="western"><surname>Patani</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>G. E.</given-names><surname>Hardingham</surname></string-name>, and <string-name name-style="western"><given-names>S. A.</given-names><surname>Liddelow</surname></string-name>. <year>2023</year>. &#8220;<article-title>Functional Roles of Reactive Astrocytes in Neuroinflammation and Neurodegeneration</article-title>.&#8221; <source>Nature Reviews. Neurology</source><volume>19</volume>: <fpage>395</fpage>&#8211;<lpage>409</lpage>.<pub-id pub-id-type="pmid">37308616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-023-00822-1</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0151"><mixed-citation publication-type="journal" id="jnc70252-cit-0151"><string-name name-style="western"><surname>Patil</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kulsange</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Kazi</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Behavioral and Proteomic Studies Reveal Methylglyoxal Activate Pathways Associated With Alzheimer's Disease</article-title>.&#8221; <source>ACS Pharmacology &amp; Translational Science</source><volume>6</volume>: <fpage>65</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">36654748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsptsci.2c00143</pub-id><pub-id pub-id-type="pmcid">PMC9841776</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0152"><mixed-citation publication-type="journal" id="jnc70252-cit-0152"><string-name name-style="western"><surname>Pellerin</surname>, <given-names>L.</given-names></string-name>, and <string-name name-style="western"><given-names>P. J.</given-names><surname>Magistretti</surname></string-name>. <year>1994</year>. &#8220;<article-title>Glutamate Uptake Into Astrocytes Stimulates Aerobic Glycolysis: A Mechanism Coupling Neuronal Activity to Glucose Utilization</article-title>.&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>91</volume>: <fpage>10625</fpage>&#8211;<lpage>10629</lpage>.<pub-id pub-id-type="pmid">7938003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.91.22.10625</pub-id><pub-id pub-id-type="pmcid">PMC45074</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0153"><mixed-citation publication-type="journal" id="jnc70252-cit-0153"><string-name name-style="western"><surname>Perry</surname>, <given-names>D. C.</given-names></string-name>, <string-name name-style="western"><given-names>V. E.</given-names><surname>Sturm</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Peterson</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Association of Traumatic Brain Injury With Subsequent Neurological and Psychiatric Disease: A Meta&#8208;Analysis</article-title>.&#8221; <source>Journal of Neurosurgery</source><volume>124</volume>: <fpage>511</fpage>&#8211;<lpage>526</lpage>.<pub-id pub-id-type="pmid">26315003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2015.2.JNS14503</pub-id><pub-id pub-id-type="pmcid">PMC4751029</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0154"><mixed-citation publication-type="journal" id="jnc70252-cit-0154"><string-name name-style="western"><surname>Phung</surname>, <given-names>T. K. T.</given-names></string-name>, <string-name name-style="western"><given-names>B. L.</given-names><surname>Waltoft</surname></string-name>, <string-name name-style="western"><given-names>T. M.</given-names><surname>Laursen</surname></string-name>, et&#160;al. <year>2010</year>. &#8220;<article-title>Hysterectomy, Oophorectomy and Risk of Dementia: A Nationwide Historical Cohort Study</article-title>.&#8221; <source>Dementia and Geriatric Cognitive Disorders</source><volume>30</volume>: <fpage>43</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">20689282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000314681</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0155"><mixed-citation publication-type="journal" id="jnc70252-cit-0155"><string-name name-style="western"><surname>Picard</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>B. S.</given-names><surname>McEwen</surname></string-name>, <string-name name-style="western"><given-names>E. S.</given-names><surname>Epel</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Sandi</surname></string-name>. <year>2018</year>. &#8220;<article-title>An Energetic View of Stress: Focus on Mitochondria</article-title>.&#8221; <source>Frontiers in Neuroendocrinology</source><volume>49</volume>: <fpage>72</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">29339091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yfrne.2018.01.001</pub-id><pub-id pub-id-type="pmcid">PMC5964020</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0156"><mixed-citation publication-type="journal" id="jnc70252-cit-0156"><string-name name-style="western"><surname>Polsky</surname>, <given-names>L. R.</given-names></string-name>, <string-name name-style="western"><given-names>K. E.</given-names><surname>Rentscher</surname></string-name>, and <string-name name-style="western"><given-names>J. E.</given-names><surname>Carroll</surname></string-name>. <year>2022</year>. &#8220;<article-title>Stress&#8208;Induced Biological Aging: A Review and Guide for Research Priorities</article-title>.&#8221; <source>Brain, Behavior, and Immunity</source><volume>104</volume>: <fpage>97</fpage>&#8211;<lpage>109</lpage>.<pub-id pub-id-type="pmid">35661679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2022.05.016</pub-id><pub-id pub-id-type="pmcid">PMC10243290</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0157"><mixed-citation publication-type="journal" id="jnc70252-cit-0157"><string-name name-style="western"><surname>Popp</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Meichsner</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>K&#246;lsch</surname></string-name>, et&#160;al. <year>2013</year>. &#8220;<article-title>Cerebral and Extracerebral Cholesterol Metabolism and CSF Markers of Alzheimer's Disease</article-title>.&#8221; <source>Biochemical Pharmacology</source><volume>86</volume>: <fpage>37</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">23291240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2012.12.007</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0158"><mixed-citation publication-type="journal" id="jnc70252-cit-0158"><string-name name-style="western"><surname>Price</surname>, <given-names>B. R.</given-names></string-name>, <string-name name-style="western"><given-names>L. A.</given-names><surname>Johnson</surname></string-name>, and <string-name name-style="western"><given-names>C. M.</given-names><surname>Norris</surname></string-name>. <year>2021</year>. &#8220;<article-title>Reactive Astrocytes: The Nexus of Pathological and Clinical Hallmarks of Alzheimer's Disease</article-title>.&#8221; <source>Ageing Research Reviews</source><volume>68</volume>: <elocation-id>101335</elocation-id>.<pub-id pub-id-type="pmid">33812051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2021.101335</pub-id><pub-id pub-id-type="pmcid">PMC8168445</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0159"><mixed-citation publication-type="journal" id="jnc70252-cit-0159"><string-name name-style="western"><surname>Profenno</surname>, <given-names>L. A.</given-names></string-name>, <string-name name-style="western"><given-names>A. P.</given-names><surname>Porsteinsson</surname></string-name>, and <string-name name-style="western"><given-names>S. V.</given-names><surname>Faraone</surname></string-name>. <year>2010</year>. &#8220;<article-title>Meta&#8208;Analysis of Alzheimer's Disease Risk With Obesity, Diabetes, and Related Disorders</article-title>.&#8221; <source>Biological Psychiatry</source><volume>67</volume>: <fpage>505</fpage>&#8211;<lpage>512</lpage>.<pub-id pub-id-type="pmid">19358976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2009.02.013</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0160"><mixed-citation publication-type="journal" id="jnc70252-cit-0160"><string-name name-style="western"><surname>Qi</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Mi</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Gu</surname></string-name>, <string-name name-style="western"><given-names>R. D.</given-names><surname>Brinton</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Yin</surname></string-name>. <year>2021</year>. &#8220;<article-title>ApoE4 Impairs Neuron&#8208;Astrocyte Coupling of Fatty Acid Metabolism</article-title>.&#8221; <source>Cell Reports</source><volume>34</volume>: <elocation-id>108572</elocation-id>.<pub-id pub-id-type="pmid">33406436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2020.108572</pub-id><pub-id pub-id-type="pmcid">PMC7837265</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0161"><mixed-citation publication-type="journal" id="jnc70252-cit-0161"><string-name name-style="western"><surname>Querol&#8208;Vilaseca</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Colom&#8208;Cadena</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Pegueroles</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>YKL&#8208;40 (Chitinase 3&#8208;Like I) is Expressed in a Subset of Astrocytes in Alzheimer's Disease and Other Tauopathies</article-title>.&#8221; <source>Journal of Neuroinflammation</source><volume>14</volume>: <elocation-id>118</elocation-id>.<pub-id pub-id-type="pmid">28599675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-017-0893-7</pub-id><pub-id pub-id-type="pmcid">PMC5466718</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0162"><mixed-citation publication-type="journal" id="jnc70252-cit-0162"><string-name name-style="western"><surname>Rae</surname>, <given-names>C. D.</given-names></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Baur</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Borges</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Brain Energy Metabolism: A Roadmap for Future Research</article-title>.&#8221; <source>Journal of Neurochemistry</source><volume>168</volume>: <fpage>910</fpage>&#8211;<lpage>954</lpage>.<pub-id pub-id-type="pmid">38183680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.16032</pub-id><pub-id pub-id-type="pmcid">PMC11102343</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0163"><mixed-citation publication-type="journal" id="jnc70252-cit-0163"><string-name name-style="western"><surname>Rathcke</surname>, <given-names>C. N.</given-names></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Vestergaard</surname></string-name>. <year>2009</year>. &#8220;<article-title>YKL&#8208;40&#8212;An Emerging Biomarker in Cardiovascular Disease and Diabetes</article-title>.&#8221; <source>Cardiovascular Diabetology</source><volume>8</volume>: <elocation-id>61</elocation-id>.<pub-id pub-id-type="pmid">19930630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2840-8-61</pub-id><pub-id pub-id-type="pmcid">PMC2789050</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0164"><mixed-citation publication-type="journal" id="jnc70252-cit-0164"><string-name name-style="western"><surname>Ricci</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Fuso</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Ippoliti</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Businaro</surname></string-name>. <year>2012</year>. &#8220;<article-title>Stress&#8208;Induced Cytokines and Neuronal Dysfunction in Alzheimer's Disease</article-title>.&#8221; <source>Journal of Alzheimer's Disease</source><volume>28</volume>: <fpage>11</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2011-110821</pub-id><pub-id pub-id-type="pmid">22124029</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0165"><mixed-citation publication-type="journal" id="jnc70252-cit-0165"><string-name name-style="western"><surname>Ricciarelli</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Canepa</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Marengo</surname></string-name>, et&#160;al. <year>2012</year>. &#8220;<article-title>Cholesterol and Alzheimer's Disease: A Still Poorly Understood Correlation</article-title>.&#8221; <source>IUBMB Life</source><volume>64</volume>: <fpage>931</fpage>&#8211;<lpage>935</lpage>.<pub-id pub-id-type="pmid">23124820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/iub.1091</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0166"><mixed-citation publication-type="journal" id="jnc70252-cit-0166"><string-name name-style="western"><surname>Ritchie</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>C. W.</given-names><surname>Ritchie</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Yaffe</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Skoog</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Scarmeas</surname></string-name>. <year>2015</year>. &#8220;<article-title>Is Late&#8208;Onset Alzheimer's Disease Really a Disease of Midlife?</article-title>&#8221; <source>Alzheimers Dement (N Y)</source><volume>1</volume>: <fpage>122</fpage>&#8211;<lpage>130</lpage>.<pub-id pub-id-type="pmid">29854932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2015.06.004</pub-id><pub-id pub-id-type="pmcid">PMC5975058</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0167"><mixed-citation publication-type="journal" id="jnc70252-cit-0167"><string-name name-style="western"><surname>Robb</surname>, <given-names>J. L.</given-names></string-name>, <string-name name-style="western"><given-names>N. A.</given-names><surname>Hammad</surname></string-name>, <string-name name-style="western"><given-names>P. G.</given-names><surname>Weightman Potter</surname></string-name>, <string-name name-style="western"><given-names>J. K.</given-names><surname>Chilton</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Beall</surname></string-name>, and <string-name name-style="western"><given-names>K. L. J.</given-names><surname>Ellacott</surname></string-name>. <year>2020</year>. &#8220;<article-title>The Metabolic Response to Inflammation in Astrocytes Is Regulated by Nuclear Factor&#8208;Kappa B Signaling</article-title>.&#8221; <source>Glia</source><volume>68</volume>: <fpage>2246</fpage>&#8211;<lpage>2263</lpage>.<pub-id pub-id-type="pmid">32277522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.23835</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0168"><mixed-citation publication-type="journal" id="jnc70252-cit-0168"><string-name name-style="western"><surname>Rocca</surname>, <given-names>W. A.</given-names></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Bower</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Maraganore</surname></string-name>, et&#160;al. <year>2007</year>. &#8220;<article-title>Increased Risk of Cognitive Impairment or Dementia in Women Who Underwent Oophorectomy Before Menopause</article-title>.&#8221; <source>Neurology</source><volume>69</volume>: <fpage>1074</fpage>&#8211;<lpage>1083</lpage>.<pub-id pub-id-type="pmid">17761551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000276984.19542.e6</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0169"><mixed-citation publication-type="journal" id="jnc70252-cit-0169"><string-name name-style="western"><surname>Rocca</surname>, <given-names>W. A.</given-names></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Lohse</surname></string-name>, <string-name name-style="western"><given-names>C. Y.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Fields</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Machulda</surname></string-name>, and <string-name name-style="western"><given-names>M. M.</given-names><surname>Mielke</surname></string-name>. <year>2021</year>. &#8220;<article-title>Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment</article-title>.&#8221; <source>JAMA Network Open</source><volume>4</volume>: <elocation-id>e2131448</elocation-id>.<pub-id pub-id-type="pmid">34762113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.31448</pub-id><pub-id pub-id-type="pmcid">PMC8586907</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0170"><mixed-citation publication-type="journal" id="jnc70252-cit-0170"><string-name name-style="western"><surname>Rodr&#237;guez&#8208;Giraldo</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>R. E.</given-names><surname>Gonz&#225;lez&#8208;Reyes</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ram&#237;rez&#8208;Guerrero</surname></string-name>, <string-name name-style="western"><given-names>C. E.</given-names><surname>Bonilla&#8208;Trilleras</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Guardo&#8208;Maya</surname></string-name>, and <string-name name-style="western"><given-names>M. O.</given-names><surname>Nava&#8208;Mesa</surname></string-name>. <year>2022</year>. &#8220;<article-title>Astrocytes as a Therapeutic Target in Alzheimer's Disease&#8208;Comprehensive Review and Recent Developments</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>23</volume>: <elocation-id>13630</elocation-id>.<pub-id pub-id-type="pmid">36362415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232113630</pub-id><pub-id pub-id-type="pmcid">PMC9654484</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0171"><mixed-citation publication-type="journal" id="jnc70252-cit-0171"><string-name name-style="western"><surname>Rodriguez&#8208;Vieitez</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Ni</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Guly&#225;s</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Astrocytosis Precedes Amyloid Plaque Deposition in Alzheimer APPswe Transgenic Mouse Brain: A Correlative Positron Emission Tomography and In&#160;Vitro Imaging Study</article-title>.&#8221; <source>European Journal of Nuclear Medicine and Molecular Imaging</source><volume>42</volume>: <fpage>1119</fpage>&#8211;<lpage>1132</lpage>.<pub-id pub-id-type="pmid">25893384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-015-3047-0</pub-id><pub-id pub-id-type="pmcid">PMC4424277</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0172"><mixed-citation publication-type="journal" id="jnc70252-cit-0172"><string-name name-style="western"><surname>Rodriguez&#8208;Vieitez</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Saint&#8208;Aubert</surname></string-name>, <string-name name-style="western"><given-names>S. F.</given-names><surname>Carter</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Diverging Longitudinal Changes in Astrocytosis and Amyloid PET in Autosomal Dominant Alzheimer's Disease</article-title>.&#8221; <source>Brain</source><volume>139</volume>: <fpage>922</fpage>&#8211;<lpage>936</lpage>.<pub-id pub-id-type="pmid">26813969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awv404</pub-id><pub-id pub-id-type="pmcid">PMC4766380</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0173"><mixed-citation publication-type="journal" id="jnc70252-cit-0173"><string-name name-style="western"><surname>Salama</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Sadaie</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hoare</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Narita</surname></string-name>. <year>2014</year>. &#8220;<article-title>Cellular Senescence and Its Effector Programs</article-title>.&#8221; <source>Genes &amp; Development</source><volume>28</volume>: <fpage>99</fpage>&#8211;<lpage>114</lpage>.<pub-id pub-id-type="pmid">24449267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.235184.113</pub-id><pub-id pub-id-type="pmcid">PMC3909793</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0174"><mixed-citation publication-type="journal" id="jnc70252-cit-0174"><string-name name-style="western"><surname>Salvad&#243;</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mil&#224;&#8208;Alom&#224;</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Shekari</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Reactive Astrogliosis Is Associated With Higher Cerebral Glucose Consumption in the Early Alzheimer's Continuum</article-title>.&#8221; <source>European Journal of Nuclear Medicine and Molecular Imaging</source><volume>49</volume>: <fpage>4567</fpage>&#8211;<lpage>4579</lpage>.<pub-id pub-id-type="pmid">35849149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-022-05897-4</pub-id><pub-id pub-id-type="pmcid">PMC9606048</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0175"><mixed-citation publication-type="journal" id="jnc70252-cit-0175"><string-name name-style="western"><surname>Sanmarco</surname>, <given-names>L. M.</given-names></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Wheeler</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Guti&#233;rrez&#8208;V&#225;zquez</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Gut&#8208;Licensed IFN&#947;+ NK Cells Drive LAMP1+TRAIL+ Anti&#8208;Inflammatory Astrocytes</article-title>.&#8221; <source>Nature</source><volume>590</volume>: <fpage>473</fpage>&#8211;<lpage>479</lpage>.<pub-id pub-id-type="pmid">33408417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-03116-4</pub-id><pub-id pub-id-type="pmcid">PMC8039910</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0176"><mixed-citation publication-type="journal" id="jnc70252-cit-0176"><string-name name-style="western"><surname>Sapolsky</surname>, <given-names>R. M.</given-names></string-name>, <string-name name-style="western"><given-names>L. C.</given-names><surname>Krey</surname></string-name>, and <string-name name-style="western"><given-names>B. S.</given-names><surname>McEwen</surname></string-name>. <year>1986</year>. &#8220;<article-title>The Neuroendocrinology of Stress and Aging: The Glucocorticoid Cascade Hypothesis</article-title>.&#8221; <source>Endocrine Reviews</source><volume>7</volume>: <fpage>284</fpage>&#8211;<lpage>301</lpage>.<pub-id pub-id-type="pmid">3527687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/edrv-7-3-284</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0177"><mixed-citation publication-type="journal" id="jnc70252-cit-0177"><string-name name-style="western"><surname>Sateia</surname>, <given-names>M. J.</given-names></string-name><year>2014</year>. &#8220;<article-title>International Classification of Sleep Disorders&#8208;Third Edition: Highlights and Modifications</article-title>.&#8221; <source>Chest</source><volume>146</volume>: <fpage>1387</fpage>&#8211;<lpage>1394</lpage>.<pub-id pub-id-type="pmid">25367475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.14-0970</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0178"><mixed-citation publication-type="journal" id="jnc70252-cit-0178"><string-name name-style="western"><surname>Sch&#246;ll</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>S. F.</given-names><surname>Carter</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Westman</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Early Astrocytosis in Autosomal Dominant Alzheimer's Disease Measured In&#160;Vivo by Multi&#8208;Tracer Positron Emission Tomography</article-title>.&#8221; <source>Scientific Reports</source><volume>5</volume>: <elocation-id>16404</elocation-id>.<pub-id pub-id-type="pmid">26553227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep16404</pub-id><pub-id pub-id-type="pmcid">PMC4639762</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0179"><mixed-citation publication-type="journal" id="jnc70252-cit-0179"><string-name name-style="western"><surname>S&#281;dzikowska</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Szablewski</surname></string-name>. <year>2021</year>. &#8220;<article-title>Insulin and Insulin Resistance in Alzheimer's Disease</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume>: <elocation-id>9987</elocation-id>.<pub-id pub-id-type="pmid">34576151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22189987</pub-id><pub-id pub-id-type="pmcid">PMC8472298</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0180"><mixed-citation publication-type="journal" id="jnc70252-cit-0180"><string-name name-style="western"><surname>Serrano&#8208;Pozo</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Li</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Astrocyte Transcriptomic Changes Along the Spatiotemporal Progression of Alzheimer's Disease</article-title>.&#8221; <source>Nature Neuroscience</source><volume>27</volume>: <fpage>2384</fpage>&#8211;<lpage>2400</lpage>.<pub-id pub-id-type="pmid">39528672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-024-01791-4</pub-id><pub-id pub-id-type="pmcid">PMC11614739</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0181"><mixed-citation publication-type="journal" id="jnc70252-cit-0181"><string-name name-style="western"><surname>Serres</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Bezancon</surname></string-name>, <string-name name-style="western"><given-names>J.&#8208;M.</given-names><surname>Franconi</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Merle</surname></string-name>. <year>2005</year>. &#8220;<article-title>Ex Vivo NMR Study of Lactate Metabolism in Rat Brain Under Various Depressed States</article-title>.&#8221; <source>Journal of Neuroscience Research</source><volume>79</volume>: <fpage>19</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">15558748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jnr.20277</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0182"><mixed-citation publication-type="journal" id="jnc70252-cit-0182"><string-name name-style="western"><surname>Sgarbi</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Matarrese</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pinti</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Mitochondria Hyperfusion and Elevated Autophagic Activity Are Key Mechanisms for Cellular Bioenergetic Preservation in Centenarians</article-title>.&#8221; <source>Aging (Albany NY)</source><volume>6</volume>: <fpage>296</fpage>&#8211;<lpage>310</lpage>.<pub-id pub-id-type="pmid">24799450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.100654</pub-id><pub-id pub-id-type="pmcid">PMC4032796</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0183"><mixed-citation publication-type="journal" id="jnc70252-cit-0183"><string-name name-style="western"><surname>Sharifi</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Chaudhari</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Martirosyan</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Reducing the Metabolic Burden of rRNA Synthesis Promotes Healthy Longevity in <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Caenorhabditis elegans</italic>
</styled-content>
</article-title>.&#8221; <source>Nature Communications</source><volume>15</volume>: <fpage>1702</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-46037-w</pub-id><pub-id pub-id-type="pmcid">PMC10894287</pub-id><pub-id pub-id-type="pmid">38402241</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0184"><mixed-citation publication-type="journal" id="jnc70252-cit-0184"><string-name name-style="western"><surname>Shaulson</surname>, <given-names>E. D.</given-names></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Cohen</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Picard</surname></string-name>. <year>2024</year>. &#8220;<article-title>The Brain&#8208;Body Energy Conservation Model of Aging</article-title>.&#8221; <source>Nature Aging</source><volume>4</volume>: <fpage>1354</fpage>&#8211;<lpage>1371</lpage>.<pub-id pub-id-type="pmid">39379694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-024-00716-x</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0185"><mixed-citation publication-type="journal" id="jnc70252-cit-0185"><string-name name-style="western"><surname>Shichkova</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Coggan</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Markram</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Keller</surname></string-name>. <year>2024</year>. &#8220;<article-title>Brain Metabolism in Health and Neurodegeneration: The Interplay Among Neurons and Astrocytes</article-title>.&#8221; <source>Cells</source><volume>13</volume>: <elocation-id>1714</elocation-id>.<pub-id pub-id-type="pmid">39451233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells13201714</pub-id><pub-id pub-id-type="pmcid">PMC11506225</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0186"><mixed-citation publication-type="journal" id="jnc70252-cit-0186"><string-name name-style="western"><surname>Shumaker</surname>, <given-names>S. A.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Legault</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Kuller</surname></string-name>, et&#160;al. <year>2004</year>. &#8220;<article-title>Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women: Women's Health Initiative Memory Study</article-title>.&#8221; <source>JAMA</source><volume>291</volume>: <fpage>2947</fpage>&#8211;<lpage>2958</lpage>.<pub-id pub-id-type="pmid">15213206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.291.24.2947</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0187"><mixed-citation publication-type="journal" id="jnc70252-cit-0187"><string-name name-style="western"><surname>Shumaker</surname>, <given-names>S. A.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Legault</surname></string-name>, <string-name name-style="western"><given-names>S. R.</given-names><surname>Rapp</surname></string-name>, et&#160;al. <year>2003</year>. &#8220;<article-title>Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial</article-title>.&#8221; <source>JAMA</source><volume>289</volume>: <fpage>2651</fpage>&#8211;<lpage>2662</lpage>.<pub-id pub-id-type="pmid">12771112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.289.20.2651</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0188"><mixed-citation publication-type="journal" id="jnc70252-cit-0188"><string-name name-style="western"><surname>Sienski</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Narayan</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Bonner</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>APOE4 Disrupts Intracellular Lipid Homeostasis in Human iPSC&#8208;Derived Glia</article-title>.&#8221; <source>Science Translational Medicine</source><volume>13</volume>: <fpage>eaaz4564</fpage>.<pub-id pub-id-type="pmid">33658354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aaz4564</pub-id><pub-id pub-id-type="pmcid">PMC8218593</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0189"><mixed-citation publication-type="journal" id="jnc70252-cit-0189"><string-name name-style="western"><surname>Sikora</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bielak&#8208;Zmijewska</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Mosieniak</surname></string-name>. <year>2014</year>. &#8220;<article-title>Cellular Senescence in Ageing, Age&#8208;Related Disease and Longevity</article-title>.&#8221; <source>Current Vascular Pharmacology</source><volume>12</volume>: <fpage>698</fpage>&#8211;<lpage>706</lpage>.<pub-id pub-id-type="pmid">24350932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570161111666131219094045</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0190"><mixed-citation publication-type="journal" id="jnc70252-cit-0190"><string-name name-style="western"><surname>Skoog</surname>, <given-names>I.</given-names></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Gustafson</surname></string-name>. <year>2006</year>. &#8220;<article-title>Update on Hypertension and Alzheimer's Disease</article-title>.&#8221; <source>Neurological Research</source><volume>28</volume>: <fpage>605</fpage>&#8211;<lpage>611</lpage>.<pub-id pub-id-type="pmid">16945211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1179/016164106X130506</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0191"><mixed-citation publication-type="journal" id="jnc70252-cit-0191"><string-name name-style="western"><surname>Skoog</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Lernfelt</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Landahl</surname></string-name>, et&#160;al. <year>1996</year>. &#8220;<article-title>15&#8208;Year Longitudinal Study of Blood Pressure and Dementia</article-title>.&#8221; <source>Lancet</source><volume>347</volume>: <fpage>1141</fpage>&#8211;<lpage>1145</lpage>.<pub-id pub-id-type="pmid">8609748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(96)90608-x</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0192"><mixed-citation publication-type="journal" id="jnc70252-cit-0192"><string-name name-style="western"><surname>Smith</surname>, <given-names>H. L.</given-names></string-name>, <string-name name-style="western"><given-names>O. J.</given-names><surname>Freeman</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Butcher</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Astrocyte Unfolded Protein Response Induces a Specific Reactivity State That Causes Non&#8208;Cell&#8208;Autonomous Neuronal Degeneration</article-title>.&#8221; <source>Neuron</source><volume>105</volume>: <fpage>855</fpage>&#8211;<lpage>866.e5</lpage>.<pub-id pub-id-type="pmid">31924446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2019.12.014</pub-id><pub-id pub-id-type="pmcid">PMC7054837</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0193"><mixed-citation publication-type="book" id="jnc70252-cit-0193"><string-name name-style="western"><surname>Soria</surname>, <given-names>L. J. A.</given-names></string-name>, <string-name name-style="western"><given-names>H. M.</given-names><surname>Gonz&#225;lez</surname></string-name>, and <string-name name-style="western"><given-names>G. C.</given-names><surname>L&#233;ger</surname></string-name>. <year>2019</year>. &#8220;<part-title>Alzheimer's Disease</part-title>.&#8221; In <source>Handbook of Clinical Neurology</source>, vol. <volume>167</volume>, <fpage>231</fpage>&#8211;<lpage>255</lpage>. <publisher-name>Elsevier</publisher-name>.<pub-id pub-id-type="pmid">31753135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-804766-8.00013-3</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0194"><mixed-citation publication-type="journal" id="jnc70252-cit-0194"><string-name name-style="western"><surname>Staessen</surname>, <given-names>J. A.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Richart</surname></string-name>, and <string-name name-style="western"><given-names>W. H.</given-names><surname>Birkenh&#228;ger</surname></string-name>. <year>2007</year>. &#8220;<article-title>Less Atherosclerosis and Lower Blood Pressure for a Meaningful Life Perspective With More Brain</article-title>.&#8221; <source>Hypertension</source><volume>49</volume>: <fpage>389</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="pmid">17283254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.HYP.0000258151.00728.d8</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0195"><mixed-citation publication-type="journal" id="jnc70252-cit-0195"><string-name name-style="western"><surname>Steculorum</surname>, <given-names>S. M.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Solas</surname></string-name>, and <string-name name-style="western"><given-names>J. C.</given-names><surname>Br&#252;ning</surname></string-name>. <year>2014</year>. &#8220;<article-title>The Paradox of Neuronal Insulin Action and Resistance in the Development of Aging&#8208;Associated Diseases</article-title>.&#8221; <source>Alzheimers Dement</source><volume>10</volume>: <fpage>S3</fpage>&#8211;<lpage>S11</lpage>.<pub-id pub-id-type="pmid">24529522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2013.12.008</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0196"><mixed-citation publication-type="journal" id="jnc70252-cit-0196"><string-name name-style="western"><surname>Steele</surname>, <given-names>M. L.</given-names></string-name>, and <string-name name-style="western"><given-names>S. R.</given-names><surname>Robinson</surname></string-name>. <year>2012</year>. &#8220;<article-title>Reactive Astrocytes Give Neurons Less Support: Implications for Alzheimer's Disease</article-title>.&#8221; <source>Neurobiology of Aging</source><volume>33</volume>: <fpage>423</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2010.09.018</pub-id><pub-id pub-id-type="pmid">21051108</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0197"><mixed-citation publication-type="journal" id="jnc70252-cit-0197"><string-name name-style="western"><surname>Steen</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Terry</surname></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Rivera</surname></string-name>, et&#160;al. <year>2005</year>. &#8220;<article-title>Impaired Insulin and Insulin&#8208;Like Growth Factor Expression and Signaling Mechanisms in Alzheimer's Disease&#8212;Is This Type 3 Diabetes?</article-title>&#8221; <source>Journal of Alzheimer's Disease</source><volume>7</volume>: <fpage>63</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/jad-2005-7107</pub-id><pub-id pub-id-type="pmid">15750215</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0198"><mixed-citation publication-type="journal" id="jnc70252-cit-0198"><string-name name-style="western"><surname>Sturm</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Bobba&#8208;Alves</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Tumasian</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Accelerating the Clock: Interconnected Speedup of Energetic and Molecular Dynamics During Aging in Cultured Human Cells</article-title>.&#8221; <source>bioRxiv</source>.</mixed-citation></ref><ref id="jnc70252-bib-0199"><mixed-citation publication-type="journal" id="jnc70252-cit-0199"><string-name name-style="western"><surname>Sturm</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>K. R.</given-names><surname>Karan</surname></string-name>, <string-name name-style="western"><given-names>A. S.</given-names><surname>Monzel</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>OxPhos Defects Cause Hypermetabolism and Reduce Lifespan in Cells and in Patients With Mitochondrial Diseases</article-title>.&#8221; <source>Communications Biology</source><volume>6</volume>: <fpage>22</fpage>.<pub-id pub-id-type="pmid">36635485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-022-04303-x</pub-id><pub-id pub-id-type="pmcid">PMC9837150</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0200"><mixed-citation publication-type="journal" id="jnc70252-cit-0200"><string-name name-style="western"><surname>Sturm</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>A. S.</given-names><surname>Monzel</surname></string-name>, <string-name name-style="western"><given-names>K. R.</given-names><surname>Karan</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>A Multi&#8208;Omics Longitudinal Aging Dataset in Primary Human Fibroblasts With Mitochondrial Perturbations</article-title>.&#8221; <source>Scientific Data</source><volume>9</volume>: <fpage>751</fpage>.<pub-id pub-id-type="pmid">36463290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41597-022-01852-y</pub-id><pub-id pub-id-type="pmcid">PMC9719499</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0201"><mixed-citation publication-type="journal" id="jnc70252-cit-0201"><string-name name-style="western"><surname>Takauji</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Wada</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Takeda</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Restriction of Protein Synthesis Abolishes Senescence Features at Cellular and Organismal Levels</article-title>.&#8221; <source>Scientific Reports</source><volume>6</volume>: <elocation-id>18722</elocation-id>.<pub-id pub-id-type="pmid">26729469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep18722</pub-id><pub-id pub-id-type="pmcid">PMC4700526</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0202"><mixed-citation publication-type="journal" id="jnc70252-cit-0202"><string-name name-style="western"><surname>Tangney</surname>, <given-names>C. C.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Tang</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Evans</surname></string-name>, and <string-name name-style="western"><given-names>M. C.</given-names><surname>Morris</surname></string-name>. <year>2009</year>. &#8220;<article-title>Biochemical Indicators of Vitamin B12 and Folate Insufficiency and Cognitive Decline</article-title>.&#8221; <source>Neurology</source><volume>72</volume>: <fpage>361</fpage>&#8211;<lpage>367</lpage>.<pub-id pub-id-type="pmid">19171834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000341272.48617.b0</pub-id><pub-id pub-id-type="pmcid">PMC2677500</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0203"><mixed-citation publication-type="journal" id="jnc70252-cit-0203"><string-name name-style="western"><surname>Trifunovic</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Wredenberg</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Falkenberg</surname></string-name>, et&#160;al. <year>2004</year>. &#8220;<article-title>Premature Ageing in Mice Expressing Defective Mitochondrial DNA Polymerase</article-title>.&#8221; <source>Nature</source><volume>429</volume>: <fpage>417</fpage>&#8211;<lpage>423</lpage>.<pub-id pub-id-type="pmid">15164064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature02517</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0204"><mixed-citation publication-type="journal" id="jnc70252-cit-0204"><string-name name-style="western"><surname>Tyacke</surname>, <given-names>R. J.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Fisher</surname></string-name>, <string-name name-style="western"><given-names>E. S. J.</given-names><surname>Robinson</surname></string-name>, et&#160;al. <year>2012</year>. &#8220;<article-title>Evaluation and Initial In&#160;Vitro and Ex&#160;Vivo Characterization of the Potential Positron Emission Tomography Ligand, BU99008 (2&#8208;(4,5&#8208;Dihydro&#8208;1H&#8208;Imidazol&#8208;2&#8208;Yl)&#8208;1&#8208; Methyl&#8208;1H&#8208;Indole), for the Imidazoline<sub>2</sub> Binding Site</article-title>.&#8221; <source>Synapse</source><volume>66</volume>: <fpage>542</fpage>&#8211;<lpage>551</lpage>.<pub-id pub-id-type="pmid">22290740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/syn.21541</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0205"><mixed-citation publication-type="journal" id="jnc70252-cit-0205"><string-name name-style="western"><surname>Tyacke</surname>, <given-names>R. J.</given-names></string-name>, <string-name name-style="western"><given-names>J. F. M.</given-names><surname>Myers</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Venkataraman</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Evaluation of 11C&#8208;BU99008, a PET Ligand for the Imidazoline2 Binding Site in Human Brain</article-title>.&#8221; <source>Journal of Nuclear Medicine</source><volume>59</volume>: <fpage>1597</fpage>&#8211;<lpage>1602</lpage>.<pub-id pub-id-type="pmid">29523627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.118.208009</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0206"><mixed-citation publication-type="journal" id="jnc70252-cit-0206"><string-name name-style="western"><surname>Ullrich</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pirchl</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Humpel</surname></string-name>. <year>2010</year>. &#8220;<article-title>Hypercholesterolemia in Rats Impairs the Cholinergic System and Leads to Memory Deficits</article-title>.&#8221; <source>Molecular and Cellular Neurosciences</source><volume>45</volume>: <fpage>408</fpage>&#8211;<lpage>417</lpage>.<pub-id pub-id-type="pmid">20696249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcn.2010.08.001</pub-id><pub-id pub-id-type="pmcid">PMC2977849</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0207"><mixed-citation publication-type="journal" id="jnc70252-cit-0207"><string-name name-style="western"><surname>V&#233;ga</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Pellerin</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Dantzer</surname></string-name>, and <string-name name-style="western"><given-names>P. J.</given-names><surname>Magistretti</surname></string-name>. <year>2002</year>. &#8220;<article-title>Long&#8208;Term Modulation of Glucose Utilization by IL&#8208;1 Alpha and TNF&#8208;Alpha in Astrocytes: Na+ Pump Activity as a Potential Target via Distinct Signaling Mechanisms</article-title>.&#8221; <source>Glia</source><volume>39</volume>: <fpage>10</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">12112371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.10080</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0208"><mixed-citation publication-type="journal" id="jnc70252-cit-0208"><string-name name-style="western"><surname>Vicente&#8208;Guti&#233;rrez</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Jim&#233;nez&#8208;Blasco</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Quintana&#8208;Cabrera</surname></string-name>. <year>2021</year>. &#8220;<article-title>Intertwined ROS and Metabolic Signaling at the Neuron&#8208;Astrocyte Interface</article-title>.&#8221; <source>Neurochemical Research</source><volume>46</volume>: <fpage>23</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">31989468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-020-02965-9</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0209"><mixed-citation publication-type="journal" id="jnc70252-cit-0209"><string-name name-style="western"><surname>Vieira</surname>, <given-names>M. N. N.</given-names></string-name>, <string-name name-style="western"><given-names>R. A. S.</given-names><surname>Lima&#8208;Filho</surname></string-name>, and <string-name name-style="western"><given-names>F. G.</given-names><surname>De Felice</surname></string-name>. <year>2018</year>. &#8220;<article-title>Connecting Alzheimer's Disease to Diabetes: Underlying Mechanisms and Potential Therapeutic Targets</article-title>.&#8221; <source>Neuropharmacology</source><volume>136</volume>: <fpage>160</fpage>&#8211;<lpage>171</lpage>.<pub-id pub-id-type="pmid">29129775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2017.11.014</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0210"><mixed-citation publication-type="journal" id="jnc70252-cit-0210"><string-name name-style="western"><surname>Vlassenko</surname>, <given-names>A. G.</given-names></string-name>, <string-name name-style="western"><given-names>S. N.</given-names><surname>Vaishnavi</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Couture</surname></string-name>, et&#160;al. <year>2010</year>. &#8220;<article-title>Spatial Correlation Between Brain Aerobic Glycolysis and Amyloid&#8208;&#946; (A&#946;) Deposition</article-title>.&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>107</volume>: <fpage>17763</fpage>&#8211;<lpage>17767</lpage>.<pub-id pub-id-type="pmid">20837517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1010461107</pub-id><pub-id pub-id-type="pmcid">PMC2955133</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0211"><mixed-citation publication-type="journal" id="jnc70252-cit-0211"><string-name name-style="western"><surname>Wang</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Perry</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Zhu</surname></string-name>. <year>2020</year>. &#8220;<article-title>Mitochondria Dysfunction in the Pathogenesis of Alzheimer's Disease: Recent Advances</article-title>.&#8221; <source>Molecular Neurodegeneration</source><volume>15</volume>: <elocation-id>30</elocation-id>.<pub-id pub-id-type="pmid">32471464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-020-00376-6</pub-id><pub-id pub-id-type="pmcid">PMC7257174</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0212"><mixed-citation publication-type="journal" id="jnc70252-cit-0212"><string-name name-style="western"><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Hao</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Wang</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>27&#8208;Hydroxycholesterol&#8208;Induced Dysregulation of Cholesterol Metabolism Impairs Learning and Memory Ability in ApoE &#949;4 Transgenic Mice</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>23</volume>: <elocation-id>11639</elocation-id>.<pub-id pub-id-type="pmid">36232940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms231911639</pub-id><pub-id pub-id-type="pmcid">PMC9569856</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0213"><mixed-citation publication-type="journal" id="jnc70252-cit-0213"><string-name name-style="western"><surname>Wheeler</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><given-names>I. C.</given-names><surname>Clark</surname></string-name>, <string-name name-style="western"><given-names>E. C.</given-names><surname>Tjon</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>MAFG&#8208;Driven Astrocytes Promote CNS Inflammation</article-title>.&#8221; <source>Nature</source><volume>578</volume>: <fpage>593</fpage>&#8211;<lpage>599</lpage>.<pub-id pub-id-type="pmid">32051591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-1999-0</pub-id><pub-id pub-id-type="pmcid">PMC8049843</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0214"><mixed-citation publication-type="journal" id="jnc70252-cit-0214"><string-name name-style="western"><surname>Whittemore</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Vera</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Mart&#237;nez&#8208;Nevado</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Sanpera</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Blasco</surname></string-name>. <year>2019</year>. &#8220;<article-title>Telomere Shortening Rate Predicts Species Life Span</article-title>.&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>116</volume>: <fpage>15122</fpage>&#8211;<lpage>15127</lpage>.<pub-id pub-id-type="pmid">31285335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1902452116</pub-id><pub-id pub-id-type="pmcid">PMC6660761</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0215"><mixed-citation publication-type="journal" id="jnc70252-cit-0215"><string-name name-style="western"><surname>Wickens</surname>, <given-names>A. P.</given-names></string-name><year>2001</year>. &#8220;<article-title>Ageing and the Free Radical Theory</article-title>.&#8221; <source>Respiration Physiology</source><volume>128</volume>: <fpage>379</fpage>&#8211;<lpage>391</lpage>.<pub-id pub-id-type="pmid">11718765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0034-5687(01)00313-9</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0216"><mixed-citation publication-type="journal" id="jnc70252-cit-0216"><string-name name-style="western"><surname>Wiley</surname>, <given-names>C. D.</given-names></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Campisi</surname></string-name>. <year>2021</year>. &#8220;<article-title>The Metabolic Roots of Senescence: Mechanisms and Opportunities for Intervention</article-title>.&#8221; <source>Nature Metabolism</source><volume>3</volume>: <fpage>1290</fpage>&#8211;<lpage>1301</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-021-00483-8</pub-id><pub-id pub-id-type="pmcid">PMC8889622</pub-id><pub-id pub-id-type="pmid">34663974</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0217"><mixed-citation publication-type="journal" id="jnc70252-cit-0217"><string-name name-style="western"><surname>Wilson</surname>, <given-names>R. S.</given-names></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Arnold</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Schneider</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Kelly</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Tang</surname></string-name>, and <string-name name-style="western"><given-names>D. A.</given-names><surname>Bennett</surname></string-name>. <year>2006</year>. &#8220;<article-title>Chronic Psychological Distress and Risk of Alzheimer's Disease in Old Age</article-title>.&#8221; <source>Neuroepidemiology</source><volume>27</volume>: <fpage>143</fpage>&#8211;<lpage>153</lpage>.<pub-id pub-id-type="pmid">16974109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000095761</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0218"><mixed-citation publication-type="journal" id="jnc70252-cit-0218"><string-name name-style="western"><surname>Wilson</surname>, <given-names>R. S.</given-names></string-name>, <string-name name-style="western"><given-names>K. R.</given-names><surname>Krueger</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Arnold</surname></string-name>, et&#160;al. <year>2007</year>. &#8220;<article-title>Loneliness and Risk of Alzheimer Disease</article-title>.&#8221; <source>Archives of General Psychiatry</source><volume>64</volume>: <fpage>234</fpage>&#8211;<lpage>240</lpage>.<pub-id pub-id-type="pmid">17283291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archpsyc.64.2.234</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0219"><mixed-citation publication-type="journal" id="jnc70252-cit-0219"><string-name name-style="western"><surname>Wordsworth</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>P. Y.</given-names><surname>Nielsen</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Fielder</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chandrasegaran</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Shanley</surname></string-name>. <year>2023</year>. &#8220;<article-title>Metabolic Slowdown as the Proximal Cause of Ageing and Death</article-title>.&#8221; <source>bioRxiv</source>.</mixed-citation></ref><ref id="jnc70252-bib-0220"><mixed-citation publication-type="journal" id="jnc70252-cit-0220"><string-name name-style="western"><surname>Xiong</surname>, <given-names>X.&#8208;Y.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Tang</surname></string-name>, and <string-name name-style="western"><given-names>Q.&#8208;W.</given-names><surname>Yang</surname></string-name>. <year>2022</year>. &#8220;<article-title>Metabolic Changes Favor the Activity and Heterogeneity of Reactive Astrocytes</article-title>.&#8221; <source>Trends in Endocrinology and Metabolism</source><volume>33</volume>: <fpage>390</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="pmid">35396164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2022.03.001</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0221"><mixed-citation publication-type="journal" id="jnc70252-cit-0221"><string-name name-style="western"><surname>Xu</surname>, <given-names>W. L.</given-names></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>Atti</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Gatz</surname></string-name>, <string-name name-style="western"><given-names>N. L.</given-names><surname>Pedersen</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Johansson</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Fratiglioni</surname></string-name>. <year>2011</year>. &#8220;<article-title>Midlife Overweight and Obesity Increase Late&#8208;Life Dementia Risk: A Population&#8208;Based Twin Study</article-title>.&#8221; <source>Neurology</source><volume>76</volume>: <fpage>1568</fpage>&#8211;<lpage>1574</lpage>.<pub-id pub-id-type="pmid">21536637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182190d09</pub-id><pub-id pub-id-type="pmcid">PMC3100125</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0222"><mixed-citation publication-type="journal" id="jnc70252-cit-0222"><string-name name-style="western"><surname>Xue&#8208;Shan</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Juan</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Qi</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Imbalanced Cholesterol Metabolism in Alzheimer's Disease</article-title>.&#8221; <source>Clinica Chimica Acta</source><volume>456</volume>: <fpage>107</fpage>&#8211;<lpage>114</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2016.02.024</pub-id><pub-id pub-id-type="pmid">26944571</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0223"><mixed-citation publication-type="journal" id="jnc70252-cit-0223"><string-name name-style="western"><surname>Yaffe</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Laffan</surname></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Harrison</surname></string-name>, et&#160;al. <year>2011</year>. &#8220;<article-title>Sleep&#8208;Disordered Breathing, Hypoxia, and Risk of Mild Cognitive Impairment and Dementia in Older Women</article-title>.&#8221; <source>JAMA</source><volume>306</volume>: <fpage>613</fpage>&#8211;<lpage>619</lpage>.<pub-id pub-id-type="pmid">21828324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2011.1115</pub-id><pub-id pub-id-type="pmcid">PMC3600944</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0224"><mixed-citation publication-type="journal" id="jnc70252-cit-0224"><string-name name-style="western"><surname>Yao</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Rettberg</surname></string-name>, <string-name name-style="western"><given-names>L. P.</given-names><surname>Klosinski</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Cadenas</surname></string-name>, and <string-name name-style="western"><given-names>R. D.</given-names><surname>Brinton</surname></string-name>. <year>2011</year>. &#8220;<article-title>Shift in Brain Metabolism in Late Onset Alzheimer's Disease: Implications for Biomarkers and Therapeutic Interventions</article-title>.&#8221; <source>Molecular Aspects of Medicine</source><volume>32</volume>: <fpage>247</fpage>&#8211;<lpage>257</lpage>.<pub-id pub-id-type="pmid">22024249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mam.2011.10.005</pub-id><pub-id pub-id-type="pmcid">PMC3658304</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0225"><mixed-citation publication-type="journal" id="jnc70252-cit-0225"><string-name name-style="western"><surname>Yin</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Sancheti</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Patil</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Cadenas</surname></string-name>. <year>2016</year>. &#8220;<article-title>Energy Metabolism and Inflammation in Brain Aging and Alzheimer's Disease</article-title>.&#8221; <source>Free Radical Biology &amp; Medicine</source><volume>100</volume>: <fpage>108</fpage>&#8211;<lpage>122</lpage>.<pub-id pub-id-type="pmid">27154981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2016.04.200</pub-id><pub-id pub-id-type="pmcid">PMC5094909</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0226"><mixed-citation publication-type="journal" id="jnc70252-cit-0226"><string-name name-style="western"><surname>Yousefzadeh</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Henpita</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Vyas</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Soto&#8208;Palma</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Robbins</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Niedernhofer</surname></string-name>. <year>2021</year>. &#8220;<article-title>DNA Damage&#8208;How and Why We Age?</article-title>&#8221; <source>eLife</source><volume>10</volume>: <elocation-id>e62852</elocation-id>.<pub-id pub-id-type="pmid">33512317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.62852</pub-id><pub-id pub-id-type="pmcid">PMC7846274</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0227"><mixed-citation publication-type="journal" id="jnc70252-cit-0227"><string-name name-style="western"><surname>Yu</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Maciejewski&#8208;Lenoir</surname></string-name>, <string-name name-style="western"><given-names>F. E.</given-names><surname>Bloom</surname></string-name>, and <string-name name-style="western"><given-names>P. J.</given-names><surname>Magistretti</surname></string-name>. <year>1995</year>. &#8220;<article-title>Tumor Necrosis Factor&#8208;Alpha and Interleukin&#8208;1 Alpha Enhance Glucose Utilization by Astrocytes: Involvement of Phospholipase A2</article-title>.&#8221; <source>Molecular Pharmacology</source><volume>48</volume>: <fpage>550</fpage>&#8211;<lpage>558</lpage>.<pub-id pub-id-type="pmid">7565637</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0228"><mixed-citation publication-type="journal" id="jnc70252-cit-0228"><string-name name-style="western"><surname>Zebhauser</surname>, <given-names>P. T.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Berthele</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Goldhardt</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Cerebrospinal Fluid Lactate Levels Along the Alzheimer's Disease Continuum and Associations With Blood&#8208;Brain Barrier Integrity, Age, Cognition, and Biomarkers</article-title>.&#8221; <source>Alzheimer's Research &amp; Therapy</source><volume>14</volume>: <fpage>61</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01004-9</pub-id><pub-id pub-id-type="pmcid">PMC9044672</pub-id><pub-id pub-id-type="pmid">35473756</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0229"><mixed-citation publication-type="journal" id="jnc70252-cit-0229"><string-name name-style="western"><surname>Zehnder</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Petrelli</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Romanos</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Mitochondrial Biogenesis in Developing Astrocytes Regulates Astrocyte Maturation and Synapse Formation</article-title>.&#8221; <source>Cell Reports</source><volume>35</volume>: <elocation-id>108952</elocation-id>.<pub-id pub-id-type="pmid">33852851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2021.108952</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0230"><mixed-citation publication-type="journal" id="jnc70252-cit-0230"><string-name name-style="western"><surname>Zhang</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Kishimoto</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Grammatikakis</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>Senolytic Therapy Alleviates A&#946;&#8208;Associated Oligodendrocyte Progenitor Cell Senescence and Cognitive Deficits in an Alzheimer's Disease Model</article-title>.&#8221; <source>Nature Neuroscience</source><volume>22</volume>: <fpage>719</fpage>&#8211;<lpage>728</lpage>.<pub-id pub-id-type="pmid">30936558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-019-0372-9</pub-id><pub-id pub-id-type="pmcid">PMC6605052</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0231"><mixed-citation publication-type="journal" id="jnc70252-cit-0231"><string-name name-style="western"><surname>Zhang</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Ye</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Picard</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Gu</surname></string-name>. <year>2017</year>. &#8220;<article-title>Independent Impacts of Aging on Mitochondrial DNA Quantity and Quality in Humans</article-title>.&#8221; <source>BMC Genomics</source><volume>18</volume>: <fpage>890</fpage>.<pub-id pub-id-type="pmid">29157198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12864-017-4287-0</pub-id><pub-id pub-id-type="pmcid">PMC5697406</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0232"><mixed-citation publication-type="journal" id="jnc70252-cit-0232"><string-name name-style="western"><surname>Zhang</surname>, <given-names>Y.&#8208;M.</given-names></string-name>, <string-name name-style="western"><given-names>Y.&#8208;B.</given-names><surname>Qi</surname></string-name>, <string-name name-style="western"><given-names>Y.&#8208;N.</given-names><surname>Gao</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Astrocyte Metabolism and Signaling Pathways in the CNS</article-title>.&#8221; <source>Frontiers in Neuroscience</source><volume>17</volume>: <elocation-id>1217451</elocation-id>.<pub-id pub-id-type="pmid">37732313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1217451</pub-id><pub-id pub-id-type="pmcid">PMC10507181</pub-id></mixed-citation></ref><ref id="jnc70252-bib-0233"><mixed-citation publication-type="journal" id="jnc70252-cit-0233"><string-name name-style="western"><surname>Zong</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Liao</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Mitochondrial Dysfunction: Mechanisms and Advances in Therapy</article-title>.&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>9</volume>: <fpage>124</fpage>.<pub-id pub-id-type="pmid">38744846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01839-8</pub-id><pub-id pub-id-type="pmcid">PMC11094169</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501330</article-id><article-id pub-id-type="pmcid-ver">PMC12501330.1</article-id><article-id pub-id-type="pmcaid">12501330</article-id><article-id pub-id-type="pmcaiid">12501330</article-id><article-id pub-id-type="pmid">40713244</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100310</article-id><article-id pub-id-type="pii">S2274-5807(25)00253-5</article-id><article-id pub-id-type="publisher-id">100310</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Disclosure of Alzheimer&#8217;s disease blood-based biomarker results in a primary care setting: Opportunities and challenges</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Bolton</surname><given-names initials="CJ">Corey J.</given-names></name><email>corey.bolton@vumc.org</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Rostamzadeh</surname><given-names initials="A">Ayda</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Chin</surname><given-names initials="N">Nathaniel</given-names></name><xref rid="aff0004" ref-type="aff">d</xref><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Fowler</surname><given-names initials="NR">Nicole R.</given-names></name><xref rid="aff0006" ref-type="aff">f</xref><xref rid="aff0007" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Heidebrink</surname><given-names initials="J">Judith</given-names></name><xref rid="aff0008" ref-type="aff">h</xref><xref rid="aff0009" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Rahman-Fillipiak</surname><given-names initials="A">Annalise</given-names></name><xref rid="aff0009" ref-type="aff">i</xref><xref rid="aff0010" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Romano</surname><given-names initials="RR">Raymond R.</given-names><suffix>III</suffix></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0011" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Clark</surname><given-names initials="LR">Lindsay R.</given-names></name><xref rid="aff0004" ref-type="aff">d</xref><xref rid="aff0005" ref-type="aff">e</xref><xref rid="aff0012" ref-type="aff">l</xref></contrib><on-behalf-of>for the Advisory Group on Risk Evidence Education in Dementia (AGREEDementia)</on-behalf-of><aff id="aff0001"><label>a</label>Vanderbilt Memory and Alzheimer&#8217;s Center, Vanderbilt University Medical Center, Nashville, TN 37203, USA</aff><aff id="aff0002"><label>b</label>Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA</aff><aff id="aff0003"><label>c</label>Department of Psychiatry, University of Cologne, Medical Faculty, Cologne 50931, Germany</aff><aff id="aff0004"><label>d</label>Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI 53792, USA</aff><aff id="aff0005"><label>e</label>Department of Medicine, Division of Geriatrics &amp; Gerontology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI 53792, USA</aff><aff id="aff0006"><label>f</label>Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA</aff><aff id="aff0007"><label>g</label>Indiana University Center for Aging Research, Indianapolis, IN 46202, USA</aff><aff id="aff0008"><label>h</label>Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA</aff><aff id="aff0009"><label>i</label>Michigan Alzheimer's Disease Center, University of Michigan, Ann Arbor, MI 48109, USA</aff><aff id="aff0010"><label>j</label>Research Program on Cognition &amp; Neuromodulation Based Interventions, Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109, USA</aff><aff id="aff0011"><label>k</label>Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA</aff><aff id="aff0012"><label>l</label>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, 53792, USA</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author at: Vanderbilt Memory and Alzheimer&#8217;s Center, 3319 West End Ave., Suite 800, Nashville, TN 37203, USA. <email>corey.bolton@vumc.org</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>7</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100310</elocation-id><history><date date-type="received"><day>5</day><month>6</month><year>2025</year></date><date date-type="rev-recd"><day>9</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><p>Blood-based biomarkers (BBMs) for Alzheimer&#8217;s disease (AD) have advanced rapidly and may be a critical tool for broad community-based screening for AD and detection of AD pathology in individuals with cognitive impairment. To meet the impending demand for AD diagnosis, BBMs could be implemented in a primary care setting to maximize accessibility and efficiency. However, this primary care implementation would be associated with numerous challenges, including issues related to disclosure of test results to patients. In this perspective article, we highlight the need for and potential challenges of AD BBM results disclosure in a primary care setting. Drawing from existing studies of AD risk disclosure, we highlight key areas of consideration to maximize patient safety and comprehension of results. Resources are suggested to aid health systems in implementing BBM testing in primary care settings. Finally, we emphasize the need for further research on the accuracy of BBMs and the practice of disclosure in primary care settings.</p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Alzheimer's disease</kwd><kwd>Blood-based biomarkers</kwd><kwd>Disclosure</kwd><kwd>P-tau217</kwd><kwd>Primary care</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0001">Alzheimer&#8217;s disease (AD) is a complex and prevalent condition that poses a significant challenge to existing healthcare systems [<xref rid="bib0001" ref-type="bibr">1</xref>]. Biomarker confirmation of AD has been limited by costly and invasive methods and has offered limited clinical utility due to a lack of treatment options once a diagnosis is reached. The recent approvals of three anti-amyloid therapies have increased efforts that focused on early identification of symptoms and diagnosis as well as public awareness about detection and treatment. Public awareness and demand for clinical evaluation is at an all-time high yet current diagnostic methods are not scalable to meet this demand [<xref rid="bib0002" ref-type="bibr">2</xref>].</p><p id="para0002">Blood-based biomarkers (BBMs) for AD have emerged in recent years and represent the most promising diagnostic tool for AD at the population level [<xref rid="bib0003" ref-type="bibr">3</xref>]. Plasma assays measuring quantities of phosphorylated tau (p-tau) [<xref rid="bib0004" ref-type="bibr">4</xref>], beta-amyloid (A&#946;) [<xref rid="bib0005" ref-type="bibr">5</xref>], neurofilament light (NfL) [<xref rid="bib0006" ref-type="bibr">6</xref>], and glial fibrillary acidic protein (GFAP) [<xref rid="bib0007" ref-type="bibr">7</xref>], amongst others, have shown great promise at identifying AD pathology (i.e., A&#946; plaques and tau neurofibrillary tangles) or concomitant processes (e.g., reactive astrocytosis, neurodegeneration) and predicting future cognitive decline. While new BBMs are constantly being developed, at present, a specific isoform of p-tau, namely p-tau217, has shown a high degree of accuracy in detecting AD pathology in the brain [<xref rid="bib0004" ref-type="bibr">4</xref>]. First measured in the blood in 2020 [<xref rid="bib0008" ref-type="bibr">8</xref>], there are now over 100 publications describing the efficacy of p-tau217 at identifying AD pathology [<xref rid="bib0004" ref-type="bibr">4</xref>], differentiating AD from other neurodegenerative diseases [<xref rid="bib0008" ref-type="bibr">8</xref>], and predicting clinical decline [<xref rid="bib0009" ref-type="bibr">9</xref>]. Recent work using a ratio of phosphorylated to non-phosphorylated p-tau217 has shown similar or better performance in detecting amyloid plaques and tau tangles as current FDA-cleared cerebrospinal fluid assays [<xref rid="bib0010" ref-type="bibr">10</xref>]. These studies have advanced the field of AD diagnostics, such that this biomarker is rapidly moving towards widespread clinical implementation, not only in specialty care settings, but also in primary care. While p-tau217 shows great promise as a standalone test, the future of BBM testing in primary care may include a panel of tests including p-tau217 as well as other markers of core AD pathology (e.g., A&#946;) and concomitant features (e.g., GFAP, NfL).</p><p id="para0003">With an ever-increasing clinical demand and more potential treatments for AD on the horizon, specialty memory clinics alone are unlikely to be able to meet the demand, and screening for, and diagnosis of, AD will instead occur more frequently in primary care [<xref rid="bib0002" ref-type="bibr">2</xref>]. Already, the vast majority of dementia diagnoses are being given outside of specialty memory clinics [<xref rid="bib0011" ref-type="bibr">11</xref>]. Primary care clinics are the frontline of healthcare delivery and provide unrivaled access to patients, thus situating the primary care clinic as a desirable setting to meet the need of large scale BBM testing. Widespread access to BBM testing could help to mitigate some of the existing health disparities in AD diagnosis. Individuals from underrepresented racial/ethnic communities have higher rates of dementia, but are consistently diagnosed less frequently, later, and less accurately than non-Hispanic Whites [<xref rid="bib0012" ref-type="bibr">12</xref>]. These disparities may be due in part to lack of access to specialized care; equipping primary care clinics with the ability to screen for AD with BBMs could be one step towards addressing these disparities. While the potential benefits of detecting and diagnosing AD in primary care clinics are numerous, there are certainly challenges in implementing this approach. In particular, communicating BBM results to patients in a primary care clinic is complex and will require additional training and resources for PCPs.</p><p id="para0004">The aim of this perspective paper is to bring attention to the unique challenges of disclosing BBM results in a primary care setting and highlight potential resources to mitigate these challenges. This discussion primarily focuses on the primary care model in the United States, although the challenges identified are likely relevant in numerous settings. Additionally, this discussion is intentionally centered on patients with cognitive symptoms, including those presenting with subjective or objective cognitive impairment. However, it should be noted that this discussion is also relevant for population-based screening for AD pathology, which could be a reality should novel treatments receive approval for preclinical administration as a preventive measure. The disclosure of BBMs is the main focus, rather than other relevant AD risk information (e.g., <italic toggle="yes">apolipoprotein-E (APOE)</italic> &#949;4 carrier status), as BBMs provide the greatest potential for clinical implementation in a primary care setting. Disclosure practices regarding genetic or other diagnostic tests are also worth consideration but given that these tests are more likely to be used in a specialty care clinic, they are not the primary focus of this paper.</p><p id="para0005">The Advisory Group on Risk Evidence Education in Dementia (AGREEDementia) is a multidisciplinary working group focused on informed discussions and development of educational material to support the communication of the results of genetic and biomarker-based prediction, detection, and quantification of dementia risk [<xref rid="bib0013" ref-type="bibr">13</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>]. The symptomatic subcommittee of AGREEDementia specifically focuses on issues related to disclosure of biomarker results to individuals with cognitive or behavioral impairment. Drawing from the collective wealth of knowledge amassed through the study of biomarker disclosure practices in AD research, we hope to offer both practical steps to ensure patient safety as well as aspirational goals for health systems to strive towards when considering patient care in this new era of AD diagnosis and management.</p></sec><sec id="sec0002"><label>2</label><title>Primary care clinics are an ideal setting for BBM testing</title><p id="para0006">Incorporation of BBMs by primary care could expedite access to dementia specialists for novel AD therapies. Current estimates based on the availability of dementia care specialists and the population of older adults who might be eligible for treatment suggest that wait times for monoclonal antibody treatments for AD could be up to four years by 2027 [<xref rid="bib0002" ref-type="bibr">2</xref>]. The integration of BBMs alongside cognitive screening may help reduce specialty care wait times by triaging patients and referring only those at highest risk for future decline, and/or those most likely to be eligible for treatments (e.g., positive BBM and abnormal cognitive test results). The addition of BBMs to a traditional cognitive screening measure substantially reduced wait times from 50 months to 12 months in one recent projection [<xref rid="bib0015" ref-type="bibr">15</xref>].</p><p id="para0007">The extended wait times projected for novel therapies are problematic as timely diagnosis and initiation of treatment is essential. Given the presumed early role of amyloid pathology (i.e., A&#946;) in the pathophysiological cascade of AD, early initiation of treatment may produce stronger benefits. Subgroup analyses of the recent TRAILBLAZER-ALZ2 study of donanemab support this hypothesis, showing stronger treatment effects in individuals with mild cognitive impairment (MCI; 39.3 % slowing of decline) compared to those with mild AD dementia (19.2 % slowing) [<xref rid="bib0016" ref-type="bibr">16</xref>]. Rate of annual volume loss in the entorhinal cortex of individuals with MCI is estimated to be &#8764;4 % [<xref rid="bib0017" ref-type="bibr">17</xref>], thus expediting treatment by even months could avoid substantial neuronal loss.</p><p id="para0008">Beyond increasing access to novel anti-amyloid therapies, there are numerous benefits to obtaining an early and accurate diagnosis of AD that can be facilitated by integration of BBMs into primary care clinics. As cognitive decline is often multifactorial, the most effective approaches to treatment are likely multi-pronged [<xref rid="bib0018" ref-type="bibr">18</xref>]. Behavioral and lifestyle interventions are effective means of reducing risk of dementia [<xref rid="bib0019" ref-type="bibr">19</xref>] and can be promoted during AD test disclosure [<xref rid="bib0020" ref-type="bibr">20</xref>], regardless of whether biomarker results are positive or negative [<xref rid="bib0021" ref-type="bibr">21</xref>]. Additionally, biomarker testing in primary care can facilitate further workup to identify causes of cognitive decline in individuals who are AD biomarker negative. If results are positive, continued cognitive decline is more likely and patients will have an opportunity to explore advanced care options and financial implications more effectively. For the PCP, knowing a patient&#8217;s biomarker result can aid in making other treatment decisions and inform the need for additional monitoring, aid in medication adherence, or the need for considering a collateral informant&#8217;s report on current health status.</p><p id="para0009">Primary care clinics are a pivotal component of healthcare delivery, serving as the frontline of diagnosis and screening efforts for a multitude of conditions. The indispensable role of PCPs is evident in the field of cancer diagnosis and treatment; through regular screenings and proactive monitoring, PCPs identify potential signs and symptoms of cancer at its earliest stages, when treatment options are often most effective. Patients who utilize primary care services more often prior to their cancer diagnosis have markedly better long-term outcomes, including a 39 % reduction in odds of metastatic disease and 21 % reduced risk of cancer-related death, than those not under routine monitoring by their PCP [<xref rid="bib0022" ref-type="bibr">22</xref>]. In addition to providing critical assistance with screening, involvement of PCPs in the care of patients with chronic conditions can extend beyond initial diagnosis to encompass holistic health management and long-term supportive care. PCPs are already managing the comorbidities that put their patients at increased risk of AD, so they are well positioned to help communicate risk for decline and strategies for reducing risk of dementia.</p></sec><sec id="sec0003"><label>3</label><title>Interest and reactions to learning biomarker results</title><p id="para0010">Full transparency and fast delivery of health information is a key element of patient-centered care [<xref rid="bib0023" ref-type="bibr">23</xref>]. This principle emphasizes that comprehensive health information is shared in a timely manner with patients to promote informed decision making. In the US, the 21st Century Cures Act has put this idea into law by requiring that test results be made available to patients electronically as soon as possible, with only a few exceptions. This reflects the fact that the vast majority of people (&gt;95 %) want to know their test results right away [<xref rid="bib0024" ref-type="bibr">24</xref>]. While patients favor the immediate release of results, healthcare professionals prefer to delay release to allow time for provider communication rather than unsupervised communication of results [<xref rid="bib0025" ref-type="bibr">25</xref>]. As of 2022, more than half of US adults surveyed reported accessing their health information online, more than twice as many as in 2014 and <italic toggle="yes">a</italic> &gt; 50 % increase from 2020 [<xref rid="bib0026" ref-type="bibr">26</xref>]. The COVID-19 pandemic is likely a large driver of this rapid increase, with patients logging onto their portal to review test results, thus highlighting the potential of electronic health portals for rapid dissemination of sensitive medical test results. While this trend has many positive aspects such as increasing patient ownership of their health, patients often view their test results before the ordering clinician has a chance to review the results [<xref rid="bib0027" ref-type="bibr">27</xref>], thus increasing the likelihood of misinterpretation or confusion.</p><p id="para0011">Even for a much-feared diagnosis such as AD, people desire to know their diagnosis. In a 2013 international survey, two-thirds of older adults reported that they would pursue diagnostic testing for AD if such a test were available, despite no available disease modifying therapies [<xref rid="bib0028" ref-type="bibr">28</xref>]. These findings have been consistently replicated in diverse patient populations. Over 95 % of older adults and their care partners enrolled in research studies on aging and dementia endorsed wanting their biomarker results, with no differences depending on race or demographic factors such as socioeconomic status or access to healthcare [<xref rid="bib0029" ref-type="bibr">29</xref>]. A recent retirement community survey showed that, even amongst cognitively healthy older adults, three-fourths of participants reported that they would want to receive their results of a blood test for AD risk [<xref rid="bib0030" ref-type="bibr">30</xref>]. Nearly three out of four caregivers of patients with cognitive decline also reported a desire to know the results of AD BBM tests, citing actionability, explanation for symptoms, and opportunities for better care and future treatment as reasons for wanting their loved one&#8217;s results [<xref rid="bib0031" ref-type="bibr">31</xref>].</p><p id="para0012">Available data suggests that disclosure of AD risk or biomarker test results can be performed safely and have numerous benefits. In research settings, disclosure of AD dementia risk based on <italic toggle="yes">APOE</italic>-&#949;4 carrier status and amyloid positivity on positron emission tomography (PET) has been shown to be safe [<xref rid="bib0032" ref-type="bibr">32</xref>,<xref rid="bib0033" ref-type="bibr">33</xref>], and may result in some benefit, as participants who learn of their increased risk have 173 % higher odds of making positive health behavior changes including diet and exercise [<xref rid="bib0020" ref-type="bibr">20</xref>] and are about 6x more likely to plan for long-term care [<xref rid="bib0034" ref-type="bibr">34</xref>]. Although patients with MCI and their caregivers in an amyloid PET disclosure-focused randomized trial did not have significant increases in depressive symptoms following a positive amyloid PET scan, moderate and sustained emotional distress was observed [<xref rid="bib0035" ref-type="bibr">35</xref>]. In the Imaging Dementia Evidence for Amyloid Scanning study, care partners of patients with dementia expressed relief and gratitude regarding positive amyloid PET results disclosure, while care partners of patients with MCI had 50 % higher odds of reporting symptoms of anxiety following learning the results of a positive amyloid PET scan [<xref rid="bib0036" ref-type="bibr">36</xref>]. Overall, the literature suggests that AD biomarker testing, while at times accompanied by some understandable distress in the case of a positive result, is not associated with any long-term psychological harm.</p><p id="para0013">There remain many unanswered questions regarding the safe and effective practice of AD BBM disclosure. Perhaps most significantly, there is a dearth of literature investigating the effects of disclosure of blood-based biomarker results or of disclosure of any biomarker results in clinical settings. Research studies on aging and dementia, and especially those specifically investigating disclosure, are prone to significant selection biases that limit the broad applicability of findings to other settings, including primary care. Patients who volunteer to participate in AD biomarker research often do so to learn of their own results [<xref rid="bib0037" ref-type="bibr">37</xref>]; in a clinic setting, patients&#8217; desire to learn their results may be mixed. Typically, patients with severe mental illness and/or substance use disorders are excluded from studies. Primary care BBM implementation would require disclosure to patients who are psychiatrically diverse and may be less knowledgeable about AD. In the absence of evidence for the safety of BBM disclosure in patients with significant psychiatric symptoms, there is a need for pre-test screening for psychiatric symptoms, as well as post-disclosure follow-up to monitor psychological response. Additional visits and screenings are not always covered by insurance and add to the time burden associated with disclosure in fast-paced clinics. More work must be done to better understand the unique challenges and barriers to effective and safe disclosure in clinical settings.</p></sec><sec id="sec0004"><label>4</label><title>Challenges associated with the communication of BBM results</title><p id="para0014">The role of the PCP in AD will likely be restricted to screening and diagnosis rather than delivery of newer therapies given the specialized testing, ongoing monitoring, and potential side effects associated with current immunotherapy options. A two-step model has been proposed in which early detection with BBMs is conducted and then further confirmatory testing is sought in cases which are ambiguous [<xref rid="bib0038" ref-type="bibr">38</xref>]. In this model, PCPs would be the ideal administrators of the first step of BBM testing given the significant demand. Although PCPs will likely not have to bear the responsibility of treatment, there are significant challenges associated with even this first stage of BBM testing that should be considered.</p><p id="para0015">Ordering a BBM or panel of BBMs necessarily implies that the PCP will be able to interpret and explain the results to the patient. Even if the patient will be referred to a specialist, given potential wait times and differing desires for pursuing further workup, the ordering physician has a duty to explain test results. AD pathogenesis is complex with shifting prominence of pathologies as the disease progresses. This complexity underscores the significance of biomarker-based diagnostics, yet interpreting these biomarkers presents a formidable challenge, particularly for PCPs lacking specialized training. While the accumulation of amyloid serves as a hallmark early event in AD, the disease's progression into symptomatic stages is associated with the ascendance of other pathologies. Amyloid biomarkers exhibit a plateau in symptomatic disease stages, while biomarkers of late-stage changes, such as neurodegeneration, assume greater predictive significance. There is evidence to suggest that certain BBMs perform differently at different disease stages. Plasma levels of p-tau217 predict cognitive decline [<xref rid="bib0009" ref-type="bibr">9</xref>,<xref rid="bib0039" ref-type="bibr">39</xref>] and amyloid status [<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0009" ref-type="bibr">9</xref>] in preclinical AD and MCI, but plasma p-tau levels do not associate with CSF or PET biomarkers in the dementia stage [<xref rid="bib0040" ref-type="bibr">40</xref>]. Plasma NfL levels, on the other hand, predict cognition in individuals with clinical dementia or MCI, but not in preclinical disease stages [<xref rid="bib0041" ref-type="bibr">41</xref>,<xref rid="bib0042" ref-type="bibr">42</xref>]. There is further evidence from the CSF biomarker literature to suggest that fluid biomarkers of AD show differing associations with clinical outcomes when examined across different disease stages. For example, CSF amyloid levels have been associated with cognition in subjective cognitive decline, while CSF p-tau levels were associated with cognition in MCI; neither biomarker was associated with cognitive functioning in dementia [<xref rid="bib0043" ref-type="bibr">43</xref>]. The predictive accuracy of BBMs is improved when simultaneously considering the patient&#8217;s cognitive status [<xref rid="bib0044" ref-type="bibr">44</xref>]. If cognitive impairment is not confirmed, positive BBM results could be misinterpreted as overly dire (e.g., if AD changes are actually asymptomatic). Further, there is an increased risk of misdiagnosis in individuals without cognitive impairment due to a greater risk of false positive BBM results when assessed in a population with a low prevalence of AD pathology (i.e., cognitively unimpaired individuals).</p><p id="para0016">While AD pathology is a significant contributor to cognitive impairment, it is crucial to recognize that cognitive decline can stem from various factors beyond AD pathology alone. A positive biomarker result indicating AD pathology, even in the presence of cognitive impairment, does not conclusively attribute AD as the sole or primary cause of the individual's impairment. Instead, biomarker results must be contextualized within the broader framework of the patient's clinical presentation and overall health. Additionally, since BBMs are not 100 % accurate compared to the clinical standard (e.g., amyloid PET scan), PCPs will need to understand the test limitations and factors that can influence accuracy. For example, medical comorbidities such as chronic kidney disease and obesity may alter biomarker levels and confound results [<xref rid="bib0045" ref-type="bibr">45</xref>]. Interpretation of fluid biomarkers in AD is nuanced, demanding a deep understanding of AD pathology, clinical staging, comorbid conditions which affect cognition, and biomarker intricacies to ensure accurate diagnosis and effective communication of results. PCPs who are not trained in the intricacies of AD pathology and biomarkers may find it difficult to interpret results themselves, much less explain results to patients.</p><p id="para0017">In addition to challenges with interpretation of results, communicating these nuanced results to participants with cognitive impairment presents another challenge. This is true in all settings, but perhaps more so in primary care settings where visit times tend to be shorter and memory changes are often not the sole focus of the visit. If results are communicated to the patient only, without a cognitively intact loved one or care partner present, there is an increased likelihood that results will be forgotten or misremembered. Further, disclosing an individual&#8217;s risk of dementia or diagnosis of AD is inherently associated with some degree of psychological risk. Thus, when communicating results, there is an impetus to monitor the patient&#8217;s and their loved ones&#8217; psychological response to the information so that further assessment and/or referral for mental health services is offered when needed. Given these challenges, the potential for misinterpretation or miscommunication of results in a PCP setting is considerable (see <xref rid="tbl0001" ref-type="table">Table 1</xref> for summary). These challenges are particularly worthy of addressing due to the potential for harm to patients and their loved ones.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Potential challenges in BBM disclosure.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"><italic toggle="yes"><underline>Misinterpretation</underline></italic></th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes"><underline>Communication Issues</underline></italic></th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes"><underline>Missed Opportunities</underline></italic></th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Test is negative and patient is told they do not have AD and no additional work-up for symptoms is completed</td><td valign="top" colspan="1" rowspan="1">Results are forgotten if not communicated to loved one in addition to patient, no written communication of results is provided</td><td valign="top" colspan="1" rowspan="1">Psychological impact of disclosure in some individuals could be missed, these patients may not be plugged in with resources that could be helpful</td></tr><tr><td valign="top" colspan="1" rowspan="1">Test is positive and risk of dementia is overstated (e.g., imminent risk in an individual with no or minimal cognitive impairment)</td><td valign="top" colspan="1" rowspan="1">If EHR allows for patients to see results prior to discussing with their doctor, patients may misinterpret results</td><td valign="top" colspan="1" rowspan="1">Entire treatment plan may revolve around biomarker results and other contributing (or primary) factors could be overlooked</td></tr><tr><td valign="top" colspan="1" rowspan="1">Test is false positive or false negative due to comorbidities or in an under-represented population lacking sufficient validation, etc.</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table></table-wrap></p></sec><sec id="sec0005"><label>5</label><title>Lessons learned in AD biomarker result communication</title><p id="para0018">While the literature surrounding disclosure of BBM results in AD is nascent, there is a substantial body of evidence on the effective disclosure of AD risk (e.g., <italic toggle="yes">APOE</italic> genetic status) or biomarker (e.g., amyloid PET) results. While there are some unique challenges associated with disclosure of BBMs in a primary care setting that limit the generalizability of past research to this area, there are still many lessons that may be gleaned (see <xref rid="tbl0002" ref-type="table">Table 2</xref> for summary).<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Lessons learned in AD biomarker disclosure.</p></caption><alt-text id="alt0002">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"><italic toggle="yes"><underline>Pre-disclosure</underline></italic></th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes"><underline>During Disclosure</underline></italic></th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes"><underline>Post-disclosure</underline></italic></th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Patient education regarding what BBMs do and do not mean</td><td valign="top" colspan="1" rowspan="1">Aiming to communicate quantitative results (as opposed to binary positive or negative)</td><td valign="top" colspan="1" rowspan="1">Monitoring psychological response over time</td></tr><tr><td valign="top" colspan="1" rowspan="1">Education tailored to patient&#8217;s current cognitive status</td><td valign="top" colspan="1" rowspan="1">Using specialized communication techniques to promote health literacy</td><td valign="top" colspan="1" rowspan="1">Encouraging active engagement in brain health strategies</td></tr><tr><td valign="top" colspan="1" rowspan="1">Expectation setting regarding potential ambiguity of results</td><td valign="top" colspan="1" rowspan="1">Using teach back methods to ensure understanding</td><td valign="top" colspan="1" rowspan="1">Ensure patient follow through with treatment recommendations</td></tr><tr><td valign="top" colspan="1" rowspan="1">Assessing psychological readiness to receive results</td><td valign="top" colspan="1" rowspan="1">Encouraging patient engagement by eliciting questions frequently</td><td valign="top" colspan="1" rowspan="1">Identify and troubleshoot barriers for patients pursuing treatment</td></tr></tbody></table></table-wrap></p><p id="para0019">A consistent theme in the study of biomarker result communication is the importance of pre-disclosure counseling and patient education [<xref rid="bib0046" ref-type="bibr">46</xref>]. Given the complexities of BBM interpretation (as discussed above), patients may benefit from an initial discussion regarding what information the test results can and cannot convey. For instance, patients could be made aware that a negative test does not mean that they do not have cognitive impairment nor that they will not develop dementia. Likewise, a positive test result does not mean that AD is the primary cause of their symptoms or that they certainly will develop dementia (in patients with MCI). Setting expectations regarding the ambiguity of results prior to disclosure can improve the patient&#8217;s experience of receiving the results. Pre-disclosure education should be tailored to an individual&#8217;s cognitive status, as the practical implications of BBM results can be drastically different for individuals who are cognitively unimpaired compared to those with mild cognitive impairment or dementia [<xref rid="bib0047" ref-type="bibr">47</xref>]. Pre-disclosure counseling can also provide an opportunity to assess the patient&#8217;s psychological readiness to receive their results. Simple questions such as &#8220;How would you feel if your test result was positive?&#8221; or &#8220;What steps would you take if you found out your test result was positive?&#8221; can provide key insights into the safety of disclosing results. Stemming from this education, a process of shared-decision making is essential to determine whether the patient wants their test results and whether it would be in their best interest to receive these results.</p><p id="para0020">There are also several factors during the act of disclosure that may increase patient understanding and response to learning their result. Providing test results in a binary fashion (i.e., positive or negative based on a predetermined cutoff value) increases the validity and interpretability of results but often leaves patients unsatisfied. Providing quantitative results can be difficult, but comprehension can be increased through the use of specialized communication techniques such as using natural frequencies instead of percentages (e.g., 3 out of 4 vs. 75 %), visual aids, and take-home education materials [<xref rid="bib0048" ref-type="bibr">48</xref>]. Having patients teach back the results and implications of the results is one method of ensuring comprehension. Encouraging the patient to ask questions regularly throughout the visit can also improve comprehension of test results.</p><p id="para0021">Following the disclosure, it is important to follow-up with patients to monitor psychological response and answer any questions that may emerge [<xref rid="bib0049" ref-type="bibr">49</xref>]. Should patients express ongoing negative psychological symptoms in response to learning their results, a behavioral health referral may be valuable. Follow-up calls or visits can also be a great opportunity to counsel patients on risk reduction strategies such as physical activity, sleep hygiene, or nutritional counseling. Finally, post-disclosure follow-up allows for ongoing monitoring of patient&#8217;s follow through with treatment recommendations, referrals to specialists, and potential barriers to receiving interventions.</p></sec><sec id="sec0006"><label>6</label><title>Resources needed for effective BBM results disclosure in primary care settings</title><p id="para0022">While there are numerous challenges to the implementation of BBM testing and results disclosure in primary care settings, there are some clear resources that could be provided to maximize the effectiveness of this practice. First and perhaps most importantly, clinician training should be prioritized. Specialized trainings focused on interpretation and communication of AD BBMs should be a prerequisite to ordering AD BBMs for PCPs without significant experience in AD and dementia.</p><p id="para0023">Further, materials should be developed to assist PCPs in facilitating results disclosure conversations. These materials could include print or electronic resources that outline key points to address during a disclosure conversation, as well as a frequently asked questions section which provides responses to common questions patients may have about their results. Materials directed towards patients may also be valuable and could include patient educational materials (e.g., describing the pathologies associated with AD and what the specific BBMs ordered are detecting) and decision support materials to aid patients in deciding whether or not to undergo BBM testing. Such decision support materials have been developed by the AGREEDementia group that are specifically targeted to patients with MCI (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.agreedementia.org/education/" id="interref0001">https://www.agreedementia.org/education/</ext-link>).</p><p id="para0024">Finding the time in a busy primary care clinic schedule to effectively educate and communicate AD BBM results to patients can be challenging. Given the importance of this topic, consideration of implementing a primary care behavioral health (PCBH) model in clinics serving large populations of older adults may be warranted. The PCBH model emphasizes a team-based approach to managing biopsychosocial issues that present in primary care, with the integration of behavioral health providers providing services in the primary care clinic setting [<xref rid="bib0050" ref-type="bibr">50</xref>]. This approach has been effective in improving psychological symptoms and promoting positive health behavior changes in difficult to manage conditions (e.g., smoking, obesity) [<xref rid="bib0050" ref-type="bibr">50</xref>]. Such an approach could allow for behavioral health specialists, who could receive in depth training in BBM results disclosure, to provide the additional counseling, education, and support necessary to ensure safe and effective results disclosure. This approach is not without its challenges, however, as staffing and resource demands for this model is high and would likely exclude lower resourced practices, thus potentially further exacerbating disparities.</p><p id="para0025">Given that the vast majority of BBM validation studies have been conducted in non-Hispanic White populations who are relatively healthy, interpreting BBM results in diverse patient populations, especially those with medical comorbidities will be challenging. Medical conditions with a high degree of racial disparity, such as chronic kidney disease and obesity, are known to have an effect on BBM levels that is independent of underlying amyloid status [<xref rid="bib0045" ref-type="bibr">45</xref>]. There is an urgent need, prior to clinical implementation, to study the performance of BBMs in diverse populations to ensure that clinical interpretation of results is accurate for all patients.</p><p id="para0026">To achieve widespread implementation of AD biomarkers within primary care settings, several key factors must be addressed. Primary care providers often report feeling inadequately prepared to manage the needs of patients with dementia, particularly in the absence of robust community support [<xref rid="bib0051" ref-type="bibr">[51]</xref>, <xref rid="bib0052" ref-type="bibr">[52]</xref>, <xref rid="bib0053" ref-type="bibr">[53]</xref>]. This challenge is even more pronounced in rural areas, where access to specialized diagnostic tools and resources is limited [<xref rid="bib0054" ref-type="bibr">54</xref>]. Therefore, establishing networks of specialists and community resources is critically necessary to facilitate the uptake of BBMs.</p><p id="para0027">At the health system level, it will be essential to have clear guidelines pertaining to next steps for patients with a positive BBM test. Implementation of AD immunotherapies has been slow and inconsistent to date; it will be pivotal for health systems to have a defined process in place for workup and referral for such therapies following a positive BBM test. Such guidelines should include how to place a referral for further workup and confirmatory testing, who the dementia specialists in the network are and how to best communicate with them, and what steps that patient will need to take prior to initiation of treatment. In addition to guidelines outlining these processes, special attention should be paid to making the pathways to specialized care and ancillary services as efficient as possible. Providing care navigators to help patients and their loved ones through this process is critical given the complexities of the current landscape. Disclosure of BBM results with no actionable next steps for patients is, at best, confusing, and at worst, potentially harmful. Additionally, the potential risk of overwhelming healthcare systems with increased demand must be carefully considered before implementing blood-based biomarkers [<xref rid="bib0055" ref-type="bibr">55</xref>]. Clear guidelines and protocols need to be established for who is eligible for testing to avoid unnecessary strain on the system. Robust technological infrastructure is needed to support the integration of biomarker data into electronic health records and to facilitate access to specialists through telemedicine, especially in underserved areas [<xref rid="bib0056" ref-type="bibr">56</xref>]. Furthermore, clear insurance and reimbursement policies must be established to ensure that biomarker testing and subsequent treatments are accessible and affordable for all patients. Collaborative care models should be developed to ensure a coordinated and effective approach to managing AD, enhancing both provider preparedness and patient outcomes [<xref rid="bib0057" ref-type="bibr">57</xref>].</p></sec><sec id="sec0007"><label>7</label><title>Summary</title><p id="para0028">The landscape of AD diagnosis and treatment has been transformed in recent years with the advent of novel immunotherapies and the development of BBMs of AD pathology. With these shifts comes an urgent need for efficient and accessible testing of patients with cognitive decline. Existing practices which rely on specialized memory clinics will not be able to meet the demands likely to follow from increased awareness of AD and the availability of disease modifying therapies. The primary care clinic is the ideal setting for AD screening using BBMs in the community. PCPs have long been critical in screening for numerous diseases and offer several advantages for BBM testing including a comprehensive understanding of their patient&#8217;s health and opportunities for more prompt assessment following onset of cognitive symptoms, potentially reducing delays in obtaining care. However, there are substantial challenges regarding the practice of interpreting and disclosing BBMs in this setting that must first be overcome. Drawing from the accumulated knowledge regarding genetic risk and biomarker test disclosure in AD can provide some guidance for health systems to adjust workflows to maximize patient-centered care in AD screening. Yet, there is little research on disclosure practices for BBMs and in clinical settings as opposed to research, thus further research in these areas is critical.</p><p id="para0029">Appropriate use recommendations for BBMs in AD have been previously published [<xref rid="bib0058" ref-type="bibr">58</xref>]. These guidelines strongly cautioned against using BBMs in primary care settings at that time, noting that additional data is needed. Several ongoing studies (e.g., SUNBIRD, BioFinder-PC) [<xref rid="bib0059" ref-type="bibr">59</xref>] will provide this data in the near future. As this data becomes available and our understanding of the accuracy of BBMs in primary care settings increases, we strongly advise revised appropriate use recommendations focused on the use of BBMs in primary care, with special attention paid to disclosure practices, as a necessary prerequisite prior to implementation.</p></sec><sec id="sec0009"><title>Funding</title><p id="para0031">Corey Bolton is funded through support from the <funding-source id="gs0001">Alzheimer's Association</funding-source> (<award-id award-type="grant" rid="gs0001">AACSF-22&#8211;924002</award-id>; PI: Bolton) and the <funding-source id="gs0002">National Institute on Aging</funding-source> (<award-id award-type="grant" rid="gs0002">K23-AG084850</award-id>; PI: Bolton). Nicole R. Fowler is funded through support from the <funding-source id="gs0003">National Institute on Aging NIA</funding-source>
<award-id award-type="grant" rid="gs0003">R01 AG056315</award-id>, <award-id award-type="grant" rid="gs0003">R01 AG059613</award-id>; PI: Fowler) and the <funding-source id="gs0004">Department of Defense</funding-source> (<award-id award-type="grant" rid="gs0004">#W81XWH-17</award-id>; PI: Fowler). Annalise Rahman-Filipiak is funded through support from the <funding-source id="gs0005">National Institute on Aging</funding-source> (<award-id award-type="grant" rid="gs0005">NIA 1K23AG07004401-A1</award-id>; PI: Rahman-Filipiak). Judith Heidebrink is supported by funding from the <funding-source id="gs0006">National Institutes of Health</funding-source> (<award-id award-type="grant" rid="gs0006">P30-AG072931</award-id>).</p></sec><sec id="sec0010"><title>Declaration of generative AI and AI-assisted technologies in the writing process</title><p id="para0032">Neither generative AI nor AI-assisted technologies were used in the writing process for this manuscript.</p></sec><sec id="sec0010a"><title>CRediT authorship contribution statement</title><p id="para0032a"><bold>Corey J. Bolton:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Project administration, Funding acquisition, Conceptualization. <bold>Ayda Rostamzadeh:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft. <bold>Nathaniel Chin:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft. <bold>Nicole R. Fowler:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft. <bold>Judith Heidebrink:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft. <bold>Annalise Rahman-Fillipiak:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft. <bold>Raymond R. Romano:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft. <bold>Lindsay R. Clark:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0033">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:</p><p id="para0034">Corey Bolton reports financial support was provided by National Institute on Aging. Corey Bolton reports financial support was provided by Alzheimer&#8217;s Association. Nicole Fowler reports financial support was provided by National Institute on Aging. Nicole Fowler reports financial support was provided by US Department of Defense. Annalise Rahman-Filipiak reports financial support was provided by National Institute on Aging. Judith Heidebrink reports financial support was provided by National Institute on Aging. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><collab>2023 Alzheimer&#8217;s disease facts and figures</collab></person-group><source>Alzheimers Dement</source><volume>19</volume><issue>4</issue><year>2023</year><fpage>1598</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1002/alz.13016</pub-id><pub-id pub-id-type="pmid">36918389</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="book" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Girosi</surname><given-names>F.</given-names></name></person-group><part-title>Modeling early detection and geographic variation in health system capacity for alzheimer&#8217;s disease&#8211;modifying therapies</part-title><year>2024</year><publisher-name>RAND Corporation</publisher-name><comment>Accessed March 25, 2024</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.rand.org/pubs/research_reports/RRA2643-1.html" id="interref0002">https://www.rand.org/pubs/research_reports/RRA2643-1.html</ext-link></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Teunissen</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Verberk</surname><given-names>I.M.W.</given-names></name><name name-style="western"><surname>Thijssen</surname><given-names>E.H.</given-names></name><etal/></person-group><article-title>Blood-based biomarkers for Alzheimer&#8217;s disease: towards clinical implementation</article-title><source>Lancet Neurol</source><volume>21</volume><issue>1</issue><year>2022</year><fpage>66</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00361-6</pub-id><pub-id pub-id-type="pmid">34838239</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Mil&#224;-Alom&#224;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Shekari</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Plasma p-tau231 and p-tau217 as state markers of amyloid-&#946; pathology in preclinical Alzheimer&#8217;s disease</article-title><source>Nat Med</source><volume>28</volume><issue>9</issue><year>2022</year><fpage>1797</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01925-w</pub-id><pub-id pub-id-type="pmid">35953717</pub-id><pub-id pub-id-type="pmcid">PMC9499867</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Fandos</surname><given-names>N.</given-names></name><name name-style="western"><surname>P&#233;rez-Grijalba</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pesini</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Plasma amyloid &#946; 42/40 ratios as biomarkers for amyloid &#946; cerebral deposition in cognitively normal individuals</article-title><source>Alzheimers Dement (Amst)</source><volume>8</volume><year>2017</year><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2017.07.004</pub-id><pub-id pub-id-type="pmid">28948206</pub-id><pub-id pub-id-type="pmcid">PMC5602863</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Giacomucci</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mazzeo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Plasma neurofilament light chain as a biomarker of Alzheimer&#8217;s disease in subjective cognitive decline and mild cognitive impairment</article-title><source>J Neurol</source><volume>269</volume><issue>8</issue><year>2022</year><fpage>4270</fpage><lpage>4280</lpage><pub-id pub-id-type="doi">10.1007/s00415-022-11055-5</pub-id><pub-id pub-id-type="pmid">35288777</pub-id><pub-id pub-id-type="pmcid">PMC9293849</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K.A.</given-names></name></person-group><article-title>GFAP as a potential biomarker for Alzheimer&#8217;s Disease: a systematic review and meta-analysis</article-title><source>Cells</source><volume>12</volume><issue>9</issue><year>2023</year><fpage>1309</fpage><pub-id pub-id-type="doi">10.3390/cells12091309</pub-id><pub-id pub-id-type="pmid">37174709</pub-id><pub-id pub-id-type="pmcid">PMC10177296</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quiroz</surname><given-names>Y.T.</given-names></name><etal/></person-group><article-title>Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders</article-title><source>JAMA</source><volume>324</volume><issue>8</issue><year>2020</year><fpage>772</fpage><pub-id pub-id-type="doi">10.1001/jama.2020.12134</pub-id><pub-id pub-id-type="pmid">32722745</pub-id><pub-id pub-id-type="pmcid">PMC7388060</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Groot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cicognola</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bali</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Diagnostic and prognostic performance to detect Alzheimer&#8217;s disease and clinical progression of a novel assay for plasma p-tau217</article-title><source>Alzheimer&#8217;s Res Therapy</source><volume>14</volume><issue>1</issue><year>2022</year><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/s13195-022-01005-8</pub-id><pub-id pub-id-type="pmcid">PMC9107269</pub-id><pub-id pub-id-type="pmid">35568889</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Barth&#233;lemy</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Salvad&#243;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>Highly accurate blood test for Alzheimer&#8217;s disease is similar or superior to clinical cerebrospinal fluid tests</article-title><source>Nat Med</source><year>2024</year><pub-id pub-id-type="doi">10.1038/s41591-024-02869-z</pub-id><comment>Published online February 21</comment><pub-id pub-id-type="pmcid">PMC11031399</pub-id><pub-id pub-id-type="pmid">38382645</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Drabo</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Barthold</surname><given-names>D.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ferido</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chang Chui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zissimopoulos</surname><given-names>J.</given-names></name></person-group><article-title>Longitudinal analysis of dementia diagnosis and specialty care among racially diverse Medicare beneficiaries</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><volume>15</volume><issue>11</issue><year>2019</year><fpage>1402</fpage><lpage>1411</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2019.07.005</pub-id><pub-id pub-id-type="pmcid">PMC6874742</pub-id><pub-id pub-id-type="pmid">31494079</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Aranda</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Kremer</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Hinton</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Impact of dementia: health disparities, population trends, care interventions, and economic costs</article-title><source>J Am Geriatr Soc</source><volume>69</volume><issue>7</issue><year>2021</year><fpage>1774</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.1111/jgs.17345</pub-id><pub-id pub-id-type="pmid">34245588</pub-id><pub-id pub-id-type="pmcid">PMC8608182</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Rahman-Filipiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Grill</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Biomarker disclosure protocols in prodromal Alzheimer&#8217;s disease clinical trials</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><volume>19</volume><issue>9</issue><year>2023</year><fpage>4270</fpage><lpage>4275</lpage><pub-id pub-id-type="doi">10.1002/alz.13380</pub-id><pub-id pub-id-type="pmcid">PMC10530125</pub-id><pub-id pub-id-type="pmid">37450489</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Rosen</surname><given-names>A.C.</given-names></name></person-group><article-title>The importance of communication and education: lessons learned from AGREEDementia</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><volume>18</volume><issue>S6</issue><year>2022</year><object-id pub-id-type="publisher-id">e066908</object-id><pub-id pub-id-type="doi">10.1002/alz.066908</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Mattke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>M.</given-names></name></person-group><article-title>Expected wait times for access to a disease-modifying Alzheimer&#8217;s treatment in the United States</article-title><source>Alzheimers Dement</source><volume>18</volume><issue>5</issue><year>2022</year><fpage>1071</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1002/alz.12470</pub-id><pub-id pub-id-type="pmid">34569686</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial</article-title><source>JAMA</source><volume>330</volume><issue>6</issue><year>2023</year><fpage>512</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Tabatabaei-Jafari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Cherbuin</surname><given-names>N.</given-names></name></person-group><article-title>Cerebral atrophy in mild cognitive impairment: a systematic review with meta-analysis</article-title><source>Alzheimers Dement (Amst)</source><volume>1</volume><issue>4</issue><year>2015</year><fpage>487</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2015.11.002</pub-id><pub-id pub-id-type="pmid">27239527</pub-id><pub-id pub-id-type="pmcid">PMC4879488</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Rationale for a multi-factorial approach for the reversal of cognitive decline in Alzheimer&#8217;s disease and MCI: a review</article-title><source>Int J Mol Sci</source><volume>24</volume><issue>2</issue><year>2023</year><fpage>1659</fpage><pub-id pub-id-type="doi">10.3390/ijms24021659</pub-id><pub-id pub-id-type="pmid">36675177</pub-id><pub-id pub-id-type="pmcid">PMC9865291</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.Y.</given-names></name><etal/></person-group><article-title>Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission</article-title><source>The Lancet</source><volume>404</volume><issue>10452</issue><year>2024</year><fpage>572</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)01296-0</pub-id><pub-id pub-id-type="pmid">39096926</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Marteau</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Silliman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cupples</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Green</surname><given-names>R.C.</given-names></name></person-group><article-title>Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study</article-title><source>Alzheimer Dis Assoc Disord</source><volume>22</volume><issue>1</issue><year>2008</year><fpage>94</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1097/WAD.0b013e31815a9dcc</pub-id><pub-id pub-id-type="pmid">18317253</pub-id><pub-id pub-id-type="pmcid">PMC2483341</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Basche</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name></person-group><article-title>Health behaviors and advanced planning in cognitively unimpaired older adults following amyloid PET disclosure: preliminary findings from the Wisconsin Registry for Alzheimer&#8217;s Prevention</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><volume>18</volume><issue>S8</issue><year>2022</year><object-id pub-id-type="publisher-id">e064559</object-id><pub-id pub-id-type="doi">10.1002/alz.064559</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Guram</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kotha</surname><given-names>N.V.</given-names></name><etal/></person-group><article-title>Association between primary care use prior to cancer diagnosis and subsequent cancer mortality in the Veterans Affairs Health System</article-title><source>JAMA Network Open</source><volume>5</volume><issue>11</issue><year>2022</year><object-id pub-id-type="publisher-id">e2242048</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.42048</pub-id><pub-id pub-id-type="pmcid">PMC9664263</pub-id><pub-id pub-id-type="pmid">36374497</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Catalyst</surname><given-names>N.E.J.M.</given-names></name></person-group><article-title>What is patient-centered care?</article-title><source>Catalyst Carryover</source><volume>3</volume><issue>1</issue><year>2017</year><pub-id pub-id-type="doi">10.1056/CAT.17.0559</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Steitz</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Turer</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.T.</given-names></name><etal/></person-group><article-title>Perspectives of patients about immediate access to test results through an online patient portal</article-title><source>JAMA Network Open</source><volume>6</volume><issue>3</issue><year>2023</year><object-id pub-id-type="publisher-id">e233572</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.3572</pub-id><pub-id pub-id-type="pmcid">PMC10028486</pub-id><pub-id pub-id-type="pmid">36939703</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Petrovskaya</surname><given-names>O.</given-names></name><name name-style="western"><surname>Karpman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Patient and health care provider perspectives on Patient access to test results via web portals: scoping review</article-title><source>J Med Internet Res</source><volume>25</volume><year>2023</year><object-id pub-id-type="publisher-id">e43765</object-id><pub-id pub-id-type="doi">10.2196/43765</pub-id><pub-id pub-id-type="pmcid">PMC10623227</pub-id><pub-id pub-id-type="pmid">37856174</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Richwine</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>W.</given-names></name><name name-style="western"><surname>Everson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>V.</given-names></name></person-group><article-title>A decade of data examined: patient access to electronic health information</article-title><source>Health IT Buzz</source><year>2023</year><comment>December 11Accessed March 25, 2024</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.healthit.gov/buzz-blog/a-decade-of-data-examined/a-decade-of-data-examined-patient-access-to-electronic-health-information" id="interref0003">https://www.healthit.gov/buzz-blog/a-decade-of-data-examined/a-decade-of-data-examined-patient-access-to-electronic-health-information</ext-link></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Steitz</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Sulieman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosenbloom</surname><given-names>S.T.</given-names></name></person-group><article-title>Association of immediate release of test results to patients with implications for clinical workflow</article-title><source>JAMA Netw Open</source><volume>4</volume><issue>10</issue><year>2021</year><object-id pub-id-type="publisher-id">e2129553</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.29553</pub-id><pub-id pub-id-type="pmcid">PMC8524306</pub-id><pub-id pub-id-type="pmid">34661667</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Wikler</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Blendon</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Benson</surname><given-names>J.M.</given-names></name></person-group><article-title>Would you want to know? Public attitudes on early diagnostic testing for Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><volume>5</volume><issue>5</issue><year>2013</year><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/alzrt206</pub-id><pub-id pub-id-type="pmid">24010759</pub-id><pub-id pub-id-type="pmcid">PMC3978817</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Rahman-Filipiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lesniak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sadaghiyani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lichtenberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hampstead</surname><given-names>B.M.</given-names></name></person-group><article-title>Perspectives from black and white participants and care partners on return of amyloid and tau PET imaging and other research results</article-title><source>Alzheimer Dis Assoc Disord</source><volume>37</volume><issue>4</issue><year>2023</year><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1097/WAD.0000000000000591</pub-id><pub-id pub-id-type="pmid">37890053</pub-id><pub-id pub-id-type="pmcid">PMC10664783</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Meador</surname><given-names>J.</given-names></name></person-group><article-title>A random population survey of adults aged 65 and over who deny recent cognitive changes asking the question &#8220;do you want to know your risk of developing Alzheimer&#8217;s Disease via a simple blood test&#8221; after being told that researchers now believe that it is possible detect Alzheimer&#8217;s Disease prior to symptoms with a simple blood test</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><volume>19</volume><issue>S23</issue><year>2023</year><object-id pub-id-type="publisher-id">e080268</object-id><pub-id pub-id-type="doi">10.1002/alz.080268</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Bolsewig</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blok</surname><given-names>H.</given-names></name><name name-style="western"><surname>Willemse</surname><given-names>E.A.J.</given-names></name><etal/></person-group><article-title>Caregivers&#8217; attitudes toward blood-based biomarker testing for Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement (Amst)</source><volume>16</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">e12549</object-id><pub-id pub-id-type="doi">10.1002/dad2.12549</pub-id><pub-id pub-id-type="pmcid">PMC10870798</pub-id><pub-id pub-id-type="pmid">38371360</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Bemelmans</surname><given-names>S.A.S.A.</given-names></name><name name-style="western"><surname>Tromp</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bunnik</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Psychological, behavioral and social effects of disclosing Alzheimer&#8217;s disease biomarkers to research participants: a systematic review</article-title><source>Alzheimers Res Ther</source><volume>8</volume><year>2016</year><pub-id pub-id-type="doi">10.1186/s13195-016-0212-z</pub-id><pub-id pub-id-type="pmcid">PMC5103503</pub-id><pub-id pub-id-type="pmid">27832826</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Burns</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Liebmann</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Bothwell</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Vidoni</surname><given-names>E.D.</given-names></name></person-group><article-title>Safety of disclosing amyloid status in cognitively normal older adults</article-title><source>Alzheimers Dement</source><volume>13</volume><issue>9</issue><year>2017</year><fpage>1024</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2017.01.022</pub-id><pub-id pub-id-type="pmid">28263740</pub-id><pub-id pub-id-type="pmcid">PMC5582024</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Zick</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Cook-Deegan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pokorski</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Green</surname><given-names>R.C.</given-names></name></person-group><article-title>Genetic testing for Alzheimer&#8217;s Disease and its impact on insurance purchasing behavior</article-title><source>Health Aff (Millwood)</source><volume>24</volume><issue>2</issue><year>2005</year><fpage>483</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1377/hlthaff.24.2.483</pub-id><pub-id pub-id-type="pmid">15757934</pub-id><pub-id pub-id-type="pmcid">PMC1761120</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Lingler</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Sereika</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Butters</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>A randomized controlled trial (RCT) of amyloid positron emission tomography (PET) results disclosure in mild cognitive impairment (MCI)</article-title><source>Alzheimers Dement</source><volume>16</volume><issue>9</issue><year>2020</year><fpage>1330</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1002/alz.12129</pub-id><pub-id pub-id-type="pmid">32588971</pub-id><pub-id pub-id-type="pmcid">PMC7541680</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;langer</surname><given-names>E.</given-names></name><name name-style="western"><surname>D&#8217;Silva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Reactions to amyloid PET scan results and levels of anxious and depressive symptoms: CARE IDEAS Study</article-title><source>Gerontologist</source><volume>63</volume><issue>1</issue><year>2022</year><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1093/geront/gnac051</pub-id><pub-id pub-id-type="pmcid">PMC9872765</pub-id><pub-id pub-id-type="pmid">35436334</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Eliacin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Polsinelli</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Epperson</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Barriers and facilitators to participating in Alzheimer&#8217;s disease biomarker research in black and white older adults</article-title><source>Alzheimer&#8217;s Dementia: Translat Res Clin Interven</source><volume>9</volume><issue>2</issue><year>2023</year><object-id pub-id-type="publisher-id">e12399</object-id><pub-id pub-id-type="doi">10.1002/trc2.12399</pub-id><pub-id pub-id-type="pmcid">PMC10242196</pub-id><pub-id pub-id-type="pmid">37287470</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Brum</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A two-step workflow based on plasma p-tau217 to screen for amyloid &#946; positivity with further confirmatory testing only in uncertain cases</article-title><source>Nat Aging</source><volume>3</volume><issue>9</issue><year>2023</year><fpage>1079</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00471-5</pub-id><pub-id pub-id-type="pmid">37653254</pub-id><pub-id pub-id-type="pmcid">PMC10501903</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Mattsson-Carlgren</surname><given-names>N.</given-names></name><name name-style="western"><surname>Salvad&#243;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>N.J.</given-names></name><etal/></person-group><article-title>Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers</article-title><source>JAMA Neurol</source><volume>80</volume><issue>4</issue><year>2023</year><fpage>360</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2022.5272</pub-id><pub-id pub-id-type="pmid">36745413</pub-id><pub-id pub-id-type="pmcid">PMC10087054</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Ortiz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kac</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Brum</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karikari</surname><given-names>T.K.</given-names></name></person-group><article-title>Plasma phospho-tau in Alzheimer&#8217;s disease: towards diagnostic and therapeutic trial applications</article-title><source>Mol Neurodegener</source><volume>18</volume><year>2023</year><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s13024-023-00605-8</pub-id><pub-id pub-id-type="pmid">36927491</pub-id><pub-id pub-id-type="pmcid">PMC10022272</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Nyberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lundquist</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nordin Adolfsson</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Elevated plasma neurofilament light in aging reflects brain white-matter alterations but does not predict cognitive decline or Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dementia: Diagn, Assessment Dis Monit</source><volume>12</volume><issue>1</issue><year>2020</year><object-id pub-id-type="publisher-id">e12050</object-id><pub-id pub-id-type="doi">10.1002/dad2.12050</pub-id><pub-id pub-id-type="pmcid">PMC7311800</pub-id><pub-id pub-id-type="pmid">32587884</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Bangen</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><volume>17</volume><issue>10</issue><year>2021</year><fpage>1756</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.1002/alz.12324</pub-id><pub-id pub-id-type="pmcid">PMC8517034</pub-id><pub-id pub-id-type="pmid">33860596</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Rami</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fortea</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients</article-title><source>J Alzheimers Dis</source><volume>23</volume><issue>2</issue><year>2011</year><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-101422</pub-id><pub-id pub-id-type="pmid">21098971</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="book" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Bolton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hohman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gifford</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jefferson</surname><given-names>A.</given-names></name></person-group><part-title>Improving the diagnostic accuracy of plasma Alzheimer&#8217;s Disease biomarkers with objective and subjective cognitive screening</part-title><comment>Presented at</comment><source>The International Neuropsychological Society Annual Meeting; February</source><year>2024</year><comment>New York, NY, US</comment></element-citation></ref><ref id="bib0045"><label>45</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Mielke</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Dage</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>R.D.</given-names></name><etal/></person-group><article-title>Performance of plasma phosphorylated tau 181 and 217 in the community</article-title><source>Nat Med</source><volume>28</volume><issue>7</issue><year>2022</year><fpage>1398</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01822-2</pub-id><pub-id pub-id-type="pmid">35618838</pub-id><pub-id pub-id-type="pmcid">PMC9329262</pub-id></element-citation></ref><ref id="bib0046"><label>46</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Erickson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Gleason</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>L.R.</given-names></name></person-group><article-title>Disclosure of preclinical Alzheimer&#8217;s disease biomarker results in research and clinical settings: why, how, and what we still need to know</article-title><source>Alzheimers Dement (Amst)</source><volume>13</volume><issue>1</issue><year>2021</year><object-id pub-id-type="publisher-id">e12150</object-id><pub-id pub-id-type="doi">10.1002/dad2.12150</pub-id><pub-id pub-id-type="pmcid">PMC7896633</pub-id><pub-id pub-id-type="pmid">33665341</pub-id></element-citation></ref><ref id="bib0047"><label>47</label><element-citation publication-type="book" id="sbref0047"><part-title>Alzheimer&#8217;s Disease Research Center</part-title><source>Biomarker disclosure toolkit</source><year>2023</year><comment>April 24</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.adrc.pitt.edu/for-researchers/biomarker-disclosure-toolkit" id="interref0004">https://www.adrc.pitt.edu/for-researchers/biomarker-disclosure-toolkit</ext-link></element-citation></ref><ref id="bib0048"><label>48</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Rabinovici</surname><given-names>G.D.</given-names></name></person-group><article-title>Amyloid imaging, risk disclosure and Alzheimer&#8217;s disease: ethical and practical issues</article-title><source>Neurodegener Dis Manag</source><volume>3</volume><issue>3</issue><year>2013</year><fpage>219</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.2217/nmt.13.25</pub-id><pub-id pub-id-type="pmid">26167204</pub-id><pub-id pub-id-type="pmcid">PMC4498486</pub-id></element-citation></ref><ref id="bib0049"><label>49</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Lingler</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Butters</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gentry</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>Development of a standardized approach to disclosing amyloid imaging research results in mild cognitive impairment</article-title><source>J Alzheimer&#8217;s Dis</source><volume>52</volume><issue>1</issue><year>2016</year><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.3233/JAD-150985</pub-id><pub-id pub-id-type="pmid">27060950</pub-id><pub-id pub-id-type="pmcid">PMC4860948</pub-id></element-citation></ref><ref id="bib0050"><label>50</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Hunter</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Funderburk</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Polaha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bauman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Goodie</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>C.M.</given-names></name></person-group><article-title>Primary care Behavioral Health (PCBH) model research: current State of the science and a call to action</article-title><source>J Clin Psychol Med Settings</source><volume>25</volume><issue>2</issue><year>2018</year><fpage>127</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1007/s10880-017-9512-0</pub-id><pub-id pub-id-type="pmid">28975500</pub-id></element-citation></ref><ref id="bib0051"><label>51</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iliffe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Downs</surname><given-names>M.</given-names></name><etal/></person-group><article-title>General practitioners&#8217; knowledge, confidence and attitudes in the diagnosis and management of dementia</article-title><source>Age Ageing</source><volume>33</volume><issue>5</issue><year>2004</year><fpage>461</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1093/ageing/afh140</pub-id><pub-id pub-id-type="pmid">15271637</pub-id></element-citation></ref><ref id="bib0052"><label>52</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Hinton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Franz</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Flores</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kravitz</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>J.C.</given-names></name></person-group><article-title>Practice constraints, behavioral problems, and dementia care: primary care physicians&#8217; perspectives</article-title><source>J Gen Intern Med</source><volume>22</volume><issue>11</issue><year>2007</year><fpage>1487</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1007/s11606-007-0317-y</pub-id><pub-id pub-id-type="pmid">17823840</pub-id><pub-id pub-id-type="pmcid">PMC2219799</pub-id></element-citation></ref><ref id="bib0053"><label>53</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>JaKa</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Rossom</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Borson</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Confidence in diagnosing and managing care for cognitive impairment in primary care: a survey comparing barriers by primary care clinician type</article-title><source>Fam Pract</source><volume>41</volume><issue>5</issue><year>2024</year><fpage>761</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1093/fampra/cmae043</pub-id><pub-id pub-id-type="pmid">39221923</pub-id><pub-id pub-id-type="pmcid">PMC11461164</pub-id></element-citation></ref><ref id="bib0054"><label>54</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Giebel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Readman</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Godfrey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Polden</surname><given-names>M.</given-names></name></person-group><article-title>Geographical inequalities in dementia diagnosis and care: a systematic review</article-title><source>Int Psychogeriatr</source><year>2025</year><object-id pub-id-type="publisher-id">100051</object-id><pub-id pub-id-type="doi">10.1016/j.inpsyc.2025.100051</pub-id><comment>Published online February 21</comment><pub-id pub-id-type="pmcid">PMC12149024</pub-id><pub-id pub-id-type="pmid">39986949</pub-id></element-citation></ref><ref id="bib0055"><label>55</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>VandeVrede</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rabinovici</surname><given-names>G.D.</given-names></name></person-group><article-title>Blood-based biomarkers for Alzheimer Disease-ready for primary care?</article-title><source>JAMA Neurol</source><volume>81</volume><issue>10</issue><year>2024</year><fpage>1030</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2024.2801</pub-id><pub-id pub-id-type="pmid">39068546</pub-id></element-citation></ref><ref id="bib0056"><label>56</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Barboi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boustani</surname><given-names>M.</given-names></name></person-group><article-title>Passive digital markers for Alzheimer&#8217;s disease and other related dementias: a systematic evidence review</article-title><source>J Am Geriatr Soc</source><volume>71</volume><issue>9</issue><year>2023</year><fpage>2966</fpage><lpage>2974</lpage><pub-id pub-id-type="doi">10.1111/jgs.18426</pub-id><pub-id pub-id-type="pmid">37249252</pub-id></element-citation></ref><ref id="bib0057"><label>57</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Heintz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Monette</surname><given-names>P.</given-names></name><name name-style="western"><surname>Epstein-Lubow</surname><given-names>G.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rowlett</surname><given-names>S.</given-names></name><name name-style="western"><surname>Forester</surname><given-names>B.P.</given-names></name></person-group><article-title>Emerging collaborative care models for dementia care in the primary care setting: a narrative review</article-title><source>Am J Geriatr Psychiatry</source><volume>28</volume><issue>3</issue><year>2020</year><fpage>320</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/j.jagp.2019.07.015</pub-id><pub-id pub-id-type="pmid">31466897</pub-id></element-citation></ref><ref id="bib0058"><label>58</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Hansson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Edelmayer</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Boxer</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>The Alzheimer&#8217;s Association appropriate use recommendations for blood biomarkers in Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><volume>18</volume><issue>12</issue><year>2022</year><fpage>2669</fpage><lpage>2686</lpage><pub-id pub-id-type="doi">10.1002/alz.12756</pub-id><pub-id pub-id-type="pmcid">PMC10087669</pub-id><pub-id pub-id-type="pmid">35908251</pub-id></element-citation></ref><ref id="bib0059"><label>59</label><element-citation publication-type="other" id="sbref0059"><article-title>Now, let&#8217;s grapple with how to use them</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.alzforum.org/news/research-news/ad-blood-tests-are-here-now-lets-grapple-how-use-them" id="interref0005">https://www.alzforum.org/news/research-news/ad-blood-tests-are-here-now-lets-grapple-how-use-them</ext-link><year>2024</year></element-citation></ref></ref-list></back></article></pmc-articleset>